<SEC-DOCUMENT>0001558370-24-002782.txt : 20240308
<SEC-HEADER>0001558370-24-002782.hdr.sgml : 20240308
<ACCEPTANCE-DATETIME>20240308074714
ACCESSION NUMBER:		0001558370-24-002782
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		137
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240308
DATE AS OF CHANGE:		20240308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				522154066
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39801
		FILM NUMBER:		24732376

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>xoma-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xoma="http://www.xoma.com/20231231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityCentralIndexKey" id="Tc_hWa8ca6Z-EqiYcS6XiIxUQ_2_1">0000791908</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentFiscalYearFocus" id="Tc_mkc00NdGP0GaF4btOFQnWg_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentFiscalPeriodFocus" id="Tc_hUl0MgJd7k-EJAHZv_0DlQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:AmendmentFlag" id="Tc_Wl0pReUL3kCnhxPQjzwxQQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" name="us-gaap:CommitmentsAndContingencies" id="Hidden_7iaka6Lt9kSEJjKqsMpKnQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_eY9I4y5F7kurZvVqqkIZyQ"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityWellKnownSeasonedIssuer" id="Hidden_uT0ww-rbBkm3D_j4aRlKvw">No</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityVoluntaryFilers" id="Hidden_2NQIBaFfIUCjiruzEJ2Apw">No</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityCurrentReportingStatus" id="Hidden_khMIdZhyK0mu3RvV6oGr0w">Yes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityInteractiveDataCurrent" id="Hidden_2cFVKmg_YkSIZ76d2oSJ8g">Yes</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA" name="us-gaap:PreferredStockValue" id="Hidden_Cv47HXb4lU6Gk7g1sUGDKg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg" name="us-gaap:PreferredStockValue" id="Hidden_tWLXBs-0PkugkSEbpf7Pgw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA" name="us-gaap:PreferredStockValue" id="Hidden_OsMuzAskf0GM04gVLpsjFg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA" name="us-gaap:PreferredStockValue" id="Hidden_MmJIXWQRREOzDoz4cg9BcA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_yKNGHsYxl0ua6mlZdK34eA">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Y2l7YTUwo0u38OqVPbafow" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_W5XKDOrmOUCVyHTuQ-wVXw">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_UE-JgzEHekiIYzHV9qlY6Q" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden__s_2kpVZCEW7Qrum_VkryA">0.02</ix:nonFraction><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_3WHRj7yXxk6Z9Qfmyl4VIA" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_UjdHxsUKK0CGYSg7vc8W1w">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A" name="xoma:LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_oKAPgn6owUGhjjDbJEhNww">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" xs:nil="true" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden_3mFvOmJiKUCxDAEe7fSXPQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden_tzBx_nlwlk2NnJLZtAgZ4Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_xQxEZRom10ipxNjFLhAhoQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" xs:nil="true" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_mFboUZF-aEWaGrU2CAFHmQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__tLB0mm090OfA60OC8q_xw" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_xpK_StUG00ybbYZa3HpmVA">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9F82xQd9GUyY0FWq2yw9Bw" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_-jeY11JkkU-_yKExwXSvYw">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7KxJyjjuEU-w1MGzNb9A3Q" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_XJQ4j8H56EGkjfAn5W1EYw">0.333</ix:nonFraction><ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Mf0qw7fgPkO317ZtY5HXgQ" name="xoma:EmploymentPeriodRetirementEligible" id="Hidden_PLUg0go3Uk-_7O-a0gyV7w">P12M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow" decimals="INF" name="xoma:DepositarySharesRatioToPreferredStock" id="Hidden_0WqPQZjVdk-rCh1KkH7IeA">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_OtbkDkOCv0OoiEEXRKx3Dg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_H7Lo4FtfLUG9U_8NFt12cA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_MsUIfPz7IkeOXLe_QrDnng" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_btS0jg_C4kSqwPe0vi-i5w">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_csVtxNTS10i9KUsxBrQxmg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_dSMEchMnFkqWypW9UGk7Lw">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lPhZaHPsnUm-UbBxAw8vBg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_3oD01eoLEkipHZzpjVu_VA">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_0bVnFNKbb0e1H3F_2kLeBg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_OTKsEhaqhEaFde7pn0r-XA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_BNfFBH3i0E-67OZGzWGTOQ" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_7zNSlE5m30-23n_Xhxv1Cw">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_NJAjCjk_ZUKFBzZS4OOcWQ" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_s0Q6hKWcX0SArB1No9n7mA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_Zy4X4SxAdEiV-KmbfWpDCA" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_ZPUZL4tmokqcSqnQL-SrmQ">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_KMb4kPRqak6KcEpfavYKYg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_YeDNFyDyWkiXwMYXPzULTA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_GMUFTnTyUE64YJmDNxHjhw" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden__Df-kChCN02M1zGD5YLDDA">0.52344</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="xoma-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_VIuDTnkCcEaZC79EMJ-tOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_D67_o-ekW0mCOHoAiNEOOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_XnnLT8lCQE-Kb6QqSuciIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iss2YrFnEUiSmHE-waxCwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2015_To_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_QVblxPuRZEOw9F6rNagv6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_d7MCNo9BZ0e94zx26toTQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:U.s.DepartmentOfDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_DqEQ-FxkkkC-biVtuHiWlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yFyujZtG9UWuos2_NLxJPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AloraPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:U.s.DepartmentOfDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2cm7F_6WkkiGYRgSmohdVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AloraPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_2qKuJw7LF0SNxUkiCX8mrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_CcXbeenPEESy7c73GXsaSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QrBLuliLBkmZRyyHG3qE9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_gy86xQDN_kOxX3_roA0-UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_plbEBxZzaEaRWFV0Pyn4DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0EETUtBX8UGfAIbmhgJkXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:Tak079AndTak169Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-11-01</xbrli:startDate><xbrli:endDate>2006-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_vL3apDyaZkCu6f5YXyWb4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_HJ3psyCDL0yJ_bjXgwInwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2027_To_7_1_2027_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_zKMEytddB06_SjlQuaXQbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsInterestAndAdministrativeFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2027-07-01</xbrli:startDate><xbrli:endDate>2027-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_mDE0bA7PrUqp9g8geI29AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ac_n1xmN8US4lumZOLANeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NH5EPARofEyZbj-06mGtVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_0JMorE6cGUCpbiydWrq72g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_keBCQhbHw0y8_i0w3euIAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_riSbvYPSGkWe1QwZUDB4KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-TWqBbOPI0edg96_YaJDsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vfK6Z82DIk-illPE02g4gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_yk_WkugXu0KU1E5kCoC55w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_KY6LHuuUC0ara8OGoTqocg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_qvLnAbo6Nki2UZIKe_V1Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_-Bb_xc6BGUyWHxxOSoMlCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_HzgT7NkX4kK_7iaixTGPCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_wNITwyTcekq4e2_GA1wpag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_3t-rhj3dwU6-3CO8uFyHug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_d4I_Xv63ZU-hiLOrOkWuoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KiCr-hkOokmigDvDkoN0tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-16</xbrli:startDate><xbrli:endDate>2024-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2023_To_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wemVoEFoIkCvcBgBQtS_rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-15</xbrli:startDate><xbrli:endDate>2023-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_11_2024_To_1_11_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_kHKXEon0m0elwS6IFTsLdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-11</xbrli:startDate><xbrli:endDate>2024-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_GWb50yHWG0Gjencq1GEsyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-21</xbrli:startDate><xbrli:endDate>2023-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Dnn6lWiT3UCbGZqz1uHJdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_pF2mvqFuzU-4j2j-TN-FwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tdEEOHOCzUWim85LeSnQxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CmMun3MJHE2TK0PBPfLoYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vN14m3xAIUKgXMq-xvIgWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-26</xbrli:startDate><xbrli:endDate>2019-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Qs55blBy0EiU6L4gvsU5Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FmZheOiEbUS5CMSbMHjZ9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bTPXO4suRkSuGzADvtOkDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_RfM78mIKA0-JJnpILkNCiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_Yf9nqgko7Ey_J1Vum-XNLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Knb1VMkj50OkZMrcsYVZ7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_x9Ly_6nZa0eN0KZmAKFNgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pH08PwEje0KIRv6GUczeEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_dtGtLvan-0WILGKknRPEsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_jXEG7wv2O0iixCaiWgcKIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_n0AlLUReN0Kwv0E-hFvvxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uYT0rItyzEy3DCuVTQGaFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TYLM5-VARkS0pBu28e5EGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_30_2023_To_10_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5j_H144ha0GnzzpObzRcdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_LUAacl6AYUSQlLyvLbzF7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ws-dALFRwk6XAWf156awmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_2QhgXTVMF0OhuPGA7tPfmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_0uMMRf1S3kW4lhwL-tOXmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-10</xbrli:startDate><xbrli:endDate>2021-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_dAlGQw-3xkK1mBDxc6h3UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_U6eB0xdgwk-Ra02haIYfXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:AldoxorubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_7RTgXi3MwkO02DSrEMpnRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:ArimoclomolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fbE-TTiMOE6nIPU6Gv7BJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XtN01G-WQUmOgtwp6LiEzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_8AcX-7SvuE20tV_Gwrd56A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-20</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_w_Edg6XtwkWHPpb5BqgAXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_IsgrsUJM7Ey5ytOSIHjpJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_4l7SozYSsUOT0k7UTF6fPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_kmKo9NmoskKPrR6gM-lu1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Mf0qw7fgPkO317ZtY5HXgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2024_To_1_7_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqWQZEkxck6aUZbAhDxrIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-07</xbrli:startDate><xbrli:endDate>2024-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_5P20gVnqp0OL89sgLmEIrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_q9ObqQzmnkSHnjz07UVHxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bEwMjcvCoE6dg4CchXXb4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AloraPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_IHaDD6BBE0CO38D7GY_WoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_6gbf0-HRZ0qDTY9O_kyUlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ZfHh5QPIlkK7My1pRgpLNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember__6fnOc6OPUS1I5ZlPUpdTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:Tak079AndTak169Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2006-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_w1WsQS9rPkSjRRaxRFYrUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:OtherAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-02-01</xbrli:startDate><xbrli:endDate>2009-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m5q_NDHLs0qf2z319qyN2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ukWUu5ueDkGldRKA40hqKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_cJ_3I5gqVUm-_Sd9MucR6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_odyIaKodm0SEW_jiL6wZ-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_stqAZ05QWkerRkwBioCcUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_N0BzlyOR4kSuTcSqKfN20g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ZZqIGqDsP0OAXaFzszUtlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_hcyXjuHEYE6D8CUHcrJ5bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Tfg4rgDuq0ufRwK2q3MQ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-RitWGIJ-ESF55jlLrVWtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IUqLnYwi60W0DrGdz3BX1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_0LRcdmUtxkWsPDjZRSRzxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fTTbXC7jbkqFXemFP-meAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Linvwi1eaEmv0RwYC9mmXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-30</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zkpfoJr1ZUGbwa1B55RwJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3MSAG2w_VE-njv8TBWI0TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-16</xbrli:startDate><xbrli:endDate>2024-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-16</xbrli:startDate><xbrli:endDate>2024-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_6yQg3Qhf9UiWbaQF-yGsrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_op1dbIKXI0auw-rLczKFjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_gaTRiap1pEa9KzeA121uZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M2cfbs9j8kSBfzVpqthphw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VUzwcKDVUk-lZVV-EniucQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_ics5zZQKZEC1GLHClhw50g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2024_To_3_4_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tizzAxoxlky8Xls0hG3qmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_J15_C70NX0OmaYeWNB6hKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_fTV55Dy5KEqyHnrS7IKYNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_2_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BoZJ1cjf3EanYPBMyrtXzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8FHApOZ_VkCpJPR1XZCtyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_0w8sMVVLj02yx0033CwvXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_G2fgy4TWqkGEN64FdHGrUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_nAi2n-UX2kK0kjYHslutOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_q0p4FSRc_k6TcIpryO7R1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_IY_E1K2-GEeCZwiLEBu6nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_QuC48dJf8E23DlxZlazDSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_UE-JgzEHekiIYzHV9qlY6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yrXa87g-0alNOMlRI8rYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wVVTmZ48EeiZT2WPXZvIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ERGTIkxok0qRddaD8mnHPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3taukphaKkSilr_NFe1nOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Syt95SBUbUaxMwPVZJcalg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHYxtsKmG0-hqBTHhnVlsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_1fyMNRl8D0iF9dish_Goew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_L1ce77euREyOrnX7bZ8mMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2XEI2tAvkOn0kqT8ijqUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3N60csckskq31gE5arvXmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y8PfkqfeykCg9sfic1605Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_XU7qWkz2d0WVvDm9lTapaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MFi4TV8yEkS7ZFZpxsfd3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YtSAydDkdkaz5GXFSbOn6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gJUEPmVke0CACVsCCPaSeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_WdFrStI1SEmbrCQr_uf_3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QfRHcV6u0k2_QDklTWc_9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_xw9SMS1FDku23HM0n9XH7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QK1CLkfR8kOQoYbaZOfjJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_9t7Xrh4erUm2DCAqplH8xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_7AXSy2l_dkerjh7MaB675Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_bkupJ_siykOMKkRtcBeUdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_9_2024_To_1_9_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VAnZAL0inEKRzb4syNlviQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-09</xbrli:startDate><xbrli:endDate>2024-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_p17Cp-2md0-zORF_i9yfng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_CPv_k4GysE6N0cJwFt__ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_kZe5UeB58EqVvQzsj0tFKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_q-zvA0nnJ0u9IWbpCyBZaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_VgCo7QDMrEqWqhFOY8kLUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6NH2D73ShkWYzzOp3xcTJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4_9OfpHHLEma607A2lr0HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pPNS9kuKzkGEzka8BT7FTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z14Y_ls6nU-Legw_e3KnHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NYJResI69kesGeTfzxA53w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_Yo1Pn10MbE-IQC5dhETm3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeTerminatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_DppoP7EaukOr-8wuDeS7oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_MQ2JB34wHEqnnlhOE_S-2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_7XNCE9fHSkejCdV6XNu2Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_PFwhQNdS_0Cvqwhdk5-nJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Q_GOADvcjEiY8_k6u1blBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_GaicAvhvREu045tkaseAEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__tLB0mm090OfA60OC8q_xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Nbz01A2AFUSN9o9T7YGxsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9F82xQd9GUyY0FWq2yw9Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7KxJyjjuEU-w1MGzNb9A3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jr06nKWQnkWcc1gc9wl75w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_JTU393H8zkS60pP-6_KFDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_RX8jSTjVsUCam5xpFx-k_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LLR4GBlfWEaaPy6t-ixdjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ATjJ9C3tUEuB5MOkEX8QXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_wMQi5PD-5kOVp3Do-Cz7aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_hM9ty2-MVUGlezJJB5CGZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pXkK2dzdNkSrOgN1r7fWyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IgF4YIWD40C1TLHU9oQ6EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ZvNKstqm10OSTijaRyyBgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_U9y-4g4fU0Ke5Az40er2DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_0srFpIQZjEeXreNfgIZggA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember__0KUigoyNEiSFG6EHS-pKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_lpNhrc2ivk27vYMf2Vaqrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_srt_AsiaPacificMember_h1HPzeTFJEK9m12ZpTyuCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_3-ttz87lbUGOlay7J25Yhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_77WH8ueaj0uJk0NC9iLw_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_VbPaWFBrc0Cn_MDgoar4GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_b-w3yCVO1UaXJ0_RnOHO7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_qTQ_SCTqPUOorHOyhK5FRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_fi1CUmq620GKCFSjTShMsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_qCQ7jqMcRkubKcfhZC2tng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__ZprmCypEEWlgZ0NIIwirQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_ukrOvK0wPUCoC4cxRPdRLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7PuIiwOfIE6NRKYOTnb75w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_5vFgsQWMw0WyWVDC99pPgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_dLKjanUZa0iaV3DbfG2Dlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_OSC8ojzXEkSJ5RzL03Kwhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_W8GylEFUmkCZLuCLShF-2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lQhUbx-dW0yCv6mncYCFTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wFKkAjcle0uyGz1v162nrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HGWd0mh5bECM6w9TDjLMqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AvM2tRL06EKNen-3oQQBug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Kfw2xvvPLECdksugQSkyRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_MTSivgxXa0q5d0yr9jPQ4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_hxT-8FvU4kmmkr5WaUc5tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jkZrlo9E8kGwNk50O_JF4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uRoDrOQqBEOHxxDn5GD5-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_FPhDw6eFSkewkz9kjfMtWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lPc163Jack2g_3qJHGxkJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tb-jqf59g0qRtmd2zX4zHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsOperatingExpensesMember_bIl9zjrGREO247K9VPfUHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsOperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_pFJTova4jkOtP18qsB8a9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsInterestAndAdministrativeFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_r98Y34qxLkWbmrz_8S1ntw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_t-cr-ApM602C1aypIMKmig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_oha9lcQVn0qkzi_7xjYWFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_cEbwO1-SA0ytFO3kPI9NlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_da-F0GyQwUWPIo1MwVDeDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_qkBguZsiw0WaOQD5kUxKeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_z_A_YFI4skKZFdejnGMUfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_B23R2xU4FUqRYRyOEOTGqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_quH6qxcvP0mDXAhJavVYWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_zym9UWjuxU-PBpIgDKhAWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_rdiiaR-KVUigBcn6d96uPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Nr-S-s7kcESAiUgmLUMTDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7QPtDO1XZ0iO8szQG-XtMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T1PJ_hKJ-UOq76YTlyMzXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_G45ViXWaZkGa0Q9Yg2KbNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AbZx0laHAUueU-IhDRrrDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_IvhJyfS6z0K0hCQsSwDDPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Whkoa4BKGkO7vhoZPfvTBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Eizh1l00wEuCnFSN_xaUow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lRxrGJiyCEKBTolJ2-Gkiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_iWAtZr3dFESpISINrOcmfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3AEODlP3-0mydkDGCWhqyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-18</xbrli:startDate><xbrli:endDate>2023-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_vTX9rZqalUujaAzAws_s7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-18</xbrli:startDate><xbrli:endDate>2023-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2-MEI4pSCUuGeRcjC_EN9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-26</xbrli:startDate><xbrli:endDate>2023-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lyRMP8iHEkWMJ8bT6bvwDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-26</xbrli:startDate><xbrli:endDate>2023-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_YlNIDoBrLEe-2gkq_aWe3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-17</xbrli:startDate><xbrli:endDate>2023-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yoj2ix91MkCiAGkREHt-GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-17</xbrli:startDate><xbrli:endDate>2023-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cvrkp9vamEm0URrVmBMi4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_9GG7R2owREOBYs3nJiZ6Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_PEaFlgcRP0SaaPOSqZfozQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gixUoEw130mjwVDdF_iufA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_KMb4kPRqak6KcEpfavYKYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_GMUFTnTyUE64YJmDNxHjhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_NJAjCjk_ZUKFBzZS4OOcWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-16</xbrli:startDate><xbrli:endDate>2023-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_Zy4X4SxAdEiV-KmbfWpDCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-16</xbrli:startDate><xbrli:endDate>2023-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_0bVnFNKbb0e1H3F_2kLeBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_BNfFBH3i0E-67OZGzWGTOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_csVtxNTS10i9KUsxBrQxmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lPhZaHPsnUm-UbBxAw8vBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_OtbkDkOCv0OoiEEXRKx3Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_MsUIfPz7IkeOXLe_QrDnng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_96UqI17DZ06cOK2CPIIPvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ttlhuKLBjUSSxoBHpLChMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_er3W3MMAy02J-0HZT7aH1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_-jTxUsLwB0m38qsZl5cPRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JWDlj2gMFEij2eL1xesPfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r_AdKEQIsUaSBQTdOEh1Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_xAActchtNUCUQIYwmgGrBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_4MybQZKMoUeRtb31Nl4fZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_DR_dvBy6JkSRBmbQK4UTeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_3WHRj7yXxk6Z9Qfmyl4VIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Y2l7YTUwo0u38OqVPbafow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_RRcaFO6M3kOh_ZaU4q8qig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_lw1Ws7NAP02fg7d3o1Pq3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_RWlyVdx2GUC3EPptM1fY5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5IIqeHWkV0S9mtFRdVUKvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_LXJN7Whj9UecRjtZBao0Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_w6rQaC_PqEy9fPUmEuULSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_pSxax3Usz0yR4JG-1OD69Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_LJGNT1o0fESPY6CsLc4PAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYNuuYoVaUKIMN5qjgyD0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2023_us-gaap_AwardDateAxis_xoma_AwardDateMay2023ToOctober2023Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DWNUD9UHZ0yY-M_tgTpaEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">xoma:AwardDateMay2023ToOctober2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wI-J9wnFokegnVOOPhGPfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_kICVKVDR1EKuBrC70GhfGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_NxeZNU-uwEaleSn6kV2D0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Pp3_l5-Makmyd588cc5PtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_FOSyLzrHjUO4zX7-HXcfvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_zoPI7MqTT0ymJt_IEkPwzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1fqxYlQgQEOjj4he88QfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_Nk99SOMJtE6XXgO_0hAWnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_8W6Ja3W_5UWikBBaH31LWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_Ye9pux6Zk0mWff5iTCN7xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_DDySBRqQAkmCyGXaQYbaTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_owbhffF5n065fOVm_kbUVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_YBo9bC2_zEW-HCuFI8kpXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_th5gLhVhr0ODI3lXcg-R3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3v-L0Vww2EuNWdV3-uHeDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_PMJBCIy7IECiFkjfjmaUzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ng_SQm0kE0GmhyCm9FCUWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zyoQf6ApEUqf3zXcyWmu_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TadyAKEHAkuV3__epaLGSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hxgRGUCPFUSaOcTTwES4QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_X3OFdmWYO06HF_9VjwDAbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_n8y0wI3G0kq3oR95Yq0yng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_iLQLrl8HzEq0ISsfhi5yuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VF70Yp-79UiP9lmggMs1vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ldCXzpF9akqsXBzaD9hxuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_je2iAxI6uUyI9xWXJ3NNKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EqHsm_Ei50WL1NlCKjVHOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_qpOCxF4gTE6XGswl1hQRNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_S4-V_keLEEabfoR9Fvi4Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_Edowbx1RqE2mAginFGRXDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_N5YIECe8E0C6IWg8obbENA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gec80tyUmkKY9InWUPJo7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QT17Poc1lk2rEi5HuNqx_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IK179fae_0q0Zg4c_AZHEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f4zBuaboQUKb6pXCfGs0MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_j8MHpbryDkKr6iuxL4IoLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_D_s-_E21uUaiUOWarzVcYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_GvxISMo_UkG51ag9NMnfUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aLLtLfhuF06YDmKVCRRdMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_4Zo0UeZYZUeUnyTVN-VWXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_8v_3XroY3UqA5FYoxvPiFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ORSwgOFEv0uBzO5uoRPJVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rqkDVECDp0uGDqsfOos4Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_JXd_9rzC90CP0igSJTsrdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jWEJG3qYf0OkSzZNmxWzdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Pt94Ra0jTUOM2_6JUiOKAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QmfRiBqenki9xaGwjiWv6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2022_To_11_21_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_EnsamhLSDEaWLpf-NafDRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_J3mRtOXpPUaCPK6vvI1eRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2024_k3qOTrtuaUOAFMh--lps5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A"><xbrli:measure>xoma:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_SNQEGGFW5kSKzKYrmjywPQ"><xbrli:measure>xoma:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_mzQmqJqZD0WOAo7brJv5KA"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ"><xbrli:measure>xoma:period</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A"><xbrli:measure>xoma:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_facility_D1loseD-e06fL52LV83oPQ"><xbrli:measure>xoma:facility</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w"><xbrli:measure>xoma:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_M_kyg1xo-wAkyvlL2hegB1iw"><xbrli:measure>xoma:M</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA"><xbrli:measure>xoma:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_m_JT2gZUYEyv5yGMX4336Q"><xbrli:measure>xoma:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_f7Yhi2gHBEKf5DFUnXrd8A"><xbrli:measure>xoma:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Right_7KYt940OV0yye1Z67B4qbA"><xbrli:measure>xoma:Right</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_payment_MZwTcjQqtk6l27rvf283Rw"><xbrli:measure>xoma:payment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw"><xbrli:measure>xoma:item</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_259eaaee_3783_4894_bc17_f8cc1f876ec6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentType" id="Narr_466S7tayZ0mF5n5tXlVbhw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentAnnualReport" id="Narr_wE-Dju-8yEmIn4GaAhU5zg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 or 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentPeriodEndDate" id="Narr_S7sKYPGvF0uB1vyIzWH3hQ"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:CurrentFiscalYearEndDate" id="Narr_tJJWT-p-J0eVkpz41nohpg"><b style="font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-weight:bold;">, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentTransitionReport" id="Narr_tmYK7FPXYk6TdmauGmgHPQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES&#160;EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><b style="font-weight:bold;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Commission File Number:&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityFileNumber" id="Narr_eJ2N0lNlh0a3numFc2YP3Q"><b style="font-weight:bold;">001-39801</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityRegistrantName" id="Narr_d0gkpR5nFEylTxErD4P0BQ"><b style="font-weight:bold;">XOMA CORPORATION</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5fd3dc42_cb01_45f8_86b7_5452446139c4"></a><a id="Tc_1r4WXCubI0yZ0AfPtI-aAA_1_0"></a><a id="Tc_XM2O4ougWUGyVkFYnTDMcQ_1_1"></a><a id="Tc_TDg1xyM2qE-d71n7re91QA_3_0"></a><a id="Tc_1HstfeSqcEm4KhGdN4PC7w_4_0"></a><a id="Tc_9ImPxe6BfEOcnR2xBeXdMQ_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityIncorporationStateCountryCode" id="Tc_o6SCdu1jnkuKHhkyhKENRA_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityTaxIdentificationNumber" id="Tc_StL3qz4pc0GCDvlKtiLcFg_0_1"><b style="font-size:9pt;font-weight:bold;">52-2154066</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b> <b style="font-weight:bold;">of incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityAddressAddressLine1" id="Narr_AkAl88uA1EuR2c5Oxv-BpQ"><b style="font-size:9pt;font-weight:bold;">2200 Powell Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityAddressAddressLine2" id="Narr_0iS4ixk6bUShJgyqvBfJIg"><b style="font-size:9pt;font-weight:bold;">Suite 310</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">,</b><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityAddressCityOrTown" id="Narr_IcFmRKgwSEGJTnfqJmzTUg"><b style="font-size:9pt;font-weight:bold;">Emeryville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityAddressStateOrProvince" id="Narr_eDfk-ck1NEii4LDhgKUN5g"><b style="font-size:9pt;font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityAddressPostalZipCode" id="Tc_YgK0t6J2QkGQEpUwBaEUvw_3_1"><b style="font-size:9pt;font-weight:bold;">94608</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:CityAreaCode" id="Narr_JQI9W1fjpE6hQQ-qR2bg1Q"><b style="font-size:9pt;font-weight:bold;">510</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:LocalPhoneNumber" id="Narr_g2qSA0xZKUWkVI6tluHotQ"><b style="font-size:9pt;font-weight:bold;">204-7200</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act: </p><a id="_c788aa25_9f64_47a4_8bef_62a9f20bc0f8"></a><a id="Tc_M_7NGegTbUWXfAKtpOQzGA_1_0"></a><a id="Tc_qmBmGriCt0ioHBnpPcfytA_1_2"></a><a id="Tc_2KUYqkgpfkKzgk5gmj_4eA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:15%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading&#160;Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A" name="dei:Security12bTitle" id="Tc_-oMOG-27ZEaSYdQQ9Sx9KA_2_0"><span style="font-size:9pt;">Common Stock, par value $0.0075 </span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A" name="dei:TradingSymbol" id="Tc_vOwLVO3rxkOewbTfPrI-gQ_2_2"><span style="font-size:9pt;">XOMA</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A" name="dei:SecurityExchangeName" id="Tc_phFjUC4x2EmgG9oUypGKdw_2_4"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg" name="dei:Security12bTitle" id="Tc_xsHp9vxQI0SbIdoifqwAFQ_3_0"><span style="font-size:9pt;">8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg" name="dei:TradingSymbol" id="Tc_e1CvUTgUSEmyJZiCpgT4kQ_3_2"><span style="font-size:9pt;">XOMAP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg" name="dei:SecurityExchangeName" id="Tc_lpicWM0BwkiHNoq3B61Rcw_3_4"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw" name="dei:Security12bTitle" id="Tc_3OlNHqVxmEOvF_xD-4otjA_4_0"><span style="font-size:9pt;">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw" name="dei:TradingSymbol" id="Tc_Srm7AuxMAECmOnjw5CVe-w_4_2"><span style="font-size:9pt;">XOMAO</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw" name="dei:SecurityExchangeName" id="Tc_So6VuolrCUuLjUIuLrgedA_4_4"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;"> </span><span style="-sec-ix-hidden:Hidden_uT0ww-rbBkm3D_j4aRlKvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">NO</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;YES&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;</span><span style="-sec-ix-hidden:Hidden_2NQIBaFfIUCjiruzEJ2Apw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">NO</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span style="-sec-ix-hidden:Hidden_khMIdZhyK0mu3RvV6oGr0w;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">YES</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;NO&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;</span><span style="-sec-ix-hidden:Hidden_2cFVKmg_YkSIZ76d2oSJ8g;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">YES</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;NO&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_abed4513_41e2_4106_8eca_7f7505653c9d"></a><a id="Tc_Dhtpm3HpOkaCi-ZnbswV7A_0_0"></a><a id="Tc_2ACvx-b7ZU2P0JYDBXGY8A_0_1"></a><a id="Tc_mYrSrO6HrkeK736DT9uStA_0_3"></a><a id="Tc_oInT2nieQkyUqBn0i_m1-Q_0_4"></a><a id="Tc_EaNKXwte3kyWglQHwZdc6Q_1_1"></a><a id="Tc_2muNRFlNWE6AW8XjmNClcA_1_3"></a><a id="Tc_lfYfUnYwIkOjUjryDqUgTQ_2_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityFilerCategory" id="Tc_5bqlZeEEsE2TzGkQRcFb4A_1_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntitySmallBusiness" id="Tc_ibPZu0Jos0S4Ff85Qc9O8w_1_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityEmergingGrowthCompany" id="Tc_V5oBC9J5R0WRTyp-RcHNRg_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:9pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:IcfrAuditorAttestationFlag" id="Narr_Hus5j5zwhE221bGnImQ3oQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_yMVnjcTkLEawhQNhLUgjUQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;YES&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:EntityShellCompany" id="Narr_UiJjieCTxEiQfr12_Yw5LA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;NO&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Global Market on June&#160;30, 2023, was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2023_J3mRtOXpPUaCPK6vvI1eRA" decimals="0" name="dei:EntityPublicFloat" id="Narr_AXJpupWrK0iSjmDURxb6XQ">123,749,750</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 4, 2024 was <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_4_2024_k3qOTrtuaUOAFMh--lps5A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_uoaRRvrAi0CH4ESA5k_uHw">11,625,826</ix:nonFraction>.<span style="background:#00ff00;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cc620864_4cea_40cb_bdb6_0a5e41ee7d4f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">2023 FORM&#160;10-K ANNUAL REPORT</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#GLOSSARYOFTERMSANDABBREVIATIONS_784176"><span style="font-style:normal;font-weight:normal;">Glossary of Terms and Abbreviations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_220029"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1Business_495058"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1Business_495058"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item 1A</span></a>.</p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1BUnresolvedStaffComments_868310"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1BUnresolvedStaffComments_868310"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1CCYBERSECURITYRISKMANAGEMENTSTRATEG"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1CCYBERSECURITYRISKMANAGEMENTSTRATEG"><span style="font-style:normal;font-weight:normal;">Cybersecurity </span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item2Properties_752211"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item2Properties_752211"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item3LegalProceedings_945310"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item3LegalProceedings_945310"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_972169"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_972169"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_531471"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item6SelectedConsolidatedFinancialData_8"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item6SelectedConsolidatedFinancialData_8"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9AControlsandProcedures_282993"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9AControlsandProcedures_282993"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_968719"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_968719"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_322550"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersCorporat"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersCorporat"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item11ExecutiveCompensation_327220"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item11ExecutiveCompensation_327220"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_208578"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item16Form10KSummary_564652"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item16Form10KSummary_564652"><span style="font-style:normal;font-weight:normal;">Form 10</span><span style="font-style:normal;font-weight:normal;">&#8209;</span><span style="font-style:normal;font-weight:normal;">K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_975745"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6f3d4e26_cbdb_4c58_8137_5ba4f481949f"></a><a id="GLOSSARYOFTERMSANDABBREVIATIONS_784176"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">GLOSSARY OF TERMS AND ABBREVIATIONS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:71.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Abbreviations</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:71.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">2010 Plan</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's 2010 Long Term Incentive and Stock Award Plan, as amended</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">2018 Common Stock ATM Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">At The Market Issuance Sales Agreement with HCW dated December 18, 2018</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">&#8216;40 Act</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Investment Company Act of 1940</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">AAA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Assignment and Assumption Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ACA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Affimed</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Affimed N.V.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Affitech</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Affitech Research AS</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Affitech CPPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Agenus</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Agenus, Inc. and certain affiliates</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Agenus RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Company's Royalty Purchase Agreement with Agenus dated September 20, 2018</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Alora</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Alora Pharmaceuticals</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Anti-TGF&#946; Antibody License Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Company's License Agreement with Novartis dated September 30, 2015</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">April 2022 Letter Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Letter Agreement to Officer Employment Agreement dated August 7, 2017, between XOMA Corporation and Thomas Burns dated April 1, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Aptevo</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Aptevo Therapeutics Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Aptevo CPPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Company&#8217;s Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as &#8220;Aptevo Commercial Payment Purchase Agreement&#8221; or &#8220;Aptevo CPPA&#8221;</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Aronora</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Aronora, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Aronora RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Royalty Purchase Agreement with Aronora dated April 7, 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">AstraZeneca</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">AstraZeneca plc</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Accounting Standards Codification</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 310</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC Topic 310, Receivables</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 326</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">ASC Topic 326, Financial Instruments &#8211; Credit Losses </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 450</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC Topic 450, Contingencies</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 606</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC Topic 606, Revenue from Contracts with Customers</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 805</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC Topic 805, Business Combinations</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 815</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC Topic 815, Derivatives and Hedging</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC 842</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASC Topic 842, Leases</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ASU</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Accounting Standards Update</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Bayer</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Bayer Pharma AG</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Bioasis</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Bioasis Technologies, Inc. and certain affiliates</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Bioasis RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Royalty Purchase Agreement with Bioasis dated February 25, 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">BLA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Biologic License Application</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Black-Scholes Model</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Black-Scholes Option Pricing Model</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Blue Owl</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Blue Owl Capital Corporation </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Blue Owl Loan</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Loan pursuant to the Blue Owl Loan Agreement </p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Blue Owl Loan Agreement </p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;">Loan agreement dated as of December 15, 2023, between XRL, the lenders from time to time party thereto and Blue Owl, as administrative agent </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Board</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Company&#8217;s Board of Directors</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">B. Riley</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">B. Riley Securities, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">BVF</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Biotechnology Value Fund, L.P.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">CCPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">California Consumer Privacy Act of 2018, collectively the Act and its regulations</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">CARES</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Coronavirus Aid, Relief, and Economic Security</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">cGMP</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">current Good Manufacturing Practice</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chiesi</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chiesi Farmaceutici S.p.A.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Company</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">XOMA Corporation, including its subsidiaries</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">CPPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Commercial Payment Purchase Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">CPRA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">California Privacy Rights Act</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="font-size:10pt;">Dsuvia</span><span style="font-family:'Segoe UI';">&#174;</span></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">sufentanil sublingual tablet</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">DoD</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">U.S. Department of Defense</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">EC</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">European Commission</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">EMA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">European Medicines Agency</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ESPP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">2015 Employee Stock Purchase Plan, as amended</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">EU</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">European Union</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">FCPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">U.S. Foreign Corrupt Practices Act of 1977, as amended</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">FDA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">U.S. Food and Drug Administration</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">FDCA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The Federal Food, Drug, and Cosmetic Act</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">FDIC</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Federal Deposit Insurance Corporation</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">GAAP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Generally accepted accounting principles</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">G&amp;A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">General and administrative</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">GDPR</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">General Data Protection Regulation</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Gevokizumab License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Company's License Agreement with Novartis dated August 24, 2017</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">HCRP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Healthcare Royalty Partners II, L.P.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">HCW</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">H.C. Wainwright &amp; Co., LLC</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">HIPAA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Federal Health Insurance Portability and Accountability Act of 1996</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">ICE&#174;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Innate cell engager</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">ImmunityBio</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ImmunityBio, Inc. (formerly NantCell, Inc.)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">ImmunityBio License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Out-license agreement to ImmunityBio from LadRx dated July 27, 2017, related to the development and commercialization of Aldoxorubicin, as amended on September 27, 2018 </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">IP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Intellectual Property</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Janssen</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Janssen Biotech, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Kinnate</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Kinnate Biopharma Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Kuros</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC, collectively</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Kuros RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Royalty Purchase Agreement with Kuros dated July 14, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">LadRx</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">LadRx Corporation (formerly CytRx Corporation)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">LadRx Agreements </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">LadRx AAA and LadRx RPA</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">LadRx AAA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company&#8217;s Assignment and Assumption Agreement with LadRx dated June 21, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">LadRx RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company&#8217;s Royalty Purchase Agreement with LadRx dated June 21, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Medexus</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Medexus Pharmaceuticals, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Merck</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Merck Sharp &amp; Dohme Corp</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Merck KGaA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Ares Trading SA </p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Merck KGaA License Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva IP Acquisition Agreement)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">NDA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">New Drug Application</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">NIH</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">National Institutes of Health</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">NOL</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">net operating loss</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Novartis</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">November 2022 Letter Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">November 1, 2022 amendment to the April 2022 Letter Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ObsEva</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ObsEva SA</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">ObsEva IP Acquisition Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Company's IP Acquisition Agreement with ObsEva dated November 21, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Ology Bioservices </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Organon</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Organon International GmbH</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Organon License Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Out-license agreement to Organon from ObsEva dated July 26, 2021, related to the development and commercialization of ebopiprant (assumed by the Company as part of the ObsEva IP Acquisition Agreement)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Palo</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Palobiofarma, S.L.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Palo RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Royalty Purchase Agreement with Palo dated September 26, 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Pfizer</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Pfizer, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">PSU</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Performance stock unit</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">R&amp;D</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Research and development</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Regeneron</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Regeneron Pharmaceuticals, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Amended Retention Plan</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">October 25, 2022 amendment to the Retention Plan</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Retention Plan</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Retention and Severance Plan dated March 31, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Rezolute</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Rezolute, Inc., formerly Antria Bio, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Rezolute License Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019 and March 2020</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Royalty Purchase Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Roche</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">F. Hoffmann-La Roche AG</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">SEC</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">U.S. Securities and Exchange Commission</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Second Bioasis RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Royalty Purchase Agreement with Bioasis dated November 2, 2020</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the 8.625% Series A cumulative, perpetual preferred stock issued in December 2020</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the 8.375% Series B cumulative, perpetual preferred stock issued in April 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Series A and Series B Preferred Stock</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Series A Preferred Stock and Series B Preferred Stock, collectively<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Series B Depositary Shares</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the depositary shares, each representing 1/1000th interest in a share of Series B Preferred Stock</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Sonnet</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Sonnet BioTherapeutics, Inc., formerly Oncobiologics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Sonnet Collaboration Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Collaboration Agreement with Sonnet dated July 23, 2012, as amended in May 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">SOX</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Sarbanes-Oxley Act of 2002</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">SVB</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Silicon Valley Bank</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Takeda</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Takeda Pharmaceutical Company Limited</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Takeda Collaboration Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">the Company's Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Talphera</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Talphera, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">TGF&#946;</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">transforming growth factor beta</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">U.S.</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">United States</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">VABYSMO&#174;</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">faricimab-svoa</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Viracta</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Viracta Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Viracta RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company's Royalty Purchase Agreement with Viracta dated March 22, 2021, as amended March 4, 2024<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">XOMA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">XOMA Corporation, a Delaware corporation, including subsidiaries </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">XRL </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">XRL 1 LLC, a wholly-owned subsidiary of XOMA </p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Zevra</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Zevra Therapeutics, Inc. (formerly KemPharm Denmark A/S)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;">Zevra APA </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Asset Purchase Agreement dated May 13, 2011 between LadRx and Orphazyme ApS, and assigned to Zevra as of June 1, 2022, related to the sale of arimoclomol from LadRx to Zevra (assumed by the Company as part of LadRx AAA)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_220029"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Annual Report on Form&#160;10-K contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, (the &#8220;Securities Act&#8221;), Section&#160;21E of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), and the Private Securities Litigation Reform Act of 1995, which are subject to the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements are based on current expectations, estimates and forecasts, as well as our management&#8217;s beliefs and assumptions and on information currently available to them, and are subject to risks and uncertainties that are difficult to predict. In some cases you can identify forward-looking statements by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;intend&#8221; &#8220;goal,&#8221; &#8220;strategy,&#8221; &#8220;continue,&#8221; &#8220;design&#8221; and similar words, expressions or the negative of such terms intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: trend analyses and statements regarding future events, future financial performance, anticipated growth, and industry prospects, our future operating expenses, our future losses, the success of our strategy as a royalty aggregator, the assumptions underlying our business model, the extent to which issued and pending patents may protect the products and processes in which we have an ownership or royalty interest and prevent the use of the covered subject matter by third parties, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the amount and timing of receipt of those payments, our ability to locate suitable assets to acquire, our ability to complete (on a timely basis or at all) and realize the benefits from acquisitions, uncertainties related to the acquisition of interest in development-stage and clinical-stage product candidates, fluctuations in, our ability to predict our operating results and cash flows, and the sufficiency of our capital resources. Forward-looking statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s); we may be unable to retain our key employees; litigation, arbitration or other disputes with third parties may have a material adverse effect on us; our product candidates subject to our out-license agreements are still being developed, and our licensees&#8217; may require substantial funds to continue development which may not be available;</i> <i style="font-style:italic;">we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; and we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties. These and other risks, and uncertainties that may cause our actual results or outcomes to differ materially and adversely from those expressed in our forward-looking statements, including those related to current economic and financial market conditions, are identified below in Item&#160;1, Business; Item&#160;1A, Risk Factors; Item&#160;7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations; and other sections of this Annual Report on Form&#160;10-K. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. Except as required by law, we do not undertake any obligation to revise or update publicly any forward-looking statements after completion of the filing of this Annual Report on Form&#160;10-K to reflect later events or circumstances or to reflect the occurrence of unanticipated events, or otherwise.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">All references to &#8220;portfolio&#8221; in this Annual Report on Form 10-K are to milestone and/or royalty rights associated with a basket of product candidates in development.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">We use our trademarks, trade names and services marks in this Annual Report on Form 10-K as well as trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk88478613"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risk Factors Summary </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K as part of your evaluation of the risks associated with an investment in our securities. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our acquisitions of potential future royalty or milestone payments may not produce anticipated revenues.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not successfully complete or realize the expected business or financial benefits of our acquisitions or investments in companies that hold royalty assets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Many of our potential royalty acquisitions may be associated with product candidates that are in clinical development and have not yet been commercialized. If our potential royalty providers&#8217; therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Actual or threatened epidemics, pandemics, outbreaks of disease, or other public health crises, natural disasters, public health crises, political crises and other catastrophic events, and unstable market and macroeconomic conditions have and may in the future, adversely affect us, our licensees or royalty-agreement counterparties or their licensees. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Biopharmaceutical products are subject to sales risks and substantial competition and the volatility of the biotechnology industry may affect us indirectly as well as directly. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on our third parties for the determination of royalty and milestone payments. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect us. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have sustained losses in the past, and we expect to sustain losses in the foreseeable future. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our royalty aggregator strategy may require us to raise additional funds.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have an obligation to pay quarterly dividends to holders of our Series A Preferred Stock and Series B Preferred Stock, and these stockholders have rights senior to those of our common stockholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Information available to us about the intellectual property or biopharmaceutical products underlying the potential royalties we buy may be limited and our future income is dependent on numerous potential milestone and royalty-specific assumptions that may prove not to be accurate. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products, and the royalties that we acquire may fall outside the biopharmaceutical industry.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to successfully identify and acquire potential milestone and royalty streams, and we may not be able to successfully manage the risks associated with integration. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Biological products and product candidates of our potential milestone and royalty providers may face more intense competition or competition sooner than anticipated.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our potential royalty providers may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership, milestone, or royalty interest.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product liability claims may diminish the returns on biopharmaceutical products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We and our potential royalty providers may be unable to protect our or their intellectual property, and litigation regarding intellectual property can be costly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We and our partners rely heavily on license and collaboration relationships and our potential milestone and royalty providers may rely on other third parties to provide services. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The marketers of biopharmaceutical products are substantially responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain of our technologies are in-licensed from third parties, so our and our licensees&#8217; use of them may be restricted and subject to additional risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to attract and retain qualified personnel, and our employees may engage in misconduct or other improper activities. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our information technology systems or data or those of our partners or contractors could be compromised, and our actual or perceived failure to comply with any data privacy or security obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn, or it may be removed voluntarily from the market.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, and as we or our potential milestone and royalty providers do more business internationally, we expect to become subject to additional political, economic and regulatory uncertainties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our share price may be volatile, which may subject us to litigation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may issue additional equity securities from time to time, and we may sell additional debt securities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We can provide no assurance that we will, at all times, in the future be able to report that our disclosure controls and internal controls over financial reporting are effective.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Stockholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have an adverse effect on us.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item1Business_495058"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1.&#160;BUSINESS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview and Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio was built through the acquisition of rights to future milestones, royalties and commercial payments since our royalty aggregator business model was implemented in 2017 combined with out-licensing our proprietary products and platforms from our legacy discovery and development business. Our royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to larger pharmaceutical partners. We also acquire milestone and royalty revenue streams on late-stage clinical assets or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to us in a short timeframe. We expect most of our future revenue to be based on payments we may receive for milestones and royalties associated with these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our strategy is to expand our portfolio by acquiring additional potential milestone and royalty revenue streams from product candidates from third parties. We believe that expanding our portfolio through these acquisitions allows for further diversification across therapeutic areas and development stages. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Royalty Portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables highlight key assets included in our portfolio of potential future milestone and royalty payment streams. These tables do not include all assets because certain assets are subject to confidentiality agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Key Portfolio Assets</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.37%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:22.87%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:26.09%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:21.35%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:28.8%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:22.87%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMPANY</b></p></td><td colspan="2" style="vertical-align:middle;width:26.09%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSET NAME</b></p></td><td colspan="2" style="vertical-align:middle;width:21.35%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TARGET</b></p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ROYALTY RATE</b></p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Alora </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DSUVIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (sufentanil sublingual tablet)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Symbol';">m</span>receptors</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15% (Commercial)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">37.5-75% (DoD)</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Day One</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DAY101 (tovorafenib)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pan-RAF</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Janssen Biotech</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">JNJ-63723283 (cetrelimab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PD-1</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.75%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Medexus</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IXINITY<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> [coagulation factor IX (recombinant)]</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor IX</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Rezolute</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RZ358</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSR</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit to mid-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Roche</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VABYSMO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (faricimab-svoa)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Angiopoietin-2 and VEGF-A</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.5%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Takeda</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TAK-079 (mezagitamab) </p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD-38</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Zevra</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">arimoclomol</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Heat-shock protein 70 </p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Large pharma assets</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.37%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:22.87%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:26.09%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:21.35%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:28.8%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:22.87%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMPANY</b></p></td><td colspan="2" style="vertical-align:middle;width:26.09%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSET NAME</b></p></td><td colspan="2" style="vertical-align:middle;width:21.35%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TARGET</b></p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ROYALTY RATE</b></p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AstraZeneca</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AZD2936</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIGIT/PD-1</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Bayer </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BAY-1213790 (osocimab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor XIa</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LG Chem (AVEO Oncology)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AV-299 (ficlatuzumab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HGF</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Novartis </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CFZ533 (iscalimab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD-40</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit to low-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Regeneron</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMP-001 (vidutolimod)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TLR9</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit to double-digit</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Biotech assets</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.37%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:22.87%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:26.09%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:21.35%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:28.8%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:22.87%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMPANY</b></p></td><td colspan="2" style="vertical-align:middle;width:26.09%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSET NAME</b></p></td><td colspan="2" style="vertical-align:middle;width:21.35%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TARGET</b></p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ROYALTY RATE</b></p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Affimed</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AFM13 (acimtamig)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD30/CD16A</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Affimed</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AFM24</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EGRF/CD16A</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aronora</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AB023 (gruticibart)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor XI</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aronora</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AB002 (E-WE thrombin)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">E-WE thrombin</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aronora</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AB054</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor XII</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AVEO Oncology</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AV-299 (ficlatuzumab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HGF</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Compugen</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COM902</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIGIT</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denovo Biopharma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">vosaroxin</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">topoisomerase II</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ImmunityBio</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">aldoxorubicin</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Albumin-linked formulation of doxorubicin</p></td><td colspan="3" style="vertical-align:middle;width:28.95%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digits to mid-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incyte </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INCAGN2385</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LAG-3</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low to mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incyte </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INCAGN02390</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIM-3</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low to mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Monopar Therapeutics</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MNPR-101</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">uPAR</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palobiofarma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-680</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A1 receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palobiofarma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-677</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A3 receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palobiofarma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-999</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A2a receptor/ Phosphodiesterase 10 (PDE-10)</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palobiofarma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-1129</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A2b receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palobiofarma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-1650</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A3 receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">National Resilience </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">G03-52-01</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Botulinum neurotoxins</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.08%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Rezolute</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RZ402</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plasma kallikrein</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquisitions &#8211; Commercial Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affitech Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we entered into the Affitech CPPA, pursuant to which we purchased a future stream of commercial payment rights to Roche&#8217;s VABYSMO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (faricimab-svoa) from Affitech for an upfront payment of $6.0 million. We are eligible to receive commercial payments from Roche consisting of 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. In 2022, VABYSMO was approved by the FDA and the EMA for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In 2022, pursuant to the Affitech CPPA, we paid Affitech $8.0 million in milestone payments tied to these marketing approvals.<span style="background:#ffffff;"> In October 2023, the FDA approved VABYSMO for the treatment of retinal vein occlusion.</span> &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Affitech CPPA, we received commercial payments totaling $7.3 million and $0.5 million in 2023 and 2022, respectively. Based on net sales of VABYSMO in 2023, we paid Affitech additional milestones totaling $6.0 million in March 2024, and we may pay up to an additional $6.0 million in milestones based on the achievement of certain sales thresholds in future periods.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aptevo Commercial Payment Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2023, we entered into the Aptevo CPPA, pursuant to which we acquired the full commercial payment stream and a portion of the milestone rights to IXINITY<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> [coagulation factor IX (recombinant)], which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. We expect to receive a mid-single digit percentage payment stream on all IXINITY sales from January 1, 2023 until the first quarter of 2035, and also expect to be entitled to receive milestone payments. Under the terms of the Aptevo CPPA, in 2023 we paid Aptevo a $9.6 million upfront payment plus a $50,000 one-time payment when the first commercial payment exceeded $0.5 million. </p><a id="_Hlk158224003"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Aptevo CPPA, we received commercial payments totaling $1.7 million in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Talphera Commercial Payment Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, we acquired an economic interest in DSUVIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (sufentanil sublingual tablet) from Talphera, for $8.0 million. DSUVIA was approved in 2018 by the FDA for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora Pharmaceuticals for an upfront payment, a 15% royalty on commercial net sales, a 75% royalty on net sales to the DoD, and up to $116.5 million in milestone payments. Under the terms of the agreement, we are entitled to receive 100% of all royalties and milestones related to DSUVIA sales until we receive $20.0 million. Once we receive $20.0 million, the 75% royalties generated from DoD purchases and the remaining $116.5 million in potential milestone payments due from Alora will be shared equally between us and Talphera. We will fully retain the 15% royalty associated with DSUVIA commercial sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Acquisitions - Pre-Commercial Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">LadRx Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we entered into the LadRx AAA pursuant to the which we acquired from LadRx all of its rights, title and interests related to arimoclomol under the Zevra RPA. We also entered into the LadRx RPA, pursuant to which we acquired the right to receive all of the future royalties, regulatory and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under the ImmunityBio License Agreement. The purchased rights related to arimoclomol include potential regulatory and commercial milestone payments of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. The purchased payments related to aldoxorubicin include potential regulatory and commercial milestone payments of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages for sales of other licensed products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the LadRx Agreements, we paid LadRx an upfront payment of $5.0 million. &#160;In January 2024, Zevra announced the FDA accepted its NDA resubmission for arimoclomol, and pursuant to the LadRx RPA, we paid LadRx a $1.0 million milestone payment. We may pay up to an additional $1.0 million commercial milestone payment related to arimoclomol and an additional $4.0 million regulatory milestone payment related to aldoxorubicin. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement</p><a id="_Hlk95249032"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, we entered into the Kuros RPA, pursuant to which we acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. We may pay additional sales-based milestone payments to Kuros of up to $142.5 million, representing a portion of the future royalties on commercial sales.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk107915979"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, we were entitled to 50% of the milestone payment, which we received in July 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, we entered into the Viracta RPA, pursuant to which we acquired the right to receive future royalties, milestone payments, and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma. We acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestone payments and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, we earned a $5.0 million milestone payment related to the FDA&#8217;s acceptance of Day One Biopharmaceuticals&#8217; NDA for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2018, we entered into the Agenus RPA, pursuant to which we acquired the right to receive 33% of the future royalties due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and sales milestone payments on sales of certain Incyte immuno-oncology assets. In addition, we acquired the right to receive 33% of the future royalties due to Agenus from Merck and 10% of all future developmental, regulatory and sales milestone payments on sales of MK-4830, an immuno-oncology product. Pursuant to the Agenus RPA, our share in future potential development, regulatory and commercial milestones is up to $59.5 million, and the royalties have no limit. Under the terms of the Agenus RPA, we paid Agenus an upfront payment of $15.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development. As a result of the advancement, Agenus earned a $10.0 million clinical development milestone payments pursuant to its license agreement with Merck, of which we received $1.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aronora Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2019, we entered into the Aronora RPA, pursuant to which we acquired the rights to potential royalties and a portion of upfront, milestone, and option payments associated with five anti-thrombotic hematology product candidates in development: three candidates subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;) and two additional early-stage candidates (the &#8220;non-Bayer Products&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, we made a $6.0 million upfront payment to Aronora&#160;when the transaction closed in June 2019, and in September 2019 we made an additional $3.0 million payment for the three Bayer Products that were active as of September 2019. Pursuant to the Aronora RPA, if we receive at least $25.0 million in cumulative royalties on net sales per product, we will be required to pay associated tiered milestones payments to Aronora in an aggregate amount of up to $85.0 million per product. The tiered milestones will be paid based on various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. We will retain royalties per product in excess of $250.0 million. We are also entitled to receive, on average, low single-digit royalties on future sales of the Bayer Products and 10% of all future developmental, regulatory and sales milestones related to the Bayer Products. In addition, we purchased from Aronora the right to receive a low single-digit percentage of net sales of the non-Bayer Products and 10% of all future payments, including upfront payments, option payments and developmental, regulatory and sales milestone payments on potential future sales of the non-Bayer Products. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, we entered into the Palo RPA, pursuant to which we acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis, nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Under the terms of the Palo RPA, we paid Palo an upfront payment of $10.0 million for the rights to potential royalty payments on future potential sales of the Palo Licensed Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">ObsEva Intellectual Property Acquisition Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we entered into the ObsEva IP Acquisition Agreement pursuant to which we acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. We also assumed ObsEva&#8217;s ongoing obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, we were eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones, and royalties that range from low to mid-teens from Organon. If ebopiprant was successfully commercialized, we would have been required to make mid-single-digit royalty payments to Merck KGaA. We paid ObsEva a $15.0 million upfront payment at closing and would have paid potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what we would have received pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 23, 2023, Organon notified us of its intent to terminate the Organon License Agreement, which we assumed pursuant to the ObsEva IP Acquisition Agreement. The termination was effective as of January 21, 2024, and we will not be entitled to any milestone payments with respect to any milestone achieved by Organon following the notice of termination. We evaluated the related intangible asset balance for impairment and recorded an impairment charge of $14.2 million as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2019, we entered into the Bioasis RPA, pursuant to which we acquired future milestone, royalty and option fee payment rights from Bioasis for product candidates that were being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. Under the terms of the Bioasis RPA, we paid Bioasis an upfront cash payment of $0.3 million and would have been required to make contingent future cash payments of up to $0.2 million to Bioasis if and when the licensed product candidates reached certain development milestones. In November 2020, we entered into the Second Bioasis RPA, pursuant to which we acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. We paid Bioasis $1.2 million upon the closing of the Second Bioasis RPA for the purchased rights. In June 2023, Bioasis announced the suspension of all of its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. We do not expect to receive any milestone, royalty or other payments under the Biosis RPA or Second Bioasis RPA. In June 2023, we recorded an impairment charge of $1.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Selected Programs Underlying Our Portfolio </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of significant licenses and collaboration agreements related to our legacy product candidates and technologies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-CD40 Antibody </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2004, we entered into an exclusive, worldwide, multi-product collaboration agreement with Chiron to research, develop and commercialize multiple antibody product candidates for the treatment of cancer, and such agreement was replaced with the Chiron Collaboration Agreement entered into in May 2005. The Chiron Collaboration Agreement was a risk-sharing arrangement whereby Chiron and we shared expenses and revenues on a 70-30 basis, with our share being 30%. It included a loan facility from Chiron to us, secured by our 30% ownership interest in the collaboration, of up to $50.0&#160;million to fund up to 75% of our share of expenses beginning in 2005. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2005, Chiron announced it had entered into a definitive merger agreement with Novartis under which Novartis acquired all of the remaining outstanding shares of Chiron. This transaction closed in 2006 at which time Novartis acquired Chiron&#8217;s interest in the Chiron Collaboration Agreement. In July 2008, Novartis and we restructured the Chiron Collaboration Agreement, which involved six development programs including iscalimab, a fully human anti-CD40 antagonist antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases. As part of the restructuring, Novartis, as successor to Chiron, was granted, among other things, control over the product development collaborations remaining thereunder, including iscalimab. In September 2015, we and Novartis agreed to reduce the royalty-style payments that we were eligible to receive on sales of Novartis&#8217; clinical-stage anti-CD40 antibodies (such as iscalimab). These royalty-style payments were previously tiered based on sales levels, and were amended to have percentage rates ranging from mid-single-digit to low teens. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in kidney transplant. In September 2022, after an interim analysis of data, Novartis also decided to discontinue its study of CFZ533 in liver transplant. Novartis is continuing iscalimab studies in other indications, such as Sj&#246;gren&#8217;s Syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our right to royalty-style payments expires on the later of&#160;the expiration of any licensed patent covering each product or&#160;10&#160;years from the first commercial sale of each product in each country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2006, we entered into the Takeda Collaboration Agreement with Takeda under which we agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Takeda Collaboration Agreement, we may receive additional milestone payments of an aggregate of up to $19.0 million relating to TAK-079 (mezagitamab) and a 4% royalty on future sales of all products subject to this license. Our right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. Our right to receive royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, we expanded our existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. We may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. Our right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. Our right to royalties expires on the later of 10&#160;years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab, and we earned a $2.0 million milestone payment from Takeda. We are eligible to receive remaining milestone payments of up to a total of $16.0 million under the Takeda Collaboration Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, Molecular Templates, Inc. assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development per the terms of its terminated collaboration agreement with Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, we earned a development milestone of $0.8 million pursuant to the Takeda Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2017, we entered into a license agreement with Rezolute pursuant to which we granted an exclusive global license to Rezolute to develop and commercialize RZ358 (previously known as &#8220;X358&#8221;) products for all indications. In addition, we entered into a common stock purchase agreement with Rezolute pursuant to which Rezolute agreed to issue to us, as consideration for receiving the license for RZ358, a certain number of its common stock in connection with any future equity financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to us of up to an aggregate of $232.0&#160;million based on the achievement of pre-specified criteria. Under the license agreement, we are also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the later of the date of expiration of the last valid patent claim covering the product in each country, or&#160;12 years&#160;from the date of the first commercial sale of the product in each country. Rezolute&#8217;s future royalty obligations in the U.S. will be reduced by&#160;20% if the manufacture, use or sale of a licensed product is not covered by a valid patent claim, until such a claim is granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, we are eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical study. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of&#160;12 years&#160;from the date of the first commercial sale of the product in each country or for so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in each country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on&#160;ninety days&#8217; notice at any time. To the extent permitted by applicable laws, we have the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No&#160;consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to us upon the occurrence of any future equity financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement, as amended, we received a total of $6.0&#160;million upon Rezolute&#8217;s equity financing activities and $8.5&#160;million in installment payments through October 2020. We also received&#160;161,861 shares of common stock of Rezolute (on an as-adjusted post reverse-split basis). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to us pursuant to the Rezolute License Agreement, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, Rezolute announced it had initiated a Phase 3 clinical study for RZ358 in congenital hyperinsulinism. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2019, we entered into an agreement with Janssen pursuant to which we granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including our patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to us. Additionally, for each product candidate, we are entitled to receive milestone payments of up to $3.0 million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, we are eligible to receive a 0.75% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, we earned a total of $1.5 million in milestone payments from Janssen, which included five milestone payments for IND filings and one milestone payment upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are subject to significant technological change. Some of the drugs our licensees or milestone and royalty partners are developing may compete with existing therapies or other product candidates in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our licensees&#8217; or royalty partners&#8217; competitors. There can be no assurance that developments by others, including, without limitation, the development of generics or biosimilars, will not render our licensees&#8217; or royalty partners&#8217; products or technologies obsolete or uncompetitive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, our royalty aggregator model faces competition on at least two fronts. First, there are other companies, funds and other investment vehicles seeking to aggregate royalties or provide alternative financing to development-stage biotechnology and pharmaceutical companies. These competitor companies, funds and other investment vehicles may have a lower target rate of return, a lower cost of capital or access to greater amounts of capital and thereby may be able to successfully acquire assets that we are also targeting for acquisitions. Second, existing or potential competitors to our partners and licensees&#8217; products, particularly large pharmaceutical companies, may have greater financial, technical and human resources than our licensees. Accordingly, these competitors may be better equipped to develop, manufacture and market products. Many of these companies also have extensive experience in preclinical studies and human clinical trials, obtaining FDA and other regulatory approvals and manufacturing and marketing pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the risks associated with our competitive environment, refer to Part I, Item&#160;1A, &#8220;Risk Factors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation and Environmental Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The research and development, manufacturing and marketing of pharmaceutical and biological products are subject to regulation by numerous governmental authorities in the U.S. and other countries. We and our partners and licensees, depending on specific activities performed, are subject to these regulations. In the U.S., pharmaceuticals and biological products are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and, for biological products, the Public Health Service Act, govern the testing, manufacture, safety, efficacy, purity, potency, labeling, storage, recordkeeping, approval, reporting, tracking and tracing, importing and exporting, and advertising, marketing and promotion of pharmaceutical and biological products, and there are other comparable laws and regulations that apply at the state level. Further, various other state and federal healthcare laws and regulations, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal data privacy and security laws and regulations, may also apply. There are similar regulations in other countries as well. For both currently marketed products and product candidates in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. Development-stage product candidates in our portfolio require approval by the FDA before we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">will recognize any royalties from sales. In addition, changes in existing regulations could have a material adverse effect on us or our partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the EU and other significant or potentially significant markets for our portfolio and product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services. In the U.S., the volume of drug pricing-related legislation has dramatically increased in recent years. For example, Congress has enacted laws requiring manufacturers to refund the Centers for Medicare &amp; Medicaid Services, or CMS, for certain discarded amounts of drugs from single-use vials beginning in 2023 and eliminating the existing cap on Medicaid rebate amounts beginning in 2024. Also, in August 2022 Congress enacted the Inflation Reduction Act of 2022, which, among other things, requires the Department of Health and Human Services to negotiate Medicare prices for certain drugs, imposes an inflation-based rebate on Medicare Part B and D utilization, restructures the Medicare Part D benefit and increases manufacturer contributions in some or all of the Medicare Part D benefit phases. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. In both the U.S. and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Further, many countries outside the U.S., including the EU member states, have established complex and lengthy procedures to obtain price approvals and coverage reimbursement and periodically review their pricing and reimbursement decisions. If any pricing-related regulation impacts products in our portfolio, it would result in lower royalties received by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe there are no significant compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we currently do not anticipate material capital expenditures arising from environmental regulation. We believe climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the risks associated with our compliance with government regulations, see Part 1, Item&#160;1A, &#8220;Risk Factors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Intellectual property is important to our business and our future income streams will depend in part on our partners and licensees&#8217; ability to obtain patents and to operate without infringing on the proprietary rights of others. We hold and have filed applications for a number of patents in the U.S. and internationally to protect our products and technology. We also have obtained or have the right to obtain licenses to, or income streams based on, certain patents and applications filed by others. However, the patent position of biotechnology companies generally is highly uncertain and consistent policy regarding the breadth of allowed claims has not emerged from the actions of the U.S. Patent and Trademark Office with respect to biotechnology patents. Accordingly, no assurance can be given that our, or our partners or licensees&#8217; patents will afford protection against competitors with similar products or that others will not obtain patents claiming aspects similar to those covered by our, or our partners&#8217; or licensees&#8217; patent applications. Some of our agreements, or those of our partners or licensees, contain &#8220;step-down&#8221; provisions where the royalty rate is reduced following patent expiration or revocation. Furthermore, there can be no assurance that our royalties will expire when expected. Any reductions in the duration of royalties relative to our estimates may adversely affect our financial condition and results of operations. Below is a list of representative patents and patent applications related to our licensed programs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:20.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:33.93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Licensee</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Program</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Representative</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Patents/Applications</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Subject Matter</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expected&#160;Last Expiration in Patent Family </b></p></th></tr><tr><td style="vertical-align:top;width:12.95%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rezolute</p></td><td style="vertical-align:top;width:13.72%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Anti-INSR</p></td><td style="vertical-align:top;width:20.43%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 9,944,698<br/>EP 2 480 254<br/>JP 5849050</p></td><td style="vertical-align:top;width:33.93%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insulin receptor-modulating antibodies having the functional properties of RZ358</p></td><td style="vertical-align:top;width:18.95%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:20.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:33.93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Licensee</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Program</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Representative</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Patents/Applications</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Subject Matter</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expected&#160;Last Expiration in Patent Family </b></p></th></tr><tr><td style="vertical-align:top;width:12.95%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.43%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,711,067</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 265 491A1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">WO2023225657A2*</p></td><td style="vertical-align:top;width:33.93%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody to the insulin receptor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RZ358 formulations</p></td><td style="vertical-align:top;width:18.95%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2036</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2043</p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ology Bioservices</p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Anti-BoNT</p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,821,879<br/>EP 2 473 191</p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Coformulations of anti- botulinum neurotoxin antibodies</p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.43%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.93%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.95%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Various</p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Phage display libraries</p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,546,307<br/>EP 2 344 686</p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XOMA phage display library components</p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2032</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AVEO</p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anti-HGF</p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 7,649,083**<span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"> </span></p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Human-Engineered anti-HGF antibodies and uses thereof</p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amolyt</p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Anti-PTH1R</p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,519,250</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 490 600A1</p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parathyroid Hormone Receptor 1 Antibodies and Uses Thereof</p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2037</p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Seeking out-license</p></td><td style="vertical-align:top;width:13.72%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Ebopiprant</p></td><td style="vertical-align:top;width:20.43%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,451,480*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP1 487 442*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">9,447,055*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">9,834,528*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">10,259,795*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 400 217*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">10,555,934 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">11,524,003 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 397 622 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11,534,428<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.93%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Generically covers ebopiprant &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ebopiprant; prodrug valine ester; method of synthesizing ebopiprant, method of treating or preventing preterm labor by administering ebopiprant&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treating pre-term labor or delaying onset of labor with&#160;Ebopiprant or prodrug valine ester plus an additional agent such as nifedipine or atosiban&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaying onset of delivery by administering ebopiprant and about 20mg of nifedipine</p></td><td style="vertical-align:top;width:18.95%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2036&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2037&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2039&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:4pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:4pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">* Jointly owned with Rezolute, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">** Jointly owned with AVEO Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">***Owned by Merck Serono S.A.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our partners and licensees may require certain licenses from others to develop and commercialize certain potential product candidates incorporating our technology. There can be no assurance that such licenses, if required, will be available on acceptable terms, if at all. If such licenses are obtained, our partners and licensees may be able to deduct some or all of the costs from the royalties they owe to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary information, in part, by confidentiality agreements with our employees, consultants and partners. These parties may breach these agreements, and we may not have adequate remedies for any breach. To the extent that we or our consultants or partners use intellectual property owned by others, we may have disputes with our consultants or partners or other third parties, as to the rights in related or resulting know-how and inventions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business model is dependent on third parties achieving specified development milestones and product sales. Our portfolio currently includes partner funded programs from which we could potentially receive royalties or other payments if the programs achieve marketability. A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in 1981 and redomiciled as a Bermuda-exempted company in December&#160;1998. Effective December&#160;31, 2011, we redomiciled from Bermuda to Delaware and changed our name from XOMA&#160;Ltd. to XOMA Corporation. References to the &#8220;Company&#8221; and &#8220;XOMA&#8221; before December&#160;31, 1998 or after December&#160;31, 2011, refer to XOMA Corporation, a Delaware corporation; references to the &#8220;Company&#8221; and &#8220;XOMA&#8221; between December&#160;31, 1998 and December&#160;31, 2011 refer to XOMA&#160;Ltd., a Bermuda company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 2200 Powell Street, Suite&#160;310, Emeryville, California 94608. Our telephone number at our principal executive offices is (510) 204-7200. Our website address is <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.xoma.com</span>. The information found on our website is not part of this or any other report filed with or furnished to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on a small number of skilled, experienced, and innovative employees to conduct the operations of our Company. As of March 4, 2024, we employed 13 full-time employees who were primarily engaged in executive, business development, legal, finance and administrative positions. We also utilize independent contractors and consultants to supplement our workforce. &#160;</p><a id="_Hlk88064321"></a><a id="_bca4699f_6efe_4427_90d2_353fba7ca873"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following risk factors and other information included in this Annual Report should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, also may impair our business operations. If any of the following risks or uncertainties occur, our business, financial condition, operating results and cash flows could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Royalty Aggregator Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;under the applicable license agreement(s)&#160;covering such potential royalties and/or milestones, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We routinely review opportunities to acquire future royalties, milestone payments and other payments related to drug development and sales as part of our royalty aggregator strategy or to acquire companies that hold royalty assets. Generally, at any time, we seek to have acquisition opportunities in various stages of active review, including, for example, our engagement of consultants and advisors to analyze particular opportunities, technical, financial and other confidential information, submission of indications of interest and involvement as a bidder in competitive auctions. Many potential acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from other royalty buyers and enterprises. These unsuccessful attempts to acquire new royalties could result in significant costs to us, could hurt our reputation and divert management and financial resources. Competition for future asset acquisition opportunities in our markets could increase the price we pay for such assets and could reduce the number of potential acquisition targets. The success of our acquisitions is based on our ability to make accurate assumptions regarding the valuation, probability, timing and amount of potential future royalty and milestone payments, as well as the viability </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the underlying technology and intellectual property. The failure of any of these acquisitions to produce anticipated revenues may materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of these acquisitions may expose us to credit risk in the event of a default by or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;that are parties to the applicable license agreement(s)&#160;covering the potential milestone and royalty streams being acquired. In addition, recent volatility in the capital markets, including financial institution instability, may limit our licensees or royalty-agreement counterparties&#8217; (or their licensees&#8217;) ability to access additional funding. While we generally try to structure our receipt of potential milestone and royalty payments to minimize the risk associated with such a default or bankruptcy, there can be no assurance that any such default or bankruptcy will not adversely affect our ability to receive future potential royalty and/or milestone payments. To mitigate this risk, on occasion we may obtain a security interest as collateral in such royalty, milestone and other payments. Our credit risk in respect of such counterparty may be exacerbated when the collateral held by us cannot be realized upon or is liquidated at prices not sufficient to recover the full amount we are due pursuant to the terms of the agreements covering the particular assets. This could occur in circumstances where the original collateral was not sufficient to cover a complete loss (e.g., our interests were only partially secured) or may result from the deterioration in value of the collateral, so that, in either such case, we are unable to recuperate our full capital outlay. Any such losses resulting therefrom could materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As we acquire and invest in companies that hold royalty assets, we may not realize the expected business or financial benefits and the acquisitions could prove difficult to integrate, disrupt our business, dilute stockholder value and adversely affect our operating results and the market value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may not be able to complete or realize the expected business or financial benefits from our potential acquisitions or investments in companies that hold royalty assets, including our planned acquisition of Kinnate. &#160;Acquisitions and other similar transactions, arrangements and investments involve numerous risks and could create unforeseen operating difficulties and expenditures, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that competing offers will be made; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential failure to successfully complete the acquisition or transaction in a timely manner, or at all, which may in turn, adversely affect us or our target&#8217;s business and the price of us or their respective common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential failure to achieve the expected benefits on a timely basis or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to integrate the acquired assets into our business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brand or reputational harm associated with our strategic investments or acquired companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges converting the acquired company&#8217;s revenue recognition policies and forecasting the related revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">division of financial and managerial resources from existing operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges entering into new markets in which we have little or no experience or where competitors may have stronger market positions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties and strain on resources in integrating acquired operations, technologies, assets and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory challenges from antitrust or other regulatory authorities that may block, delay or impose conditions (such as divestitures, ownership or operational restrictions or other structural or behavioral remedies) on the completion of transactions or the integration of acquired operations;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to fully assimilate, integrate or retrain acquired employees, which may lead to retention risk with respect to both key acquired employees and our existing key employees or disruption to existing teams;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to generate sufficient revenue to offset acquisition or investment costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges with the acquired company&#8217;s customers and partners, including the inability to maintain such relationships and changes to perception of the acquired business as a result of the acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential for acquired products to impact the profitability of existing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated expenses related to acquired assets or its integration into our business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">known and potential unknown liabilities associated with the acquired businesses, including due to litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in and financial costs of addressing acquired compensation structures inconsistent with our compensation structure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional stock-based compensation issued or assumed in connection with the acquisition, including the impact on stockholder dilution and our results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ineffective or inadequate controls, procedures and policies at the acquired company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the tax effects of any such acquisitions including related integration and business operation changes, and assessment of the impact on the realizability of our future tax assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these risks could harm our business or negatively impact our results of operations. In addition, to facilitate acquisitions or investments, we may seek additional equity or debt financing, which may not be available on terms favorable to us or at all, which may affect our ability to complete subsequent acquisitions or investments, and which may affect the risks of owning our common stock. For example, if we finance acquisitions by issuing equity or convertible or other debt securities or loans, our existing stockholders may be diluted, or we could face constraints related to the terms of, and repayment obligation related to, the incurrence of indebtedness that could affect the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our potential royalty acquisitions may be associated with product candidates that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of additional uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our royalty aggregator strategy, we may continue to purchase future potential milestone and royalty streams associated with product candidates which are in clinical development and have not yet received marketing approval by any regulatory authority or been commercialized. There can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products can be brought to market on a timely basis or at all, or that the market will be receptive to such products. To the extent that any such product candidates are not successfully developed and subsequently commercialized, the value of our acquired potential milestone and royalty streams may be negatively affected. The ultimate success of our royalty aggregator strategy depends on our ability to properly identify and acquire high quality products and the ability of the applicable counterparty to innovate, develop and commercialize their products, in increasingly competitive and highly regulated markets. Their inability to do so may negatively affect potential royalty and/or milestone payments. In addition, we are dependent, to a large extent, on third parties to enforce certain rights for our benefit, such as prosecution, maintenance and protection of a patent estate, adequate reporting and other protections, and their failure to do so could negatively impact our financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalty, the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market, which could negatively impact potential royalty and/or milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs, if such programs are continued at all. If other product developers introduce and market products that are more effective, safer, less invasive or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which may result in a loss for us. Losses from such assets could have a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to continue to pursue, and may expand, this strategy of acquiring development-stage product candidates. While we believe that we can reasonably evaluate the likelihood of a development-stage product candidate&#8217;s achievement of regulatory approval and potential sales, there can be no assurance that our assumptions, estimates, forecasts and expectations will prove correct. We may have limited information concerning the intellectual property or products generating the royalties we are evaluating for acquisition and therefore, there may be material information that relates to such intellectual property products that we do not have. In addition, market data that we obtain may also prove to be incomplete or incorrect. In addition, there can be no assurance that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market on a timely basis or at all, or that such products will achieve commercial success. Any of these factors could have a material effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or threatened epidemics, pandemics, outbreaks of disease, or other public health crises have and may in the future, adversely affect us and our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual or threatened epidemics, pandemics, outbreaks of disease, or other public health crises have in the past and may in the future adversely impact us, our licensees or royalty-agreement counterparties or their licensees, which have and could further cause delays, suspensions or cancellations of their drug development efforts including, without limitation, their clinical trials, which would correspondingly delay, suspend or negate the timing of our potential receipts of milestones and royalties under our out-licensing or royalty acquisition agreements. These disruptions to our licensees or RPA counterparties or their licensees could include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in recruiting and enrolling new patients in their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as their clinical trial sites and hospital staff supporting the conduct of their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring patient dosing and data analysis;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on the conduct of their clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption in global shipping that may affect the transport of clinical trial supplies and materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential refusal by the FDA to accept data, including from clinical trials in affected geographies or failure to comply with updated FDA guidance and expectations related to the conduct of clinical trials during the COVID-19 pandemic; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other delays in development of product candidates underlying our biopharmaceutical assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving approval from the FDA, the EMA and other U.S. and foreign federal, state and local regulatory authorities to initiate their planned clinical trials or to market their products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty accessing capital or credit markets on favorable terms, if at all, which could affect our ability to fund our business operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to sales risks. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, including lack of acceptance by healthcare programs or insurance plans, changes in our licensees&#8217; or royalty-agreement counterparties&#8217; strategic priorities, obsolescence, loss of patent protection, government regulations or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our future potential milestones and/or royalties may be reduced or cease. In addition, these potential payments may be delayed, causing our near-term financial performance to be weaker than expected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to substantial competition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a potential milestone or royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a potential milestone or royalty, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our potential milestones and royalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Competitive factors affecting the market position and success of each product include:</span>&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety and side effect profile; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price, including third-party insurance reimbursement policies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing and introduction of the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of marketing strategy and execution; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply and distribution; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property protections;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governmental regulation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of lower-cost generics and/or biosimilars; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment innovations that eliminate or minimize the need for a product; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical products that have the potential to generate future milestones and royalties for us may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products, more effective commercialization, or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. These developments could have a material adverse effect on the sales of the biopharmaceutical products that have potential to generate our milestones and royalties, and consequently could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties (and their licensees) for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties (and their licensees), our independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies, if available, to resolve any disputes resulting from any such audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The royalty, milestone and other payments we may receive are dependent on our licensees and royalty agreement counterparties and their licensees&#8217; achievement of regulatory and developmental milestones and product sales. Each licensee&#8217;s calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of its sales and accounting functions, and errors may occur from time to time in the calculations made by a licensee and/or a licensee may fail to report the achievement of royalties or milestones in whole or in part. Our license and royalty agreements typically provide us the primary or back-up right to audit the calculations and sales data for the associated royalty payments; however, such audits may occur many&#160;months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on our part. Further, our licensees and royalty-agreement counterparties (and their licensees) may be uncooperative or have insufficient records, which may complicate and delay the audit process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we intend to exercise our royalty audit rights as necessary and to the extent available, we rely in the first instance on our licensees and royalty-agreement counterparties (and their licensees) to accurately report the achievement of milestones and royalty sales and calculate and pay applicable milestones and royalties and, upon exercise of such royalty and other audit rights, we rely on licensees&#8217; and royalty-agreement counterparties&#8217; (and their licensees&#8217;) cooperation in performing such audits. In the absence of such cooperation, we may be forced to incur expenses to exercise legal remedies, if available, to enforce our agreements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally acquire milestone and royalty rights that have limited secondary resale markets and may be subject to transfer restrictions. The illiquidity of most of our milestone and royalty receivable assets may make it difficult for us to dispose of them at a favorable price if at all and, as a result, we may suffer losses if we are required to dispose of any or all such assets in a forced liquidation or otherwise. In addition, if we liquidate all or a portion of our potential future milestone and/or purchased royalty stream interests more quickly than planned or in connection with a forced liquidation, we may realize significantly less than the value we anticipate or at which we had previously recorded these interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;and interpretations of the SEC and the courts, relating to the definition of &#8220;investment company&#8221; are very complex. While we currently intend to conduct our operations so as not to be considered an &#8220;investment company,&#8221; and we do not believe we are an &#8220;investment company&#8221; under applicable SEC rules, we can provide no assurance that the SEC will not take the position that the Company is required to register under the &#8216;40 Act and comply with the &#8216;40 Act&#8217;s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. We monitor our assets and income for compliance under the &#8216;40 Act and seek to conduct our business activities in a manner such that we do not fall within its definitions of &#8220;investment company&#8221; or that we qualify under one of the exemptions or exclusions provided by the &#8216;40 Act and corresponding SEC regulations. However, if we were to be considered an &#8220;investment company&#8221; and become subject to the restrictions of the &#8216;40 Act, those restrictions likely would require significant changes in the way we do business and add significant administrative costs and burdens to our operations. Additionally, we may need to take various actions which we might otherwise not pursue in order to not come within scope of the &#8216;40 Act. These actions may include, among others, restructuring the Company and/or modifying our mixture of assets and income or a liquidation of certain of our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our licensees or royalty-agreement counterparties or their licensees could be subject to natural disasters, public health crises, political crises and other catastrophic events that could hinder or disrupt development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties and their licensees to successfully develop and commercialize product candidates for which we may receive milestone, royalty and other payments in the future. Our licensees and royalty-agreement counterparties and their licensees operate research and development efforts in various locations in the U.S. and internationally. If any of their facilities is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods, monsoons or wild fires, public health crises, such as pandemics and epidemics, geopolitical instability, crises such as terrorism, war, political instability, labor disputes or strikes, other conflict, including the ongoing conflict in Ukraine, conflict in the Middle East and surrounding areas and rising tensions between China and Taiwan, or other events outside of their control, their research and development efforts could be disrupted, which could result in the delay or discontinuation of development of one or more of the product candidates in which we have rights to future milestone and/or royalty payments which could have a material adverse effect on our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because many of the companies with which we do business also are in the biotechnology industry, the volatility of that industry can affect us indirectly as well as directly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Financial Results and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have sustained losses in the past, and we expect to sustain losses in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception. We generated net losses of $40.8 million and negative cash flows from operations of $18.2 million for the year ended December 31, 2023, and we had an accumulated deficit of $1.2 billion as of December 31, 2023. We do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily through the sale of equity securities and debt and royalty interests, and payments received under our collaboration and licensing arrangements. The size of our future net losses depends, in part, on the rate of our future expenditures and our and our partners&#8217; ability to generate revenues. If our partners&#8217; product candidates are not successfully developed or commercialized, or if revenues are insufficient following regulatory approval, we may not achieve profitability and our business may fail. Our ability to achieve profitability is dependent in large part on the success of our and our partners&#8217; ability to license product candidates, and the success of our partners&#8217; development programs, both of which are uncertain. Our success is also dependent on our partners&#8217; obtaining regulatory approval to market product candidates which may not materialize or prove to be successful. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and macroeconomic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, may have adverse consequences on our business, financial condition and stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The global credit and financial markets have experienced volatility, including as a result of trade and other international disputes, significant natural disasters (including as a result of climate change), new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotechnology industries), tighter credit, high interest rates, and economic inflation, which has included diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth or recession, high inflation, uncertainty about economic stability and changes in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of geopolitical instability, including military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the U.S. and other countries in response to such conflicts, including the one in Ukraine and the Middle East, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could heighten market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our royalty aggregator strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. Failure to secure any necessary financing in a timely manner could have a material adverse effect on our growth strategy, financial performance and stock price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank, Signature Bank and Silvergate Capital Corp. were each swept into receivership. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships but could also include factors involving financial markets or the financial services industry generally.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require us to raise additional funds to acquire<span style="font-style:normal;font-weight:normal;"> </span>milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may need to commit substantial additional funds to continue our business, and we may not be able to obtain sufficient funds on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult and more costly. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us and/or result in dilution to our stockholders, including pursuant to our 2018 Common Stock ATM Agreement, as amended and to our 2021 Series B Preferred Stock ATM Agreement. If we raise additional funds through licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a license arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose. If we raise additional funds through borrowings, we have in the past and may in the future repay the principal and interest of the loan from certain of our royalty payments and/or use our royalties as collateral for such borrowings. For example, on December 15, 2023, we, through XRL, a newly formed, wholly-owned subsidiary, entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140.0 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc. In the event of a default under such secured borrowings, one or more of our creditors or their assignees could obtain control of certain of our royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If adequate funds are not available on a timely basis, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce or eliminate royalty aggregation efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further reduce our capital or operating expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">curtail our spending on protecting our intellectual property; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take other actions which may adversely affect our financial condition or results of operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the potential royalty acquisition market, including its structure, participants, growth rate, level of competition or financing methods, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire potential milestones and royalties, fewer potential milestones and royalties (or potential milestones or royalties of significant scale) being available, or increased competition for potential royalties. Even if we continue to acquire potential royalties and they become actual royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors, such as the underlying products, or intellectual property, other competitive products, market conditions, or the structure of the transaction. As a result, we may not be able to continue to acquire potential milestones and royalties as we have in the past, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have an obligation to pay quarterly dividends to holders of our Series A Preferred Stock and Series B Preferred Stock, which we expect to be an on-going expenditure for us and may limit our ability to borrow additional funds.</span><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Dividends on the Series A Preferred Stock accumulate and are cumulative from, and including, the date of original issuance by us of the Series A Preferred Stock. Dividends are payable in arrears on or about the 15th day of January, April, July and October. In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of shares of Series A Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared), before any distribution or payment may be made to holders of shares of common stock or any other class or series of our equity stock ranking, as to liquidation rights, junior to the Series A Preferred Stock. The shares of Series A Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26.00 per share to $25.00 per share, plus any accrued and unpaid dividends, depending on the date of redemption. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share of Series B Preferred Stock or $2.09375 per year per depositary share). Dividends on the Series B Preferred Stock accumulate and are cumulative from, and including, the date of original issuance by us of the Series B Preferred Stock. Dividends are payable in arrears on or about the 15th day of January, April, July and October. The shares of Series B Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26,000.00 per share ($26.00 per depositary share) to $25,000.00 per share ($25.00 per depositary share), plus any accrued and unpaid dividends, depending on the date of redemption. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The payment of cash dividends and share repurchases is subject to limitations under applicable laws and the discretion of our Board after considering current conditions, including earnings, other operating results and capital requirements. Decreases in asset values or increases in liabilities can reduce net earnings and stockholders&#8217; equity. A deficit in stockholders&#8217; equity could limit our ability to pay dividends and make share repurchases under Delaware law. On the other hand, our continued obligation to pay dividends to the holders of our Series A Preferred Stock and depositary shares representing interests in Series B Preferred Stock could restrict us from additional borrowings or make them more costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The holders of preferred stock have rights that are senior to those of our common stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had 984,000 shares of Series A Preferred Stock issued and outstanding with a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Additionally, as of December 31, 2023, we had 1,600,000 depositary shares issued and outstanding, each representing a 1/1000th fractional interest in a share of our Series B Preferred Stock with a liquidation preference of $25,000 per share of Series B Preferred Stock ($25.00 per depositary share), plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Our preferred stock is senior to our shares of common stock in right of payment of dividends and other distributions. In the event of our bankruptcy, dissolution or liquidation, the holders of our preferred stock must be satisfied before any distributions can be made to our common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information available to us about the intellectual property or biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may have limited information concerning the intellectual property or products generating the future potential milestones and royalties we are evaluating for acquisition. The information we have regarding intellectual property or products underlying a potential milestone or royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such intellectual property or products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by sponsors of the products or others or the nature or number of any complaints from doctors or users of such products or the nature or number of adverse effects of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a potential royalty may be significantly lower than our estimates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our business model is based on multiple-year internal and external forecasts regarding potential product sales and numerous product-specific assumptions in connection with each potential milestone and royalty acquisition, including in circumstances where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding potential product sales or competition, patent expirations or license terms or terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product, such as uncertainties around the patent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">estate and the terms of the license agreement, as well as the development, labeling, regulatory approval, commercialization, manufacturing and supply of product candidates. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us potential royalties may also prove to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate our projected returns or in the time periods we expect. This could negatively impact our results of operations for a given period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reductions or declines in income from potential milestones and royalties, or significant reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired, could have a material adverse effect on our financial condition and results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount and duration of a royalty varies on a country-by-country basis and depends on a number of factors, such as payments to third party licensors, whether the product is sold singly or in combination, patent expiration dates, regulatory exclusivity, years from first commercial sale of the applicable product candidate, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, claims of patent misuse, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing of the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. If an unexpected reduction in a royalty amount or shortening of a potential royalty term were to occur, it could result in a reduction in potential income from milestones and royalties, a significant reduction in potential milestones and royalty payments compared to expectations, or a permanent impairment of such potential milestones and royalty payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our asset portfolio is not fully diversified by product, therapeutic area, geographic region or other criteria. Any significant deterioration in the amount or likelihood of receipt of potential cash flows from the top products in our asset portfolio could have a material adverse effect on our business, financial condition and results of operations. For example, in September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in kidney transplant. In September 2022, after an interim analysis of data, Novartis also decided to discontinue its study of CFZ533 in liver transplant, and in<span style="background:#ffffff;"> July 2023, Novartis announced that it is discontinuing its Phase 3 trial investigating NIS793 in first-line metastatic pancreatic ductal adenocarcinoma. In August 2023, Novartis communicated to us that it intends to discontinue development activities related to NIS793 and will cease enrolling patients in the remaining active clinical studies.</span> <span style="background:#ffffff;">This, and any future deterioration in cash flows from the top products in our asset portfolio, could adversely affect our business and financial conditions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, should the payor of any future potential milestones or royalties decline to pay such potential milestones and royalties for any reason, such failure may result in a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have discretion as to the types of assets that we may acquire. While we expect to acquire assets that primarily fall within the biopharmaceutical industry, we are not obligated to do so and may acquire other types of assets that are peripheral to or outside of the biopharmaceutical industry. Consequently, our asset acquisitions in the future, and the cash flows from such assets, may not resemble those of the assets in our current portfolio. There can be no assurance that assets acquired in the future will have returns similar to the returns expected of the assets in our current portfolio or be profitable at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Milestone and Royalty Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To grow and diversify our business, we plan to continue our business development efforts to identify and seek to acquire potential milestone and royalty streams or companies and/or to in-license rights to potential products, product candidates, and programs. &#160;Future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, indemnification and risk allocation, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess or are otherwise unable to mitigate or prevent. Any failure in identifying and managing these risks and uncertainties could have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or that a product fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our potential royalty providers&#8217; therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential royalty providers&#8217; product candidates cannot be manufactured and marketed in the U.S. or any other countries without required regulatory approvals. The U.S. government and governments of other countries extensively regulate many aspects of our partners&#8217; product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical development and testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">record keeping;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promotion and marketing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">importing and exporting.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the FDA regulates pharmaceutical products under the FDCA and other laws, including, in the case of biologics, the Public Health Service Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Initiation of clinical trials requires approval by health authorities. Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials must be conducted in accordance with the requirements of the FDA and International Conference on Harmonization Good Clinical Practices and the European Clinical Trials Directive, as applicable, under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Other national, foreign and local regulations also may apply. The developer of the drug must provide information relating to the characterization and controls of the product before administration to the patients participating in the clinical trials. This may require developing authorized assays of the product to test before administration to the patient and during the conduct of the trial. In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a NDA for a drug, and in the form of a BLA for a biological product, requesting approval to commence commercial sales. In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals determining that the product is safe and effective, or in the case of a biologic, safe, pure, and potent, for its intended use, request additional information or further research, or deny the application if they determine the application does not satisfy regulatory approval criteria. Regulatory approval of an NDA, BLA, or supplement is never guaranteed. The approval process can take several&#160;years, is extremely expensive and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Our potential royalty providers ultimately may not be able to obtain approval in a timely fashion or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes. Despite the time and expense incurred, failure can occur at any stage, and our potential development partners could encounter problems that cause abandonment of clinical trials or cause them to repeat or perform additional preclinical, clinical or manufacturing-related studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process, and as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our licensees&#8217; submissions or whether the FDA or other regulatory agencies will raise questions that may be material and delay or preclude product approval or manufacturing facility approval. In light of this discretion and the complexities of the scientific, medical and regulatory environment, our or our potential royalty providers&#8217; interpretation or understanding of the FDA&#8217;s or other regulatory agencies&#8217; requirements, guidelines or expectations may prove incorrect, which also could delay further or increase the cost of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug development has inherent risk, and our potential milestone and royalty providers are required to demonstrate through adequate and well-controlled clinical trials that product candidates are effective, with a favorable benefit-risk profile for use in their target profiles before they can seek regulatory approvals for commercial use. It is possible our potential royalty providers may never receive regulatory approval for any licensed product candidates. Even if a product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers&#8217; product candidates require significant research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales. This process is lengthy and expensive, often taking a number of&#160;years. As clinical results frequently are susceptible to varying interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly. As a result, it is uncertain whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers&#8217; future filings will be delayed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers&#8217; preclinical studies will be successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers will be successful in generating viable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will be successful in finding collaboration and licensing partners to advance our product candidates on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers will be able to provide necessary data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of future clinical trials by our potential milestone and royalty providers will justify further development; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers ultimately will achieve regulatory approval for product candidates in which we have an interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timing of the commencement, continuation and completion of clinical trials by our potential milestone and royalty providers may be subject to significant delays relating to various causes, including failure to complete preclinical testing and earlier-stage clinical trials in a timely manner, inability to engage contract research organizations and other service providers, scheduling conflicts with participating clinicians and clinical institutions, changes in key personnel at clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria and shortages of available drug supply. In addition, since we and our royalty agreement counterparties license our product candidates to others to fund and conduct clinical trials, we, and they, have limited control over how quickly and efficiently such licensees advance those trials. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the concentration of patients in specialist centers, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol under which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, or changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our potential milestone and royalty providers may conduct clinical trials in foreign countries, which may subject them to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, and may expose our potential milestone and royalty providers to risks associated with foreign currency transactions to make contract payments denominated in the foreign currency where the trial is being conducted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our potential milestone and royalty providers may seek to obtain orphan drug designation for certain future product candidates, but they may be unable to ultimately obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our milestone or royalty revenue, if any, to be reduced.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of our potential milestone or royalty providers may obtain orphan drug designation for their product candidates. Under the Orphan Drug Act, the FDA may designate a drug or biological product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. Orphan drug designation must be requested before submitting a BLA. In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the U.S. may also be unavailable if our royalty providers seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even with an orphan drug designation for its current and potential future product candidates, our royalty providers may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if a royalty provider obtains orphan drug exclusivity for an existing or future product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties still can be approved for the same condition even with an orphan drug designation. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s interpretation of the scope of orphan drug exclusivity may change. The FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; In the September 2021 case Catalyst Pharmaceuticals, Inc. v. FDA, a federal circuit court set aside the FDA&#8217;s narrow interpretation and ruled that orphan drug exclusivity covers the full scope of the orphan-designated disease or condition regardless of whether the drug obtains approval only for a narrower use. The decision concerned amifampridine, a drug used to treat Lambert-Eaton myasthenic syndrome (LEMS). Depending on how the FDA applies the decision beyond this case, it may limit the drugs that can receive exclusivity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The ability of our potential milestone and royalty providers to obtain and maintain orphan drug designation and the benefits thereof, including orphan drug exclusivity, may materially impact the potential milestones and royalties we receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Biological products and product candidates of our potential milestone and royalty providers may</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">face</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">competition sooner than anticipated, which may materially impact the potential milestones and royalties we receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt -0.7pt 0pt 0pt;"><span style="color:#231f20;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The ACA includes</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a subtitle</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">called</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the Biologics</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Price Competition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and Innovation</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Act of 2009 (&#8220;BPCIA&#8221;), which created</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">an abbreviated</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">approval</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pathway for biological</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">biosimilar</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">interchangeable</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA-licensed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">biological</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Under</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">BPCIA,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">an application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">highly</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">similar</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">&#8220;biosimilar&#8221;</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">submitted</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">until</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">four</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years following</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">date</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">was</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">first</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">approved</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">addition,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">approval</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a biosimilar</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">made</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">effective</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">until</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">12</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">date</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reference product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">was</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">first</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">approved.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">During</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">this</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">12-year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">period</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">another</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">company</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">still</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">market</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a competing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">version</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">if</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">approves</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">full</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">BLA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">containing the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sponsor&#8217;s</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">own preclinical</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adequate</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">well-controlled</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">demonstrate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the safety,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">purity</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and potency</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">its</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The biological products and, if approved, product candidates of our royalty providers</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">could</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be considered</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">products entitled</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">12-year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">However,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">there</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risk</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">this</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">could</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">shortened</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">due</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to congressional</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">action</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">otherwise,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">consider</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">candidate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> a </span><span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">products,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">potentially</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">creating</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">opportunity</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">sooner</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">than</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">anticipated.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Other aspects</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">BPCIA,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">some</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">impact</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">BPCIA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">provisions,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">have</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">also</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">been</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">subject of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">recent</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">litigation.</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">Moreover,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">extent</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">biosimilar,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">once</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">approved,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">substituted</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">any</span> <span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">way</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">similar</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">traditional</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">generic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">substitution</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">non-biological</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">yet clear,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">depend</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">number</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">marketplace</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">factors</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">still</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">developing. Any of these events may materially impact the potential milestones and royalties we receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.23;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of the products or product candidates of our potential milestone or royalty providers that receive marketing approval under NDAs, or such authorities do not grant their product candidates appropriate periods of data or market exclusivity before approving generic versions of our product candidates, the sales of their product candidates could be adversely affected, which may materially affect the potential milestones and royalties we receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.23;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an NDA is approved, the drug covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations.&#8221; Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications (&#8220;ANDAs&#8221;) in the U.S. In support of an ANDA, a generic manufacturer need not conduct clinical trials demonstrating safety and efficacy. Rather, the applicant generally must show that its drug is pharmaceutically equivalent to the reference listed drug, in that it has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug, and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic drugs may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic drugs are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2)&#160;NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent for other conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch these generic drugs following the expiration of the marketing exclusivity period, even if our potential milestone or royalty providers still have patent protection for our drug competition, and their products may therefore face from generic versions of their products and, if approved, their product candidates. This could materially and adversely impact their future revenue, profitability and cash flows and substantially limit their ability to obtain a return on the investments we have made in those products and, if approved, product candidates. Their future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on their investments in those product candidates may be substantially limited if their products are not afforded the appropriate periods of non-patent exclusivity. <span style="color:#231f20;">Any of these events may materially impact the potential milestones and royalties we receive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">New products and technologies of other companies may render some or all of our potential milestone and royalty providers&#8217; product candidates noncompetitive or obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New developments by others may render our potential milestone and royalty providers&#8217; product candidates or technologies obsolete or uncompetitive. Technologies developed and utilized by the biotechnology and pharmaceutical industries are changing and evolving. Competition in antibody-based technologies is intense and is expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. Many of these competitors may be able to develop products and processes competitive with or superior to our potential milestone and royalty providers for many reasons, including that they may have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significantly greater financial resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">larger research and development staffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extensive experience in preclinical testing and human clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These and other factors may enable others to develop products and processes competitive with or superior to our own or those of our potential milestone and royalty providers. In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations. These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements. Furthermore, many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later. As a result, we and our potential milestone and royalty providers may not be able to track development of competitive products, particularly at the early stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Positive developments in connection with a potentially competing product may have an adverse impact on our future potential for receiving revenue derived from development milestones and royalties. For example, if another product is perceived to have a competitive advantage, or another product&#8217;s failure is perceived to increase the likelihood that our licensed product will fail, our potential milestone and royalty providers may halt development of product candidates in which we have an interest.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential royalty providers may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of our products, which would prevent our potential royalty providers&#8217; products from becoming profitable and negatively affect the royalties we may receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our current or potential royalty providers succeed in bringing product candidates to the market, they may not be considered cost effective, and reimbursement to the patient may not be available or may not be sufficient to allow our potential royalty providers to sell the products on a competitive basis. In both the U.S. and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Significant uncertainty exists as to the coverage and reimbursement status of any products for which our potential royalty providers may obtain regulatory approval. Even if coverage is available, the associated reimbursement rate may not be adequate for our potential royalty providers to cover related marketing costs. Additionally, coverage and reimbursement policies for pharmaceutical products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for pharmaceutical products among third-party payors in the U.S. Therefore, the process of obtaining coverage and reimbursement is often time-consuming and costly. Thus, even if our partners&#8217; product candidates are approved by the FDA, our royalty partners may not be able to price the products effectively or obtain coverage and adequate reimbursement for their products, which could adversely affect the royalties we receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. In the U.S., there have been, and we expect, will continue to be a number of federal and state proposals to implement government controls on pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the emphasis on managed care in the U.S. has increased and, we expect to continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our or our potential milestone and royalty providers&#8217; businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if product candidates in which we have an interest receive approval in the future, they may not be accepted in the marketplace. In addition, our potential royalty providers may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community. Our potential royalty providers may not have sales, marketing or distribution capabilities or may not be able to develop these capabilities in an effective manner, or at all. We have no assurance healthcare providers and patients will accept such products, if developed. Similarly, physicians may not accept a product if they believe other products to be more effective or more cost effective or are more comfortable prescribing other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over a product in which we have an ownership or royalty interest). Consequently, we do not know if physicians or patients will adopt or use products in which we have an ownership or royalty interest for their approved indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even approved and marketed products are subject to risks relating to changes in the market for such products. Introduction or increased availability of generic or biosimilar versions of products can alter the market acceptance of branded products. In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market which may lead to litigation, increased costs and delays or removal of the product from the market.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Product liability claims may diminish the returns on biopharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The developer, manufacturer or marketer of a product could become subject to product liability claims. A product liability claim, regardless of its merits, could adversely affect the sales of the product and the amount of any related royalty payments, and consequently, could adversely affect the ability of a payor to make payments with respect to a royalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe we should not bear responsibility in the event of a product liability claim against the developer, manufacturer, marketer or other seller of a product that generates our royalty, such claims could adversely affect our business, financial condition and results of operations due to the lower than expected cash flows from the royalty. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we and our potential royalty providers are unable to protect our or their intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers&#8217; ability to compete in the market will be harmed, and we may not realize our profit potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our potential royalty providers rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and deter others from duplicating our or their products or product candidates. However, these means may afford only limited protection and may not:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from duplicating our products and those of our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from using technologies or solutions similar to those incorporated into our products or product candidates, or those of our potential royalty providers in jurisdictions where we have not obtained patent protection and, further, exporting infringing products to territories where we have patent protection but where our enforcement efforts may be inadequate and protection in general of patented technology may be less robust than it is in the U.S.; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from gaining access to our proprietary information and technology and that of our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit us or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to gain or maintain a competitive advantage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the length of time and the expense associated with bringing new products to the marketplace, we and our potential royalty providers hold and are in the process of applying for a number of patents in the U.S. and abroad to protect product candidates and important processes and also have obtained or have the right to obtain exclusive licenses to certain patents and applications filed by others. However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. Federal Courts, the U.S. Patent&#160;&amp; Trademark Office or equivalent national courts or patent offices elsewhere may invalidate our patents or the patents of our royalty providers or find them unenforceable. The America Invents Act introduced post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions. U.S. patents owned or licensed by us <span style="letter-spacing:-0.1pt;">or our licensees</span><span style="letter-spacing:-0.1pt;"> </span>may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. A decision in such proceedings adverse to our interests could result in the loss of valuable patent rights, which would have a material adverse effect on our business. In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If our, and our potential royalty providers intellectual property rights are not protected adequately, our potential royalty providers or our licensees may not be able to commercialize technologies or products in which we have an ownership or royalty interest, and their competitors could commercialize such technologies or products, which could result in a decrease in our potential royalty providers&#8217; or our licensees&#8217; sales and market share that would harm our business and operating results. Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions. The legal standards governing the validity of biotechnology patents are in transition, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and current defenses as to issued biotechnology patents may not be adequate or available in the future. Accordingly, there is uncertainty as to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether any pending or future patent applications held by us or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> will result in an issued patent, or whether issued patents will provide meaningful protection against competitors or competitive technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether competitors will be able to design around our or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, reduce the royalty rate due to us, and prevent our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from using our technology or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our potential royalty providers may require licenses from others to develop and commercialize certain potential products in which we have an ownership or royalty interest. These licenses, if required, may not be available on acceptable terms, or may trigger contractual royalty offset clauses in our license agreements, or those of our royalty-agreement counterparties. We may become involved in litigation to determine the proprietary rights of others, and any such litigation will presumably be costly, time consuming, may not be adequately covered by insurance and may have other adverse effects on our business, such as inhibiting our potential royalty providers&#8217; ability to compete in the marketplace and absorbing significant management time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position. Our employees and contractors are typically required to sign confidentiality agreements under which they agree not to use or disclose any of our proprietary information. Research and development contracts and relationships between us and our scientific consultants and potential licensees provide access to aspects of our know-how that are protected generally under confidentiality agreements. These confidentiality agreements may be breached or may not be enforced by a court. To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may adversely affect our licensees&#8217; ability to develop or commercialize our products by giving others a competitive advantage or by undermining our patent position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us or our royalty providers to stop the infringement of our or their patents or the marketing of competing products in violation of our or their proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, in some instances, we have no ability to control the prosecution, maintenance, enforcement or defense of patent rights of our royalty providers. In such instances, there can be no assurance that they will vigorously prosecute, maintain, enforce or defend such rights, or that they will be successful in doing so. Any infringement of their intellectual property may adversely affect our royalty interest and consequently adversely affect our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">No assurance can be given that our, or our partners or licensees&#8217; patents will be extended upon expiration, which may have an effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We hold and have filed applications for a number of patents in the U.S. and internationally to protect our products and technology and have the right to obtain licenses to, or income streams based on, certain patents and applications filed by others. However, the life of a patent, and thus the protection it affords, is limited. Patent terms may be inadequate to protect our competitive position for an adequate amount of time. Significant patents in our portfolio are expected to expire in the coming years and while various extensions may be available, on a jurisdiction-by-jurisdiction basis, continuous patent protection is not guaranteed. While we expect to seek, and expect our partners to seek, extensions of patent terms for issued patents where available and when necessary, failure to secure patent extensions may have an effect on our financial condition and results of operations. Furthermore, there can be no assurance that our partners will seek extensions of their patent terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Litigation regarding intellectual property and/or the enforcement of our contractual rights against licensees and third parties can be costly and expose us to risks of counterclaims against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we are required to engage in litigation, arbitration or other proceedings to protect our intellectual property and/or enforce our contractual rights against former or current licensees or third parties, including third-party collaborators of such licensees or royalty agreement counterparties. The cost to us of complex proceedings of this type, even if resolved in our favor, can be substantial, and the parties opposing us in such proceedings may be able to sustain the cost of such proceedings more effectively than we can if they have substantially greater resources than we have. Any such proceedings and any negotiations leading up to them also may be time-consuming and can divert management&#8217;s attention and resources. If a proceeding of this type is resolved against us, we may lose the value associated with contract rights contained in our arrangements with licensees and third parties, the patents that are the subject of such proceeding may be declared invalid, we could be exposed to counterclaims against us, and we could be held liable for significant damages, fees and/or costs. While it is our current plan to continue to review and pursue, on a selective basis, potential material contractual breaches against licensees and third parties (including third-party collaborators of licensees and royalty agreement counterparties) and/or infringement of our intellectual property rights or technology, there can be no assurance that any such enforcement actions will be successful, or if successful, the timing of such success or that we will have sufficient capital to prosecute any such actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, in June 2021, we initiated a binding arbitration proceeding with one of our licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under our license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, we received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award us damages and ruled that the license agreement has expired. The panel ruled that we were responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; and administrative fees previously incurred by the Licensee of $4.1 million, <span style="background:#ffffff;">which we paid in April 2023</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be subject to claims that we, or our licensees or our royalty agreement counterparties&#8217; licensees, are infringing other parties&#8217; patents. If such claims are resolved against us, we or our licensees or our royalty agreement counterparties&#8217; licensees may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we or our licensees or our royalty agreement counterparties&#8217; licensees obtain a license from the other party. Such a license may not be available on reasonable terms or at all, thus preventing us, or our licensees or our royalty agreement counterparties&#8217; licensees, from using or licensing these products, processes or services and adversely affecting our potential future revenue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Uncertainties resulting from our participation in litigation, arbitration or other proceedings involving intellectual property and/or contractual rights could have a material adverse effect on our or our partners&#8217; ability to compete in the marketplace. There could also be public announcements of the results of hearings, motions or interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the perceived value of the product candidates as to which we hold potential milestone or royalty interests, or intellectual property or contractual rights could be diminished. Accordingly, the market price of our common stock may decline. Uncertainties resulting from the initiation and continuation of litigation, arbitration or other proceedings involving intellectual property and/or contractual rights could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and our partners rely heavily on license and collaboration relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including our ability to receive milestone payments and future potential royalty and other revenues. License or collaboration agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our potential milestones, royalties and other payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">License or collaboration agreements relating to the products generating our future potential milestones and royalties and other payment rights have in the past been and may in the future be terminated, which may adversely affect sales of such products and therefore the potential payments we may receive. For example, under certain license or collaboration agreements, marketers may retain the right to unilaterally terminate the agreements. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate the applicable license or collaboration agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor (which may be us in the case of our out-licensed products) or collaborator may no longer receive all of the payments it expected to receive from the applicable licensee or collaborator and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license or collaboration agreement that has been terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 23, 2023, Organon notified us of its intent to terminate the Organon License Agreement, which we assumed pursuant to the ObsEva IP Acquisition Agreement. The termination was effective as of January 21, 2024, and we will not be entitled to any milestone payments with respect to any milestone achieved by Organon following the notice of termination. We evaluated the related intangible asset balance for impairment and recorded an impairment charge of $14.2 million as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, license or collaboration agreements may fail to provide significant protection for the applicable licensor (which may be us in the case of our out-licensed products) or collaborator in case of the applicable licensee&#8217;s or collaborator&#8217;s failure to perform or in the event of disputes. License and collaboration agreements which relate to the products underlying our potential future milestones, royalties and other payment rights, are complex and certain provisions in such agreements may be susceptible to multiple interpretations. Disputes may arise regarding intellectual property, royalty terms, payment rights or other contractual terms subject to a license or collaboration agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope or duration of rights granted under the license or collaboration agreement and other interpretative issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts or timing of royalties, milestones or other payments due under the license or collaboration agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent or other rights under our license or collaboration relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diligence obligations under the license or collaboration </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreement and what activities satisfy such diligence obligations:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the creation or use of intellectual property by us or our partners; and </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The resolution of any contract interpretation disagreement that may arise could narrow what the licensor (which may be us in the case of our out-licensed products) or collaborator believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee&#8217;s or collaborator&#8217;s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our potential royalties, milestone payments and other payments and have a material adverse effect on our business, financial condition, results of operations and prospects. If a marketer were to default on its obligations under a license or collaboration agreement, the licensor&#8217;s or collaborator&#8217;s remedy may be limited either to terminating certain licenses or collaborations related to certain countries or to generally terminate the license or collaboration agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor or collaborator (if not us) and we may be required to rely on the resources and willingness of the licensor or collaborator (if not us) to enforce its rights against the applicable licensee or collaborator. In any of these situations, if the expected upfront, milestone, royalty or other payments under the license or collaboration agreements do not materialize, this could result in a significant loss to us and materially adversely affect our business, financial condition and results of operations. At any given time, the Company may be engaged in discussions with its licensees or collaborators regarding the interpretation of the payment and other provisions relating to products as to which we have milestones and potential royalty or other payment rights. Should any such discussions result in a disagreement regarding a particular product that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product should it successfully progress through clinical development and be approved for commercialization. Should our milestone and future potential royalty or other payment interests be reduced or eliminated as a result of any such disagreement, it could have an adverse effect on our business, financial condition, results of operations and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future arrangements to develop and commercialize our unpartnered assets. For example, in June 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, we do not expect to receive any milestone, royalty or other payments under the Biosis RPA or Second Bioasis RPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Generally, our current licensees have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all or failing to engage in commercially reasonable efforts to develop products if required), our product development under these agreements will be delayed or terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In addition, we could face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaborative agreement with any such new party will depend, among other factors, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our potential milestone and royalty providers&#8217; product candidate development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties provide services in connection with preclinical and clinical development programs, including <i style="font-style:italic;">in vitro </i>and <i style="font-style:italic;">in vivo</i> studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which our potential milestone and royalty providers have contracted, or cease to continue operations, and our potential milestone and royalty partners are not able to find a replacement provider quickly or lose information or items associated with their product candidates, our potential milestone and royalty providers&#8217; development programs and receipt of any potential resulting income may be delayed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The marketers of biopharmaceutical products are, in certain instances, substantially responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In certain instances, the holders of royalties on products have granted regulatory approval, commercialization, manufacturing and marketing rights to the licensees of such products. Such licensees have substantial control over those efforts and discretion to determine the extent and priority of the resources they will commit to their program for a product. Accordingly, the successful commercialization of a product depends on the licensee&#8217;s efforts and is beyond our control. If a licensee does not devote adequate resources to the ongoing regulatory approval, commercialization and manufacture of a product, or if a licensee engages in illegal or otherwise unauthorized practices, the product&#8217;s sales may not generate sufficient royalties, or the product&#8217;s sales may be suspended, and consequently, could adversely affect our business. In addition, if licensees of biopharmaceutical products decide to discontinue product programs or we believe the commercial prospects of assets have been reduced, we may recognize material non-cash impairment charges related to the financial royalty asset associated with those programs or assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreements with other third parties, many of which are material to our business, expose us to numerous risks and have caused us to incur additional liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because our licensees, suppliers and contractors are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they apply related to activities relevant to their agreements with us. If these licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own or otherwise compel them to perform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not know whether we or our licensees will be able to successfully develop and market any of the products that are or may become the subject of any of our licensing arrangements. In addition, third-party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure of our potential milestone and royalty providers&#8217; product candidates to meet current Good Manufacturing Practice standards may cause delays in regulatory approval and penalties for noncompliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under cGMP to meet acceptable standards for use in clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce our potential milestone and royalty providers&#8217; product candidates on the schedule required for clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with our potential milestone and royalty providers or may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of our potential milestone and royalty providers&#8217; product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities for compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer&#8217;s compliance with these regulations and standards. Any difficulties or delays in contractors&#8217; manufacturing and supply of our potential milestone and royalty providers&#8217; product candidates or any failure of our potential milestone and royalty providers&#8217; contractors to maintain compliance with the applicable regulations and standards could increase costs, reduce revenue, cause our licensees to postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our potential milestone and royalty providers&#8217; product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">candidates, or cause any of our potential milestone and royalty providers&#8217; products that may be approved for commercial sale to be recalled or withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, so our and our licensees&#8217; use of them may be restricted and subject to additional risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have licensed technologies from third parties. These technologies include phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program and antibody products. However, our and our licensees and collaborators&#8217; use of these technologies is limited by certain contractual provisions in the licenses relating to them, and although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex. If we are unable to maintain our licenses, patents or other intellectual property, we could lose important protections that are material to continuing our operations and for future prospects. Our licensors also may seek to terminate our license(s), which could cause us and our licensees to lose the right to use the licensed intellectual property and adversely affect our and our licensees&#8217; ability to commercialize our technologies, products or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employees, Location, Data Integrity, and Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The loss of or changes in any of our key personnel could delay or prevent achieving our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business efforts could be adversely affected by the loss of one or more key members of our staff. We currently do not have key person insurance on any of our employees. Changes in management, including due to potential acquisitions, may cause disruptions in our business, strategic and employee relationships, which may delay or prevent the achievement of our business objectives. During the transition periods, there may be uncertainty among investors, employees and others concerning our future direction and performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we are a small biotech royalty aggregator with limited resources, we may not be able to attract and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had 13 full-time employees as of March 4, 2024. We may require additional experienced executive, accounting, legal, administrative and other personnel from time to time in the future. We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. There is intense competition for the services of these personnel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our business may suffer, and we may be unable to implement our current initiatives or grow effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely and will continue to rely on outsourcing arrangements for many of our activities, including financial reporting and accounting and human resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to our small number of employees, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including financial reporting and accounting and human resources, as well as for certain of our functions as a public company. We may have limited control over these third parties, and we cannot guarantee that they will perform their obligations in an effective and timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our information technology systems or data or those of our partners or contractors are compromised, our business could experience adverse consequences, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; and loss of revenue or profits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including cloud-based systems, to support business processes as well as internal and external communications. In the ordinary course of our business, we maintain sensitive data on our networks, including personal information of our employees, legacy clinical trial patients, vendors and others, our intellectual property and proprietary or confidential business information relating to our business and that of our business partners. The secure maintenance and protection of this information is critical to our business and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity threats have generally increased in sophistication, scale, and frequency in recent years. While we have implemented security measures that are intended to protect our data and information technology systems, our computer systems, and those of the third parties on which we rely, are still vulnerable to damage from data breaches, security incidents or other unauthorized intrusions or access, including cyberattacks or computer viruses, or from natural disasters, terrorism, war and telecommunication and electrical failures. Moreover, the prevalence of remote work on mobile devices that access confidential and sensitive information increases the risk of such an event occurring. Threats to our systems and personal, confidential and proprietary information can come from a variety of sources, ranging in sophistication. Such threats also may be intentional or accidental. It is often difficult to anticipate or immediately identify these threats and the damage might cause. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Data breaches, security incidents and other unauthorized intrusions or access to our data or systems, or those of the third parties on which we rely, could result in system disruptions, downtime or the compromise of personal information, our intellectual property and sensitive business information, all of which may interrupt our normal business operations and require substantial expenditure of financial and administrative resources to remedy. Such events could have a material adverse effect on our business, financial condition and results of operations. Theft of proprietary information could be used to compete against us and could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. Furthermore, to the extent that any disruption, security breach, or other event were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we may be required to comply with notification requirements, be subject to litigation or regulatory action, or otherwise be subject to liability under applicable laws. These risks would expose us to significant expense and cause significant harm to our reputation and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we have insurance coverage, we cannot be sure that our policy will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay for future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Compliance with the stringent and changing obligations related to data privacy and security is an onerous and resource-intensive process. Our actual or perceived failure to comply with any data privacy or security obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Federal, state, local and foreign legislators and/or regulators are increasingly regulating data privacy and security and may impose significant penalties for failure to comply with these requirements. For example, in the U.S., the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) establishes a privacy framework for covered businesses, which applies to a broad range of personal information and entities who conduct business in California. Further, the California Privacy Rights Act (&#8220;CPRA&#8221;), which amends the CCPA, became fully operative on January 1, 2023 and expands upon the CCPA, imposing additional data protection obligations on covered businesses. The CCPA/CPRA gives California residents certain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">rights related to their personal information, including the rights to request the correction of, access to and deletion of their personal information, the right to opt out of certain personal information sharing, and the right to receive detailed information about how their information is processed. If we, or the third parties on which we rely, fail to comply with the CCPA/CPRA, we may face significant fines, penalties and regulatory enforcement costs that could adversely affect our reputation, business, financial condition and results of operations. The CCPA/CPRA provides for civil penalties of up to $2,500 per violation, and $7,500 per intentional violation, following investigation by the state Attorney General and allows private litigants affected by certain data breaches to recover significant statutory damages. Similar comprehensive state privacy laws are now in effect in Virginia, Colorado, Connecticut, and Utah, and many have passed in other states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compliance with laws, regulations, rules, guidance, industry standards, and contractual obligations concerning data privacy, security, governance and protection is an onerous and resource-intensive process, that may require us to put in place additional mechanisms and incur substantial expenditure. Achieving compliance could also require us to change our business practices in a manner that does not align with our business objectives. Furthermore, the regulatory landscape continues to evolve, making it difficult to maintain compliance. Further, in the event that we, or one of the third parties on which we rely, is subject to a data breach, security incident, or other unauthorized intrusion or access that leads to the disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could result in fines, increased costs or loss of revenue as a result of: harm to our reputation; fines imposed on us by regulatory authorities; remediation measures taken to respond to the event and prevent similar events from occurring in the future; additional compliance obligations under federal, state or foreign laws (including notification obligations); requirements for mandatory corrective action to be taken by us; and requirements to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, cyber incidents can be difficult to detect, and any delay in identifying them may lead to increased harm as described above. While we have implemented security measures to protect our data and information technology systems, such measures may not prevent such events. We also cannot guarantee that we are in compliance with all applicable data privacy, security and protection laws and regulations as they are enforced now or as they evolve. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our potential acquisitions of other companies could increase our exposure to litigation risk. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our exposure to risks associated with various claims, including claims related to the use of intellectual property as well as securities and related stockholder derivative claims, may be increased as a result of our acquisitions of other companies, including our potential acquisition of Kinnate, and we may ultimately be subject to liability or settlement costs. Additionally, we may have a lower level of visibility into the development process with respect to intellectual property or the care taken to safeguard against infringement risks with respect to acquired companies or assets. In addition, third parties may make claims in connection with our acquisitions, and they may also make infringement and similar or related claims after we have acquired assets that had not been asserted prior to our acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn, or it may be removed voluntarily from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if our potential royalty providers receive regulatory approval for our product candidates, they will be subject to ongoing regulatory oversight and review by the FDA and other regulatory entities. The FDA, the EMA, or another regulatory agency may impose, as a condition of the approval, ongoing requirements for post-approval studies or post-approval obligations, including additional research and development and clinical trials, and the FDA, EMA or other regulatory agency subsequently may withdraw approval based on these additional trials or obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even for approved products, the FDA, EMA or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and production of such product. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for such products are subject to extensive regulatory requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, marketing approval of a product may be withdrawn by the FDA, the EMA or another regulatory agency or such product may be withdrawn voluntarily by our potential royalty providers based, for example, on subsequently arising safety concerns. The FDA, EMA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. and some foreign jurisdictions have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our potential royalty providers&#8217; ability to sell products in which we have ownership or<span style="letter-spacing:-0.1pt;"> </span>and royalty interests, if approved, profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which, among other things, substantially changed the way healthcare is financed by both governmental and private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been judicial, Congressional and executive branch challenges to the ACA. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how other such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Also, there has been heightened governmental scrutiny recently in the U.S. over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, <span style="background:#ffffff;">in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions will take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. In addition, beginning in 2023, Centers for Medicare &amp; Medicaid Services, or CMS, will require manufacturers to refund CMS for certain discarded amounts of single-dose container and single-use package drugs. </span>At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and regulations have been designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An expansion in the government&#8217;s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription pharmaceutical products, lower reimbursements for providers, and reduced product utilization, any of which could adversely affect our business and results of operations. We expect that additional healthcare reform measures will be adopted in the future. We cannot know what form any such new legislation may take or the market&#8217;s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our potential royalty providers from being able to generate revenue, attain profitability, develop, or commercialize our current product candidates in which we have an ownership or royalty interest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and our potential milestone and royalty providers are subject to various state and federal healthcare-related laws and regulations that if violated may impact the commercialization of our product candidates for which we possess milestone or royalty rights or could subject us to significant fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations may be directly or indirectly subject to various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act, state analogues of those laws, and various state and federal data privacy and security laws. These laws may impact, among other things, the commercial operations for any of our product candidates that may be approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing or arranging for the purchase, lease, or order of a good or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The ACA modified the federal Anti-Kickback Statute&#8217;s intent requirement so that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to violate it to have committed a violation. In addition, several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been implicated. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal false claims laws, including the False Claims Act, and civil monetary penalties laws prohibit, among other things, persons and entities from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Certain suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individual, commonly known as a &#8220;whistleblower,&#8221; or &#8220;relator&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend and/or settle a False Claims Act action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including a private payor, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, health care benefits, items or services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information by entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many states also have adopted laws similar to each of the federal laws described above, some of which apply to healthcare items or services reimbursed by any source, not only federal healthcare programs, such as the Medicare and Medicaid programs. In addition, some states have laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government. Additionally, certain state and local laws require the registration of pharmaceutical sales representatives, restrict payments that may be made to healthcare providers and other potential referral sources, and require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers. Further, some states have laws governing the privacy and security of health information in certain circumstances, many of which are not preempted by HIPAA and differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws, and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our or our potential milestone and royalty providers&#8217; business activities could be subject to challenge under one or more of such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or our potential milestone and royalty providers are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare laws, we or our potential milestone and royalty providers may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, reputational harm, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our or our potential milestone and royalty providers&#8217; operations, any of which could have a material adverse effect on our business and results of operations. In addition, we and our licensees may be subject to certain analogous foreign laws and violations of such laws could result in significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. Our operations are subject to anti-corruption laws including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. We and the royalty agreement counterparties and licensees who generate our royalties operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose activities could potentially subject us to liability under the FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the U.S. and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anticorruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control laws by the U.S. or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts to confirm that our business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the royalty agreement counterparties and licensees who generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the royalty agreement counterparties and licensees who generate our royalties are found to be in violation of any of these laws or any other governmental regulations, we or the royalty agreement counterparties and licensees who generate our royalties may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or the royalty agreement counterparties and licensees who generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting enforcement landscape and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">As we or our potential milestone and royalty providers do more business internationally, we expect to become subject to additional political, economic and regulatory uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We or our potential milestone and royalty providers may not be able to operate successfully in any foreign market. We believe that because the pharmaceutical industry is global in nature, international activities are expected to become a significant part of future business activities and when and if we or our potential milestone and royalty providers are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the U.S. Foreign regulatory agencies often establish standards different from those in the U.S., and an inability to obtain foreign regulatory approvals on a timely basis, if at all, could put us at a competitive disadvantage or make it uneconomical to proceed with a product or product candidate&#8217;s development. International sales may be limited or disrupted by many factors, including without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of government controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">export license requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">political or economic instability or conflict;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">international disputes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in tariffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on repatriating profits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exchange rate fluctuations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evolving government regulations, including those related to healthcare reimbursement and data privacy and security; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withholding and other taxation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The trading market for our common stock can be influenced by the research and reports that industry or securities analysts publish about our business. Currently, coverage of our Company by industry and securities analysts is limited. Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or us or fail to publish reports about the Company regularly, our common stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations. Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our share price may be volatile, which may subject us to litigation, and there may not be an active trading market for our common stock, Series A Preferred Stock or our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the market price of our common stock will not decline below its present market price. Additionally, there may not be an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. The market prices of biotechnology companies have been and are likely to continue to be highly volatile, and are affected by a number of factors, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our operating results; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market and macroeconomic conditions, including market conditions in our industry and the industries of our collaborators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the coverage of our common stock by the financial media, including television, radio and press reports and blogs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to realize benefits from strategic partnerships, acquisitions or investments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading activity or positions by a limited number of stockholders who together beneficially own a significant portion of our outstanding common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of shares of common stock by us, including as consideration in or in conjunction with acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to execute on our share repurchase program as planned, including failure to meet internal or external expectations around the timing or price of share repurchases, and any reductions or discontinuances of repurchases thereunder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of debt or other convertible securities, including as consideration in or in conjunction with acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to conclude that our internal controls over financial reporting are effective;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to our credit ratings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market perception or investment sentiment regarding us or our business strategy. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have experienced significant volatility in the price of our common stock in the past. From January&#160;1, 2023, through March 4, 2024, the share price of our common stock has ranged from a high of $25.91 to a low of $13.48. From January&#160;1, 2023, through March 4, 2024, the share price of our Series A Preferred Stock has ranged from a high of $25.98 to a low of $21.40. From January 1, 2023, through March 4, 2024, the share price of our Series B Preferred Stock has ranged from a high of $25.37 to a low of $20.43. Additionally, we currently have two significant holders of our common stock that could affect the liquidity of our stock and have a significant negative impact on our stock price if those holders were to sell their ownership positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our results of operations could be materially and adversely affected by macroeconomic conditions generally, both in the U.S. and elsewhere around the world. Concerns over inflation, slower growth or recession, new or increased tariffs or other barriers to trade, changes in fiscal and monetary policy or government budget dynamics, interest rates, high unemployment, labor availability constraints, currency fluctuations, epidemics and other public health crises (such as the COVID-19 pandemic), significant natural disasters (including as a result of climate change), rising energy costs, geopolitical conflict, such as the ongoing conflict in Ukraine, the Middle East and surrounding areas and the rising tensions between China and Taiwan, the availability and cost of credit, and the volatility in U.S. financial markets have in the past contributed to, and may continue in the future contribute to, increased volatility and diminished expectations for the economy and the U.S. and global markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have issued equity securities and may issue additional equity securities from time to time, that materially and adversely affect the price of our common stock, including our Series X Preferred Stock, Series A Preferred Stock and depositary shares representing interests in our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in such a manner as we determine from time to time, including pursuant to our 2018 Common Stock ATM Agreement, as amended, and 2021 Series B Preferred Stock ATM Agreement. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. If we issue additional equity securities, the price of our existing securities may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2023, there were 5,003 shares of Series&#160;X Preferred Stock issued and outstanding. Each share of Series&#160;X Preferred Stock is convertible into 1,000 shares of registered common stock. The total number of shares of common stock issuable upon conversion of all issued Series&#160;X Preferred Stock would be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder is prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which was initially set at 19.99% of our total common stock then issued and outstanding immediately following the conversion of such shares. A holder of Series X Preferred Stock may elect to increase or decrease the conversion blocker above or below 19.99% on 61 days&#8217; notice, provided the conversion blocker does not exceed the limits under Nasdaq Listing Rule 5635(b), to the extent then applicable. If holders of our Series X Preferred Stock elect to convert their preferred shares into common stock such conversion would dilute our currently outstanding common stock both in number and in earnings per share. BVF (and its affiliates), as current holders of all of the shares of our Series X Preferred Stock, would, if they converted all such shares to common stock, obtain majority voting control of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company. As of December 31, 2023, BVF owned approximately 31.6% of our total outstanding shares of common stock, and if all of its shares of the Series X Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 52.3% of our total outstanding shares of common stock. Additionally, as of December 31, 2023, we had issued and outstanding 984,000 shares of Series A Preferred Stock and 1,600,000 depositary shares, each representing a 1/1000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> fractional interest in a share of our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, funding from collaboration partners and others has in the past and may in the future involve issuance by us of our common stock. We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any issuance by us of equity securities, whether through an underwritten public offering, an at the market offering, a private placement, in connection with a collaboration or otherwise could result in dilution in the value of our issued and outstanding shares, and a decrease in the trading price of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to raise additional funds to support our operations, we may sell additional equity or convertible debt securities, which would result in dilution to our stockholders and/or debt securities which may impose restrictive covenants that would adversely impact our business. The sale of additional equity or convertible debt securities could result in additional dilution or result in other rights or obligations that adversely affect our stockholders. For example, holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Additionally, holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and by-laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our Board to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board may determine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These provisions of our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company in the U.S., we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our disclosure controls and internal controls over financial reporting are effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companies that file reports with the SEC, including us, are subject to the requirements of Section&#160;404 of the SOX. Section&#160;404 requires management to establish and maintain a system of internal control over financial reporting, and annual reports on Form&#160;10-K filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), must contain a report from management assessing the effectiveness of our internal control over financial reporting. Ensuring we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a time-consuming effort that needs to be re-evaluated frequently. Failure on our part to have effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to use our NOL carry-forwards and certain other tax attributes to offset taxable income or taxes may be limited. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net operating loss, or NOL, carryforwards could expire unused and/or be unavailable to offset future income tax liabilities. As of December 31, 2023, we had U.S. federal NOL carryforwards of $137.8 million, of which $13.6 million will begin to expire in 2036. Under the federal income tax law, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the federal tax law. In addition, Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and corresponding provisions of state law, generally limit the ability of a corporation that undergoes an &#8220;ownership change&#8221; to utilize its NOL carry-forwards and certain other tax attributes against any taxable income in taxable periods after the ownership change. An &#8220;ownership change&#8221; is generally defined as a greater than 50% change, by value, in a corporation&#8217;s equity ownership over a three-year period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section 382 of Code, we experienced an ownership change in February 2017, that significantly limits the availability of our tax attributes to offset future income. To the extent that we do not utilize our carry forwards within the applicable statutory carry-forward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carry-forwards will also expire unused. As of December 31, 2023, we had $55.4 million in federal net operating loss carryforwards subject to an annual limitation of $0.9 million. Of this amount, $13.6 million will begin to expire in 2036, if not utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in tax laws or regulations</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">that</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">are applied</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">adversely</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to us may</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">have a material adverse</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">effect</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">on our business,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">cash flow, financial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">condition,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">or results</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">of operations</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For instance, the recently enacted Inflation Reduction Act imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. In particular, changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future tax expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stockholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Securities-related class action and stockholder derivative litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their product development programs, and could be increased as a result of our acquisitions of other companies, including our potential acquisition of Kinnate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that suits will be filed, or allegations received from stockholders, naming us and/or our officers and directors as defendants. These potential lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of any such lawsuits is uncertain. We could be forced to expend significant time and resources in the defense of these suits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. Although we carry insurance to protect us from such claims, our insurance may not provide adequate coverage. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, increased insurance costs, and could have a material adverse effect on our cash flow, results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Monitoring, initiating and defending against legal actions, including any currently pending litigation, are time-consuming for our management, are likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of any future litigation could lead to increased volatility in our stock price and a decrease in the value of an investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dc42f321_ac29_41f5_9d97_3572af16cbb1"></a><a id="Item1BUnresolvedStaffComments_868310"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. UNRESOLVED STAFF COMMENTS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_188dcbd3_af7d_4c55_ae0c_fdcb3398b6bd"></a><a id="Item1CCYBERSECURITYRISKMANAGEMENTSTRATEG"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1C. CYBERSECURITY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risk Management and Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We evaluate our cybersecurity strategy annually, including our processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein, within our overall enterprise risk management framework. Our cybersecurity strategy takes a multi-faceted approach, one which focuses on the following key areas: (i) the human element within the organization; (ii) perimeter security; (iii) network security; (iv) application security; (v) endpoint security; and (vi) data security. We use a wide array of processes, mechanisms, controls, technologies, systems, strategies and tools in each of these areas, including but not limited to: routine security awareness training, formal evaluations of third-party applications, password strength policies, antivirus software, firewalls, routine patch management, encryption software, data backups and data redundancies, email security software, multi-factor authentication tools, network security monitoring, and web vulnerability scanning. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We engage outside consultants on a regular basis to help us design internal controls and processes to address cybersecurity risks. We also leverage these outside consultants and other third parties, when appropriate, to implement appropriate processes, policies, and internal controls designed to help prevent, detect, and/or mitigate these cyberthreats. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">In the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity threats that, if realized, are reasonably likely to materially affect us. These threats include but are not limited to: (i) ransomware and malware attacks; (ii) endpoint attacks; (iii) compromised business email and other social engineering threats; and (iv) vulnerabilities related to inadequate patch management. Our licensees, suppliers, contractors, and consultants also face similar cybersecurity risks, which could have an adverse impact on our business. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the headings &#8220;If our information technology systems or data or those of our partners or contractors are compromised, our business could experience adverse consequences, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; and loss of revenue or profits&#8221; and &#8220;Compliance with the stringent and changing obligations related to data privacy and security is an onerous and resource-intensive process. Our actual or perceived failure to comply with any data privacy or security obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, led by our Chief Executive Officer and the Senior Vice President, Finance and Chief Financial Officer, is responsible for assessing cybersecurity risks and for confirming we have an appropriate cybersecurity strategy to assess and manage those risks, including responding to attacks or breaches. Our Chief Executive Officer and the Senior Vice President, Finance and Chief Financial Officer each have experience in senior leadership roles in which they have been responsible for the entity&#8217;s enterprise risk management, including management of cybersecurity risks. The Chief Executive Officer and the Senior Vice President, Finance and Chief Financial Officer meet regularly with the individuals charged with the day-to-day IT operations and infrastructure, and at least quarterly to review and assess potential cybersecurity threats to determine whether any changes need to be made to our cybersecurity strategy. The Chief Executive Officer and the Senior Vice President, Finance and Chief Financial Officer sponsor periodic cybersecurity awareness training for all employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also maintain an Incident Response Plan that sets forth a protocol in the event we are exposed to a cyber-attack or breach. The Incident Response Plan provides a framework for our response, including the appropriate communication and escalation channels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee of the Board, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. Management provides regular updates to the Audit Committee of the Board regarding risk assessments, developing threats, and the current and planned cybersecurity strategy, and promptly provides notification of significant attacks or breaches as part of the Incident Response Plan. &#160;The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis. &#160; </p><a id="_5ee2fb34_7499_498b_b917_ed457ec0d96e"></a><a id="Item2Properties_752211"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease space for our corporate headquarters in Emeryville, California. As of December 31, 2023, we expect to incur incremental undiscounted costs of $0.5 million associated with our building lease until it expires in April 2029. We believe our facilities are adequate to meet our current requirements.</p><a id="_e514e571_3e46_4847_a3eb_7a0d7d2054d0"></a><a id="Item3LegalProceedings_945310"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;LEGAL PROCEEDINGS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are not currently engaged in any legal proceedings that, in the opinion of our management, if determined adversely to us, would individually or taken together, have a material adverse effect on our business, results of operations, financial position or cash flows. However, from time to time, we may become involved in litigation, arbitration or other proceedings relating to claims arising from the ordinary course of business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may become involved in material legal proceedings in the future, and the potential impact on us of any on-going proceeding which we do not currently believe to be material could become material. Such matters are subject to significant uncertainties, and there can be no assurance that any legal proceedings in which we are or may become involved will not have a material adverse effect on our business, results of operations, financial position or cash flows.</p><a id="_df3227c2_e7fe_4d20_8b1c_9d8cd0be1085"></a><a id="Item4MineSafetyDisclosures_972169"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_af949fb7_b49b_4cb5_acdf_d39d50e52c80"></a><a id="PARTII_531471"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market for Registrant&#8217;s Common Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;XOMA.&#8221; On March 4, 2024, there were 188 stockholders of record of our common stock, one of which was Cede&#160;&amp; Co., a nominee for Depository Trust Company (&#8220;DTC&#8221;). Shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede&#160;&amp; Co., and we are unable to estimate the total number of stockholders represented by these record holders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not paid dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. Holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year per share) per year. Holders of our Series B Preferred Stock are entitled to receive, when and as declared by our Board, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per year of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share of Series B Preferred Stock or $2.09375 per year per depositary share).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b9673d7a_e257_4a44_b36c_2d0c8f76f58d"></a><a id="Item6SelectedConsolidatedFinancialData_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;RESERVED</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_481dcc27_a920_41b0_9708_826c57dde1a1"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio was built through the acquisition of rights to future milestones, royalties and commercial payments, since our royalty aggregator business model was implemented in 2017, combined with out-licensing our proprietary products and platforms from our legacy discovery and development business. Our royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to large-cap partners. We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to deliver a financial return to us in a short timeframe. We expect most of our future revenue to be based on payments we may receive for milestones and royalties associated with these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The generation of future revenues related to licenses, milestone payments, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. We generated a net loss of $40.8 million and net cash used in operating activities was $18.2 million for the year ended December 31, 2023, and we had an accumulated deficit of $1.2 billion as of December 31, 2023. We generated a net loss of $17.1 million and net cash used in operating activities was $12.9 million for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Significant Business Developments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Kinnate Acquisition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 16, 2024, we entered into an agreement to acquire Kinnate for a base cash purchase price of $2.3352 per share and an additional cash payment amount of up to $0.2527 per share upon the closing of the merger plus a non-transferable contingent value right per share, representing the right to receive 85% of the net proceeds, if any, from any out license or sale of the Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds, if any, from any out license or sale of certain Kinnate programs entered into prior to the closing of the merger. &#160;We expect this acquisition to provide additional cash to our balance sheet and potentially add several programs to our portfolio. This merger is expected to close in April 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Blue Owl Loan Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, our wholly owned subsidiary, XRL, entered into the Blue Owl Loan Agreement, pursuant to which we borrowed $130.0 million. &#160;We received a net cash amount of $119.6 million after the payment of $4.1 million in fees and lender expenses and $6.3 million that was deposited into reserve accounts to pay interest, administrative fees and XRL&#8217;s operating expenses. We also incurred $0.6 million in direct issuance costs related to the Blue Owl Loan Agreement. The Blue Owl Loan is secured by, and is expected to be repaid based upon, commercial payments from Roche&#8217;s VABYSMO, pursuant to the Affitech CPPA (see Note 8 to the consolidated financial statements). The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Blue Owl Loan Agreement, we issued warrants to certain funds associated with Blue Owl to purchase (i) up to 40,000 shares of our common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of our common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of our common stock at an exercise price of $50.00 per share (collectively, the &#8220;Blue Owl Warrants&#8221;) (see Note 12 to the consolidated financial statements). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Owen Hughes Appointed as Chief Executive Officer </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January 7, 2024, the Board appointed Owen Hughes as our Chief Executive Officer (principal executive officer) and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes previously served as our Executive Chairman and Interim Chief Executive Officer beginning on January 1, 2023. In connection with his appointment, Mr. Hughes will receive an annual base salary of $575,000 and will be eligible to receive an annual discretionary cash bonus with a target amount equal to 60% of his annual base salary upon the achievement of annual performance milestones to be established by the Board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock Repurchase Program </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, our Board authorized our first stock repurchase program, which permits us to purchase up to $50.0 million of our common stock through January 2027. Under the program, we have discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, as part of accelerated share repurchases or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at our sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate us to acquire any particular amount of our common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. As of March 4, 2024, we have purchased 660 shares of common stock pursuant to this stock repurchase program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Portfolio Updates &#8211; Royalty and Commercial Payment Purchase Agreements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Talphera Commercial Payment Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, we acquired an economic interest in DSUVIA from Talphera, for $8.0 million. DSUVIA was approved in 2018 by the FDA for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora Pharmaceuticals for an upfront payment, a 15% royalty on commercial net sales, a 75% royalty on net sales to the DoD, and up to $116.5 million in milestone payments. Under the terms of the agreement, we are entitled to receive 100% of all royalties and milestones related to DSUVIA sales until we receive $20.0 million. Once we receive $20.0 million, the 75% royalties generated from DoD purchases and the remaining $116.5 million in potential milestone payments due from Alora will be shared equally between us and Talphera. We will fully retain the 15% royalty associated with DSUVIA commercial sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">LadRx Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we entered into the LadRx AAA pursuant to the which we acquired from LadRx all of its rights, title and interests related to arimoclomol under the Zevra RPA. We also entered into the LadRx RPA, pursuant to which we acquired the right to receive all of the future royalties, regulatory and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under the ImmunityBio License Agreement. The purchased rights related to arimoclomol include potential regulatory and commercial milestone payments of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. The purchased payments related to aldoxorubicin include potential regulatory and commercial milestone payments of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages for sales of other licensed products. Upon closing of the LadRx Agreements, we paid LadRx an upfront payment of $5.0 million. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, Zevra announced the FDA accepted its NDA resubmission for arimoclomol, and pursuant to the LadRx RPA, we paid LadRx a $1.0 million milestone payment in January 2024. We may pay up to an additional $1.0 million commercial milestone related to arimoclomol and an additional $4.0 million regulatory milestone related to aldoxorubicin. &#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Viracta Royalty Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In October 2023, we earned a $5.0 million milestone payment related to the FDA&#8217;s acceptance of Day One Biopharmaceuticals&#8217; NDA for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Affitech Commercial Payment Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to our Affitech CPPA, we are eligible to receive commercial payments from Roche consisting of 0.5% of net sales of VABYSMO for a ten-year period following the first commercial sale in each applicable jurisdiction. In 2022, VABYSMO was approved by the FDA and the EMA for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. <span style="background:#ffffff;">In October 2023, the FDA approved VABYSMO for the treatment of retinal vein occlusion. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Payments are due from Roche within 60 days of December 31 and June 30 of each year. &#160;In 2023 and 2022, w</span>e received commercial payments totaling $7.3 million and $0.5 million, respectively, and in February 2024, we received $7.4 million. Based on net sales of VABYSMO in 2023, we paid Affitech sales milestones totaling $6.0 million in March 2024, and we may pay up to an additional $6.0 million in milestones based on the achievement of certain sales thresholds in future periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Aptevo Commercial Payment Purchase Agreement</i><i style="font-weight:normal;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2023, we entered into the Aptevo CPPA, pursuant to which we acquired the full commercial payment stream and a portion of the milestone rights to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. We are eligible to receive a mid-single digit percentage payment stream on all IXINITY sales from January 1, 2023 until the first quarter of 2035, and also expect to be entitled to receive milestone payments. Under the terms of the Aptevo CPPA, in 2023 we paid Aptevo a $9.6 million upfront payment plus a $50,000 one-time payment when the first commercial payment exceeded $0.5 million. In 2023, we received $1.7 million in commercial payments pursuant to this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ObsEva IP Acquisition Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, Organon notified us of its intent to terminate the Organon License Agreement effective as of January 21, 2024, which we assumed pursuant to the ObsEva IP Acquisition Agreement dated November 21, 2022. We were not entitled to any milestone payments with respect to any milestone achieved by Organon following the termination date. We evaluated the related intangible asset balance for impairment in the fourth quarter of 2023 and recorded an impairment charge of $14.2 million as of December 31, 2023 (see note 4 to the consolidated financial statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Bioasis</i><i style="font-weight:normal;"> Royalty Purchase Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, Bioasis announced the suspension of all of its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. We do not expect to receive any milestone, royalty or other payments under the Biosis RPA or Second Bioasis RPA and accordingly, we recorded an impairment charge of $1.6 million in the second quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Portfolio Updates -<span style="background:#ffffff;"> </span>License and Collaboration Agreements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, we earned a $0.5 million milestone payment from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In addition, during 2023, we also earned $1.0 million in milestone payments for five additional milestones related to IND filings, pursuant to our agreement with Janssen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">contingent assets and liabilities. We routinely evaluate our estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Critical accounting estimates are those estimates that involve a significant level of judgment and/or estimation uncertainty and could have or are reasonably likely to have a material impact on our financial condition or results of operations. We believe the following critical accounting policies and estimates describe the more significant judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestone payments, royalties and option fees on sales of products currently in clinical development or recently commercialized. We acquire such rights from various entities and record the amount paid for these rights as long-term royalty receivables. We have accounted for the purchased rights as a financial asset in accordance with ASC 310 (see Note 5 to the consolidated financial statements). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Receivables </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Except for VABYSMO and IXINITY, our other developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. VABYSMO received FDA approval in January 2022, was approved by Japan&#8217;s Ministry of Health, Labour, and Welfare in March 2022, and was approved by the EU&#8217;s EC in September 2022. In October 2023, the FDA approved VABYSMO for the treatment of retinal vein occlusion. As of December 31, 2023, these recently commercialized products have not yet established a reliable sales pattern under the respective royalty term. The carrying balances of receivables for VABYSMO and IXINITY are classified as current receivables based on whether payments to be received in the near term are presumed to become probable and reasonably estimable. Under the cost recovery method, any milestone, royalty, or other payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected will be recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Contingent Payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future licensed products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value during each reporting period. Any changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Allowance for Current Expected Credit Losses </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review our allowance for current expected credit losses for impairment on a quarterly basis based on updates from our partners, press releases and public information on clinical trials. If we determine an impairment is necessary, the impairment recorded will be based on an estimate of discounted future cash flows, which will rely on assumptions including probability of technical success and discount rate. Changes to these assumptions could have a material impact on our financial statements. In June 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi and, as a result, we recorded an impairment charge of $1.6 million (see Note 5 to the consolidated financial statements).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our intangible assets consist of IP acquired in the ObsEva IP Acquisition Agreement in 2022. We review our intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. In October 2023, Organon notified us of its intent to terminate the Organon License Agreement effective as of January 21, 2024, which we assumed pursuant to the ObsEva IP Acquisition Agreement. As such, in the fourth quarter of 2023 we recorded an impairment charge of $14.2 million (see Note 4 to the consolidated financial statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense for stock options and other stock awards is estimated at the grant date based on the award&#8217;s fair value-based measurement. The valuation of stock-based compensation awards is determined on the date of grant using the Black-Scholes Model. This model requires highly complex and subjective inputs, such as the expected term of the option and expected volatility. These inputs are subjective and generally require significant analysis and judgment to develop. Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation expense recognized in future periods. To establish an estimate of expected term, we consider the vesting period and contractual period of the award and our historical experience of stock option exercises, post-vesting cancellations and volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues. Forfeitures are recognized as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair values of PSUs with market conditions are determined using the Monte Carlo valuation model. This model requires highly complex and subjective inputs, such as probability estimates. We record compensation expense for PSUs based on graded expense attribution over the requisite service periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review our valuation assumptions quarterly and update our valuation assumptions used to value stock-based awards granted in future periods utilizing then-current data. In future periods, as additional empirical evidence regarding input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value-based measurement of stock options granted in the future. Changes in the fair value-based measurement of stock awards could materially impact our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total revenues for the&#160;years ended December 31, 2023 and 2022, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,650</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,500)</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,877</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 231</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,758</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,027</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,269)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue from Contracts with Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue from contracts with customers includes upfront fees, annual license fees and milestone payments related to the out-licensing of our legacy product candidates and technologies. Revenue from contracts with customers for the year ended December 31, 2023 primarily included milestone payments of $1.5 million and $1.0 million pursuant to the license agreements with Janssen and an undisclosed licensee, respectively. Revenue from contracts with customers for the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">year ended December 31, 2022 primarily included milestone payments of $2.0 million pursuant to our Rezolute License Agreement, $0.8 million pursuant to the Takeda Collaboration Agreement, $0.8 million pursuant to our license agreement with an undisclosed licensee &#160;and $0.5 million pursuant to our Sonnet Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue Recognized under Units-of-Revenue Method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue recognized under the units-of-revenue method includes the amortization of unearned revenue from the sale of royalty interests to HCRP in 2016. The increase for the year ended December 31, 2023 compared with the year ended December 31, 2022 was due to increased sales of products underlying the agreements with HCRP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">R&amp;D Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expense was $0.1 million for the year ended December 31, 2023, which was consistent with $0.2 million for the year ended December 31, 2022. We expect our R&amp;D expenses to increase in 2024 related to our acquisition of Kinnate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">G&amp;A Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses include salaries and related personnel costs, professional fees, and facilities costs. For the year ended December 31, 2023, G&amp;A expenses were $25.6 million compared with $23.2 million for the year ended December 31, 2022. <span style="background:#ffffff;">The increase of $2.4 million was primarily due to a $5.5 million increase in stock-based compensation, partially offset by a $2.1 million decrease in consulting and legal expenses and a $0.9 million decrease in salaries and related expenses. We expect G&amp;A expenses to increase in 2024 due to the appointment of Mr. Hughes as our full-time Chief Executive Officer in January 2024. &#160;We expect G&amp;A expenses to further increase due to an anticipated increase in activity related to our evaluation of potential royalty acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Impairment Charges</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Impairment charges of $15.8 million for the year ended December 31, 2023 consisted of the impairment recorded related to our Bioasis RPAs of $1.6 million in the second quarter of 2023 and the impairment of our ObsEva intangible asset of $14.2 million in the fourth quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Arbitration Settlement Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arbitration settlement costs of $4.1 million for the year ended December 31, 2023 consisted of the costs incurred related to the settlement of an arbitration proceeding with one of our licensees in the first quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accretion of debt discount and debt issuance costs is included in interest expense. Interest expense is shown below for the years ended December 31, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 535</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 535</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accretion of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 569</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the periods presented, we had no debt outstanding or interest expense incurred until we executed the Blue Owl Loan Agreement on December 15, 2023. &#160;The $0.6 million interest expense reported for the year ended December </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">31, 2023, represents interest incurred on the Blue Owl Loan since its inception. Interest expense is expected to increase in future years so long as the Blue Owl Loan remains outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table shows our activity in other income (expense), net for the&#160;years ended December 31, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,685</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 991</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (174)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (439)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 265</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40)</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,586</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,291</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investment income increased by $1.0 million for the year ended December 31, 2023 compared with the year ended December 31, 2022 due to higher market interest rates. For the years ended December 31, 2023 and 2022, the change in fair value of equity securities was due to the change in market price of shares of Rezolute&#8217;s common stock. &#160;For the year ended December 31, 2023, the change in fair value of contingent consideration was due to the reduction in the fair value of the $75,000 contingent consideration to zero related to the Bioasis RPA (see Note 5 to the consolidated financial statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Provision for Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded no income tax provision for the year ended December 31, 2023 and an income tax benefit of $15,000 for the year ended December 31, 2022. We continue to maintain a full valuation allowance against our remaining net deferred tax assets. We had a total of $5.9 million of gross unrecognized tax benefits, none of which would impact our effective tax rate to the extent that we continue to maintain a full valuation allowance against our deferred tax assets. We do not expect our unrecognized tax benefits to change significantly over the next twelve months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our unrestricted cash and cash equivalents, our working capital and our cash flow activities as of and for each of the periods presented (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 153,290</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 57,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 95,464</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 149,814</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 95,379</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18,158)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,279)</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (711)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (20,221)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,510</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 120,593</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,451)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 125,044</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 101,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37,551)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 139,275</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk93561944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Net cash used in operating activities for the year ended December 31, 2023 was $18.2 million and primarily included our operating expenses of $46.6 million partially offset by non-cash expenses of $26.2 million, which primarily </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">included stock-based compensation of $9.1 million and impairment charges of $15.8 million, a $1.5 million milestone payment received from Janssen and a $1.0 million milestone payment received from an undisclosed licensee. Net cash used in operating activities for the year ended December 31, 2022 was $12.9 million and primarily included our operating expenses of $23.4 million, partially offset by non-cash expenses of $4.4 million, which primarily included stock-based compensation of $3.6 million, partially offset by a $2.0 million milestone payment received from Rezolute, a $0.8 million milestone payment received from Takeda and a $0.8 million milestone payment received from an undisclosed licensee.</span></p><a id="_Hlk100751667"></a><a id="_Hlk53658901"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Net cash used in investing activities for the&#160;year ended December 31, 2023 was $0.7 million, and primarily included a $9.6 million payment to Aptevo for the acquisition of payment rights pursuant to the Aptevo CPPA in March 2023 and a $5.0 million payment to LadRx for the acquisition of payment rights pursuant to the LadRx Agreements in June 2023, partially offset by $7.3 million in commercial payments from sales of VABYSMO, $1.7 million in commercial payments from sales attributable to IXINITY and $5.0 million in milestone payments pursuant to the Viracta RPA. Net cash used in investing activities for the&#160;year ended December 31, 2022 was $20.2 million, and primarily included $15.2 million paid for the IP acquired pursuant to the ObsEva IP Acquisition Agreement in November 2022 and $8.0 million of regulatory milestone payments pursuant to the Affitech CPPA, partially offset by a $2.5 million milestone payment received from Kuros in July 2022 and a $0.5 million commercial payment received from Roche in August 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Net cash provided by financing activities for the year ended December 31, 2023 was $120.6 million and primarily included net proceeds of $125.7 million after the payment of $4.3 million of debt issuance costs and fees paid related to the Blue Owl Loan, partially offset by a payment of dividends of $5.5 million on our Series A and Series B Preferred Stock. <span style="background:#ffffff;">Net cash used in financing activities for the&#160;year ended December&#160;31, 2022 was $4.5 million and primarily included dividends on our Series A and Series B Preferred Stock of $5.5 million, partially offset by the receipt of net cash provided from the exercise of stock options after related tax payments of $1.0 million. </span></p><a id="_Hlk95311840"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 21.3pt;"><span style="font-style:italic;font-weight:bold;">Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have incurred significant operating losses since our inception and as of December 31, 2023, we had an accumulated deficit of $1.2 billion. As of December 31, 2023, we had $153.3 million in unrestricted cash and cash equivalents and $6.3 in restricted cash. Based on our current cash balance and our planned discretionary spending, such as royalty acquisitions, we believe that our current financial resources are sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have primarily financed our operations and acquisitions through debt facilities, the issuance of our common stock, Series A and Series B Preferred Stock, and amounts received as milestone payments under our license agreements. In December 2023, XRL entered into the Blue Owl Loan Agreement (see further details below in &#8220;Long-Term Debt&#8221;). We intend to use the net cash received from the Blue Owl Loan, together with our existing capital resources, to fund our ongoing company operations, to repurchase common stock and for working capital and other general corporate purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The generation of future revenues related to licenses, milestone payments, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Milestone payments earned in the years ended December 31, 2022 and 2023 are not indicative of anticipated milestone payments in future periods. We may seek additional capital through our 2018 Common Stock ATM Agreement or our 2021 Series B Preferred Stock ATM Agreement (see Note 12 to the consolidated financial statements), or through other public or private debt or equity transactions. Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common and preferred stock, which are subject to a number of development and business risks and uncertainties, our creditworthiness and whether were are able to raise such additional capital at a price or on terms that are favorable to us, if at all. If we are unable to raise additional funds when we need them, our business and operations may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Material Cash Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our material cash requirements in the short and long term consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Operating expenditures:</b> Our primary uses of cash and our operating expenses include employee and related costs, consultant fees to support our administrative and business development efforts, legal and accounting fees, insurance </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">costs and costs associated with our investor relations and IT services. Our planned spending includes increased personnel-related costs associated with the appointment of Mr. Hughes to Chief Executive Officer in a full-time capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To support our royalty aggregator business model, we engage third parties to assist in the evaluation of potential acquisitions of milestone payments and royalty streams. Additional operating expenses, including consulting and legal costs, may increase in 2024 in response to an anticipated increase in the volume of acquisition targets evaluated or completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2023 we entered into a lease for our headquarters in Emeryville, California. The lease commenced in November 2023 and has a term of 65 months. As of December 31, 2023, we expect to incur incremental undiscounted costs of $0.5 million associated with our building lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Long-Term Debt: </b>Under the Blue Owl Loan Agreement, the outstanding principal balance will bear interest at an annual rate of 9.875%. &#160;XRL is expected to make payments of interest under the Blue Owl Loan Agreement semi-annually, beginning in March 2024 using the royalties received on worldwide net sales of VABYSMO, pursuant to the Affitech CPPA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any royalty payments in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. As of December 31, 2023, XRL held restricted cash of $6.3 million in reserve accounts that may only be used to pay interest and administrative fees and XRL&#8217;s operating expenses pursuant to the Blue Owl Loan Agreement. As of December 31, 2023, the current and non-current portion of the initial term loan was $5.5 million and $118.5 million, respectively, and $0.2 million and $6.1 million of the restricted cash is classified as current and non-current, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">RPAs, AAAs and CPPAs: </b>A significant component of our business model is to acquire rights to potential future milestone payments and royalty payment streams. We expect to continue deploying capital toward these acquisitions in the near and long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have potential contingent consideration of $7.0 million recorded on our consolidated balance sheets as of December 31, 2023, which consists of $6.0 million for sales milestones due under our agreement with Affitech and $1.0 million for a milestone payment due under our agreement with LadRx. We have up to an additional $6.0 million and $5.0 million in milestone payments that may become due under the Affitech CPPA and LadRx Agreement, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we have potential sales-based milestone payments that may become due under our agreements with Aronora and Kuros. All of these milestones and royalty payments represent a portion of the funds we may receive in the future pursuant to these agreements, and therefore we expect these payments to be fully funded by the related royalty or commercial payment receipts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Collaborative Agreements, Royalties and Milestone Payments</b>: We may need to make potential future milestone payments and pay legal fees to third parties as part of our licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by our licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on our consolidated balance sheet as of December 31, 2023. We are unable to determine precisely when and if our payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. We expect all payments due to be funded by a portion of the related milestone or royalty revenue we receive or we expect these payments to be reimbursed by our licensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Dividends</b>: Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per share of Series A Preferred Stock per year). Holders of Series B Depositary Shares are entitled to receive, when and as declared by our Board, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year, which is equivalent to $2,093.75 per year per share of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Series B Preferred Stock ($2.09375 per year per depositary share). Dividends on the Series A and Series B Preferred Stock are payable in arrears on or about the 15th day of January, April, July and October of each year. Since original issuance, all dividends have been paid as scheduled. We expect to continue making these dividend payments as scheduled using our existing capital resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 2 to the consolidated financial statements for information regarding new accounting pronouncements.</p><a id="_30c60c81_6a73_42b6_8326_65277abe366b"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f165d101_fa4a_421f_ab29_6f9d872c8cfd"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following consolidated financial statements of the registrant, related notes and report of independent registered public accounting firm are set forth beginning on page&#160;F-1 of this report.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Deloitte_Audit_Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID No. 34)</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_29154"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_524071"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"><span style="font-style:normal;font-weight:normal;">Notes&#160;to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_50bf7140_7e80_4466_9612_fab7993688cd"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1c86de19_c8a8_41fa_88e9_7fe905ca5829"></a><a id="Item9AControlsandProcedures_282993"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and our Senior Vice President, Finance and Chief Financial Officer (our principal financial and accounting officer), we conducted an evaluation of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Our disclosure controls and procedures are intended to help ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms and (ii)&#160;accumulated and communicated to our management, including our Chief Executive Officer and Senior Vice President, Finance and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures. Based on this evaluation, our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management, including our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)). The Company&#8217;s internal control system was designed to provide reasonable assurance to our management and Board regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with accounting principles generally accepted in the U.S.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control&#8212;<i style="font-style:italic;">Integrated Framework (2013 Framework)</i>. Based on this assessment, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report does not include an attestation report from our registered public accounting firm regarding our internal control over financial reporting due to an exemption for &#8220;non-accelerated filers.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.<span style="font-size:12pt;"> &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0baf5b7b_4388_406f_8a85_86cbe0e2cb5e"></a><a id="Item9BOtherInformation_968719"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(b) Trading Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal quarter ended December 31, 2023, no director or Section 16 officer <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_HxFDfUSCw0iX3AKlWFtcvw">adopted</ix:nonNumeric> or <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_P43-eYyK_keh2MYxlIPNIA">terminated</ix:nonNumeric> any Rule 10b5-1 trading arrangement or <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_xLT7NSq_4kGgn5IcOhJW0A">non-Rule 10b5-1</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_z5EOs4rM40GupkV3bNTKzQ">trading arrangement</ix:nonNumeric> (in each case, as defined in Item 408(a) of Regulation S-K).</p><a id="_e33a19c7_756c_425b_b8e3_a721ba344b0e"></a><a id="risk"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable. </p><a id="_Hlk91769520"></a><a id="_6d20a9e4_fd8b_4c42_87c9_56b40ba41c21"></a><a id="PARTIII_322550"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III </p><a id="Item10DirectorsExecutiveOfficersCorporat"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;10.&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;">Our Board currently consists of seven members. The following is a brief biography of each member of our Board. There are no family relationships among any of our directors or executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.1pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Age</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Owen Hughes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">49</p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jack L. Wyszomierski</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chairman of the Board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Heather L. Franklin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">58</p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Natasha Hernday</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">52</p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Barbara Kosacz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Joseph M. Limber</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">71</p></td></tr><tr><td style="vertical-align:bottom;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Matthew Perry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">51</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Owen Hughes</i> was appointed full-time Chief Executive Officer in January 2024 after serving as our Executive Chairman of the Board and Interim Chief Executive Officer since January 2023. Mr. Hughes has served as the Chief Executive Officer of Sail Bio, Inc., a private biotechnology company focused on addressing toxic proteinopathies, since February 2022 and served as the Chief Executive Officer and co-founder of Cullinan Oncology, Inc., a publicly-traded oncology company, from September 2017 to October 2021. Previously, Mr. Hughes served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc., a biotechnology company focused on type II diabetes, from February 2013 to August 2017. Prior to his operating roles, Mr. Hughes spent 16 years on Wall Street in various capacities, including roles at Brookside Capital, an operating division of Bain Capital and Pyramis Global Advisors, a Fidelity Investments Company. Mr. Hughes has served on the Board of Ikena Oncology, Inc., a publicly-traded oncology </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">company, since December 2022 and as a member of the Board of Directors of C4 Therapeutics since December 2023. Mr. Hughes served on the Board of Radius Health, Inc., a publicly-traded biopharmaceutical company, from April 2013 to August 2022 until its sale to Gurnet Point Capital and Patient Square Capital; Translate Bio, Inc., a messenger RNA therapeutics company, from July 2016 until its acquisition by Sanofi in September 2021; and FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital, from February 2021 to December 2021. Mr. Hughes received a B.A. in History from Dartmouth College. Mr. Hughes has significant experience with biopharmaceutical companies and brings the unique perspective of the Chief Executive Officer of the Company to the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Heather L. Franklin</i> has been a director since August 2021. Ms. Franklin has over 30 years of broad biotechnology expertise. She founded Blaze Bioscience, Inc. in 2011 and has led the company from its infancy to becoming a late clinical stage company. She has served as its Executive Board Chair since January 2024 and served as its President and Chief Executive Officer from 2011 through 2023. Prior to establishing Blaze, Ms. Franklin spent 10 years at ZymoGenetics in positions of increasing responsibility, ultimately serving as senior vice president, business development. &#160;She was a member of the executive management team and was responsible for business development including structuring and negotiating in- and out-licenses and collaboration agreements for products at all stages of development from research through commercial. &#160;Her other responsibilities included alliance management, strategic planning, portfolio management and pipeline marketing. Earlier in her career, she held roles in program management at Amgen and Targeted Genetics. Ms. Franklin received her M.B.A. from The Wharton School of the University of Pennsylvania, her M.S. from the University of Washington and her B.S. from University of North Carolina at Chapel Hill. Ms. Franklin brings to the Board extensive executive management experience including early to late-stage licensing expertise and financial oversight in the biotechnology industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Natasha Hernday </i>has been a director since July 2020. Ms. Hernday was the Chief Business Officer and a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc., where she worked from 2011 to 2023. &#160;She helped execute the sale of Seagen to Pfizer in 2023 and was a member of the executive integration planning team to merge the two oncology businesses. From 1994 through 2010, after starting her career in molecular and mammalian cell biology, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including as Director, Mergers &amp; Acquisitions and as Director, Out-Partnering. She serves on the Board for Alpine Immune Sciences, Inc. and on the Knight Campus External Advisory Board for the University of Oregon. Ms. Hernday previously served on the Board of PDL BioPharma, Inc. Ms. Hernday received her BA in microbiology from the University of California at Santa Barbara and M.B.A. from Pepperdine University. Ms. Hernday brings to the Board extensive experience in advising biotechnology companies on matters of leadership, corporate strategy, collaborations and acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Barbara Kosacz</i> has been a director since January 2019. From July 2020 until February 2024, Ms. Kosacz served as Chief Operating Officer and General Counsel of Kronos Bio, Inc., where she continues as a strategic advisor. &#160;Ms. Kosacz was previously a partner at Cooley LLP since 2002, where she currently serves as a Senior Counsel, and has more than 25 years of experience in counseling clients in the life sciences arena, ranging from early-stage startups to larger public companies, venture funds, investment banks and non-profit institutions. She serves on the Board of Directors of Athira Pharma, Inc., where she serves as Chair of the compensation committee, and has also served on the Board of Directors of Phoenix Biotech Acquisition Corp., Locus Walk Acquisition Corp., and Arsenal Biosciences, Inc. &#160;She also has served as a member of the BIO Emerging Companies&#8217; Section Governing Board, the Board of Trustees of the Keck Graduate Institute, and the advisory board of Locust Walk Partners. &#160;Ms. Kosacz has been a speaker at multiple life sciences-related conferences, as well as guest lecturer at the University of California, Berkeley School of Law, Stanford University, the University of Pennsylvania and Columbia University on biotechnology law, biotech business models, corporate partnering negotiations and deal structures and bioethics. Recognized by Best Lawyers in America since 2008, Ms. Kosacz and was listed as a &#8220;leading lawyer&#8221; for healthcare and life sciences in the 2018 Legal 500, as a &#8220;Band 1&#8221; attorney in the 2018 edition of Chambers USA: America&#8217;s Leading Lawyers for Business and recognized as a &#8220;highly recommended transactions&#8221; lawyer by IAM Patent 1000 for her &#8220;nearly three decades advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.&#8221; She received her Juris Doctor degree from the University of California, Berkeley School of Law, and her bachelor&#8217;s degree from Stanford University. Ms. Kosacz brings extensive experience in structuring and negotiating strategic combinations and business development &#160;transactions and advising biotechnology companies to the Board.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Joseph M. Limber</i> has been a director since December 2012. Mr. Limber currently serves as President and Chief Executive Officer and a member of the Board of Secura Bio, Inc., a position he has held since February 2019. Prior to that, Mr. Limber served as President and Chief Executive Officer of Genoptix, Inc. from March 2017 through December 2018. Mr. Limber served as Executive Chairman of ImaginAb from January 2016 through November 2017. Mr. Limber served as President and Chief Executive Officer of Gradalis, Inc. from July 2013 through April 2015. Mr. Limber served as President and Chief Executive Officer of Prometheus Laboratories Inc., a subsidiary of Nestl&#233; Health Science, from December 2003 through April 2013 and as a member of its Board from January 2004 through April 2013. From January 2003 to July 2003, Mr. Limber was a consultant and interim Chief Executive Officer for Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was the President and Chief Executive Officer of ACLARA BioSciences, Inc. (now Monogram Biosciences, Inc.), a developer of assay technologies and lab-on-a-chip systems for life science research. From 1996 to 1998, he was the President and Chief Operating Officer of Praecis Pharmaceuticals, Inc. (acquired by GlaxoSmithKline plc), a biotechnology company focused on the discovery and development of pharmaceutical products. Prior to Praecis, Mr. Limber served as Executive Vice President of SEQUUS Pharmaceuticals, Inc. (acquired by Alza Corporation and now part of the Johnson &amp; Johnson family of companies). He also held management positions in marketing and sales with Syntex Corporation (now F. Hoffmann-La Roche Ltd.) and with Ciba-Geigy Corporation (now Novartis AG). Mr. Limber holds a B.A. from Duquesne University. Mr. Limber brings to the Board his experience in successfully developing markets for specialty pharmaceutical products and managing the critical transition from research organization to commercial entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Matthew Perry </i>has been a director since February 2017. Mr. Perry was the President of Biotechnology Value Fund Partners L.P. (&#8220;BVF&#8221;) and portfolio manager for the underlying funds managed by the firm. BVF Partners is a private investment partnership that has focused on small-cap, value-oriented investment opportunities for more than 20 years. Mr. Perry joined BVF Partners in December 1996 and has been a successful lead investor in dozens of transactions. He has positively influenced corporate direction for numerous biotechnology companies during the course of his career. In January 2016, Mr. Perry was named to CTI BioPharma Corp.&#8217;s Board and was a member of its Compensation Committee until the company was sold in June 2023.. Mr. Perry is also a co-founder and director of Nordic Biotech Advisors ApS, a venture capital firm based in Copenhagen, Denmark. He holds a B.S. degree from the Biology Department at the College of William and Mary. Mr. Perry brings extensive management consulting experience and experience investing in biotechnology companies to the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Jack L. Wyszomierski</i> has been a director since August 2010 and was appointed Chairman of the Board in January 2024. From 2004 until his retirement in 2009, Mr. Wyszomierski was Executive Vice President and Chief Financial Officer of VWR International, LLC, a global laboratory supply, equipment and distribution business that serves the world&#8217;s pharmaceutical and biotechnology companies, as well as industrial and governmental organizations. At Schering-Plough, a global health care company which had worldwide sales of over $8 billion in 2004, Mr. Wyszomierski held positions of increasing responsibility from 1982 to 2004 culminating in his appointment as Executive Vice President and Chief Financial Officer. Mr. Wyszomierski also serves on the Board of Athersys, Inc., Exelixis, Inc. and SiteOne Landscape Supply, Inc., and served on the Board of Unigene Laboratories, Inc. from 2012 to 2013. He holds an M.S. in Industrial Administration and a B.S. in Administration, Management Science and Economics from Carnegie Mellon University. Mr. Wyszomierski brings his considerable financial expertise to the Board, the Audit Committee and the Compensation Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biographical and other information regarding our executive officers is set forth below. For Mr. Hughes&#8217; biographical information, see &#8220;Directors&#8221; above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Thomas Burns</i>, age 50, has been our Senior Vice President, Finance and Chief Financial Officer since March 2017. He joined the Company in August 2006 and since then has held various senior finance and accounting roles. Mr. Burns has over 25 years of experience in accounting and finance in both biotechnology and high-technology companies. Prior to his employment with the Company, he held multiple senior financial management positions at high-technology companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates) and Conner Technology. Mr. Burns received his M.B.A. from Golden Gate University and his Bachelor&#8217;s degree from Santa Clara University. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Bradley Sitko</i>, age 43, has been our Chief Investment Officer since January 2023. Mr. Sitko served as Managing Director, Strategic Finance, at RTW Investments, LP, a global, full life-cycle investment firm in the biopharmaceutical and medical technology sectors from November 2019 to January 2023 where he led the royalty monetization, structured finance and alternatives efforts of the firm. He also served as a member of the Board of such firm&#8217;s Irish collective asset-management vehicle (ICAV), RTW Investments ICAV. During that same time, he was Chief Financial Officer of Ji Xing Pharmaceuticals Limited, a Shanghai-based biopharmaceutical company, incubated by RTW Investments, LP with responsibilities involving company formation, scaling operations, fundraising, and in-licensing of biotech assets. From March 2015 to November 2019, Mr. Sitko served as Vice President, Finance, Operations and Corporate Development of DNAnexus, Inc., a genetic data management company with responsibilities involving restructuring and recapitalization, fundraising, finance and operations, strategic planning and industry partnerships. Mr. Sitko also served as a Director at MTS Health Partners, an investment bank, from October 2008 to March 2015, where he advised on royalty monetization, financing, restructurings, and mergers and acquisitions within the biopharmaceutical and healthcare services sectors. Mr. Sitko received a B.A. in History and Sociology of Science from the University of Pennsylvania and an M.B.A. from Columbia Business School.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has adopted a Code of Ethics that applies to all of our employees, officers and directors including the Chief Executive Officer (principal executive officer) and the Senior Vice President, Finance and Chief Financial Officer (principal financial and principal accounting officer), or persons performing similar functions. Our Code of Ethics is posted on the Company&#8217;s website at https://investors.xoma.com/corporate-governance. We intend to satisfy the applicable disclosure requirements regarding amendments to certain provisions of the Code of Ethics, or waivers of the Code of Ethics granted to executive officers, by posting such information on our website within four business days following the date of the amendment or waiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Delinquent Section 16(a) Reports</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section 16(a) of the Exchange Act requires the Company&#8217;s directors, officers and persons who beneficially own more than 10% of a registered class of our equity securities to file initial reports of ownership and reports of changes in ownership of our equity securities with the SEC. To our knowledge, based solely on our review of Forms 3, 4 and 5 filed with the SEC or written representations that no Form 5 was required, during the year ended December 31, 2023, we believe that our directors, officers and persons who beneficially own more than 10% of a registered class of our equity securities filed the required reports on a timely basis, except that, due to administrative error, one Form 3 was filed late with respect to Mr. Hughes and one Form 4 to report grants of stock options was filed late with respect to Mr. Sitko. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Audit Committee and Audit Committee Financial Expert</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has a separately designated Audit Committee comprised solely of independent directors. Each of Mr. Limber, Ms. Hernday and Mr. Wyszomierski qualifies as an &#8220;audit committee financial expert,&#8221; as that term is defined in the rules and regulations established by the SEC, and all members of the Audit Committee are &#8220;financially literate&#8221; under Nasdaq listing rules.</p><a id="_Hlk91769647"></a><a id="_576cab3c_0e79_4d94_8be4_2855733c8776"></a><a id="Item11ExecutiveCompensation_327220"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;EXECUTIVE COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The primary objectives of our executive compensation program are to enable the Company to attract, motivate and retain outstanding individuals and to align their success with that of our stockholders through the creation of stockholder value. We attract and retain executives by providing an executive compensation package that is competitive with the companies with which we compete for talent. We seek to create alignment between executive compensation and the interests of our stockholders through a focus on short-term and long-term incentive compensation programs that tie each executive officer&#8217;s pay to the Company&#8217;s near term and longer-term performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;">The following table sets forth certain summary information for the years indicated concerning the compensation earned by the Company&#8217;s principal executive officer and the other most highly compensated executive officers during 2023 (&#8220;named executive officers&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:28.1pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b></p></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus</b></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock Awards</b></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option Awards</b></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Equity Incentive Plan Compensation</b></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All Other Compensation</b></p></td><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"> (3)</sup></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"> (4)</sup></p></td><td style="vertical-align:bottom;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> ($)</b></p></td><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:top;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 125,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,288,985</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,482,735</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Burns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 453,871</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 112,567</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,509,645</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 181,549</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,250</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,268,882</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Senior Vice President, Finance and Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:top;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 424,950</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 470,850</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 101,988</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,250</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,008,038</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:top;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 110,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 449,276</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,243,870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 250,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,083</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,560,229</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Chief Investment Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;border-bottom:1px solid #000000;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amounts in this column for 2023 include Mr. Sitko&#8217;s sign-on bonus, as described in more detail under &#8220;Employment Agreements and Change of Control Severance Agreements&#8221; below, and retention bonus payments made to Mr. Burns in January 2023 of $27,016 and October 2023 of $85,551 pursuant to the Company&#8217;s Amended Retention Plan. </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The amounts in this column represent the aggregate grant date fair value of PSUs, calculated in accordance with FASB ASC Topic 718. See Note 10 to the consolidated financial statements for information regarding assumptions underlying valuation of PSUs.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(3)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The amounts in this column represent the aggregate grant date fair value for option awards calculated in accordance with FASB ASC 718. See Note 10 to the consolidated financial statements for information regarding assumptions underlying valuation of option awards.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amounts in this column for 2023 represent the bonuses earned by the named executive officers under the 2023 Cash Bonus Plan, as described in more detail under &#8220;Narrative to Summary Compensation Table&#8212;2023 Cash Bonus Plan&#8221; below.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(5)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Hughes was appointed Interim Chief Executive Officer effective January 1, 2023, and subsequently appointed Chief Executive Officer on January 7, 2024.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(6)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This amount reflects the fair value on the date of contribution of 626 shares of common stock contributed by the Company to Mr. Burns&#8217; account under the Deferred Savings Plan (as defined below).</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(7)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Sitko was appointed Chief Investment Officer effective January 3, 2023.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This amount reflects the fair value on the date of contribution of 394 shares of common stock contributed by the Company to Mr. Sitko&#8217;s account under the Deferred Savings Plan (as defined below).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Narrative to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Process for Setting Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our Compensation Committee has primary responsibility for the implementation and oversight of our executive officer compensation. The Compensation Committee considers the recommendations of Mr. Hughes on the compensation for our executive officers (other than himself) but makes the final determinations regarding executive compensation decisions. Our Compensation Committee has retained the services of Compensia to assist in the development and design of our executive compensation program. &#160;In 2023, Compensia developed a peer group to be used by our Compensation Committee in the evaluation of 2023 executive and director compensation determinations. &#160;In addition, Compensia presented peer group and industry data with respect to base salaries, target annual bonuses and equity compensation. &#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Base Salary</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our Compensation Committee recognizes the importance of base salary as an element of compensation that helps to attract and retain our executive officers. We provide base salary as a fixed source of cash compensation to recognize each named executive officer&#8217;s day-to-day responsibilities, which is designed to provide an appropriate and competitive base level of current cash income for the named executive officers. The 2023 annual base salary of Mr. Burns was determined and approved by the Compensation Committee in February 2023, effective as of January 1, 2023. The annual base salary of Mr. Hughes and Mr. Sitko was approved by the Board in connection with the negotiation of their employment agreements effective January 2023. The 2023 base salaries were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:34.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023 Base Salary</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 125,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Burns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 453,871</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 500,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Mr. Hughes served in a part-time capacity during 2023.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">2023 Cash Bonus Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In February 2023, the Board approved the 2023 Cash Bonus Plan for the 2023 fiscal year and approved target bonus opportunities for each named executive officer under the 2023 Cash Bonus Plan as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:42.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target Bonus </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:42.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(as a % of FY23 Base Salary)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Burns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Bonuses under the 2023 Cash Bonus Plan were based 100% upon the Company&#8217;s achievement of the following corporate objectives: (a) total shareholder return, (b) acquisition of non-dilutive capital and (c) royalty asset acquisitions, each established by the Board in February 2023. The bonuses earned by each named executive officer under the 2023 Cash Bonus Plan set forth in the &#8220;Non-Equity Incentive Plan Compensation&#8221; column of the Summary Compensation Table above were approved by our Compensation Committee based on achievement of the 2023 corporate objectives at 100% of target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our executive officers with the financial interests of our stockholders. In addition, we believe that our ability to grant equity-based awards helps us to attract, retain and motivate executive officers, and encourages them to devote their best efforts to our business and financial success. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inducement Stock Options </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of their respective employment agreements, on January 3, 2023, we granted inducement stock options to each of Mr. Hughes and Mr. Sitko in accordance with Nasdaq Listing Rule 5635(c)(4). A portion of the options were granted with an exercise price equal to the closing price on the date of grant, while the remainder were granted with an exercise price of $30.00, an over 60% premium to closing price on such date. The table below sets forth the number of shares subject to each inducement stock option grant:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$18.66 Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$30.00 Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 300,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 250,000</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The inducement options granted to Mr. Hughes with an $18.66 exercise price vested in four equal quarterly installments through December 31, 2023, and the inducement options granted to Mr. Hughes with a $30.00 exercise price vest in equal monthly installments until January 1, 2026. All of the inducement options granted to Mr. Sitko vest as to 25% on the first anniversary of the date of grant and monthly thereafter through the fourth anniversary of the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">PSUs </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">In May 2023, Mr. Burns and Mr. Sitko were granted 91,600 and 30,200 PSUs, respectively, under our 2010 Plan. Vesting of the PSUs requires satisfaction of both a performance requirement and a service-based requirement. The performance requirement is achieved with respect to the number of PSUs set forth in the table below when the volume-weighted average price of our common stock equals or exceeds the prices set forth below for any 30 consecutive calendar-day period prior to the earlier of the third anniversary of the date of grant or the Company&#8217;s 2026 annual meeting of shareholders:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$30.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$35.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$40.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$45.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total PSUs</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas M. Burns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,320</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,770</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,937</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,573</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,600</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,067</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,067</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,200</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The service based requirement vests as to one-third on the date the performance requirement is achieved, as to one-third on the later of the second anniversary of the date of grant or the date the performance requirement is achieved, and as to one-third on the later of the third anniversary of the date of grant or the date the performance requirement is achieved, in each case, subject to the named executive officer&#8217;s continued employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In January 2024, pursuant to the terms of Mr. Hughes&#8217; amended and restated employment agreement, he was granted 275,000 PSUs under our 2010 Plan with the same terms as the PSUs granted to Mr. Burns in May 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$30.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$35.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$40.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$45.00 Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total PSUs</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 160,078</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,350</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,835</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,737</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 275,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards as of December&#160;31, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The following table provides information as of December&#160;31, 2023, regarding unexercised options held by each of our named executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;white-space:nowrap;width:50.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option Awards</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:41.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock Awards</b></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Underlying</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercised</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercisable</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Underlying</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercised</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercisable</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Price</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Expiration</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:21.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Incentive</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)(1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,917</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,083</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas M. Burns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/27/2014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 652</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 178.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/27/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6/16/2014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,350</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 93.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6/16/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/26/2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,537</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/26/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4/3/2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4/3/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/22/2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/22/2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75,778</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/10/2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/14/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/14/2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/13/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14.33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/13/2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/13/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/13/2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/17/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,941</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38.93</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/17/2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/22/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,889</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2/22/2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/8/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,973</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,027</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;">   11/8/2032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5/18/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,600</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,694,600</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 300,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 250,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1/3/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5/18/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,200</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 558,700</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amounts in this column reflect the value of outstanding PSUs as of December 31, 2023, based on a per share price of $18.50, the closing price of our common stock on December 29, 2023, the last trading day of 2023.</p></td></tr><tr><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These option awards vested in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.</p></td></tr><tr><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(3)</p></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These option awards vest in equal monthly installments over 36 months following the date of grant.</p></td></tr><tr><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">One-third of the shares subject to the award vested on the first anniversary of the date of grant and the remaining shares vest monthly over the two years thereafter.</p></td></tr><tr><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(5)</p></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These PSUs vest upon achievement of the stock price hurdles and satisfaction of the service requirement described under &#8220;Narrative to Summary Compensation Table&#8212;Equity Compensation&#8212;PSUs&#8221; above.</p></td></tr><tr><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(6)</p></td><td style="vertical-align:top;width:96.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">One-fourth of the shares subject to the award vested on the first anniversary of the date of grant and the remaining shares vest monthly over the three years thereafter.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Retirement Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We do not maintain and have not ever maintained a defined benefit pension plan or non-qualified deferred compensation plan. Each of our named executive officers is eligible to participate in the Company&#8217;s Deferred Savings Plan, a defined contribution retirement plan under Section 401(a) of the Internal Revenue Code of 1986, on the same basis as other eligible employees. Participants may make contributions to defer up to 80% of their eligible compensation (subject to applicable limits). The Company may, at its sole discretion, make matching contributions each plan year, in cash or in shares of common stock. In January 2024, the Company made matching contributions in shares of common stock equal to 50% of each participant&#8217;s 2023 deferrals. Matching contributions vest on a straight-line at 25% per year of continuous service and a participant is 100% vested after four years of continuous service. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Employment Agreements and Change of Control Severance Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Owen Hughes Employment Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In connection with his appointment as Interim Chief Executive Officer, we entered into an employment agreement with Mr. Hughes (the &#8220;2023 Agreement&#8221;) pursuant to which he was eligible to receive an annual base salary of $125,000 and a target annual bonus equal to 55% of his base salary. In addition, the 2023 Agreement provided for the grant of inducement stock options, as described in more detail above. In January 2024, Mr. Hughes&#8217; employment agreement was amended and restated in connection with his appointment as Chief Executive Officer (the &#8220;2024 Agreement&#8221;). Under the 2024 Agreement, Mr. Hughes is eligible to receive an annual base salary of $575,000 and a target annual bonus equal to 60% of his annual base salary. In addition, the 2024 Agreement provided for the grant of 275,000 PSUs, as described in more detail above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under the 2023 Agreement, if Mr. Hughes&#8217; employment has been terminated as a result of the appointment of a new Chief Executive Officer prior to January 1, 2024, then, subject to his execution of a release of claims, he would have been eligible to receive severance in the form of base salary continuation through January 1, 2024. Under the 2024 Agreement, Mr. Hughes is eligible to receive severance benefits in the event of a termination by us without cause, a resignation by Mr. Hughes for good reason or his death or disability, subject to his execution of a release of claims, as follows: (i) 1.0 times his base salary; (ii) any earned but unpaid bonus for the prior year; (iii) a pro-rata portion of his target bonus for the year of termination; (iv) subsidized continued health coverage for up to 12 months; and (v) except in the event of death or disability, 12 months of outplacement services not to exceed $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">However, if the termination without cause or resignation for good reason occurs during the period beginning two months before and ending 12 months after a change in control of the Company, Mr. Hughes would instead be eligible to receive the following severance benefits: (i) 2.0 times his base salary; (ii) any earned but unpaid bonus for the prior year; (iii) 2.0 times his target bonus for the year of termination; (iv) subsidized continued health coverage for up to 24 months; (v) accelerated vesting of 100% of outstanding time-based equity awards, with the post-termination exercise period of any stock options extended for 60 months (or through the remainder of the original maximum term); (vi) accelerated vesting of a pro-rated portion of outstanding performance-based awards, based on actual performance through the date of such termination; and (vii) 12 months of outplacement services not to exceed $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Thomas Burns Employment Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On August 7, 2017, the Company entered into an amended and restated employment agreement with Mr. Burns, which was subsequently amended on April 4, 2022 and November 1, 2022. Under the employment agreement, upon a termination of Mr. Burns&#8217; employment by the Company without cause, due to his death or permanent disability, or upon his resignation for good reason, in each case subject to execution or a release of claims, Mr. Burns will be entitled to: (i) a severance payment equal to 75% of his base salary; (ii) a severance payment equal to the pro-rated portion of his target bonus for the year of termination; (iii) payment of any earned but unpaid bonus for the prior performance period; (iv) if elected, the full cost of continuation coverage under the Company&#8217;s group health plans for up to nine months; and (v) outplacement services for nine months not to exceed $15,000 in value. Pursuant to his employment agreement, all payments and benefits to Mr. Burns thereunder are subject to his compliance with the confidentiality and non-competition </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">provisions thereof. Under the amendments to his employment agreement, Mr. Burns was deemed &#8220;retirement eligible&#8221; for purposes of his equity awards under the terms of his equity award agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Thomas Burns Change of Control Severance Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Mr. Burns has also entered into a change of control severance agreement with the Company, which provides for severance benefits (in lieu of those described under his employment agreement) if his employment is terminated by the Company without cause or if he resigns with good reason, in either case, within two months prior to signing an agreement for a change of control or within 12&#160;months after a change of control. Subject to execution of a release of claims, these severance payments and benefits include: (i) accelerated vesting of 100% of outstanding time-based equity awards, with the post-termination exercise period of any stock options extended for 60 months (or through the remainder of the original maximum term); (ii) accelerated vesting of a pro-rated portion of outstanding performance-based awards, based on actual performance through the date of such termination; (iii) a severance payment equal to 1.5x his base salary and 1.5x his target bonus for the year of termination; (iv) if elected, the full cost of continuation coverage under the Company&#8217;s group health plans for up to 18 months; and (v) outplacement services for 12 months not to exceed $15,000 in value. The agreement also includes a &#8220;better&#160;after-tax&#8221;&#160;provision, pursuant to which payments to Mr. Burns are either reduced or paid in full, whichever results in a greater economic benefit to the executive officer (after calculation of all taxes, including any excise taxes, on such payments).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under the change of control severance agreement, a &#8220;change of control&#8221; is generally defined as the occurrence of any of the following events: (i)&#160;a merger, amalgamation or acquisition in which the Company is not the surviving or continuing entity, except for a transaction the principal purpose of which is to change the jurisdiction of the Company&#8217;s organization; (ii)&#160;the sale, transfer or other disposition of all or substantially all of the assets of the Company; (iii)&#160;any other reorganization or business combination in which 50% or more of the Company&#8217;s outstanding voting securities are transferred to different holders in a single transaction or series of related transactions; (iv)&#160;any approval by the stockholders of the Company of a plan of complete liquidation of the Company; (v)&#160;any person becoming the &#8220;beneficial owner,&#8221; directly or indirectly, of securities of the Company representing more than 50% of the total voting power represented by the Company&#8217;s then-outstanding voting securities; or (vi)&#160;a change in the composition of the Board, as a result of which fewer than a majority of the directors are incumbent directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Bradley Sitko Employment Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In connection with his appointment as Chief Investment Officer, we entered into an employment agreement with Mr. Sitko, pursuant to which he was eligible to receive an annual base salary of $500,000, a target annual bonus equal to 50% of his base salary, and a $110,000 signing bonus. The signing bonus was subject to repayment if Mr. Sitko resigned without good reason or was terminated for cause prior to January 3, 2024. In addition, the employment agreement provided for the grant of inducement stock options, as described in more detail above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under his employment agreement, Mr. Sitko is eligible to receive severance benefits in the event of a termination by us without cause, a resignation by Mr. Sitko for good reason or his death or disability, subject to his execution of a release of claims, as follows: (i) 1.0 times his base salary; (ii) a pro-rata portion of his target bonus for the year of termination; (iii) any earned but unpaid bonus for the prior year; (iv) subsidized continued health coverage for up to 12 months; and (v) except in the event of death or disability, 12 months of outplacement services not to exceed $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">However, if the termination without cause or resignation for good reason occurs during the period beginning two months before and ending 12 months after a change in control of the Company, Mr. Sitko would instead be eligible to receive the following severance benefits: (i) 1.5 times his base salary; (ii) 1.5 times his target bonus for the year of termination; (iii) any earned but unpaid bonus for the prior year; (iv) subsidized continued health coverage for up to 18 months; (v) accelerated vesting of 100% of outstanding time-based equity awards, with the post-termination exercise period of any stock options extended for 60 months (or through the remainder of the original maximum term); (vi) accelerated vesting of a pro-rated portion of outstanding performance-based awards, based on actual performance through the date of such termination; and (vii) 12 months of outplacement services not to exceed $15,000.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_AEIOULastRenderedPageBreakAEIOU64"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt;"><b style="font-weight:bold;">Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Our director compensation program is designed to attract and retain non-employee directors while aligning the interests of our non-employee directors with those of our stockholders. Our Compensation Committee, in consultation with Compensia, evaluates our director compensation policy on an annual basis in consideration of the director compensation programs at the companies in our Peer Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Director Compensation Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">After consultation with Compensia and pursuant to the compensation review process described above, the Compensation Committee made certain changes to&#160;the&#160;non-employee&#160;director&#160;compensation program which were effective as of May 17, 2023. Specifically, the annual equity grant to continuing directors was increased from $100,000 to $150,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">During 2023, each non-employee director was entitled to receive an annual retainer of $40,000, plus an additional (1) $20,000, in the case of the Chair of the Audit Committee, (2) $9,000, in the case of any other member of the Audit Committee, (3) $15,000, in the case of the Chair of the Compensation Committee, (4) $7,500, in the case of any other member of the Compensation Committee, (5) $12,000, in the case of the Chair of the Nominating &amp; Governance Committee, (6) $6,000, in the case of any other member of the Nominating &amp; Governance Committee and (7) $40,000, in the case of the Chairman of the Board or Lead Independent Director. The Company&#8217;s directors do not receive meeting fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Each non-employee director whose service continues following the annual meeting is entitled to receive an annual option grant valued at $150,000 that vests monthly over one year. Each new non-employee director is entitled to receive an initial option grant valued at $250,000 that vests monthly over three years and a pro-rata portion of the annual option grant that vests monthly from grant date until the next annual grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Directors who are employees of the Company receive no additional compensation for services as members of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;">The 2010 Plan limits director compensation, including cash fees and the grant date fair value of any stock awards, to $750,000 for each calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt;"><b style="font-weight:bold;">Director Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;">The table below sets forth the 2023 compensation for non-employee directors who served at any time during 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Earned or</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Paid in</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Cash ($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Awards</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Heather L. Franklin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,912</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 203,949</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natasha Hernday</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 207,640</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barbara Kosacz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 196,037</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph M. Limber</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 210,037</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Perry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 197,537</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">W. Denman Van Ness<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,693</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,693</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jack L. Wyszomierski</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,488</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 232,525</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;background:#ffffff;border-bottom:1px solid #000000;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The amounts in this column represent the aggregate grant date fair value for option awards computed in accordance with FASB ASC Topic&#160;718. See Note&#160;10 to the consolidated financial statements for information&#160;regarding assumptions underlying valuation of equity awards. As of December&#160;31, 2023, the aggregate number of options outstanding for each&#160;non-employee&#160;director were as follows: Ms. Franklin: 37,245, Ms. Hernday: 38,315, Ms. Kosacz: 59,362, Mr. Limber: 60,600, Mr. Perry: 59,657 and Mr. Wyszomierski: 60,600.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Van Ness did not stand for re-election at the 2023 annual meeting of stockholders.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk91769690"></a><a id="_1c38ccb3_4161_4c0c_ad3f_8c30cf095edc"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;12.&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The following table sets forth certain information regarding: (i) each stockholder or group of stockholders known by the Company to be the beneficial owner of more than 5% of the Company&#8217;s issued and outstanding Common Stock, (ii) each of our directors and nominees, (iii) each of our named executive officers and (iv) all of our current directors and executive officers as a group. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Beneficial ownership is determined in accordance with the rules of the SEC, and thus represents voting or investment power with respect to our securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days after January 31, 2024. The percentages in the table below are based on an aggregate of 11,550,728 shares of Common Stock issued and outstanding as of January 31, 2024 (plus any shares that such person has the right to acquire within 60 days after the date of this table). Except as otherwise indicated in the footnotes, amounts are as of January 31, 2024, and, to our knowledge, each of the stockholders has sole voting and investment power with respect to all shares of Common Stock beneficially owned, subject to community property laws where applicable. The address for each director and executive officer listed in the table below is c/o XOMA Corporation, 2200 Powell Street, Suite 310, Emeryville, California 94608.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Shares of Common Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Beneficially Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Beneficially Owned(%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5% Stockholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Entities affiliated with BVF Inc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,633,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FMR LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,155,033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Named Executive Officers and Directors:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Burns<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 275,564</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bradley Sitko<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 167,911</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Owen Hughes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 132,667</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew D. Perry<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 69,628</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jack L. Wyszomierski<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,237</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph M. Limber<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64,982</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barbara A. Kosacz<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57,534</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natasha Hernday<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,487</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Heather L. Franklin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,593</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All directors and current executive officers as a group as of the record date (9 persons)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 903,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;background:#ffffff;"><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicates less than 1%.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Based on a Schedule 13D/A filed on January 16, 2024. Consists of (i) 1,789,844 shares held by Biotechnology Value Fund, L.P. (&#8220;BVF&#8221;), (ii) 1,618,637 shares held by Biotechnology Value Fund II, L.P. (&#8220;BVF2&#8221;), (iii) 75,287 shares held by Biotechnology Value Trading Fund OS, L.P. (&#8220;Trading Fund OS&#8221;) and (iv) 149,975 shares held in certain partners managed accounts (the &#8220;Partners Managed Accounts&#8221;). Excludes 5,003,000 shares issuable upon the conversion of 5,003 shares of Series X Preferred Stock, the conversion of which is subject to a beneficial ownership limitation of 19.99% of the outstanding common stock. BVF I GP LLC (&#8220;BVF GP&#8221;), as the general partner of BVF, may be deemed to beneficially own the shares beneficially owned by BVF. BVF II GP LLC (&#8220;BVF2 GP&#8221;), as the general partner of BVF2, may be deemed to beneficially own the shares beneficially owned by BVF2. BVF Partners OS Ltd. (&#8220;Partners OS&#8221;) as the general partner of Trading Fund OS, may be deemed to beneficially own the shares beneficially owned by Trading Fund OS. BVF GP Holdings LLC (&#8220;BVF GPH&#8221;) as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the shares beneficially owned in the aggregate by BVF and BVF2. BVF Partners L.P. (&#8220;Partners&#8221;) as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Accounts, and the sole member of Partners OS, may be deemed to beneficially own the shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Accounts. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to </p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;background:#ffffff;"><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">beneficially own the shares beneficially owned by BVF Inc. Each of BVF, BVF2 and Trading Fund OS shares with Partners voting and dispositive power over the shares each entity beneficially owns. BVF shares with BVF GP voting and dispositive power over the shares beneficially owned by BVF. BVF2 shares with BVF2 GP voting and dispositive power over the shares beneficially owned by BVF2. Each of BVF GP and BVF2 GP shares with BVF GPH voting and dispositive power over the shares each such entity beneficially owns. Trading Fund OS shares with Partners OS voting and dispositive power over the shares beneficially owned by Trading Fund OS. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares they may be deemed to beneficially own with BVF, BVF GP, BVF2, BVF2 GP, Trading Fund OS, Partners OS, BVF GPH and held in the Partners Managed Accounts. Each of Mr. Lampert and the entities specifically disclaims beneficial ownership of the securities that he or it does not directly own. The address of BVF, BVF GP, BVF2, BVF2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert is 44 Montgomery St., 40th Floor, San Francisco, California 94104. The address of Trading Fund OS and Partners OS is P.O. Box 309 Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Based on the Schedule 13G/A filed on February 9, 2024 by FMR LLC (&#8220;FMR&#8221;) and Abigail P. Johnson, and consists of shares held by subsidiaries of FMR. Ms. Johnson is a director, the Chairman and Chief Executive Officer of FMR. Members of the Johnson family, including Ms. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR, representing 49% of the voting power of FMR. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR. FMR and Ms. Johnson have the sole power to dispose or direct the disposition of 1,155,033 shares of Common Stock. The business address of each person and entity listed above is 245 Summer Street, Boston, Massachusetts 02210.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(3)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 263,455 shares of Common Stock underlying options exercisable within 60 days of the date of this table, and 5,554 shares of Common Stock that are held in an account under the Company&#8217;s Deferred Savings Plan.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 160,417 shares of Common Stock underlying options exercisable within 60 days of the date of this table, and 394 shares of Common Stock that are held in an account under the Company&#8217;s Deferred Savings Plan.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(5)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 129,167 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(6)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 57,829 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(7)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 58,772 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 58,772 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(9)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 57,534 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(10)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 36,487 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(11)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 33,593 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(12)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Includes 856,026 shares of Common Stock underlying options exercisable within 60 days of the date of this table.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">The following table provides certain information with respect to our equity compensation plans in effect as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to be</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">issued upon</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">exercise of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">options,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">warrants</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">and</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">rights (a)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">exercise</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">price of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">options,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">warrants</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">and rights</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(b)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">remaining</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">available</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for issuance</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">under equity</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">plans</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(excluding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">reflected in</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">column (a))</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;"> (c) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans approved by stockholders:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,453,668</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 634,363</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;"> (3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans not approved by stockholders:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 725,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,178,668</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20.88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 634,363</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;background:#ffffff;"><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Includes outstanding stock options and PSUs granted under the 2010 Plan.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Reflects the weighted-average exercise price of stock options granted under the 2010 Plan. PSUs reflected in column (a) are not included in this column as they do not have an exercise price.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(3)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Includes (i) 409,477 shares of Common Stock available for issuance under our 2010 Plan and (ii) 224,886 shares of Common Stock available for issuance under our 2015 Employee Stock Purchase Plan.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(4)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Includes outstanding stock options granted as inducement awards in compliance with Nasdaq Listing Rule 5635(c)(4).</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(5)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Reflects the weighted-average exercise price of stock options granted as inducement awards.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk91769712"></a><a id="_66819867_86e7_44d2_ab1c_3e5199638b38"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;13.&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Except as disclosed below, there were no reportable transactions with related persons during fiscal years 2023 or 2022. We or a subsidiary may occasionally enter into transactions with certain related persons, such as executive officers, directors or nominees for directors, their immediate family members or beneficial owners of more than 5% of our outstanding Common Stock, in which the related party has a direct or indirect material interest. Each such transaction is subject to review and pre-approval by the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Indemnification Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">We have entered into agreements to indemnify our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of the Company or that person&#8217;s status as a member of our Board or as an officer, as applicable, to the maximum extent allowed under Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Procedures for Approval of Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Our Board reviews the relationships that each director has with the Company and shall endeavor to have a majority of directors that are &#8220;independent directors&#8221; as defined by the SEC and Nasdaq rules, the Board also reviews the relationships that each officer has with the Company. As part of the review process, the Company distributes and collects questionnaires that solicit information about any direct or indirect transactions with the Company from each of our directors and officers and legal counsel reviews the responses to these questionnaires and reports any related party transactions to the Audit Committee. We may enter into arrangements in the ordinary course of our business that involve the Company&#8217;s receiving or providing goods or services on a&#160;non-exclusive&#160;basis and at arm&#8217;s length negotiated rates or in accordance with regulated price schedules with corporations and other organizations in which a Company director, executive officer or nominee for director may also be a director, trustee or investor, or have some other direct or indirect relationship.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Our Code of Ethics requires all directors, officers and employees to avoid any situation that involves an actual or potential conflict of interest with the Company&#8217;s objectives and best interests. Employees are encouraged to direct any questions regarding conflicts of interest to the Company&#8217;s Chief Financial Officer or legal department. All related party transactions involving the Company&#8217;s directors or executive officers or members of their immediate families must be reviewed and approved in writing in advance by the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:18pt;margin:0pt;"><b style="font-weight:bold;">Board Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:6pt 0pt 0pt 0pt;">As required under the Nasdaq listing standards, a majority of the members of a listed company&#8217;s Board must be comprised of &#8220;independent&#8221; directors, as affirmatively determined by the Board. In addition, Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent within the meaning of Nasdaq listing rules. Audit Committee members must also satisfy heightened independence criteria under the Exchange Act and Nasdaq listing rules. Our Board undertook a review of the independence of each director and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities as a director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including the beneficial ownership of our Common Stock by each non-employee director, our Board determined that each of Ms. Franklin, Ms. Hernday, Ms. Kosacz, Mr. Limber, Mr. Perry and Mr. Wyszomierski qualifies as an &#8220;independent&#8221; director within the meaning of the Nasdaq listing rules. Mr. Hughes is not deemed to be independent under Nasdaq listing rules by virtue of his employment with the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Our Board also determined that each of the directors currently serving on the Audit Committee and the Compensation Committee satisfy the heightened independence standards for audit committees and compensation committees, as applicable, established by the SEC and Nasdaq listing rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk91769742"></a><a id="_b9f2b4b5_0709_4549_9881_363528f79fe3"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;14.&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;background:#ffffff;margin:0pt;">Deloitte &amp; Touche LLP has served as our independent registered public accounting firm since 2018. The total fees billed and expected to be billed by Deloitte &amp; Touche LLP, our current independent registered public accounting firm, for the services rendered during the last two fiscal years are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 897,065</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 659,895</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Related Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All Other Fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,895</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,895</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 898,960</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 661,790</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Audit Fees include the audit of annual financial statements included in the Annual Report on Form 10-K, reviews of quarterly financial statements included in Quarterly Reports on Form 10-Q, consultations on matters addressed during the audit or quarterly reviews, and services provided in connection with SEC filings, including consents and comfort letters.</p></td></tr><tr><td style="vertical-align:top;width:3.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:96%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">All Other Fees include fees for a technical research tool subscription service.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Pre-Approval&#160;Policies and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The Audit Committee has adopted procedures requiring the pre-approval of all audit and permissible non-audit services provided by the Company&#8217;s independent accountants. Pre-approval generally is provided for up to one year, is detailed as to the particular service or category of services and generally is subject to a specific budget. The Audit Committee may also pre-approve particular services on a case-by-case basis. In assessing requests for services by the independent accountants, the Audit Committee considers whether such services are consistent with the auditor&#8217;s independence, whether the independent accountants are likely to provide the most effective and efficient service based on their familiarity with the Company, and whether the services could enhance the Company&#8217;s ability to manage or control risk or improve audit quality. The Audit Committee has delegated pre-approval authority to its Chair, who must report any decisions to the Audit Committee at its next scheduled meeting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The Audit Committee&#160;pre-approved&#160;100% of all audit and other services provided by Deloitte&#160;&amp; Touche LLP, our current independent registered public accounting firm, in 2022 and 2023, in accordance with these procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c0ca9e48_4fc9_436b_a149_38e13eb47577"></a><a id="PARTIV_208578"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following documents are included as part of this Annual Report on Form&#160;10-K:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All financial statements of the registrant referred to in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All financial statements schedules have been omitted because the required information is included in the consolidated financial statements or the notes thereto or is not applicable or required.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K12G3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000069/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/31/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184314002585/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/28/2014</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184316012481/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/18/2016</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312517046823/d317392dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312520316015/d39862dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of 8.625% Series A Cumulative Perpetual Preferred Stock</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/11/2020</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521110287/d123419dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex3d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock</span></a> </p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.10</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">By-laws of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K12G3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reference is made to Exhibits <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.1</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000095016212000069/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.2</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000117184314002585/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.3</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000117184316012481/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.4</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312517046823/d317392dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.5</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312518348826/d677241dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.6</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312521110287/d123419dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.7</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex3d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.8</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.9</span></a><span style="background:#ffffff;"> and </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.10</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen of Common Stock Certificate</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521110287/d123419dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Deposit Agreement, dated effective April 9, 2021, by and among XOMA Corporation, American Stock Transfer &amp; Trust Company, LLC, as depositary, and the holders of the depositary receipts issued thereunder</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018019989/xoma-ex46_73.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrants (May 2018 Warrants)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019016040/xoma-ex47_58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrants (March 2019 Warrants)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2019</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523298155/d669381dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (December 2023) ($35.00 Exercise Price)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/19/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523298155/d669381dex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (December 2023) ($42.50 Exercise Price)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/19/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523298155/d669381dex43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (December 2023) ($50.00 Exercise Price)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/19/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/791908/000119312523090874/d344283ddef14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2010 Long Term Incentive and Stock Award Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DEF 14A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">Appendix   A</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/04/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000114036112015529/ex10_6a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement for Amended and Restated 2010 Long Term Incentive and Stock Award Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/14/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523148115/d491233dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Performance Stock Unit Agreement under the Amended and Restated 2010 Long Term Incentive and Stock Award Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/18/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459016017643/xoma-ex101_350.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2016 Non-Equity Incentive Compensation Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2016</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000119312517181624/d402926dex102.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended 2015 Employee Share Purchase Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/24/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312515197056/d931351dex992.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Subscription Agreement and Authorization of Deduction under the 2015 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-204367</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/21/2015</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022003022/tmb-20211231xex10d26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated December 15, 2021, between XOMA Corporation and James R. Neal</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/8/2022</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex108_173.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Officer Employment Agreement, dated August 7, 2017, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#*</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022007241/tmb-20220331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Amendment to Officer Employment Agreement dated April 1, 2022, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/05/2022</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup>*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex10d10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Amendment to Officer Employment Agreement dated November 1, 2022, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex1010_171.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Change of Control Severance Agreement, dated August 7, 2017, to the Change of Control Severance Agreement, dated October 28, 2015, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d56.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Indemnification Agreement for Directors and Officers</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.56</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup>*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022007241/tmb-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The Retention and Severance Plan dated, March 31, 2022</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/05/2022</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#*</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023003259/xoma-20221231xex10d14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The Amended Retention and Severance Plan dated, October 25, 2022</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023003259/xoma-20221231xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Officer Employment Agreement, dated January 3, 2023, between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Officer Employment Agreement, dated January 8, 2024, between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023003259/xoma-20221231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Officer Employment Agreement, dated January 3, 2023, between XOMA Corporation and Bradley Sitko</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex992.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex993.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex994.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Bradley Sitko</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex995.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Bradley Sitko</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.5</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d57.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited (&#8220;XOMA&#8221;) Sesen Bio, Inc. and (formerly Viventia Biotech Inc.)</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.57</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated July 24, 2020, to the Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited (&#8220;XOMA&#8221;) and Sesen Bio, Inc</span></a>. </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.58</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016202001662/xoma10qa120402ex1043.txt"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement by and between XOMA Ireland Limited and MorphoSys AG, dated as of February 1, 2002</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.43</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/04/2002</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312507049517/dex1046.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration Agreement, dated as of November 1, 2006, between Takeda Pharmaceutical Company Limited and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.46</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/08/2007</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312507110182/dex1048.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Collaboration Agreement, effective as of February 28, 2007, between Takeda Pharmaceutical Company Limited and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.48</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/10/2007</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312509051006/dex1031b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Collaboration Agreement, effective as of February 9, 2009, among Takeda Pharmaceutical Company Limited and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31B</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/11/2009</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016210000099/ex10_35.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Discovery Collaboration Agreement dated September 9, 2009, by and between XOMA Development Corporation and Arana Therapeutics Limited</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/05/2010</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312509051006/dex1024c.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Research, Development and Commercialization Agreement, executed November 7, 2008, by and between Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation) and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24C</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/11/2009</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000114036112015529/ex10_25b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Amended and Restated Research, Development and Commercialization Agreement, effective as of April 30, 2010, by and between Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation) and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25B</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/14/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837020012713/tmb-20200930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Research, Development and Commercialization Agreement, between the Company and Novartis Vaccine and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Diagnostics, Inc., dated September 30, 2015 </span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2020</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.32</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000114036115030673/ex10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated June 19, 2015, by and between XOMA (US) LLC and Novartis Vaccines and Diagnostics, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/10/2015</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.33<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837020012713/tmb-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement between the Company and Novartis International Pharmaceutical Ltd., dated September 30, 2015 </span></a><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;"> </span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2020</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.34<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">IL-1b Target License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.35<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.36&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018004731/xoma-ex1066_607.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.66</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.37&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018012453/xoma-ex101_237.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated March 30, 2018, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio, Inc.)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2018</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.38&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019006621/xoma-ex1071_267.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2, dated January 7, 2019, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.71</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/07/2019</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.39</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex104_177.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated November 4, 2015, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.40<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.41<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment and Restatement, dated February 2, 2017, to the Asset Purchase Agreement, dated November 4, 2015, and License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.42</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1060_339.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Protective Rights Agreement dated December 21, 2016 by and between XOMA (US) LLC and HealthCare Royalty Partners II, L.P. relating to the Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P. and the Amended and Restated License Agreement, dated effective as of October 27, 2006, between XOMA (US) LLC and DYAX, Corp.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.60</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.43</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1061_1989.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Protective Rights Agreements dated December 21, 2016 by and between XOMA (US) LLC and HealthCare Royalty Partners II, L.P. relating to the Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P. and the License Agreement, dated effective as of August 18, 2005, between XOMA (US) LLC and Wyeth Pharmaceuticals</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.61</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.44</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1062_340.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P., relating to the Amended and Restated License Agreement, dated effective as of October 27, 2006, between XOMA (US) LLC and DYAX, Corp.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.62</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.45</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1063_1988.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P., relating to the License Agreement, dated effective as of August 18, 2005, between XOMA (US) LLC and Wyeth Pharmaceuticals</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.63</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.46</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1064_1433.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment of Section 6.10(a) and (b), dated March 8, 2017, to Royalty Interest Acquisition Agreements dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.64</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.47</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000119312518352159/d675667dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/18/2018</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.48<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d59.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated March 10, 2021, to the Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.59</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.49<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At Market Issuance Sales Agreement, dated August 5, 2021, by and between XOMA Corporation and B. Riley Securities, Inc.</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.50&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018027722/xoma-ex109_282.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement dated September 20, 2018, between XOMA Corporation and Agenus Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.51<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019029005/xoma-ex101_307.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement dated April 7, 2019, between XOMA (US) LLC and Aronora, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/06/2019</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.52<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019040075/xoma-ex101_227.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement dated September 26, 2019, between XOMA (US) LLC and Palobiofarma, S.L</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2019</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.53<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021006088/tmb-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Royalty Purchase Agreement dated March 22, 2021 between XOMA (US) LLC and Viracta Therapeutics, Inc.</span></a></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.54<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021014454/tmb-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Royalty Purchase Agreement, dated July 14, 2021, by and among XOMA (US) LLC and Kuros Royalty Fund (US) LLC</span></a></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/04/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.55<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Settlement and Release Agreement, dated April 15, 2021, by and among XOMA (US) LLC and Affimed N.V., Affimed GmbH Affimed</span></a></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.56<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022003022/tmb-20211231xex10d48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial Payment Purchase Agreement, dated October 6, 2021, by and among XOMA (US) LLC and Affitech Research AS</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.48</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.57<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023003259/xoma-20221231xex10d56.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Intellectual Property Acquisition Agreement, dated November 21, 2022 between XOMA Corporation and ObsEva, SA</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.56</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.58<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023003259/xoma-20221231xex10d57.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated July 26, 2021, between ObsEva, SA and Organon International GmbH</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.57</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.59<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023003259/xoma-20221231xex10d58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated June 10, 2015, between ObsEva, SA and Ares Trading S.A.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.58</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.60<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023008670/xoma-20230331xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Payment Interest Purchase Agreement, dated March 29, 2023, by and between Aptevo Therapeutics Inc. and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.61<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023013756/xoma-20230630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assignment and Assumption Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/08/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.62<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837023013756/xoma-20230630xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/08/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.63<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex10d63.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan Agreement dated December 15, 2023, between XRL 1 LLC, the lenders from time to time party thereto and Blue Owl Capital Corporation</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.64<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="xoma-20231231xex10d64.htm">Sale, Contribution and Servicing Agreement</a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="xoma-20231231xex10d64.htm">dated as of December 15, 2023 by and among XOMA (US) LLC, as Seller, and solely for purposes of </a><a style="-sec-extract:exhibit;" href="xoma-20231231xex10d64.htm">&#8206;</a><a style="-sec-extract:exhibit;" href="xoma-20231231xex10d64.htm">Section 2.03 and </a><a style="-sec-extract:exhibit;" href="xoma-20231231xex10d64.htm">&#8206;</a><a style="-sec-extract:exhibit;" href="xoma-20231231xex10d64.htm">Section 4.03(b)(ii) therein, XOMA CORPORATION, as Parent, on the one hand and XRL 1 LLC, as Purchaser, on the other hand</a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.65<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex10d65.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Office Lease dated June 27, 2023 between KBSIII Towers at Emeryville, LLC and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. &#167;1350</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20231231xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Incentive Compensation Clawback Policy</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104 </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Confidential treatment has been granted with respect to certain portions of this exhibit. This exhibit omits the information subject to this confidentiality request. Omitted portions have been filed separately with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;Indicates a management contract or compensation plan or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;&#160;&#160;&#160;&#160; Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">#&#160;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material and (ii)&#160;the omitted material is of the type that the Registrant treats as private or confidential.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Furnished herewith. The certifications that accompany this Annual Report on Form 10-K are not deemed filed with the SEC and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</span></td></tr></table><div style="margin-top:12pt;"><a id="_fbbe3a43_3fb6_4c48_b223_04ce3222a994"></a><a id="Item16Form10KSummary_564652"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16.&#160;FORM&#160;10-K SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fdf8ddd7_d188_4491_9626_3eba1baf523a"></a><a id="SIGNATURES_975745"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day of March&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XOMA Corporation</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ OWEN HUGHES</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4cd8ad8c_699b_4fdf_a1ad_35885a445ece"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Owen Hughes and Thomas Burns, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:56.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Owen Hughes</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal Executive Officer) </p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Owen Hughes)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Thomas Burns</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Chief Financial Officer</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Thomas Burns)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Principal Accounting Officer)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Jack L. Wyszomierski</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Jack L. Wyszomierski)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Heather L. Franklin</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Heather L. Franklin)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Natasha Hernday</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Natasha Hernday)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Barbara Kosacz)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Joseph M. Limber</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Joseph M. Limber)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Matthew Perry</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 8, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Matthew Perry)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_69398196_e706_49a5_acf9_c6e6b7877732"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Index to Consolidated Financial Statements</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Deloitte_Audit_Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID No. <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:AuditorFirmId" id="Narr_bteudAFYf0W3EXKlgqTVKg">34</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_29154"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_524071"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"><span style="font-style:normal;font-weight:normal;">Notes to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d221e81d_2252_4a9a_a649_99a33d433551"></a><a id="Deloitte_Audit_Report"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and the Board of Directors of XOMA Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of XOMA Corporation and subsidiaries (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows, for the each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Critical Audit Matter </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Long-term royalty and commercial payment receivables &#8212; Refer to Notes 2 and 5 to the financial statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Critical Audit Matter Description</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The carrying value of the long-term royalty and commercial payment receivables (&#8220;milestone and royalty rights&#8221;) is $58.0 million as of December 31, 2023. The Company accounts for milestone and royalty rights on a non-accrual basis using the cost recovery method. The developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The commercial payment products have limited available </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">historical sales information, and as such the Company is unable to reasonably estimate the amount and timing of the commercial payments to be received. Management assesses the long-term royalty and commercial payment receivables for current expected credit losses and records an impairment as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination of current expected credit losses requires obtaining and assessing all available information regarding the developmental pipeline products and the commercial payment product as of the Company&#8217;s financial reporting dates. The Company obtains information through available sources including: 1) updates from the selling party of the milestone and royalty rights, 2) publicly available clinical trial data and news, and 3) public disclosures provided by the research companies developing the products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We identified the accounting evaluation of expected credit losses as a critical audit matter, primarily due to the Company&#8217;s reliance on third parties to disclose updates to the Company timely for the Company's required financial reporting deadlines. The timing of disclosure to the Company of a change in the use, or intent for future use, of the licenses related to the milestone and royalty rights could have a significant impact on the fair value of milestone and royalty rights and a significant change in fair value could cause a significant impairment. Performing audit procedures to evaluate whether management had appropriately identified expected credit losses involved challenging and complex auditor judgment, including the need to involve more experienced auditors in assessing the completeness of available information and if any available public information represents an indicator of expected credit losses as of the Company&#8217;s financial reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">How the Critical Audit Matter Was Addressed in the Audit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our audit procedures related to the evaluation of assumptions used in the Company&#8217;s expected credit losses assessment of the long-term royalty receivables included, but were not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Considering the impact of changes in the regulatory environment on management&#8217;s expected credit loss conclusions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the Company&#8217;s assessment of expected credit losses by developing an independent expectation of expected credit losses through research of third-party disclosures and clinical trial news for programs associated with the milestone and royalty rights and comparing such expectation to those included in the Company&#8217;s analysis.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We inspected the Company&#8217;s documentation of inquiries and written correspondence to obtain program updates from the selling parties of the milestone and royalty rights throughout the year and through the Company&#8217;s reporting date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Confirmed with the selling parties of the milestone and royalty rights that complete information known to the selling party regarding the associated research programs was provided timely, completely, and accurately to the Company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:AuditorName" id="Narr_RCdzKIcCMES5B39ElBs52Q">Deloitte &amp; Touche LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="dei:AuditorLocation" id="Narr_Eh8SAcU5oUOp3Lpc4w1wYg">San Francisco, California</ix:nonNumeric><span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">March 8, 2024  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk96681587"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company's auditor since 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b231d0c3_e398_49ed_9136_46403a2e15f1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p><a id="CONSOLIDATEDBALANCESHEETS_29154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and </b><b style="font-weight:bold;">per share amounts</b><b style="font-weight:bold;">)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_ef4950f5_bd5f_4ba1_b800_cec20cab062d"></a><a id="Tc_5nyDRy9AkE2eSLu-eT5mYQ_1_2"></a><a id="Tc_4CVBO65j5U2bDVLN07yM1g_1_5"></a><a id="Tc_w9vKf8YiR0KbZ7ppqu_z7Q_2_2"></a><a id="Tc_np9PguqEI0auzdST6qXemA_2_5"></a><a id="Tc_N4vyfh6kyEyUcDsmdbLw4A_3_0"></a><a id="Tc_mJ1DTJmZ_0Ks0xERTDx8Qw_4_0"></a><a id="Tc_Az7eY5Kz8Ei88UKps3tUYA_5_0"></a><a id="Tc_i-vjzTGDGE-pIhpksTB-XQ_5_2"></a><a id="Tc_HZblSAGFIk24f_X5Uw55AQ_5_5"></a><a id="Tc_ssMgz3rVdku1CK-jvMIjDg_6_0"></a><a id="Tc_F_BCCDyc60-KfNlsekzbmg_6_6"></a><a id="Tc_yMKlu3uMjECSa0k3VenUyg_7_0"></a><a id="Tc_KtjFEPqThEGBljfr4eC73A_8_0"></a><a id="Tc_Wpzr99ZSxkG-sfbIR3JDfQ_9_0"></a><a id="Tc_HRFmYegTT0WQX-Mi_2tAiQ_10_0"></a><a id="Tc_gyNXIGha1U2O4b7Y4zqyQQ_11_0"></a><a id="Tc_Ci2r-e22pUmLULkp6gvBvw_13_0"></a><a id="Tc_iHPmFwLLVEimSBOVziW3yA_13_6"></a><a id="Tc_d-_N8Gzi8UGKwPl2ETt_xg_14_0"></a><a id="Tc_AtfVLBuxpkCaxkQwfDZNYw_15_0"></a><a id="Tc_JKBg9AVPTECz1T9MAOiJxg_16_0"></a><a id="Tc_oDY6U8TOjEOySgwQkCNNMA_17_0"></a><a id="Tc_PX0nu7jwVU-QFXanQ0aTMw_17_3"></a><a id="Tc_0u3_RilGXkCu2l-VseMS-w_18_0"></a><a id="Tc_c8zbsp5eL0WBfU6p2JXAcw_19_0"></a><a id="Tc_UtGCKrHLz0aUY3ZxR-jT6Q_19_2"></a><a id="Tc_1P5Uhhdl4ke6dLWjib0Bug_19_5"></a><a id="Tc_X_aPLj71j0Wdkg3DQcRQ-w_21_0"></a><a id="Tc_5t9PSLnheEWf4BU7K4-1Ag_22_0"></a><a id="Tc_VLzsA0v82UKiYXpNI7V1Mw_23_0"></a><a id="Tc_du12yXdUwEGc7Qdfp9nJ2Q_23_2"></a><a id="Tc_AQ2u9S0pcU2ZNqAJZKRRcw_23_5"></a><a id="Tc_dY_dKI0jykO3Pf5EEsfVwA_24_0"></a><a id="Tc_VvAv7_h23U6mZFSEroKwOQ_25_0"></a><a id="Tc_V3BBzkb9NkKXM1UnNjao4w_26_0"></a><a id="Tc_3URcmx_QBUiAUjJGlfA71A_27_0"></a><a id="Tc_oJn9Sv010ESDXvkLDR-U9A_28_0"></a><a id="Tc_1BrjY5zWbk-648rmtai3mg_29_0"></a><a id="Tc_owboYfWQqEOcYuPiddQ83Q_29_6"></a><a id="Tc_wONB6n0q3k6DOrPKJbux2w_30_0"></a><a id="Tc_DvPKv1_n0UODqmvc60Mr-w_31_0"></a><a id="Tc_OtXsC_Hagk-NBOyqSskoMA_32_0"></a><a id="Tc_-x2_v6i7WUmzxXlC35reQQ_32_6"></a><a id="Tc_LZ3NvPss0UiVkXq5t52_DQ_33_0"></a><a id="Tc_aQx0U8oyJUCoeyIQwSlHZg_33_6"></a><a id="Tc_2Wj8fjxlfUuAYJfiWMauCg_34_0"></a><a id="Tc_qjUgdP-IsEqbmG8aXWi7zg_36_0"></a><a id="Tc_p7NTjeo-Y0qTXeNZ8NRt5Q_38_0"></a><a id="Tc_9DKEZtlIuUqIWX9hY6vN5Q_39_0"></a><a id="Tc_wNK0ixlTs0KxCEUMniuQDg_40_0"></a><a id="Tc_171Sh7qSdUa2lKqgcqeazA_41_0"></a><a id="Tc_11HO0lZFcEGOfjRhdo70QA_42_0"></a><a id="Tc_1BNiHdKg-UGpp3q3RVqEhQ_43_0"></a><a id="Tc_rqvR5JVT8EaESH7wq0MiwQ_44_0"></a><a id="Tc_8A8aT7wotEi4UIqAYFiSdw_45_0"></a><a id="Tc_ZZcMyQL350ym4kUEg6DZUQ_46_0"></a><a id="Tc_ne3u-QNvAUGScU6RNHvRUw_47_0"></a><a id="Tc_groCQnkyP0iUdEfWTPqSfg_47_2"></a><a id="Tc_GLA7FIcrKUePUAtYeLeqdw_47_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Current assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Cash and cash equivalents </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_hmsciegP9ECWRSRe22KL7Q_5_3">153,290</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ag0mnlekwEyonog_GPEhew_5_6">57,826</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Short-term restricted cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_gn9p3xcN60SVp4bVIRk_-Q_6_3">160</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Short-term equity securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_Tif3EANFG0uyD_l6Sci0WA_7_3">161</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_ro_ILmP6bU2Bg5vPOYuUWA_7_6">335</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Trade and other receivables, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_-h-AolC5DEG8tLzDSbJNfg_8_3">1,004</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_BIjr4b-m_06FdXD_C_L3xw_8_6">1</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Short-term royalty and commercial payment receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_3m2nxPULGEGXGXY4tXwCjg_9_3">14,215</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_0jLQPaPhNUaIF13Wrs0PoA_9_6">2,366</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_MeASCJoD7EeBEeZEYH145A_10_3">483</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_qNSXX7jQzE2Ykp4xJklTIg_10_6">725</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_K4_oD_8wrUGXepfEjAHrNQ_11_3">169,313</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_1zBnWrpzFkO6aZfkrFkb-g_11_6">61,253</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Long-term restricted cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_GkX5HXUEr0KVJQzDt6EuFg_13_3">6,100</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_kmGLj6bSSEWd_Rgif9ArcA_14_3">25</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_7tAuHepEwUOA0bCOuB9O9Q_14_6">7</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_QDGjCW0PZUaHPdINRx-oTA_15_3">378</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_cByeAI2Wc0yKVbbV2Iwaww_15_6">29</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Long-term royalty and commercial payment receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_5WlqY1hAxUmbFSDx9GJSBw_16_3">57,952</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_LMNAf5OEn02qzgMp8D8x5w_16_6">63,683</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Intangible assets, net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_VvYlu3JlkEuV6-b3jQEFAA_17_6">15,150</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Other assets - long term</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_ajhYe4QUa0KJIYCbyODUqg_18_3">533</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_KAc83PL750ORaDSoht4NkA_18_6">260</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Mt9mRUzyC0aSmvyp79Xo-Q_19_3">234,301</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_5kJeOLmeh0W-HaQowIRkWQ_19_6">140,382</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Current liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_ywh9EXnBuE2WwqbYc5zSig_23_3">653</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_9EuZFWSA40S8KmI2pWMDkQ_23_6">524</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Accrued and other liabilities </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_7l_3t-QMdU2M83d-mWMUzQ_24_3">2,768</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_0iWkVKOQx0WXOSbbvaRXuQ_24_6">2,918</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Contingent consideration under RPAs, AAAs and CPPAs </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_1XbSkHtKzE6yH7X8-lwAWA_25_3">7,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_rWC0ygyMZkC2Td0GgWtXTg_25_6">75</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_RlwqS_dUVUWdaJg7QYTxFg_26_3">54</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_BUURm264ukO8HIJQyoXpSw_26_6">34</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Unearned revenue recognized under units-of-revenue method</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_71wWXP5uCEe8p59SfJH6qA_27_3">2,113</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_rBISOREiUUSrRR3XTkZv7w_27_6">1,899</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Preferred stock dividend accrual </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedPreferredStockDividendCurrent" scale="3" id="Tc_ijYmrmfuNkSgOr4HPR13zg_28_3">1,368</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedPreferredStockDividendCurrent" scale="3" id="Tc_RFBBPtYtqkaAabjxT8dSbQ_28_6">1,368</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Current portion of long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_DzhhI1mesEujT8a5xvjs-g_29_3">5,543</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_K1rlzKvTAEuSHJg2NhpncA_30_3">19,499</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_P3n_in_RjkK7mNTFNbqnGQ_30_6">6,818</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Unearned revenue recognized under units-of-revenue method &#8211; long-term</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_RU4FiQqX3k6jOcZ-iYMMKw_31_3">7,228</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_i2_5Ueyy70KTZb2uvlOESA_31_6">9,550</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Long-term operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_szVEDZZoqUeeQY5nPVPTAg_32_3">335</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_mlK8ZpxPzU-Rq9AvdDZv1A_33_3">118,518</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_R1gBmAelTkyJD10Wqv5ByQ_34_3">145,580</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_jNbqXedd2k2tyF8rZ7NW9Q_34_6">16,368</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Commitments and Contingencies (Note 13)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stockholders&#8217; equity:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Preferred Stock, </span><span style="font-size:7.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_eD6nxub-0EaFKBmogdysPw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_BJrGjAbBhEKEEXM0Lq6Z1A">0.05</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> par value, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_8gJxpW913USZf_BcVXqFpA"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_svnEO6XW0EuWE-eiEbweHQ">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares authorized:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_er3W3MMAy02J-0HZT7aH1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_tPXGlI4WUU-pEWBMCxl0HQ"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_45uU6FXaGECAjKys6j18Uw">8.625</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:7.5pt;"> Series A cumulative, perpetual preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_jqaMYRI-00ypxPOKtHvmrw"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_wD9gAsCG402gv2nVIhFt9w"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_EDRSLescwk60j7PlAeouAQ"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_LLiecn2qCk6wHkGUk6biUQ">984,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2023 and December 31, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_w8lsLyoUpEabiaen1jTMKw_40_3">49</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_EfifcxGfTU2JX_aYSrnf5A_40_6">49</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ttlhuKLBjUSSxoBHpLChMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_wvVjwo8PFkunkV0DvnJDOw"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_96UqI17DZ06cOK2CPIIPvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_h6KqniROXUSJutggaut8eA">8.375</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:7.5pt;"> Series B cumulative, perpetual preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_i1Mmx4I9SUGwFBoT3rLb1A"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_WxYsaDthd0-0XNSOfj09mw"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Cq3vqaFVB0GUKp-nQmdXAA"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_WGoO-AMcVkaniJ3RRL5eNw">1,600</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2023 and December 31, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Cv47HXb4lU6Gk7g1sUGDKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_tWLXBs-0PkugkSEbpf7Pgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Convertible preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_sfHoXNsAhkaaZrwlM5J3lA"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_Xnp0xq916UKPV0G6nFr5Lg"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_XuEXA8YX4UuVFDbnXMXKWg"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_U7xp5FCGdUy4i68SyIhAMw">5,003</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2023 and December 31, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_OsMuzAskf0GM04gVLpsjFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_MmJIXWQRREOzDoz4cg9BcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Common stock, </span><span style="font-size:7.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BO3YvwrJyEq3zAVhEa9yHQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_erh5ptuFBE2Tq3zW3neeeg">0.0075</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> par value, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Fri_DWP_Y0qStLhknF6uSA"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_c3aDChbsh0SwzKl5Nn28Hw">277,333,332</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares authorized, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_uiPjpsQZgkeoQ48N_AK-OA"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_odf2RGBCoU-TikEWHiFqeg">11,495,492</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> and </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_7AoUGvyGHkK8gKefhqePzg"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Ifl4JYVJ3US9V5Q-Jz1nrQ">11,454,025</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2023 and December 31, 2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_I2riWmF2okmhDC8oulKevA_43_3">86</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc__UUq2ajzokKvLVW-Neyy7A_43_6">86</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Additional paid-in capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_-NoaY2Nh6kaKlM0rK7sqLg_44_3">1,311,809</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_z8GyWnxDykKI0tduaY9Chg_44_6">1,306,271</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Accumulated deficit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_S_q8SjlX7kC0Pcx6wdRMPw_45_3">1,223,223</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_zKgnKlZN9Ey4UULO9nhxVg_45_6">1,182,392</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_PQraEevPS0CAMnKJsfbiDw_46_3">88,721</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qtVo4ol-C02VOCjCHjW8dA_46_6">124,014</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:middle;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:7.5pt;">Total liabilities and stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_9Xvv-U6Qnku_Y93u1EcXCQ_47_3">234,301</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_5z3rIwxwO0eFlQWkv2J04A_47_6">140,382</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f8b8a194_005d_4624_852a_c172c96cbebb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eb8df63f_dbff_41ae_acbd_8e3ae1506f69"></a><a id="_4db16b99_e128_4095_b1cc_b6d9215cb5ae"></a><a id="Tc_TWFLU155SUuc7_9XWokipA_1_2"></a><a id="Tc_HWenGsPzrE-ZzXalJY1gLw_2_2"></a><a id="Tc_mFtSTUKZakW5pmBI4Kmp7A_3_2"></a><a id="Tc_gLKbZHLqfEi38X4bHsUCVA_3_5"></a><a id="Tc_sL9k20uV802SF1uFNMd0qg_4_0"></a><a id="Tc_62Cvd5GuBESUuA5J6kjh7w_5_0"></a><a id="Tc_hxbXHBsrbkyhB3zK8Mmo1g_5_2"></a><a id="Tc_Oe1onMfmnEuL7JJqGWodWQ_5_5"></a><a id="Tc_Ou4nsFH4AUyMA1oz38TFQQ_6_0"></a><a id="Tc_9SE7RHJFh0uKUDTuJKvh0w_7_0"></a><a id="Tc_h6i1A4IRfESjPa2rNIcKSQ_9_0"></a><a id="Tc_38yi_vGIhEudoIvr7gq27A_10_0"></a><a id="Tc_ko92OCobYUywO9DLzF54VA_11_0"></a><a id="Tc_9Ru0RYa_pUe9WHu7vmSJ2A_12_0"></a><a id="Tc_fZobfc8BVEqBsD9fPXQ1_A_12_6"></a><a id="Tc_bkZxplVtI0qQzzlTie25WQ_13_0"></a><a id="Tc_CHuI2B2hcUqkgAvH0puG1A_13_6"></a><a id="Tc_kKWqdUUr3U-OSj9j7DR55A_14_0"></a><a id="Tc_zqnGpF_6CEW42rzYlPkJbA_15_0"></a><a id="Tc_hgfxjw4WaEmxAFBivf9Q7g_17_0"></a><a id="Tc_7c6B3gkMhE6XFj-XfLoLsQ_19_0"></a><a id="Tc_AV8F1UqPq0WoGRk3FWZkTw_20_0"></a><a id="Tc_EMrqMXBgykqUFVGe-sXtTw_20_6"></a><a id="Tc_ixtEf5bw90Oqa_mcvZX2lQ_21_0"></a><a id="Tc_M-uImR6uTUO5E31n48uEXA_22_0"></a><a id="Tc_FLQQ_tHtNEeCe3ordr1ayw_23_0"></a><a id="Tc_jSnkvct7lU2G8ZQt70xJNg_23_3"></a><a id="Tc_P4fXftATgkuFNAzhBbuOsw_24_0"></a><a id="Tc_ztrPPctbb0mUH5AcGSN2bA_24_2"></a><a id="Tc_sdqGqrWv70q4mY7u0lUYvw_24_5"></a><a id="Tc_jFRM9Lr9_ESK2_4SfDND_w_25_0"></a><a id="Tc_D_NURdWTeUazEbA52IiFaw_25_2"></a><a id="Tc_IKabNnHDAEOwzDo4vID8lw_25_5"></a><a id="Tc_JLAtB7GohEyg1CRN_2xN4g_26_0"></a><a id="Tc_E5ZnDtXDQkuZW7w5d2EG_g_26_2"></a><a id="Tc_RorXDFWzL06jJGfLfbe83g_26_5"></a><a id="Tc_nBKAG56zYUq8Y0w5DvzXQw_27_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_w-Hf69_Rfku0VyBeEI-6pQ_5_3">2,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GQJsb4EjlEqix6FIyJVVHw_5_6">4,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_yOGlS_-21U6NXZOHkjM-Ng_6_3">2,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_ZAnXioX6sEasuYzSqO0ZfA_6_6">1,877</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_1wh2xR9fpUOSDHE__LCjOQ_7_3">4,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5aDOZkTn3UiKxN2jXceUmw_7_6">6,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_e4TrPYxazE6BgVlQ2H9NNQ_10_3">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_9lgf9wzVHkCVUYsyv_bYiA_10_6">153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_kpMznbThW0WyAhTI4ozgUQ_11_3">25,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_GT5dPPnboUazw59I9jLeEQ_11_6">23,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Impairment charges (Note 4, Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" scale="3" id="Tc_JSZukDTt-UGocCDAeQbVmw_12_3">15,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Arbitration settlement costs (Note 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="3" id="Tc_jZXhYjcZk0iBZJxPMbJkNg_13_3">4,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_yZAWGPRKNEmlZjRYePNsUQ_14_3">897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_yZZIj-s9hUy-xlwnqaDZZQ_14_6">97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_F3vTI27ll0SY6R2aN4tuug_15_3">46,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_KgA6gaXk0E6Naxm6sRqiMg_15_6">23,441</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_3lmEYtZdBkOl8__4HgGM8g_17_3">41,848</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_uyb3Mztax0ChJc1GYUIgzA_17_6">17,414</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_aGUargVRF0GTCy-8NEsrmw_20_3">569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Other income (expense), net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_TXQ2mcQQ0UCOD3ucv7rueQ_21_3">1,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_Z3Thon9DvEqtOCOzgLelgQ_21_6">295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_wEKbvXRVc0aa2F7o-T_C8w_22_3">40,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_xy7dtGMmAEu6LHHnEYTtPQ_22_6">17,119</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_WUDIsOItwUeoJHg0g2L7IQ_23_6">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Net loss and comprehensive loss   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uNZV8hpI6EK99gU5UAcCoQ_24_3"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_uNZV8hpI6EK99gU5UAcCoQ_24_3_2">40,831</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_c_0s8mQWfUi1aZUV33eHmg_24_6"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_c_0s8mQWfUi1aZUV33eHmg_24_6_2">17,104</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss attributable to common stockholders, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_lkTOEPJVr0iREyPfVEn5BA_25_3"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_lkTOEPJVr0iREyPfVEn5BA_25_3_2">46,303</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_zFZcAj5SrU-9Fo516qV70Q_25_6"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_zFZcAj5SrU-9Fo516qV70Q_25_6_2">22,576</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_bVwXq6cd6kujN2ecMBGcmg_26_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_bVwXq6cd6kujN2ecMBGcmg_26_3_2">4.04</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_MmFIdpmECkyiPd915RMETA_26_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_MmFIdpmECkyiPd915RMETA_26_6_2">1.98</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JJzqP1xmJ0OYPkpD3ygWXg_27_3"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_JJzqP1xmJ0OYPkpD3ygWXg_27_3_2">11,471</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_qx940NZw8USQFnWDsH2hkQ_27_6"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_qx940NZw8USQFnWDsH2hkQ_27_6_2">11,413</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e8f75b10_b84d_47ff_91ab_0527f3e14f93"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p><a id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b25a3d61_0084_4cc6_866a_1f280648c953"></a><a id="Tc_3aHYLbjItEa7aGyC0rWpLQ_1_1"></a><a id="Tc_ejbKaxTFAEWr1QvqYOQTtg_1_6"></a><a id="Tc_mzkrWB6dMESU4Ia-GsPCMg_1_11"></a><a id="Tc_YIzeeX8OqkSV53ddiy3ysA_1_21"></a><a id="Tc_OZVVuoXCdkG3sp8XHkg5aQ_1_27"></a><a id="Tc_eN-V4PuL-kKNBlUTbWfK2w_2_1"></a><a id="Tc_OrdmIII-EEC5nF-AIwP2cw_2_6"></a><a id="Tc_MH_CO2AAXkmK8mZi2U9I8w_2_11"></a><a id="Tc_hYvFsp0geU65DW1QKiaaKQ_2_16"></a><a id="Tc_5k7Ql-ljgkOm0X7e8jRUxA_2_21"></a><a id="Tc_vQ9rdv6a8Uy6Utg_srcHAQ_2_24"></a><a id="Tc_jRALnAkFa0-_cng9owz-DA_2_27"></a><a id="Tc_ZhP-umHaskq07DiKIz3Vag_3_1"></a><a id="Tc_HpcptcISDES6R2Nnhx7QbA_3_3"></a><a id="Tc_L0GdjQZ_2km8lgvUKSlvVg_3_6"></a><a id="Tc_bg7X1dxMukS4mVmswgddIg_3_8"></a><a id="Tc_ucKexhoBj0-QLoBFi1ylow_3_11"></a><a id="Tc_dUDoRMMl60Wxl1-nmE21NQ_3_13"></a><a id="Tc_A00b2Fw4D0uds1SkuLAm7g_3_16"></a><a id="Tc_xESEPwkZ90u-SX2OedrwNw_3_18"></a><a id="Tc_nmV7kyEIQ0inRXTgvydL-A_3_21"></a><a id="Tc_S4CrgKxgOUSu6mEf8wlX9Q_3_24"></a><a id="Tc_UbCVoi-juUGiV7AGTyyOzQ_3_27"></a><a id="Tc_47pP_5QgGkWbS0ELdkszYg_4_0"></a><a id="Tc_mljx0Sw-t0OPqA3wwME34Q_4_3"></a><a id="Tc_-kuFsoMQaU6LUgyhtbB3Ow_4_8"></a><a id="Tc_z7vgIQlEikSIA6YX479W6Q_4_9"></a><a id="Tc_jNwlQdVZDEOk3qonwhgpJQ_4_13"></a><a id="Tc_eWTMrZjX30GbR51WPO8zWw_4_14"></a><a id="Tc_RQWT8yx-5UmHpGUEIVVfvQ_4_18"></a><a id="Tc_qYOwPy5q70SUgBnPKvi00w_4_21"></a><a id="Tc_SRJcEitjKEiVJWmIezaoxQ_4_24"></a><a id="Tc_Lfz5goZjzESI0zxE56_Q4Q_4_27"></a><a id="Tc_51dKCx_BhE2PPSwGUu8epw_5_0"></a><a id="Tc_oc0DH82jbUGnzsNA-PaaCA_5_1"></a><a id="Tc_6McK9NK1t0eqMcOSQcLuZg_5_4"></a><a id="Tc_-m7cxCGLpEm6RTWOBWI0VQ_5_6"></a><a id="Tc_YNIi_bJT60aXgX8__vPNLA_5_9"></a><a id="Tc_2_iGuSajykGcYO_a4MDmjw_5_11"></a><a id="Tc_WNsNc8pZZEqcRdWH2VdYYA_5_14"></a><a id="Tc_yKhZmVgFuUeQCXLQG-RFdg_5_19"></a><a id="Tc_4-NjwPXbE0ec5IquQbcJfA_5_25"></a><a id="Tc_W1Jv2Y-6CkGAhNTPgR16OA_6_0"></a><a id="Tc_-aThIi71D0ON-hDvGMVxiQ_6_1"></a><a id="Tc_mkhSmwWvyEGPRJp5mKCxzw_6_4"></a><a id="Tc_2ZlB76nn9kmiuduxhR-FZw_6_6"></a><a id="Tc_GArmXdoC9UmHESH4L8J_RA_6_9"></a><a id="Tc_wUIoB9fDgUWSQG4u32_cww_6_11"></a><a id="Tc_U0qRJ7vjJUGO8UrSq5NcVA_6_14"></a><a id="Tc_8f0-FUETykGn522G5SQCEw_6_16"></a><a id="Tc_xB_oOoDAdUed7qKsLwHMQg_6_19"></a><a id="Tc_xaT__qcOIk-Gblu43O3Jug_6_25"></a><a id="Tc_pGwhbd16a0arIQa1RldH2A_7_0"></a><a id="Tc_sC3-C-X9EEGnEaHnuHNnMA_7_1"></a><a id="Tc_N-5x0CqlX0CRytmXaHpvVw_7_4"></a><a id="Tc_m3eX8uk4WUSC3al4Yfmr9A_7_6"></a><a id="Tc_b7e9h7jdHE-JWwKoSVHSqg_7_9"></a><a id="Tc_fe7ersv7zEGL7RlQvCVlnw_7_11"></a><a id="Tc_GSeBQfqyvEC60IiOAxpMQg_7_14"></a><a id="Tc_LWACCtUxG0mM7qAXgP06jw_7_16"></a><a id="Tc_s84iECenJkSgPoRwkLfoWw_7_19"></a><a id="Tc_vgJrTU6KykyZSnQkk6hwWQ_7_25"></a><a id="Tc_AUwQ7voFCE6AE_orClu8RQ_8_0"></a><a id="Tc_ec4b_URrfkSATHzrlzLxIA_8_1"></a><a id="Tc_KNSbdkgnoEOeUTP1EavHyg_8_4"></a><a id="Tc_BaWRN7UMyEiLaSOzQ4P5VA_8_6"></a><a id="Tc_M0izkA5i3UerSwCA4N_Xdw_8_9"></a><a id="Tc_J5AIxkbPtEm7brb2U2EVWw_8_11"></a><a id="Tc_MozfzP4iukqB4pPTvXKvYw_8_14"></a><a id="Tc_LT1JUhqOJUOBjaEw6cdgYg_8_19"></a><a id="Tc_xbAHULaySky5Sa73McRZTg_8_25"></a><a id="Tc_E3VEBC0dA0y36ibl_YNV7w_9_0"></a><a id="Tc_WREXhV4QuU-9gf7QTDzSbA_9_1"></a><a id="Tc_GKlSRDjEg0WxSN2Me5BnEg_9_4"></a><a id="Tc_a2TeKIJzLkqz3aPz6rraZQ_9_6"></a><a id="Tc_MvI8-xRBHUGtdJPdoWPiKQ_9_9"></a><a id="Tc_hqGbY2BcAkOTAXof3We5Gw_9_11"></a><a id="Tc_KEWXM9RMm0yHfehPT8svVQ_9_14"></a><a id="Tc_nYJpWGEP4kGZk0hqAZVTKw_9_16"></a><a id="Tc_PokI38hOlUi_zurRed3cJQ_9_19"></a><a id="Tc_m3DsSoOWXUGv4wA7P_FIdw_9_25"></a><a id="Tc_YksovPzQf0qWNwK8ucxF4Q_10_0"></a><a id="Tc_luX7Jvmz_EGOvNGI7ENa1g_10_1"></a><a id="Tc_2v6EcDC6U0ygztHjJGc-Aw_10_4"></a><a id="Tc_Gu2mbXmdYkeIeGX_5iUrBg_10_6"></a><a id="Tc_UYMI2kV_nkWsiSIc8mWNVg_10_9"></a><a id="Tc__l3hbAZqDkq50Xq7q7ypZw_10_11"></a><a id="Tc_hnNQzFrPXEKC-oxV7aiq8w_10_14"></a><a id="Tc_Bqd7F30epUGytpS85Vn-1Q_10_16"></a><a id="Tc_v0yAVnzIS02iNntMrJI4YQ_10_19"></a><a id="Tc_4DxwUGMzrkakk-I56Ah_LQ_10_22"></a><a id="Tc_jyHkGZcDZkiTJbXVgyjB9g_11_0"></a><a id="Tc_CDn8yclO0EiqKJdDy1Zlug_11_3"></a><a id="Tc_F7x8HMRjLE-cfDGHG21Ypg_11_8"></a><a id="Tc_ybUa6ndbmka3JWO35KIjrw_11_9"></a><a id="Tc_cwwdjPpRbU6et76jZ-2ZxQ_11_13"></a><a id="Tc_RqkWbo0coEmBdiolSzlPHg_11_14"></a><a id="Tc_rKeySN3oAkCLANinu5SflQ_11_18"></a><a id="Tc_it_fOz5dZ02RFtq-65UZJQ_11_21"></a><a id="Tc_7W_LKSly9kGeEP0klzNVtg_11_24"></a><a id="Tc_KMux8YUOjUCd8UsS9Am5xg_11_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_6T2eRzXt-Ea20j5T__ax5g_4_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1tFjK5l0m0quCh0KjQ0Gng_4_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3N60csckskq31gE5arvXmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_YIl-XCa0906_hR3S_EYCzw_4_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y8PfkqfeykCg9sfic1605Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_K5cZkLZu9kSuc3c45lZGqw_4_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_EAKNQJ2IfkCBX3O5iMF81g_4_16">11,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_o2q9aHyzYEKEpB86M5pjbQ_4_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3taukphaKkSilr_NFe1nOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yxoiD3fjZE6ZAvbxfkCflw_4_22">1,306,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ERGTIkxok0qRddaD8mnHPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_bc9-UHZO10KJdvrxZbvGXw_4_25">1,182,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XHzZzTbP7U-arJJTJWLNQA_4_28">124,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8FHApOZ_VkCpJPR1XZCtyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_QQL_S6iF_UiozYwOx9I7iw_5_16">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_GhMcxsjP90ytTmL2IRridA_5_22">235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_9BWxFB86DkuNMVRUe-d7Iw_5_28">235</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Pmb2EVCJYka8rokUuXhFFw_6_22">9,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_8rvr4OayHUC1uYbNQq3Xwg_6_28">9,099</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_T-Hhj5cjVUWh8Bk_IYd9jw_7_22">1,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_yp-fD7Zn70iuTmaulbEWXA_7_28">1,470</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution and ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8FHApOZ_VkCpJPR1XZCtyg" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" scale="3" id="Tc_bNJz7QWslUmD4oxllANXGQ_8_16">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_1P4Xv6WHEEqybtOF-kWifQ_8_22">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_GAHMPqFvpUCaLAtLgMitvQ_8_28">206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_B4oPaB4MP0qNo0h4Zb-PTA_9_22">5,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_SAUJKSfkiEGRCs3awNOH-A_9_28">5,472</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JWDlj2gMFEij2eL1xesPfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_vz8r6GW-R0KCyjgM42PooQ_10_25">40,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_r_E4DMeXUUaQG8D33cQCew_10_28">40,831</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_L1ce77euREyOrnX7bZ8mMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_yYxx986w10m2gEkgloTChg_11_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_L1ce77euREyOrnX7bZ8mMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_j9K8FszWSESbAGBWYAUV3A_11_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_1fyMNRl8D0iF9dish_Goew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_gRuMQqdxeEmlnqGKArdFuw_11_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2XEI2tAvkOn0kqT8ijqUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_qRCZa9qOLUymiWqfMPkaqQ_11_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_M3NDjWrUrkS_uwrcvg_LBw_11_16">11,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-eOVE32buUeoar4oNSo7KQ_11_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wVVTmZ48EeiZT2WPXZvIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cyp4_pgFakCS8mfUfHHckw_11_22">1,311,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yrXa87g-0alNOMlRI8rYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dLnpUPG8M0uDsywpLC3ctw_11_25">1,223,223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dwSidYUBz0u5uLEDMM-q-Q_11_28">88,721</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_3bdc08a7_8b87_4788_a5c9_11d94525ad69"></a><a id="Tc_FWEU7nfJUE2GwqrqIdaD5A_1_1"></a><a id="Tc_pFnKCHEGxESVgpaRDlrn3Q_1_6"></a><a id="Tc_1dH95BwtyUKxc-HE2UT9WQ_1_11"></a><a id="Tc__HW6872qFk-LGFJeANmwGA_1_21"></a><a id="Tc_wFcGmMOtz0yYpmoenRQqoQ_1_27"></a><a id="Tc_u328YDkHakqLSLyyaV7erg_2_1"></a><a id="Tc__XqMklpJW06cjAEKPBM11w_2_6"></a><a id="Tc_WlmcxUCdRUSa3aCZG30zwA_2_11"></a><a id="Tc_-JTny1TiM0aDW7u7BH6gbw_2_16"></a><a id="Tc_8L76IoZKQUGoiTl5ZVduLQ_2_21"></a><a id="Tc_KkMXllwRsEGo4hdMBu2TtA_2_24"></a><a id="Tc_ckAdV4LgHE-xw8XH_-0dbA_2_27"></a><a id="Tc_9VE4BlCZn0WSzyCwwMYciQ_3_1"></a><a id="Tc_dLVfQBJxCESv1QRQ-CryOw_3_3"></a><a id="Tc_T8nEhtl76Eu9vxrXJi4pMg_3_6"></a><a id="Tc_JzZMGzG9oEeshWswSrBmYA_3_8"></a><a id="Tc_MevLasCR5UmsGiWOXMIGRw_3_11"></a><a id="Tc_S_UNTJUznk26Oblfodo-1g_3_13"></a><a id="Tc_8RCplsoQ0Uqom_o3QNx_qQ_3_16"></a><a id="Tc_s99YTEdQs06YKGgmOVVB5w_3_18"></a><a id="Tc_TnRb_ZkjPkSctbJIrASx1A_3_21"></a><a id="Tc_844HMGu5O0yV0m2fge6fvA_3_24"></a><a id="Tc_ZeRJprffe0qCXi2O-Hsong_3_27"></a><a id="Tc_jBkN9Aq9M0WdU0RKl2Ap0g_4_0"></a><a id="Tc_XFmzgqXI1kmHqRrEPKdtqg_4_3"></a><a id="Tc_xuGyRjG6-ke03OwqC2Nz-w_4_8"></a><a id="Tc_Pz-kNYfT7023ObBXi8mU0g_4_9"></a><a id="Tc_M9S-HthZRU2wRlBWSEh9JA_4_13"></a><a id="Tc_y6kAtDA4uU6njHhWpQPuOw_4_14"></a><a id="Tc_bjd9YG2Ku0i0Bqr9pF1-Rw_4_18"></a><a id="Tc_LAIzmnSlV02w1SiGl6Qd3w_4_21"></a><a id="Tc_UbfQypkOz0eY52UIaF4yaA_4_24"></a><a id="Tc_wDHg-1KXbUa7jjbu_iS7fA_4_27"></a><a id="Tc_RFyYVNmxYEOS7JwXu4qweA_5_0"></a><a id="Tc_EPUQJs1ObUm0zDyLzgJtlA_5_1"></a><a id="Tc_6ykEkfO-DkGKiU8NTQJZIA_5_4"></a><a id="Tc_fDZzTla4hkmlWnLUSr3zJg_5_6"></a><a id="Tc__0r2SDYehE6JD1YmKog07A_5_9"></a><a id="Tc_ODtUhqb-vUSDIK6_Byfw3A_5_11"></a><a id="Tc_eBzm5VBQ7UONiJ1UG2Nufw_5_14"></a><a id="Tc_50V-m-TA9UKRbZXyzHH7XQ_5_25"></a><a id="Tc_ZPLeNm1UBUKXOhd_gSFaoQ_6_0"></a><a id="Tc_h1qSws1d1UuP21MCNiN9eg_6_1"></a><a id="Tc_vx5xy1yVJk-V3BABR8Xt4Q_6_4"></a><a id="Tc_hXa4RFYWhU299zLm6CA5nw_6_6"></a><a id="Tc_XVMdevmdpUG_7lQehtWfAA_6_9"></a><a id="Tc_gThrQ-eZ-U-x3rxxBRLlbg_6_11"></a><a id="Tc_zZ5WK9KGdUe8O1485yv2AQ_6_14"></a><a id="Tc_lfpU4LwkqUeuql_wv95gRg_6_16"></a><a id="Tc_c_G5oYMKqEWwTiN8V83sOg_6_19"></a><a id="Tc_lVObcBn-Ck-F5geIiQwpjA_6_25"></a><a id="Tc_LDwVRiTDUkCBJ8zFkZ_NdA_7_0"></a><a id="Tc_m4Pc-WT68U2gY87W_AQEKg_7_1"></a><a id="Tc_ZfkAf6603EWg3XdwCfc7DQ_7_4"></a><a id="Tc__ayiVheko0G52T4AlHPJxg_7_6"></a><a id="Tc_VVGHxnmFPkOZvV5jR_SLtw_7_9"></a><a id="Tc_m3mim_TxyU-15aS8rOSJhg_7_11"></a><a id="Tc_rMFys4XdhE2aZZIpo9q1fQ_7_14"></a><a id="Tc_xUC0w6eHl0WPBJ06QsZuKw_7_19"></a><a id="Tc_JMPtq388u0m6Fh5wIu0f6A_7_25"></a><a id="Tc_aivEYlyOl0GsQK6NP_-e8g_8_0"></a><a id="Tc_VRk2lDtcy0WmNTkmHxrLLw_8_4"></a><a id="Tc_FMxXuhGwIkOm44yXyIzQkA_8_9"></a><a id="Tc_7sNbFUHdI0SaYIwbqzpPSw_8_14"></a><a id="Tc_m4F_L80xAk2Wd47pUWdwVw_8_16"></a><a id="Tc_G49clvqvV0K65gQPU4ZPMg_8_19"></a><a id="Tc_RGGI151MwUqHMtmTVOVK3g_8_25"></a><a id="Tc_c5tfoBKzdkyck_AymoCe_Q_9_0"></a><a id="Tc__xXYmkyTkEe3DLHH9lrg8w_9_1"></a><a id="Tc_FZdL_Kz3L0mcRilkDXuIZw_9_4"></a><a id="Tc_U52lkps1K0OFbJMKIr8t1g_9_6"></a><a id="Tc_2wIZwAcx6kiYgLHl9e7bcA_9_9"></a><a id="Tc_wv2VHSfd2EGTB9OWXMpddw_9_11"></a><a id="Tc_ukGS5lULSkuaSAkwXQuCRg_9_14"></a><a id="Tc_vaZ9v0OskUiMY2QctnmeEQ_9_16"></a><a id="Tc_xxEXtJbBdUmAqasoKBvVEA_9_19"></a><a id="Tc_ftwyMiDFMkOOmrFtnbwMIw_9_22"></a><a id="Tc_flKXoJ4E-0WiS5fE_6p3mw_10_0"></a><a id="Tc_w3UcCyqTKkCfzznISFGTuA_10_3"></a><a id="Tc_vjawZoOqfEi9U6P0waYsng_10_8"></a><a id="Tc_KFMGf7qWQEGHLOp1DHtA7g_10_9"></a><a id="Tc_9YkjbMBJakCjc2HcFq2TXQ_10_13"></a><a id="Tc_iG4ExsVgrUSdBkIMQp8Lsg_10_14"></a><a id="Tc_sbO_KgIrMk6C-DxIeNhDTw_10_18"></a><a id="Tc_-MsqZES2E0Or28ReQYyOgQ_10_21"></a><a id="Tc_6aAtE9y_wUqGpGrMtMkrmQ_10_24"></a><a id="Tc_DNWOV3uQY0eR41FtvwIaIQ_10_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_yTO40TT2JUWD1XLB530RTA_4_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gRiQcYTDDEidx0DF8eVxPA_4_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_XU7qWkz2d0WVvDm9lTapaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_FZI7l1qsWEuo9DfGKjwEtg_4_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MFi4TV8yEkS7ZFZpxsfd3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_5bXUCoOkmEKhT_0sQ69OkQ_4_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YtSAydDkdkaz5GXFSbOn6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_G3GKx0yQHkiYVE63E1fmWA_4_16">11,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YtSAydDkdkaz5GXFSbOn6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tN8shUhFqk-VvXFXc0FYwg_4_19">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHYxtsKmG0-hqBTHhnVlsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_liaqXwiW5EKuLqEFfof3tA_4_22">1,307,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Syt95SBUbUaxMwPVZJcalg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_9H5ASYbW8EKUwF3gJHbiXw_4_25">1,165,288</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Q9fxGAjRSECu78jil6ZFvA_4_28">141,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_6o-7SQj2sUuoxfdxDp26xw_5_16">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_HlT_E_Bf7Uq-kEbQqPte_A_5_19">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7rodXzjGXUinQMs7Toe0Lg_5_22">929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XFpilFYdg02a5TG-kjfcfw_5_28">930</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lNA8446J7UieZ67MGZjrwg_6_22">3,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ByjpEl58Ak6ECjxM9WsMhQ_6_28">3,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution and ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" scale="3" id="Tc_Oo5ZCO2d1EK_ZXKvLzgGQA_7_16">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_sLq828DcQUWJNdz4nB9OJQ_7_22">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_pmhvQ-IWKUWb4UarWhDCDA_7_28">176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_KFQB0qsBSk-Q4or8NpUMqg_8_22">5,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_2etUdxxHH0e5SHtYArbKrQ_8_28">5,472</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r_AdKEQIsUaSBQTdOEh1Fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fqIlo4Gd6kyj65vDACoN3A_9_25">17,104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mOs-qxn98E-ujXqGtneWRA_9_28">17,104</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_KHJTUY2YikCJN1aRzxe6nQ_10_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zZP14lN0106rvbucGWxGbw_10_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3N60csckskq31gE5arvXmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_U0XELIrDEE2bdwAwZie4-w_10_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y8PfkqfeykCg9sfic1605Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_gew35eLri0Wz8ggUaso9uw_10_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_MaR7_qvd3EewVtrOph-84A_10_16">11,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_i6ZhUgmuzESrKgrR6_m-3w_10_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3taukphaKkSilr_NFe1nOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6f2AE90pw0mQFuDPFlPI2w_10_22">1,306,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ERGTIkxok0qRddaD8mnHPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mRX25Jq08kmEX_AtW8lF9g_10_25">1,182,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aT3fyeD5SU2wwFUv6AkURw_10_28">124,014</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6213f591_845c_4d3f_86a9_eb079918974e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_524071"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8d779f07_0503_4111_b4d6_eda4a9ab93a9"></a><a id="Tc_SK83c_4I6UOhQmI2cMV5rg_1_2"></a><a id="Tc_B_DWIf82BEqsDt28dX71lg_2_2"></a><a id="Tc_di7fQl5XCUy3RDI-Sdmgaw_2_5"></a><a id="Tc_xXC51ng24kqQxfsRUz_q4w_3_0"></a><a id="Tc_6OyEHWjq2UarNvToJX11WQ_4_0"></a><a id="Tc_3pGvNfkS1Ui7zc6FRKjlBg_4_2"></a><a id="Tc_I_PblauG1k6MDY7GhKNh9Q_4_5"></a><a id="Tc_4ahS0nEFA0uOOCEtW_dhFw_5_0"></a><a id="Tc_NWUdq1cXJkKoUNRfe6cIjg_6_0"></a><a id="Tc_YyvphND07EiWXFC_OV0X3A_7_0"></a><a id="Tc_oxXaz8nBmkGjZFvSdpx3mA_7_6"></a><a id="Tc_aN0YMCC6JkWz-sVi-w78Lg_8_0"></a><a id="Tc_T0ftw7dTR0O8tM1hluW0Mg_8_6"></a><a id="Tc_-HJrIDwu1kuiFI1ehyri8Q_9_0"></a><a id="Tc_lN5Z-HKNVE6MuHqnhd-_rg_10_0"></a><a id="Tc_JwMKlVYRdkizqtzqM1wyWA_11_0"></a><a id="Tc_ju3RxJ_Y9UWPkzInfvt9lA_12_0"></a><a id="Tc_BcMUvAUWzkukpzxu6MSwqg_12_6"></a><a id="Tc_Td8r-RCMiECe-wMzINzP7g_13_0"></a><a id="Tc_BJ6Dn3rIJEivfnocr1mUVA_14_0"></a><a id="Tc_Z8HuR1xL2UilsjPJFpGplg_15_0"></a><a id="Tc_oD-5-Q1TV0WOc9mJFpIWEQ_16_0"></a><a id="Tc_nUzr1s8ljEy2sHtYokhuWg_17_0"></a><a id="Tc_tlrIHw_hKEGg7nbXi2V3SA_18_0"></a><a id="Tc_gec2qsoCHkSCtgYSusEFZg_19_0"></a><a id="Tc_mQV9Ovq_Lka6RgOoS9OALQ_19_3"></a><a id="Tc_y3JzHK12XkCKlFicUGFKBg_20_0"></a><a id="Tc_xu0XefT2mECMZ283zx2cAw_21_0"></a><a id="Tc_P4iGDjO2T0GFZZf6i3lV1Q_22_0"></a><a id="Tc_CIPhPLrMVkG70OhGSBSVSg_24_0"></a><a id="Tc_ywh6AudTqECcLtxHzBDT1w_25_0"></a><a id="Tc__3mXFmzPVEmprVCCHIiS4g_26_0"></a><a id="Tc_TSwu9ROHNUO7igKFnUZtDw_27_0"></a><a id="Tc_7knZSxhTtkWdgkTgmfguTQ_27_3"></a><a id="Tc_YXrZRwK0c0usfg46HN_hOg_28_0"></a><a id="Tc_mCVqc39-v069EZ6RbEIIqg_28_6"></a><a id="Tc_88Fh5QeIEECMAfozSDQWqg_29_0"></a><a id="Tc_R-SQxSxFHU6aM6rCYFVslg_31_0"></a><a id="Tc_n0vnrc2pb02FC5oHmImFjg_32_0"></a><a id="Tc_Q5PfE-cfFkeZhZQRnYkz3w_32_6"></a><a id="Tc_lQiwdAuXHEipO-wsMvs8DA_33_0"></a><a id="Tc_XZystGmP5ka4CMD0bWG1Lg_33_6"></a><a id="Tc_0XSysjCEN06_9TxVCCQtoA_34_0"></a><a id="Tc_Hn-X86ALy0q4j0JMdA7fsQ_35_0"></a><a id="Tc_PrargTAnQ0ipLjeFudFt3g_36_0"></a><a id="Tc_iV23bzz_vE6czIiMJRL6KQ_37_0"></a><a id="Tc_u4oSZnAa7UqJDYj0HSK8dA_39_0"></a><a id="Tc_SCxtKFzOy0mBTWKAZe78Vg_40_0"></a><a id="Tc_TZaOKDs7mE2vJlmGLVqhWQ_41_0"></a><a id="Tc_Ixz8LaMRu0Cv4g1NMvh7BQ_41_2"></a><a id="Tc_mGsQFyZvtk2OXYrkiBxFZA_41_5"></a><a id="Tc_rMabNwsXRE24Z1DCMe7qKw_43_0"></a><a id="Tc_5uG1lv7ZiECDQQogOCLt2w_44_0"></a><a id="Tc_VisxE6fVI0mlKJGBC3gwww_44_2"></a><a id="Tc_3s7815JNtEmq36yAYZz4Bw_44_3"></a><a id="Tc_TRNEqZpSE0OY4JAeDdnEJA_44_5"></a><a id="Tc_BlPYBAQNJkGQOYm1675ttg_45_0"></a><a id="Tc_VJazaH0XoEytBuoZYUEHcA_45_2"></a><a id="Tc_tZR705o9gk65dmGCFboxOw_45_5"></a><a id="Tc_RM55V-lqv0CFKgVnZHOtEg_45_6"></a><a id="Tc_w-6r1it3tkC-Be6adUZCnQ_46_0"></a><a id="Tc_9MG7e1RV_0iIDErqiucLng_47_0"></a><a id="Tc_9CyqFecEAkeQjJKcV9hQfw_47_2"></a><a id="Tc_kZ980WP7hEiVQmd3e3O0Tw_47_5"></a><a id="Tc_hdYSf8kNoUGCK9S1JLE4UA_47_6"></a><a id="Tc_BoqxEymQhEyb6yHUYvyFsw_48_0"></a><a id="Tc_qB3ixzAcS0mnR43wA432zg_48_2"></a><a id="Tc_7vM0OZaHW06FD-OqSVMrYw_48_5"></a><a id="Tc_jogyhoOBNUKm3XqmYhZ-Fg_48_6"></a><a id="Tc_ri1PoqEAF0KCRDk7Nqr1Ag_49_0"></a><a id="Tc_1DUrx8Nu9kWAVquVQs6n7A_49_2"></a><a id="Tc__NYc8lXGuESV8o9S52KEnQ_49_5"></a><a id="Tc_V2xhTFEIwU2Lm9B6KgjBXA_50_0"></a><a id="Tc_3ZFlhMlCjUqnPQ3ibAOM-w_50_2"></a><a id="Tc_xOYShMwAxkqT541HQf-LoQ_50_5"></a><a id="Tc_NuUI4tfa90qkI_GGxmf8TA_50_6"></a><a id="Tc_winqrnwcYEmLkDxaKCaiOQ_51_0"></a><a id="Tc_y5xeQO6uEkmUIRiaTWJlaw_51_2"></a><a id="Tc_11sV04fsekGZyZTvu61KCQ_51_3"></a><a id="Tc_3R3WavUzb0ywrNgnkxIJsw_51_5"></a><a id="Tc_9hBekdGZgkShHstBuZ8ENg_52_0"></a><a id="Tc_vNv_QRG_OESxdnnRhwRObg_52_2"></a><a id="Tc_i3-QEL8xu0GNZseTcjIvaA_52_5"></a><a id="Tc_idOjsADFlU6MeKT-XPGGiw_52_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_H26cW_vBQUWO5s4E9iVsXg_4_3">40,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_EQRzWmydaUSDWe1VnhtQ2Q_4_6">17,104</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_audLXrsm30iFciJDR_hyvg_6_3">9,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_9XcSStMOFEOIyLYx_2xCXQ_6_6">3,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Impairment charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" scale="3" id="Tc_VG53TOVHL0-s2QRCM99_Bw_7_3">15,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="3" id="Tc_c9GN-WnKDUqFqDoo-pZLdg_8_3">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Common stock contribution to 401(k)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_gOekGOKtq0ioMRUTc4JnDg_9_3">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_nTmZIfYgW0a9dcPY1jYJBA_9_6">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_XTlcDl8hS0K9042YQAwV_w_10_3">897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_HsYKoqS1ok-juczKXSQ98w_10_6">97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationNonproduction" scale="3" id="Tc_CqHXWvWB9kiSrsIQ-Ygenw_11_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationNonproduction" scale="3" id="Tc_MXXOVy3mg0mA_-J15af2tQ_11_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accretion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_6z88Mz6OPkufVg0Gb_20bw_12_3">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc__seJdGWA_kaC_mdyh8Y3Ow_13_3">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_ZAJU2n4C4keOIZIqCByx1w_13_6">170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="3" id="Tc_1QUq-NecA0S-_F0NzcF7ow_14_3">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="3" id="Tc_VBhbqKwZmEa0e5awyN0pTg_14_6">439</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Trade and other receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_mj85wMNASk-Qd-9TSJw4Kg_16_3">1,003</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_UcNK7F4DOkiC_gfWj73v8Q_16_6">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc__qVCH8rasEis1AYEqNESSg_17_3">219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_UgqDY6VCZUmoxvmwKaFhDw_17_6">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_4ndDMyOog0GfzVbdQvquow_18_3">523</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_dXMI62lB0UC8oVQNku-1JA_18_6">1,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" sign="-" scale="3" id="Tc_HxgT3x3nt06g3VFwk9WDtw_19_6">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_hpz3Y_I5mUWESu-luLwMlg_20_3">114</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_bZhSZYsJYkazKDBUk5YwoA_20_6">195</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Unearned revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_el1Q3tYpwEKOON7VMHR-dQ_21_3">2,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_ChLRaOKToE-TqHLKuKAnbw_21_6">1,877</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_6NMfehsLnE-AnSQwGYSIeQ_22_3">18,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_o3Pqp1ZixUWmAjYPitPamQ_22_6">12,879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payments of consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="3" id="Tc_aJTtwa-mPEComIZ-iLe-8Q_25_3">14,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="3" id="Tc_Be7PYKjeUUal94H-g6NXVA_25_6">8,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Receipts under RPAs, AAAs and CPPAs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="3" id="Tc_jmXCzYuN7Eiijraj72aU6A_26_3">13,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="3" id="Tc_-oqB5fsN-UyDl5kry7f_qw_26_6">3,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment for IP acquired under the ObsEva IP Acquisition Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_PTVZjuifN0WXslOPUeShlQ_27_6">15,247</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_n-K8S51Qa0yJveQmpUtZJg_28_3">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_YlZ4vtYHjEaYGpj6ar-uXA_29_3">711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_WkybNUGGgkqDV7W_tWhmRA_29_6">20,221</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Tc_vVg0Ub7bFUW6GxF7XwLYrQ_32_3">130,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Debt issuance costs and loan fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_z33_-JKfakGmAywSRxqYjg_33_3">4,253</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment of preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="Tc_e-pCdYndzES6HcdwPy9QBw_34_3">5,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="Tc_874R5mxte0K6rL5QnHHgPA_34_6">5,472</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of options and other share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_phFYYgGICU-TWyL17z33bg_35_3">466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_GoVQLuaHWEuQeSNFP-7pVw_35_6">2,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Taxes paid related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_q-IWTE6vOEapDfWlrwGT4Q_36_3">148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_IJDSnGM2pEyIs8PjXjBj2A_36_6">1,398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_H5EMpS3SG0OzzRvFen6ZKQ_37_3">120,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_sXyEtGEnhk-flg--CqtJNg_37_6">4,451</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_8muhKvP4_kCDuf8iUYwynA_39_3">101,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_Q9C9aQPjlEypGoDK9mGlmQ_39_6">37,551</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_He4EvKs3ck6FjAW8Nv_T7A_40_3">57,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ZGg5drdrCU-E9hH0pWVIUg_40_6">95,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hDi_dDshg0eSv9NmO6H3wg_41_3">159,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_twAHjs1BzUOrXD5xic1FIg_41_6">57,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Supplemental Cash Flow Information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash paid for taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_uQz4JQLJlEmejI1UA4DJPQ_44_6">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_3jE6f4QX4U-X-1JlNDCvyw_45_3">468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-cash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock warrants in connection with long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:IssuanceOfWarrantsDebtFinancing" scale="3" id="Tc_T1VdZVBby0qzK6yf999OYw_47_3">1,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrued issuance costs in connection with issuance of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_iKIIe2Xw-kebPZ7Ldllk5g_48_3">501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Preferred stock dividend accrual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="Tc_dUG2CmtF10qO1B356OHJZg_49_3">1,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="Tc_J2CbdDiuN0aNFPRPCcyqzQ_49_6">1,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Estimated fair value of contingent consideration under the LadRx Agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" scale="3" id="Tc_PmizMcrk5UWKQwyR1yaTeQ_50_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrued transaction costs in connection with ObsEva IP Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedTransactionCostsRelatedToPurchaseAgreements" scale="3" id="Tc_ZQ8Rv1qb0U6r9GZxvC2MWw_51_6">122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrual of contingent consideration under the Affitech CPPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccrualOfContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_FcEmebwwnkm1s55mW8jebA_52_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9a2ab560_0ded_42d3_b833_3f1580fd224e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:NatureOfOperations" id="Tb_PTM5IOZgqk6w1R7jACduxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA Corporation, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through the acquisition of rights to future milestone payments, royalties and commercial payments, since its royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. XOMA also acquires milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to the Company in a relatively short timeframe. &#160;The Company&#8217;s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects most of its future revenue to be based on milestone payments the Company may receive for milestones and royalties associated with these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December&#160;31, 2023, the Company had unrestricted and restricted cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="Narr_6QDP4upInEajdL9U_xPBKQ">159.6</ix:nonFraction> million primarily related to financing cash inflows received in December 2023 pursuant to the Blue Owl Loan Agreement (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_tDdRcfNJQE-HqC9xqNXDuw">153.3</ix:nonFraction> million and restricted cash of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_1QStCvqwQkqSKID1tdcc0w">6.3</ix:nonFraction> million. As of December 31, 2023, $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="Narr_Eo9ho9y_eUCJKFqAs-AS4g">0.2</ix:nonFraction> million of restricted cash was classified as current and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_rNYp1cMJ9ES87IZtzaPMFQ">6.1</ix:nonFraction> million was classified as non-current. The restricted cash balance may only be used to pay interest expense, administrative fees and other allowable expenses pursuant to the Blue Owl Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s current cash balance and its planned spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" format="ixt:booleanfalse" name="us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear" id="Narr_gmpjYkx-IESa4BDk5dA4WQ">one year</ix:nonNumeric> following the date that these consolidated financial statements are issued.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_symJqX6pvkenOiQMurz09w" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_74FdCennt0uoMcA8Z-EUcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:UseOfEstimates" id="Tb_RL8X3KX8TU-u7GrKzkJxpQ" continuedAt="Tb_RL8X3KX8TU-u7GrKzkJxpQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration, amortization of the Blue Owl Loan, valuation of warrants, accrued expenses and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk90551798"></a><a id="_ca4c5864_6c34_48d3_b9c6_2a696164b31f"></a><a id="Tc_4OSf6aXGkEiLSZnQPO2saw_2_2"></a><a id="Tc_UShHr5o3qkecuEDO8U3TMQ_3_2"></a><a id="Tc_1yEKCnFzLkWArwu07fcNmQ_3_5"></a><a id="Tc_kNhen3-gTk2Rt-dWbaRrNw_4_0"></a><a id="Tc_grQiwm4qqUykrvmARq5VbQ_4_2"></a><a id="Tc_JPkIqIzfvUa4xoK6TcYvlQ_4_5"></a><a id="Tc_utznvfq-zk-XSIwKARZ2Ew_5_0"></a><a id="Tc_gK8Lc6CINkawoYQudbtmjQ_5_6"></a><a id="Tc_sCBhE8yKjkqUE1JZ8v0f-g_6_0"></a><a id="Tc_5b1botqBkUauPl2xLScE8Q_6_2"></a><a id="Tc_I8HO4Ij-10iSibcVkxcSyQ_6_5"></a><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont1" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont2"><ix:continuation id="Tb_RL8X3KX8TU-u7GrKzkJxpQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, including estimates such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. In addition, the Company&#8217;s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_8xHFRyBwh02obD6j_IgKnQ" continuedAt="Tb_8xHFRyBwh02obD6j_IgKnQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Unrestricted and Restricted Cash and Cash Equivalents </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_wE78pLUUrk-FpJEgdx97VQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_eGE7c3vT_UGPOytjJmI5hw_4_3">153,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_y5KvB8d2Gk2zxfOP3K9a8w_4_6">57,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_OCGCaJv3J0K2mQfVor-84g_5_3">6,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total unrestricted and restricted cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_7SuGn7WGU0Cm-8EEgy8_2Q_6_3">159,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_QRKC7Xz9u0qNtJO0xub0VA_6_6">57,826</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are generally in money market funds.<span style="display:inline-block;width:2.25pt;"></span><span style="display:inline-block;width:18pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Unrestricted Cash and Cash Equivalents </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had an unrestricted cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_et3D9Xj9o0SKZgaoM6rOcQ">124.9</ix:nonFraction> million and an unrestricted cash equivalent balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_vWuEQpqpnEuQ5ediMsRXFA">28.4</ix:nonFraction> million. As of December 31, 2022, the Company had an unrestricted cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_vaGTnaYKK0eb3c1AnAeiiA">27.5</ix:nonFraction> million and an unrestricted cash equivalent balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_FPTLY0Bxf0i9E1H_Hz_7kQ">30.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Restricted Cash </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, XRL deposited $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_r98Y34qxLkWbmrz_8S1ntw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr__iafchRkT0OwUxg0iP98pQ">6.3</ix:nonFraction> million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_pFJTova4jkOtP18qsB8a9Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_Yt5xL3HMAEy4so8rv6TDtQ">5.8</ix:nonFraction> million was deposited into a reserve account for interest and administrative fees and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsOperatingExpensesMember_bIl9zjrGREO247K9VPfUHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_9qInSRuKeEqE3ZcljkUqoQ">0.5</ix:nonFraction> million was deposited into an operating reserve account to cover operating expenses of XRL. As of December 31, 2023, the Company had a short-term restricted cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="Narr_70-9vwyMx0-c47QRjo_O1g">0.2</ix:nonFraction> million and a long-term restricted cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_NzMpsihC5ESXh9XP0ad6Rg">6.1</ix:nonFraction> million on its consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_7_1_2027_To_7_1_2027_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_zKMEytddB06_SjlQuaXQbA" decimals="-5" format="ixt:numdotdecimal" name="xoma:RestrictedCashAdditionalToBeFunded" scale="6" id="Narr_IaziQVGyYE69-EH1BvjqmA">0.8</ix:nonFraction> million into the administrative fee escrow account on July 1, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_7S09LNSBFkuY7ekacPaAeQ">no</ix:nonFraction> restricted cash or cash equivalent balances. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont2" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont3"><ix:continuation id="Tb_8xHFRyBwh02obD6j_IgKnQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_g7_QrrNkAUiKQElLos5oBg" continuedAt="Tb_g7_QrrNkAUiKQElLos5oBg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont3" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont4"><ix:continuation id="Tb_g7_QrrNkAUiKQElLos5oBg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock" id="Tb_7Fn-XyvPck2gns0pZ_0e6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_v-Mm96XY306yZ1O1NBWxIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:EquitySecuritiesPolicy" id="Tb_s8qhw1lawU6XVftFAbkFAQ" continuedAt="Tb_s8qhw1lawU6XVftFAbkFAQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont4" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont5"><ix:continuation id="Tb_s8qhw1lawU6XVftFAbkFAQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive loss in the period of sale.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" id="Tb_xR2STplUhkSg8ERIeiV_cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:CreditLossContractWithCustomerAssetPolicyTextBlock" id="Tb_KPuytmQa_UySYlzP5pNHhQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Allowance for Current Expected Credit Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:AssetAcquisitionsPolicyPolicyTextBlock" id="Tb_UoBwHqhwMkuB2Mchopr34A" continuedAt="Tb_UoBwHqhwMkuB2Mchopr34A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (see Note 4). </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont5" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont6"><ix:continuation id="Tb_UoBwHqhwMkuB2Mchopr34A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s consolidated statements of cash flows. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_d43RuZJcBE66Q78bHQym_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset was amortized on a straight-line basis over its estimated useful life of <ix:nonNumeric contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_EnsamhLSDEaWLpf-NafDRA" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_dND_7SkoEkylHo7ind_Rnw">17 years</ix:nonNumeric>. The straight-line method of amortization represented the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset was carried at cost less accumulated amortization. Amortization was included in amortization of intangible assets in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_oz0fAYotp0mUGRBUZG1bFg">14.2</ix:nonFraction> million was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheet and included a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_wYwpTq2UP0y1LVrHSMW6OQ">14.2</ix:nonFraction> million impairment charge in the <span style="-sec-ix-hidden:Hidden_yKNGHsYxl0ua6mlZdK34eA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of operations</span></span> and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_dPIE5yS3VEeOEmSxIvyC9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:DebtPolicyTextBlock" id="Tb_NJt5NUAZskuHuGVPNrRJug" continuedAt="Tb_NJt5NUAZskuHuGVPNrRJug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Long-Term Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-term debt represents the Company&#8217;s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the effective interest rate method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont6" continuedAt="Tb_symJqX6pvkenOiQMurz09w_cont7"><ix:continuation id="Tb_NJt5NUAZskuHuGVPNrRJug_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the effective interest rate method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:WarrantsPolicyTextBlock" id="Tb_8rlx0LIV_keM59-vdK0OhA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Warrants </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company&#8217;s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company&#8217;s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_p79-MUn5REOQ8U080cv8Iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_A46db6bVTUmn-VcclNOsXQ" continuedAt="Tb_A46db6bVTUmn-VcclNOsXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#8217;s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_symJqX6pvkenOiQMurz09w_cont7"><ix:continuation id="Tb_A46db6bVTUmn-VcclNOsXQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_zFrKFWlub0yF-8yZg5Mz6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive (Loss) Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_VMwg4Y7cjU696DgM42UEPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt annual requirements under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_93dd08a8_2bd4_4c54_8544_ebd13ad9f883"></a><a id="Tc_Z4ab5EMW-kKqC_0L4wG90Q_1_5"></a><a id="Tc_LeJmv_BY3UmF3_br6fhleA_1_8"></a><a id="Tc_6ciB57VI1EylNma64bCtnQ_1_11"></a><a id="Tc_15t5mUG9N0qZogz272bMKA_2_2"></a><a id="Tc_Dwjv1Oih4UeEw2-d8ZMsZA_2_5"></a><a id="Tc_mHownSHiOU2RfXWCUoQY8g_2_8"></a><a id="Tc_AGbJYrG1BUmbdPra9xbaJg_2_11"></a><a id="Tc_wyDkPo1g90qdMciOa2xkhQ_3_0"></a><a id="Tc_LMMKjeh-WU-2_Bvec8Wlag_4_0"></a><a id="Tc_1AbTHIs4rkqDxKkUire-Bg_4_2"></a><a id="Tc_scuH4zlStk2cQl-f1Pio-w_4_5"></a><a id="Tc_rbTZRBqn9k-vQYWVB7BG5g_4_8"></a><a id="Tc_S_2Y3oxxNUSCikTIi9IE4g_4_11"></a><a id="Tc_ONCRTc8K9U21RFJ8QPQ-tw_4_12"></a><a id="Tc_GO5fuOwkf0-pNAGquf14Rw_5_0"></a><a id="Tc_5hzZXAA4SEWgtbciBSZWdg_5_2"></a><a id="Tc_IocXPq3H0UKzbHU-6PvRdQ_5_5"></a><a id="Tc_elx_dzTfT06BA0sVx57EJg_5_8"></a><a id="Tc_b3OWj8kprUO6aFlaOKYZdA_5_11"></a><a id="Tc_UEE7zLCLMkOj5OmTv6az1Q_5_12"></a><a id="_62b43d3e_f9eb_465d_bc5a_349c2ed52e1a"></a><a id="Tc_Xl-c7su-EkSjhdAFma5MEg_1_5"></a><a id="Tc_0gplCTCsrUWXz_VpxNzOKQ_1_8"></a><a id="Tc_1SOwinQGOUmfRQWt6zQeag_2_2"></a><a id="Tc_E6FsJyRMX0yINGQYU_bovQ_2_5"></a><a id="Tc_heJhZDN1L0KB8FqRUSFGlw_2_8"></a><a id="Tc_J4qZBVvGGEONFA9wsGl7PQ_3_0"></a><a id="Tc_F80X8kyU2ECkUOf01lW_Vw_4_0"></a><a id="Tc_S0Lqg3qUrECKoUpcse6zuw_4_2"></a><a id="Tc_B2cFIdhii0y8iYQfcJBqjA_4_5"></a><a id="Tc_UwMv-0xXmUmNHFyQZVir7A_4_8"></a><a id="Tc_URk4p6lvoEimGR-cTmfTIQ_5_0"></a><a id="Tc_jjepCw8pOEyQJUsWf7TWXQ_5_2"></a><a id="Tc_ZshgciCxdkemtepo-iaVAg_5_5"></a><a id="Tc_5f5POXgN-0eRTdABuNWaAA_5_8"></a><a id="_50ab1c9b_b1c0_4142_87b4_7bf42f962f0d"></a><a id="Tc_3YXN4trEDUyDh7fIQ6vEAA_1_2"></a><a id="Tc_HlmZm3BHqUqj3VmFClnVpQ_1_5"></a><a id="Tc_grSONppFw0CzYy-kijtiOQ_2_2"></a><a id="Tc_AMInrXz3IUiiiLqIIWtMOg_2_5"></a><a id="Tc_vtKlChlmy0iJNEZL4i9u7g_3_0"></a><a id="Tc__gsPinxClUOe4Z6HPBxtJQ_4_0"></a><a id="Tc_dOcX8AhsEUqvSbSZZ90D3g_5_0"></a><a id="Tc_vmmIp5YU0UuovKp95BIGJA_6_0"></a><a id="Tc_jogQBTD4XEqhVJVvbzNJUQ_7_0"></a><a id="Tc_-oV4634uM0-V7AUblyR7dQ_7_2"></a><a id="Tc__XQTXIVPsUuDuQdF4lx5Aw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_CaU5uAPmyk2EIzjoYbjOfw" continuedAt="Tb_CaU5uAPmyk2EIzjoYbjOfw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Consolidated Financial Statement Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, equity securities consisted of an investment in Rezolute&#8217;s common stock of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_w6rQaC_PqEy9fPUmEuULSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="Narr_0Ns4_1Ajwki6MeCuAaNyGQ">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_pSxax3Usz0yR4JG-1OD69Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="Narr_vjp9EJAlbkS85m_2TV_UiA">0.3</ix:nonFraction> million, respectively (see Note 4). For the years ended December 31, 2023 and 2022, the Company recognized a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_lw1Ws7NAP02fg7d3o1Pq3w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="6" id="Narr_SFsM8D3C5Uqf6mkPu45yVw">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_RWlyVdx2GUC3EPptM1fY5A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="6" id="Narr_W69Pq2tpPESkEBY4HjOFIg">0.4</ix:nonFraction> million, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Intangible Assets, Net </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_du9X-q16hEa7Ojrk22zKGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, impairment charge and net carrying value of the Company&#8217;s intangible assets as of December 31, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Charge </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_RRcaFO6M3kOh_ZaU4q8qig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_XNwmLc5AJkSKcpCx-TM-qg_4_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_RRcaFO6M3kOh_ZaU4q8qig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_7ZC0mhwJmU2V6Dgt9tQ0IQ_4_6">994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Y2l7YTUwo0u38OqVPbafow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="Tc_wJRohUKtLkOsT_VmBdY5cQ_4_9">14,253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_lxPfC00yxkerfpclASCwBQ_5_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_xquuyB8IVE6SHI2Q9vEH9w_5_6">994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="Tc_fB5I6L2WgkaLNio-wG9uXA_5_9">14,253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_uxTs1Y2sU0qP2YppBFt-lg">14.2</ix:nonFraction> million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_xc-mtl1h_02K0eu8gdujFw">14.2</ix:nonFraction> million impairment charge in the <span style="-sec-ix-hidden:Hidden_W5XKDOrmOUCVyHTuQ-wVXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statements of operations</span></span> and comprehensive loss.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of intangible assets as of December 31, 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_58KtJYOdX0Wgp_iBh5jS7Q_4_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_TJJ_EmuhHUSqXGRllAxU8Q_4_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_KCE1wwuyw0CDTuJedoru9w_4_9">15,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_7Ro5wPzbC0qPSIIHMQKKQQ_5_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_8bLSK5qZTE-0Rzx_YyoGGg_5_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_UpnQeKCd1EyXjWQY664yyw_5_9">15,150</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accrued and Other Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_4y-NFZSTcky57yRHJBMiFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_GXDTZ5Uq8E6seq3FVcVITA_3_3">1,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_Xhc3wlSi10eRzaOHwxTueA_3_6">562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_Nena77wELU-6F7GGirN6sA_4_3">791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_DGsz_uXx0E6B1iCgWt2nCA_4_6">867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll, severance and retention costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedSalariesAndEmployeeBenefitsCurrent" scale="3" id="Tc_wXGRcb3AfkqMpTq5kbi-ng_5_3">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedSalariesAndEmployeeBenefitsCurrent" scale="3" id="Tc_yqv-zPeN_0mgqalFClDpWg_5_6">1,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_oGe7zuzTt0WYYN-R3tPHAQ_6_3">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_IepiFQNAhkqA1l5EJpuLKA_6_6">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_C_rt1oisoU6Ux6BH6CE79A_7_3">2,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_OxRcDbKJREWZykmnPV5f3g_7_6">2,918</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Arbitration Proceeding </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company initiated a binding arbitration proceeding with <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_6_1_2021_To_6_30_2021_dtGtLvan-0WILGKknRPEsA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfArbitrationProceedingsInitiated" scale="0" id="Narr_l7v8-zp-x0aTPHOt2YBX2w">one</ix:nonFraction> of its licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, and sought milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement had </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_CaU5uAPmyk2EIzjoYbjOfw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">expired. The panel ruled that the Company was responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; fees and administrative fees previously incurred by the Licensee of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="Narr_jzALMjAAqEKjk_os3BGvMA">4.1</ix:nonFraction> million, which the Company paid in April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:LicensingAndOtherArrangementsTextBlock" id="Tb_E-n79cYtwUualAPFvn8bJw" continuedAt="Tb_E-n79cYtwUualAPFvn8bJw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive an aggregate of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember__6fnOc6OPUS1I5ZlPUpdTQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_v0bGRKGv1UqmB6h1Y1lwZQ">19.0</ix:nonFraction> million relating to TAK-079 (mezagitamab) and low single-digit royalties on future sales of all products subject to this license. The Company&#8217;s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to receive royalties expires on the later of <ix:nonNumeric contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0EETUtBX8UGfAIbmhgJkXQ" format="ixt-sec:duryear" name="xoma:RoyaltiesPeriodMinimum" id="Narr_9Gp_Lo4dc0Ws_PWNGF0Ftg">13.5</ix:nonNumeric>&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or <ix:nonNumeric contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0EETUtBX8UGfAIbmhgJkXQ" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimumScenarioOne" id="Narr_53as3vHUXkqTIpW9f9atgQ">12 years</ix:nonNumeric> from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_w1WsQS9rPkSjRRaxRFYrUg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" scale="6" id="Narr_F8hDVnsopkGP3U30Uth0Bw">3.3</ix:nonFraction> million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#8217;s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to receive royalties expires on the later of <ix:nonNumeric contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_w1WsQS9rPkSjRRaxRFYrUg" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_1npef7JHtEmG0jWjoT_wpg">10 years</ix:nonNumeric> from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_hxT-8FvU4kmmkr5WaUc5tw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Dcgh_FsJ4Euv7xAyqVC0OA">2.0</ix:nonFraction> million milestone payment from Takeda. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_dLKjanUZa0iaV3DbfG2Dlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_xiM8zPkmUUm22L2DC3ADdw">0.8</ix:nonFraction> million as revenue from contracts with customers in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. &#160;<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_fi1CUmq620GKCFSjTShMsA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_QVdJMDj5zUGGA5coiWxkCg">No</ix:nonFraction> milestone revenue was recognized for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized annual license fee revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_qCQ7jqMcRkubKcfhZC2tng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_d8cF6L8cO0CIe8St9tIUNw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_OSC8ojzXEkSJ5RzL03Kwhg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_l-T1o_JCTE2N8o1deUVh9g">0.1</ix:nonFraction></ix:nonFraction> million from Takeda in the consolidated statement of operations and comprehensive loss for the each of the years ended December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_JvsNEEdL70uDZZzmcZHb2Q"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_bCG69XnSTE-4fRp9k9WfjQ"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_sxlOuSEjh02Ih5M4yuBVeg"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_Quf8fTffhU6NMWC0qcY1oQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_H0r1yUlcQEWloymp8PEARA"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_vDFcfTH4eUmGdn7zNinqjA">none</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_1_2020_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_MTSivgxXa0q5d0yr9jPQ4Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_kLefBdEWEk2gcjmO3leSaw">3.0</ix:nonFraction> million of milestone payments since the inception of the agreement and is eligible to receive additional milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_gcv21_e8WkqBKwiHoRoZTQ">16.0</ix:nonFraction> million under the Takeda Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize RZ358 (previously known as &#8220;X358&#8221;) products for all indications. In addition, the Company entered into a common stock purchase agreement with </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk7587136"></a><ix:continuation id="Tb_E-n79cYtwUualAPFvn8bJw_cont1" continuedAt="Tb_E-n79cYtwUualAPFvn8bJw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rezolute pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock in connection with any future equity financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_IHaDD6BBE0CO38D7GY_WoQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_PMYhdnDiIUm9UxQibeURMw">232.0</ix:nonFraction> million based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the later of the date of expiration of the last valid patent claim covering the product in each country, or <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_gy86xQDN_kOxX3_roA0-UA" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_70h2ijo_5Uq0TbiIpcZt9g">12 years</ix:nonNumeric> from the date of the first commercial sale of the product in each country. Rezolute&#8217;s future royalty obligations in the U.S. will be reduced by <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfDecreaseInFutureRoyaltyObligations" scale="-2" id="Narr_6IabxAlOFkeHNg_RNvDhpw">20</ix:nonFraction>% if the manufacture, use or sale of a licensed product is not covered by a valid patent claim, until such a claim is confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical study. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_plbEBxZzaEaRWFV0Pyn4DQ" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_4OBMjpErHEmRh5RQRFejZA">12 years</ix:nonNumeric> from the date of the first commercial sale of the product in each country or for so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in each country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_Y9y7yjEiyUS67tOWI6nEpw">ninety days</ix:nonNumeric>&#8217; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A" decimals="-5" format="ixt-sec:numwordsen" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_TaSwHhmuPESYua1pzzTYwg">No</ix:nonFraction> consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" scale="6" id="Narr_0GtiJpbbuku8BGfaocpTRQ">6.0</ix:nonFraction> million upon Rezolute&#8217;s equity financing activities and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementInstallmentPaymentsReceived" scale="6" id="Narr_HcCVxv3VbEC5LDy59d_L7w">8.5</ix:nonFraction> million in installment payments through October 2020. The Company also received <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:LicenseAgreementSharesReceived" scale="0" id="Narr_-ZbW--L3s0S-XikbCOEldw">161,861</ix:nonFraction> shares of Rezolute&#8217;s common stock (as adjusted for the <span style="-sec-ix-hidden:Hidden__s_2kpVZCEW7Qrum_VkryA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>:50 reverse stock split in October 2020). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AvM2tRL06EKNen-3oQQBug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Zk7Zy2JsGUieYH0zD_FBuQ">2.0</ix:nonFraction> million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__ZprmCypEEWlgZ0NIIwirQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_LjUERAr6O0uDzPtiqSgNhA">No</ix:nonFraction> revenue was recognized for the year ended December 31, 2023. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_W8GylEFUmkCZLuCLShF-2Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_dEyBIwRNakyeJWZ6_xCrqg">2.0</ix:nonFraction> million from contracts with customers in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_E-n79cYtwUualAPFvn8bJw_cont2" continuedAt="Tb_E-n79cYtwUualAPFvn8bJw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_0-lQazqAikS4zIurC8X8Hg"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_BIJ-0sD2zUqAwbGUot4c5g"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_XbLq5o4aA0ep3wuf7VQNQw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_nkY4_KwZqUKQd5l2Sg572g">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_niDMWvk5fkS25v5KMGvZhA"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_hgVmpIGg10qJKyLfgsfrlA">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMA&#8217;s patents and know-how. Under the agreement, Janssen made a one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_TfMI0yx-pkOYNgT8xeCDXQ">2.5</ix:nonFraction> million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" scale="6" id="Narr_uawgqJCm5ky8B-M-iZhgfQ">3.0</ix:nonFraction> million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw" decimals="4" format="ixt:numdotdecimal" name="xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization" scale="-2" id="Narr_Kd0BiWA05Ue4hmHulNzR7w">0.75</ix:nonFraction>% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uRoDrOQqBEOHxxDn5GD5-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_32LNZ4HFQ0WEfl2QnC87Vw">2.5</ix:nonFraction> million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_M8C0LnA4WkSRl7loKPptFw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_wOLe3KY_HEyy7yVJToWEOg"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_6cwetVbx2E-O6ZzwDK6FjA"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_SQS7vGfLHE6kKOldYPN6aA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_xngm2k6nNU-S81Jt7IACig"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_-cPOECiP106PJVRCiyYV-Q">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_5vFgsQWMw0WyWVDC99pPgA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_bQaaJOAXeUeWzO6uuO5wzQ">1.5</ix:nonFraction> million in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023. &#160;The Company did <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HGWd0mh5bECM6w9TDjLMqQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_rvr4yQXwd06AetT98kcK8A">no</ix:nonFraction>t recognize any revenue related to this arrangement in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">ObsEva </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#8217;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA was eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_pkZG2E_eREWXSRXOQwQ7GA">475.0</ix:nonFraction> million in payments for ebopiprant development, commercialization and sales-based milestones. If ebopiprant was successfully commercialized, the Company would have been entitled to receive royalties on net sales that range from low to mid-teens from Organon and would have been required to make mid-single-digit royalty payments on net sales to Merck KGaA. The Company paid ObsEva a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_gKQlPKeg1Uam2Si1rAIbpQ">15.0</ix:nonFraction> million upfront payment at closing and would have paid potential earn-out payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPayments" scale="6" id="Narr_xhpe7Us4yUC3dC7PXqlSMw">97.5</ix:nonFraction> million for development, regulatory and sales-based milestones, representing a portion of what the Company would have received pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The transaction was treated as an acquisition of a finite-lived intangible asset (see Note 2). As such, the Company&#8217;s cost to acquire said intangible asset was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="Narr_TgYrsdF3hEGorMhOKOtRxA">15.2</ix:nonFraction> million, which consisted of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_boRK_Rg15EG-vsq1yqxN8A">15.0</ix:nonFraction> million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="6" id="Narr_UOqk4Ey7n065hIRVtbrn5g">0.2</ix:nonFraction> million, which was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk91748058"></a><ix:continuation id="Tb_E-n79cYtwUualAPFvn8bJw_cont3" continuedAt="Tb_E-n79cYtwUualAPFvn8bJw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the intangible asset at acquisition represented <ix:nonNumeric contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_x36Nhb2MEEmzaRrN6adNZw">17 years</ix:nonNumeric>. No impairment indicators were identified, and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_DR_dvBy6JkSRBmbQK4UTeA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_SuzgbTIkZ06i8Vw3RvlxWg">no</ix:nonFraction> impairment was recorded as of December 31, 2022. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ORSwgOFEv0uBzO5uoRPJVQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_T2Z8azg2SkO3Quaw3Uj8fQ">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rqkDVECDp0uGDqsfOos4Pw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr__GhBPcczYUisuUqUZvuwdg">0.1</ix:nonFraction> million of amortization expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" scale="6" id="Narr_qRyBN05oNU6eCgXaUjagTA">46.5</ix:nonFraction> million, sales-based milestones payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments" scale="6" id="Narr_dd3OXTSPWkOyTT-yM6xqqA">51.0</ix:nonFraction> million and royalty payments to Merck KGaA did not meet the definition of a derivative under ASC 815 and a liability would have been recognized at the time that the underlying revenue was recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 would require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expected the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would have been recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 23, 2023, Organon notified the Company of its intent to terminate for convenience the Organon License Agreement, which <span style="background:#ffffff;">XOMA assumed pursuant to the ObsEva IP Acquisition Agreement dated November 21, 2022.</span> The termination was effective as of January 21, 2024. The Company will not be entitled to any milestone payments with respect to any milestone achieved by Organon following the notice of termination. No material early termination penalties will be payable by either party. The Company evaluated the related intangible asset balance for impairment in the fourth quarter of 2023 and recorded an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_3WHRj7yXxk6Z9Qfmyl4VIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_PswHrHUmDEuDBj9MTsXzXA">14.2</ix:nonFraction> million, writing off the entire finite-lived intangible asset in the consolidated balance sheet and recognizing an intangible asset impairment in its <span style="-sec-ix-hidden:Hidden_UjdHxsUKK0CGYSg7vc8W1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations</span></span> and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the Anti-TGF&#946; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#946; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Anti-TGF&#946; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#946; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_raZj1dx7GUG2f1B4rZEqhg">180 days</ix:nonNumeric>&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGF&#946; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_3MQlNYOe4ke3SviFlop7uA">one</ix:nonFraction> combined performance obligation. The Company recognized the entire upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tb-jqf59g0qRtmd2zX4zHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_di0ppqls9E6gaknD9eWeww"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tb-jqf59g0qRtmd2zX4zHA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_DhuM34WPZEuUPpdr67uDYA">37.0</ix:nonFraction></ix:nonFraction> million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ZfHh5QPIlkK7My1pRgpLNQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_EKx2UZDKnkKGS2eP7Ue0eg">480.0</ix:nonFraction> million in development, regulatory and commercial milestones under the Anti-TGF&#946; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#946; Antibody License Agreement, and as a result, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lPc163Jack2g_3qJHGxkJA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_UB0TUUFxtUag9okm_4HxJg">10.0</ix:nonFraction> million milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk93938130"></a><a id="_Hlk95303077"></a><a id="_Hlk94259450"></a><ix:continuation id="Tb_E-n79cYtwUualAPFvn8bJw_cont4" continuedAt="Tb_E-n79cYtwUualAPFvn8bJw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#8217; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_L9Ww6N0B8UmNRJCzwMQXNA">ten years</ix:nonNumeric> from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jkZrlo9E8kGwNk50O_JF4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_tNEvPhruBEqKfw8vY5--mg">25.0</ix:nonFraction> million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#946; Antibody License Agreement, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jkZrlo9E8kGwNk50O_JF4g" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_H2QaWYCCv0umDL9UIOVIew">17.7</ix:nonFraction> million in cash, and the remaining balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_DDySBRqQAkmCyGXaQYbaTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" sign="-" scale="6" id="Narr_IHC4OHbx80SL_u9td5B9mg">7.3</ix:nonFraction> million was recognized as a reduction to the Company's debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Kfw2xvvPLECdksugQSkyRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_K8vEkSRbK0yVugiIwyl6kA">35.0</ix:nonFraction> million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2023, Novartis communicated to the Company that it intends to discontinue development activities related to NIS793. Novartis will cease enrolling patients in the remaining active TGF&#223; clinical studies and will collect all data upon conclusion of these studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_K15bbo7jWUuuDe1Qfxh1Wg"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_zBhWjiLiBEerbKSfUAKsWw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_Hs1OzmsqGUe7kQbtNVV6Pw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_6i3q1vnZUEaovWIbGHXMsg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_AoMxnGNgK0O1P_8XiSntAA"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_SK1Tul6-C0Cuv5CqLn28Hg">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wFKkAjcle0uyGz1v162nrQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_v_XnfSzX20iOVAY8VXRFXw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7PuIiwOfIE6NRKYOTnb75w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_E2KbdvRnkkm9Ji0qPR4JwQ">no</ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_Vamdixfgi0GzqzqjNEi5Kg">30.0</ix:nonFraction> million for the license and rights granted to Novartis. Of the total consideration, $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_J8OI4i89L0WobQnzslqjdg">15.7</ix:nonFraction> million was paid in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_yqsVfzTm6k-eF6bSHTp9Og">14.3</ix:nonFraction> million (equal to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_mzQmqJqZD0WOAo7brJv5KA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_pCrcqI4v90W1cY6_lecX8Q">12.0</ix:nonFraction> million) was paid by Novartis, on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, Novartis extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_C2k0UM6Hg0WhjWjGPdmIHw">5.0</ix:nonFraction> million cash related to the sale of <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_IY_E1K2-GEeCZwiLEBu6nw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_o4GEr5Oo7kWiXB8JLX6L1g">539,131</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_7AXSy2l_dkerjh7MaB675Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_AIpnSabH_E2ilt-9MiLrsg">9.2742</ix:nonFraction> per share. The fair market value of the common stock issued to Novartis was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_IY_E1K2-GEeCZwiLEBu6nw" decimals="-5" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock" scale="6" id="Narr_7urI46B9mEmMN3VGmZG0EQ">4.8</ix:nonFraction> million, based on the closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_7AXSy2l_dkerjh7MaB675Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_HJ4SONKx_Umm9upzazKPRg">8.93</ix:nonFraction> per share on August&#160;24, 2017, resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_Q7v30Kk1gkaVAoFo7oX6mw">0.2</ix:nonFraction> million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_6gbf0-HRZ0qDTY9O_kyUlg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_oasmn47QOky4F-z3XZsAzQ">438.0</ix:nonFraction> million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_yk_WkugXu0KU1E5kCoC55w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_PxxhLa7gwUqrMiCY63SaEw">10.0</ix:nonFraction> million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_E-n79cYtwUualAPFvn8bJw_cont5" continuedAt="Tb_E-n79cYtwUualAPFvn8bJw_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The <ix:nonFraction unitRef="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementsNumber" scale="0" id="Narr_6EG_Qx_waEW55_IT_3yBWw">two</ix:nonFraction> agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_EK9Ezbam2kyXpIm2Hhn9_g">six months</ix:nonNumeric>&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ArrangementsNumber" scale="0" id="Narr_owRQsRpv0UmX7-excOC93g">one</ix:nonFraction> arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_nJdgcAadr0mjpH-sGk1g-A">two</ix:nonFraction> distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementTransactionPrice" scale="6" id="Narr_lO7YqFmEZEKp0s4fwHJ8mg">40.2</ix:nonFraction> million, which consisted of the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_FllTTQOxd06hYSAPXidYKQ">25.7</ix:nonFraction> million upfront cash payments, the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_Xg5Do9skTkqmkyrQEJoo2Q">14.3</ix:nonFraction> million Servier Loan payoff and the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_Q5N3N725z0C9nIPtfZ3UkA">0.2</ix:nonFraction> million premium on the sale of the common stock. The transaction price was allocated to the <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_E63PgAEpak-2cYZsaVbl_Q">two</ix:nonFraction> performance obligations based on their standalone selling prices. The Company determined that the nature of the <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_WkU6y0pk0U-i3UTndc9ToA">two</ix:nonFraction> performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_FPhDw6eFSkewkz9kjfMtWw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_GfFJyuFJaE28FXooQd2IIQ">40.2</ix:nonFraction> million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_WSPihTb0M0i5VhIkGo3FgQ"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_l-AxThO_EkSrpyYHR71w1g"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_8DOijJXBwE61zSrIYSz6Pw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_U6E7gxHVPk-nlUnIlAWy2A">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_Et9s47fcy0WWOEEHzrXvYw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_fcI21WcpB0243fBj9x7FRg">none</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lQhUbx-dW0yCv6mncYCFTQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_lE_5ki5FkUGKFVuFOKXMYg"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_ukrOvK0wPUCoC4cxRPdRLQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_meiY8N20okmgfgBzimoBhQ">no</ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;21, 2016, the Company entered into <ix:nonFraction unitRef="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementsNumber" scale="0" id="Narr_Y41WDlwjeUWRwNdvz58wxA">two</ix:nonFraction> royalty interest sale agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_qvLnAbo6Nki2UZIKe_V1Tg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_bZhCP67WX0q0GAf8JlEeBg">6.5</ix:nonFraction> million, plus potential additional payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_5P20gVnqp0OL89sgLmEIrw" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" scale="6" id="Narr_EV38E2cZUkecV1tR5KlHFw">4.0</ix:nonFraction> million in the event <ix:nonFraction unitRef="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_5P20gVnqp0OL89sgLmEIrw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:MilestonePeriodsNumber" scale="0" id="Narr_h-kUuKve8UetLQ2DFay5fQ">three</ix:nonFraction> specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_E-n79cYtwUualAPFvn8bJw_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_KY6LHuuUC0ara8OGoTqocg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_v_yXtr8DOUW2gr7UAjPOQQ">11.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="Narr_Fqkct3ldjUeL7xeaJInR6A">18.0</ix:nonFraction> million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the <ix:nonFraction unitRef="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementsNumber" scale="0" id="Narr_zfzfslL8D02nHtpSyxGojA">two</ix:nonFraction> Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_b-w3yCVO1UaXJ0_RnOHO7Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_qNqEaZox10G7Uu-Y3JD_2g">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_qTQ_SCTqPUOorHOyhK5FRg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_tmze2wGByUyX7kqMVZ5tBA">1.9</ix:nonFraction> million as revenue under the units-of-revenue method under these arrangements during the&#160;years ended December 31, 2023 and 2022, respectively. As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_8W6Ja3W_5UWikBBaH31LWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_0RElS123PkqDfbLDTXO2qg">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_8W6Ja3W_5UWikBBaH31LWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_PKGPKXjoskCbLQo10GygSw">9.6</ix:nonFraction> million, respectively. As of December&#160;31, 2023, the Company classified $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_Nk99SOMJtE6XXgO_0hAWnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_644Ludc_KkqMTIpaUUdnYA">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_Nk99SOMJtE6XXgO_0hAWnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_iYHH4v0dtk2rbVEiV3h4mA">7.2</ix:nonFraction> million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk156898097"></a><a id="_Hlk140183954"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:RoyaltyPurchaseAgreementTextBlock" id="Tb_HmwB08o3qEKDm6K1WF8jUQ" continuedAt="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term royalty and commercial payment receivables were $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_y3UY36HyuUK0uh1i963zhA">14.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_Y--cbn8DrU6v4d1hsuBDzQ">2.4</ix:nonFraction> million as of December 31, 2023 and 2022, respectively. Long-term royalty and commercial payment receivables were $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_gfc2oJV9FkWwQvjSpuRmxw">58.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_V46o1FbqfUGiaTLsbBYU4Q">63.7</ix:nonFraction> million as of December 31, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">LadRx Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased rights related to arimoclomol include potential regulatory and commercial milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_7RTgXi3MwkO02DSrEMpnRA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" scale="6" id="Narr_ucApwLZ2okGZIR4tkWpTqw">52.5</ix:nonFraction> million (net of certain payment obligations of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_7RTgXi3MwkO02DSrEMpnRA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" scale="6" id="Narr_wo3vcGLycUS3wncqm4NILA">9.5</ix:nonFraction> million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased payments related to aldoxorubicin include potential regulatory and commercial milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_U6eB0xdgwk-Ra02haIYfXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" scale="6" id="Narr_6_KHDgL-oUOXtRn586beFg">342.7</ix:nonFraction> million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages for sales of other licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_SnKoy3yDc0a6QnME2LVCDQ">5.0</ix:nonFraction> million and may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" scale="6" id="Narr_yHXDPinoykSkKXs74Nt1dg">6.0</ix:nonFraction> million in regulatory and commercial sales milestone payments which included $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="Narr_5mpBFStb7EOcza9KRMhk6A">5.0</ix:nonFraction> million related to regulatory milestone payments and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_TDjFzNhcYUSzUko8E9rM0w">1.0</ix:nonFraction> million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="Narr_7qkHyRSbWU60xy_umoJ_7Q">5.0</ix:nonFraction> million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont1" continuedAt="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the regulatory milestone payments was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_EdvP5zj2eEWGJwXFNC-zDA">1.0</ix:nonFraction> million. The Company concluded the commercial milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_Cwb7AaYFFE2ceI_J1ek-1Q">1.0</ix:nonFraction> million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the LadRx Agreements, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_kjAfs1w2DkSYpz0lcvU68Q">6.0</ix:nonFraction> million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>payment rights acquired, which included the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_oNkTajm2X0yQQkhUGB6xFw">5.0</ix:nonFraction> million upfront payment and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_PMMyEWCMLky6gr7i0d9CVw">1.0</ix:nonFraction> million for the estimated fair value of the regulatory milestone payments.<span style="display:inline-block;width:15.22pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, there was <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_BUFjwIeF0ESO3uobBxBydw">no</ix:nonFraction> change in the estimated fair value of the regulatory milestone payments from the initial value. <span style="display:inline-block;width:0.86pt;"></span>On January 11, 2024, the milestone was achieved and the Company made a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_11_2024_To_1_11_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_kHKXEon0m0elwS6IFTsLdQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_GNiRsshww06rdi4JatBihg">1.0</ix:nonFraction> million milestone payment to LadRx (see Note 15).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_PMJBCIy7IECiFkjfjmaUzw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_tepSHMW-zk-nAlJ9xwsueQ">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023. <span style="display:inline-block;width:1.41pt;"></span> <span style="display:inline-block;width:15.5pt;"></span><span style="display:inline-block;width:18pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aptevo Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesReceivableMaximum" scale="6" id="Narr_oCcM7dGIDEq60M8TZfuw4A">5.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Aptevo CPPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_t8rO8HH4A0GD7mpIYVRlwg">9.7</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet which included a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_LqmN-m0sn0mkHtAooC6XUw">9.6</ix:nonFraction> million upfront payment and a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="0" id="Narr_90WKhflQkEaW563tP1bxjQ">50,000</ix:nonFraction> one-time payment, which would be due if XOMA received more than $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommercialPaymentThresholdOneTimePayment" scale="6" id="Narr_EtU5_8tvmkq9Vdx9K3jSKw">0.5</ix:nonFraction> million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_1DE8XS7A3E28kJKFWgPj8A">50,000</ix:nonFraction> was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet (the &#8220;Aptevo Contingent Consideration&#8221;) at inception. The Company paid the one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Dnn6lWiT3UCbGZqz1uHJdQ" decimals="-4" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="0" id="Narr_aIwe2oa_m0qx9w44w92aUA">50,000</ix:nonFraction> in June 2023 when related receipts exceeded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_mDE0bA7PrUqp9g8geI29AQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_BJv4lGP7fUOs82XLGD3UmA">0.5</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, the Company received total commercial payments pursuant to the Aptevo CPPA of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ac_n1xmN8US4lumZOLANeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_ev5JMpAfr0mRBLua04HitA">1.7</ix:nonFraction> million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it has a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet date of December 31, 2023 and, as such, $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_TmxXgj1um0uhFTnvaQ9kcQ">2.0</ix:nonFraction> million was recorded as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_3O2RPxwH1U2X0AqDUrZLvg">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pH08PwEje0KIRv6GUczeEA" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr__0qtslkJNUGwGYp77XL46g">33</ix:nonFraction>% of the future royalties on <ix:nonFraction unitRef="Unit_Standard_product_SNQEGGFW5kSKzKYrmjywPQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pH08PwEje0KIRv6GUczeEA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" scale="0" id="Narr_RK28KH7QWkuYgDYWaYI1Yw">six</ix:nonFraction> Incyte Europe S.a.r.l. (&#8220;Incyte&#8221;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-TWqBbOPI0edg96_YaJDsA" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_pBfQ4FnLiESxv8TXTpUC8A">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont2" continuedAt="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vfK6Z82DIk-illPE02g4gg" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_xBx6_Z2tSk-l7ZGbSHZBNg">33</ix:nonFraction>% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_riSbvYPSGkWe1QwZUDB4KQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_9qLOdyrjjE-a61Jlcl9xfw">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vfK6Z82DIk-illPE02g4gg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_xSMXyZwYvkOKRUMvCnXhZw">59.5</ix:nonFraction> million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bTPXO4suRkSuGzADvtOkDQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_diPyGdSXhkaqRWCvqY97Cg">15.0</ix:nonFraction> million. At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bTPXO4suRkSuGzADvtOkDQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_EfL-LvbNdUmZHjRdk0UFOw">15.0</ix:nonFraction> million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ws-dALFRwk6XAWf156awmQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_dGayx2NsCEyhDRRL8lzlHA">10.0</ix:nonFraction> million clinical development milestone payment under its license agreement with Merck, of which the Company earned $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_LUAacl6AYUSQlLyvLbzF7A" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_uHl9ucPWVkCFKuhCd0PQkA">1.0</ix:nonFraction> million. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_LUAacl6AYUSQlLyvLbzF7A" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_b6z_1pSxF0yQmpepqRC2Cg">1.0</ix:nonFraction> million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Agenus RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestone and royalty payments received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TadyAKEHAkuV3__epaLGSw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_LiXfc6IEcU-LWQ2jk0nTPA">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that were being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QrBLuliLBkmZRyyHG3qE9w" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_J1JbITowtUiKyK_jERUxZw">0.4</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the contingent future cash payments upon achievement of certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;) of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Tfg4rgDuq0ufRwK2q3MQ0A" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_qDRLaGpmpk21foRaIV87OA">75,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_ytjN-icb1kyk1iKdCEuL3g">1.2</ix:nonFraction> million upon the closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_-6R4EGaT10KF6sCsbKzuJg">1.2</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 20, 2023, Bioasis announced the suspension of all of its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, the Company recorded an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrentCreditLossExpense" scale="6" id="Narr__-eBtOZi7kW3dB047VkGCQ">1.6</ix:nonFraction> million in its <span style="-sec-ix-hidden:Hidden_oKAPgn6owUGhjjDbJEhNww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of operations</span></span> and comprehensive loss and a reduction of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" scale="6" id="Narr_LlDVzB_zz0my7QPo4nEwow">1.6</ix:nonFraction> million under long-term royalty receivables related to the Bioasis RPA and Second Bioasis RPA. Due to the assessment that the credit loss will not potentially reverse in the future, the Company wrote off the royalty asset receivable and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_IujPki4ZcUC8FCVdHfP_rA">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023. The fair value of the Bioasis Contingent Consideration was reduced to <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_08Y18578W0S0MV6Pef48ZQ">zero</ix:nonFraction> with the change in the estimated fair value recognized in other income (expense), net in the consolidated statement of operations and comprehensive loss. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk20239215"></a><a id="_Hlk93562521"></a><a id="_Hlk20239517"></a><ix:continuation id="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont3" continuedAt="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aronora<span style="font-style:normal;font-weight:normal;"> </span>Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone and option payments (the &#8220;Non-Royalties&#8221;) related to <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_gZktRILmHU6FwmdNSW6U9w">five</ix:nonFraction> anti-thrombotic hematology product candidates. <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_68uwHQnUJU6MTlm6aAAR6Q">Three</ix:nonFraction> candidates were subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;), including <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber" scale="0" id="Narr_Xj7pBMTdlECWTz_1AtPwzQ">one</ix:nonFraction> which was subject to an exclusive license option by Bayer. The Company will receive <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ukWUu5ueDkGldRKA40hqKw" decimals="INF" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_NRpRB719V0mXs2Z2EdyoEw">100</ix:nonFraction>% of future royalties and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_M_ny79iq6ESRMa-kz0SpyQ">10</ix:nonFraction>% of future Non-Royalties economics from these Bayer Products. The other <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zkpfoJr1ZUGbwa1B55RwJg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_pORA7IvOGEamy_rDIlp87w">two</ix:nonFraction> candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive a low single-digit percentage of net sales and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zkpfoJr1ZUGbwa1B55RwJg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_2dRYVzvhdUu1qobb9YeBkg">10</ix:nonFraction>% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_QyRyLDXLLE6CV2wtO_O_3g">10</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" scale="-2" id="Narr_oJy8xQMzWUyamWzRrfjLyg">5</ix:nonFraction>% upon the Company&#8217;s receipt of <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementPaymentPercentageFactor" scale="0" id="Narr_2suQpCiAy0qIKiD8GgNzdQ">two</ix:nonFraction> times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_pVu5ZVgkVkiQJPA5DwdEmw">6.0</ix:nonFraction> million upfront payment at the close of the transaction. The Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FmZheOiEbUS5CMSbMHjZ9g" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_sfbNcOiGk0KBU4XFwSVSog">3.0</ix:nonFraction> million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ukWUu5ueDkGldRKA40hqKw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPaymentsPerProduct" scale="6" id="Narr_PBWIlPINpUysluXbaKn2gg">1.0</ix:nonFraction> million for each of the <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_-e0LRNJfMkWAP6CBPiZhPQ">three</ix:nonFraction> Bayer Products that were active on September 1, 2019 (up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_hcyXjuHEYE6D8CUHcrJ5bA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_oEvNeeqpbU-yPA3qHtVtuw">3.0</ix:nonFraction> million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora RPA, if the Company receives at least $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m5q_NDHLs0qf2z319qyN2A" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_1t6XoJa32UCoLhol5Os0Yg">25.0</ix:nonFraction> million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesPaymentsToAggregateAmountOfPerProduct" scale="6" id="Narr_Ewxv2BKhG0W0wsgKj1nADw">85.0</ix:nonFraction> million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_iKtY_SppBECw4s2NhpeBuA">250.0</ix:nonFraction> million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_4zbWVAftykqvGYUy4RJoQg">250.0</ix:nonFraction> million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_bGO-Xak-2EmMO-sikOKzag">9.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_9AfKWsdTk0KEszpChqWAFw">3.0</ix:nonFraction> million. In September 2019, the Company paid the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Qs55blBy0EiU6L4gvsU5Ag" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_slLcq5-6lUSYPOnDXSdqSQ">3.0</ix:nonFraction> million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Aronora RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zyoQf6ApEUqf3zXcyWmu_w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_L1wCiCbqt0Cbv12BVDjgRw">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_KzUmwidLlk67q4eSwva64g">six</ix:nonFraction> product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vN14m3xAIUKgXMq-xvIgWQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_pzsmpzvFNEiRrJyUKqOq6w">10.0</ix:nonFraction> million payment at the close of the transaction, which occurred simultaneously upon parties&#8217; entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_eEgNr2VcGE6v1KiF-_e3qg">10.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3v-L0Vww2EuNWdV3-uHeDQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_8RjTUEX7ak-QeNVYqrcf2g">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk138947369"></a><a id="_Hlk92457586"></a><ix:continuation id="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont4" continuedAt="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestone payments and other payments related to <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_zN-nXUmOj0OroCeoqEclPQ">two</ix:nonFraction> clinical-stage drug candidates for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CmMun3MJHE2TK0PBPfLoYA" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_zC-m-uEC9UiLMwT2Em2MzA">13.5</ix:nonFraction> million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum" scale="6" id="Narr__8C_efc6wUaa79jWXly84Q">54.0</ix:nonFraction> million in potential milestone payments, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumConsiderationRetained" scale="6" id="Narr_sZzCovRwkE-pvoMUKj5g7g">5.0</ix:nonFraction> million retained by Viracta, and (ii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig" decimals="-5" format="ixt:numdotdecimal" name="xoma:RegulatoryAndCommercialMilestonesReceivableMaximum" scale="6" id="Narr_mQplSSi4xUmuig8r6ohrlA">57.0</ix:nonFraction> million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CmMun3MJHE2TK0PBPfLoYA" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_sTFKBx-Lo0mew3ALBR3NhQ">13.5</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2023, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_30_2023_To_10_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5j_H144ha0GnzzpObzRcdw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_ms0xVz0YtESFoIJD2_nIBA">5.0</ix:nonFraction> million milestone payment pursuant to the Viracta RPA related to the FDA&#8217;s acceptance of Day One Biopharmaceuticals&#8217; NDA for tovorafenib. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_30_2023_To_10_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5j_H144ha0GnzzpObzRcdw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_pEcx6S3bW0uD9SUpOC6tcA">5.0</ix:nonFraction> million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance. As of December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_th5gLhVhr0ODI3lXcg-R3A" decimals="-5" format="ixt-sec:numwordsen" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_TX6Auoc7I0yIPtmmLV6aSg">no</ix:nonFraction> further payments were probable to be received under the Viracta RPA in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_th5gLhVhr0ODI3lXcg-R3A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_tnVdS2er-UWJZFzlg6zaGQ">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w" decimals="INF" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_ovkZONCib0GzOQzUKZ-KCA">100</ix:nonFraction>% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" scale="6" id="Narr_KmL7WfbIIEinHvD2TnvItw">25.5</ix:nonFraction> million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr__jvgss21Hke-Uo-o9ALW3Q">7.0</ix:nonFraction> million. The Company may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XtN01G-WQUmOgtwp6LiEzQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_AIOpp6TynkKjTQz44Xtzgg">142.5</ix:nonFraction> million to Kuros in sales-based milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_H9Md8qI32kaK9qU4-jjpJw">7.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uYT0rItyzEy3DCuVTQGaFA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonePaymentReceivedCounterparty" scale="6" id="Narr_A5kkfVUl_0qm2bpFPfDmVA">5.0</ix:nonFraction> million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TYLM5-VARkS0pBu28e5EGA" decimals="INF" format="ixt:numdotdecimal" name="xoma:MilestonePaymentReceivablePercentage" scale="-2" id="Narr_A-f27B7ZN0aMPUeVmgSMXA">50</ix:nonFraction>% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TYLM5-VARkS0pBu28e5EGA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_W-lX9HwcSU2QWocnIqtTAA">2.5</ix:nonFraction> million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ng_SQm0kE0GmhyCm9FCUWw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_b3QMUZZGiE-2s0qKIHyx8A">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affitech Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_MrYwcWrX1UmVoh_HXSeuQA">6.0</ix:nonFraction> million. The Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fTTbXC7jbkqFXemFP-meAQ" decimals="3" format="ixt:numdotdecimal" name="xoma:CommercialSalesReceivablePercentageOnNetSales" scale="-2" id="Narr_l_Q6PP8mw0OeFXIcnXaUSg">0.5</ix:nonFraction>% of future net sales of faricimab for a <ix:nonNumeric contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fTTbXC7jbkqFXemFP-meAQ" format="ixt-sec:durwordsen" name="xoma:CommercialPaymentReceivableTerm" id="Narr_lw747EVGP02oPDzLHRnzRQ">ten-year</ix:nonNumeric> period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fbE-TTiMOE6nIPU6Gv7BJA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" scale="6" id="Narr_aajDWhc27UaFkX4ghVC6ag">20.0</ix:nonFraction> million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="6" id="Narr_MkEKRIFTPEGQC-aezB-y5A">14.0</ix:nonFraction> million as long-term royalty receivables which included the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_lOcscJkzIkqeH3X1zHYz4g">6.0</ix:nonFraction> million </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk98867428"></a><ix:continuation id="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont5" continuedAt="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">upfront payment and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ZZqIGqDsP0OAXaFzszUtlQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_FsbU-S4qBEilbOSMZIjXQw">8.0</ix:nonFraction> million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ZZqIGqDsP0OAXaFzszUtlQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_XgmLK_4jFEGN7gKg0lZEsA">8.0</ix:nonFraction> million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fbE-TTiMOE6nIPU6Gv7BJA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_zW16U9j-cEq_hzuZSYKvXA">12.0</ix:nonFraction> million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tdEEOHOCzUWim85LeSnQxw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_vUPQXYeW1E60OkCY0siaZA">5.0</ix:nonFraction> million milestone payment tied to the U.S. marketing approvals and a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_pF2mvqFuzU-4j2j-TN-FwA" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_ux2536ldNUiKN65pRQLDNg">3.0</ix:nonFraction> million milestone payment tied to the EC approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Commercial payments are due from Roche within <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg" format="ixt-sec:durwordsen" name="xoma:CommercialPaymentPeriodDue" id="Narr_HDQT_nzK0EqoaTIYbOVrcA">60 days</ix:nonNumeric> of December 31 and June 30 of each year. In accordance with the cost recovery method, commercial payments received are recorded as direct reductions of short-term and long-term receivable balances, as applicable. During the years ended December 31, 2022 and 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NH5EPARofEyZbj-06mGtVQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_ahMKFaeBhE2GJVioBG_cpw">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_mNSw3aGLeUaqem6F_Oirug">7.3</ix:nonFraction> million from Roche, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it had a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet date of December 31, 2023 and, as such, $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_6bnWNH-CDUa8_5wnw5IDsg">12.2</ix:nonFraction> million was recorded as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The achievement of the first and second sales-based milestone payment under the Affitech CPPA was considered probable as of December 31, 2023, and the Company recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_7bihfa3Yn0ORwuW1-s87BA">6.0</ix:nonFraction> million contingent liability in the consolidated balance sheet. The Company may pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumAdditionalPayableOnSalesMilestone" scale="6" id="Narr_ZDnp80qga06kSIeJTILoXg">6.0</ix:nonFraction> million in additional sales-based milestone payments upon the achievement of certain incremental sales milestones in the future which are not assessed as probable and as a result not recorded as a contingent liability as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_QKO43phiuk6Dnt-d3dreMg">no</ix:nonFraction> allowance for credit losses was recorded as of December 31, 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7d7f3abe_a83b_45bd_ac07_93aee150d32b"></a><a id="Tc_fydPx6k-s0KOrMTk4MTWTA_1_2"></a><a id="Tc_X6qhWOGmS0qVDI_oYviPpQ_1_4"></a><a id="Tc_9Yqgt8-Aokm-6-UkYI2lcw_2_0"></a><a id="Tc_2WdE4Fov2UywFOeKhe4GBQ_2_2"></a><a id="Tc_IkbbPxzZDk-P2kzoqjia5Q_2_3"></a><a id="Tc_A2otyeMoqkGjI-8Az-6dEA_2_4"></a><a id="Tc_koQQKG2YuUKDUso40RV_6g_3_0"></a><a id="Tc_TaXbGfzf_U29OsXb5BTuog_4_0"></a><a id="Tc_I84lDNNfmES3zEfCh-64Gg_4_3"></a><a id="Tc_5sfcpPscS0qQgIBWt96gBQ_5_0"></a><a id="Tc_rnmXDrCB_E2EzSIUjDEu_Q_5_3"></a><a id="Tc_LrK6OGXRkUuExgIanAp67Q_6_0"></a><a id="Tc_i2RQakSPtE2clVofAyRq5g_7_0"></a><a id="Tc_F-YD27Vl0U-ZaG_YC_pe1w_8_0"></a><a id="Tc_L2Pt9vjpnEiZavScKNSX5Q_8_2"></a><a id="Tc_IqZBePWBFU25pkA2R6Kp6A_8_4"></a><a id="Tc_PchS8aE48UyVidSJeXZD7w_9_0"></a><a id="Tc_y4QWNaVH5ESKPkDfpozq6A_10_0"></a><a id="Tc_2vLaw0UI6USM3dJ9IM-qVw_10_3"></a><a id="Tc_ttwF-1VPoUaUGI641nbO1w_11_0"></a><a id="Tc_pbEGuwyOrEOpraZgnB83KA_11_3"></a><a id="Tc_GzrY_k1U0EiL9B5FmKun6A_12_0"></a><a id="Tc_oFjpFSDry0mrLk6BytxQeg_13_0"></a><a id="Tc_WfhoQlk8j0-GOEXpiyQpGA_13_5"></a><a id="Tc_adQX8_9IH0qIE7XAoyCdhw_14_0"></a><a id="Tc_JTGzS_aUMUCwMX2CY4qrxg_14_3"></a><a id="Tc_rA7K-8LF7keyy8MdWAGxsw_15_0"></a><a id="Tc_rbMm6YZVgEWeO5ObEYBaHA_16_0"></a><a id="Tc_qA1rL2Ol9EGSIIL0EmoIPg_17_0"></a><a id="Tc_QPfGNcS6oEylz7ByMgkQIQ_17_3"></a><a id="Tc_wGxAefIKLkWQYJn4VuMUzA_18_0"></a><a id="Tc_k09W05wGO0CS7ZVXKUsqeA_19_0"></a><a id="Tc_IsqkHFy5D0eQDR0GdGcguQ_20_0"></a><a id="Tc_RuBTpXhiuE2Hq3_O52aO-Q_21_0"></a><a id="Tc_6ZIbg-ryck6muDl3KGCBLQ_22_0"></a><a id="Tc_TzBixs3EAkmJ9tP4IaTG7w_22_3"></a><a id="Tc_1Lo7oY5YVEWLo59a4LV4vQ_23_0"></a><a id="Tc_ToJTVfGb60unRSvCduyG4Q_23_2"></a><a id="Tc_s5PHz-Ff_k-GqPmx4IEpHw_23_4"></a><ix:continuation id="Tb_HmwB08o3qEKDm6K1WF8jUQ_cont6"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" id="Tb_h6VrB3WGW02XeHAqnj1HyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities during the years ended December 31, 2023 and 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_cBJLbeJi8U6qPSLZuPQfgw_2_5">69,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_keBCQhbHw0y8_i0w3euIAA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_n_T3YgAE40Gb9g0s7c6i6w_4_5">2,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_DQ1bMNnhLk2ptmJBLUM0mA_5_5">526</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ShortTermRightsReceivableReclassification" scale="3" id="Tc_qob-Z9eXhkW6TJcdgfg42w_7_3">2,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableReclassification" scale="3" id="Tc_OCH3tqs57Eq2xreZFdRF8A_7_5">2,366</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_38ht9cjzn0eUJVIUqnc7Uw_8_3">2,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_WdVU8FSN4UGvJN4GPn7wmg_8_5">63,683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_NAhvgKKjyEyHMeafHs9IBA_10_5">9,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">LadRx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_CcXbeenPEESy7c73GXsaSA" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_SnhnC9FK-ECX0-XD9EmVeg_11_5">6,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" scale="3" id="Tc_mSHE2CjghkCvWoZNXWK-rw_13_3">7,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_UhMVsv-tqU6CRPQMuAMcGw_14_5">1,673</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_0JMorE6cGUCpbiydWrq72g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_a0v6Wei740KRYiS3BaK6hA_15_5">5,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_8AcX-7SvuE20tV_Gwrd56A" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" scale="3" id="Tc_ly9o05FsjUegkoNzK0UtRQ_17_5">1,575</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ShortTermRightsReceivableReclassification" scale="3" id="Tc__Uo7q1URaEucL0CoccU88A_19_3">17,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableReclassification" scale="3" id="Tc_Mn8DiscaM0abiopwOptZpA_19_5">17,109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ShortTermRightsReceivableReclassification" scale="3" id="Tc_eJqCRNk7hUycSKRUGfdbMA_20_3">2,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableReclassification" scale="3" id="Tc_tplBScxBAkeREWjQprsjrw_20_5">2,024</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Recognition of contingent consideration:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" scale="3" id="Tc_sckhyR7RTkaOsXZyxff1SQ_22_5">6,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_vvri0dKOh06Cqe_E2NGuag_23_3">14,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_Ofqi3CWv90mNrtF3sraKHg_23_5">57,952</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_A_3WDr_T6UmsB_hYxlLMTw" continuedAt="Tb_A_3WDr_T6UmsB_hYxlLMTw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#160;&#8211; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ec9766a5_df29_4601_81de_fb8eae989eb8"></a><a id="Tc_kQ9VSPW-cEmLRl8u5tdzjw_1_2"></a><a id="Tc_N5Oycd78kUWnTpiGyT8m-Q_2_2"></a><a id="Tc_8rjntzZa50aFMmDm1MxVPg_2_5"></a><a id="Tc_A23W_n_yzUGUy97Locqnug_2_8"></a><a id="Tc_F0qHPe3s4E-MMqQ8UW9k4w_3_2"></a><a id="Tc_tqOOKATAuEeZC_PFuOld7Q_3_5"></a><a id="Tc_QO1BeeWHzUKk-s8hzhe8SA_3_8"></a><a id="Tc_6hb4zwAXhEyPEibaKNCwLg_4_2"></a><a id="Tc_aKy85dOX-kq4yiI_rFfL6w_4_5"></a><a id="Tc_foNNpfDulkKSAIyqCZ0qBQ_4_8"></a><a id="Tc_qz0UVS3pQkqj_T6Stg6vAQ_5_2"></a><a id="Tc_CIDyzE0ILkWY4bnT1WtnFg_5_5"></a><a id="Tc_nZKc2LlSAEW8bXIgxKftCQ_5_8"></a><a id="Tc_-7F_-CnREkCcmX7KVzSjhw_5_11"></a><a id="Tc_0QB3G_JMAEeTSKko4AXOwA_6_0"></a><a id="Tc_CjF0CdugE0CqmnMEgu_41A_7_0"></a><a id="Tc_Vqc0mqWd-E6qCb5Tl07CMA_8_0"></a><a id="Tc_9qC5ppBUb0Snd3azPzalDQ_8_2"></a><a id="Tc_qkKsctwY8UiwG0--CUmlAg_8_5"></a><a id="Tc_fr8HtIHcv0WiikVk6Sy12Q_8_6"></a><a id="Tc_Tm3G6YVE_kamVqcPl1JBXA_8_8"></a><a id="Tc_okCeNtZV9UKbGCTHTujsew_8_9"></a><a id="Tc_Z_ZA3_weVke6SHduw8fK-w_8_11"></a><a id="Tc_Qg6AlNLaLkaugFPHRevimQ_9_0"></a><a id="Tc_Y80332rMskW5-5hjOvBBkQ_9_6"></a><a id="Tc_9SvSDl4TF06IxKAqQu1KPw_9_9"></a><a id="Tc_R41VfYSnVE2F2SeTuECQgQ_10_0"></a><a id="Tc_kinu9HwFuEqjiW-qdNrzGg_10_6"></a><a id="Tc_dEUUcYc3gEKRJA1jiy8wdg_10_9"></a><a id="Tc_U6roAs06Lke2ef9nSv_rBQ_11_0"></a><a id="Tc_bk7DaeSY0USsNsB292-D6g_11_2"></a><a id="Tc_bw7Ey4PlZU2QYEl7VQHaSQ_11_5"></a><a id="Tc_L0G0O23vwU2dYtiEXCqaoQ_11_6"></a><a id="Tc_zzFc184XGUat-rz4IMTnAg_11_8"></a><a id="Tc_WgKpNZIZjUO-YZC2M95EdQ_11_9"></a><a id="Tc_XpGAn4RA9k-auRzXckvAhg_11_11"></a><a id="Tc_JX2dXUSs20-vXsr1q-n6yg_12_0"></a><a id="Tc_E-UunfCwmESYmwEMu5n6Gw_13_0"></a><a id="Tc_wPKjc0lBW0y-7_5f2CgKdg_13_2"></a><a id="Tc_tguDPE-go0e7DmMEeYWNcA_13_3"></a><a id="Tc_CHkbOodgtkKEdmvp92gpMQ_13_5"></a><a id="Tc_e7wDspxzlUWNZxFx5nIVYQ_13_6"></a><a id="Tc_ixcvduiGqUCEGruiFsrMIA_13_8"></a><a id="Tc_O8NYZqlT3kmE6emcikvIgw_13_11"></a><a id="_9031d949_855f_47ff_856a_4a288230abda"></a><a id="Tc_amR6XBAmeE-6Vt4Eg3WGeA_1_2"></a><a id="Tc_T5NRZQp5VkuRw1V8CJi8Ag_2_2"></a><a id="Tc_zcWoF9hS30SwTUmyf3SEGw_2_5"></a><a id="Tc_7d2YGx6-SEyHOALJX_YqIA_2_8"></a><a id="Tc_AR1GEz1o6EmEpvSrc-5Urg_3_2"></a><a id="Tc_16L9nfhH_Em6bUry-sGyBg_3_5"></a><a id="Tc_f1o8E4csbEO6C2qNC-Y3kA_3_8"></a><a id="Tc_C9AN984uK0Kc3QdUknq8lg_4_2"></a><a id="Tc_vHiqOqigPk-TMDWyHbB8yQ_4_5"></a><a id="Tc_OmCaUEVS6EKcmvz7ZHVBoQ_4_8"></a><a id="Tc_930VCLIMdUC8oR6BsJ-aFQ_5_2"></a><a id="Tc_R9FBJycrKE6RvGt0DVW0Jw_5_5"></a><a id="Tc_D5Ov_JKXyk2L5QdKqD-yeg_5_8"></a><a id="Tc_aa6BWzvBt0e2o8XLNRaZMQ_5_11"></a><a id="Tc_KToJ_mFZYkKB_jSZRLgUYA_6_0"></a><a id="Tc_wK1HNUAaaUyrBLfZZgP8bQ_7_0"></a><a id="Tc_E4rAi53TZ0K65fD_hwc9zg_8_0"></a><a id="Tc_phTPtSZmOEWmJTxnOYDCjA_8_2"></a><a id="Tc_g-qzYxkr1kCjGTjHvJUqKQ_8_5"></a><a id="Tc_qNvRFnUsdEOT081PGRHTAg_8_6"></a><a id="Tc_q_YHt1vnqkGWyBzzq0-Erw_8_8"></a><a id="Tc_GLNXtAhffEGJwaA4apVZoA_8_9"></a><a id="Tc_JvvAHxloo0a4JeUIVUGCHg_8_11"></a><a id="Tc_emPh_uM-LkCPCWbebNALvw_9_0"></a><a id="Tc_6KxkxOUUlUKmEDaDG1gxiw_9_6"></a><a id="Tc_3z8jNE53ukSMRnYl2JdENw_9_9"></a><a id="Tc_Iq8OrTFk50yJu7ubOJbVpA_10_0"></a><a id="Tc_VmDIpark_0SyGopmS7uZmA_10_6"></a><a id="Tc_wuJy6sVdp02CPN-AXki_vw_10_9"></a><a id="Tc_nIYx7Ssj1k--mOVdW5OJJQ_11_0"></a><a id="Tc_BgURLhu-TkOhCPCTQrgWog_11_2"></a><a id="Tc_w6Pr2QXIKEWeBhpaxyheVA_11_5"></a><a id="Tc__J3YyYCtpkWIEPbuH5HBOg_11_6"></a><a id="Tc_EcQMq6fnyEGFTDF_nLfc2w_11_8"></a><a id="Tc_tdBGytTx2EekISURcHrQxg_11_9"></a><a id="Tc_2motrcaSqUSmOkBGAuJadA_11_11"></a><a id="Tc_3odpQaBZ90SfDc0JkLvydA_12_0"></a><a id="Tc_CK3ghvnON0q8jOS1TSO6vA_13_0"></a><a id="Tc_trk8mE_q7kielFoYPY6Dpw_13_2"></a><a id="Tc_7L7Zu1aFlk-3buGmPxOr2Q_13_3"></a><a id="Tc_Hz7j-SWX3UyxIkMNN5difA_13_5"></a><a id="Tc_OwJdzvwWqEixHRRadXLgWA_13_6"></a><a id="Tc_hvk8LdxzD0mFQ0vjYUzycQ_13_8"></a><a id="Tc_FtcCFMKdV0eFkl75z5J3fQ_13_11"></a><ix:continuation id="Tb_A_3WDr_T6UmsB_hYxlLMTw_cont1" continuedAt="Tb_A_3WDr_T6UmsB_hYxlLMTw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_at-uVa41MUK30gACYw2F7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2023 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gec80tyUmkKY9InWUPJo7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_y-CQUhbpg0i1tTPKn2sABw_8_3">28,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QT17Poc1lk2rEi5HuNqx_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_LB9KTAleF02fZGcL3Vqveg_8_12">28,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ZrS7UJW7E0-XY6R5OzZXMA_9_3">28,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_zauWPiAa2UeS7-S7tvqMPg_9_12">28,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_RayU2DdTRkyxVUb5-c35hg_10_3">161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_Wh74J9eCeUuvrv6aYFllfw_10_12">161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_hVNxRKAajESV5Kk2c3kpqQ_11_3">28,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_ngImWqMXkkKSmqx4ph_Yfw_11_12">28,513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-RitWGIJ-ESF55jlLrVWtA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_COUzYgHQ5USQAwkq8SG5nA_13_9">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_vaVDOVyf10qTLAItTZbvGA_13_12">1,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IK179fae_0q0Zg4c_AZHEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_weV4uOzkDEONR4TxOUHvOA_8_3">30,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f4zBuaboQUKb6pXCfGs0MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_r6UzCWs4jkGHibdhXAsf6Q_8_12">30,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_QQXU6ag8TEG_XPcTfzRiRg_9_3">30,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_iqbmg-lLWka1NrrQEdWZzw_9_12">30,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_9YRZCQfWBU-WZfZqPosQuA_10_3">335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_1EMgfJHN90iFqeVvsfadKw_10_12">335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_X0Bc83oBXkeU24WSJPOGpA_11_3">30,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_tdeGy9QAh0qrAH_H2b594w_11_12">30,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IUqLnYwi60W0DrGdz3BX1w" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_uOKkcbbVT0e3Q4MarVc6qQ_13_9">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_OsZNNZYNG0mweDdbEsqs6g_13_12">75</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2023 and 2022. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss. As of December 31, 2023 and 2022, the Company valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the Nasdaq Stock Market of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5IIqeHWkV0S9mtFRdVUKvw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_UG7XqyJXrk-V6cPEpPcRsg">0.99</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_LXJN7Whj9UecRjtZBao0Hg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_wPaO_LBtwkqk1lX9ZD9Iow">2.07</ix:nonFraction>, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the LadRx contingent consideration liability of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_cJ_3I5gqVUm-_Sd9MucR6w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_4HlCneWSDEqsYzoskYVxZg">1.0</ix:nonFraction> million at the inception of the LadRx Agreements represents the future consideration that is contingent upon the achievement of specified regulatory milestones for the product candidates related to arimoclomol and aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each product candidate. Such contingent consideration is remeasured at fair value at each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss until settlement. As of December 31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_6wK7NYgyK0iUW2UMlpUeTw">no</ix:nonFraction> changes in the estimated fair value from the initial value of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_2l2Upq16wkSDeajM3KIBlA">1.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Linvwi1eaEmv0RwYC9mmXw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" sign="-" scale="6" id="Narr_n9fVOiTXSkqboSohcwOsNg">0.1</ix:nonFraction> million of contingent consideration as of December 31, 2022 recorded pursuant to the Bioasis RPA was written off during the second quarter of 2023 (see Note 5). &#160;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_A_3WDr_T6UmsB_hYxlLMTw_cont2"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d6abca43_99e9_4bb9_b523_9e1d37de87a8"></a><a id="Tc_8ppWNNcAikioopImfgFCag_1_0"></a><a id="Tc_SqobVn2KNE6TGrsjA2_BaQ_1_2"></a><a id="Tc_48U3hI57NEOIYOw5_nejyg_2_0"></a><a id="Tc_ya9J15ymuESSbsLC7rWn3w_2_2"></a><a id="Tc_OzUV1czRWUWoIEctnSmlxw_3_0"></a><a id="Tc_Cc3VGKdy30mC6X4DqOuY8w_4_0"></a><a id="Tc_AHFkMcaHIk6oapbFRHoxhw_5_0"></a><a id="Tc_aG2ctmNB8E21IJrxpHvcuw_6_0"></a><a id="Tc_ofro2_Z2eES3eSiAtr8MBA_7_0"></a><a id="Tc_khQW93eCOEOSgL2c6tHCmQ_8_0"></a><a id="Tc_r2YBACYbr0Wq9eI4nofKeg_9_0"></a><a id="Tc_F7jnW1yHYkGqKr2GXWLPNg_10_0"></a><a id="Tc_ndCMsQ47skimVFluJavdJQ_10_2"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:LeaseDisclosureTextBlock" id="Tb_tR780hPYKUCUAXoKCBAw4Q" continuedAt="Tb_tR780hPYKUCUAXoKCBAw4Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Lease Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company leases <ix:nonFraction unitRef="Unit_Standard_facility_D1loseD-e06fL52LV83oPQ" contextRef="Duration_1_1_2023_To_1_31_2023_RfM78mIKA0-JJnpILkNCiQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:OperatingLeasesNumberOfLeasedFacilities" scale="0" id="Narr_jWaIAdu4cEiqZQZLK0InpQ">one</ix:nonFraction> facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term <ix:nonNumeric contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_xAActchtNUCUQIYwmgGrBw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_wgGPjJLRXUitha87C3dafQ">five months</ix:nonNumeric> from its original expiration of February 28, 2023 to July 31, 2023 (the &#8220;amended lease agreement&#8221; or the &#8220;amended lease&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company retained <ix:nonNumeric contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_4MybQZKMoUeRtb31Nl4fZQ" format="ixt:booleanfalse" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_kDe4H5Hu8kGUtaT_psgrCw">no</ix:nonNumeric> option to further extend, renew or terminate the amended lease under the amended terms and all other material terms and conditions, including the monthly base rent, remained consistent with the original lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the&#160;right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_4MybQZKMoUeRtb31Nl4fZQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" scale="6" id="Narr_z6T5HIo8lkmoWPdn6CwxOw">0.1</ix:nonFraction> million to reflect the changes in the lease payments due to the extended lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">On June 27, 2023, the Company executed the second lease amendment for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing amended lease which expired in July 2023 (the &#8220;new lease agreement&#8221; or the &#8220;new lease&#8221;). The new lease agreement commenced November 10, 2023 and has a term of <ix:nonNumeric contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_evZqlIA5v0eAGr2vlq3w8A">65 months</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the new lease agreement, the Company retained access to its original premises under the amended lease which expired in July 2023, until the new premise became available on November 10, 2023. Payments made between when the lease expired in July 2023 and the commencement date of the new premises of November 10, 2023 were recorded as variable lease costs in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In accordance with ASC 842, the Company accounted for the new lease as a separate contract and the Company recognized an operating lease right-of-use assets of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_BouSCEsvRUejTxTpHdY_WA">0.4</ix:nonFraction> million and operating lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr__WXQdD4uckS0bll4EuHWpw">0.4</ix:nonFraction> million on November 10, 2023, the commencement date of the lease.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_ma-c_tUmm0GC8eiYU1oA2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes maturity of the new lease through the <ix:nonNumeric contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_1cCLMQKa-ESFgU2tdIY9fQ">65</ix:nonNumeric>-month term of the Company&#8217;s operating lease liabilities as of December 31, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rent&#160;Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_EpsC9DtxAkGOyouTpm1Rtg_2_3">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_UFHC7pYhz0u9QVWlcDEkRw_3_3">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_LcyMj2iB-EmqjxCGtXSj3w_4_3">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_7PzsC5bYHES9KL0iWKEYDA_5_3">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_hJSRlCFT4U-4r6j3fZ2ugg_6_3">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_4JGUIMJcKUyZWhdXitcujg_7_3">36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_KR4sjUKeKEyZaBB9Kpc9Rw_8_3">485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_1X1YGK2Q0UeKvCZdS1qO2g_9_3">96</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total net lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_R4DdA6jt8Uqz3ySGGw9d5w_10_3">389</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the total net lease liability was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_ijXGdNunsECq8AW4BTsSrg">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Narr_AGDzdazWxkyJBY3Pllyg4w">34,000</ix:nonFraction>, respectively. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2023 the Company&#8217;s current and non-current operating lease liabilities were $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="Narr_vc9TvzpOq0CU5GKiLQHb8g">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="Narr_VC2ZYGK2D06POLd9gY_ITQ">0.3</ix:nonFraction> million, respectively. As of December 31, 2022 the Company&#8217;s $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Narr_7UPBC3YJbEymeRqQ6VokZg">34,000</ix:nonFraction> lease liability was classified as a current liability. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bba066ec_68df_4ee6_9390_d1cb33a8ccce"></a><a id="Tc_0PJl0ZMa10uouhtF5HMSjQ_1_2"></a><a id="Tc_VtH1zsFGAUieNh91NekPaw_2_2"></a><a id="Tc_tyV8eULDskyAPQ11itMNEg_2_5"></a><a id="Tc_hJu5TpjiMEeyHK7Je5YlRg_3_0"></a><a id="Tc_70mUQfzB70icoVV2uWXAUA_4_0"></a><a id="Tc_auC5oiXvGEyYNIaMUO_nNw_4_2"></a><a id="Tc_EOGQ1SGF7kOaYS3U4yoJPA_4_5"></a><a id="Tc_W8u-oce9BEejWEINa5j2mA_5_0"></a><a id="Tc_Piih3aCX-0-dHoGU_pVSkw_6_0"></a><a id="Tc_MuEhJeELKEeAF0RBo5iRJQ_6_2"></a><a id="Tc_-opaEelPxky6cKHmTzBK_w_6_5"></a><a id="_c479213d_76c0_4907_86e5_b427db274a75"></a><a id="Tc_jJJ50fRolEa66Kxp_66gyg_1_2"></a><a id="Tc_zmjC09I4i06qUCQ65yqdWA_2_2"></a><a id="Tc_SyHdlDGJREuMSb6mpyPN2A_2_5"></a><a id="Tc_ErvlmNTOrkS1z4YWjXX-MQ_3_0"></a><a id="Tc_WrKf2ElXqk2IAyaDYdKo_w_4_0"></a><a id="Tc_c4b2GJ_RHEKIKfR8CTx0_A_4_2"></a><a id="Tc_doTKxgCugkue6ewHNCrFzA_4_5"></a><a id="_Hlk95210281"></a><a id="_5bb60a2c_5bad_4a29_b772_dd4bd5301f67"></a><a id="Tc_CMLILYSknE2jylbrNnMpTw_1_2"></a><a id="Tc_wQB-exkE4k-PXlUyprN-vQ_1_5"></a><a id="Tc_CIdGjviXf0Sdj3h7x8MoTw_2_2"></a><a id="Tc_9-mqxilSqUOki0BVTWWltA_2_5"></a><a id="Tc_IVsnSzSSZkKUzc4iqxWX2A_3_0"></a><a id="Tc_CDyasL3IU0yWaEi1vWsq6w_3_2"></a><a id="Tc_wM79uuq-pUC9auGS-Ulbbg_3_3"></a><a id="Tc_Dtl2HR3blkWT_Vuen8wJ2g_3_5"></a><a id="Tc_kDY74xfPw0mfwaJYnvPXRQ_3_6"></a><a id="Tc_xaEt0oFbI0OL5QQZGCodyA_4_0"></a><a id="Tc_vJQQpeoihUO4pB5BNB5zYg_4_3"></a><a id="Tc_WAdlGqTUJk-qGgH0voRpFA_4_6"></a><ix:continuation id="Tb_tR780hPYKUCUAXoKCBAw4Q_cont1"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:LeaseCostTableTextBlock" id="Tb_fOzp2KvEokWwRJCLE87Jaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company&#8217;s operating leases for the years ended December 31, 2023 and 2022, respectively (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_4_pCeylGpkCnbsexOovcmg_4_3">131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_DB69m1EHTE2WCYfH5HXyRg_4_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_lWnfUeUuoUuRljxQU51Gmg_5_3">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_jP1Ykys4TUG56lR-lc5LlQ_5_6">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_ODO0rhIZ0UWMcFmY0Z6Dtw_6_3">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_p28be9CxL0aMPLV2---XpA_6_6">189</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the original, amended and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="Tb_DWlXEkHVlEOgfNyPubHK0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the consolidated statements of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_74GmnRc1xkmtSF0gIsuKZA_4_3">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_i_gJFvd7S0Cs5l875_yXUg_4_6">202</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company&#8217;s new and original operating lease as of December 31, 2023 and 2022, respectively, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="Tb_VPNLIEwdeU-A55ova2J8Ug" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_4zjaruO7LUWzF8JRe0_x5Q">5.33</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_u4zsqsA7zEesWWEngqUzOw">0.17</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_fKS68VDFpkm3qsUvqNtbnQ_4_2">8.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_lBQx2cb420SZRVkhUUqv5g_4_5">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(2)</span>The new lease that commenced November 10, 2023 has a lease term of <ix:nonNumeric contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_YCOadm6H402_EV1sti9bkw">65 months</ix:nonNumeric>.</div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:LongTermDebtTextBlock" id="Tb_3v-QfUBLe0CJ6dK9ZlKbZg" continuedAt="Tb_3v-QfUBLe0CJ6dK9ZlKbZg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Long-Term Debt </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, XOMA transferred to XRL, a newly formed wholly owned subsidiary, all its rights, title and interest in the commercial payments from Roche&#8217;s VABYSMO under the Affitech CPPA and related assets (the &#8220;Commercial Payments&#8221;). The VABYSMO-related assets and rights transferred to XRL are referred to herein as the &#8220;Transferred Assets.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Simultaneously, XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders, pursuant to which XRL was extended certain senior secured credit facilities in an aggregate principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_RDsVKBBnCUG5h0prcpniHQ">140.0</ix:nonFraction> million. The principal and interest of the loan are to be paid from the Commercial Payments. XRL is obligated to make semi-annual interest payments, starting in March 2024, at a fixed rate of <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_yzrGppba_UaGVT7RgY8sxA">9.875</ix:nonFraction>% per annum until the commercial payment-backed loan is repaid, at which time the Commercial Payments will revert back to XOMA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any Commercial Payment in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The loan matures on December 15, 2038, provided that XRL may repay it in full at any time prior to December 15, 2038, subject to the terms of the Blue Owl Loan Agreement. The Blue Owl Loan includes (i) an initial term loan in an aggregate principal amount equal to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_KoyQGmlq1ESuGVNCVUljSw">130.0</ix:nonFraction> million and (ii) a delayed draw term loan in an aggregate principal amount of </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5fbfb0b2_d08a_4087_bf7c_21b313c6ad91"></a><a id="Tc_s0fnNO3pUUy7MV2ONiUQSA_1_2"></a><a id="Tc_JWVdoiQBIUeaZXjc7JPvDA_2_0"></a><a id="Tc_FENoZMOCA0-MF0SM5E_vMQ_2_2"></a><a id="Tc_Q4kjCBrIo02hn7y7TEEV7g_3_0"></a><a id="Tc_QTIAVUtLJU2DAr3hiEu-JA_4_0"></a><a id="Tc_bQxlxY9gqEav-ze_yOLWbw_5_0"></a><a id="Tc_B6liJ853yU6Es71CdrmydQ_6_0"></a><a id="Tc_R1H4bR17gkm7k4cZzF_OFg_6_2"></a><ix:continuation id="Tb_3v-QfUBLe0CJ6dK9ZlKbZg_cont1" continuedAt="Tb_3v-QfUBLe0CJ6dK9ZlKbZg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_Ye9pux6Zk0mWff5iTCN7xg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_ZuWK15uE7UujnLVqb6JGLw">10.0</ix:nonFraction> million to be funded at the option of the XRL upon receipt by the lenders of payments of principal and interest from the proceeds of Commercial Payments in excess of an agreed upon amount on or prior to March 15, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The payment obligations under the Blue Owl Loan Agreement are limited to XRL, and Blue Owl has no recourse under the Blue Owl Loan Agreement against XOMA or any assets other than the Transferred Assets and XOMA&#8217;s equity interest in XRL. In connection with the Blue Owl Loan Agreement, (i) XRL granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the Affitech CPPA and (b) all other assets of XRL and (ii) XOMA granted Blue Owl a first-priority perfected lien on, and security interest in <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA" decimals="2" format="ixt:numdotdecimal" name="xoma:SecurityInterestInPercentageOfEquity" scale="-2" id="Narr_GwBe-CXX2k23gmfQwWufdw">100</ix:nonFraction>% of the equity of XRL. The Blue Owl Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, the Company borrowed the initial term loan of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_wRH3kfSXnkSnBr367661pw">130.0</ix:nonFraction> million and received $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_15_2023_To_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wemVoEFoIkCvcBgBQtS_rg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromIssuanceOfLongTermDebtNet" scale="6" id="Narr_1-CMImu1OkSqwCVMPYlnOA">119.6</ix:nonFraction> million, net of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_15_2023_To_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wemVoEFoIkCvcBgBQtS_rg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsOfFinancingCostsFeesAndLenderExpenses" scale="6" id="Narr_XlpEd_jSdUW8uHS7mAd7Pw">4.1</ix:nonFraction> million in fees and lender expenses and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="xoma:AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" scale="6" id="Narr_nCD7aZf5akCBjrSGX-1dig">6.3</ix:nonFraction> million that was deposited into reserve accounts to pay interest, administrative fees and XRL&#8217;s operating expenses (see Note 2). The Company also incurred $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_zKpoy7bpOUWGDqA-E378Cg">0.6</ix:nonFraction> million of direct issuance costs related to the Blue Owl Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Blue Owl Loan Agreement, XOMA issued to Blue Owl and certain funds affiliated with Blue Owl warrants to purchase: (i) up to <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_8DQQ1TYCn0iiESWCmd2x2A">40,000</ix:nonFraction> shares of XOMA&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_RFqrZRNcyk-vPHKbdN8ohg">35.00</ix:nonFraction> per share; (ii) up to <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_7F8OR8kQpkWhm6Hqn_VAVw">40,000</ix:nonFraction> shares of XOMA&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_TKT3rcFvk06zq2NL3j2yxQ">42.50</ix:nonFraction> per share; and (iii) up to <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_v5XgANaGzEaqYcv4HMlUJg">40,000</ix:nonFraction> shares of XOMA&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_qDhiZzEgEEiylN9IFr8g1Q">50.00</ix:nonFraction> per share (collectively, the &#8220;Blue Owl Warrants&#8221;) (see Note 12). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_w3TMrICDnUeuy954BcP70A">1.5</ix:nonFraction> million. As of December 31, 2023, all Blue Owl Warrants were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The initial term loan of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_-Vk72bi3M0i2gcEr8x19NA">130.0</ix:nonFraction> million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the effective interest rate was determined to be <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_MDHWgGH7VkqwqYSIDSN6Ig">11.01</ix:nonFraction>%. The Company recorded a debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_mzoBaFsa5k2N9vGuaZcJ6A">5.3</ix:nonFraction> million, which included $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="xoma:DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" scale="6" id="Narr_f3tz_pyN0kyMUXLxu4Womw">3.8</ix:nonFraction> million in allocated fees and lender expenses and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_hEbNChTsREONepAsq03GaA">1.5</ix:nonFraction> million for the fair value of the Blue Owl Warrants. The Company also recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_EHhf1Gt8q0-bDSpMIA5Srg">0.6</ix:nonFraction> million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_gf0Aa5ylRkC3pm0v9Gkeaw">5.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_HQweZnHYGkGwPXczv5sruA">0.6</ix:nonFraction> million of direct debt issuance costs over the expected term of the initial term loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the closing date of December 15, 2023, the Company recorded the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_Ye9pux6Zk0mWff5iTCN7xg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="Narr_H6vZIUeii0WcEFAbEfYl9A">0.3</ix:nonFraction> million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_oha9lcQVn0qkzi_7xjYWFA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Narr_86x8tlN-4UCvqB2qgIe3Ug">no</ix:nonFraction> amount had been drawn from the delayed draw term loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the short and long-term portion of the initial term loan was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="Narr_cQ4UkOKFyUmpgo6KCvYQbg">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="Narr_LFevQeFvJ0OEBsS0zjdEqg">118.5</ix:nonFraction> million, respectively as of December 31, 2023. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseLongTermDebt" scale="6" id="Narr_BhNpDa5iN0CRqmeAErpHAg">0.6</ix:nonFraction> million in interest expense during the year ended December 31, 2023.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_KBekyC4a2UmgbLvilKOwRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the impact of the initial term loan on the Company&#8217;s consolidated balance sheet as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross principal </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_ZRS9_y511ES5H4Vdt65KFA_2_3">130,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_WlJt6XlqakOSNgypjHpwwQ_3_3">5,939</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total carrying value net of unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_8_0oy9VqnE-fz35xyBSCcw_4_3">124,061</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_sYQzflBdakyx0KXJSYnTIA_5_3">5,543</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_VMU9gp4bG02qHc-gHNj00g_6_3">118,518</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-term debt on the Company&#8217;s consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. There was <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="3" id="Narr_NLDemiluFEegbzId81L2gw">no</ix:nonFraction> long-term debt on the Company&#8217;s consolidated balance sheet as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9d3c6119_7622_4436_b7dc_432325c12618"></a><a id="Tc_AFbr6aQwcUeqa84JLGq93Q_1_0"></a><a id="Tc_FdtmPoM7x0SwT3fN0Ia0vA_1_2"></a><a id="Tc_8KDBxDoC8kyfTpa8m06hsQ_2_0"></a><a id="Tc_LG9KN_hSq0O0z8UCR22vyw_2_2"></a><a id="Tc_hQQ9nIAknkexga2ek4Yd7Q_3_0"></a><a id="Tc_vE4gkarMa0muSdDhJxu4JQ_4_0"></a><a id="Tc_GZbvAwEIZ0aFfqrygVqBvQ_5_0"></a><a id="Tc_UzKKyBJ8zUedF1oN3GxIBA_6_0"></a><a id="Tc_241lkl1iVUytu22TNkss6Q_7_0"></a><a id="Tc_6y9wPo9Q1EmCFhyG8SLKPQ_8_0"></a><a id="Tc_psnAD8S7l0aCITfn2Penqg_8_2"></a><a id="_6bd8df00_9cf6_4ad9_b5f8_fd551b7b4caa"></a><a id="Tc_9nf6ZgxrG0KJ6MCzMVeLjw_1_2"></a><a id="Tc_1BfCcgoRyU21hga9w5HCbQ_2_2"></a><a id="Tc_HjqsYo8_j0uU2PA5Y80VIw_3_2"></a><a id="Tc_T3-WwvuXZkCBCbzV6k9sSQ_3_5"></a><a id="Tc_5p1jnfuzBkyAiFaLncP2Uw_4_0"></a><a id="Tc_1thhsn3JAUaQbqCMUelmCw_4_2"></a><a id="Tc_ss6yuqe_xUuwrM02Qi3T4w_4_5"></a><a id="Tc_Ru7w-CmKJ0SsZ-Dv3u99iw_4_6"></a><a id="Tc_wIKbp7A8gE6MBXoWIZGH0w_5_0"></a><a id="Tc_Bs9_4MYJtUajbEugFV1Vjw_5_6"></a><a id="Tc_bmrLnQHNt0OeD7pjvBeiRg_6_0"></a><a id="Tc_A-rIn3i98EiSg5ved9-YEA_6_2"></a><a id="Tc_8AjGAHWF906ZneEfnEmxAw_6_5"></a><a id="Tc_EQaTcPZ7DUClPRBPMUgDYA_6_6"></a><ix:continuation id="Tb_3v-QfUBLe0CJ6dK9ZlKbZg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_3im1MW4NeUGaVXTaRhnysw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aggregate projected future principal payments of the initial term loan as of December 31, 2023, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_4xnx9U4vQUiJXsuC7_o48g_2_3">6,594</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_rj_JMZbxF0WP-vr7kbeh-g_3_3">8,767</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_S2GWjObZf0ely8B-mIcvgw_4_3">14,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="Tc_S3dx-q9Xo0qfc9Ru3zK3bQ_5_3">19,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="Tc_ozOypNjtk0WnHZHAnZJnVQ_6_3">23,872</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="Tc_dZsAGkaMkUWAxQ6ZtWUt2Q_7_3">57,412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_Q2-eYBCb50aZv139_O-Q0A_8_3">130,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accretion of debt discounts and issuance costs are included in interest expense. <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="xoma:ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" id="Group_ucarX5IKkki4503W4P5a2Q" continuedAt="Group_ucarX5IKkki4503W4P5a2Q_2" escape="true">Interest expense in the consolidated statements of operations and comprehensive loss for the&#160;year ended December&#160;31, 2023 relates to the initial term loan (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_ucarX5IKkki4503W4P5a2Q_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_O_bY6iF3NEq9TnxhLGh3Nw_4_3">535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_ja3GslGSs0GeK4NlOLHjrQ_5_3">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseLongTermDebt" scale="3" id="Tc_bHQzxJshEkCHiBJNiyMNFw_6_3">569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><a id="_8a1fe9a3_7d18_43ae_9426_fc68cba20308"></a><a id="Tc_OVLSHmDtOU-u3ozu1qhVog_1_2"></a><a id="Tc_ij4zZW-ouEyiJee1-CJYkA_2_2"></a><a id="Tc_mPPpA0G1zUKEsWw7cekCXA_2_5"></a><a id="Tc_AqfnVM-LHEOwlYUu4TNMoQ_3_0"></a><a id="Tc_KnnvRihyQkeyH8df6Ri2Eg_3_2"></a><a id="Tc_GFciqDMBEkCd17lGXb6b1w_3_3"></a><a id="Tc_RRucdxRIhkS_vY491NfhlA_3_5"></a><a id="Tc_T_6CMsM5zEaOb6JNI5nnIg_4_0"></a><a id="Tc_Z16RNrLfuE-oCHF7CYnqpg_4_3"></a><a id="Tc_-VNgQwhQPk6wQiWuj7aRMw_4_6"></a><a id="Tc_sQ1YZMVwGk6BpHWGpHhsCQ_5_0"></a><a id="Tc_1SnOPTPCpUi5zv7sTlCSzw_5_2"></a><a id="Tc_fDpZC1YKq0CFFAabfMEaIw_5_3"></a><a id="Tc_07bcCni960GTTOBKdda9tQ_5_5"></a><a id="_e913e8dc_7f27_459c_b914_8b006bb55fc5"></a><a id="Tc_WAUeMbxg-kCNB24IQEp2og_1_2"></a><a id="Tc_GEKkEyKt006Y8hqqxHN8CA_2_2"></a><a id="Tc_UknXJNsQU0mbSjsdA72wxg_2_4"></a><a id="Tc_7ieWeGxb5kyqLFVvaF6t-w_3_0"></a><a id="Tc_ZyLzqyvUkk6_W3q_qf_p7w_3_3"></a><a id="Tc_4aq0fId73UmViURu0ujl8w_3_5"></a><a id="Tc_mYCFblH9O0KckwAnkC1-DA_4_0"></a><a id="Tc_asARykqoWE6Nwa7Jmxi7RQ_4_3"></a><a id="Tc_fAq8tEPwykOR73FvjO__aw_4_4"></a><a id="Tc_8UB017K_HUmeuGrAZVgXEA_4_5"></a><a id="Tc_5o9eFfSjpk-dhOhhgRJwaA_5_0"></a><a id="Tc_3dcfWD2_k0GQ9Quw9Ei-QQ_5_3"></a><a id="Tc_lcaBw_FypkSHA47WxPW3Cw_5_5"></a><a id="Tc_BmbbiGHxSkKRaJyT47zyJQ_6_0"></a><a id="Tc_tHdfzpxBxEO6IB3lQvbs6g_6_3"></a><a id="Tc__mQjuUxPWkSBDavQO5YqiQ_6_5"></a><a id="Tc_U1xiysZEZ0-sin_-LJG2Aw_7_0"></a><a id="Tc_Gz9xtUAad0u_QvoHuamsIQ_7_3"></a><a id="Tc_539r78SmqkKIxGVlviW2JA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_G3b0hLTolE-_U4_fggcftw" continuedAt="Tb_G3b0hLTolE-_U4_fggcftw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">9. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had pre-tax book loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="6" id="Narr_tuYEmP9SFUGPR4Fl44i1Rg">40.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="6" id="Narr__fkX69lTmkGl0WjRDIVDCQ">17.1</ix:nonFraction> million for the years ended December 31, 2023 and 2022, respectively. The Company had <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-4" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_ChiEzLk2XU6ABhxxIVLAIw">no</ix:nonFraction> income tax provision for the year ended December 31, 2023 and a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Narr_Di5XDSPsMU6HArLdaDXpTQ">15,000</ix:nonFraction> income tax benefit for the&#160;year ended December&#160;31, 2022. &#160;</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_G_PGWzGld0eP7rzO34J9cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" sign="-" scale="3" id="Tc_4jIYeTVX1UusxcEo8tBijA_3_6">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_AbPIHCBEA0iGp1XctbVloA_5_6">15</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#8217;s actual effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_-ee3quFzH0uBw1jPfD2d_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc__GkFCfwBdkSCW5c-G8HB6w_3_2">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_8-QJGimF20i1FFDHEVdB4A_3_4">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_WalWqfVCZ0afulQygLVQYA_4_2">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" sign="-" scale="-2" id="Tc_IV3IrTUsh0GDeVClPN7fLw_5_2">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" sign="-" scale="-2" id="Tc_xscOAO4woEyRrplxiOnEEw_5_4">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_NzKqNVC6AEOx-GNA-a9QUQ_6_2">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_l0BuofMrVEGVQI9suzlIMQ_6_4">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3mFvOmJiKUCxDAEe7fSXPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_tzBx_nlwlk2NnJLZtAgZ4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Presentation for the fiscal year ended 2022 adjusted to conform with the fiscal year ended 2023 </span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_651c729e_3d16_42d0_b126_ba38ad169971"></a><a id="Tc_cNHhSq8pzUmnRKklBDw-VA_1_2"></a><a id="Tc_lm6mkpgisUikaweDUpAqHQ_2_2"></a><a id="Tc_ajXBrcXh-E694sJJSx31dA_2_5"></a><a id="Tc_rvVtQFHnPkiYsjnYlb8Jbg_3_0"></a><a id="Tc_XN7lvduIykmu7wLUXNJpEg_3_2"></a><a id="Tc_vP0NBsMpGEe2S1BnjYEUag_3_5"></a><a id="Tc_6p2K87XwgE2LO0YSuYbHmg_4_0"></a><a id="Tc_E37P0p0UtkWRMuzB_kfH7g_5_0"></a><a id="Tc_2vIQdaXrwkCIdwtRmxkrAA_6_0"></a><a id="Tc_fbdEfeILCkKcro6EKe7c8Q_7_0"></a><a id="Tc_3vznv67Lq0mi2xbG8ngwig_8_0"></a><a id="Tc_Rd2COiNFc0CztghoM9hgBw_9_0"></a><a id="Tc_pnRMPkbRIkurKDk0Kcrn4w_10_0"></a><a id="Tc_YWnY2QJHaU6YR_MsO8CEFg_11_0"></a><a id="Tc_91GM2Hlk5E6njrbLs8PehQ_12_0"></a><a id="Tc_wXt2r46BIkSYkf5_kufHIw_12_2"></a><a id="Tc_YJxQLs6i30iFm3ZBvRO2pQ_12_5"></a><ix:continuation id="Tb_G3b0hLTolE-_U4_fggcftw_cont1" continuedAt="Tb_G3b0hLTolE-_U4_fggcftw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_OUlPzXQ-wE-0G7DE2fBLRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The significant components of net deferred tax assets at December&#160;31, 2023 and 2022 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_YktWUbzZ_EOHiYworwjdhA_3_3">2,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_IZwdtK6hWkO1PuKboeTcHA_3_6">4,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_CB2ps4_NUk2Bge--Us4Ysw_4_3">30,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_WX5EXEyd50Sm1TsMO7flRw_4_6">23,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_ylYqYj7PrUa12yr0Ima7LQ_5_3">13,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_9igEQlv5gEOpOdfS9oJeCQ_5_6">13,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_xHQyQlDWwEWFZj9bRC-FcA_6_3">5,864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_rIjqHVoKD0e8XAdKyKrhSw_6_6">4,715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_7YzHumNG60y02riRD4QTWA_7_3">1,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_xQIKDJZeh0-vQRAmTjjlzg_7_6">2,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty Receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="xoma:DeferredTaxAssetsRoyaltyReceivable" scale="3" id="Tc_RpKWdkYlSkCoMf_QkW2szA_8_3">4,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:DeferredTaxAssetsRoyaltyReceivable" scale="3" id="Tc_Py9wKGEd60OvS7Z2v4NRLw_8_6">466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_H_cq3u8k2UK-V3PaUzW7BQ_9_3">756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_1zVZewzRpUqAHmzJ2crZmA_9_6">858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_FPWHHoep1k2h5zw4p1apBw_10_3">58,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_U4_m13CPNUOSEfwIl5krlA_10_6">50,329</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_3Fmlo0Ny_UKcwk7lX4hC2A_11_3">58,326</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_-jGHEavmy0aAyXnjqg_FAg_11_6">50,329</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xQxEZRom10ipxNjFLhAhoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_mFboUZF-aEWaGrU2CAFHmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net increase in the valuation allowance was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_2SZ7EB9LR0qdTwWofZ651A">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_LU8yAoYukUyJwaDxFR4tSw">3.3</ix:nonFraction> million, for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company&#8217;s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company&#160;has determined that total deferred tax assets should be fully offset by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February&#160;2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per&#160;year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2023 and 2022.&#160;To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal NOL carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_xk3sSFn4SUKTbVNRCHoWjQ">137.8</ix:nonFraction> million and state NOL carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_-jTxUsLwB0m38qsZl5cPRA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_6mDVFY_7I0aX8_19UstFJw">22.1</ix:nonFraction> million to offset future taxable income. $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA" decimals="-5" format="ixt:numdotdecimal" name="xoma:OperatingLossCarryForwardSubjectToExpiration" scale="6" id="Narr_DcUXoPcrHUW37bhJ_odb9Q">13.6</ix:nonFraction> million of federal NOL carryforwards will begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_n0AlLUReN0Kwv0E-hFvvxQ" name="xoma:NetOperatingLossCarryforwardsExpirationYear" id="Narr_HPnPJugckE6vwOAOOukR_g">2036</ix:nonNumeric> and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_jXEG7wv2O0iixCaiWgcKIA" name="xoma:NetOperatingLossCarryforwardsExpirationYear" id="Narr_U6zZrTivTkaIS2Y2ZzTapw">2033</ix:nonNumeric>. The Company had federal orphan credit of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_fTV55Dy5KEqyHnrS7IKYNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_7iaPHawnE0yohwff-UJo0Q">2.0</ix:nonFraction> million which if not utilized will expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_VIuDTnkCcEaZC79EMJ-tOw" name="xoma:TaxCreditCarryForwardExpirationYear" id="Narr_I241KtDPq0CaVmY4QtUtuw">2037</ix:nonNumeric>. The Company also had $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_J15_C70NX0OmaYeWNB6hKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_WR3Zxd6kLkuoB6YM66QXhA">19.8</ix:nonFraction> million of California research and development tax credits which have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2017 Tax Cuts and Jobs Act, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" scale="-2" id="Narr_E41WTAME4EykzUsvPCUxeA">80</ix:nonFraction>% of taxable income annually. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the provisions under the 2017 Tax Cuts and Jobs Act that became effective in tax years beginning after December 31, 2021 required the capitalization and amortization of research and experimental expenditures. The change in this U.S. tax law did not have an impact on the Company's consolidated financial statements. The Company will continue to evaluate the impact of this tax law change on future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Act&#8221;) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act did not have an impact on the Company&#8217;s consolidated financial statements and related notes.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_509a5efb_3441_4142_a766_0b3b25c7ba34"></a><a id="Tc_OOYf6-baGkKZOv5u2eU7Sg_1_2"></a><a id="Tc_ZGUvKtuoOkKG0-1gVET3ug_2_2"></a><a id="Tc_YBXuIoznBEKOCgYwVEX93Q_2_5"></a><a id="Tc_dWn0p2rX3E2oADJ6gL8pSw_3_0"></a><a id="Tc_2u00yTa1F0OsXV8rPAjcTg_3_2"></a><a id="Tc__onLxhZO9UW8Cxnkow_oPA_3_5"></a><a id="Tc_0pr5KqFbFUyhGS2r6D4GEQ_4_0"></a><a id="Tc_QqtHL_PSqkupmi4LnjxDjw_5_0"></a><a id="Tc_SWiKhzAuE0yu9_3sJCf5jw_6_0"></a><a id="Tc_rg0una7J70GbPMkOD6s-VQ_6_2"></a><a id="Tc_NCB13Rgb_k-1zlM9j7_jWg_6_5"></a><ix:continuation id="Tb_G3b0hLTolE-_U4_fggcftw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company&#8217;s federal income tax returns for tax&#160;years 2020 and beyond remain subject to examination by the Internal Revenue Service. The Company&#8217;s state income tax returns for tax&#160;years 2019 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future&#160;years are still subject to adjustment.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_oYdfOKns5E-dv1W91bC2xg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_AvxgokFwA0aFP_a8yw1Naw_3_3">5,938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc__FqsSM15O0-6u9BJz4ClDA_3_6">5,938</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_szud6j0_jk2o6opA0UJA1A_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_F6LOTkufzkyV0XPmP-g3Yw_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:zerodash" name="xoma:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_atVeWrGREEqP09tWRpAl_g_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:zerodash" name="xoma:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_dfhaPmzlw0OXbhA2BQOdzQ_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_U8s8t52-b06dYCDTavKZFw_6_3">5,938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_3l1CI6xJqUOGPpt7k9QG2A_6_6">5,938</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_P226hA0gDkKc7Uq71mdmLQ">5.9</ix:nonFraction> million of gross unrecognized tax benefits, <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="Narr_GjY4rKPORkCIDqGPGAJkyw">none</ix:nonFraction> of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" scale="6" id="Narr_FpYzNnLq00qDeF4OIDbddA">no</ix:nonFraction>t expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2023, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_xRGo_nrtIEGduo_6oyUl7w">no</ix:nonFraction>t accrued interest or penalties related to uncertain tax positions.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_ER69yZUtKUKGXTFGm5FunA" continuedAt="Tb_ER69yZUtKUKGXTFGm5FunA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Stock Based Compensation and Other Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_3gBbru_zskC8Zpu8k8h16g">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2015, the Company&#8217;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#8220;2015 ESPP&#8221;), which replaced the Company&#8217;s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_qpOCxF4gTE6XGswl1hQRNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_h8jR6RcUHE6VNu18QJ8J4g">15,000</ix:nonFraction> shares of common stock for issuance as of its effective date of July&#160;1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" scale="-2" id="Narr_dLAfqPSpUkWVNCbw0c9qyQ">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2015 ESPP initially provided for <ix:nonNumeric contextRef="Duration_5_1_2015_To_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_QVblxPuRZEOw9F6rNagv6Q" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_kXTCT6psVkiaM9eq0ELRkg">six-month</ix:nonNumeric> offering periods ending on May&#160;31 and November&#160;30 of each&#160;year. At the end of each offering period, employees were able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_1A3TBYHOV02Wyse1eMksoA">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Compensation Committee and the Board adopted, and in May&#160;2017, the Company&#8217;s stockholders approved, an amendment to the Company&#8217;s 2015 ESPP. The amendment (a)&#160;increased by <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NYJResI69kesGeTfzxA53w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Ap46r1E4GUqzSpVYr9qCoQ">250,000</ix:nonFraction> the shares of common stock (from <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z14Y_ls6nU-Legw_e3KnHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_1LgoeTBp70OXMc_4RAH7sQ">15,000</ix:nonFraction> shares to a total of <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pPNS9kuKzkGEzka8BT7FTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_1NBs-wtjukSql7f--lFxSA">265,000</ix:nonFraction> shares) available for issuance under the 2015 ESPP; and (b)&#160;increased the maximum number of shares of common stock an employee may purchase in any offering period to <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NYJResI69kesGeTfzxA53w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="Narr_4EoWv9YUZkqlKlCIkCXIZA">2,500</ix:nonFraction>. As of December 31, 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4_9OfpHHLEma607A2lr0HQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_24fzjhLe7EW5u-JwGh3nIA">224,886</ix:nonFraction> remaining authorized shares available for purchase under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Effective December 1, 2023, the 2015 ESPP consists of consecutive <ix:nonNumeric contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g" format="ixt-sec:durmonth" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_NKOrJGervEKZS-NLspnhGQ">24</ix:nonNumeric>-month overlapping offering periods that begin on December 1 and June 1 and end <ix:nonNumeric contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_9B3cewzrZUuMhDBpQwIcEw">24 months</ix:nonNumeric> later on November 30 and May 31, respectively. Each offering period </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ER69yZUtKUKGXTFGm5FunA_cont1" continuedAt="Tb_ER69yZUtKUKGXTFGm5FunA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">is comprised of <ix:nonFraction unitRef="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4_9OfpHHLEma607A2lr0HQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" scale="0" id="Narr_9lcq-04wlUeUQpHlrkR5oA">four</ix:nonFraction> consecutive <ix:nonNumeric contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" id="Narr_34-2rRokc0aCNbx0Fu2UwA">six-month</ix:nonNumeric> purchase periods starting on December 1 and June 1 and ending on November 30 and May 31, respectively. Employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_gQ8K6Ejlb0KV-R_X3vWNLQ">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the purchase period. The plan includes a rollover mechanism for the purchase price if the fair market value of the Company&#8217;s common stock on the purchase date is less than the fair market value of the Company&#8217;s common stock on the first trading day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2023 and 2022, employees purchased <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" id="Narr_SfrwVbBdfkyaJTzAKmGpuA">6,051</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_bkupJ_siykOMKkRtcBeUdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" id="Narr_D8YUGzgj40Sar9qbs08Wiw">6,090</ix:nonFraction> shares of common stock, respectively, under the 2015 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Savings Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Section 401(k)&#160;of the Internal Revenue Code of 1986, the Board has adopted a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_BP91nIGUoUGhIn0UV3EXKA"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_Pv6kz6KYkEOagHh7c23-mw">50</ix:nonFraction></ix:nonFraction>% of their eligible compensation per payroll period, up to a maximum for 2023 and 2022 of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_kICVKVDR1EKuBrC70GhfGA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_G6BIEKKd4kCRg2c7E6GURg">22,500</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Pp3_l5-Makmyd588cc5PtQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_dNb9VAHN_0yeOOBUm4C7ig">20,500</ix:nonFraction>, respectively (or $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_NxeZNU-uwEaleSn6kV2D0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_uBbCLH4xI0Ck2aPWocT7DQ">30,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_FOSyLzrHjUO4zX7-HXcfvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_TaECcO7dYUuG3uP7B1MCow">27,000</ix:nonFraction>, respectively, for employees over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" format="ixt-sec:durwordsen" name="xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" id="Narr_06QrcEzp5EmWszbZuo87QA"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" format="ixt-sec:durwordsen" name="xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" id="Narr_jk7jynWtu0qZ35z59-D6FQ">50 years</ix:nonNumeric></ix:nonNumeric> of age). The Company may, at its sole discretion, make contributions each plan&#160;year, in cash or in shares of the Company&#8217;s common stock, in amounts which match up to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1fqxYlQgQEOjj4he88QfPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_ngUXajQ8jEmU4tfMPFSbHQ"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_zoPI7MqTT0ymJt_IEkPwzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_wllz4XcJ5kyBp8gDBerQmw">50</ix:nonFraction></ix:nonFraction>% of the salary deferred by the participants. The expense related to these contributions was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_32v21EukEEiOmgswnaDfgw"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_FhP4NGtaw0mqHt8M8H5qoA"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_OFRmhGomT0ue2SVdetgoBA"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_PmMsKkgnl0itbv3F_KAfyA">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the&#160;years ended December 31, 2023 and 2022, and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="INF" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" scale="-2" id="Narr_e2nY6jE6LECqMMXSSYXHCA"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="INF" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" scale="-2" id="Narr_DLIiPx0elky2gp7XVWb2MQ">100</ix:nonFraction></ix:nonFraction>% was paid in common stock for each&#160;year. When available, the Company applies shares from plan forfeitures of terminated employees toward the Company&#8217;s matching contribution. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2010 Plan Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2010, the Compensation Committee and Board adopted, and in July 2010 the Company&#8217;s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_1xu20gXIgEOEZA3LZay7CA">ten years</ix:nonNumeric> from the date of the grant or <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_Yo1Pn10MbE-IQC5dhETm3Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_5cLJ5iCBj0qYM-3Nst7j6w">three months</ix:nonNumeric> from the date of termination of employment (longer in case of death, certain retirements or subject to certain terminations pursuant to the Retention Plan).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6NH2D73ShkWYzzOp3xcTJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_Mtawg4NBmkyeFG30uRiMPQ">409,477</ix:nonFraction> shares available for grant under the 2010 Plan. As of December&#160;31, 2023, options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6NH2D73ShkWYzzOp3xcTJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_ASHbws49FUaI7TtRUzStKA">2,730,068</ix:nonFraction> shares of common stock were outstanding under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options issued under the 2010 Plan generally vest monthly over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_JTU393H8zkS60pP-6_KFDw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_UsA6UcPdvUmk5HWePEhmRw">three years</ix:nonNumeric> for employees and <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_RX8jSTjVsUCam5xpFx-k_w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_FExOPQSSMEesQbAtLeCUPA">one year</ix:nonNumeric> for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="Narr_GybP3d3iFECppDeWYUh5lg">55 years</ix:nonNumeric> of age and the sum of their age plus years of full-time employment with the Company exceeds <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="Narr_Ak2qKvXWAUWvtR-M-Vs-gA">70 years</ix:nonNumeric>) vest on the earlier of scheduled vest date or the date of retirement.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_uDG9IX-lEk2waB0LeJ8Qlg_1_2"></a><a id="Tc_8BLpFBcKEUyPs30kL14dwg_2_2"></a><a id="Tc_auO7mk9GzkiRg8hn7lzhTw_2_4"></a><a id="Tc_kghwhxycPEyXZOPfHOz41Q_3_0"></a><a id="Tc_DtckIN3EDkinysJgD417Fg_3_3"></a><a id="Tc_H8ZUHAOaVEiN36U3kD-SkA_3_5"></a><a id="Tc_ohzRalY920-CMD3gdHuZew_4_0"></a><a id="Tc_y-geXm-PlkaxeyWxk7AsBg_4_3"></a><a id="Tc_Hu1ZT7n4T0uwGDhMOC-6xA_4_5"></a><a id="Tc_3OXjMVXkwE-sGc2KBIoEXA_5_0"></a><a id="Tc_bAM3z46mH06CEA9N8Cb2HA_5_3"></a><a id="Tc_dOg3-t02xk2bL8RUjI75Fg_5_5"></a><a id="Tc_v1rqL7Zr-kGXJn92NRe-nA_6_0"></a><a id="Tc_r75RhTpLjUCV82m_RKKi6g_6_2"></a><a id="Tc_28irwu4OrE2bam5L6yWOUw_6_4"></a><a id="_3271de1d_3a0a_49cd_ada3_a6b6160d0d03"></a><a id="Tc_gMQvQ-7jykSaTmDO5iKtnw_1_2"></a><a id="Tc_fLEQBRKArU-vlLblqtI6Pw_2_2"></a><a id="Tc_sJSl6bP5CkO4798AG8KyyA_2_4"></a><a id="Tc_KhhfwxbFFkOXUe_Fu05Mag_3_0"></a><a id="Tc_nPtbyFrZmUCygZ0Na_bNXw_3_3"></a><a id="Tc_Zj59a9ZOy0Ku0eIE0dm99g_3_4"></a><a id="Tc__vsidIz0TEui9uOLBnoTKQ_4_0"></a><a id="Tc_Va3C7_Cn6kaL9qg5fM5MuQ_4_3"></a><a id="Tc_C6IOEMeQ1UKd4zCEyPAPLw_4_4"></a><a id="Tc_kv0RkNMDWEOuz5btst19FA_5_0"></a><a id="Tc_zv0KHvh9mk20lTLIQK4qxA_5_3"></a><a id="Tc_ZG57g0Gh9Uiar4Da5kQEmw_5_4"></a><a id="Tc_jZCdBJOAlkiqYaOR828wuw_6_0"></a><a id="Tc_TG57MBa72EmgzAX0R-PwKA_6_2"></a><a id="Tc_WPo9M3xg6UqWQYP4IwW6DA_6_4"></a><ix:continuation id="Tb_ER69yZUtKUKGXTFGm5FunA_cont2" continuedAt="Tb_ER69yZUtKUKGXTFGm5FunA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;background:#ffffff;">Fair Value Assumptions of 2010 Plan Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted under the 2010 Plan during the years ended December 31, 2023 and 2022, was estimated based on the following weighted average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_0srFpIQZjEeXreNfgIZggA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_WJ712dUNikaLYRT3nmcVyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_oRy7usCRTE-S6RT74QqcbA_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_jAhFmz1p0UKH0Ef86Q9YQg_3_4">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_gjsUL6Yiu0W-Rc3rmonWJg_4_2">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ed0MxqaVoUeaLRVBe1j4pQ_4_4">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_2sY6sNFdekic0E-WuUFTaQ_5_2">3.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_vpfK6nOMNkaI1wF1Tn4Y9w_5_4">2.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_CBNMBKASb0WlmcuMzqzIxA">5.79</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_OEts2d1bHEiWouHvma6DOg">5.64</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The weighted-average grant-date fair value per share of the options granted under the 2010 Plan during the year ended December 31, 2023 and 2022 was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_4mEa5lRSzkuA4bbEpbxgVg">13.18</ix:nonFraction></span><span style="background:#ffffff;">&#160;and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_hehvjLHxjE6I52T9Q9GStA">12.01</ix:nonFraction></span><span style="background:#ffffff;">, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Option Inducement Awards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Company&#8217;s Chief Investment Officer, effective as of January&#160;1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_D67_o-ekW0mCOHoAiNEOOw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_1zEbazKOfUabc2sEIZ19sQ">two</ix:nonFraction> separate awards of non-qualified stock options on January 3, 2023 (collectively, the &#8220;Stock Option Inducement Awards&#8221;) when the Company&#8217;s stock price was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_9t7Xrh4erUm2DCAqplH8xw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_UTU3SN7UbkyiUgFIBixoXw">18.66</ix:nonFraction> per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Hughes <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_XnnLT8lCQE-Kb6QqSuciIw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_DdYal6lShk63NDoqtfbq9Q">two</ix:nonFraction> separate non-qualified stock options to purchase: (i) <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_6SKWZqNxg02cWotgwC68fg">100,000</ix:nonFraction> shares of the Company&#8217;s common stock at a fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_-_Qfpx898EyFwhxw-OA8XA">18.66</ix:nonFraction> per share that vested in a series of <ix:nonFraction unitRef="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" scale="0" id="Narr_4MkcB7ZDykCqIwI8GKeZgg">four</ix:nonFraction> equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Pr1Bc-D_zkqrj26vMLzvEg">75,000</ix:nonFraction> shares of the Company&#8217;s common stock at an above fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr__ODw9rp3gU6uM6P344nf_Q">30.00</ix:nonFraction> per share that will vest in a series of <ix:nonFraction unitRef="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_5CCMweKrKkW4S6x6rAivzw">36</ix:nonFraction> successive equal monthly installments from January 1, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Sitko <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_D67_o-ekW0mCOHoAiNEOOw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_s12t4udhlkWpnUpfMyCBQA">two</ix:nonFraction> separate non-qualified stock options to purchase: (i) <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_kZe5UeB58EqVvQzsj0tFKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_gpLNoqT750ehzpkRmJ1G1w">300,000</ix:nonFraction> shares of the Company&#8217;s common stock at a fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_kZe5UeB58EqVvQzsj0tFKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_9KdUrwkNGkmrHWoz57Oajw">18.66</ix:nonFraction> per share and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_CPv_k4GysE6N0cJwFt__ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_g2regQWlTUqF4PknP0JzsQ">250,000</ix:nonFraction> shares of the Company&#8217;s common stock at an above fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_CPv_k4GysE6N0cJwFt__ZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_47j0G5TQo0-KGpj_7IlMTQ">30.00</ix:nonFraction> per share. <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Nbz01A2AFUSN9o9T7YGxsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_jZsfua1tlE6qR6PtvfRxDA">25</ix:nonFraction>% of the shares subject to Mr. Sitko&#8217;s option grants vested and became exercisable on January 3, 2024, and the balance of the shares will vest and become exercisable in a series of <ix:nonFraction unitRef="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iss2YrFnEUiSmHE-waxCwQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_dEy9vmr6Xke14NCCduLSyw">36</ix:nonFraction> successive equal monthly installments thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Fair Value Assumptions of Stock Option Inducement Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_lpNhrc2ivk27vYMf2Vaqrw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_8VrXcGJMsEKuvqBxALzkVA">18.66</ix:nonFraction> per share during the year ended December 31, 2023, was estimated based on the following weighted average assumptions: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_lpNhrc2ivk27vYMf2Vaqrw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_8XtHO3Amdkq7ANexAGVtQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_4lDHhrrBxUi8V2aFgpG5dA_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ZY9PA7j7Uk67mVhiuUGW-g_4_2">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_2OLUzKWhx0KgTYtEP7uxUQ_5_2">3.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_RlPUO0MkIkSRATBEQD76iQ">5.79</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_VgCo7QDMrEqWqhFOY8kLUQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_31Mqyl7Wtki9GiDa1GjT1w">No</ix:nonFraction> Stock Option Inducement Awards were granted during the year ended December 31, 2022.</div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_p17Cp-2md0-zORF_i9yfng" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_hVqiRGO3lE-mA4GujhpMpw">18.66</ix:nonFraction> per share in January 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_p17Cp-2md0-zORF_i9yfng" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_TKp4JWLlg0e6pqLzGYjoGg">11.91</ix:nonFraction>.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7d267493_7ce3_443c_a41e_d82cd506a01f"></a><a id="Tc_W_Td-lCb80OGLZOlvEiHPA_1_2"></a><a id="Tc_pc9x3fPkf0q8U39qtcWOnA_2_2"></a><a id="Tc_iBelZ6QODUifH4rm9297nA_2_4"></a><a id="Tc_CS1L1j70ZUObBjPSF9cTGw_3_0"></a><a id="Tc_N0xxA27cAUWY-CPNWe72Zw_3_3"></a><a id="Tc_Gv5O9Ul0Dk-mBJsPkGaIOQ_3_4"></a><a id="Tc_lT-X75BjuU2Mr-2o8wfnlQ_4_0"></a><a id="Tc_K7-e7JrTl0Cu3sGihOAaxQ_4_3"></a><a id="Tc_sl0BHeQVvkWjdJ84fYWZYQ_4_4"></a><a id="Tc_i4Naot3dgUSIPq45TWzaPw_5_0"></a><a id="Tc_Np9wKOn7pkWygdTF1-1Fzw_5_3"></a><a id="Tc_tgz9dfHLtUGfsPEnktTiTA_5_4"></a><a id="Tc_oF5rGHN7YEqz2gmEVB4WGA_6_0"></a><a id="Tc_S7ypfjOJcE240Y_siUQKVA_6_2"></a><a id="Tc_MyzPKPyw00e3zuk3Dz0izA_6_4"></a><a id="_01d238c5_87e0_4308_bea6_681545e821bc"></a><a id="Tc_X0TNhd9O5k-VqYijaqevbA_1_5"></a><a id="Tc_q3QDM6vOt0uyghldo4CAoQ_1_8"></a><a id="Tc_Nr22RWIIDESQMRlTu7i5sQ_2_5"></a><a id="Tc_ML-9BY89hkqjltDZvlS7XA_2_8"></a><a id="Tc__9aDhaHPYk6H5kbAlZnTsg_2_11"></a><a id="Tc_Clxp968Qf0aHM0yt5NGEzA_3_5"></a><a id="Tc_R9JD_h1NO0GqC1cbuUQBlA_3_8"></a><a id="Tc_bl4tzSwzKkuvk4QwOOgBJQ_3_11"></a><a id="Tc_71S5m4cpIUifEejhn41hdw_4_2"></a><a id="Tc_PL5BvHcIJUivcYMgwZl1sQ_4_5"></a><a id="Tc_gfcxRASwDU-2uZmyoyvHjA_4_8"></a><a id="Tc_oFx34lIfwkm3R1QMS7qFdQ_4_11"></a><a id="Tc_SongFRO_9UCpb5g68PxWRw_5_2"></a><a id="Tc_ttxZ5nENL0-iQ4HQdrCNow_5_5"></a><a id="Tc_m0lRHyB8aUKCNP2OhaRlgg_5_8"></a><a id="Tc_B0yuxfH2P0GHO-k264kV9g_5_11"></a><a id="Tc_gs6IRs12e0OyS4qkhTH_6A_6_0"></a><a id="Tc_BBro91ysM0qis3f2uNAC5g_6_5"></a><a id="Tc_nJaCKXM8kUOWcFhLPaXc4A_6_11"></a><a id="Tc_K9ZsMRi2zkKAk32A6wnWLQ_7_0"></a><a id="Tc_1uhNelaUt0Cqf9z1nHN6Cg_8_0"></a><a id="Tc_UCZUxkb03UeemMr1kH3k3Q_9_0"></a><a id="Tc_3hiP3hOeEEKbnfanuqIcOA_10_0"></a><a id="Tc_JEvvtzuJ2k-M5524mVJpww_10_5"></a><a id="Tc_lX60Aca6m0GUXqiiPv0cDg_10_11"></a><a id="Tc_932x3zxov0WYQ_HpRxl_XA_11_0"></a><a id="Tc_y8rVVKNVD0K-EAGT7dDLMQ_11_5"></a><a id="Tc_r2adCFtuK0akaTWxExWbTg_11_11"></a><ix:continuation id="Tb_ER69yZUtKUKGXTFGm5FunA_cont3" continuedAt="Tb_ER69yZUtKUKGXTFGm5FunA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_HHiYTOa0A0uZNNg2Ywhozg">30.00</ix:nonFraction> per share in January 2023 was estimated based on the following weighted average assumptions: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember__0KUigoyNEiSFG6EHS-pKQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_GVzf40_Q7UaIFKt4i9UnlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_zZnGmE6WCEyybN2qt82TlQ_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_1NKBdV49WkGjeKNKZ3ncRQ_4_2">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_IvL2QuQUakus6iT6HR69gg_5_2">3.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_qOfx-rG0XEy4V4htkbQOJw">8.01</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_q-zvA0nnJ0u9IWbpCyBZaQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_kGNq3aqKdka7O59sFnbaow">No</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the year ended December 31, 2022.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_kGwFf_evEECFpuOCUz3gRw">30.00</ix:nonFraction> per share during January 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Uzxbmv496UiiKH6tvrqFrA">14.68</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The activity for all stock options for the year ended December 31, 2023, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_gPudZsvPvE6jncVmm2UMDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_omW7BspUik6ngokuXuSDwQ_6_3">2,025,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_T-WCogPXg0KdkqGA2lmDsA_6_6">20.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_g6tcavpNd06mvqoCVNeqVQ_6_9"> 6.10</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_UnA-AduhDEygpSe1SgppvA_6_12">10,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_9vBpViZAmkq3PQYXWNrMVQ_7_3">804,302</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_x_eJntkNJESG3wu382wunQ_7_6">23.44</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_dzOg9gHjVkS8hcQY5x_OFQ_8_3">28,473</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_cN6Wc_MBfUK7cnQtz_OiNQ_8_6">8.27</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_M9EZPRLry0aU2KjglGfA9Q_9_3">71,303</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_o1JnKTFqnU6hA4nq1KztoQ_9_6">36.51</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_wyjK3jZaOEiXxbduxzeySQ_10_3">2,730,068</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_W6qUmY_ik0Olz0Wk_tB-Cg_10_6">20.88</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_gGRdrWU5_kGoKzd2Ug__sQ_10_9"> 6.29</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_42qVV8Hzf0euM51rjSxprA_10_12">10,638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_Nrq3a9A7ikyuGC2M-1isAA_11_3">1,961,143</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_M_JBwyaDrEuk_ym2DBgEkw_11_6">19.73</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_8T48kL_XDkiKukEYrpkhig_11_9"> 5.27</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_RpExTHxmw0uF1NTWLCr95w_11_12">10,606</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_vO3_dCcUZkihLv6dW_JLSg">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_dg_3K92etk-Hy80FByHKFQ">2.8</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYNuuYoVaUKIMN5qjgyD0A" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_Nr4QS5wJ1kqxX7uNOFz4wQ">8.0</ix:nonFraction> million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wI-J9wnFokegnVOOPhGPfA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_jKoE2FWnMU-1XYqp4zGCAQ">2.64</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Performance Stock Unit Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company granted employees <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_MQ2JB34wHEqnnlhOE_S-2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_tHC_UND0hEqEEvzffA0lpA">430,400</ix:nonFraction> PSUs under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company&#8217;s common stock as compared to <ix:nonFraction unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw" contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." scale="0" id="Narr_AvMFIp_NgkqLsj_oLKYZ9w">four</ix:nonFraction> stock price hurdles over a <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jr06nKWQnkWcc1gc9wl75w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_G3igBWk-dEWljTGTrgIZgA">three-year</ix:nonNumeric> period from the May 2023 grant date (the &#8220;performance period&#8221;). A stock price hurdle is considered attained when, at any time during the performance period, the Company&#8217;s volume-weighted average stock price equals or exceeds the hurdle stock price value for <ix:nonFraction unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w" contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" scale="0" id="Narr_F8e_7ggXC0-Z_eL2c8ZUpQ">30</ix:nonFraction> consecutive calendar days. Upon attainment of a stock price hurdle, <span style="-sec-ix-hidden:Hidden_xpK_StUG00ybbYZa3HpmVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> of the earned PSUs will vest immediately upon achievement, <span style="-sec-ix-hidden:Hidden_-jeY11JkkU-_yKExwXSvYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> will vest upon the <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9F82xQd9GUyY0FWq2yw9Bw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_pz2oE6wcnkiQLXV508yKgQ">two-year</ix:nonNumeric> anniversary of the grant date and <span style="-sec-ix-hidden:Hidden_XJQ4j8H56EGkjfAn5W1EYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> will vest on the <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7KxJyjjuEU-w1MGzNb9A3Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_gZ7k-NMV6kaFoem8dWa8iA">three-year</ix:nonNumeric> anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Company granted an additional <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_DppoP7EaukOr-8wuDeS7oQ" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_7JO_nzlo_EmfKBFRxH7YUg">18,200</ix:nonFraction> PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk149049582"></a><a id="Tc_KBWXGJ3qv0ueguHs9ZgxDw_1_9"></a><a id="Tc_2zAfWWcHd0iz6sIyCiagZQ_2_0"></a><a id="Tc_kgVEZRSLfk2kN7j_sEDl4g_2_3"></a><a id="Tc_HUI5Hj2w_UeRNRow5SV4Sg_2_6"></a><a id="Tc_QB1lo09liU6T0PXuOHQePw_2_9"></a><a id="Tc_EZPw4MdAU0SnG1bcSpnTMQ_3_0"></a><a id="Tc_axYrsX1Gmki1diikqOTgAA_3_3"></a><a id="Tc_k4hDaCCkI0CgT4ge3RFbpg_3_6"></a><a id="Tc_VSzNRriWQUmXe0kaUTpMdQ_3_9"></a><a id="Tc_fd28gzaD5UmLo1s82KaYIg_4_0"></a><a id="Tc_TxMJ_DBzJ0ayHUS6xW-G0Q_4_6"></a><a id="Tc_YCYs90fTiUe_u_CeoqpYgg_4_7"></a><a id="Tc_MHn_F5LD-UKcMe7gLngEGw_4_10"></a><a id="Tc_GY6G49K1ZkGexxLB9XfZ0A_5_0"></a><a id="Tc_vCLpX8j390qXmyfuSlHJVA_5_6"></a><a id="Tc_ibVZRezWNEiSNtWK3vQC4A_5_7"></a><a id="Tc_mpR5b9zzAkC4scgkc8rktw_5_10"></a><a id="Tc_9t-iq_4MwU2oZoK8f0mBnA_6_0"></a><a id="Tc_4F4sdfmEFkKhsbZ-0ep94g_6_6"></a><a id="Tc_FIseC97pm0eKz7XvgkQy3w_6_7"></a><a id="Tc_UR5kHEf2XUmS_Bm3Zwk67w_6_10"></a><a id="Tc_6rjfdlQ6DEKCt_A_CtOKCA_7_0"></a><a id="Tc_jGSsQQ3SFkeNFFq8Bt2P_w_7_6"></a><a id="Tc_FE4ahcTMVkGiNH0s0HwNng_7_7"></a><a id="Tc_uNXtYaQ3TE2-Tjso1OY6hQ_7_10"></a><a id="Tc_ILoQLhyhJkSE1tkWeNsgaQ_1_5"></a><a id="Tc_qD3gzyOEtkG7wfqDnHRU_g_2_5"></a><a id="Tc_iUbb3x6ndkGLrq5BNpTSyg_3_5"></a><a id="Tc_gbHcrjuZbkWGFsfBzGc0FQ_4_2"></a><a id="Tc_ee4ebmfF4UmRvgw6hxuM4g_4_5"></a><a id="Tc_lxdVEYZEa0K7p1NNIHwUpA_5_2"></a><a id="Tc_YQbSp05s6ka1_mPRWXVVsQ_5_5"></a><a id="Tc_UeZjtTR460aZMlPA-V2DTg_6_0"></a><a id="Tc_5zTm6mOhPE6FNV56ETCcAQ_6_3"></a><a id="Tc_yQYn-brysEm04QPmgQJLyw_6_5"></a><a id="Tc_SDhuqHciTUG6GfjWAY0Uow_6_6"></a><a id="Tc_g7AVnhWgOkaAm-2gdstaSw_7_0"></a><a id="Tc_EcflePG7T0-M8_u1UgLkKw_8_0"></a><a id="Tc_HFR3TVYM30KYkhv3pDCwTA_8_3"></a><a id="Tc_Yr_GdwE_r0CSPAHoddcgMA_8_6"></a><a id="Tc_xlSTvuV47UieSuC20mefNg_9_0"></a><a id="Tc_Y-LA_dtStke4fvc9I7rwUQ_9_3"></a><a id="Tc_NXxvaK792E-nJgL6JMd4Eg_9_6"></a><a id="Tc_2XKr-toMe0qZwUbD1NzGCw_10_0"></a><a id="Tc_GCpOxvn8HUCPE12-B_7hdw_10_5"></a><a id="_67e17c2c_1d2c_444e_b9f0_df2accb445d3"></a><a id="Tc_Ls2AT-CjkEqyb3Jl6ZrIjg_1_2"></a><a id="Tc_Hb5JtGOGA0u3EldIyu3SDQ_2_2"></a><a id="Tc_RwjjqHNWdUyQ5joIwBrtrg_2_5"></a><a id="Tc_21S0A6yx5EeaPn5PCbsrNQ_3_0"></a><a id="Tc_teodKkOhVEmhAIN1MBN3rQ_3_2"></a><a id="Tc_z7Nb5vM_lU6t-790n5-HSw_3_5"></a><ix:continuation id="Tb_ER69yZUtKUKGXTFGm5FunA_cont4" continuedAt="Tb_ER69yZUtKUKGXTFGm5FunA_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Fair Value Assumptions of Performance Stock Unit Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The range of grant date fair values of the PSUs granted during the year ended December 31, 2023 was estimated as follows: &#160;</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="Tb_wyjoyeSEfUeyZH0bEyVJ9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derived</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Hurdle Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Service Period</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QK1CLkfR8kOQoYbaZOfjJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_gKiaD1WhQk-4nYstNomoGA_4_1">30.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_GaicAvhvREu045tkaseAEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_Df5HMG-5QUGSmdaMRixf7Q_4_4">243,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_hM9ty2-MVUGlezJJB5CGZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_aWGt-U4XGE-YoXPIiYmhyQ">11.42</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_U9y-4g4fU0Ke5Az40er2DA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_TX8I4ZGuOkKq7VvJ8pxPDw">17.45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_hM9ty2-MVUGlezJJB5CGZA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_BGS8GTf9MEar9UX2u2vdKA">0.69</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_U9y-4g4fU0Ke5Az40er2DA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_cRjlZSrvCk-f8J2IyziDfA">2.59</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_xw9SMS1FDku23HM0n9XH7Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_oXYR5ZyS002w6zcy7m1_Ow_5_1">35.00</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Q_GOADvcjEiY8_k6u1blBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_ITUzzqdpuEiqtxDN7BZXvg_5_4">91,239</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_wMQi5PD-5kOVp3Do-Cz7aA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_XkOj_oM_wk6mjEWzTV7KDg">10.16</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ZvNKstqm10OSTijaRyyBgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_W4iAB7kaJkKC8h7RIwPnjw">16.07</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_wMQi5PD-5kOVp3Do-Cz7aA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_W9-qbkqSXEC6qZWqk53kQw">0.93</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ZvNKstqm10OSTijaRyyBgA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_T5hT8CzuAE678kAb5Pv9mg">2.59</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QfRHcV6u0k2_QDklTWc_9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_kuvFpfKV2kOk7KluP93E9Q_6_1">40.00</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_PFwhQNdS_0Cvqwhdk5-nJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_GHE4mbMhDUKeq1R8zk_YTg_6_4">60,024</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ATjJ9C3tUEuB5MOkEX8QXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_DlLLKVbKhEq1TdD6YdkdYw">9.07</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IgF4YIWD40C1TLHU9oQ6EA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_F3W6uwAXTkO7Al6uNPWOFw">14.84</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ATjJ9C3tUEuB5MOkEX8QXQ" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_8_Uaz2uR6kmaK72w1npUfw">1.12</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IgF4YIWD40C1TLHU9oQ6EA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_x1Qj_oRb206wfKg24QZDWQ">2.59</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_WdFrStI1SEmbrCQr_uf_3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_P_10KrzY7EaF6xU2vcIIVQ_7_1">45.00</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_7XNCE9fHSkejCdV6XNu2Yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_1CGzF69JukmqPFzyauuBCw_7_4">53,787</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LLR4GBlfWEaaPy6t-ixdjQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_0bV7C17QO0uc4selHo7Gqw">8.12</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pXkK2dzdNkSrOgN1r7fWyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_E3gOrUGyF0KxJts3AhKqMQ">13.72</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LLR4GBlfWEaaPy6t-ixdjQ" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_7-kLMHMeiEyWKTxjJwLWDA">1.27</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pXkK2dzdNkSrOgN1r7fWyQ" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_BXJG2jJCxk-utEWgdsEyVA">2.59</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_DF0-iJmGeU2XIhApUkyh5Q_8_4">448,600</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates that it will recognize total stock-based compensation expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_10_31_2023_us-gaap_AwardDateAxis_xoma_AwardDateMay2023ToOctober2023Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DWNUD9UHZ0yY-M_tgTpaEA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_gDZ-gZ05TUiU-g5-d2z5ag">6.9</ix:nonFraction> million in aggregate for the PSUs granted in May and October 2023 using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The activity for all PSUs for the year ended December 31, 2023, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="Tb_CKrxJbrmx0KN4IRHgTEU4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unvested PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_F443Dx_2Vk-HzWMDRghr4A_7_3">448,600</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_lBpkCYEE9ESDqSu7PWBClA_7_6">15.40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Zk0OoIDLe0SQRhhQsJk-Mw_10_3">448,600</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_h0Jp2LMQKkqlUCnTuUqxhw_10_6">15.40</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_eLRCt69HFkmy5k2LKwIPVg">2.8</ix:nonFraction> million of stock-based compensation expense related to the PSUs during the year ended December 31, 2023. As of December 31, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_Pbj2WlN20UGvhiF6AadwiA">4.1</ix:nonFraction> million in unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_PfTzOG_8J0-FhcwMYknUDQ">1.38</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation Expense</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_qaZTWtiAHEWf5K9QOcrA_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jWEJG3qYf0OkSzZNmxWzdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Pp6Hoy1Kj0eThVM4A2_s7g_3_3">9,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QmfRiBqenki9xaGwjiWv6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9-O6iBi-NEiw1Mc3MhVYFQ_3_6">3,608</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ER69yZUtKUKGXTFGm5FunA_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Thomas Burns Equity Awards Modification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2022 and November 2022, the Company entered into letter agreements with Thomas Burns that amended and supplemented his amended and restated employment agreement. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remained employed by the Company for a <span style="-sec-ix-hidden:Hidden_PLUg0go3Uk-_7O-a0gyV7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span>-month period beginning on November 1, 2022, he would be deemed &#8220;retirement eligible&#8221; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. The unrecognized stock-based compensation cost for the unvested stock options as of November 1, 2022 was recognized over the shorter of (1) <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_kmKo9NmoskKPrR6gM-lu1A" format="ixt-sec:durwordsen" name="xoma:EmploymentPeriodRetirementEligible" id="Narr_lWZ5gl2GhkaNGwvMVupGGw">twelve months</ix:nonNumeric> and (2) the remaining original vesting period (the &#8220;Revised Vesting Term&#8221;). During the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_JXd_9rzC90CP0igSJTsrdg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_9D3jXqgJT026o29tJGCdaw">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Pt94Ra0jTUOM2_6JUiOKAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_Pxj7qyxHi0CXYINjuhrg6Q">0.6</ix:nonFraction> million, respectively, related to Mr. Burns&#8217; option awards. As of December 31, 2023, there was <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_LJGNT1o0fESPY6CsLc4PAQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_FpJsERcq50W2qKJCe4aSzQ">no</ix:nonFraction> unrecognized compensation expense related to Mr. Burns&#8217; stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Employee Retention Bonus </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company approved the Amended Retention Plan which provided that each of its then current employees, excluding the Chief Executive Officer, would be eligible to receive a cash retention bonus if employed through each of <ix:nonFraction unitRef="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ" contextRef="As_Of_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_Yf9nqgko7Ey_J1Vum-XNLg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPeriodsCashRetentionBonus" scale="0" id="Narr__-Cv6z4m50OXYee2s6gOmw">two</ix:nonFraction> periods: (1) the <ix:nonNumeric contextRef="Duration_10_1_2022_To_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_wNITwyTcekq4e2_GA1wpag" format="ixt-sec:durwordsen" name="xoma:PeriodOneRetentionBonusEligibility" id="Narr_L8gXCciePUukZIQdvfASsA">three-month</ix:nonNumeric> anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the <ix:nonNumeric contextRef="Duration_10_1_2022_To_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_wNITwyTcekq4e2_GA1wpag" format="ixt-sec:durwordsen" name="xoma:PeriodTwoRetentionBonusEligibility" id="Narr_FtsbJgVyNUa3Uga26Bx9BQ">nine-month</ix:nonNumeric> period immediately following the Initial Period. All other terms of the Amended Retention Plan remained consistent with the Retention Plan. The Company accrued and recognized the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_vL3apDyaZkCu6f5YXyWb4w" decimals="-5" format="ixt:numdotdecimal" name="xoma:RetentionBonusExpenseAccrued" scale="6" id="Narr_UcW6Gd0Hl02r9_GbsMQgAg">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_HJ3psyCDL0yJ_bjXgwInwA" decimals="-5" format="ixt:numdotdecimal" name="xoma:RetentionBonusExpenseAccrued" scale="6" id="Narr_l-E7oTy5QUK7gwzxwUJNXg">0.1</ix:nonFraction> million for cash retention bonuses in operating expenses in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_6yQg3Qhf9UiWbaQF-yGsrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedRetentionBonus" scale="6" id="Narr_A-eDSCcZckiRgYrHxsMacQ">0.1</ix:nonFraction> million of cash retention bonuses recorded in accrued and other liabilities in the consolidated balance sheet. All cash retention bonuses were paid in full on October 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">James R. Neal Departure and Continuity Incentive </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">James R. Neal retired as the Company&#8217;s Chief Executive Officer effective as of December 31, 2022 (the &#8220;Departure Date&#8221;) and resigned as a member of the Board and Chairman of the Board, effective January 1, 2023. Pursuant to Mr. Neal&#8217;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal was entitled to a cash payment of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_op1dbIKXI0auw-rLczKFjA" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedCompensationContinuityIncentive" scale="6" id="Narr__PXX2GGCuUy7TvShRAOB5A">1.2</ix:nonFraction>&#160;million (the &#8220;Continuity Incentive&#8221;) which was made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company recorded the full&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_0LRcdmUtxkWsPDjZRSRzxA" decimals="-5" format="ixt:numdotdecimal" name="xoma:CompensationExpenseEmploymentAgreement" scale="6" id="Narr_djJf-qpSXkSHuwRZxdvmbg">1.2</ix:nonFraction>&#160;million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. The unpaid accrued Continuity Incentive&#160;recorded in accrued and other liabilities in the consolidated balance sheets as of December 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_0LRcdmUtxkWsPDjZRSRzxA" decimals="-5" format="ixt:numdotdecimal" name="xoma:CompensationExpenseEmploymentAgreement" scale="6" id="Narr_LC-fx8y6DkikzRt9B4V4lw">1.2</ix:nonFraction>&#160;million. The Continuity Incentive was paid in full as of December 31, 2023.<b style="font-weight:bold;"> </b></p></ix:continuation><a id="_3da5e197_ae40_490b_8e3a_c22fd0c57d05"></a><a id="Tc_D1--EWBEy0K_xcCPjlvAgg_1_2"></a><a id="Tc_WDejpDgHu02DDz-gpkt0LA_2_2"></a><a id="Tc_sIqFRtx7H02NjBrL9NgK0g_2_4"></a><a id="Tc_1Lyz10pvgEOZtcWaNZVqMg_3_0"></a><a id="Tc_-8aMWi8IV0Ok3m_UlI1-Uw_4_0"></a><a id="Tc_KM0wlh0kEUe_b9zg2uI__w_5_0"></a><a id="Tc_1zTPM1eOO06Ejc2CHxopGA_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_cJQXnHGT40a0vA6PuhcRtA" continuedAt="Tb_cJQXnHGT40a0vA6PuhcRtA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Net Loss Per Share Attributable to Common Stockholders </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_uvjtpF3W0ECbAEJFdJvBTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_GvxISMo_UkG51ag9NMnfUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Vsyl7Ua-fEuVbOKwOiNkNA_3_2">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_8v_3XroY3UqA5FYoxvPiFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_bhCmlbv6cUOZeyw2UmRGnQ_3_4">5,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_D_s-_E21uUaiUOWarzVcYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_UwCEz9rZJEyTX09aLK7nIw_4_2">1,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_4Zo0UeZYZUeUnyTVN-VWXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_I548DwdVIkGKtGVcr7YoMA_4_4">885</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_j8MHpbryDkKr6iuxL4IoLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Nho7GEywQEuZ5WrTvHacXg_5_2">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aLLtLfhuF06YDmKVCRRdMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc__yoatRzuw0OZgl9PQ00nxQ_5_4">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_4vL9y1vWZ0-fqDnWIcf2FA_6_2">6,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_C9pgZOdE0EqeWKPRaBwhiA_6_4">5,894</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c42a741_2daf_4f9e_adff_42f67d57d4f1"></a><a id="_d6714aa3_24fd_4504_847e_1788707dbf36"></a><a id="Tc_GFRduBsluEup91DXMqmmgg_1_2"></a><a id="Tc_ZGc9Hj90FUOGJNIRirkvKA_2_2"></a><a id="Tc_fvUnJIu-KUuUA4seTBjtyA_2_5"></a><a id="Tc_wP00K7U6S0mdiXwQglQeqw_3_0"></a><a id="Tc_YwMzwmY3wUuypAtWL3Adhg_4_0"></a><a id="Tc_1L8azL2Uxk-o4tDxk7oKFQ_4_2"></a><a id="Tc_elHsQKrCLU2PaesK5uXs8g_4_5"></a><a id="Tc_ACJfujFKDUKpQyRcNrmTOQ_5_0"></a><a id="Tc_PxeAHpgBM0mkbcIKX20rlw_6_0"></a><a id="Tc_7hq9cvzXJ0eTHxaGJ5P5fg_7_0"></a><a id="Tc_6sSKOlmiLkqU4YK5F7SEDw_7_2"></a><a id="Tc_Mvtbld0Blk-WchBZKz75Ig_9_0"></a><a id="Tc_Nr7HXgyB6kexAANSt9vNcw_10_0"></a><a id="Tc_XkiHaxwyyUe-JLQe2LPdgQ_11_0"></a><a id="Tc_a9OkBMAYKUCLK3nkXMIfMA_11_2"></a><a id="Tc_bMEuEj7QUUqYceeWj2GpzQ_11_5"></a><ix:continuation id="Tb_cJQXnHGT40a0vA6PuhcRtA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Narr_-VVRjH-Cbk-zZRw8jVkPLQ">No</ix:nonFraction> shares would be issuable based on the market price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_SvedTawQYEmZEsOm4Bj_yA">18.50</ix:nonFraction> per share as of December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_2AEt3n61DkyrAGOGYpLi-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RI_bSHeUk02U2x7JE8uEUg_4_3">40,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_yLu_E5y3dUSDiAXU3bPTfQ_4_6">17,104</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_Q1vdEIZjO02abZK4AP4ddg_5_3">2,122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_er3W3MMAy02J-0HZT7aH1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_mbpCcEH9z0mkPUS52olpeg_5_6">2,122</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_96UqI17DZ06cOK2CPIIPvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_Upt9BVSk1UyhAYb5MxBZBg_6_3">3,350</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ttlhuKLBjUSSxoBHpLChMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_-hHwKgfCOkmqD_JibYfMFw_6_6">3,350</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_DdItBfQV9Ea4vAs3_dK98g_7_3"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_DdItBfQV9Ea4vAs3_dK98g_7_3_2">46,303</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_1uL5RVcai0eUMJ7WMCQl4w_7_6"><ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_1uL5RVcai0eUMJ7WMCQl4w_7_6_2">22,576</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_WnJS4jf7H0OnoryLs8cqbw_10_3"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_WnJS4jf7H0OnoryLs8cqbw_10_3_2">11,471</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_yFseof-iPUKQ8NGD_Y5sSA_10_6"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_yFseof-iPUKQ8NGD_Y5sSA_10_6_2">11,413</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_u2vqAJFSNkijTcmtuRunlw_11_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_u2vqAJFSNkijTcmtuRunlw_11_3_2">4.04</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_mrOf8LIwSUKfEx_sZ1S2RA_11_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_mrOf8LIwSUKfEx_sZ1S2RA_11_6_2">1.98</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_nl8DLY_4l0KgTJrO6ZEoUg" continuedAt="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series X and Series Y Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_QuC48dJf8E23DlxZlazDSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SegTSigCdEu3sjU4MC6giQ">5,003</ix:nonFraction> shares of Series X Convertible Preferred Stock in 2017 and <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_q0p4FSRc_k6TcIpryO7R1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_c2eONn28Gkmm684QulhJtw">1,252.772</ix:nonFraction> shares of Series Y Convertible Preferred Stock in 2018. There were <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_cEbwO1-SA0ytFO3kPI9NlQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_NWmnnW5wKUiMYj7bTc8BQw">no</ix:nonFraction> shares of Series Y Convertible Preferred Stock outstanding as of December 31, 2021, after BVF converted all Series Y Convertible Preferred Stock into common stock on April 15, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_qkBguZsiw0WaOQD5kUxKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_80N4WbpBIEqnO1BQgJOvUQ"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_da-F0GyQwUWPIo1MwVDeDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_-GUWa7ORl0-Ozm02AU3HXg"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_qkBguZsiw0WaOQD5kUxKeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_O8qDj8pJakGjSNX7TxwKvg"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_da-F0GyQwUWPIo1MwVDeDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_gdGIfpnSakiBKtcbCwpXkA">5,003</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized and issued of Series X Convertible Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series&#160;X and Series Y Convertible Preferred Stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212; </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212; </i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion&#8212; </i>Each share of Series&#160;X and Series Y Convertible Preferred Stock is convertible into <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_YBo9bC2_zEW-HCuFI8kpXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_TiTDW4pfMUSfmKCuFHKIGQ"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_owbhffF5n065fOVm_kbUVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_sd3HZsHXj02oUTJwZz--qw">1,000</ix:nonFraction></ix:nonFraction> shares of registered common stock based on a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_HzgT7NkX4kK_7iaixTGPCg" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockConversionPricePerShare" scale="0" id="Narr_MYmznQSC-EiRQpUg4Vzq9g">4.03</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_-Bb_xc6BGUyWHxxOSoMlCQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockConversionPricePerShare" scale="0" id="Narr_kPSx6M-dlEWYG2REmBzVbw">13.00</ix:nonFraction> per share of common stock respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212; </i>Series&#160;X and Series Y Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95476618"></a><a id="_Hlk95468970"></a><ix:continuation id="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont1" continuedAt="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212; </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the shares of Series&#160;X and Series Y Convertible Preferred Stock are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#8217;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the Series&#160;X and Series Y Convertible Preferred Stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series A Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2020, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_G2fgy4TWqkGEN64FdHGrUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_O8e79_mnpEGEESlhlJeF3A">984,000</ix:nonFraction> shares of its <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_t_JFYlzupk-SbV1pM81V7Q">8.625</ix:nonFraction>% Series A cumulative, perpetual preferred stock at the price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_uIP82Xr_MkiEDC0OnzJYwQ">25.00</ix:nonFraction> per share, through a public offering for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_i198d1H3E0iBx1RcQ_Rtkg">24.6</ix:nonFraction> million. Total offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_AwtFYGK_ck-HJBu7Fy4YSw">2.0</ix:nonFraction> million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromIssuanceOrSaleOfEquityNet" scale="6" id="Narr__VpZ_DO8HkqjpntShHYNdA">22.6</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_K0_0KrxJPU6GuLsxsLLu2w"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_octg4ErdbkyGmfkNqDE85A"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_P6N_V9AwpEeVrlE4VkKp9g"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_rkdYbcXmsUSVkpOCyKru6w">984,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized and issued of Series A Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212;&#160;</i>Holders of <span style="background:#ffffff;">the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board and declared by the Corporation, cumulative cash dividends at the rate of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_nLuuGZrTh0KgaMe8as63EA">8.625</ix:nonFraction>%</span><span style="background:#ffffff;"> per annum of the </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_14Gx2K64S0qH93ZYpcicsg">25.00</ix:nonFraction></span><span style="background:#ffffff;"> liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the </span>Series<span style="background:#ffffff;"> A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full dividend period shall be prorated and computed on the basis of a&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodYearProrated" scale="0" id="Narr_pTjkL2Cutk2qUAq5diqJ3Q">360</ix:nonFraction></span><span style="background:#ffffff;">-day&#160;year consisting of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_M_kyg1xo-wAkyvlL2hegB1iw" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:PreferredStockDividendPeriodProratedMonthsInYear" scale="0" id="Narr_BOpPvTRNkEqzcCFbEhKVnQ">twelve</ix:nonFraction></span><span style="background:#ffffff;">&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodMonth" scale="0" id="Narr_TeCEhxA_e0StgZQFe5FaUw">30</ix:nonFraction></span><span style="background:#ffffff;">-day&#160;months.&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212;&#160;</i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of Series A Preferred Stock will <span style="background:#ffffff;">rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or&#160;winding-up and on parity with respect to the </span>distribution<span style="background:#ffffff;"> of assets with the Company&#8217;s Series X Preferred Stock. </span>The Series A Preferred Stock have a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_2ul7uaiY806jf0ZrOrSOrg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_FWpdnRNk40CamoRn4ciWaQ">0.05</ix:nonFraction></ix:nonFraction> per share and a liquidation preference of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_Qy3Ox5BnVUem4ZWOqBkNIA">25.00</ix:nonFraction> per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption&#8212;&#160;</i>The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_iWAtZr3dFESpISINrOcmfg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_SdpirEtK3ku7V6FmNxVtHg">26.00</ix:nonFraction> per share between December 15, 2021 and December 15, 2022, (ii) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Whkoa4BKGkO7vhoZPfvTBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_ohOyBqeYI0qF4Okt6WQqdQ">25.75</ix:nonFraction> per share between December 15, 2022 and December 15, 2023, (iii) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_G45ViXWaZkGa0Q9Yg2KbNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_hfqZGC659UOq8prafOhSdA">25.50</ix:nonFraction> per share between December 15, 2023 and December 15, 2024 (iv) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Nr-S-s7kcESAiUgmLUMTDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_8hYg-s5ogU-D4Yf-YtrZDg">25.25</ix:nonFraction> per share between December 15, 2024 and December 15, 2025 and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_quH6qxcvP0mDXAhJavVYWA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_UKkXkPwJpEyT6cR08G_KhQ">25.00</ix:nonFraction> per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, <span style="background:#ffffff;">upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockRedemptionPricePerShareOptionalRedemption" scale="0" id="Narr_D8E35zNBTkO2UDT5Erqcuw">25.00</ix:nonFraction></span><span style="background:#ffffff;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Conversion&#8212;&#160;</i>The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common stock per share equal to the lesser of (A) (i) the sum of the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_CrqppXkq_0WLPptQtUvfbA">25.00</ix:nonFraction> liquidation preference per share of Series A Preferred Stock to be converted plus (ii) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable, divided by (iii) &#160;the common stock price and (B) <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw" decimals="5" format="ixt:numdotdecimal" name="xoma:PreferredStockShareCap" scale="0" id="Narr_wn3UskZo_ESVkuvIqaZjyw">1.46071</ix:nonFraction> (the &#8220;Share Cap&#8221;). The common stock price to be </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont2" continuedAt="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company&#8217;s common stock on the <ix:nonFraction unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockConvertibleThresholdConsecutiveTradingDays" scale="0" id="Narr_xzbwNYUEMUCX4enZv4fDZw">10</ix:nonFraction> consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212;&#160;</i>Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212;</i>The Company evaluated the Series A Preferred Stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Depositary Shares Representing Interest in Series B Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 9, 2021, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Hwledlm92kCLamGoMe4Hbg">1,600,000</ix:nonFraction> Series B Depositary Shares, at the price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Htr9ghtfT0ONud315VwhhQ">25.00</ix:nonFraction> per Series B Depositary Share, through a public offering for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_OYmfduWm0kKCyjepJMBwxA">40.0</ix:nonFraction> million. Each Series B Depositary Share represents <span style="-sec-ix-hidden:Hidden_0WqPQZjVdk-rCh1KkH7IeA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/1000</span></span> interest in a share of Series B Preferred Stock. Total offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_Ga6vuzxfPEmyRk0exBiwig">2.9</ix:nonFraction> million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromIssuanceOfPreferredStockNet" scale="6" id="Narr_VkWuUFEpYUOi9_FnWD9ctg">37.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spouse of James Neal, then Chief Executive Officer and Chairman of the Board, purchased <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_t-cr-ApM602C1aypIMKmig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nCFZNAeNX0-kaAuf7a6MDg">8,000</ix:nonFraction> shares of the Series B Depositary Shares in the public offering at the public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gJUEPmVke0CACVsCCPaSeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_xgv82rJ_S0GywV6mSLhZPA">25.00</ix:nonFraction> per share for an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_t-cr-ApM602C1aypIMKmig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_ts5DpDqh7Ey0_xVhRPF2kQ">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_JwPvkWuXV06NIlU-SSv9oQ"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_apQuUM0GwUCOMmMTidwW0w">3,600</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_6KSwIWoYc0m30sKHZ-jlrw"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_cn59iIWNUk-xz3rlnlZt4Q">1,600</ix:nonFraction></ix:nonFraction> issued of Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_XNTZ4K88pU-HPJ1sQri6JA">8.375</ix:nonFraction>% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends</i>&#8212; Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_y8naGbReD0qzykD9sCkrRw">8.375</ix:nonFraction>% per annum of the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_nvXTtK38n0qgcP4FlaR2aw">25,000.00</ix:nonFraction> liquidation preference per share, which equals $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendAmountPerShare" scale="0" id="Narr_DdAYprlTh0e0GympId_lfg">2,093.75</ix:nonFraction> per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a <ix:nonFraction unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ" decimals="0" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodYearProrated" scale="0" id="Narr_pAzO0sujqUez3NGPYuZvRw">360</ix:nonFraction>-day year consisting of <ix:nonFraction unitRef="Unit_Standard_M_kyg1xo-wAkyvlL2hegB1iw" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:PreferredStockDividendPeriodProratedMonthsInYear" scale="0" id="Narr_s5etKjH5R0GWJ2NRTBsBsw">twelve</ix:nonFraction> <ix:nonFraction unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ" decimals="0" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodMonth" scale="0" id="Narr_rClM6DjYTUmt-i_BF5d8mw">30</ix:nonFraction>-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Preference</i> - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_BZdS2ic0VUuyVByW2pfJ9g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_t5N-PQbchESsxD--12SaLA">0.05</ix:nonFraction></ix:nonFraction> per share and a liquidation preference of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_yOqVx0B0A0SlouQ5Jd2Liw">25,000.00</ix:nonFraction> per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption</i> - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Eizh1l00wEuCnFSN_xaUow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_D84iyJRFEEubK5O7QyvIZw">26,000.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lRxrGJiyCEKBTolJ2-Gkiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_4-AwR4AzA0WiHQSo8CI7lw">26.00</ix:nonFraction> per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AbZx0laHAUueU-IhDRrrDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_ARTYx049-EGfJj0DRVaXBA">25,750.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_IvhJyfS6z0K0hCQsSwDDPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_RVO1M0Baj0KoTVucgqFvTg">25.75</ix:nonFraction> per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7QPtDO1XZ0iO8szQG-XtMg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr__CwfSg6lgEehZGTbV63qIA">25,500.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T1PJ_hKJ-UOq76YTlyMzXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_5h9oN2F_kkC0xQjcJiE4xg">25.50</ix:nonFraction> per depositary share), (iv) between April 15, 2025 to April 15, 2026, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_zym9UWjuxU-PBpIgDKhAWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_iovnRGm0xkuXIrhZqgTXtw">25,250.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_rdiiaR-KVUigBcn6d96uPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_LgvROXKTm0uvZ9erdl1zSg">25.25</ix:nonFraction> per depositary share), and (v) after April 15, 2026, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_z_A_YFI4skKZFdejnGMUfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_QDHZehbIiEu9kdyoJs17QQ">25,000.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_B23R2xU4FUqRYRyOEOTGqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_EGpEbV-3Qkimn_kpWfSGDA">25.00</ix:nonFraction> per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95224052"></a><a id="_021c2111_9592_41ad_b83a_57d4743d89c2"></a><a id="Tc_dPUFckwJo0i35N0Bv-Ngkw_1_2"></a><a id="Tc_gwXVVrifPE2TVlDKhw5vCw_1_5"></a><a id="Tc_TcYAdWKU_0-h2JF4QRKtnA_2_2"></a><a id="Tc_h0k4y0AiPk6HmTmOSl-Wkw_2_5"></a><a id="Tc_Ikjcvkm3ZU6XsBsKEgKs9w_3_0"></a><a id="Tc_LcM_vmeNJ0GJfzCgzTwcxA_3_2"></a><a id="Tc_olGHM2MpyEWymq-lTwDqeg_3_5"></a><a id="Tc__TCOhMV24Ue73bRwJUKNIw_3_8"></a><a id="Tc_4Vskw9PWbUGTLJh_ioYgug_4_0"></a><a id="Tc_tCN4XmNQJEWYjV1QLbNiAg_4_8"></a><a id="Tc_ulEFNl2gPE6Xeco8FMcBaA_5_0"></a><a id="Tc_exNkbe7EHk-f69KUPgaoWw_5_8"></a><a id="Tc__L_DgAktJU-2nM7vLca31A_6_0"></a><a id="Tc_tuVhMWBNQEy1dAiSpE34Ww_6_8"></a><a id="Tc_Mmh4QXg4A0ylvsdCLHrEmQ_7_0"></a><a id="Tc_IYABAmqrN0WNpzlfPgoxIw_7_8"></a><a id="Tc_2d0EiGLk0kWRJSWnds1uPw_8_0"></a><a id="Tc_KaYBk5LwhkSPhLYyQXjp_A_8_8"></a><ix:continuation id="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont3" continuedAt="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockRedemptionPricePerShareOptionalRedemption" scale="0" id="Narr_w4Fg-qX5okeydzI5YJBDZg">25,000.00</ix:nonFraction> per share plus accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion </i>- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_aj2BeMo3Mk-pNPs80PKu5A">25,000.00</ix:nonFraction> per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the &#8220;Conversion Rate&#8221;); and (B) <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockShareCap" scale="0" id="Narr_4-KWyJQMFUCr0ofZDTFgKg">1,253.13</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow" decimals="5" format="ixt:numdotdecimal" name="xoma:PreferredStockShareCap" scale="0" id="Narr_7enMRM85PkSlnItVe_HNiQ">1.25313</ix:nonFraction> per depositary share) (i.e., the &#8220;Share Cap&#8221;), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights</i>&#8212; Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification</i>&#8212;The Company evaluated the Series B Preferred Stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, the Company&#8217;s Board declared and paid cash dividends on the Company&#8217;s Series A Preferred Stock and Series B Depositary shares as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:DividendsDeclaredTableTextBlock" id="Tb_wkJlbVwldU6g7qDD72xMzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_H7Lo4FtfLUG9U_8NFt12cA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_PEaFlgcRP0SaaPOSqZfozQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_w1dPVVI1kE6K7PqD41U9kg_4_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_btS0jg_C4kSqwPe0vi-i5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gixUoEw130mjwVDdF_iufA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_otEkfBWz1Um4DRzyyOUKVQ_4_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">February 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dSMEchMnFkqWypW9UGk7Lw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cvrkp9vamEm0URrVmBMi4Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_jBTImAm8ZEOHHvmujPgrZA_5_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_3oD01eoLEkipHZzpjVu_VA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_9GG7R2owREOBYs3nJiZ6Lg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_-H-8sNvJ4EKIuJsHUbk2Ig_5_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 17, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OTKsEhaqhEaFde7pn0r-XA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_YlNIDoBrLEe-2gkq_aWe3w" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_dWlesQWMvUCgUfjiC-5Z9w_6_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7zNSlE5m30-23n_Xhxv1Cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yoj2ix91MkCiAGkREHt-GQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_Pu-HgcU2dUO2dZOVryjyPA_6_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 26, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s0Q6hKWcX0SArB1No9n7mA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2-MEI4pSCUuGeRcjC_EN9g" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_iWquTgIhnk2AJxd9p3rrvQ_7_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZPUZL4tmokqcSqnQL-SrmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lyRMP8iHEkWMJ8bT6bvwDw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_6zgDxZFGIUeeq0fGTwr5eQ_7_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 16, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 18, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YeDNFyDyWkiXwMYXPzULTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3AEODlP3-0mydkDGCWhqyQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_1Y8ESuc_4kq-r1SNID3qWg_8_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__Df-kChCN02M1zGD5YLDDA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_vTX9rZqalUujaAzAws_s7Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_0yHnbFjUgk-PtgqQkogPhA_8_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 15, 2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, BVF owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_cAsWd6bK3kKil-NBlwcz5w">31.6</ix:nonFraction>% of the Company&#8217;s total outstanding shares of common stock, and if all the shares of Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A" decimals="3" format="ixt:numdotdecimal" name="xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" scale="-2" id="Narr_4BhqLYzz2k2_2uuBOxyTlA">52.3</ix:nonFraction>% of the Company&#8217;s total outstanding shares of common stock. The Company&#8217;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2023, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_dAlGQw-3xkK1mBDxc6h3UQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_wh_5-_ZiI0ad7QzBKTVPyg">30.0</ix:nonFraction> million. HCW may sell the shares by any method permitted </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_8BqwTLX53EuGNro9mey05Q_1_6"></a><a id="Tc_dRSo66LJiUqLoOzwbcAIRg_1_9"></a><a id="Tc_gTWQTjRWYUmWZ7P587odsA_1_11"></a><a id="Tc_Y92ULatXM0qzKQADosrl9A_2_0"></a><a id="Tc_oFCHrKRiUUu_v9tQS2udjw_2_2"></a><a id="Tc_uDHl51iVp0GzLMADQGesGQ_2_4"></a><a id="Tc_P8SvUslJvESUmgHxYk-PuQ_2_6"></a><a id="Tc_Su-7OueQ-k6lFJd49y8TYw_2_9"></a><a id="Tc_CA_WCHKmxkquKgNqicISjQ_2_11"></a><a id="Tc_w6yVWZuSEEqRE4nge46DPg_3_0"></a><a id="Tc_F-2tg911WkOFCi8RJqeoFQ_3_2"></a><a id="Tc_FRp1Ovh-1UCacebTyXQDxQ_3_4"></a><a id="Tc_llTedwc3HU6oS1A9gH-Z8A_3_6"></a><a id="Tc_XPKLeV2fZkWCKc5vPAiDlg_4_0"></a><a id="Tc_gt9ztKNOyk6GSSC2ympNIw_4_2"></a><a id="Tc_iH80_RfEVU-_psEfs2VQfQ_4_4"></a><a id="Tc_VREZYBwfFk-9O5Gab9Rorw_4_6"></a><a id="Tc_DUJXdXjMB0mm0sDGOJ0-Gw_5_0"></a><a id="Tc_K8sJUyt36kWoRjjYDI0EwQ_5_2"></a><a id="Tc_eFfFwZNJ2kWIrBwaogzyGQ_5_4"></a><a id="Tc_Z1XBFbUxdECbK6qR4DGMDQ_5_6"></a><a id="Tc_vbSIhaDqD0K-hNMYLlNY9Q_5_11"></a><a id="Tc_JbiqjHb9Sk2-VYAufIgyzw_6_0"></a><a id="Tc_fWCBk13zFk-13p3Zr2jhTA_6_2"></a><a id="Tc_D-WhcdefCkqb3uX4LDfWoA_6_4"></a><a id="Tc_69rzho58D0C7TiPhc6g6fw_6_6"></a><a id="Tc_XFjhKtdQf0Ck5wMJIAR2ZA_6_11"></a><a id="Tc_OYxOa9foxkKylk2r96LOug_7_0"></a><a id="Tc_xCvEV0lZSkiFE1kjn5lmMQ_7_2"></a><a id="Tc_5kfjgDevT0SMwHHDYT0jjA_7_4"></a><a id="Tc_K_qcBP7zskmrw_VO1ywxRQ_7_6"></a><a id="Tc_m4mcmv7a-EaymIh79l2RYg_7_11"></a><ix:continuation id="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont4" continuedAt="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_d4I_Xv63ZU-hiLOrOkWuoA" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" scale="-2" id="Narr_jV6SyWYgyE2vG9q_oTyj4A">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_0uMMRf1S3kW4lhwL-tOXmQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_osXiAV2DqkSp3av-2nhJyQ">50.0</ix:nonFraction> million. <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_12_1_2018_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_nAi2n-UX2kK0kjYHslutOA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wyLnZHHzY0e2s8sv8ANttQ">No</ix:nonFraction> shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_2QhgXTVMF0OhuPGA7tPfmQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_AfXMiliDb0yTJ-ZMlLPMHQ">50.0</ix:nonFraction> million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_3t-rhj3dwU6-3CO8uFyHug" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares" scale="-2" id="Narr_gX9yWsxkMkm0iZHFPiV3og">3</ix:nonFraction>% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_8_5_2021_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_0w8sMVVLj02yx0033CwvXQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_EugN6kNHSEGu0hqKl2MbMA">No</ix:nonFraction> shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December&#160;31, 2023 and 2022, the following common stock warrants were outstanding:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_3VUf5yPdlE-R3-AjvvSxYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_93cl5tEq3024aEiiSbSlYQ_3_7">23.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_KphdVw2fLkqUMS8nCZq3GQ_3_9">6,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_S4-V_keLEEabfoR9Fvi4Yw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_G3aUKzkyyke0Uj_uGD9cbg_3_11">6,332</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_N5YIECe8E0C6IWg8obbENA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_UPNqdqcchkmAhiDAHJi1GA_4_7">14.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_N5YIECe8E0C6IWg8obbENA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_9hlmn6Y8Xk22KEwPoYKupA_4_9">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_Edowbx1RqE2mAginFGRXDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_PuByR5dZ2UqJdkALW1hnxg_4_11">4,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_j_6m9VgCa06Wf11c_SxhHQ_5_7">35.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_90kmB78FbUW-jBEKB__14g_5_9">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_7Xu5_UaJtES1XzYaHPTRyw_6_7">42.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_0XKgY-IhQEC9i_OggASb9g_6_9">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_aizhdWp9NUKCNA3b4uPHSQ_7_7">50.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_8IE9AYMquUuyksPpmKz53Q_7_9">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_bFOBNdDRpkWWVG1mzyWqQQ_8_9">131,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_INoYwPHRfU6_Owr2PivVLg_8_11">11,177</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, the Company issued SVB a warrant in connection with the legacy SVB Loan Agreement which is exercisable in whole or in part for up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_m7zoG4K-L0iS6aa3s6qXAA">6,332</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_9LeAUCRzdUmraa7998a6jQ">23.69</ix:nonFraction> per share. The warrant may be exercised on a cashless basis and is exercisable within <ix:nonNumeric contextRef="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_4l7SozYSsUOT0k7UTF6fPA" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_GQhp8uuuMkalgl8cmWNUiw">10 years</ix:nonNumeric> from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_IB0MCtCo7EmcVr3Hv92zwQ">0.1</ix:nonFraction> million. The warrant is classified in stockholders&#8217; equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the legacy SVB Loan Agreement was amended to extend the draw period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_lXubxgrd3U-MrmBu--f6bA">4,845</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_2Fr_AyENsUi6ziEo30C2Mg">14.71</ix:nonFraction> per share. The second warrant may be exercised on a cashless basis and is exercisable within <ix:nonNumeric contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_IsgrsUJM7Ey5ytOSIHjpJQ" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_2_K-s3TAJkm1yXb_IPeaEw">10 years</ix:nonNumeric> from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_oRKlGCEp7UOfgT8ojFcC6w">0.1</ix:nonFraction> million.<span style="letter-spacing:-0.1pt;">&#160;</span>The warrant is classified in stockholders&#8217; equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In December 2023, in connection with the Blue Owl Loan, the Company issued the Blue Owl Warrants to certain funds affiliated with Blue Owl, which are exercisable in whole or in part to purchase up to an aggregate of </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1jw5W-6JdUCvmkaVgSHOsQ">120,000</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares of the Company&#8217;s common stock, inclusive of warrants to purchase (i) up to </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ODcbzKnl-kGkOEtk4yftTw">40,000</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares of XOMA&#8217;s common stock at an exercise price of </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_e9UH6wlw1Ey4MulIDin18A">35.00</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> per share; (ii) up to </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_78W12jgpgU6LBFy2qHjIlA">40,000</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares of XOMA&#8217;s common stock at an exercise price of </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lkrJU__EsUKbfcyqAIVUAA">42.50</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> per share; and (iii) up to </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ktfueYRfm0GfofP3iDEFFw">40,000</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares of XOMA&#8217;s common stock at an exercise price of </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_f-qJ5_PIbk-TH3FbV6DVcQ">50.00</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> per share. The Blue Owl Warrants may be exercised on a cashless basis and are exercisable within </span><ix:nonNumeric contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_w_Edg6XtwkWHPpb5BqgAXA" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_YaurxtFaP0WbFPdlEWYvHA"><span style="letter-spacing:-0.1pt;">10 years</span></ix:nonNumeric><span style="letter-spacing:-0.1pt;"> from the date of issuance or upon the consummation of certain acquisitions of the Company. </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_y8qHEd_NM0iJTrVRZ99vtQ_1_2"></a><a id="Tc_VcCrObt7aUG7Z2oBxLEmmA_2_2"></a><a id="Tc_qSPbULZbZkaRXr8OXUeltw_2_4"></a><a id="Tc_OIo1HiUvv0-vVm1oSSTqVQ_3_0"></a><a id="Tc_pffre6C0L0qOmEjbz6QXMQ_3_3"></a><a id="Tc_y_tnH-_hYEC9DAexAPaVKw_3_4"></a><a id="Tc_c1eCJUgcBkOBB7h8poPv1A_3_5"></a><a id="Tc_2U9GrmG1Zku3Ny92XgXaJQ_4_0"></a><a id="Tc_DI22DctXlE-LlFMRKwPLKg_4_3"></a><a id="Tc_tqMSuRqUs0SgHo_KzKkinw_4_4"></a><a id="Tc_oyxoY_KxR0uTjVfrNExWpQ_4_5"></a><a id="Tc_Tr71i0l_DUK8A15mU_0GYA_5_0"></a><a id="Tc_Nw35iuzXYESWCokRvN-UFw_5_3"></a><a id="Tc_6ZaqUVQYhEmVI7umEui2vA_5_4"></a><a id="Tc_t7zLhEqAM0K_DV2Jgs7Wyg_5_5"></a><a id="Tc_OEl0i-rb4E-Wmzdm4Ti3Ug_6_0"></a><a id="Tc_SMRUQ2KaLUufzaqbqI7WCA_6_2"></a><a id="Tc_R4JWfFb4pEG-ALuepNt4_w_6_4"></a><ix:continuation id="Tb_nl8DLY_4l0KgTJrO6ZEoUg_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value per share of <span style="letter-spacing:-0.1pt;">Blue Owl</span> Warrants issued at the exercise prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_C1eB-EINlkeVEy960vO0Uw">35.00</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_J0shzflXJ0CJ0oskD0eG9A">42.50</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_W2QAF9uCV0SwIz_I3bxYMQ">50.00</ix:nonFraction> per share during the fourth quarter of 2023 was determined using the Black-Scholes Model <span style="letter-spacing:-0.1pt;">to be </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg" decimals="2" format="ixt:numdotdecimal" name="xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights" scale="0" id="Narr_mmF254Q67U-OuR56gqhmPw">12.53</ix:nonFraction></span><span style="letter-spacing:-0.1pt;">, </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ" decimals="2" format="ixt:numdotdecimal" name="xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights" scale="0" id="Narr_WiJvo0jqjUGpW0xXF9TYNA">12.23</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> and </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw" decimals="2" format="ixt:numdotdecimal" name="xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights" scale="0" id="Narr_v_9vACr_B0WlnUJ6I9HeBA">11.97</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> per share, respectively, </span>based on the following weighted average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_dd1EsJfkkUq64_xnkMMEjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_ics5zZQKZEC1GLHClhw50g" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-1" id="Tc_wqlqPwl4KUenxFoThbigNA_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M2cfbs9j8kSBfzVpqthphw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_QPPucGysvEmtfgN18EoUOA_4_2">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_gaTRiap1pEa9KzeA121uZA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_gyduQdols0WNGdxJbpQZgQ_5_2">3.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_f7Yhi2gHBEKf5DFUnXrd8A" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VUzwcKDVUk-lZVV-EniucQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_mT8LM4g1S0S5Ue_ed2SDKg">10</ix:nonFraction> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="letter-spacing:-0.1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate <span style="letter-spacing:-0.1pt;">fair value of the Blue Owl Warrants </span>of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_O8af_LeyLEqJAPKVSHKNmw">1.5</ix:nonFraction> million is classified in stockholders&#8217; equity on the consolidated balance sheets.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_-7Ur4HbVXEaFCLsjPnjkow" continuedAt="Tb_-7Ur4HbVXEaFCLsjPnjkow_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContractualObligationEstimatedMilestonePayments" scale="6" id="Narr_-kGVP1gmdE65IyFFlMy4DA">6.3</ix:nonFraction> million (assuming <ix:nonFraction unitRef="Unit_Standard_product_SNQEGGFW5kSKzKYrmjywPQ" contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" scale="0" id="Narr_5ZdGi0NWqE23eQP4nKp2uA">one</ix:nonFraction> product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s agreements with Bioasis, Aronora, Kuros, Affitech, ObsEva and Aptevo the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones and the Aptevo Contingent Consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company included $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_N0BzlyOR4kSuTcSqKfN20g" decimals="0" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_MwovrdhtRkG7fNC3JOtvcg">75,000</ix:nonFraction> for the Bioasis Contingent Consideration that represented the estimated fair value of the potential future payments of the Bioasis RPA as of December 31, 2022. The Bioasis Contingent Consideration was remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. During the second quarter of 2023, the estimated fair value of the Bioasis Contingent Consideration was reduced to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_odyIaKodm0SEW_jiL6wZ-g" decimals="0" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_aWe_NeZqBUubMuNr-HOflA">0</ix:nonFraction> and, as such, <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw" decimals="0" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_1iY6DTBrq0CE5XhmTqDCag">no</ix:nonFraction> balance remains as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_Oe9Yt3_DGU2mwnla8ZUy3Q">1.0</ix:nonFraction> million for the LadRx contingent consideration that represents the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>at the inception of the LadRx Agreements. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of December 31, 2023, there has been <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_bL3AMYfKvUmitIGVR0Nczw">no</ix:nonFraction> change in the estimated fair value from the initial value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the first quarter of 2023, the Company recorded a contingent liability of $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_stqAZ05QWkerRkwBioCcUQ" decimals="0" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_NB3tpmjh0kWRVF7R5f9ciQ">50,000</ix:nonFraction> under ASC 450 for the Aptevo Contingent Consideration at the inception of the Aptevo CPPA. During the year ended December 31, 2023, the contingent liability recorded pursuant to the Aptevo CPPA decreased to <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg" decimals="0" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_Xl47va2VxUO2gkQ9wsfgIg">zero</ix:nonFraction> after the Company paid Aptevo $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Dnn6lWiT3UCbGZqz1uHJdQ" decimals="0" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="0" id="Narr_0RgzJBRe5U-krpv-7h7slg">50,000</ix:nonFraction> upon achievement of the related commercial sales milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_JjgtMRaLtk6T_mPWnX2sxg">6.0</ix:nonFraction> million liability was recorded in contingent consideration under RPAs, AAAs and CPPAs and a corresponding $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_9fVLioULsEKeSDL_V2gakw">6.0</ix:nonFraction> million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-7Ur4HbVXEaFCLsjPnjkow_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones and LadRx milestones will be recorded when the amounts, by product, are estimable and probable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, none of the Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones or LadRx milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet<b style="font-weight:bold;">.</b></p></ix:continuation><a id="_bf1c89fc_6fc5_4ea2_b38e_db68e7f160f9"></a><a id="Tc_0krEZKAwOUeanEy4FAvpNQ_1_2"></a><a id="Tc_e4ZtG5mh20ehXupaFGeEhA_2_2"></a><a id="Tc_NhJVo6K_-UaBTth7D4Uk2w_2_5"></a><a id="Tc_-46N8O_YBUqPY-5oGCXsSw_3_0"></a><a id="Tc_1lfnwrY8AUmP48pfYPhCGw_3_2"></a><a id="Tc_00SXBujSwU-LFmrj_zHXnQ_3_5"></a><a id="Tc_r3Rzfbdla0aS-xr04b5hwA_4_0"></a><a id="Tc_kX36nGRjWU2Vm1j6O90t9g_5_0"></a><a id="Tc_pVgHBJqaIU2Q37jGHFMzoQ_5_2"></a><a id="Tc_MsCI3SduhUSLKyw3D98q1w_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="Tb_mYK_QMr3TUm4vX1xHmR2Hw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Concentration of Risk, Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, restricted cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Knb1VMkj50OkZMrcsYVZ7A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_2DLu0M1d2U2c1g2Q_adQ-w">three</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_n8y0wI3G0kq3oR95Yq0yng" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_ZEyQWkQCJE-jAy2bUx4J9A">44</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_X3OFdmWYO06HF_9VjwDAbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_NxHdQOt_PUOYw50RcvTN2g">32</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hxgRGUCPFUSaOcTTwES4QQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_Qq0DdzcgJkiF5nJC982KFg">21</ix:nonFraction>% of total revenues. For the year ended December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_x9Ly_6nZa0eN0KZmAKFNgg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_NN4MqQ-G20iVgwyezzRbxA">four</ix:nonFraction> partners represented&#160;<ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EqHsm_Ei50WL1NlCKjVHOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_-IKtQ8Mbd02C79J3NFHK_A">33</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_je2iAxI6uUyI9xWXJ3NNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_evP0XtWg5Uayvd8iRheGuQ">31</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ldCXzpF9akqsXBzaD9hxuw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_Fsg0s-c69USdholyugcdVA">13</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VF70Yp-79UiP9lmggMs1vA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_9HtLRGHUMUifrzUfy1sJoQ">12</ix:nonFraction>% of total revenues. <ix:nonFraction unitRef="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_iLQLrl8HzEq0ISsfhi5yuQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_B-LAinj9OUa8AsOZVXBmlg">One</ix:nonFraction> partner represented <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_iLQLrl8HzEq0ISsfhi5yuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_luUzKp_DY02OyEGzdoZ7nw">100</ix:nonFraction>% of the trade receivables, net balance as of December 31, 2023. There were <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_DbJiur56TEORw-pHEYCBuA">no</ix:nonFraction> trade receivables, net balance as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates in <ix:nonFraction unitRef="Unit_Standard_segment_m_JT2gZUYEyv5yGMX4336Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_dXM0mwR1Ckmiw0thepiSBw">one</ix:nonFraction> business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Geographic Information</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="Tb_RZLKBULlYUyWfu7lVhb92A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_3-ttz87lbUGOlay7J25Yhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wfM7kWiMukWB7Cp560WTjQ_3_3">3,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_VbPaWFBrc0Cn_MDgoar4GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5whW8qupAEeSKfbKTEevnA_3_6">4,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_srt_AsiaPacificMember_h1HPzeTFJEK9m12ZpTyuCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_KrFTYBTDWEWHl6EQU8IY_g_4_3">1,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_77WH8ueaj0uJk0NC9iLw_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_4JlDxhiIH0SNDi9gDaXc4Q_4_6">1,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_28iT3RgdJkyQZBT1dWW2ew_5_3">4,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3YgU11IFHkOHYuL9SOnIXw_5_6">6,027</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s property and equipment is held in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_JPyT1Fr6H0WbD-MgfaO5eQ" continuedAt="Tb_JPyT1Fr6H0WbD-MgfaO5eQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Repurchase Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 2, 2024, the Board authorized the Company&#8217;s first stock repurchase program, which permits the Company to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_1_2_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BoZJ1cjf3EanYPBMyrtXzg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="Narr_PiKQnPagNUGK8yIcvSLI1Q">50.0</ix:nonFraction> million of its common stock through January 2027. Under the program, the Company has discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, as part of accelerated share repurchases or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at the Company&#8217;s sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JPyT1Fr6H0WbD-MgfaO5eQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate the Company to acquire any particular amount of its common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. As of March 4, 2024, the Company has purchased a total of <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_3_4_2024_To_3_4_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tizzAxoxlky8Xls0hG3qmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_nVrppYYDXEyCqupg5t1prg">660</ix:nonFraction> shares of its common stock pursuant to the stock repurchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Appointment of Owen Hughes as Chief Executive Officer </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2024, the Board appointed Owen Hughes, previously Interim Chief Executive Officer, to serve as the Company&#8217;s full-time Chief Executive Officer. In connection with this appointment, the Company and Mr. Hughes entered into an amendment and restatement of Mr. Hughes&#8217; employment agreement (the &#8220;Amended and Restated Employment Agreement&#8221;), pursuant to which his annual base salary was increased to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_7_2024_To_1_7_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqWQZEkxck6aUZbAhDxrIQ" decimals="0" format="ixt:numdotdecimal" name="xoma:EmploymentAgreementAnnualSalary" scale="0" id="Narr_KqXE2TpfNUqLR2j0IoU5Yw">575,000</ix:nonFraction> and his initial target annual cash bonus amount was increased to <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_7_2024_To_1_7_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqWQZEkxck6aUZbAhDxrIQ" decimals="2" format="ixt:numdotdecimal" name="xoma:EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" scale="-2" id="Narr_RWQJPLRG-Ea91Pe1nrlBJA">60</ix:nonFraction>% of his base salary, subject to the achievement of annual performance milestones to be established by the Board. Mr. Hughes is also eligible to receive certain termination benefits. On January 9, 2024, the Company granted Mr. Hughes a target award of <ix:nonFraction unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg" contextRef="Duration_1_9_2024_To_1_9_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VAnZAL0inEKRzb4syNlviQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_D1Q1AIF1wE-_SmxWWcnisg">275,000</ix:nonFraction> performance share units that will vest upon the Company&#8217;s achievement of specified stock price performance conditions established by the Board and which are granted pursuant to, and are subject to the terms and conditions of, the Company&#8217;s 2010 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisition of Economic Interest in DSUVIA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company acquired an economic interest in DSUVIA (sufentanil sublingual tablet) from Talphera, for $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_GWb50yHWG0Gjencq1GEsyg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_B9j2KD0dj0OOKwBz3tzmfQ">8.0</ix:nonFraction> million. DSUVIA was approved in 2018 by the FDA for use in adults with indication in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2cm7F_6WkkiGYRgSmohdVg" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_ZaFxo1c9MUORNoRd9WbShA">15</ix:nonFraction>% royalty on commercial net sales, a <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yFyujZtG9UWuos2_NLxJPA" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_IkzNImcGOUqRwGx6MMqSEQ">75</ix:nonFraction>% royalty on net sales to the DoD, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bEwMjcvCoE6dg4CchXXb4w" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" scale="6" id="Narr_l94ncFUIA0mqyAuKTd-geQ">116.5</ix:nonFraction> million in milestone payments. Under the terms of the agreement, the Company will receive <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_GWb50yHWG0Gjencq1GEsyg" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" scale="-2" id="Narr_KlBDicbbB0-cVqrEQst6lg">100</ix:nonFraction>% of all royalties and milestones related to DSUVIA sales until the Company receives $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_2qKuJw7LF0SNxUkiCX8mrg" decimals="-5" format="ixt:numdotdecimal" name="xoma:RoyaltyAndMilestonesReceivableThreshold" scale="6" id="Narr_e3wCaPDeBkeT8EPXJhgbHw">20.0</ix:nonFraction> million. Thereafter, the Company fully retains the <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_DqEQ-FxkkkC-biVtuHiWlA" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_RLouedPzhkOCW9YcXpb3HQ">15</ix:nonFraction>% royalty associated with DSUVIA commercial sales. The <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_d7MCNo9BZ0e94zx26toTQw" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" scale="-2" id="Narr_pbHrtBmUN0KH3e6kVnT_hA">75</ix:nonFraction>% royalties generated from DoD purchases and the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_q9ObqQzmnkSHnjz07UVHxg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" scale="6" id="Narr_igAjuvN39UyvRyL4Do9QJA">116.5</ix:nonFraction> million in potential milestone payments due from Alora will be shared equally between the Company and Talphera.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA Acceptance of Arimoclomol NDA Resubmission</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx RPA, the Company made a $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="Duration_1_11_2024_To_1_11_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_kHKXEon0m0elwS6IFTsLdQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_2LuVThs4d0Gz_yMDmoeXbg">1.0</ix:nonFraction> million milestone payment to LadRx in January 2024. As of December 31, 2023, the $<ix:nonFraction unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_cJ_3I5gqVUm-_Sd9MucR6w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_m7jXKhZ63EWKny_yE0kvfg">1.0</ix:nonFraction> million milestone payment was accrued in contingent consideration under RPAs, AAAs, and CPPAs in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Kinnate Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 16, 2024, the Company entered into an Agreement and Plan of Merger with Kinnate and XRA 1 Corp., a Delaware corporation and a wholly-owned subsidiary of the Company, pursuant to which the Company expects to acquire Kinnate through a cash tender offer (the &#8220;Offer&#8221;) for a cash amount of between $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3MSAG2w_VE-njv8TBWI0TA" decimals="4" format="ixt:numdotdecimal" name="xoma:PaymentToAcquireBusinessPricePerShareCashAmount" scale="0" id="Narr___OVbEnphEGHMo90L3LnGA">2.3352</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KiCr-hkOokmigDvDkoN0tw" decimals="4" format="ixt:numdotdecimal" name="xoma:PaymentToAcquireBusinessPricePerShareCashAmount" scale="0" id="Narr_ZcUWa-2wZEShydLcXabyKA">2.5879</ix:nonFraction> per outstanding share of Kinnate common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew" decimals="4" format="ixt:numdotdecimal" name="xoma:CommonStockParOrStatedValuePerShareAcquiree" scale="0" id="Narr_H19vxdz3UUqKyycoWgjNzw">0.0001</ix:nonFraction> per share (each, a &#8220;Kinnate Share&#8221;), consisting of a base price per Kinnate Share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA" decimals="4" format="ixt:numdotdecimal" name="xoma:PaymentToAcquireBusinessPricePerShareBaseCashAmount" scale="0" id="Narr_suUsttEPlUCVINSolM6BGQ">2.3352</ix:nonFraction> and an additional price per Kinnate Share of up to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA" contextRef="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA" decimals="4" format="ixt:numdotdecimal" name="xoma:PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" scale="0" id="Narr_DdQX5-JKtkirTC5Dz5jADg">0.2527</ix:nonFraction>, &#160;plus <ix:nonFraction unitRef="Unit_Standard_Right_7KYt940OV0yye1Z67B4qbA" contextRef="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AcquisitionNumberOfContingentValueRights" scale="0" id="Narr_hRw88kTWLUmP01c5CGYW5w">one</ix:nonFraction> non-transferable contingent value right per Kinnate Share, representing the right to receive <ix:nonFraction unitRef="Unit_Standard_payment_MZwTcjQqtk6l27rvf283Rw" contextRef="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3MSAG2w_VE-njv8TBWI0TA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AcquisitionValueRightNumberOfCashPayments" scale="0" id="Narr_Ef4a9FmFo0GqHbyiIWKbTA">one</ix:nonFraction> or more potential cash payments equal to (i) <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew" decimals="INF" format="ixt:numdotdecimal" name="xoma:ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" scale="-2" id="Narr_PSk3PfGCLUeP_hbTnWI4dQ">100</ix:nonFraction>% of net proceeds payable, if any, from any license, sale or disposition (each, a &#8220;Disposition&#8221;) entered into by Kinnate prior to the expiration of the Offer related to exarafenib, an inhibitor for the treatment of patients with lung cancer, melanoma and other solid tumors, and/or any other pan-RAF inhibitor, and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw" contextRef="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew" decimals="INF" format="ixt:numdotdecimal" name="xoma:ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" scale="-2" id="Narr_zeBlk1km60aSeHGC-18xhg">85</ix:nonFraction>% of net proceeds payable, if any, from any Disposition entered into by the Company or any of its affiliates after expiration of the Offer related to exarafenib or any other research program active at Kinnate at the closing of the related merger. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>xoma-20231231xex4d9.htm
<DESCRIPTION>EX-4.9
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:29 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:right;margin:30pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 4.9</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following is a description of the Common Stock, $0.0075 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Preferred Stock, $0.05 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and depositary shares of XOMA Corporation (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">we</font><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">us</font><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">our</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; or the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Company</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock, $0.05 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series A Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and the depositary shares (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series B Depositary Shares</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) each representing a 1/1000th interest in a share of the Company&#8217;s 8.375% Series B Cumulative Perpetual Preferred Stock, $0.05 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series B Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General. </font><font style="font-family:'Times New Roman','Times','serif';">The Company is authorized to issue up to 277,333,332 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable. The following description is based on (i) the Company&#8217;s Certificate of Incorporation, as amended (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Certificate of Incorporation</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), (ii) the Company&#8217;s By-laws, as currently in effect (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">By-laws</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and (iii) the Delaware General Corporation Law (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">DGCL</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The following summary description of the Common Stock of the Company is qualified in its entirety by reference to the provisions of the Certificate of Incorporation and By-laws, copies of which have been filed as exhibits to the Company&#8217;s Annual Report on Form 10-K filed herewith, and the applicable provisions of the DGCL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividend Rights. </font><font style="font-family:'Times New Roman','Times','serif';">The holders of our Common Stock have the right to receive dividends and distributions, whether payable in cash or otherwise, as may be declared from time to time by our Board of Directors (our &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Board</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), from legally available funds. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights. </font><font style="font-family:'Times New Roman','Times','serif';">Each holder of our Common Stock is generally entitled to one vote for each share of Common Stock owned of record on all matters submitted to a vote of our stockholders. Except as otherwise required by law, holders of Common Stock (as well as holders of any Preferred Stock entitled to vote with the common stockholders) will generally vote together as a single class on all matters presented to the stockholders for their vote or approval, including the election of directors. Any matter brought before the stockholders for a vote, other than the election of directors, will generally be decided by a majority of the votes cast on the matter, unless the matter is one in which an express provision of the DGCL, the Certificate of Incorporation, the By-laws, the rules or regulations of any stock exchange applicable to us, applicable law or any regulation applicable to us or our securities requires a different vote, in which case the express provision will govern and control the decision of the matter. Directors will be elected by a plurality of the votes cast and entitled to vote on the election of directors. There are no cumulative voting rights with respect to the election of directors or any other matters.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">No Preemptive or Similar Rights. </font><font style="font-family:'Times New Roman','Times','serif';">Holders of our Common Stock have no redemption rights, conversion rights or preemptive rights to purchase or subscribe for our securities.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Right to Receive Liquidation Distributions. </font><font style="font-family:'Times New Roman','Times','serif';">In the event of our liquidation, dissolution or winding-up, holders of our Common Stock will be entitled to share ratably in the assets remaining and available for distribution after payment of all liabilities and the liquidation preferences of our Preferred Stock (if any).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The rights of the holders of our Common Stock are subject to, and may be adversely affected by, the rights of holders of shares of any Preferred Stock that we may designate and issue in the future.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Under our Certificate of Incorporation, our Board is authorized to issue up to 1,000,000 shares of Preferred Stock, and, by resolution, to divide the Preferred Stock into series and, with respect to each series, to determine the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights, redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. Our Board can, without stockholder approval but subject to the terms of the Certificate of Incorporation and to any resolution of the stockholders approved by at least 75% of all issued shares entitled to vote in respect thereof, issue Preferred Stock with voting and other rights that could adversely affect the voting power of the holders of our Common Stock and which could have certain anti-takeover effects. Before we may issue any series of Preferred Stock, our Board will be required to adopt resolutions creating and designating such series of Preferred Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following summary description of the Preferred Stock of the Company, including the Series B Depositary Shares, is qualified in its entirety by reference to the provisions of the Certificate of Incorporation, By-laws and the certificates of designation of preferences, rights and limitations of each series of the Preferred Stock, copies of which have been filed as exhibits to the Company&#8217;s Annual Report on Form 10-K, and the applicable provisions of the DGCL. As of December 31, 2023, 5,003 shares of Series X Convertible Preferred Stock, $0.05 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series X Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), 984,000 shares of Series A Preferred Stock and 1,600,000 Series B Depositary Shares, representing 1,600 shares of Series B Preferred Stock, were issued and outstanding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><a name="_Hlk65341734"></a><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">The 8.625% Series A Cumulative Perpetual Preferred Stock.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">We have designated 984,000 shares of our Preferred Stock as Series A Preferred Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Series A Preferred Stock will rank, as to dividend rights and rights upon our liquidation, dissolution or winding up:</font></p><div style="margin-top:12pt;"></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">senior to all classes or series of our Common Stock and to all other equity securities issued by us expressly designated as ranking junior to the Series A Preferred Stock;</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">senior with respect to the payment of dividends and on parity with respect to the distribution of assets upon our liquidation, dissolution or winding up with our Series X Preferred Stock and on parity with any future class or series of our equity securities expressly designated as ranking on parity with the Series A Preferred Stock;</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">junior to all equity securities issued by us with terms specifically providing that those equity securities rank senior to the Series A Preferred Stock with respect to the payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, none of which exists on the date hereof; and;</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">effectively junior to all our existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) and to the indebtedness and other liabilities of (as well as any preferred equity interests held by others in) our existing or future subsidiaries.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> We will pay cumulative cash dividends on the Series A Preferred Stock, when and as declared by our Board, at the rate of 8.625% of the $25.00 liquidation preference per share per year (equivalent to $2.15625 per year). Dividends will be payable quarterly in arrears, on or about the 15th day of January, April, July and October; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable on that dividend payment date may be paid on the immediately preceding or next succeeding business day, and no interest, additional dividends or other sums will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance. The first dividend, which was paid on April 15, 2021 in the amount of $0.71875 per share of Series A Preferred Stock, was for more than a full quarter and covered the period from, and including, the first date we issued and sold the Series A Preferred Stock through, but not including, April 15, 2021. Dividends on the Series A Preferred Stock will continue to accumulate whether or not we have earnings, whether or not there are funds legally available for the payment of such dividends, and whether or not such dividends are authorized or declared.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> The liquidation preference of each share of Series A Preferred Stock is $25.00. Upon liquidation, holders of our Series A Preferred Stock will be entitled to receive the liquidation preference with respect to their shares of Series A Preferred Stock plus an amount equal to any accumulated but unpaid dividends with respect to such shares up to but excluding the date of payment. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Optional Redemption</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> On and after December 15, 2021, but prior to December 15, 2022, the shares of Series A Preferred Stock were redeemable at our option, in whole or in part, at a redemption price equal to $26.00 per share, plus any accrued and unpaid dividends. On and after December 15, 2022 but prior to December 15, 2023, the shares of Series A Preferred Stock were redeemable at our option, in whole or in part, at a redemption price equal to $25.75 per share, plus any accrued and unpaid dividends. On and after December 15, 2023 but prior to December 15, 2024, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.50 per share, plus any accrued and unpaid dividends. On and after December 15, 2024 but prior to December 15, 2025, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.25 per share, plus any accrued and unpaid dividends. On and after December 15, 2025, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.00 per share, plus any accrued and unpaid dividends.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Special Optional Redemption Upon a Change of Control or Delisting Event</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event (as defined below), we may, at our option, redeem the Series A Preferred Stock, in whole or in part, within 90 days after the first date on which such Delisting Event occurred, for cash, at a redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series A Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of Series A Preferred Stock, both (i) the shares of Series A Preferred Stock are no longer listed on Nasdaq Stock Market (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Nasdaq</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), the New York Stock Exchange (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">NYSE</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) or the NYSE American LLC (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">NYSE AMER</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER, and (ii) we are not subject to the reporting requirements of the Exchange Act, but any Series A Preferred Stock is still outstanding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Upon the occurrence of a Change of Control (as defined below), we may, at our option, redeem the Series A Preferred Stock, in whole or in part within 120 days after the first date on which such Change of Control occurred, for cash, at a redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series A Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of the Series A Preferred Stock, the following have occurred and are continuing:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition by any person, including any syndicate or group deemed to be a &#8220;person&#8221; under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of shares of our stock entitling that person to exercise more than 50% of the total voting power of all shares of our stock entitled to vote generally in elections of directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">following the closing of any transaction referred to in the bullet point above, neither we nor any acquiring or surviving entity (or if, in connection with such transaction shares of our Common Stock are converted into or exchanged for (in whole or in part) common equity securities of another entity), has a class of common securities (or American depositary receipts (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">ADRs</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) representing such securities) listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We refer to redemption following a Delisting Event or Change of Control as a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">special optional redemption</font><font style="font-family:'Times New Roman','Times','serif';">.&#8221; If, prior to the Delisting Event Conversion Date (as defined below) or the Change of Control Conversion Date (as defined below), as applicable, we have provided or provide notice of exercise of any of our redemption rights relating to the Series A Preferred Stock (whether our optional redemption right or our special optional redemption right), the holders of the Series A Preferred Stock will not have the conversion right described below.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event or a Change of Control, as applicable, each holder of Series A Preferred Stock will have the right (unless, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide notice of our election to redeem the Series A Preferred Stock) to convert some or all of the Series A Preferred Stock held by such holder on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, into a number of shares of our Common Stock (or equivalent value of alternative consideration) per share of Series A Preferred Stock equal to the lesser of:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quotient obtained by dividing (1) the sum of the $25.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable is after a record date for a Series A Preferred Stock dividend payment and prior to the corresponding Series A Preferred Stock dividend payment date, in which case no additional amount for such accumulated and unpaid dividend will be included in this sum) by (2) the Common Stock Price (as defined below); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.46071 (i.e., the Share Cap), subject to certain adjustments; and subject, in each case, to certain conditions, including, under specified circumstances, an aggregate cap on the total number of shares of our Common Stock issuable upon conversion and to provisions for the receipt of alternative consideration.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series A Preferred Stock will not have any right to convert the Series A Preferred Stock, and any Series A Preferred Stock subsequently selected for redemption that has been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable. </font><br><font style="font-family:'Times New Roman','Times','serif';">In the event that the conversion would result in the issuance of fractional shares of Common Stock, we will pay the holder of Series A Preferred Stock cash in lieu of such fractional shares. </font><br><font style="font-family:'Times New Roman','Times','serif';">Except as provided above in connection with a Delisting Event or Change of Control, shares of the Series A Preferred Stock are not convertible into or exchangeable for any other securities or property.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series A Preferred Stock, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our Board that is not fewer than 20 days nor more than 35 days after the date on which we provide notice to the holders of the Series A Preferred Stock of a Change of Control.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series A Preferred Stock, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Change of Control will be: (1) if the consideration to be received in the Change of Control by the holders of our Common Stock is solely cash, the amount of cash consideration per share of Common Stock; and (2) if the consideration to be received in the Change of Control by holders of our Common Stock is other than solely cash (x) the average of the closing prices for our Common Stock (or, if no closing sale price is reported, the average of the closing bid and ask prices per share or, if more than one in either case, the average of the average closing bid and the average closing ask prices per share) for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred as reported on the principal U.S. securities exchange on which our Common Stock is then traded, or (y) the average of the last quoted bid prices for our Common Stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred, if our Common Stock is not then listed for trading on a U.S. securities exchange. The &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Delisting Event will be the average of the closing price per share of our Common Stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series A Preferred Stock, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our Board that is not fewer than 20 days nor more than 35 days after the date on which we provide notice to the holders of the Series A Preferred Stock of a Delisting Event.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights.</font><font style="font-family:'Times New Roman','Times','serif';"> Holders of Series A Preferred Stock generally will have no voting rights. However, if we do not pay dividends on any outstanding shares of Series A Preferred Stock for six or more quarterly dividend periods (whether or not declared or consecutive), holders of Series A Preferred Stock (voting separately as a class with all other outstanding series of preferred stock upon which like voting rights have been conferred and are exercisable) will be entitled to elect two additional directors to our Board to serve until all unpaid dividends have been fully paid or declared and set apart for payment. In addition, certain material and adverse changes to the terms of the Series A Preferred Stock cannot be made without the affirmative vote of holders of at least 66 2/3% of the outstanding shares of Series A Preferred Stock, voting as a separate class. In any matter in which the Series A Preferred Stock may vote, each share of Series A Preferred Stock shall be entitled to one vote per $25.00 of liquidation preference.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">The 8.375% Series B Cumulative Perpetual Preferred Stock and the Series B Depositary Shares.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">We have designated 3,600 shares of our Preferred Stock as Series B Preferred Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Series B Preferred Stock underlying the Series B Depositary Shares will rank, as to dividend rights and rights upon our liquidation, dissolution or winding up:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">senior to all classes or series of our Common Stock and to all other equity securities issued by us expressly designated as ranking junior to the Series B Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">senior with respect to the payment of dividends and on parity with respect to the distribution of assets upon our liquidation, dissolution or winding up with our Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on parity with our Series A Preferred Stock, and with any future class or series of our equity securities expressly designated as ranking on parity with the Series B Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">junior to all equity securities issued by us with terms specifically providing that those equity securities rank senior to the Series B Preferred Stock with respect to the payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, none of which exists on the date hereof; and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively junior to all our existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) and to the indebtedness and other liabilities of (as well as any preferred equity interests held by others in) our existing or future subsidiaries.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> We will pay cumulative cash dividends on the Series B Preferred Stock, when and as declared by our Board, at the rate of 8.375% per annum of the $25,000.00 liquidation preference ($25.00 per Series B Depository Share) per year (equivalent to $2,093.75 per share of Series B Preferred Stock per year or $2.09375 per Series B Depository Share per year). Dividends will be payable quarterly in arrears, on or about the 15th day of January, April, July and October; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable on that dividend payment date may be paid on the immediately preceding business day or the next succeeding business day, and no interest, additional dividends or other sums will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance. Dividends on the Series B Preferred Stock underlying the Series B Depositary Shares will continue to accumulate whether or not we have earnings, whether or not there are funds legally available for the payment of such dividends, and whether or not such dividends are authorized or declared.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> The liquidation preference of each share of Series B Preferred Stock is $25,000.00 ($25.00 per Series B Depository Share). Upon liquidation, holders of our Series B Preferred Stock will be entitled to receive the liquidation preference with respect to their shares of Series B Preferred Stock plus an amount equal to any accumulated but unpaid dividends with respect to such shares up to but excluding the date of payment. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Optional Redemption</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> On and after April&#160;15, 2022 but prior to April 15, 2023, the shares of Series B Preferred Stock were redeemable at our option, in whole or in part, at a redemption price equal to $26,000.00 per share ($26.00 per Series B Depository Share), plus any accrued and unpaid dividends. On and after April&#160;15, 2023 but prior to April 15, 2024, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,750.00 per share ($25.75 per Series B Depository Share), plus any accrued and unpaid dividends. On and after April&#160;15, 2024 but prior to April 15, 2025, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,500.00 per share ($25.50 per Series B Depository Share), plus any accrued and unpaid dividends. On and after April&#160;15, 2025 but prior to April 15, 2026, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,250.00 per share ($25.25 per Series B Depository Share), plus any accrued and unpaid dividends. On and after April&#160;15, 2026 but prior to April 15, 2027, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,000.00 per share ($25.00 per Series B Depository Share), plus any accrued and unpaid dividends. On or after the date fixed for redemption of shares of Series B Preferred Stock, each holder of Series B Depositary Shares to be redeemed must present and surrender the depositary receipts evidencing the Series B Depositary Shares to the depositary at the place designated in the notice of redemption. The redemption price of such Series B Depositary Shares will then be paid to or on the order of the person whose name appears on such depositary receipts as the owner thereof.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Special Optional Redemption Upon a Change of Control or Delisting Event</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event (as defined below), we may, at our option, redeem the Series B Preferred Stock, in whole or in part, within 90 days after the first date on which such Delisting Event occurred, for cash, at a redemption price of $25,000.00 per share (equivalent to $25.00 per Series B Depository Share), plus any accrued and unpaid dividends up to, but not including, the date of redemption, and the depositary will redeem a proportional number of Series B Depositary Shares representing the shares redeemed.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series B Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of Series B Preferred Stock, both (i)&#160;the shares of Series B Preferred Stock (or the Series B Depositary Shares) are no longer listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER, and (ii)&#160;we are not subject to the reporting requirements of the Exchange Act, but any Series B Preferred Stock is still outstanding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Upon the occurrence of a Change of Control (as defined below), we may, at our option, redeem the Series B Preferred Stock underlying the Series B Depositary Shares, in whole or in part within 120 days after the first date on which such Change of Control occurred, for cash, at a redemption price of $25,000.00 per share (equivalent to $25.00 per Series B Depository Share), plus any accrued and unpaid dividends up to, but not including, the date of redemption, and the depositary will redeem a proportional number of Series B Depositary Shares representing the shares redeemed.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series B Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of the Series B Preferred Stock, the following have occurred and are continuing:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition by any person, including any syndicate or group deemed to be a &#8220;person&#8221; under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of shares of our stock entitling that person to exercise more than 50% of the total voting power of all shares of our stock entitled to vote generally in elections of directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">following the closing of any transaction referred to in the bullet point above, neither we nor any acquiring or surviving entity (or if, in connection with such transaction shares of our Common Stock are converted into or exchanged for (in whole or in part) common equity securities of another entity), has a class of common securities (or ADRs representing such securities) listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We refer to redemption following a Delisting Event or Change of Control as a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">special optional redemption</font><font style="font-family:'Times New Roman','Times','serif';">.&#8221; If, prior to the Delisting Event Conversion Date or the Change of Control Conversion Date (each as defined below), as applicable, we have provided or provide notice of exercise of any of our redemption rights relating to the Series B Preferred Stock (whether our optional redemption right or our special optional redemption right), the holders of Series B Depositary Shares representing interests in the Series B Preferred Stock will not have the conversion right described below.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event or a Change of Control, as applicable, each holder of Series B Depositary Shares representing interests in the Series B Preferred Stock will have the right (unless, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide notice of our election to redeem the Series B Preferred Stock) to direct the depositary, on such holder&#8217;s behalf, to convert some or all of the Series B Preferred Stock underlying the Series B Depositary Shares held by such holder on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable into a number of shares of our Common Stock (or equivalent value of alternative consideration) per Series B Depositary Share equal to the lesser of:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quotient obtained by dividing (1) the sum of the $25.00 per depositary share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and unpaid dividend will be included in this sum) by (2) the Common Stock Price (as defined herein); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.25313 (i.e., the Share Cap), subject to certain adjustments; and subject, in each case, to certain conditions, including, under specified circumstances, an aggregate cap on the total number of shares of our Common Stock issuable upon conversion and to provisions for the receipt of alternative consideration.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series B Depositary Shares representing interests in the Series B Preferred Stock will not have any right to direct the depositary to convert the Series B Preferred Stock, and any Series B Preferred Stock subsequently selected for redemption that has been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Because each Series B Depository Share represents a 1/1000th interest in a share of the Series B Preferred Stock, the number of shares of Common Stock ultimately received for each Series B Depositary Share will be equal to the number of shares of Common Stock received upon conversion of each share of Series B Preferred Stock divided by 1,000. In the event that the conversion would result in the issuance of fractional shares of Common Stock, we will pay the holder of Series B Depositary Shares cash in lieu of such fractional shares.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as provided above in connection with a Delisting Event or Change of Control, shares of the Series B Preferred Stock are not convertible into or exchangeable for any other securities or property.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the underlying Series B Preferred Stock and the Series B Depositary Shares, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our Board that is not fewer than 20 days nor more than 35 days after the date on which we provide the notice described above to the holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the underlying Series B Preferred Stock and the Series B Depositary Shares, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Change of Control will be: (1) if the consideration to be received in the Change of Control by the holders of our Common Stock is solely cash, the amount of cash consideration per share of Common Stock; and (2)&#160;if the consideration to be received in the Change of Control by holders of our Common Stock is other </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">than solely cash (x)&#160;the average of the closing prices for our Common Stock (or, if no closing sale price is reported, the average of the closing bid and ask prices per share or, if more than one in either case, the average of the average closing bid and the average closing ask prices per share) for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred as reported on the principal U.S. securities exchange on which our Common Stock is then traded, or (y)&#160;the average of the last quoted bid prices for our Common Stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred, if our Common Stock is not then listed for trading on a U.S. securities exchange. The &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Delisting Event will be the average of the closing price per share of our Common Stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our Board that is not fewer than 20 days nor more than 35 days after the date on which we provide the notice described above to the holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights.</font><font style="font-family:'Times New Roman','Times','serif';"> Holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock generally will have no voting rights. However, if we do not pay dividends on any outstanding shares of Series B Preferred Stock for six or more quarterly dividend periods (whether or not declared or consecutive), holders of Series B Preferred Stock (voting separately as a class with all other outstanding series of preferred stock upon which like voting rights have been conferred and are exercisable) will be entitled to elect two additional directors to our Board to serve until all unpaid dividends have been fully paid or declared and set apart for payment. In addition, certain material and adverse changes to the terms of the Series B Preferred Stock cannot be made without the affirmative vote of holders of at least 66 2/3% of the outstanding shares of Series B Preferred Stock, voting as a separate class. In any matter in which the Series B Preferred Stock may vote, each share of Series B Preferred Stock shall be entitled to one vote per $25,000.00 of liquidation preference. As a result, each Series B Depository Share will be entitled to 1/1000th of a vote.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">The Series X Preferred Stock.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">We have designated 5,003 shares of our Preferred Stock as Series X Preferred Stock. The Series X Preferred Stock ranks: </font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">senior to any class or series of our capital stock created specifically ranking by its terms junior to the Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on parity to our Common Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on parity to any class or series of our capital stock created specifically ranking by its terms on parity with the Series X Preferred Stock; and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">junior to any class or series of our capital stock created specifically ranking by its terms senior to the Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Holders of Series X Preferred Stock are entitled to receive dividends on shares of Series X Preferred Stock equal (on an as-converted basis) to and in the same form as dividends actually paid on our Common Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> In the event of our liquidation, dissolution, or winding up, holders of our Series X Preferred Stock will rank: (i) senior to any class or series of our capital stock specifically ranked by its terms junior to any Series X Preferred Stock; (ii) on parity with the Common Stock and any other class or series of capital stock specifically ranked by its terms on parity with the Series X Preferred Stock; and (iii) junior to any class or series of capital stock specifically ranked by its terms senior to any Series X Preferred Stock.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Redemption</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> We are not obligated to redeem or repurchase any shares of Series X Preferred Stock. Shares of Series X Preferred Stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> The Series X Preferred Stock is convertible at the option of the holders thereof at any time after issuance into the number of shares of Common Stock determined by dividing the aggregate stated value of the Series X Preferred Stock being converted by the conversion price then in effect. The initial conversion price is $4.03 and is subject to adjustment as described below. No holder may request a conversion of its Series X Preferred Stock to the extent such conversion would result in the holder and its affiliates beneficially owning more than a pre-set conversion blocker threshold, which will initially be set at 19.99% of our Common Stock then outstanding (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The amount of beneficial ownership of a holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and regulations of that section.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion Price Adjustment-Stock Dividends and Stock Splits</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> If we pay a stock dividend or otherwise make a distribution payable in shares of Common Stock with respect to the then outstanding shares of Common Stock, subdivide or combine our outstanding Common Stock, or reclassify our Common Stock in such a way that we issue additional shares of our capital stock, the conversion price will be adjusted by multiplying the then-existing conversion price by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately before the distribution, dividend, adjustment or recapitalization and the denominator of which is the number of shares of Common Stock outstanding immediately after such action. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Fundamental Transaction.</font><font style="font-family:'Times New Roman','Times','serif';"> If we effect a &#8220;fundamental transaction&#8221; (as defined below), then upon any future conversion of the Series X Preferred Stock, the holders will have the right to receive, for each share of Common Stock they would have received upon such conversion, the same kind and amount of securities, cash or property as such holder would have been entitled to receive in the fundamental transaction had it been the holder of Common Stock immediately prior to the fundamental transaction. The term &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">fundamental transaction</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any of the following:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the Company is not the surviving entity;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any completed tender offer or exchange offer involving holders of Common Stock in which more than 50% of the Common Stock not held by us or any other person making such offer is converted or exchanged into other securities, cash or property; or</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any reclassification of Common Stock or any compulsory share exchange by which our Common Stock is effectively converted into or exchanged for other securities, cash or property (but not a reverse stock split).</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If the holders of Common Stock are given a choice as to the securities, cash or property to be received in a fundamental transaction, the holders of Series X Preferred Stock will be given the same choice on conversion of such holders&#8217; shares. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights.</font><font style="font-family:'Times New Roman','Times','serif';"> The Series X Preferred Stock has no voting rights, except to the extent expressly provided in our Certificate of Incorporation or as otherwise required by law. However, so long as at least 50% of the authorized shares of Series X Preferred Stock are outstanding, we may not take any of the following actions without the affirmative consent of holders of a majority of the outstanding Series X Preferred Stock: </font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend our Certificate of Incorporation, By-laws or other charter documents so as to materially, specifically and adversely affect the preferences, rights, or privileges of the Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue additional shares of Series X Preferred Stock or increase or decrease the number of authorized shares of Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, monetize, pledge or otherwise divest or encumber our rights under any material license agreement, joint venture or other partnership agreement to which we are a party and involving any drug or drug candidate;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue or commit to issue any other equity securities, with certain exceptions;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue any equity-based award or compensation to certain of our officers, unless the award has been unanimously approved by our compensation committee at a time when a designee appointed by the Series X Preferred holders is then serving on that committee; or</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any agreement or understanding to take any of the actions listed above.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:18pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Anti-takeover Effects of Provisions of our Certificate of Incorporation and By-laws and Delaware Law</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:18pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Certificate of Incorporation and By-laws Provisions. </font><font style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation authorizes our Board to issue up to 1,000,000 shares of Preferred Stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board may determine. In addition, our By-laws require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings. Our By-laws also provide that our Board is able to elect a director to fill a vacancy created by the expansion of the Board or due to the resignation or departure of an existing board member. Provisions of Delaware law and our Certificate of Incorporation and By-laws could make the acquisition of our Company through a tender offer, a proxy contest or other means more difficult and could make the removal of incumbent officers and directors more difficult. We expect these provisions to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of our Company to first negotiate with our Board. We believe that the benefits provided by our ability to negotiate with the proponent of an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal could result in an improvement of its terms.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:18pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delaware Law. </font><font style="font-family:'Times New Roman','Times','serif';">We are subject to Section 203 of the DGCL, an anti-takeover provision. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the date the person became an interested stockholder, unless: </font></p><div style="margin-top:18pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:25pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, beneficially owns, or is an affiliate of the corporation and within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s outstanding voting securities. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our Board does not approve in advance.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>xoma-20231231xex10d10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:29 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:11.9pt;text-align:right;margin:30pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.10</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">November 1, 2022 </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thomas Burns </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">VIA EMAIL/DOCUSIGN </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dear Thomas: </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As you know, you are employed by XOMA Corporation (the &#8220;Company&#8221;) pursuant to the terms of an Officer Employment Agreement dated August 7, 2017, as amended on April 1, 2022 (the &#8220;Agreement&#8221;). You and the Company are hereby agreeing to amend the Agreement to modify the retention benefit contained therein, as set forth below (the &#8220;Amendment&#8221;). </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the existing terms of the Agreement, in order to be eligible for the retention benefit, you must remain employed by the Company for a twelve (12)-month period (the &#8220;Period&#8221;) following the first day of employment of the Company&#8217;s new Chief Executive Officer. By the terms of this Amendment, the Period shall be accelerated to start on November 1, 2022. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Other than set forth herein, the terms of the Agreement shall remain in full force and effect. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Amendment forms the complete and exclusive agreement between you and the Company with respect to this subject matter. It supersedes any other agreements or promises made to you by anyone, whether oral or written, with respect to such subject matter. Changes to the terms of this Amendment require a written modification signed by an officer of the Company. This Amendment may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Please sign and date this letter and return it to me. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sincerely, </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Jim Neal </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">On behalf of the Board of Directors </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Understood and Accepted: </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Thomas Burns</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:1.44pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u> </u><font style="display:inline-block;width:33.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">              </font><font style="display:inline-block;width:1pt;"></font><font style="display:inline-block;width:36pt;"></font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">November 1, 2022     </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thomas Burns </font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';">Date</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>xoma-20231231xex10d16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:30 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><a name="_mps009951520000000000000004054000000000"></a><a name="_mpv339064660000010000000000000000000000"></a><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk121483250"></a>Exhibit 10.16</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">AMENDED AND RESTATED OFFICER EMPLOYMENT AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Amended and Restated Officer Employment Agreement (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) between Owen Hughes (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee</u>&#8221;) and XOMA Corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">the Company</u>&#8221;) (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221;) is effective as of January 8, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement Effective Date</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Employee is currently employed by the Company as its Interim Chief Executive Officer, and the Company desires to change Employee&#8217;s title to Chief Executive Officer commencing on the Agreement Effective Date, and Employee desires to serve in such capacity, pursuant to the terms and conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</u>. Employee&#8217;s employment with XOMA in the position of Chief Executive Officer shall commence on the Agreement Effective Date. Employee&#8217;s employment with XOMA will be governed by the terms set forth in this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position and Responsibilities</u>. Employee shall devote reasonable best efforts and substantially all of Employee&#8217;s working time and attention to employment with XOMA. Employee shall perform those duties and responsibilities associated with Chief Executive Officer and as may be directed by the Board of Directors of XOMA (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) and the Non-Executive Chairman of the Board or Lead Independent Director, if any, to whom Employee will report. While employed by XOMA, Employee may not accept consulting or other business or non-profit opportunities without first obtaining written approval from the Board. In addition, while employed by XOMA, except on behalf of XOMA, Employee will not directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any other person, corporation, firm, partnership or other entity whatsoever known by Employee to compete with XOMA (or that is planning or preparing to compete with XOMA), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by XOMA; <i style="font-style:italic;">provided, however,</i> that Employee may purchase or otherwise acquire up to (but not more than) five percent (5%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term of Employment</u>. The term of Employee&#8217;s employment with XOMA shall be the period from the Agreement Effective Date until Employee&#8217;s employment is terminated pursuant to Section 7. Consistent with XOMA policy, Employee&#8217;s employment relationship with XOMA is at-will. Accordingly, Employee may resign Employee&#8217;s employment with XOMA at any time and for any reason whatsoever simply by notifying XOMA; and XOMA may terminate Employee&#8217;s employment at any time, with or without Cause (as defined in Section 7(d)) or advance notice, subject to the provisions of Sections 7, 8 and 9.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps586101060000000000000004054000000000"></a>-1-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251657216;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">278679798 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation and Reimbursement of Expenses</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u>. Employee will receive for services to be rendered hereunder a base salary paid at the rate of $575,000 per year, less applicable payroll deductions and withholdings (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>&#8221;), paid on XOMA&#8217;s ordinary payroll cycle. In addition, Employee shall be eligible to participate in XOMA&#8217;s Corporate Achievement Goals plan (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAGs</u>&#8221;), as it may be amended from time to time in accordance with its terms, with an initial target rate of 60% of Base Salary (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>&#8221;), which can be adjusted from time to time by the Board. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Awards</u>. &#160;On the Agreement Effective Date, the Company will grant Employee an award of performance units pursuant to the Company&#8217;s Equity Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;) covering a target number of shares of the Company&#8217;s common stock equal to 275,000 shares (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance Units</u>&#8221;). &#160;The Performance Units shall vest based upon the achievement of performance-based vesting criteria set forth in the award agreement evidencing the grant (subject to Employee&#8217;s continuous service). Employee may be eligible for additional annual equity grants at the discretion of the Board. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement of Expenses</u>. XOMA shall reimburse Employee for all reasonable travel and other expenses incurred in performing Employee&#8217;s obligations under this Agreement in a manner consistent with XOMA policies.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Benefit Plans</u>. The payments provided in Section 4 are in addition to benefits Employee is entitled to under any employee benefit plan of XOMA for which Employee is or becomes eligible. The Employee shall be entitled to participate in any benefit plan for which key executives of the Company are eligible. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Proprietary Information Agreement and XOMA Policies</u>. As a condition of employment with XOMA under this Agreement, Employee will continue to be bound by the obligations set forth in that certain Employee Confidential Information and Inventions Assignment Agreement dated December 27, 2022 by and between the Company and Employee (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</u>&#8221;). In addition, Employee is required to abide by XOMA&#8217;s policies and procedures (including but not limited to XOMA&#8217;s Employee Handbook), as adopted or modified from time to time within XOMA&#8217;s discretion; <i style="font-style:italic;">provided, however,</i> that in the event the terms of this Agreement differ from or are in conflict with XOMA&#8217;s general employment policies or practices, this Agreement shall control.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Employment</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by Employee</u>. As provided in Section 3, Employee may resign Employee&#8217;s employment with XOMA at any time and for any reason. Employee will not be entitled to any of the severance benefits set forth in Section 8 or 9 if Employee resigns, unless such resignation is for Good Reason. For purposes of this Agreement, Employee shall have &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; for resignation from employment with XOMA if any of the following actions are taken by XOMA without Employee&#8217;s prior express written consent: <a name="_Hlk122431114"></a>(i) a reduction in Employee&#8217;s Target Bonus unless consistent to target bonus reductions for all other members of XOMA&#8217;s senior management team, (ii) a reduction in Employee&#8217;s Base Salary by more than 10%; (iii) a material reduction in Employee&#8217;s title or duties (including responsibilities and/or authorities); or (iv) any </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-2-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">other material breach of this Agreement. &#160;In order for Employee to resign for Good Reason, each of the following requirements must be met: (A) Employee must provide written notice to the Board within ninety (90) days after the occurrence of the event giving rise to Good Reason setting forth the basis for Employee&#8217;s resignation, (B) Employee must allow XOMA at least thirty (30) days from receipt of such written notice to cure such event, (C) such event is not reasonably cured by XOMA within such thirty (30) day period (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), and (D) Employee must resign from all positions Employee then holds with XOMA not later than thirty (30) days after the expiration of the Cure Period. If Employee resigns for Good Reason, Employee shall be entitled to the severance benefits set forth in Section&#160;8 or 9, as applicable. <i style="font-style:italic;"> </i></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by XOMA Without Cause</u>. Employee may be terminated by XOMA without Cause, but in such case, Employee shall be entitled to the severance benefits set forth in Section 8 or 9, as applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Upon Death or Permanent Disability</u>. Except as required by law and as provided in Section 8, all benefits and other rights of Employee under this Agreement shall be terminated by Employee&#8217;s death or Permanent Disability. For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permanent Disability</u>&#8221; is defined as Employee being incapable of performing duties to XOMA by reason of any medically determined physical or mental impairment that can be expected to last for a period of more than six (6) consecutive months from the first date of Employee&#8217;s absence due to the disability. XOMA will give Employee at least four (4) weeks written notice of termination due to such disability.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by XOMA for Cause</u>. XOMA may terminate Employee&#8217;s employment for Cause, in which case, Employee will not be entitled to any severance benefits under Section 8 or 9. &#160;For purposes of this Agreement, XOMA will have Cause to terminate Employee&#8217;s employment as the result of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>willful material fraud or material dishonesty in connection with Employee&#8217;s performance under this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>material breach of this Agreement or of XOMA&#8217;s Code of Ethics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>misappropriation of a material business opportunity of XOMA;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>misappropriation of any XOMA funds or property; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>conviction of, or the entering of a plea of guilty or no contest with respect to, a felony.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice and Opportunity to Cure</u>. It shall be a condition precedent to XOMA&#8217;s right to terminate Employee&#8217;s employment for the reasons set forth in Section 7(d)(ii) of this Agreement that (i) XOMA shall first have given Employee written notice stating with specificity the reason for the termination (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breach</u>&#8221;) and (ii) if such Breach is capable of cure or remedy, Employee will have a period of thirty (30 days after the notice is given to remedy the Breach. <i style="font-style:italic;"> </i></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-3-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignation from any XOMA Boards</u>. Upon termination of employment for any reason, and as a precondition to Employee&#8217;s receipt of the severance benefits set forth in Section 8 or 9, Employee shall resign from any and all positions Employee holds with any board of any XOMA entity, including any XOMA subsidiaries, to be effective no later than the date of Employee&#8217;s employment termination (or such other date requested or permitted by the Board).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of XOMA Property</u>. Upon termination of employment for any reason, and as a precondition to Employee&#8217;s receipt of the severance benefits set forth in Section 8 or 9, Employee shall immediately return to XOMA all documents, telephones, computers, keys, credit cards, other property and records of XOMA, and shall return or destroy all copies, within Employee&#8217;s possession, custody or control.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Claims</u>. As a condition of entering into this Agreement and receiving the severance benefits set forth in Section 8 or 9, Employee shall execute and deliver to XOMA a release of claims in favor of XOMA substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release Agreement</u>&#8221;) within the timeframe set forth in the Release Agreement, but not later than forty-five (45) days following Employee&#8217;s employment termination date, and allow the Release Agreement to become effective according to its terms (by not invoking any legal right to revoke it) within any applicable time period set forth in the Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Benefits Outside of Change of Control Protection Period</u>. Subject to Sections 7(f), 7(g) and 7(h) and Employee&#8217;s continued compliance with the terms of this Agreement, the following provisions of this Section 8 shall apply upon the occurrence of an event of termination of Employee&#8217;s employment with XOMA as provided in Section 7(a) for Good Reason outside of a Change of Control Protection Period (as defined below in Section 9(f)), Section 7(b) for termination without Cause outside of a Change of Control Protection Period, or Section 7(c) due to death or Permanent Disability at any time (whether inside or outside of a Change of Control Protection Period), in each case, provided that the termination of Employee&#8217;s employment with XOMA constitutes a &#8220;separation from service&#8221; as provided in Treas. Reg. Section 1.409A-1(h).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Severance</u>. XOMA shall pay Employee, or in the event of Employee&#8217;s death or Permanent Disability, Employee&#8217;s beneficiaries, as severance pay: (i) one (1) times Employee&#8217;s Base Salary in effect as of Employee&#8217;s employment termination date <a name="_Hlk121740495"></a>(disregarding any reduction in the Employee&#8217;s Base Salary that would give rise to Employee&#8217;s right to resign with Good Reason); and (ii) a prorated portion of Employee&#8217;s Target Bonus for the fiscal year in which the termination occurs, calculated by multiplying the annual Target Bonus by a fraction, the numerator of which shall be the number of months (including a portion of a month, if applicable) of the fiscal year during which Employee was employed prior to the occurrence of the termination, and the denominator of which shall be twelve (12). In addition, if Employee is terminated without Cause after the completion of any fiscal year for which Employee was eligible to receive a bonus payment under CAGs, but before such CAGs payment is made, Employee shall be entitled to receive a bonus payment for such year consistent with Employee&#8217;s performance against CAGs objectives and the good faith determination by the Board that CAGs bonuses are payable for such year. The severance payment described in Section 8(a)(i) shall be paid in monthly installments over twelve (12) months, with the first two (2) of such monthly installments being paid in a lump sum sixty (60) days after Employee&#8217;s employment termination date, and the remaining </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-4-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">installments being paid monthly thereafter until fully paid. The severance payments described in Section 8(a)(ii) shall be paid in a lump sum sixty (60) days after Employee&#8217;s employment termination date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Group Health Coverage and Certain Other Benefits</u>. For a period of twelve (12) months following an event of termination under Section 7(a) for Good Reason or under Section 7(b) without Cause (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA Premium Period</u>&#8221;), XOMA shall pay the full cost of COBRA continuation coverage (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA Premiums</u>&#8221;) of Employee and Employee&#8217;s spouse and eligible dependents (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Persons</u>&#8221;), <i style="font-style:italic;">provided, however,</i> that (A)&#160;each Covered Person constitutes a qualified beneficiary, as defined in Section 4980B(g)(1) of the Internal Revenue Code of 1986, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221;); and (B)&#160;Employee elects continuation coverage within the prescribed time period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;). The payments by XOMA for such group health coverage shall cease prior to the expiration of the twelve (12) month period in this Section 8(b), upon commencement of substantially similar coverage for all Covered Persons as a result of the employment of Employee by another employer, or when Employee ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. Notwithstanding the foregoing, if XOMA determines, in its sole discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Covered Persons elect or are eligible for COBRA coverage, XOMA instead shall pay to Employee, on the first day of each calendar month following Employee&#8217;s employment termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for all Covered Persons and an additional amount to pay for the taxes on all such amounts), less required payroll deductions and withholdings (such amount, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Cash Payment</u>&#8221;), for the remainder of the COBRA Premium Period. Employee may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outplacement Program</u>. Upon the occurrence of an event of termination under Section 7(a) for Good Reason only or under Section 7(b) without Cause, Employee will be entitled to participate in a twelve (12)-month executive outplacement program provided by an executive coaching or outplacement service, at XOMA&#8217;s expense not to exceed $15,000 and paid directly to the coach or outplacement service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outplacement Services</u>&#8221;). The Outplacement Services will commence after the Effective Date of the Release Agreement (as defined therein).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Benefits During a Change of Control Protection Period</u>. Subject to Sections 7(f), 7(g) and 7(h) and Employee&#8217;s continued compliance with the terms of this Agreement, the following provisions of this Section 9 shall apply upon the occurrence of an event of termination of Employee&#8217;s employment with XOMA as provided in Section 7(a) for Good Reason during a Change of Control Protection Period or Section 7(b) for termination without Cause during a Change of Control Protection Period, in each case, provided that the termination of Employee&#8217;s employment with XOMA constitutes a &#8220;separation from service&#8221; as provided in Treas. Reg. Section 1.409A-1(h).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Severance</u>. &#160;Employee shall be entitled to receive a severance payment of (i) two (2) times Employee&#8217;s Base Salary in effect immediately prior to termination of employment (disregarding any reduction in the Employee&#8217;s Base Salary that would give rise to </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-5-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Employee&#8217;s right to resign with Good Reason), (ii) two (2) times Employee&#8217;s Target Bonus in effect for the fiscal year in which the termination occurs; <a name="_Hlk121867246"></a>and (iii) any earned but unpaid bonus for any prior performance period (Sections 9(a)(i)-(iii) collectively the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Protection Period Severance Payments&#8221;)</u>. The Change in Control Protection Period Severance Payments shall be paid in a lump sum sixty (60) days after Employee&#8217;s employment termination date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Group Health Coverage and Certain Other Benefits</u>. For a period of twenty-four (24) months, XOMA shall pay the full cost of the COBRA Premiums of the Covered Persons, subject to the same terms and conditions set forth in Section 8(b).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outplacement Program</u>. Employee will be entitled to the Outplacement Services for twelve (12) months, subject to the same terms and conditions set forth in Section 8(c).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Acceleration and Extended Option Exercise Period</u>. &#160;The vesting of all time-based equity awards granted to Employee by XOMA (including any such options granted or assumed by the surviving or continuing entity of the Change of Control) and still outstanding (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time-Based Awards</u>&#8221;) shall automatically be accelerated so that all the Time-Based Awards may be exercised (if applicable) immediately upon Employee&#8217;s termination date for any or all of the subject shares, and the post-termination exercise period of each Time-Based Award (if applicable) shall be extended to the earlier of sixty (60) months after the date of such termination and the remainder of the maximum term of such Time-Based Award); and (B) with respect to any performance-based stock awards (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance Awards</u>&#8221;) at the time of such termination, the Board (or its Compensation Committee) will assess in good faith the level of achievement of any performance goals for such Performance Awards and will determine in its sole discretion the degree of achievement of the performance goal(s) underlying such Performance Awards. The Time-Based Awards and Performance Awards shall continue to be subject to all other terms and conditions of the applicable equity incentive or share option plans and the applicable award agreements between the Parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</u>&#8221; means the occurrence of any of the following events:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i) <font style="display:inline-block;width:21.67pt;"></font>a merger, amalgamation or acquisition in which XOMA is not the surviving or continuing entity, except for a transaction the principal purpose of which is to change the jurisdiction of XOMA&#8217;s organization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii) <font style="display:inline-block;width:18.34pt;"></font>the sale, transfer or other disposition of all or substantially all of the assets of XOMA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii) <font style="display:inline-block;width:15.01pt;"></font>any other reorganization or business combination in which fifty percent (50%) or more of XOMA&#8217;s outstanding voting securities are transferred to different holders in a single or series of related transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iv) <font style="display:inline-block;width:15.67pt;"></font>approval by the shareholders of XOMA of a plan of complete liquidation of XOMA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt;">(v) <font style="display:inline-block;width:19.01pt;"></font>any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becoming the &#8220;beneficial owner&#8221; (as defined in </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-6-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rule 13d-3 under said Act), directly or indirectly, of securities of XOMA representing more than fifty percent (50%) of the total voting power represented by XOMA&#8217;s then outstanding voting securities; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(vi) <font style="display:inline-block;width:15.67pt;"></font>a change in the composition of the Board, as a result of which fewer than a majority of directors are Incumbent Directors. &#8220;Incumbent Directors&#8221; shall mean directors who (A) are directors of XOMA as of the date hereof, (B) are elected, or nominated for election, to the Board with the affirmative votes of the directors of XOMA as of the date hereof, or (C) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of those directors whose election or nomination was not in connection with any transaction described in subsections (i) through (v) or in connection with an actual or threatened proxy contest relating to the election of directors of XOMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font>For purposes of this Agreement, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control Protection Period</u>&#8221; means the period commencing two (2) months prior to the execution of the definitive agreement for a Change of Control and terminating twelve (12) months following the closing of a Change of Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>(i)<font style="display:inline-block;width:24.67pt;"></font>In the event that the benefits provided for in this Section 9 would constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;) (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">280G Payment</u>&#8221;), then any such 280G Payment (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>&#8221;) shall be equal to the Reduced Amount. The &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduced Amount</u>&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction Method</u>&#8221;) that results in the greatest economic benefit for Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Reduction Method</u>&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>(ii)<font style="display:inline-block;width:21.34pt;"></font>Notwithstanding any provision to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Employee as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A shall be </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-7-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>(iii)<font style="display:inline-block;width:18pt;"></font>Unless Employee and XOMA agree on an alternative accounting firm, XOMA&#8217;s accountants shall perform the foregoing calculations. &#160;If the accountants are serving as accountant or auditor for the individual, entity or group effecting the Change of Control transaction, XOMA shall appoint a nationally recognized accounting firm to make the determinations required by this Section. &#160;For purposes of making the calculations required by this Section, the accountants may make reasonable assumptions and approximations and may rely on interpretations concerning the application of the Code for which there is a &#8220;substantial authority&#8221; tax reporting position. The Parties shall furnish such information and documents as the accountants may reasonably request in order to make a determination under this Section. &#160;XOMA shall bear all reasonable costs the accountants incur in connection with calculations contemplated by this Section. &#160;XOMA shall use commercially reasonable efforts to cause the accountants to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Employee and XOMA within fifteen (15) calendar days after the date on which Employee&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Employee or XOMA) or such other time as requested by Employee or XOMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>(iv)<font style="display:inline-block;width:18.67pt;"></font>If Employee receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 9(g)(i) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Employee agrees to promptly return to XOMA a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 9(g)(i)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y), Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Agreement</u>. This Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective permitted successors and assigns.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Section 409A of the Code</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>It is intended that this Agreement will comply with Section 409A of the Code and its regulations and guidelines (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u>&#8221;), to the extent the Agreement is subject to Section 409A, and the Agreement shall be interpreted on a basis consistent with such intent. If an amendment of the Agreement is necessary in order for it to comply with Section 409A, the Parties will negotiate in good faith to amend the Agreement in a manner that preserves the original intent of the Parties to the extent reasonably possible. No action or failure to act under this Section 11 shall subject XOMA to any claim, liability, or expense, and XOMA shall not have any obligation to indemnify or otherwise protect Employee from the obligation to pay any taxes, interest or penalties under Section 409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>With respect to any reimbursement or in-kind benefit arrangements of XOMA and its subsidiaries that constitute deferred compensation for purposes of Section 409A, except as otherwise permitted by Section 409A, the following conditions shall be applicable: (A) the amount eligible for reimbursement, or in-kind benefits provided, under any such arrangement </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-8-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">in one calendar year may not affect the amount eligible for reimbursement, or in-kind benefits to be provided, under such arrangement in any other calendar year (except that the benefit plans may impose a limit on the amount that may be reimbursed or paid), (B) any reimbursement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (C) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. Whenever payments under this Agreement are to be made in installments, each such installment shall be deemed to be a separate payment for purposes of Section 409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>If Employee is deemed on the date of &#8220;separation from service&#8221; (under Treas. Reg. Section 1.409A-1(h)) to be a &#8220;specified employee&#8221; (under Treas. Reg. Section 1.409A-1(i)), then with regard to any payment or benefit that is considered deferred compensation under Section 409A of the Code payable on account of a &#8220;separation from service&#8221; that is required to be delayed under Section 409A(a)(2)(B) of the Code (after taking into account any applicable exceptions to such requirement), such payment or benefit shall be made or provided on the earlier of (i) the expiration of the six (6)-month period measured from the date of Employee&#8217;s &#8220;separation from service,&#8221; or (ii) the date of Employee&#8217;s death (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay Period</u>&#8221;). Upon expiration of the Delay Period, all payments and benefits delayed under this Section 11(c) shall be paid or reimbursed to Employee in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided on the payment dates specified. For purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment, references to Employee&#8217;s &#8220;termination of employment&#8221; (and corollary terms) shall be construed to refer to Employee&#8217;s &#8220;separation from service&#8221; (under Treas. Reg. Section 1.409A-1(h)).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given upon actual confirmed receipt by mail, courier or email. In the case of Employee, mailed notices shall be addressed to Employee at the home or personal email address that Employee most recently communicated to XOMA in writing. In the case of XOMA, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA&#8217;s Successors</u>. Any successor to XOMA (direct or indirect, by purchase, lease, merger, amalgamation, consolidation, liquidation or otherwise) to all or substantially all of XOMA&#8217;s business or assets shall assume XOMA&#8217;s obligations under this Agreement and agree expressly to perform XOMA&#8217;s obligations under this Agreement in the same manner and to the same extent as XOMA would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA</u>&#8221; shall include any successor to XOMA&#8217;s business or assets which executes and delivers the assumption agreement described in this Section 13(a) or which becomes bound by the terms of this Agreement by operation of law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee&#8217;s Successors</u>. Without the written consent of XOMA, Employee shall not assign or transfer this Agreement or any right or obligation under this Agreement to any other person or entity. However, except as otherwise set forth herein, the terms of this Agreement </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-9-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">and all rights of Employee shall inure to the benefit of, and be enforceable by, Employee&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Agreement</u>. Changes in Employee&#8217;s employment terms, other than those changes expressly reserved to XOMA&#8217;s or the Board&#8217;s discretion in this Agreement, require a written modification approved by XOMA and signed by Employee and a duly authorized officer of XOMA other than Employee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. Any party&#8217;s failure to enforce any provision or provisions of the Agreement will not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Agreement. The rights granted to the Parties herein are cumulative and will not constitute a waiver of any party&#8217;s right to assert all other legal remedies available to it under the circumstances.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">16.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">17.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u>. The Parties shall each bear their own costs, expert fees, attorneys&#8217; fees and other fees incurred in connection with this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">19.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">20.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u>. &#160;To ensure the timely and economical resolution of disputes that may arise between Employee and the Company, both Employee and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, Employee will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or Employee&#8217;s employment with the Company (including but not limited to all statutory claims); or the termination of Employee&#8217;s employment with the Company (including but not limited to all statutory claims). &#160;BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EMPLOYEE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING. &#160;The Arbitrator will have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this section and to determine any procedural questions </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-10-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">which grow out of such disputes, claims or causes of action and bear on their final disposition. &#160;All claims, disputes, or causes of action under this section, whether by Employee or the Company, must be brought solely in an individual capacity, and will not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. &#160;The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. &#160;To the extent that the preceding sentences in this paragraph are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class will proceed in a court of law rather than by arbitration. &#160;Any arbitration proceeding under this Arbitration section will be presided over by a single arbitrator and conducted by JAMS, Inc. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JAMS</u>&#8221;) in San Francisco, CA under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at &#160;http://www.jamsadr.com/rules-employment-arbitration/). &#160;Employee and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&#8217;s own expense. &#160;The Arbitrator will: (a) have the authority to compel adequate discovery for the resolution of the dispute; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or all remedies that Employee or the Company would be entitled to seek in a court of law. &#160;The Company will pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Employee if the dispute were decided in a court of law. &#160;This section will not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Claims</u>&#8221;). &#160;In the event Employee brings multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. &#160;Nothing in this section is intended to prevent either Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">21.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. &#160;Employee will continue to be bound by the obligations set forth in that certain indemnification agreement dated January 1, 2023 by and between the Company and Employee. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">22.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Complete Agreement</u>. This Agreement, together with Employee&#8217;s Confidentiality Agreement and the other agreements referenced herein, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter, and supersedes and replaces any other agreements or promises made to Employee by anyone, whether oral or written.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[signature page to follow]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-11-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-12-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="_Hlk121483251"></a>/s/</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:30pt 0pt 0pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:222.6pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 21.75pt;"><font style="background:#ffff00;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font>Chairman of the Board<font style="background:#ffff00;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 18pt 21.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:30pt 0pt 0pt 0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jack L. Wyszomierski</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:83.96pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 21.75pt;">Jack L. Wyszomierski<font style="background:#ffff00;"><br></font>Chairman of the Board<font style="background:#ffff00;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 18pt 21.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">EMPLOYEE:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:6pt 0pt 0pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">By: /s/ Owen Hughes</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:119.6pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Owen Hughes </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><a name="_mps490873670000000000000004054000000000"></a>-13-</p><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM RELEASE OF CLAIMS AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Release of Claims Agreement (&#8220;Release Agreement&#8221;) is entered into between XOMA Corporation (&#8220;XOMA&#8221;) and Owen Hughes (&#8220;Employee&#8221;). XOMA and Employee (collectively, the &#8220;Parties&#8221;) are parties to an Officer Employment Agreement (&#8220;Employment Agreement&#8221;) and agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. Employee&#8217;s employment with XOMA terminated on _______, 20__.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Claims</u>. In exchange for the compensation, benefits and other consideration to be provided to Employee under the Employment Agreement that Employee is not otherwise entitled to receive, Employee hereby generally and completely releases XOMA and XOMA (US) LLC, and their past and present officers, agents, directors, employees, investors, shareholders, administrators, partners, attorneys, agents, insurers, affiliates, divisions, subsidiaries, parents, predecessor and successor corporations, and assigns (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Parties</u>&#8221;), from, and agrees not to sue or otherwise institute any legal or administrative proceedings concerning, any and all claims, duties, liabilities, obligations and causes of action, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring prior to or on the date Employee signs this Release Agreement (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Claims</u>&#8221;).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Released Claims include but are not limited to:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>all claims arising out of or in any way related to Employee&#8217;s employment with XOMA or the termination of that employment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>all claims related to compensation or benefits from XOMA, including salary, bonuses, commissions, vacation, paid time off, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity or profits interests in XOMA (including but not limited to any right to purchase, or actual purchase, of shares of stock of XOMA);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>all tort claims, including claims for fraud, defamation, emotional distress and discharge in violation of public policy;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>all federal, state and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees or other claims arising under the Federal Civil Rights Act of 1964, the federal Civil Rights Act of 1991, the federal Age Discrimination in Employment Act of 1967 (the &#8220;ADEA&#8221;), the federal Americans with Disabilities Act of 1990, the federal Fair Labor Standards Act, the federal the Employee Retirement Income Security Act of 1974, the federal Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act and the California Labor Code, and all amendments to and regulations issued under each such statute;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251656192;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>all claims for violation of the federal or any state constitution;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>all claims arising out of any other laws and regulations relating to employment or employment discrimination; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font>all claims for attorneys&#8217; fees and costs.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment of Waiver of Claims under ADEA</u>. Employee acknowledges that Employee is knowingly and voluntarily waiving and releasing any rights Employee may have under the ADEA, and that the consideration given for the waiver and release in this Section 3 is in addition to anything of value to which Employee is already entitled. Employee further acknowledges that Employee has been advised, as required by the ADEA, that: (a) Employee&#8217;s waiver and release do not apply to any rights or claims that may arise after the date Employee signs this Release Agreement; (b) Employee should consult with an attorney prior to signing this Release Agreement (although Employee may choose voluntarily not to do so); (c) Employee has twenty-one (21) days to consider this Release Agreement (although Employee may choose voluntarily to sign it earlier); (d) Employee has seven (7) days following the date Employee signs this Release Agreement to revoke the Release Agreement (by providing written notice of Employee&#8217;s revocation to the Legal Department at XOMA); and (e) this Release Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth (8th) day after the date that this Release Agreement is signed by Employee provided that Employee does not revoke it (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Unknown Claims</u>. In giving the releases set forth in this Release Agreement, which include claims which may be unknown to Employee at present, Employee acknowledges that Employee has read and understands Section 1542 of the California Civil Code which reads as follows:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 72pt 12pt 72pt;"><b style="font-weight:bold;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Employee hereby expressly waives and relinquishes all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to Employee&#8217;s release of claims herein, including but not limited to the release of unknown and unsuspected claims.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Claims</u>. Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;Excluded Claims&#8221;): (a) any rights or claims for indemnification Employee may have pursuant to any written indemnification agreement with XOMA to which Employee is a party or under applicable law; (b) any rights which cannot be waived as a matter of law; (c) any rights Employee has to file or pursue a claim for workers&#8217; compensation or unemployment insurance; and (d) any claims for breach of the Employment Agreement or this Release Agreement. <b style="font-weight:bold;">In addition, nothing in this Release Agreement prevents Employee from filing, cooperating with or participating in any proceedings before the Equal Employment </b></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251656192;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><b style="font-weight:bold;">Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing or any analogous federal or state government agency, except that Employee acknowledges and agrees that Employee hereby waives Employee&#8217;s right to any monetary benefits in connection with any such claim, charge or proceeding.</b> Employee represents and warrants that, other than the Excluded Claims, Employee is not aware of any claims Employee has or might have against any of the Released Parties that are not included in the Released Claims.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations</u>. Employee represents that Employee has been paid all compensation owed and for all time worked; Employee has received all the leave and leave benefits and protections for which Employee is eligible pursuant to the federal Family and Medical Leave Act, the California Family Rights Act, any applicable law or XOMA policy; and Employee has not suffered any on the job injury for which Employee has not already filed a workers&#8217; compensation claim.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nondisparagement</u>. Employee agrees not to make any statement intending disparage XOMA, and XOMA&#8217;s officers, directors, employees, shareholder, members and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation. XOMA agrees that its directors and officers will not make any statements intending to disparage Employee in any manner likely to be harmful to Employee&#8217;s business reputation or personal reputation. Nothing in this provision, however, shall prevent either Employee or XOMA from responding accurately and fully to any request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Release Agreement is intended to prohibit or restrain Employee in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation. Nothing in this Release Agreement prevents Employee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Employee has reason to believe is unlawful.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Voluntary Adverse Action</u>. Employee agrees that Employee will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other formal proceeding of any kind brought against XOMA, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall Employee induce or encourage any person or entity to bring any such claims; <i style="font-style:italic;">provided, however,</i> that Employee must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of XOMA Property; Compliance with Proprietary Information Agreement</u>. Employee represents that Employee has complied fully with Section 7(g) of the Employment Agreement and the provisions of Employee&#8217;s Employee Confidential Information and Invention Assignment Agreement with XOMA (the &#8220;Confidentiality Agreement&#8221;), and further agrees to continue to abide by Employee&#8217;s continuing obligations under the Confidentiality Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u>. The Parties shall each bear their own costs, expert fees, attorneys&#8217; fees and other fees incurred in connection with this Release Agreement.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251656192;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Representations</u>. Employee represents that Employee has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Release Agreement. Neither Party has relied upon any representations or statements made by the other Party which are not specifically set forth in this Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Release Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Release Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Release Agreement, together with the Employment Agreement, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter. This Release Agreement may only be modified or amended in a writing signed by Employee and a duly authorized officer of XOMA other than Employee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Release Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Release Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.</div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:30pt 0pt 0pt 0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:205.26pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 21.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">EMPLOYEE:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:6pt 0pt 0pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:222.6pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Owen Hughes </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251656192;"><img src="xoma-20231231xex10d16002.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.63
<SEQUENCE>5
<FILENAME>xoma-20231231xex10d63.htm
<DESCRIPTION>EX-10.63
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:32 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.63</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">THE FOLLOWING INFORMATION IS SUPPLIED SOLELY FOR U.S. FEDERAL INCOME TAX PURPOSES. &#160;THE LOAN UNDER THIS AGREEMENT ARE TREATED AS HAVING BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (&#8220;OID&#8221;) WITHIN THE MEANING OF SECTION 1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE &#8220;CODE&#8221;), AND THIS LEGEND IS REQUIRED BY SECTION 1275(c) OF THE CODE. &#160;INFORMATION INCLUDING THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE AND THE YIELD TO MATURITY WILL BE PROVIDED IN WRITING TO A LENDER PROMPTLY UPON REQUEST TO THE BORROWER AT 2200 POWELL STREET, SUITE 310 EMERYVILLE, CA 94608 [***].</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk152431940"></a><a name="_Hlk152022326"></a><a name="_Hlk153362876"></a></font><b style="font-weight:bold;">LOAN AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">dated as of December 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">among</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">XRL 1 LLC</b>,</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">as Borrower,</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk151981009"></a></font><b style="font-weight:bold;">THE LENDERS FROM TIME TO TIME PARTY HERETO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BLUE OWL CAPITAL CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">as Administrative Agent<br><font style="font-size:12pt;"><a name="_Hlk152431941"></a></font><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Page</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488558">Article I CERTAIN DEFINITIONS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488558"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488558">1</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488559">Section 1.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488559">Definitions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488559"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488559">1</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488560">Section 1.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488560">Rules of Construction</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488560"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488560">19</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488561">Article II TERM LOANS; DISBURSEMENT; CERTAIN FEES</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488561"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488561">20</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488562">Section 2.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488562">Term Loans</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488562"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488562">20</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488563">Article III REPAYMENT</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488563"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488563">21</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488564">Section 3.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488564">Amortization; Maturity Date</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488564"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488564">21</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488565">Section 3.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488565">Mandatory Prepayment; Voluntary Prepayment</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488565"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488565">22</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488566">Section 3.03</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488566">Increased Cost</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488566"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488566">23</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488567">Article IV INTEREST; FEES; EXPENSES; MAKING OF PAYMENTS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488567"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488567">24</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488568">Section 4.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488568">Interest Rate; Fees</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488568"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488568">24</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488569">Section 4.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488569">Reserve Account.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488569"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488569">24</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488570">Section 4.03</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488570">Operating Account.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488570"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488570">25</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488571">Section 4.04</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488571">Collection Account</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488571"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488571">25</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488572">Section 4.05</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488572">Application of Payments; Ratable Sharing.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488572"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488572">26</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488573">Section 4.06</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488573">Interest on Late Payments</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488573"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488573">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488574">Section 4.07</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488574">Administration and Enforcement Expenses</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488574"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488574">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488575">Section 4.08</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488575">Making of Payments</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488575"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488575">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488576">Section 4.09</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488576">Setoff or Counterclaim</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488576"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488576">28</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488577">Article V TAXES</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488577"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488577">28</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488578">Section 5.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488578">Taxes</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488578"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488578">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488579">Section 5.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488579">Receipt of Payment</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488579"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488579">30</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488580">Section 5.03</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488580">Other Taxes</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488580"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488580">30</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488581">Section 5.04</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488581">Indemnification</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488581"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488581">30</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488582">Section 5.05</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488582">Registered Obligation</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488582"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488582">30</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488583">Section 5.06</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488583">Tax Treatment</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488583"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488583">31</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488584">Section 5.07</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488584">Treatment of Certain Refunds</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488584"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488584">32</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488585">Article VI CONDITIONS PRECEDENT</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488585"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488585">32</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488586">Section 6.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488586">Closing Date</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488586"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488586">32</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488587">Section 6.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488587">Conditions to Each Credit Extension</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488587"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488587">33</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488590">Article VII REPRESENTATIONS AND WARRANTIES</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488590"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488590">34</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488591">Section 7.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488591">Representations and Warranties of Borrower</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488591"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488591">34</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488592">Section 7.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488592">[Reserved]</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488592"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488592">38</a></font></font></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488593">Section 7.03</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488593">Survival of Representations and Warranties</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488593"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488593">38</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488594">Article VIII AFFIRMATIVE COVENANTS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488594"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488594">38</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488595">Section 8.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488595">Maintenance of Existence</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488595"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488595">38</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488596">Section 8.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488596">Use of Proceeds</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488596"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488596">39</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488597">Section 8.03</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488597">Financial Statements and Information</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488597"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488597">39</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488598">Section 8.04</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488598">Books and Records</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488598"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488598">40</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488599">Section 8.05</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488599">Governmental Authorizations</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488599"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488599">41</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488600">Section 8.06</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488600">Compliance with Laws and Contracts</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488600"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488600">41</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488601">Section 8.07</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488601">Plan Assets</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488601"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488601">41</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488602">Section 8.08</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488602">Notices</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488602"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488602">41</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488603">Section 8.09</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488603">Payment of Taxes</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488603"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488603">42</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488604">Section 8.10</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488604">Waiver of Stay, Extension or Usury Laws</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488604"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488604">42</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488605">Section 8.11</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488605">[Reserved]</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488605"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488605">42</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488606">Section 8.12</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488606">Security Documents; Further Assurances</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488606"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488606">42</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488607">Section 8.13</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488607">Information Regarding Collateral</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488607"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488607">43</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488608">Section 8.14</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488608">Additional Collateral</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488608"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488608">43</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488609">Article IX NEGATIVE COVENANTS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488609"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488609">43</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488610">Section 9.01</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488610">Activities of Borrower</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488610"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488610">43</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488611">Section 9.02</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488611">Merger; Sale of Assets</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488611"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488611">45</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488612">Section 9.03</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488612">Liens</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488612"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488612">45</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488613">Section 9.04</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488613">Investment Company Act</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488613"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488613">45</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488614">Section 9.05</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488614">Limitation on Additional Indebtedness</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488614"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488614">45</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488615">Section 9.06</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488615">Limitation on Transactions with Controlled Affiliates</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488615"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488615">45</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488616">Section 9.07</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488616">ERISA</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488616"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488616">46</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488617">Section 9.08</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488617">Dividends and Distributions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488617"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488617">46</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488618">Section 9.09</a></font><font style="display:inline-block;width:4.25%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488618">Roche APA.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488618"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488618">46</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488620">Article X EVENTS OF DEFAULT</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488620"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488620">47</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488621">Section 10.01</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488621">Events of Default</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488621"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488621">47</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488622">Section 10.02</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488622">Default Remedies</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488622"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488622">47</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488623">Section 10.03</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488623">Right of Set-off; Sharing of Set-off</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488623"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488623">47</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488624">Section 10.04</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488624">Rights Not Exclusive</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488624"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488624">48</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488625">Article XI INDEMNIFICATION</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488625"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488625">48</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488626">Section 11.01</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488626">Losses</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488626"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488626">48</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488627">Section 11.02</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488627">Assumption of Defense; Settlements</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488627"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488627">48</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488628">Article XII ADMINISTRATIVE AGENT</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488628"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488628">49</a></font></font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488629">Section 12.01</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488629">Appointment of Administrative Agent.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488629"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488629">49</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488630">Section 12.02</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488630">Powers and Duties.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488630"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488630">49</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488631">Section 12.03</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488631">General Immunity.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488631"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488631">50</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488632">Section 12.04</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488632">Administrative Agent Entitled to Act as Lender.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488632"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488632">51</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488633">Section 12.05</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488633">Lenders&#8217; Representations, Warranties and Acknowledgment.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488633"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488633">51</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488634">Section 12.06</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488634">Right to Indemnity.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488634"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488634">51</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488635">Section 12.07</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488635">Successor Administrative Agent.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488635"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488635">52</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488636">Section 12.08</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488636">Collateral Documents.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488636"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488636">53</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488637">Section 12.09</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488637">Agency for Perfection.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488637"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488637">53</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488638">Section 12.10</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488638">Reports and Other Information; Confidentiality; Disclaimers</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488638"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488638">54</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488639">Section 12.11</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488639">Erroneous Payments.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488639"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488639">55</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;text-align:justify;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488640">Article XIII MISCELLANEOUS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488640"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488640">57</a></font></font></p><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488641">Section 13.01</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488641">Assignments</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488641"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488641">57</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488642">Section 13.02</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488642">Successors and Assigns</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488642"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488642">58</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488643">Section 13.03</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488643">Notices</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488643"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488643">58</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488644">Section 13.04</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488644">Entire Agreement</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488644"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488644">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488645">Section 13.05</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488645">Modification</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488645"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488645">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488646">Section 13.06</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488646">No Delay; Waivers; etc.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488646"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488646">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488647">Section 13.07</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488647">Severability</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488647"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488647">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488648">Section 13.08</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488648">Determinations</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488648"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488648">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488649">Section 13.09</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488649">Recourse.</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488649"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488649">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488651">Section 13.10</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488651">Governing Law</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488651"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488651">59</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488652">Section 13.11</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488652">Jurisdiction</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488652"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488652">60</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488653">Section 13.12</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488653">Waiver of Jury Trial</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488653"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488653">60</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488654">Section 13.13</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488654">Waiver of Immunity</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488654"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488654">60</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488655">Section 13.14</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488655">Counterparts; Delivery</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488655"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488655">60</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488656">Section 13.15</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488656">Limitation on Rights of Others</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488656"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488656">60</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488657">Section 13.16</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488657">Survival</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488657"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488657">61</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488658">Section 13.17</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488658">Confidentiality</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488658"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488658">61</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:81pt;text-indent:-81pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488659">Section 13.18</a></font><font style="display:inline-block;width:3.35%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488659">Patriot Act Notification</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488659"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153488659">61</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendices</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Appendix A</font></font>Term Loan Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits </u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Hlk152156398"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit A</font></font>Form of Assignment and Acceptance<br>Exhibit B<font style="display:inline-block;width:29.53pt;"></font>Funding Notice</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit C</font></font>Notice of Prepayment<br>Exhibit D<font style="display:inline-block;width:28.92pt;"></font>Form of Payment Date Distribution Report</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit E</font></font>Forms of Tax Certificates</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit F</font></font>Form of Officer&#8217;s Certificates</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit G</font></font>Form of Blocked Account Control Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit H</font></font>Form of Springing Account Control Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedules</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.01(a)<font style="display:inline-block;width:33.47pt;"></font>Account Banks</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.01(b)<font style="display:inline-block;width:32.85pt;"></font>Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.01(c)<font style="display:inline-block;width:33.47pt;"></font>Material Contracts</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This <b style="font-weight:bold;">LOAN AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) dated as of December 15, 2023, is entered into by and among XRL 1 LLC, a Delaware limited liability company (&#8220;Borrower&#8221;), the Lenders from time to time party hereto, and BLUE OWL CAPITAL CORPORATION (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blue Owl</u>&#8221;), as administrative agent for the Lenders (in such capacity, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Agent</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Lenders have agreed to extend certain senior secured credit facilities to Borrower, in an aggregate principal amount not to exceed $140,000,000, consisting of (a) an initial term loan in an aggregate principal amount equal to $130,000,000 and (b) a delayed draw term loan in an aggregate principal amount of $10,000,000, in each case, subject to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article I</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488558"></a><b style="font-size:11pt;font-weight:bold;">CERTAIN DEFINITIONS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 1.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488559"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;The following terms used herein, including in the preamble, recitals, exhibits and schedules hereto, shall have the following meanings:</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Account Bank</u>&#8221; means<a name="_9kR3WTr26648GgPpqip1jRo0u8gDw7"></a> Silicon Valley Bank, a division of <a name="_9kR3WTr26648HUCv69UE23A7wBaDw7oqOQQlbIK"></a>First-Citizens Bank &amp; Trust Company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Account Bank</u>&#8221;), any institution listed on Schedule 1.01(a) hereto and such other bank or financial institution requested by Borrower and approved by the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accreted Principal</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Act</u>&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Agent</u>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Fee Escrow Amount</u>&#8221; means the sum of (i) $[***] (the &#8220;Initial Administrative Fee Escrow Amount&#8221;), <i style="font-style:italic;">plus</i> (ii) such additional amounts as deposited into the Reserve Account after the Closing Date designated, in writing to the Administrative Agent, as additional Administrative Fee Escrow Amounts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u>&#8221; means any Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with another Person. &#160;Any reference to an Affiliate of Blue Owl (or its Affiliates) shall include any Person that is controlled or managed by Blue Owl, or where Blue Owl has a direct or indirect majority economic interest therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affitech Assignment Agreement</u>&#8221; means that certain <a name="_9kR3WTr26648IQH6xmszrt9XF32qz02I"></a>Assignment Agreement, made as of October 6, 2021, by and among <a name="_9kMHG5YVt48867EP6im1yimcU23m03uT9"></a>Affitech Research AS, Company, F. Hoffmann-La Roche Ltd, and Hoffman-La Roche Inc., as amended from time to time (but subject to the terms of this Agreement with respect to the amendment thereof) and to the extent sold and assigned to Borrower on the Closing Date pursuant to the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aggregate Accrual</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)(v)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221; has the meaning set forth in the preamble hereto.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amortization Payments</u>&#8221; means the principal payments of the Term Loan due under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.05(a)</u> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Law</u>&#8221; means, with respect to any Person, all laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<a name="_9kR3WTr19A459KH6xmsriHN43w21tswmWCP68O3"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assigned Commercial Payment Reports</u>&#8221; means the reports to be delivered by Roche to Borrower (as successor to Company) pursuant to Section 3.7 of the Affitech Assignment Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee</u>&#8221; means any other Person to which a Lender has assigned or is assigning its rights and obligations hereunder, whether in whole or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment and Acceptance</u>&#8221; means a written instrument of assignment in the form set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> hereto, executed by and between the parties to an assignment under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.01</u> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bankruptcy Law</u>&#8221; means Title 11 of the United States Code entitled &#8220;<a name="_9kR3WTr26645AM0juzA99x3"></a>Bankruptcy&#8221; and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions (domestic or foreign) from time to time in effect and affecting the rights of creditors generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bill of Sale</u>&#8221; means the Bill of Sale and <a name="_9kR3WTr26645BMH694082y4RF32qz02I"></a>Assumption Agreement, dated as of the Closing Date, delivered by Company to Borrower under the Sale Agreement with respect to the Transferred Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blue Owl</u>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blue Owl Lenders</u>&#8221; means Lenders that are Blue Owl, its Affiliates or any Person that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by Blue Owl or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blocked Account Control Agreement</u>&#8221; means any agreement entered into by the Account Bank, Borrower and the Administrative Agent, in form and substance reasonably satisfactory to Administrative Agent (it being understood that the form attached hereto as Exhibit G is satisfactory to the Administrative Agent), pursuant to which, among other things, Administrative Agent shall have sole dominion and control over the Reserve Account identified therein (within the meaning of Section 9-104 of the UCC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Borrower</u>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Borrower&#8217;s Organizational Documents</u>&#8221; means the certificate of formation and operating agreement (or similar documents) of Borrower or the functional equivalent of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u>&#8221; means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by Applicable Law to remain closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Stock</u>&#8221; of any Person means any and all shares, interests, memberships, ownership interest units, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) equity of such Person, including any preferred stock, and including, if such Person is a partnership, partnership interests (whether general or limited) and any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such partnership, and including, if such Person is a limited liability company, membership interests and any </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other interest or participation that confers on a Person the right to receive an interest in the profits and losses of, or distributions of property of, such limited liability company, in each case whether outstanding on the date hereof or issued after the date hereof, but excluding any Indebtedness convertible into or exchangeable for such equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</u>&#8221; means:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font>any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act) of more than thirty-five percent (35%) of the equity interests of Parent entitled to vote for members of its board of directors of Parent on a fully diluted basis (and taking into account all such securities that such person or group has the right to acquire by conversion or exercise of other securities or option rights, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition);</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font>consummation of any transaction or series of related transactions that results in the sale, disposition or other transfer of all or substantially all of the assets of Parent and its Subsidiaries on a consolidated basis to a Person that is not a Subsidiary of Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font>Parent shall cease to beneficially own and control 100% on a fully diluted basis of the economic and voting interest in the Capital Stock of Company; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font>Company shall cease to beneficially own and control 100% on a fully diluted basis of the economic and voting interest in the Capital Stock of Borrower, free and clear of all Liens other than the Lien granted to Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</u>&#8221; means December 15, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collateral</u>&#8221; means all of Borrower&#8217;s right, title and interest in, to and under, the following property, whether now owned or hereafter acquired and wherever located:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font>the Transferred Assets, the Sale Agreement, and the Bill of Sale;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font>the Operating Account, the Collection Account and the Reserve Account and all money and other property deposited or maintained in the Operating Account, Collection Account and the Reserve Account;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font>all accounts, chattel paper, deposit accounts (and all money and other property deposited or maintained therein), documents, equipment, fixtures, general intangibles, goods, instruments (including intercompany promissory notes), inventory, investment property, letter-of-credit rights, letters of credit, commercial tort claims, money, and supporting obligations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font>all rights (contractual and otherwise and whether constituting accounts, contract rights, financial assets, cash, investment property or general intangibles) arising under, connected with or in any way related to the assets described in the foregoing clauses (a), (b), or (c) (including, without limitation, (i) the right to receive the Assigned Commercial Payment Reports, (ii) the right to audit as described in Section 3.10 of the Affitech Assignment Agreement, and (iii) the right to make claims against a Covered Agreement Counterparty for breach of a Covered Agreement);</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font>all accessions, substitutions and replacements for, and all rents, profits and products of, any assets described in the foregoing clauses (a), (b), (c), or (d);</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font>all proceeds of any assets described in the foregoing clauses (a), (b), (c), (d), or (e); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font>all books and records related to any assets described in the foregoing clauses (a), (b), (c), (d), (e), or (f).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary herein or in the Loan Documents, Collateral shall not include the Excluded Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collateral Documents</u>&#8221; means the Security Agreement, the Pledge Agreement, each Control Agreement and all other instruments, documents and agreements delivered by any Loan Party pursuant to this Agreement or any of the other Loan Documents in order to grant to Administrative Agent a Lien on any Collateral, in each case, as such Collateral Documents may be amended or otherwise modified from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collection Account</u>&#8221; means that certain deposit account ending in [***] established and maintained by Borrower at the Initial Account Bank, subject to a Springing Account Control Agreement, solely for the purpose of receiving remittance of Commercial Payments of Borrower pursuant to the Covered Agreements and disbursement thereof as provided herein, and any other Collection Account entered into in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.04</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk152687163"></a><a name="_Hlk152598606"></a>&#8220;<a name="_Hlk152279914"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Payment</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">s</u>&#8221; means all payments (together with the right to receive such payments) in respect of the Transferred Assets (including in each case payments constituting royalties, settlement payments, judgments (net of any reasonable and documented out-of-pocket expenses incurred in connection with the litigation that gave rise to such judgments), securities, consideration or any other remuneration of any kind payable or received in respect of, or in substitution or compensation for, or otherwise in lieu of, such payments under the Covered Agreements and all &#8220;accounts&#8221; and &#8220;payment intangibles&#8221; (as such terms are defined in the UCC) in respect of the Transferred Assets evidencing or giving rise to any of the foregoing). &#160;For the avoidance of doubt, Commercial Payments includes all amounts due to Borrower under Sections 6.1(b)(i) and 6.1(b)(iii) of the Commercial Payment Purchase Agreement, Sections 2.1 and 3.10 of the Affitech Assignment Agreement, and Sections 4.01(j)(iii), 4.01(j)(v) and 4.03(b) of the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Payment Interest</u>&#8221; means the right to receive Commercial Payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk152676729"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Payment Purchase Agreement</u>&#8221; means that certain Commercial Payment Purchase Agreement, dated as of October 6, 2021, between <a name="_9kR3WTr26645CN4gkzwgkaS01ky1sR7"></a>Affitech Research AS, as <a name="_9kR3WTr26645DgLltnu"></a>Seller and Company, as <a name="_9kR3WTr26645EeY7qhgsxx"></a>Purchaser, as amended from time to time (but subject to the terms of this Agreement and the Sale Agreement with respect to the amendment thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221; means XOMA (US) LLC, a Delaware limited liability company, provided that at the election of the Company and with the consent of the Administrative Agent (not to be unreasonably withheld), the Company may be replaced by an Affiliate of the Company pursuant to joinder, assignment and/or other documentation (including legal opinions) with respect to the Loan Documents, reasonably requested by, and reasonably acceptable to, the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; means any and all non-public, proprietary or confidential information provided by either Party to the other (including, without limitation, any notices or other </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">information provided pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.08</u>), either directly or indirectly, whether in graphic, written, electronic, tangible, intangible or oral form, and marked or identified at the time of disclosure as confidential, or which by its context would reasonably be deemed to be confidential, including without limitation information relating to a Party&#8217;s revenues, net sales, costs, technology, products and services, and any business, financial or customer information relating to a Party. &#160;Confidential Information shall not include any information that a Party can demonstrate was: (i) known to the general public at the time of its disclosure to such Party or its Affiliates, or thereafter became generally known to the general public, other than as a result of actions or omissions of the receiving Party, its Affiliates, or anyone to whom the receiving Party or its Affiliates disclosed such portion; (ii) known by the receiving Party or its Affiliates prior to the date of disclosure by the disclosing Party; (iii) disclosed to the receiving Party or its Affiliates on an non-confidential basis from a source unrelated to the disclosing Party and not known by the receiving Party or its Affiliates (after due inquiry) to be under a duty of confidentiality to the disclosing Party; or (iv) independently developed by the receiving Party or its Affiliates by personnel that did not use the Confidential Information of the disclosing Party in connection with such development. &#160;For clarity, this Agreement shall supersede the Confidentiality Agreement and the Confidentiality Agreement shall cease to be of any force and effect following the execution of this Agreement; provided, however, that all information falling within the definition of &#8220;Confidential Information&#8221; set forth in the Confidentiality Agreement shall also be deemed Confidential Information disclosed pursuant to this Agreement, and the use and disclosure of such Confidential Information following the date of this Agreement shall be subject to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;13.17</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</u>&#8221; means that certain Confidentiality Agreement, dated as of February 7, 2023, by and between Owl Rock Capital Advisors LLC and Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract</u>&#8221; means any agreement, contract, lease, commitment, license and other arrangement that is legally binding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Control Agreement</u>&#8221; means a Blocked Account Control Agreement or a Springing Account Control Agreement, in form and substance reasonably satisfactory to Administrative Agent, it being understood that the form attached hereto as Exhibit G and Exhibit H are satisfactory to the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controlled Affiliate</u>&#8221; with respect to any Person means any other Person directly or indirectly controlling, controlled by or under common control with, such Person. &#160;For the purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">control</u>&#8221; (including, with correlative meaning, the terms &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">controlling</u>&#8221; and &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">controlled</u>&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Agreement Counterparty</u>&#8221; means, with respect to any Covered Agreement, the party or parties thereto other than Borrower or any of its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk152687275"></a><a name="_Hlk153105402"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Agreements</u>&#8221; means, collectively, the Commercial Payment Purchase Agreement and the Affitech Assignment Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Credit Date</u>&#8221; means the date of a Credit Extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Credit Extension</u>&#8221; means the making of a Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default</u>&#8221; means any condition or event which constitutes an Event of Default or which, with the giving of notice or the lapse of time or both (in each case to the extent described in the relevant </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sub-clauses of the definition of &#8220;Event of Default&#8221;) would, unless cured or waived, become an Event of Default.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default Rate</u>&#8221; means, for any period for which an amount is overdue, a rate per annum equal for each day in such period to the lesser of (i) [***] plus the rate of interest otherwise applicable to the Term Loan as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.01</u> and the definition of &#8220;Fixed Interest&#8221; and (ii)&#160;the maximum rate of interest permitted under Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deficiency Amount</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Draw Commitment Period</u>&#8221; means the time period commencing on Closing Date through and including the Delayed Draw Commitment Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Draw Commitment Termination Date</u>&#8221; means March 27, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Draw Funding Milestone</u>&#8221; means the Lenders shall have received, as of any Interest Payment Date occurring on or prior to March 15, 2026, together with all principal and interest paid to the Lenders using the proceeds of Commercial Payments on the immediately preceding Interest Payment Date, payments of principal and interest paid from the proceeds of Commercial Payments [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Draw Term Loan Commitment</u>&#8221; means the commitment of a Lender to make or otherwise fund the Delayed Draw Term Loan. &#160;The amount of each Lender&#8217;s Delayed Draw Term Loan Commitment, if any, is set forth on Appendix A or in the applicable Assignment and Acceptance, subject to any adjustment or reduction pursuant to the terms and conditions hereof. &#160;The aggregate amount of the Delayed Draw Term Loan Commitments as of the Closing Date is $10,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Draw Term Loans</u>&#8221; means the Term Loans funded after the Closing Date pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(a)(ii)</u>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disqualified Capital Stock</u>&#8221; of any Person means any class of Capital Stock of such Person that, by its terms, or by the terms of any related agreement or of any security into which it is convertible, puttable or exchangeable, is, or upon the happening of any event (other than an event that would constitute a Change of Control) or the passage of time would be, required to be redeemed by such Person, whether or not at the option of the holder thereof, or matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, in whole or in part, on or prior to the date which is ninety one (91) days after the Scheduled Maturity Date; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that any class of Capital Stock of such Person that, by its terms, authorizes such Person to satisfy in full its obligations with respect to the payment of dividends or upon maturity, redemption (pursuant to a sinking fund or otherwise) or repurchase thereof or otherwise by the delivery of Capital Stock that is not Disqualified Capital Stock, and that is not convertible, puttable or exchangeable for Disqualified Capital Stock or Indebtedness, will not be deemed to be Disqualified Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dollars</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">$</u>&#8221; means lawful money of the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Benefit Plan</u>&#8221; means any &#8220;employee benefit plan&#8221; as defined in Section 3(3) of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ERISA</u>&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneous Payment</u>&#8221; has the meaning specified in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneous Payment Subrogation Rights</u>&#8221; has the meaning specified in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11(d)</u>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Event of Default</u>&#8221; means the occurrence of one or more of the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Hlk152686968"></a><font style="font-size:11pt;">Borrower fails to pay any principal of the Term Loan within three (3) Business Days after the same becomes due and payable (it being understood that, other than a failure to pay on the Maturity Date, unless the Term Loans have been accelerated in accordance with Section 10.02, such principal amount shall be due and payable in accordance with Section 4.05(a)), whether on the Maturity Date or otherwise (excluding any prepayment of principal of the Term Loan pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(b)</u><font style="font-size:11pt;">).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">(i) Except as permitted by </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01</u><font style="font-size:11pt;"> or </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.01</u><font style="font-size:11pt;">, Borrower fails to pay any interest on the Term Loan (including, without limitation, Fixed Interest) (it being understood that, other than a failure to pay on the Maturity Date, unless the Term Loans have been accelerated in accordance with Section 10.02, such interest to the extent not accreted shall be due and payable in accordance with Section 4.05(a)) or make payment of any other amounts payable and written notice of such other amounts being so due and payable shall have been provided under this Agreement within ten (10) Business Days after the same becomes due and payable or (ii) Company fails to make any payment due under the Fee Letter within three (3) Business Days after the same becomes due and payable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Any representation or warranty of a Loan Party in any Loan Document to which it is party or in any certificate or other document delivered by a Loan Party in connection with the Loan Documents to Administrative Agent proves to have been incorrect in any material respect at the time it was made or deemed made (except that any representation or warranty that is qualified as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221;, or by reference to an objective standard (e.g., a specified Dollar amount), shall be true and correct in all respects); </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, that if the consequences of the failure of such representation or warranty to be true and correct can be cured, such failure continues for a period of thirty (30) days without such cure after the earlier of (x) the date Borrower becomes aware of such failure or (y) the date Lender provides Notice of such failure to Borrower.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">Borrower fails to perform or observe (i) any covenant or agreement contained in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.01</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.02</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.06</u><font style="font-size:11pt;">, or </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.08(a)</u><font style="font-size:11pt;">, or </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IX</u><font style="font-size:11pt;"> (other than </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.03</u><font style="font-size:11pt;">, which is covered under clause (e) below)</font><a name="_cp_change_736"></a><font style="font-size:11pt;"> or (ii) any covenant or agreement contained in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.05</u><font style="font-size:11pt;"> and, in the case of this clause (ii) only, such failure continues for a period of ten (10) Business Days. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">Borrower fails to perform or observe any other covenant or agreement contained in the Loan Documents to which it is a party (other than those referred to in the preceding clauses of this definition) and, solely if the consequences of the failure to perform or observe such covenant or agreement can be cured, such failure continues for a period of thirty (30) days without such cure after the earlier of (x) the date Borrower becomes aware of such failure and (y) the date Administrative Agent provides notice of such failure to Borrower.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">A Seller Event of Default occurs and is continuing.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><font style="font-size:11pt;">Borrower (i) fails to pay when due (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise) any Indebtedness (other than the Obligations hereunder) of $50,000 or more or (ii) fails to perform or observe any covenant or agreement to be performed or observed by it contained in any agreement or in any instrument evidencing any of its Indebtedness (other than the Obligations hereunder) of $50,000 or more and, as a result of such failure, any other party to that </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">agreement or instrument is entitled to exercise the right to accelerate the maturity of any Indebtedness thereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><font style="font-size:11pt;">Any uninsured judgment, decree or order in an amount in excess of $50,000 shall be rendered against Borrower and either (i) enforcement proceedings shall have been commenced upon such judgment, decree or order or (ii) such judgment, decree or order shall not have been stayed or bonded pending appeal, vacated or discharged, within thirty (30) days from entry.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">An Insolvency Event occurs.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><font style="font-size:11pt;">(i) Any of the Loan Documents ceases to be in full force and effect, (ii) the validity or enforceability of any Loan Document is disaffirmed or challenged in writing by Borrower, Company or any of their respective Affiliates, or by any Person (other than Lender) asserting an interest in any portion of the Collateral and such written disaffirmation or challenge is not withdrawn or disavowed by such Person within thirty (30) days after its communication or Borrower has not brought appropriate proceedings for declaratory or other relief negating such disaffirmation or challenge within thirty (30) days after such communication and has not obtained an order granting such relief within one hundred twenty (120) days after commencement of such proceedings, or (iii) this Agreement, the Security Agreement or the Pledge Agreement ceases to give the Administrative Agent or Lender the rights purported to be created hereby or thereby (including a first priority perfected Lien on the assets of Borrower that constitute Collateral (except as otherwise expressly provided herein and therein)) other than as a direct result of any action by Administrative Agent or failure of Administrative Agent to perform an obligation of Administrative Agent hereunder or thereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><font style="font-size:11pt;">Borrower fails to perform or observe any covenant or agreement contained in any Material Contract to which it is a party or any of Borrower&#8217;s Organizational Documents, and such failure is not cured or waived within any applicable grace period, and in the case of any provision in Borrower&#8217;s Organizational Documents, if not cured, is not waived by Lender, or any Material Contract shall cease to be in full force and effect, and in the case of any provision in a Material Contract, such failure to perform or observe results in a termination of such Material Contract and any such failure, cessation or termination could reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(l)</font><font style="font-size:11pt;">A Covered Agreement is terminated.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(m)</font><a name="_9kR3WTr1AB468ZUmgjdnrFPE5u09E"></a><font style="font-size:11pt;">Roche or Company </font><font style="font-size:11pt;">exercise or otherwise assert a contractual right under Section 5.3.2 of the Roche APA to convert any portion of the </font><a name="_9kR3WTr1AB469JH6xmsriHN43w21tswmWCP68OU"></a><font style="font-size:11pt;">Assigned Commercial Payments</font><font style="font-size:11pt;"> (as defined in the Affitech Assignment Agreement) into a </font><a name="_9kR3WTr1AB46APCrkjZJzCtvB"></a><font style="font-size:11pt;">Final Payment</font><font style="font-size:11pt;"> (as defined in the Affitech Assignment Agreement) other than in connection with a transaction that results in concurrent Payment in Full.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(n)</font><font style="font-size:11pt;">Any security interest purported to be created by a Collateral Document ceases to be in full force and effect, or shall cease to give the rights, powers and privileges purported to be created and granted hereunder or thereunder (including a perfected first priority security interest in and Lien on the Collateral (except as otherwise expressly provided herein and therein)) in favor of Lender pursuant hereto or thereto (other than as a result of the failure by the Administrative Agent or a Lender of taking any action required to maintain the perfection of such security interests), or shall be asserted by Borrower not to be a valid, perfected, first priority (except as otherwise expressly provided in this Agreement or such Security Agreement) security interest in the Collateral and/or Borrower takes any action that could reasonably be expected to impair Administrative Agent&#8217;s security interest in any of the Collateral (other than granting Permitted Liens or permitting such Permitted Liens to exist).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(o)</font><font style="font-size:11pt;">The occurrence of a Change of Control.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Assets</u>&#8221; means those assets described in clause (d) of Purchased Commercial Payments (as defined in the Commercial Payment Purchase Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Taxes</u>&#8221; means any of the following Taxes imposed on or with respect to or required to be withheld or deducted from a payment to any Lender, (i) any Taxes imposed on (or measured by) net income (however denominated), branch profits Taxes, or any franchise or similar Taxes imposed in lieu thereof, imposed by any Governmental Authority, in each case (x) as a result of such Lender being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (y) that are Other Connection Taxes, (ii) any U.S. federal withholding Tax imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in the Term Loan or commitment pursuant to a law in effect on the date on which (x) such Lender acquires such interest in such commitment or (y) such Lender designates a new lending office, except in each case to the extent that amounts with respect to such Taxes were payable pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.01</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.04</u> either to such Lender&#8217;s assignor immediately before such Lender acquired such applicable interest in the Term Loan or commitment (as applicable) or to such Lender immediately before it changed its lending office, as applicable, (iii) any Tax that is attributable to such Lender&#8217;s failure to comply with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.01(b)</u> and (iv) any Tax withheld pursuant to FATCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expense Reserve Amount</u>&#8221; means $[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>&#8221; means any and all reasonable and documented out-of-pocket fees, costs and expenses of Borrower, including (i) the reasonable fees, costs, expenses and indemnities of the Servicer (provided, that, with respect to the Servicer, such expenses shall be limited to the Servicing Fee and reasonable out-of-pocket costs and expenses), (ii) reasonable and customary directors and officers liability insurance for any managers and officers of Borrower, (iii) the fees and out-of-pocket expenses of the Independent Manager and of counsel to the Independent Manager due pursuant to the Independent Manager Engagement Letter, (iv) the fees, expenses and charges of any Account Bank in connection with the Reserve Account, Operating Account or Collection Account, (v) the fees and out-of-pocket expenses of Borrower incurred after the Closing Date in connection with the transactions contemplated by the Transaction Documents, and (vi) any expenses incurred in connection with the exercise of audit rights at the direction of Administrative Agent pursuant to Section 8.03(d) of this Agreement or otherwise by the Borrower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FATCA</u>&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to current Section 1471(b)(1) of the Code (or any amended or successor version described above) and any fiscal or regulatory legislation, or official administrative rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fee Letter</u>&#8221; means, collectively, (i) that certain <a name="_9kR3WTr26646BQ8eMHwCyxUE21pyz1H"></a>Fee Letter, dated as of the Closing Date, between Parent, Borrower and Administrative Agent and (ii) that certain <a name="_9kR3WTr26649BIG4olskwYGmUP4K65"></a>Arranger Fee Letter, dated as of the Closing Date, between Borrower and ORCA I LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements</u>&#8221; means as of the Closing Date, (a) the audited financial statements of Parent and its Subsidiaries, for the fiscal years ended December 31, 2021 and December 31, 2022, consisting of balance sheets and the related consolidated statements of income, stockholders&#8217; equity and cash flows for such fiscal year, and (b) the financial statements of Parent and its Subsidiaries for the fiscal </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">quarter ended September 30, 2023, consisting of balance sheets and the related consolidated statements of income, stockholders&#8217; equity and cash flows for such fiscal quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fixed Interest</u>&#8221; means&#160;interest with respect to the Term Loan, accruing with respect to the outstanding principal balance thereof at a rate <i style="font-style:italic;">per annum</i> equal to 9.875%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Lender</u>&#8221; means any Lender which is not a &#8220;United States person&#8221; within the meaning of Section 7701(a)(30) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Funding Notice</u>&#8221; means a written notice substantially in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GAAP</u>&#8221; means the generally accepted accounting principles in the United States of America in effect from time to time; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that in the event such principles change after the Closing Date in a manner which affects compliance with this Agreement by Borrower (including without limitation in the determination of Commercial Payments), such change shall be ignored for the purpose of determining such compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</u>&#8221; means any nation or government, any state or other political subdivision thereof, and any entity exercising executive, legislative, judicial, regulatory or administrative functions of, or pertaining to, government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guarantee</u>&#8221; means, as to any Person: &#160;(a)&#160;any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">primary obligor</u>&#8221;) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect (i)&#160;to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii)&#160;to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part); or (b)&#160;any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Included Commercial Payments</u>&#8221; means, with respect to each Semi-Annual Period, commencing with the Semi-Annual Period ending December 31, 2023, the Commercial Payments received in respect of such Semi-Annual Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indebtedness</u>&#8221; with respect to any Person means (i) all&#160;indebtedness pursuant to an agreement or instrument involving or evidencing money borrowed, the advance of credit, a conditional sale or a transfer with recourse or with an obligation to repurchase (but excluding trade credit and accounts payable in the ordinary course of business), (ii)&#160;all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments (iii) all capitalized lease obligations, (iv)&#160;all obligations with respect to Disqualified Capital Stock, (v)&#160;all indebtedness of a third party secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on assets owned or acquired by such Person, whether or not the indebtedness secured thereby has been assumed<a name="_cp_text_1_1088"></a> (but only to the extent of such Lien), (vi)&#160;net amounts owing pursuant to an interest rate protection agreement, foreign currency exchange agreement or other hedging arrangement, (vii)&#160;all reimbursement obligations under letters of credit issued for the account of such Person, and (viii) all Guarantees with respect to Indebtedness </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the types specified in clauses (i) through (vii) above of another Person. &#160;For the avoidance of doubt, the Indebtedness of any Person shall include the Indebtedness of any other entity to the extent such Person is directly liable therefor as a result of such Person&#8217;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Liabilities</u>&#8221; means, collectively, any and all liabilities, obligations, losses, damages, penalties, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the reasonable fees and disbursements of counsel for Indemnitees in connection with any investigative, administrative or judicial proceeding commenced or threatened by any Person whether or not any such Indemnitee shall be designated as a party or a potential party thereto, and whether or not such Indemnitee is required by Applicable Law to be involved therein, and any fees or expenses actually incurred by Indemnitees in enforcing the indemnity provided herein), whether direct, indirect or consequential, whether based on any federal, state or foreign laws, statutes, rules or regulations (including securities and commercial laws, statutes, rules or regulations), on common law or equitable cause or on contract or otherwise, imposed on, incurred by, or asserted against any such Indemnitee, in any manner relating to or arising out of this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby (including any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the Collateral)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Taxes</u>&#8221; means all (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of Borrower under any Loan Documents and (ii) to the extent not otherwise described in (i), Other Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitee</u>&#8221; means each Lender and its Affiliates and their respective officers, partners, directors, trustees, employees, agents and controlling Persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Manager</u>&#8221; has the meaning given the Limited Liability Company Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Manager Engagement Letter</u>&#8221; means that certain engagement letter, by and between CT Corporation Staffing, Inc., a Delaware corporation and Borrower, as in effect on the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Funding Date</u>&#8221; means the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Term Loan</u>&#8221; means the Term Loan funded on the Initial Funding Date pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(a)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Term Loan Commitment</u>&#8221; means the commitment of a Lender to make or otherwise fund the Initial Term Loan and &#8220;Initial Term Loan Commitments&#8221; means such commitments of all such Lenders in the aggregate. &#160;The amount of each Lender&#8217;s Initial Term Loan Commitment, if any, is set forth on Appendix A or in the applicable Assignment and Acceptance, subject to any adjustment or reduction pursuant to the terms and conditions hereof. &#160;The aggregate amount of the Initial Term Loan Commitments as of the Closing Date is $130,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insolvency Event</u>&#8221; means the occurrence of any of the following with respect to any Transaction Party:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-right:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="text-decoration-line:none;"><a name="_DV_C324"></a></font><font style="font-size:11pt;text-decoration-line:none;">(A) an involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking (x)&#160;relief in respect of such Transaction Party, or of a substantial part of the property of such Transaction Party, under any Bankruptcy Law now or hereafter in effect, (y)&#160;the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-right:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;text-decoration-line:none;">such Transaction Party for a substantial part of the property of such Transaction Party or (z)&#160;the winding-up or liquidation of such Transaction Party, which proceeding or petition shall continue undismissed for sixty (60)&#160;calendar days or (B) an order of a court of competent jurisdiction approving or ordering any of the foregoing shall be entered;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font>such Transaction Party shall (A)&#160;voluntarily commence any proceeding or file any petition seeking relief under any Bankruptcy Law now or hereafter in effect, (B)&#160;apply for the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official itself or for a substantial part of its property, (C)&#160;fail to contest in a timely and appropriate manner any proceeding or the filing of any petition described in clause&#160;(i) of this definition, (D)&#160;file an answer admitting the material allegations of a petition filed against it in any proceeding described in clause (i) of this definition, (E)&#160;make a general assignment for the benefit of creditors or (F)&#160;wind up or liquidate (except as permitted under this Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iii)</font></font>such Transaction Party shall take any action in furtherance of or for the purpose of effecting, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clause (i) or (ii) of this definition; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iv)</font></font>such Transaction Party shall become unable, admit in writing its inability, or fail generally, to pay its debts as they become due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest Payment Date</u>&#8221; means, for each applicable Semi-Annual Period, each of March 31 and September 30, or if any such day is not a Business Day, on the next succeeding Business Day, beginning on March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest Reserve Amount</u>&#8221; means $[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Knowledge</u>&#8221; means, with respect to any Transaction Party, the actual knowledge, after due inquiry, of the Chief Executive Officer, Chief Financial Officer, Chief Investment Officer, General Counsel or President of any such Transaction Party, or to the extent such officer does not exist, the actual knowledge of another person with similar responsibility, regardless of title, of any Transaction Party, respectively, relating to a particular matter; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that a person charged with responsibility for the aspect of the business relevant or related to the matter at issue shall be deemed to have knowledge of a particular matter if, in the prudent exercise of his or her duties and responsibilities in the ordinary course of business, such person should have known of such matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</u>&#8221; means any federal, state, local or foreign law, including common law, and any regulation, rule, requirement, policy, judgment, order, writ, decree, ruling, award, approval, authorization, consent, license, waiver, variance, guideline or permit of, or any agreement with, any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lender</u>&#8221; means each lender listed on the signature pages hereto as a Lender, and any other Person that becomes a party hereto pursuant to an Assignment and Acceptance other than any Person that ceases to be a party hereto pursuant to any Assignment and Acceptance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lender Expenses</u>&#8221; means (a) all reasonable and documented out-of-pocket costs and expenses of preparation, negotiation, execution and administration of the Loan Documents and any consents, amendments, waivers or other modifications thereto incurred by the Administrative Agent and/or the Lenders; (b) all the reasonable and documented fees, expenses and disbursements of counsel (limited to one (1) counsel for each relevant jurisdiction (as determined by the Administrative Agent), other then in the case of conflicts) to the Administrative Agent and the Lenders in connection with the negotiation, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">preparation, execution and administration of the Loan Documents and any consents, amendments, waivers or other modifications thereto and any other documents or matters requested by Borrower; (c) all the actual out-of-pocket costs and reasonable expenses of creating and perfecting Liens in favor of the Administrative Agent including filing and recording fees, out-of-pocket expenses and taxes, stamp or documentary taxes, search fees, title insurance premiums and reasonable and documented fees, expenses and disbursements of counsel to the Administrative Agent; and (d) after the occurrence of an Event of Default, all costs and expenses, including reasonable and documented attorneys&#8217; fees and costs of settlement, incurred by the Administrative Agent and/or the Lenders in enforcing any Obligations of or in collecting any payments due from Borrower hereunder or under the other Loan Documents by reason of such Event of Default (including in connection with the sale of, collection from, or other realization upon any of the Collateral or in connection with any refinancing or restructuring of the Obligations in the nature of a &#8220;work out&#8221; or pursuant to any insolvency or bankruptcy cases or proceedings).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lender Register</u>&#8221; has the meaning set forth in Section 13.01(e).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lien</u>&#8221; means any mortgage or deed of trust, pledge, hypothecation, lien, charge, attachment, set-off, encumbrance or other security interest in the nature thereof (including any conditional sale agreement, equipment trust agreement or other title retention agreement, a lease with substantially the same economic effect as any such agreement or a transfer or other restriction) or other encumbrance, right or claim of any nature whatsoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limited Liability Company Agreement</u>&#8221; means the <a name="_9kR3WTr2664AJPBmoogh"></a>Amended and <a name="_9kR3WTr2664AKhKs8rsxiQQyz74pXXtnw78HYsd"></a>Restated Limited Liability Company Agreement of Borrower, dated as of the Closing Date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loan Documents</u>&#8221; means this Agreement, each Fee Letter, the Security Agreement, the Pledge Agreement, the Sale Agreement, the Bill of Sale, each Control Agreement, each Payment Date Distribution Report, <a name="_9kR3WTr79448Emimajvz82ozzxx4F02IO9w5ALI"></a><font style="letter-spacing:-0.05pt;">and</font> <font style="letter-spacing:-0.05pt;">all</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">other</font><font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.05pt;">documents</font> (excluding, for the avoidance of doubt, any Warrant and any document, certificate or writing <font style="letter-spacing:-0.05pt;">delivered</font><font style="letter-spacing:-0.1pt;"> </font>in <font style="letter-spacing:-0.05pt;">connection</font><font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.05pt;">therewith</font>) <font style="letter-spacing:-0.05pt;">delivered</font><font style="letter-spacing:-0.1pt;"> </font>in <font style="letter-spacing:-0.05pt;">connection</font><font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.05pt;">therewith.</font><font style="letter-spacing:-0.05pt;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loan Party</u>&#8221; means each of Borrower and Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk152597920"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Adverse Effect</u>&#8221; means (a) an Insolvency Event, (b) a material adverse change in the business, operations, properties, results of operations or financial condition of Borrower, taken as a whole; (c) a material adverse effect on the validity or enforceability of the Loan Documents taken as a whole or any material provision hereof or thereof; (d) a material adverse effect on the ability of any Loan Party to consummate the transactions contemplated by the Loan Documents, or on the ability of any Loan Party to perform its obligations under the Loan Documents to which it is a party; (e) a material adverse effect on the rights or remedies of Administrative Agent or the Lenders under any of the Loan Documents, taken as a whole; or (f) an adverse effect in any material respect on any of the timing, amount or duration of (i) the Commercial Payments or the Commercial Payment Interest or (ii) the right of Administrative Agent to receive payments based on the Commercial Payments or the Commercial Payment Interest<a name="_cp_change_943"></a><a name="_cp_change_995"></a>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Contract</u>&#8221; means, collectively, any Contract to which Borrower or Company, as the case may be in the context in which used, is a party or any of the respective assets or properties of Borrower or Company are bound or committed (other than the Transaction Documents) and solely in the case of Company, for which any breach, violation, nonperformance or early cancellation could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. &#160;The Material Contracts as of the date hereof are identified on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.01(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Contract Counterparty</u>&#8221; means a counterparty to any Material Contract.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maturity Date</u>&#8221; means the earlier of (i) the Scheduled Maturity Date and (ii) the date of satisfaction in full of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Accrual</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)(v)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Lawful Rate</u>&#8221; means the highest rate of interest permissible under Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice and Instruction Letters</u>&#8221; has the meaning set forth in the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Prepayment</u>&#8221; means a written notice of prepayment, in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> hereto or such other form as approved by the Administrative Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>&#8221; means, collectively, notices, consents, approvals, reports, designations, requests, waivers, elections and other communications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations</u>&#8221; means, without duplication, the Term Loan, Fixed Interest and all present and future Indebtedness, taxes, liabilities, obligations, covenants, duties, and debts, owing by Borrower to Lender, arising under or pursuant to the Loan Documents, including all principal, interest, premium, charges, expenses, fees, Erroneous Payment Subrogation Rights and any other sums chargeable to Borrower hereunder and under the other Loan Documents (and including any interest, fees and other charges that would accrue but for the filing of a bankruptcy action with respect to Borrower, whether or not such claim is allowed in such bankruptcy action).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk152679026"></a></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Account</u>&#8221; means that certain deposit account ending in [***] established and maintained by Borrower at the Initial Account Bank, subject to a Springing Account Control Agreement, solely for the purpose of holding the Expense Reserve Amount, holding the proceeds of capital contributions from the Company and making disbursements of the same and any successor Operating Account entered into in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.03</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organizational Document</u>&#8221; means, with respect to any Person, (i) in the case of any corporation, the certificate of incorporation and by-laws (or similar documents) of such Person, (ii) in the case of any limited liability company, the certificate of formation and operating agreement (or similar documents) of such Person, (iii) in the case of any limited partnership, the certificate of formation and limited partnership agreement (or similar documents) of such Person, (iv) in the case of any general partnership, the partnership agreement (or similar document) of such Person, and (v) in any other case, the functional equivalent of the foregoing. &#160;For the avoidance of doubt, the <a name="_9kR3WTr2664BCVUtdlu70v406WSy5G13JPL9XbO"></a>Organization Documents of Borrower include the (i) Limited Liability Company Agreement and (ii) the <a name="_9kR3WTr2664BDUBjkejqrt9XF32qz02I"></a>Management Agreement executed in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Connection Taxes</u>&#8221; means, with respect to any Lender, Taxes imposed as a result of a present or former connection between such Lender and the jurisdiction imposing such Tax (other than connections arising from such Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in the Term Loan, commitment or Loan Document).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Taxes</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.03</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</u>&#8221; means XOMA Corporation, a Delaware corporation and its successors reasonably consented to by the Administrative Agent.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participant Register</u>&#8221; has the meaning set forth in Section 13.01(e).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u>&#8221; and &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221; means Administrative Agent, the Lenders and Borrower, individually and collectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patriot Act</u>&#8221; means the USA Patriot Act, Public Law No.&#160;107-56.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Account</u>&#8221; means such account of Administrative Agent maintained at such banking institution as Administrative Agent may specify in its discretion from time to time in writing to Borrower at least five (5) Business Day prior to any Interest Payment Date or other date on which payments are to be made to pursuant to the Loan Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Date Distribution Report</u>&#8221; means any Payment Date Distribution Report, in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u> hereto. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment in Full</u>&#8221; &#160;means the payment in full in good funds of the Term Loan and other Obligations (other than contingent indemnification obligations for which no claims have been made).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221; means due and owing payments of Amortization Payments and Fixed Interest (each under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.05</u> hereof), including, in each case any default, additional interest or prepayment premium charged hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Liens</u>&#8221; means:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;padding-left:9pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Liens created pursuant to any Loan Document;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;padding-left:9pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Liens in favor of a banking or other financial institution arising as a matter of law or under customary contractual provisions encumbering deposits or other funds maintained with such banking or other financial institution (including the right of set off and grants of security interests in deposits and/or securities held by such banking or other financial institution) and that are within the general parameters customary in the banking industry;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;padding-left:9pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Liens securing Taxes, assessments, fees or other governmental charges or </font><a name="_9kR3WTr5DA48Cvkv0kv"></a><font style="font-size:11pt;">levies</font><font style="font-size:11pt;"> which are being contested in good faith and by appropriate proceedings diligently conducted and in respect of which adequate reserves with respect thereto are maintained by Borrower in accordance with GAAP and other similar Liens (other than any Lien imposed pursuant to Section 430(k) of the Internal Revenue Code or by ERISA) arising in connection with court proceedings so long as the enforcement of such Liens is effectively stayed and the judgment claims secured thereby do not otherwise constitute an Event of Default under clause (i) of the definition of &#8220;Event of Default&#8221;; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:9pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="font-size:11pt;">banker&#8217;s liens for collection or rights of set off or similar rights and remedies as to deposit accounts or other funds maintained with depositary institutions; provided that such deposit accounts or funds are not established or deposited for the purpose of providing collateral for any Indebtedness and are not subject to restrictions on access by Borrower in excess of those required by applicable banking regulations.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</u>&#8221; means any natural person, firm, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any other legal entity, including public bodies, whether acting in an individual, fiduciary or other capacity.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Assets</u>&#8221; means assets of any (i) Employee Benefit Plan subject to the fiduciary responsibility provisions of Title&#160;I of ERISA, (ii) plan (as defined in Section 4975(e)(1) of the Code) subject to Section 4975 of the Code or (iii) entity whose underlying assets include assets of any such employee benefit plan or plan by reason of the investment by an employee benefit plan or plan in such entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pledge Agreement</u>&#8221; means the <a name="_9kR3WTr2664BEYPlehj"></a>Pledge and Security Agreement, dated as of the Closing Date, between Company and Administrative Agent pursuant to which the Capital Stock of Borrower is pledged to Administrative Agent, as supplemented by any amendments or supplements thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Principal Amount</u>&#8221; means, as to each Term Loan, as of any date of determination, and without duplication, the amount equal to the sum of: (i) the original amount of such Term Loan, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</u>, (ii) any Accreted Principal accrued as of such date, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</u>, (iii) any payment in respect of principal as provided for in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.02</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.05</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Share</u>&#8221; means, with respect to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font>(i) a Lender&#8217;s obligation to make the Initial Term Loan, the percentage obtained by dividing (A) such Lender&#8217;s Initial Term Loan Commitment by (B) the Total Initial Term Loan Commitment and (ii) a Lender&#8217;s obligation to make a Delayed Draw Term Loan, the percentage obtained by dividing (A) such Lender&#8217;s Delayed Draw Term Loan Commitment by (B) the aggregate amount of the Lenders&#8217; Delayed Draw Term Loan Commitments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font>a Lender&#8217;s right to receive payments of interest, fees and principal with respect to a Term Loan, the percentage obtained by dividing (i) the aggregate unpaid principal amount of such Lender&#8217;s portion of the Term Loan, by (ii) the aggregate unpaid principal amount of the Term Loan; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font>all other matters, the percentage obtained by dividing (i) the sum of such Lender&#8217;s Delayed Draw Term Loan Commitment and the unpaid principal amount of such Lender&#8217;s portion of the Term Loan, by (ii) the sum of the Total Delayed Draw Term Loan Commitment and the aggregate unpaid principal amount of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceeding</u>&#8221; means an action or proceeding brought against a Party as a defendant, for purposes of all legal proceedings arising out of or relating to this Agreement or the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.17(a)</u>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Register</u>&#8221; means a record of ownership in which Borrower registers by book entry the interests (including any rights to receive payment hereunder) of each Lender in the Term Loan and any assignment of any such interest, obligation or right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Change</u>&#8221; means (i) the adoption after the date hereof (or with respect to any Lender that becomes a Lender after the date hereof, after the date such Lender becomes a Lender) of any applicable law, rule or regulation or any change therein after the date hereof, or (ii) any change after the date hereof in the interpretation or administration thereof by any governmental authority, central bank or comparable agency charged with the interpretation or administration thereof, either generally or as effected through compliance with any request or directive (whether or not having the force of law) of any such authority, central bank or comparable agency.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representative</u>&#8221; means, with respect to any Person, directors, officers, employees, agents, co-investors, advisors, potential investors, underwriters, rating agencies, permitted assignees, sources of financing and trustees of such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Lenders</u>&#8221; means (i) at any time (other than when the Blue Owl Lenders constitute the Required Lenders pursuant to clause (ii) below) when there are three (3) or fewer Lenders, all Lenders and (ii) at all other times, Lenders whose Pro Rata Share (calculated in accordance with clause (c) of the definition thereof) aggregate at least 50.1%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reserve Account</u>&#8221; means that certain deposit account ending in [***] established and maintained by Borrower at the Initial Account Bank, subject to a Blocked Account Control Agreement, solely for the purpose of holding the Interest Reserve Amount and the Administrative Fee Escrow Amount, and/or any successor Reserve Account entered into in accordance with Section 4.03.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Roche</u>&#8221; has the meaning given in the Affitech Assignment Agreement (together with any successors or permitted assigns of Roche pursuant to the Affitech Assignment Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Roche APA</u>&#8221; has the meaning set forth in the Affitech Assignment Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale</u>&#8221; means the sale, transfer, assignment, contribution and conveyance of the Transferred Assets pursuant to the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale Agreement</u>&#8221; means the Sale, <a name="_9kR3WTr26649CLFx38yjwF406tuyea6OGyzBAYT"></a>Contribution and <a name="_9kR3WTr26645FiLr91jkwvJE21pyz1H"></a>Servicing Agreement, dated as of the Closing Date, between Parent, Company and Borrower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Scheduled Maturity Date</u>&#8221; means December 15, 2038. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u>&#8221; means the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Event of Default</u>&#8221; has the meaning set forth in the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Agreement</u>&#8221; means the Security Agreement, dated as of the Closing Date, between Administrative Agent and Borrower, securing the Obligations of Borrower hereunder and the other Loan Documents (other than the Warrant), as supplemented by any amendments or supplements thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Semi-Annual Interest Shortfall</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.05(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Semi-Annual Period</u>&#8221; means each six month period commencing on January 1 and July 1 of each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Senior Officer</u>&#8221; means any President, Vice President, Secretary, Treasurer, Chief Executive Officer, Chief Financial Officer, or Chief Investment Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicer</u>&#8221; has the meaning set forth in the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicing Fee</u>&#8221; has the meaning set forth in the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Set-off</u>&#8221; means any right of set off, rescission, counterclaim, reduction, deduction or defense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Springing Account Control Agreement</u>&#8221; means any agreement entered into by the Account Bank, Borrower and the Administrative Agent, in the form and substance reasonably satisfactory </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to Administrative Agent (it being understood that the form attached hereto as Exhibit H is satisfactory to the Administrative Agent), pursuant to which, among other things, Administrative Agent shall have control over the Collection Account and Operating Account identified therein (within the meaning of Section 9-104 of the UCC), which such form, for the avoidance of doubt, shall provide for &#8220;springing&#8221; or &#8220;shifting control&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</u>&#8221; <font style="letter-spacing:-0.05pt;">means,</font> with respect to any Person, at any time, any entity of which more than fifty percent (50%) of the outstanding voting stock or other equity interest entitled ordinarily to vote in the election of the directors or other governing body (however designated) is at the time beneficially owned or controlled directly or indirectly by such Person, by one or more such entities or by such Person and one or more such entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Person</u>&#8221; means, with respect to any Person involved in or that makes any disposition, the Person formed by or surviving such disposition or the Person to which such disposition is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>&#8221; means all present and future taxes, levies, duties, imposts, deductions, charges, fees or withholdings (including backup withholdings), and all interest, penalties and additions to tax with respect thereto, that are imposed by any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term Loan</u>&#8221; means, collectively, the Initial Term Loan and each Delayed Draw Term Loan (together with all Accreted Principal on any such Term Loan).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term Loan Commitments</u>&#8221; means, collectively, the Initial Term Loan Commitments and the Delayed Draw Term Loan Commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u>&#8221; means any Person other than Borrower or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total Delayed Draw Term Loan Commitment</u>&#8221; means the sum of the amounts of the Lenders&#8217; Delayed Draw Term Loan Commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total Initial Term Loan Commitment</u>&#8221; means the sum of the amounts of the Lenders&#8217; Initial Term Loan Commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Documents</u>&#8221; means the Loan Documents and the Organizational Documents. <a name="_Hlk152687251"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Parties</u>&#8221; means, collectively, Parent, Company and Borrower. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferred Assets</u>&#8221; has the meaning set forth in the Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S</u>.&#8221; means the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UCC</u>&#8221; means the Uniform Commercial Code as in effect from time to time in New York; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that, if, with respect to any financing statement or by reason of any provisions of Applicable Law, the perfection or the effect of perfection or non-perfection of the security interest or any portion thereof granted pursuant to the Loan Documents is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than New York, then &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UCC</u>&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrant</u>&#8221; means, collectively, each Warrant to Purchase Stock set forth on Schedule 1.01(b).</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 1.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488560"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rules of Construction</u>. &#160;Unless the context otherwise requires, in this Agreement:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">An accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">The definitions of terms shall apply equally to the singular and plural forms of the terms defined.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">The terms &#8220;include&#8221;, &#8220;including&#8221; and similar terms shall be construed as if followed by the phrase &#8220;without limitation&#8221;.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">Unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with the terms thereof (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth herein or in any of the other Transaction Documents) and include any annexes, exhibits and schedules attached thereto.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">References to any Applicable Law shall include such Applicable Law as from time to time in effect, including any amendment, modification, codification, replacement or reenactment thereof or any substitution therefor.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><font style="font-size:11pt;">References to any Person shall be construed to include such Person&#8217;s successors and permitted assigns (subject to any restrictions on assignment, transfer or delegation set forth herein or in any of the other Transaction Documents), and any reference to a Person in a particular capacity excludes such Person in other capacities.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><font style="font-size:11pt;">The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">The words </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">hereof</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;,</font><font style="font-size:11pt;"> </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">herein</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;,</font><font style="font-size:11pt;"> </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">hereunder</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;</font><font style="font-size:11pt;"> and similar terms when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision hereof, and Article, Section and Exhibit references herein are references to Articles and Sections of, and Exhibits to, this Agreement unless otherwise specified.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><font style="font-size:11pt;">In the computation of a period of time from a specified date to a later specified date, the word </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">from</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;</font><font style="font-size:11pt;"> means </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">from and including</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;</font><font style="font-size:11pt;"> and each of the words </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">to</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;</font><font style="font-size:11pt;"> and </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">until</font><font style="font-size:11pt;font-variant:small-caps;">&#8221;</font><font style="font-size:11pt;"> means </font><font style="font-size:11pt;font-variant:small-caps;">&#8220;</font><font style="font-size:11pt;">to but excluding&#8221;.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><font style="font-size:11pt;">Where any payment is to be made, any funds are to be applied or any calculation is to be made under this Agreement on a day that is not a Business Day, unless this Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">19</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article II</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488561"></a><b style="font-size:11pt;font-weight:bold;">TERM LOANS; DISBURSEMENT; CERTAIN FEES</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 2.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488562"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term Loans</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Term Loans; Delayed Draw Term Loans</u><font style="font-size:11pt;">. &#160;Subject to the terms and conditions hereof:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">each Lender severally agrees to make, on the Initial Funding Date, an Initial Term Loan to Borrower in an amount equal to such Lender&#8217;s Initial Term Loan Commitment; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">each Lender severally agrees to make, on one occasion during the Delayed Draw Commitment Period, Delayed Draw Term Loans to Borrower in an aggregate amount not to exceed such Lender&#8217;s Delayed Draw Term Loan Commitment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Borrower may make only one borrowing under the Initial Term Loan Commitment, which shall be on the Initial Funding Date, and may make only one borrowing under the Delayed Draw Term Loan Commitment. &#160;Any amount borrowed under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(a)</u> and subsequently repaid or prepaid may not be reborrowed. &#160;Each Lender&#8217;s Initial Term Loan Commitment and Delayed Draw Term Loan Commitment shall terminate immediately and without further action on the Credit Date on which such Lender funds Initial Term Loans or Delayed Draw Term Loans, respectively, after giving effect to the funding of such Term Loans on such Credit Date.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Borrowing Mechanics for Term Loans</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">Borrower shall deliver to Administrative Agent a fully executed Funding Notice no later than three (3) Business Days prior to the Initial Funding Date (or such shorter period permitted by Administrative Agent) with respect to Term Loans made on the Initial Funding Date. &#160;Following the Initial Funding Date (and subject to the conditions set forth in Article VI), whenever Borrower desires that Lenders make the Delayed Draw Term Loan, Borrower shall deliver to Administrative Agent a fully executed and delivered Funding Notice no later than 10:00 a.m. (New York City time) at least ten (10) Business Days in advance of the proposed Credit Date. &#160;Each such Funding Notice shall be irrevocable once delivered to Administrative Agent. &#160;Promptly upon receipt by Administrative Agent of any such Funding Notice, Administrative Agent shall notify each Lender of the proposed borrowing. &#160;Administrative Agent and Lenders (A) may act without liability upon the basis of written or emailed notice believed by Administrative Agent in good faith to be from Borrower (or from any Senior Officer thereof designated in writing purportedly from Borrower to Administrative Agent), (B) shall be entitled to rely conclusively on any Senior Officer&#8217;s authority to request a Term Loan on behalf of Borrower until Administrative Agent receives written notice to the contrary, and (C) shall have no duty to verify the authenticity of the signature appearing on any written Funding Notice.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">Each Lender shall make its applicable Term Loan available to Administrative Agent not later than 12:00 p.m. on the applicable Credit Date, by wire transfer of same day funds in Dollars to Administrative Agent. &#160;Upon satisfaction or waiver of the conditions precedent specified herein, Administrative Agent shall make the proceeds of the applicable Term Loans available to Borrower on the applicable Credit Date by causing an amount of same day funds in Dollars equal to the proceeds of all such Term Loans received by Administrative Agent from Lenders to be credited to the account of Borrower or to such other account as may be designated in writing to Administrative Agent by Borrower; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that the Initial Term Loans shall be funded net of: (i) the fees set forth in the Fee Letter and required to be paid on the Closing Date, and (ii) accrued Lender Expenses to the extent invoiced at least one (1) Business Day prior to the Closing Date. &#160;It is understood that the Initial Administrative Fee </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">20</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="font-size:11pt;">Escrow Amount and the Interest Reserve Amount shall be funded into the Reserve Account and the Expense Reserve Amount shall be funded into the Operating Account, in each case, on the Closing Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">During the Delayed Draw Commitment Period, Borrower may make one (1) draw of Delayed Draw Term Loans in a minimum amount of $10,000,000.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Shares; Availability of Funds</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Shares</u><font style="font-size:11pt;">. &#160;All Term Loans shall be made by Lenders simultaneously and proportionately to their respective Pro Rata Shares, it being understood that no Lender shall be responsible for any default by any other Lender in such other Lender&#8217;s obligation to make a Term Loan requested hereunder nor shall any Term Loan Commitment of any Lender be increased or decreased as a result of a default by any other Lender in such other Lender&#8217;s obligation to make a Term Loan requested hereunder or purchase a participation required hereby.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Availability of Funds</u><font style="font-size:11pt;">. &#160;Unless Administrative Agent shall have been notified by any Lender prior to the applicable Credit Date that such Lender does not intend to make available to Administrative Agent the amount of such Lender&#8217;s Term Loan requested on such Credit Date, Administrative Agent may assume that such Lender has made such amount available to Administrative Agent on such Credit Date and Administrative Agent may, in its sole discretion, but shall not be obligated to, make available to Borrower a corresponding amount on such Credit Date. &#160;If such corresponding amount is not in fact made available to Administrative Agent by such Lender, Administrative Agent shall be entitled to recover such corresponding amount on demand from such Lender together with interest thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the customary rate set by Administrative Agent for the correction of errors among banks. &#160;If such Lender does not pay such corresponding amount forthwith upon Administrative Agent&#8217;s demand therefor, Administrative Agent shall promptly notify Borrower and Borrower shall immediately pay such corresponding amount to Administrative Agent together with interest thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the rate payable hereunder. &#160;Nothing in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(c)(ii)</u><font style="font-size:11pt;"> shall be deemed to relieve any Lender from its obligation to fulfill its Term Loan Commitments hereunder or to prejudice any rights that Borrower may have against any Lender as a result of any default by such Lender hereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article III</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488563"></a><b style="font-size:11pt;font-weight:bold;">RE</b><b style="font-size:11pt;font-weight:bold;">P</b><b style="font-size:11pt;font-weight:bold;">AYMENT</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 3.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488564"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amortization; Maturity Date</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">If not earlier repaid in full, the unpaid balance of the outstanding Principal Amount of the Term Loan, together with any accrued and unpaid interest, and all other Obligations then outstanding, shall be due and payable in cash to the Payment Account on the Maturity Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">The outstanding principal balance of the Term Loan and any interest or premium due with respect thereto shall be repayable solely from Commercial Payments except (i) in connection with voluntary prepayment of the Term Loan pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(b)</u><font style="font-size:11pt;"> or </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.03</u><font style="font-size:11pt;"> or (ii) in connection with prepayments required pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">If the remaining Interest Reserve Amount in the Reserve Account for any Interest Payment Date is insufficient to satisfy the Semi-Annual Interest Shortfall (the difference between the Semi-Annual Interest Shortfall and the remaining Interest Reserve Amount in the Reserve Account the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deficiency Amount</u><font style="font-size:11pt;">&#8221;), then any such Deficiency Amount, unless paid in cash by Borrower on the Interest </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">21</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">Payment Date with the proceeds of a substantially concurrent capital contribution from Company, shall increase the outstanding Principal Amount of the Term Loan by an amount equal to the Deficiency Amount for the applicable Interest Payment Date (rounded up to the nearest whole dollar) and each Lender shall be deemed to have made an additional term loan in a Principal Amount equal to its Pro Rata Share of the aggregate amount of such Deficiency Amount (such additional term loan, &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accreted Principal</u><font style="font-size:11pt;">&#8221;). &#160;Accreted Principal shall be deemed to be part of the Term Loan made to Borrower for all purposes under this Agreement, and the Term Loan shall bear interest on such increased Principal Amount from and after the applicable Interest Payment Date in accordance with </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.01</u><font style="font-size:11pt;">. In the event of any repayment or prepayment of the Term Loan (including, without limitation, principal payments due under </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.05(a)(ii)</u><font style="font-size:11pt;">), accrued and unpaid Fixed Interest on the Principal Amount repaid or prepaid shall be payable on the date of such repayment or prepayment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 3.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488565"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mandatory Prepayment; Voluntary Prepayment</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mandatory Prepayment</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">During the continuance of an Event of Default the Administrative Agent may declare the outstanding Principal Amount of the Term Loan, </font><i style="font-size:11pt;font-style:italic;">plus</i><font style="font-size:11pt;"> any accrued and unpaid interest thereon, to be immediately due and payable hereunder, in whole but not in part, to the extent permitted by law, together with all other Obligations, including those fees set forth in the Fee Letter and payable upon such prepayment, then outstanding or due in connection therewith, to the Payment Account.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">In connection with the prepayment in full of the Term Loan outstanding under </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)</u><font style="font-size:11pt;">, any unpaid amounts in respect of such prepaid Term Loan not consisting of principal or Fixed Interest (i.e., any unpaid amounts for indemnification, tax gross-up, default interest, expense reimbursement and other amounts not consisting of principal or interest) shall be immediately due and payable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">In connection with any prepayment under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)</u><font style="font-size:11pt;">, Borrower shall provide to Administrative Agent a Notice of Prepayment showing the calculation of the amount to be prepaid and all other amounts payable in connection therewith under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><font style="font-size:11pt;">Notwithstanding anything in this Agreement or in any other Loan Document to the contrary, if the Term Loan shall remain outstanding after the fifth (5th) anniversary of the initial issuance thereof and the aggregate amount that would be includible in the gross income of a Lender with respect to the Term Loan (within the meaning of Section 163(i) of the Code or any successor provision) for the periods ending on or before any Interest Payment Date that occurs after such fifth (5th) anniversary (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aggregate Accrual</u><font style="font-size:11pt;">&#8221;) would otherwise exceed an amount equal to the sum of (i) the aggregate amount of interest to be paid (within the meaning of Section 163 (i) of the Code) under the Term Loan on or before such Interest Payment Date, and (ii) the product of (A) the issue price (as defined in Section 1273(b) of the Code) of the Term Loan and (B) the yield to maturity (interpreted in accordance with Section 163(i) of the Code) of the Term Loan (such sum, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Accrual</u><font style="font-size:11pt;">&#8221;), then Borrower shall pay on each applicable Interest Payment Date occurring after such fifth (5th) anniversary that portion of the outstanding Principal Amount of the Term Loan necessary to prevent the Term Loan from constituting an &#8220;applicable high yield discount obligation&#8221; within the meaning of Section 163(i) of the Code, up to an amount equal to the excess, if any, of the Aggregate Accrual over the Maximum Accrual (each such payment, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AHYDO Payment</u><font style="font-size:11pt;">&#8221;) and the amount of such AHYDO Payment and any interest thereon shall be treated for U.S. federal income tax purposes as an amount of interest to be paid (within the meaning of Section 163(i)(2)(B)(i) of the Code) under the Term Loan. &#160;This provision is intended to prevent the Term Loan from being classified as an &#8220;applicable high yield discount obligation,&#8221; as defined in Section 163(i) of the Code, and shall be interpreted consistently therewith.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">22</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voluntary Prepayment</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">Subject to the terms of the Fee Letter, Borrower may prepay the outstanding Principal Amount of the Term Loan, </font><i style="font-size:11pt;font-style:italic;">plus</i><font style="font-size:11pt;"> any accrued and unpaid interest thereon, in whole but not in part, to the extent permitted by law, together with all other Obligations, including those fees set forth in the Fee Letter and payable in connection with such prepayment, then outstanding or due in connection therewith, to the Payment Account.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">In connection with the prepayment in full of the Term Loan outstanding under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(b)</u><font style="font-size:11pt;">, any unpaid amounts in respect of such prepaid Term Loan not consisting of principal or Fixed Interest (i.e., any unpaid amounts for indemnification, tax gross-up, default interest, expense reimbursement and other amounts not consisting of principal or interest) shall be immediately due and payable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">The date of prepayment of the Term Loan and any other amounts due to Lender under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(b)</u><font style="font-size:11pt;">, shall be a Business Day not more than 10 Business Days following the date Borrower has provided to Administrative Agent a Notice of Prepayment showing the calculation of the amount to be prepaid and all other amounts payable in connection therewith under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(b)</u><font style="font-size:11pt;">. &#160;Such Notice of Prepayment shall constitute Borrower&#8217;s irrevocable commitment to prepay the Term Loan outstanding and all such other amounts on such prepayment date; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that such Notice of Prepayment may state that such notice is conditioned upon the effectiveness of any credit facilities or one or more other events specified therein (including the occurrence of a Change of Control), in which case such notice may be revoked by Borrower (by notice to Lender on or prior to the specified effective date) if such condition is not satisfied.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 3.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488566"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Increased Cost</u>.<font style="display:inline-block;width:4.19pt;"></font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">If any Regulatory Change occurs that has or would have the effect of: </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">imposing, modifying or deeming applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, Lender; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">subjecting Lender to any Taxes (other than (A) Indemnified Taxes or (B) Excluded Taxes) with respect to the Term Loan, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">imposing on Lender any other condition, cost or expense (other than Taxes) affecting this Agreement or Term Loan made by Lender;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:12.0pt;text-align:justify;margin:0pt;">and the result of any of the foregoing shall be to reduce the rate of return on the capital of Lender as a consequence of its obligations hereunder or arising in connection herewith to a level below that which Lender could have achieved but for such introduction, change or compliance (taking into consideration the policies of Lender with respect to capital adequacy) by an amount deemed by Lender to be material, then from time to time, on the first Interest Payment Date occurring at least thirty (30) days after demand by Lender (which demand shall be accompanied by a statement setting forth the basis for such demand and a description of the computation of such demand), Borrower shall pay directly to Lender such additional amount or amounts as will compensate Lender for such reduction. &#160;Lender will take such actions reasonably requested by Borrower, at the expense of Borrower, if such actions will avoid the need for, or reduce the amount of, such compensation and will not, in the judgment of Lender, be otherwise disadvantageous to it or inconsistent with its internal policies and procedures. &#160;In no event will Lender be expected or required to </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">23</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">monitor the occurrence of any of the events or contingencies described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.03(a)</u>. &#160;Notwithstanding the foregoing, in no event shall Borrower be required to compensate Lender pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.03</u> for any amounts under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.03</u> incurred more than one hundred and eighty (180) days prior to the date that Lender notifies Borrower of such amount and of Lender&#8217;s intention to claim compensation therefor.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">In determining any amount provided for in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.03</u><font style="font-size:11pt;">, Lender shall use commercially reasonable averaging and attribution methods. &#160;If Lender makes a claim under this Section 3.03,&#160;it shall submit to Borrower a certificate setting forth the basis for such demand and a description of the computation of such demand as to such additional or increased cost or reduction, which certificate shall be conclusive absent manifest error.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">If a Lender submits a demand in writing to Borrower to pay any additional amounts pursuant to this Section 3.03, Borrower may elect, in its sole discretion, upon ten (10) Business Days prior written notice to such Lender and the Administrative Agent, to repay the Loan held by such Lender in full in accordance with Section 3.02(b) and such repayment may be on a non-pro rata basis; provided that such demand has not been rescinded in writing by such Lender or any permitted Assignee prior to the making of such repayment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article IV</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488567"></a><b style="font-size:11pt;font-weight:bold;">INTEREST; FEES; EXPENSES; MAKING OF PAYMENTS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488568"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest Rate; Fees</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">The outstanding Principal Amount of the Term Loan shall bear interest consisting of Fixed Interest, which shall be paid in cash as provided in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.01</u><font style="font-size:11pt;"> or accreted as set forth in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Borrower agrees to pay all fees payable by it in the Fee Letter in the amounts and at the times specified therein.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_Hlk152696993"></a><font style="font-size:11pt;">All interest hereunder in respect of Fixed Interest and all fees referred to in this Section 4.01(b) shall be computed on the basis of a 360-day year of twelve 30-day months.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><a name="_Hlk152697124"></a><font style="font-size:11pt;">Fixed Interest on the Term Loan shall be payable solely from the Commercial Payments, except (i) in connection with voluntary prepayment of the Term Loan pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(b)</u><font style="font-size:11pt;"> or </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.03</u><font style="font-size:11pt;"> and (ii) in connection with prepayments required pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">For the avoidance of doubt, Fixed Interest that is not paid in cash on the date due but that is added to the Principal Amount of the Term Loan as Accreted Principal in accordance with Section 3.01(c) shall accrue Fixed Interest from the date at which it is incorporated as Accreted Principal.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488569"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reserve Account.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">On or before the Closing Date, Borrower (i) shall establish with an Account Bank the Reserve Account and (ii) together with Administrative Agent and such Account Bank, enter into a Blocked Account Control Agreement. &#160;In accordance with </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(b)(ii)</u><font style="font-size:11pt;">, Administrative Agent shall deposit the Interest Reserve Amount and the Initial Administrative Fee Escrow Amount from the proceeds of the Initial Term Loan into the Reserve Account on the Initial Funding Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Borrower shall promptly pay for any fees, expenses and charges of the Account Bank required to be made to the Account Bank with respect to the Reserve Account and pursuant to the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">24</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">terms of the Blocked Account Control Agreement by transferring from the Operating Account sufficient funds into the Reserve Account when such fees, expenses and charges are due.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Prior to the Payment in Full, Borrower shall have no right to (i) terminate the Reserve Account or (ii) direct the use of balances on deposit therein, except, with respect to this clause (ii) only, as set forth in the immediately following clause (d) and in Section 4.05(a)(iv).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">On any Interest Payment Date on which the Included Commercial Payments to be applied to Fixed Interest and Amortization Payments is equal to or greater than $[***], Borrower may elect, by written notice to Administrative Agent, for a portion of the Interest Reserve Amount not to exceed $[***] to be either (x) released to the Operating Account (for distribution to Company) or (y) applied in repayment of the principal amount of the Term Loan and any fees due in respect of such prepayment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488570"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Account.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">On or before the Closing Date, Borrower shall (i) establish with the Account Bank the Operating Account and (ii) together with Administrative Agent and the Account Bank, enter into a Springing Account Control Agreement. &#160;In accordance with </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(b)(ii)</u><font style="font-size:11pt;">, Administrative Agent shall deposit the Expense Reserve Amount into the Operating Account on the Initial Funding Date simultaneous with the funding of the Initial Term Loan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Prior to the Payment in Full, Borrower shall have no right to terminate the Operating Account. &#160;The Operating Account shall be used solely for (i) holding the Expense Reserve Amount, (ii) holding the proceeds of capital contributions from Company and (iii) making payments (including as contemplated by Section 4.02(b)) with respect to Taxes and Expenses. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Prior to the Payment in Full, Borrower shall have no right to terminate the Operating Account without Administrative Agent&#8217;s prior written consent; provided that, without Lender&#8217;s consent, Borrower shall have the right from time to time to establish a replacement Operating Account with a replacement Account Bank, provided that such replacement Account Bank has entered into a Springing Account Control Agreement with the Administrative Agent with respect to such replacement account effective no later than the date of such replacement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of this Agreement, any reference to the &#8220;Operating Account,&#8221; or the Springing Account Control Agreement entered into in connection therewith shall refer to such replacement Operating Account and Springing Account Control Agreement or Account Bank, as the context require.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488571"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collection Account</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">On or before the Closing Date or such later date as Administrative Agent may agree in is sole discretion, Borrower shall (i) establish with the Account Bank the Collection Account and (ii) together with Administrative Agent and the Account Bank, enter into a Springing Account Control Agreement with the Account Bank.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Borrower shall promptly pay for all fees, expenses and charges of the Account Bank required to be made to the Account Bank with respect to the Collection Account and pursuant to the terms of the applicable Springing Account Control Agreement by depositing sufficient funds into the Collection Account when such fees, expenses and charges are due (it being understood that such amounts may be disbursed out of the Operating Account in accordance with Section 4.05). </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">25</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Prior to the Payment in Full, Borrower shall have no right to terminate the Collection Account without Administrative Agent&#8217;s prior written consent; provided that, without Lender&#8217;s consent to the change of location of such accounts (provided such location is in the United States), Borrower shall have the right from time to time to establish a replacement Collection Account with a replacement Account Bank, provided that such replacement Account Bank entered into a Springing Account Control Agreement with respect to such replacement accounts effective no later than the date of replacement, and Borrower instructs the applicable Covered Agreement Counterparties to make payments to such new accounts.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of this Agreement, any reference to the &#8220;Collection Account,&#8221; or the Springing Account Control Agreement entered into in connection therewith shall refer to such replacement Collection Account and Springing Account Control Agreement or Account Bank, as the context requires.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">On or before the Closing Date, Borrower shall deliver a written notice to each Covered Agreement Counterparty as to the sale and assignment of the </font><font style="font-size:11pt;">Transferred Assets</font><font style="font-size:11pt;"> to Borrower and instructions for payment thereafter with respect to all payments that are due and payable to Borrower in respect of or derived from the Covered Agreements (which notice and instructions shall be in the form attached to the Sale Agreement or otherwise reasonably satisfactory to Administrative Agent) and shall provide that each Covered Agreement Counterparty is to remit all amounts payable to Borrower in respect thereof to the Collection Account.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">To the extent any Commercial Payments are paid directly to Borrower (other than to the Collection Account), Borrower</font><font style="font-size:11pt;"> shall (i) remit to the Collection Account all such amounts within five (5) Business Days of receipt of any such funds, (ii) promptly instruct such Covered Agreement Counterparty to remit any future payments to the Collection Account and (iii) promptly provide to Administrative Agent a copy of such notice.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.05</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488572"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Application of Payments; Ratable Sharing</u><font style="text-decoration-color:#000000;text-decoration-line:none;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Hlk153455498"></a><font style="font-size:11pt;">On each Interest Payment Date, the Borrower shall (1) promptly deliver to the Administrative Agent the Payment Date Distribution Report and (2) distribute from the Collection Account all Included Commercial Payments received since the immediately preceding Interest Payment Date in the order of priority set forth below but, in each case, only to the extent that all amounts then required to be paid ranking prior thereto have been paid in full</font><font style="font-size:11pt;">:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">first, to the Operating Account such amount as necessary, when taken together with all amounts then on deposit in the Operating Account, for payment of all Taxes then due and payable by Borrower, if any, in the amount shown in all supporting documentation attached to the Payment Date Distribution Report;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">second, to the Payment Account for application to all accrued and unpaid Lender Expenses (it being understood that invoices for such Lender Expenses shall have been provided at least ten (10) Business Days prior to the applicable Interest Payment Date);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">third, to the Operating Account such amount as necessary, when taken together with all amounts then on deposit in the Operating Account, for the payment of all Expenses not previously paid or reimbursed, in the amount requested by the Borrower and shown in supporting documentation attached to the Payment Date Distribution Report; provided, however, that: (1) unless and until a </font><a name="_9kR3WTr1AB4BFcLr91jgwmUz802v2B7DehE7N"></a><font style="font-size:11pt;">Servicer Termination Event</font><font style="font-size:11pt;"> (as defined in the Sale Agreement) has occurred and a new Servicer (as defined in the Sale Agreement) that is not an Affiliate of Borrower has been appointed in accordance with Section 5.05 of the Sale Agreement, no Servicing Fee shall be permitted to be paid under this Section </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">26</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="font-size:11pt;">4.05(a)(iii) and (2) all fees payable under this Section 4.05(a)(iii) for any Semi-Annual Period shall not exceed the lesser of (x) an amount necessary, after application of all amounts then on deposit in the Operating Account, to pay such Expenses and (y) $25,000;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><font style="font-size:11pt;">fourth, to the Payment Account for application, on the Interest Payment Date, to all accrued and unpaid Fixed Interest on the Term Loan for the period from and including the prior Interest Payment Date to and including the day before the current Interest Payment Date; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that if Included Commercial Payments for such period are insufficient to pay all amounts of Fixed Interest due on the Term Loan for such period (the amount of such shortfall, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Semi-Annual Interest Shortfall</u><font style="font-size:11pt;">&#8221;), Administrative Agent shall instruct the Account Bank, with respect to the Interest Reserve Amount, to release to Administrative Agent, for distribution to the Lenders in payment of Fixed Interest, an amount equal to the Semi-Annual Interest Shortfall or, if the Interest Reserve Amount remaining in the Reserve Account is less than the Semi-Annual Interest Shortfall, all remaining Interest Reserve Amounts in the Reserve Account (it being understood that any Fixed Interest remaining unpaid after application of all Interest Reserve Amounts shall not be required to be paid in cash and shall instead become Accredited Principal in accordance with Section 3.01); &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><font style="font-size:11pt;">fifth, to the extent the Included Commercial Payments for such period exceeds the amounts payable under the foregoing clauses (i)-(iv) (such amount, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amortization Payment</u><font style="font-size:11pt;">&#8221;), the Amortization Payment shall be disbursed to the Payment Account and applied by the Administrative Agent to repay, on a pro rata basis, principal on the Term Loans outstanding at par.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Administrative Agent shall promptly distribute to each Lender at such address as such Lender shall indicate in writing, a copy of the Payment Date Distribution Report and such Lender&#8217;s applicable Pro Rata Share of all payments and prepayments of principal and interest due hereunder, together with all other amounts due with respect thereto, including, without limitation, all fees payable with respect thereto, to the extent received by Administrative Agent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Lenders hereby agree among themselves that, except as otherwise provided in the Collateral Documents with respect to amounts realized from the exercise of rights with respect to Liens on the Collateral, if any of them shall, whether by voluntary payment (other than a voluntary prepayment of Term Loans made and applied in accordance with the terms hereof), through the exercise of any right of set off or banker&#8217;s lien, by counterclaim or cross action or by the enforcement of any right under the Loan Documents or otherwise, or as adequate protection of a deposit treated as cash collateral under the Bankruptcy Code, receive payment or reduction of a proportion of the aggregate amount of principal, interest, fees and other amounts then due and owing to such Lender hereunder or under the other Loan Documents (collectively, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aggregate Amounts Due</u><font style="font-size:11pt;">&#8221; to such Lender) which is greater than the proportion received by any other Lender in respect of the Aggregate Amounts Due to such other Lender having Term Loans, then the Lender receiving such proportionately greater payment shall (a) notify Administrative Agent and each other Lender of the receipt of such payment and (b) apply a portion of such payment to purchase participations (which it shall be deemed to have purchased from each seller of a participation simultaneously upon the receipt by such seller of its portion of such payment) in the Aggregate Amounts Due to the other Lenders so that all such recoveries of Aggregate Amounts Due shall be shared by all Lenders having Term Loans in proportion to the Aggregate Amounts Due to them; provided, if all or part of such proportionately greater payment received by such purchasing Lender is thereafter recovered from such Lender upon the bankruptcy or reorganization of Borrower or otherwise, those purchases shall be rescinded and the purchase prices paid for such participations shall be returned to such purchasing Lender ratably to the extent of such recovery, but without interest. &#160;Borrower expressly consents to the foregoing arrangement and agrees that any holder of a participation so purchased may exercise any and all rights of banker&#8217;s lien, set off or counterclaim with respect to any and all monies owing by Borrower to that holder with respect thereto as fully as if that holder were owed the amount of the participation held by that holder.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">27</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.06</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488573"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest on Late Payments</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If any amount payable by Borrower to Administrative Agent hereunder is not paid (or accreted in accordance with Section 3.01(c)) when due (whether at stated maturity, by acceleration or otherwise), interest shall accrue on any such unpaid amounts, both before and after judgment during the period from and including the applicable due date, to but excluding the day the overdue amount is paid in full, at a rate per annum equal to the Default Rate. &#160;Interest accruing under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.06</u> shall be payable on demand of Administrative Agent acting at the direction of the Required Lenders. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, any Accreted Principal shall also accrue interest at the Default Rate in the event that Fixed Interest that is not paid in cash on the date due but that is added to the Principal Amount of the Term Loan as Accreted Principal in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01(c)</u> shall accrue Fixed Interest from the date at which it is incorporated as Accreted Principal and shall thereafter accrue interest at the Default Rate in the event that the Principal Amount of the Term Loan generally bears interest at the Default Rate.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.07</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488574"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration and Enforcement Expenses</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall promptly reimburse Administrative Agent and each Lender on demand for all Lender Expenses.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.08</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488575"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Making of Payments</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary contained herein, any payment stated to be due hereunder on a given day in a specified month shall be made or shall end (as the case may be), (i) if there is no such given day or corresponding day, on the last Business Day of such month or (ii) if such given day or corresponding day is not a Business Day, on the next succeeding Business Day.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 4.09</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488576"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Setoff or Counterclaim</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each payment by Borrower under this Agreement and the Fee Letter shall be made without setoff, deduction or counterclaim. &#160;Administrative Agent and each Lender shall have the right to set off any and all amounts owed by Borrower under this Agreement as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.03</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article V</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488577"></a><b style="font-size:11pt;font-weight:bold;">TAXES</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488578"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Except as otherwise required by Applicable Law, all payments by Borrower under this Agreement or any other Loan Document (including payments with respect to the Term Loan) shall be made free and clear of and without deduction for any present or future Taxes. &#160;If Borrower or any other applicable withholding agent shall be required by Applicable Law to deduct any Taxes from or in respect of any sum payable to Administrative Agent or any Lender under this Agreement or any other Loan Document, (i) if such Taxes are Indemnified Taxes, the sum payable by Borrower shall be increased as necessary so that after all required deductions for Indemnified Taxes have been made by the applicable withholding agent (including deductions applicable to additional sums payable under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.01(a)</u><font style="font-size:11pt;">), Administrative Agent or such Lender receives an amount equal to the sum it would have received had no such deductions been made, (ii) the applicable withholding agent shall make such deductions and (iii) the applicable withholding agent shall pay the full amount deducted to the relevant Governmental Authority in accordance with Applicable Law.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">28</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Status of Lenders</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to any payments made under any Loan Document shall deliver to Borrower, at the time or times reasonably requested by Borrower, such properly completed and executed documentation reasonably requested by Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding. &#160;In addition, any Lender, if reasonably requested by Borrower, shall deliver such other documentation prescribed by Applicable Law or reasonably requested by Borrower as will enable Borrower to determine whether or not such Lender is subject to backup withholding or information reporting requirements.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">Without limiting the generality of the foregoing: </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font><font style="font-size:11pt;">If a Lender is a Foreign Lender, then such Lender shall provide to Borrower (i) in the case of a Foreign Lender claiming exemption from U.S. federal withholding tax under Section 871(h) or 881(c) of the Code with respect to payments of &#8220;portfolio interest,&#8221; (x) two accurate and complete original signed copies of </font><a name="_9kR3WTr266478Py9yL43"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8BEN-</font><a name="_9kR3WTr266479MH1W1C1O76"></a><font style="font-size:11pt;">E or IRS Form</font><font style="font-size:11pt;"> W-8BEN (or a successor form), as applicable, properly completed and duly executed by such Foreign Lender and (y) a certificate substantially in the form of Exhibit E-1 to the effect that such Foreign Lender is not (A) a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, (B) a &#8220;10 percent shareholder&#8221; of Borrower within the meaning of Section 881(c)(3)(B) of the Code or (C) a &#8220;controlled foreign corporation&#8221; described in Section 881(c)(3)(C) of the Code, (ii) if the payments receivable by the Foreign Lender are effectively connected with the conduct of a trade or business in the United States, two accurate and complete original signed copies of </font><a name="_9kMHG5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8ECI (or a successor form), (iii) in the case of a Foreign Lender that is entitled to benefits under an income tax treaty to which the United States is a party, two accurate and complete original signed copies of </font><a name="_9kMIH5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8BEN-</font><a name="_9kR3WTr26649EPH1W1C1O76"></a><font style="font-size:11pt;">E or </font><a name="_9kMJI5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8BEN, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the applicable article(s) of such tax treaty or (iv) to the extent a Foreign Lender is not the beneficial owner, two accurate and complete original signed copies of </font><a name="_9kMKJ5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8IMY, accompanied by two accurate and complete copies of </font><a name="_9kMLK5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8ECI, </font><a name="_9kMML5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8BEN, or </font><a name="_9kMNM5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-8BEN-E, as applicable, a certificate substantially in the form of Exhibit E-2 or Exhibit E-3, </font><a name="_9kMON5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership (and not a participating Lender) and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a certificate substantially in the form of Exhibit E-4 on behalf of such direct and indirect partner(s). &#160;Such forms or certificates shall be delivered by such Foreign Lender on or prior to the date that it becomes a Lender under this Agreement, at any time thereafter if any form or certification previously delivered expires or becomes obsolete or inaccurate in any respect, and upon a reasonable written request of Borrower. &#160;Notwithstanding any other provision of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.01(b)</u><font style="font-size:11pt;">, no Foreign Lender shall be required to deliver any form pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.01(b)</u><font style="font-size:11pt;"> that such Foreign Lender is not legally eligible to deliver.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font><font style="font-size:11pt;">Each Lender that is not a Foreign Lender shall provide two properly completed and duly executed copies of </font><a name="_9kMPO5YVt48869AR0B0N65"></a><font style="font-size:11pt;">IRS Form</font><font style="font-size:11pt;"> W-9 (or successor form) certifying that such Lender is exempt from U.S. federal backup withholding tax on or prior to the date on which such Lender becomes a Lender under this Agreement, at any time thereafter if any form or certification previously delivered expires or becomes obsolete or inaccurate in any respect, and upon a reasonable written request of Borrower. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(3)</font><font style="font-size:11pt;">Any Foreign Lender shall, to the extent it is legally eligible to do so, deliver to Borrower (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">29</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">thereafter upon the reasonable request of Borrower), executed copies of any other form prescribed by Applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by Applicable Law to permit Borrower to determine the withholding or deduction required to be made; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(4)</font><font style="font-size:11pt;">If a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to Borrower at the time or times prescribed by Applicable Law and at such time or times reasonably requested by Borrower such documentation prescribed by Applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by Borrower as may be necessary for Borrower to comply with its obligations under FATCA, to determine whether such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. &#160;Solely for purposes of this clause (D), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">Each Lender having assigned its rights and obligations hereunder in whole or in part shall collect from such assignee at the time of the assignment the documents described in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 5.01(b)(ii)(1)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)(ii)(2)</u><font style="font-size:11pt;"> as applicable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488579"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receipt of Payment</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Within thirty (30) days after the date of any payment of Taxes by Borrower pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</u>, Borrower shall furnish to Administrative Agent the original or a certified copy of a receipt evidencing payment thereof or other evidence reasonably satisfactory to Administrative Agent.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488580"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Taxes</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall promptly pay any registration, transfer, stamp or documentary, recording or similar Taxes arising from any payment made under any Loan Document, or from the execution, delivery, performance, enforcement or registration of, the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes with respect to an assignment by a Lender that are Other Connection Taxes (all such non-excluded Taxes, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Taxes</u>&#8221;), to the relevant Governmental Authority in accordance with Applicable Law.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488581"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. &#160; </div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If Administrative Agent or any Lender pays any Indemnified Taxes that Borrower is required to pay pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</u>, Borrower shall indemnify Administrative Agent or such Lender on demand in full (including any Indemnified Taxes imposed by any jurisdiction on amounts payable under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.04</u>), whether or not such Taxes were correctly or legally asserted. &#160;A certificate of Administrative Agent or any affected Lender claiming any compensation under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.04</u>, setting forth the amounts to be paid thereunder and delivered to Borrower, shall be conclusive, binding and final for all purposes, absent manifest error.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.05</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488582"></a><a name="_DV_C128"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registered Obligation</u>.<a name="_DV_C129"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_DV_M337"></a><font style="font-size:11pt;">Borrower shall establish and maintain, at its address referred to in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.03</u><font style="font-size:11pt;">, (i) a Register in which Borrower agrees to register by book entry the interests (including any rights to receive payment hereunder) of Lender in the Term Loan, each of its obligations under this Agreement to </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">30</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">participate in the Term Loan, and any assignment of any such interest, obligation or right, and (ii)&#160;accounts in the Register in accordance with its usual practice in which it shall record (1)&#160;the names and addresses of Lender(s) (and each change thereto pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 12.01</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.02</u><font style="font-size:11pt;">), (2)&#160;the amount of the Term Loan described in clause (i) above, </font><a name="_9kR3WTr8EAAFJH"></a><font style="font-size:11pt;">(3)</font><font style="font-size:11pt;">&#160;the amount of any principal or interest due and payable or paid, and (4)&#160;any other payment received and its application to the Term Loan. &#160;The entries in the Register shall be conclusive, in the absence of manifest error, and Borrower and each Lender shall treat each person whose name is recorded in the Register as the owner of the Term Loans for all purposes of this Agreement, notwithstanding notice to the contrary. &#160;No error in the Register shall diminish any of Borrower&#8217;s obligations to any Lender under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Notwithstanding anything to the contrary contained in this Agreement or elsewhere, the Term Loan (including any note evidencing such Term Loan) are registered obligations, the right, title and interest of Lender and its assignees in and to the Term Loan shall be transferable only upon notation of such transfer in the Register and no assignment thereof shall be effective until recorded therein. &#160;The parties hereto intend that the Term Loan will be at all times maintained in &#8220;registered form&#8221; within the meaning of Section 5f.103-1(c) of the U.S. Treasury Regulations, Sections 163(f), 871(h)(2) and 881(c)(2) of the Code and any related regulations (and any successor provisions). &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.06</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488583"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Treatment</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For U.S. federal income and applicable state and local income tax purposes, the Parties agree to the following: </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">the Term Loan is debt; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">any contingency associated with the Term Loan is described in Treasury Regulation Section 1.1272-1(c) and/or Treasury Regulations Section 1.1275-2(h) and therefore the Term Loan is not governed by the rules set out in Treasury Regulations Section 1.1275-4; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">interest payable on the Term Loan is not contingent interest within the meaning of Sections 871(h)(4) and 881(c)(4) of the Code;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">the Term Loan and Warrant constitutes an investment unit within the meaning of Section 1273 of the Code; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">the Parties shall determine the fair market value of the Warrant as promptly as practicable after the Closing Date; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">this Agreement is not intended to create a partnership, association or joint venture between or among Lender and/or Borrower or any Subsidiary and each Party agrees not to refer to the other as a &#8220;partner&#8221; or the relationship as a &#8220;partnership&#8221; or &#8220;joint venture&#8221;.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each Party agrees not to take any position that is inconsistent with the intended tax treatment set forth in this Section 5.06 on any Tax return or in any audit or other administrative or judicial proceeding unless (i) each other Party has consented to such actions; or (ii) as a result of a material change in Applicable Law following the date of this Agreement, counsel for such Party has advised it in writing that taking such a position would, notwithstanding compliance with all applicable reporting requirements and disclosure obligations, subject such Party to penalties under the Code.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">31</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 5.07</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488584"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Certain Refunds</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</u> (including by the payment of additional amounts pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</u>), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</u> with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). &#160;Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.07</u> (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. &#160;Notwithstanding anything to the contrary in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.07</u>, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.07</u> the payment of which would place the indemnified party in a less favorable net <a name="_9kR3WTr26647AjauutjNy"></a>after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. &#160;This <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.07</u> shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article VI</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488585"></a><b style="font-size:11pt;font-weight:bold;">CONDITIONS PRECEDENT</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 6.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488586"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The effectiveness of this Agreement, and the obligation of each Lender to make a Credit Extension on the Initial Funding Date, is subject to the satisfaction of the following conditions on or before the Closing Date:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">This Agreement and the other Loan Documents shall have been executed and delivered to Administrative Agent by each party thereto.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Administrative Agent shall have received an executed copy of:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;white-space:pre-wrap;"> </font><font style="font-size:11pt;">an opinion of counsel to the Transaction Parties, dated the Closing Date in form and substance reasonably satisfactory to Administrative Agent and each Lender;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">a certificate of each Loan Party, executed respectively by a Senior Officer thereof, dated the Closing Date, substantially in the form of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit F</u><font style="font-size:11pt;"> hereto; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">Each Notice and Instruction Letter.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Each Loan Party shall have delivered to Lender a certificate, dated the Closing Date, of a Senior Officer (the statements in which shall be true and correct on and as of the Closing Date): (i) attaching copies, certified by such officer as true and complete, of such party&#8217;s certificate of incorporation or other organizational documents (together with any and all amendments thereto) certified by the appropriate Governmental Authority as being true, correct and complete copies; (ii)&#160;attaching copies, certified by such officer as true and complete, of resolutions of the Board of Directors (or similar governing body) of such party authorizing and approving the execution, delivery and performance by such party of the Loan Documents to which it is a party and the transactions contemplated herein and therein; (iii) setting </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">32</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">forth the incumbency of the officer of such party who executed and delivered such Loan Documents, including therein a signature specimen of each such officer; and (iv) attaching copies, certified by such officer as true and complete, of certificates of the appropriate Governmental Authority of the jurisdiction of formation, stating that such party was in good standing under the laws of such jurisdiction as of the Closing Date (or a date immediately prior thereto acceptable to Lender).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">The Transaction Documents shall be in full force and effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">All necessary governmental and third-party approvals, consents and filings, including in connection with the Term Loan, the Security Agreement, the Sale Agreement and the other Loan Documents shall have been obtained or made and shall remain in full force and effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">Borrower shall have delivered to Administrative Agent certified copies of UCC, tax and judgment lien searches, or equivalent reports or searches, each of a recent date listing all effective financing statements, lien notices or comparable documents that name Borrower as debtor and that are filed in those state and county jurisdictions in which Borrower is organized or maintains its principal place of business and such other searches that Administrative Agent deems necessary or appropriate, none of which encumber the Collateral covered or intended to be covered by the Loan Documents (other than any Permitted Liens).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><font style="font-size:11pt;">Administrative Agent shall have received all UCC financing statements in appropriate form for filing under the UCC, and all other certificates, agreements, instruments, filings, recordings and other actions, that are necessary or reasonably requested by Administrative Agent in order to establish, protect, preserve and perfect the security interest in the assets of Borrower constituting Collateral as provided in the Security Agreement as a valid and perfected first priority security interest with respect to such assets shall have been duly effected (or arrangements therefor satisfactory to Lender shall have been made).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><font style="font-size:11pt;">Administrative Agent and each Lender shall have received all documentation and other information required by bank regulatory authorities under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including without limitation, the Patriot Act, including and the information described in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;12.18</u><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">Parent shall have executed and delivered the Warrants. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><font style="font-size:11pt;">Borrower shall have paid (or caused to be paid) all fees, costs and expenses (including legal fees and expenses) agreed in writing to be paid by it to Administrative Agent in connection herewith (including pursuant to the Fee Letter) to the extent due on the closing date; provided that any invoices shall be provided at least one (1) Business Days prior to the Closing Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><font style="font-size:11pt;">Administrative Agent shall have received such other approvals, opinions, documents or materials as it may reasonably request.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 6.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488587"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions to Each Credit Extension</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153369591"></a><a name="_Toc153398162"></a><a name="_Toc153488588"></a></u><font style="text-decoration-line:none;">.</font><font style="text-decoration-line:none;"> &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc152286078"></a><a name="_Toc153369592"></a><a name="_Toc153398163"></a><a name="_Toc153488589"></a></u><font style="text-decoration-color:#000000;text-decoration-line:none;">The obligation of each Lender to make the Initial Term Loan on the Initial Funding Date or any other Term Loan on any date following the Closing Date is subject to the satisfaction or waiver of the following conditions precedent:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Administrative Agent shall have received a fully executed and delivered Funding Notice as and when required by </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(b)(i)</u><font style="font-size:11pt;">.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">33</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">As of as of the applicable Credit Date, no event shall have occurred and be continuing that (i) constitutes a Default or an Event of Default or (ii) could reasonably be expected to constitute a Material Adverse Effect (without giving effect to the cure period applicable to an Event of Default based thereon), in each case both at the time of, and immediately after giving effect to, the making of any Term Loan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">As of as of the applicable Credit Date, the representations and warranties contained herein and in each other Loan Document, certificate or other writing delivered to Administrative Agent or any Lender pursuant hereto or thereto on or prior to the Credit Date shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of that Credit Date to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of such earlier date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">On each Credit Date, the Loan Parties shall have paid all fees, costs and expenses then payable by the Loan Parties pursuant to this Agreement and the other Loan Documents; provided that any invoices shall be provided at least one (1) Business Days prior to the applicable Credit Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">With respect to the Delayed Draw Term Loan, on or prior to such Credit Date, Administrative Agent shall have received, upon request, evidence reasonably satisfactory to it that the Delayed Draw Funding Milestone has been satisfied.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article VII</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488590"></a><b style="font-size:11pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 7.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488591"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Borrower</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">In order to induce Administrative Agent and Lenders to enter into this Agreement and to make each Credit Extension to be made thereby, Borrower represents and warrants to Administrative Agent and Lender, on the Closing Date and on each Credit Date, that the following statements are true and correct:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Borrower is a limited liability company duly organized, validly existing and in good standing under the laws of the state of Delaware and has all powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all Governmental Authorities, required to own its property and conduct its business as now conducted. &#160;Borrower is duly qualified to transact business and is in good standing in every jurisdiction in which such qualification or good standing is required by Applicable Law (except where the failure to be so qualified or in good standing would not result in, and could not reasonably be expected to have resulted in a Material Adverse Effect). </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">None of the execution and delivery by Borrower of any of the Loan Documents to which Borrower is party, the performance by Borrower of the obligations contemplated hereby or thereby or the consummation of the transactions contemplated hereby or thereby will: (i) contravene, conflict with, result in a breach, violation, cancellation or termination of, constitute a default (with or without notice or lapse of time, or both) under, require prepayment under, give any Person the right to exercise any remedy (including termination, cancellation or acceleration) or obtain any additional rights under, or accelerate the maturity or performance of or payment under, in any respect, (A) any Applicable Law or any judgment, </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">34</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">order, writ, decree, permit or license of any Governmental Authority to which Borrower or any of its assets or properties may be subject or bound, (B) any term or provision of any contract, agreement, indenture, lease, license, deed, commitment, obligation or instrument to which Borrower is a party or by which Borrower or any of its assets or properties is bound or committed or (C) any term or provision of any of the organizational documents of Borrower, except in the case of clause (A) or (B) where any such event would not result in a Material Adverse Effect; or (ii), except as provided in or contemplated by any of the Transaction Documents, result in or require the creation or imposition of any Lien.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_Hlk152698055"></a><font style="font-size:11pt;">Other than pursuant to the Loan Documents, Borrower has not granted or agreed to grant any Lien on the Transferred Assets (other than, after the Closing Date, Permitted Liens), nor does there exist any Lien on the Transferred Assets or its Capital Stock (other than, after the Closing Date, Permitted Liens). </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">Borrower has all powers and authority to execute and deliver, and perform its obligations under, the Loan Documents to which it is party and to consummate the transactions contemplated hereby and thereby. &#160;The execution and delivery of each of the Loan Documents to which Borrower is party and the performance by Borrower of its obligations hereunder and thereunder have been duly authorized by Borrower. &#160;Each of the Loan Documents to which Borrower is party has been duly executed and delivered by Borrower. &#160;Each of the Loan Documents to which Borrower is party constitutes the legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar Applicable Laws affecting creditors&#8217; rights generally, general equitable principles and principles of public policy.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">Upon giving effect to the Sale (and subject to the terms and conditions thereof), Borrower shall be the exclusive owner of the entire right, title (legal and equitable) and interest in, to and under the Collateral, free and clear of all Liens, other than Permitted Liens, and Borrower shall be entitled to be the sole recipient of all Commercial Payments. &#160;Upon granting by Borrower of the security interests in the Collateral to Administrative Agent, Administrative Agent shall acquire a first priority security interest in the Collateral, free and clear of all Liens, other than Permitted Liens. &#160;Borrower has not caused, and to the Knowledge of Borrower no other Person has caused, the claims and rights of Administrative Agent or any Lender created by any Loan Document in and to the Collateral, to be subordinated to any creditor or any other Person.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">The execution and delivery by Borrower of the Loan Documents to which Borrower is party, the performance by Borrower of its obligations hereunder and thereunder and the consummation of any of the transactions contemplated hereunder and thereunder (including the granting of security interests in the Collateral to Administrative Agent) do not require any consent, approval, license, order, authorization or declaration from, notice to, action or registration by or filing with any Governmental Authority or any other Person, except for (i) the filing of any applicable notices under securities laws, (ii) the filings necessary to perfect Liens created by the Loan Documents, (iii) those previously obtained and in full force and effect, and (iv) consents, filings and registrations in connection with the Sale as contemplated by the Sale Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><font style="font-size:11pt;">There is no action, suit, arbitration proceeding, claim, citation, summons, subpoena, investigation or other proceeding (whether civil, criminal, administrative, regulatory, investigative or informal, and including by or before a Governmental Authority) pending or, to the Knowledge of Borrower, threatened in writing (or, in the case of a threat by a Governmental Authority, threatened orally or in writing) by or against Borrower or any of its Subsidiaries, at law or in equity, that (i) if adversely determined, would result in a Material Adverse Effect or (ii) challenges or seeks to prevent </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">35</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">or delay the consummation of any of the transactions contemplated by any of the Loan Documents to which Borrower is party. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><font style="font-size:11pt;">Upon consummation of the transactions contemplated by the Loan Documents and the application of the proceeds of the Term Loan to be made on the applicable Credit Date, (i) the present fair saleable value of the properties and assets of Borrower will be greater than the sum of its debts, liabilities and other obligations, including contingent liabilities, (ii) the present fair saleable value of the properties and assets of Borrower will not be less than the amount that would be required to pay its probable liabilities on its existing debts, liabilities and other obligations, including contingent liabilities, as they become absolute and matured, (iii) Borrower will be generally able to realize upon its assets and pay its debts, liabilities and other obligations, including contingent obligations, as they become absolute and matured, (iv) Borrower will not have unreasonably small capital with which to engage in its business as now conducted, (v) Borrower has not incurred debts or other obligations or liabilities beyond its ability to pay such debts or other obligations or liabilities as they become absolute and matured, (vi) Borrower will not have become subject to any Insolvency Event and (vii) Borrower will not have been rendered insolvent within the meaning of any Applicable Law. &#160;No step has been taken by Borrower or, to its Knowledge, any other Person to make Borrower subject to an Insolvency Event.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">No Default or Event of Default has occurred and is continuing, and no such event will occur upon the making of the Term Loan to be made on the applicable Credit Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><font style="font-size:11pt;">Borrower has timely filed (or caused to be filed) all Tax returns and reports required by Applicable Law to have been filed by it and has paid all Taxes required to be paid by it (including in its capacity as a withholding agent), except any such Taxes that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP have been set aside on its books or where any such failure to file or pay would not result, individually or in the aggregate, in a Material Adverse Effect. &#160;None of the payments received (or to be received) by Borrower in respect of the Commercial Payment Interest has been, or under current Law will be, subject to any deduction or withholding of any Tax.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><font style="font-size:11pt;">Borrower has not taken any action that would entitle any person or entity to any commission or broker&#8217;s fee in connection with the transactions contemplated by this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(l)</font><font style="font-size:11pt;">Borrower (i) has not violated, is not in violation of, is not under investigation with respect to, and has not been threatened to be charged with or been given notice of any violation of, any Applicable Law or any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority and (ii) is not subject to any judgment, order, writ, decree, injunction, stipulation, consent order, permit or license granted, issued or entered by any Governmental Authority, in each case, that would result in a Material Adverse Effect. &#160;Borrower is in compliance with the requirements of all Applicable Laws, a breach of any of which would result in a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(m)</font><font style="font-size:11pt;">Borrower is not engaged in the business of extending credit for the purpose of buying or carrying margin stock, and no portion of the Term Loan shall be used by Borrower for a purpose that violates Regulation T, U or X promulgated by the Board of Governors of the Federal Reserve System from time to time.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(n)</font><font style="font-size:11pt;">As of the Closing Date, Borrower is not a party to any Material Contract (other than, (i) after giving effect to the Sale thereof under the Sale Agreement, the Affitech Assignment Agreement and (ii) the Transaction Documents). </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">36</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(o)</font><a name="_Hlk152535704"></a><font style="font-size:11pt;">Neither Borrower nor, to the Knowledge of Borrower, any Covered Agreement Counterparty, as applicable, has taken any action or omitted to take any action that would adversely impact the right of Lender to take a security interest in the Collateral.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(p)</font><font style="font-size:11pt;">Each Covered Agreement is in full force and effect and has not been waived, altered or modified in any respect, whether by consent or otherwise. &#160;No party to any Covered Agreement has been released, in whole or in part, from any of its obligations under such Covered Agreement. &#160;No Covered Agreement has been satisfied in full, discharged, canceled, terminated, subordinated or rescinded, in whole or in part. &#160;Each Covered Agreement is the entire agreement among the parties thereto relating to the subject matter thereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(q)</font><font style="font-size:11pt;">Borrower has not received (i) any written notice or, to the Knowledge of Borrower, oral communication of any Covered Agreement Counterparty&#8217;s intention to terminate a Covered Agreement in whole or in part, or (ii) any written notice or, to the Knowledge of Borrower, oral communication requesting any amendment, alteration or modification to any Covered Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(r)</font><a name="_Hlk153459109"></a><font style="font-size:11pt;">To the Knowledge of Borrower, nothing has occurred and no condition exists that would adversely impact the right of Borrower to receive any Commercial Payments</font><font style="font-size:11pt;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(s)</font><font style="font-size:11pt;">To the Knowledge of Borrower, all Commercial Payments required to be made under the Covered Agreements have been made. &#160;To the Knowledge of Borrower, no Commercial Payment has been subject to any claim pursuant to any right of rescission, set-off, counterclaim, reduction or defense and except as otherwise expressly provided under any Covered Agreement, no Covered Agreement Counterparty has a right of set-off, rescission, counterclaim, reduction, deduction or defense against the Commercial Payment Interest or any Commercial Payments thereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(t)</font><font style="font-size:11pt;">The execution, delivery and performance of the Covered Agreements was and is within the corporate powers or other organizational power of Company and its Affiliates and, to the Knowledge of Borrower, each Covered Agreement Counterparty. &#160;Each Covered Agreement was duly authorized by all necessary action on the part of, and validly executed and delivered by, Company and its Affiliates and, to the Knowledge of Borrower, each Covered Agreement Counterparty. &#160;There is no breach or default, or event which upon notice or the passage of time, or both, could give rise to any breach or default, in the performance of any Covered Agreement by Borrower, Company or its Affiliate or, to the Knowledge of Borrower, each Covered Agreement Counterparty, that could reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(u)</font><font style="font-size:11pt;">Neither Borrower nor, to Borrower&#8217;s Knowledge, any Material Contract Counterparty is in breach or default of any Material Contract and no circumstances or grounds exist that would, upon the giving of notice, the passage of time or both, give rise (i) to a claim by Borrower or any Material Contract Counterparty of a breach or default of any Material Contract, or (ii) to a right of rescission, termination, revision, setoff, or any other rights, by any Person, in, to or under any Material Contract. &#160;Borrower has not received from, or delivered to, any Material Contract Counterparty, any notice alleging a breach or default under any Material Contract, which breach or default has not been cured as of the date hereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><font style="font-size:11pt;">Upon the Sale thereof to, and assumption thereof by, Borrower, the Affitech Assignment Agreement shall be a valid and binding obligation of Borrower and, to the Knowledge of Borrower, of the applicable Covered Agreement Counterparties, enforceable against each of Borrower and, to the Knowledge of Borrower, each applicable Covered Agreement Counterparty in accordance with its terms, except as may be limited by general principles of equity (regardless of whether considered in a proceeding at law or in equity) and by applicable bankruptcy, insolvency, moratorium and other similar </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">37</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">laws of general application relating to or affecting creditors&#8217; rights generally. &#160;Borrower has not received any notice from any Material Contract Counterparty or any other Person challenging the validity or enforceability of any Material Contract. &#160;Neither Borrower, nor to the Knowledge of Borrower, any other Person, has delivered or intends to deliver any written notice to Borrower or a Material Contract Counterparty challenging the validity or enforceability of any Material Contract.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(w)</font><font style="font-size:11pt;">Neither Borrower nor to the Knowledge of Borrower, any Material Contract Counterparty, is contemplating to commence any case, proceeding or other action relating to Material Contract Counterparty&#8217;s bankruptcy, insolvency, liquidation or dissolution or reorganization by any of the foregoing means.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(x)</font><font style="font-size:11pt;">No Capital Stock has been issued by Borrower other than the Capital Stock issued to Company that is subject to the pledge to Administrative Agent under the Pledge Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(y)</font><font style="font-size:11pt;">The chief place of business, the chief executive office and each office where Borrower keeps its records regarding the Commercial Payment Interest are, as of the date hereof, each located at 2200 Powell Street, Suite 310, Emeryville, CA 94608. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(z)</font><font style="font-size:11pt;">Borrower (or any predecessor by merger or otherwise) has not, within the five (5) year period preceding the date hereof, had a name that differs from its name as of the date hereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(aa)</font><font style="font-size:11pt;">Borrower is not an &#8220;investment company&#8221;, or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221;, within the meaning of the Investment Company Act of 1940.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(bb)</font><a name="_Hlk152536353"></a><font style="font-size:11pt;">All written information heretofore or herein supplied by or on behalf of Borrower or Company to Administrative Agent or any Lender is accurate and complete in all material respects; provided that all written information heretofore or herein supplied by or on behalf of Borrower to Lender and produced by any Third Party is accurate and complete in all material respects to the Knowledge of Borrower. &#160;There is no fact or circumstance known to Borrower that could reasonably be expected to have a Material Adverse Effect that has not been expressly disclosed to Administrative Agent and each Lender</font><font style="font-size:11pt;"> or in required reports and other information filed with the SEC under the Act and the Exchange Act (to the extent publicly available).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 7.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488592"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Reserved]</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 7.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488593"></a><a name="_Hlk152686504"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Representations and Warranties</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">All representations and warranties by Borrower, whether with respect to Borrower, Company, any respective Affiliate or any asset or property, contained in this Agreement shall survive the execution, delivery and acceptance thereof by the Parties and the closing of the transactions described in this Agreement and continue in effect until payment of all amounts due to Lender under the Loan Documents.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article VIII</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488594"></a><b style="font-size:11pt;font-weight:bold;">AFFIRMATIVE COVENANTS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Borrower covenants and agrees with Lender that, until Payment in Full:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488595"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintenance of Existence</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">Borrower shall at all times (a)&#160;preserve, renew and maintain in full force and effect its legal existence (except as otherwise permitted pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.02(a)</u> hereof) and good standing as a </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">38</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">corporation under the Laws of the jurisdiction of its organization; (b) not change its name or its chief executive office as set forth herein without having given Lender the notice thereof required under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.13</u>; and (c) take all reasonable action to maintain all rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488596"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Proceeds</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall use the net proceeds of the Term Loan received by it to (i) acquire assets from Company pursuant to the Sale Agreement, (ii) pay the fees and Lender Expenses due pursuant to the Loan Documents and (iii) fund the Reserve Account.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488597"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements and Information</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">In the event that any such information need not be filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act, Borrower shall furnish to Administrative Agent, on or before the forty-fifth (45</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) day after the close of each of the first three quarters of each fiscal year, the unaudited consolidated balance sheet of Parent as at the close of such quarter and unaudited consolidated statement of operations and comprehensive loss and cash flows of Parent for such quarter, duly certified by the chief financial officer of Parent as having been prepared in accordance with GAAP. &#160;In the event that such quarterly financial statement is required to be filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act, Borrower shall furnish such statement to Administrative Agent concurrently with such filing (which requirement may be satisfied by Borrower sending Lender a hyperlink to EDGAR where such information is available). &#160;Concurrently with the delivery or filing of the statements described in the preceding two sentences, Borrower shall furnish to Administrative Agent a certificate of the chief financial officer of Parent, which certificate shall include a statement that such officer has no knowledge, except as specifically stated, of any condition, event or act which constitutes a Default or Event of Default. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">In the event that any such information need not be filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act, Borrower shall furnish to Administrative Agent, on or before the 75th day after the close of each fiscal year, Parent&#8217;s audited financial statements as at the close of such fiscal year, including the consolidated balance sheet as at the end of such fiscal year and consolidated statement of operations and cash flows of Parent for such fiscal year, in each case accompanied by the report thereon of independent registered public accountant of nationally recognized standing reasonably satisfactory to Administrative Agent. &#160;In the event that such annual financial statement is required to be filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act, Borrower shall furnish such statement to Administrative Agent concurrently with such filing (which requirement may be satisfied by Borrower sending Lender a hyperlink to EDGAR where such information is available). &#160;Concurrently with delivery or filing of the documents described in the preceding sentence, Borrower shall furnish to Administrative Agent a certificate of the chief financial officer of Parent, which certificate shall include a statement that such officer has no knowledge, except as specifically stated, of any condition, event or act which constitutes a Default or Event of Default. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Borrower shall, promptly upon receipt thereof, forward or cause to be forwarded to Administrative Agent copies of all Notices, reports, updates and other data or information (i) pertaining to the Commercial Payment Interest and other Collateral, (ii) received from any Third Party which relate to events or circumstances that could reasonably be expected to have a Material Adverse Effect, or (iii) that Administrative Agent reasonably requests.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">For each Semi-Annual Period ending after the Closing Date, Borrower shall, within five (5) Business Days following receipt thereof, deliver or cause to be delivered to Administrative </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">39</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">Agent a true copy of the Assigned Commercial Payment Report for such Semi-Annual Period, together with a certificate of a Senior Officer of Borrower, certifying that to the Knowledge of Borrower such Assigned Commercial Payment Report is a true, correct and complete copy of the Assigned Commercial Payment Report as provided to Borrower by Roche, and such additional information as is reasonably requested by Administrative Agent. &#160;Administrative Agent shall have the right to direct Borrower to exercise the audit rights under Section 3.10 of the Affitech Assignment Agreement (subject to all restrictions and limitations thereon contained therein). &#160;Borrower shall not have the right to exercise the audit rights under Section 3.10 of the Affitech Assignment Agreement without the prior written consent of Administrative Agent. &#160;Any additional Commercial Payments due from Roche in connection with any such audit shall be paid by the Roche to the Collection Account, and any refund due to Roche from any overpayment in respect of the Commercial Payment Interest determined in any such audit shall be paid by Parent in accordance with the Affitech Assignment Agreement. &#160;Borrower and Administrative Agent will each provide reasonable prior written notice of its intent to exercise such audit rights and will reasonably cooperate in the exercise of such audit rights in order to avoid unnecessary limitations on the timing, scope and conduct of such audits within the parameters specified in the Affitech Assignment Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">Administrative Agent and its Representatives shall have the right, from time to time, not more than once per calendar quarter, during normal business hours and upon at least ten (10) Business Days&#8217; prior written notice to Borrower (provided that, after the occurrence and during the continuance of an Event of Default, Lender shall have the right, as often, at such times and with such prior notice, as Administrative Agent determines in its reasonable discretion), to visit the offices and properties of Borrower and Company where books and records relating or pertaining to the Commercial Payment Interest and the Collateral are kept and maintained (or, at Administrative Agent&#8217;s option, to conduct a meeting by telecommunications), to discuss, with officers of Borrower and Company, the business, operations, properties and financial and other condition of Borrower and Company, to discuss the Covered Agreement, to discuss the Assigned Commercial Payment Report, to verify compliance with the provisions of the Loan Documents regarding receipt and application of the Commercial Payments and, upon physical visits, to inspect and make extracts from and copies of the books and records of Borrower and Company relating or pertaining to the Commercial Payment Interest and the Collateral. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">All written information supplied by or on behalf of Borrower to Administrative Agent and the Lenders pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.03</u><font style="font-size:11pt;"> (other than </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 8.03(a)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.03(b)</u><font style="font-size:11pt;">) shall be accurate and complete in all material respects as of its date or the date so supplied and the financial statements provided pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 8.03(a)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.03(b)</u><font style="font-size:11pt;"> fairly present in all material respects the financial positions and results of operations as of the dates indicated therein. &#160;For the avoidance of doubt, Borrower makes no representations or warranties regarding the accuracy or completeness of any information it receives from a Third Party that it is required to furnish to Administrative Agent or Lenders pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.03</u><font style="font-size:11pt;">, unless to the Knowledge of Borrower or Parent such information is inaccurate or incomplete, in which case Borrower or Parent shall specify such inaccuracy or incompleteness.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488598"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Books and Records</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall keep proper books, records and accounts in which entries in conformity with sound business practices and all requirements of Law applicable to it shall be made of all dealings and transactions in relation to its business, assets and activities and as shall permit the preparation of the consolidated financial statements of Borrower in accordance with GAAP.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">40</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.05</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488599"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authorizations</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall obtain, make and keep in full force and effect all authorizations from and registrations with Governmental Authorities that may be required for the validity or enforceability against Borrower of this Agreement and the other Loan Documents to which it is a party.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.06</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488600"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws and Contracts</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Borrower shall comply with all Applicable Laws and perform its obligations under all Material Contracts, if any, entered into after the Closing Date relative to the conduct of its business, except where the failure to comply could not reasonably be expected to result in a Material Adverse Effect. &#160;Borrower shall use commercially reasonable efforts to take all actions necessary to enforce its rights under each Material Contract, and perform all of its material obligations under each Material Contract, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect (subject to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.01(a)</u><font style="font-size:11pt;">).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Borrower shall at all times comply with the margin requirements set forth in Section 7 of the Exchange Act and any regulations issued pursuant thereto, including, without limitation, </font><a name="_9kR3WTr26647BbKgx3kt2y49q"></a><font style="font-size:11pt;">Regulations T</font><font style="font-size:11pt;">, U and X of the Board of Governors of the Federal Reserve System, 12 C.F.R., Chapter II.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.07</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488601"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Assets</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall not take any action that causes its assets to be deemed to be Plan Assets at any time.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.08</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488602"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall, promptly after an officer becomes aware thereof, give written Notice to Administrative Agent of:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Hlk152698387"></a><font style="font-size:11pt;">of each Default, Event of Default and each other event that has or could reasonably be expected to have a Material Adverse Effect; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;"> that in any of the foregoing situations where Borrower knows a press release or other public disclosure is to be made, Borrower shall use all commercially reasonable efforts to provide such information to Lender as early as possible but in no event later than simultaneously with such release or other public disclosure.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">of any default or event of default under any Material Contracts.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">any litigation or proceedings to which Borrower is a party or which could reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">any litigation or proceedings challenging the validity of any Covered Agreement or otherwise required under a Covered Agreement, the Transaction Documents or any of the transactions contemplated therein.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">any representation or warranty made or deemed made by Borrower in any of the Loan Documents or in any certificate delivered to Administrative Agent pursuant hereto shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made or deemed made.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-size:11pt;">the occurrence of any Material Adverse Effect.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">41</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><font style="font-size:11pt;">receipt of any written notice from a Covered Agreement Counterparty of an event which has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, provide a copy of such notice to Administrative Agent together with a summary of Borrower&#8217;s intended response to such Covered Agreement Counterparty.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.09</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488603"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Taxes</u>. &#160; </div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall pay all material Taxes imposed on or in respect of Borrower&#8217;s income or assets that are due and payable and before any Lien on any of its assets exists as a result of nonpayment except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.03</u> hereof and except for Taxes contested in good faith by appropriate proceedings and for which adequate reserves are maintained in accordance with GAAP. &#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.10</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488604"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Stay, Extension or Usury Laws</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of this Agreement or the other Loan Documents, if at any time the rate of interest payable by any Person under the Loan Documents exceeds the Maximum Lawful Rate, then, so long as the Maximum Lawful Rate would be exceeded, such rate of interest shall be equal to the Maximum Lawful Rate. &#160;If at any time thereafter the rate of interest so payable is less than the Maximum Lawful Rate, such Person shall continue to pay interest at the Maximum Lawful Rate until such time as the total interest received from such Person is equal to the total interest that would have been received had applicable law not limited the interest rate so payable. &#160;In no event shall the total interest received by Lender under this Agreement and the other Loan Documents exceed the amount which such Lender could lawfully have received, had the interest due been calculated from the Closing Date at the Maximum Lawful Rate. &#160;Without limiting the foregoing, Borrower will not at any time, to the extent that it may lawfully not do so, insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay or extension law or other law that would prohibit or forgive Borrower from paying all or any portion of the principal of or premium, if any, or interest on the Term Loan as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the performance of this Agreement; and, to the extent that it may lawfully do so, Borrower hereby expressly waives all benefit or advantage of any such law and expressly agrees that it will not hinder, delay or impede the execution of any power herein granted to Lender, but will suffer and permit the execution of every such power as though no such law had been enacted.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.11</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488605"></a></u><font style="text-decoration-color:#000000;text-decoration-line:none;">[</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reserved</u><font style="text-decoration-color:#000000;text-decoration-line:none;">]</font>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.12</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488606"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Documents; Further Assurances</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">Borrower shall promptly, upon the reasonable request of Administrative Agent, at Borrower&#8217;s expense, (a) execute, acknowledge and deliver, or cause the execution, acknowledgment and delivery of, and thereafter register, file or record, or cause to be registered, filed or recorded, in an appropriate governmental office, any document or instrument supplemental to or confirmatory of the Loan Documents or otherwise deemed by Lender reasonably necessary or desirable for the continued validity, perfection and priority of the Liens on the Collateral covered thereby subject to no other Liens except as permitted by the applicable Loan Document, or obtain any consents or waivers as may be necessary or appropriate in connection therewith; (b) deliver or cause to be delivered to Administrative Agent from time to time such other documentation, consents, authorizations, approvals and orders in form and substance reasonably satisfactory to Administrative Agent and Administrative Agent shall reasonably deem necessary to perfect or maintain the Liens on the Collateral pursuant to the Loan Documents; and (c) upon the exercise by Administrative Agent of any power, right, privilege or remedy pursuant to any Loan Document which requires any consent, approval, registration, qualification or authorization of any Governmental Authority execute and deliver all applications, certifications, instruments and other documents and papers that Lender </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">42</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">may require. &#160;In addition, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.12(b)</u>, Borrower shall promptly, at its sole cost and expense, execute and deliver to Administrative Agent such further instruments and documents, and take such further action, as Administrative Agent may, at any time and from time to time, reasonably request in order to carry out the intent and purpose of this Agreement and the other Loan Documents to which it is a party and to establish and protect the rights, interests and remedies created, or intended to be created, in favor of Administrative Agent hereby and thereby.<font style="background:#ffffff;"> </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.13</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488607"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information Regarding Collateral</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall not effect any change (i)&#160;in its legal name, (ii)&#160;in the location of its chief executive office, (iii)&#160;in its identity or organizational structure, or (iv)&#160;in its federal <a name="_9kR3WTr26647CeIt9nx2wbIlwC8vwun5EAGqsO6"></a>Taxpayer Identification Number or organizational identification number, if any (in each case, including by merging with or into any other entity, reorganizing, dissolving, liquidating, reorganizing or organizing in any other jurisdiction), until (A)&#160;it shall have given Administrative Agent not less than ten (10)&#160;days prior written notice (in the form of an certificate of a duly authorized officer of Borrower), or such lesser notice period agreed to by Administrative Agent, of its intention so to do, clearly describing such change and providing such other information in connection therewith as Administrative Agent may reasonably request and (B)&#160;it shall have taken all action reasonably satisfactory to Administrative Agent to maintain the perfection and priority of the security interest of Administrative Agent in the Collateral, if applicable (subject to the limitations set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.12(b)</u>). &#160;Borrower shall not effect any change in its jurisdiction of organization. &#160;Borrower agrees to provide promptly to Administrative Agent with certified Borrower&#8217;s Organizational Documents reflecting any of the changes described in the preceding sentence. &#160;Borrower also agrees to notify promptly Administrative Agent of any change in the location of any office in which it maintains books or records relating to Collateral owned by it or any office or facility at which any portion of Collateral is located (including the establishment of any such new office or facility).</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 8.14</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488608"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Collateral</u>. </div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">With respect to any Collateral acquired after the Closing Date by Borrower that is not already subject to the Lien created by any of the Loan Documents or specifically excluded from the requirement to be subject to such Lien in the Loan Documents, Borrower shall promptly (and in any event within 30&#160;days after the acquisition thereof) (i)&#160;execute and deliver to Administrative Agent such amendments or supplements to the relevant Loan Documents or such other documents as Administrative Agent shall deem necessary or advisable to grant for its benefit, a Lien on such property subject to no Liens other than Permitted Liens, and (ii)&#160;take all actions necessary to cause such Lien to be duly perfected in accordance with all applicable requirements of Law, including the filing of financing statements in such jurisdictions as may be reasonably requested by Administrative Agent. &#160;Borrower shall otherwise take such actions and execute and/or deliver to Lender such documents as Administrative Agent shall reasonably require to confirm the validity, perfection and priority of the Lien of the Security Agreement on such after-acquired Collateral.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article IX</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488609"></a><b style="font-size:11pt;font-weight:bold;">NEGATIVE COVENANTS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrower covenants and agrees with Lender that, until Payment in Full:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488610"></a><a name="_Hlk153105895"></a><a name="_Hlk153098920"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Activities of Borrower</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Hlk152691547"></a><font style="font-size:11pt;">Borrower shall not (i) amend, modify, waive or terminate any provision of, or permit or agree to the amendment, modification, waiver or termination (other than expiration in accordance with its terms) of any provision of any of the Transaction Documents or any Covered Agreement other than </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">43</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">a change in the party names by way of assignment as permitted under the Sale Agreement and not materially adverse to the interests of the Lenders), without the consent of Administrative Agent and each Lender in its sole and absolute discretion or (ii) take any action to amend, waive, supplement, restate, cancel, terminate, discharge, compromise or otherwise modify in any respect the Commercial Payment Interest. &#160;Borrower shall not establish or acquire any Subsidiaries or acquire any assets other than capital contributions permitted pursuant to the Transaction Documents and the Transferred Assets (and any proceeds thereof and assets relating thereto). &#160; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Borrower shall not:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">fail to hold itself out to the public and all other persons as a legal entity separate from the owners of its Capital Stock and from any other person (it being understood that customary activities resulting from or relating to consolidation for tax or accounting purposes shall in no event be deemed a breach of this requirement);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">commingle its assets with assets of any other Person, except to the extent expressly permitted under the Sale Agreement (it being understood that the fact that the Covered Agreements include Transferred Assets and non-Transferred Assets shall in no event be deemed a breach of this requirement);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">fail to conduct its business only in its own name, nor fail to comply with all organizational formalities necessary to maintain its separate existence;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><font style="font-size:11pt;">fail to maintain separate financial statements, showing its assets and liabilities separate and apart from those of any other person nor have its assets listed on any financial statement of any other person; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that Borrower&#8217;s assets may be included in a consolidated financial statement of its Affiliates in conformity with applicable provisions of GAAP (provided that such assets shall also be listed on Borrower&#8217;s own separate balance sheet);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><font style="font-size:11pt;">fail to pay its own liabilities and expenses only out of its own funds; provided that the foregoing shall not prohibit the payment of any liabilities and expenses by Company on behalf of Borrower so long as such payments are subject to reimbursement or are otherwise recorded as capital contributions or intercompany loans;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font><font style="font-size:11pt;">enter into any transaction with an Affiliate except transactions that are at prices and on terms and conditions that could be obtained on an arm&#8217;s-length basis (or at least as favorable basis) from unrelated Third Parties (other than capital contributions made by the Company to the Borrower);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vii)</font><font style="font-size:11pt;">issue any securities of any kind except as contemplated by this Agreement and the other Transaction Documents;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(viii)</font><font style="font-size:11pt;">fail to correct any known misunderstanding regarding its separate identity and not identify itself as a department or division of any other Person;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ix)</font><font style="font-size:11pt;">fail to maintain adequate capital in light of its contemplated business purpose, transactions and liabilities; provided, however, that the foregoing shall not require the holders of its Capital Stock to make additional capital contributions to Borrower;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(x)</font><font style="font-size:11pt;">fail to cause the representatives of Borrower to act at all times with respect to Borrower consistently and in furtherance of the foregoing and in the best interests of Borrower;</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">44</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(xi)</font><font style="font-size:11pt;">make any payment or distribution of assets with respect to any obligation of any other person; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(xii)</font><a name="_Hlk153097592"></a><a name="_Hlk153105995"></a><font style="font-size:11pt;">engage in any business activity other than exercising its rights under the Covered Agreements and the payment and repayment of amounts provided for hereunder and under the other Loan Documents and any activities ancillary or related thereto</font><font style="font-size:11pt;">;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(xiii)</font><font style="font-size:11pt;">fail to file any tax returns and pay any taxes as may be required under Law (except for taxes contested in good faith by appropriate proceedings and for which adequate reserves are maintained in accordance with GAAP); or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(xiv)</font><font style="font-size:11pt;">except as required by applicable law, employ any employees.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Borrower shall not issue any Capital Stock in certificated form.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488611"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger; Sale of Assets</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Borrower shall not merge or consolidate with or into (whether or not Borrower is the Surviving Person) any other Person.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_Hlk153106136"></a><font style="font-size:11pt;">Borrower shall not sell, assign, convey, transfer, lease, sublease, license, sublicense or otherwise dispose of (including by way of merger or consolidation) any right, title or interest in or to, any of its assets, including, without limitation, the Covered Agreement or the Commercial Payment Interest, other than by virtue of Liens that constitute Permitted Liens.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488612"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liens</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall not create or suffer to exist any Lien on or with respect to any of its properties or assets, except for Permitted Liens.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488613"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Company Act</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Neither Borrower nor any of its Subsidiaries shall be or become an investment company subject to registration under the Investment Company Act of 1940.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.05</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488614"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation on Additional Indebtedness</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower shall not, directly or indirectly, incur or suffer to exist any Indebtedness except for:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Indebtedness under this Agreement; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">unsecured Indebtedness to trade creditors incurred in the ordinary course of business and not overdue (unless subject to a good faith dispute); and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Indebtedness consisting of the financing of insurance premiums with the providers of such insurance or their affiliates in the ordinary course of business.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.06</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488615"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation on Transactions with Controlled Affiliates</u>. &#160; </div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">Borrower shall not, directly or indirectly, enter into any transaction or series of related transactions or participate in any arrangement (including any purchase, sale, lease or exchange of assets or </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">45</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the rendering of any service) with any Controlled Affiliate other than the Transaction Documents or in the ordinary course of business of Borrower upon fair and reasonable terms no less favorable to Borrower than it would obtain in a comparable arm&#8217;s-length transaction with a <a name="_9kR3WTr26647DzwxMI06B720unKHtx45v7C"></a>non-Controlled Affiliate. </p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.07</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488616"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ERISA</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Borrower shall not sponsor, maintain or contribute to, or agree to sponsor, maintain or contribute to, any Employee Benefit Plan whether or not subject to ERISA (or take any action or fail to take any action with respect to such Employee Benefit Plan), that could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or result in the imposition of a Lien.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Borrower shall not engage in a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Code or in any transaction that, assuming that no assets of Lender are or are deemed to be Plan Assets, would cause any obligation or action taken or to be taken hereunder (or the exercise by Lender of any of its rights under this Agreement or the other Loan Documents) to be a non-exempt prohibited transaction under such provisions.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Borrower shall not incur any liability with respect to any obligation to provide medical benefits with respect to any person beyond their retirement or other termination of service, other than coverage mandated by law, that could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.08</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488617"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends and Distributions</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Borrower will not, directly or indirectly, make any dividends or other distributions to holders of its Capital Stock. </p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 9.09</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488618"></a><a name="_Hlk152698751"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Roche APA</u><font style="text-decoration-color:#000000;text-decoration-line:none;">.</font><font style="text-decoration-color:#000000;text-decoration-line:none;"> &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Hlk152277745"></a><a name="_Toc152286109"></a><a name="_Toc153369622"></a><a name="_Toc153398193"></a><a name="_Toc153488619"></a></u><font style="text-decoration-color:#000000;text-decoration-line:none;">Borrower acknowledges and agrees that </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_cp_change_2"></a><a name="_cp_change_3"></a></u><font style="text-decoration-color:#000000;text-decoration-line:none;">damages may be difficult to establish and Administrative Agent and Lenders will have no adequate remedy at law if Borrower fails to enforce the obligations under Sections 4.01 and 4.03 of the Sale Agreement and Section 2.5 of the Affitech Assignment Agreement. &#160;In such event, Borrower agrees that the other Parties shall have the right, in addition to any other rights it may have (whether at law or in equity), to seek specific performance of this Agreement, Sections 4.01 and 4.03 of the Sale Agreement, Section 2.5 of the Affitech Assignment Agreement and to pursue any other equitable remedies including an injunction, without being required to prove actual damages or post any bond. &#160;In furtherance of the foregoing, Borrower hereby designates, makes, constitutes and appoints Administrative Agent, and each of its designees or agents, as its true and lawful proxy and attorney-in-fact (coupled with an interest), irrevocably and with power of substitution, and with authority to take any and all appropriate action and to execute any and all documents and instruments that may be necessary to cause this Agreement, Sections 4.01 and 4.03 of the Sale Agreement, and/or Section 2.5 of the Affitech Assignment Agreement to be specifically performed by Borrower and each Covered Agreement Counterparty or to seek an injunction against any pending or proposed violation of this Agreement, Sections 4.01 and 4.03 of the Sale Agreement and/or Section 2.5 of the Affitech Assignment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If, notwithstanding the foregoing and the prohibition contained in Section 2.5 of the Affitech Assignment Agreement, Borrower receives any Final Payment, Borrower hereby agrees to: (i) hold such amount in trust for the Lenders and (ii) deposit such amount in the Collection Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;"><a name="_Hlk152278472"></a></font>THE POWER OF ATTORNEY AND PROXY GRANTED IN THIS SECTION ARE COUPLED WITH AN INTEREST AND SHALL BE IRREVOCABLE UNTIL PAYMENT IN FULL. &#160;THIS POWER OF </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">46</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">ATTORNEY IS CONFERRED ON THE ADMINISTRATIVE AGENT SOLELY, DURING THE CONTINUANCE OF AN EVENT OF DEFAULT, TO PROTECT, PRESERVE AND REALIZE UPON ITS RIGHTS UNDER THIS AGREEMENT AND SHALL NOT IMPOSE ANY DUTY UPON THE ADMINISTRATIVE AGENT TO EXERCISE ANY SUCH POWERS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article X</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488620"></a><b style="font-size:11pt;font-weight:bold;">EVENTS OF DEFAULT</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 10.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488621"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Events of Default</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If one or more of Events of Default occurs and is continuing, Administrative Agent shall be entitled to the remedies set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.02</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 10.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488622"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default Remedies</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If any Event of Default shall occur and be continuing, Administrative Agent may, or at the direction of the Required Lenders shall, by Notice to Borrower, (a) exercise all rights and remedies available to Lender hereunder and under the other Loan Documents and applicable law (which exercise may be determined in its sole discretion and which such exercise shall not constitute an election of remedies), including enforcement of the security interests created thereby, (b) declare the Term Loan, all interest thereon and all other Obligations to be immediately due and payable, whereupon all such amounts shall become immediately due and payable, all without diligence, presentment, demand of payment, protest or further notice of any kind, which are expressly waived by Borrower and (c) declare the obligations of Lender hereunder to be terminated, whereupon such obligations shall terminate; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that if any event of any kind referred to in clause (i) of the definition of &#8220;Event of Default&#8221; herein occurs, the obligations of Lender hereunder shall immediately terminate, all amounts payable hereunder by Borrower shall become immediately due and payable and Administrative Agent shall be entitled to exercise rights and remedies under the Loan Documents and applicable law without diligence, presentment, demand of payment, protest or notice of any kind (including any notice by Administrative Agent or the Required Lenders of a declaration requiring prepayment of the Term Loan under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)</u>, should Administrative Agent or Required Lenders so elect), all of which are hereby expressly waived by Borrower. &#160;Each Notice delivered pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.02</u> shall be effective when sent.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 10.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488623"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of Set-off; Sharing of Set-off</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">If any amount payable hereunder is not paid as and when due, Borrower irrevocably authorizes Administrative Agent and each Lender (i) to proceed, to the fullest extent permitted by Applicable Law, without prior notice, by right of set-off, bankers&#8217; lien, counterclaim or otherwise, against any assets of Borrower in any currency that may at any time be in the possession of Administrative Agent or such Lender or any Affiliate thereof, to the full extent of all amounts payable to Administrative Agent or such Lender hereunder or (ii) to charge to Borrower&#8217;s account with Administrative Agent or such Lender, or any Affiliate of thereof, to the full extent of all amounts payable by Borrower to Administrative Agent or such Lender hereunder; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that Administrative Agent or such Lender shall notify Borrower of the exercise of such right promptly following such exercise.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Any payments obtained under this Section 10.03 shall be subject to the provisions of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.05(c)</u><font style="font-size:11pt;">.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">47</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 10.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488624"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights Not Exclusive</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The rights provided for herein are cumulative and are not exclusive of any other rights, powers, privileges or remedies provided by Law.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article XI</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488625"></a><b style="font-size:11pt;font-weight:bold;">INDEMNIFICATION</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 11.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488626"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Borrower agrees to defend (subject to Indemnitees&#8217; selection of counsel), indemnify, pay and hold harmless, each Indemnitee from and against any and all Indemnified Liabilities, in all cases, arising, in whole or in part, out of or relating to any claim, notice, suit or proceeding commenced or threatened in writing (including, without limitation, by electronic means) by any Person (including any Governmental Authority) other than Borrower, Company or any of Administrative Agent&#8217;s or Lender&#8217;s Affiliates; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;"> Borrower shall not have any obligation to any Indemnitee hereunder with respect to any Indemnified Liabilities to the extent such Indemnified Liabilities arise from the gross negligence or willful misconduct of such Indemnitee or the breach by Lender of its obligations to make the Term Loan. &#160;To the extent that the undertakings to defend, indemnify, pay and hold harmless set forth in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.01</u><font style="font-size:11pt;"> may be unenforceable in whole or in part because they violate of any law or public policy, Borrower shall contribute the maximum portion that it is permitted to pay and satisfy under applicable law to the payment and satisfaction of all Indemnified Liabilities incurred by Indemnitees or any of them. &#160;This </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.01</u><font style="font-size:11pt;"> shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. &#160;arising from any </font><a name="_9kR3WTr26647E0wxdLw"></a><font style="font-size:11pt;">non-Tax</font><font style="font-size:11pt;"> claim.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">To the extent permitted by applicable law, no Party shall assert, and each Party hereby waives, any claim against each other Party and such Party&#8217;s Affiliates, directors, employees, attorneys or agents, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with, as a result of, or in any way related to, this Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby or referred to herein or therein, the transactions contemplated hereby or thereby, the Term Loan or the use of the proceeds thereof or any act or omission or event occurring in connection therewith, and each Party hereby waives, releases and agrees not to sue upon any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 11.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488627"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption of Defense; Settlements</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">If Administrative Agent or any Lender is entitled to indemnification under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;XI</u> with respect to any action or proceeding brought by a third party that is also brought against Borrower, Borrower shall be entitled to assume the defense of any such action or proceeding with counsel reasonably satisfactory to Administrative Agent and/or such Lender. &#160;Upon assumption by Borrower of the defense of any such action or proceeding, Administrative Agent and/or Lender, as applicable, shall have the right to participate in such action or proceeding and to retain its own counsel but Borrower shall not be liable for any legal expenses of other counsel subsequently incurred by such Party in connection with the defense thereof unless (i)&#160;Borrower has otherwise agreed to pay such fees and expenses, (ii)&#160;Borrower shall have failed to employ counsel reasonably satisfactory to Administrative Agent and/or Lender, as applicable, in a timely manner or (iii)&#160;Administrative Agent and/or Lender, as applicable, shall have been advised by counsel that there are actual or potential conflicting interests between Borrower and Administrative Agent or Lender, as applicable, including situations in which there are one or more legal defenses available to Administrative Agent and/or Lender, as applicable, that are different from or additional to those available </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">48</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to Borrower; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that Borrower shall not, in connection with any one such action or proceeding or separate but substantially similar actions or proceedings arising out of the same general allegations, be liable for the fees and expenses of more than one separate firm of attorneys at any time for Administrative Agent and/or Lender, as applicable, except to the extent that local counsel, in addition to its regular counsel, is required in order to effectively defend against such action or proceeding. &#160;Borrower shall not consent to the terms of any compromise or settlement of any action defended by Borrower in accordance with the foregoing without the prior written consent of Administrative Agent and/or Lender<a name="_DV_C30"></a>, as applicable, unless such compromise or settlement (x) includes an unconditional release of Administrative Agent and/or Lender, as applicable, from all liability arising out of such action and (y) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of Administrative Agent and/or Lender, as applicable. &#160;Borrower shall not be required to indemnify Administrative Agent or Lender for any amount paid or payable by Administrative Agent or Lender in the settlement of any action, proceeding or investigation without the written consent of Borrower, which consent shall not be unreasonably withheld, conditioned or delayed.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article XII</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488628"></a><b style="font-size:11pt;font-weight:bold;">ADMINISTRATIVE AGENT</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488629"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appointment of Administrative Agent.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Blue Owl is hereby appointed Administrative Agent hereunder and under the other Loan Documents and each Lender hereby authorizes Blue Owl, in such capacity, to act as its agent in accordance with the terms hereof and the other Loan Documents to perform, exercise and enforce any and all other rights and remedies of the Lenders with respect to the Loan Parties, the Obligations or otherwise related to any of same to the extent reasonably incidental to the exercise by Administrative Agent of the rights and remedies specifically authorized to be exercised by Administrative Agent by the terms of this Agreement or any other Loan Parties.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Administrative Agent hereby agrees to act upon the express conditions contained herein and the other Loan Documents, as applicable. &#160;The provisions of this Article XII are solely for the benefit of Administrative Agent and Lenders and no Loan Party shall have any rights as a third party beneficiary of any of the provisions thereof. &#160;In performing its functions and duties hereunder, Administrative Agent shall act solely as an agent of Lenders and does not assume and shall not be deemed to have assumed any obligation towards or relationship of agency or trust with or for Borrower or any of its Subsidiaries.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488630"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Powers and Duties.</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each Lender irrevocably authorizes Administrative Agent to take such action on such Lender&#8217;s behalf and to exercise such powers, rights and remedies hereunder and under the other Loan Documents as are specifically delegated or granted to Administrative Agent by the terms hereof and thereof, together with such powers, rights and remedies as are reasonably incidental thereto. &#160;Administrative Agent shall have only those duties and responsibilities that are expressly specified herein and the other Loan Documents. &#160;Administrative Agent may exercise such powers, rights and remedies and perform such duties by or through its agents or employees Administrative Agent shall not have, by reason hereof or any of the other Loan Documents, a fiduciary relationship in respect of any Lender; and nothing herein or any of the other Loan Documents, expressed or implied, is intended to or shall be so construed as to impose upon Administrative Agent any obligations in respect hereof or any of the other Loan Documents except as expressly set forth herein or therein.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">49</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488631"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Immunity.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Responsibility for Certain Matters</u><font style="font-size:11pt;">. &#160;Administrative Agent shall not be responsible to any Lender for the execution, effectiveness, genuineness, validity, enforceability, collectability or sufficiency hereof or any other Loan Document or for any representations, warranties, recitals or statements made herein or therein or made in any written or oral statements or in any financial or other statements, instruments, reports or certificates or any other documents furnished or made by Administrative Agent to Lenders or by or on behalf of any Loan Party to Administrative Agent or any Lender in connection with the Loan Documents and the transactions contemplated thereby or for the financial condition or business affairs of any Loan Party or any other Person liable for the payment of any Obligations, nor shall Administrative Agent be required to ascertain or inquire as to the performance or observance of any of the terms, conditions, provisions, covenants or agreements contained in any of the Loan Documents or as to the use of the proceeds of the Term Loans or as to the existence or possible existence of any Event of Default or Default or to make any disclosures with respect to the foregoing. &#160;Anything contained herein to the contrary notwithstanding, Administrative Agent shall not have any liability arising from confirmations of the amount of outstanding Term Loans or the component amounts thereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exculpatory Provisions</u><font style="font-size:11pt;">. &#160;Neither Administrative Agent nor any of its officers, partners, directors, employees or agents shall be liable to Lenders for any action taken or omitted by Administrative Agent under or in connection with any of the Loan Documents except to the extent caused by Administrative Agent&#8217;s gross negligence or willful misconduct, as determined by a court of competent jurisdiction in a final, non-appealable order. &#160;Administrative Agent shall be entitled to refrain from any act or the taking of any action (including the failure to take an action) in connection herewith or any of the other Loan Documents or from the exercise of any power, discretion or authority vested in it hereunder or thereunder unless and until Administrative Agent shall have received instructions in respect thereof from Required Lenders (or such other Lenders as may be required to give such instructions under </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.05</u><font style="font-size:11pt;">) and, upon receipt of such instructions from Required Lenders (or such other Lenders, as the case may be), Administrative Agent shall be entitled to act or (where so instructed) refrain from acting, or to exercise such power, discretion or authority, in accordance with such instructions. &#160;Without prejudice to the generality of the foregoing, (i) Administrative Agent shall be entitled to rely, and shall be fully protected in relying, upon any communication, instrument or document believed by it to be genuine and correct and to have been signed or sent by the proper Person or Persons, and shall be entitled to rely and shall be protected in relying on opinions and judgments of attorneys (who may be attorneys for Borrower and its Subsidiaries), accountants, experts and other professional advisors selected by it; and (ii) no Lender shall have any right of action whatsoever against Administrative Agent as a result of Administrative Agent acting or (where so instructed) refraining from acting hereunder or any of the other Loan Documents in accordance with the instructions of Required Lenders (or such other Lenders as may be required to give such instructions under </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.05</u><font style="font-size:11pt;">).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Default</u><font style="font-size:11pt;">. &#160;Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default, except with respect to Events of Default in the payment of principal, interest and fees required to be paid to Administrative Agent for the account of the Lenders, unless Administrative Agent shall have received written notice from a Lender or the Loan Party referring to this Agreement, describing such Default or Event of Default and stating that such notice is a &#8220;notice of default.&#8221; &#160;Administrative Agent will notify the Lenders of its receipt of any such notice. &#160;Administrative Agent shall take such action with respect to any such Default or Event of Default as may be directed by the Required Lenders in accordance with Article X; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that unless and until Administrative Agent has received any such direction, Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable or in the best interest of the Lenders.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">50</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488632"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Agent Entitled to Act as Lender</u><font style="text-decoration-color:#000000;text-decoration-line:none;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The agency hereby created shall in no way impair or affect any of the rights and powers of, or impose any duties or obligations upon, Administrative Agent in its individual capacity as a Lender hereunder. &#160;With respect to its participation in the Term Loans, Administrative Agent shall have the same rights and powers hereunder as any other Lender and may exercise the same as if it were not performing the duties and functions delegated to it hereunder, and the term &#8220;Lender&#8221; shall, unless the context clearly otherwise indicates, include Administrative Agent in its individual capacity. &#160;Administrative Agent and its Affiliates may accept deposits from, lend money to, own securities of, and generally engage in any kind of banking, trust, financial advisory or other business with Borrower or any of its Affiliates as if it were not performing the duties specified herein, and may accept fees and other consideration from Company for services in connection herewith and otherwise without having to account for the same to Lenders.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.05</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488633"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lenders&#8217; Representations, Warranties and Acknowledgment.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Each Lender represents and warrants that it has made its own independent investigation of the financial condition and affairs of Borrower and its Subsidiaries in connection with Credit Extensions hereunder and that it has made and shall continue to make its own appraisal of the creditworthiness of Borrower and its Subsidiaries. &#160;Administrative Agent shall not have any duty or responsibility, either initially or on a continuing basis, to make any such investigation or any such appraisal on behalf of Lenders or to provide any Lender with any credit or other information with respect thereto, whether coming into its possession before the making of the Term Loans or at any time or times thereafter, and Administrative Agent shall not have any responsibility with respect to the accuracy of or the completeness of any information provided to Lenders.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Each Lender, by delivering its signature page to this Agreement and funding its Term Loan on the Closing Date, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be approved by Administrative Agent, Required Lenders or Lenders, as applicable on the Closing Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Each Lender (i) represents and warrants that as of the Closing Date neither such Lender nor its Affiliates or </font><a name="_9kR3WTr26647FfKlirwhJVAu0"></a><font style="font-size:11pt;">Related Funds</font><font style="font-size:11pt;"> owns or controls, or owns or controls any Person owning or controlling, any trade debt or Indebtedness of any Loan Party other than the Obligations or any Capital Stock of any Loan Party and (ii) covenants and agrees that from and after the Closing Date neither such Lender nor its Affiliates and </font><a name="_9kMHG5YVt48869HhMnktyjLXCw2"></a><font style="font-size:11pt;">Related Funds</font><font style="font-size:11pt;"> shall purchase any trade debt or Indebtedness of any Loan Party other than the Obligations or Capital Stock described in clause (i) above without the prior written consent of Administrative Agent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.06</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488634"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Indemnity.</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">EACH LENDER, IN PROPORTION TO ITS PRO RATA SHARE, SEVERALLY AGREES TO INDEMNIFY ADMINISTRATIVE AGENT, ITS AFFILIATES AND ITS RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, EMPLOYEES AND AGENTS OF ADMINISTRATIVE AGENT (EACH, AN &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEMNITEE AGENT PARTY</u>&#8221;), TO THE EXTENT THAT SUCH INDEMNITEE AGENT PARTY SHALL NOT HAVE BEEN REIMBURSED BY ANY LOAN PARTY, FOR AND AGAINST ANY AND ALL LIABILITIES, OBLIGATIONS, LOSSES, DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES (INCLUDING COUNSEL FEES AND DISBURSEMENTS) OR DISBURSEMENTS OF ANY KIND OR NATURE WHATSOEVER WHICH MAY BE IMPOSED ON, INCURRED BY OR ASSERTED AGAINST SUCH INDEMNITEE AGENT PARTY IN EXERCISING ITS POWERS, RIGHTS AND REMEDIES OR PERFORMING ITS DUTIES HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">51</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">OTHERWISE IN ITS CAPACITY AS SUCH INDEMNITEE AGENT PARTY IN ANY WAY RELATING TO OR ARISING OUT OF THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS, IN ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH INDEMNITEE AGENT PARTY; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PROVIDED</u>, NO LENDER SHALL BE LIABLE FOR ANY PORTION OF SUCH LIABILITIES, OBLIGATIONS, LOSSES, DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES OR DISBURSEMENTS RESULTING FROM SUCH INDEMNITEE AGENT PARTY&#8217;S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL, NON-APPEALABLE ORDER. &#160;IF ANY INDEMNITY FURNISHED TO ANY INDEMNITEE AGENT PARTY FOR ANY PURPOSE SHALL, IN THE OPINION OF SUCH INDEMNITEE AGENT PARTY, BE INSUFFICIENT OR BECOME IMPAIRED, SUCH INDEMNITEE AGENT PARTY MAY CALL FOR ADDITIONAL INDEMNITY AND CEASE, OR NOT COMMENCE, TO DO THE ACTS INDEMNIFIED AGAINST UNTIL SUCH ADDITIONAL INDEMNITY IS FURNISHED; PROVIDED, IN NO EVENT SHALL THIS SENTENCE REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION, LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT, SUIT, COST, EXPENSE OR DISBURSEMENT IN EXCESS OF SUCH LENDER&#8217;S PRO RATA SHARE THEREOF; AND PROVIDED FURTHER, THIS SENTENCE SHALL NOT BE DEEMED TO REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION, LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT, SUIT, COST, EXPENSE OR DISBURSEMENT DESCRIBED IN THE PROVISO IN THE IMMEDIATELY PRECEDING SENTENCE.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.07</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488635"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successor Administrative Agent.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Administrative Agent may resign at any time by giving thirty days&#8217; (or such shorter period as shall be agreed by the Required Lenders) prior written notice thereof to Lenders and Borrower. &#160;Upon any such notice of resignation, Required Lenders shall have the right, upon five Business Days&#8217; notice to Borrower, to appoint a successor Administrative Agent. &#160;If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may, on behalf of the Lenders appoint a successor Administrative Agent from among the Lenders. &#160;Upon the acceptance of any appointment as Administrative Agent hereunder by a successor Administrative Agent that successor Administrative Agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall promptly (i) transfer to such successor Administrative Agent all sums, securities or Capital Stock and other items of Collateral held under the Collateral Documents, together with all records and other documents necessary or appropriate in connection with the performance of the duties of the successor Administrative Agent under the Loan Documents, and (ii) execute and deliver to such successor Administrative Agent such amendments to financing statements, and take such other actions, as may be necessary or appropriate in connection with the assignment to such successor Administrative Agent of the security interests created under the Collateral Documents, whereupon such retiring Administrative Agent shall be discharged from its duties and obligations hereunder. &#160;After any retiring Administrative Agent&#8217;s resignation hereunder as Administrative Agent, the provisions of this Article XII shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Administrative Agent hereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Notwithstanding anything herein to the contrary, Administrative Agent may assign its rights and duties as Administrative Agent, as applicable, hereunder to an Affiliate of Blue Owl without the prior written consent of, or prior written notice to, Borrower or the Lenders; provided that Borrower and the Lenders may deem and treat such assigning Administrative Agent as Administrative Agent for all purposes hereof, unless and until such assigning Administrative Agent provides written notice to Borrower </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">52</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">and the Lenders of such assignment. &#160;Upon such assignment such Affiliate shall succeed to and become vested with all rights, powers, privileges and duties as Administrative Agent hereunder and under the other Loan Documents.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Administrative Agent may perform any and all of its duties and exercise its rights and powers under this Agreement or under any other Loan Document by or through any one or more sub-agents appointed by Administrative Agent. &#160;Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. &#160;The exculpatory, indemnification and other provisions of Section 12.03, Section 12.06 and of this Section 12.07 shall apply to any of the Affiliates of Administrative Agent and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. &#160;All of the rights, benefits and privileges (including the exculpatory and indemnification provisions) of Section 12.03, Section 12.06 and of this Section 12.07 shall apply to any such sub-agent and to the Affiliates of any such sub-agent, and shall apply to their respective activities as sub-agent as if such sub-agent and Affiliates were named herein. &#160;Notwithstanding anything herein to the contrary, with respect to each sub-agent appointed by Administrative Agent, (i) such sub-agent shall be a third party beneficiary under this Agreement with respect to all such rights, benefits and privileges (including exculpatory and rights to indemnification) and shall have all of the rights, benefits and privileges of a third party beneficiary, including an independent right of action to enforce such rights, benefits and privileges (including exculpatory rights and rights to indemnification) directly, without the consent or joinder of any other Person, against any or all of the Loan Parties and the Lenders, (ii) such rights, benefits and privileges (including exculpatory rights and rights to indemnification) shall not be modified or amended without the consent of such sub-agent, and (iii) such sub-agent shall only have obligations to Administrative Agent and not to any Loan Party, Lender or any other Person and no Loan Party, Lender or any other Person shall have the rights, directly or indirectly, as a third party beneficiary or otherwise, against such sub-agent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.08</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488636"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collateral Documents</u><font style="text-decoration-color:#000000;text-decoration-line:none;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Agent under Collateral Documents</u><font style="font-size:11pt;">. &#160;Each Lender hereby further authorizes Administrative Agent on behalf of and for the benefit of Lenders, to be the agent for and representative of Lenders with respect the Collateral and the Collateral Documents. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Realize on Collateral</u><font style="font-size:11pt;">. &#160;Anything contained in any of the Loan Documents to the contrary notwithstanding, Company, Administrative Agent and each Lender hereby agree that (i) no Lender shall have any right individually to realize upon any of the Collateral, it being understood and agreed that all powers, rights and remedies hereunder may be exercised solely by Administrative Agent, on behalf of Lenders in accordance with the terms hereof and all powers, rights and remedies under the Collateral Documents may be exercised solely by Administrative Agent, and (ii) in the event of a foreclosure by Administrative Agent on any of the Collateral pursuant to a public or private sale or any sale of the Collateral in a case under the Bankruptcy Code, Administrative Agent or any Lender may be the purchaser of any or all of such Collateral at any such sale and Administrative Agent, as agent for and representative of </font><a name="_9kR3WTr26647GhLct9uhTLuE6s3"></a><font style="font-size:11pt;">Secured Parties</font><font style="font-size:11pt;"> (but not any Lender or Lenders in its or their respective individual capacities unless Required Lenders shall otherwise agree in writing) shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such public sale, to use and apply any of the Obligations as a credit on account of the purchase price for any collateral payable by Administrative Agent at such sale.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.09</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488637"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agency for Perfection.</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;">Administrative Agent and each Lender hereby appoints each other Lender as agent and bailee for the purpose of perfection the security interests in and liens upon the Collateral in assets which, in </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">53</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accordance with Article 9 of the UCC, can be perfected only by possession or control (or where the security interest of a secured party with possession or control has priority over the security interest of another secured party) and Administrative Agent and each Lender hereby acknowledges that it holds possession of or otherwise controls any such Collateral for the benefit of the Lenders as secured party. &#160;Should any Lender obtain possession or control of any such Collateral, such Lender shall notify Administrative Agent thereof, and, promptly upon Administrative Agent&#8217;s request therefore shall deliver such Collateral to Administrative Agent or in accordance with Administrative Agent&#8217;s instructions. &#160;In addition, Administrative Agent shall also have the power and authority hereunder to appoint such other sub-agents as may be necessary or required under applicable state law or otherwise to perform its duties and enforce its rights with respect to the Collateral and under the Loan Documents. &#160;Each Loan Party by its execution and delivery of this Agreement hereby consents to the foregoing.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.10</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488638"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports and Other Information; Confidentiality; Disclaimers</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">By becoming a party to this Agreement, each Lender:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">is deemed to have requested that Administrative Agent furnish such Lender or Administrative Agent, promptly after it becomes available, a copy of each report with respect to Borrower or its Subsidiaries (each a &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Report</u><font style="font-size:11pt;">&#8221; and collectively, &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports</u><font style="font-size:11pt;">&#8221;) prepared by or at the request of Administrative Agent, and Administrative Agent shall so furnish each Lender with such Reports,</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">expressly agrees and acknowledges that Administrative Agent does not (i) make any representation or warranty as to the accuracy of any Report, and (ii) shall not be liable for any information contained in any Report,</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">expressly agrees and acknowledges that the Reports are not comprehensive audits or examinations, that Administrative Agent or other party performing any audit or examination will inspect only specific information regarding Borrower and its Subsidiaries and will rely significantly upon Borrower&#8217;s and its Subsidiaries&#8217; books and records, as well as on representations of such Person&#8217;s personnel,</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">agrees to keep all Reports and other material, non-public information regarding Parent and its Subsidiaries and their operations, assets, and existing and contemplated business plans in a confidential manner in accordance with </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.17</u><font style="font-size:11pt;">, and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">without limiting the generality of any other indemnification provision contained in this Agreement, agrees: &#160;(i) to hold Administrative Agent and any other Lender preparing a Report harmless from any action the indemnifying Lender may take or fail to take or any conclusion the indemnifying Lender may reach or draw from any Report in connection with any loans or other credit accommodations that the indemnifying Lender has made or may make to Company, or the indemnifying Lender&#8217;s participation in, or the indemnifying Lender&#8217;s purchase of, a loan or loans of Company, and (ii) to pay and protect, and indemnify, defend and hold Administrative Agent, and any such other Lender preparing a Report harmless from and against, the claims, actions, proceedings, damages, costs, expenses, and other amounts (including, attorneys&#8217; fees and costs) incurred by Administrative Agent and any such other Lender or agent preparing a Report as the direct or indirect result of any third parties who might obtain all or part of any Report through the indemnifying Lender or Administrative Agent.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">In addition to the foregoing: &#160;(x) any Lender may from time to time request of Administrative Agent in writing that Administrative Agent provide to such Lender a copy of any report or document provided by Parent or its Subsidiaries to Administrative Agent that has not been contemporaneously provided by Parent or such Subsidiary to such Lender, and, upon receipt of such request, Administrative Agent promptly shall </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">54</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">provide a copy of same to such Lender, (y) to the extent that Administrative Agent is entitled, under any provision of the Loan Documents, to request additional reports or information from Parent or its Subsidiaries, any Lender may, from time to time, reasonably request Administrative Agent to exercise such right as specified in such Lender&#8217;s notice to Administrative Agent, whereupon Administrative Agent promptly shall request the additional reports or information reasonably specified by such Lender, and, upon receipt thereof from Parent or such Subsidiary, Administrative Agent promptly shall provide a copy of same to such Lender, and (z) any time that Administrative Agent renders to Company a statement regarding the <a name="_9kR3WTr26647HbOkkL5erAAA"></a>Loan Account, Administrative Agent shall send a copy of such statement to each Lender.<a name="_Toc153192307"></a></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 12.11</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488639"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneous Payments.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">If Administrative Agent (x) notifies a Lender or any Person who has received funds on behalf of a Lender (any such Lender or other recipient (and each of their respective successors and assigns), a &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Recipient</u><font style="font-size:11pt;">&#8221;) that Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding clause (b)) that any funds (as set forth in such notice from Administrative Agent) received by such Payment Recipient from Administrative Agent or any of its Affiliates were erroneously or mistakenly transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender or other Payment Recipient on its behalf) (any such funds, whether transmitted or received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneous Payment</u><font style="font-size:11pt;">&#8221;) and (y) demands in writing the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of Administrative Agent pending its return or repayment as contemplated below in this &#8206;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11</u><font style="font-size:11pt;"> and held in trust for the benefit of Administrative Agent, and such Lender shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two (2) Business Days thereafter (or such later date as Administrative Agent may, in its sole discretion, specify in writing), return to Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon (except to the extent waived in writing by the Administrative Agent) in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the </font><a name="_9kMIH5YVt4886FIQAfgvsnTXCw2rU38"></a><font style="font-size:11pt;">Federal Funds Rate</font><font style="font-size:11pt;"> and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect. &#160;A notice of Administrative Agent to any Payment Recipient under this clause (a) shall be conclusive, absent manifest error.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Without limiting immediately preceding clause (a), each Lender or any Person who has received funds on behalf of a Lender (and each of their respective successors and assigns), agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in this Agreement or in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Lender or other such recipient, otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part), then in each such case:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-size:11pt;">it acknowledges and agrees that (A) in the case of immediately preceding clauses (x) or (y), an error and mistake shall be presumed to have been made (absent written confirmation from Administrative Agent to the contrary) or (B) an error and mistake has been made (in the case of immediately preceding clause (z)), in each case, with respect to such payment, prepayment or repayment; and</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">55</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:0pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">such Lender shall (and shall use commercially reasonable efforts to cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within one (1) Business Day of its knowledge of the occurrence of any of the circumstances described in immediately preceding clauses (x), (y) and (z)) notify Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying Administrative Agent pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11(b)</u><font style="font-size:11pt;">.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, the failure to deliver a notice to Administrative Agent pursuant to this &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11(b)</u> shall not have any effect on a Payment Recipient&#8217;s obligations pursuant to &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11(a)</u> or on whether or not an Erroneous Payment has been made.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Each Lender hereby authorizes Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under any Loan Document, or otherwise payable or distributable by Administrative Agent to such Lender under any Loan Document with respect to any payment of principal, interest, fees or other amounts, against any amount that Administrative Agent has demanded to be returned under immediately preceding clause (a).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">The parties hereto agree that (x) irrespective of whether Administrative Agent may be equitably subrogated, in the event that an Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights and interests of such Payment Recipient (and, in the case of any Payment Recipient who has received funds on behalf of a Lender, to the rights and interests of such Lender, as the case may be) under the Loan Documents with respect to such amount (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneous Payment Subrogation Rights</u><font style="font-size:11pt;">&#8221;) and (y) an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower; provided that this &#8206;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11</u><font style="font-size:11pt;"> shall not be interpreted to increase (or accelerate the due date for), or have the effect of increasing (or accelerating the due date for), the Obligations of the Borrower relative to the amount (or timing for payment) of the Obligations that would have been payable had such Erroneous Payment not been made by Administrative Agent; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u><font style="font-size:11pt;">, that for the avoidance of doubt, immediately preceding clauses (x) and (y) shall not apply to the extent any such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by Administrative Agent from, or on behalf of (including through the exercise of remedies under any Loan Document), the Borrower for the purpose of a payment on the Obligations.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-size:11pt;">To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by Administrative Agent for the return of any Erroneous Payment received, including, without limitation, any defense based on &#8220;discharge for value&#8221; or any similar doctrine.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Each party&#8217;s obligations, agreements and waivers under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.11</u> shall survive the resignation or replacement of Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender, or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">56</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-size:11pt;white-space:nowrap;">Article XIII</font><b style="font-size:11pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc153488640"></a><b style="font-size:11pt;font-weight:bold;">MISCELLANEOUS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.01</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488641"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignments</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Borrower shall not be permitted to assign this Agreement without the prior written consent of Lender (in the event such assignment is to be to an Affiliate of Borrower, such consent not to be unreasonably withheld) and any purported assignment in violation of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.01</u><font style="font-size:11pt;"> shall be null and void.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Lender may at any time</font><a name="_cp_text_1_3601"></a><font style="font-size:11pt;"> assign its rights and obligations hereunder, in whole or in part, to an Assignee solely with the consent of the Borrower (such consent not to be unreasonably withheld); provided that no such consent of the Borrower shall be required (a) for assignments by a Lender to an Affiliate of such Lender or any Person that is engaged in making, purchasing, holding or investing &#160;in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by such Lender or its Affiliates, (b) if an Event of Default is continuing [***]. &#160;Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender; provided that no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">The parties to each assignment shall execute and deliver to Borrower an Assignment and Acceptance. &#160;Upon the effectiveness of a permitted assignment pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.01(a)</u><font style="font-size:11pt;"> or an assignment pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.01(b)</u><font style="font-size:11pt;"> hereunder, (i) each reference in this Agreement to &#8220;Lender&#8221; shall be deemed to be a reference to the assignor and the assignee to the extent of their respective interests, (ii) such assignee shall be a Lender party to this Agreement and shall have all the rights and obligations of a Lender and (iii) the assignor shall be released from its obligations hereunder to a corresponding extent of the assignment, and no further consent or action by any party shall be required.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-size:11pt;">Borrower and Lender shall, from time to time at the request of the other party hereto, execute and deliver any documents that are necessary to give full force and effect to an assignment permitted hereunder.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:64.8pt;margin:0pt 0pt 0pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:39.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font>Administrative Agent, acting solely for this purpose as a non-fiduciary agent of Loan Parties, shall maintain at its office a copy of each Assignment and Acceptance delivered to it and a register for the recordation of the names and addresses of each Lender, and the commitments of, and principal amount (and stated interest) of the Term Loan owing to, such Lender pursuant to the terms hereof (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lender Register</u>&#8221;). &#160;The entries in such Lender Register shall be conclusive, absent manifest error, and Loan Parties, Administrative Agent and Lenders shall treat each Person whose name is recorded therein pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. &#160;Such Lender Register shall be available for inspection by Loan Parties and any Lender, at any reasonable time upon reasonable prior notice to Administrative Agent. &#160;Each Lender that sells a participation shall, acting solely for this purpose as an agent of Loan Parties maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#8217;s interest in the Obligations (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participant Register</u>&#8221;). &#160;The entries in the Participant Registers shall be conclusive, absent manifest error. &#160;Each Participant Register shall be available for inspection by Loan Parties and Administrative Agent at any reasonable time upon reasonable prior notice to the applicable Lender; provided, that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant&#8217;s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person (including Loan Parties) except to the extent that such disclosure is </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">57</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. &#160;For the avoidance of doubt, Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.02</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488642"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.03</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488643"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">All Notices authorized or required to be given pursuant to this Agreement shall be given in writing and either personally delivered to the Party to whom it is given or delivered by an established delivery service by which receipts are given or mailed by registered or certified mail, postage prepaid, or sent by electronic mail with a copy sent on the following Business Day by one of the other methods of giving notice described herein, addressed to the Party at its address listed below:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">If to Borrower:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">XRL 1 LLC<br>2200 Powell Street, Suite 310</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Emeryville, CA 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Attention:<font style="display:inline-block;width:27.39pt;"></font>Legal Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Email:<font style="display:inline-block;width:6.67pt;"></font><font style="display:inline-block;width:36pt;"></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">With a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Gibson, Dunn &amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">200 Park Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">New York, NY 10166-0193</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Attention:<font style="display:inline-block;width:27.39pt;"></font>Jin Hee Kim</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">Email:<font style="display:inline-block;width:6.67pt;"></font><font style="display:inline-block;width:36pt;"></font>JhKim@gibsondunn.com</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">If to Administrative Agent:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><a name="_Hlk152244255"></a>Blue Owl Capital Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">399 Park Avenue, 37th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">New York, NY 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Email:<font style="display:inline-block;width:6.67pt;"></font><font style="display:inline-block;width:36pt;"></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 144pt;">Cooley LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 144pt;">1299 Pennsylvania Avenue, NW, Suite 700</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 144pt;">Washington, DC 20004-2400</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 144pt;">Attention: &#160;<font style="display:inline-block;width:21.89pt;"></font>Michael Tollini</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 144pt;">Email: <font style="display:inline-block;width:3.92pt;"></font><font style="display:inline-block;width:36pt;"></font>mtollini@cooley.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any Party may change its address for the receipt of Notices at any time by giving Notice thereof to the other Party. &#160;Except as otherwise provided herein, any Notice authorized or required to be given by this Agreement shall be effective when received.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">58</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.04</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488644"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Agreement, together with the Exhibits and Schedules hereto (which are incorporated herein by reference), and the other Loan Documents constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior agreements (including the Confidentiality Agreement), understandings and negotiations, both written and oral, between the Parties with respect to the subject matter of this Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.05</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488645"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">No Loan Document or provision thereof may be waived, amended or modified except, in the case of this Agreement, by an agreement or agreements in writing executed by Borrower and Lender or, in the case of any other Loan Document, by an agreement or agreements in writing entered into by the parties thereto with the prior written consent of Lender.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.06</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488646"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_9kR3WTr2664AEN6liw"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_9kR3WTr2664AFhLe0xu9"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; etc.</u> &#160;<font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">No delay on the part of Lender in exercising any power or right hereunder shall operate as a waiver thereof nor shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power or right. &#160;Lender shall not be deemed to have waived any rights hereunder unless such waiver shall be in writing and signed by Lender.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.07</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488647"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect. &#160;Any provision of this Agreement held invalid or unenforceable only in part or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid or unenforceable. &#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.08</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488648"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determinations</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each determination or calculation by Lender hereunder shall, in the absence of manifest error, be conclusive and binding on the Parties.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.09</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488649"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recourse</u><font style="text-decoration-color:#000000;text-decoration-line:none;">.</font><font style="text-decoration-color:#000000;text-decoration-line:none;"> </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72.7pt;margin:0pt 0pt 12pt 3.6pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488650"></a></u><font style="text-decoration-color:#000000;text-decoration-line:none;">Except as otherwise expressly provided in this Agreement or in any other Loan Documents, the payment and performance of the Obligations shall be fully recourse solely to Borrower and its respective properties and assets.</font><font style="text-decoration-color:#000000;text-decoration-line:none;"> </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.10</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488651"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS AGREEMENT AND EACH NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, INCLUDING GENERAL OBLIGATIONS LAW SECTIONS 5-1401 AND 5-1402 BUT OTHERWISE WITHOUT GIVING EFFECT TO LAWS CONCERNING CONFLICT OF LAWS OR CHOICE OF FORUM THAT WOULD REQUIRE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">59</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.11</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488652"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Each Party irrevocably submits to the jurisdiction of the courts of the State of New York and of the United States sitting in the State of New York, and of the courts of its own corporate domicile with respect to any and all Proceedings. &#160;Each Party irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any Proceeding and any claim that any Proceeding has been brought in an inconvenient forum. &#160;Any process or summons for purposes of any Proceeding may be served on Borrower by mailing a copy thereof by registered mail, or a form of mail substantially equivalent thereto, addressed to it at its address as provided for Notices hereunder.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.12</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488653"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Each Party hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any action, proceeding, claim or counterclaim arising out of or relating to any Transaction Document or the transactions contemplated under any Transaction Document </b><b style="font-weight:bold;">(WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). &#160;THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO ANY TRANSACTION DOCUMENT. &#160;EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 13.12</b><b style="font-weight:bold;text-transform:uppercase;">.</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.13</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488654"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Immunity</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">To the extent that Borrower has or hereafter may be entitled to claim or may acquire, for itself or any of its assets, any immunity from suit, jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, or otherwise) with respect to itself or any of its property, Borrower hereby irrevocably waives such immunity in respect of its obligations hereunder to the fullest extent permitted by law.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.14</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488655"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts; Delivery</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. &#160;Delivery of an executed counterpart of a signature page of this Agreement in <a name="_9kR3WTr2664AGbS17ramqJOu1CxzFiYHG08"></a>Portable Document Format (PDF) or by facsimile transmission shall be effective as delivery of a manually executed original counterpart of this Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.15</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488656"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation on Rights of Others</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Except for the Indemnitees referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.01</u>, no Person other than a Party shall have any legal or equitable right, remedy or claim under or in respect of this Agreement.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">60</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.16</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488657"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The obligations of Borrower contained in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4.05</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.06</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XI</u> and this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.16</u> shall survive the repayment of the Term Loan and the termination of the other obligations of Borrower hereunder.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.17</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488658"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Until the payment of all amounts required pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.01</u><font style="font-size:11pt;">, and for a period of three (3) years thereafter, each Party shall maintain in strict confidence all Confidential Information and materials disclosed or provided to it by the other Party, except as approved in writing in advance by the disclosing Party, and shall not use or reproduce the disclosing Party&#8217;s Confidential Information for any purpose other than as required to carry out its obligations and exercise its rights pursuant to this Agreement (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</u><font style="font-size:11pt;">&#8221;). &#160;Notwithstanding the foregoing, the obligations of confidentiality and non-use set forth in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.17</u><font style="font-size:11pt;"> shall not apply to the extent that the receiving Party or its Affiliates: (a) discloses such Confidential Information solely on a &#8220;need to know basis&#8221; to its employees, consultants and Affiliates as well as any actual or potential acquirers, merger partners, licensees, permitted assignees, collaborators (including licensees), subcontractors, investment bankers, investors, limited partners, partners, lenders, or other financial partners, and its and their respective directors, employees, contractors and agents, on a confidential basis to the extent requested by an authorized representative of a U.S. or foreign tax authority, or (b) discloses Confidential Information in response to a routine audit or examination by, or a blanket document request from, a Governmental Authority. &#160;A Party receiving any such Confidential Information hereunder agrees to institute measures to protect the Confidential Information in a manner consistent with the measures it uses to protect its own most sensitive proprietary and confidential information, which in any event must not be less than a reasonable standard of care. &#160;Each Party shall be responsible for the breach of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.17</u><font style="font-size:11pt;"> by its employees, consultants or Third Parties to whom such disclosure is made pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.17</u><font style="font-size:11pt;">. &#160;Each Party shall immediately notify the other Party upon discovery of any loss or unauthorized disclosure of the other Party&#8217;s Confidential Information. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-size:11pt;">The obligations of confidentiality and non-use set forth in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.17(a)</u><font style="font-size:11pt;"> shall not apply to the extent that the receiving Party or its Affiliates is required to disclose Confidential Information pursuant to: (i) an order of a court of competent jurisdiction; (ii) Applicable Laws; (iii) regulations or rules of a securities exchange; or (iv) requirement of a Governmental Authority. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-size:11pt;">This Agreement supersedes the Confidentiality Agreement and the Confidentiality Agreement shall cease to be of any force and effect as of the Closing Date; provided, however, that all information falling within the definition of &#8220;Confidential Information&#8221; set forth in the Confidentiality Agreement shall also be deemed Confidential Information disclosed pursuant to this Agreement and subject to the provisions of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.17</u><font style="font-size:11pt;">. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:3.6pt;text-align:justify;text-indent:32.4pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">Section 13.18</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="_Toc153488659"></a></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patriot Act Notification</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Lender hereby notifies Borrower that, consistent with the Patriot Act, regulations promulgated thereunder and under other Applicable Law, Lender&#8217;s procedures and customer due diligence standards may require it to obtain, verify and record information that identifies Borrower, including among other things name, address, information regarding Persons with authority or control over Borrower, and other information regarding Borrower, its operations and transactions with Lender. &#160;Borrower agrees to provide such information and take such actions as are reasonably requested by Lender in order to assist Lender in maintaining compliance with its procedures, the Patriot Act and any other Applicable Laws.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">61</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">62</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">XRL 1 LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as Borrower</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Loan Agreement]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR LENDING LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR LENDING II LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR LENDING III LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR LENDING IC LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR TECH LENDING LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR TECH LENDING II LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OR TECH LENDING IC LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as a Lender</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Loan Agreement]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;width:275.5pt;"></font><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">BLUE OWL CAPITAL CORPORATION</b></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">as Administrative Agent</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49.24%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Loan Agreement]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">APPENDIX A<br>TO LOAN AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Term Loan Commitment</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:35.58%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:44.88%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Initial Term Loan Commitment</b></p></td><td style="vertical-align:top;width:19.52%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Pro Rata Share</b></p></td></tr><tr><td style="vertical-align:top;width:35.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;">[***]</p></td><td style="vertical-align:middle;width:44.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"> <font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 72pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;width:44.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><b style="font-weight:bold;">$  130,000,000.00 </b></p></td><td style="vertical-align:top;width:19.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">100%</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Draw Term Loan Commitments</u></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:35.58%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Lender</b></p></td><td style="vertical-align:top;width:45.33%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Delayed Draw Term Loan Commitment</b></p></td><td style="vertical-align:top;width:19.08%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Pro Rata Share</b></p></td></tr><tr><td style="vertical-align:top;width:35.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;">[***]</p></td><td style="vertical-align:top;width:45.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"> <font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 72pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:top;width:45.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><b style="font-weight:bold;">$           10,000,000.00 </b></p></td><td style="vertical-align:top;width:19.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:3pt 0pt 4pt 0pt;"><b style="font-weight:bold;">100%</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Appendix A</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.64
<SEQUENCE>6
<FILENAME>xoma-20231231xex10d64.htm
<DESCRIPTION>EX-10.64
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:48 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.64</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk153395127"></a><b style="font-weight:bold;">SALE, CONTRIBUTION AND SERVICING AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">dated as of December 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">between</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">XOMA (US) LLC</b>,<br>as Seller, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Solely for purposes of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 2.03</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.03(b)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</u>, <b style="font-weight:bold;">XOMA CORPORATION</b>,<br>as Parent, on the one hand</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">XRL 1 LLC</b>,<br>as Purchaser, on the other hand<br><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Page</b></p><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521005">Article I. DEFINITIONS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521005"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521005">1</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521006">Section 1.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521006">Definitions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521006"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521006">1</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521007">Section 1.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521007">General Interpretive Principles</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521007"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521007">3</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521008">Article II. SALE AND Assignment OF THE TRANSFERRED ASSETS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521008"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521008">4</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521009">Section 2.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521009">Sale and Assignment of Transferred Assets on the Closing Date</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521009"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521009">4</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521010">Section 2.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521010">Required Financing Statements; Marking of Records; Notice and Instruction Letters</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521010"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521010">4</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521011">Section 2.03.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521011">General Provisions Regarding the Sale and Transfer of the Transferred Assets</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521011"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521011">5</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521012">Section 2.04.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521012">Intent</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521012"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521012">5</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521013">Article III. REPRESENTATIONS AND WARRANTIES</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521013"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521013">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521014">Section 3.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521014">Representations and Warranties of Seller</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521014"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521014">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521015">Section 3.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521015">Survival of Representations and Warranties</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521015"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521015">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521016">Article IV. COVENANTS OF THE SELLER AND Purchaser; SELLER EVENT OF DEFAULT</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521016"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521016">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521017">Section 4.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521017">Seller Covenants</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521017"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521017">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521018">Section 4.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521018">Purchaser Covenants</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521018"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521018">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521019">Section 4.03.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521019">Consequences of Seller Event of Default</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521019"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521019">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521020">Article V. SERVICING</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521020"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521020">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521021">Section 5.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521021">Appointment of Seller</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521021"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521021">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521022">Section 5.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521022">Certain Seller Actions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521022"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521022">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521023">Section 5.03.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521023">Compliance with the Loan Agreement</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521023"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521023">12</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521024">Section 5.04.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521024">Services as Servicer</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521024"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521024">12</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521025">Section 5.05.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521025">Replacement Servicer</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521025"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521025">13</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521026">Article VI. TERMINATION; SURVIVAL</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521026"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521026">13</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521027">Section 6.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521027">Termination</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521027"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521027">13</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521028">Section 6.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521028">Effect of Termination</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521028"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521028">13</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521029">Section 6.03.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521029">Survival</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521029"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521029">13</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521030">Article VII. INDEMNIFICATION PAYMENTS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521030"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521030">14</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521031">Section 7.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521031">Indemnification</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521031"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521031">14</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521032">Article VIII. MISCELLANEOUS PROVISIONS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521032"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc153521032">15</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521033">Section 8.01.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521033">Amendment</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521033"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521033">15</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521034">Section 8.02.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521034">Governing Law; Waiver of Trial by Jury; Jurisdiction</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521034"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521034">15</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(i)</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521035">Section 8.03.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521035">Notices</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521035"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521035">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521036">Section 8.04.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521036">Severability of Provisions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521036"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521036">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521037">Section 8.05.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521037">Assignment</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521037"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521037">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521038">Section 8.06.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521038">Further Assurances</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521038"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521038">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521039">Section 8.07.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521039">Waiver; Cumulative Remedies; Waiver of Immunities</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521039"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521039">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521040">Section 8.08.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521040">Counterparts</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521040"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521040">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521041">Section 8.09.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521041">Binding</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521041"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521041">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521042">Section 8.10.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521042">Merger and Integration</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521042"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521042">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521043">Section 8.11.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521043">Headings</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521043"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521043">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521044">Section 8.12.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521044">Schedules and Exhibits</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521044"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521044">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521045">Section 8.13.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521045">Non-Petition</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521045"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521045">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:90pt;text-indent:-90pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521046">Section 8.14.</a></font><font style="display:inline-block;width:5.27%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521046">Intended Third Party Beneficiaries</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521046"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc153521046">18</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit A</font></font>Form of Notice and Instruction Letters</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Exhibit B</font></font>Bill of Sale</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(ii)</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This <b style="font-weight:bold;">SALE</b>, <b style="font-weight:bold;">CONTRIBUTION AND SERVICING AGREEMENT</b> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), dated as of December 15, 2023, is entered between XOMA (US) LLC, a Delaware limited liability company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller</u>&#8221;), and solely for purposes of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 2.03</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.03(b)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</u>, XOMA Corporation., a Delaware corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</u>&#8221;), on the one hand; and XRL 1 LLC, a Delaware limited liability company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser</u>&#8221;), on the other hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">RECITALS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Seller owns 100% of the equity interests of Purchaser;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Seller desires to sell, contribute, assign, transfer and convey to Purchaser all its right, title and interest in, to and under the Transferred Assets in exchange for receiving from Purchaser the Purchase Price;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Purchaser desires to purchase and acquire all of Seller&#8217;s right, title and interest in, to and under the Transferred Assets on the <a name="_9kR3WTr2664AIQCv3yutK9w1"></a>Closing Date in exchange for paying to Seller the cash portion of the Purchase Price and accepting and reflecting in its financial accounts a capital contribution from Seller of the additional value of the Transferred Assets in excess of the Purchase Price;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Purchaser desires Seller to manage, on behalf of Purchaser, Purchaser&#8217;s relationship with any <a name="_9kR3WTr2664AJRF5wtuhEC0znwxzFfVKKKCBN7A"></a>Covered Agreement Counterparty under each <a name="_9kR3WTr2664AKSF5wtuhEC0znwxzF"></a>Covered Agreement, to administer, on Purchaser&#8217;s behalf, enforcement of such <a name="_9kMHG5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement (including the collection and enforcement of all payments due to Purchaser under such <a name="_9kMIH5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement from time to time), and Seller desires to perform such services on Purchaser&#8217;s behalf; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Purchaser and Seller agree that the transactions contemplated under this Agreement shall be disregarded for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article I.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc153521005"></a>DEFINITIONS</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 1.01.</font><a name="_Ref153174305"></a><a name="_Toc153521006"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;Unless otherwise defined herein, capitalized terms used herein shall have the meanings set forth in the Loan Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">As used herein, the following terms have the following respective meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221; means the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Assets</u>&#8221; means all of Seller&#8217;s right, title and interest in, to and under the <a name="_9kR3WTr2664BCWY7qhgsxjGQF24J"></a>Purchased Assets described in clause (d) of the definition thereof set forth in the <a name="_9kR3WTr2664BDKFwvoutlkoeO4Hy0GtpO7yx9EX"></a>Commercial Payment Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.01</u>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loan Agreement</u>&#8221; means that certain Loan Agreement, dated as of the date hereof, among Purchaser, as <a name="_9kR3WTr2664BEKE15390w"></a>Borrower, the lenders from time to time party thereto (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lenders</u>&#8221;) and <a name="_9kR3WTr2664BFLB1vQd7O8s16zsVTFHFI58HDJ"></a>Blue Owl Capital Corporation, as administrative agent for the Lenders (in such capacity, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrative Agent</u>&#8221;), as such Loan Agreement may be amended, restated, supplemented or otherwise modified from time to time, in accordance with the terms thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.01</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice and Assignment Letters</u>&#8221; has the meaning set forth in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.02(c</u>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u>&#8221; means an amount equal to the sum of (i) the aggregate principal amount of the <a name="_9kR3WTr2664BGeMr0VSoo"></a>Term Loan made on <a name="_9kR3WTr2664BHUKryzhlRVAuq10RG38"></a>Initial Funding Date under the Loan Agreement and (ii) the aggregate principal amount of any <a name="_9kR3WTr2664BIQ6liw1hHQu0uX2Bgdzz"></a>Delayed Draw Term Loan made after the <a name="_9kMHG5YVt4886CKSEx50wvMBy3"></a>Closing Date under the Loan Agreement, less the <a name="_9kR3WTr2664BJZEnnfuVWEwvA23"></a>Lender Expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recharacterization</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 2.01(a</u>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Roche APA</u>&#8221; has the meaning given to such term in the <a name="_9kMHG5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sell</u>&#8221; has the meaning set forth in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(a</u>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Event of Default</u>&#8221; means the occurrence of one or more of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font>Any representation or warranty of Seller in any <a name="_9kR3WTr2664BKiZnk3rcw3z5VRx4F02IO"></a>Transaction Document to which it is party or in any certificate or other document delivered by Seller in connection with the <a name="_9kMHG5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents proves to have not been true and correct in all material respects at the time it was made or deemed made &#160;(except that any representation or warranty that is qualified as to &#8220;materiality&#8221; or &#8220;<a name="_9kR3WTr2664BLcBputyimNA241G4RNvvt9"></a>Material Adverse Effect&#8221; shall be true and correct in all respects); provided, that if the consequences of the failure of such representation or warranty to be true and correct can be cured, such failure continues for a period of [***] days without such cure after the earlier of the date Seller becomes aware of such failure or the date Purchaser, or Administrative Agent on behalf of Purchaser, provides Notice of such failure to Seller.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font>Seller fails to perform or observe any covenant or agreement contained in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4.01(f)</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(g)</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(h)(i)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(j)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font>Seller fails to perform or observe any covenant or agreement contained in the <a name="_9kMIH5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents to which it is a party (other than those referred to in preceding subclause (b))<font style="background:#ffffff;"> and, solely if the consequences of the failure to perform or observe such covenant or </font><a name="_9kMJI5YVt4666AKS7vuirsuA"></a><font style="background:#ffffff;">agreement</font><font style="background:#ffffff;"> can be cured, such failure continues for a period of [***] days without such cure after the earlier of (x) the date Seller becomes aware of such failure and (y) the date Purchaser, or Administrative Agent on behalf of Purchaser, provides notice of such failure to Seller</font>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font>(i) Any of the <a name="_9kMJI5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents to which Seller is a party shall cease to be in full force and effect, or (ii) the validity or enforceability of any of the <a name="_9kMKJ5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents to which Seller is a party is disaffirmed or challenged in writing by Seller or any of its <a name="_9kR3WTr2664CDH4gkrsiuzz"></a>Affiliates or any <a name="_9kR3WTr2664CEXIr640"></a>Person (other than Administrative Agent or the Lenders) asserting an interest in any of the <a name="_9kR3WTr2664CFLFvtjsxwto"></a>Collateral and such written disaffirmation or challenge is not withdrawn or disavowed by such <a name="_9kMHG5YVt4886EGZKt862"></a>Person within [***] days after its communication or Seller has not brought appropriate proceedings for declaratory or other relief negating such disaffirmation or challenge within [***] days after such communication and has not obtained an order granting such relief within [***] days after commencement of such proceedings, or (iii) this Agreement or </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the <a name="_9kR3WTr2664CGZPlehjEBzymvwyE"></a>Pledge Agreement shall cease to give Administrative Agent (directly or as assignee of Purchaser) the rights purported to be created hereby or thereby (including a first priority perfected <a name="_9kR3WTr2664CHWIio3"></a>Lien on all of the <a name="_9kMHG5YVt4886EHNHxvluzyvq"></a>Collateral in the event of a Recharacterization (except as otherwise expressly provided herein and therein)) other than as a direct result of any action by Administrative Agent or failure of Administrative Agent to perform an obligation of Administrative Agent under the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font>Any security interest purported to be created by this Agreement or the <a name="_9kMHG5YVt4886EIbRngjlGD10oxy0G"></a>Pledge Agreement shall cease to be in full force and effect, or shall cease to give the rights, powers and privileges purported to be created and granted hereunder or thereunder (including a perfected first priority security interest in and <a name="_9kMHG5YVt4886EJYKkq5"></a>Lien on substantially all of the <a name="_9kMIH5YVt4886EHNHxvluzyvq"></a>Collateral in the event of a Recharacterization (except as otherwise expressly provided herein and therein)) in favor of Purchaser pursuant hereto or thereto (other than as a result of the failure by Administrative Agent or Purchaser of taking action required to maintain the perfection of such security interests), or shall be asserted by Seller not to be a valid, perfected, first priority (except as otherwise expressly provided in this Agreement or the <a name="_9kMIH5YVt4886EIbRngjlGD10oxy0G"></a>Pledge Agreement) security interest in the <a name="_9kMJI5YVt4886EHNHxvluzyvq"></a>Collateral, and/or Seller takes any action which could reasonably be expected to impair Administrative Agent&#8217;s security interest in any of the <a name="_9kMKJ5YVt4886EHNHxvluzyvq"></a>Collateral (other than granting Permitted Liens or permitting such Permitted Liens to exist).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font>An <a name="_9kR3WTr2664CJVK13x5zsr3gY5yE"></a>Insolvency Event with respect to Seller shall occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicer</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.01</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicer Termination Event</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.05</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicing Fee</u>&#8221; means, with respect to each calendar quarter, an amount equal to [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicing Standard</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.01</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferred Assets</u>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.01(a)</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 1.02.</font><a name="_Toc153521007"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Interpretive Principles</u>. &#160;For purposes of this Agreement except as otherwise expressly provided or unless the context otherwise requires:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>the terms defined in this Agreement have the meanings assigned to them in this Agreement and include the plural as well as the singular, and the use of any gender herein shall be deemed to include the other gender;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>accounting terms not otherwise defined herein have the meanings assigned to them in accordance with GAAP;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>references herein to &#8220;Articles&#8221;, &#8220;Sections&#8221;, &#8220;Subsections&#8221;, &#8220;paragraphs&#8221;, and other subdivisions without reference to a document are to designated Articles, Sections, Subsections, paragraphs and other subdivisions of this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>a reference to a Subsection without further reference to a Section is a reference to such Subsection as contained in the same Section in which the reference appears, and this rule shall also apply to paragraphs and other subdivisions;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>the words &#8220;herein&#8221;, &#8220;hereof&#8221;, &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular provision; and</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>the term &#8220;include&#8221; or &#8220;including&#8221; shall mean without limitation by reason of enumeration.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article II.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref152677004"></a><a name="_Toc153521008"></a>SALE AND Assignment OF THE TRANSFERRED ASSETS</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.01.</font><a name="_Ref152675772"></a><a name="_Toc153521009"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale and Assignment of Transferred Assets on the Closing Date</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref152675401"></a>On the <a name="_9kMIH5YVt4886CKSEx50wvMBy3"></a>Closing Date, and subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 2.01(b)</u>, Seller shall sell, transfer, assign, contribute and otherwise convey (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sell</u>&#8221;) to Purchaser, and Purchaser shall purchase, acquire and accept from Seller, without recourse except to the extent provided in this Agreement, all of Seller&#8217;s rights, title and interest in, to, and under the following assets:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>the <a name="_9kR3WTr2664CKO4gkzwgkJPE5u07z1HfNBAy78A"></a>Affitech Assignment Agreement (including Seller&#8217;s right to all payments in respect of the <a name="_9kR3WTr2664CLRFwvoutlkoeO4Hy0GM"></a>Commercial Payments [***];</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>the <a name="_9kR3WTr2664CMfY7qhgsxjIO54x32utxnXDQ79P"></a>Purchased Commercial Payments and Purchased Assets (as each such term is defined in the <a name="_9kMIH5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement but excluding the Excluded Assets);</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>any rights to erroneous payments in respect of the <a name="_9kMHG5YVt4886DEYa9sjiuzlISH46L"></a>Purchased Assets under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(b)(i)</u> of the <a name="_9kMJI5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement and any rights to interest with respect to such erroneous payments under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(b)(iii)</u> of the <a name="_9kMKJ5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>all proceeds of the foregoing;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">in each case free and clear of any and all <a name="_9kMIH5YVt4886EJYKkq5"></a>Liens (such rights, title and interest, together with all proceeds thereof, collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferred Assets</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Seller and Purchaser intend and agree that the sale, transfer, assignment contribution and conveyance of the Transferred Assets under this Agreement shall be, and is, a true, complete, absolute and irrevocable <a name="_cp_change_522"></a>sale, contribution, assignment, transfer, conveyance and grant by Seller to Purchaser of the Transferred Assets and that such sale, contribution, assignment, transfer, conveyance and grant shall provide Purchaser with all of Seller&#8217;s rights, title and interest in and to the Transferred Assets. </p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref152676258"></a>In full consideration of the sale, transfer, assignment contribution and conveyance of the Transferred Assets to Purchaser, Purchaser shall pay (or cause to be paid) the Purchase Price to Seller on the <a name="_9kMJI5YVt4886CKSEx50wvMBy3"></a>Closing Date, by transferring (or causing to be transferred) an amount equal to the Purchase Price to Seller to the account of Seller specified by it in writing and accepting and reflecting in its financial accounts a capital contribution from Seller in an amount equal to any additional value of the Transferred Assets in excess of the Purchase Price. &#160;Seller, concurrently with execution and delivery of this Agreement, hereby contributes to Purchaser all of the value of the Transferred Assets in excess of the Purchase Price, as a contribution to the capital of Purchaser. &#160;Purchaser acknowledges receipt of such capital contribution and its entry in the financial records of Purchaser as a capital contribution.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.02.</font><a name="_Toc153521010"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Financing Statements; Marking of Records; Notice and Instruction Letters</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>All financing statements (or documents of similar import) shall meet the requirements of <a name="_9kR3WTr2664DEHE0xrjccosTK2"></a>Applicable Law. &#160;Seller irrevocably authorizes Purchaser and Administrative Agent at any time and from time to time in the sole discretion of Purchaser or Administrative, and appoints Purchaser and Administrative Agent as its attorney-in-fact, to act on behalf of Seller (i) to execute on behalf of Seller </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">as debtor and to file financing statements necessary or appropriate in Purchaser or Administrative Agent&#8217;s sole discretion to perfect and to maintain the perfection and priority of the interest of Purchaser in the Transferred Assets and (ii) to file a carbon, photographic or other reproduction of this Agreement or any financing statement with respect to the Transferred Assets as a financing statement in such offices as Purchaser or its assigns in their sole discretion deem necessary or appropriate to perfect and to maintain the perfection and priority of Purchaser&#8217;s interests in such Transferred Assets. &#160;Purchaser shall provide Seller with copies of any such filings. &#160;This appointment is coupled with an interest and is irrevocable. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>In view of the intention of the parties hereto that the assignment and transfer of the Transferred Assets made hereunder shall constitute outright sales or contributions of the Transferred Assets rather than loans secured thereby, in connection with the transfer and conveyance of the <a name="_9kR3WTr2664DFbZnk3wjwAylISH46Lvc2A4B"></a>Transferred Assets Seller has, at its own expense caused its records to be marked on the <a name="_9kMLK5YVt4886CKSEx50wvMBy3"></a>Closing Date to show that the Transferred Assets have been transferred to Purchaser in accordance with this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref152711481"></a>On the <a name="_9kMML5YVt4886CKSEx50wvMBy3"></a>Closing Date, Seller and Purchaser shall execute and deliver (i) to <a name="_9kR3WTr2664DGJ4gkzwgk"></a>Affitech, the <a name="_9kR3WTr2664DHXQ3yifeosOTAHHJ55C8EmYDTFE"></a>Notice and Instruction Letter substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A-1</u> and (ii) to Roche, the <a name="_9kMHG5YVt4886FJZS50khgquQVCJJL77EAGoaFV"></a>Notice and Instruction Letter substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A-2</u> (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice and Assignment Letters</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>On the <a name="_9kMNM5YVt4886CKSEx50wvMBy3"></a>Closing Date, Seller and Purchaser shall execute and deliver the <a name="_9kR3WTr2664DIM8ptxsXNns"></a>Bill of Sale attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.03.</font><a name="_Ref153440828"></a><a name="_Toc153521011"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions Regarding the Sale and Transfer of the Transferred Assets</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">[***], the sale and assignment of the Transferred Assets pursuant to this Agreement shall be without recourse to Seller or Parent; it being understood that Seller shall be liable to Purchaser for all representations, warranties, covenants and indemnities made by Seller pursuant to the terms of this Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.04.</font><a name="_Ref152676189"></a><a name="_Ref152676202"></a><a name="_Toc153521012"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intent</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref152675788"></a>Seller and Purchaser intend that the sale and transfer by Seller to Purchaser of the Transferred Assets pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.01</u> hereof shall be true, absolute and irrevocable, shall constitute a valid transfer and conveyance by Seller of the Transferred Assets and shall provide Purchaser with the full benefits of ownership of the Transferred Assets, and that the Transferred Assets shall be removed from the estate of Seller and shall not be part of Seller&#8217;s estate in the event of the insolvency or bankruptcy of Seller.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref152711504"></a>Without limiting the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.04(a)</u>, as a precaution to address the possibility that, notwithstanding that Seller and Purchaser expressly intend and expect that the sale, assignment, transfer, contribution and conveyance of the Transferred Assets hereunder shall be a true, absolute and irrevocable sale and assignment and a true, absolute and irrevocable contribution for all purposes, to protect the interest of Purchaser in the event that such sale and assignment is recharacterized as other than a true sale or true contribution or such sale, transfer or contribution will for any reason be ineffective or unenforceable as such, as determined in a judicial, administrative or other proceeding (any of the foregoing being a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recharacterization</u>&#8221;), Seller does hereby grant to Purchaser a continuing security interest (which shall be of first priority) in all of Seller&#8217;s right, title and interest in, to and under the Transferred Assets, whether now or hereafter existing, and any and all &#8220;proceeds&#8221; thereof (as such term is defined in the UCC), in each case, for the benefit of Purchaser as security for the prompt and complete payment of a loan deemed to have been made in an amount equal to the Purchase Price together with the performance when due of all of Purchaser&#8217;s obligations now or hereafter existing under this Agreement and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">the other <a name="_9kMLK5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents, which security interest will, upon the filing of a duly prepared financing statement in the appropriate filing office, be perfected and prior to all other <a name="_9kMJI5YVt4886EJYKkq5"></a>Liens on the rights of Seller to the Transferred Assets. &#160;In the event of a Recharacterization, Purchaser will have, in addition to the rights and remedies which it may have under this Agreement, all other rights and remedies provided to a secured creditor after default under the UCC and other <a name="_9kMHG5YVt4886FGJG2ztleequVM4"></a>Applicable Law, which rights and remedies will be cumulative. &#160;This Agreement shall constitute a security agreement in respect of such security interest. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Seller and Purchaser intend that their operations and business would not be substantively consolidated in the event of an <a name="_9kMHG5YVt4886ELXM35z71ut5ia70G"></a>Insolvency Event with respect to Seller and that the separate existence of Seller and Purchaser would not be disregarded in the event of an <a name="_9kMIH5YVt4886ELXM35z71ut5ia70G"></a>Insolvency Event with respect to Seller. &#160;Purchaser and Seller acknowledge that the <a name="_9kR3WTr2664DJaUtdlu70v406tsWU07I35LRNBn"></a>Organizational Documents of Purchaser contains provisions intended to maintain the separate existence and identity of Purchaser and the parties agree that they will duly observe such provisions and <a name="_9kMIH5YVt4886FGJG2ztleequVM4"></a>Applicable Law in support of such separate existence and identity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article III.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc153521013"></a>REPRESENTATIONS AND WARRANTIES</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.01.</font><a name="_Toc153521014"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Seller</u>. &#160;Seller represents and warrants that the representations and warranties set forth under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.02</u> of the Loan Agreement are true and correct, and such representations and warranties are hereby made herein by Seller as though set forth in full herein. &#160;Purchaser has relied upon such representations and warranties in accepting the conveyance of the Transferred Assets and the other parties to the transactions contemplated hereby have relied upon such representations and warranties in executing each of the <a name="_9kMML5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents to which it is a party. &#160;Such representations and warranties shall survive until the <a name="_9kR3WTr2664DKcEu7oq62xVXA2"></a>Payment in Full.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.02.</font><a name="_Ref152623841"></a><a name="_Ref152676870"></a><a name="_Toc153521015"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Representations and Warranties</u>. &#160;All representations and warranties by Seller contained in this Agreement shall survive the execution, delivery and acceptance thereof by the <a name="_9kR3WTr2664DLdEn7zlw"></a>Parties and the closing of the transactions contemplated in this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article IV.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc153521016"></a>COVENANTS OF THE SELLER AND Purchaser; SELLER EVENT OF DEFAULT</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.01.</font><a name="_Ref152675911"></a><a name="_Ref152675964"></a><a name="_Ref152676311"></a><a name="_Toc153521017"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Covenants</u>. &#160;Seller hereby covenants and agrees with Purchaser, in connection with the sale, assignment and transfer of the Transferred Assets, as follows:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref152676831"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements and Information</u>. &#160;Seller will facilitate Purchaser undertakings regarding financial statements (to the extent such financial statements relate to Seller) set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.03</u> of the Loan Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</u>. &#160;All written information supplied by or on behalf of Seller to Purchaser pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.01</u> (other than pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 8.03(a)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.03(b)</u> of the Loan Agreement) shall be accurate and complete in all material respects as of its date or the date so supplied and the financial statements provided pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 8.03(a)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.03(b)</u> of the Loan Agreement fairly present in all material respects the financial positions and results of operations as of the dates indicated therein. &#160;For the avoidance of doubt, Seller makes no representations or warranties regarding the accuracy or completeness of any information it receives from a <a name="_9kR3WTr2664DMiPlwsRJsCK"></a>Third Party that it is required to furnish to Purchaser pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.01</u>, unless to the actual <a name="_9kR3WTr2664DNaMx75ohkmvxcWw4y5"></a>Knowledge of Seller such information is inaccurate or incomplete, in which case Seller shall specify such inaccuracy or incompleteness.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Books and Records</u>. &#160;Seller shall keep proper books, records and accounts in which entries in conformity with sound business practices and all requirements of <a name="_9kR3WTr2664EFSAs"></a>Law applicable to it shall be made of all dealings and transactions in relation to its business, assets and activities and as shall permit the preparation of the consolidated financial statements of Seller in accordance with GAAP.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintenance of Insurance</u>. &#160;Seller shall maintain coverage under its general liability and property damage insurance policies naming Purchaser and its assigns as additional insured (in the case of liability insurance) and loss payee (in the case of property insurance). &#160;Seller shall furnish to Purchaser from time to time upon written request full information as to the insurance carried.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authorizations</u>. &#160;Seller shall obtain, make and keep in full force and effect all authorizations from and registrations with <a name="_9kR3WTr2664EGOJ5wt3zrt9xqRVL95GBEV"></a>Governmental Authorities that may be required for the validity or enforceability against Seller of this Agreement and the other <a name="_9kMNM5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents to which it is a party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref152674991"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws and Contracts</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref152676071"></a>Seller shall comply with all <a name="_9kMJI5YVt4886FGJG2ztleequVM4"></a>Applicable Laws applicable to the Transferred Assets, and perform its obligations under all <a name="_9kR3WTr2664EHVBputyimPN5BGyk4"></a>Material Contracts, if any, entered into after the date of execution of the Loan Agreement relative to the conduct of its business, except where the failure to comply could not reasonably be expected to result in a <a name="_9kMHG5YVt4886DNeDrwv0koPC463I6TPxxvB"></a>Material Adverse Effect. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref152676126"></a>Seller will comply, in all material respects, with all acts, rules, regulations, orders, decrees and directions of any <a name="_9kMHG5YVt4886GIQL7yv51tvBzsTXNB7IDGX"></a>Governmental Authority applicable to the Transferred Assets. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref152675023"></a><a name="_Ref152841002"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conveyance of Transferred Assets; Security Interests</u>. &#160;Except for the transfers and conveyances hereunder and any Permitted Liens, Seller will not sell, contribute, pledge, assign, dispose of or transfer to any other <a name="_9kMIH5YVt4886EGZKt862"></a>Person, or grant, create, incur, assume or suffer to exist any <a name="_9kMKJ5YVt4886EJYKkq5"></a>Lien on the <a name="_9kR3WTr2664EIMF5wtuhEC0znwxzFL"></a>Covered Agreements, the Transferred Assets, the Excluded Assets or any interest therein and Seller shall defend the right, title, and interest of Purchaser and its successors and assigns in, to, and under the <a name="_9kMHG5YVt4886GKOH7yvwjGE21pyz1HN"></a>Covered Agreements, the Excluded Assets and Transferred Assets, against all claims of third parties claiming through or under Seller. &#160;Seller acknowledges and agrees that, having assigned and transferred the Transferred Assets to Purchaser, Seller shall not, without the prior written consent of Administrative Agent, waive, modify, amend or terminate any provision of, or grant any consent under, any <a name="_9kMJI5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement (including, without limitation, any consents pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(c)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u> of the <a name="_9kMLK5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement) [***].<a name="_cp_change_640"></a><a name="_cp_change_638"></a>Notwithstanding the foregoing, Seller&#8217;s reasonable decision not to enforce its rights under any <a name="_9kR3WTr2664EKOF5wtuhEC0znwxzF84Hvn5z2E"></a>Covered Agreement for Roche&#8217;s failure to timely remit any due and payable <a name="_9kMHG5YVt4886ENTHyxqwvnmqgQ6J02IO"></a>Commercial Payments during any reasonable grace period, which shall not, in any event, extend beyond [***] days, shall not constitute a waiver or consent under any <a name="_9kMKJ5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="_Ref152675030"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. &#160;Seller shall promptly:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>upon obtaining <a name="_9kR3WTr2664ELXMx75ohkm"></a>Knowledge of the same give written Notice to Purchaser and Administrative Agent of each <a name="_9kR3WTr2664EMR6fcs44"></a>Default, <a name="_9kR3WTr2664ENTOvo46tJDmjzBB"></a>Event of Default, or Servicer Termination Event and each other event that has or could reasonably be expected to have a <a name="_9kMIH5YVt4886DNeDrwv0koPC463I6TPxxvB"></a>Material Adverse Effect; provided that in any of the foregoing situations where Seller knows a press release or other public disclosure is to be made by Seller or any of its <a name="_9kMIH5YVt4886EFJ6imtukw11"></a>Affiliates, Seller shall use all commercially reasonable efforts to provide such information to Purchaser and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:0pt;">Administrative Agent as early as possible but in no event later than simultaneously with such release or other public disclosure;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>give written <a name="_9kR3WTr2664EOdQ3yifx8fgFypo055"></a>Notice to Purchaser and Administrative Agent upon receiving notice, or otherwise obtaining <a name="_9kMHG5YVt4886GNZOz97qjmo"></a>Knowledge, of any default or event of default under any <a name="_9kMHG5YVt4886GJXDrwv0koRP7DI0m6"></a>Material Contract;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>upon obtaining <a name="_9kMIH5YVt4886GNZOz97qjmo"></a>Knowledge thereof, give written <a name="_9kMHG5YVt4886GQfS50khzAhiH0rq277"></a>Notice to Purchaser and Administrative Agent of any litigation or proceedings to which Seller is a party or which could reasonably be expected to have a <a name="_9kMJI5YVt4886DNeDrwv0koPC463I6TPxxvB"></a>Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>upon obtaining <a name="_9kMJI5YVt4886GNZOz97qjmo"></a>Knowledge thereof, give written <a name="_9kMIH5YVt4886GQfS50khzAhiH0rq277"></a>Notice to Purchaser and Administrative Agent of any litigation or proceedings challenging the validity of any <a name="_9kMLK5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement, the <a name="_9kMON5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents or any of the transactions contemplated therein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>upon obtaining <a name="_9kMKJ5YVt4886GNZOz97qjmo"></a>Knowledge thereof, give written <a name="_9kMJI5YVt4886GQfS50khzAhiH0rq277"></a>Notice to Purchaser and Administrative Agent of any representation or warranty made or deemed made by Seller in any of the <a name="_9kMPO5YVt4886DMkbpm5tey517XTz6H24KQ"></a>Transaction Documents or in any certificate delivered pursuant thereto shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made or deemed made;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font>upon obtaining <a name="_9kMLK5YVt4886GNZOz97qjmo"></a>Knowledge thereof give written <a name="_9kMKJ5YVt4886GQfS50khzAhiH0rq277"></a>Notice to Purchaser and Administrative Agent of the occurrence of any <a name="_9kMKJ5YVt4886DNeDrwv0koPC463I6TPxxvB"></a>Material Adverse Effect; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref152676656"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Taxes</u>. &#160;Seller shall file all tax returns required to be filed by it and <a name="_cp_change_900"></a>pay, discharge or otherwise satisfy <a name="_cp_change_901"></a>all material taxes of any kind imposed on or in respect of its income or assets <a name="_cp_change_902"></a>as the same shall become due and payable and in any event before any <a name="_9kMML5YVt48867GcKkq5"></a>Lien on any of the Transferred Assets exists as a result of nonpayment except for Permitted Liens and taxes contested in good faith by appropriate proceedings or where any such failure to file or pay would not result, individually or in the aggregate, in a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref152675039"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Payment Purchase Agreement; Roche APA; Turnover</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>Seller acknowledges and agrees that, having retained all obligations of Seller under the <a name="_9kMIH5YVt4886GKOH7yvwjGE21pyz1HN"></a>Covered Agreements, it shall fully perform, as and when due, all obligations of Seller under the <a name="_9kMJI5YVt4886GKOH7yvwjGE21pyz1HN"></a>Covered Agreements, including, without limitation, paying, as and when due, any Purchase Price (as defined in the <a name="_9kMML5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement) due to <a name="_9kMHG5YVt4886FIL6im1yim"></a>Affitech under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u> of the <a name="_9kMNM5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref152845600"></a>Unless Administrative Agent provides consent, Seller shall enforce its rights under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u> of the <a name="_9kMON5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement, in each case, as and when necessary to effect the full sale of the Transferred Assets to Purchaser, free and clear of all liens, including, without limitation, seeking specific performance under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u> of the <a name="_9kMPO5YVt4886DFMHyxqwvnmqgQ6J02IvrQ90zB"></a>Commercial Payment Purchase Agreement. Notwithstanding the foregoing, Seller&#8217;s reasonable decision not to enforce its rights under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u> of the <a name="_9kMHzG6ZWu5997EGNIzyrxwonrhR7K13JwsRA10"></a>Commercial Payment Purchase Agreement for Roche&#8217;s failure to timely remit any due and payable <a name="_9kMIH5YVt4886ENTHyxqwvnmqgQ6J02IO"></a>Commercial Payments during any reasonable </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:0pt;">grace period, which shall not, in any event, extend beyond [***] days, shall not constitute a breach of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.01(j)(ii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>If any amount is paid to Seller under the <a name="_9kMKJ5YVt4886GKOH7yvwjGE21pyz1HN"></a>Covered Agreements on account of the Transferred Assets on or after the <a name="_9kMON5YVt4886CKSEx50wvMBy3"></a>Closing Date and prior to <a name="_9kMIH5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full, Seller shall hold such amount in trust for Purchaser, shall segregate such amount from other funds of Seller, and shall, promptly upon receipt of such amount by Seller, turn over such amount to Purchaser in the exact form received by Seller (duly indorsed by Seller to Purchaser, if required), for deposit in the <a name="_9kMHG5YVt48878ANHxvphx406TDmzIII"></a>Collection Account.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Documents; Further Assurances</u>. &#160;Seller shall promptly, upon the reasonable request of Purchaser or Administrative Agent, at Seller&#8217;s sole cost and expense, (a) execute, acknowledge and deliver, or cause the execution, acknowledgment and delivery of, and thereafter register, file or record, or cause to be registered, filed or recorded, in an appropriate governmental office, any document or instrument supplemental to or confirmatory of the <a name="_9kR3WTr266569VOkkOKqx8tvBH"></a>Loan Documents or otherwise deemed by Purchaser or Administrative Agent reasonably necessary or desirable for the continued validity, perfection and priority of the assignment of the Transferred Assets or the <a name="_9kMLK5YVt4886EJYKkq5"></a>Liens thereon secured pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.04</u> subject to no other <a name="_9kMML5YVt4886EJYKkq5"></a>Liens except as permitted by the applicable <a name="_9kMHG5YVt48878BXQmmQMszAvxDJ"></a>Loan Document, or obtain any consents or waivers as may be necessary or appropriate in connection therewith; (b) deliver or cause to be delivered to Purchaser and Administrative Agent from time to time such other documentation, consents, authorizations, approvals and orders in form and substance reasonably satisfactory to Purchaser and the Administrative Agent as Purchaser or Administrative Agent shall reasonably deem necessary to perfect or maintain the assignment of the Transferred Assets or the <a name="_9kMNM5YVt4886EJYKkq5"></a>Liens thereon secured pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.04</u>; and (c) upon the exercise by Purchaser or Administrative Agent of any power, right, privilege or remedy pursuant to any <a name="_9kMIH5YVt48878BXQmmQMszAvxDJ"></a>Loan Document which requires any consent, approval, registration, qualification or authorization of any <a name="_9kMIH5YVt4886GIQL7yv51tvBzsTXNB7IDGX"></a>Governmental Authority execute and deliver all applications, certifications, instruments and other documents and papers that Purchaser or Administrative Agent may require. &#160;In addition, Seller shall promptly, at its sole cost and expense, execute and deliver to Purchaser and Administrative Agent such further instruments and documents, and take such further action, as Purchaser or Administrative may, at any time and from time to time, reasonably request in order to carry out the intent and purpose of this Agreement and the other <a name="_9kMHzG6ZWu5997ENlcqn6ufz628YU07I35LR"></a>Transaction Documents to which it is a party and to establish and protect the rights, interests and remedies created, or intended to be created, in favor of Purchaser and Administrative Agent hereby and thereby.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Information Regarding Seller, Etc</u>. &#160;Seller shall provide information that Purchaser or Administrative Agent reasonably request from Seller with respect to the Transferred Assets relating to any period prior to the Effective Date, including information that may be reasonably requested under the Loan Agreement. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font>[<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reserved</u>]. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Purchaser Covenants and Organizational Documents</u>. &#160;Seller shall, so long as it is the sole member of Purchaser and prior to <a name="_9kMJI5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full, cause Purchaser to be managed and operated in a manner consistent with the negative covenants contained in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.01</u> of the Loan Agreement and the <a name="_9kMHG5YVt4886FLcWvfnw92x628vuYW29K57NTP"></a>Organizational Documents of Purchaser.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Contributions</u>. &#160;Prior to <a name="_9kMKJ5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full, Seller will limit capital contributions to Purchaser to [***]; provided that the foregoing shall not create an obligation to effect capital contributions, which shall be in Seller&#8217;s sole discretion, and provided further that the following shall not be included in such limits and shall be permitted without restriction: (i) a capital contribution effected pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01(b)</u> hereof, (ii) capital contributions to effect <a name="_9kMLK5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full, (iii) capital contributions necessary to pay <a name="_9kMHG5YVt4886DLbGpphwXYGyxC45"></a>Lender Expenses then due and payable but only to the extent the remaining balance of the <a name="_9kR3WTr26656APQ8qp4wWRz00I6MPAJJJ"></a>Expense Reserve Amount is insufficient to pay such amounts and (iv) capital contributions to make principal payments pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.02(a)(iv)</u> of the Loan Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.02.</font><a name="_Toc153521018"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser Covenants</u>. &#160;Purchaser hereby covenants and agrees with Seller as follows: </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements and Information</u>. &#160;For each <a name="_9kR3WTr26656BeLmrGG08woeS1640"></a>Semi-Annual Period ending after the <a name="_9kMPO5YVt4886CKSEx50wvMBy3"></a>Closing Date, Purchaser shall, promptly following receipt thereof under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.7</u> of the <a name="_9kMIH5YVt4886EMQ6im1yimLRG7w2913JhPDC09"></a>Affitech Assignment Agreement, deliver or cause to be delivered (or otherwise made available) to Seller a true copy of the reports contemplated thereunder for such <a name="_9kMHG5YVt48878DgNotII2AyqgU3862"></a>Semi-Annual Period.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Merger, Consolidation or Reorganization of Purchaser</u>. &#160;Purchaser shall not merge or consolidate with any other entity and shall not enter into any other transaction that results in a reorganization of Purchaser.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Additional Indebtedness of Purchaser</u>. &#160;Purchaser shall not incur any <a name="_9kR3WTr26656CVKmedtxisu0F"></a>Indebtedness other than <a name="_9kMHG5YVt48878EXMogfvzkuw2H"></a>Indebtedness under or permitted by the Loan Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Law</u>. &#160;Purchaser will comply, in all material respects, with all acts, rules, regulations, orders, decrees and directions of any <a name="_9kMJI5YVt4886GIQL7yv51tvBzsTXNB7IDGX"></a>Governmental Authority applicable to the Transferred Assets or any part thereof; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that Purchaser may contest any act, regulation, order, decree or direction of any <a name="_9kMKJ5YVt4886GIQL7yv51tvBzsTXNB7IDGX"></a>Governmental Authority in any reasonable manner which shall not have a <a name="_9kMLK5YVt4886DNeDrwv0koPC463I6TPxxvB"></a>Material Adverse Effect. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_cp_change_824"></a><a name="_cp_change_822"></a>[<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reserved</u>].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Amendment to the Covered Agreements</u>. &#160;Purchaser shall not amend, modify or supplement any <a name="_9kMML5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement or waive any of its rights under the foregoing or permit any amendment, modification or supplementing of such <a name="_9kMNM5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement with respect to the foregoing, without the prior written consent of Seller; provided an assignment of the Roche APA that solely changes the parties to Seller from Affitech Research AS (or its successors and assigns) or any of its Affiliates shall not constitute such amendment, modification or supplement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.03.</font><a name="_Ref152623909"></a><a name="_Ref152675751"></a><a name="_Ref152676891"></a><a name="_Toc153521019"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consequences of Seller Event of Default</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Each of Seller and Purchaser hereby acknowledges and agrees that damages may be difficult to establish and the Administrative Agent and Lenders will have no adequate remedy at law if a Seller Event of Default has occurred and is continuing. &#160;In any such event, the parties agree that Administrative Agent shall have the right, in addition to any other rights it may have (whether at law or in equity), to seek specific performance of this Agreement and to pursue any other equitable remedies, including an injunction, without being required to prove actual damages or post any bond. &#160;In furtherance of the foregoing, Seller hereby designates, makes, constitutes and appoints Administrative Agent, and each of its designees or agents, as its true and lawful proxy and attorney-in-fact (coupled with an interest), irrevocably and with power of substitution, and with authority to take any and all appropriate action and to execute any and all documents and instruments that may be necessary to cause this Agreement to be </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">specifically performed by Seller and to seek an injunction against any pending or proposed violation of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.01</u> of this Agreement or to correct or prevent the continuation of any such Seller Event of Default &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref153440839"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[***]</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>THE POWER OF ATTORNEY AND PROXY GRANTED IN THIS SECTION 4.03 ARE COUPLED WITH AN INTEREST AND SHALL BE IRREVOCABLE UNTIL PAYMENT IN FULL. &#160;THIS POWER OF ATTORNEY IS CONFERRED ON THE ADMINISTRATIVE AGENT SOLELY TO PROTECT, PRESERVE AND REALIZE UPON ITS RIGHTS UNDER THIS AGREEMENT AND SHALL NOT IMPOSE ANY DUTY UPON THE ADMINISTRATIVE AGENT TO EXERCISE ANY SUCH POWERS.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article V.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref152677035"></a><a name="_Toc153521020"></a>SERVICING </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.01.</font><a name="_Ref152675075"></a><a name="_Ref152675360"></a><a name="_Ref152675674"></a><a name="_Ref152676363"></a><a name="_Toc153521021"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appointment of Seller</u>. &#160;Purchaser shall appoint a servicer (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicer</u>&#8221;) to perform certain servicing, management and administrative functions on behalf of Purchaser with respect to the Transferred Assets.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Purchaser hereby appoints Seller as the initial Servicer hereunder, and Seller hereby accepts such appointment hereunder, to perform the duties described in or by reference in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;V</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>In consideration for its performing such duties hereunder, Seller, as initial Servicer, shall be entitled to receive the Servicing Fee from Purchaser.<a name="_Ref52828574"></a><a name="_cp_change_1237"></a> &#160;The Servicing Fee, if any, shall be payable semi-annually in arrears on each <a name="_9kR3WTr2664AGcZqo8wv3BqN3GxzFgI5A"></a>Interest Payment Date and shall be paid in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.05(a)(iii)</u> of the Loan Agreement; provided, however, that any Servicing Fee due hereunder to an <a name="_9kR3WTr26656EP4gkrsiuzvxZjI1sr388"></a>Affiliate of Purchaser shall be deferred until <a name="_9kMNM5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full. &#160;In performing such duties hereunder, Seller shall have full power and authority to do or cause to be done, on behalf of Purchaser, any and all things in connection with such servicing, management and administration which it may deem necessary or desirable, consistent with the terms hereof (including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.03</u>), any <a name="_9kMON5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement and the Loan Agreement. &#160;Seller agrees that it shall service, manage, administer, and perform on behalf of Purchaser under each <a name="_9kMPO5YVt4886CMUH7yvwjGE21pyz1H"></a>Covered Agreement and enforce the rights of Purchaser thereunder in good faith, with reasonable care, in accordance with <a name="_9kMKJ5YVt4886FGJG2ztleequVM4"></a>Applicable Law, in compliance with Purchaser&#8217;s obligations under the <a name="_9kMH0H6ZWu5997ENlcqn6ufz628YU07I35LR"></a>Transaction Documents, using substantially the same degree of diligence and skill that it uses to service and perform agreements such as the <a name="_9kMLK5YVt4886GKOH7yvwjGE21pyz1HN"></a>Covered Agreements (such standards and requirements of performance, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicing Standard</u>&#8221;); provided that the Seller shall not be authorized to grant any consents under this Agreement on behalf of the Purchaser, or waive any rights of the Purchaser under this Agreement or any <a name="_9kMHzG6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement. &#160;Notwithstanding the foregoing, Seller&#8217;s reasonable decision not to enforce its rights under any Covered Agreement for Roche&#8217;s failure to timely remit any due and payable Commercial Payments during any reasonable grace period, which shall not, in any event, extend beyond [***]days, shall not constitute a waiver under any Covered Agreement. &#160;Seller, as Servicer on behalf of Purchaser, shall maintain any licenses or authorizations necessary to service the Transferred Assets and any <a name="_9kMH0H6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.02.</font><a name="_Toc153521022"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Seller Actions</u>. &#160;So long as it is the Servicer, Seller will take such actions on behalf of Purchaser, in accordance with the Servicing Standard, as are necessary to protect and defend the rights of Purchaser under each <a name="_9kMH1I6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement, including, without limitation, to the extent necessary, seeking specific performance of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.5</u> of the <a name="_9kMKJ5YVt4886EMQ6im1yimLRG7w2913JhPDC09"></a>Affitech Assignment Agreement and pursuing any other equitable remedies including injunction with respect to any violations of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.5</u> of the <a name="_9kMLK5YVt4886EMQ6im1yimLRG7w2913JhPDC09"></a>Affitech Assignment Agreement. </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.03.</font><a name="_Ref152676342"></a><a name="_Toc153521023"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with the Loan Agreement</u>. &#160;Notwithstanding anything to the contrary herein, Seller&#8217;s servicing obligations hereunder shall at all times be subject to the terms of the Loan Agreement. &#160;Seller and Purchaser agree that Seller shall take no action with respect to any <a name="_9kMH2J6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement, nor instruct Purchaser to take any such action, that is inconsistent with the terms of the Loan Agreement, the obligations of Purchaser thereunder or the rights of Administrative Agent or the Lenders thereunder. &#160;For the avoidance of doubt, Seller will not, and will not instruct Purchaser to, take any action without the consent of Administrative Agent where such consent is required pursuant to the Loan Agreement and Seller shall not agree to, or cause or permit any amendment, waiver, termination or modification of any <a name="_9kMH3K6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement or any <a name="_9kMIH5YVt4886GJXDrwv0koRP7DI0m6"></a>Material Contract except as permitted to be effected by Purchaser under the Loan Agreement; provided an assignment of the Roche APA that solely changes the parties to Seller from Affitech Research AS (or its successors and assigns) or any of its Affiliates shall not constitute such amendment, waiver, termination or modification. &#160;Notwithstanding the foregoing, Seller&#8217;s reasonable decision not to enforce its rights under any <a name="_9kMHG5YVt4886GMQH7yvwjGE21pyz1HA6Jxp714"></a>Covered Agreement for Roche&#8217;s failure to timely remit any due and payable <a name="_9kMJI5YVt4886ENTHyxqwvnmqgQ6J02IO"></a>Commercial Payments during any reasonable grace period, which shall not, in any event, extend beyond [***] days, shall not constitute a waiver or consent under any <a name="_9kMH4L6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement or a waiver or consent under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.04.</font><a name="_Ref152681176"></a><a name="_Ref152681329"></a><a name="_Toc153521024"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services as Servicer</u>. &#160;In addition to (and not in limitation of) the provision of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.01</u>, Seller shall perform the following services on behalf of Purchaser:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>review all written documents, notices and other written communications under any <a name="_9kMH5M6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement and provide such copies to Administrative Agent as are required under the Loan Agreement, together with any responses as Purchaser is required to provide in respect thereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>monitor the performance of any <a name="_9kMHG5YVt4886CLTH7yvwjGE21pyz1HhXMMMEDP"></a>Covered Agreement Counterparty under any <a name="_9kMH6N6ZWu5997DNVI8zwxkHF32qz02I"></a>Covered Agreement, and take such actions as may be necessary to enforce the rights of Purchaser thereunder and collect amounts due to Purchaser thereunder, on behalf of Purchaser, and procure and supervise the services of any third parties necessary or appropriate in connection with the monitoring, enforcement, collection and remittance of the proceeds of the Transferred Assets;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>maintain each of the <a name="_9kR3WTr26656FeSpsps1wvJAjwFFF"></a>Operating Account, <a name="_9kR3WTr266577JFvtnfv2y4RBkxGGG4z3ZeMEDE"></a>Collection Account and Interest Reserve Accounts in accordance with Purchaser&#8217;s obligations under the Loan Agreement and the <a name="_9kR3WTr266578KFx384zMC0znwxzFL"></a>Control Agreements, and maintain and enforce the instructions to Roche to pay amounts due to Purchaser under the <a name="_9kMML5YVt4886GKOH7yvwjGE21pyz1HN"></a>Covered Agreements;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref152676395"></a>cause Purchaser to maintain its organizational existence by filing all returns required in its jurisdiction of organization, and providing for its general administrative needs and overhead relating to the Transferred Assets, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.01</u> of the Loan Agreement and its <a name="_9kR3WTr266579XUtdlu70v406tsWU07I35LR"></a>Organizational Documents; </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref152676408"></a>identify and forward as required under the Loan Agreement any payments that are to be made to a <a name="_9kMJI5YVt48878ANHxvphx406TDmzIII"></a>Collection Account but when made are made to Purchaser, Seller or any misdirected account, and in consultation with Administrative Agent, effect the transfer thereof as required under the Loan Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref152676416"></a>make on behalf of Purchaser any security filings or other actions required to perfect or ensure the continued perfection of Purchaser&#8217;s rights in the Transferred Assets and Administrative Agent&#8217;s rights in <a name="_9kMLK5YVt4886EHNHxvluzyvq"></a>Collateral. </div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt;">In performing as Servicer, Seller shall not instruct any <a name="_9kMIH5YVt4886CLTH7yvwjGE21pyz1HhXMMMEDP"></a>Covered Agreement Counterparty or any other <a name="_9kMKJ5YVt4886EGZKt862"></a>Person to pay amounts in respect of the Transferred Assets to any account other than the <a name="_9kMKJ5YVt48878ANHxvphx406TDmzIII"></a>Collection Account </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required under the Loan Agreement or cause any such payments to be paid to any account other than such <a name="_9kMLK5YVt48878ANHxvphx406TDmzIII"></a>Collection Account.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.05.</font><a name="_Ref152675238"></a><a name="_Ref152676437"></a><a name="_Toc153521025"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replacement Servicer</u>. &#160;Seller may be terminated as Servicer hereunder and replaced with a new Servicer by Purchaser (or by Administrative Agent on behalf of Purchaser in the event that Purchaser shall fail to replace the Servicer within five (5) Business Days after a Servicer Termination Event, or in the event that an <a name="_9kMHG5YVt4886GPVQxq68vLFol1DD"></a>Event of Default has occurred and is continuing) following the occurrence of any of the following events (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Servicer Termination Event</u>&#8221;):</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Seller fails to perform or observe any covenant or agreement contained in this Article V and, solely if the consequences of the failure to perform or observe such covenant or agreement can be cured, in the case of any covenant or agreement contained in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 5.04(d)</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(e)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(f)</u>, such failure continues for a period of [***] <a name="_9kMHG5YVt488789LMAzvsyDZC4N"></a>Business Days without such cure after the earlier of (x) the date Seller becomes aware of such failure and (y) the date Purchaser, or Administrative Agent on behalf of Purchaser, provides notice of such failure to Seller; </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>an <a name="_9kR3WTr26657ASK13x5zsr3gY5yEG3ic2A4B"></a>Insolvency Event of Seller; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>a Seller Event of Default shall occur and be continuing.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Termination of Seller as Servicer hereunder shall be without prejudice to any rights of Purchaser or Administrative Agent that may have accrued through such date. &#160;In the event that Seller is terminated as Servicer, (i) a replacement Servicer shall be appointed by Purchaser in consultation with, and with the prior written consent of, Administrative Agent, or by Administrative Agent on behalf of Purchaser as provided in the first sentence of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;5.05</u>) and (ii) Seller shall cooperate reasonably with Purchaser and Administrative Agent and any replacement Servicer designated by Purchaser or Administrative Agent, to transfer any information and materials to such replacement Servicer or undertake any other reasonable and necessary actions to ensure an effective transition of services required in the servicing of the Transferred Assets to the successor Servicer.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article VI.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc153521026"></a>TERMINATION; SURVIVAL</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.01.</font><a name="_Ref152676457"></a><a name="_Toc153521027"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. &#160;The respective obligations and responsibilities of Seller and Purchaser created by this Agreement shall not terminate prior to <a name="_9kMON5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full and may terminate upon <a name="_9kMPO5YVt4886FMeGw9qs84zXZC4"></a>Payment in Full.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.02.</font><a name="_Toc153521028"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination</u>. &#160;No termination or rejection or failure to assume the executory obligations of this Agreement in the bankruptcy of Seller or Purchaser shall be deemed to impair or affect the obligations pertaining to any executed conveyance or executed obligations, including without limitation breaches of representations and warranties by Seller or Purchaser occurring prior to the date of such termination. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.03.</font><a name="_Ref152676674"></a><a name="_Toc153521029"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. &#160;Notwithstanding <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6.01</u> hereof, the obligations of Seller contained in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;VII</u> , <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</u> and this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6.03</u> (Survival) shall survive the termination of this Agreement and <a name="_9kR3WTr26657BaEu7oq6"></a>Payment in <a name="_9kR3WTr26657CRO1t"></a>Full.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article VII.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref152623873"></a><a name="_Toc153521030"></a>INDEMNIFICATION PAYMENTS</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 7.01.</font><a name="_Ref152623985"></a><a name="_Ref152676716"></a><a name="_Toc153521031"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref152688471"></a>Seller agrees to indemnify and hold harmless Purchaser, Administrative Agent and Lenders and their respective officers, directors, members, partners, employees and agents (each, an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221;) against any and all liabilities, losses, damages, penalties, costs and expenses (including reasonable and documented, out of pocket costs of defense and legal fees and expenses) (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>&#8221;) which may be incurred or suffered by such Indemnified Party (except to the extent caused by the gross negligence or willful misconduct of the Indemnified Party) awarded against, or incurred or suffered by, such Indemnified Party, whether or not involving a third party claim, demand, action, suit or proceeding, arising out of (i) the failure of any representation, warranty or certification of Seller in the <a name="_9kMH1I6ZWu5997ENlcqn6ufz628YU07I35LR"></a>Transaction Documents or any certificate given by Seller pursuant to any of the <a name="_9kMH2J6ZWu5997ENlcqn6ufz628YU07I35LR"></a>Transaction Documents, to be true when made; (ii) a breach of any covenant by Seller set forth in, or failure by Seller to perform its duties under or otherwise comply with, the <a name="_9kMH3K6ZWu5997ENlcqn6ufz628YU07I35LR"></a>Transaction Documents (whether or not a Seller Event of Default or Servicer Termination Event), or Seller&#8217;s engaging in intentional misconduct, bad faith or negligence in the performance of such duties; or (iii) the transfer by Seller of any interest in the Transferred Assets to any <a name="_9kMLK5YVt4886EGZKt862"></a>Person other than Purchaser, or any attempt by any <a name="_9kMML5YVt4886EGZKt862"></a>Person to void the transfer of the Transferred Assets to Purchaser.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">It is the intention of the parties hereto that the above indemnities shall not be interpreted to provide indemnification for any damages, losses or costs that have the effect of recourse for non-payment or insufficient payment under the Transferred Assets and factors affecting the performance of the Transferred Assets and payments generated thereby that are not specifically represented, warranted or agreed to in the <a name="_9kMH4L6ZWu5997ENlcqn6ufz628YU07I35LR"></a>Transaction Documents which may include but are not limited to product obsolescence, competition, changes in government healthcare policies or other healthcare provider reimbursement, and withholding taxes related to the Transferred Assets. &#160;This &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.01(a</u>) shall not apply to <a name="_9kR3WTr26657DgItyu"></a>Taxes other than any <a name="_9kMHG5YVt48879FiKv0w"></a>Taxes that represent losses, claims, damages, etc. &#160;arising from any <a name="_9kR3WTr26657E1wxdLw"></a>non-Tax claim.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>The provisions of this indemnity shall run directly to, and be enforceable by, an injured party and shall survive the termination of this Agreement. &#160;Without limiting the foregoing or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.05</u> hereof, Purchaser&#8217;s rights under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.01</u> shall be assignable by Purchaser on a non-exclusive basis to Administrative Agent pursuant to the terms of the Loan Agreement and the <a name="_9kR3WTr26657FhLct9y1IaD10oxy0G"></a>Security Agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref152676734"></a>If any claim, demand, action or proceeding (including any investigation by any <a name="_9kMLK5YVt4886GIQL7yv51tvBzsTXNB7IDGX"></a>Governmental Authority) shall be brought or alleged against an Indemnified Party in respect of which indemnity is to be sought pursuant to this Section, the Indemnified Party shall, promptly after receipt of notice of the commencement of any such claim, demand, action or proceeding, notify Seller in writing of the commencement of such claim, demand, action or proceeding, enclosing a copy of all papers served, if any; provided, that the omission to so notify Seller will not relieve Seller from any liability that it may have to any Indemnified Party under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;7.01(c)</u>&#160;unless, and only to the extent that, Seller is actually materially prejudiced by such omission. &#160;In case any such action is brought against an Indemnified Party and it notifies Seller of the commencement thereof, Seller will be entitled, at Seller&#8217;s sole cost and expense, to participate therein and, to the extent that it may wish, to assume the defense thereof, with counsel reasonably satisfactory to such Indemnified Party (who shall not, except with the consent of the Indemnified Party, be counsel to Seller), and, after notice from Seller to such Indemnified Party of its election so to assume the defense thereof, Seller will not be liable to such Indemnified Party under this Section for any legal or other expenses subsequently incurred by such Indemnified Party in connection with the defense thereof other than reasonable costs of investigation. &#160;In any such proceeding, an Indemnified Party shall </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the expense of such Indemnified Party unless (a)&#160;Seller and the Indemnified Party shall have mutually agreed to the retention of such counsel, (b)&#160;Seller has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel or (c)&#160;the named parties to any such proceeding (including any impleaded parties) include both Seller and the Indemnified Party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them. &#160;It is agreed that Seller shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such Indemnified Parties. &#160;Seller shall not be liable for any settlement of any proceeding effected without its written consent, but, if settled with such consent or if there be a final judgment for the plaintiff, Seller agrees to indemnify the Indemnified Party from and against any Losses by reason of such settlement or judgment. &#160;Seller shall not, without the prior written consent of the Indemnified Party, effect any settlement, compromise or discharge of any claim or pending or threatened proceeding in respect of which any Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement, compromise or discharge, as the case may be, (i)&#160;includes an unconditional written release of such Indemnified Party from all liability on claims that are the subject matter of such claim or proceeding, (ii)&#160;does not include any statement as to an admission of fault, culpability or failure to act by or on behalf of any Indemnified Party and (iii)&#160;does not impose any continuing material obligation or restrictions on any Indemnified Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">Article VIII.</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref152623885"></a><a name="_Toc153521032"></a>MISCELLANEOUS PROVISIONS</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.01.</font><a name="_Toc153521033"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u>. &#160;This Agreement may be amended from time to time only by the written agreement of Seller and Purchaser and, prior to <a name="_9kMHzG6ZWu5997GNfHxArt950YaD5"></a>Payment in Full, Administrative Agent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.02.</font><a name="_Ref152676762"></a><a name="_Toc153521034"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Waiver of Trial by Jury; Jurisdiction</u>. &#160;<font style="display:inline-block;width:7.62pt;"></font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman Bold';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">(A)</b></font><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">THIS AGREEMENT AND ANY AMENDMENTS HEREOF SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, INCLUDING GENERAL OBLIGATIONS LAW SECTIONS 5-1401 AND 5-1402 BUT OTHERWISE WITHOUT GIVING EFFECT TO LAWS CONCERNING CONFLICT OF LAWS OR CHOICE OF FORUM THAT WOULD REQUIRE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">(B)</b></font><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">Each Party hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any action, proceeding, claim or counterclaim arising out of or relating to any Transaction Document or the transactions contemplated under any Transaction Document (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). &#160;THIS WAIVER</b><b style="font-weight:bold;"> SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO ANY TRANSACTION DOCUMENT. &#160;EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.02</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(B)</b><b style="font-weight:bold;">.</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">15</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Each of Purchaser and Seller irrevocably submits to the jurisdiction of the courts of the State of New York and of the United States sitting in the State of New York, and of the courts of its own corporate domicile with respect to any and all <a name="_9kR3WTr26657GfV1nehhmxw2"></a>Proceedings. &#160;Each of Purchaser and Seller irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any <a name="_9kR3WTr266588WV1nehhmxw"></a>Proceeding and any claim that any <a name="_9kMHG5YVt4887AAYX3pgjjozy"></a>Proceeding has been brought in an inconvenient forum. &#160;Any process or summons for purposes of any <a name="_9kMIH5YVt4887AAYX3pgjjozy"></a>Proceeding may be served on Purchaser or Seller by mailing a copy thereof by registered mail, or a form of mail substantially equivalent thereto, addressed to it at its address as provided for Notices hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Notwithstanding the other terms of this Section 8.02:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>THE OBLIGATION TO TRANSFER ALL RIGHTS UNDER THE AFFITECH ASSIGNMENT AGREEMENT FROM SELLER TO PURCHASER AS SET FORTH IN SECTION 2.01 SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE SUBSTANTIVE LAWS OF SWITZERLAND, WITHOUT REGARD TO THE CONFLICT OF LAW RULES.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>The exclusive place of jurisdiction for any disputes arising out of or in connection with the obligation to transfer all rights under the Affitech Assignment Agreement from Seller to Purchaser as set forth in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.01</u> shall be the City of Zurich, Switzerland, venue being Zurich 1.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.03.</font><a name="_Ref152675830"></a><a name="_Ref152675858"></a><a name="_Ref152675880"></a><a name="_Ref152675933"></a><a name="_Ref152675944"></a><a name="_Toc153521035"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. &#160;All demands, notices, and communications under this Agreement shall be in writing personally delivered, or sent by email (provided that no undeliverable message is received in response to such email) or sent by internationally recognized overnight courier service, at the following address:</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">Seller:<br><br>XOMA (US) LLC<br>2200 Powell Street, Suite 310<br>Emeryville, CA 94608<br>Attn:<font style="display:inline-block;width:13.39pt;"></font>[***] Legal Department<br>Email: <font style="display:inline-block;width:3.92pt;"></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">with a copy (which shall not constitute notice) to:<br><br>Gibson, Dunn &amp; Crutcher LLP <br>555 Mission Street<br>San Francisco, CA 94105<br>Attention: Ryan Murr; Todd Trattner<br>Email: rmurr@gibsondunn.com; ttrattner@gibsondunn.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">Purchaser:<br><br>XLR 1 LLC<br>c/o XOMA (US) LLC<br>2200 Powell Street, Suite 310<br>Emeryville, CA 94608<br>Attn:<font style="display:inline-block;width:13.39pt;"></font>[***] Legal Department<br>Email: <font style="display:inline-block;width:3.92pt;"></font>[***]</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">16</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">with a copy (which shall not constitute notice) to:<br><br>Gibson, Dunn &amp; Crutcher LLP <br>555 Mission Street<br>San Francisco, CA 94105<br>Attention: Ryan Murr; Todd Trattner<br>Email: rmurr@gibsondunn.com; ttrattner@gibsondunn.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">Administrative Agent:<br><br>Blue Owl Capital Corporation<br>399 Park Avenue, 37th Floor<br>New York, NY 10022<br><font style="white-space:pre-wrap;">Email:  [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 0pt 72pt;">with a copy (which shall not constitute notice) to:<br><br>Cooley LLP<br>1299 Pennsylvania Avenue, NW, Suite 700<br>Washington, DC 20004-2400<br><font style="white-space:pre-wrap;">Attention:  </font><font style="display:inline-block;width:21.89pt;"></font>Michael Tollini<br>Email: <font style="display:inline-block;width:3.92pt;"></font><font style="display:inline-block;width:36pt;"></font>mtollini@cooley.com<br><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">or at other such address as shall be designated by such party in a written notice to the other parties.  Notice shall be effective and deemed received (a) two (2) days after being delivered to the courier service, if sent by courier, or (b) when delivered, if delivered by hand or sent by email. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Wherever notice or a report is required to be given or delivered to Purchaser, a copy of such notice or report shall also be given or delivered concurrently to Administrative Agent.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.04.</font><a name="_Toc153521036"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability of Provisions</u>. &#160;If any one or more of the covenants, agreements, provisions, or terms of this Agreement shall be for any reason whatsoever held invalid, then such covenants, agreements, provisions, or terms shall be deemed severable from the remaining covenants, agreements, provisions, or terms of this Agreement and shall in no way affect the validity or enforceability of the other provisions of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.05.</font><a name="_Ref152689711"></a><a name="_Toc153521037"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. &#160;Notwithstanding anything to the contrary contained in this Agreement, this Agreement may not be assigned by Seller without the prior written consent of Purchaser [***] and this Agreement may not be assigned by Purchaser without the prior written consent of Administrative Agent and, so long as no Seller Event of Default has occurred and is continuing, Seller.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.06.</font><a name="_Toc153521038"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u>. &#160;Each of Seller and Purchaser agrees to do such further acts and things and to execute and deliver such additional assignments, agreements, powers and instruments as are reasonably required to carry into effect the purposes of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.07.</font><a name="_Toc153521039"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver; Cumulative Remedies; Waiver of Immunities</u>. &#160;No failure to exercise and no delay in exercising, on the part of Purchaser or Seller, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise hereof or the exercise of any other right, remedy, power or privilege. &#160;The rights, remedies, powers and privileges herein provided are cumulative and not exhaustive of any rights, remedies, powers and privilege provided by law. &#160;To the extent that Seller has or </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">17</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">hereafter may be entitled to claim or may acquire, for itself or any of its assets, any immunity from suit, jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, or otherwise) with respect to itself or any of its property, Seller hereby irrevocably waives such immunity in respect of its obligations hereunder to the fullest extent permitted by law.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.08.</font><a name="_Toc153521040"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. &#160;This Agreement may be executed in two or more counterparts (and by different parties on separate counterparts), each of which shall be an original, but all of which shall constitute one and the same instrument.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.09.</font><a name="_Toc153521041"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding</u>. &#160;This Agreement will inure to the benefit of and be binding upon the parties hereto, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;8.14</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.10.</font><a name="_Toc153521042"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger and Integration</u>. &#160;Except as specifically stated otherwise herein, this Agreement sets forth the entire understanding of the parties relating to the subject matter hereof, and all prior understandings, written or oral, are superseded by this Agreement. &#160;This Agreement may not be modified, amended, waived or supplemented except as provided herein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.11.</font><a name="_Toc153521043"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. &#160;The headings herein are for purposes of reference only and shall not otherwise affect the meaning or interpretation of any provision hereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.12.</font><a name="_Toc153521044"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedules and Exhibits</u>. &#160;The schedules and exhibits attached hereto and referred to herein shall constitute a part of this Agreement and are incorporated into this Agreement for all purposes.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.13.</font><a name="_Ref152863643"></a><a name="_Toc153521045"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Petition</u>. &#160;Each of the parties hereto covenants and agrees that, prior to the date that is one year and one day after the <a name="_9kMH0H6ZWu5997GNfHxArt950YaD5"></a>Payment in Full, no party hereto shall institute against, or join any other <a name="_9kMNM5YVt4886EGZKt862"></a>Person in instituting against, either of Purchaser or Seller any bankruptcy, reorganization, arrangement, insolvency or liquidation proceedings or other similar proceedings under any federal, state or foreign bankruptcy or similar law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.14.</font><a name="_Ref152676845"></a><a name="_Toc153521046"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intended Third Party Beneficiaries</u>. &#160;Administrative Agent is a third party beneficiary of this Agreement and, as such, shall have full power and authority to enforce the provisions of this Agreement against the parties hereto. &#160;In addition, the parties hereto acknowledge that Administrative Agent is entitled under the <a name="_9kMJI5YVt48878BXQmmQMszAvxDJ"></a>Loan Documents to make claims directly to Seller for indemnities in favor of Purchaser, without prejudice to its rights as an Indemnified Party hereunder; and nothing herein limits the rights of Administrative Agent under the <a name="_9kMJI5YVt4886EIbRngjlGD10oxy0G"></a>Pledge Agreement, which rights may be exercised in Administrative Agent&#8217;s sole discretion from time to time whether or not it has exercised or is then exercising its rights as a third party beneficiary or its rights and remedies under <a name="_9kMLK5YVt4886FGJG2ztleequVM4"></a>Applicable Law.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:11pt;line-height:0pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">18</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective officers as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 24pt 216pt;"><b style="font-weight:bold;">XOMA(US) LLC</b>, as Seller</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 216pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:232.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 24pt 216pt;">Name: <br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 36pt 216pt;">Solely for purposes of &#8206;Section 2.03 and &#8206;Section 4.03(b)(ii), <b style="font-weight:bold;">XOMA CORPORATION</b>, as Parent</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 216pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:232.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 24pt 216pt;">Name: <br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 36pt 216pt;"><b style="font-weight:bold;">XLR 1 LLC</b>, as Purchaser</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 216pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:232.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 24pt 216pt;">Name: <br>Title:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 24pt 216pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 24pt 0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 24pt 0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:11pt;line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 24pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[Sale, Contribution and Servicing Agreement]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Form of Notice and Instruction Letters</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_mps380058450000000000000008665000000000"></a></font></font><font style="display:inline-block;width:0pt;"></font><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Form of Bill of Sale</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_mps095142430000000000000008665000000000"></a></font></font>3<font style="display:inline-block;width:0pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.65
<SEQUENCE>7
<FILENAME>xoma-20231231xex10d65.htm
<DESCRIPTION>EX-10.65
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:51 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:4.05pt 0pt 0pt 129.55pt;"><b style="font-weight:bold;">Exhibit 10.65</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:4.05pt 0pt 0pt 129.55pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECOND</b><b style="font-weight:bold;letter-spacing:-0.25pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AMENDMENT</b><b style="font-weight:bold;letter-spacing:-0.3pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TO</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OFFICE</b><b style="font-weight:bold;letter-spacing:-0.25pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 5.75pt 0pt 0pt;">This<font style="letter-spacing:0.7pt;"> </font>SECOND<font style="letter-spacing:0.75pt;"> </font>AMENDMENT<font style="letter-spacing:0.75pt;"> </font>TO<font style="letter-spacing:0.7pt;"> </font>OFFICE<font style="letter-spacing:0.75pt;"> </font>LEASE<font style="letter-spacing:0.85pt;"> </font>(this<font style="letter-spacing:0.8pt;"> </font>&#8220;<b style="font-weight:bold;">Amendment</b>&#8221;),<font style="letter-spacing:0.8pt;"> </font>dated<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>June<font style="letter-spacing:-0.6pt;"> &#160;27, 2023 </font>(the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), is entered into by and between KBSIII TOWERS AT EMERYVILLE, LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), and XOMA (US) LLC, a<font style="letter-spacing:-0.1pt;"> </font>Delaware limited liability company (&#8220;<b style="font-weight:bold;">Tenant</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1pt;margin:0pt 0pt 0pt 431.1pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:11.14pt 0.25pt 0pt 2.25pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">R</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">E</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">C</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">I</u><u style="letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">L</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="letter-spacing:-0.25pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">S</u><font style="letter-spacing:-0.25pt;">:</font></p><div style="margin-top:11.85pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.9pt;text-indent:0pt;white-space:nowrap;">A.</font>Pursuant to that certain Office Lease dated September<font style="letter-spacing:-0.05pt;"> </font>20, 2017 (the &#8220;<b style="font-weight:bold;">Original Lease</b>&#8221;), as amended by that certain First Amendment to Office Lease dated January 13, 2023 (the &#8220;<b style="font-weight:bold;">First Amendment</b>,&#8221; and collectively, the &#8220;<b style="font-weight:bold;">Lease</b>&#8221;), Tenant currently leases from Landlord those certain premises commonly known as Suite 310 (the &#8220;<b style="font-weight:bold;">Current Premises</b>&#8221;), containing approximately 3,637 rentable square feet, located at 2200 Powell Street, Emeryville, California (the &#8220;<b style="font-weight:bold;">Building</b>&#8221;), which is part of the Towers Emeryville (the &#8220;<b style="font-weight:bold;">Project</b>&#8221;), as more particularly described in the Lease.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:12.19pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:44pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Capitalized</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">defined</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">herein</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">have</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">meanings</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">given</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:44pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Lease</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Term</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">scheduled</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">expire</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">its</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">July</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">31,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">2023.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:11.94pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.9pt;text-indent:0pt;white-space:nowrap;">D.</font>The parties desire to amend the Lease in order to, among other things, extend the Lease Term, relocate Tenant to those certain premises containing approximately 1,620 rentable square feet on the third (3<sup style="font-size:8.25pt;vertical-align:top;">rd</sup>) floor of the Building, formerly known as Suite 370, as depicted on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> attached<font style="letter-spacing:2pt;"> </font>hereto (the &#8220;<b style="font-weight:bold;">New Premises</b>&#8221;), and further amend the Lease, pursuant to the terms and conditions set forth <font style="letter-spacing:-0.1pt;">below.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:12.14pt 0.1pt 0pt 2.25pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;">A</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;">G</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;">R</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;">E</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:dashed;">E</u><font style="letter-spacing:-0.05pt;"> </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">M E</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="letter-spacing:-0.25pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T</u><font style="letter-spacing:-0.25pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:11.8pt 5.7pt 0pt 8pt;">NOW, THEREFORE, in consideration of the foregoing Recitals, the mutual covenants and agreements contained in this Amendment and other good and valuable consideration, the receipt and sufficiency of such are hereby acknowledged, Landlord and Tenant hereby agree as follows:</p><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Premises</u>.<font style="letter-spacing:2pt;"> </font>Tenant hereby leases from Landlord, and Landlord hereby leases to Tenant, the New Premises on the terms and conditions hereinafter set forth.<font style="letter-spacing:2pt;"> </font>As of the &#8220;New Premises Commencement Date&#8221; (as defined in the Work Letter attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>):<font style="letter-spacing:2pt;"> </font>(a) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> attached hereto depicting the New Premises is incorporated into and made a part of the Lease; (b) all references in the Lease to the defined term &#8220;Premises&#8221; shall mean and refer to the New Premises; and (c) the rentable square footage of the &#8220;Premises&#8221; (New Premises) shall be 1,620 rentable square feet.<font style="letter-spacing:2pt;"> </font>Tenant&#8217;s use and occupancy of the New Premises shall be in accordance with all of the terms and conditions of the Lease, as amended by this Amendment (the &#8220;<b style="font-weight:bold;">Amended Lease</b>&#8221;).<font style="letter-spacing:2pt;"> </font>Landlord shall not be obligated to deliver the New Premises until Landlord has received from Tenant copies of Tenant&#8217;s insurance certificates as required under the Amended Lease with respect to the New Premises; provided, however, if Landlord&#8217;s delivery of the New Premises is delayed as a result of Tenant&#8217;s failure to provide said insurance certificates, the New Premises Commencement Date shall remain unchanged.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12.05pt 5.6pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Current Premises</u>.<font style="letter-spacing:2pt;"> </font>Tenant shall surrender the Current Premises to Landlord in the condition required pursuant to this Section 2 no later than 11:59 p.m. on the date which is fourteen (14) days following the New Premises Commencement Date (the &#8220;<b style="font-weight:bold;">Surrender Date</b>&#8221;).<font style="letter-spacing:4pt;"> </font>If Tenant surrenders the Current Premises by the Surrender Date, Tenant&#8217;s obligation to pay Rent and other charges for the Current Premises shall cease as of the New Premises Commencement Date, otherwise Tenant shall continue to pay Rent for the Current Premises until Tenant actually surrenders the Current Premises in accordance with the terms of the Amended Lease.<font style="letter-spacing:2pt;"> </font>Tenant agrees to surrender possession of the Current Premises to Landlord on the Surrender Date, broom clean and in good order, condition and repair, ordinary wear and tear excepted, and otherwise in compliance with the terms of the Amended Lease regarding<font style="letter-spacing:1.4pt;"> </font>surrender<font style="letter-spacing:1.45pt;"> </font>as<font style="letter-spacing:1.35pt;"> </font>if<font style="letter-spacing:1.35pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>Lease<font style="letter-spacing:1.45pt;"> </font>had<font style="letter-spacing:1.35pt;"> </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">1</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.05pt 5.6pt 0pt 8pt;">expired<font style="letter-spacing:1.45pt;"> </font>as<font style="letter-spacing:1.35pt;"> </font>to<font style="letter-spacing:1.45pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>Current<font style="letter-spacing:1.5pt;"> </font>Premises.<font style="letter-spacing:1.4pt;"> &#160;</font>Upon<font style="letter-spacing:1.45pt;"> </font>such<font style="letter-spacing:1.3pt;"> </font>surrender,<font style="letter-spacing:1.3pt;"> </font><font style="letter-spacing:-0.25pt;">all</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">2</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:4.05pt 5.75pt 0pt 8pt;">rights of Tenant to possession and occupancy of the Current Premises and Tenant&#8217;s obligations with respect to the Current Premises will terminate except as to Tenant&#8217;s surviving obligations under the Amended Lease,<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>all of<font style="letter-spacing:-0.1pt;"> </font>Tenant&#8217;s<font style="letter-spacing:-0.1pt;"> </font>rights and obligations under<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Amended<font style="letter-spacing:-0.15pt;"> </font>Lease<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>relate solely<font style="letter-spacing:-0.1pt;"> </font>to the New Premises; provided, however, if Tenant fails to surrender the Current Premises on or before the Surrender Date, Tenant shall be deemed in holdover of the Current Premises subject to the holdover provisions in the Lease, and such holding over shall not operate to release Tenant from its obligations<font style="letter-spacing:2pt;"> </font>with respect to the New Premises.</p><div style="margin-top:12.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Extended Term</u>.<font style="letter-spacing:2pt;"> </font>The Lease Term is hereby extended for sixty-five (65) months (the &#8220;<b style="font-weight:bold;">Second Extended</b><b style="font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-weight:bold;">Term</b>&#8221;) commencing as of the New Premises Commencement Date and<font style="letter-spacing:-0.05pt;"> </font>expiring on the last day of the sixty-fifth (65<sup style="font-size:8.25pt;vertical-align:top;">th</sup>) full calendar month thereafter, unless sooner terminated in accordance with the terms of the Amended Lease.<font style="letter-spacing:2pt;"> </font>Furthermore, in the event the &#8220;Tenant Improvements&#8221; are not &#8220;substantially completed&#8221; by July 31, 2023 (as each term is defined in the Work Letter attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>), (a) Tenant shall be entitled to occupy the Current Premises until the Surrender Date, and<font style="letter-spacing:2.8pt;"> </font>(b)<font style="letter-spacing:2.8pt;"> </font>Base<font style="letter-spacing:2.8pt;"> </font>Rent<font style="letter-spacing:2.7pt;"> </font>for<font style="letter-spacing:2.7pt;"> </font>the<font style="letter-spacing:2.8pt;"> </font>Current<font style="letter-spacing:2.7pt;"> </font>Premises<font style="letter-spacing:2.9pt;"> </font>during<font style="letter-spacing:2.75pt;"> </font>such<font style="letter-spacing:2.65pt;"> </font>period<font style="letter-spacing:2.65pt;"> </font>of<font style="letter-spacing:2.8pt;"> </font>occupancy<font style="letter-spacing:2.8pt;"> </font>shall<font style="letter-spacing:2.8pt;"> </font>be<font style="letter-spacing:2.65pt;"> </font>reduced<font style="letter-spacing:2.65pt;"> </font>to</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0.05pt 5.8pt 0pt 8pt;">$7,533.00 per month.<font style="letter-spacing:2pt;"> </font>No such extensions shall operate to release Tenant from liability for any amounts owed or defaults which exist under the Lease prior to the New Premises Commencement Date.</p><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>.<font style="letter-spacing:4pt;"> </font>Prior to the New Premises Commencement Date, Tenant shall continue to<font style="letter-spacing:2pt;"> </font>pay Base Rent for the Current Premises pursuant to the terms of the Lease.<font style="letter-spacing:2pt;"> </font>Commencing as of the New Premises Commencement Date and continuing for the duration of the Second Extended Term, Tenant shall pay Base Rent for the New Premises in accordance with the following schedule:</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:87.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:64.11%;"><tr style="height:14.6pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0pt 0pt 0.25pt;"><b style="font-weight:bold;">Lease</b><b style="font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Months</b></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin:1pt 0pt 0pt 29.25pt;"><b style="font-weight:bold;">Monthly</b><b style="font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-weight:bold;">Base</b><b style="font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;">Rent</b></p></td></tr><tr style="height:14.75pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1.14pt 0.15pt 0pt 0.25pt;">1* -<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.35pt;">12</font></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin:1.14pt 0pt 0pt 52.55pt;"><font style="letter-spacing:-0.1pt;">$7,533.00**</font></p></td></tr><tr style="height:14.6pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0.15pt 0pt 0.25pt;">13 -<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.35pt;">24</font></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0pt 0pt 0.45pt;"><font style="letter-spacing:-0.1pt;">$7,758.99</font></p></td></tr><tr style="height:14.6pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0.15pt 0pt 0.25pt;">25 -<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.35pt;">36</font></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0pt 0pt 0.45pt;"><font style="letter-spacing:-0.1pt;">$7,991.76</font></p></td></tr><tr style="height:14.6pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0.15pt 0pt 0.25pt;">37 -<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.35pt;">48</font></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0pt 0pt 0.45pt;"><font style="letter-spacing:-0.1pt;">$8,231.51</font></p></td></tr><tr style="height:14.7pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1.1pt 0.15pt 0pt 0.25pt;">49 -<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.35pt;">60</font></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1.1pt 0pt 0pt 0.45pt;"><font style="letter-spacing:-0.1pt;">$8,478.46</font></p></td></tr><tr style="height:14.6pt;"><td style="vertical-align:top;width:51.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0.15pt 0pt 0.25pt;">61 -<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.35pt;">65</font></p></td><td style="vertical-align:top;width:48.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:center;margin:1pt 0pt 0pt 0.45pt;"><font style="letter-spacing:-0.1pt;">$8,732.81</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:12.05pt 0pt 0pt 8pt;">*Includes<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>first<font style="letter-spacing:-0.2pt;"> </font>full<font style="letter-spacing:-0.25pt;"> </font>month<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>any<font style="letter-spacing:-0.15pt;"> </font>partial<font style="letter-spacing:-0.1pt;"> </font>month<font style="letter-spacing:-0.3pt;"> </font>at<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Second<font style="letter-spacing:-0.3pt;"> </font>Extended<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:11.94pt 5.5pt 0pt 8pt;">**Notwithstanding the foregoing, provided Tenant is not in default under the Amended Lease, Landlord hereby agrees<font style="letter-spacing:-0.05pt;"> </font>to abate Tenant&#8217;s obligation<font style="letter-spacing:-0.05pt;"> </font>to pay Base Rent during the first (1<sup style="font-size:8.25pt;vertical-align:top;">st</sup>),<font style="letter-spacing:-0.1pt;"> </font>thirteenth (13<sup style="font-size:8.25pt;vertical-align:top;">th</sup>), twenty- fifth (25<sup style="font-size:8.25pt;vertical-align:top;">th</sup>), thirty-seventh (37<sup style="font-size:8.25pt;vertical-align:top;">th</sup>), and forty-ninth (49<sup style="font-size:8.25pt;vertical-align:top;">th</sup>) full calendar months of the Second Extended Term (such total amount of abated Base Rent being hereinafter referred to as the &#8220;<b style="font-weight:bold;">Abated Amount</b>&#8221;).<font style="letter-spacing:2pt;"> </font>During such abatement periods, Tenant will still be responsible for the payment of all other monetary obligations under the Amended Lease, including, without limitation, parking charges and Direct Expenses.<font style="letter-spacing:2pt;"> </font>Tenant acknowledges<font style="letter-spacing:-0.15pt;"> </font>that any<font style="letter-spacing:-0.05pt;"> </font>default<font style="letter-spacing:-0.1pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>Tenant under<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Amended<font style="letter-spacing:-0.2pt;"> </font>Lease<font style="letter-spacing:-0.05pt;"> </font>will cause<font style="letter-spacing:-0.15pt;"> </font>Landlord<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>incur costs not contemplated hereunder, the exact amount of such costs being extremely difficult and impracticable to ascertain.<font style="letter-spacing:2pt;"> </font>Therefore, should Tenant at<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.1pt;"> </font>time during<font style="letter-spacing:-0.15pt;"> </font>the Second Extended Term<font style="letter-spacing:-0.05pt;"> </font>be in default under the Amended Lease beyond any applicable notice and cure period, then, in addition to all of Landlord&#8217;s other rights and remedies, the total unamortized sum of<font style="letter-spacing:-0.1pt;"> </font>such<font style="letter-spacing:-0.15pt;"> </font>Abated Amount (amortized on a straight line basis over the Second Extended Term) so conditionally excused shall become immediately due and payable by Tenant to Landlord.<font style="letter-spacing:2pt;"> </font>Tenant acknowledges and agrees that nothing in this subsection is intended to limit any other remedies available to Landlord at law or in equity under applicable law (including, without limitation, the remedies under Civil Code Section 1951.2 and/or 1951.4 and any successor statutes or similar laws), in the event Tenant defaults under the Amended Lease beyond any applicable notice and cure<font style="letter-spacing:-0.45pt;"> </font>period.<font style="letter-spacing:1.95pt;"> </font>Upon<font style="letter-spacing:-0.7pt;"> </font>reasonable<font style="letter-spacing:-0.6pt;"> </font>notice<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.65pt;"> </font>Tenant<font style="letter-spacing:-0.6pt;"> </font>at<font style="letter-spacing:-0.55pt;"> </font>any<font style="letter-spacing:-0.7pt;"> </font>time<font style="letter-spacing:-0.7pt;"> </font>prior<font style="letter-spacing:-0.65pt;"> </font>to<font style="letter-spacing:-0.65pt;"> </font>application<font style="letter-spacing:-0.65pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>entire<font style="letter-spacing:-0.55pt;"> </font>Abated<font style="letter-spacing:-0.6pt;"> </font>Amount, Landlord shall have the right to purchase from Tenant any and all then remaining Abated Amount as it applies to one or more of the remaining abatement months by paying to Tenant an amount equal to the unused<font style="letter-spacing:0.65pt;"> </font>balance<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.8pt;"> </font>Abated<font style="letter-spacing:0.75pt;"> </font>Amount<font style="letter-spacing:0.85pt;"> </font>that<font style="letter-spacing:0.85pt;"> </font>Landlord<font style="letter-spacing:0.65pt;"> </font>elects<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.8pt;"> </font>purchase<font style="letter-spacing:0.8pt;"> </font>back<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.85pt;"> </font>Tenant<font style="letter-spacing:0.85pt;"> </font>(the<font style="letter-spacing:0.8pt;"> </font><font style="letter-spacing:-0.1pt;">&#8220;</font><b style="font-weight:bold;letter-spacing:-0.1pt;">Abated</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:10.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">3</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:4.05pt 5.6pt 0pt 8pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Amount</b><b style="font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Purchase</b><b style="font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Price</b><font style="letter-spacing:-0.1pt;">&#8221;).</font><font style="letter-spacing:2pt;"> </font><font style="letter-spacing:-0.1pt;">Upon</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.1pt;">Landlord&#8217;s</font><font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">payment</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:-0.1pt;">to</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">Tenant</font><font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">of</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">Abated</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">Amount</font><font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">Purchase</font><font style="letter-spacing:-0.5pt;"> </font><font style="letter-spacing:-0.1pt;">Price</font><font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">with </font>respect<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>applicable<font style="letter-spacing:-0.5pt;"> </font>remaining<font style="letter-spacing:-0.5pt;"> </font>abatement<font style="letter-spacing:-0.55pt;"> </font>months,<font style="letter-spacing:-0.6pt;"> </font>Tenant<font style="letter-spacing:-0.45pt;"> </font>shall<font style="letter-spacing:-0.45pt;"> </font>thereupon<font style="letter-spacing:-0.5pt;"> </font>be<font style="letter-spacing:-0.5pt;"> </font>required<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>pay<font style="letter-spacing:-0.25pt;"> </font>Base<font style="letter-spacing:-0.5pt;"> </font>Rent during such months in an amount equal to the Abated Amount that Tenant would have been entitled to receive<font style="letter-spacing:-0.5pt;"> </font>but<font style="letter-spacing:-0.45pt;"> </font>for<font style="letter-spacing:-0.5pt;"> </font>Landlord&#8217;s<font style="letter-spacing:-0.5pt;"> </font>payment<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>Tenant<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Abated<font style="letter-spacing:-0.4pt;"> </font>Amount<font style="letter-spacing:-0.4pt;"> </font>Purchase<font style="letter-spacing:-0.5pt;"> </font>Price.</p><div style="margin-top:12.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Condition of the Premises</u>.<font style="letter-spacing:2pt;"> </font>Tenant acknowledges that it is presently in possession of the Current Premises, it is fully aware of the condition of the Current Premises, and except as expressly provided<font style="letter-spacing:-0.1pt;"> </font>in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> attached hereto, Landlord shall<font style="letter-spacing:-0.05pt;"> </font>not be obligated<font style="letter-spacing:-0.1pt;"> </font>to refurbish or improve<font style="letter-spacing:-0.1pt;"> </font>the Current Premises or the New Premises in any manner whatsoever or to otherwise provide funds for the improvement of the Current Premises or the New Premises in conjunction with this Amendment, and Tenant hereby accepts the Premises &#8220;AS-IS&#8221;.<font style="letter-spacing:2pt;"> </font>Tenant further acknowledges that except as expressly provided in the Lease or this Amendment, neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Premises, the improvements, refurbishments, or alterations therein, or the Building or the Project or with respect to the functionality thereof or the suitability of any of the foregoing for the conduct of Tenant&#8217;s business and that all representations and warranties of Landlord, if any, are as set forth in the Lease and this Amendment.<font style="letter-spacing:4pt;"> </font>Pursuant to Section 1938 of the California Civil Code, Landlord hereby advises Tenant that as of the date of this Amendment neither the Current Premises, nor the New Premises, nor the Building, nor the Project has undergone inspection by a Certified Access Specialist.<font style="letter-spacing:2pt;"> </font>Further, pursuant to Section 1938 of the California Civil Code, Landlord notifies Tenant of the following:<font style="letter-spacing:2pt;"> </font>&#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.<font style="letter-spacing:2pt;"> </font>Although state law does not require a CASp inspection<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>subject premises, the commercial<font style="letter-spacing:-0.05pt;"> </font>property owner or<font style="letter-spacing:-0.05pt;"> </font>lessor<font style="letter-spacing:-0.1pt;"> </font>may<font style="letter-spacing:-0.1pt;"> </font>not prohibit the<font style="letter-spacing:-0.1pt;"> </font>lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential<font style="letter-spacing:2pt;"> </font>occupancy<font style="letter-spacing:-0.05pt;"> </font>of the<font style="letter-spacing:-0.05pt;"> </font>lessee<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>tenant, if<font style="letter-spacing:-0.05pt;"> </font>requested<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>lessee<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>tenant.<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.05pt;"> </font>parties shall mutually<font style="letter-spacing:-0.1pt;"> </font>agree<font style="letter-spacing:-0.05pt;"> </font>on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;<font style="letter-spacing:2pt;"> </font>Therefore and notwithstanding anything to the contrary contained in the Amended Lease, Landlord and Tenant agree that (a) Tenant may, at its option and at its sole cost, cause a CASp to inspect the Premises and determine whether the Premises complies with all of the applicable construction-related accessibility standards under California law, (b) the parties shall mutually coordinate and reasonably approve of the timing of any such CASp inspection so that Landlord may, at its option, have a representative present during such inspection, and (c) Tenant shall be solely responsible for the cost of any repairs necessary to correct violations of construction-related accessibility standards within the Premises, the Building, or the Project identified by any such CASp inspection.<font style="letter-spacing:2pt;"> </font>Tenant shall reimburse Landlord upon demand, as Additional Rent, for any cost to Landlord of<font style="letter-spacing:2pt;"> </font>performing such alterations and repairs; provided, however, unless such repair or alterations relate solely to other alterations to the Premises which Tenant is obligated to, or elects to, remove upon the expiration or earlier termination of the Amended Lease (in which case Tenant shall simultaneously also remove any CASp-identified alterations and repairs), Tenant shall have no obligation to remove any repairs or alterations made pursuant to a CASp inspection under this Section.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Direct Expenses</u>.<font style="letter-spacing:2pt;"> </font>During the Second Extended Term, Tenant shall continue to pay Tenant&#8217;s Share of Direct Expenses in accordance with the Amended Lease; provided, however, (a) Tenant&#8217;s Share with respect to the New Premises shall be 0.70%, based on the New Premises consisting<font style="letter-spacing:2pt;"> </font>of approximately 1,620 rentable square feet and the Building consisting of approximately 232,210<font style="letter-spacing:2pt;"> </font>rentable square feet, and (b) the &#8220;Base Year&#8221; shall be adjusted to the calendar year 2024.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12.05pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Deposit</u>.<font style="letter-spacing:2pt;"> </font>Landlord and Tenant acknowledge that Landlord currently holds a Security Deposit under the Lease in the amount of $41,243.58.<font style="letter-spacing:2pt;"> </font>Provided that during the Lease Term preceding the New Premises Commencement Date, Tenant has not been in default under the Amended Lease, Tenant shall have the right to reduce the Security Deposit by $18,644.58 as of the New Premises Commencement Date.<font style="letter-spacing:2pt;"> </font>Notwithstanding anything to the contrary contained herein, if an Event of Default has occurred under<font style="letter-spacing:-0.05pt;"> </font>the Amended Lease<font style="letter-spacing:-0.1pt;"> </font>at any time prior to the New<font style="letter-spacing:-0.05pt;"> </font>Premises Commencement Date,<font style="letter-spacing:-0.1pt;"> </font>then</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:10.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">4</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:4.05pt 5.75pt 0pt 8pt;">Tenant shall have no right to reduce the Security Deposit as described herein.<font style="letter-spacing:2pt;"> </font>If Tenant is entitled to a reduction in the Security Deposit, Tenant shall provide Landlord with written notice requesting that the Security Deposit be reduced as provided above (the &#8220;<b style="font-weight:bold;">Security Reduction Notice</b>&#8221;).<font style="letter-spacing:2pt;"> </font>If Tenant provides Landlord with a Security Reduction Notice, and Tenant is entitled to reduce the Security Deposit as provided herein, Landlord shall refund the applicable portion of the Security Deposit to Tenant within forty-five (45) days after the later to occur of (a) Landlord&#8217;s receipt of the Security Reduction Notice, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 5.7pt 0pt 8pt;">(b)<font style="letter-spacing:-0.15pt;"> </font>the New Premises Commencement Date.<font style="letter-spacing:4pt;"> </font>In no event shall the remaining Security Deposit ever be<font style="letter-spacing:2pt;"> </font>less than $22,599.00.</p><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parking</u>.<font style="letter-spacing:2pt;"> </font>During the Second Extended Term, Tenant shall have the right, but not the obligation,<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>lease up<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>five<font style="letter-spacing:-0.05pt;"> </font>(5)<font style="letter-spacing:-0.05pt;"> </font>unreserved<font style="letter-spacing:-0.05pt;"> </font>vehicle<font style="letter-spacing:-0.05pt;"> </font>parking spaces<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>parking<font style="letter-spacing:-0.05pt;"> </font>lot<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>lots<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Project designated by Landlord for the use of tenants of the Building, subject to payment of the prevailing monthly rate for such parking spaces (which is currently one hundred twenty dollars ($120.00) per unreserved parking space per month), subject to the terms of the Amended Lease.<font style="letter-spacing:2pt;"> </font>Such parking is in lieu of, not in addition<font style="letter-spacing:-0.05pt;"> </font>to, all previous parking<font style="letter-spacing:-0.05pt;"> </font>rights granted under the Lease.<font style="letter-spacing:2pt;"> </font>Tenant shall notify Landlord<font style="letter-spacing:-0.05pt;"> </font>in writing<font style="letter-spacing:-0.15pt;"> </font>of Tenant&#8217;s election<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>lease<font style="letter-spacing:-0.1pt;"> </font>each of the unreserved parking spaces.<font style="letter-spacing:2pt;"> </font>In the<font style="letter-spacing:-0.1pt;"> </font>event<font style="letter-spacing:-0.05pt;"> </font>Tenant<font style="letter-spacing:-0.05pt;"> </font>elects not to lease some or all of its unreserved parking spaces for longer than ninety (90) days, Landlord may lease said unreserved parking spaces to other tenants, and Tenant&#8217;s ability to thereafter re-lease said unreserved parking spaces shall be on a month-to-month basis and subject to availability.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12pt 5.9pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">After-Hours</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HVAC</u>.<font style="letter-spacing:2pt;"> </font>For<font style="letter-spacing:-0.15pt;"> </font>informational purposes,<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>current after-hours<font style="letter-spacing:-0.05pt;"> </font>usage<font style="letter-spacing:-0.15pt;"> </font>charge<font style="letter-spacing:-0.15pt;"> </font>for the Building is $135.00 per hour.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12.05pt 5.6pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FF&amp;E</u>.<font style="letter-spacing:2pt;"> </font>Effective as of the New Premises Commencement Date, Tenant shall be deemed to have conveyed to Landlord via quitclaim bill of sale and for consideration of one dollar ($1.00), the cabling, IT rack, and workstations currently existing in the Current Premises (the &#8220;<b style="font-weight:bold;">FF&amp;E</b>&#8221;), with the exception of six (6) workstations which Tenant shall relocate to the New Premises.<font style="letter-spacing:2pt;"> </font>Notwithstanding anything to the contrary contained in the Amended Lease, Tenant shall leave the FF&amp;E in the Current Premises upon surrender thereof, and Tenant&#8217;s conveyance of the FF&amp;E shall be &#8220;AS-IS&#8221; and without<font style="letter-spacing:2pt;"> </font>any representations or warranties by Tenant.<font style="letter-spacing:2pt;"> </font>Landlord shall designate the six (6) specific workstations to be relocated to the New Premises, in Landlord&#8217;s sole and absolute discretion.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:11.94pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Access</u>.<font style="letter-spacing:2pt;"> </font>So long as Landlord has received from Tenant certificates and endorsements satisfactory to Landlord evidencing the insurance required to be carried by Tenant under<font style="letter-spacing:2pt;"> </font>the Amended Lease, and so long as Tenant and its contractors and employees do not interfere with the completion of the Tenant Improvements, Landlord shall use reasonable efforts to permit Tenant and Tenant&#8217;s designated contractors access to the New Premises approximately three (3) weeks prior to the New Premises Commencement Date (the &#8220;<b style="font-weight:bold;">Early Access Period</b>&#8221;) for purposes of installing Tenant&#8217;s furniture, fixtures, and equipment (&#8220;<b style="font-weight:bold;">Tenant&#8217;s Work</b>&#8221;).<font style="letter-spacing:2pt;"> </font>Tenant&#8217;s Work shall be performed by Tenant at Tenant&#8217;s sole cost and expense.<font style="letter-spacing:4pt;"> </font>Tenant&#8217;s access to the New Premises during the Early Access Period shall be subject to all terms and conditions of the Amended Lease, except that Tenant shall not be obligated to pay Rent for the New Premises during the Early Access Period until the New Premises Commencement Date.<font style="letter-spacing:2pt;"> </font>Tenant agrees to provide Landlord with prior notice of any such intended early access<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>to cooperate with Landlord<font style="letter-spacing:-0.15pt;"> </font>during<font style="letter-spacing:-0.15pt;"> </font>the Early Access Period so as not<font style="letter-spacing:-0.05pt;"> </font>to interfere with<font style="letter-spacing:-0.15pt;"> </font>Landlord in the completion of the Tenant Improvements.<font style="letter-spacing:2pt;"> </font>Should Landlord determine such early access interferes with the Tenant Improvements, Landlord may deny Tenant access to the New Premises until the Tenant Improvements are substantially completed.<font style="letter-spacing:2pt;"> </font>Tenant shall promptly surrender any keys or other means of access to the New Premises and otherwise comply with such denial.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12.14pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signage</u>.<font style="letter-spacing:2pt;"> </font>Tenant shall have the right to have placed by Landlord, at Landlord&#8217;s expense, Tenant&#8217;s name and New Premises suite number on a Building-standard suite entry sign, in the elevator lobby directory board for the third (3<sup style="font-size:8.25pt;vertical-align:top;">rd</sup>) floor, and on the Building lobby main directory board.<font style="letter-spacing:2pt;"> </font>Landlord agrees<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>cause<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1pt;"> </font>New<font style="letter-spacing:0.95pt;"> </font>Premises<font style="letter-spacing:1.05pt;"> </font>suite<font style="letter-spacing:1pt;"> </font>number<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.9pt;"> </font>remain<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>same<font style="letter-spacing:1pt;"> </font>as<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.1pt;"> </font>Current<font style="letter-spacing:1.05pt;"> </font>Premises,<font style="letter-spacing:1.05pt;"> </font>i.e.,<font style="letter-spacing:1pt;"> </font>Suite</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 8pt;">310.<font style="letter-spacing:2.15pt;"> &#160;</font>Subsequent<font style="letter-spacing:2.25pt;"> </font>changes<font style="letter-spacing:2.2pt;"> </font>to<font style="letter-spacing:2.2pt;"> </font>Tenant&#8217;s<font style="letter-spacing:2.25pt;"> </font>signs<font style="letter-spacing:2.25pt;"> </font>and/or<font style="letter-spacing:2.2pt;"> </font>any<font style="letter-spacing:2.25pt;"> </font>additional<font style="letter-spacing:2.25pt;"> </font>signs,<font style="letter-spacing:2.15pt;"> </font>to<font style="letter-spacing:2.25pt;"> </font>the<font style="letter-spacing:2.25pt;"> </font>extent<font style="letter-spacing:2.3pt;"> </font>permitted<font style="letter-spacing:2.3pt;"> </font><font style="letter-spacing:-0.25pt;">by</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:10.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">5</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:4.05pt 1.45pt 0pt 8pt;">Landlord, shall be made or installed by Landlord at Tenant&#8217;s sole cost and expense.<font style="letter-spacing:4pt;"> </font>All aspects of any<font style="letter-spacing:4pt;"> </font>such signs shall be subject to the prior written consent of Landlord.</p><div style="margin-top:12.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extension Option</u>.<font style="letter-spacing:2pt;"> </font>Notwithstanding anything to the contrary contained in the First Amendment, Tenant shall continue to have one (1) Extension Option pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rider No. 1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rider</u> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No. 2</u> to the Original Lease.<font style="letter-spacing:4pt;"> </font>Landlord and Tenant hereby acknowledge and agree that any other provisions of the Lease providing for an extension or renewal of the Lease Term are hereby deleted in their entirety and Tenant has no other options to extend or renew the Second Extended Term of the Amended Lease.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:44pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">14.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">and</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warranties</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Tenant</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">hereby</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">represents,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">warrants,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">agrees</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">that:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0.05pt 5.7pt 0pt 8pt;">(a)<font style="letter-spacing:-0.1pt;"> </font>there exists no breach, default, or event of default by Landlord under the Lease, or any event or condition which, with notice or passage of time or both, would constitute a breach, default, or event of default by Landlord under the Lease; (b) the Lease continues to be a legal, valid, and binding agreement and obligation of Tenant; and (c) Tenant has no<font style="letter-spacing:-0.1pt;"> </font>current offset or<font style="letter-spacing:-0.05pt;"> </font>defense to<font style="letter-spacing:-0.1pt;"> </font>its performance or obligations under the Lease.<font style="letter-spacing:2pt;"> </font>Tenant hereby waives and releases all demands, charges, claims, accounts, or causes of action of any nature whatsoever against Landlord or Landlord&#39;s members, managers, officers, employees or agents, including without limitation, both known and unknown demands, charges, claims, accounts,<font style="letter-spacing:2pt;"> </font>and causes of action that have previously arisen out of or in connection with the Lease.</p><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</u>.<font style="letter-spacing:2pt;"> </font>Each signatory of this Amendment on behalf of Tenant represents hereby that he or she has the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">16.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>.<font style="letter-spacing:2pt;"> </font>This Amendment shall extend to, be binding upon, and inure to the benefit of, the respective successors and permitted assigns and beneficiaries of the parties hereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12.05pt 5.55pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">17.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker</u>.<font style="letter-spacing:2pt;"> </font>Tenant represents and warrants to Landlord that, with the exception of Cushman &amp; Wakefield, it is not aware of any brokers, agents or finders who may claim a fee or commission in connection with the consummation of the transactions contemplated by this Amendment.<font style="letter-spacing:4pt;"> </font>If any claims for brokers&#8217; or finders&#8217; fees in connection with the transactions contemplated by this Amendment arise, then Tenant agrees to indemnify, protect, hold harmless and defend Landlord (with counsel reasonably satisfactory to Landlord) from and against any such claims if they shall be based upon any statement, representation or agreement made by Tenant.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:12pt 5.75pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">18.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Modification</u>.<font style="letter-spacing:2pt;"> </font>Landlord and Tenant agree that except as otherwise specifically modified in this Amendment, the Lease has not been modified, supplemented, amended, or otherwise changed in any way and the Lease remains in full force and effect between the parties hereto as modified by this Amendment.<font style="letter-spacing:4pt;"> </font>To the extent of any inconsistency between the terms and conditions of the Lease and the terms and conditions of this Amendment,<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>terms<font style="letter-spacing:-0.1pt;"> </font>and conditions of this<font style="letter-spacing:-0.1pt;"> </font>Amendment shall apply and govern the parties.<font style="letter-spacing:4pt;"> </font>This Amendment may be executed in counterparts, each of which shall be<font style="letter-spacing:2pt;"> </font>deemed<font style="letter-spacing:-0.1pt;"> </font>an original,<font style="letter-spacing:-0.1pt;"> </font>but<font style="letter-spacing:-0.05pt;"> </font>all<font style="letter-spacing:-0.05pt;"> </font>of which, together,<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>constitute<font style="letter-spacing:-0.1pt;"> </font>one<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>same<font style="letter-spacing:-0.1pt;"> </font>instrument.<font style="letter-spacing:2pt;"> </font>For purposes of this Amendment, signatures by facsimile or electronic PDF shall be binding to the same extent as original signatures.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 53.6pt;">[NO<font style="letter-spacing:-0.4pt;"> </font>FURTHER<font style="letter-spacing:-0.3pt;"> </font>TEXT<font style="letter-spacing:-0.25pt;"> </font>ON<font style="letter-spacing:-0.15pt;"> </font>THIS<font style="letter-spacing:-0.25pt;"> </font>PAGE;<font style="letter-spacing:-0.2pt;"> </font>SIGNATURES<font style="letter-spacing:-0.3pt;"> </font>ON<font style="letter-spacing:-0.25pt;"> </font>FOLLOWING<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">PAGE]</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:10.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">6</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.65pt;margin:4.05pt 0pt 0pt 44pt;">IN<font style="letter-spacing:1.35pt;"> </font>WITNESS<font style="letter-spacing:1.4pt;"> </font>WHEREOF,<font style="letter-spacing:1.4pt;"> </font>the<font style="letter-spacing:1.35pt;"> </font>parties<font style="letter-spacing:1.4pt;"> </font>have<font style="letter-spacing:1.35pt;"> </font>executed<font style="letter-spacing:1.35pt;"> </font>this<font style="letter-spacing:1.4pt;"> </font>Amendment<font style="letter-spacing:1.5pt;"> </font>as<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.35pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>date<font style="letter-spacing:1.4pt;"> </font>set<font style="letter-spacing:1.65pt;"> </font><font style="letter-spacing:-0.1pt;">forth</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.65pt;margin:0pt 0pt 0pt 8pt;"><font style="letter-spacing:-0.1pt;">above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 8pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Tenant:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:11.44pt 0pt 0pt 8pt;">XOMA<font style="letter-spacing:-0.2pt;"> </font>(US)<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.2pt;">LLC,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 8pt;">a<font style="letter-spacing:-0.25pt;"> </font>Delaware<font style="letter-spacing:-0.3pt;"> </font>limited<font style="letter-spacing:-0.2pt;"> </font>liability<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.1pt;">company</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 315.1pt 0pt 8pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:158.75pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u> Name:<font style="letter-spacing:2pt;"> </font>Tom Burns</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.55pt;margin:0pt 0pt 0pt 8pt;">Title:<font style="letter-spacing:2.6pt;"> </font><font style="letter-spacing:-0.25pt;">CFO</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 8pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Landlord:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:1pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="padding-left:5.85pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:42.46%;"><tr style="height:31pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.2pt;margin:0pt 0pt 0pt 2.5pt;">KBSIII<font style="letter-spacing:-0.4pt;"> </font>TOWERS<font style="letter-spacing:-0.25pt;"> </font>AT<font style="letter-spacing:-0.3pt;"> </font>EMERYVILLE,<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.2pt;">LLC,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin:0pt 0pt 0pt 2.5pt;">a<font style="letter-spacing:-0.2pt;"> </font>Delaware<font style="letter-spacing:-0.25pt;"> </font>limited<font style="letter-spacing:-0.15pt;"> </font>liability<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">company</font></p></td></tr><tr style="height:55.95pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:5.75pt 0pt 0pt 2.5pt;"><font style="display:inline-block;text-indent:0pt;width:35.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">By:</font></font>KBS<font style="letter-spacing:-0.25pt;"> </font>Capital<font style="letter-spacing:-0.15pt;"> </font>Advisors,<font style="letter-spacing:-0.2pt;"> LLC,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.05pt 0pt 0pt 37.75pt;">a<font style="letter-spacing:-0.4pt;"> </font>Delaware<font style="letter-spacing:-0.5pt;"> </font>limited<font style="letter-spacing:-0.4pt;"> </font>liability<font style="letter-spacing:-0.5pt;"> </font>company Its:<font style="letter-spacing:2pt;"> </font>Authorized Agent</p></td></tr><tr style="height:24.65pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11.85pt;margin:11.8pt 0pt 0pt 38.45pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">By:</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:159.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr style="height:12.6pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11.6pt;margin:0pt 0pt 0pt 38.45pt;">Name:<font style="letter-spacing:3.75pt;"> </font>Brent <font style="letter-spacing:-0.1pt;">Carroll</font></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11.4pt;margin:0pt 0pt 0pt 38.45pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Title:</font></font>Senior<font style="letter-spacing:-0.2pt;"> </font>Vice<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">President</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11.4pt;margin:0pt 0pt 0pt 38.45pt;"><font style="letter-spacing:-0.1pt;">Date signed: 6/27/23</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-family:'Lucida Console';font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:10.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:46.52%;max-width:53.48%;position:absolute;top:695.68pt;width:38.55pt;z-index:-9223372036603117568;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.55pt;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:38.54pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">PAGE<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">7</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:5.05pt 0pt 0pt 0pt;"><font style="font-family:'Lucida Console';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0.15pt 0pt 2.25pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:11.94pt 0.3pt 0pt 2.25pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NEW</b><b style="font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PREMISES</b></p><div style="height:538.65pt;left:4.2%;max-width:95.8%;position:relative;top:0pt;width:441.54pt;z-index:-9223372036603117568;"><div style="height:538.65pt;left:0pt;padding-bottom:0pt;position:relative;width:441.54pt;"><img src="xoma-20231231xex10d65003.jpg" alt="Graphic" style="height:538.65pt;width:441.54pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:2.09pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.7pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:44.85%;max-width:55.15%;position:absolute;top:695.68pt;width:51.7pt;z-index:-9223372036603115520;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:51.7pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">EXHIBIT<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">A</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:3.4pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 2.25pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:12pt 0.3pt 0pt 2.25pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WORK</b><b style="font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LETTER</b></p><div style="margin-top:12.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">1.</font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT IMPROVEMENTS</b>.<font style="letter-spacing:2pt;"> </font>Landlord shall construct and, except as provided below to the contrary, pay for the entire cost of constructing the tenant improvements (&#8220;<b style="font-weight:bold;">Tenant Improvements</b>&#8221;) shown in the scope of work attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u> (the &#8220;<b style="font-weight:bold;">Scope of Work</b>&#8221;).<font style="letter-spacing:2pt;"> </font>Tenant may request changes to the Scope of Work provided that (a) the changes shall not be of a lesser quality than<font style="letter-spacing:2pt;"> </font>Landlord&#8217;s standard specifications<font style="letter-spacing:-0.1pt;"> </font>for<font style="letter-spacing:-0.1pt;"> </font>tenant improvements for the Building, as the same may be changed from time to time by Landlord (the &#8220;<b style="font-weight:bold;">Standards</b>&#8221;); (b) the changes conform to applicable governmental regulations and necessary governmental permits and approvals can be secured; (c) the changes do not require building service beyond the levels normally provided to other tenants in the Building; (d) the changes do not have any adverse effect on the structural integrity or systems of the Building; (e) the changes will not, in Landlord&#8217;s opinion, unreasonably delay construction of the Tenant Improvements; and (f) Landlord has determined in its sole discretion that the changes are of a nature and quality consistent with the overall objectives of Landlord for the Building.<font style="letter-spacing:2pt;"> </font>If Landlord approves a change requested by Tenant, then, as a condition to the effectiveness of Landlord&#8217;s approval, Tenant shall pay to Landlord upon demand by Landlord the increased cost attributable to such change, as reasonably determined by Landlord.<font style="letter-spacing:3.6pt;"> </font>To the extent any such change results in a delay of completion of construction of the Tenant Improvements, then such delay shall constitute a delay caused by Tenant as described <font style="letter-spacing:-0.1pt;">below.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.05pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">2.</font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONSTRUCTION OF TENANT IMPROVEMENTS</b>.<font style="letter-spacing:4pt;"> </font>Upon Tenant&#8217;s payment to Landlord<font style="letter-spacing:2pt;"> </font>of the total amount of the cost of any changes to the Scope of Work, if any, Landlord&#8217;s contractor shall commence and diligently proceed with the construction of the Tenant Improvements, subject to Tenant Delays (as described in Section 4 below) and Force Majeure Delays (as described in Section 5 below). Landlord may furnish Tenant with a construction schedule letter setting forth the projected completion dates therefor and showing the deadlines for any actions required to be taken by Tenant during such construction, and Landlord may from time to time during construction of the Tenant Improvements modify such schedule.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:35.95pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NEW</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.4pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PREMISES</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.3pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMMENCEMENT</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DATE</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.3pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AND</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUBSTANTIAL</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPLETION</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><div style="margin-top:11.94pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">(a)</font><b style="font-weight:bold;">New Premises Commencement Date</b>.<font style="letter-spacing:2pt;"> </font>The Second Extended Term shall commence on the date (the<font style="letter-spacing:-0.1pt;"> </font>&#8220;<b style="font-weight:bold;">New Premises</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;">Commencement Date</b>&#8221;) which<font style="letter-spacing:-0.05pt;"> </font>is the<font style="letter-spacing:-0.05pt;"> </font>later of:<font style="letter-spacing:2pt;"> </font>(i) August 1,<font style="letter-spacing:-0.25pt;"> </font>2023, or<font style="letter-spacing:-0.05pt;"> </font>(ii) the date<font style="letter-spacing:-0.1pt;"> </font>the Tenant Improvements have been &#8220;substantially completed&#8221; (as defined below) in the New Premises; provided,<font style="letter-spacing:-0.1pt;"> </font>however,<font style="letter-spacing:-0.1pt;"> </font>that<font style="letter-spacing:-0.2pt;"> </font>if<font style="letter-spacing:-0.2pt;"> </font>substantial<font style="letter-spacing:-0.05pt;"> </font>completion<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Tenant<font style="letter-spacing:-0.05pt;"> </font>Improvements<font style="letter-spacing:-0.2pt;"> </font>is<font style="letter-spacing:-0.2pt;"> </font>delayed as<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>result<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>any Tenant Delays described in Section 4 below, then the New Premises Commencement Date as would otherwise have been established pursuant to this Section 3(a)(ii) shall be accelerated by the number of days of such Tenant Delays.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.05pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:35.9pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Substantial Completion; Punch-List</b>.<font style="letter-spacing:2pt;"> </font>For purposes of Section 3(a)(ii) above, the Tenant Improvements shall be deemed to be &#8220;<b style="font-weight:bold;">substantially completed</b>&#8221; when Landlord: (i) is able to provide Tenant reasonable access to the New Premises and (ii) has substantially performed the Tenant Improvements described in the Scope of Work, other than decoration and minor &#8220;punch-list&#8221; type items and adjustments which do not materially interfere with Tenant&#8217;s access to or use of the New Premises. Within ten (10) days after such substantial completion, Tenant shall conduct a walk-through inspection of the New<font style="letter-spacing:-0.05pt;"> </font>Premises with Landlord<font style="letter-spacing:-0.1pt;"> </font>and provide<font style="letter-spacing:-0.1pt;"> </font>to Landlord a written<font style="letter-spacing:-0.1pt;"> </font>punch-list specifying<font style="letter-spacing:-0.1pt;"> </font>those decoration and other punch-list items which require completion, which items Landlord shall thereafter diligently complete; provided, however, that Tenant shall be responsible, at Tenant&#8217;s sole cost and expense, for the remediation of any items on the punch-list caused by Tenant&#8217;s acts or omissions.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.05pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Delivery of Possession</b>.<font style="letter-spacing:2pt;"> </font>Landlord agrees to deliver possession of the New Premises to Tenant when the Tenant Improvements have been substantially completed in accordance with Section (b) above.</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:10pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:44.91%;max-width:55.09%;position:absolute;top:695.68pt;width:51.15pt;z-index:-9223372036603113472;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:51.15pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">EXHIBIT<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">B</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:4.05pt 5.7pt 0pt 8pt;">Tenant agrees that if Landlord is unable to deliver possession of the New Premises to Tenant on or prior<font style="letter-spacing:2pt;"> </font>to any particular date, the Amended Lease shall not be void or voidable, nor shall Landlord be liable to Tenant for any loss or damage resulting therefrom.</p><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">4.</font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT DELAYS</b>.<font style="letter-spacing:3.75pt;"> </font>For purposes of this Work Letter, &#8220;<b style="font-weight:bold;">Tenant Delays</b>&#8221; shall mean any delay in the completion of the Tenant Improvements resulting from any or all of the following:<font style="letter-spacing:2pt;"> </font>(a) Tenant&#8217;s failure to timely perform any of its obligations pursuant to this Work Letter, including any failure to complete, on or before the due date therefor, any action item which is Tenant&#8217;s responsibility pursuant to any schedule delivered by Landlord to Tenant pursuant to this Work Letter; (b) Tenant&#8217;s changes to the Scope<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>Work;<font style="letter-spacing:-0.2pt;"> </font>(c)<font style="letter-spacing:-0.05pt;"> </font>Tenant&#8217;s<font style="letter-spacing:-0.1pt;"> </font>request<font style="letter-spacing:-0.2pt;"> </font>for<font style="letter-spacing:-0.2pt;"> </font>materials,<font style="letter-spacing:-0.2pt;"> </font>finishes,<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>installations<font style="letter-spacing:-0.1pt;"> </font>which<font style="letter-spacing:-0.1pt;"> </font>are<font style="letter-spacing:-0.1pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>readily<font style="letter-spacing:-0.1pt;"> </font>available or which<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:-0.05pt;"> </font>incompatible<font style="letter-spacing:-0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Standards; (d)<font style="letter-spacing:-0.05pt;"> </font>any delay<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>Tenant in<font style="letter-spacing:-0.1pt;"> </font>making<font style="letter-spacing:-0.05pt;"> </font>payment to<font style="letter-spacing:-0.1pt;"> </font>Landlord for Tenant&#8217;s share of any costs<font style="letter-spacing:-0.05pt;"> </font>in excess of the cost of the<font style="letter-spacing:-0.05pt;"> </font>Tenant Improvements as described in the Scope of Work; or (e) any other<font style="letter-spacing:-0.05pt;"> </font>act<font style="letter-spacing:-0.05pt;"> </font>or failure to<font style="letter-spacing:-0.1pt;"> </font>act by Tenant,<font style="letter-spacing:-0.1pt;"> </font>Tenant&#8217;s<font style="letter-spacing:-0.1pt;"> </font>employees,<font style="letter-spacing:-0.1pt;"> </font>agents, architects,<font style="letter-spacing:-0.1pt;"> </font>independent contractors, consultants and/or any other person performing or required to perform services on behalf of <font style="letter-spacing:-0.1pt;">Tenant.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.1pt 5.75pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">5.</font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORCE MAJEURE DELAYS</b>.<font style="letter-spacing:2pt;"> </font>For purposes of this Work Letter, &#8220;<b style="font-weight:bold;">Force Majeure Delays</b>&#8221; shall mean any actual delay beyond the reasonable control of Landlord in the construction of the Tenant Improvements,<font style="letter-spacing:-0.25pt;"> </font>which<font style="letter-spacing:-0.2pt;"> </font>is<font style="letter-spacing:-0.1pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.15pt;"> </font>Tenant<font style="letter-spacing:-0.05pt;"> </font>Delay<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>which<font style="letter-spacing:-0.25pt;"> </font>is<font style="letter-spacing:-0.15pt;"> </font>caused<font style="letter-spacing:-0.1pt;"> </font>by<font style="letter-spacing:-0.1pt;"> </font>any<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>causes<font style="letter-spacing:-0.1pt;"> </font>described<font style="letter-spacing:-0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Section</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;text-align:justify;margin:0pt 0pt 0pt 8pt;">29.17<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>Original <font style="letter-spacing:-0.1pt;">Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.6pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.55pt 0pt 8pt;"><font style="display:inline-block;min-width:35.95pt;white-space:nowrap;">6.</font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IT ALLOWANCE</b>.<font style="letter-spacing:2pt;"> </font>Landlord shall provide to Tenant an allowance of up to $2.00 per rentable square foot of the New Premises (i.e., up to $3,240.00, based on the New Premises consisting of approximately 1,620<font style="letter-spacing:-0.1pt;"> </font>rentable square feet,<font style="letter-spacing:-0.1pt;"> </font>hereinafter<font style="letter-spacing:-0.1pt;"> </font>referred to<font style="letter-spacing:-0.1pt;"> </font>as the &#8220;<b style="font-weight:bold;">Allowance</b>&#8221;)<font style="letter-spacing:-0.05pt;"> </font>to reimburse Tenant for the procurement and installation of internet and telecommunications infrastructure in the New Premises, provided that Tenant submits to Landlord copies of contracts, receipts, invoices, and other<font style="letter-spacing:2pt;"> </font>back-up documentation reasonably requested by Landlord evidencing such IT costs (collectively, the &#8220;<b style="font-weight:bold;">Cost Documentation</b>&#8221;), if at all, within six (6) months following the Effective Date (the &#8220;<b style="font-weight:bold;">Outside Date</b>&#8221;).<font style="letter-spacing:2pt;"> </font>Landlord shall not reimburse Tenant for any costs for which Tenant fails to submit Cost Documentation prior to the Outside Date.<font style="letter-spacing:2pt;"> </font>Notwithstanding anything in the Amended Lease to the contrary, Landlord shall not be obligated to pay any portion of the Allowance during the continuance of<font style="letter-spacing:2pt;"> </font>an uncured default under the Amended Lease.</div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:12pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:44.91%;max-width:55.09%;position:absolute;top:695.68pt;width:51.15pt;z-index:-9223372036603113472;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:51.15pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">EXHIBIT<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.5pt;">B</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.76%;border-width:0;"><div style="max-width:100%;padding-left:10.46%;padding-right:10.78%;position:relative;"><div style="margin-top:9.1pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:3.4pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0.3pt 0pt 2.25pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCHEDULE</b><b style="font-weight:bold;letter-spacing:-0.45pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:12pt 0.25pt 0pt 2.25pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCOPE</b><b style="font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OF</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> WORK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.65pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>Landlord to combine the westernmost two (2) offices into one aluminum-framed glass front conference<font style="letter-spacing:-0.2pt;"> </font>room.<font style="letter-spacing:-0.1pt;"> </font>The<font style="letter-spacing:-0.05pt;"> </font>glass<font style="letter-spacing:-0.2pt;"> </font>on<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>conference<font style="letter-spacing:-0.1pt;"> </font>room<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>partially<font style="letter-spacing:-0.25pt;"> </font>frosted<font style="letter-spacing:-0.1pt;"> </font>similar<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Current<font style="letter-spacing:-0.05pt;"> </font>Premises.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.64pt 5.85pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>Electrical to be distributed where needed throughout the New Premises per a mutually agreed upon furniture plan, including outlets for 2 WAP locations in the ceiling<font style="letter-spacing:0.8pt;"> </font>and a connect track in the floor<font style="letter-spacing:2pt;"> </font>of the new large conference room providing electrical and data access to the conference room table from the south wall of that room.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.8pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>Landlord to install new lower and upper cabinetry, dishwasher (provided with appropriate plumbing), backsplash, and hard surface countertop in the kitchen.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.55pt 5.85pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>New paint to be installed throughout and the stained areas of the carpet to either be repaired (to match existing) or replaced throughout.<font style="letter-spacing:2pt;"> </font>New LVT/LVP in kitchen area.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.6pt 5.85pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>The wall that separates the kitchen area from the balance of the suite to be removed or substantially opened up to create an open kitchen feel.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 5.7pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>Landlord shall confirm the kitchen is plumbed for a refrigerator with an ice machine and that an in-sink disposal is in-place and functional.<font style="letter-spacing:2pt;"> </font>Refrigerator and other non-built-in kitchen appliances to be provided by Tenant.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12.6pt 5.55pt 0pt 8pt;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">&#9679;</font>Both conference rooms to have wall (south) mount backing/strapping or painted mounting board for TV installs, which will accommodate Tenant&#8217;s two (2) TV&#8217;s on the south wall of the large conference room, and one (1) TV on the south wall of the small conference room.<font style="letter-spacing:2pt;"> </font>All mounts to be centered on the walls.<font style="letter-spacing:2pt;"> </font>TV&#8217;s to be provided by Tenant.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.7pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:13.05pt;left:43.81%;max-width:56.19%;position:absolute;top:695.68pt;width:61.6pt;z-index:-9223372036603111424;"><div style="height:13.05pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:61.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;">SCHEDULE<font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.5pt;">1</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.46%;margin-right:10.78%;margin-top:30pt;page-break-after:avoid;width:78.76%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>8
<FILENAME>xoma-20231231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:51 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 21.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="clear:left;float:left;margin-bottom:1em;margin-right:1.92%;width:99.89%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries of the Company </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction of Organization </b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XOMA Technology Ltd.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Bermuda</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XOMA (US) LLC</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Delaware</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XOMA UK Limited</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">United Kingdom</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XRL 1 LLC</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Delaware</font></p></td></tr></table></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>xoma-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:24:55 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;background:#ffffff;">Exhibit 23.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'TimesNewRomanPS-BoldMT';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'TimesNewRomanPS-BoldMT';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'TimesNewRomanPS-BoldMT';font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:8pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';">We consent to the incorporation by reference in Registration Statement Nos. 333-269459, 333-151416, 333-171429, 333-174730, 333-181849, 333-198719, 333-204367, 333-212238, 333-218378, 333-232398, 333-265248 and 333-272054 on Form S-8 and Registration Statement No. 333-254073 on Form S-3 of our report dated March 8, 2024, relating to the consolidated financial statements of XOMA Corporation, appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:8pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';">/s/ Deloitte &amp; Touche LLP</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';">San Francisco, California</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';">March 8, 2024</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>xoma-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:25:07 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Owen Hughes, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this annual report on Form 10-K of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March 8, 2024</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ OWEN HUGHES</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>xoma-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:25:08 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Thomas Burns, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this annual report on Form 10-K of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March 8, 2024</font></p></td><td style="vertical-align:top;width:57.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>xoma-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:25:11 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Owen Hughes, Chief Executive Officer of XOMA Corporation (the &#8220;Company&#8221;), and Thomas Burns, Senior Vice President, Finance and Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The information contained in Exhibit 32.1 fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 8</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;day of March, 2024</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;width:54.61%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ OWEN HUGHES</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of XOMA Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></td></tr></table><div style="margin-top:8pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>13
<FILENAME>xoma-20231231xex97.htm
<DESCRIPTION>EX-97
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/8/2024 03:25:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Exhibit 97</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">XOMA Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Incentive Compensation Recoupment Policy</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">1.</font><b style="font-size:11pt;font-variant:small-caps;font-weight:bold;">Introduction</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">The Compensation Committee (the &#8220;<font style="font-style:italic;font-weight:bold;">Compensation Committee</font>&#8221;) of the Board of Directors (the &#8220;<font style="font-style:italic;font-weight:bold;">Board</font>&#8221;) of XOMA Corporation, a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#8220;<font style="font-style:italic;font-weight:bold;">Policy</font>&#8221;) providing for the Company&#8217;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#8220;<font style="font-style:italic;font-weight:bold;">Rule 10D-1</font>&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;<font style="font-style:italic;font-weight:bold;">Listing Standards</font>&#8221;).</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">2.</font><b style="font-size:11pt;font-variant:small-caps;font-weight:bold;">Effective Date</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;<font style="font-style:italic;font-weight:bold;">Effective Date</font>&#8221;). Incentive Compensation is deemed &#8220;<font style="font-style:italic;font-weight:bold;">received</font>&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">3.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">Definitions</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Accounting Restatement</font>&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Accounting Restatement Date</font>&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Administrator</font>&#8221; means the Compensation Committee or, in the absence of such committee, the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Code</font>&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Covered Officer</font>&#8221; means each current and former Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Exchange</font>&#8221; means The Nasdaq Stock Market LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Executive Officer</font>&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Financial Reporting Measures</font>&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#8220;<font style="font-style:italic;font-weight:bold;">TSR</font>&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Incentive Compensation</font>&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Lookback Period</font>&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk136880315"></a></font>&#8220;<font style="font-style:italic;font-weight:bold;">Recoverable Incentive Compensation</font>&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (<i style="font-style:italic;">i.e.</i>, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">SEC</font>&#8221; means the U.S. Securities and Exchange Commission.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">4.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">Recoupment</b></div><div style="margin-top:11pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:11pt;font-weight:bold;">Applicability of Policy. </b><font style="font-size:11pt;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv)&#160;during the Lookback Period. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:11pt;font-weight:bold;">Recoupment Generally. &#160;</b><font style="font-size:11pt;">Pursuant to the provisions of this Policy, if there is an </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:11pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed. &#160;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:11pt;font-weight:bold;">Impracticability of Recovery.</b><font style="font-size:11pt;"> Recoupment may be determined to be impracticable if, and only if:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:11pt;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="margin-top:11pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-size:11pt;font-weight:bold;">Sources of Recoupment.</b><font style="font-size:11pt;"> &#160;To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><i style="font-size:11pt;font-style:italic;">e.g.</i><font style="font-size:11pt;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-size:11pt;font-weight:bold;">No Indemnification of Covered Officers.</b><font style="font-size:11pt;"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-size:11pt;font-weight:bold;">Indemnification of Administrator.</b><font style="font-size:11pt;"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:11pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:11pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><b style="font-size:11pt;font-weight:bold;">No &#8220;Good Reason&#8221; for Covered Officers.</b><font style="font-size:11pt;"> &#160;Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="margin-top:11pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">5.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">Administration</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. &#160;Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">6.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">Severability</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">7.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">No Impairment of Other Remedies</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;<font style="font-style:italic;font-weight:bold;">SOX 304</font>&#8221;) that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:11pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">8.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">Amendment; Termination</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;min-width:36pt;white-space:nowrap;">9.</font><b style="font-family:'Times New Roman Bold';font-size:11pt;font-variant:small-caps;font-weight:bold;">Successors</b></div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Required Filings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;">The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">*</font></font>*<font style="display:inline-block;width:30.5pt;"></font>*<font style="display:inline-block;width:30.5pt;"></font>*<font style="display:inline-block;width:30.5pt;"></font>*</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:11pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">XOMA Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Incentive Compensation Recoupment Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 11pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Form of Executive Acknowledgment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-size:11pt;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the XOMA Corporation Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#8220;<font style="font-style:italic;font-weight:bold;">Policy</font>&#8221;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with XOMA Corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-size:11pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Agreed and Acknowledged:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-size:11pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:216pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11pt;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;">Name: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:183.93pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;">Title: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:189.42pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 11pt 0pt;">Date: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:189.43pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>xoma-20231231xex10d16002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xoma-20231231xex10d16002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  I 90# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>xoma-20231231xex10d65003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xoma-20231231xex10d65003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,> HX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-FA_^#*'_P"*H Z:BN9_X6=X._Z&S0__  90_P#Q5'_"SO!W_0V:'_X,H?\
MXJ@#IJ*YG_A9W@[_ *&S0_\ P90__%4?\+.\'?\ 0V:'_P"#*'_XJ@#IJ*YG
M_A9W@[_H;-#_ /!E#_\ %4?\+.\'?]#9H?\ X,H?_BJ .FHKF?\ A9W@[_H;
M-#_\&4/_ ,51_P +.\'?]#9H?_@RA_\ BJ .FHKF?^%G>#O^ALT/_P &4/\
M\51_PL[P=_T-FA_^#*'_ .*H Z:BN9_X6=X._P"ALT/_ ,&4/_Q5'_"SO!W_
M $-FA_\ @RA_^*H Z:BN9_X6?X.'_,VZ'_X,H?\ XJND1UD4,I#*1D$'((H
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MS_GUU/\ .U_^/T?\-;^#/^?74_SM?_C]%F%SVVBO$O\ AK?P9_SZZG^=K_\
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M_P!\"OERP_Y(M_W!'_\ 1)KZD\,?\BUI/_7I#_Z *&"-.BBBI&%%%(2%!)(
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MXS(Q\9PG>0IL;$;<#@_VQ:<U:^/'_(S_  __ .OJ\_\ 29JH11^''_)7[?\
M[ 5W_P"E%M7LL47GV4T>=N]I5SZ99J\:^''_ "5^W_[ 5W_Z46U>TV?^I;_K
MI)_Z&:3!&;X.\._\(GX;LM)^T?:OLRL/.V;-V6+=,G'7UKE=4^$TDTMRFFZP
M-.L);R._2T:U\U89ESDK\XP#GD8["O0Z*0SD_P"P?%O_ $-=M_X*5_\ CE6O
M"GA2;P[=:K<W%^+Z?4)4FD98?* 8+@\;CU//M7144 4M3M;RY^R_8[T67EW"
M239A$GG1#.Z/D_+GCYAR,4G_ #&_^W?_ -FJ]5'_ )C?_;O_ .S4 8_P]_Y
M-U_V%M3_ /2^>NFKDK/PAJ^EBYCL?$;06LMU<72Q/91N4,LSRL-W<!G./:I_
M[!\1_P#0T_\ E/C_ ,: .FHKF?[!\1_]#3_Y3X_\:/[!\1_]#3_Y3X_\: .F
MHKF?[!\1_P#0T_\ E/C_ ,:/[!\1_P#0T_\ E/C_ ,: .FHKF?[!\1_]#3_Y
M3X_\:/[!\1_]#3_Y3X_\: .FHKF?[!\1_P#0T_\ E/C_ ,:/[!\1_P#0T_\
ME/C_ ,: .FHKF?[!\1_]#3_Y3X_\:/[!\1_]#3_Y3X_\: .FKY<_:1L6F\0>
M((9C>:?/+#I=_IEREC-/%=20?:UD17C4@,AFC)5RN<CD [A[[_8/B/\ Z&G_
M ,I\?^-']@^(_P#H:?\ RGQ_XT ?/\/[9/B%(8UF^'!DF"@.\5Y>*K-CD@&Q
M) SVR?J:?_PV7KO_ $367_P.N_\ Y!KWW^P?$?\ T-/_ )3X_P#&C^P?$?\
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M_P!BZ_\ Z4BCX.QO+XY^("HI8A]&; ] 9"3^0-/H'4]XHHHJ1A1110 4444
M%%%% !1110 4444 07__ !XW'_7-OY5!#_R&[O\ Z]X?_0I:L7BE[.=5!+&-
M@ ._%0Q1N-7N9"I"-!$H;L2&DR/U'YT 7**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH @?_ (_H?^N;_P UJ>H'_P"/Z'_KF_\ -:GH ***
M* "BBB@"CH7_ "!-._Z]X_\ T$5>JCH7_($T[_KWC_\ 015Z@ HHHH ****
M"BBB@ HHHH *\B\:?\ELL?\ L7I/_2E*]=KR+QI_R6RQ_P"Q>D_]*4IH3)_A
M3_R4?Q]_URT[_P! EKU:O*?A3_R4?Q]_URT[_P! EKU:A[@@HHHI#"BBB@ H
MHHH *\3B_:Y\$W-QJ:VFF>,-1M--O)["ZU#3_"FH75K'-"Q65?-BB93M(.<&
MO;*^'OV=]-\87?A;X@MH7Q?TOP);'QEK@6SO-%M[MHV^TMF3?)*IP>N",<4
M>]7?[6_P\^U:);Z1/K/BR76=-.KV:^&=%NM19K593"TC+%&S)MD!1@P!4\'!
MXIDO[7WPWL;76GU2[UC0+W2;!M3N=,UO1+NPNS;*P5I(XYHU,@!(!V9([U\<
M?LO0^(=?^-GA_2O ^L:7X9O](\(ZQ8R:[<6#ZK::R$UH>;=1*9HB%FD?<&W$
M+M90,8Q8_:+@\0:B?B7:_&37HYO'7A_PO=OX3MM-LEM-+OK*=HUGN(F+,[S
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M#&:X+'O^\D89] *!'I=%%% '#?&__DE'B?\ Z\9?_0#7!Z+_ ,@:P_Z]X_\
MT$5WGQO_ .24>)_^O&7_ - -<'HO_(&L/^O>/_T$52V)9BZQ_P AWQ;_ ->=
MM_Z:-0KZ/KYOUG/]N>+< $_8K? )Q_S"-0KW:UN_$3R$7.EZ9$F.&BU*1SGZ
M&W7^=#&CR'XJ?\EOT[_L77_]*15SX$?\E#^(?_7/3/\ T":J?Q4_Y+?IW_8N
MO_Z4BK?P)X^(?Q#_ .N>F?\ H$U'0.I[;1114C"BBB@ HHHH **** "BBB@
MHHHH **3I1D9QGF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH JSB0WD/ELJGRWY9=W=?<4_9<_\ /:+_ +]'_P"*H?\ X_H?^N;_ ,UJ
M>@!L8<*-[!F]5&!_,TZBB@".5921Y;HH]&0M_44S9<_\]HO^_1_^*J>B@"AH
M.?[#T[/7[-'_ .@BK]4="_Y FG?]>\?_ *"*O4 %%%% !1110 4444 %%%%
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MBBB@"CH7_($T[_KWC_\ 015ZJ.A?\@33O^O>/_T$5>H **** "BBB@ HHHH
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X;XW_\ )*/$_P#UXR_^@&N#T7_D#6'_ %[Q_P#H(KO/C?\ \DH\3_\
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M*O/E2'@#G:YZ8)VUU= !1110 4444 %%%% !1110 45Y1XE\?^+O^$[UC1-
MBT2.UTV&W=I-2CF=W:56;C8P  V^E5_^$L^)?][PI_WXN?\ XY3L*YZ_17D'
M_"6?$O\ O>%/^_%S_P#'*/\ A+/B7_>\*?\ ?BY_^.46"YZ_17D'_"6?$O\
MO>%/^_%S_P#'*/\ A+/B7_>\*?\ ?BY_^.46"YZ_17D'_"6?$O\ O>%/^_%S
M_P#'*/\ A+/B7_>\*?\ ?BY_^.46"YZ_17D'_"6?$O\ O>%/^_%S_P#'*/\
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M,7_QNKU% $-G;+96D%NC,R0HL89NI &.<5-110 4444 %%%% !1110 4444
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MV_\ 31J%?1]2RD<1JO\ R#[/_KK<?^C36!%_R%KG_KA%_P"A25OZK_R#[/\
MZZW'_HTUE;0&+8&XC!..2/\ )--"%K \0_\ (R>!_P#L/1_^B)ZWZP/$/_(R
M>!_^P]'_ .B)Z8'M5%%%04%%%% !1110 4444 %%%% $%_\ \>-Q_P!<V_E4
M$/\ R&[O_KWA_P#0I:MS1":&2,G =2N?K3$M@EY+<;CNDC2,KZ;2Q_\ 9OTH
M FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E]4!T3
MQKINH 8MM4C_ +-N3Z2+ND@8^@_UR>YD0=JZBN;^(D;?\(=J%R@+26&S44"]
M6:!UF 'U\O'XUT2.LJ*Z$,C#((Z$4 .HHHH **** "BBB@#QF3_DL'C?_KAI
MW_HN2MNL23_DL'C?_KAIW_HN2MNK)"BBB@04444 %%%% !1110 4444 %85;
MM85 '+ZR,ZYXM&<?Z%;\CM_Q*-0KW:UT&^MY"TGB34[D$8V2QVH ]_EA!KPK
M6/\ D.^+?^O.V_\ 31J%?1])E(XC5?\ D'V?_76X_P#1IK!U)BENA4D'SHAD
M'L9%S7/>+_C)9:'J,6BS>'?$<M_$UQ+LBT[.^/S2!(N6!92?X@,5@V?Q73Q%
M=7D%IX<\2,UJULTD/]G$M&3(2-P4G&X*,9ZD<4(1Z36!XA_Y&3P/_P!AZ/\
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M/^%X:/\ ] 7Q+_X)9_\ "BP'HE%>=_\ "\-'_P"@+XE_\$L_^%'_  O#1_\
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M_-+ZTP-6BBBD 4444 %%%% !1110 5#=W*V=K-<."4B1I&"]2 ,\5-5'7?\
MD":C_P!>\G_H)H /[1N/^@9=_P#?47_QRIK:YDG+;[6:VQT,I0Y^FUC5*2SB
MO=:N!,I=4MXBHW$ 9:3/&?8?E5VVL8+,L84V%NO)/\Z +%17$K0Q[DA>=L_<
MC*@_^/$#]:EJ*XMX[J/RY5W)G.,D4 5O[1N/^@9=_P#?47_QRE2_G9U!TVZ0
M$X+%HL#WX>D_L2R_YX_^/M_C2IH]G&ZLL.&4Y!W'_&@"[1110!1.H3@G_B67
M1]]T7_Q=']HW'_0,N_\ OJ+_ ..4'1;-B28<D\GYV_QH_L2R_P">/_C[?XT
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M>\G_ *": )8[EFU&>W(&R.*.0'OEBX/_ *"*LU1A_P"0W=_]>\/_ *%+5Z@
MHHHH **** "BBB@ HHHH **** "JUW<M!NV@'$3R<^HQC^=6:HZE_'_U[R_^
MRT 6;:0S6T4C8#.@8X]Q4M06'_'C;_\ 7-?Y5/0 4444 %%%% !1110 4444
M %%%% !5;4+EK6!70 DRQ1_-Z,ZJ?T-6:HZS_P >D?\ U\0?^CDH EM;EIY[
MQ&  AE$:X[C8C<_BQJS5'3O^/O4_^O@?^B8ZO4 %%%% !1110 4444 %%%%
M!1110 5Y9^T7*9_A5XHM6 $:16<@(ZY:Z4'_ -!'ZUZG7E/[0O\ R3?Q7_U[
MV/\ Z5TT!U?Q$_Y!VC_]AFP_]*$KS;X _P#)4OB]_P!A-/\ T?=UZ3\1/^0=
MH_\ V&;#_P!*$KS;X _\E2^+W_833_T?=T=!'NE%%%(84444 >5?M _\@?P_
M_P!ABS_]*(JS*T_V@?\ D#^'_P#L,6?_ *415F52V)84444Q!1110!G:;XKU
MCP=XRUZ^L_#,VLVFH6UE&DB7D4.UH4=6X8YZM^E=KH7Q%\3ZXKR)X"N8X5)7
M?_:EL?FXXQD=C7-UZ!\/?^0//_UW/_H*TF-'F'Q..SXS:;&?O#PZW3IQ<"G?
M!BV:Z\>?$%$(!!TB3YO1?-8_H*9\4_\ DN&G?]BZ_P#Z4BKGP(_Y*'\0_P#K
MGIG_ *!-1T'U/;****D84444 %%%% !1110 4444 %%%% $5S&9K:6-<!G0J
M,^XJ..V9=1GN"1L>*.,#OE2Y/_H0JS10 4444 %%%% !1110 4444 %5M2MF
MO-.NK=" \L3QJ6Z D$<U9HH K1VS+J,]P2-CQ1Q@=\J7)_\ 0A7Y^>%OVP?C
M!\7Y?$FI>'?%OPV\&7^FWD\%GX \1EXM2N1'TC9I&4%V^[\I W @[.M?H/=Q
MRS6LT<,OV>9D*I+M#;&(X;!ZX/.*_/[QC\-OBCXBM]8T?XD_LS^&_BMXFDEE
M6U\;Z1J=KI?VE&R(VDVA9!M]V4X&.#\Q!GK?A[]I'XB7W[1'PB\#>(?#UIX7
M3Q+X<NM1UG2I )IH+F+[2!Y<JN1L;R48#DX;!.:Y3]MW]KOQW^S]\2]-T+PL
MNE&QN/#DNJ/]NM6E?SEED48(<?+A1Q7"^%/V7?C;\"3\&/'FG:;:_$3Q%X3L
MKW3]1\-G4UA>*VF:4QQQ3R?*VQ9F'&<$ *&6J7QY^ WQO_:M\1Z]XUU#X<Q^
M"VT[PV-'T?0I]9MKBYOIFN-S,7RJ( LDA^8K]Q0-V3A =Q\:OCG^T-\-O@I9
M_%JTU;P1)X7NM.TNZ73WL)VO ]S%"'S\P3'F.Q'/"XZFH?C%\=/VB/@=X(\+
M:MX@U[P!-)XGUBRT^SN8+.=(;..2*5I&GWD<#]V=P/ 5N#GCT#]HCX(^-?'7
M["^D?#W0]%^W>,(-,T:WDT[[5!'MD@\GS1YCN(SMV-R&P<<9JI^VM\$O&OQ1
M^%GPPT[PQX2C\77N@ZS:7VHZ1+>V]NDD,<#*Z,\KA2&)VG&[[V<$4 6OA9\0
M_BUK_P 0=$L-3^+GP;\0Z=+/FYTSP]<-)?SQ*I9Q"-Q^8 $]. ":[3]HWQY\
M7?#.K:59_#[2_#&E>'C;276K^-?&-X(]/L-N=L117#@G ^<J5^=1QR1Y=\)?
M"GBGPY\2/#]_%^QUX<\#!+I8Y?$=CXFTV2;3XG!2254C0,V$9OE7D@D=Z]#_
M &D9_BO9^(]/&@> -&^+'PRO;,P:QX5N9(8+DSABRR;YLHT?^K^7:3E6SU!
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MJ^&Q*MM=6Y9592LOS;@7'.!]UN. 3]*5\I_ KX>?$+QK^T[XB^-7C[PDO@&
MZ%'H.EZ%)J$=Y.PWJ[RN\? &58 $ _/TXR?JRF(*K7=LT^[:0,Q/'SZG&/Y5
M9HH BMHS#;11M@LB!3CV%2T44 %%%% !1110 4444 %%%% !1110 56U"V:Z
M@5$(!$L4GS>BNK']!5FB@"M:VS03WCL01-*)%QV&Q%Y_%35FBB@ HHHH ***
M* "BBB@ HHHH **** "O+/VBXC!\*O%%TQ!C>*SC '7*W2D_^A#]:]3KS']I
M7_DBGB/_ +=O_2F*F@.C^(G_ "#M'_[#-A_Z4)7FWP!_Y*E\7O\ L)I_Z/NZ
M[?XS:[%X;\,:??S07%RD6KV+>3:IOD?$RMA1D9)Q@>^*X#]FZZDU'Q[\3[Z2
MQN]/6]NX+J.&^B,4NQY;IE)7Z']#1T$>^4444AA1110!Y5^T#_R!_#__ &&+
M/_THBK,K3_:!_P"0/X?_ .PQ9_\ I1%695+8EA1113$%%%% !7H'P]_Y \__
M %W/_H*UY_7H'P]_Y \__7<_^@K28T>7_%+YOC9ISCE?^$=?G_MY%6?@=,D'
MQ!^(32-M4II:@^Y68 ?F15?XE_\ )8=-_P"Q=/\ Z4"F?"'_ )'CQ_\ ]=-%
M_P#0I*.@=3WJBBBI*"BBB@ HHHH **** "BBB@ HHHH :[K&C.QPJC)/H*03
M(TS1!OWBJ&*^@)(!_0_E4=__ ,>-Q_US;^500_\ (;N_^O>'_P!"EH O4444
M %%%% !1110 4444 %,FF2WADED;;'&I9F] .2:?5'7?^0)J/_7O)_Z": +8
MF1IFB#?O%4,5] 20#^A_*GU1A_Y#=W_U[P_^A2U>H **** "BBB@ HHHH **
M** "BBB@ IDDR19WMC"EOP'4_K3ZHZE_'_U[R_\ LM %Q'61%=3E6&0?44ZH
M+#_CQM_^N:_RJ>@ HHHH **** "BBB@ HHHH **** "F2S) H:1MJEE4'W)
M _,BGU1UG_CTC_Z^(/\ T<E %N.9)7D56RT;;6'H< X_(C\Z?5'3O^/O4_\
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M/=(&4C@@@G@TC>+M"4*6UK3P&&5)NH^1G&1SZ@_E7YY_L@A?B3X,\8>)M?\
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M !5'6?\ CTC_ .OB#_T<E7J* *.G?\?>I_\ 7P/_ $3'5ZBB@ HHHH ****
M"BBB@ HHHH **** "O*?VA?^2;^*_P#KWL?_ $KKU:O,?VE?^2*>(_\ MV_]
M*8J: Z/XB?\ (.T?_L,V'_I0E>;? '_DJ7Q>_P"PFG_H^[KTGXB?\@[1_P#L
M,V'_ *4)7FWP!_Y*E\7O^PFG_H^[HZ"/=****0PHHHH **** "BBB@ HHHH
M**** /!_BI_R6_3O^Q=?_P!*15SX$?\ )0_B'_USTS_T":JGQ,Y^,6FL>6_X
M1X\GK_Q\"D^#TC1>.?B 48J2^C+D''!:0$?D35=!=3WBBBBI&%%%% !1110
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M\0<4 7:*IV,C/=:B&8L$G"J">@\J,X'XD_G5R@ HHHH **** "BBB@ HHHH
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M /89L/\ TH2O-O@#_P E2^+W_833_P!'W=>D_$3_ )!VC_\ 89L/_2A*\V^
M/_)4OB]_V$T_]'W='01[I1112&%%%% !1110 4444 %%%% !1110!X1\43L^
M->G(/N_\(Z_'TN15OX$?\E#^(?\ USTS_P! FJG\5/\ DM^G?]BZ_P#Z4BK?
MP)('Q#^(>3C]WIG_ *!-5=!=3VVBBBI&%%%% !1110 4444 %%%% !1110 4
M4G2C(SC/- "T444 %%%% !1110 4444 %%%(2 "2< 4 +129&<9YI: "BBB@
M HHHH **** "BBB@ HHHH ***0D#O0 M%)UI: "BBB@ HHHH **** "BBB@
MHHHH ***0D#J<4 +12 @YYZ4M !1110 4444 %%%% !1110 4444 %>8_M*_
M\D4\1_\ ;M_Z4Q5Z=7F/[2AS\%?$8[_Z-Q_V\Q4UN!T?Q$_Y!VC_ /89L/\
MTH2O-O@#_P E2^+W_833_P!'W=>D_$3_ )!VC_\ 89L/_2A*\V^ /_)4OB]_
MV$T_]'W='01[I1112&%%%% !1110 4444 %%%% !1110!X1\3QO^,VFR'K_P
MCK<?6X%,^$/_ "/'C_\ ZZ:+_P"A24_XE_\ )8--_P"Q>/\ Z4"F?"'_ )'C
MQ_\ ]=-%_P#0I*KH3U/>J***DH**** "BBB@ HHHH **** "BBB@""__ ./&
MX_ZYM_*H(?\ D-W?_7O#_P"A2U/?_P#'C<?]<V_E4$/_ "&[O_KWA_\ 0I:
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MT61&1AE6&"/44@A19FE"_O&4*6]0"2!^I_.GT4 %%%% !1110 4444 %%%%
M!3)H4N(7BD4-&ZE64]P>"*?10 P0HLS2A0)&4*6]0,D#]3^=/HHH **** "B
MBB@ HHHH **** "BBB@ IDD*2YWKG*E?P/4?I3Z* &HBQHJ*,*HP!Z"G444
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M-W?_ %[P_P#H4M %ZBBB@ HHHH **** "BBB@ JMJ=P]GIMW/'C?%"[KGID
MD59JCKO_ "!-1_Z]Y/\ T$T 2QW#MJ4\!QL2&-QZY8N#_P"@BK-48?\ D-W?
M_7O#_P"A2U>H **** "BBB@ HHHH **** "BBB@ JM=W#P;MN.(7?GU&,?SJ
MS5'4OX_^O>7_ -EH LVLAFMHI&QN9 QQ[BI:@L/^/&W_ .N:_P JGH ****
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M:,,>V015BB@"NEL4OYKC<-LD21A>XVES_P"S?I5BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O,?VE?^2*>(_\ MV_]*8J].KS']I7_ )(IXC_[
M=O\ TIBIK<#4^+?_ "#O#7_8QZ9_Z4+7"_ '_DJ7Q>_[":?^C[NNZ^+?_(.\
M-?\ 8QZ9_P"E"UPOP!_Y*E\7O^PFG_H^[HZ"/=****0PHHHH **** "BBB@
MHHHH **** /!_BI_R6_3O^Q=?_TI%7/@1_R4/XA_]<],_P#0)JI_%3_DM^G?
M]BZ__I2*N? C_DH?Q#_ZYZ9_Z!-5=!=3VRBBBI&%%%% !1110 4444 %%%%
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M_10?"O\ X.K;_P"+H_X7I\-O^B@^%?\ P=6W_P 77@/_  RI\ /^AITW_O\
M:3_\CT?\,J? #_H:=-_[_:3_ /(] 'OW_"]/AM_T4'PK_P"#JV_^+H_X7I\-
MO^B@^%?_  =6W_Q=> _\,J? #_H:=-_[_:3_ /(]'_#*GP _Z&G3?^_VD_\
MR/0![]_PO3X;?]%!\*_^#JV_^+H_X7I\-O\ HH/A7_P=6W_Q=> _\,J? #_H
M:=-_[_:3_P#(]'_#*GP _P"AITW_ +_:3_\ (] 'OW_"]/AM_P!%!\*_^#JV
M_P#BZ/\ A>GPV_Z*#X5_\'5M_P#%UX#_ ,,J? #_ *&G3?\ O]I/_P CT?\
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MJ*2;2PR2M A=3O@+9#$CYB3ZG- 'U3_PO3X;?]%!\*_^#JV_^+H_X7I\-O\
MHH/A7_P=6W_Q=> _\,J? #_H:=-_[_:3_P#(]'_#*GP _P"AITW_ +_:3_\
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M>C_AE3X ?]#3IO\ W^TG_P"1Z /?O^%Z?#;_ **#X5_\'5M_\71_PO3X;?\
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M]_>NDKF8"-0^(MRXY32].6$,.F^>3>Z_4+!"?^!BNFH **** "BBB@ HHHH
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M_P!\SU\/_ /_ )1O^+O]Z^_]&)7V_P#L\QHFF1%5"EM TG) Z_+/7Q!\ _\
ME&_XN_WK[_T8E/J'0^@_V7?^3+_@E_V&+3_TY25Z3\ ?^2I?%[_L)I_Z/NZ\
MV_9=_P"3+_@E_P!ABT_].4E>D_ '_DJ7Q>_[":?^C[NA; ]SW2BBBD 4444
M%%%% !1110 4444 %%%% '@_Q4_Y+?IW_8NO_P"E(JY\"/\ DH?Q#_ZYZ9_Z
M!-5/XJ?\EOT[_L77_P#2D5<^!'_)0_B'_P!<],_] FJN@NI=^$/_ "-LW_8O
MVW_I;?5Z_7D'PA_Y&V;_ +%^V_\ 2V^KU^DQA1112 *KZA?V^EV%Q>W<JP6M
MO&TLLKG"HBC))]@!5BN1UAE\8>(4T2/]YI>G.EQJ;#[KRC#0V^>_.)''H$!X
M>@"WX#L9X-$:^O8S%J.JS-?W*-]Z,OC9&?=(Q&G_  "NCHHH **** "BBB@
MHHHH **** "BBB@ HHHH \6A_P"2L^/_ /KK8_\ I*M6/AK_ ,B%\1/^PMJ7
M_HM:KP_\E9\?_P#76Q_])5JQ\-?^1"^(G_86U+_T6M4);G1?"+_4>(O^OVT_
M]-=C7?UP'PB_U'B+_K]M/_378UW]2,**** "LSQ+K:>'-"O-09/.:%/W4(.#
M-*>(XQ[LQ51[D5IUR%O(/&?BD3J=^B:+(RQL/NW-YRK,/58AE?0NS=XQ0!L^
M%=%;P_H%G922":Y52]Q,/^6LSDO*_P#P)V8_C6M110 4444 %%%% !1110 4
M444 %%%% !1110!X=X-_Y"GC3_L8KS^:UUW[/_\ R2;1O^NMW_Z52UR/@W_D
M*>-/^QBO/YK77?L__P#))M&_ZZW?_I5+5,E'H=%%%24%%%% !1110 4444 %
M%%% !1110 4444 <IHQ&@^-=5TIOEMM37^U+0=MXPEP@_'RW^LK>E=76'XMT
M.76=.CDLF6'5K*075C,_190"-K'^ZZED;_98]\59\.Z]!XDTJ*]@5HF.4FMY
M1B2"4</&X[,IX/YC((- &G1110 4444 >0?L]_\ (+@_[ &D_P#H,]?%7[,&
MC_VU_P $_P#Q#ISW#QI?7MS!O4 F(/+$GR_J>>YK[5_9[_Y!<'_8 TG_ -!G
MKYU^*G_!/#X=?#_X<ZUJ.A^(?&=FD,D<D=@NL*+9=\Z*1L$>2 &XR<\#)-/J
M'0\,^+'PM\=_LL^"O $FE_&#7=3T>#Q+96=OHS@VMG 29)MX7S'  :,\$$?,
M37W!^S=(]UXW^)%[)<Z?<O?36MX?[-N//B3S)+IMF[ R1GT]*\P\2?\ !/'X
M<:%/X>OYM=\8ZTL&MV)%GJVKK/ ^9U4[E\L=02."#@FO4?V=K.WT_P")/Q:M
M[6".VMXM1C1(H4"(BB:[   X   &*.@'O5%%%( HHHH **** "BBB@ HHHH
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M&!U%A86^E6,%G:0I;VL"".**,85% P *6RLK?3;.&TM(4MK:%!''#$H544#
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MEJF2CT.BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O./VB/^2.^(/^W?_P!*(J]'KSC]HC_DCOB#_MW_ /2B*FMP-SXB?\@[1_\
ML,V'_I0E>;? '_DJ7Q>_[":?^C[NO2?B)_R#M'_[#-A_Z4)7FWP!_P"2I?%[
M_L)I_P"C[NCH(]THHHI#"BBB@ HHHH **** "BBB@ HHHH \'^*G_);]._[%
MU_\ TI%7/@1_R4/XA_\ 7/3/_0)JI_%3_DM^G?\ 8NO_ .E(JY\"/^2A_$/_
M *YZ9_Z!-5=!=3VRBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >+0_P#)6?'_ /UUL?\ TE6MWX$_\@OQ7_V,5Y_)*PH?^2L^/_\
MKK8_^DJUN_ G_D%^*_\ L8KS^253V$MSTRBBBI&%%%% !1110 4444 %%%%
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M!'NE%%%(84444 %%%% !1110 4444 %%%% '@_Q4_P"2WZ=_V+K_ /I2*N?
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MPTTZ>2UCG_9!\)0PN45YRVBML4XRV F3@<XH ^J^M%( %  & .@%+0 4444
M%%%% !1110!XM#_R5GQ__P!=;'_TE6MWX$_\@OQ7_P!C%>?R2L*'_DK/C_\
MZZV/_I*M;OP)_P"07XK_ .QBO/Y)5/82W/3****D84444 %%%<+\=O%FI> _
M@KX[\1Z,F_5M*T2\O+7Y=P65(696([@$ D>@H Z>]\3Z/INH16%WJUC:WTV/
M+MI[E$D?/3"DY/X5+?Z[INE2+'>ZA:V<C#<J3SJA(]0":\)^#7[-'PPUCX.>
M'[O6O"ND>,=3U_3+?4-3U[6;9+R\OYYHE=Y3.X+C)8E=K#:,8Q7Q]\-8GU+]
MKOQ+X.U#P+_PNW1/!UAJFB:/INHM:3R6]I'?0.A9[YUC<PF5H00Q?#8P *!G
MZ7CQ;H9C+C6=/**0I;[4F 3G SGV/Y&A/%FAR$A-9T]R 6.VZ0X ZGK7Q#\=
M?!VC6*_"DP?L]Z?X5DN_'$$4_A>*#2 =:1;2X*JYAD,) +N )6&.?7G3^//@
MG0[3]GOXGWR?L[:;\+KRUT*5[?6DM]'\PLSHC1HUI(\BDJS9)P, C/.""/M>
M^U.STRS:[O+N"TM% +3SR*D8!Z98G%00^(M*N-,&HQ:G9R:>3@7:7"&(\X^_
MG'7WKY;^'GA?2OC9^T5XSL?'5C;^(-*\$:)H4.@Z)J2":S3[5:&6>Z,+91Y"
MXV!R"0%QZ5Q_[:'P4\"_#CP+K^H^%DATF]UF;25NO!%C+!!I]\$U* ?:C:[>
M'^98C(,+A\,"3F@#[/3Q=H4C!5UK3F9C@ 749)/YUK5\Q>'_ (;:<VO::)_V
M2_"FC0FYB#ZBAT9S:KO&90J)N)4?-A>>..:^G: "BBB@ HHHH **** /#O!O
M_(4\:?\ 8Q7G\UKKOV?_ /DDVC?]=;O_ -*I:Y'P;_R%/&G_ &,5Y_-:Z[]G
M_P#Y)-HW_76[_P#2J6J9*/0Z***DH**** "BBB@ HHHH *SM7\1Z3X?$1U35
M++31*<1_:[A(MY]!N(S6C7RC^R9\-?"GQK^%J?$WQ]X?TWQAXS\3W=[)?SZ[
M:I>?8T2ZEB2TB24,(HXU11M4#G)/:@#ZBO-9T_3X8IKJ^MK:&7_5R33*BOQG
M@D\U5'B[0F#$:UIQ"C)(NH^!T]?<5^;OQ:T"S\#_ +7_ (<^&.C^'(_&W@:T
MU.WU>S\#3&*6.WFN+.X$MO%]I(A2,^6LOENZ@$C8.N/0?VHO!6AV?[-'C^^C
M_9XT[X8WD TP0ZBEOH_F3[M3M0T2M:2.RY'7=A2*0S[BB\6:'-(D<>LZ?)(Y
M"JBW2$L3T &:NIJ%K)9?;%N86M-I?[0) 8]HZG=TQ[U\TZ+X!T![_=+^RMI?
M@KR8I9X]?:VT%OL4D<;/'(/L\K2AMZJ 4&02#P 2/%?V>],M_BC;?L\_#SQ.
MOVKP1#X*N_$3:1*3]FU2]2\$2),G218U8R!#D9/((IB/O;3O$ND:O:3W5CJM
ME>VT&?.FM[A)$CP,G<P) X]:A_X3'0/^@WIO_@7'_C7S9^U'\"/AKX+^&_BW
MQ;HXLOA[K47A76K"*UT0V^GP:T)+";%O-"%Q/C:74* P*Y!XKDOA+\/[2Z^%
M?@R9OV3?"VN-)HMDYU29]'WWF8$/G-O7=E_O'=SSSS0,^U8I4GB22-UDC<!E
M=3D,#T(/<4^J>CV4&G:396EM91:;;00)%%90*JQVZJH C4+P%4#  XP.*N4"
M"BBB@ KSC]HC_DCOB#_MW_\ 2B*O1Z\X_:(_Y([X@_[=_P#THBIK<#<^(G_(
M.T?_ +#-A_Z4)7FWP!_Y*E\7O^PFG_H^[KTGXB?\@[1_^PS8?^E"5YM\ ?\
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M9L/_ $H2O-O@#_R5+XO?]A-/_1]W1T$>Z4444AA1110 4444 %%%% !1110
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M^"?^AQT#_P &D'_Q5 '545RO_"U_!/\ T..@?^#2#_XJC_A:_@G_ *''0/\
MP:0?_%4 =517*_\ "U_!/_0XZ!_X-(/_ (JC_A:_@G_H<= _\&D'_P 50!U5
M%<K_ ,+7\$_]#CH'_@T@_P#BJ/\ A:_@G_H<= _\&D'_ ,50!P$/_)6?'_\
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MPM?P3_T..@?^#2#_ .*H \X\&_\ (4\:?]C%>?S6NN_9_P#^23:-_P!=;O\
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MXM^'=;L8[W3CJ]_9RYV7%MH5])&V"0<,(<'!!'U!JU_PL72O^?37O_">O_\
MXQ7BVA? WXL^&M+BT[3/'MG9V,)<QPQ[]J[F+'^#N6)_&M#_ (55\9_^BC6W
M_C__ ,119 >L_P#"Q=*_Y]->_P#">O\ _P",4?\ "Q=*_P"?37O_  GK_P#^
M,5Y-_P *J^,__11K;_Q__P"(H_X55\9_^BC6W_C_ /\ $460'K/_  L72O\
MGTU[_P )Z_\ _C%'_"Q=*_Y]->_\)Z__ /C%>3?\*J^,_P#T4:V_\?\ _B*/
M^%5?&?\ Z*-;?^/_ /Q%%D!ZS_PL72O^?37O_">O_P#XQ1_PL72O^?37O_">
MO_\ XQ7DW_"JOC/_ -%&MO\ Q_\ ^(H_X55\9_\ HHUM_P"/_P#Q%%D!ZS_P
ML72O^?37O_">O_\ XQ1_PL72O^?37O\ PGK_ /\ C%>3?\*J^,__ $4:V_\
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MC_A8NE?\^FO?^$]?_P#QBO)O^%5?&?\ Z*-;?^/_ /Q%'_"JOC/_ -%&MO\
MQ_\ ^(HL@/6?^%BZ5_SZ:]_X3U__ /&*/^%BZ5_SZ:]_X3U__P#&*\F_X55\
M9_\ HHUM_P"/_P#Q%'_"JOC/_P!%&MO_ !__ .(HL@/6?^%BZ5_SZ:]_X3U_
M_P#&*S]5^,_A70FC&HS:G8&1'D07.B7T>Y5QN89AZ#<N3VR/6O-O^%5?&?\
MZ*-;?^/_ /Q%59_@A\4-3GE?5/&&EZINLI[)#=+*WE+*4W%0%'/[M>3GIT-%
MD!Z]:?%#0[^UAN;:+6KBVF19(IHM OV1U(R&!$."""#FI?\ A8NE?\^FO?\
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M /&*R=4^.G@[1)Y(=0O;^QEB19)$N-'O4**Q(4D&'@$@@'O@UYY_PJKXS_\
M11K;_P ?_P#B*R]1_9^^)&LVVLIJ7BG2-0GU**"%[BX64R*L3LRA2%  RQ['
MKVHL@/;?^%BZ5_SZ:]_X3U__ /&*/^%BZ5_SZ:]_X3U__P#&*\F_X55\9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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4J"@HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>xoma-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 3:25:01 AM-->
<!--Modified on: 3/8/2024 3:25:01 AM-->
<xsd:schema targetNamespace="http://www.xoma.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xoma="http://www.xoma.com/20231231" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" id="DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails">
        <link:definition>40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" id="DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails">
        <link:definition>40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" id="DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2">
        <link:definition>40702 - Disclosure - Leases - Maturity of lease liabilities (Details) (calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails" id="DisclosureLeaseAgreementLeaseCostsDetails">
        <link:definition>40703 - Disclosure - Lease Agreement - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" id="DisclosureLongTermDebtSummaryOfLongTermDebtDetails">
        <link:definition>40802 - Disclosure - Long-Term Debt - Summary of long-term debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" id="DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails">
        <link:definition>40803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" id="DisclosureLongTermDebtInterestExpenseDetails">
        <link:definition>40804 - Disclosure - Long-Term Debt - Interest expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" id="DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails">
        <link:definition>40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>40903 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" id="DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails">
        <link:definition>41102 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementTables" id="DisclosureLeaseAgreementTables">
        <link:definition>30703 - Disclosure - Lease Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" id="DisclosureStockBasedCompensationAndOtherBenefitPlansTables">
        <link:definition>31003 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" id="DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails">
        <link:definition>40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" id="DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails">
        <link:definition>40302 - Disclosure - Consolidated Financial Statements Details - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails">
        <link:definition>40304 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" id="DisclosureLicensingAndOtherArrangementsTakedaDetails">
        <link:definition>40401 - Disclosure - Licensing and Other Arrangements - Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" id="DisclosureLicensingAndOtherArrangementsRezoluteDetails">
        <link:definition>40402 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails" id="DisclosureLicensingAndOtherArrangementsJanssenDetails">
        <link:definition>40403 - Disclosure - Licensing and Other Arrangements - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" id="DisclosureLicensingAndOtherArrangementsObsevaDetails">
        <link:definition>40404 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" id="DisclosureLicensingAndOtherArrangementsNovartisNis793Details">
        <link:definition>40405 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" id="DisclosureLicensingAndOtherArrangementsNovartisVpm087Details">
        <link:definition>40406 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" id="DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails">
        <link:definition>40407 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails">
        <link:definition>40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails">
        <link:definition>40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails">
        <link:definition>40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails">
        <link:definition>40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails">
        <link:definition>40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails">
        <link:definition>40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails">
        <link:definition>40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails">
        <link:definition>40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails">
        <link:definition>40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails">
        <link:definition>40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails">
        <link:definition>40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" id="DisclosureFairValueMeasurementsEquitySecuritiesDetails">
        <link:definition>40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" id="DisclosureFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" id="DisclosureLeaseAgreementLeasedFacilitiesDetails">
        <link:definition>40701 - Disclosure - Lease Agreement - Leased facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails" id="DisclosureLeaseAgreementAdditionalInformationDetails">
        <link:definition>40704 - Disclosure - Lease Agreement - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtDetails" id="DisclosureLongTermDebtDetails">
        <link:definition>40801 - Disclosure - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" id="DisclosureIncomeTaxesNolDetails">
        <link:definition>40904 - Disclosure - Income Taxes - NOL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" id="DisclosureIncomeTaxesTaxCreditCarryforwardDetails">
        <link:definition>40905 - Disclosure - Income Taxes - Tax credit carryforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>40906 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails">
        <link:definition>41001 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails">
        <link:definition>41002 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails">
        <link:definition>41003 - Disclosure - Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails">
        <link:definition>41004 - Disclosure - Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails">
        <link:definition>41005 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails">
        <link:definition>41006 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails">
        <link:definition>41007 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails">
        <link:definition>41008 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails">
        <link:definition>41009 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails">
        <link:definition>41010 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails">
        <link:definition>41011 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails">
        <link:definition>41012 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails">
        <link:definition>41013 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" id="DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails">
        <link:definition>41101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" id="DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails">
        <link:definition>41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" id="DisclosureCapitalStockSeriesPreferredStockDetails">
        <link:definition>41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" id="DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails">
        <link:definition>41203 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" id="DisclosureCapitalStockDividendsDetails">
        <link:definition>41204 - Disclosure - Capital Stock - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" id="DisclosureCapitalStockBvfOwnershipDetails">
        <link:definition>41205 - Disclosure - Capital Stock - BVF Ownership (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" id="DisclosureCapitalStockAtmAgreementsDetails">
        <link:definition>41206 - Disclosure - Capital Stock - ATM Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" id="DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails">
        <link:definition>41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" id="DisclosureCapitalStockCommonStockWarrantsDetails">
        <link:definition>41208 - Disclosure - Capital Stock - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails" id="DisclosureCapitalStockWeightedAverageAssumptionsDetails">
        <link:definition>41209 - Disclosure - Capital Stock - Weighted average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" id="DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails">
        <link:definition>41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" id="DisclosureCommitmentsAndContingenciesContingentConsiderationDetails">
        <link:definition>41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails">
        <link:definition>41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails">
        <link:definition>41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41501 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails" id="DisclosureConsolidatedFinancialStatementsDetails">
        <link:definition>10301 - Disclosure - Consolidated Financial Statements Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" id="DisclosureLicensingAndOtherArrangements">
        <link:definition>10401 - Disclosure - Licensing and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements">
        <link:definition>10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10601 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreement" id="DisclosureLeaseAgreement">
        <link:definition>10701 - Disclosure - Lease Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>10801 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10901 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans" id="DisclosureStockBasedCompensationAndOtherBenefitPlans">
        <link:definition>11001 - Disclosure - Stock Based Compensation and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>11101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStock" id="DisclosureCapitalStock">
        <link:definition>11201 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11301 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformation">
        <link:definition>11401 - Disclosure - Concentration of Risk, Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11501 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables" id="DisclosureConsolidatedFinancialStatementsDetailsTables">
        <link:definition>30303 - Disclosure - Consolidated Financial Statements Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables">
        <link:definition>30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30603 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables">
        <link:definition>30803 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30903 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>31103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockTables" id="DisclosureCapitalStockTables">
        <link:definition>31203 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables">
        <link:definition>31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" id="DisclosureDescriptionOfBusinessLiquidityDetails">
        <link:definition>40101 - Disclosure - Description of Business - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" id="DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails">
        <link:definition>41303 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails">
        <link:definition>41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20231231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20231231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20231231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20231231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="AccruedAndOtherLiabilitiesCurrent" id="xoma_AccruedAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" id="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ConsolidatedFinancialStatementDetailAbstract" id="xoma_ConsolidatedFinancialStatementDetailAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndOtherArrangementsTextBlock" id="xoma_LicensingAndOtherArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndOtherArrangementsAbstract" id="xoma_LicensingAndOtherArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementTextBlock" id="xoma_RoyaltyPurchaseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" id="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognitionDeferredRevenuePolicyTextBlock" id="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquitySecuritiesPolicy" id="xoma_EquitySecuritiesPolicy" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RezoluteIncMember" id="xoma_RezoluteIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceived" id="xoma_LicenseAgreementConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromUpfrontPayment" id="xoma_ProceedsFromUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockPremium" id="xoma_CommonStockPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NovartisPharmaAGMember" id="xoma_NovartisPharmaAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="XOMA052LicenseAgreementMember" id="xoma_XOMA052LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IL1TargetLicenseAgreementMember" id="xoma_IL1TargetLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementMember" id="xoma_LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NovartisInternationalPharmaceuticalLtdMember" id="xoma_NovartisInternationalPharmaceuticalLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementTerminationPriorWrittenNoticePeriod" id="xoma_AgreementTerminationPriorWrittenNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPerformanceObligations" id="xoma_NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementTransactionPrice" id="xoma_LicenseAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" id="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PurchasedPercentageOfMilestones" id="xoma_PurchasedPercentageOfMilestones" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" id="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" id="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementMember" id="xoma_RoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgenusIncMember" id="xoma_AgenusIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SiliconValleyBankMember" id="xoma_SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NovartisNoteMember" id="xoma_NovartisNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyReceivablePercentageOnNetSales" id="xoma_RoyaltyReceivablePercentageOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisablePeriodOfWarrants" id="xoma_ExercisablePeriodOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FederalOrphanCreditMember" id="xoma_FederalOrphanCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" id="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetOperatingLossCarryforwardsExpirationYear" id="xoma_NetOperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" id="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" id="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandFifteenEmployeeStockPurchasePlanMember" id="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" id="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" id="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" id="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" id="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" id="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BiotechnologyValueFundLPMember" id="xoma_BiotechnologyValueFundLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockConversionPricePerShare" id="xoma_PreferredStockConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandEighteenAtMarketAgreementMember" id="xoma_TwoThousandEighteenAtMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TenYearWarrantsIssuedThirdRangeMember" id="xoma_TenYearWarrantsIssuedThirdRangeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractualObligationEstimatedMilestonePayments" id="xoma_ContractualObligationEstimatedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="xoma_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="xoma_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasesNumberOfLeasedFacilities" id="xoma_OperatingLeasesNumberOfLeasedFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner1Member" id="xoma_Partner1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner2Member" id="xoma_Partner2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner3Member" id="xoma_Partner3Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfMajorPartners" id="xoma_NumberOfMajorPartners" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BioasisTechnologiesIncMember" id="xoma_BioasisTechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementAndCommonStockPurchaseAgreementMember" id="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasePaymentsNonCash" id="xoma_OperatingLeasePaymentsNonCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfDecreaseInFutureRoyaltyObligations" id="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfRoyaltyOnNetSalesUponCommercialization" id="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AronoraIncMember" id="xoma_AronoraIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PalobiofarmaSLMember" id="xoma_PalobiofarmaSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BayerProductsMember" id="xoma_BayerProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonBayerProductsMember" id="xoma_NonBayerProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangesInEstimatedFairValueOfContingentConsideration" id="xoma_ChangesInEstimatedFairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MilestonesPaymentsToAggregateAmountOfPerProduct" id="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ContingentConsiderationFairValueDisclosure" id="xoma_ContingentConsiderationFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementConsiderationReceivedDebtRepayment" id="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueNewIssuesCommonStock" id="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" id="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ArrangementsNumber" id="xoma_ArrangementsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesPeriodMinimum" id="xoma_RoyaltiesPeriodMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementRz358Member" id="xoma_LicenseAgreementRz358Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyInterestAcquisitionAgreementsMember" id="xoma_RoyaltyInterestAcquisitionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FirstRoyaltyInterestAcquisitionAgreementMember" id="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecondRoyaltyInterestAcquisitionAgreementMember" id="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HealthCareRoyaltyPartnersTwoLimitedPartnersMember" id="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePeriodsNumber" id="xoma_MilestonePeriodsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IncyteImmunoOncologyAssetsMember" id="xoma_IncyteImmunoOncologyAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MerckImmunoOncologyProductMember" id="xoma_MerckImmunoOncologyProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementDrugCandidatesNumber" id="xoma_AgreementDrugCandidatesNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" id="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EmployeeMember" id="xoma_EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeUnderAgeFiftyMember" id="xoma_EmployeeUnderAgeFiftyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAgeFiftyOrOverMember" id="xoma_EmployeeAgeFiftyOrOverMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeasedFacilitiesEmeryvilleCaliforniaMember" id="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantExercisePrice14.71Member" id="xoma_CommonStockWarrantExercisePrice14.71Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="XomaCorporationMember" id="xoma_XomaCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" id="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" id="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="JanssenBiotechInc.Member" id="xoma_JanssenBiotechInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementDrugCandidatesExclusiveLicenseOptionNumber" id="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EmployeeTerminatedMember" id="xoma_EmployeeTerminatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentFutureCashPaymentsPerProduct" id="xoma_ContingentFutureCashPaymentsPerProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AgreementPaymentPercentageFactor" id="xoma_AgreementPaymentPercentageFactor" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseDisclosureTextBlock" id="xoma_LeaseDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementNonRz358ProductsMember" id="xoma_LicenseAgreementNonRz358ProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementMember" id="xoma_CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" id="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAchieved" id="xoma_MilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOrSaleOfEquityNet" id="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockDividendPeriodYearProrated" id="xoma_PreferredStockDividendPeriodYearProrated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockDividendPeriodMonth" id="xoma_PreferredStockDividendPeriodMonth" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockDividendPeriodProratedMonthsInYear" id="xoma_PreferredStockDividendPeriodProratedMonthsInYear" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockRedemptionPricePerShareOptionalRedemption" id="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PreferredStockShareCap" id="xoma_PreferredStockShareCap" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" id="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" id="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TaxCreditCarryForwardExpirationYear" id="xoma_TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryForwardSubjectToExpiration" id="xoma_OperatingLossCarryForwardSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PreferredStockConvertibleThresholdConsecutiveTradingDays" id="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherAntibodiesMember" id="xoma_OtherAntibodiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesPeriodMinimumScenarioOne" id="xoma_RoyaltiesPeriodMinimumScenarioOne" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ViractaTherapeuticsInc.Member" id="xoma_ViractaTherapeuticsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedPreferredStockDividendCurrent" id="xoma_AccruedPreferredStockDividendCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ProceedsFromIssuanceOfPreferredStockNet" id="xoma_ProceedsFromIssuanceOfPreferredStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DepositarySharesRatioToPreferredStock" id="xoma_DepositarySharesRatioToPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MilestonesReceivableExcludingConsiderationRetainedMaximum" id="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MaximumConsiderationRetained" id="xoma_MaximumConsiderationRetained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RegulatoryAndCommercialMilestonesReceivableMaximum" id="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PreferredStockDividendAmountPerShare" id="xoma_PreferredStockDividendAmountPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" id="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementInstallmentPaymentsReceived" id="xoma_LicenseAgreementInstallmentPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" id="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementSharesReceived" id="xoma_LicenseAgreementSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AtMarketIssuanceSalesAgreement2021Member" id="xoma_AtMarketIssuanceSalesAgreement2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumValueOfStockToBeIssued" id="xoma_MaximumValueOfStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TakedaPharmaceuticalCompanyLimitedMember" id="xoma_TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesXAndSeriesYConvertiblePreferredStockMember" id="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesXConvertiblePreferredStockMember" id="xoma_SeriesXConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesYConvertiblePreferredStockMember" id="xoma_SeriesYConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialPaymentPurchaseAgreementMember" id="xoma_CommercialPaymentPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialSalesReceivablePercentageOnNetSales" id="xoma_CommercialSalesReceivablePercentageOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AffitechResearchAsMember" id="xoma_AffitechResearchAsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" id="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialPaymentReceivableTerm" id="xoma_CommercialPaymentReceivableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPayableOnSalesMilestone" id="xoma_MaximumPayableOnSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfGrossProceedsPaidToAgentForSaleOfShares" id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedSalariesAndEmployeeBenefitsCurrent" id="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ContingentConsiderationUnderPurchaseAgreements" id="xoma_ContingentConsiderationUnderPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LongTermRightsReceivableNonCurrent" id="xoma_LongTermRightsReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ContingentConsiderationRegulatoryMilestonesMember" id="xoma_ContingentConsiderationRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" id="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RightsReceivableCurrent" id="xoma_RightsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MilestonePaymentReceivedCounterparty" id="xoma_MilestonePaymentReceivedCounterparty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentReceivablePercentage" id="xoma_MilestonePaymentReceivablePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner4Member" id="xoma_Partner4Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermRightsReceivableReclassification" id="xoma_LongTermRightsReceivableReclassification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FinancialAssetsFairValueDisclosure" id="xoma_FinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ShortTermRightsReceivableReclassification" id="xoma_ShortTermRightsReceivableReclassification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" id="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" id="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" id="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FaricimabProductMember" id="xoma_FaricimabProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FaricimabSvoaVabysmoProductMember" id="xoma_FaricimabSvoaVabysmoProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPeriodsCashRetentionBonus" id="xoma_NumberOfPeriodsCashRetentionBonus" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PeriodOneRetentionBonusEligibility" id="xoma_PeriodOneRetentionBonusEligibility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodTwoRetentionBonusEligibility" id="xoma_PeriodTwoRetentionBonusEligibility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmploymentPeriodRetirementEligible" id="xoma_EmploymentPeriodRetirementEligible" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" id="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentEmployeesExcludingChiefExecutiveOfficerMember" id="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndCommercialRightsAcquiredNonCurrent" id="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ObsevaIntellectualPropertyRightsMember" id="xoma_ObsevaIntellectualPropertyRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OrganonMember" id="xoma_OrganonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" id="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CompensationExpenseEmploymentAgreement" id="xoma_CompensationExpenseEmploymentAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AccruedCompensationContinuityIncentive" id="xoma_AccruedCompensationContinuityIncentive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ChiefExecutiveOfficerRetiredMember" id="xoma_ChiefExecutiveOfficerRetiredMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefExecutiveOfficerInterimMember" id="xoma_ChiefExecutiveOfficerInterimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefInvestmentOfficerMember" id="xoma_ChiefInvestmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmploymentAgreementAnnualSalary" id="xoma_EmploymentAgreementAnnualSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentArrangementNumberOfAwardsGrants" id="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RetentionBonusExpenseAccrued" id="xoma_RetentionBonusExpenseAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AccruedTransactionCostsRelatedToPurchaseAgreements" id="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfArbitrationProceedingsInitiated" id="xoma_NumberOfArbitrationProceedingsInitiated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumEarnOutPayments" id="xoma_MaximumEarnOutPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" id="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumEarnOutPaymentsSalesBasedMilestonePayments" id="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AssetAcquisitionsPolicyPolicyTextBlock" id="xoma_AssetAcquisitionsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AptevoMember" id="xoma_AptevoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" id="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionInducementAwardsMember" id="xoma_StockOptionInducementAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CreditLossContractWithCustomerAssetPolicyTextBlock" id="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedRetentionBonus" id="xoma_AccruedRetentionBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockOptionInducementAwardOneMember" id="xoma_StockOptionInducementAwardOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionInducementAwardTwoMember" id="xoma_StockOptionInducementAwardTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" id="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MilestonesReceivableMaximum" id="xoma_MilestonesReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CommercialPaymentThresholdOneTimePayment" id="xoma_CommercialPaymentThresholdOneTimePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LadrxMember" id="xoma_LadrxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArimoclomolMember" id="xoma_ArimoclomolMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="StockPriceHurdlesOfDollar30Member" id="xoma_StockPriceHurdlesOfDollar30Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPriceHurdlesOfDollar35Member" id="xoma_StockPriceHurdlesOfDollar35Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPriceHurdlesOfDollar40Member" id="xoma_StockPriceHurdlesOfDollar40Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPriceHurdlesOfDollar45Member" id="xoma_StockPriceHurdlesOfDollar45Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" id="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentOfConsiderationUnderAgreementsInvestingActivities" id="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReceiptsUnderAgreementsInvestingActivities" id="xoma_ReceiptsUnderAgreementsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LeasedFacilitiesTwoEmeryvilleCaliforniaMember" id="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PerformanceStockUnitsMember" id="xoma_PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" id="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" id="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AldoxorubicinMember" id="xoma_AldoxorubicinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Tak079AndTak169Member" id="xoma_Tak079AndTak169Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AgreementsNumber" id="xoma_AgreementsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccrualOfContingentConsiderationUnderPurchaseAgreements" id="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" id="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" id="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" id="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfEarningsPerShareTable" id="xoma_ScheduleOfEarningsPerShareTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarningsPerShareLineItems" id="xoma_EarningsPerShareLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" id="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsPolicyTextBlock" id="xoma_WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" id="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BlueOwlCommercialPaymentBackedLoanAgreementMember" id="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" id="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" id="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" id="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecurityInterestInPercentageOfEquity" id="xoma_SecurityInterestInPercentageOfEquity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" id="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TalpheraMember" id="xoma_TalpheraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AloraPharmaceuticalsMember" id="xoma_AloraPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedCashAdditionalToBeFunded" id="xoma_RestrictedCashAdditionalToBeFunded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" id="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" id="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" id="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashReserveAccountsInterestAndAdministrativeFeesMember" id="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashReserveAccountsOperatingExpensesMember" id="xoma_CashReserveAccountsOperatingExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentsOfFinancingCostsFeesAndLenderExpenses" id="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromIssuanceOfLongTermDebtNet" id="xoma_ProceedsFromIssuanceOfLongTermDebtNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" id="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" id="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="U.s.DepartmentOfDefenseMember" id="xoma_U.s.DepartmentOfDefenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AllCustomersExcludingU.s.DepartmentOfDefenseMember" id="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" id="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RoyaltyAndMilestonesReceivableThreshold" id="xoma_RoyaltyAndMilestonesReceivableThreshold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" id="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" id="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsRoyaltyReceivable" id="xoma_DeferredTaxAssetsRoyaltyReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="KinnateMember" id="xoma_KinnateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentToAcquireBusinessPricePerShareBaseCashAmount" id="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" id="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumAdditionalPayableOnSalesMilestone" id="xoma_MaximumAdditionalPayableOnSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AwardDateMay2023ToOctober2023Member" id="xoma_AwardDateMay2023ToOctober2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AcquisitionOfEconomicInterestAgreementMember" id="xoma_AcquisitionOfEconomicInterestAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestoneMember" id="xoma_MilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentToAcquireBusinessPricePerShareCashAmount" id="xoma_PaymentToAcquireBusinessPricePerShareCashAmount" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockParOrStatedValuePerShareAcquiree" id="xoma_CommonStockParOrStatedValuePerShareAcquiree" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" id="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" id="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AcquisitionNumberOfContingentValueRights" id="xoma_AcquisitionNumberOfContingentValueRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AcquisitionValueRightNumberOfCashPayments" id="xoma_AcquisitionValueRightNumberOfCashPayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IssuanceOfWarrantsDebtFinancing" id="xoma_IssuanceOfWarrantsDebtFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClassOfWarrantOrRightFairValueOfWarrantsOrRights" id="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CommercialPaymentPeriodDue" id="xoma_CommercialPaymentPeriodDue" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LongTermRightsReceivableNonCurrentCreditLossExpense" id="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" id="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" type="enum2:enumerationSetItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" enum2:linkrole="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" enum2:domain="us-gaap:IncomeStatementAbstract" enum2:headUsable="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>xoma-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 3:25:01 AM-->
<!--Modified on: 3/8/2024 3:25:01 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" roleURI="http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtSummaryOfLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtInterestExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638454650950927331" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638454650950927331" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650950927331" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638454650950927331" xlink:to="us-gaap_RestrictedCashCurrent_638454650950927331" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638454650950927331" xlink:to="us-gaap_EquitySecuritiesFvNi_638454650950927331" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638454650950927331" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638454650950927331" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638454650950927331" xlink:to="xoma_RightsReceivableCurrent_638454650950927331" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638454650950927331" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638454650950927331" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638454650950927331" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638454650950937318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638454650950937318" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638454650950937318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638454650950937318" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650950937318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650950937318" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638454650950937318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638454650950937318" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638454650950937318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638454650950937318" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638454650950937318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638454650950937318" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638454650950947312" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638454650950947312" xlink:to="us-gaap_LiabilitiesCurrent_638454650950947312" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="us-gaap_AccountsPayableCurrent_638454650950947312" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638454650950947312" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650950947312" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638454650950947312" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638454650950947312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="us-gaap_DeferredIncomeCurrent_638454650950947312" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638454650950957309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="us-gaap_LongTermDebtCurrent_638454650950957309" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent_638454650950957309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638454650950947312" xlink:to="xoma_AccruedPreferredStockDividendCurrent_638454650950957309" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638454650950957309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638454650950947312" xlink:to="us-gaap_DeferredIncomeNoncurrent_638454650950957309" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638454650950957309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638454650950947312" xlink:to="us-gaap_LongTermDebtNoncurrent_638454650950957309" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650950957309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638454650950947312" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650950957309" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638454650950957309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638454650950957309" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638454650950967308" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638454650950967308" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638454650950967308" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638454650950967308" xlink:to="us-gaap_PreferredStockValue_638454650950967308" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638454650950967308" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638454650950967308" xlink:to="us-gaap_CommonStockValue_638454650950967308" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638454650950967308" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638454650950967308" xlink:to="us-gaap_AdditionalPaidInCapital_638454650950967308" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638454650950967308" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638454650950967308" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638454650950967308" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_1" xlink:to="us-gaap_NetIncomeLoss_638454650950977310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638454650950977310" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650950977310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650950977310" xlink:to="us-gaap_OperatingIncomeLoss_638454650950977310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638454650950977310" xlink:to="us-gaap_Revenues_638454650950977310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638454650950977310" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650950977310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638454650950977310" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638454650950977310" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638454650950977310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638454650950977310" xlink:to="us-gaap_OperatingExpenses_638454650950977310" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638454650950977310" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638454650950987311" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638454650950977310" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638454650950987311" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638454650950977310" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650950987311" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638454650950977310" xlink:to="us-gaap_LitigationSettlementExpense_638454650950987311" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638454650950977310" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638454650950987311" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650950977310" xlink:to="us-gaap_InterestExpenseDebt_638454650950987311" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638454650950987311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650950977310" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638454650950987311" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638454650950977310" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638454650950997310" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_ProfitLoss_638454650950997310" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_ShareBasedCompensation_638454650950997310" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650950997310" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650950997310" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638454650950997310" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638454650950997310" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_DepreciationNonproduction_638454650951007318" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650951007318" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="xoma_OperatingLeasePaymentsNonCash_638454650951007318" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638454650951007318" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638454650951007318" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638454650951007318" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638454650951007318" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638454650951007318" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638454650951017314" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638454650951017314" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638454650951017314" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650950997310" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638454650951017314" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650951017314" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650951017314" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650951017314" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650951017314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650951017314" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650951017314" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638454650951027306" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650951017314" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638454650951027306" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638454650951027306" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650951017314" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638454650951027306" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638454650951027306" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638454650951027306" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638454650951027306" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_PaymentsOfFinancingCosts_638454650951027306" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650951027306" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650951027306" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_638454650951037313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_PaymentsOfDividends_638454650951037313" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638454650951037313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638454650951037313" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638454650951037313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638454650951037313" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638454650951037313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650951027306" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638454650951037313" order="7" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650951047314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650951047314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638454650951047314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash_638454650951047314" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="AccruedAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638454650951047314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_638454650951047314" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638454650951047314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638454650951047314" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638454650951047314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638454650951047314" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638454650951047314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638454650951047314" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="FinancialAssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinancialAssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638454650951057320" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinancialAssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638454650951057320" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638454650951057320" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638454650951057320" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638454650951057320" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638454650951057320" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638454650951057320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638454650951057320" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638454650951067312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638454650951067312" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Maturity of lease liabilities (Details) (calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638454650951067312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638454650951067312" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638454650951067312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638454650951067312" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Lease Agreement - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638454650951067312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638454650951067312" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638454650951067312" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638454650951067312" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Long-Term Debt - Summary of long-term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638454650951077319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638454650951077319" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638454650951077319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638454650951077319" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638454650951077319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638454650951077319" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638454650951077319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638454650951077319" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638454650951077319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638454650951077319" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638454650951077319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638454650951077319" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638454650951087313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638454650951087313" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638454650951087313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638454650951087313" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Long-Term Debt - Interest expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638454650951087313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638454650951087313" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650951087313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650951087313" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638454650951087313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638454650951087313" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638454650951097311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638454650951097311" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638454650951097311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638454650951097311" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638454650951097311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638454650951097311" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638454650951097311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638454650951097311" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638454650951097311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638454650951097311" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638454650951097311" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638454650951097311" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638454650951107313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638454650951107313" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638454650951107313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638454650951107313" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638454650951107313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638454650951107313" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638454650951107313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638454650951107313" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DeferredTaxAssetsRoyaltyReceivable" xlink:label="xoma_DeferredTaxAssetsRoyaltyReceivable_638454650951107313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="xoma_DeferredTaxAssetsRoyaltyReceivable_638454650951107313" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638454650951107313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638454650951097311" xlink:to="us-gaap_DeferredTaxAssetsOther_638454650951107313" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638454650951117330" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638454650951117330" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650951117330" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650951117330" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638454650951117330" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650951117330" xlink:to="us-gaap_NetIncomeLoss_638454650951117330" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638454650951117330" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650951117330" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638454650951117330" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638454650951117330" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638454650951117330" order="1" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>xoma-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 3:25:01 AM-->
<!--Modified on: 3/8/2024 3:25:01 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansTables" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsTakedaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsJanssenDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsObsevaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsNovartisNis793Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtSummaryOfLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtInterestExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesNolDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesTaxCreditCarryforwardDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockSeriesPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockDividendsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockBvfOwnershipDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockWeightedAverageAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="RestrictedCashCurrent" xlink:title="definition: AssetsAbstract to RestrictedCashCurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="RestrictedCashNoncurrent" xlink:title="definition: AssetsAbstract to RestrictedCashNoncurrent" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:title="us-gaap_AssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:AssetsAbstract To us-gaap_AssetImpairmentCharges" order="10" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_1" xlink:title="us-gaap_AssetImpairmentCharges_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_AssetImpairmentCharges_1" order="66" priority="0" />
    <link:loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:title="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" order="67" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="DividendsAxis" xlink:title="DividendsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="DividendsDomain" xlink:title="DividendsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DividendsAxis" xlink:to="DividendsDomain" xlink:title="definition: DividendsAxis to DividendsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:title="EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:title="EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:title="definition: EquityMethodInvestmentNonconsolidatedInvesteeAxis to EquityMethodInvestmentNonconsolidatedInvesteeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="PortionAtFairValueFairValueDisclosureMember" xlink:title="PortionAtFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="PortionAtFairValueFairValueDisclosureMember" xlink:title="definition: FairValueByMeasurementBasisAxis to PortionAtFairValueFairValueDisclosureMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" xlink:title="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1" xlink:to="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" xlink:title="definition:us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1 To us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_AccruedPreferredStockDividendCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:to="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_DividendsPreferredStockStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_StockOptionInducementAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xlink:to="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsOperatingExpensesMember" xlink:label="xoma_CashReserveAccountsOperatingExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xlink:to="xoma_CashReserveAccountsOperatingExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RestrictedCashAdditionalToBeFunded" xlink:label="xoma_RestrictedCashAdditionalToBeFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="xoma_RestrictedCashAdditionalToBeFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_OrganonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Details - Intangible Assets, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_OrganonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - Takeda (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Tak079AndTak169Member" xlink:label="xoma_Tak079AndTak169Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_Tak079AndTak169Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_OtherAntibodiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneMember" xlink:label="xoma_MilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimumScenarioOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementRz358Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementSharesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Janssen (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_JanssenBiotechInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_OrganonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisPharmaAGMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommonStockPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementsNumber" xlink:label="xoma_AgreementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ArrangementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementsNumber" xlink:label="xoma_AgreementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePeriodsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ArimoclomolMember" xlink:label="xoma_ArimoclomolMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_ArimoclomolMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AldoxorubicinMember" xlink:label="xoma_AldoxorubicinMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_AldoxorubicinMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesReceivableMaximum" xlink:label="xoma_MilestonesReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentThresholdOneTimePayment" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialPaymentThresholdOneTimePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_IncyteImmunoOncologyAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MerckImmunoOncologyProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestoneAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_BayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_NonBayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementPaymentPercentageFactor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_PalobiofarmaSLMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumConsiderationRetained" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestoneAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePaymentReceivedCounterparty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePaymentReceivablePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xlink:type="extended" xlink:title="40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FaricimabProductMember" xlink:label="xoma_FaricimabProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_FaricimabProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_FaricimabSvoaVabysmoProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPeriodDue" xlink:label="xoma_CommercialPaymentPeriodDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialPaymentPeriodDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialPaymentReceivableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumAdditionalPayableOnSalesMilestone" xlink:label="xoma_MaximumAdditionalPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumAdditionalPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xlink:type="extended" xlink:title="40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ShortTermRightsReceivableReclassification" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableReclassification" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="xoma_FinancialAssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="xoma_ContingentConsiderationFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreement - Leased facilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Long-Term Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SecurityInterestInPercentageOfEquity" xlink:label="xoma_SecurityInterestInPercentageOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_SecurityInterestInPercentageOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOfLongTermDebtNet" xlink:label="xoma_ProceedsFromIssuanceOfLongTermDebtNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_ProceedsFromIssuanceOfLongTermDebtNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" xlink:label="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" xlink:label="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" xlink:label="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Long-Term Debt - Summary of long-term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Long-Term Debt - Interest expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Income Taxes - NOL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_OperatingLossCarryForwardSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_NetOperatingLossCarryforwardsExpirationYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Income Taxes - Tax credit carryforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FederalOrphanCreditMember" xlink:label="xoma_FederalOrphanCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="xoma_FederalOrphanCreditMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TaxCreditCarryForwardExpirationYear" xlink:label="xoma_TaxCreditCarryForwardExpirationYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_TaxCreditCarryForwardExpirationYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeUnderAgeFiftyMember" xlink:label="xoma_EmployeeUnderAgeFiftyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeUnderAgeFiftyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeAgeFiftyOrOverMember" xlink:label="xoma_EmployeeAgeFiftyOrOverMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeAgeFiftyOrOverMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeTerminatedMember" xlink:label="xoma_EmployeeTerminatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeTerminatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_StockOptionInducementAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefExecutiveOfficerInterimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefInvestmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar30Member" xlink:label="xoma_StockPriceHurdlesOfDollar30Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar30Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar35Member" xlink:label="xoma_StockPriceHurdlesOfDollar35Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar35Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar40Member" xlink:label="xoma_StockPriceHurdlesOfDollar40Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar40Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar45Member" xlink:label="xoma_StockPriceHurdlesOfDollar45Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar45Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AwardDateMay2023ToOctober2023Member" xlink:label="xoma_AwardDateMay2023ToOctober2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="xoma_AwardDateMay2023ToOctober2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xlink:type="extended" xlink:title="41011 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentPeriodRetirementEligible" xlink:label="xoma_EmploymentPeriodRetirementEligible" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="xoma_EmploymentPeriodRetirementEligible" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="41012 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_PeriodOneRetentionBonusEligibility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_PeriodTwoRetentionBonusEligibility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_RetentionBonusExpenseAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedRetentionBonus" xlink:label="xoma_AccruedRetentionBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_AccruedRetentionBonus" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xlink:type="extended" xlink:title="41013 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_AccruedCompensationContinuityIncentive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_CompensationExpenseEmploymentAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfEarningsPerShareTable" xlink:label="xoma_ScheduleOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="xoma_ScheduleOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EarningsPerShareLineItems" xlink:label="xoma_EarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="xoma_EarningsPerShareLineItems" xlink:to="xoma_ScheduleOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_EarningsPerShareLineItems" xlink:to="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_EarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesXConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesYConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockConversionPricePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodYearProrated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockShareCap" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_DepositarySharesRatioToPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_ProceedsFromIssuanceOfPreferredStockNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendAmountPerShare" xlink:label="xoma_PreferredStockDividendAmountPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendAmountPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodYearProrated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockShareCap" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Capital Stock - Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Capital Stock - BVF Ownership (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_BiotechnologyValueFundLPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="xoma_XomaCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Capital Stock - ATM Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_MaximumValueOfStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xlink:type="extended" xlink:title="41208 - Disclosure - Capital Stock - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="xoma_ExercisablePeriodOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="41209 - Disclosure - Capital Stock - Weighted average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner4Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xoma_NumberOfMajorPartners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaPacificMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionOfEconomicInterestAgreementMember" xlink:label="xoma_AcquisitionOfEconomicInterestAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_AcquisitionOfEconomicInterestAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TalpheraMember" xlink:label="xoma_TalpheraMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_TalpheraMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AloraPharmaceuticalsMember" xlink:label="xoma_AloraPharmaceuticalsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AloraPharmaceuticalsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_TalpheraMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" xlink:label="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_U.s.DepartmentOfDefenseMember" xlink:label="xoma_U.s.DepartmentOfDefenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_U.s.DepartmentOfDefenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KinnateMember" xlink:label="xoma_KinnateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="xoma_KinnateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="10" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentAgreementAnnualSalary" xlink:label="xoma_EmploymentAgreementAnnualSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementAnnualSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" xlink:label="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndMilestonesReceivableThreshold" xlink:label="xoma_RoyaltyAndMilestonesReceivableThreshold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_RoyaltyAndMilestonesReceivableThreshold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareCashAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareCashAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockParOrStatedValuePerShareAcquiree" xlink:label="xoma_CommonStockParOrStatedValuePerShareAcquiree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_CommonStockParOrStatedValuePerShareAcquiree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionNumberOfContingentValueRights" xlink:label="xoma_AcquisitionNumberOfContingentValueRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_AcquisitionNumberOfContingentValueRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionValueRightNumberOfCashPayments" xlink:label="xoma_AcquisitionValueRightNumberOfCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_AcquisitionValueRightNumberOfCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>xoma-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 3:25:01 AM-->
<!--Modified on: 3/8/2024 3:25:01 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Class Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.625% Series A Cumulative, Perpetual Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Depositary Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation State Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address City Or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security12b Title</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.375% Series B Cumulative, Perpetual Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RightsReceivableCurrent" xlink:to="xoma_RightsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rights Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty receivable, Balance as of end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty receivable, Balance as of beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty and commercial payment receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNonCurrent" xlink:to="xoma_LongTermRightsReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty receivable, Balance as of end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty receivable, Balance as of beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty and commercial payment receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets - long term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued And Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Under Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under RPAs, AAAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method, current</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedPreferredStockDividendCurrent" xlink:to="xoma_AccruedPreferredStockDividendCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Preferred Stock Dividend, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend accrual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current portion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method - long-term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies (Note 13)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,495,492 and 11,454,025 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, dividend rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Not from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent. Also includes the amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Non-Current, Credit Loss Expense and Impairment of Intangible Assets, Finite-Lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charges (Note 4, Note 5)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Settlement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arbitration settlement costs (Note 3)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arbitration settlement costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Benefit) provision for income taxes, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share attributable to common stockholders (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share attributable to common stockholders (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing basic net loss per share attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing diluted net loss per share attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Stockholders Equity Roll Forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:to="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Benefit Plan and Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to 401(k) contribution and ESPP</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:to="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Benefit Plan and Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to 401(k) contribution and ESPP (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Preferred Stock, Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated fair value of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes In Estimated Fair Value Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined contribution plan issuance of Common stock for services or claims.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Issuance Of Common Stock For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock contribution to 401(k)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Of Financing Costs And Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of debt discount and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasePaymentsNonCash" xlink:to="xoma_OperatingLeasePaymentsNonCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease payments, non cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments Non Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of equity securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) recognized due to change in fair value of investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Consideration Under Agreements, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of consideration under RPAs, AAAs and CPPAs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of consideration under RPAs, AAAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts Under Agreements, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts under RPAs, AAAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for IP acquired under the ObsEva IP Acquisition Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs and loan fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options and other share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of preferred and common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted and restricted cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrestricted and restricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IssuanceOfWarrantsDebtFinancing" xlink:label="xoma_IssuanceOfWarrantsDebtFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IssuanceOfWarrantsDebtFinancing" xlink:to="xoma_IssuanceOfWarrantsDebtFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IssuanceOfWarrantsDebtFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock warrants issued in connection with long-term debt financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IssuanceOfWarrantsDebtFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Warrants, Debt Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IssuanceOfWarrantsDebtFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock warrants in connection with long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued issuance costs in connection with issuance of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend accrual</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of contingent consideration under asset acquisition agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value Of Contingent Consideration Under Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of contingent consideration under the LadRx Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xlink:to="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued transaction costs in connection with acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Transaction Costs Related To Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued transaction costs in connection with ObsEva IP Acquisition</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements" xlink:to="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual of contingent consideration under purchase agreements.  May include royalty purchase agreements and commercial payment purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual Of Contingent Consideration Under Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual of contingent consideration under the Affitech CPPA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated financial statement detail.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Financial Statement Details</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Financial Statement Details</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsTextBlock" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing And Other Arrangements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementTextBlock" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeaseDisclosureTextBlock" xlink:to="xoma_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation and Other Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation and Other Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risk segment and geographic information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk, Segment and Geographic Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk, Segment and Geographic Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted and Restricted Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for sale of future revenue streams.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition Deferred Revenue Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Future Revenue Streams</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesPolicy" xlink:to="xoma_EquitySecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:to="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Policy for future milestones, royalties purchase rights and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xlink:to="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Loss, Contract With Customer Asset [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Current Expected Credit Losses</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:to="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for asset acquisitions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leases Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_WarrantsPolicyTextBlock" xlink:label="xoma_WarrantsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_WarrantsPolicyTextBlock" xlink:to="xoma_WarrantsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive (Loss) Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unrestricted and restricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost, accumulated amortization, impairment charge and net carrying value of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:to="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the changes in royalty and commercial payment receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of royalty and commercial payment receivable activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Maturity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturity/ undiscounted future rent payments associated with the new lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost components of operating leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental cash flows information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of supplemental cash flow information related to operating leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Supplemental Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of present value assumptions used in calculating the present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of projected future principal payments of initial term loan</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" xlink:label="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" xlink:to="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of accretion of debt discounts and issuance costs included in interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accretion of Debt Discounts and Issuance Costs Included in Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Provision for Income Taxes (All Current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Net Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Long Term Incentive and Share Award Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Ten Long Term Incentive And Stock Award Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Plan</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionInducementAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Stock Option Inducement Awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionInducementAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockOptionInducementAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Awards</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionInducementAwardOneMember" xlink:to="xoma_StockOptionInducementAwardOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionInducementAwardOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to first Stock Option Inducement Award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionInducementAwardOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Award, One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockOptionInducementAwardOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Award, Exercise price of $18.66 per share</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionInducementAwardTwoMember" xlink:to="xoma_StockOptionInducementAwardTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionInducementAwardTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to second Stock Option Inducement Award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionInducementAwardTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Award, Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockOptionInducementAwardTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Award, Exercise price of $30.00 per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Unit Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of valuation assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of grant date fair values of PSUs granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of performance shares, outstanding activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding securities considered anti-dilutive</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="us-gaap_DividendsDeclaredTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDeclaredTableTextBlock" xlink:to="us-gaap_DividendsDeclaredTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Declared [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of declared and paid cash dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Common Stock Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions used to calculate fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Revenue From External Customers Attributed To Foreign Countries By Geographic Area [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue by Geographical Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern, within One Year [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern, within One Year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xlink:to="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cash reserve accounts for interest and administrative fees and to cover operating expenses of subsidiary, established in conjunction with the funding of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Reserve Accounts, Interest and Administrative Fees and Operating Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash reserve accounts</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" xlink:to="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cash reserve accounts for interest and administrative fees, established in conjunction with the funding of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Reserve Accounts, Interest and Administrative Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash reserve account, Interest and administrative fees</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsOperatingExpensesMember" xlink:label="xoma_CashReserveAccountsOperatingExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CashReserveAccountsOperatingExpensesMember" xlink:to="xoma_CashReserveAccountsOperatingExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CashReserveAccountsOperatingExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cash reserve accounts to cover operating expenses of subsidiary, established in conjunction with the funding of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CashReserveAccountsOperatingExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Reserve Accounts, Operating Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CashReserveAccountsOperatingExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash reserve account, Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents Items [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted and Restricted Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted cash equivalents</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RestrictedCashAdditionalToBeFunded" xlink:label="xoma_RestrictedCashAdditionalToBeFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RestrictedCashAdditionalToBeFunded" xlink:to="xoma_RestrictedCashAdditionalToBeFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RestrictedCashAdditionalToBeFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional amount of cash required to be added to  restricted account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RestrictedCashAdditionalToBeFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Additional To Be Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RestrictedCashAdditionalToBeFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional amount of cash required to fund reserve account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash or restricted cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OrganonMember" xlink:to="xoma_OrganonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Organon. The Company entered into an Acquisition Agreement with ObsEva in November 2022 pursuant to which the Company assumed ObsEva's ongoing rights and obligations under the License Agreement between Organon and ObsEva.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva, Organon</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ebopiprant IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life of intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Finite-Lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of intangible asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment Charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RezoluteIncMember" xlink:to="xoma_RezoluteIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Equity Securities, FV-NI [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities And Other Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued incentive compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued legal and accounting fees</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries and Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll, severance and retention costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfArbitrationProceedingsInitiated" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arbitration proceedings initiated by entity against one of its licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Arbitration Proceedings Initiated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arbitration proceedings initiated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda Pharmaceutical Company Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda Pharmaceutical Company Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda Pharmaceutical Company Limited</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CollaborationAgreementMember" xlink:to="xoma_CollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about collaboration agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Or Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Tak079AndTak169Member" xlink:label="xoma_Tak079AndTak169Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Tak079AndTak169Member" xlink:to="xoma_Tak079AndTak169Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Tak079AndTak169Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mezagitamab antibody (TAK-079) and TAK-169.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Tak079AndTak169Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TAK-079 and TAK-169 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Tak079AndTak169Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TAK-079 and TAK-169</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OtherAntibodiesMember" xlink:to="xoma_OtherAntibodiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other antibody technologies.  Excludes TAK-079 (mezagitamab).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Antibodies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other antibodies</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneMember" xlink:label="xoma_MilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestoneMember" xlink:to="xoma_MilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone achieved in arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable per discovery product candidate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Per Discovery Product Candidate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable per discovery product candidate</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltiesPeriodMinimum" xlink:to="xoma_RoyaltiesPeriodMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties, Period, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period eligible to receive royalties</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:to="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties Period, Minimum, Scenario One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment period from the first commercial sale of each royalty-bearing discovery product</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract With Customer Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Contract Cost Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized contract costs</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement and common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement and Common Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement and Common Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementRz358Member" xlink:to="xoma_LicenseAgreementRz358Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement related to activities associated with RZ358.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement RZ358 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, RZ358</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementNonRz358ProductsMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement related to activities associated with non-RZ358 products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Non-RZ358 Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Non-RZ358 products</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Decrease In Future Royalty Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of decrease in future royalty obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Termination Prior Written Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination prior written notice period</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceived" xlink:to="xoma_LicenseAgreementConsiderationReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payments received upon achievement of financing activities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received, Achievement of Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments received upon achievement of financing activities</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of installment payments received during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Installment Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Installment payments received</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementSharesReceived" xlink:to="xoma_LicenseAgreementSharesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of counterparty's common stock entity received under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Shares Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_JanssenBiotechInc.Member" xlink:to="xoma_JanssenBiotechInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen Biotech, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen Biotech Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromUpfrontPayment" xlink:to="xoma_ProceedsFromUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payment received</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on net sales upon commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Royalty On Net Sales Upon Commercialization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on worldwide net sales of each product upon commercialization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ObsevaIntellectualPropertyRightsMember" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva intellectual property rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva Intellectual Property Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payment at closing</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPayments" xlink:to="xoma_MaximumEarnOutPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for various milestones under arrangement. Contingent consideration will be recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost to acquire assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement. Contingent consideration will be recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments, Development And Regulatory Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments for development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments, Sales-Based Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments for sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International Pharmaceutical Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International Pharmaceutical Ltd. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisNoteMember" xlink:to="xoma_NovartisNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured note agreement and subsequent amendments with Novartis referred to as the "Note Agreement".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Note</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPerformanceObligations" xlink:to="xoma_NumberOfPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in debt obligation</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisPharmaAGMember" xlink:to="xoma_NovartisPharmaAGMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">XOMA-052 license agreement and IL1 target license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma 052 License Agreement And IL1 Target License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement and IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XOMA052LicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">XOMA 052 License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 target license agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 Target License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementTransactionPrice" xlink:to="xoma_LicenseAgreementTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement transaction price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction price</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of license agreement consideration received as repayment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received, Debt Repayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received, repayment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockPremium" xlink:to="xoma_CommonStockPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock premium received on sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock premium</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementsNumber" xlink:label="xoma_AgreementsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementsNumber" xlink:to="xoma_AgreementsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ArrangementsNumber" xlink:to="xoma_ArrangementsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arrangements the agreements are accounted for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners II, L.P (HCRP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners Two Limited Partners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners II, L.P.</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Interest Acquisition Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Interest Acquisition Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Sale Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Interest Acquisition Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Interest Acquisition Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePeriodsNumber" xlink:to="xoma_MilestonePeriodsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Periods, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone periods</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LadrxMember" xlink:to="xoma_LadrxMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LadrxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to LadRx.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LadrxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LadRx [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LadrxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LadRx</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement and Royalty Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement and Royalty Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement and Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ArimoclomolMember" xlink:label="xoma_ArimoclomolMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ArimoclomolMember" xlink:to="xoma_ArimoclomolMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ArimoclomolMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arimoclomol.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ArimoclomolMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arimoclomol [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ArimoclomolMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arimoclomol</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AldoxorubicinMember" xlink:label="xoma_AldoxorubicinMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AldoxorubicinMember" xlink:to="xoma_AldoxorubicinMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AldoxorubicinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aldoxorubicin.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AldoxorubicinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aldoxorubicin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AldoxorubicinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aldoxorubicin</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under purchase agreements related to regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum potential regulatory and commercial milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments, under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payments Based On Achievement Of Regulatory and Commercial Milestones, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum potential regulatory and commercial milestone payments, net</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:to="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment obligations based on a portion of regulatory and commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payment Obligations Based On A Portion of Regulatory and Commercial Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment obligations based on a portion of regulatory and commercial milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payments Based On Achievement Of Regulatory and Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum regulatory and commercial sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPayableOnSalesMilestone" xlink:to="xoma_MaximumPayableOnSalesMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payable on Sales Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum commercial sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">For contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Arrangements, Range of Outcomes, Value, High</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, high-end of range</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty, interest and commercial payment rights acquired, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty And Commercial Rights Acquired, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of royalty and commercial payment receivables, Long-Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for credit losses</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AptevoMember" xlink:to="xoma_AptevoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AptevoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Aptevo.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AptevoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aptevo [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AptevoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aptevo</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentPurchaseAgreementMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payment purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesReceivableMaximum" xlink:label="xoma_MilestonesReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesReceivableMaximum" xlink:to="xoma_MilestonesReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones receivable under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone payments entitled to receive</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentThresholdOneTimePayment" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentThresholdOneTimePayment" xlink:to="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Threshold, One-Time Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payments attributable to net sales threshold</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of Royalty and Commercial Payment Receivable Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of royalty and commercial payments, Long-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in long-term royalty receivable balance due to receipt of payment</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgenusIncMember" xlink:to="xoma_AgenusIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IncyteImmunoOncologyAssetsMember" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte immuno-oncology assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte Immuno-Oncology Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte Immuno-Oncology Assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MerckImmunoOncologyProductMember" xlink:to="xoma_MerckImmunoOncologyProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck immuno-oncology product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck Immuno-Oncology Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck Immuno-Oncology Product</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyReceivablePercentageOnNetSales" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has the right to receive as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Receivable Percentage On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has right to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products related to milestones and royalties purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Licensed Products Related To Milestones And Royalties Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products related to milestone and royalties</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfMilestones" xlink:to="xoma_PurchasedPercentageOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestones entity has the right to receive as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments entity has right to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestoneAchieved" xlink:to="xoma_MilestoneAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payments earned under agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BioasisTechnologiesIncMember" xlink:to="xoma_BioasisTechnologiesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis Technologies Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis Technologies Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Non-Current, Credit Loss Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charge, Long-term royalty receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indicates line item in statement of income or comprehensive income that includes credit loss expense of long-term rights receivable, noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Right Receivable, Non-Current, Credit Loss Expense, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Right Receivable, Non-Current, Credit Loss Expense, Statement of Income or Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xlink:to="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Noncurrent, Decrease Due To Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of royalty and commercial payment receivables, Long-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in long-term royalty and commercial rights receivables due to impairment</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AronoraIncMember" xlink:to="xoma_AronoraIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BayerProductsMember" xlink:to="xoma_BayerProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer Products</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NonBayerProductsMember" xlink:to="xoma_NonBayerProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Bayer Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Bayer Products</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SiliconValleyBankMember" xlink:to="xoma_SiliconValleyBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Silicon Valley Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB Loan</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesNumber" xlink:to="xoma_AgreementDrugCandidatesNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Drug Candidates, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates subject to exclusive license option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Drug Candidates, Exclusive License Option, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates subject to exclusive license option</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of non-royalties on net sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Non Royalties On Net Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-royalties to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future non-royalty payments to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementPaymentPercentageFactor" xlink:to="xoma_AgreementPaymentPercentageFactor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier used in determining change in payment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Payment Percentage, Factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier for cumulative amount of consideration paid</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPaymentsPerProduct" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Future Cash Payments, Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent future cash payment for each product</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Royalties On Net Sales Per Product, Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of cumulative royalties on net sales per product</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Payments To Aggregate Amount Of Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum royalty milestone payments to be paid per product</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PalobiofarmaSLMember" xlink:to="xoma_PalobiofarmaSLMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palobiofarma, S.L.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palobiofarma, S.L {Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palo</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ViractaTherapeuticsInc.Member" xlink:to="xoma_ViractaTherapeuticsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta Therapeutics, Inc. ("Viracta").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta Therapeutics Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Receivable, Excluding Consideration Retained, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones, potential royalties on sales and other payments receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumConsiderationRetained" xlink:to="xoma_MaximumConsiderationRetained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Consideration Retained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum consideration retained</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory and Commercial Milestones Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential regulatory and commercial milestones receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kuros</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of pre-commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commercial milestone payments, maximum</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePaymentReceivedCounterparty" xlink:to="xoma_MilestonePaymentReceivedCounterparty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Received, Counterparty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received by Kuros</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePaymentReceivablePercentage" xlink:to="xoma_MilestonePaymentReceivablePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestone payment received by counterparty entity is entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Receivable, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestone payment received by Kuros that company is entitled to receive</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AffitechResearchAsMember" xlink:to="xoma_AffitechResearchAsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech Research AS, a Norwegian biotech company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech Research AS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FaricimabProductMember" xlink:label="xoma_FaricimabProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FaricimabProductMember" xlink:to="xoma_FaricimabProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FaricimabProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FaricimabProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab, Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FaricimabProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FaricimabSvoaVabysmoProductMember" xlink:to="xoma_FaricimabSvoaVabysmoProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab-svoa, (VABYSMO) products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab-Svoa, (VABYSMO), Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VABYSMO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments entity eligible to receive as a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Sales, Receivable Percentage On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments eligible to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPeriodDue" xlink:label="xoma_CommercialPaymentPeriodDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentPeriodDue" xlink:to="xoma_CommercialPaymentPeriodDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentPeriodDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from each royalty payment date payment is due from customer,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentPeriodDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment, Period Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentPeriodDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from each royalty payment date payment is due</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentReceivableTerm" xlink:to="xoma_CommercialPaymentReceivableTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Receivable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payment receivable term</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of Royalty and Commercial Payment Receivable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of royalty and commercial payments, Short-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in short-term royalty receivable balance due to receipt of payment</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xlink:to="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in long-term rights receivable due to recognition of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Receivable Non Current, Recognition of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of contingent consideration, Long-Term</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumAdditionalPayableOnSalesMilestone" xlink:label="xoma_MaximumAdditionalPayableOnSalesMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumAdditionalPayableOnSalesMilestone" xlink:to="xoma_MaximumAdditionalPayableOnSalesMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumAdditionalPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum additional amount payable on sales milestone. Excludes amounts recognized in balance sheet as contingent consideration as of balance sheet date. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumAdditionalPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Additional Payable on Sales Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumAdditionalPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum additional commercial sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShortTermRightsReceivableReclassification" xlink:to="xoma_ShortTermRightsReceivableReclassification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in short term rights receivable due to reclassification from/to long-term rights receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Rights Receivable, Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to short-term royalty and commercial payment receivables, Short-Term</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableReclassification" xlink:to="xoma_LongTermRightsReceivableReclassification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in long term rights receivable due to reclassification from/to short-term rights receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to short-term royalty and commercial payment receivables, Long-Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Prices in Active Markets for Identical Assets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity securities</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FinancialAssetsFairValueDisclosure" xlink:to="xoma_FinancialAssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationFairValueDisclosure" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Common Stock Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Fv Ni Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities in Emeryville, California with lease expiration date of July 31, 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased Facilities, Emeryville, California [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities, Emeryville, California, with lease expiration of July 31, 2023</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:to="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities in Emeryville, California, in different location than previous lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased Facilities, Two, Emeryville, California [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities, Emeryville, California, different location than previous lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, number of leased facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases Number Of Leased Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, number of leased facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of lease extension</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Existence of option to extend</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:to="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of adjustment to right of use asset resulting from modification of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease Modification, Adjustment to Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to right of use asset for lease modification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Remaining Lease Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Discount Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blue Owl Commercial Payment-Backed Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blue Owl Loan Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining initial term loan from Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blue Owl Commercial Payment-Backed Loan Agreement, Initial Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blue Owl Loan Agreement, Initial term loan</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to pertaining delayed draw term loan under Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blue Owl Commercial Payment-Backed Loan Agreement, Delayed Draw Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blue Owl Loan Agreement, Delayed draw term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant issued on December 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrant Issued, December Twenty Twenty Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Issued December 2023</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to common stock warrants at an exercise price of $35.00 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants at an Exercise Price of $35.00 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to common stock warrants at an exercise price of $42.50 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants at an Exercise Price of $42.50 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to common stock warrants at an exercise price of $50.00 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants at an Exercise Price of $50.00 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SecurityInterestInPercentageOfEquity" xlink:label="xoma_SecurityInterestInPercentageOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecurityInterestInPercentageOfEquity" xlink:to="xoma_SecurityInterestInPercentageOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecurityInterestInPercentageOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The security interest provided by entity as a percentage of equity of specified wholly owned subsidiary under loan agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecurityInterestInPercentageOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Interest in Percentage of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SecurityInterestInPercentageOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security interest as a percentage of equity of wholly owned subsidiary</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOfLongTermDebtNet" xlink:label="xoma_ProceedsFromIssuanceOfLongTermDebtNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromIssuanceOfLongTermDebtNet" xlink:to="xoma_ProceedsFromIssuanceOfLongTermDebtNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromIssuanceOfLongTermDebtNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer, net of fees and lender expenses and reserve accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromIssuanceOfLongTermDebtNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Long Term Debt, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromIssuanceOfLongTermDebtNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of long-term debt, net</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" xlink:label="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" xlink:to="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for loan fees and lender expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs, Fees and Lender Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fees and lender expenses</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" xlink:label="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" xlink:to="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount deposited into reserve accounts to pay interest, administrative fees and operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Deposited into Reserve Accounts to Pay Interest, Administrative Fees and Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount deposited into reserve accounts to pay interest, administrative fees and operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate number of unregistered shares of common stock called by warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable In Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discount costs</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" xlink:label="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" xlink:to="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, after accumulated amortization, of debt discount associated with allocated fees and lender expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount, Allocated Fees and Lender Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discount, allocated fees and lender expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Noncurrent, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated costs for the term loan commitment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaccreted debt discount and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total carrying value net of unaccreted debt discount and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt, Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense Benefit Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Benefit) provision for income taxes, Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation between the tax provision computed at the federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax at statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation and other permanent differences (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for executive compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nondeductible executive compensation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets In Process Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development and other tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DeferredTaxAssetsRoyaltyReceivable" xlink:label="xoma_DeferredTaxAssetsRoyaltyReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DeferredTaxAssetsRoyaltyReceivable" xlink:to="xoma_DeferredTaxAssetsRoyaltyReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DeferredTaxAssetsRoyaltyReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from royalty receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DeferredTaxAssetsRoyaltyReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Royalty Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DeferredTaxAssetsRoyaltyReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:to="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carry forward that is subject to expiration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry Forward Subject To Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forward subject to expiration</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:to="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards expiration year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CALIFORNIA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FederalOrphanCreditMember" xlink:label="xoma_FederalOrphanCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FederalOrphanCreditMember" xlink:to="xoma_FederalOrphanCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FederalOrphanCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal orphan tax credit carryforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FederalOrphanCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Orphan Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FederalOrphanCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Orphan Credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward amount</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TaxCreditCarryForwardExpirationYear" xlink:label="xoma_TaxCreditCarryForwardExpirationYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TaxCreditCarryForwardExpirationYear" xlink:to="xoma_TaxCreditCarryForwardExpirationYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward expiration year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carry Forward Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward expiration year</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:to="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards offset of taxable income percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Offset Of Taxable Income Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforward offset (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase related to current year tax position</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits increase (decrease) resulting from prior period tax positions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) related to prior year tax position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits that would impact effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits expected to change significantly over the next twelve months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties related to uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Employee Stock Purchase Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Fifteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price of common stock under plan (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for purchase</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of consecutive purchase periods within each offering period under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Number of Consecutive Purchase Periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive purchase periods within each offering period</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The length of each consecutive purchase period within each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Purchase Period Within Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Length of each consecutive purchase period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in aggregate number of shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum shares per employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeUnderAgeFiftyMember" xlink:label="xoma_EmployeeUnderAgeFiftyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeUnderAgeFiftyMember" xlink:to="xoma_EmployeeUnderAgeFiftyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeUnderAgeFiftyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity under 50 years old.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeUnderAgeFiftyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Under Age Fifty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmployeeUnderAgeFiftyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Under Age Fifty</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeAgeFiftyOrOverMember" xlink:label="xoma_EmployeeAgeFiftyOrOverMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeAgeFiftyOrOverMember" xlink:to="xoma_EmployeeAgeFiftyOrOverMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity age 50 or over.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Age Fifty or Over [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Age Fifty or Over</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Savings Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum annual contribution per employee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Maximum Annual Contributions Per Employee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum annual contribution per employee</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:to="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Age Required For Catch Up Contribution Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Age requirement for participant to be eligible for a catch-up contribution, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer matching contribution (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:to="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of defined contribution plan expense paid through the issuance of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred savings plan expense paid in common shares (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeTerminatedMember" xlink:label="xoma_EmployeeTerminatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeTerminatedMember" xlink:to="xoma_EmployeeTerminatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeTerminatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terminated employee of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeTerminatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Terminated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmployeeTerminatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terminated employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age required for employees to qualify for immediate vesting of award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age required for employees to qualify for immediate vesting of award</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold years required for retirement age</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefExecutiveOfficerInterimMember" xlink:to="xoma_ChiefExecutiveOfficerInterimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of interim chief executive officer and Executive Chairman of the Board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, Interim [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Chairman of the Board and Interim CEO, Owen Hughes</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefInvestmentOfficerMember" xlink:to="xoma_ChiefInvestmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of  chief investment officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Investment Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Investment Officer, Bradley Sitko</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Three</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Number of Awards Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Quarterly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal quarterly vesting installments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Monthly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of successive equal monthly vesting installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Remaining Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Remaining Term, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to stock options (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which unrecognized compensation expense is expected to be recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which unrecognized compensation expense is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PerformanceStockUnitsMember" xlink:to="xoma_PerformanceStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock units under a share-based payment arrangement awarded for meeting performance target.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Unit Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of PSUs (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock price hurdles in a share based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number of Hurdles.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of hurdles</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Calendar Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive calendar days used to calculate volume-weighted average stock price</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar30Member" xlink:label="xoma_StockPriceHurdlesOfDollar30Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar30Member" xlink:to="xoma_StockPriceHurdlesOfDollar30Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $30.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Price Hurdles of Dollar 30 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $30.00</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar35Member" xlink:label="xoma_StockPriceHurdlesOfDollar35Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar35Member" xlink:to="xoma_StockPriceHurdlesOfDollar35Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $35.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Price Hurdles of Dollar 35 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $35.00</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar40Member" xlink:label="xoma_StockPriceHurdlesOfDollar40Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar40Member" xlink:to="xoma_StockPriceHurdlesOfDollar40Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $40.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Price Hurdles of Dollar 40 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $40.00</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar45Member" xlink:label="xoma_StockPriceHurdlesOfDollar45Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar45Member" xlink:to="xoma_StockPriceHurdlesOfDollar45Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $45.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Price Hurdles of Dollar 45 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $45.00</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AwardDateMay2023ToOctober2023Member" xlink:label="xoma_AwardDateMay2023ToOctober2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AwardDateMay2023ToOctober2023Member" xlink:to="xoma_AwardDateMay2023ToOctober2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AwardDateMay2023ToOctober2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award dates from May 2023 to October 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AwardDateMay2023ToOctober2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date, May 2023 to October 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AwardDateMay2023ToOctober2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award dates from May 2023 to October 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derived Service Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense, not yet recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Unvested PSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:to="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Vice President, Finance and Chief Financial Officer of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Vice President, Finance and Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Vice President, Finance and Chief Financial Officer, Thomas Burns</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentPeriodRetirementEligible" xlink:label="xoma_EmploymentPeriodRetirementEligible" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentPeriodRetirementEligible" xlink:to="xoma_EmploymentPeriodRetirementEligible_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentPeriodRetirementEligible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which individual will be deemed retirement eligible for purposes of equity award if employed through the period under terms of amended employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentPeriodRetirementEligible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Period, Retirement Eligible</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentPeriodRetirementEligible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which individual will be deemed retirement eligible for purposes of equity award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current employees of entity, excluding Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Employees, Excluding Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current employees, excluding Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Departure and Continuity Incentive</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPeriodsCashRetentionBonus" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Periods, Cash Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of periods in which employees will be eligible to receive cash retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodOneRetentionBonusEligibility" xlink:to="xoma_PeriodOneRetentionBonusEligibility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period One, Retention Bonus Eligibility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial period for which employees will be eligible for retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodTwoRetentionBonusEligibility" xlink:to="xoma_PeriodTwoRetentionBonusEligibility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Two, Retention Bonus Eligibility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period following initial period for which employees will be eligible for retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RetentionBonusExpenseAccrued" xlink:to="xoma_RetentionBonusExpenseAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recorded as expense during the period for cash retention bonuses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retention Bonus, Expense Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of retention bonus expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedRetentionBonus" xlink:label="xoma_AccruedRetentionBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedRetentionBonus" xlink:to="xoma_AccruedRetentionBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense for cash retention bonus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefExecutiveOfficerRetiredMember" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of chief executive officer prior to retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, Retired [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, Retired, James R. Neal</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedCompensationContinuityIncentive" xlink:to="xoma_AccruedCompensationContinuityIncentive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense for compensation under employment agreement related to retirement of individual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Compensation, Continuity Incentive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued cash payment related to Continuity Incentive under Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CompensationExpenseEmploymentAgreement" xlink:to="xoma_CompensationExpenseEmploymentAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for compensation under employment agreement related to retirement of individual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Expense, Employment Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense related to Continuity Incentive under Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable based on market price</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfEarningsPerShareTable" xlink:label="xoma_ScheduleOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ScheduleOfEarningsPerShareTable" xlink:to="xoma_ScheduleOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ScheduleOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The table contains disclosure pertaining to an entity's earnings per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ScheduleOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EarningsPerShareLineItems" xlink:label="xoma_EarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EarningsPerShareLineItems" xlink:to="xoma_EarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income loss available to common stockholders basic and diluted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Basic And Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividends and Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated preferred dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X and series Y convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X And Series Y Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X And Series Y Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesXConvertiblePreferredStockMember" xlink:to="xoma_SeriesXConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Y convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Y Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Y Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Shares Issued Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for each share of convertible preferred stock that is converted</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockConversionPricePerShare" xlink:to="xoma_PreferredStockConversionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock conversion price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock conversion price per share</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:to="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendPeriodYearProrated" xlink:to="xoma_PreferredStockDividendPeriodYearProrated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Period, Year Prorated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days in year over which dividend will be prorated and computed</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Period, Prorated Months in Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of months in year over which dividend will be prorated and compute</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendPeriodMonth" xlink:to="xoma_PreferredStockDividendPeriodMonth_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendPeriodMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendPeriodMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Period, Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendPeriodMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days in month over which dividend will be prorated and computed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Redemption Price Per Share, Optional Redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockShareCap" xlink:to="xoma_PreferredStockShareCap_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockShareCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockShareCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Share Cap</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockShareCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share cap (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:to="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate Family Member of Management or Principal Owner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party - Spouse of James Neal, then CEO and Chairman of the Board of Directors</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DepositarySharesRatioToPreferredStock" xlink:to="xoma_DepositarySharesRatioToPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DepositarySharesRatioToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents depositary share's fractional interest in share of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DepositarySharesRatioToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depositary Shares, Ratio To Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DepositarySharesRatioToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depositary share's fractional interest in share of preferred stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:to="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Preferred Stock, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendAmountPerShare" xlink:label="xoma_PreferredStockDividendAmountPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendAmountPerShare" xlink:to="xoma_PreferredStockDividendAmountPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendAmountPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The dividend amount per share based on the dividend rate on preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendAmountPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividend Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendAmountPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, dividend amount (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_DividendsPayableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividends Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend declared (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividends, Per Share, Cash Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend paid (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BiotechnologyValueFundLPMember" xlink:to="xoma_BiotechnologyValueFundLPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biotechnology Value Fund, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biotechnology Value Fund LP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BVF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XomaCorporationMember" xlink:to="xoma_XomaCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Ownership Percentage, Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership interest, if shares are converted (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the Market Agreement, 2018 in which the company may sell common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Eighteen At Market Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Common Stock ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Issuance Sales Agreement 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumValueOfStockToBeIssued" xlink:to="xoma_MaximumValueOfStockToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of stock to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of shares to be issued</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales commission paid per transaction (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales commission paid per transaction, preferred stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten Year Warrants Issued Third Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Issued May 2018</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantExercisePrice14.71Member" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant with exercise price of $14.71 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrant, Exercise Price 14.71 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Issued March 2019</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ExercisablePeriodOfWarrants" xlink:to="xoma_ExercisablePeriodOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable Period Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable period of warrants</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Fair Value of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated time to liquidity of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants measurement input</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="xoma_CommitmentsAndContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePayments" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation Estimated Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Estimated Milestone Payments, Number Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed number of products per contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customers [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner1Member" xlink:to="xoma_Partner1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 1</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner2Member" xlink:to="xoma_Partner2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 2</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner3Member" xlink:to="xoma_Partner3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 3</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner4Member" xlink:to="xoma_Partner4Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A fourth partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 4 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 4</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfMajorPartners" xlink:to="xoma_NumberOfMajorPartners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Major Partners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major partners</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaPacificMember" xlink:to="srt_AsiaPacificMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaPacificMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asia Pacific [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AsiaPacificMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asia Pacific</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues From External Customers And Long Lived Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues from External Customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CEO, Owen Hughes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance share units</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionOfEconomicInterestAgreementMember" xlink:label="xoma_AcquisitionOfEconomicInterestAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AcquisitionOfEconomicInterestAgreementMember" xlink:to="xoma_AcquisitionOfEconomicInterestAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AcquisitionOfEconomicInterestAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of economic interest agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AcquisitionOfEconomicInterestAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Economic Interest Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AcquisitionOfEconomicInterestAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of economic interest agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TalpheraMember" xlink:label="xoma_TalpheraMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TalpheraMember" xlink:to="xoma_TalpheraMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TalpheraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Talphera.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TalpheraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Talphera [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TalpheraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Talphera</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AloraPharmaceuticalsMember" xlink:label="xoma_AloraPharmaceuticalsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AloraPharmaceuticalsMember" xlink:to="xoma_AloraPharmaceuticalsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AloraPharmaceuticalsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Alora Pharmaceuticals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AloraPharmaceuticalsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alora Pharmaceuticals [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AloraPharmaceuticalsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alora Pharmaceuticals</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" xlink:label="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" xlink:to="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All customers excluding U.S. Department of Defense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Customers, Excluding U.S. Department of Defense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All customers excluding DoD</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_U.s.DepartmentOfDefenseMember" xlink:label="xoma_U.s.DepartmentOfDefenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_U.s.DepartmentOfDefenseMember" xlink:to="xoma_U.s.DepartmentOfDefenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_U.s.DepartmentOfDefenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Department of Defense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_U.s.DepartmentOfDefenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Department of Defense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_U.s.DepartmentOfDefenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DoD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KinnateMember" xlink:label="xoma_KinnateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_KinnateMember" xlink:to="xoma_KinnateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_KinnateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kinnate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_KinnateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kinnate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_KinnateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kinnate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Program Authorized Dollar Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock repurchase program amount authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Shares, Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares repurchased</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentAgreementAnnualSalary" xlink:label="xoma_EmploymentAgreementAnnualSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementAnnualSalary" xlink:to="xoma_EmploymentAgreementAnnualSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementAnnualSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount of annual base salary pursuant to employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementAnnualSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Annual Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementAnnualSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of annual base salary</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" xlink:label="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" xlink:to="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Target annual cash bonus amount as a percent of base salary, subject to achievement of annual performance milestones, pursuant to employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Target Annual Cash Bonus, Percent of Base Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Target annual cash bonus (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares granted</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties and milestones entity has the right to receive as a percentage, up to specified threshold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Receivable Percentage On Net Sales and Percentage of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties and milestones entity has the right to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndMilestonesReceivableThreshold" xlink:label="xoma_RoyaltyAndMilestonesReceivableThreshold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndMilestonesReceivableThreshold" xlink:to="xoma_RoyaltyAndMilestonesReceivableThreshold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndMilestonesReceivableThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount for royalties and milestones for determining amount for entity has the right to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndMilestonesReceivableThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Milestones Receivable, Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyAndMilestonesReceivableThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount for royalties and milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has the right to receive as a percentage shared with counterparty upon reaching threshold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Receivable Percentage On Net Sales Shared With Counterparty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties shared equally with counterparty (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable, upon achievement of milestones, to be shared with counterparty of agreement, including portion received received by entity prior to meeting threshold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Milestones, Shared with Counterparty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum remaining milestones to be shared equally</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareCashAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentToAcquireBusinessPricePerShareCashAmount" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareCashAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock. Includes base price and additional contingent amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment to Acquire Business, Price Per Share, Cash Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash amount of consideration per outstanding share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockParOrStatedValuePerShareAcquiree" xlink:label="xoma_CommonStockParOrStatedValuePerShareAcquiree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockParOrStatedValuePerShareAcquiree" xlink:to="xoma_CommonStockParOrStatedValuePerShareAcquiree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockParOrStatedValuePerShareAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount or stated value per share of common stock of acquiree.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockParOrStatedValuePerShareAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share, Acquiree</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockParOrStatedValuePerShareAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquiree's common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The base cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment to Acquire Business, Price Per Share, Base Cash Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The additional contingent cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment to Acquire Business, Price Per Share, Additional Cash Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional cash price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionNumberOfContingentValueRights" xlink:label="xoma_AcquisitionNumberOfContingentValueRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AcquisitionNumberOfContingentValueRights" xlink:to="xoma_AcquisitionNumberOfContingentValueRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AcquisitionNumberOfContingentValueRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non-transferable contingent value rights each acquiree share has right to receive. representing  right to receive one or more potential cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AcquisitionNumberOfContingentValueRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition, Number Of Contingent Value Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AcquisitionNumberOfContingentValueRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non-transferable contingent value rights for each acquiree share</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionValueRightNumberOfCashPayments" xlink:label="xoma_AcquisitionValueRightNumberOfCashPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AcquisitionValueRightNumberOfCashPayments" xlink:to="xoma_AcquisitionValueRightNumberOfCashPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AcquisitionValueRightNumberOfCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of cash payments each value right provides  under terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AcquisitionValueRightNumberOfCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition, Value Right, Number Of Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AcquisitionValueRightNumberOfCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of cash payments for each contingent value right</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" xlink:to="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of net proceeds from license, sale or disposition entered into by acquiree prior to expiration of offer acquiree has right to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds Payable, License, Sale or Disposition, Prior to Expiration of Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of net proceeds from disposition entered into by acquiree prior to expiration of offer acquiree has right to receive</label>
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" xlink:to="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of net proceeds payable from license, sale or disposition entered into by entity after expiration of offer, the acquiree has right to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds Payable, License, Sale or Disposition, After Expiration of Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of net proceeds payable from disposition entered into by entity after expiration of offer acquiree has right to receive</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>xoma-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2024 3:25:01 AM-->
<!--Modified on: 3/8/2024 3:25:01 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureDescriptionOfBusiness" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangements" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreement" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebt" roleURI="http://www.xoma.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlans" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholders" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStock" roleURI="http://www.xoma.com/role/DisclosureCapitalStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformation" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.xoma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsTables" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementTables" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtTables" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansTables" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockTables" roleURI="http://www.xoma.com/role/DisclosureCapitalStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureDescriptionOfBusinessLiquidityDetails" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsTakedaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsJanssenDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsObsevaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsNovartisNis793Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLeaseAgreementAdditionalInformationDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtSummaryOfLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureLongTermDebtInterestExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesNolDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesTaxCreditCarryforwardDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockSeriesPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockDividendsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockBvfOwnershipDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCapitalStockWeightedAverageAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638454650953647362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="us-gaap_StatementTable_638454650953647362" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650953647362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953647362" xlink:to="us-gaap_StatementClassOfStockAxis_638454650953647362" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650953647362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953647362" xlink:to="us-gaap_ClassOfStockDomain_638454650953647362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650953647362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953647362" xlink:to="us-gaap_CommonStockMember_638454650953647362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953647362" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650953657371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953647362" xlink:to="dei_AdrMember_638454650953657371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953647362" xlink:to="us-gaap_StatementLineItems_638454650953657371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentType_638454650953657371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentAnnualReport_638454650953657371" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentPeriodEndDate_638454650953657371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentTransitionReport_638454650953657371" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityFileNumber_638454650953657371" order="5" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityRegistrantName_638454650953657371" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638454650953657371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityIncorporationStateCountryCode_638454650953657371" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityTaxIdentificationNumber_638454650953667351" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityAddressAddressLine1_638454650953667351" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityAddressAddressLine2_638454650953667351" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityAddressCityOrTown_638454650953667351" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityAddressStateOrProvince_638454650953667351" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityAddressPostalZipCode_638454650953667351" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_CityAreaCode_638454650953667351" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_LocalPhoneNumber_638454650953667351" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638454650953667351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_Security12bTitle_638454650953667351" order="16" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_TradingSymbol_638454650953677343" order="17" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_SecurityExchangeName_638454650953677343" order="18" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityWellKnownSeasonedIssuer_638454650953677343" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityVoluntaryFilers_638454650953677343" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityCurrentReportingStatus_638454650953677343" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityInteractiveDataCurrent_638454650953677343" order="22" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638454650953677343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityFilerCategory_638454650953677343" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntitySmallBusiness_638454650953687342" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityEmergingGrowthCompany_638454650953687342" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_IcfrAuditorAttestationFlag_638454650953687342" order="26" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638454650953687342" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityShellCompany_638454650953687342" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityPublicFloat_638454650953687342" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638454650953687342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityCommonStockSharesOutstanding_638454650953687342" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638454650953697342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_AuditorFirmId_638454650953697342" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638454650953697342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_AuditorName_638454650953697342" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638454650953697342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_AuditorLocation_638454650953697342" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638454650953697342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_EntityCentralIndexKey_638454650953697342" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638454650953697342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_CurrentFiscalYearEndDate_638454650953697342" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638454650953697342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentFiscalYearFocus_638454650953697342" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638454650953707343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_DocumentFiscalPeriodFocus_638454650953707343" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638454650953707343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953657371" xlink:to="dei_AmendmentFlag_638454650953707343" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638454650953707343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638454650953707343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650953707343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953707343" xlink:to="us-gaap_StatementClassOfStockAxis_638454650953707343" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650953707343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953707343" xlink:to="us-gaap_ClassOfStockDomain_638454650953707343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953707343" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650953717348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953707343" xlink:to="us-gaap_SeriesBPreferredStockMember_638454650953717348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953707343" xlink:to="us-gaap_ConvertiblePreferredStockMember_638454650953717348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953707343" xlink:to="us-gaap_StatementLineItems_638454650953717348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953717348" xlink:to="us-gaap_AssetsAbstract_638454650953717348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_AssetsCurrentAbstract_638454650953717348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650953717348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="us-gaap_RestrictedCashCurrent_638454650953717348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="us-gaap_EquitySecuritiesFvNi_638454650953717348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638454650953717348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650953717348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="xoma_RightsReceivableCurrent_638454650953717348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638454650953727343" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638454650953717348" xlink:to="us-gaap_AssetsCurrent_638454650953727343" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_RestrictedCashNoncurrent_638454650953727343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638454650953727343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638454650953727343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650953727343" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638454650953727343" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_OtherAssetsNoncurrent_638454650953727343" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638454650953727343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638454650953717348" xlink:to="us-gaap_Assets_638454650953727343" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953717348" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="us-gaap_AccountsPayableCurrent_638454650953737344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638454650953737344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650953737344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638454650953737344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638454650953737344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="us-gaap_DeferredIncomeCurrent_638454650953737344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="xoma_AccruedPreferredStockDividendCurrent_638454650953747343" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="us-gaap_LongTermDebtCurrent_638454650953747343" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638454650953737344" xlink:to="us-gaap_LiabilitiesCurrent_638454650953747343" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_DeferredIncomeNoncurrent_638454650953747343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650953747343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_LongTermDebtNoncurrent_638454650953747343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638454650953747343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_Liabilities_638454650953747343" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638454650953757344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_CommitmentsAndContingencies_638454650953757344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638454650953757344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638454650953737344" xlink:to="us-gaap_StockholdersEquityAbstract_638454650953757344" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638454650953757344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638454650953757344" xlink:to="us-gaap_PreferredStockValue_638454650953757344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638454650953757344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638454650953757344" xlink:to="us-gaap_CommonStockValue_638454650953757344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638454650953757344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638454650953757344" xlink:to="us-gaap_AdditionalPaidInCapital_638454650953757344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638454650953757344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638454650953757344" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638454650953757344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638454650953767344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638454650953757344" xlink:to="us-gaap_StockholdersEquity_638454650953767344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638454650953767344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953717348" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638454650953767344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638454650953767344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638454650953767344" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650953767344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953767344" xlink:to="us-gaap_StatementClassOfStockAxis_638454650953767344" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650953767344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953767344" xlink:to="us-gaap_ClassOfStockDomain_638454650953767344" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650953767344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953767344" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650953767344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953767344" xlink:to="us-gaap_SeriesBPreferredStockMember_638454650953777346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650953767344" xlink:to="us-gaap_ConvertiblePreferredStockMember_638454650953777346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953767344" xlink:to="us-gaap_StatementLineItems_638454650953777346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638454650953777346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_PreferredStockSharesAuthorized_638454650953777346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638454650953777346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_PreferredStockSharesIssued_638454650953777346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_PreferredStockSharesOutstanding_638454650953777346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638454650953777346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_CommonStockSharesAuthorized_638454650953777346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638454650953777346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_CommonStockSharesIssued_638454650953777346" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953777346" xlink:to="us-gaap_CommonStockSharesOutstanding_638454650953787344" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_RevenuesAbstract_638454650953787344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638454650953787344" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650953787344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638454650953787344" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638454650953787344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638454650953787344" xlink:to="us-gaap_Revenues_638454650953787344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_OperatingExpensesAbstract_638454650953787344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638454650953787344" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638454650953787344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638454650953787344" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638454650953787344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650953787344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638454650953787344" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650953787344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638454650953787344" xlink:to="us-gaap_LitigationSettlementExpense_638454650953797349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638454650953787344" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638454650953797349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638454650953787344" xlink:to="us-gaap_OperatingExpenses_638454650953797349" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_OperatingIncomeLoss_638454650953797349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638454650953797349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638454650953797349" xlink:to="us-gaap_InterestExpenseDebt_638454650953797349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638454650953797349" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638454650953797349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650953797349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638454650953797349" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638454650953797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_NetIncomeLoss_638454650953797349" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638454650953807345" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650953807345" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638454650953807345" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_EarningsPerShareBasic_638454650953807345" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_EarningsPerShareDiluted_638454650953807345" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638454650953807345" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638454650953807345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract_1" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638454650953807345" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638454650953817345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953817345" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650953817345" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650953817345" xlink:to="us-gaap_PreferredStockMember_638454650953817345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650953817345" xlink:to="us-gaap_CommonStockMember_638454650953817345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650953817345" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638454650953817345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650953817345" xlink:to="us-gaap_RetainedEarningsMember_638454650953817345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650953817345" xlink:to="us-gaap_EquityComponentDomain_638454650953817345" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953817345" xlink:to="us-gaap_StatementClassOfStockAxis_638454650953817345" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650953817345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953817345" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650953817345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953817345" xlink:to="us-gaap_SeriesBPreferredStockMember_638454650953827346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953817345" xlink:to="us-gaap_ConvertiblePreferredStockMember_638454650953827346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650953817345" xlink:to="us-gaap_ClassOfStockDomain_638454650953827346" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638454650953817345" xlink:to="us-gaap_StatementLineItems_638454650953827346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638454650953827346" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_StockholdersEquity_638454650953827346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_SharesOutstanding_638454650953827346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638454650953827346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638454650953827346" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638454650953827346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638454650953827346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638454650953827346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638454650953837344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_638454650953837344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_638454650953837344" xlink:to="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_638454650953837344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_DividendsPreferredStockStock_638454650953837344" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_NetIncomeLoss_638454650953837344" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638454650953837344" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638454650953837344" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650953837344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638454650953837344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_StockholdersEquity_638454650953837344" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638454650953827346" xlink:to="us-gaap_SharesOutstanding_638454650953847347" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_ProfitLoss_638454650953847347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_ShareBasedCompensation_638454650953847347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived_638454650953847347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650953847347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638454650953847347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638454650953847347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638454650953857350" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_DepreciationNonproduction_638454650953857350" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650953857350" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="xoma_OperatingLeasePaymentsNonCash_638454650953857350" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638454650953857350" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638454650953857350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638454650953857350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638454650953857350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638454650953857350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638454650953857350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638454650953867347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638454650953857350" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638454650953867347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638454650953847347" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638454650953867347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650953867347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650953867347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638454650953867347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638454650953867347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638454650953867347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638454650953867347" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638454650953877349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638454650953877349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_PaymentsOfFinancingCosts_638454650953877349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_PaymentsOfDividends_638454650953877349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638454650953877349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638454650953877349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638454650953877349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650953887347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638454650953887347" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650953887347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650953887347" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638454650953887347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638454650953877349" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638454650953887347" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638454650953887347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638454650953887347" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638454650953887347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638454650953887347" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384546509538873471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384546509538873471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638454650953887347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638454650953887347" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638454650953897347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638454650953887347" xlink:to="us-gaap_IncomeTaxesPaidNet_638454650953897347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638454650953897347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638454650953887347" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638454650953897347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IssuanceOfWarrantsDebtFinancing" xlink:label="xoma_IssuanceOfWarrantsDebtFinancing_638454650953897347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" xlink:to="xoma_IssuanceOfWarrantsDebtFinancing_638454650953897347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_638454650953897347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_638454650953897347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_638454650953897347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_638454650953897347" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_638454650953907346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_638454650953907346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_638454650953907346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" xlink:to="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_638454650953907346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements_638454650953907346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638454650953897347" xlink:to="xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements_638454650953907346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638454650953917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638454650953917353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation and Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638454650953917353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638454650953917353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails" xlink:type="extended" xlink:title="10301 - Disclosure - Consolidated Financial Statements Details" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638454650953957369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638454650953957369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xlink:type="extended" xlink:title="10401 - Disclosure - Licensing and Other Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_638454650953967385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_638454650953967385" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" xlink:type="extended" xlink:title="10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_638454650953967385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_638454650953967385" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10601 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638454650953967385" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638454650953967385" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreement" xlink:type="extended" xlink:title="10701 - Disclosure - Lease Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock_638454650953977353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LeaseDisclosureTextBlock_638454650953977353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10801 - Disclosure - Long-Term Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_638454650953977353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_638454650953977353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638454650953977353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638454650953977353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans" xlink:type="extended" xlink:title="11001 - Disclosure - Stock Based Compensation and Other Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638454650953987351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638454650953987351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="extended" xlink:title="11101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638454650953987351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638454650953987351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStock" xlink:type="extended" xlink:title="11201 - Disclosure - Capital Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638454650953987351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638454650953987351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11301 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638454650953997351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638454650953997351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" xlink:type="extended" xlink:title="11401 - Disclosure - Concentration of Risk, Segment and Geographic Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_638454650953997351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_638454650953997351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11501 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638454650954007353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638454650954007353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638454650954007353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638454650954007353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638454650954007353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_638454650954007353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638454650954007353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_EquitySecuritiesPolicy_638454650954007353" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_638454650954007353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_638454650954007353" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_638454650954017352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_AssetAcquisitionsPolicyPolicyTextBlock_638454650954017352" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638454650954017352" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638454650954017352" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638454650954017352" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_WarrantsPolicyTextBlock" xlink:label="xoma_WarrantsPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_WarrantsPolicyTextBlock_638454650954017352" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638454650954017352" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638454650954017352" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638454650954017352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638454650954017352" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638454650954027346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638454650954027346" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638454650954027346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638454650954027346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Consolidated Financial Statements Details (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638454650954027346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638454650954027346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638454650954027346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638454650954027346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_638454650954037355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_638454650954037355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638454650954037355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638454650954037355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementTables" xlink:type="extended" xlink:title="30703 - Disclosure - Lease Agreement (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638454650954037355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638454650954037355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638454650954047354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638454650954047354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_638454650954047354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_638454650954047354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_638454650954047354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_638454650954047354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="30803 - Disclosure - Long-Term Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638454650954047354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638454650954047354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638454650954047354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638454650954047354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock" xlink:label="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock_638454650954047354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock_638454650954047354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638454650954057354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638454650954057354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638454650954057354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638454650954057354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954057354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954057354" xlink:to="us-gaap_PlanNameAxis_638454650954057354" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638454650954057354" xlink:to="us-gaap_PlanNameDomain_638454650954057354" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650954057354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650954057354" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650954057354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650954057354" xlink:to="xoma_StockOptionInducementAwardsMember_638454650954067353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638454650954067353" xlink:to="xoma_StockOptionInducementAwardOneMember_638454650954067353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638454650954067353" xlink:to="xoma_StockOptionInducementAwardTwoMember_638454650954067353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954057354" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638454650954067353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638454650954067353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_638454650954067353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_638454650954067353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638454650954067353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954067353" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638454650954067353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" xlink:title="31103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638454650954077354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638454650954077354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638454650954077354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638454650954077354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockTables" xlink:type="extended" xlink:title="31203 - Disclosure - Capital Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_638454650954077354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsDeclaredTableTextBlock_638454650954077354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638454650954077354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638454650954077354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638454650954077354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638454650954077354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" xlink:type="extended" xlink:title="31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_638454650954087353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_638454650954087353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638454650954087353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638454650954087353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650954087353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650954087353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638454650954087353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCash_638454650954087353" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638454650954087353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCashCurrent_638454650954087353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent_638454650954097353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_638454650954097353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_638454650954097353" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_638454650954097353" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638454650954097353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638454650954097353" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638454650954097353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638454650954097353" xlink:to="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_638454650954097353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsInterestAndAdministrativeFeesMember" xlink:label="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_638454650954097353" xlink:to="xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_638454650954097353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CashReserveAccountsOperatingExpensesMember" xlink:label="xoma_CashReserveAccountsOperatingExpensesMember_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_638454650954097353" xlink:to="xoma_CashReserveAccountsOperatingExpensesMember_638454650954097353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_638454650954097353" xlink:to="srt_StatementScenarioAxis_638454650954097353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638454650954097353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638454650954097353" xlink:to="srt_ScenarioUnspecifiedDomain_638454650954097353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650954097353" xlink:to="srt_ScenarioForecastMember_638454650954107354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_638454650954097353" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638454650954107354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_RestrictedCash_638454650954107354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638454650954107354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_Cash_638454650954107354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638454650954107354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_RestrictedCashCurrent_638454650954107354" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638454650954107354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_RestrictedCashNoncurrent_638454650954107354" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RestrictedCashAdditionalToBeFunded" xlink:label="xoma_RestrictedCashAdditionalToBeFunded_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="xoma_RestrictedCashAdditionalToBeFunded_638454650954117352" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_638454650954107354" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638454650954117352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954117352" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954117352" xlink:to="srt_CounterpartyNameAxis_638454650954117352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954117352" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954117352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954117352" xlink:to="xoma_OrganonMember_638454650954117352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954117352" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954117352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954117352" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954117352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638454650954117352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954117352" xlink:to="xoma_LicenseAgreementMember_638454650954117352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954117352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954127350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954127350" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954127350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954127350" xlink:to="us-gaap_IntellectualPropertyMember_638454650954127350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954117352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954127350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954127350" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638454650954127350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954127350" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638454650954127350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954127350" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954127350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638454650954127350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638454650954127350" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638454650954127350" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638454650954137357" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638454650954137357" xlink:to="srt_EquityMethodInvesteeNameDomain_638454650954137357" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638454650954137357" xlink:to="xoma_RezoluteIncMember_638454650954137357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638454650954127350" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638454650954137357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638454650954137357" xlink:to="us-gaap_EquitySecuritiesFvNi_638454650954137357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638454650954137357" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638454650954137357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Details - Intangible Assets, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract_1" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954137357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954137357" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954137357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954137357" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954137357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638454650954137357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954137357" xlink:to="us-gaap_IntellectualPropertyMember_638454650954137357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954137357" xlink:to="srt_CounterpartyNameAxis_638454650954147352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954147352" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954147352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954147352" xlink:to="xoma_OrganonMember_638454650954147352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954137357" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954147352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954147352" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954147352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954147352" xlink:to="xoma_LicenseAgreementMember_638454650954147352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638454650954137357" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954147352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638454650954147352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638454650954147352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638454650954147352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638454650954147352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638454650954147352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638454650954157350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638454650954147352" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954157350" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" xlink:to="us-gaap_AccruedBonusesCurrent_638454650954157350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638454650954157350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638454650954157350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638454650954157350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638454650954157350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638454650954157350" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638454650954157350" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract_2" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638454650954167355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638454650954167355" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_638454650954167355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638454650954167355" xlink:to="us-gaap_LitigationSettlementExpense_638454650954167355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - Takeda (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954167355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954167355" xlink:to="srt_CounterpartyNameAxis_638454650954167355" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954167355" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954167355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954167355" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember_638454650954167355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954167355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954167355" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954167355" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954167355" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954177356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954177356" xlink:to="xoma_CollaborationAgreementMember_638454650954177356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954167355" xlink:to="srt_ProductOrServiceAxis_638454650954177356" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638454650954177356" xlink:to="srt_ProductsAndServicesDomain_638454650954177356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Tak079AndTak169Member" xlink:label="xoma_Tak079AndTak169Member_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954177356" xlink:to="xoma_Tak079AndTak169Member_638454650954177356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954177356" xlink:to="xoma_OtherAntibodiesMember_638454650954177356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneMember" xlink:label="xoma_MilestoneMember_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954177356" xlink:to="xoma_MilestoneMember_638454650954177356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954177356" xlink:to="us-gaap_LicenseMember_638454650954177356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954167355" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954177356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638454650954177356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638454650954177356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638454650954187352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="xoma_RoyaltiesPeriodMinimum_638454650954187352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_638454650954187352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="xoma_RoyaltiesPeriodMinimumScenarioOne_638454650954187352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954187352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954187352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638454650954187352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="us-gaap_ContractWithCustomerAssetNet_638454650954187352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638454650954187352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="us-gaap_ContractWithCustomerLiability_638454650954187352" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638454650954187352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954177356" xlink:to="us-gaap_CapitalizedContractCostNet_638454650954187352" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954197358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954197358" xlink:to="srt_CounterpartyNameAxis_638454650954197358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954197358" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954197358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954197358" xlink:to="xoma_RezoluteIncMember_638454650954197358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954197358" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954197358" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954197358" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954197358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954197358" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638454650954197358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638454650954197358" xlink:to="xoma_LicenseAgreementMember_638454650954197358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_638454650954197358" xlink:to="xoma_LicenseAgreementRz358Member_638454650954197358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_638454650954197358" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_638454650954197358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954197358" xlink:to="dei_LegalEntityAxis_638454650954197358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638454650954197358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638454650954197358" xlink:to="dei_EntityDomain_638454650954197358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_6384546509541973581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638454650954197358" xlink:to="xoma_RezoluteIncMember_6384546509541973581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954197358" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954207354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_RoyaltiesPeriodMinimum_638454650954207354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_638454650954207354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638454650954207354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_LicenseAgreementConsiderationReceived_638454650954207354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954207354" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_638454650954207354" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_638454650954207354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived_638454650954207354" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived_638454650954217349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="xoma_LicenseAgreementSharesReceived_638454650954217349" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638454650954217349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638454650954217349" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638454650954217349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="us-gaap_ContractWithCustomerAssetNet_638454650954217349" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638454650954217349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="us-gaap_ContractWithCustomerLiability_638454650954217349" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638454650954217349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954207354" xlink:to="us-gaap_CapitalizedContractCostNet_638454650954217349" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Janssen (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954217349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954217349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954217349" xlink:to="srt_CounterpartyNameAxis_638454650954227356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954227356" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954227356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954227356" xlink:to="xoma_JanssenBiotechInc.Member_638454650954227356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954217349" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954227356" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954227356" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954227356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954227356" xlink:to="xoma_LicenseAgreementMember_638454650954227356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954217349" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="xoma_ProceedsFromUpfrontPayment_638454650954227356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638454650954227356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_638454650954227356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954227356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954227356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="us-gaap_ContractWithCustomerAssetNet_638454650954237352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="us-gaap_ContractWithCustomerLiability_638454650954237352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954227356" xlink:to="us-gaap_CapitalizedContractCostNet_638454650954237352" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract_1" xlink:to="us-gaap_AssetAcquisitionTable_638454650954237352" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638454650954237352" xlink:to="us-gaap_AssetAcquisitionAxis_638454650954237352" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638454650954237352" xlink:to="us-gaap_AssetAcquisitionDomain_638454650954237352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638454650954237352" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember_638454650954237352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638454650954237352" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954237352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954237352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954237352" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954237352" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954237352" xlink:to="xoma_LicenseAgreementMember_638454650954247357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638454650954237352" xlink:to="srt_CounterpartyNameAxis_638454650954247357" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954247357" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954247357" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954247357" xlink:to="xoma_OrganonMember_638454650954247357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638454650954237352" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954247357" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638454650954247357" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954247357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638454650954247357" xlink:to="us-gaap_IntellectualPropertyMember_638454650954247357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638454650954237352" xlink:to="us-gaap_AssetAcquisitionLineItems_638454650954247357" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954247357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638454650954247357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638454650954247357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="xoma_MaximumEarnOutPayments_638454650954257352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638454650954257352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638454650954257352" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638454650954257352" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638454650954257352" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954257352" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638454650954257352" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_638454650954257352" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_638454650954257352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_638454650954257352" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638454650954267354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_ContractWithCustomerAssetNet_638454650954267354" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638454650954267354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_ContractWithCustomerLiability_638454650954267354" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954267354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638454650954247357" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954267354" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954267354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954267354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954267354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954267354" xlink:to="srt_CounterpartyNameAxis_638454650954267354" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954267354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954267354" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954267354" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954267354" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_638454650954277356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954267354" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954277356" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954277356" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954277356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954277356" xlink:to="xoma_LicenseAgreementMember_638454650954277356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954267354" xlink:to="us-gaap_DebtInstrumentAxis_638454650954277356" order="3" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650954277356" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650954277356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650954277356" xlink:to="xoma_NovartisNoteMember_638454650954277356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954267354" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638454650954277356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="xoma_NumberOfPerformanceObligations_638454650954277356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638454650954277356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="xoma_ProceedsFromUpfrontPayment_638454650954277356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954287353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954287353" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="xoma_RoyaltiesPeriodMinimum_638454650954287353" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_638454650954287353" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="us-gaap_ContractWithCustomerAssetNet_638454650954287353" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="us-gaap_ContractWithCustomerLiability_638454650954287353" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638454650954287353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954277356" xlink:to="us-gaap_CapitalizedContractCostNet_638454650954287353" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954297353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954297353" xlink:to="srt_CounterpartyNameAxis_638454650954297353" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954297353" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954297353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954297353" xlink:to="xoma_NovartisPharmaAGMember_638454650954297353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954297353" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954297353" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954297353" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954297353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954297353" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638454650954297353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638454650954297353" xlink:to="xoma_XOMA052LicenseAgreementMember_638454650954297353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638454650954297353" xlink:to="xoma_IL1TargetLicenseAgreementMember_638454650954297353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954297353" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650954297353" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650954297353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650954297353" xlink:to="us-gaap_EquityComponentDomain_638454650954297353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650954297353" xlink:to="us-gaap_CommonStockMember_638454650954307356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954297353" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_LicenseAgreementTransactionPrice_638454650954307356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_LicenseAgreementConsiderationReceived_638454650954307356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_ProceedsFromUpfrontPayment_638454650954307356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_638454650954307356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638454650954307356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650954307356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638454650954307356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_SharesIssuedPricePerShare_638454650954307356" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_638454650954317351" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_SharePrice_638454650954317351" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_CommonStockPremium_638454650954317351" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650954317351" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementsNumber" xlink:label="xoma_AgreementsNumber_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_AgreementsNumber_638454650954317351" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638454650954317351" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_ArrangementsNumber_638454650954317351" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_638454650954317351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="xoma_NumberOfPerformanceObligations_638454650954317351" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954327350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638454650954327350" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638454650954327350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_ContractWithCustomerAssetNet_638454650954327350" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638454650954327350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_ContractWithCustomerLiability_638454650954327350" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638454650954327350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954307356" xlink:to="us-gaap_CapitalizedContractCostNet_638454650954327350" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954327350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954327350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954327350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954327350" xlink:to="srt_CounterpartyNameAxis_638454650954327350" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954327350" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954337358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954337358" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_638454650954337358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954327350" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954337358" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954337358" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954337358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954337358" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_638454650954337358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_638454650954337358" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_638454650954337358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_638454650954337358" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_638454650954337358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954327350" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementsNumber" xlink:label="xoma_AgreementsNumber_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="xoma_AgreementsNumber_638454650954337358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="xoma_ProceedsFromUpfrontPayment_638454650954337358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_638454650954337358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_638454650954337358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="xoma_MilestonePeriodsNumber_638454650954347355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638454650954347355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638454650954347355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="us-gaap_DeferredIncomeCurrent_638454650954347355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954337358" xlink:to="us-gaap_DeferredIncomeNoncurrent_638454650954347355" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RightsReceivableCurrent_638454650954347355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650954347355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650954347355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" xlink:to="srt_CounterpartyNameAxis_638454650954357363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954357363" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954357363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954357363" xlink:to="xoma_LadrxMember_638454650954357363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954357363" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954357363" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954357363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954357363" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650954357363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650954357363" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954357363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638454650954357363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" xlink:to="srt_ProductOrServiceAxis_638454650954357363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638454650954357363" xlink:to="srt_ProductsAndServicesDomain_638454650954367361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ArimoclomolMember" xlink:label="xoma_ArimoclomolMember_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954367361" xlink:to="xoma_ArimoclomolMember_638454650954367361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AldoxorubicinMember" xlink:label="xoma_AldoxorubicinMember_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954367361" xlink:to="xoma_AldoxorubicinMember_638454650954367361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638454650954367361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638454650954367361" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638454650954367361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638454650954367361" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650954367361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" xlink:to="us-gaap_SubsequentEventTypeAxis_638454650954367361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638454650954367361" xlink:to="us-gaap_SubsequentEventTypeDomain_638454650954367361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638454650954367361" xlink:to="us-gaap_SubsequentEventMember_638454650954367361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954357363" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_638454650954377357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_638454650954377357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954377357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638454650954377357" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_MaximumPayableOnSalesMilestone_638454650954377357" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_638454650954377357" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954377357" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650954377357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650954377357" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954387359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954387359" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954387359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954367361" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954387359" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954387359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954387359" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954387359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954387359" xlink:to="srt_CounterpartyNameAxis_638454650954387359" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954387359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954387359" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954387359" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638454650954387359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954387359" xlink:to="xoma_AptevoMember_638454650954387359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954387359" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954397362" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954397362" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954397362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954397362" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638454650954397362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954387359" xlink:to="srt_RangeAxis_638454650954397362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650954397362" xlink:to="srt_RangeMember_638454650954397362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650954397362" xlink:to="srt_MinimumMember_638454650954397362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954387359" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesReceivableMaximum" xlink:label="xoma_MilestonesReceivableMaximum_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_MilestonesReceivableMaximum_638454650954397362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954397362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954397362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954397362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_MaximumPayableOnSalesMilestone_638454650954407361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentThresholdOneTimePayment" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_CommercialPaymentThresholdOneTimePayment_638454650954407361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954407361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650954407361" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_RightsReceivableCurrent_638454650954407361" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954407361" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954407361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954397362" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954407361" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" xlink:to="srt_CounterpartyNameAxis_638454650954417358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954417358" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954417358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954417358" xlink:to="xoma_AgenusIncMember_638454650954417358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954417358" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954417358" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954417358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954417358" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954417358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" xlink:to="srt_ProductOrServiceAxis_638454650954417358" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638454650954417358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638454650954417358" xlink:to="srt_ProductsAndServicesDomain_638454650954417358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954417358" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_638454650954427354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954417358" xlink:to="xoma_MerckImmunoOncologyProductMember_638454650954427354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" xlink:to="dei_LegalEntityAxis_638454650954427354" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638454650954427354" xlink:to="dei_EntityDomain_638454650954427354" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638454650954427354" xlink:to="xoma_AgenusIncMember_638454650954427354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954417358" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638454650954427354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_638454650954427354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_PurchasedPercentageOfMilestones_638454650954427354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_638454650954427354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_638454650954427354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954437359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954437359" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954437359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954437359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved_638454650954437359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_MilestoneAchieved_638454650954437359" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954437359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954437359" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954437359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="xoma_RightsReceivableCurrent_638454650954437359" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954437359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954427354" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954437359" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954447366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954447366" xlink:to="srt_CounterpartyNameAxis_638454650954447366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954447366" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954447366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954447366" xlink:to="xoma_BioasisTechnologiesIncMember_638454650954447366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954447366" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954447366" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954447366" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954447366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954447366" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954447366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954447366" xlink:to="srt_RangeAxis_638454650954447366" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650954447366" xlink:to="srt_RangeMember_638454650954447366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650954447366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650954447366" xlink:to="srt_MaximumMember_638454650954447366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954447366" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954457360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954457360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_638454650954457360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954457360" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrentCreditLossExpense" xlink:label="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_LongTermRightsReceivableNonCurrentCreditLossExpense_638454650954457360" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638454650954457360" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_638454650954457360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_638454650954457360" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954507366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954507366" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650954507366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954457360" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650954507366" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" xlink:to="srt_CounterpartyNameAxis_638454650954517388" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954517388" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954517388" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954517388" xlink:to="xoma_AronoraIncMember_638454650954517388" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954517388" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954517388" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954517388" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954517388" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954517388" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" xlink:to="srt_ProductOrServiceAxis_638454650954517388" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638454650954517388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638454650954517388" xlink:to="srt_ProductsAndServicesDomain_638454650954517388" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954517388" xlink:to="xoma_BayerProductsMember_638454650954527360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954517388" xlink:to="xoma_NonBayerProductsMember_638454650954527360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" xlink:to="us-gaap_DebtInstrumentAxis_638454650954527360" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650954527360" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650954527360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650954527360" xlink:to="xoma_SiliconValleyBankMember_638454650954527360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" xlink:to="srt_RangeAxis_638454650954527360" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650954527360" xlink:to="srt_RangeMember_638454650954527360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650954527360" xlink:to="srt_MaximumMember_638454650954527360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638454650954527360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650954527360" xlink:to="srt_MinimumMember_638454650954527360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954517388" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_AgreementDrugCandidatesNumber_638454650954537356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_638454650954537356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638454650954537356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_638454650954537356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_638454650954537356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_AgreementPaymentPercentageFactor_638454650954537356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954537356" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_638454650954537356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_638454650954537356" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_638454650954547354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_638454650954547354" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_638454650954547354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_638454650954547354" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954547354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954547354" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954547354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954547354" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954547354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="xoma_RightsReceivableCurrent_638454650954547354" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954547354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954537356" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954547354" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954557356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954557356" xlink:to="srt_CounterpartyNameAxis_638454650954557356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954557356" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954557356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954557356" xlink:to="xoma_PalobiofarmaSLMember_638454650954557356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954557356" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954557356" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954557356" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954557356" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954557356" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954557356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954557356" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" xlink:to="xoma_AgreementDrugCandidatesNumber_638454650954557356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954557356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954557356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650954567361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954567361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" xlink:to="xoma_RightsReceivableCurrent_638454650954567361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954557356" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954567361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954567361" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954567361" xlink:to="srt_CounterpartyNameAxis_638454650954567361" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954567361" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954567361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954567361" xlink:to="xoma_ViractaTherapeuticsInc.Member_638454650954567361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954567361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954567361" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954567361" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954567361" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954577361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954577361" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954577361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954567361" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_AgreementDrugCandidatesNumber_638454650954577361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954577361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_638454650954577361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_MaximumConsiderationRetained_638454650954577361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_638454650954577361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954577361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_MilestoneAchieved_638454650954577361" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954577361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954577361" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="xoma_RightsReceivableCurrent_638454650954587361" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954577361" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954587361" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954587361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954587361" xlink:to="srt_CounterpartyNameAxis_638454650954587361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954587361" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954587361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954587361" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638454650954587361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954587361" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954587361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954587361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954587361" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954587361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954587361" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954597359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954587361" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638454650954597359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_638454650954597359" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954597359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_MaximumPayableOnSalesMilestone_638454650954597359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954597359" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_MilestonePaymentReceivedCounterparty_638454650954597359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_MilestonePaymentReceivablePercentage_638454650954597359" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954597359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954597359" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_RightsReceivableCurrent_638454650954607357" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954607357" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650954607357" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954597359" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650954607357" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xlink:type="extended" xlink:title="40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" xlink:to="srt_CounterpartyNameAxis_638454650954607357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954607357" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954607357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638454650954607357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954607357" xlink:to="xoma_AffitechResearchAsMember_638454650954607357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954617360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954617360" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954617360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954617360" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638454650954617360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638454650954617360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638454650954617360" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638454650954617360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638454650954617360" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650954617360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" xlink:to="srt_ProductOrServiceAxis_638454650954617360" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638454650954617360" xlink:to="srt_ProductsAndServicesDomain_638454650954617360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FaricimabProductMember" xlink:label="xoma_FaricimabProductMember_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954617360" xlink:to="xoma_FaricimabProductMember_638454650954617360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638454650954617360" xlink:to="xoma_FaricimabSvoaVabysmoProductMember_638454650954617360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638454650954617360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" xlink:to="srt_StatementGeographicalAxis_638454650954617360" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638454650954617360" xlink:to="srt_SegmentGeographicalDomain_638454650954627354" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638454650954627354" xlink:to="country_US_638454650954627354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638454650954627354" xlink:to="srt_EuropeMember_638454650954627354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954607357" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650954627354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales_638454650954627354" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPeriodDue" xlink:label="xoma_CommercialPaymentPeriodDue_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_CommercialPaymentPeriodDue_638454650954627354" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_CommercialPaymentReceivableTerm_638454650954627354" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638454650954627354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638454650954627354" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954637355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh_638454650954637355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954637355" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_MaximumPayableOnSalesMilestone_638454650954637355" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638454650954637355" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954637355" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_638454650954637355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_638454650954637355" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954647356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_RightsReceivableCurrent_638454650954647356" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_638454650954647356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_638454650954647356" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumAdditionalPayableOnSalesMilestone" xlink:label="xoma_MaximumAdditionalPayableOnSalesMilestone_638454650954647356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="xoma_MaximumAdditionalPayableOnSalesMilestone_638454650954647356" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954647356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954627354" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638454650954647356" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xlink:type="extended" xlink:title="40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954647356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954647356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954647356" xlink:to="srt_CounterpartyNameAxis_638454650954657364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954657364" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" xlink:to="xoma_AffitechResearchAsMember_638454650954657364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" xlink:to="xoma_AptevoMember_638454650954657364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" xlink:to="xoma_LadrxMember_638454650954657364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" xlink:to="xoma_BioasisTechnologiesIncMember_638454650954657364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" xlink:to="xoma_ViractaTherapeuticsInc.Member_638454650954657364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954657364" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638454650954657364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638454650954647356" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_RightsReceivableCurrent_638454650954657364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_638454650954657364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification_638454650954657364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_ShortTermRightsReceivableReclassification_638454650954657364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_RightsReceivableCurrent_638454650954667356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650954667356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638454650954667356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638454650954667356" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment" xlink:label="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment_638454650954667356" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_LongTermRightsReceivableReclassification_638454650954667356" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration" xlink:label="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_638454650954667356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration_638454650954667356" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_6384546509546673561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638454650954657364" xlink:to="xoma_LongTermRightsReceivableNonCurrent_6384546509546673561" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638454650954677360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638454650954677360" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638454650954677360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638454650954677360" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638454650954677360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638454650954677360" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638454650954677360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638454650954677360" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638454650954677360" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638454650954677360" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638454650954677360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638454650954677360" xlink:to="us-gaap_FairValueInputsLevel1Member_638454650954677360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638454650954677360" xlink:to="us-gaap_FairValueInputsLevel3Member_638454650954677360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638454650954677360" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638454650954677360" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638454650954677360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638454650954677360" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638454650954677360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638454650954677360" xlink:to="us-gaap_MoneyMarketFundsMember_638454650954687358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638454650954677360" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954687358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954687358" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638454650954687358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638454650954687358" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638454650954687358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638454650954687358" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638454650954687358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638454650954687358" xlink:to="xoma_FinancialAssetsFairValueDisclosure_638454650954687358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954687358" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638454650954687358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_638454650954687358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638454650954687358" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_638454650954687358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954697358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954697358" xlink:to="us-gaap_MeasurementInputTypeAxis_638454650954697358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638454650954697358" xlink:to="us-gaap_MeasurementInputTypeDomain_638454650954697358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638454650954697358" xlink:to="us-gaap_MeasurementInputSharePriceMember_638454650954697358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954697358" xlink:to="srt_CounterpartyNameAxis_638454650954697358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954697358" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954697358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954697358" xlink:to="xoma_RezoluteIncMember_638454650954697358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954697358" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650954697358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_638454650954697358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650954697358" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_638454650954697358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954707361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954707361" xlink:to="srt_CounterpartyNameAxis_638454650954707361" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650954707361" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954707361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954707361" xlink:to="xoma_BioasisTechnologiesIncMember_638454650954707361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650954707361" xlink:to="xoma_LadrxMember_638454650954707361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954707361" xlink:to="us-gaap_TypeOfArrangementAxis_638454650954707361" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650954707361" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954707361" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954707361" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650954707361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954707361" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650954707361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638454650954707361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650954707361" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638454650954707361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954707361" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638454650954717358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638454650954717358" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638454650954717358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638454650954717358" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650954717358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650954707361" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954717358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954717358" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650954717358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638454650954717358" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650954717358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreement - Leased facilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638454650954717358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638454650954717358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638454650954717358" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638454650954717358" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638454650954717358" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638454650954727358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638454650954727358" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638454650954727358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638454650954727358" xlink:to="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_638454650954727358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638454650954717358" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_638454650954727358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638454650954727358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638454650954727358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_638454650954727358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638454650954727358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638454650954727358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638454650954727358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_OperatingLeaseLiability_638454650954727358" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638454650954737358" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638454650954727358" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650954737358" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638454650954737358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638454650954737358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638454650954737358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638454650954737358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638454650954737358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638454650954737358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638454650954737358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638454650954737358" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638454650954747361" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638454650954747361" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638454650954747361" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638454650954747361" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Lease Agreement - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract_638454650954747361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638454650954747361" xlink:to="us-gaap_OperatingLeaseCost_638454650954747361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638454650954747361" xlink:to="us-gaap_VariableLeaseCost_638454650954747361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638454650954747361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638454650954747361" xlink:to="us-gaap_LeaseCost_638454650954747361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Lease Agreement - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments_638454650954757362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638454650954757362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638454650954757362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Long-Term Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638454650954757362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954757362" xlink:to="us-gaap_DebtInstrumentAxis_638454650954757362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650954757362" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650954757362" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650954757362" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954757362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954757362" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954767361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954757362" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_638454650954767361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954757362" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638454650954767361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638454650954767361" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638454650954767361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650954767361" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650954767361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650954767361" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_638454650954767361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650954767361" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_638454650954767361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650954767361" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_638454650954767361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954757362" xlink:to="us-gaap_DebtInstrumentLineItems_638454650954767361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638454650954767361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638454650954767361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638454650954767361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DebtInstrumentFaceAmount_638454650954767361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SecurityInterestInPercentageOfEquity" xlink:label="xoma_SecurityInterestInPercentageOfEquity_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="xoma_SecurityInterestInPercentageOfEquity_638454650954777360" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOfLongTermDebtNet" xlink:label="xoma_ProceedsFromIssuanceOfLongTermDebtNet_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="xoma_ProceedsFromIssuanceOfLongTermDebtNet_638454650954777360" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638454650954777360" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses" xlink:label="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses_638454650954777360" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses" xlink:label="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses_638454650954777360" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DeferredFinanceCostsNet_638454650954777360" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638454650954777360" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638454650954777360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638454650954777360" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638454650954787363" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638454650954787363" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638454650954787363" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638454650954787363" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses" xlink:label="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses_638454650954787363" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_638454650954787363" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638454650954787363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_LongTermDebtCurrent_638454650954787363" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_LongTermDebtNoncurrent_638454650954797355" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954767361" xlink:to="us-gaap_InterestExpenseLongTermDebt_638454650954797355" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Long-Term Debt - Summary of long-term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_DebtInstrumentTable_638454650954797355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954797355" xlink:to="us-gaap_DebtInstrumentAxis_638454650954797355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650954797355" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650954797355" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650954797355" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954797355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954797355" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954797355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638454650954797355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954797355" xlink:to="us-gaap_DebtInstrumentLineItems_638454650954797355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954797355" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638454650954807363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954797355" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638454650954807363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954797355" xlink:to="us-gaap_LongTermDebt_638454650954807363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954797355" xlink:to="us-gaap_LongTermDebtCurrent_638454650954807363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954797355" xlink:to="us-gaap_LongTermDebtNoncurrent_638454650954807363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638454650954807363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954807363" xlink:to="us-gaap_DebtInstrumentAxis_638454650954807363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650954807363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650954807363" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650954807363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650954807363" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954817361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954817361" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954817361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954807363" xlink:to="us-gaap_DebtInstrumentLineItems_638454650954817361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638454650954817361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638454650954817361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638454650954817361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638454650954817361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638454650954817361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638454650954817361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638454650954817361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954817361" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638454650954817361" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Long-Term Debt - Interest expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_DebtInstrumentTable_638454650954827356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954827356" xlink:to="us-gaap_DebtInstrumentAxis_638454650954827356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650954827356" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650954827356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650954827356" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954827356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650954827356" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_638454650954827356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638454650954827356" xlink:to="us-gaap_DebtInstrumentLineItems_638454650954827356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954827356" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638454650954827356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954827356" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638454650954827356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt_638454650954827356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638454650954827356" xlink:to="us-gaap_InterestExpenseLongTermDebt_638454650954827356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638454650954837361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638454650954837361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638454650954837361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638454650954837361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638454650954837361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638454650954837361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638454650954837361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638454650954837361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954837361" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638454650954837361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638454650954847363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638454650954847363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638454650954847363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638454650954847363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638454650954847363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DeferredTaxAssetsRoyaltyReceivable" xlink:label="xoma_DeferredTaxAssetsRoyaltyReceivable_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="xoma_DeferredTaxAssetsRoyaltyReceivable_638454650954847363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsOther_638454650954847363" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638454650954847363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsGross_638454650954847363" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638454650954857365" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_DeferredTaxAssetsNet_638454650954857365" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638454650954847363" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638454650954857365" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Income Taxes - NOL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638454650954857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638454650954857365" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638454650954857365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638454650954857365" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638454650954857365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638454650954857365" xlink:to="us-gaap_DomesticCountryMember_638454650954857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638454650954857365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638454650954857365" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638454650954857365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638454650954857365" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638454650954867363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638454650954867363" xlink:to="us-gaap_OperatingLossCarryforwards_638454650954867363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638454650954867363" xlink:to="xoma_OperatingLossCarryForwardSubjectToExpiration_638454650954867363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638454650954867363" xlink:to="xoma_NetOperatingLossCarryforwardsExpirationYear_638454650954867363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Income Taxes - Tax credit carryforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638454650954867363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638454650954867363" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638454650954867363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638454650954867363" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638454650954867363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638454650954867363" xlink:to="stpr_CA_638454650954867363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638454650954867363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638454650954867363" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638454650954867363" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638454650954867363" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638454650954877366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_FederalOrphanCreditMember" xlink:label="xoma_FederalOrphanCreditMember_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638454650954877366" xlink:to="xoma_FederalOrphanCreditMember_638454650954877366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638454650954877366" xlink:to="us-gaap_ResearchMember_638454650954877366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638454650954867363" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638454650954877366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638454650954877366" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638454650954877366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TaxCreditCarryForwardExpirationYear" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638454650954877366" xlink:to="xoma_TaxCreditCarryForwardExpirationYear_638454650954877366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638454650954877366" xlink:to="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_638454650954877366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="us-gaap_UnrecognizedTaxBenefits_638454650954887365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638454650954887365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_638454650954887365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6384546509548873651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="us-gaap_UnrecognizedTaxBenefits_6384546509548873651" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638454650954887365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_638454650954887365" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638454650954877366" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638454650954887365" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954887365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954887365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954887365" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650954897363" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650954897363" xlink:to="us-gaap_EquityComponentDomain_638454650954897363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650954897363" xlink:to="us-gaap_CommonStockMember_638454650954897363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954887365" xlink:to="us-gaap_PlanNameAxis_638454650954897363" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638454650954897363" xlink:to="us-gaap_PlanNameDomain_638454650954897363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650954897363" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_638454650954897363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954887365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638454650954897363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_638454650954897363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638454650954897363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638454650954897363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638454650954897363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638454650954897363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods_638454650954907359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods_638454650954907359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod_638454650954907359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod_638454650954907359" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638454650954907359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638454650954907359" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638454650954907359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638454650954907359" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638454650954907359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638454650954907359" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638454650954907359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954897363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638454650954907359" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638454650954917363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638454650954917363" xlink:to="srt_TitleOfIndividualAxis_638454650954917363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650954917363" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954917363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954917363" xlink:to="xoma_EmployeeMember_638454650954917363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeUnderAgeFiftyMember" xlink:label="xoma_EmployeeUnderAgeFiftyMember_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_EmployeeMember_638454650954917363" xlink:to="xoma_EmployeeUnderAgeFiftyMember_638454650954917363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeAgeFiftyOrOverMember" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_EmployeeMember_638454650954917363" xlink:to="xoma_EmployeeAgeFiftyOrOverMember_638454650954917363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638454650954917363" xlink:to="srt_RangeAxis_638454650954917363" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650954917363" xlink:to="srt_RangeMember_638454650954917363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650954917363" xlink:to="srt_MaximumMember_638454650954917363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638454650954917363" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638454650954917363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638454650954917363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638454650954927358" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" xlink:to="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_638454650954927358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638454650954927358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638454650954927358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638454650954917363" xlink:to="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_638454650954927358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" xlink:to="us-gaap_PlanNameAxis_638454650954927358" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638454650954927358" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638454650954927358" xlink:to="us-gaap_PlanNameDomain_638454650954927358" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650954927358" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650954937362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650954937362" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650954937362" xlink:to="us-gaap_EquityComponentDomain_638454650954937362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650954937362" xlink:to="us-gaap_CommonStockMember_638454650954937362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" xlink:to="us-gaap_AwardTypeAxis_638454650954937362" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650954937362" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954937362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954937362" xlink:to="us-gaap_EmployeeStockOptionMember_638454650954937362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" xlink:to="srt_RangeAxis_638454650954937362" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650954937362" xlink:to="srt_RangeMember_638454650954937362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650954937362" xlink:to="srt_MinimumMember_638454650954937362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650954937362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" xlink:to="srt_TitleOfIndividualAxis_638454650954937362" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650954937362" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954947363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeTerminatedMember" xlink:label="xoma_EmployeeTerminatedMember_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954947363" xlink:to="xoma_EmployeeTerminatedMember_638454650954947363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954927358" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638454650954947363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638454650954947363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638454650954947363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638454650954947363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638454650954947363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638454650954947363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954947363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638454650954947363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954957360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954957360" xlink:to="us-gaap_AwardTypeAxis_638454650954957360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650954957360" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954957360" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954957360" xlink:to="us-gaap_EmployeeStockOptionMember_638454650954957360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954957360" xlink:to="us-gaap_PlanNameAxis_638454650954957360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638454650954957360" xlink:to="us-gaap_PlanNameDomain_638454650954957360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650954957360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650954957360" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650954957360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954957360" xlink:to="srt_TitleOfIndividualAxis_638454650954967368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650954967368" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954967368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954967368" xlink:to="xoma_EmployeeMember_638454650954967368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954967368" xlink:to="srt_DirectorMember_638454650954967368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954957360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638454650954967368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_638454650954967368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_638454650954967368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650954967368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650954967368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638454650954977366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650954967368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638454650954977366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638454650954977366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650954967368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638454650954977366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638454650954977366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650954967368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638454650954977366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638454650954977366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650954967368" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638454650954977366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650954977366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954967368" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650954977366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" xlink:to="us-gaap_PlanNameAxis_638454650954987370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638454650954987370" xlink:to="us-gaap_PlanNameDomain_638454650954987370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650954987370" xlink:to="xoma_StockOptionInducementAwardsMember_638454650954987370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638454650954987370" xlink:to="xoma_StockOptionInducementAwardOneMember_638454650954987370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638454650954987370" xlink:to="xoma_StockOptionInducementAwardTwoMember_638454650954987370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" xlink:to="us-gaap_AwardTypeAxis_638454650954987370" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650954987370" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954987370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650954987370" xlink:to="us-gaap_EmployeeStockOptionMember_638454650954987370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" xlink:to="srt_TitleOfIndividualAxis_638454650954987370" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954987370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650954987370" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954987370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954987370" xlink:to="xoma_ChiefExecutiveOfficerInterimMember_638454650954997365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650954987370" xlink:to="xoma_ChiefInvestmentOfficerMember_638454650954997365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" xlink:to="us-gaap_VestingAxis_638454650954997365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638454650954997365" xlink:to="us-gaap_VestingDomain_638454650954997365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638454650954997365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638454650954997365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638454650954997365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650954987370" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_638454650954997365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_638454650954997365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638454650955007365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_SharePrice_638454650955007365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638454650955007365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638454650955007365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638454650955007365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638454650955007365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638454650955007365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638454650955007365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638454650955007365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638454650955007365" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638454650955057372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638454650955057372" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638454650955057372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638454650955057372" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650955057372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650955057372" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638454650955067398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650955057372" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638454650955067398" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638454650955067398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650955057372" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638454650955067398" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638454650955067398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650955057372" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638454650955067398" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638454650955067398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638454650955057372" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638454650955067398" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955067398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650954997365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955067398" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955077371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955077371" xlink:to="us-gaap_AwardTypeAxis_638454650955077371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955077371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955077371" xlink:to="us-gaap_EmployeeStockOptionMember_638454650955077371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638454650955077371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638454650955077371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638454650955077371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638454650955077371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638454650955077371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384546509550773711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384546509550773711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638454650955087367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638454650955087367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638454650955087367" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638454650955087367" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638454650955087367" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384546509550873671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384546509550873671" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638454650955087367" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638454650955087367" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638454650955087367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638454650955087367" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638454650955097360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638454650955097360" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638454650955097360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638454650955097360" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638454650955097360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638454650955097360" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955097360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955097360" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638454650955097360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638454650955097360" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638454650955097360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955077371" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638454650955097360" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955107365" xlink:to="us-gaap_AwardTypeAxis_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650955107365" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955107365" xlink:to="xoma_PerformanceStockUnitsMember_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955107365" xlink:to="us-gaap_PlanNameAxis_638454650955107365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638454650955107365" xlink:to="us-gaap_PlanNameDomain_638454650955107365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638454650955107365" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955107365" xlink:to="us-gaap_VestingAxis_638454650955107365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638454650955107365" xlink:to="us-gaap_VestingDomain_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638454650955107365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638454650955107365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638454650955107365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638454650955107365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638454650955117365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638454650955107365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638454650955117365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955107365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638454650955117365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._638454650955117365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638454650955117365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_638454650955117365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638454650955117365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955117365" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638454650955117365" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" xlink:to="us-gaap_AwardTypeAxis_638454650955127361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650955127361" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955127361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955127361" xlink:to="xoma_PerformanceStockUnitsMember_638454650955127361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" xlink:to="srt_StatementScenarioAxis_638454650955127361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638454650955127361" xlink:to="srt_ScenarioUnspecifiedDomain_638454650955127361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar30Member" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650955127361" xlink:to="xoma_StockPriceHurdlesOfDollar30Member_638454650955127361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar35Member" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650955127361" xlink:to="xoma_StockPriceHurdlesOfDollar35Member_638454650955127361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar40Member" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650955127361" xlink:to="xoma_StockPriceHurdlesOfDollar40Member_638454650955127361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_StockPriceHurdlesOfDollar45Member" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_638454650955127361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650955127361" xlink:to="xoma_StockPriceHurdlesOfDollar45Member_638454650955127361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" xlink:to="us-gaap_AwardDateAxis_638454650955137366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_638454650955137366" xlink:to="us-gaap_AwardDateDomain_638454650955137366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AwardDateMay2023ToOctober2023Member" xlink:label="xoma_AwardDateMay2023ToOctober2023Member_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638454650955137366" xlink:to="xoma_AwardDateMay2023ToOctober2023Member_638454650955137366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" xlink:to="srt_RangeAxis_638454650955137366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650955137366" xlink:to="srt_RangeMember_638454650955137366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650955137366" xlink:to="srt_MinimumMember_638454650955137366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650955137366" xlink:to="srt_MaximumMember_638454650955137366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955127361" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" xlink:to="us-gaap_SharePrice_638454650955137366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638454650955137366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638454650955137366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955147364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955147364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638454650955147364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638454650955147364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638454650955147364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955137366" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638454650955147364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955147364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955147364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650955147364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955147364" xlink:to="us-gaap_AwardTypeAxis_638454650955147364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955147364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650955147364" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955147364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955147364" xlink:to="xoma_PerformanceStockUnitsMember_638454650955157366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638454650955147364" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955157366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955157366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638454650955157366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638454650955157366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638454650955157366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638454650955157366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638454650955157366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384546509551573661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638454650955157366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384546509551573661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955157366" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638454650955157366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638454650955157366" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638454650955157366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638454650955157366" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638454650955157366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638454650955157366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638454650955157366" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638454650955157366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638454650955157366" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638454650955167365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638454650955157366" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638454650955167365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638454650955157366" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638454650955167365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955167365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955167365" xlink:to="us-gaap_IncomeStatementLocationAxis_638454650955167365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638454650955167365" xlink:to="us-gaap_IncomeStatementLocationDomain_638454650955167365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638454650955167365" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638454650955167365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955167365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955167365" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955167365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955167365" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638454650955177369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xlink:type="extended" xlink:title="41011 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955177369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955177369" xlink:to="srt_TitleOfIndividualAxis_638454650955177369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650955177369" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955177369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955177369" xlink:to="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_638454650955177369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955177369" xlink:to="srt_RangeAxis_638454650955177369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650955177369" xlink:to="srt_RangeMember_638454650955177369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650955177369" xlink:to="srt_MaximumMember_638454650955177369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955177369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638454650955177369" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955177369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentPeriodRetirementEligible" xlink:label="xoma_EmploymentPeriodRetirementEligible_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955177369" xlink:to="xoma_EmploymentPeriodRetirementEligible_638454650955187368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955177369" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638454650955187368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955177369" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638454650955187368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638454650955177369" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638454650955187368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="41012 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_2" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955187368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955187368" xlink:to="srt_TitleOfIndividualAxis_638454650955187368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955187368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650955187368" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955187368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955187368" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_638454650955197367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955187368" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus_638454650955197367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" xlink:to="xoma_PeriodOneRetentionBonusEligibility_638454650955197367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" xlink:to="xoma_PeriodTwoRetentionBonusEligibility_638454650955197367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" xlink:to="xoma_RetentionBonusExpenseAccrued_638454650955197367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedRetentionBonus" xlink:label="xoma_AccruedRetentionBonus_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955197367" xlink:to="xoma_AccruedRetentionBonus_638454650955197367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xlink:type="extended" xlink:title="41013 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_4" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955197367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650955197367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955197367" xlink:to="srt_TitleOfIndividualAxis_638454650955197367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650955197367" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955207368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955207368" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember_638454650955207368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638454650955197367" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955207368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955207368" xlink:to="xoma_AccruedCompensationContinuityIncentive_638454650955207368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638454650955207368" xlink:to="xoma_CompensationExpenseEmploymentAgreement_638454650955207368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638454650955207368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638454650955207368" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638454650955207368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638454650955207368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638454650955207368" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638454650955207368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638454650955207368" xlink:to="us-gaap_PreferredStockMember_638454650955217370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638454650955207368" xlink:to="us-gaap_StockCompensationPlanMember_638454650955217370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638454650955207368" xlink:to="us-gaap_WarrantMember_638454650955217370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638454650955207368" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650955217370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650955217370" xlink:to="us-gaap_EquityComponentDomain_638454650955217370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650955217370" xlink:to="us-gaap_CommonStockMember_638454650955217370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638454650955207368" xlink:to="us-gaap_AwardTypeAxis_638454650955217370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650955217370" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955217370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955217370" xlink:to="xoma_PerformanceStockUnitsMember_638454650955217370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638454650955207368" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638454650955217370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638454650955217370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638454650955217370" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638454650955217370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638454650955217370" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638454650955227360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638454650955217370" xlink:to="us-gaap_SharePrice_638454650955227360" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ScheduleOfEarningsPerShareTable" xlink:label="xoma_ScheduleOfEarningsPerShareTable_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="xoma_ScheduleOfEarningsPerShareTable_638454650955227360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ScheduleOfEarningsPerShareTable_638454650955227360" xlink:to="us-gaap_StatementClassOfStockAxis_638454650955227360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650955227360" xlink:to="us-gaap_ClassOfStockDomain_638454650955227360" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955227360" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650955227360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955227360" xlink:to="us-gaap_SeriesBPreferredStockMember_638454650955227360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EarningsPerShareLineItems" xlink:label="xoma_EarningsPerShareLineItems_638454650955227360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ScheduleOfEarningsPerShareTable_638454650955227360" xlink:to="xoma_EarningsPerShareLineItems_638454650955227360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_EarningsPerShareLineItems_638454650955227360" xlink:to="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638454650955237368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638454650955237368" xlink:to="us-gaap_NetIncomeLoss_638454650955237368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638454650955237368" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638454650955237368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638454650955237368" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638454650955237368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638454650955237368" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638454650955237368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_EarningsPerShareLineItems_638454650955227360" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638454650955237368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638454650955237368" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638454650955237368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638454650955237368" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638454650955237368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638454650955237368" xlink:to="us-gaap_EarningsPerShareBasic_638454650955237368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638454650955237368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638454650955237368" xlink:to="us-gaap_EarningsPerShareDiluted_638454650955237368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955247366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955247366" xlink:to="us-gaap_StatementClassOfStockAxis_638454650955247366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650955247366" xlink:to="us-gaap_ClassOfStockDomain_638454650955247366" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955247366" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_638454650955247366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955247366" xlink:to="xoma_SeriesXConvertiblePreferredStockMember_638454650955247366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955247366" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_638454650955247366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955247366" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955247366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638454650955247366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" xlink:to="us-gaap_PreferredStockSharesOutstanding_638454650955247366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" xlink:to="us-gaap_PreferredStockSharesAuthorized_638454650955257370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" xlink:to="us-gaap_PreferredStockSharesIssued_638454650955257370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638454650955257370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955247366" xlink:to="xoma_PreferredStockConversionPricePerShare_638454650955257370" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955257370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955257370" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650955257370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650955257370" xlink:to="us-gaap_EquityComponentDomain_638454650955257370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650955257370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650955257370" xlink:to="us-gaap_CommonStockMember_638454650955257370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650955257370" xlink:to="us-gaap_PreferredStockMember_638454650955267368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955257370" xlink:to="srt_StatementScenarioAxis_638454650955267368" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638454650955267368" xlink:to="srt_ScenarioUnspecifiedDomain_638454650955267368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650955267368" xlink:to="srt_ScenarioForecastMember_638454650955267368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955257370" xlink:to="us-gaap_StatementClassOfStockAxis_638454650955267368" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650955267368" xlink:to="us-gaap_ClassOfStockDomain_638454650955267368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955267368" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650955267368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955257370" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955267368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638454650955267368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638454650955267368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_SharesIssuedPricePerShare_638454650955277364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650955277364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638454650955277364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_638454650955277364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PreferredStockSharesAuthorized_638454650955277364" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PreferredStockSharesIssued_638454650955277364" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PreferredStockLiquidationPreference_638454650955277364" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_PreferredStockDividendPeriodYearProrated_638454650955277364" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638454650955277364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638454650955277364" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth_638454650955287369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_PreferredStockDividendPeriodMonth_638454650955287369" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638454650955287369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638454650955287369" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_638454650955287369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_638454650955287369" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638454650955287369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638454650955287369" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap_638454650955287369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_PreferredStockShareCap_638454650955287369" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_638454650955287369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955267368" xlink:to="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_638454650955287369" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955297367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955297367" xlink:to="us-gaap_StatementClassOfStockAxis_638454650955297367" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650955297367" xlink:to="us-gaap_ClassOfStockDomain_638454650955297367" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955297367" xlink:to="us-gaap_SeriesBPreferredStockMember_638454650955297367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955297367" xlink:to="dei_AdrMember_638454650955297367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955297367" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638454650955297367" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638454650955297367" xlink:to="us-gaap_RelatedPartyDomain_638454650955297367" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638454650955297367" xlink:to="us-gaap_RelatedPartyMember_638454650955297367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_638454650955297367" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_638454650955297367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638454650955297367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955297367" xlink:to="srt_StatementScenarioAxis_638454650955297367" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638454650955297367" xlink:to="srt_ScenarioUnspecifiedDomain_638454650955307369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638454650955307369" xlink:to="srt_ScenarioForecastMember_638454650955307369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955297367" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955307369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_SharesIssuedPricePerShare_638454650955307369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638454650955307369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_DepositarySharesRatioToPreferredStock_638454650955307369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PreferredStockSharesAuthorized_638454650955307369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638454650955307369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PreferredStockSharesIssued_638454650955307369" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638454650955317365" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_ProceedsFromIssuanceOfPreferredStockNet_638454650955317365" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638454650955317365" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PreferredStockLiquidationPreference_638454650955317365" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendAmountPerShare" xlink:label="xoma_PreferredStockDividendAmountPerShare_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_PreferredStockDividendAmountPerShare_638454650955317365" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_PreferredStockDividendPeriodYearProrated_638454650955317365" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638454650955317365" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth_638454650955317365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_PreferredStockDividendPeriodMonth_638454650955317365" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638454650955327361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638454650955327361" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638454650955327361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638454650955327361" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_638454650955327361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_638454650955327361" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap_638454650955327361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955307369" xlink:to="xoma_PreferredStockShareCap_638454650955327361" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Capital Stock - Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable_638454650955327361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsPayableTable_638454650955327361" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638454650955327361" xlink:to="us-gaap_StatementClassOfStockAxis_638454650955337371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650955337371" xlink:to="us-gaap_ClassOfStockDomain_638454650955337371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955337371" xlink:to="us-gaap_SeriesAPreferredStockMember_638454650955337371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955337371" xlink:to="dei_AdrMember_638454650955337371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638454650955327361" xlink:to="us-gaap_DividendsPayableLineItems_638454650955337371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems_638454650955337371" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638454650955337371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems_638454650955337371" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid_638454650955337371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Capital Stock - BVF Ownership (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955337371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955337371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955337371" xlink:to="dei_LegalEntityAxis_638454650955347373" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638454650955347373" xlink:to="dei_EntityDomain_638454650955347373" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638454650955347373" xlink:to="xoma_BiotechnologyValueFundLPMember_638454650955347373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955337371" xlink:to="srt_OwnershipAxis_638454650955347373" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638454650955347373" xlink:to="srt_OwnershipDomain_638454650955347373" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638454650955347373" xlink:to="xoma_XomaCorporationMember_638454650955347373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955337371" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650955347373" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650955347373" xlink:to="us-gaap_EquityComponentDomain_638454650955347373" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650955347373" xlink:to="us-gaap_CommonStockMember_638454650955347373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955337371" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638454650955347373" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955347373" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638454650955347373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_638454650955347373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955347373" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_638454650955347373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Capital Stock - ATM Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638454650955357365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638454650955357365" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638454650955357365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638454650955357365" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_638454650955357365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638454650955357365" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member_638454650955357365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" xlink:to="us-gaap_StatementEquityComponentsAxis_638454650955357365" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638454650955357365" xlink:to="us-gaap_EquityComponentDomain_638454650955357365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638454650955357365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638454650955357365" xlink:to="us-gaap_CommonStockMember_638454650955357365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" xlink:to="us-gaap_StatementClassOfStockAxis_638454650955367373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638454650955367373" xlink:to="us-gaap_ClassOfStockDomain_638454650955367373" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638454650955367373" xlink:to="dei_AdrMember_638454650955367373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" xlink:to="srt_RangeAxis_638454650955367373" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650955367373" xlink:to="srt_RangeMember_638454650955367373" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650955367373" xlink:to="srt_MaximumMember_638454650955367373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638454650955357365" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638454650955367373" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955367373" xlink:to="xoma_MaximumValueOfStockToBeIssued_638454650955367373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955367373" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_638454650955367373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_638454650955367373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955367373" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_638454650955367373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638454650955367373" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638454650955377365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638454650955377365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638454650955377365" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638454650955377365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638454650955377365" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638454650955377365" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955377365" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_638454650955377365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955377365" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_638454650955377365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955377365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955377365" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955377365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955377365" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_638454650955387370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955377365" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_638454650955387370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955377365" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_638454650955387370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638454650955377365" xlink:to="us-gaap_DebtInstrumentAxis_638454650955387370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650955387370" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650955387370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650955387370" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650955387370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638454650955377365" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638454650955387370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955387370" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638454650955387370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638454650955387370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955387370" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638454650955387370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xlink:type="extended" xlink:title="41208 - Disclosure - Capital Stock - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638454650955397370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638454650955397370" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638454650955397370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638454650955397370" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638454650955397370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955397370" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_638454650955397370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955397370" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_638454650955397370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955397370" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955397370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955397370" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_638454650955397370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955397370" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_638454650955397370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember" xlink:label="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955397370" xlink:to="xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_638454650955397370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638454650955397370" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638454650955397370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638454650955397370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638454650955407370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" xlink:to="xoma_ExercisablePeriodOfWarrants_638454650955407370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638454650955407370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638454650955397370" xlink:to="xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_638454650955407370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638454650955397370" xlink:to="us-gaap_DebtInstrumentAxis_638454650955407370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650955407370" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650955407370" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650955407370" xlink:to="xoma_SiliconValleyBankMember_638454650955407370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650955407370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650955407370" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650955407370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="41209 - Disclosure - Capital Stock - Weighted average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650955417368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650955417368" xlink:to="us-gaap_MeasurementInputTypeAxis_638454650955417368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638454650955417368" xlink:to="us-gaap_MeasurementInputTypeDomain_638454650955417368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638454650955417368" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638454650955417368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638454650955417368" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638454650955417368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638454650955417368" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638454650955417368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638454650955417368" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638454650955417368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650955417368" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638454650955417368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638454650955417368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638454650955417368" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638454650955417368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember" xlink:label="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638454650955417368" xlink:to="xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_638454650955427364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650955417368" xlink:to="us-gaap_DebtInstrumentAxis_638454650955427364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638454650955427364" xlink:to="us-gaap_DebtInstrumentNameDomain_638454650955427364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember" xlink:label="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638454650955427364" xlink:to="xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_638454650955427364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638454650955417368" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650955427364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650955427364" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638454650955427364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638454650955427364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638454650955427364" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638454650955427364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_638454650955437373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_638454650955437373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_CommitmentsAndContingenciesTable_638454650955437373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638454650955437373" xlink:to="us-gaap_TypeOfArrangementAxis_638454650955437373" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650955437373" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955437373" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955437373" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650955437373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955437373" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638454650955437373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955437373" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638454650955437373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650955437373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638454650955437373" xlink:to="srt_CounterpartyNameAxis_638454650955437373" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650955437373" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955447370" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955447370" xlink:to="xoma_BioasisTechnologiesIncMember_638454650955447370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955447370" xlink:to="xoma_LadrxMember_638454650955447370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955447370" xlink:to="xoma_AptevoMember_638454650955447370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955447370" xlink:to="xoma_AffitechResearchAsMember_638454650955447370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638454650955437373" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638454650955447370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638454650955447370" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638454650955447370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638454650955447370" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650955447370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638454650955437373" xlink:to="xoma_CommitmentsAndContingenciesLineItems_638454650955447370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638454650955447370" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650955447370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650955447370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638454650955447370" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650955447370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650955457367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638454650955447370" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638454650955457367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638454650955457367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638454650955447370" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638454650955457367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_638454650955457367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_638454650955457367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638454650955457367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LitigationSettlementExpense_638454650955457367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638454650955467373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638454650955467373" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638454650955467373" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638454650955467373" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638454650955467373" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638454650955467373" xlink:to="us-gaap_CustomerConcentrationRiskMember_638454650955467373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638454650955467373" xlink:to="us-gaap_CreditConcentrationRiskMember_638454650955467373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638454650955467373" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638454650955467373" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638454650955467373" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638454650955467373" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638454650955467373" xlink:to="us-gaap_SalesRevenueNetMember_638454650955467373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638454650955467373" xlink:to="us-gaap_AccountsReceivableMember_638454650955467373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638454650955467373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638454650955467373" xlink:to="srt_MajorCustomersAxis_638454650955467373" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638454650955467373" xlink:to="srt_NameOfMajorCustomerDomain_638454650955477372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638454650955477372" xlink:to="xoma_Partner1Member_638454650955477372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638454650955477372" xlink:to="xoma_Partner2Member_638454650955477372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638454650955477372" xlink:to="xoma_Partner3Member_638454650955477372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638454650955477372" xlink:to="xoma_Partner4Member_638454650955477372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638454650955467373" xlink:to="us-gaap_ConcentrationRiskLineItems_638454650955477372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638454650955477372" xlink:to="xoma_NumberOfMajorPartners_638454650955477372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638454650955477372" xlink:to="us-gaap_ConcentrationRiskPercentage1_638454650955477372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638454650955477372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638454650955477372" xlink:to="us-gaap_AccountsReceivableNetCurrent_638454650955477372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638454650955487366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638454650955487366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638454650955487366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638454650955487366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638454650955487366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638454650955487366" xlink:to="srt_StatementGeographicalAxis_638454650955487366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638454650955487366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638454650955487366" xlink:to="srt_SegmentGeographicalDomain_638454650955487366" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638454650955487366" xlink:to="country_US_638454650955497371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638454650955487366" xlink:to="srt_AsiaPacificMember_638454650955497371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638454650955487366" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638454650955497371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638454650955497371" xlink:to="us-gaap_Revenues_638454650955497371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638454650955497371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="us-gaap_SubsequentEventTypeAxis_638454650955497371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638454650955497371" xlink:to="us-gaap_SubsequentEventTypeDomain_638454650955497371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638454650955497371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638454650955497371" xlink:to="us-gaap_SubsequentEventMember_638454650955497371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="srt_TitleOfIndividualAxis_638454650955507374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638454650955507374" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955507374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638454650955507374" xlink:to="srt_ChiefExecutiveOfficerMember_638454650955507374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="us-gaap_AwardTypeAxis_638454650955507374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638454650955507374" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955507374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638454650955507374" xlink:to="us-gaap_PerformanceSharesMember_638454650955507374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="us-gaap_TypeOfArrangementAxis_638454650955507374" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638454650955507374" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955507374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionOfEconomicInterestAgreementMember" xlink:label="xoma_AcquisitionOfEconomicInterestAgreementMember_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955507374" xlink:to="xoma_AcquisitionOfEconomicInterestAgreementMember_638454650955507374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650955507374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638454650955507374" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638454650955507374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="srt_CounterpartyNameAxis_638454650955517367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638454650955517367" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955517367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TalpheraMember" xlink:label="xoma_TalpheraMember_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955517367" xlink:to="xoma_TalpheraMember_638454650955517367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AloraPharmaceuticalsMember" xlink:label="xoma_AloraPharmaceuticalsMember_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955517367" xlink:to="xoma_AloraPharmaceuticalsMember_638454650955517367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638454650955517367" xlink:to="xoma_LadrxMember_638454650955517367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="dei_LegalEntityAxis_638454650955517367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638454650955517367" xlink:to="dei_EntityDomain_638454650955517367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_TalpheraMember" xlink:label="xoma_TalpheraMember_6384546509555173671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638454650955517367" xlink:to="xoma_TalpheraMember_6384546509555173671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638454650955517367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="srt_MajorCustomersAxis_638454650955517367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638454650955517367" xlink:to="srt_NameOfMajorCustomerDomain_638454650955527364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember" xlink:label="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638454650955527364" xlink:to="xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_638454650955527364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_U.s.DepartmentOfDefenseMember" xlink:label="xoma_U.s.DepartmentOfDefenseMember_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638454650955527364" xlink:to="xoma_U.s.DepartmentOfDefenseMember_638454650955527364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638454650955527364" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638454650955527364" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638454650955527364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638454650955527364" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638454650955527364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="us-gaap_BusinessAcquisitionAxis_638454650955527364" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638454650955527364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638454650955527364" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638454650955527364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_KinnateMember" xlink:label="xoma_KinnateMember_638454650955537371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638454650955527364" xlink:to="xoma_KinnateMember_638454650955537371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638454650955537371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="srt_RangeAxis_638454650955537371" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638454650955537371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638454650955537371" xlink:to="srt_RangeMember_638454650955537371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638454650955537371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650955537371" xlink:to="srt_MinimumMember_638454650955537371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638454650955537371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638454650955537371" xlink:to="srt_MaximumMember_638454650955537371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638454650955537371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638454650955497371" xlink:to="us-gaap_SubsequentEventLineItems_638454650955537371" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_638454650955547372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_638454650955547372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired_638454650955547372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="us-gaap_TreasuryStockSharesAcquired_638454650955547372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentAgreementAnnualSalary" xlink:label="xoma_EmploymentAgreementAnnualSalary_638454650955547372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_EmploymentAgreementAnnualSalary_638454650955547372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary" xlink:label="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary_638454650955547372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary_638454650955547372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638454650955547372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638454650955547372" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650955547372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638454650955547372" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638454650955557370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638454650955557370" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650955557370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones_638454650955557370" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones_638454650955557370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones_638454650955557370" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyAndMilestonesReceivableThreshold" xlink:label="xoma_RoyaltyAndMilestonesReceivableThreshold_638454650955557370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_RoyaltyAndMilestonesReceivableThreshold_638454650955557370" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty_638454650955557370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty_638454650955557370" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty_638454650955557370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty_638454650955557370" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650955567374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638454650955567374" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareCashAmount_638454650955567374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareCashAmount_638454650955567374" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_CommonStockParOrStatedValuePerShareAcquiree" xlink:label="xoma_CommonStockParOrStatedValuePerShareAcquiree_638454650955567374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_CommonStockParOrStatedValuePerShareAcquiree_638454650955567374" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount_638454650955567374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount_638454650955567374" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount" xlink:label="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount_638454650955567374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount_638454650955567374" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionNumberOfContingentValueRights" xlink:label="xoma_AcquisitionNumberOfContingentValueRights_638454650955577369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_AcquisitionNumberOfContingentValueRights_638454650955577369" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_AcquisitionValueRightNumberOfCashPayments" xlink:label="xoma_AcquisitionValueRightNumberOfCashPayments_638454650955577369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_AcquisitionValueRightNumberOfCashPayments_638454650955577369" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer_638454650955577369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer_638454650955577369" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20231231.xsd#xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer" xlink:label="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer_638454650955577369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638454650955537371" xlink:to="xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer_638454650955577369" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669928576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XOMA CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2154066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">2200 Powell Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line2</a></td>
<td class="text">Suite 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">204-7200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,749,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,625,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000791908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, par value $0.0075 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMAP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMAO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671481488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 153,290,000<span></span>
</td>
<td class="nump">$ 57,826,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Short-term equity securities</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">335,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="nump">14,215,000<span></span>
</td>
<td class="nump">2,366,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">483,000<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">169,313,000<span></span>
</td>
<td class="nump">61,253,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">378,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">57,952,000<span></span>
</td>
<td class="nump">63,683,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets - long term</a></td>
<td class="nump">533,000<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">234,301,000<span></span>
</td>
<td class="nump">140,382,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">653,000<span></span>
</td>
<td class="nump">524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">2,768,000<span></span>
</td>
<td class="nump">2,918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">2,113,000<span></span>
</td>
<td class="nump">1,899,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedPreferredStockDividendCurrent', window );">Preferred stock dividend accrual</a></td>
<td class="nump">1,368,000<span></span>
</td>
<td class="nump">1,368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">5,543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,499,000<span></span>
</td>
<td class="nump">6,818,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method - long-term</a></td>
<td class="nump">7,228,000<span></span>
</td>
<td class="nump">9,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">118,518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">145,580,000<span></span>
</td>
<td class="nump">16,368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,495,492 and 11,454,025 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,311,809,000<span></span>
</td>
<td class="nump">1,306,271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,223,223,000)<span></span>
</td>
<td class="num">(1,182,392,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">88,721,000<span></span>
</td>
<td class="nump">124,014,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">234,301,000<span></span>
</td>
<td class="nump">140,382,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedPreferredStockDividendCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedPreferredStockDividendCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670314464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0075<span></span>
</td>
<td class="nump">$ 0.0075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">277,333,332<span></span>
</td>
<td class="nump">277,333,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">11,495,492<span></span>
</td>
<td class="nump">11,454,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,495,492<span></span>
</td>
<td class="nump">11,454,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948673174080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">4,758<span></span>
</td>
<td class="nump">6,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,606<span></span>
</td>
<td class="nump">23,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived', window );">Impairment charges (Note 4, Note 5)</a></td>
<td class="nump">15,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Arbitration settlement costs (Note 3)</a></td>
<td class="nump">4,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">46,606<span></span>
</td>
<td class="nump">23,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,848)<span></span>
</td>
<td class="num">(17,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,586<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(40,831)<span></span>
</td>
<td class="num">(17,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,831)<span></span>
</td>
<td class="num">(17,104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(40,831)<span></span>
</td>
<td class="num">(17,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(46,303)<span></span>
</td>
<td class="num">(22,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (46,303)<span></span>
</td>
<td class="num">$ (22,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (4.04)<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (4.04)<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">11,471<span></span>
</td>
<td class="nump">11,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">11,471<span></span>
</td>
<td class="nump">11,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent. Also includes the amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670226240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>8.625% Series A Cumulative, Perpetual Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>8.375% Series B Cumulative, Perpetual Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Convertible preferred stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 1,307,030<span></span>
</td>
<td class="num">$ (1,165,288)<span></span>
</td>
<td class="nump">$ 141,876<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan', window );">Issuance of common stock related to 401(k) contribution and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans', window );">Issuance of common stock related to 401(k) contribution and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,104)<span></span>
</td>
<td class="num">(17,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,306,271<span></span>
</td>
<td class="num">(1,182,392)<span></span>
</td>
<td class="nump">124,014<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan', window );">Issuance of common stock related to 401(k) contribution and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans', window );">Issuance of common stock related to 401(k) contribution and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,831)<span></span>
</td>
<td class="num">(40,831)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 1,311,809<span></span>
</td>
<td class="num">$ (1,223,223)<span></span>
</td>
<td class="nump">$ 88,721<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669685696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (40,831)<span></span>
</td>
<td class="num">$ (17,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived', window );">Impairment charges</a></td>
<td class="nump">15,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims', window );">Common stock contribution to 401(k)</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of long-term debt</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLeasePaymentsNonCash', window );">Non-cash lease expense</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables, net</a></td>
<td class="num">(1,003)<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">219<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(523)<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="num">(2,108)<span></span>
</td>
<td class="num">(1,877)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,158)<span></span>
</td>
<td class="num">(12,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="num">(14,650)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="nump">13,956<span></span>
</td>
<td class="nump">3,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for IP acquired under the ObsEva IP Acquisition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(711)<span></span>
</td>
<td class="num">(20,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs and loan fees</a></td>
<td class="num">(4,253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of preferred stock dividends</a></td>
<td class="num">(5,472)<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of options and other share-based compensation</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(1,398)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">120,593<span></span>
</td>
<td class="num">(4,451)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">101,724<span></span>
</td>
<td class="num">(37,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents at the beginning of the period</a></td>
<td class="nump">57,826<span></span>
</td>
<td class="nump">95,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">159,550<span></span>
</td>
<td class="nump">57,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_IssuanceOfWarrantsDebtFinancing', window );">Issuance of common stock warrants in connection with long-term debt</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Accrued issuance costs in connection with issuance of long-term debt</a></td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Preferred stock dividend accrual</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition', window );">Estimated fair value of contingent consideration under the LadRx Agreements</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedTransactionCostsRelatedToPurchaseAgreements', window );">Accrued transaction costs in connection with ObsEva IP Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements', window );">Accrual of contingent consideration under the Affitech CPPA</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual of contingent consideration under purchase agreements.  May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedTransactionCostsRelatedToPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued transaction costs in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedTransactionCostsRelatedToPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan issuance of Common stock for services or claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of contingent consideration under asset acquisition agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_IssuanceOfWarrantsDebtFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock warrants issued in connection with long-term debt financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_IssuanceOfWarrantsDebtFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent. Also includes the amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasePaymentsNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments, non cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasePaymentsNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671157856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA Corporation, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through the acquisition of rights to future milestone payments, royalties and commercial payments, since its royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. XOMA also acquires milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to the Company in a relatively short timeframe. &#160;The Company&#8217;s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects most of its future revenue to be based on milestone payments the Company may receive for milestones and royalties associated with these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December&#160;31, 2023, the Company had unrestricted and restricted cash and cash equivalents of $159.6 million primarily related to financing cash inflows received in December 2023 pursuant to the Blue Owl Loan Agreement (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had unrestricted cash and cash equivalents of $153.3 million and restricted cash of $6.3 million. As of December 31, 2023, $0.2 million of restricted cash was classified as current and $6.1 million was classified as non-current. The restricted cash balance may only be used to pay interest expense, administrative fees and other allowable expenses pursuant to the Blue Owl Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s current cash balance and its planned spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671166016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration, amortization of the Blue Owl Loan, valuation of warrants, accrued expenses and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, including estimates such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. In addition, the Company&#8217;s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Unrestricted and Restricted Cash and Cash Equivalents </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total unrestricted and restricted cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 159,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are generally in money market funds.<span style="display:inline-block;width:2.25pt;"></span><span style="display:inline-block;width:18pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Unrestricted Cash and Cash Equivalents </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had an unrestricted cash balance of $124.9 million and an unrestricted cash equivalent balance of $28.4 million. As of December 31, 2022, the Company had an unrestricted cash balance of $27.5 million and an unrestricted cash equivalent balance of $30.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Restricted Cash </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL. As of December 31, 2023, the Company had a short-term restricted cash balance of $0.2 million and a long-term restricted cash balance of $6.1 million on its consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had no restricted cash or cash equivalent balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive loss in the period of sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Allowance for Current Expected Credit Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s consolidated statements of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset was amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represented the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset was carried at cost less accumulated amortization. Amortization was included in amortization of intangible assets in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheet and included a $14.2 million impairment charge in the <span style="-sec-ix-hidden:Hidden_yKNGHsYxl0ua6mlZdK34eA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of operations</span></span> and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Long-Term Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-term debt represents the Company&#8217;s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the effective interest rate method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the effective interest rate method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Warrants </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company&#8217;s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company&#8217;s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#8217;s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive (Loss) Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt annual requirements under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671086560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Consolidated Financial Statement Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Consolidated Financial Statement Details</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Consolidated Financial Statement Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, equity securities consisted of an investment in Rezolute&#8217;s common stock of $0.2 million and $0.3 million, respectively (see Note 4). For the years ended December 31, 2023 and 2022, the Company recognized a loss of $0.2 million and $0.4 million, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Intangible Assets, Net </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, impairment charge and net carrying value of the Company&#8217;s intangible assets as of December 31, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Charge </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $14.2 million impairment charge in the <span style="-sec-ix-hidden:Hidden_W5XKDOrmOUCVyHTuQ-wVXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statements of operations</span></span> and comprehensive loss.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of intangible assets as of December 31, 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accrued and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 562</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll, severance and retention costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,449</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,918</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Arbitration Proceeding </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company initiated a binding arbitration proceeding with one of its licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, and sought milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement had </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">expired. The panel ruled that the Company was responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; fees and administrative fees previously incurred by the Licensee of $4.1 million, which the Company paid in April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676177792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsAbstract', window );"><strong>Licensing and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsTextBlock', window );">Licensing and Other Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive an aggregate of up to $19.0 million relating to TAK-079 (mezagitamab) and low single-digit royalties on future sales of all products subject to this license. The Company&#8217;s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to receive royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#8217;s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to receive royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $0.8 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. &#160;No milestone revenue was recognized for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized annual license fee revenue of $0.1 million from Takeda in the consolidated statement of operations and comprehensive loss for the each of the years ended December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company has received $3.0 million of milestone payments since the inception of the agreement and is eligible to receive additional milestone payments of up to $16.0 million under the Takeda Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize RZ358 (previously known as &#8220;X358&#8221;) products for all indications. In addition, the Company entered into a common stock purchase agreement with </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rezolute pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock in connection with any future equity financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to an aggregate of $232.0 million based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the later of the date of expiration of the last valid patent claim covering the product in each country, or 12 years from the date of the first commercial sale of the product in each country. Rezolute&#8217;s future royalty obligations in the U.S. will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid patent claim, until such a claim is confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical study. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of 12 years from the date of the first commercial sale of the product in each country or for so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in each country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#8217; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute&#8217;s equity financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute&#8217;s common stock (as adjusted for the <span style="-sec-ix-hidden:Hidden__s_2kpVZCEW7Qrum_VkryA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>:50 reverse stock split in October 2020). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No revenue was recognized for the year ended December 31, 2023. The Company recognized $2.0 million from contracts with customers in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMA&#8217;s patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized milestone payments of $1.5 million in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023. &#160;The Company did not recognize any revenue related to this arrangement in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">ObsEva </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#8217;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA was eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. If ebopiprant was successfully commercialized, the Company would have been entitled to receive royalties on net sales that range from low to mid-teens from Organon and would have been required to make mid-single-digit royalty payments on net sales to Merck KGaA. The Company paid ObsEva a $15.0 million upfront payment at closing and would have paid potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company would have received pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The transaction was treated as an acquisition of a finite-lived intangible asset (see Note 2). As such, the Company&#8217;s cost to acquire said intangible asset was $15.2 million, which consisted of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, which was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the intangible asset at acquisition represented 17 years. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022. The Company recognized $0.9 million and $0.1 million of amortization expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA did not meet the definition of a derivative under ASC 815 and a liability would have been recognized at the time that the underlying revenue was recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 would require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expected the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would have been recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 23, 2023, Organon notified the Company of its intent to terminate for convenience the Organon License Agreement, which <span style="background:#ffffff;">XOMA assumed pursuant to the ObsEva IP Acquisition Agreement dated November 21, 2022.</span> The termination was effective as of January 21, 2024. The Company will not be entitled to any milestone payments with respect to any milestone achieved by Organon following the notice of termination. No material early termination penalties will be payable by either party. The Company evaluated the related intangible asset balance for impairment in the fourth quarter of 2023 and recorded an impairment charge of $14.2 million, writing off the entire finite-lived intangible asset in the consolidated balance sheet and recognizing an intangible asset impairment in its <span style="-sec-ix-hidden:Hidden_UjdHxsUKK0CGYSg7vc8W1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations</span></span> and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the Anti-TGF&#946; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#946; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Anti-TGF&#946; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#946; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon 180 days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGF&#946; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGF&#946; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#946; Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#8217; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#946; Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2023, Novartis communicated to the Company that it intends to discontinue development activities related to NIS793. Novartis will cease enrolling patients in the remaining active TGF&#223; clinical studies and will collect all data upon conclusion of these studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#8364;12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, Novartis extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#8217;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;21, 2016, the Company entered into two royalty interest sale agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $2.1 million and $1.9 million as revenue under the units-of-revenue method under these arrangements during the&#160;years ended December 31, 2023 and 2022, respectively. As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. As of December&#160;31, 2023, the Company classified $2.1 million and $7.2 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671171872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyPurchaseAgreementTextBlock', window );">Royalty and Commercial Payment Purchase Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term royalty and commercial payment receivables were $14.2 million and $2.4 million as of December 31, 2023 and 2022, respectively. Long-term royalty and commercial payment receivables were $58.0 million and $63.7 million as of December 31, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">LadRx Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased rights related to arimoclomol include potential regulatory and commercial milestone payments of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased payments related to aldoxorubicin include potential regulatory and commercial milestone payments of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages for sales of other licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and may pay up to an additional $6.0 million in regulatory and commercial sales milestone payments which included $5.0 million related to regulatory milestone payments and $1.0 million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.<span style="display:inline-block;width:15.22pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, there was no change in the estimated fair value of the regulatory milestone payments from the initial value. <span style="display:inline-block;width:0.86pt;"></span>On January 11, 2024, the milestone was achieved and the Company made a $1.0 million milestone payment to LadRx (see Note 15).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023. <span style="display:inline-block;width:1.41pt;"></span> <span style="display:inline-block;width:15.5pt;"></span><span style="display:inline-block;width:18pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aptevo Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables in its consolidated balance sheet which included a $9.6 million upfront payment and a $50,000 one-time payment, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet (the &#8220;Aptevo Contingent Consideration&#8221;) at inception. The Company paid the one-time payment of $50,000 in June 2023 when related receipts exceeded $0.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, the Company received total commercial payments pursuant to the Aptevo CPPA of $1.7 million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it has a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet date of December 31, 2023 and, as such, $2.0 million was recorded as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (&#8220;Incyte&#8221;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone payment under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Agenus RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestone and royalty payments received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that were being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the contingent future cash payments upon achievement of certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;) of $75,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon the closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 20, 2023, Bioasis announced the suspension of all of its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, the Company recorded an impairment charge of $1.6 million in its <span style="-sec-ix-hidden:Hidden_oKAPgn6owUGhjjDbJEhNww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of operations</span></span> and comprehensive loss and a reduction of $1.6 million under long-term royalty receivables related to the Bioasis RPA and Second Bioasis RPA. Due to the assessment that the credit loss will not potentially reverse in the future, the Company wrote off the royalty asset receivable and no allowance for credit losses was recorded as of December 31, 2023. The fair value of the Bioasis Contingent Consideration was reduced to zero with the change in the estimated fair value recognized in other income (expense), net in the consolidated statement of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aronora<span style="font-style:normal;font-weight:normal;"> </span>Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone and option payments (the &#8220;Non-Royalties&#8221;) related to five anti-thrombotic hematology product candidates. Three candidates were subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive a low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#8217;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora RPA, if the Company receives at least $25.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Aronora RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties&#8217; entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestone payments and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2023, the Company earned a $5.0 million milestone payment pursuant to the Viracta RPA related to the FDA&#8217;s acceptance of Day One Biopharmaceuticals&#8217; NDA for tovorafenib. In accordance with the cost recovery method, the $5.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance. As of December 31, 2023, no further payments were probable to be received under the Viracta RPA in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affitech Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">upfront payment and $8.0 million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone payment tied to the U.S. marketing approvals and a $3.0 million milestone payment tied to the EC approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Commercial payments are due from Roche within 60 days of December 31 and June 30 of each year. In accordance with the cost recovery method, commercial payments received are recorded as direct reductions of short-term and long-term receivable balances, as applicable. During the years ended December 31, 2022 and 2023, the Company received $0.5 million and $7.3 million from Roche, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it had a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet date of December 31, 2023 and, as such, $12.2 million was recorded as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The achievement of the first and second sales-based milestone payment under the Affitech CPPA was considered probable as of December 31, 2023, and the Company recognized a $6.0 million contingent liability in the consolidated balance sheet. The Company may pay up to $6.0 million in additional sales-based milestone payments upon the achievement of certain incremental sales milestones in the future which are not assessed as probable and as a result not recorded as a contingent liability as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities during the years ended December 31, 2023 and 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,075</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,500)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,366)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,683</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,650</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">LadRx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,284)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,673)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,575)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,109)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,024)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Recognition of contingent consideration:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,952</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668829392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#160;&#8211; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2023 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,513</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2023 and 2022. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss. As of December 31, 2023 and 2022, the Company valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the Nasdaq Stock Market of $0.99 and $2.07, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the LadRx contingent consideration liability of $1.0 million at the inception of the LadRx Agreements represents the future consideration that is contingent upon the achievement of specified regulatory milestones for the product candidates related to arimoclomol and aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each product candidate. Such contingent consideration is remeasured at fair value at each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss until settlement. As of December 31, 2023, there were no changes in the estimated fair value from the initial value of $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $0.1 million of contingent consideration as of December 31, 2022 recorded pursuant to the Bioasis RPA was written off during the second quarter of 2023 (see Note 5). &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676168176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LeaseDisclosureTextBlock', window );">Lease Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Lease Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company leases one facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term five months from its original expiration of February 28, 2023 to July 31, 2023 (the &#8220;amended lease agreement&#8221; or the &#8220;amended lease&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company retained no option to further extend, renew or terminate the amended lease under the amended terms and all other material terms and conditions, including the monthly base rent, remained consistent with the original lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the&#160;right-of-use asset of $0.1 million to reflect the changes in the lease payments due to the extended lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">On June 27, 2023, the Company executed the second lease amendment for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing amended lease which expired in July 2023 (the &#8220;new lease agreement&#8221; or the &#8220;new lease&#8221;). The new lease agreement commenced November 10, 2023 and has a term of 65 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the new lease agreement, the Company retained access to its original premises under the amended lease which expired in July 2023, until the new premise became available on November 10, 2023. Payments made between when the lease expired in July 2023 and the commencement date of the new premises of November 10, 2023 were recorded as variable lease costs in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In accordance with ASC 842, the Company accounted for the new lease as a separate contract and the Company recognized an operating lease right-of-use assets of $0.4 million and operating lease liabilities of $0.4 million on November 10, 2023, the commencement date of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes maturity of the new lease through the 65-month term of the Company&#8217;s operating lease liabilities as of December 31, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rent&#160;Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 485</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96)</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total net lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the total net lease liability was $0.4 million and $34,000, respectively. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2023 the Company&#8217;s current and non-current operating lease liabilities were $0.1 million and $0.3 million, respectively. As of December 31, 2022 the Company&#8217;s $34,000 lease liability was classified as a current liability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company&#8217;s operating leases for the years ended December 31, 2023 and 2022, respectively (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the original, amended and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the consolidated statements of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company&#8217;s new and original operating lease as of December 31, 2023 and 2022, respectively, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(2)</span>The new lease that commenced November 10, 2023 has a lease term of 65 months.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676362544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Long-Term Debt </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, XOMA transferred to XRL, a newly formed wholly owned subsidiary, all its rights, title and interest in the commercial payments from Roche&#8217;s VABYSMO under the Affitech CPPA and related assets (the &#8220;Commercial Payments&#8221;). The VABYSMO-related assets and rights transferred to XRL are referred to herein as the &#8220;Transferred Assets.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Simultaneously, XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders, pursuant to which XRL was extended certain senior secured credit facilities in an aggregate principal amount of up to $140.0 million. The principal and interest of the loan are to be paid from the Commercial Payments. XRL is obligated to make semi-annual interest payments, starting in March 2024, at a fixed rate of 9.875% per annum until the commercial payment-backed loan is repaid, at which time the Commercial Payments will revert back to XOMA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any Commercial Payment in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The loan matures on December 15, 2038, provided that XRL may repay it in full at any time prior to December 15, 2038, subject to the terms of the Blue Owl Loan Agreement. The Blue Owl Loan includes (i) an initial term loan in an aggregate principal amount equal to $130.0 million and (ii) a delayed draw term loan in an aggregate principal amount of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$10.0 million to be funded at the option of the XRL upon receipt by the lenders of payments of principal and interest from the proceeds of Commercial Payments in excess of an agreed upon amount on or prior to March 15, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The payment obligations under the Blue Owl Loan Agreement are limited to XRL, and Blue Owl has no recourse under the Blue Owl Loan Agreement against XOMA or any assets other than the Transferred Assets and XOMA&#8217;s equity interest in XRL. In connection with the Blue Owl Loan Agreement, (i) XRL granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the Affitech CPPA and (b) all other assets of XRL and (ii) XOMA granted Blue Owl a first-priority perfected lien on, and security interest in 100% of the equity of XRL. The Blue Owl Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, the Company borrowed the initial term loan of $130.0 million and received $119.6 million, net of $4.1 million in fees and lender expenses and $6.3 million that was deposited into reserve accounts to pay interest, administrative fees and XRL&#8217;s operating expenses (see Note 2). The Company also incurred $0.6 million of direct issuance costs related to the Blue Owl Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Blue Owl Loan Agreement, XOMA issued to Blue Owl and certain funds affiliated with Blue Owl warrants to purchase: (i) up to 40,000 shares of XOMA&#8217;s common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of XOMA&#8217;s common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of XOMA&#8217;s common stock at an exercise price of $50.00 per share (collectively, the &#8220;Blue Owl Warrants&#8221;) (see Note 12). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $1.5 million. As of December 31, 2023, all Blue Owl Warrants were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The initial term loan of $130.0 million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the effective interest rate was determined to be 11.01%. The Company recorded a debt discount of $5.3 million, which included $3.8 million in allocated fees and lender expenses and $1.5 million for the fair value of the Blue Owl Warrants. The Company also recorded $0.6 million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $5.3 million and $0.6 million of direct debt issuance costs over the expected term of the initial term loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the closing date of December 15, 2023, the Company recorded the $0.3 million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of December 31, 2023, no amount had been drawn from the delayed draw term loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively as of December 31, 2023. The Company recorded $0.6 million in interest expense during the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the impact of the initial term loan on the Company&#8217;s consolidated balance sheet as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross principal </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,939)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total carrying value net of unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,061</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,543)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,518</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-term debt on the Company&#8217;s consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. There was no long-term debt on the Company&#8217;s consolidated balance sheet as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aggregate projected future principal payments of the initial term loan as of December 31, 2023, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,594</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,767</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,200</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,155</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,872</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,412</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive loss for the&#160;year ended December&#160;31, 2023 relates to the initial term loan (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676485440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">9. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had pre-tax book loss of $40.8 million and $17.1 million for the years ended December 31, 2023 and 2022, respectively. The Company had no income tax provision for the year ended December 31, 2023 and a $15,000 income tax benefit for the&#160;year ended December&#160;31, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#8217;s actual effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3mFvOmJiKUCxDAEe7fSXPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_tzBx_nlwlk2NnJLZtAgZ4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Presentation for the fiscal year ended 2022 adjusted to conform with the fiscal year ended 2023 </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The significant components of net deferred tax assets at December&#160;31, 2023 and 2022 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,732</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,974</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,176</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,715</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,408</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty Receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 858</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,329</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,329)</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xQxEZRom10ipxNjFLhAhoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_mFboUZF-aEWaGrU2CAFHmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net increase in the valuation allowance was $8.0 million and $3.3 million, for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company&#8217;s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company&#160;has determined that total deferred tax assets should be fully offset by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February&#160;2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per&#160;year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2023 and 2022.&#160;To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal NOL carry-forwards of approximately $137.8 million and state NOL carry-forwards of approximately $22.1 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2017 Tax Cuts and Jobs Act, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the provisions under the 2017 Tax Cuts and Jobs Act that became effective in tax years beginning after December 31, 2021 required the capitalization and amortization of research and experimental expenditures. The change in this U.S. tax law did not have an impact on the Company's consolidated financial statements. The Company will continue to evaluate the impact of this tax law change on future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Act&#8221;) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act did not have an impact on the Company&#8217;s consolidated financial statements and related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company&#8217;s federal income tax returns for tax&#160;years 2020 and beyond remain subject to examination by the Internal Revenue Service. The Company&#8217;s state income tax returns for tax&#160;years 2019 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future&#160;years are still subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2023, the Company has not accrued interest or penalties related to uncertain tax positions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671302736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Based Compensation and Other Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Based Compensation and Other Benefit Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Stock Based Compensation and Other Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2015, the Company&#8217;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#8220;2015 ESPP&#8221;), which replaced the Company&#8217;s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July&#160;1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2015 ESPP initially provided for six-month offering periods ending on May&#160;31 and November&#160;30 of each&#160;year. At the end of each offering period, employees were able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Compensation Committee and the Board adopted, and in May&#160;2017, the Company&#8217;s stockholders approved, an amendment to the Company&#8217;s 2015 ESPP. The amendment (a)&#160;increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b)&#160;increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2023, the Company had 224,886 remaining authorized shares available for purchase under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Effective December 1, 2023, the 2015 ESPP consists of consecutive 24-month overlapping offering periods that begin on December 1 and June 1 and end 24 months later on November 30 and May 31, respectively. Each offering period </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">is comprised of four consecutive six-month purchase periods starting on December 1 and June 1 and ending on November 30 and May 31, respectively. Employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the purchase period. The plan includes a rollover mechanism for the purchase price if the fair market value of the Company&#8217;s common stock on the purchase date is less than the fair market value of the Company&#8217;s common stock on the first trading day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2023 and 2022, employees purchased 6,051 and 6,090 shares of common stock, respectively, under the 2015 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Savings Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Section 401(k)&#160;of the Internal Revenue Code of 1986, the Board has adopted a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50% of their eligible compensation per payroll period, up to a maximum for 2023 and 2022 of $22,500 and $20,500, respectively (or $30,000 and $27,000, respectively, for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan&#160;year, in cash or in shares of the Company&#8217;s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the&#160;years ended December 31, 2023 and 2022, and 100% was paid in common stock for each&#160;year. When available, the Company applies shares from plan forfeitures of terminated employees toward the Company&#8217;s matching contribution. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2010 Plan Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2010, the Compensation Committee and Board adopted, and in July 2010 the Company&#8217;s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three months from the date of termination of employment (longer in case of death, certain retirements or subject to certain terminations pursuant to the Retention Plan).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had 409,477 shares available for grant under the 2010 Plan. As of December&#160;31, 2023, options to purchase 2,730,068 shares of common stock were outstanding under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;background:#ffffff;">Fair Value Assumptions of 2010 Plan Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted under the 2010 Plan during the years ended December 31, 2023 and 2022, was estimated based on the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.64 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The weighted-average grant-date fair value per share of the options granted under the 2010 Plan during the year ended December 31, 2023 and 2022 was </span><span style="background:#ffffff;">$13.18</span><span style="background:#ffffff;">&#160;and </span><span style="background:#ffffff;">$12.01</span><span style="background:#ffffff;">, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Option Inducement Awards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Company&#8217;s Chief Investment Officer, effective as of January&#160;1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the &#8220;Stock Option Inducement Awards&#8221;) when the Company&#8217;s stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Hughes two separate non-qualified stock options to purchase: (i) 100,000 shares of the Company&#8217;s common stock at a fair market value exercise price of $18.66 per share that vested in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 and (ii) 75,000 shares of the Company&#8217;s common stock at an above fair market value exercise price of $30.00 per share that will vest in a series of 36 successive equal monthly installments from January 1, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Sitko two separate non-qualified stock options to purchase: (i) 300,000 shares of the Company&#8217;s common stock at a fair market value exercise price of $18.66 per share and (ii) 250,000 shares of the Company&#8217;s common stock at an above fair market value exercise price of $30.00 per share. 25% of the shares subject to Mr. Sitko&#8217;s option grants vested and became exercisable on January 3, 2024, and the balance of the shares will vest and become exercisable in a series of 36 successive equal monthly installments thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Fair Value Assumptions of Stock Option Inducement Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the year ended December 31, 2023, was estimated based on the following weighted average assumptions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>No Stock Option Inducement Awards were granted during the year ended December 31, 2022.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share in January 2023 was $11.91.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share in January 2023 was estimated based on the following weighted average assumptions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.01 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the year ended December 31, 2022.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during January 2023 was $14.68.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The activity for all stock options for the year ended December 31, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,025,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,804</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804,302</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.44</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,473)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.27</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,303)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.51</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,730,068</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.88</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.29</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,638</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,961,143</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.73</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.27</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,606</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $0.3 million and $2.8 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, $8.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.64 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Performance Stock Unit Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company granted employees 430,400 PSUs under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company&#8217;s common stock as compared to four stock price hurdles over a three-year period from the May 2023 grant date (the &#8220;performance period&#8221;). A stock price hurdle is considered attained when, at any time during the performance period, the Company&#8217;s volume-weighted average stock price equals or exceeds the hurdle stock price value for 30 consecutive calendar days. Upon attainment of a stock price hurdle, <span style="-sec-ix-hidden:Hidden_xpK_StUG00ybbYZa3HpmVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> of the earned PSUs will vest immediately upon achievement, <span style="-sec-ix-hidden:Hidden_-jeY11JkkU-_yKExwXSvYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> will vest upon the two-year anniversary of the grant date and <span style="-sec-ix-hidden:Hidden_XJQ4j8H56EGkjfAn5W1EYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one third</span></span> will vest on the three-year anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Company granted an additional 18,200 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Fair Value Assumptions of Performance Stock Unit Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The range of grant date fair values of the PSUs granted during the year ended December 31, 2023 was estimated as follows: &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derived</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Hurdle Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Service Period</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.42-17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69-2.59</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,239</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.16-16.07</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.93-2.59</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,024</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.07-14.84</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.12-2.59</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,787</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.12-13.72</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.27-2.59</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448,600</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates that it will recognize total stock-based compensation expense of approximately $6.9 million in aggregate for the PSUs granted in May and October 2023 using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The activity for all PSUs for the year ended December 31, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unvested PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448,600</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.40</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448,600</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.40</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $2.8 million of stock-based compensation expense related to the PSUs during the year ended December 31, 2023. As of December 31, 2023, there was $4.1 million in unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of 1.38 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,608</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Thomas Burns Equity Awards Modification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2022 and November 2022, the Company entered into letter agreements with Thomas Burns that amended and supplemented his amended and restated employment agreement. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remained employed by the Company for a <span style="-sec-ix-hidden:Hidden_PLUg0go3Uk-_7O-a0gyV7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span>-month period beginning on November 1, 2022, he would be deemed &#8220;retirement eligible&#8221; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. The unrecognized stock-based compensation cost for the unvested stock options as of November 1, 2022 was recognized over the shorter of (1) twelve months and (2) the remaining original vesting period (the &#8220;Revised Vesting Term&#8221;). During the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation expense of $1.4 million and $0.6 million, respectively, related to Mr. Burns&#8217; option awards. As of December 31, 2023, there was no unrecognized compensation expense related to Mr. Burns&#8217; stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Employee Retention Bonus </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company approved the Amended Retention Plan which provided that each of its then current employees, excluding the Chief Executive Officer, would be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remained consistent with the Retention Plan. The Company accrued and recognized the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $0.6 million and $0.1 million for cash retention bonuses in operating expenses in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2022, the Company had $0.1 million of cash retention bonuses recorded in accrued and other liabilities in the consolidated balance sheet. All cash retention bonuses were paid in full on October 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">James R. Neal Departure and Continuity Incentive </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">James R. Neal retired as the Company&#8217;s Chief Executive Officer effective as of December 31, 2022 (the &#8220;Departure Date&#8221;) and resigned as a member of the Board and Chairman of the Board, effective January 1, 2023. Pursuant to Mr. Neal&#8217;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal was entitled to a cash payment of&#160;$1.2&#160;million (the &#8220;Continuity Incentive&#8221;) which was made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company recorded the full&#160;$1.2&#160;million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. The unpaid accrued Continuity Incentive&#160;recorded in accrued and other liabilities in the consolidated balance sheets as of December 31, 2022 was $1.2&#160;million. The Continuity Incentive was paid in full as of December 31, 2023.<b style="font-weight:bold;"> </b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671302736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Net Loss Per Share Attributable to Common Stockholders </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 885</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $18.50 per share as of December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (40,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,104)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.04)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670295552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series X and Series Y Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF 5,003 shares of Series X Convertible Preferred Stock in 2017 and 1,252.772 shares of Series Y Convertible Preferred Stock in 2018. There were no shares of Series Y Convertible Preferred Stock outstanding as of December 31, 2021, after BVF converted all Series Y Convertible Preferred Stock into common stock on April 15, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were 5,003 shares authorized and issued of Series X Convertible Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series&#160;X and Series Y Convertible Preferred Stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212; </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212; </i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion&#8212; </i>Each share of Series&#160;X and Series Y Convertible Preferred Stock is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212; </i>Series&#160;X and Series Y Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212; </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the shares of Series&#160;X and Series Y Convertible Preferred Stock are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#8217;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the Series&#160;X and Series Y Convertible Preferred Stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series A Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were 984,000 shares authorized and issued of Series A Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212;&#160;</i>Holders of <span style="background:#ffffff;">the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board and declared by the Corporation, cumulative cash dividends at the rate of </span><span style="background:#ffffff;">8.625%</span><span style="background:#ffffff;"> per annum of the </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the </span>Series<span style="background:#ffffff;"> A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full dividend period shall be prorated and computed on the basis of a&#160;</span><span style="background:#ffffff;">360</span><span style="background:#ffffff;">-day&#160;year consisting of </span><span style="background:#ffffff;">twelve</span><span style="background:#ffffff;">&#160;</span><span style="background:#ffffff;">30</span><span style="background:#ffffff;">-day&#160;months.&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212;&#160;</i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of Series A Preferred Stock will <span style="background:#ffffff;">rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or&#160;winding-up and on parity with respect to the </span>distribution<span style="background:#ffffff;"> of assets with the Company&#8217;s Series X Preferred Stock. </span>The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption&#8212;&#160;</i>The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, <span style="background:#ffffff;">upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Conversion&#8212;&#160;</i>The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (ii) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable, divided by (iii) &#160;the common stock price and (B) 1.46071 (the &#8220;Share Cap&#8221;). The common stock price to be </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company&#8217;s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212;&#160;</i>Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212;</i>The Company evaluated the Series A Preferred Stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Depositary Shares Representing Interest in Series B Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Each Series B Depositary Share represents <span style="-sec-ix-hidden:Hidden_0WqPQZjVdk-rCh1KkH7IeA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/1000</span></span> interest in a share of Series B Preferred Stock. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spouse of James Neal, then Chief Executive Officer and Chairman of the Board, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends</i>&#8212; Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals $2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Preference</i> - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption</i> - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion </i>- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the &#8220;Conversion Rate&#8221;); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the &#8220;Share Cap&#8221;), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights</i>&#8212; Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification</i>&#8212;The Company evaluated the Series B Preferred Stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, the Company&#8217;s Board declared and paid cash dividends on the Company&#8217;s Series A Preferred Stock and Series B Depositary shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_H7Lo4FtfLUG9U_8NFt12cA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_btS0jg_C4kSqwPe0vi-i5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">February 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dSMEchMnFkqWypW9UGk7Lw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_3oD01eoLEkipHZzpjVu_VA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 17, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OTKsEhaqhEaFde7pn0r-XA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7zNSlE5m30-23n_Xhxv1Cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 26, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s0Q6hKWcX0SArB1No9n7mA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZPUZL4tmokqcSqnQL-SrmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 16, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 18, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YeDNFyDyWkiXwMYXPzULTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__Df-kChCN02M1zGD5YLDDA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 15, 2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, BVF owned approximately 31.6% of the Company&#8217;s total outstanding shares of common stock, and if all the shares of Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 52.3% of the Company&#8217;s total outstanding shares of common stock. The Company&#8217;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2023, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December&#160;31, 2023 and 2022, the following common stock warrants were outstanding:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, the Company issued SVB a warrant in connection with the legacy SVB Loan Agreement which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders&#8217; equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the legacy SVB Loan Agreement was amended to extend the draw period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.<span style="letter-spacing:-0.1pt;">&#160;</span>The warrant is classified in stockholders&#8217; equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In December 2023, in connection with the Blue Owl Loan, the Company issued the Blue Owl Warrants to certain funds affiliated with Blue Owl, which are exercisable in whole or in part to purchase up to an aggregate of </span><span style="letter-spacing:-0.1pt;">120,000</span><span style="letter-spacing:-0.1pt;"> shares of the Company&#8217;s common stock, inclusive of warrants to purchase (i) up to </span><span style="letter-spacing:-0.1pt;">40,000</span><span style="letter-spacing:-0.1pt;"> shares of XOMA&#8217;s common stock at an exercise price of </span><span style="letter-spacing:-0.1pt;">$35.00</span><span style="letter-spacing:-0.1pt;"> per share; (ii) up to </span><span style="letter-spacing:-0.1pt;">40,000</span><span style="letter-spacing:-0.1pt;"> shares of XOMA&#8217;s common stock at an exercise price of </span><span style="letter-spacing:-0.1pt;">$42.50</span><span style="letter-spacing:-0.1pt;"> per share; and (iii) up to </span><span style="letter-spacing:-0.1pt;">40,000</span><span style="letter-spacing:-0.1pt;"> shares of XOMA&#8217;s common stock at an exercise price of </span><span style="letter-spacing:-0.1pt;">$50.00</span><span style="letter-spacing:-0.1pt;"> per share. The Blue Owl Warrants may be exercised on a cashless basis and are exercisable within </span><span style="letter-spacing:-0.1pt;">10 years</span><span style="letter-spacing:-0.1pt;"> from the date of issuance or upon the consummation of certain acquisitions of the Company. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value per share of <span style="letter-spacing:-0.1pt;">Blue Owl</span> Warrants issued at the exercise prices of $35.00, $42.50 and $50.00 per share during the fourth quarter of 2023 was determined using the Black-Scholes Model <span style="letter-spacing:-0.1pt;">to be </span><span style="letter-spacing:-0.1pt;">$12.53</span><span style="letter-spacing:-0.1pt;">, </span><span style="letter-spacing:-0.1pt;">$12.23</span><span style="letter-spacing:-0.1pt;"> and </span><span style="letter-spacing:-0.1pt;">$11.97</span><span style="letter-spacing:-0.1pt;"> per share, respectively, </span>based on the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="letter-spacing:-0.1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate <span style="letter-spacing:-0.1pt;">fair value of the Blue Owl Warrants </span>of $1.5 million is classified in stockholders&#8217; equity on the consolidated balance sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675268144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s agreements with Bioasis, Aronora, Kuros, Affitech, ObsEva and Aptevo the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones and the Aptevo Contingent Consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company included $75,000 for the Bioasis Contingent Consideration that represented the estimated fair value of the potential future payments of the Bioasis RPA as of December 31, 2022. The Bioasis Contingent Consideration was remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. During the second quarter of 2023, the estimated fair value of the Bioasis Contingent Consideration was reduced to $0 and, as such, no balance remains as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $1.0 million for the LadRx contingent consideration that represents the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>at the inception of the LadRx Agreements. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of December 31, 2023, there has been no change in the estimated fair value from the initial value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the first quarter of 2023, the Company recorded a contingent liability of $50,000 under ASC 450 for the Aptevo Contingent Consideration at the inception of the Aptevo CPPA. During the year ended December 31, 2023, the contingent liability recorded pursuant to the Aptevo CPPA decreased to zero after the Company paid Aptevo $50,000 upon achievement of the related commercial sales milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $6.0 million liability was recorded in contingent consideration under RPAs, AAAs and CPPAs and a corresponding $6.0 million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones and LadRx milestones will be recorded when the amounts, by product, are estimable and probable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, none of the Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones or LadRx milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet<b style="font-weight:bold;">.</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675268144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract', window );"><strong>Concentration of Risk, Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration of Risk, Segment and Geographic Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Concentration of Risk, Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, restricted cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, three partners represented 44%, 32% and 21% of total revenues. For the year ended December 31, 2022, four partners represented&#160;33%, 31%, 13% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of December 31, 2023. There were no trade receivables, net balance as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,477</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,550</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,027</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s property and equipment is held in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of risk segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675268144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Repurchase Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 2, 2024, the Board authorized the Company&#8217;s first stock repurchase program, which permits the Company to purchase up to $50.0 million of its common stock through January 2027. Under the program, the Company has discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, as part of accelerated share repurchases or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at the Company&#8217;s sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate the Company to acquire any particular amount of its common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. As of March 4, 2024, the Company has purchased a total of 660 shares of its common stock pursuant to the stock repurchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Appointment of Owen Hughes as Chief Executive Officer </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2024, the Board appointed Owen Hughes, previously Interim Chief Executive Officer, to serve as the Company&#8217;s full-time Chief Executive Officer. In connection with this appointment, the Company and Mr. Hughes entered into an amendment and restatement of Mr. Hughes&#8217; employment agreement (the &#8220;Amended and Restated Employment Agreement&#8221;), pursuant to which his annual base salary was increased to $575,000 and his initial target annual cash bonus amount was increased to 60% of his base salary, subject to the achievement of annual performance milestones to be established by the Board. Mr. Hughes is also eligible to receive certain termination benefits. On January 9, 2024, the Company granted Mr. Hughes a target award of 275,000 performance share units that will vest upon the Company&#8217;s achievement of specified stock price performance conditions established by the Board and which are granted pursuant to, and are subject to the terms and conditions of, the Company&#8217;s 2010 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisition of Economic Interest in DSUVIA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, the Company acquired an economic interest in DSUVIA (sufentanil sublingual tablet) from Talphera, for $8.0 million. DSUVIA was approved in 2018 by the FDA for use in adults with indication in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales, a 75% royalty on net sales to the DoD, and up to $116.5 million in milestone payments. Under the terms of the agreement, the Company will receive 100% of all royalties and milestones related to DSUVIA sales until the Company receives $20.0 million. Thereafter, the Company fully retains the 15% royalty associated with DSUVIA commercial sales. The 75% royalties generated from DoD purchases and the remaining $116.5 million in potential milestone payments due from Alora will be shared equally between the Company and Talphera.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA Acceptance of Arimoclomol NDA Resubmission</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx RPA, the Company made a $1.0 million milestone payment to LadRx in January 2024. As of December 31, 2023, the $1.0 million milestone payment was accrued in contingent consideration under RPAs, AAAs, and CPPAs in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Kinnate Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 16, 2024, the Company entered into an Agreement and Plan of Merger with Kinnate and XRA 1 Corp., a Delaware corporation and a wholly-owned subsidiary of the Company, pursuant to which the Company expects to acquire Kinnate through a cash tender offer (the &#8220;Offer&#8221;) for a cash amount of between $2.3352 and $2.5879 per outstanding share of Kinnate common stock, par value $0.0001 per share (each, a &#8220;Kinnate Share&#8221;), consisting of a base price per Kinnate Share of $2.3352 and an additional price per Kinnate Share of up to $0.2527, &#160;plus one non-transferable contingent value right per Kinnate Share, representing the right to receive one or more potential cash payments equal to (i) 100% of net proceeds payable, if any, from any license, sale or disposition (each, a &#8220;Disposition&#8221;) entered into by Kinnate prior to the expiration of the Offer related to exarafenib, an inhibitor for the treatment of patients with lung cancer, melanoma and other solid tumors, and/or any other pan-RAF inhibitor, and (ii) 85% of net proceeds payable, if any, from any Disposition entered into by the Company or any of its affiliates after expiration of the Offer related to exarafenib or any other research program active at Kinnate at the closing of the related merger. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670372992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration, amortization of the Blue Owl Loan, valuation of warrants, accrued expenses and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, including estimates such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. In addition, the Company&#8217;s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Unrestricted and Restricted Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Unrestricted and Restricted Cash and Cash Equivalents </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total unrestricted and restricted cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 159,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are generally in money market funds.<span style="display:inline-block;width:2.25pt;"></span><span style="display:inline-block;width:18pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Unrestricted Cash and Cash Equivalents </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had an unrestricted cash balance of $124.9 million and an unrestricted cash equivalent balance of $28.4 million. As of December 31, 2022, the Company had an unrestricted cash balance of $27.5 million and an unrestricted cash equivalent balance of $30.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Restricted Cash </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL. As of December 31, 2023, the Company had a short-term restricted cash balance of $0.2 million and a long-term restricted cash balance of $6.1 million on its consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had no restricted cash or cash equivalent balances. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock', window );">Sale of Future Revenue Streams</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EquitySecuritiesPolicy', window );">Equity Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive loss in the period of sale.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock', window );">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CreditLossContractWithCustomerAssetPolicyTextBlock', window );">Allowance for Current Expected Credit Losses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Allowance for Current Expected Credit Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AssetAcquisitionsPolicyPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (see Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s consolidated statements of cash flows. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset was amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represented the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset was carried at cost less accumulated amortization. Amortization was included in amortization of intangible assets in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheet and included a $14.2 million impairment charge in the <span style="-sec-ix-hidden:Hidden_yKNGHsYxl0ua6mlZdK34eA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statement of operations</span></span> and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Long-Term Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Long-term debt represents the Company&#8217;s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the effective interest rate method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the effective interest rate method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Warrants </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company&#8217;s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company&#8217;s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#8217;s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive (Loss) Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive (Loss) Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt annual requirements under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AssetAcquisitionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AssetAcquisitionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CreditLossContractWithCustomerAssetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CreditLossContractWithCustomerAssetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policy for future milestones, royalties purchase rights and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sale of future revenue streams.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671105040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of unrestricted and restricted cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total unrestricted and restricted cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 159,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671439216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Consolidated Financial Statement Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of cost, accumulated amortization, impairment charge and net carrying value of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, impairment charge and net carrying value of the Company&#8217;s intangible assets as of December 31, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Charge </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $14.2 million impairment charge in the <span style="-sec-ix-hidden:Hidden_W5XKDOrmOUCVyHTuQ-wVXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidated statements of operations</span></span> and comprehensive loss.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of intangible assets as of December 31, 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 562</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll, severance and retention costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,449</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,918</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669897408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock', window );">Summary of royalty and commercial payment receivable activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities during the years ended December 31, 2023 and 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,075</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,500)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,366)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,683</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,650</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">LadRx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,284)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,673)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,575)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,109)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,024)</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Recognition of contingent consideration:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,952</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in royalty and commercial payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948677703440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2023 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,352</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,513</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670226544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity/ undiscounted future rent payments associated with the new lease</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes maturity of the new lease through the 65-month term of the Company&#8217;s operating lease liabilities as of December 31, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rent&#160;Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 485</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96)</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total net lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of cost components of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company&#8217;s operating leases for the years ended December 31, 2023 and 2022, respectively (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the original, amended and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock', window );">Summary of supplemental cash flow information related to operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the consolidated statements of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock', window );">Schedule of present value assumptions used in calculating the present value of lease payments</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(2)</span>The new lease that commenced November 10, 2023 has a lease term of 65 months.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flows information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676145984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the impact of the initial term loan on the Company&#8217;s consolidated balance sheet as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross principal </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,939)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total carrying value net of unaccreted debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,061</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,543)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,518</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of projected future principal payments of initial term loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aggregate projected future principal payments of the initial term loan as of December 31, 2023, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,594</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,767</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,200</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,155</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,872</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,412</p></td></tr><tr><td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text">Interest expense in the consolidated statements of operations and comprehensive loss for the&#160;year ended December&#160;31, 2023 relates to the initial term loan (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of accretion of debt discounts and issuance costs included in interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669730672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes (All Current)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3mFvOmJiKUCxDAEe7fSXPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_tzBx_nlwlk2NnJLZtAgZ4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Presentation for the fiscal year ended 2022 adjusted to conform with the fiscal year ended 2023 </span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The significant components of net deferred tax assets at December&#160;31, 2023 and 2022 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,732</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,974</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,176</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,715</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,408</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty Receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 858</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,329</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,329)</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xQxEZRom10ipxNjFLhAhoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_mFboUZF-aEWaGrU2CAFHmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669842848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,025,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,804</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804,302</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.44</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,473)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.27</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,303)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.51</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,730,068</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.88</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.29</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,638</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,961,143</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.73</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.27</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,606</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of grant date fair values of PSUs granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derived</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Hurdle Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Service Period</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.42-17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69-2.59</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,239</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.16-16.07</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.93-2.59</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,024</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.07-14.84</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.12-2.59</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,787</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.12-13.72</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.27-2.59</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448,600</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Schedule of performance shares, outstanding activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unvested PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448,600</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.40</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 448,600</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.40</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,608</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.64 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>No Stock Option Inducement Awards were granted during the year ended December 31, 2022.</div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.01 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the year ended December 31, 2022.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671074736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding securities considered anti-dilutive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 885</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (40,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,104)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.04)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676405808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of declared and paid cash dividends</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_H7Lo4FtfLUG9U_8NFt12cA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_btS0jg_C4kSqwPe0vi-i5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">February 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dSMEchMnFkqWypW9UGk7Lw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_3oD01eoLEkipHZzpjVu_VA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 17, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OTKsEhaqhEaFde7pn0r-XA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7zNSlE5m30-23n_Xhxv1Cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 26, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s0Q6hKWcX0SArB1No9n7mA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZPUZL4tmokqcSqnQL-SrmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 16, 2023</p></td></tr><tr><td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 18, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YeDNFyDyWkiXwMYXPzULTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__Df-kChCN02M1zGD5YLDDA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 15, 2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Common Stock Warrants Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of weighted average assumptions used to calculate fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670498272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract', window );"><strong>Concentration of Risk, Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Revenue by Geographical Region</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,477</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,550</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,027</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of risk segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668177920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Unrestricted and restricted cash and cash equivalents</a></td>
<td class="nump">$ 159,550<span></span>
</td>
<td class="nump">$ 57,826<span></span>
</td>
<td class="nump">$ 95,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Unrestricted cash and cash equivalents</a></td>
<td class="nump">153,290<span></span>
</td>
<td class="nump">$ 57,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">6,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear', window );">Substantial Doubt about Going Concern, within One Year</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -SubTopic 40<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479710/205-40-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670007424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2027</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Unrestricted and Restricted Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total unrestricted and restricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,826<span></span>
</td>
<td class="nump">$ 95,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Unrestricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash or restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember', window );">Cash reserve accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Unrestricted and Restricted Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesMember', window );">Cash reserve account, Interest and administrative fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Unrestricted and Restricted Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesMember', window );">Cash reserve account, Interest and administrative fees | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Unrestricted and Restricted Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RestrictedCashAdditionalToBeFunded', window );">Additional amount of cash required to fund reserve account</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsOperatingExpensesMember', window );">Cash reserve account, Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Unrestricted and Restricted Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RestrictedCashAdditionalToBeFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional amount of cash required to be added to  restricted account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RestrictedCashAdditionalToBeFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsInterestAndAdministrativeFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsOperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=xoma_CashReserveAccountsOperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670345952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_OrganonMember', window );">ObsEva, Organon | License Agreement | Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948672328352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details - Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Short-term equity securities</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(439)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Short-term equity securities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670279792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 15,247<span></span>
</td>
<td class="nump">$ 15,247<span></span>
</td>
<td class="nump">$ 15,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">15,247<span></span>
</td>
<td class="nump">15,247<span></span>
</td>
<td class="nump">15,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Ebopiprant IP | ObsEva, Organon | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment Charge</a></td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948673181376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statements Details - Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued and other liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentive compensation</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting fees</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedSalariesAndEmployeeBenefitsCurrent', window );">Accrued payroll, severance and retention costs</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,768<span></span>
</td>
<td class="nump">$ 2,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedSalariesAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedSalariesAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670193632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfArbitrationProceedingsInitiated', window );">Number of arbitration proceedings initiated | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Arbitration settlement costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfArbitrationProceedingsInitiated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arbitration proceedings initiated by entity against one of its licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfArbitrationProceedingsInitiated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669483408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">38 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2006</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079 and TAK-169</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Minimum period eligible to receive royalties</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimumScenarioOne', window );">Royalty payment period from the first commercial sale of each royalty-bearing discovery product</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate', window );">Maximum eligible milestone payments receivable per discovery product candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Minimum period eligible to receive royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Collaboration Agreement | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Collaboration Agreement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable per discovery product candidate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimumScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimumScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_Tak079AndTak169Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_Tak079AndTak169Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669437424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Rezolute (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement and Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities', window );">Payments received upon achievement of financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementInstallmentPaymentsReceived', window );">Installment payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementSharesReceived', window );">Number of shares received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations', window );">Percentage of decrease in future royalty obligations</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement, RZ358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Minimum period eligible to receive royalties</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement, Non-RZ358 products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Minimum period eligible to receive royalties</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments received upon achievement of financing activities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementInstallmentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of installment payments received during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementInstallmentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of counterparty's common stock entity received under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfDecreaseInFutureRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669347232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member', window );">Janssen | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate', window );">Maximum eligible milestone payments receivable per discovery product candidate</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization', window );">Percentage of royalty on worldwide net sales of each product upon commercialization</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable per discovery product candidate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales upon commercialization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948667924512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - ObsEva (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | ObsEva, Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPayments', window );">Maximum earn-out payments</a></td>
<td class="nump">97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments', window );">Maximum earn-out payments for development and regulatory milestones</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments', window );">Maximum earn-out payments for sales-based milestones</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | ObsEva, Organon | Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember', window );">ObsEva IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash payment at closing</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire assets</a></td>
<td class="nump">15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for various milestones under arrangement. Contingent consideration will be recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement. Contingent consideration will be recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669040224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis - NIS793 (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Reduction in debt obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Minimum period eligible to receive royalties</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948667986640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis - VPM087 (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>USD ($) </div>
<div>item </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>EUR (&#8364;) </div>
<div>item </div>
<div>agreement </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementsNumber', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ArrangementsNumber', window );">Number of arrangements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">&#8364; 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="nump">$ 438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">539,131<span></span>
</td>
<td class="nump">539,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.2742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Issuance of common stock, fair value</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ArrangementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arrangements the agreements are accounted for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ArrangementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock premium received on sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license agreement consideration received as repayment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669997280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>period </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,108)<span></span>
</td>
<td class="num">$ (1,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P. | Royalty Sale Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementsNumber', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P. | First Royalty Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones', window );">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePeriodsNumber', window );">Number of milestone periods | period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P. | Second Royalty Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePeriodsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePeriodsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668933568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 14,215<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 57,952<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669694720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - LadRx (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2024</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones', window );">Maximum regulatory and commercial sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum commercial sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, high-end of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Arimoclomol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet', window );">Maximum potential regulatory and commercial milestone payments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments', window );">Maximum payment obligations based on a portion of regulatory and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Aldoxorubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet', window );">Maximum potential regulatory and commercial milestone payments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payment obligations based on a portion of regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential regulatory and commercial milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments, under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_ArimoclomolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_ArimoclomolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_AldoxorubicinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_AldoxorubicinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669157456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Aptevo (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,956,000<span></span>
</td>
<td class="nump">3,026,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215,000<span></span>
</td>
<td class="nump">$ 2,366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,673,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesReceivableMaximum', window );">Maximum milestone payments entitled to receive</a></td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">9,600,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum commercial sales milestone payments</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentThresholdOneTimePayment', window );">Commercial payments attributable to net sales threshold</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo | Commercial Payment Purchase Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialPaymentThresholdOneTimePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialPaymentThresholdOneTimePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential milestones receivable under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AptevoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AptevoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669040400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Agenus (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone payments earned under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased', window );">Number of licensed products related to milestone and royalties | product</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Milestone payments entity has right to receive (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Milestone payments entity has right to receive (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones', window );">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</a></td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone payments earned under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of licensed products related to milestones and royalties purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of milestones entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669514016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,650,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,952,000<span></span>
</td>
<td class="nump">63,683,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,075,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment', window );">Decrease in long-term royalty and commercial rights receivables due to impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrentCreditLossExpense', window );">Impairment charge, Long-term royalty receivable</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Long-Term Right Receivable, Non-Current, Credit Loss Expense, Statement of Income or Comprehensive Income</a></td>
<td class="text">Impairment charges (Note 4, Note 5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment', window );">Decrease in long-term royalty and commercial rights receivables due to impairment</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes credit loss expense of long-term rights receivable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrentCreditLossExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrentCreditLossExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669399424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Aronora (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 07, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage', window );">Future non-royalty payments to be received (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementPaymentPercentageFactor', window );">Multiplier for cumulative amount of consideration paid | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount', window );">Threshold amount of cumulative royalties on net sales per product</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct', window );">Maximum royalty milestone payments to be paid per product</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount', window );">Threshold amount of cumulative royalties on net sales per product</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber', window );">Number of drug candidates subject to exclusive license option | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPaymentsPerProduct', window );">Contingent future cash payment for each product</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Bayer Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Non-Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates subject to exclusive license option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementPaymentPercentageFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiplier used in determining change in payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementPaymentPercentageFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesPaymentsToAggregateAmountOfPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of non-royalties on net sales of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_BayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_BayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_NonBayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_NonBayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676556080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Palo (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,952<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember', window );">Palo | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948672342416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Viracta (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member', window );">Viracta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member', window );">Viracta | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum', window );">Maximum amount of potential milestones, potential royalties on sales and other payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumConsiderationRetained', window );">Amount of maximum consideration retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RegulatoryAndCommercialMilestonesReceivableMaximum', window );">Maximum amount of potential regulatory and commercial milestones receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone payments earned under agreement</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumConsiderationRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumConsiderationRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RegulatoryAndCommercialMilestonesReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RegulatoryAndCommercialMilestonesReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675117840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2021</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,956<span></span>
</td>
<td class="nump">3,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,952<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones', window );">Pre-commercial milestone payments, maximum</a></td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum commercial sales milestone payments</a></td>
<td class="nump">142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePaymentReceivedCounterparty', window );">Milestone payment received by Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePaymentReceivablePercentage', window );">Percentage of milestone payment received by Kuros that company is entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of pre-commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePaymentReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of milestone payment received by counterparty entity is entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePaymentReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePaymentReceivedCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePaymentReceivedCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669439456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,956<span></span>
</td>
<td class="nump">3,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent', window );">Reduction in short-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration', window );">Recognition of contingent consideration, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentPeriodDue', window );">Period from each royalty payment date payment is due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones', window );">Maximum regulatory and commercial sales milestone payments</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum commercial sales milestone payments</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumAdditionalPayableOnSalesMilestone', window );">Maximum additional commercial sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | Faricimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialSalesReceivablePercentageOnNetSales', window );">Payments eligible to receive (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentReceivableTerm', window );">Commercial payment receivable term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | VABYSMO | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | VABYSMO | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialPaymentPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from each royalty payment date payment is due from customer,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialPaymentPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialPaymentReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialPaymentReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialSalesReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments entity eligible to receive as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialSalesReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumAdditionalPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional amount payable on sales milestone. Excludes amounts recognized in balance sheet as contingent consideration as of balance sheet date. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumAdditionalPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in long-term rights receivable due to recognition of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_FaricimabProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_FaricimabProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669424896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty receivable, Balance as of beginning of period</a></td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty receivable, Balance as of end of period</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty receivable, Balance as of beginning of period</a></td>
<td class="nump">63,683<span></span>
</td>
<td class="nump">69,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty receivable, Balance as of end of period</a></td>
<td class="nump">57,952<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent', window );">Receipt of royalty and commercial payments, Short-Term</a></td>
<td class="num">(7,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShortTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivables, Short-Term</a></td>
<td class="nump">17,109<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivables, Long-Term</a></td>
<td class="num">(17,109)<span></span>
</td>
<td class="num">(2,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration', window );">Recognition of contingent consideration, Long-Term</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShortTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivables, Short-Term</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">9,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="num">(1,673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivables, Long-Term</a></td>
<td class="num">(2,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment receivables, Long-Term</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment', window );">Impairment of royalty and commercial payment receivables, Long-Term</a></td>
<td class="num">(1,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member', window );">Viracta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,500)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long term rights receivable due to reclassification from/to short-term rights receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in long-term rights receivable due to recognition of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShortTermRightsReceivableReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in short term rights receivable due to reclassification from/to long-term rights receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShortTermRightsReceivableReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AptevoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AptevoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675157392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 28,352<span></span>
</td>
<td class="nump">$ 30,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FinancialAssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">28,513<span></span>
</td>
<td class="nump">30,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">28,352<span></span>
</td>
<td class="nump">30,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">28,352<span></span>
</td>
<td class="nump">30,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FinancialAssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">28,513<span></span>
</td>
<td class="nump">30,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">28,352<span></span>
</td>
<td class="nump">30,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668908672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Equity Securities (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Closing Common Stock Price | Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">2.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669747888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Consideration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671494784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreement - Leased facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLeasesNumberOfLeasedFacilities', window );">Operating leases, number of leased facilities | facility</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember', window );">Leased facilities, Emeryville, California, with lease expiration of July 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Period of lease extension</a></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset', window );">Adjustment to right of use asset for lease modification</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember', window );">Leased facilities, Emeryville, California, different location than previous lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of adjustment to right of use asset resulting from modification of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasesNumberOfLeasedFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases, number of leased facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasesNumberOfLeasedFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675148144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Agreement - Maturity of lease liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(96,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total net lease liability</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669857968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreement - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948670398160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreement - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">5 years 3 months 29 days<span></span>
</td>
<td class="text">2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">5.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671518976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember', window );">Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">9.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_SecurityInterestInPercentageOfEquity', window );">Security interest as a percentage of equity of wholly owned subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember', window );">Blue Owl Loan Agreement | Common Stock Warrants, Issued December 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember', window );">Blue Owl Loan Agreement | Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember', window );">Blue Owl Loan Agreement | Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember', window );">Blue Owl Loan Agreement | Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember', window );">Blue Owl Loan Agreement, Initial term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromIssuanceOfLongTermDebtNet', window );">Proceeds from issuance of long-term debt, net</a></td>
<td class="nump">119,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses', window );">Fees and lender expenses</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses', window );">Amount deposited into reserve accounts to pay interest, administrative fees and operating expenses</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross principal</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">11.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount costs</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses', window );">Debt discount, allocated fees and lender expenses</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember', window );">Blue Owl Loan Agreement, Delayed draw term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Allocated costs for the term loan commitment</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount deposited into reserve accounts to pay interest, administrative fees and operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount associated with allocated fees and lender expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan fees and lender expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromIssuanceOfLongTermDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer, net of fees and lender expenses and reserve accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromIssuanceOfLongTermDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_SecurityInterestInPercentageOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The security interest provided by entity as a percentage of equity of specified wholly owned subsidiary under loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_SecurityInterestInPercentageOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676365168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of long-term debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value net of unaccreted debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="num">$ (5,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">118,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember', window );">Blue Owl Loan Agreement, Initial term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross principal</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unaccreted debt discount and debt issuance costs</a></td>
<td class="num">(5,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value net of unaccreted debt discount and debt issuance costs</a></td>
<td class="nump">124,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="num">(5,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 118,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676426288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Aggregate projected future principal and discounts (Details) - Blue Owl Loan Agreement, Initial term loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">8,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">19,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">23,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">57,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total payments</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948667908288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Interest expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and debt issuance costs</a></td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember', window );">Blue Owl Loan Agreement, Initial term loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Accrued interest expense</a></td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and debt issuance costs</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Total interest expense</a></td>
<td class="nump">$ 569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671500880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (40,831)<span></span>
</td>
<td class="num">$ (17,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">(Benefit) provision for income taxes, Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948776621040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation between statutory rate and effective rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation between the tax provision computed at the federal statutory income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent', window );">Stock compensation and other permanent differences (as a percent)</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent', window );">Nondeductible executive compensation (as a percent)</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance (as a percent)</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total (as a percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for executive compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675055872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of net deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenses</a></td>
<td class="nump">$ 2,336<span></span>
</td>
<td class="nump">$ 4,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">30,130<span></span>
</td>
<td class="nump">23,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development and other tax credit carryforwards</a></td>
<td class="nump">13,176<span></span>
</td>
<td class="nump">13,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">5,864<span></span>
</td>
<td class="nump">4,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Unearned revenue</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">2,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DeferredTaxAssetsRoyaltyReceivable', window );">Royalty Receivable</a></td>
<td class="nump">4,080<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">58,326<span></span>
</td>
<td class="nump">50,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(58,326)<span></span>
</td>
<td class="num">(50,329)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in the valuation allowance</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DeferredTaxAssetsRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from royalty receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DeferredTaxAssetsRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671366272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - NOL (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 137.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLossCarryForwardSubjectToExpiration', window );">Net operating loss carry forward subject to expiration</a></td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 22.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NetOperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NetOperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLossCarryForwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carry forward that is subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLossCarryForwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668097648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax credit carryforward (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage', window );">Operating loss carryforward offset (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=xoma_FederalOrphanCreditMember', window );">Federal Orphan Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_TaxCreditCarryForwardExpirationYear', window );">Tax credit carry forward expiration year</a></td>
<td class="text">2037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California | Research</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward amount</a></td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards offset of taxable income percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_TaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_TaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=xoma_FederalOrphanCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=xoma_FederalOrphanCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671387440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation between the tax provision computed at the federal statutory income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Increase (decrease) related to prior year tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">5,938<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Unrecognized tax benefits expected to change significantly over the next twelve months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase (decrease) resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669703136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - ESPP (Details) - 2015 ESPP<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>period </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>period </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions', window );">Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock under plan (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for purchase</a></td>
<td class="nump">224,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods', window );">Number of consecutive purchase periods within each offering period | period</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod', window );">Length of each consecutive purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,051<span></span>
</td>
<td class="nump">6,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in aggregate number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum shares per employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of consecutive purchase periods within each offering period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The length of each consecutive purchase period within each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676496496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contribution per employee (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum', window );">Age requirement for participant to be eligible for a catch-up contribution, minimum</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage', window );">Deferred savings plan expense paid in common shares (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_EmployeeUnderAgeFiftyMember', window );">Employee, Under Age Fifty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_EmployeeAgeFiftyOrOverMember', window );">Employee, Age Fifty or Over</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of defined contribution plan expense paid through the issuance of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeUnderAgeFiftyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeUnderAgeFiftyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeAgeFiftyOrOverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeAgeFiftyOrOverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676606480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">2,730,068<span></span>
</td>
<td class="nump">2,025,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">409,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">2,730,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Employee Stock Option | Minimum | Terminated employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeTerminatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeTerminatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669347184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details) - Employee Stock Option - 2010 Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward', window );">Minimum age required for employees to qualify for immediate vesting of award</a></td>
<td class="text">55 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge', window );">Threshold years required for retirement age</a></td>
<td class="text">70 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.71%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 13.18<span></span>
</td>
<td class="nump">$ 12.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum age required for employees to qualify for immediate vesting of award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668382544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2023 </div>
<div>installment </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants', window );">Number of award grants | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants', window );">Number of award grants | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of successive equal monthly vesting installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments', window );">Number of equal quarterly vesting installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of successive equal monthly vesting installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669427104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning of period</a></td>
<td class="nump">2,025,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">804,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(28,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Forfeited, expired or cancelled</a></td>
<td class="num">(71,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="nump">2,730,068<span></span>
</td>
<td class="nump">2,025,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable at end of period</a></td>
<td class="nump">1,961,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</a></td>
<td class="nump">$ 20.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="nump">23.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">8.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</a></td>
<td class="nump">36.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at end of period</a></td>
<td class="nump">20.88<span></span>
</td>
<td class="nump">$ 20.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable at end of period</a></td>
<td class="nump">$ 19.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Remaining Term, Outstanding</a></td>
<td class="text">6 years 3 months 14 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Remaining Term, Exercisable</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 10,638<span></span>
</td>
<td class="nump">$ 10,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">10,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised, aggregate intrinsic value</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669397680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details) - Performance Stock Unit Awards<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>item </div>
<div>D </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.', window );">Number of hurdles | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays', window );">Number of consecutive calendar days used to calculate volume-weighted average stock price | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Share-Based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">18,200<span></span>
</td>
<td class="nump">430,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock price hurdles in a share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948672397488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details) - Performance Stock Unit Awards - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">448,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock-based compensation expense, not yet recognized</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Award dates from May 2023 to October 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock-based compensation expense, not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $30.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">243,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $30.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $30.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $35.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">91,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $35.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $35.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 16.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $40.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">60,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $40.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">1 year 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $40.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 14.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $45.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">53,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $45.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 8.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">1 year 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $45.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=xoma_AwardDateMay2023ToOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=xoma_AwardDateMay2023ToOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar30Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar30Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar35Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar35Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar40Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar40Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar45Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar45Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669572624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details) - Performance Stock Unit Awards<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Unvested PSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">448,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding at end of period | shares</a></td>
<td class="nump">448,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock-based compensation expense, not yet recognized | $</a></td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">1 year 4 months 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948673142448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,099<span></span>
</td>
<td class="nump">$ 3,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948672346128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details) - Senior Vice President, Finance and Chief Financial Officer, Thomas Burns - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentPeriodRetirementEligible', window );">Period for which individual will be deemed retirement eligible for purposes of equity award</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentPeriodRetirementEligible', window );">Period for which individual will be deemed retirement eligible for purposes of equity award</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentPeriodRetirementEligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which individual will be deemed retirement eligible for purposes of equity award if employed through the period under terms of amended employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentPeriodRetirementEligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676309360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details) - Current employees, excluding Chief Executive Officer<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>period</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Employee Retention Bonus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPeriodsCashRetentionBonus', window );">Number of periods in which employees will be eligible to receive cash retention bonus | period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PeriodOneRetentionBonusEligibility', window );">Initial period for which employees will be eligible for retention bonus</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PeriodTwoRetentionBonusEligibility', window );">Period following initial period for which employees will be eligible for retention bonus</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RetentionBonusExpenseAccrued', window );">Amount of retention bonus expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedRetentionBonus', window );">Accrued retention bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedRetentionBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expense for cash retention bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedRetentionBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPeriodsCashRetentionBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPeriodsCashRetentionBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodOneRetentionBonusEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodOneRetentionBonusEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodTwoRetentionBonusEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodTwoRetentionBonusEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RetentionBonusExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recorded as expense during the period for cash retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RetentionBonusExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671299168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details) - Chief Executive Officer, Retired, James R. Neal<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Departure and Continuity Incentive</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedCompensationContinuityIncentive', window );">Accrued cash payment related to Continuity Incentive under Employment Agreement</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CompensationExpenseEmploymentAgreement', window );">Compensation expense related to Continuity Incentive under Employment Agreement</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedCompensationContinuityIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expense for compensation under employment agreement related to retirement of individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedCompensationContinuityIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CompensationExpenseEmploymentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for compensation under employment agreement related to retirement of individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CompensationExpenseEmploymentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerRetiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerRetiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668191232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">6,813,000<span></span>
</td>
<td class="nump">5,894,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Performance Stock Unit Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Shares issuable based on market price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,003,000<span></span>
</td>
<td class="nump">5,003,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">1,793,000<span></span>
</td>
<td class="nump">885,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669461872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (40,831)<span></span>
</td>
<td class="num">$ (17,104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(46,303)<span></span>
</td>
<td class="num">(22,576)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (46,303)<span></span>
</td>
<td class="num">$ (22,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per share attributable to common stockholders</a></td>
<td class="nump">11,471<span></span>
</td>
<td class="nump">11,413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">11,471<span></span>
</td>
<td class="nump">11,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (4.04)<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (4.04)<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Accumulated preferred dividends</a></td>
<td class="num">$ (2,122)<span></span>
</td>
<td class="num">$ (2,122)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Accumulated preferred dividends</a></td>
<td class="num">$ (3,350)<span></span>
</td>
<td class="num">$ (3,350)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income loss available to common stockholders basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669403056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Series X and Series Y Convertible Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember', window );">Series X And Series Y Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each share of convertible preferred stock that is converted</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockConversionPricePerShare', window );">Preferred stock conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember', window );">Series Y Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">1,252.772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockConversionPricePerShare', window );">Preferred stock conversion price per share</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668589568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Series A Preferred Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>USD ($) </div>
<div>D </div>
<div>M </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Net proceeds from issuance of stock | $</a></td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodYearProrated', window );">Number of days in year over which dividend will be prorated and computed | D</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear', window );">Number of months in year over which dividend will be prorated and compute | M</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodMonth', window );">Number of days in month over which dividend will be prorated and computed | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="nump">$ 25.75<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption', window );">Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockShareCap', window );">Share cap (in shares) | shares</a></td>
<td class="nump">1.46071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays', window );">Trading days | D</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | 8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodProratedMonthsInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodYearProrated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodYearProrated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockRedemptionPricePerShareOptionalRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockShareCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockShareCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromIssuanceOrSaleOfEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromIssuanceOrSaleOfEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668381440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($) </div>
<div>D </div>
<div>M </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 15, 2026 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 25,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendAmountPerShare', window );">Preferred stock, dividend amount (in dollars per share)</a></td>
<td class="nump">$ 2,093.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodYearProrated', window );">Number of days in year over which dividend will be prorated and computed | D</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear', window );">Number of months in year over which dividend will be prorated and compute | M</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodMonth', window );">Number of days in month over which dividend will be prorated and computed | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption', window );">Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)</a></td>
<td class="nump">$ 25,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,750.00<span></span>
</td>
<td class="nump">$ 26,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockShareCap', window );">Share cap (in shares) | shares</a></td>
<td class="nump">1,253.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000.00<span></span>
</td>
<td class="nump">$ 25,250.00<span></span>
</td>
<td class="nump">$ 25,500.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DepositarySharesRatioToPreferredStock', window );">Depositary share's fractional interest in share of preferred stock | shares</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromIssuanceOfPreferredStockNet', window );">Net proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.75<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockShareCap', window );">Share cap (in shares) | shares</a></td>
<td class="nump">1.25313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares | Related party - Spouse of James Neal, then CEO and Chairman of the Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DepositarySharesRatioToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents depositary share's fractional interest in share of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DepositarySharesRatioToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The dividend amount per share based on the dividend rate on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodProratedMonthsInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodYearProrated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodYearProrated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockRedemptionPricePerShareOptionalRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockShareCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockShareCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromIssuanceOfPreferredStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromIssuanceOfPreferredStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668193424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 15, 2024</div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
<th class="th"><div>Oct. 16, 2023</div></th>
<th class="th"><div>Jul. 26, 2023</div></th>
<th class="th"><div>Jul. 17, 2023</div></th>
<th class="th"><div>May 17, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676051008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - BVF Ownership (Details) - BVF - Xoma Corporation - Common Stock<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest (as a percent)</a></td>
<td class="nump">31.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted', window );">Ownership interest, if shares are converted (as a percent)</a></td>
<td class="nump">52.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=xoma_XomaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=xoma_XomaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676502272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - ATM Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">29 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember', window );">2018 Common Stock ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares', window );">Sales commission paid per transaction (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember', window );">2018 Common Stock ATM Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumValueOfStockToBeIssued', window );">Maximum amount of shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares', window );">Sales commission paid per transaction, preferred stock (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement | Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumValueOfStockToBeIssued', window );">Maximum amount of shares to be issued</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumValueOfStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of stock to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumValueOfStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676530384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Summary of Common Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">131,177<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Common Stock Warrants, Issued May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">6,332<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common Stock Warrants, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 42.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 42.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669655952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Common Stock Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Common Stock Warrants, Issued May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Common Stock Warrants, Issued May 2018 | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common Stock Warrants, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common Stock Warrants, Issued March 2019 | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember', window );">Common Stock Warrants, Issued December 2023 | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated fair value of warrants</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value per share (in dollars per share)</a></td>
<td class="nump">$ 12.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">42.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value per share (in dollars per share)</a></td>
<td class="nump">$ 12.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 42.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value per share (in dollars per share)</a></td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember', window );">Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share | Blue Owl Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ExercisablePeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ExercisablePeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676254576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Weighted average assumptions (Details) - Common Stock Warrants, Issued December 2023 - Blue Owl Loan Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Y</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated fair value of warrants | $</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input | Y</a></td>
<td class="nump">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948671163120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePayments', window );">Estimate of milestone payments | $</a></td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts', window );">Assumed number of products per contract | product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668656656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent Consideration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,650,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,952,000<span></span>
</td>
<td class="nump">63,683,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember', window );">Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember', window );">Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember', window );">Commercial Payment Purchase Agreement | Aptevo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember', window );">Commercial Payment Purchase Agreement | Affitech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember', window );">Commercial Payment Purchase Agreement | Affitech | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AptevoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AptevoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669204128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Arbitration Proceeding (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfArbitrationProceedingsInitiated', window );">Number of arbitration proceedings initiated | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Arbitration settlement costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfArbitrationProceedingsInitiated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arbitration proceedings initiated by entity against one of its licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfArbitrationProceedingsInitiated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948668336864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivable, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues | Partner 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues | Partner 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues | Partner 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfMajorPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfMajorPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948774807488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract', window );"><strong>Concentration of Risk, Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of risk segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948676492128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,758<span></span>
</td>
<td class="nump">$ 6,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,658<span></span>
</td>
<td class="nump">4,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948662930784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>Right </div>
<div>payment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember', window );">Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember', window );">Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased | shares</a></td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Kinnate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockParOrStatedValuePerShareAcquiree', window );">Acquiree's common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount', window );">Base price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount', window );">Additional cash price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AcquisitionNumberOfContingentValueRights', window );">Number of non-transferable contingent value rights for each acquiree share | Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer', window );">Percentage of net proceeds from disposition entered into by acquiree prior to expiration of offer acquiree has right to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer', window );">Percentage of net proceeds payable from disposition entered into by entity after expiration of offer acquiree has right to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Kinnate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentToAcquireBusinessPricePerShareCashAmount', window );">Cash amount of consideration per outstanding share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AcquisitionValueRightNumberOfCashPayments', window );">Number of cash payments for each contingent value right | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Kinnate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentToAcquireBusinessPricePerShareCashAmount', window );">Cash amount of consideration per outstanding share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Alora Pharmaceuticals | Talphera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones', window );">Maximum eligible milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Alora Pharmaceuticals | Talphera | All customers excluding DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Alora Pharmaceuticals | Talphera | DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Acquisition of economic interest agreement | Talphera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndMilestonesReceivableThreshold', window );">Threshold amount for royalties and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Acquisition of economic interest agreement | Talphera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones', window );">Royalties and milestones entity has the right to receive (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty', window );">Maximum remaining milestones to be shared equally</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Acquisition of economic interest agreement | Talphera | All customers excluding DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Acquisition of economic interest agreement | Talphera | DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty', window );">Royalties shared equally with counterparty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementAnnualSalary', window );">Amount of annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary', window );">Target annual cash bonus (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | CEO, Owen Hughes | Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AcquisitionNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-transferable contingent value rights each acquiree share has right to receive. representing  right to receive one or more potential cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AcquisitionNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AcquisitionValueRightNumberOfCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of cash payments each value right provides  under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AcquisitionValueRightNumberOfCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockParOrStatedValuePerShareAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock of acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockParOrStatedValuePerShareAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable, upon achievement of milestones, to be shared with counterparty of agreement, including portion received received by entity prior to meeting threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementAnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of annual base salary pursuant to employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementAnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Target annual cash bonus amount as a percent of base salary, subject to achievement of annual performance milestones, pursuant to employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional contingent cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The base cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentToAcquireBusinessPricePerShareCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock. Includes base price and additional contingent amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentToAcquireBusinessPricePerShareCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net proceeds payable from license, sale or disposition entered into by entity after expiration of offer, the acquiree has right to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net proceeds from license, sale or disposition entered into by acquiree prior to expiration of offer acquiree has right to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndMilestonesReceivableThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount for royalties and milestones for determining amount for entity has the right to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndMilestonesReceivableThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and milestones entity has the right to receive as a percentage, up to specified threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage shared with counterparty upon reaching threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=xoma_KinnateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=xoma_KinnateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AloraPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AloraPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_TalpheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_TalpheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_U.s.DepartmentOfDefenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_U.s.DepartmentOfDefenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AcquisitionOfEconomicInterestAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AcquisitionOfEconomicInterestAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_TalpheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_TalpheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948675886464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (40,831)<span></span>
</td>
<td class="num">$ (17,104)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139948669684880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>130
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<Y==CPL4!R3>M@D87BN@UK!!P*@4,&H4,.P-H/LK6&-&)/,96*11&B+5(N_
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M8G-)O8"F>0#__3Y)V,^=_+6M[;N)D_\ 4$L#!!0    ( .,]:%C\7] 0_0@
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M\P"FLZC.-58_%%^;HX%SKA0OS.6*41@V;0#/%YRKW0_]@OWITO&_4$L#!!0
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MN/S^OX+])W1GX[,>W:'$L-3%7N9(&,^GXWEOBJ?](TL\B3,-GH$+7 7<,3^
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M!GQXQ,L*7WKD6 #O"XL^[F[80?_MN/@;4$L#!!0    ( .,]:%B 2I^!9"8
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MEHUW(B,B$5W-JJE-CHV#VEZ!3&F,Q&OP:?&8;?TH)FBUZEB-L"V(H6W+X1T
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M^8#P W3F[A !I13E55GP)8MR+5'Z\5JA[$H  HH3:7'GW0_M^2ML+02&(XB
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ML&\=NJ)-/,5%9_\%Q0Z2<;-N)M,)"&>,':ZPR62CB"9OO/0NI"8[$(B:28"
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M#^5OB\I@C*%\OR.!/H@;],.!P_U=?:, <A?[#QPIH5R=77@[,AHP%/$;Y[-
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M5H?C;'\+Z@VGSWID (21M:1G[!%5FB\C;+#CNC57G:EF.3L+X,.I_ %Y!1,
M,Q<79T]GP>F!QWZ$Y=Y10.G(I=R(8F4UUEV)@!LAZ[J0O?EGU=2Z%K84MC3=
M\2] 2%[P%1BJ0O%[@QDIX+JU/.9WM]NA4-AG7RA1^N1S=%6$M\MXNLI>%[;%
M*E-.1[,0PI:]!!.1$?,[G4 >R75J_)';D@X.GR^N1[-%>"BFO__ GXL945W<
MWV7!X10*TO5D?GDVI_N":#@F<"7R"A98O9,$^)O 68=W3."1JMB^4#O#F;_&
M9Q1?BF!;%<S5&HZ*JPF@-D<#/MVQEIS"P9=1U:/.!-3$;=YL6=!B^#9)/G_P
MK0Q'-<';QJ?%U8?+N!VT$+^;B!<I[;]6PC5%A6;OH.<:.IGFVY=,LXM/VT;9
MN@.WZQR^IBX5I0!X0JSFQ9*)BVQX<'E,>*BZ3]D<(GG#G?F!R< -UVS.N@[(
M9,,.4T;0GGIUA"_-M;,.^MXBTF$0B9P\N%6_>6FIOE,>'#F4]9N7CPZSE;C3
MPX:'UHM0)_/W"9UA\3EB.MIA#Y*88\%M^W>T)D;ETF-6+C[X*OD.FMYUL0S\
M;!G&(#(^,X,EF#(Z=0S8)!4-ZZQ)W4816:?+@R];JOFB/P/1^"HU%*\CZGGB
MX>4\5Q0+"#^B<H>[>!B\^]Q1;^'/5^],36_DZWQLCK&MA%Q>"[ZX4(G#NZ/*
M?ZCS&5W+FM9#1;3#98]^NVM+(3Z.("3I3 1+?" '[0IBYY(HDQ^IDU*N06#M
MPNW5L=1+[KLM*8/4!&U>IF 27 GGG8(])L^.Q""Q[IHZ198#-:L#'#E89>VE
MKZ<H$I13L3[",I6O1EW'J,D"F$T(&1[>4% J8%#%MGJHDEKSZG8J1ZQD*AS=
MB_E";:GOD9N^,TGN1&M@+QCU]O3*1DV\^!:FH7UXU8=QS/T,<9 5!BGXH%JM
MG);V(F$#=\,$>@C=NYW1O#Q<""9EHD0HZN 0UT-T#R$#!6>B0'MJ+Q>A@8_0
MT;AI[]"<>>O&"BLP+IMABVYTH;.UUB07-+RQ:G:/S)4.02'O03T,^-LJQZ5J
M-ET>\3?U1E&$R*E+VQ#P@')Y"QSW-#9T]Y#Z $*9"'31I(.)D$ I,HGM[OY
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M9L>SX\059V9W[C>(A"Q,2$(#D+9U?_WM;@ D^))DQ]FI;-TOB242KWZ</MT
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MSZ.3\TF(/+-E>+8XU6E?5S#ES\]F( W#$-K8Q>XBM]/IEGBK)M<OY.LF*?!
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MN)B67MSU:\['WB]T@PYNZ7?(D5=!V#0_UEU^&[B?.I^97_BN7C>_DW[%U*V
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M0VNS>=./]I5R3<%F>S"4R?%==%$?:6"=5N,*B%8=BP^$3HP%Y_[X1/RTT=K
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M:ES/@K.*RX:G46F[!)I#-; 1T:8/?IID3R7AK@[5>Z>+<_+;32/X>;'O=_+
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M7%FK,O<7O^J8Q@7P/E'*5@,44-_-WOP+4$L#!!0    ( .,]:%BYM0C\C0H
M ,$?   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;+59:7/;.!+]*RB-
M,V57R;*HPY;/*B>9W9VJ>.-*,M='B 0E3$A" X!6O+]^7P/@I2O.;/:++8+H
M1I^ON\&;M=*?S5((R[[D66%N>TMK5U=G9R9>BIR;@5J) F]2I7-N\:@79V:E
M!4\<49Z=C8;#\[.<RZ)W=^/6'O7=C2IM)@OQJ)DI\YSKY]<B4^O;7M2K%C[(
MQ=+2PMG=S8HOQ$=A?UD]:CR=U5P2F8O"2%4P+=+;WGUT]7I"^]V&7Z58F]9O
M1IK,E?I,#S\GM[TA"20R$5OBP/'O2;P164:,(,9?@6>O/I((V[\K[O]PND.7
M.3?BC<I^DXE=WO9F/9:(E)>9_:#6_Q)!GRGQBU5FW%^V]GNQS.+26)4'8DB0
MR\+_YU^"'5H$L^$>@E$@&#FY_4%.RK?<\KL;K=9,TVYPHQ].54<-X61!3OEH
M-=Y*T-F[=ZI8G'X2.F=OQ=S>G%GPI#=G<:!_[>E'>^BC$7M0A5T:]E.1B*3+
MX S"U!*-*HE>CPYR?"OB 1M'?38:CL8'^(UK#<>.W_G?UM#3CW?34U9<F16/
MQ6T/86^$?A*]NQ]_B,Z'UP>DF]3230YQ?X%TA^EG ]9EP7[\838:CJ_9^P+/
ML<CG0K-HZLW99[^_?[AG5O/"I$)KD3"KV.\?WO499X589\^,\AS+ZZ7*\*36
M!1Y,.3<RD4A:[,LR)JUAFL+=])F5-A.,%PF3A14PD,4/9I>"Q2K/A8XES]B*
M/R.1095JE;,/"M!"8D87UX;]>O_ZCX\/[UF)^-&.\#Y-I17QDKUY?+QWK+7(
MN(4@W!@!+L>TBQB,AM=OFE,>PRGN371],F"?L"_P/]W@X=@Z'7:8@W$M"'+J
MM24T@UK<L-;1GUIT]X[K(!S-/LH<L, +H4J3P6K$4SC[.#LIQ^9U5@KV?IW!
M@[Q@]PLM!,D/!+#+YB4)F@DR#JR]*K4I.?: Q7HI82/BO(9<XHNE30F+A;8
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M^KOJKK0+Q5#G%.B(F/MLVJY9[FPBK"LR(D/:YTX]AY #]G,!G"R*T$^[*G5
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M_NM3]6#5RGVD14MJ5>Y^+@5'MTT;\#Y5&+C" QU0?[6_^R]02P,$%     @
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M<5@&ZZKIONRO2A3@P^C!#(T,1)62DJ3X<I%CVNQ;-@B@(#<IE0V/0@I6[\!
M\R78R"A #GD,-G;/XPJB1*VTA!%-W^B1= ,?N#08!JYJ0*@@L+^-_X.+_\27
M50-($Z4]:]W%YBCX FJIP8U1@GC[90DY TP<(CP'L>!E84/%[!&A L>R&+PD
M)4\!60X-M5:@C*)]_BP^AXD30-F8R98P_20@MT8J>US[;%65><_]T0;AOQIB
M-SP>3=V;YRR^C<';4->=L-#LQIJG)(JSI<L5/@! 5.1-SHJ&; _FV,,<2,/8
M&*5]:UFB("_I*QH8C[Q)  CCBH@!Y-/FK6%?/]^E+(K&WGP^A;B"M0C2BIMZ
M4U;B_Q!$: /NK-@RT:Y8*>/:AD,[;V?:UGL3\&@A:[W@0O*DH7'1V'CO+:\R
ML KRV+XG4VI>\C4( 235SD72_J4IN/Z(OAN-6:Y@= 8AFOS ]7E\3(4##W/!
M5O&?W<-B!CP>E$U1JQ*H2>!]53959P%M_&F1@.9:UG%5ZPATD&?]S)%LMMCK
M[QF!>G)2+DW1'WPF:U+DGF%F09-@.8>'"R%SLL3N>$)<XCNLRI*DK"[D]\2B
MQTK,9Z\;^HKW,"-1 @.KVW%I,@[X$+GYR"PA95,OF"C3@D^+?0BG:U;>4# #
MCCBP6 '-C_$ML"85;E,8ZZ-N%XR#\.SSN5G4&P#Y%0!M]@&A28,B2DE<X6(^
M]9S<0<A;Y0\,O?$7IY))S;0N8% F@D;0+KJK!I_=H,,E KY I,'PF<>?$784
M=266C<(H"E;2%!JL3!X$*Z@BBW<,%E"#8QO;D;6.>I#H:43AF:Z=1@%^[DJ>
MG<&PTY'*6NJI&7[NZZ>W<'2-2:#M!"'EFI_[_:+1PS" L%66L" $<!57V&M
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M *@40Z53AK9M'IT 8(!E):N@D.@"S R,&I.)YV9%Z=R&>^H\,ADU>*25'#$
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MUJ15@E@B;(QCH9\BA\P@!WK+)VR(4/Z I*-D"N-!A%BP$V,A :(-8A*=Y@T
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M\@*\7QB(?WW#&[2_WUS^"U!+ P04    " #C/6A8'F4I99H$  !Q"P  &0
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M5;=(4"WQNWU=W8 <  PB^02" OB08E'77R;XF.HR](<-EG&2&PD\5Q0+U+-
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MXV//08J79\#'0:% $IHEW1XV7K9NUZ@ S>#B;VQ1[7$%C,E0.*ZJ!P$6T#]
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M),>2R@M>8Z5W,BY*JK0JUIZL!=+4&I6%1WP_]DK**F<ZMFL+,1WS1A6LPH4
MV90E%=LY%GPS<0)GO[!DZUR9!6\ZKND:;U']4R^$UKS.2\I*K"3C%0C,)LXL
MN)H/S'E[X#/#C3R0P3!9<?[5*!_2B>,;0%A@HHP'JE_W>(-%81QI&-]V/ITN
MI#$\E/?>WUONFLN*2KSAQ1>6JGSBC!Q(,:--H99\\R?N^$3&7\(+:9^P:<_&
M P>21BI>[HPU@I)5[9L^[/)P8##R3QB0G0&QN-M %N5;JNAT+/@&A#FMO1G!
M4K76&ARK3%%NE="[3-NIZ9)O::&V0*L4;GA9HD@8+6!!MSKS"A:-2')-&F9K
M@6B6)/3NZ*I V1][2@,P;KQD%VS>!B,G@@4$/O%*Y1+>52FF_W?@:>0=?+*'
M/R=G/;[%Y +"P 7BD_",O[!+1VC]Q2^6CF-9:&.$QV.8-KN2-4UPXN@^DBCN
MT9F^>17$_O49!H..P>"<]^EMVUW ,Q '9)+O9.H=&8$)LGM3R[8WF&)XE,[Y
M@'<Y0L8+W=VL6H.R_MH69_^B!*6W?P4(I(VP#K7]%JF0@.;.@*XXEBL47=6M
M5RT0Z+%*'^>-U"NR?P5O7HV('U[_\OLVYT+]<8>BA(^\6K?2G!:T2C12:5+\
M%ZT:D^T6"X'7UC@@UUJ*+UU_&,'2L*O5XP613T?\=R.X/+IK0N_U'G$CW^_#
M+,N8PB1_W" B<=\ +JB4+&,)M5].Q4':5"B3@*<7\ZEL3N(C;AC'AW2TVO^A
M C_>!]*=?[VSUY4(W7@4PBSYUC#)+*?GM,<S"C.K%=[SGQ)\Z<:1#Q]INGQX
MM BQZ_O^;[DU)_/<&[ID-.C_!.D(FZ/7)G#C8=B'STSH_J6/XNA%AF(?/I0U
M9<(F^S>58\XXE>P)G1*XT3!ZN:O_$D4)AF[@7QY M'K_5%&(ZY/!8:]HU1+B
MZZJ[\HG^^^J/J@&K1<E2%);G"\ ]?HW/]VIXT*O!P"5!I(5HZ%Y&71<?^R-Z
M!^..KL':#G52,VHJU4X^W6HW-\[:<>G[\7;H_$3%FE42"LRTJ7\QC!P0[2#7
M*HK7=GA:<:5',2OF>O9%80[H_8QSM5=,@&Z:GOX'4$L#!!0    ( .,]:%AB
MWB(OP0,  &D0   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;.U8;6\:
M.1#^*Z-M5342RKX%DB: 1&BK5FI4+B^]SV9WEK7BM:GM#>7?WWAWV9($2+BV
M=SI=O^#7>>89>_S T%\H?6MR1 O?"B'-P,NMG9_ZODER+)@Y5'.4M)(I73!+
M0SWSS5PC2RNC0OA1$/3\@G'I#?O5W$0/^ZJT@DN<:#!E43"]/$>A%@,O]%83
MEWR66S?A#_MS-L,KM#?SB::1WZ*DO$!IN)*@,1MXH_#T_,CMKS9\X;@P:WUP
MD4R5NG6#C^G "QPA%)A8A\"HN<,Q"N& B,;7!M-K73K#]?X*_7T5.\4R90;'
M2OS)4YL/O!,/4LQ8*>RE6GS )IZNPTN4,-4G+)J]@0=)::PJ&F-B4'!9M^Q;
M<P[/,8@:@ZCB73NJ6+YEE@W[6BU N]V$YCI5J)4UD>/27<J5U;3*R<X.WS.N
MX0L3)<(%,E-JI!.W!EY?LZE <]#W+7EQ>_VD03RO$:,MB&$$%TK:W, [F6)Z
M'\ G>BW':,7Q/-J)^!:30XC##D1!%._ B]N8XPJOMU_,FT*M@>+-0.[!G)HY
M2W#@T8LPJ._0&[YZ$?:"LQTTCUJ:1[O0AU?T --2(*@,,BZ93#@3P(Q!NA\F
M4Q"<3;G@EJ.!H@XD!68A<_'=5?&YO*>WDY1:<SES^<LWQKF;R76.D"E!#]B!
MV"HS@&C0I+8Y6%H>JV+.Y/+5BY,H/#XSZQQRCIKI)%^Z[<")_,^,AB :;I2T
M7!(951K",P>GX-@$\=F_UFY[7!05Y3064]1M7L.-H9@><_ZC5)8.8J)Y0@=#
M :X6KOA,\HPG3%KX3%>@-ZX\E^JH4D>X8/K678B[J=72YZG+;'?I[=2-5(\G
MGVH_IA0\L1(PJF^]79#S<OMP6_OZ$]ZA@/!@U8O:7GP U\JVCGY](HR9R0&_
MEISRU-WPK_=($HM+^B)PUP592?G>+KV$Z*03=Z.UB>I91F<[9QJC^N"2!P$]
M\O_ Q7J[#OO4? /SCCS9)4D*/>U: 1YN#'OA#SMS&'5XCP3HWC%TPWC_LW-&
MG[Y+V#^0<_0E2XI!MP.)HA])*:EL]4.'DH'$X'(R,AT8C4:UNHXGU7B+L.X7
M;=@)@F#K^#\@MM%OL?TMMC]+;..@$\='>SZAQNB98OO Q=_5OP;F:;&-X^Z/
M.R.,)\66&/5Z;_8_.V?T/Q';X^Z]P::ZPE\K_PK4LZK(-42TE+:N!-O9MHX>
MU>7C]^UU$4Z2-./2@,",3(/#XZX'NBYLZX%5\ZJ8G"I+I6G5S9'1&;@-M)XI
M4M!FX!RT_RX,_P)02P,$%     @ XSUH6%[=4)M]!   L@T  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&ULQ5=M;]LV$/XKA)H5"=!:;_%+$MM DF[8
M@!4+DJS%/M+2V>9*B1I)Q?5^_>ZH%\NQJ[G8AWV11.KXW'-W#T_4=*/T%[,&
ML.QK)G,S\];6%M>^;Y(U9-P,5 $YOEDJG7&+0[WR3:&!IVY1)OTH"$9^QD7N
MS:=N[D'/IZJT4N3PH)DILXSK[1U(M9EYH==,/(K5VM*$/Y\6? 5/8'\O'C2.
M_!8E%1GD1JB<:5C.O-OP^FY,]L[@DX"-Z3PSBF2AU!<:_)+.O( (@83$$@+'
MVPO<@Y0$A#3^JC&]UB4M[#XWZ#^YV#&6!3=PK^1GD=KUS)MX+(4E+Z5]5)N?
MH8YG2'B)DL9=V::V#3R6E,:JK%Z,##*15W?^M<[#*0NB>D'D>%>.',L/W/+Y
M5*L-TV2-:/3@0G6KD9S(J2A/5N-;@>OL_%? D-CM2@-@JBT[?^8+">9BZEM$
M)QL_J9'N*J3H&TAAQ#ZJW*X-^S%/(=T'\)%6RRUJN-U%O8@?(!FP.'S'HB"*
M>_#B-M;8X8U.B_58B!5 ?!R -LBU*7@",P]W@ '] M[\[9MP%-STT+MLZ5WV
MH<^?<,.EI02FEEAA6VIAMSXK\U281)6YA90M2YP&W Q8J8)O*0K#N#$J$9S>
M;X1=,[L&EN-VD!3NL2#[:3SC\J62N%M%OF*6Y%!O6?$WF)89L=SSA".MRE7E
M?S1\GY$8F 6=-:;W*BMXOGW[9A*%XQO#L+-H;LE+!2 %7P@IK  *BE:A B!;
M@&Y5P,Y%CEBJ-#Q/S<4U([ @OOGF_0_@F@1)7O;0&H-'RN5#DTOT<<G.V"2F
MIV%K-!G2>+0;3V@\/O!V%=+\Y& ^#"*&><6NN<2$M-/QB#TKR^5^D:MDM.5]
MC76)9!Y(?<C[A<L2&$__Q$;AMN]KX_.KT47M(\<.OY_G;6MVQN+)58^$AZV$
MAR=+.%'&XB4K5.[BP*E7!3?'Q-GOX%_$22H[XO<$\1F$U<YPBXHQ#*B''=$?
MRHX>HG>X"4T![ILBM]\MRU-E^YI#\]YQ(1ZL:FH4M/E^M[^]VH$N=SM1A'%(
MU_&8?<($NV1W[,[#BT-Q7NXT']7"VRTQ7>SQL#N:7.TT&U[T2''42G'4+\7J
ME$'E-V512-?RD4W"S9HM44!,Y-69ICI>2-= K3I)I/VN]T6Z[Z:H=J[9)T6[
M7RI#O;V18:)RHZ1('2UC\98U<FY#,'V\_Q]-=@81NR>B!1>IBXIGU. ,)B21
M):$X?L RI(N1N_Z%T1U^"TY7<2<SV%*1WT%2.I+K]/,SXMLCNG$KNO')_:_8
M[]$&VU1!(D!JI@H^X3(I946/$K&_HDU%\R4X)L1^.O^UXD?+?&+M/[OS,*3O
M^0N68$6'%OI'V/4:=S)HE@P'<5QWWO-HUU:"03ANIK';'& V7TV&18;=UWDP
M#-@/'>QAV!D2$/HX5FV_<X[.0*_<WX)ASD5UI&YGVQ^2V^H<OC.O_F8^<KT2
M6&L)2UP:#,;X7=/5'T(UL*IPI_*%LGC&=X]K_*D"30;X?JF4;0;DH/U-F_\#
M4$L#!!0    ( .,]:%@7R(?,  0  ' +   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;*56VV[C-A#]%4);+!) C6Z6?(EMP$EZ62 +!)MLBS[2TMAF
MER)5DHKC?GV'E*TX:UMUVA=1)&<.SXAG1C->2_5-KP ,>2FYT!-O94PU"@*=
MKZ"D^DI6('!G(55)#4[5,M"5 EHXIY('<1AF04F9\*9CM_:@IF-9&\X$/"BB
MZ[*D:G,#7*XG7N3M%KZPY<K8A6 ZKN@2'L%\K1X4SH(6I6 E",VD( H6$V\6
MC6XR:^\,?F.PUGOOQ$8RE_*;G7PJ)EYH"0&'W%@$BL,SW +G%@AI_+7%]-HC
MK>/^^P[]9Q<[QC*G&FXE_YT59C7Q!AXI8$%K;K[(]:^PC2>U>+GDVCW)NK'-
MAA[):VUDN75&!B43S4A?MM]ASV$0GG"(MPZQX]T<Y%C>44.G8R771%EK1+,O
M+E3GC>28L)?R:!3N,O0STWLIEC\^@2K)'<P-N7BB<P[Z<AP8!+<F0;X%NFF
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M06> U[2JVO)*,+)PK?!"&FRLW6N*?S*@K '.+Z4TC6 7:/^-)O\"4$L#!!0
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M5@MQ!/!'+P""&A \ PPG+P"&-6!X*F!4 T:GAC2N 677W:KOI7 A460^%?P
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MEGT3R3(A/!8S\1ASDHB89UJF?/LW+F:^;951RS.-O=<U[M@^D*,% C49H;0
M2@M1M*9 :I.1VDW&6Y$6 BG-H5HG6KZ8 )7-N*O"M.-=2IXY4ZW>D3WT:,5
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M\C(!&H,T ?A\*83>W9@.FO/+V7]02P,$%     @ XSUH6'_Y8^47!@  /"P
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M!\<LYONX53>_.7%OJ@;J"8'20E :@:+9JAE?R',;0W_NXX4>V^AV5C5+J8?
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M21!_O<4QVR\<Z!QN/))M)/4-=SE/T18_8?F</G!UY58J(4DP%811P/%FX=S
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MB7*%O#BB*RXD2_-#JQ<F)4OR8H21BN9U!?5\P]1F5UYH ]5!Z?)?4$L#!!0
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M>Z[L /W_BNNSH-S($E3OL4S_ U!+ P04    " #C/6A8Y@K(\NL%  #^+@
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M1^+Y1S80WZ^(&(>K'=E!O7YY^A]02P,$%     @ XSUH6 #L1$IE!P  D#P
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M7BI9;Y'7)UILJCW@!Z&UR*K#-:,PT90/P/VE@"6<.2D3-/^H,/L74$L#!!0
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M+-^=G!\(NLLVQ[Y2(6B4?=P2+%?A:0/Y_9I2<3Q(.RCWB,_^ U!+ P04
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M704<=:1NF/.YROCX!_A<T_ <!?@,^9X?-+A/CW?WZ^XNS&PQO7XQO;[!ZQW
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M-SHGH)M>U#A65>$YWRGKFD,P"]>^4?L M[Y2RNX=WR&Z'T+V%U!+ P04
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MF.CK/_; L"#E%N7:A@M45L4#,$2S^DIGL/UK^C/?UBU-=4MJ#CBL_:5[./?
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M &<65% W\+S(+3!A3A+;L8E(8KY4E#"8""2718'%ZQ H7P\<W]D./))%KLR
MF\0E7L 4U',Y$;KG-BP9*8!)PAD2,!\XM_[-*#+Q-N W@;7<:2/C9,;YB^G<
M9P/',X* 0JH, ]:_%8R 4D.D9?RM.9UF20/<;6_9[ZQW[66&)8PX_4,RE0^<
M:P=E,,=+JA[Y^B?4?GJ&+^54VB]:5[']OH/2I52\J,%:04%8]<>;.@\[ #\Z
M @AJ0/ >T#T""&M :(U6RJRM,58XB05?(V&B-9MIV-Q8M'9#F-G%J1)ZEFB<
M2NY9R@M 3W@#$EVBB> K8G=('Q"T-WD^!H4)E1T=]CP=H_.S#CI#A*&GG"\E
M9IF,7:45&5XWK5<?5JL'1U;W _3 F<HE^L$RR/8)7&VE\1-L_0R#DXQC2*]0
MZ%^@P O"%D&CC\.#$W+")KVAY8L^D-ZV]%3HL!UM;O"-+'$* T=?40EB!4[R
M]8L?>=_;K'T2V9[1;F.T>XH]^<6E1#/0IP;TF;"F%=ZT6:YXNI;'U)A5<MGU
MKD,_=E>[9EK"_+[O?VO"]F3V&IF]DS+/A\!@3E0'E7LG_4TRR MT!QD(3-O4
MGZ3_WPVKR'I['GOM!J/&8/0)!I^X:K<7'63=>[<OAQ&'FMV=>E2 6-@R+5'*
METQ55[D9;5Z"6UL WXT/]0M1%?0WFNIY><!B09A$%.::TKOJZRR*JF17'<5+
M6_5F7.D::INY?N5 F  ]/^=<;3MF@>;=3/X!4$L#!!0    ( .,]:%C8$-2?
M#@,  ,<)   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;*U676_:,!3]
M*U:F34S:R <M91U$*G35^M"I:KONV20W8-6Q,_L&Z+^?[80,JA"J;B\0?YSC
M<^[UM3U>2_6DEP!(-CD7>N(M$8MSW]?)$G*J^[( 848RJ7**IJD6OBX4T-2!
M<NY'03#T<\J$%X]=WZV*Q[)$S@3<*J++/*?J>0I<KB=>Z&T[[MABB;;#C\<%
M7< ]X,_B5IF6W["D+ >AF11$03;Q+L+SV<C.=Q,>&:SUSC>Q3N92/MG&=3KQ
M BL(."1H&:CY6\$,.+=$1L;OFM-KEK3 W>\M^Y7S;KS,J8:9Y+]8BLN)-_)(
M"ADM.=[)]7>H_9Q:OD1R[7[)NIX;>"0I-<J\!AL%.1/5/]W4<=@!A,,#@*@&
M1"\!)P< @QHP<$8K9<[6)44:CY5<$V5G&S;[X6+CT,8-$S:+]ZC,*#,XC*]%
M(G,@#W0#FGPF=Y!(D3#.J OR'' -((A&BB5*]4P412!4I 2R#%P*JJ[>)2!E
M7'\<^VAD67(_J25,*PG1 0EA1&ZDP*4FWT0*Z3Z!;_PTIJ*MJ6G4R7@)29\,
MPD\D"J)!BZ#9Z^%1AYQ!$^.!XQL>X#L05%P"0;HAA9(KYJK"I*(H$5)"T8UF
MD(*B?"?\K$J7A=FPMP6[TC)HUV(/A7-=T 0FGJEZ#6H%7OSA73@,OK8%ZC^1
M[87MI G;21=[?%6[MV9-0%[LP1[5A)("5 ("6W==Q1Y6.]^>9JLXZ$?AV%_M
M.CPV:T_Z:2/]M%/Z/<KDR:73G'=5UFW-2)-4937G5!C5)&6FB!2(Q-3><3_=
M2_;"?A"\;P/..H%O3.*PB<2P4]8/:6NZ-"?%G .!#22E.S3V8G/<>_<B'=[?
M -SS>=;X/.MD>J2\K!/-S<U(34Y?8:N;LQ=^.>CK"#(*CAD;-<9&G50/$DT-
M'K?2R=*^R4B;L7_GJ6SZ.W=B#FKAG@K:[+M28'63-+W-:^3"7<(O^J?FE5(]
M*O[25$^<&ZH63&C"(3.40?_,%)JJG@U5 V7A;MZY1'./N\^E>6F!LA/,>"8E
M;AMV@>;M%O\!4$L#!!0    ( .,]:%B. =)KS@,  ,,,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<R+GAM;*U7VV[C-A#]%4)=%+M -[I:EE/;0&*WZ#YL
M&^2R?6:DL25$(E62MI-^?8>4+%]$:X-B7VR1FCD\<S2:&4UW7+S('$"1UZID
M<N;D2M77KBO3'"HJKW@-#.^LN*BHPJ58N[(60#/C5)5NX'FQ6]&".?.IV;L3
M\RG?J+)@<">(W%05%6^W4/+=S/&=_<9]L<Z5WG#GTYJNX0'44WTG<.5V*%E1
M 9,%9T3 :N;<^-<+/](.QN); 3MY=$UT*,^<O^C%EVSF>)H1E) J#4'Q;PL+
M*$N-A#S^:4&=[DSM>'R]1__=!(_!/%,)"U[^760JGSF)0S)8T4VI[OGN#V@#
M&FF\E)?2_))=:^LY)-U(Q:O6&1E4!6O^Z6LKQ)&#'U]P"%J'X-PANN 0M@ZA
M";1A9L):4D7G4\%W1&AK1-,71AOCC=$43#_&!R7P;H%^:OZ%I;P"\DA?09+/
M9,&KFC-@2A*^(G]B&BUA!4) IDW(C92 MSXN0=&BE)_0X^EA23Y^^$0^D(*1
MQYQO)&69G+H*R>DCW+0E<ML0"2X0\0/RE3.52_(;RR [!7 QJBZT8!_:;3"(
MN(3TBH3^+R3P@M!":/%^]V" 3M@I'1J\^ +>J;0,I<WVTBJ4EAII;;HUL*$=
M5K_FU[*F*<P<?(\EB"TX\Y]_\F/O5UO,/PCL1(&H4R :0I\O:%TH6A;_8L@:
MG8HT)Y@M*,06ZTF-U4$1>,4*)<&J1 ,?&7A=G[;S( SCJ;L]CK!O%(W#H#,Z
M83[JF(\&F>L7 2NGH*I@:U)R*4E*A7C#,KJCPI[N#>+HB$?H^:%WQK9O%823
M<62G&W=TXT&Z]Y?$U6NN<A FY5+,O4)]/Y*XQ]$/_?&Y[M^S.HEDW$4R'HSD
M0?'TA6")TDE!=>&W$1SWCAXE<73&KV\4C?V1G5[2T4L&Z3TQU)F9=-X"VX"-
M7-+799*<D^L;!9&7V,E-.G*3X2S@;[14;^0>4BBV]+FTTIOT9?&2\RRU&,47
MGJSO'3J/-\CO+YV(UD;A]8X;C\[3S6*4C"XHYA]U0W^0TR/' O7>PMQBG>9=
M&/286LR\,)A<X!H<N :#7+_1<D.;6:C$:8RRU/J 6Y3CXS];:=KL!G@>^IX_
MV%1,\7ROHO^C/1%;F_L!0*?1'GJ</]SD<*#"<5J"'H<PP<GVG4^IW[82SSM_
M#RU687ADU7!VC\;!"L3:3,G8L?B&J69\ZG:[2?S&S)]G^[=Z0C=CY@&F&>^_
M4K$NF"0EK!#2NQICVHAF8FX6BM=FZ'SF"D=8<YGC5P8(;8#W5YRK_4(?T'VW
MS/\#4$L#!!0    ( .,]:%BQ+^(2O@(   T)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;+66:V_:,!2&_XJ555,KK>0&@78A4BFK5JDWE77[;)(#
M>'7LS#:$_OO93DBI%#*I6K^ [?A]SV/'/B=QR<6S7 $HM,TIDV-GI51Q[KHR
M74&.98\7P/23!1<Y5KHKEJXL!.#,BG+J!IX7N3DFS$EB._8@DIBO%24,'@22
MZSS'XF4"E)=CQW=V X]DN5)FP$WB B]A!NJI>!"ZYS8N&<F!2<(9$K 8.Q?^
M^<2W COC)X%2[K616<J<\V?3N<[&CF>(@$*JC 76?QNX!$J-D^;X4YLZ34PC
MW&_OW*_LXO5BYEC"):>_2*968V?DH P6>$W5(R^_0[V@@?%+.97V%Y75W,'
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M+X'SLO^]B)?/B&LBEY0K8+@PJD%O:"X667;F<J%%X;KAH]"FM[II9EXS**V
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MDI"J,/Y<Y W*Y_H,:W^T\>LV8N"09Z!"M@7X3S0;GAC6GAAV0LWVPP=/NEQ
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ML0>V0\(D+U@456<;%CPF/Y$^R9<LXWGSI^N<SZC!L9H:)+#K[/4DGP>=I--
M>C[0[J0H-G7VEYQ388>G+KD2=/U<77+!P277T<!)37*Z264G^CE?L8 _]$0O
MF?-LPWOCO__-&@[^V>4(),Q'PB@(IKC#W;O#U=''OZWC9W&7I_/&PU?DWQE+
M"N&<_YZ^<B9:IJECD#"_AGD5K!PF-^/1P'4&]GU_<VAR4)V*R;V]R3VMR>D/
MG@5ASLDJ"P-./H4)F:51Q+*<K(0K*JMW=9\3+=;4ZDB87\-N#ZQN.S>NVS(Z
MJ$K%Z,.]T8=:H^N'K2YK:WFFUD;"?"2,@F"*4V[W3KF%C06W2'<@83X21D$P
MQ1VCO3M&9]PCIKW2Z.C>MT8WPZ%Z[T^U-9M:' FC()AB\;N]Q>\^T"N)(5B,
M%<&Z%%-DNF2AD$9).52+B3F9I.*0:I[^50S761B3*7V\(H];GI"?UXME]\"M
M;8[I782$^4@8!<$4GUH#*:H&L&ZM08$\ J7Y4!I%T52G'"A=Z\R)+BMO+K(H
MI[GE+59*N4[/6$=3R=8L<JJOTMC<2!I%T51SV]+<]L=ZMNDRY'/QS8;G1?7-
MXWPN!I[LBDPR-HOXCGP/BY>TTS/:JHWO&23-A](HBJ8Z44IU"Z?5+:A8A])\
M*(VB:*I3I&"WSE7LYW9DQYKXJ".#:G HC:)HJKFE6+?T:AW5D8DCZ]NICK8^
ML5V-R83[%A7RBOPN7@=B;O>8\$Y'0@, 4)H/I5$43?6YC!580UR_!XT30&D^
ME$91--4I,E9@:;7O^ ]Q?X7)@GQB.6&E)@W$/=.I2!N091WT>(,;VVMW>M H
M )1&4335UC(08)T3"?C_=GJ_;[LG>TBQ/X72?"B-HFBJSV4HPKK#=7K0. *4
MYD-I%$53UQ]E*,'6JN+#Y9EU$/ \+T-!_*\UBTA<KG5&.[)I^L6#Y<EJ-BC?
M=GFPJ?=P4NBT8W;ZMIGZ!4JC*)KJ%QE-L/71!&T'>45:2SS"?3]505$92NWT
M"3( ,(72?"B-HFBJ]V1PPK9A79T-#39 :3Z41E$TU2DRV&!K=?,[5Z+U4&/W
M0,,.4!IM:(<]]F#?8:LVE[$$6Q]+>/=2M)YK;';WG#4D_[S#**IMJDUEP,#V
MM)W+GU5VFKALV89G;,$)R_-U7(T4W5<P5-5#:3Z41E$TU3%2U=OZ%(!7QUR_
M.J:*G%W/6,')G(49V;!H;7030*5_0RN72>3E;=W<6>V[ "KJ4335)U+4VWI1
M_^%YU 762/5--G8K-,H I5$4376^C#+8(]PT#!H&@-)\*(VB:*I39!C UJ<D
MO',:=G<T.;$&Y4];4D*E/I1&430U+59*?4<O]=\]%VNX;V7@Z*LW3H"%JGD4
M336]5//.N;D!=6A%_,K$>/'NX(ISG#K@MKT!5>=0&D715&](=>Y\('7@S#G!
M![(+]*TSSCJ'"GXHC:)HJI\/-@+@L@L<J,R'TGPHC:)HJE-D1,"YQ'X YSC%
MP.D:_O65&QL>FF> HJF&EV$#YT*[ ISCY/O.X1\:&(#2*(JFFEX&!IP/[ TX
M5X3&JRC=<:[LC^MT%S1H *7Y4!I%T52ORM""H]]<8!J'<Z"R'TKSH32*HJF.
MD;+?T2<7^.$FG/%D1G8AC[KV>4[T &-70,5^0U.32UH1:%2-JH&EA'?T$I[^
M6/&@O/(W:21F5%%8[#JM#%W$A]+\AM9*X1F.[I2?MMDO(>!=*>!=O8#_%N8O
MU_-,C %A&6T4RH-DK.A<Z=63C#=00I5]0[-LQ?0#Y^YH#^4E1+LK1;NK%^W[
MJUS8NC/O55_>V,A0P?[&N7EDQ\N9WUV=Y9$3RR4SMNO<Q8UJF.H&J=9=M%IW
MQ-4TT&="Z.LT=AU4@T-I%$53O2<UN(O3X"Y4@T-I/I1&4335*0=;\B^R)Q^[
M*1^[*Q^JU-WC:,.)3 A7RF_W0O);SS4VN]<12&DM $-KI"B::G>IO5U]JKVI
M2G.A\AE*\Z$TBJ*ICI'RV=6OS,.S)?3U&7ON]CCJY0J!T+Y7H,(915-=(H6S
M^X&L_'.F6A=(EM WV=BK4*D.I5$4376^%/4N+CW?A2I[*,V'TBB*IOXC'RGY
MO;/3\PUF:MYQ[OVM=[Q8HJ_;U.Y0&D715+M+[>^]I?W?^R^4:JZKF5]-]74;
MVQVZ-(^BJ7:78M_3B_V+;4=IZM5N1]&WS=@O4!F/HJE^D3+>TRI2R,S@ RD3
M^M:9CC=0F@^E411-];.,#'@N;!+@0>,!4)H/I5$4377*P;_STX<.WCD).%;Z
MMM>1,J&OW-CPT-@!BJ8:7L8.//VZ_?MG <,S9@'0T "41E$TU>XR-."AD_8[
M=.BY^1+ZMAAW8]!E>2B-HFBJ5V5TP=-GXYM&XCRH\H?2?"B-HFBJ8Z3R]_3+
M^6_G2^@!QJZ ZGVO:R6__8]A+Z'BAU+%#]_*O#\K7T)/,;4RE.8WM%:^1'OO
M&$55JAI:RO:A7K8;9$CH2<;&ADKZAG:4(3%J[T1%5:N:6ZKUH5ZMOYDAH2]O
M;&2H/G_CW$9-AH1S,B\"U9S:^/V#ARS$/%M43[?(A0A;)T7]0(']I_LG:'RI
MGAO1^MRW/M/Z.1@24S^6XU>6+<(D)Q&?"^3@YE;,KK/Z21?UFR)=58]R>$Z+
M(HVKETO.9CPK#Q#?S].T>'U35K!_WLCX?U!+ P04    " #C/6A8<YUPP$H%
M  #1&   &0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6RUF5%SVC@0Q[^*
MANO<M#,IV#(8DDN824COK@^]9IJF]RSL!32U)4X2(;E/?RO;L;$Q2O E+V ;
M:;6_W97TMSC?2O53KP ,>4@3H2]Z*V/69X.!CE:0,MV7:Q#XRT*JE!F\5<N!
M7BM@<=8I30;4\\)!RKCH3<^S9S=J>BXW)N$";A31FS1EZO$*$KF]Z/F]IP??
M^')E[(/!]'S-EG +YFY]H_!N4%J)>0I"<RF(@L5%[](_F]&A[9"U^,%AJW>N
MB4692_G3WGR.+WJ>]0@2B(PUP?#K'F:0)-82^O%/8;17CFD[[EX_6?\]@T>8
M.=,PD\G?/#:KB]ZD1V)8L$UBOLGMGU  C:R]2"8Z^R3;HJW7(]%&&YD6G=&#
ME(O\FST4@=CI0$<'.M"B VUV" YT"(H.00::>Y9A73/#IN=*;HFRK=&:O<AB
MD_5&&BYL&F^-PE\Y]C/36R.CG^0* Q&3F4RQ.C3+XRMB\M6L0)$K$+#@AMPD
M3&CRD>1=OJZS9I<V#=P\DO?78!A/] =L<7=[3=Z_^T#>D0'1*Z9 $R[(G>!&
MG^!#O/Z^DAN-0^CS@4$*Z\L@*CR^RCVF!SSV*?DBA5EI\DG$$-<-#!"_C %]
MBL$5=5J\AJA/ O^$4(\&+0[-7MZ=.MP)RI0$F;WP4$ILQ#[.LY1$.REI"U5N
M*6BW9)> ,[UF$5ST<(YK4/?0F_[ZBQ]ZO[5AOI*Q&O2PA!ZZK$__VJ1SK#6Y
M* KFA'S=&&VP1+A8$F;(')9<"'N#;=:@N(S; I*/,LI&L4O8_12S,AH-,3'W
MNZQ.;SJRCDK6T9&L?R@F3+.6<Z#1'M#$&P9>D\<Y8D>>L.0)C^3Y]  JXKJ=
M*-PC^D@GPW'0('*.V9%H7!*-CR3"/6,!''-T0N!AS17.3:E(Q$2$.U [YWB?
M<^P'7I/3Z4E'SDG).?E_LPYP%W#.M\G^?!L'*"$F#<J6=HUY60,X+0%.NY4>
MFR?P(H#3/<?\T]#WA\TT.?WHF";?JW9IS\GY=R9'L.@N[T&AO"IG&+E1/,)/
M#$*V;W1=-XOQQ[4$]>FP$06WFUW#L"-6_-<*@V-)+0:Q+!5LT!_NP3J=Z0I+
M*UCZ6K#.];88IH8[Z=-QD];I35?:2O3X3GEQ#&V'M;@8O!:#(.R/_&80WD(#
M^94(\MTJJ/LT?W:=*T:N%[W7GS07ZJ+=X86@CE9I'M\M>HZOYA<OX<7(X]H:
MWM\3%&X'N^:V$DF^6R7M!6"&;S$*7V,W+"'?P+YRVUQ^!Y76LMM*[!XJ)(_
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M/\953N7GY_F-D>OL"'HNC9%I=KD"%H.R#?#WA93FZ<8.4/Z+,?T/4$L#!!0
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M&NQT;ICC703*!N#WN91F-[$_:&ZWY!]02P,$%     @ XSUH6&,SGKB2 P
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M476+7 ^,+'W3N);&MJ#^,K=?%:A<@+V?26GV _> ]CLE_@]02P,$%     @
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M3E<&$UVZN[:L*9?*X($*-#!&A;D@F$NF+'R R>P!IE@Q0[7!$#?1BH2J!;W
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MH-"[.U"$)O*]MOT9N4B:O>3,59J$<<6-2H=O"X?],PYC'WWB3.TENF<QQ&T
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M1:K$>/EQH%Q(EIOWZQ63ZFW='&XQ4H\A+:"NKQF3AX6^0?V)9O(_4$L#!!0
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M<7\#WUN-UM6B@;-K)"ZD.^]G1O#+* Y+8QMC>=S6D<^4\D%T*!+R4,$ZJ7J
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M;SB-]QOT'UJ2MR@Y)&VF,**[F@(2YD'"?$A8  D+@6 -YXPJYXRN6UQ&D.Z
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MQQ =V*H.[)<=+YW&+46TOY7.0Q-4H4"AN0Q;C8)'A\]H4/$!BL:@T%S:K/[
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M0L,KF218U=SOF2G%4J./R0V:H_< 1I ,09$P")MH?2GF0'XL!?DN64HN)@H
MI37D@/"4W'(A+'[/-YB1Y>6/"O:7.?MP"WL,TR!->IR'>7P8D,.#(_+R'LC'
MDI1U"<NZA ZYLP7YFG%%GIBE?0M,SY7C6TDQ!VI6 ]E3=:XS-H*^A\=&@UJ
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M1PHV3>\UAM-UN.]K[:A[PG!'SQ4:[T#K&ZW=V? MU#V Q1]02P,$%     @
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M\H41H)K&VTQ05JYWK26:3NB&A7FK0-D L[^1$@\3>T#W^J7? 5!+ P04
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MVL3I^8+^V6DW6HY8P4;0GZ34319\"% )%>ZHWHO^*PQZ[BU>(:AROZ@?8J,
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MO3=UI5\R;VC1NL$^"FW6Q!T;\RZ!M 'FOA)"7PQ;8'SI\C]02P,$%     @
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M^#ZN.RG;JT:VNRLW=9*ZL=(9/[11@FH6JMFHYJ":BVI>HTD7T=(W-['8NP2
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MBK<!]/:JMP?H[55O#]#;=W^V 7I[U=L#]/:JMP?H[55O#]#;J]X>H+=7O3U
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MY^^_+S\N]J.,[UP/7S.FF[]02P,$%     @ Y#UH6"BDL[1T @  $ST  !,
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MQW'_C^.79]Q7[?":GRS_A;[Y"5!+ 0(4 Q0    ( .,]:%@'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ XSUH6$1A#D7O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ XSUH6)E<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #C/6A8
MWFORV[$(  "M/0  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ XSUH6';?1M2>!P  $R<  !@
M     ("!]1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M .,]:%BIUOD,2@0  ,L4   8              " @<D8  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #C/6A8Z55K/Z@%  !W%P  &
M            @(%)'0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ XSUH6,#1=?\8!P  IS@  !@              ("!)R,  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .,]:%C\7] 0_0@  &DJ
M   8              " @74J  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #C/6A8.ARAW>(%  !'#@  &               @(&H,P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ XSUH6(!*GX%D
M)@  H(4  !@              ("!P#D  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( .,]:%A";78*]P4   P2   8              "
M@5I@  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #C/6A8
M?C9!G.@;   4=@  &0              @(&'9@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( .,]:%AL57.$N!4   Q>   9
M      " @::"  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ XSUH6)H3A==O"   "!X  !D              ("!E9@  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #C/6A8+TVW##D'  "G%0
M&0              @($[H0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( .,]:%BYM0C\C0H  ,$?   9              " @:NH  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ XSUH6$RED_O:
M"@   B   !D              ("!;[,  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #C/6A8EB'[H6H4  "12P  &0
M@(& O@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .,]
M:%AF,4\DH 0  -D-   9              " @2'3  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ XSUH6)R94IQ #@   C,  !D
M         ("!^-<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #C/6A8;"HS]EX&  #+$0  &0              @(%OY@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .,]:%@>92EEF@0  '$+
M   9              " @03M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ XSUH6(+^A/[9"0  7Q@  !D              ("!U?$
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #C/6A8XKH%
MSHPG  "+CP  &0              @('E^P  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( .,]:%@9ZMK?PP(  $$'   9
M  " @:@C 0!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MXSUH6,7SORS. P  ) T  !D              ("!HB8! 'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #C/6A8U2?UAI@#  !9"P  &0
M            @(&G*@$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( .,]:%ABWB(OP0,  &D0   9              " @78N 0!X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ XSUH6%[=4)M]!
ML@T  !D              ("!;C(! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #C/6A8%\B'S  $  !P"P  &0              @($B
M-P$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .,]:%B&
MK(V_%04  !</   9              " @5D[ 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ XSUH6 $3V"Y\!@  "1L  !D
M     ("!I4 ! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .,]:%B.;<Z(.04   (K   9              "
M@2]6 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ XSUH
M6/OSG> "!   B18  !D              ("!GUL! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #C/6A8ETF:(OD"  #;"0  &0
M        @('87P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( .,]:%C3>*'=0P0  )46   9              " @0AC 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ XSUH6)Y09U'+ @  V <
M !D              ("!@F<! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #C/6A8DRTIX*H"   ?!P  &0              @(&$:@$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .,]:%@E=&IS
M@08  &XY   9              " @65M 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ XSUH6+2&[=8*!P  =C\  !D
M ("!'70! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #C
M/6A8269:USH$  #+%   &0              @(%>>P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( .,]:%A_^6/E%P8  #PL   9
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M970T."YX;6Q02P$"% ,4    " #C/6A8  YF=%H&  #3,@  &0
M    @(%EG $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M .,]:%CF"LCRZP4  /XN   9              " @?:B 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ XSUH6"[O&HH6!@  @2D  !D
M             ("!&*D! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " #C/6A8.1D2_= %  #++   &0              @(%EKP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .,]:%@ [$1*90<
M ) \   9              " @6RU 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ XSUH6)F\V;O\ P  JA,  !D              ("!
M"+T! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #C/6A8
M'51[K4<%  "T(   &0              @($[P0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( .,]:%@8AL1J&P8  "\N   9
M      " @;G& 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ XSUH6"?DY)>=!@  UB\  !D              ("!"\T! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #C/6A8OUA0<2H%  #K'P
M&0              @('?TP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( .,]:%AEB@3:-P0  $@4   9              " @4#9 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ XSUH6%(TAZ5/
M @  ' 8  !D              ("!KMT! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " #C/6A82AU?K1($  !]&0  &0
M@($TX $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .,]
M:%B&=J')H00  -D<   9              " @7WD 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ XSUH6)^@(4@@ P  L P  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( .,]:%BO]Y!PW@(  *H)   9
M  " @3S^ 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
MXSUH6$4[HKZO @  K@<  !D              ("!40$" 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " #C/6A8S?AN(I4"  !#!P  &0
M            @($W! ( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( .,]:%C8$-2?#@,  ,<)   9              " @0,' @!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ XSUH6(X!TFO. P
MPPP  !D              ("!2 H" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    " #C/6A8L2_B$KX"   -"0  &0              @(%-
M#@( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( .,]:%A%
MN8':V (  "L)   9              " @4(1 @!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ XSUH6'V2:@U_ P  [0H  !D
M     ("!410" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .,]:%B F-Z)RPD  'MD   9              "
M@:4I @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ XSUH
M6'.=<,!*!0  T1@  !D              ("!IS," 'AL+W=O<FMS:&5E=',O
M<VAE970X,2YX;6Q02P$"% ,4    " #C/6A8N].]*I$$   C'   &0
M        @($H.0( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0
M   ( .,]:%BZ(RO%Z 8  %\W   9              " @? ] @!X;"]W;W)K
M<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ XSUH6!3O#<6) P  F@H
M !D              ("!#T4" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q0
M2P$"% ,4    " #C/6A8-'+N7H<"  #I!@  &0              @('/2 (
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( .,]:%AC,YZX
MD@,  .<-   9              " @8U+ @!X;"]W;W)K<VAE971S+W-H965T
M.#8N>&UL4$L! A0#%     @ XSUH6-[19'IN P  LPP  !D
M ("!5D\" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " #C
M/6A8T.K/A)H"   5!@  &0              @('[4@( >&PO=V]R:W-H965T
M<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( .,]:%BM5\4,)@0  $@5   9
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M970Y,RYX;6Q02P$"% ,4    " #C/6A8\B3T]P($  !%'P  &0
M    @('#=0( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    (
M .,]:%ACI/S<+0(  -@$   9              " @?QY @!X;"]W;W)K<VAE
M971S+W-H965T.34N>&UL4$L! A0#%     @ XSUH6-2^Q,KX!   ,2H  !D
M             ("!8'P" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"
M% ,4    " #C/6A8%RF#/9H$  #X(   &0              @(&/@0( >&PO
M=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( .,]:%AK-Q4#(0<
M !=!   9              " @6"& @!X;"]W;W)K<VAE971S+W-H965T.3@N
M>&UL4$L! A0#%     @ XSUH6-P&2B4Q P  Q0L  !D              ("!
MN(T" 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " #C/6A8
M%GG27E,"   ,!0  &@              @($@D0( >&PO=V]R:W-H965T<R]S
M:&5E=#$P,"YX;6Q02P$"% ,4    " #C/6A8#S?\QI@(  "9<@  &@
M        @(&KDP( >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4
M    " #C/6A822D'3Y0"   )!P  &@              @(%[G ( >&PO=V]R
M:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " #C/6A8N^5KH1($  !R
M%P  &@              @(%'GP( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX
M;6Q02P$"% ,4    " #C/6A8N5QR2RH"  #U!   &@              @(&1
MHP( >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " #C/6A8
MO?#'3?D"  #="@  &@              @('SI0( >&PO=V]R:W-H965T<R]S
M:&5E=#$P-2YX;6Q02P$"% ,4    " #D/6A8VS.O7 8/  #EV   &@
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M2P$"% ,4    " #D/6A8,,:<)@P#  !O/P  &@              @ '0R0(
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #D/6A8**2S
MM'0"   3/0  $P              @ $4S0( 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     = !T .P?  "YSP(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>420</ContextCount>
  <ElementCount>499</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>148</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Consolidated Financial Statements Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails</Role>
      <ShortName>Consolidated Financial Statements Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Licensing and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements</Role>
      <ShortName>Licensing and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Lease Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreement</Role>
      <ShortName>Lease Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stock Based Compensation and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Concentration of Risk, Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Consolidated Financial Statements Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables</Role>
      <ShortName>Consolidated Financial Statements Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Lease Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementTables</Role>
      <ShortName>Lease Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLeaseAgreement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCapitalStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails</Role>
      <ShortName>Description of Business - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails</Role>
      <ShortName>Consolidated Financial Statements Details - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Consolidated Financial Statements Details - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails</Role>
      <ShortName>Consolidated Financial Statements Details - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Licensing and Other Arrangements - Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails</Role>
      <ShortName>Licensing and Other Arrangements - Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails</Role>
      <ShortName>Licensing and Other Arrangements - Rezolute (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Licensing and Other Arrangements - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails</Role>
      <ShortName>Licensing and Other Arrangements - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails</Role>
      <ShortName>Licensing and Other Arrangements - ObsEva (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details</Role>
      <ShortName>Licensing and Other Arrangements - Novartis - NIS793 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details</Role>
      <ShortName>Licensing and Other Arrangements - Novartis - VPM087 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails</Role>
      <ShortName>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - LadRx (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Palo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Lease Agreement - Leased facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails</Role>
      <ShortName>Lease Agreement - Leased facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Agreement - Maturity of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Lease Agreement - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails</Role>
      <ShortName>Lease Agreement - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Lease Agreement - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Lease Agreement - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Long-Term Debt - Summary of long-term debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Summary of long-term debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails</Role>
      <ShortName>Long-Term Debt - Aggregate projected future principal and discounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Long-Term Debt - Interest expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt - Interest expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation between statutory rate and effective rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Income Taxes - NOL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails</Role>
      <ShortName>Income Taxes - NOL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Income Taxes - Tax credit carryforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails</Role>
      <ShortName>Income Taxes - Tax credit carryforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>41007 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>41008 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>41009 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>41010 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>41011 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>41012 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>41013 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails</Role>
      <ShortName>Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails</Role>
      <ShortName>Capital Stock - Series A Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails</Role>
      <ShortName>Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Capital Stock - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails</Role>
      <ShortName>Capital Stock - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Capital Stock - BVF Ownership (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails</Role>
      <ShortName>Capital Stock - BVF Ownership (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>41206 - Disclosure - Capital Stock - ATM Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails</Role>
      <ShortName>Capital Stock - ATM Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Capital Stock - Summary of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>41208 - Disclosure - Capital Stock - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails</Role>
      <ShortName>Capital Stock - Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>41209 - Disclosure - Capital Stock - Weighted average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails</Role>
      <ShortName>Capital Stock - Weighted average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails</Role>
      <ShortName>Commitments and Contingencies - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails</Role>
      <ShortName>Commitments and Contingencies - Arbitration Proceeding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="xoma-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>xoma-20231231.xsd</File>
    <File>xoma-20231231_cal.xml</File>
    <File>xoma-20231231_def.xml</File>
    <File>xoma-20231231_lab.xml</File>
    <File>xoma-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="xoma-20231231x10k.htm">xoma-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="839">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>137
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "xoma-20231231x10k.htm": {
   "nsprefix": "xoma",
   "nsuri": "http://www.xoma.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "xoma-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "xoma-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xoma-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "xoma-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xoma-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "xoma-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 331,
   "keyCustom": 168,
   "axisStandard": 38,
   "axisCustom": 0,
   "memberStandard": 45,
   "memberCustom": 97,
   "hidden": {
    "total": 38,
    "http://fasb.org/us-gaap/2023": 27,
    "http://www.xoma.com/20231231": 3,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "contextCount": 420,
   "entityCount": 1,
   "segmentCount": 148,
   "elementCount": 900,
   "unitCount": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 839,
    "http://xbrl.sec.gov/dei/2023": 44,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusiness",
     "longName": "10101 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails",
     "longName": "10301 - Disclosure - Consolidated Financial Statements Details",
     "shortName": "Consolidated Financial Statements Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements",
     "longName": "10401 - Disclosure - Licensing and Other Arrangements",
     "shortName": "Licensing and Other Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements",
     "longName": "10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements",
     "shortName": "Royalty and Commercial Payment Purchase Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurements",
     "longName": "10601 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreement",
     "longName": "10701 - Disclosure - Lease Agreement",
     "shortName": "Lease Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.xoma.com/role/DisclosureLongTermDebt",
     "longName": "10801 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxes",
     "longName": "10901 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans",
     "longName": "11001 - Disclosure - Stock Based Compensation and Other Benefit Plans",
     "shortName": "Stock Based Compensation and Other Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "longName": "11101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStock",
     "longName": "11201 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11301 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation",
     "longName": "11401 - Disclosure - Concentration of Risk, Segment and Geographic Information",
     "shortName": "Concentration of Risk, Segment and Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.xoma.com/role/DisclosureSubsequentEvents",
     "longName": "11501 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "longName": "30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables",
     "longName": "30303 - Disclosure - Consolidated Financial Statements Details (Tables)",
     "shortName": "Consolidated Financial Statements Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables",
     "longName": "30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "30603 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementTables",
     "longName": "30703 - Disclosure - Lease Agreement (Tables)",
     "shortName": "Lease Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtTables",
     "longName": "30803 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesTables",
     "longName": "30903 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables",
     "longName": "31003 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)",
     "shortName": "Stock Based Compensation and Other Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "31103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockTables",
     "longName": "31203 - Disclosure - Capital Stock (Tables)",
     "shortName": "Capital Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables",
     "longName": "31403 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)",
     "shortName": "Concentration of Risk, Segment and Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
     "longName": "40101 - Disclosure - Description of Business - Liquidity (Details)",
     "shortName": "Description of Business - Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
     "longName": "40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Unrestricted and Restricted Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
     "longName": "40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
     "longName": "40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)",
     "shortName": "Consolidated Financial Statements Details - Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_w6rQaC_PqEy9fPUmEuULSQ",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
     "longName": "40302 - Disclosure - Consolidated Financial Statements Details - Intangible Assets, Net (Details)",
     "shortName": "Consolidated Financial Statements Details - Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails",
     "longName": "40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)",
     "shortName": "Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails",
     "longName": "40304 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)",
     "shortName": "Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_6_1_2021_To_6_30_2021_dtGtLvan-0WILGKknRPEsA",
      "name": "xoma:NumberOfArbitrationProceedingsInitiated",
      "unitRef": "Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
     "longName": "40401 - Disclosure - Licensing and Other Arrangements - Takeda (Details)",
     "shortName": "Licensing and Other Arrangements - Takeda (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_1_2020_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_MTSivgxXa0q5d0yr9jPQ4Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "xoma:LicensingAndOtherArrangementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
     "longName": "40402 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)",
     "shortName": "Licensing and Other Arrangements - Rezolute (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ",
      "name": "xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
     "longName": "40403 - Disclosure - Licensing and Other Arrangements - Janssen (Details)",
     "shortName": "Licensing and Other Arrangements - Janssen (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw",
      "name": "xoma:ProceedsFromUpfrontPayment",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
     "longName": "40404 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)",
     "shortName": "Licensing and Other Arrangements - ObsEva (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ",
      "name": "xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
     "longName": "40405 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)",
     "shortName": "Licensing and Other Arrangements - Novartis - NIS793 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_DDySBRqQAkmCyGXaQYbaTw",
      "name": "us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
     "longName": "40406 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)",
     "shortName": "Licensing and Other Arrangements - Novartis - VPM087 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew",
      "name": "xoma:LicenseAgreementTransactionPrice",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
     "longName": "40407 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "shortName": "Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenue",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg",
      "name": "xoma:AgreementsNumber",
      "unitRef": "Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
     "longName": "40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "xoma:RightsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
     "longName": "40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - LadRx (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q",
      "name": "xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "xoma:RoyaltyPurchaseAgreementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
     "longName": "40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q",
      "name": "xoma:MilestonesReceivableMaximum",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
     "longName": "40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Agenus (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ws-dALFRwk6XAWf156awmQ",
      "name": "xoma:MilestoneAchieved",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
     "longName": "40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ",
      "name": "xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
     "longName": "40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Aronora (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w",
      "name": "xoma:AgreementDrugCandidatesNumber",
      "unitRef": "Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
     "longName": "40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Palo (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A",
      "name": "xoma:AgreementDrugCandidatesNumber",
      "unitRef": "Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
     "longName": "40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Viracta (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig",
      "name": "xoma:AgreementDrugCandidatesNumber",
      "unitRef": "Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
     "longName": "40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Kuros (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w",
      "name": "xoma:RoyaltyReceivablePercentageOnNetSales",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
     "longName": "40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Affitech (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg",
      "name": "xoma:CommercialPaymentPeriodDue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
     "longName": "40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "xoma:RightsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ",
      "name": "xoma:ShortTermRightsReceivableReclassification",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails",
     "longName": "40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
     "longName": "40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)",
     "shortName": "Fair Value Measurements - Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5IIqeHWkV0S9mtFRdVUKvw",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5IIqeHWkV0S9mtFRdVUKvw",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
     "longName": "40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)",
     "shortName": "Fair Value Measurements - Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails",
     "longName": "40701 - Disclosure - Lease Agreement - Leased facilities (Details)",
     "shortName": "Lease Agreement - Leased facilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_1_31_2023_RfM78mIKA0-JJnpILkNCiQ",
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "unitRef": "Unit_Standard_facility_D1loseD-e06fL52LV83oPQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_1_31_2023_RfM78mIKA0-JJnpILkNCiQ",
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "unitRef": "Unit_Standard_facility_D1loseD-e06fL52LV83oPQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails",
     "longName": "40702 - Disclosure - Lease Agreement - Maturity of lease liabilities (Details)",
     "shortName": "Lease Agreement - Maturity of lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails",
     "longName": "40703 - Disclosure - Lease Agreement - Lease costs (Details)",
     "shortName": "Lease Agreement - Lease costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails",
     "longName": "40704 - Disclosure - Lease Agreement - Additional information (Details)",
     "shortName": "Lease Agreement - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
     "longName": "40801 - Disclosure - Long-Term Debt (Details)",
     "shortName": "Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails",
     "longName": "40802 - Disclosure - Long-Term Debt - Summary of long-term debt (Details)",
     "shortName": "Long-Term Debt - Summary of long-term debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
     "longName": "40803 - Disclosure - Long-Term Debt - Aggregate projected future principal and discounts (Details)",
     "shortName": "Long-Term Debt - Aggregate projected future principal and discounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
     "longName": "40804 - Disclosure - Long-Term Debt - Interest expense (Details)",
     "shortName": "Long-Term Debt - Interest expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
     "longName": "40901 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw",
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails",
     "longName": "40902 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)",
     "shortName": "Income Taxes - Reconciliation between statutory rate and effective rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "longName": "40903 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
     "longName": "40904 - Disclosure - Income Taxes - NOL (Details)",
     "shortName": "Income Taxes - NOL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails",
     "longName": "40905 - Disclosure - Income Taxes - Tax credit carryforward (Details)",
     "shortName": "Income Taxes - Tax credit carryforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails",
     "longName": "40906 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
     "longName": "41001 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_qpOCxF4gTE6XGswl1hQRNw",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_qpOCxF4gTE6XGswl1hQRNw",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
     "longName": "41002 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
     "longName": "41003 - Disclosure - Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - 2010 Plan Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
     "longName": "41004 - Disclosure - Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - FV Assumptions 2010 Plan Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
     "longName": "41005 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock Option Inducement Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_9t7Xrh4erUm2DCAqplH8xw",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
     "longName": "41006 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
     "longName": "41007 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.",
      "unitRef": "Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
     "longName": "41008 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2023_us-gaap_AwardDateAxis_xoma_AwardDateMay2023ToOctober2023Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DWNUD9UHZ0yY-M_tgTpaEA",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
     "longName": "41009 - Disclosure - Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Performance Stock Unit Awards Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails",
     "longName": "41010 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jWEJG3qYf0OkSzZNmxWzdw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jWEJG3qYf0OkSzZNmxWzdw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
     "longName": "41011 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_JXd_9rzC90CP0igSJTsrdg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_JXd_9rzC90CP0igSJTsrdg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
     "longName": "41012 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "As_Of_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_Yf9nqgko7Ey_J1Vum-XNLg",
      "name": "xoma:NumberOfPeriodsCashRetentionBonus",
      "unitRef": "Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_Yf9nqgko7Ey_J1Vum-XNLg",
      "name": "xoma:NumberOfPeriodsCashRetentionBonus",
      "unitRef": "Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
     "longName": "41013 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)",
     "shortName": "Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_op1dbIKXI0auw-rLczKFjA",
      "name": "xoma:AccruedCompensationContinuityIncentive",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_op1dbIKXI0auw-rLczKFjA",
      "name": "xoma:AccruedCompensationContinuityIncentive",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
     "longName": "41101 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
     "longName": "41102 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg",
      "name": "us-gaap:PreferredStockDividendsAndOtherAdjustments",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
     "longName": "41201 - Disclosure - Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)",
     "shortName": "Capital Stock - Series X and Series Y Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_owbhffF5n065fOVm_kbUVw",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
     "longName": "41202 - Disclosure - Capital Stock - Series A Preferred Stock (Details)",
     "shortName": "Capital Stock - Series A Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
     "longName": "41203 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)",
     "shortName": "Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
     "longName": "41204 - Disclosure - Capital Stock - Dividends (Details)",
     "shortName": "Capital Stock - Dividends (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3AEODlP3-0mydkDGCWhqyQ",
      "name": "us-gaap:PreferredStockDividendsPerShareDeclared",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3AEODlP3-0mydkDGCWhqyQ",
      "name": "us-gaap:PreferredStockDividendsPerShareDeclared",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
     "longName": "41205 - Disclosure - Capital Stock - BVF Ownership (Details)",
     "shortName": "Capital Stock - BVF Ownership (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
     "longName": "41206 - Disclosure - Capital Stock - ATM Agreements (Details)",
     "shortName": "Capital Stock - ATM Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_d4I_Xv63ZU-hiLOrOkWuoA",
      "name": "xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
     "longName": "41207 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)",
     "shortName": "Capital Stock - Summary of Common Stock Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
     "longName": "41208 - Disclosure - Capital Stock - Common Stock Warrants (Details)",
     "shortName": "Capital Stock - Common Stock Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
     "longName": "41209 - Disclosure - Capital Stock - Weighted average assumptions (Details)",
     "shortName": "Capital Stock - Weighted average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg",
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_ics5zZQKZEC1GLHClhw50g",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails",
     "longName": "41301 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "shortName": "Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
     "longName": "41302 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)",
     "shortName": "Commitments and Contingencies - Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow",
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA",
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails",
     "longName": "41303 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)",
     "shortName": "Commitments and Contingencies - Arbitration Proceeding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "Duration_6_1_2021_To_6_30_2021_dtGtLvan-0WILGKknRPEsA",
      "name": "xoma:NumberOfArbitrationProceedingsInitiated",
      "unitRef": "Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails",
     "longName": "41401 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)",
     "shortName": "Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails",
     "longName": "41402 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)",
     "shortName": "Concentration of Risk, Segment and Geographic Information - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_m_JT2gZUYEyv5yGMX4336Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_m_JT2gZUYEyv5yGMX4336Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
     "longName": "41403 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)",
     "shortName": "Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_3-ttz87lbUGOlay7J25Yhw",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41501 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_2_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BoZJ1cjf3EanYPBMyrtXzg",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "107",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R108": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "108",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xoma-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables, net",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r686"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258"
     ]
    },
    "xoma_AccrualOfContingentConsiderationUnderPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccrualOfContingentConsiderationUnderPurchaseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual of contingent consideration under purchase agreements.  May include royalty purchase agreements and commercial payment purchase agreements.",
        "label": "Accrual Of Contingent Consideration Under Purchase Agreements",
        "terseLabel": "Accrual of contingent consideration under the Affitech CPPA"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AccruedAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued incentive compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "xoma_AccruedCompensationContinuityIncentive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccruedCompensationContinuityIncentive",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense for compensation under employment agreement related to retirement of individual.",
        "label": "Accrued Compensation, Continuity Incentive",
        "terseLabel": "Accrued cash payment related to Continuity Incentive under Employment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities And Other Liabilities [Abstract]",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AccruedPreferredStockDividendCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccruedPreferredStockDividendCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preferred Stock Dividend, Current",
        "terseLabel": "Preferred stock dividend accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued legal and accounting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "xoma_AccruedRetentionBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccruedRetentionBonus",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense for cash retention bonus.",
        "label": "Accrued Retention Bonus",
        "terseLabel": "Accrued retention bonus"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AccruedSalariesAndEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccruedSalariesAndEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries and Employee Benefits, Current",
        "terseLabel": "Accrued payroll, severance and retention costs"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AccruedTransactionCostsRelatedToPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AccruedTransactionCostsRelatedToPurchaseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued transaction costs in connection with acquisition.",
        "label": "Accrued Transaction Costs Related To Purchase Agreements",
        "terseLabel": "Accrued transaction costs in connection with ObsEva IP Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible asset",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "xoma_AcquisitionNumberOfContingentValueRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AcquisitionNumberOfContingentValueRights",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-transferable contingent value rights each acquiree share has right to receive. representing  right to receive one or more potential cash payments.",
        "label": "Acquisition, Number Of Contingent Value Rights",
        "terseLabel": "Number of non-transferable contingent value rights for each acquiree share"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AcquisitionOfEconomicInterestAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AcquisitionOfEconomicInterestAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of economic interest agreement.",
        "label": "Acquisition of Economic Interest Agreement [Member]",
        "terseLabel": "Acquisition of economic interest agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AcquisitionValueRightNumberOfCashPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AcquisitionValueRightNumberOfCashPayments",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of cash payments each value right provides  under terms of agreement.",
        "label": "Acquisition, Value Right, Number Of Cash Payments",
        "terseLabel": "Number of cash payments for each contingent value right"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Consolidated Financial Statement Details",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r686",
      "r896"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r544",
      "r805",
      "r806",
      "r807",
      "r869",
      "r897"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r357"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Warrant Issued",
        "terseLabel": "Issuance of common stock warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r126"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdrMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADR [Member]",
        "terseLabel": "Series B Depositary Shares",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "xoma_AffitechResearchAsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AffitechResearchAsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affitech Research AS, a Norwegian biotech company.",
        "label": "Affitech Research AS [Member]",
        "terseLabel": "Affitech"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AgenusIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AgenusIncMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agenus Inc.",
        "label": "Agenus [Member]",
        "terseLabel": "Agenus"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r723",
      "r733",
      "r759"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r726",
      "r736",
      "r762"
     ]
    },
    "xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AgreementDrugCandidatesExclusiveLicenseOptionNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of drug candidates subject to exclusive license option.",
        "label": "Agreement, Drug Candidates, Exclusive License Option, Number",
        "terseLabel": "Number of drug candidates subject to exclusive license option"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AgreementDrugCandidatesNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AgreementDrugCandidatesNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of drug candidates under the terms of the agreement.",
        "label": "Agreement, Drug Candidates, Number",
        "terseLabel": "Number of drug candidates"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AgreementPaymentPercentageFactor": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AgreementPaymentPercentageFactor",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiplier used in determining change in payment percentage.",
        "label": "Agreement, Payment Percentage, Factor",
        "terseLabel": "Multiplier for cumulative amount of consideration paid"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AgreementTerminationPriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AgreementTerminationPriorWrittenNoticePeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Agreement Termination Prior Written Notice Period",
        "terseLabel": "Agreement termination prior written notice period"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AgreementsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AgreementsNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Agreements, Number",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AldoxorubicinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AldoxorubicinMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aldoxorubicin.",
        "label": "Aldoxorubicin [Member]",
        "terseLabel": "Aldoxorubicin"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AllCustomersExcludingU.s.DepartmentOfDefenseMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All customers excluding U.S. Department of Defense.",
        "label": "All Customers, Excluding U.S. Department of Defense [Member]",
        "terseLabel": "All customers excluding DoD"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r727",
      "r737",
      "r754",
      "r763",
      "r767",
      "r775"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r391"
     ]
    },
    "xoma_AloraPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AloraPharmaceuticalsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Alora Pharmaceuticals.",
        "label": "Alora Pharmaceuticals [Member]",
        "terseLabel": "Alora Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseLongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Accretion of long-term debt",
        "verboseLabel": "Accretion of debt discount and debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r456",
      "r666",
      "r667",
      "r799"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r56",
      "r60"
     ]
    },
    "xoma_AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount deposited into reserve accounts to pay interest, administrative fees and operating expenses.",
        "label": "Amount Deposited into Reserve Accounts to Pay Interest, Administrative Fees and Operating Expenses",
        "terseLabel": "Amount deposited into reserve accounts to pay interest, administrative fees and operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "xoma_AptevoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AptevoMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Aptevo.",
        "label": "Aptevo [Member]",
        "terseLabel": "Aptevo"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ArimoclomolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ArimoclomolMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arimoclomol.",
        "label": "Arimoclomol [Member]",
        "terseLabel": "Arimoclomol"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AronoraIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AronoraIncMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aronora, Inc.",
        "label": "Aronora, Inc. [Member]",
        "terseLabel": "Aronora"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "xoma_ArrangementsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ArrangementsNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of arrangements the agreements are accounted for.",
        "label": "Arrangements, Number",
        "terseLabel": "Number of arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaPacificMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AsiaPacificMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Cost to acquire assets",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset acquisition",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "xoma_AssetAcquisitionsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AssetAcquisitionsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for asset acquisitions.",
        "label": "Asset Acquisitions, Policy [Policy Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r169",
      "r194",
      "r241",
      "r247",
      "r251",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r423",
      "r427",
      "r448",
      "r507",
      "r583",
      "r686",
      "r700",
      "r822",
      "r823",
      "r879"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r176",
      "r194",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r423",
      "r427",
      "r448",
      "r686",
      "r822",
      "r823",
      "r879"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment and Assumption Agreement and Royalty Purchase Agreement.",
        "label": "Assignment and Assumption Agreement and Royalty Purchase Agreement [Member]",
        "terseLabel": "Assignment and Assumption Agreement and Royalty Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_AtMarketIssuanceSalesAgreement2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AtMarketIssuanceSalesAgreement2021Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.",
        "label": "At Market Issuance Sales Agreement 2021 [Member]",
        "terseLabel": "2021 ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r719"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r719"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r719"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "xoma_AwardDateMay2023ToOctober2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "AwardDateMay2023ToOctober2023Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award dates from May 2023 to October 2023.",
        "label": "Award Date, May 2023 to October 2023 [Member]",
        "terseLabel": "Award dates from May 2023 to October 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "xoma_BayerProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "BayerProductsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer products.",
        "label": "Bayer Products [Member]",
        "terseLabel": "Bayer Products"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_BioasisTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "BioasisTechnologiesIncMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioasis Technologies Inc.",
        "label": "Bioasis Technologies Inc [Member]",
        "terseLabel": "Bioasis"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_BiotechnologyValueFundLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "BiotechnologyValueFundLPMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biotechnology Value Fund, L.P.",
        "label": "Biotechnology Value Fund LP [Member]",
        "terseLabel": "BVF"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to pertaining delayed draw term loan under Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.",
        "label": "Blue Owl Commercial Payment-Backed Loan Agreement, Delayed Draw Term Loan [Member]",
        "terseLabel": "Blue Owl Loan Agreement, Delayed draw term loan"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining initial term loan from Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.",
        "label": "Blue Owl Commercial Payment-Backed Loan Agreement, Initial Term Loan [Member]",
        "terseLabel": "Blue Owl Loan Agreement, Initial term loan"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "BlueOwlCommercialPaymentBackedLoanAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Blue Owl Loan Agreement, senior secured credit facilities, of which the principal and interest of the loan are to be paid from commercial payments.",
        "label": "Blue Owl Commercial Payment-Backed Loan Agreement [Member]",
        "terseLabel": "Blue Owl Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r675",
      "r676"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r420",
      "r675",
      "r676"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost Net",
        "terseLabel": "Capitalized contract costs",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Unrestricted cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r509",
      "r555",
      "r578",
      "r686",
      "r700",
      "r792"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Unrestricted cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r166",
      "r653"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "parentTag": "xoma_FinancialAssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "verboseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "verboseLabel": "Unrestricted and Restricted Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents at the beginning of the period",
        "terseLabel": "Unrestricted and restricted cash and cash equivalents",
        "totalLabel": "Total unrestricted and restricted cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r111",
      "r192"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Unrestricted cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r891"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cash reserve accounts for interest and administrative fees and to cover operating expenses of subsidiary, established in conjunction with the funding of loan.",
        "label": "Cash Reserve Accounts, Interest and Administrative Fees and Operating Expenses [Member]",
        "terseLabel": "Cash reserve accounts"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CashReserveAccountsInterestAndAdministrativeFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CashReserveAccountsInterestAndAdministrativeFeesMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cash reserve accounts for interest and administrative fees, established in conjunction with the funding of loan.",
        "label": "Cash Reserve Accounts, Interest and Administrative Fees [Member]",
        "terseLabel": "Cash reserve account, Interest and administrative fees"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CashReserveAccountsOperatingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CashReserveAccountsOperatingExpensesMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cash reserve accounts to cover operating expenses of subsidiary, established in conjunction with the funding of loan.",
        "label": "Cash Reserve Accounts, Operating Expenses [Member]",
        "terseLabel": "Cash reserve account, Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "xoma_ChangesInEstimatedFairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ChangesInEstimatedFairValueOfContingentConsideration",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated fair value of contingent consideration.",
        "label": "Changes In Estimated Fair Value Of Contingent Consideration",
        "negatedLabel": "Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs",
        "terseLabel": "Changes in estimated fair value of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ChiefExecutiveOfficerInterimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ChiefExecutiveOfficerInterimMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of interim chief executive officer and Executive Chairman of the Board.",
        "label": "Chief Executive Officer, Interim [Member]",
        "terseLabel": "Executive Chairman of the Board and Interim CEO, Owen Hughes"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "CEO, Owen Hughes"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "xoma_ChiefExecutiveOfficerRetiredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ChiefExecutiveOfficerRetiredMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer prior to retirement.",
        "label": "Chief Executive Officer, Retired [Member]",
        "terseLabel": "Chief Executive Officer, Retired, James R. Neal"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ChiefInvestmentOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ChiefInvestmentOfficerMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of  chief investment officer.",
        "label": "Chief Investment Officer [Member]",
        "terseLabel": "Chief Investment Officer, Bradley Sitko"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r173",
      "r174",
      "r175",
      "r194",
      "r220",
      "r224",
      "r231",
      "r233",
      "r239",
      "r240",
      "r262",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r314",
      "r315",
      "r318",
      "r321",
      "r328",
      "r448",
      "r537",
      "r538",
      "r539",
      "r540",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r570",
      "r592",
      "r610",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r783",
      "r801",
      "r809"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "positiveTerseLabel": "Exercise price of warrants (in dollars per share)",
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "xoma_ClassOfWarrantOrRightFairValueOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ClassOfWarrantOrRightFairValueOfWarrantsOrRights",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Class of Warrant or Right, Fair Value of Warrants or Rights",
        "terseLabel": "Fair value per share (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Warrants",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Aggregate number of unregistered shares of common stock called by warrants (in shares)",
        "verboseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Outstanding",
        "positiveTerseLabel": "Warrant outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "xoma_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about collaboration agreement member.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Agreements",
        "verboseLabel": "Licensing and other arrangements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "xoma_CommercialPaymentPeriodDue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommercialPaymentPeriodDue",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from each royalty payment date payment is due from customer,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Payment, Period Due",
        "terseLabel": "Period from each royalty payment date payment is due"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommercialPaymentPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommercialPaymentPurchaseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial payment purchase agreement.",
        "label": "Commercial Payment Purchase Agreement [Member]",
        "terseLabel": "Commercial Payment Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommercialPaymentReceivableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommercialPaymentReceivableTerm",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Payment Receivable Term",
        "terseLabel": "Commercial payment receivable term"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommercialPaymentThresholdOneTimePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommercialPaymentThresholdOneTimePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.",
        "label": "Commercial Payment Threshold, One-Time Payment",
        "terseLabel": "Commercial payments attributable to net sales threshold"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommercialSalesReceivablePercentageOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommercialSalesReceivablePercentageOnNetSales",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments entity eligible to receive as a percentage of net sales.",
        "label": "Commercial Sales, Receivable Percentage On Net Sales",
        "terseLabel": "Payments eligible to receive (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies.",
        "terseLabel": "Commitments and Contingencies (Note 13)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r88",
      "r508",
      "r569"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r276",
      "r277",
      "r637",
      "r819"
     ]
    },
    "xoma_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "verboseLabel": "Common stock reserved for future issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r691",
      "r693",
      "r694",
      "r695",
      "r696",
      "r805",
      "r806",
      "r869",
      "r894",
      "r897"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "xoma_CommonStockParOrStatedValuePerShareAcquiree": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockParOrStatedValuePerShareAcquiree",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock of acquiree.",
        "label": "Common Stock, Par or Stated Value Per Share, Acquiree",
        "terseLabel": "Acquiree's common stock, par value (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommonStockPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock premium received on sale of common stock.",
        "label": "Common Stock Premium",
        "terseLabel": "Common stock premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r570"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r95",
      "r570",
      "r589",
      "r897",
      "r898"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,495,492 and 11,454,025 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r511",
      "r686"
     ]
    },
    "xoma_CommonStockWarrantExercisePrice14.71Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockWarrantExercisePrice14.71Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $14.71 per share.",
        "label": "Common Stock Warrant, Exercise Price 14.71 [Member]",
        "terseLabel": "Common Stock Warrants, Issued March 2019"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant issued on December 2023.",
        "label": "Common Stock Warrant Issued, December Twenty Twenty Three [Member]",
        "terseLabel": "Common Stock Warrants, Issued December 2023"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockWarrantsAtExercisePriceOf35.00PerShareMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants at an exercise price of $35.00 per share.",
        "label": "Common Stock Warrants at an Exercise Price of $35.00 Per Share [Member]",
        "terseLabel": "Common Stock Warrants, Issued December 2023, Exercise price of $35.00 per share"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockWarrantsAtExercisePriceOf42.50PerShareMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants at an exercise price of $42.50 per share.",
        "label": "Common Stock Warrants at an Exercise Price of $42.50 Per Share [Member]",
        "terseLabel": "Common Stock Warrants, Issued December 2023, Exercise price of $42.50 per share"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CommonStockWarrantsAtExercisePriceOf50.00PerShareMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to common stock warrants at an exercise price of $50.00 per share.",
        "label": "Common Stock Warrants at an Exercise Price of $50.00 Per Share [Member]",
        "terseLabel": "Common Stock Warrants, Issued December 2023, Exercise price of $50.00 per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Based Compensation and Other Benefit Plans",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r129",
      "r130",
      "r131"
     ]
    },
    "xoma_CompensationExpenseEmploymentAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CompensationExpenseEmploymentAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for compensation under employment agreement related to retirement of individual.",
        "label": "Compensation Expense, Employment Agreement",
        "terseLabel": "Compensation expense related to Continuity Incentive under Employment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation and Other Benefit Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of net deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r178",
      "r180",
      "r186",
      "r503",
      "r518"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive (Loss) Income",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ConcentrationOfRiskSegmentAndGeographicInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of risk segment and geographic information.",
        "label": "Concentration of Risk, Segment and Geographic Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r82",
      "r83",
      "r256",
      "r636"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r82",
      "r83",
      "r256",
      "r534",
      "r636"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r82",
      "r83",
      "r256",
      "r636",
      "r788"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration of Risk, Segment and Geographic Information",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of Risk",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk (as a percent)",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r82",
      "r83",
      "r256"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r48",
      "r49",
      "r82",
      "r138",
      "r636"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r82",
      "r83",
      "r256",
      "r636"
     ]
    },
    "xoma_ConsolidatedFinancialStatementDetailAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ConsolidatedFinancialStatementDetailAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated financial statement detail.",
        "label": "Consolidated Financial Statement Details"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in agreements, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815.",
        "label": "Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration, high-end of range"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ContingentConsiderationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContingentConsiderationFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration, fair value disclosure.",
        "label": "Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ContingentConsiderationRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContingentConsiderationRegulatoryMilestonesMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration under purchase agreements related to regulatory milestones.",
        "label": "Contingent Consideration, Regulatory Milestones [Member]",
        "terseLabel": "Regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ContingentConsiderationUnderPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContingentConsiderationUnderPurchaseAgreements",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Contingent Consideration Under Purchase Agreements",
        "terseLabel": "Contingent consideration under RPAs, AAAs and CPPAs"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ContingentFutureCashPaymentsPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContingentFutureCashPaymentsPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Contingent Future Cash Payments, Per Product",
        "terseLabel": "Contingent future cash payment for each product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Allowance for Credit Loss",
        "terseLabel": "Amount of allowance for credit losses",
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r333"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r344"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability",
        "terseLabel": "Contract liabilities",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r344"
     ]
    },
    "xoma_ContractualObligationEstimatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContractualObligationEstimatedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.",
        "label": "Contractual Obligation Estimated Milestone Payments",
        "terseLabel": "Estimate of milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ContractualObligationEstimatedMilestonePaymentsNumberOfProducts",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.",
        "label": "Contractual Obligation, Estimated Milestone Payments, Number Of Products",
        "terseLabel": "Assumed number of products per contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r318",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Number of shares issued for each share of convertible preferred stock that is converted",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r64",
      "r94",
      "r124",
      "r324"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r294",
      "r316",
      "r476",
      "r655",
      "r657"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "xoma_CreditLossContractWithCustomerAssetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CreditLossContractWithCustomerAssetPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.",
        "label": "Credit Loss, Contract With Customer Asset [Policy Text Block]",
        "terseLabel": "Allowance for Current Expected Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of cumulative royalties on net sales per product under the terms of the agreement",
        "label": "Cumulative Royalties On Net Sales Per Product, Threshold Amount",
        "terseLabel": "Threshold amount of cumulative royalties on net sales per product"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "CurrentEmployeesExcludingChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current employees of entity, excluding Chief Executive Officer.",
        "label": "Current Employees, Excluding Chief Executive Officer [Member]",
        "terseLabel": "Current employees, excluding Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r256"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r91",
      "r92",
      "r141",
      "r143",
      "r201",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r457",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Gross principal",
        "totalLabel": "Total payments",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r143",
      "r308"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r291",
      "r457",
      "r664",
      "r665"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Increase (Decrease), Net",
        "negatedLabel": "Reduction in debt obligation",
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r85",
      "r311",
      "r457"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r292"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Long-term debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r457",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r201",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r457",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r64",
      "r67",
      "r84",
      "r85",
      "r87",
      "r89",
      "r123",
      "r125",
      "r201",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r457",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Unamortized Discount",
        "terseLabel": "Debt discount costs",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r825"
     ]
    },
    "xoma_DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount associated with allocated fees and lender expenses.",
        "label": "Debt Instrument, Unamortized Discount, Allocated Fees and Lender Expenses",
        "terseLabel": "Debt discount, allocated fees and lender expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unaccreted debt discount and debt issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r297",
      "r309",
      "r664",
      "r665"
     ]
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Accrued issuance costs in connection with issuance of long-term debt",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Long-Term Debt",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Employee Retention Bonus",
        "verboseLabel": "Departure and Continuity Incentive",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r825"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "terseLabel": "Allocated costs for the term loan commitment",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income, Current",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, current",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method - long-term",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, noncurrent",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Unearned revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Capitalized research and development expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r863"
     ]
    },
    "xoma_DeferredTaxAssetsRoyaltyReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "DeferredTaxAssetsRoyaltyReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from royalty receivable.",
        "label": "Deferred Tax Assets, Royalty Receivable",
        "terseLabel": "Royalty Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Research and development and other tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.",
        "label": "Defined Contribution Plan Age Required For Catch Up Contribution Minimum",
        "terseLabel": "Age requirement for participant to be eligible for a catch-up contribution, minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Contribution expense",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of defined contribution plan expense paid through the issuance of common shares.",
        "label": "Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage",
        "terseLabel": "Deferred savings plan expense paid in common shares (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Deferred Savings Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution (as a percent)",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan issuance of Common stock for services or claims.",
        "label": "Defined Contribution Plan Issuance Of Common Stock For Services Or Claims",
        "terseLabel": "Common stock contribution to 401(k)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Amount",
        "terseLabel": "Maximum annual contribution per employee",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent",
        "terseLabel": "Maximum annual contribution per employee (as a percent)",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "xoma_DepositarySharesRatioToPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "DepositarySharesRatioToPreferredStock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents depositary share's fractional interest in share of preferred stock.",
        "label": "Depositary Shares, Ratio To Preferred Stock",
        "terseLabel": "Depositary share's fractional interest in share of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Directors"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r895"
     ]
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsDeclaredTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of declared and paid cash dividends",
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable",
        "terseLabel": "Preferred stock dividend accrual",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r142",
      "r697",
      "r889"
     ]
    },
    "us-gaap_DividendsPayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable [Line Items]",
        "terseLabel": "Dividends",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable [Table]",
        "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_DividendsPreferredStockStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStockStock",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Preferred Stock, Stock",
        "negatedLabel": "Preferred stock dividends",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r126"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r719"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "terseLabel": "Document Financial Statement Error Correction Flag",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r719",
      "r755"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic",
        "verboseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r217",
      "r220",
      "r231",
      "r232",
      "r233",
      "r237",
      "r437",
      "r438",
      "r504",
      "r519",
      "r659"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Diluted",
        "verboseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r220",
      "r231",
      "r232",
      "r233",
      "r237",
      "r437",
      "r438",
      "r504",
      "r519",
      "r659"
     ]
    },
    "xoma_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Policy [Text Block]",
        "verboseLabel": "Net Loss per Share Attributable to Common Stockholders",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r234",
      "r235",
      "r236"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "verboseLabel": "Federal tax at statutory rate (as a percent)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r398",
      "r416"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r864"
     ]
    },
    "xoma_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for executive compensation.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent",
        "terseLabel": "Nondeductible executive compensation (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent",
        "terseLabel": "Stock compensation and other permanent differences (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable per discovery product candidate.",
        "label": "Eligible Milestone Payments Receivable Per Discovery Product Candidate",
        "terseLabel": "Maximum eligible milestone payments receivable per discovery product candidate"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of milestones. May include, but not limited to, development, regulatory, commercial, sales-based and clinical milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Milestones",
        "terseLabel": "Maximum eligible milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable, upon achievement of milestones, to be shared with counterparty of agreement, including portion received received by entity prior to meeting threshold.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Milestones, Shared with Counterparty",
        "terseLabel": "Maximum remaining milestones to be shared equally"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of pre-commercial milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones",
        "terseLabel": "Pre-commercial milestone payments, maximum"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible potential additional payments receivable upon achievement of specified future net sales milestones.",
        "label": "Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones",
        "terseLabel": "Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmployeeAgeFiftyOrOverMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmployeeAgeFiftyOrOverMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity age 50 or over.",
        "label": "Employee, Age Fifty or Over [Member]",
        "terseLabel": "Employee, Age Fifty or Over"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity.",
        "label": "Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period over which unrecognized compensation expense is expected to be recognized",
        "verboseLabel": "Period over which unrecognized compensation expense is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock-based compensation expense, not yet recognized",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation expense related to stock options (in dollars)",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmployeeTerminatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmployeeTerminatedMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated employee of entity.",
        "label": "Employee, Terminated [Member]",
        "terseLabel": "Terminated employee"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmployeeUnderAgeFiftyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmployeeUnderAgeFiftyMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity under 50 years old.",
        "label": "Employee, Under Age Fifty [Member]",
        "terseLabel": "Employee, Under Age Fifty"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmploymentAgreementAnnualSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmploymentAgreementAnnualSalary",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of annual base salary pursuant to employment agreement.",
        "label": "Employment Agreement, Annual Salary",
        "terseLabel": "Amount of annual base salary"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Target annual cash bonus amount as a percent of base salary, subject to achievement of annual performance milestones, pursuant to employment agreement.",
        "label": "Employment Agreement, Target Annual Cash Bonus, Percent of Base Salary",
        "terseLabel": "Target annual cash bonus (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_EmploymentPeriodRetirementEligible": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EmploymentPeriodRetirementEligible",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which individual will be deemed retirement eligible for purposes of equity award if employed through the period under terms of amended employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employment Period, Retirement Eligible",
        "terseLabel": "Period for which individual will be deemed retirement eligible for purposes of equity award"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r162",
      "r182",
      "r183",
      "r184",
      "r202",
      "r203",
      "r204",
      "r206",
      "r212",
      "r214",
      "r238",
      "r263",
      "r264",
      "r330",
      "r388",
      "r389",
      "r390",
      "r412",
      "r413",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r472",
      "r529",
      "r530",
      "r531",
      "r544",
      "r610"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Short-term equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r447",
      "r654"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities Fv Ni Measurement Input",
        "terseLabel": "Valuation assumptions, measurement input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity securities",
        "terseLabel": "Gain (loss) recognized due to change in fair value of investment",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r815"
     ]
    },
    "xoma_EquitySecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EquitySecuritiesPolicy",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity securities.",
        "label": "Equity Securities Policy",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r723",
      "r733",
      "r759"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of contingent consideration under asset acquisition agreements.",
        "label": "Estimated Fair Value Of Contingent Consideration Under Asset Acquisition",
        "terseLabel": "Estimated fair value of contingent consideration under the LadRx Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900",
      "r901",
      "r902"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "xoma_ExercisablePeriodOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ExercisablePeriodOfWarrants",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable Period Of Warrants",
        "terseLabel": "Exercisable period of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r445"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r445"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of weighted average assumptions used to calculate fair value",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r441",
      "r480",
      "r481",
      "r482",
      "r664",
      "r665",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r443",
      "r444",
      "r446"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r346",
      "r351",
      "r441",
      "r480",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r441",
      "r482",
      "r664",
      "r665",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r480",
      "r481",
      "r482",
      "r664",
      "r665",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r446"
     ]
    },
    "xoma_FaricimabProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "FaricimabProductMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Faricimab products.",
        "label": "Faricimab, Product [Member]",
        "terseLabel": "Faricimab"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_FaricimabSvoaVabysmoProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "FaricimabSvoaVabysmoProductMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Faricimab-svoa, (VABYSMO) products.",
        "label": "Faricimab-Svoa, (VABYSMO), Product [Member]",
        "terseLabel": "VABYSMO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense Benefit Continuing Operations",
        "terseLabel": "(Benefit) provision for income taxes, Federal",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r397"
     ]
    },
    "xoma_FederalOrphanCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "FederalOrphanCreditMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal orphan tax credit carryforward.",
        "label": "Federal Orphan Credit [Member]",
        "terseLabel": "Federal Orphan Credit"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_FinancialAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "FinancialAssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial assets.",
        "label": "Financial Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r271"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r489",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets, net",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Carrying Value",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r489"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_FirstRoyaltyInterestAcquisitionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "FirstRoyaltyInterestAcquisitionAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Royalty Interest Acquisition Agreement.",
        "label": "First Royalty Interest Acquisition Agreement [Member]",
        "terseLabel": "First Royalty Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policy for future milestones, royalties purchase rights and commercial payments.",
        "label": "Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]",
        "terseLabel": "Purchase of Rights to Future Milestones, Royalties and Commercial Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r594"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "HealthCareRoyaltyPartnersTwoLimitedPartnersMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCare Royalty Partners II, L.P (HCRP).",
        "label": "HealthCare Royalty Partners Two Limited Partners [Member]",
        "terseLabel": "HealthCare Royalty Partners II, L.P."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_IL1TargetLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "IL1TargetLicenseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IL-1 target license agreement with Novartis.",
        "label": "IL-1 Target License Agreement [Member]",
        "terseLabel": "IL-1 Target License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r719"
     ]
    },
    "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immediate Family Member of Management or Principal Owner [Member]",
        "terseLabel": "Related party - Spouse of James Neal, then CEO and Chairman of the Board of Directors",
        "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom they might be controlled or influenced, because of the family relationship."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible asset",
        "verboseLabel": "Impairment Charge",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r817"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income tax",
        "verboseLabel": "Loss before income tax",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102",
      "r145",
      "r241",
      "r246",
      "r250",
      "r252",
      "r505",
      "r515",
      "r661"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r595"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r595"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r393",
      "r399",
      "r404",
      "r410",
      "r414",
      "r417",
      "r418",
      "r419",
      "r542"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense Benefit",
        "negatedTerseLabel": "Income tax benefit",
        "totalLabel": "(Benefit) provision for income taxes, Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r157",
      "r213",
      "r214",
      "r244",
      "r397",
      "r415",
      "r521"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r395",
      "r396",
      "r404",
      "r405",
      "r409",
      "r411",
      "r536"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables, net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accrued Income Taxes Payable",
        "terseLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r798"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Stockholders Equity Roll Forward",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Shares issuable based on market price",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r233",
      "r359"
     ]
    },
    "xoma_IncyteImmunoOncologyAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "IncyteImmunoOncologyAssetsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte immuno-oncology assets.",
        "label": "Incyte Immuno-Oncology Assets [Member]",
        "terseLabel": "Incyte Immuno-Oncology Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r727",
      "r737",
      "r754",
      "r763",
      "r767",
      "r775"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r779"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r779"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r779"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r485",
      "r486",
      "r487",
      "r489",
      "r658"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58"
     ]
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "terseLabel": "Ebopiprant IP",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense Debt",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r304",
      "r312",
      "r666",
      "r667"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseLongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Accrued interest expense",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r305",
      "r666",
      "r667"
     ]
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Long-Term Debt",
        "terseLabel": "Interest expense",
        "totalLabel": "Total interest expense",
        "documentation": "Aggregate amount of interest paid or due on all long-term debt."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r160",
      "r161"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "parentTag": "xoma_FinancialAssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Fair Value Disclosure",
        "terseLabel": "Equity securities",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "xoma_IssuanceOfWarrantsDebtFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "IssuanceOfWarrantsDebtFinancing",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock warrants issued in connection with long-term debt financing.",
        "label": "Issuance of Warrants, Debt Financing",
        "terseLabel": "Issuance of common stock warrants in connection with long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_JanssenBiotechInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "JanssenBiotechInc.Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech, Inc.",
        "label": "Janssen Biotech Inc. [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_KinnateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "KinnateMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kinnate.",
        "label": "Kinnate [Member]",
        "terseLabel": "Kinnate"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.",
        "label": "Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC. [Member]",
        "terseLabel": "Kuros"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LadrxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LadrxMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to LadRx.",
        "label": "LadRx [Member]",
        "terseLabel": "LadRx"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r685"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of cost components of operating leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "xoma_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LeasedFacilitiesEmeryvilleCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LeasedFacilitiesEmeryvilleCaliforniaMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased facilities in Emeryville, California with lease expiration date of July 31, 2023",
        "label": "Leased Facilities, Emeryville, California [Member]",
        "terseLabel": "Leased facilities, Emeryville, California, with lease expiration of July 31, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LeasedFacilitiesTwoEmeryvilleCaliforniaMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased facilities in Emeryville, California, in different location than previous lease.",
        "label": "Leased Facilities, Two, Emeryville, California [Member]",
        "terseLabel": "Leased facilities, Emeryville, California, different location than previous lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Existence of option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of maturity/ undiscounted future rent payments associated with the new lease",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of adjustment to right of use asset resulting from modification of operating lease.",
        "label": "Lessee, Operating Lease Modification, Adjustment to Right Of Use Asset",
        "terseLabel": "Adjustment to right of use asset for lease modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Period of lease extension",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flows information related to leases.",
        "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Summary of supplemental cash flow information related to operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LesseeOperatingLeaseSupplementalInformationTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.",
        "label": "Lessee, Operating Lease, Supplemental Information [Table Text Block]",
        "terseLabel": "Schedule of present value assumptions used in calculating the present value of lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r194",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r424",
      "r427",
      "r428",
      "r448",
      "r568",
      "r660",
      "r700",
      "r822",
      "r879",
      "r880"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r144",
      "r513",
      "r686",
      "r803",
      "r816",
      "r871"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r165",
      "r194",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r424",
      "r427",
      "r428",
      "r448",
      "r686",
      "r822",
      "r879",
      "r880"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementAndCommonStockPurchaseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement and common stock purchase agreement.",
        "label": "License Agreement and Common Stock Purchase Agreement [Member]",
        "terseLabel": "License Agreement and Common Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementConsiderationReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementConsiderationReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement consideration received.",
        "label": "License Agreement Consideration Received",
        "terseLabel": "License agreement consideration received"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments received upon achievement of financing activities during the period.",
        "label": "License Agreement Consideration Received, Achievement of Financing Activities",
        "terseLabel": "Payments received upon achievement of financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementConsiderationReceivedDebtRepayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementConsiderationReceivedDebtRepayment",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license agreement consideration received as repayment of debt.",
        "label": "License Agreement Consideration Received, Debt Repayment",
        "terseLabel": "License agreement consideration received, repayment of debt"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementInstallmentPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementInstallmentPaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of installment payments received during the period.",
        "label": "License Agreement, Installment Payments Received",
        "terseLabel": "Installment payments received"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementNonRz358ProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementNonRz358ProductsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement related to activities associated with non-RZ358 products.",
        "label": "License Agreement, Non-RZ358 Products [Member]",
        "terseLabel": "License Agreement, Non-RZ358 products"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementRz358Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementRz358Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement related to activities associated with RZ358.",
        "label": "License Agreement RZ358 [Member]",
        "terseLabel": "License Agreement, RZ358"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementSharesReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementSharesReceived",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of counterparty's common stock entity received under the terms of the agreement.",
        "label": "License Agreement, Shares Received",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicenseAgreementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicenseAgreementTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement transaction price.",
        "label": "License Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "terseLabel": "License",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "xoma_LicensingAndOtherArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicensingAndOtherArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing and Other Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LicensingAndOtherArrangementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LicensingAndOtherArrangementsTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing And Other Arrangements [Text Block]",
        "terseLabel": "Licensing and Other Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Arbitration settlement costs (Note 3)",
        "verboseLabel": "Arbitration settlement costs",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt",
        "totalLabel": "Total carrying value net of unaccreted debt discount and debt issuance costs",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r143",
      "r298",
      "r310",
      "r664",
      "r665",
      "r890"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Current",
        "negatedLabel": "Less: current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r201",
      "r826"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r201",
      "r302"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r201",
      "r302"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r201",
      "r302"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r201",
      "r302"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAggregateProjectedFuturePrincipalAndDiscountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r201",
      "r302"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtSummaryOfLongTermDebtDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Text Block]",
        "terseLabel": "Long-Term Debt",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "xoma_LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes credit loss expense of long-term rights receivable, noncurrent.",
        "label": "Long-Term Right Receivable, Non-Current, Credit Loss Expense, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Long-Term Right Receivable, Non-Current, Credit Loss Expense, Statement of Income or Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LongTermRightsReceivableNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LongTermRightsReceivableNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer.",
        "label": "Long Term Rights Receivable, Non-Current",
        "periodEndLabel": "Long-term royalty receivable, Balance as of end of period",
        "periodStartLabel": "Long-term royalty receivable, Balance as of beginning of period",
        "terseLabel": "Long-term royalty and commercial payment receivables"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LongTermRightsReceivableNonCurrentCreditLossExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LongTermRightsReceivableNonCurrentCreditLossExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent.",
        "label": "Long Term Rights Receivable, Non-Current, Credit Loss Expense",
        "terseLabel": "Impairment charge, Long-term royalty receivable"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on long-term rights receivable, noncurrent. Also includes the amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Long Term Rights Receivable, Non-Current, Credit Loss Expense and Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment charges (Note 4, Note 5)",
        "verboseLabel": "Impairment charges"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LongTermRightsReceivableNoncurrentDecreaseDueToImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LongTermRightsReceivableNoncurrentDecreaseDueToImpairment",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in long-term royalty and commercial rights receivables, noncurrent, during the period due to impairment.",
        "label": "Long Term Rights Receivable, Noncurrent, Decrease Due To Impairment",
        "negatedLabel": "Impairment of royalty and commercial payment receivables, Long-Term",
        "terseLabel": "Decrease in long-term royalty and commercial rights receivables due to impairment"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_LongTermRightsReceivableReclassification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "LongTermRightsReceivableReclassification",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long term rights receivable due to reclassification from/to short-term rights receivable.",
        "label": "Long Term Rights Receivable, Reclassification",
        "negatedLabel": "Reclassification to short-term royalty and commercial payment receivables, Long-Term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r671",
      "r829",
      "r892",
      "r893"
     ]
    },
    "xoma_MaximumAdditionalPayableOnSalesMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumAdditionalPayableOnSalesMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional amount payable on sales milestone. Excludes amounts recognized in balance sheet as contingent consideration as of balance sheet date. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Maximum Additional Payable on Sales Milestone",
        "terseLabel": "Maximum additional commercial sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumConsiderationRetained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumConsiderationRetained",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.",
        "label": "Maximum Consideration Retained",
        "terseLabel": "Amount of maximum consideration retained"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumEarnOutPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumEarnOutPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for various milestones under arrangement. Contingent consideration will be recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Maximum Earn-Out Payments",
        "terseLabel": "Maximum earn-out payments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement. Contingent consideration will be recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Maximum Earn-Out Payments, Development And Regulatory Milestone Payments",
        "terseLabel": "Maximum earn-out payments for development and regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumEarnOutPaymentsSalesBasedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Maximum Earn-Out Payments, Sales-Based Milestone Payments",
        "terseLabel": "Maximum earn-out payments for sales-based milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r354",
      "r484",
      "r528",
      "r560",
      "r561",
      "r616",
      "r619",
      "r623",
      "r624",
      "r626",
      "r647",
      "r648",
      "r662",
      "r668",
      "r677",
      "r688",
      "r824",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "xoma_MaximumPayableOnSalesMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumPayableOnSalesMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Maximum Payable on Sales Milestone",
        "terseLabel": "Maximum commercial sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payment obligations based on a portion of regulatory and commercial milestone payments.",
        "label": "Maximum Payment Obligations Based On A Portion of Regulatory and Commercial Payments",
        "terseLabel": "Maximum payment obligations based on a portion of regulatory and commercial milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential regulatory and commercial milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments, under the agreement.",
        "label": "Maximum Payments Based On Achievement Of Regulatory and Commercial Milestones, Net",
        "terseLabel": "Maximum potential regulatory and commercial milestone payments, net"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated.",
        "label": "Maximum Payments Based On Achievement Of Regulatory and Sales Milestones",
        "terseLabel": "Maximum regulatory and commercial sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MaximumValueOfStockToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MaximumValueOfStockToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of stock to be issued.",
        "label": "Maximum Value Of Stock To Be Issued",
        "terseLabel": "Maximum amount of shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "terseLabel": "Estimated time to liquidity of shares",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Closing Common Stock Price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MerckImmunoOncologyProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MerckImmunoOncologyProductMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck immuno-oncology product.",
        "label": "Merck Immuno-Oncology Product [Member]",
        "terseLabel": "Merck Immuno-Oncology Product"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestoneAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestoneAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone achieved.",
        "label": "Milestone Achieved",
        "terseLabel": "Amount of milestone payments earned under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestoneMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone achieved in arrangement.",
        "label": "Milestone [Member]",
        "terseLabel": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestonePaymentReceivablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestonePaymentReceivablePercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of milestone payment received by counterparty entity is entitled to receive.",
        "label": "Milestone Payment Receivable, Percentage",
        "terseLabel": "Percentage of milestone payment received by Kuros that company is entitled to receive"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestonePaymentReceivedCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestonePaymentReceivedCounterparty",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.",
        "label": "Milestone Payment Received, Counterparty",
        "terseLabel": "Milestone payment received by Kuros"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestonePeriodsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestonePeriodsNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.",
        "label": "Milestone Periods, Number",
        "terseLabel": "Number of milestone periods"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestonesPaymentsToAggregateAmountOfPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestonesPaymentsToAggregateAmountOfPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement.",
        "label": "Milestones Payments To Aggregate Amount Of Per Product",
        "terseLabel": "Maximum royalty milestone payments to be paid per product"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestonesReceivableExcludingConsiderationRetainedMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones.",
        "label": "Milestones Receivable, Excluding Consideration Retained, Maximum",
        "terseLabel": "Maximum amount of potential milestones, potential royalties on sales and other payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_MilestonesReceivableMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "MilestonesReceivableMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential milestones receivable under the terms of the agreement.",
        "label": "Milestones Receivable, Maximum",
        "terseLabel": "Maximum milestone payments entitled to receive"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r354",
      "r484",
      "r528",
      "r560",
      "r561",
      "r616",
      "r619",
      "r623",
      "r624",
      "r626",
      "r647",
      "r648",
      "r662",
      "r668",
      "r677",
      "r688",
      "r824",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Ownership interest (as a percent)",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r671",
      "r829",
      "r892",
      "r893"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations",
        "terseLabel": "Description of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss and comprehensive loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r113",
      "r146",
      "r163",
      "r177",
      "r179",
      "r184",
      "r194",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r229",
      "r241",
      "r246",
      "r250",
      "r252",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r438",
      "r448",
      "r517",
      "r591",
      "r608",
      "r609",
      "r661",
      "r698",
      "r822"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net loss attributable to common stockholders, basic",
        "verboseLabel": "Net loss attributable to common stockholders, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r217",
      "r218",
      "r230",
      "r233",
      "r241",
      "r246",
      "r250",
      "r252",
      "r661"
     ]
    },
    "xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income loss available to common stockholders basic and diluted.",
        "label": "Net Income Loss Available To Common Stockholders Basic And Diluted [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Diluted",
        "totalLabel": "Net loss attributable to common stockholders, diluted",
        "verboseLabel": "Net loss attributable to common stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r233"
     ]
    },
    "xoma_NetOperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NetOperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards expiration year.",
        "label": "Net Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NonBayerProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NonBayerProductsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-bayer products.",
        "label": "Non-Bayer Products [Member]",
        "terseLabel": "Non-Bayer Products"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r754",
      "r763"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted",
        "terseLabel": "Ownership interest, if shares are converted (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NovartisInternationalPharmaceuticalLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NovartisInternationalPharmaceuticalLtdMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis International Pharmaceutical Ltd.",
        "label": "Novartis International Pharmaceutical Ltd. [Member]",
        "terseLabel": "Novartis International"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NovartisNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NovartisNoteMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured note agreement and subsequent amendments with Novartis referred to as the \"Note Agreement\".",
        "label": "Novartis Note [Member]",
        "terseLabel": "Novartis Note"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NovartisPharmaAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NovartisPharmaAGMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Pharma AG.",
        "label": "Novartis Pharma AG [Member]",
        "terseLabel": "Novartis Pharma AG"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NumberOfArbitrationProceedingsInitiated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NumberOfArbitrationProceedingsInitiated",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of arbitration proceedings initiated by entity against one of its licensees.",
        "label": "Number of Arbitration Proceedings Initiated",
        "terseLabel": "Number of arbitration proceedings initiated"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of licensed products related to milestones and royalties purchased.",
        "label": "Number Of Licensed Products Related To Milestones And Royalties Purchased",
        "terseLabel": "Number of licensed products related to milestone and royalties"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NumberOfMajorPartners": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NumberOfMajorPartners",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major partners.",
        "label": "Number Of Major Partners",
        "terseLabel": "Number of major partners"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "xoma_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_NumberOfPeriodsCashRetentionBonus": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "NumberOfPeriodsCashRetentionBonus",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.",
        "label": "Number of Periods, Cash Retention Bonus",
        "terseLabel": "Number of periods in which employees will be eligible to receive cash retention bonus"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ObsevaIntellectualPropertyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ObsevaIntellectualPropertyRightsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ObsEva intellectual property rights.",
        "label": "ObsEva Intellectual Property Rights [Member]",
        "terseLabel": "ObsEva IP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r246",
      "r250",
      "r252",
      "r661"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r685"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Total net lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementMaturityOfLeaseLiabilitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Non-current operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r467"
     ]
    },
    "xoma_OperatingLeasePaymentsNonCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "OperatingLeasePaymentsNonCash",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payments, non cash.",
        "label": "Operating Lease Payments Non Cash",
        "negatedLabel": "Non-cash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r685"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term, Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r685"
     ]
    },
    "xoma_OperatingLeasesNumberOfLeasedFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "OperatingLeasesNumberOfLeasedFacilities",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases, number of leased facilities.",
        "label": "Operating Leases Number Of Leased Facilities",
        "terseLabel": "Operating leases, number of leased facilities"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_OperatingLossCarryForwardSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "OperatingLossCarryForwardSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carry forward that is subject to expiration.",
        "label": "Operating Loss Carry Forward Subject To Expiration",
        "terseLabel": "Net operating loss carry forward subject to expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry-forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards offset of taxable income percentage.",
        "label": "Operating Loss Carryforwards Offset Of Taxable Income Percentage",
        "terseLabel": "Operating loss carryforward offset (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_OrganonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "OrganonMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Organon. The Company entered into an Acquisition Agreement with ObsEva in November 2022 pursuant to which the Company assumed ObsEva's ongoing rights and obligations under the License Agreement between Organon and ObsEva.",
        "label": "Organon [Member]",
        "terseLabel": "ObsEva, Organon"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "xoma_OtherAntibodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "OtherAntibodiesMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other antibody technologies.  Excludes TAK-079 (mezagitamab).",
        "label": "Other Antibodies [Member]",
        "terseLabel": "Other antibodies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets - long term",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense",
        "verboseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r725",
      "r735",
      "r761"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r728",
      "r738",
      "r764"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r728",
      "r738",
      "r764"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PalobiofarmaSLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PalobiofarmaSLMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palobiofarma, S.L.",
        "label": "Palobiofarma, S.L {Member]",
        "terseLabel": "Palo"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_Partner1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "Partner1Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 1 [Member]",
        "terseLabel": "Partner 1"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_Partner2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "Partner2Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 2 [Member]",
        "terseLabel": "Partner 2"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_Partner3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "Partner3Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 3 [Member]",
        "terseLabel": "Partner 3"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_Partner4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "Partner4Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fourth partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 4 [Member]",
        "terseLabel": "Partner 4"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PaymentOfConsiderationUnderAgreementsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.",
        "label": "Payment of Consideration Under Agreements, Investing Activities",
        "negatedLabel": "Payments of consideration under RPAs, AAAs and CPPAs",
        "terseLabel": "Payments of consideration under RPAs, AAAs and CPPAs"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PaymentToAcquireBusinessPricePerShareAdditionalCashAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PaymentToAcquireBusinessPricePerShareAdditionalCashAmount",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional contingent cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock.",
        "label": "Payment to Acquire Business, Price Per Share, Additional Cash Amount",
        "terseLabel": "Additional cash price per share (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PaymentToAcquireBusinessPricePerShareBaseCashAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PaymentToAcquireBusinessPricePerShareBaseCashAmount",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The base cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock.",
        "label": "Payment to Acquire Business, Price Per Share, Base Cash Amount",
        "terseLabel": "Base price per share (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PaymentToAcquireBusinessPricePerShareCashAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PaymentToAcquireBusinessPricePerShareCashAmount",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock. Includes base price and additional contingent amount.",
        "label": "Payment to Acquire Business, Price Per Share, Cash Amount",
        "terseLabel": "Cash amount of consideration per outstanding share (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Dividends",
        "negatedLabel": "Payment of preferred stock dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt issuance costs and loan fees",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "xoma_PaymentsOfFinancingCostsFeesAndLenderExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PaymentsOfFinancingCostsFeesAndLenderExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan fees and lender expenses.",
        "label": "Payments of Financing Costs, Fees and Lender Expenses",
        "terseLabel": "Fees and lender expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of preferred and common stock issuance costs",
        "verboseLabel": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Payment for IP acquired under the ObsEva IP Acquisition Agreement",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Cash payment at closing",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.",
        "label": "Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions",
        "terseLabel": "Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PercentageOfDecreaseInFutureRoyaltyObligations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PercentageOfDecreaseInFutureRoyaltyObligations",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.",
        "label": "Percentage Of Decrease In Future Royalty Obligations",
        "terseLabel": "Percentage of decrease in future royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares",
        "terseLabel": "Sales commission paid per transaction (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfShares",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares",
        "terseLabel": "Sales commission paid per transaction, preferred stock (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PercentageOfRoyaltyOnNetSalesUponCommercialization",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on net sales upon commercialization.",
        "label": "Percentage Of Royalty On Net Sales Upon Commercialization",
        "terseLabel": "Percentage of royalty on worldwide net sales of each product upon commercialization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance share units",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock units under a share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Stock Units [Member]",
        "terseLabel": "Performance Stock Unit Awards"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PeriodOneRetentionBonusEligibility": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PeriodOneRetentionBonusEligibility",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period One, Retention Bonus Eligibility",
        "terseLabel": "Initial period for which employees will be eligible for retention bonus"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PeriodTwoRetentionBonusEligibility": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PeriodTwoRetentionBonusEligibility",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period Two, Retention Bonus Eligibility",
        "terseLabel": "Period following initial period for which employees will be eligible for retention bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "xoma_PreferredStockConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockConversionPricePerShare",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock conversion price per share.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Preferred stock conversion price per share"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockConvertibleThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Preferred Stock, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Trading days"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PreferredStockDividendAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockDividendAmountPerShare",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The dividend amount per share based on the dividend rate on preferred stock.",
        "label": "Preferred Stock Dividend Amount Per Share",
        "terseLabel": "Preferred stock, dividend amount (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PreferredStockDividendPeriodMonth": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockDividendPeriodMonth",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.",
        "label": "Preferred Stock, Dividend Period, Month",
        "terseLabel": "Number of days in month over which dividend will be prorated and computed"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PreferredStockDividendPeriodProratedMonthsInYear": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockDividendPeriodProratedMonthsInYear",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.",
        "label": "Preferred Stock, Dividend Period, Prorated Months in Year",
        "terseLabel": "Number of months in year over which dividend will be prorated and compute"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PreferredStockDividendPeriodYearProrated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockDividendPeriodYearProrated",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.",
        "label": "Preferred Stock, Dividend Period, Year Prorated",
        "terseLabel": "Number of days in year over which dividend will be prorated and computed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred stock, dividend rate (as a percent)",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r617",
      "r620",
      "r622",
      "r627"
     ]
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Less: Accumulated preferred dividends",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r782",
      "r811"
     ]
    },
    "us-gaap_PreferredStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividend paid (in dollars per share)",
        "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "terseLabel": "Cash dividend declared (in dollars per share)",
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference (in dollars per share)",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r94",
      "r801",
      "r827"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r693",
      "r694",
      "r695",
      "r696",
      "r894",
      "r897"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r314"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Redemption price (in dollars per share)",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r66"
     ]
    },
    "xoma_PreferredStockRedemptionPricePerShareOptionalRedemption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockRedemptionPricePerShareOptionalRedemption",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.",
        "label": "Preferred Stock, Redemption Price Per Share, Optional Redemption",
        "terseLabel": "Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PreferredStockShareCap": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PreferredStockShareCap",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.",
        "label": "Preferred Stock, Share Cap",
        "terseLabel": "Share cap (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r570"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r314"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r570",
      "r589",
      "r897",
      "r898"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred Stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r510",
      "r686"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r537"
     ]
    },
    "xoma_ProceedsFromIssuanceOfLongTermDebtNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ProceedsFromIssuanceOfLongTermDebtNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer, net of fees and lender expenses and reserve accounts.",
        "label": "Proceeds From Issuance Of Long Term Debt, Net",
        "terseLabel": "Proceeds from issuance of long-term debt, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Gross proceeds from issuance of preferred stock",
        "verboseLabel": "Proceeds from issuance of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "xoma_ProceedsFromIssuanceOfPreferredStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ProceedsFromIssuanceOfPreferredStockNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds From Issuance Of Preferred Stock, Net",
        "terseLabel": "Net proceeds from issuance of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of options and other share-based compensation",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "xoma_ProceedsFromIssuanceOrSaleOfEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNet",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.",
        "label": "Proceeds from Issuance or Sale of Equity, Net",
        "terseLabel": "Net proceeds from issuance of stock"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ProceedsFromUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ProceedsFromUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.",
        "label": "Proceeds From Upfront Payment",
        "terseLabel": "Cash payment received"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net proceeds payable from license, sale or disposition entered into by entity after expiration of offer, the acquiree has right to receive.",
        "label": "Proceeds Payable, License, Sale or Disposition, After Expiration of Offer",
        "terseLabel": "Percentage of net proceeds payable from disposition entered into by entity after expiration of offer acquiree has right to receive"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net proceeds from license, sale or disposition entered into by acquiree prior to expiration of offer acquiree has right to receive.",
        "label": "Proceeds Payable, License, Sale or Disposition, Prior to Expiration of Offer",
        "terseLabel": "Percentage of net proceeds from disposition entered into by acquiree prior to expiration of offer acquiree has right to receive"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r488",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r651",
      "r669",
      "r687",
      "r790",
      "r820",
      "r821",
      "r829",
      "r892"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r488",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r651",
      "r669",
      "r687",
      "r790",
      "r820",
      "r821",
      "r829",
      "r892"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r177",
      "r179",
      "r190",
      "r194",
      "r205",
      "r213",
      "r214",
      "r241",
      "r246",
      "r250",
      "r252",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r422",
      "r425",
      "r426",
      "r438",
      "r448",
      "r505",
      "r516",
      "r543",
      "r591",
      "r608",
      "r609",
      "r661",
      "r683",
      "r684",
      "r699",
      "r797",
      "r822"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r506",
      "r514",
      "r686"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeasedFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.",
        "label": "Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones",
        "terseLabel": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PurchasedPercentageOfMilestones": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PurchasedPercentageOfMilestones",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of milestones entity has the right to receive as a percentage.",
        "label": "Purchased Percentage Of Milestones",
        "terseLabel": "Milestone payments entity has right to receive (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased percentage of non-royalties on net sales of products.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products",
        "terseLabel": "Non-royalties to be received (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage",
        "terseLabel": "Future non-royalty payments to be received (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r345",
      "r354",
      "r382",
      "r383",
      "r384",
      "r483",
      "r484",
      "r528",
      "r560",
      "r561",
      "r616",
      "r619",
      "r623",
      "r624",
      "r626",
      "r647",
      "r648",
      "r662",
      "r668",
      "r677",
      "r688",
      "r691",
      "r818",
      "r824",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r345",
      "r354",
      "r382",
      "r383",
      "r384",
      "r483",
      "r484",
      "r528",
      "r560",
      "r561",
      "r616",
      "r619",
      "r623",
      "r624",
      "r626",
      "r647",
      "r648",
      "r662",
      "r668",
      "r677",
      "r688",
      "r691",
      "r818",
      "r824",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.",
        "label": "Receipt of Royalty and Commercial Payment Receivable Current",
        "negatedLabel": "Receipt of royalty and commercial payments, Short-Term",
        "terseLabel": "Reduction in short-term royalty receivable balance due to receipt of payment"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in long-term rights receivable due to receipt of royalty and commercial payments.",
        "label": "Receipt of Royalty and Commercial Payment Receivable Non Current",
        "negatedLabel": "Receipt of royalty and commercial payments, Long-Term",
        "terseLabel": "Reduction in long-term royalty receivable balance due to receipt of payment"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ReceiptsUnderAgreementsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ReceiptsUnderAgreementsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.",
        "label": "Receipts Under Agreements, Investing Activities",
        "terseLabel": "Receipts under RPAs, AAAs and CPPAs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward",
        "terseLabel": "Reconciliation between the tax provision computed at the federal statutory income tax rate",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "xoma_RegulatoryAndCommercialMilestonesReceivableMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RegulatoryAndCommercialMilestonesReceivableMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.",
        "label": "Regulatory and Commercial Milestones Receivable, Maximum",
        "terseLabel": "Maximum amount of potential regulatory and commercial milestones receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r473",
      "r474",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r588",
      "r590",
      "r615"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r473",
      "r474",
      "r475",
      "r476",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r588",
      "r590",
      "r615"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r473",
      "r474",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r588",
      "r590",
      "r615",
      "r878"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r294",
      "r316",
      "r476",
      "r656",
      "r657"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r392",
      "r887"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r721",
      "r731",
      "r757"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r722",
      "r732",
      "r758"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r800",
      "r888",
      "r891"
     ]
    },
    "xoma_RestrictedCashAdditionalToBeFunded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RestrictedCashAdditionalToBeFunded",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional amount of cash required to be added to  restricted account.",
        "label": "Restricted Cash, Additional To Be Funded",
        "terseLabel": "Additional amount of cash required to fund reserve account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash or restricted cash equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r166",
      "r192"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Unrestricted and Restricted Cash and Cash Equivalents",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Short-term restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r800"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long-term restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r793",
      "r800"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r126",
      "r512",
      "r532",
      "r533",
      "r541",
      "r571",
      "r686"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r202",
      "r203",
      "r204",
      "r206",
      "r212",
      "r214",
      "r263",
      "r264",
      "r388",
      "r389",
      "r390",
      "r412",
      "r413",
      "r429",
      "r431",
      "r432",
      "r434",
      "r436",
      "r529",
      "r531",
      "r544",
      "r897"
     ]
    },
    "xoma_RetentionBonusExpenseAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RetentionBonusExpenseAccrued",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recorded as expense during the period for cash retention bonuses.",
        "label": "Retention Bonus, Expense Accrued",
        "terseLabel": "Amount of retention bonus expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue from contracts with customers",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r245",
      "r248",
      "r249",
      "r253",
      "r254",
      "r256",
      "r342",
      "r343",
      "r488"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r650"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue recognized under units-of-revenue method",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RevenueRecognitionDeferredRevenuePolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for sale of future revenue streams.",
        "label": "Revenue Recognition Deferred Revenue Policy [Text Block]",
        "terseLabel": "Sale of Future Revenue Streams"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r194",
      "r242",
      "r243",
      "r245",
      "r248",
      "r249",
      "r253",
      "r254",
      "r256",
      "r262",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r448",
      "r505",
      "r822"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues From External Customers And Long Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RezoluteIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RezoluteIncMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rezolute, Inc.",
        "label": "Rezolute, Inc. [Member]",
        "terseLabel": "Rezolute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r685"
     ]
    },
    "xoma_RightsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RightsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.",
        "label": "Rights Receivable, Current",
        "periodEndLabel": "Short-term royalty receivable, Balance as of end of period",
        "periodStartLabel": "Short-term royalty receivable, Balance as of beginning of period",
        "terseLabel": "Short-term royalty and commercial payment receivables"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltiesPeriodMinimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltiesPeriodMinimum",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Royalties, Period, Minimum",
        "terseLabel": "Minimum period eligible to receive royalties"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltiesPeriodMinimumScenarioOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltiesPeriodMinimumScenarioOne",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Royalties Period, Minimum, Scenario One",
        "terseLabel": "Royalty payment period from the first commercial sale of each royalty-bearing discovery product"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Royalty and Commercial Payment Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in long-term rights receivable due to recognition of contingent consideration.",
        "label": "Royalty and Commercial Payment Receivable Non Current, Recognition of Contingent Consideration",
        "terseLabel": "Recognition of contingent consideration, Long-Term"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyAndCommercialRightsAcquiredNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, interest and commercial payment rights acquired, classified as noncurrent.",
        "label": "Royalty And Commercial Rights Acquired, Non-Current",
        "terseLabel": "Acquisition of royalty and commercial payment receivables, Long-Term"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyAndMilestonesReceivableThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyAndMilestonesReceivableThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount for royalties and milestones for determining amount for entity has the right to receive.",
        "label": "Royalty and Milestones Receivable, Threshold",
        "terseLabel": "Threshold amount for royalties and milestones"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyInterestAcquisitionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyInterestAcquisitionAgreementsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Interest Acquisition Agreements.",
        "label": "Royalty Interest Acquisition Agreements [Member]",
        "terseLabel": "Royalty Sale Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Member]",
        "terseLabel": "Royalty Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyPurchaseAgreementTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Text Block]",
        "verboseLabel": "Royalty and Commercial Payment Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyReceivablePercentageOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyReceivablePercentageOnNetSales",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties entity has the right to receive as a percentage.",
        "label": "Royalty Receivable Percentage On Net Sales",
        "terseLabel": "Royalties entity has right to receive (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and milestones entity has the right to receive as a percentage, up to specified threshold.",
        "label": "Royalty Receivable Percentage On Net Sales and Percentage of Milestones",
        "terseLabel": "Royalties and milestones entity has the right to receive (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties entity has the right to receive as a percentage shared with counterparty upon reaching threshold.",
        "label": "Royalty Receivable Percentage On Net Sales Shared With Counterparty",
        "terseLabel": "Royalties shared equally with counterparty (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Member]",
        "terseLabel": "Revenues",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r787"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r808"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r355",
      "r784",
      "r808"
     ]
    },
    "xoma_ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of accretion of debt discounts and issuance costs included in interest expense.",
        "label": "Schedule of Accretion of Debt Discounts and Issuance Costs Included in Interest Expense [Table Text Block]",
        "terseLabel": "Schedule of interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of accrued and other liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of outstanding securities considered anti-dilutive",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of unrestricted and restricted cash and cash equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes (All Current)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of long-term debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r64",
      "r67",
      "r84",
      "r85",
      "r87",
      "r89",
      "r123",
      "r125",
      "r664",
      "r666",
      "r804"
     ]
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r128"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net loss per share attributable to common stockholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "xoma_ScheduleOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ScheduleOfEarningsPerShareTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's earnings per share.",
        "label": "Schedule of Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59",
      "r489"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of cost, accumulated amortization, impairment charge and net carrying value of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of projected future principal payments of initial term loan",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r139",
      "r891"
     ]
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue From External Customers Attributed To Foreign Countries By Geographic Area [Text Block]",
        "terseLabel": "Revenue by Geographical Region",
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]",
        "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r101"
     ]
    },
    "xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in royalty and commercial payment receivables.",
        "label": "Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]",
        "terseLabel": "Summary of royalty and commercial payment receivable activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of valuation assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Common Stock Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Equity Securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r861"
     ]
    },
    "xoma_SecondRoyaltyInterestAcquisitionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SecondRoyaltyInterestAcquisitionAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Royalty Interest Acquisition Agreement.",
        "label": "Second Royalty Interest Acquisition Agreement [Member]",
        "terseLabel": "Second Royalty Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "xoma_SecurityInterestInPercentageOfEquity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SecurityInterestInPercentageOfEquity",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The security interest provided by entity as a percentage of equity of specified wholly owned subsidiary under loan agreement.",
        "label": "Security Interest in Percentage of Equity",
        "terseLabel": "Security interest as a percentage of equity of wholly owned subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r557",
      "r558",
      "r559",
      "r618",
      "r621",
      "r625",
      "r628",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r652",
      "r670",
      "r691",
      "r829",
      "r892"
     ]
    },
    "xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SeniorVicePresidentFinanceAndChiefFinancialOfficerMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Vice President, Finance and Chief Financial Officer of entity.",
        "label": "Senior Vice President, Finance and Chief Financial Officer [Member]",
        "terseLabel": "Senior Vice President, Finance and Chief Financial Officer, Thomas Burns"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "8.625% Series A Cumulative, Perpetual Preferred Stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r828"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "8.375% Series B Cumulative, Perpetual Preferred Stock",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r828"
     ]
    },
    "xoma_SeriesXAndSeriesYConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SeriesXAndSeriesYConvertiblePreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X and series Y convertible preferred stock.",
        "label": "Series X And Series Y Convertible Preferred Stock [Member]",
        "terseLabel": "Series X And Series Y Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_SeriesXConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SeriesXConvertiblePreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X convertible preferred stock.",
        "label": "Series X Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_SeriesYConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SeriesYConvertiblePreferredStockMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Y convertible preferred stock.",
        "label": "Series Y Convertible Preferred Stock [Member]",
        "terseLabel": "Series Y Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Derived Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of PSUs (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair Value Per Share (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Unvested PSUs",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Performance Stock Unit Awards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee",
        "terseLabel": "Maximum shares per employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum age required for employees to qualify for immediate vesting of award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award",
        "terseLabel": "Minimum age required for employees to qualify for immediate vesting of award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Increase in aggregate number of shares authorized for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Calendar Days",
        "terseLabel": "Number of consecutive calendar days used to calculate volume-weighted average stock price"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of consecutive purchase periods within each offering period under the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Number of Consecutive Purchase Periods",
        "terseLabel": "Number of consecutive purchase periods within each offering period"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock price hurdles in a share based compensation arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number of Hurdles.",
        "terseLabel": "Number of hurdles"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Shares authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available for grant",
        "verboseLabel": "Shares available for purchase",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "periodEndLabel": "Number of shares, Exercisable at end of period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable at end of period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Options exercised, aggregate intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of shares, Forfeited, expired or cancelled",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "verboseLabel": "Number of shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period",
        "terseLabel": "Number of options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding at end of period",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at beginning of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364"
     ]
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The length of each consecutive purchase period within each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Purchase Period Within Offering Period",
        "terseLabel": "Length of each consecutive purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares granted",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
        "terseLabel": "Shares purchased (in shares)",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age",
        "terseLabel": "Threshold years required for retirement age"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Monthly Installments",
        "terseLabel": "Number of successive equal monthly vesting installments"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Quarterly Installments",
        "terseLabel": "Number of equal quarterly vesting installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "verboseLabel": "Exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche Three",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "Schedule of performance shares, outstanding activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Schedule of grant date fair values of PSUs granted",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShareBasedPaymentArrangementNumberOfAwardsGrants",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.",
        "label": "Share-Based Payment Arrangement, Number of Awards Grants",
        "terseLabel": "Number of award grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Stock price (in dollars per share)",
        "verboseLabel": "Price per share (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting (as a percent)",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Remaining Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Balance (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Contractual Remaining Term, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Purchase price of common stock under plan (as a percent)",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "xoma_ShortTermRightsReceivableReclassification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ShortTermRightsReceivableReclassification",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in short term rights receivable due to reclassification from/to long-term rights receivable.",
        "label": "Short Term Rights Receivable, Reclassification",
        "terseLabel": "Reclassification to short-term royalty and commercial payment receivables, Short-Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Unrecognized tax benefits expected to change significantly over the next twelve months",
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "xoma_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "SVB Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Class Of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r173",
      "r174",
      "r175",
      "r194",
      "r220",
      "r224",
      "r231",
      "r233",
      "r239",
      "r240",
      "r262",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r314",
      "r315",
      "r318",
      "r321",
      "r328",
      "r448",
      "r537",
      "r538",
      "r539",
      "r540",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r570",
      "r592",
      "r610",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r783",
      "r801",
      "r809"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r31",
      "r162",
      "r182",
      "r183",
      "r184",
      "r202",
      "r203",
      "r204",
      "r206",
      "r212",
      "r214",
      "r238",
      "r263",
      "r264",
      "r330",
      "r388",
      "r389",
      "r390",
      "r412",
      "r413",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r472",
      "r529",
      "r530",
      "r531",
      "r544",
      "r610"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r557",
      "r558",
      "r559",
      "r618",
      "r621",
      "r625",
      "r628",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r652",
      "r670",
      "r691",
      "r829",
      "r892"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r238",
      "r488",
      "r535",
      "r556",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r590",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r692"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUnrestrictedAndRestrictedCashAndCashEquivalentsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r355",
      "r784",
      "r785",
      "r808"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r238",
      "r488",
      "r535",
      "r556",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r590",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r692"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r724",
      "r734",
      "r760"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Common stock options",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan and Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to 401(k) contribution and ESPP (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of preferred stock (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r94",
      "r95",
      "r126",
      "r537",
      "r610",
      "r630"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r94",
      "r95",
      "r126",
      "r368"
     ]
    },
    "xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan and Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to 401(k) contribution and ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value New Issues",
        "verboseLabel": "Issuance of preferred stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r94",
      "r95",
      "r126",
      "r544",
      "r610",
      "r630",
      "r699"
     ]
    },
    "xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.",
        "label": "Stock Issued During Period Value New Issues, Common Stock",
        "verboseLabel": "Issuance of common stock, fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r31",
      "r126"
     ]
    },
    "xoma_StockOptionInducementAwardOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockOptionInducementAwardOneMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to first Stock Option Inducement Award.",
        "label": "Stock Option Inducement Award, One [Member]",
        "terseLabel": "Stock Option Inducement Award, Exercise price of $18.66 per share"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_StockOptionInducementAwardTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockOptionInducementAwardTwoMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to second Stock Option Inducement Award.",
        "label": "Stock Option Inducement Award, Two [Member]",
        "terseLabel": "Stock Option Inducement Award, Exercise price of $30.00 per share"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_StockOptionInducementAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockOptionInducementAwardsMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Stock Option Inducement Awards.",
        "label": "Stock Option Inducement Awards [Member]",
        "terseLabel": "Stock Option Inducement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_StockPriceHurdlesOfDollar30Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockPriceHurdlesOfDollar30Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $30.",
        "label": "Stock Price Hurdles of Dollar 30 [Member]",
        "terseLabel": "Hurdle Price Per PSU - $30.00"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_StockPriceHurdlesOfDollar35Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockPriceHurdlesOfDollar35Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $35.",
        "label": "Stock Price Hurdles of Dollar 35 [Member]",
        "terseLabel": "Hurdle Price Per PSU - $35.00"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_StockPriceHurdlesOfDollar40Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockPriceHurdlesOfDollar40Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $40.",
        "label": "Stock Price Hurdles of Dollar 40 [Member]",
        "terseLabel": "Hurdle Price Per PSU - $40.00"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_StockPriceHurdlesOfDollar45Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "StockPriceHurdlesOfDollar45Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $45.",
        "label": "Stock Price Hurdles of Dollar 45 [Member]",
        "terseLabel": "Hurdle Price Per PSU - $45.00"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program Authorized Dollar Amount",
        "terseLabel": "Stock repurchase program amount authorized",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r98",
      "r99",
      "r116",
      "r572",
      "r589",
      "r611",
      "r612",
      "r686",
      "r700",
      "r803",
      "r816",
      "r871",
      "r897"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r193",
      "r313",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r330",
      "r435",
      "r613",
      "r614",
      "r634"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r479"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary Sale Of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXAndSeriesYConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Sale of stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern, within One Year [true false]",
        "terseLabel": "Substantial Doubt about Going Concern, within One Year",
        "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "xoma_Tak079AndTak169Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "Tak079AndTak169Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mezagitamab antibody (TAK-079) and TAK-169.",
        "label": "TAK-079 and TAK-169 [Member]",
        "terseLabel": "TAK-079 and TAK-169"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_TakedaPharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_TalpheraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TalpheraMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Talphera.",
        "label": "Talphera [Member]",
        "terseLabel": "Talphera"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_TaxCreditCarryForwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TaxCreditCarryForwardExpirationYear",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forward expiration year",
        "label": "Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Tax credit carry forward expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carry forward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "xoma_TenYearWarrantsIssuedThirdRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TenYearWarrantsIssuedThirdRangeMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.",
        "label": "Ten Year Warrants Issued Third Range [Member]",
        "terseLabel": "Common Stock Warrants, Issued May 2018"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r877"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Number of shares repurchased",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r95",
      "r126"
     ]
    },
    "xoma_TwoThousandEighteenAtMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TwoThousandEighteenAtMarketAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the Market Agreement, 2018 in which the company may sell common shares.",
        "label": "Two Thousand Eighteen At Market Agreement [Member]",
        "terseLabel": "2018 Common Stock ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Employee Stock Purchase Plan and subsequent amendments.",
        "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2015 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "TwoThousandTenLongTermIncentiveAndStockAwardPlanMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansFvAssumptions2010PlanStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2010 Long Term Incentive and Share Award Plan and subsequent amendments.",
        "label": "Two Thousand Ten Long Term Incentive And Stock Award Plan [Member]",
        "terseLabel": "2010 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Arrangement [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "xoma_U.s.DepartmentOfDefenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "U.s.DepartmentOfDefenseMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Department of Defense",
        "label": "U.S. Department of Defense [Member]",
        "terseLabel": "DoD"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r401"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "verboseLabel": "Accrued interest or penalties related to uncertain tax positions",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "xoma_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase (decrease) resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase (decrease) related to prior year tax position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax position",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r153",
      "r154",
      "r155",
      "r156"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in the valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r685"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionInducementAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "xoma_ViractaTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "ViractaTherapeuticsInc.Member",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viracta Therapeutics, Inc. (\"Viracta\").",
        "label": "Viracta Therapeutics Inc. [Member]",
        "terseLabel": "Viracta"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants for common stock",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Not Settleable In Cash Fair Value Disclosure",
        "terseLabel": "Estimated fair value of warrants",
        "verboseLabel": "Fair value of warrants",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "xoma_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrants.",
        "label": "Warrants [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "totalLabel": "Weighted average shares used in computing diluted net loss per share attributable to common stockholders",
        "verboseLabel": "Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r233"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted average shares used in computing basic net loss per share attributable to common stockholders",
        "verboseLabel": "Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r233"
     ]
    },
    "xoma_XOMA052LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "XOMA052LicenseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gevokizumab License Agreement with Novartis.",
        "label": "XOMA 052 License Agreement [Member]",
        "terseLabel": "Gevokizumab License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA-052 license agreement and IL1 target license agreement.",
        "label": "Xoma 052 License Agreement And IL1 Target License Agreement [Member]",
        "terseLabel": "Gevokizumab License Agreement and IL-1 Target License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xoma_XomaCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.xoma.com/20231231",
     "localname": "XomaCorporationMember",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xoma Corporation.",
        "label": "Xoma Corporation [Member]",
        "terseLabel": "Xoma Corporation"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "SubTopic": "40",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479710/205-40-50-13"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>138
<FILENAME>0001558370-24-002782-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-002782-xbrl.zip
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MM50R3J::8C8)SKG<)B#2:\*G+V";^GC[7:QYH$!/-+!%EI!1IC/WU\2;;T7
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M&':A%&DX !^)X\UL;X[1M)/[@K6MJ%A#/B[)EK(H4DQ=(8I*->0")K1J1LH
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M[XYTK)]QN[Q]<O>\*JM*7PIQ()J>=QI''K K/%*@;$U8L"W,B%(%K@?O;1+
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M9Q:3(,*:M(4(ZI^D?:C((K(.G9R:6431^!K>29.VBHUZ)VD-,C*(K$ G;Z=
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M&XM1/PA?92B*3/<=OV^TN>6P)BZH4R/;X%W<BH2,Z]XO_F92S(+1E>DI4^Y
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M@:>R[0I;9";,:PFD\69166QMP6$*'9,8L*QLW8CY90UP6B.$:\O2,CEG@C(
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MS*VREJBQ!$=_U6SS?'1B0UD TYFR?@0LP-$'LYIXER/JZ8;Q^N7.%ZB#7Q3
MMDM9&WP.X"AC[KHLI0%[X'81KQ%Y0"ZB8YKN5:([%,L'BV)= /E\E-6ER%)O
M^F.NR%0I'^E_J6+87WY_\%?K.#ITSM>#O"B ;#Z-8I=S &>4T$/3UO&]JU?V
MDC,JC*/"GF",*-4$D Q(>80H,01'<RHZ,J@-P:6@^GP%5>[57<@=#EV-?5>Y
M.)BME_J>JTP^'(W<$[Q%)-[=!TZ6 )WN3+;L?$P7-N'D):L"9ALFGZYD+,#1
MSH)2Z;"0KEOD1"A=$A?+KU'V[*I /0UUP.R[9/IIX&'HC=8M#E=/B&SJ>Q Z
MA"5[+I5:8+9?PGV7"A=P!DC])6(Z?J]>W2!A2-Q?,/:^^4$]KE^O*IA-F&RX
MJ+$"1VNES6'C'D!0%LQV3#J-\6F'HXB,-ND&&$1J1E5_,239WOK.,WLDEUU'
MA]F]VAH'E,LH\_XT.._5JP/8<:G=JJBS!%*+:I<NL@H '/JZ5BG0'^"+F<)9
M=^_LQ$ZRIL*P-*7AHJPS,O16F?9+$N05'I]CHGD[985*  [X:@I096AH15S@
MD!V8<L2J[Z$L/_'7D/YTGQ!WS5[A7!&43M/U);]5"P#6'0T5Z7('9T*K'H8+
MEG?RB:VI$@ W@-X$U\00''U=YE JEB=\T[#^",H"<!/H:4? QTBK3Q6]=NF_
MT.$=>LT+4$,] &=__36H@2<XPZ1P-%VBYX8;96Y)  X O2'"Y0*0.IIV;K*"
M %P$FLH8<H?6\PK2Z"(3%X>UB]8^<(H9@Z,KP;ZDV:_97 _6!EM;>PH<PE%C
M>79NU)VH,*Q-M;Y_1\ 6("T=N&M>G:!MH[OXVR I@66_\>/TF,P0O\6YVA4K
M15H#UBY;6TE2WN H3?O^ <J-0_/>6UMET[AYJ![D9.$$W)( /-AZ6N%R 4<=
MI9Q?TM".HV( ]N#Z,UJ5!3A:F'N>G_5\[_CT7'#A;/W8$4$\A*4![*SU="+D
M!(YJ'E!,N4?>E4-"N@1&<]=--DG \F;0<YSO^F*49W-% #MK/86I, 5'=\>\
M*>\*0.RRNZ[_D'31M+-IB1<!,H;ZP(G R@-T[[!3\AK%OGM8B!J3 OV@GA1H
M]A^5+O[[=S9)D$T29),$V21!-DG0D3YLDB";)*CO<[]-$F23!-DD0=U=F'07
MNR I4U[J5[I'),V>K^35%%<&,,>IZ5.5(3A'T2K%V5,'\R1>4_+^C>I/#*A6
M C#SM='7,2-0]51@OAXHD]2J7,JGLU(;9:*JDW$=J+$#57.9C:5OE^J,KJ("
M"$=<VY%5, %;-^)W;I1K ;CO;J^E$1ZZZ7@YI[G+4*H)X+Y;365*W(!4F^+F
M0EH#  I56TV0MQ5'9$I7)F'I,=72ZJ&!1@X JZ1Y08+S[-K'5@_@J?%A^$9H
M_\?"H<*]LFNX%?HL?RKB\8G^\^7J[NEQMKBFORTN_NOOB]O+JX?'_W=V]7^^
MWCS]T]X,=2<QTQA[SQ*'*:A/X7:(7V>*-T1\3@Z#ZQ.(+*%[^J2W1H*RP"Z.
M9/9VG#+TB!LXJM'PCIMWB0NT(C4O\=D(A"N\M#XV7$T<E0/@0E66/(=\.&-
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M/T;T /7BNRAC^P&Y>)6I4Y9&8/AN 7@O>YA>AI?3M$SQ-X<0)XRE0)T6[0!
MEHYD+#7&ATY@*IMAKS;; .\0.D<A%7O,WBIB3Q7E?\U ?GGB8O:MINW^FP<
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ML8F=TC'W-E3T[,TJ=E-TC=*GC_8O*%^]LI482:YN^FP=P$5;'T-D[P?O4S8
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M]J@U ,":051]Q"@@S6<3NB?98O^&V'4.\N8OE+,5^AJA91+<^DOAS72G)@'
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M@67ZX9B\3>9HDSF.#-4^W2<^321\A/7$YUW"!+)8TOZ6F)YT0Q<U/,C;5 ,
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ML1.GT]XO"*^(LUW[KA,(9GY)V?&G?P&></CI7R*%\;67!1V4*1&N 9*RYM>
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MWZYV*S!\\U++KF#*=/D;Y4GT^LPBGA+5ZP+PP;<T2<F+Z")FATOSH:&;IAH
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M=.,GI+#QC*54$\8I2\,ZE;0W\$FK/C]>;1#9O?A!@"Z<P%]B$OJ.Y!Y-HS:
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MP&E(W>;V"ZX.AP.HI^BK"*=E'$3[CFGYCV+EJ->%L,?55XTZ?]:!-[&+!.O
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M4.0P>#AF;Q]*DX$O%1KUCQ:,^A]?7W<#SG<?.':U"(6%\K@[7[>RO<H1V((
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M^JK&X36^6FI[)VH*H"2'NB(W?[FXOS5B>Y-PJ)@>E<R&&0(C>VW;AK[#(8\
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M0\V]2:M9. VT(]?9;4KS%.07*QT8P'C'8FVY61:N6%[HR>>3$=ZTS"!J0$$
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M;XZG\?AVU.H)L?-ZNV41M?>B3Z6)<]!-L+,\]ILE%S\O]%WFR+1E40 D3#U
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MALZT_JM^#69?(ST'%A3R?()>VJ+=-E1;C_8T2#[H\C"I&RS<7GB0A*J?*W4
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MLV\$)^ VX4MER^P>;QX>QW,=,E%(Z@FCH=YUZ 8B=AVUO&6NHW(4<M=13_/
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M DA. 0$2B$(#Y%WF5,R_1UZ4:L^Z5CS0X(J%ML\7W%-R\WC)%9U!08J>DFP
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M^,70.9PY26ZV)$5(;CTB49(T649!.G^ MP#U&K'5=*IXSUP=F9?T2F%^\$O
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MG#85:R-Z%%'=;[-]H('H;<,MM:'97>,,S)ZF%;>YUZD=CMT#M2-^>%G(8XY
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MD74F&H[R(L%IK)K!/!)1*WJ#;TP$I-.AK/HG7V;N?&]W\4R#/EUU1WDJ%O
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M.U8LV#:=#)10=T4*HPO^%G!XH:-MAA2R2;[^/$7K%S9HX2VC4'>S;7>CAY-
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MU2GC:=\+.<E31'))>2\I*P%AB936"O@N[1,\T_03I:%X;,0,6> W0^Y#QE_
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M/#KBI;8K,BY7V&I\]% A%K[PSO)-M$9)#Y)@P<OP/'9 $"NM!+_T<&FS7VC
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MZK+\LA<-Z]_UST6B.QC+"/<_%P4<X53Y74S;6I!791.OB"X<^2=_E+=.P-.
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M+N7RK_CS=:A3NV4$(2;(C9+4=#5:(V;.N0C[WBK;QFH3>B--PKC9P$X31OC
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M:04E[-AD7]+=K]%]8K2@GP)ET.DJ"E.F"0U=GR9U+QCZ]L$YOP=I7(D';.N
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M9R?@*>V2':6I:7@V^\U*_$C!D!2?4K$D.4\;D&UG(,,P5*-+#1=K\/TA@]/
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M@&ZV>5SS.S:H;SXS$X5.4 32A=Y=%+[<^:_46R<)36OS96LCBGNBZ[%9Y='
M)(IX(4.37F,G6\X>D$4]20 )2"Y"*:P3,J:"%(2+080<5E/>7*KU9HN572>^
M<^] \4RW]H*PJ0U.N&G5*(^)/6N #PS:Q1R?3LUWB"1IY^)K?KUL. 0#H>;L
MON@$PR:0PSDK==FIO/R/I85OKFO3:/++PX$+U9WE>SO[!MO6&\S*IB1[3N@?
M&=L3W4!2UM:M1GU3W-C1IE]E6U#3#N^<;Y5VM!.JB!).U;1+>;7SZ?;F,W4S
M* *_V;)5F<:-SF5[:YR#LJ>6N</9TA3?T.PK\.C+$Z!-%'$BJ=OS1V=5]F:S
M(IM/-"1_SUYV=A[ W]-X&\5[.,Q_Y 4D6]^_-[?&.15[:EE>(AJ:XIN*?04>
M'3)8T"6"L-VG[R;TY#5421;Z.NM#K-T_,C_QX3IXL[UAHS7:^VY>X'G]$E->
M+*4Y 'M@?YPS<;0E5##7D,[(8[Q&J3+^'E<Q@UL2*MD55<"=G*'98#";1LC9
MD9P?40PMQGPC'1;ZD/#)"0X[&CO-6'?6 C&:U6NC\*KZ9^2(U"#L^#,06:@+
MRH51-J;X"LO'VH'&J>.'<$V;1B3G:Q9Z-&N;D[,('3-II-$)"J+8N6?NU=YQ
M*=M+N4Y0O]7H;HT8$KJU+-R9QJ;(H:*'X+/#!I>!G AAV'V9SPRUVMGT2PRK
MJA-UBC/_F\]ND'EL 'W\-OGVFD(4/8SSS?::;J'"9!L:C:""&J7&6J6$7D-)
MH$>UT0J-'_L!<=4U&LV9DH_?/GY+"K;@G4O&IA'.BDD4SQ6YZ6$3J[B(9LQ<
M1]?Z4',P0"X8"X?!WI(1;MZ!V3Q!C6*6+24MHM"\*H\#ELG74F^SQ ]IDI1.
MJ5K*532WQHD\/;4L7TLU-,5[+=4E\-@!F=,EY0-,>_4GZM2$?\:TO49?GW[+
M&[RUFG<-XTJG90WH>M%U#NT5R9F0WP2;,<.\P='[WWX8.FF+8W?: .>(;-9%
M.6Z5OR)WU.IE'3NH)#6S6\=95+#H8\VB#X) T+N.8/.6YCBAH*^>+4&A=_B#
MP3LEUA<<>F<YC-N8JE9F8QJYOS_0 [/:C@EU'T<OL;-?9^DNBOW_IMYZ#^_9
MFQ*K].^-?*X.LT)EZO;KBG@F#U1@]&@'/J1@1"0G4K BUU$0.#$1+.U,=J/6
MB MK'*0U',Z .(JC#51XBJF39/&12RE"'>4>P&NP6WL/W+._A[;E&=_2'.\L
M[R/T^+PD@C;AQ%<R5%=M&T]'L)F)/*?"1<*'1$0E%_-XS'1MV!K?[ ]!=(1]
MF@J\6X=AY@2/#@/)8]TFH;L+SIDX1%^UH>YHCWR+W5=Z#8$L<DEAP]7A' BT
M( GG0]C 33*'_3F-"%4RV8K(G=LJ!?TBW)8!E3"+X&%^:S^WTNN6[S\K7#TY
M\0N5NEPYR>YM%&:)3'2WV;YE4@R"L@'DE@5S0^W4!H%]:2T/'@=K-C[T%!CE
MD\5EK,@S\%*^>2F5(LRJTG1:D21[_B_J<CAUW)U/7VE^3ROI'4J/??9^0),T
M"L%;0@_$QNQ?#]+RJTBL!@$(EV"5Y_($&X,4F'#<_IBUG_B3.]^@JG<5[0\T
M3/BD7\<QTY0;Z>VQ:'+O" -^<F)/>.VW29)1[S9D5O.CINVG;AXXUX]9+5HY
MU-+) .^F>!XU1Q\) =$WG!<IRT-* I'G(RFWDT(1+E6^\R9",.*'1(AFYR0-
ME7'/MNPO3(Y4YW;](3HZ07HL,K\6&9TWX0>:\LKUZ] K_7K[7JW_=>O)9(HX
M44RCM90C/(T<<E]8DW*C3Q(X>Y_-&2?T2BXK8;S\]$AVCG@K$_LO.^Z]B@S%
M]+1NTXID!_AS<J"0"8T!5,HF5+*+ L^L;XO"GL=24NM2-GJR"0D3@7 9N,%+
M?V/H5<AAWK]%8;<1XW"R"]R.^$SC0LO".$_YX&XQ98^N^#&\K_ZG8-W5;QFH
MW%N+T3N[G%)^_  )[^.FN0!_]"B;QWOQ4K'4IV.:6,'@V:V7@RV8J>!4*2B@
MF%E#5%QCR+!+S-U][Q]^NKL"T6@,[PAJCX2GD<,/I%/L-,P3KJ>U#,"=I-ET
MWV.@TRNVFQ[YQ"0B;DDDY@Q#;1X*A\3PHARQ*SRK37OYP4(" B*0L@Q(?>#9
M!Z$<5/2/S F"8\W@FLOEO0G\%Y]IK98K>7!36K4^'N!5@KKY*&\!^D/]3'P0
MKP%S6K:X+YR!"?)58U:5Q\[D]\YG?Y_M"97"%=X7.4CQ*G6>^%IQ<IU8OCMD
MZ\]SRU(#EX_%19H?YD^V#U$L*L2)M<LK_O%\S!>Z0^PS7Y$QV%.:6ERI4'['
M7*AB:Y&?R)>W& 0$(R7)>*'0TN=[+'TXN\L;2BOGLR6F>YE_I[3AK0Q]N2#J
M6^^D^D^1C!W,W\?=Q[X+2S_7&"YV18Q-G4F'DT"\2HVTAUJ !O9'OK:,U69T
MMF:XUB^B^=C'2GR/RC*?:>R$R9;&L;CY<ZK)%1WRG#_MW// 6 'R![@3R](D
M=4*^(HCLL]!>/OG\*F%L]GM&)(% VF_)+5\]V,1[%E'K3%-^?N!X'F<&T0=1
M""L%CU[APII=*4Q_E?P.%I*""8XD9[DBG"GL:P3(KT3@BH4'#O@&;/W8^YJ-
M78\_ TEX"_Y;C3N8*SZ:>53XO1-OXD<VO:GWBQ-DR@#Y<^<Z"P[KCAC)1]A!
MH?B OL@1?(PF8R?#.P>@4DX&-K Y*_(*O(J1+J9) ;AE+#8+HR9-(WCE[T<8
M.S"08$@XQS*"YES-PZ=)DZSK%^ 5VR#&<M#,#96]5@L(W]'@ )^100R=$^PR
MS!&NTD .I5,T&G^O184?ZMKWC/'YN)J-/<S/Y9'8^)U=S39Z6VR*BB4=!4ZO
MU?Y, UHW$%LZ9K?9:!ARUU&Z!/QNU6L*BM<?'_P)ZZ:^P3!P+T18 ,3/8J^2
M!?@@-8WYI?QL(K1]L[U2\X;O2!X@,J$VKGQ 7\2(/M0"=56<6CLBQ^O!:DQ_
M.A%&X9L<=?G%5@FJQ9:4A\,D!*):%*+*&0$1,V<QAY Y03Q3!S ^CZ:!&[4H
M)ON($3A$*;13,T[>3%DK&36OU2L)&.4GV&Q)P4P>C AV5BM%H1M^/-KU? C.
M@KZ%JLH,;'3FUZ8=ENOLO S\[6>#.@!N[[D<!.ZIQ_0Y4($^,<A+0Q^R2+WZ
M<#M'LI YR@0"P9-*_(<UN)S91!6\+$%C!3S!>#E'JY!I:;PH8*Q'3HU'$G'D
M4NHE3"- ZCOF'(?\K3O=Q-=^<HB$&>XAN.@INOE\\,6F;K/=;+?UB8"GDT0,
MIIKL51Q23*.'''AU:3=ZLUQYDA=2CKM<(@+?E 1"H!4D!>'^JU<(!7%U5!Q9
M0.C2L?!15*0=50(#^0A$+EK5NM%F#REL6S^WM11@1>YR>S]*>Y?$X*<7PJXW
M%;MR82P<6=BV7L?8G7FH&E]BUENF@\X%II'@\I>7=EL-75SJJ5W&TM*AVPR3
M\R $&K' R$!N!T2NF[ K_I!I>0O,7-]@X/+"Q5C4VF)Y\$X9J[T7E__W+X5U
M[MB__M?_D_]&RON__G]02P,$%     @ Y#UH6"]O["PDJ0  \/(- !4   !X
M;VUA+3(P,C,Q,C,Q7W!R92YX;6SLO5ESZ[B6)OK>$?<_J/,^W.J(RDS/WCY1
MISOD*8_K>%N^MG=FU7W)H$E(PDF*5'+0MO/77X"#) X  1(@0%#1U2>W;0Q<
MW_JP,*VU\!__YV/E3C8@"*'O_?V'XY^.?I@ S_8=Z"W^_D,<S7_\\L/_^=__
MU__XC__YXX__=?WR.'%\.UX!+YK8 ; BX$R^PV@Y>?/7:\N;? 5! %UW<AU
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MI T$K3K09E?21F)J0^IW*&U$JF]!]6ZEE20U]17O7-J(45-=[UU,&R'Y6Q_
MCJ8-$"V[4+V[:35CUM0?QGZ@Y?J@92_:W"T\PC]CZ,#HL]41-&.3 UDK?_-0
M830V;;3<0V5?MC_@2R&\ D+_P1=@&\MM?6C?XV<-!/4'5,Y;0#0NIF$(^H.5
MV*^^>YCT]O45V'$ (R2"Q&LC8E?ZHE-6*)IV)0)$ZTU?C- P".+$C"2+L$=H
MO4-7-I<8.E6$F(-6I7AYRB1%\ ZSJ?XY\&T L+-=6]3$=:S=[>Z;]0=PK%;
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M:>$K/<^&+BCL\]]\,29'1E>C(65OX$E]?J[_W7:6R*YXH4U;#U<*ZT:QWIA
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M_)CJ2 N5"P@=B"QO =_=]#&(\!ZBM3=XA!O@U"XYF.L-BQ7=Q,HY8<C9Y2-
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M=P_IUR-<ZNY\./G%U=K@J=5=6JGK%H6L^N8%:8:HOQ)T,EL>OOBN>^\'WZW
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MT\+?_.P F*X T3]V"S_TP^^/8&&Y=UZ$EIPUR_Z:$KIH6-EBGQ4379Y1;>9
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MO/[\:OW+#VY<*PPIRVF.%G0ABHA%=E>Q!=VY*EEZ4V3?24ZT\RU;T8T\70G
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MJ NG9+V#-DXV\8$C-ZY1Y4-H^478K^O5T9=+WA" BVXA +\^?T6='D( #B$
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MY[()VEO@V_,D!'">+@#(GK+,+8R8:9R@F)4<I8(&^L<-^AE&K0A67WO$Y.(
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MV=9Z?SB.O*A*SVF> 9(M2=3A.?E+PU/;#F) .LKJT.*!W9P[MW:("LH$U_1
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MH%C5SI#<H#49L&/LOK<U$<F$6+LFE]A=00E71Y>GYU=FLUH)H%H][RF:TT4
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M!E!@M.RX#",[(!0'A#&%UI[I%<7):'A%B-Q+:"T^'88>OB)LCMXKE]5:42T
M+QVE<XFMIQ7O(WG/UC.F[5:;+YV-0IXI.W:7@V OWD/Z\U?_+)L:,%X. P52
MO26F4AU3>K_9,B3+YH'O@I&4&AO4NU>\H5DV#ZR7A*A9X<6)S&W>B[G[6,/
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M9-3U6]3=)=+=Q3#'14>Z2AXXS-";=:4N!<-??7Q2YB*)^AXXQ9X/0Z?7H<,
M_N&,DXCB"PS_N \ >/"0=&B3UM?0J>OW,'!Z&3C,T)OU1EWK>$*:\<%>%-2#
M5BD='@8*=:#TA_EA,[,?F)6$'(8/6=CM;P NE@B]Z08$U@(D?[Q%IF:+M*1
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MP#?AZ@*U$5>DJB*8;G(7':T .-GSRFE(@^.-#1":@7=G^^=PL_D:1J12[]X
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M\/ 205FLF>6@P=SC JVF$PXU]"[*(K2+CGX/XC<T]Y<^6E 78VY9**BK0="
M3DDXDPNP)&)?PPC-O9C^3A>[("BLE'1.QTM"NL&OO88"64<U/;?3#<>I-/Q
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MPS9?7*,^<QAV\<:&:.<&S?\:GZIP1]36("C%9X0DK5II0M,L]!;&?N*_HU?
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M1YDN^"]5,TI#8TMOR!^23D5#@U^^B*+TO6@/@3CMES-Y^31=N+$R7=A_\!X
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M]8RX04OL@%P(S@*;;MZX!9^D@;7)KWE-62DRWM2J]:%%3(;)9V?D_*8="_O
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M;*MV)34  /<UK=[)*F2+0FJC=&O!VH)4B2> [Q+I!>,(P#@,#1S4<I-DFOC
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MA"JDB+@5(?AJH!OK,L;/,?H]H^KH-B)JHUI91MJI(35"IO56]*I9@S:$/P$
M ;4EY5/ER= TFWE9LD:I=:7+9 SXXSVA (K8GMZ7]F,:X&Z+LRPA])$,N[0I
M'+6Z?&EEB*ETW$#PJ09EL=8$Z=V&O.-1$[YJ&4/N=9=?VXQ=,YDRNI S28?*
M&@,.^150BIDW>N,8"9^5C!=#@UE+3.].USX_:/E1)6,;;G3%MN"'P%N7!)<;
M\#RW<K:2]AZFUXU1OF;AG3$*>R6FMC274J<>-R?I#;W"!?*G*!W:PN'V='!_
MO771P ^#]E;'[_;*V-7N](!'2(LVVM[JZF52:T^V_1"OQ@:*!2ALJ=-9N61P
M]O].77I>B4, 9SP>2@EY2IRD^]9*[I69^2B57TR(?N1T^W&)_#VRGB6R/D'7
MKXM-$*=-AFX//'EYDEN3.&LBF=A)BWOQ:6FAUAXQ3<@8KDK"DG]G,)\"\E[K
MOHHY,4RNVLA03LJQ:+92GLVKD3,'GQ>#]P@6(O(_VIOOJ_8@YQ5$^6X[F0AC
M(^JN<FJ_$?6L<.H!OCM0&[@Q[OYK<Z>R.E/)$+=G.'\1VDDEP^J; 6MR= >5
M,URGF!XSL=7POFCU@U"=];VY=#<T6"_G(B]UO'AT*/N#]G$LU"3=Z+J*B#&@
MN05-4=*\ F//H?3ZJ.TN76-YV4).5FMZKJGJIEQCC'9ZTD 4&XL<DL,[>_U1
M<[K/$C;$E)KOK0A70\,%;QC@;(S1Q2HSGC RG< R0VN0*O<GD?,@7A#Z6%8V
M<W;F<N9TY/)M &V3&W=:8'[M_.7RHM<:4O):D-. &XZ(:6%M5.($L&TRXQ-M
M,GT;[8 /3_XJ='='%OMIV'P]],NM7/%=&1F6?I!P*T.@6%,2&/"0I'3':- P
M.RN]+JF2!<7#)_X3<D7),*W]_8['1)_.D'ZS49[!T4E76\Q1NI[-F9.Z2E6,
MN*U1?YB0X6;J/L:"< HBL+2710BBV.R\V4GRN"4K%F4^;+)6:;(VUY!KUEQ&
ME:&&X[FX@?M5YG.]2>N\T.?!)JWSH5_6Z_L\<_(!Y#M F7LM.P+Q._R4%Y]4
M"SVFW/?654DXZITKD5CDZ-&BM5$UF2UKLPV:X;KE=>0:V3X0B4L*1\YU"42\
M/L+5<$S(SB\*HL?YM?R\V^OA2G0>5. HN@&8J7?^E+#MC@.4:S_I<S(WHE:-
MF; D=2HM3I*D,.WW1\G(F8WW&SP$)1Z/:H3>I7_D)#):<H#MMYD\*C&CC0G0
M] ]L9;Q>(M[_<MXSR&5Z,T6X-*O0(Q1+DC,[DK'K';1=$.-[5]I#!=<V;Q+@
MII!CZ<<W%'NT-XE4]K"&5P:%0CJ?IU"23F0+F=* [^EQ ]F32SK.Z!E25'A5
MMO%5M&5Y/.D';4U]Z7XHF3MK093\0ZY/-P@TA;^CV=*3T1A%RNTANBAT!CF:
MEQU.B9LW>YLXX2+O+EE#PQZ:1?  MFCLL'<X#3/E$WM;WUG;IC* <NFVU"WQ
MRT9V."Y/4RVFHLBU3,/!YNW)O-Z,F_[["*U^C@W&4I<'80;@X'G^'?HH_]L!
M,A2O/&BO/0G0G'W6\BP.>G^OOGL;%R&$)KI_8.F<?R23NJ* D;Y+[UWCF4^/
M-5I(TPS'8I744&&XN=B)&Y[]4OAK,=*=??HW>1.NY-SC:CCR@Z8OU_X"R#5G
MSRK6LL>*M?OB5 6::4(M+^G>SI6/M1-^1ZFO$JO2*"DH&J=6DL.95BWG5ZW(
M90(>",%[=(F[ K^N/\OZKS_+!ENILRM'1K=HQ7D\N[OX%N5/6U-H$"Z51KHH
MP0_M[+^C_%=8SVRQ.8.1V5F[#=;MXL#@XN97/UWYW^3-SU#^Y[+GG3?NL[9Y
M-Q0/H(E8H$>.WRBID[2SDKJOKT2JJ07?+)3K)KH8XYL$EELX33R2Q7/?<K3X
MK2J]<XK_Q)7+YQXA'H28?%T,!BT<ST.GU45A?:5J%2M='$MQ\Z>"$X,76,/5
MZ>^[37G@0&/_=7#'8MIRC[-3-BS()45LUX@D.EW4?B^\'[A'-WCP$J6 1.FX
M&.2OE\&MAG:D>SO)):)FN7]YQ<@[X3P[/'D?1]P<UH836P&6;C@-28&FI6L?
M"4Z^WC%/J/*)2FJRZ'(JPK-BKF$+[73<1#'0CGD/^7D,(3[(T)#K8"+;S.]B
ME^;76T_Z.S@KY&83NNA40$T7592E>OQ,JJ=70R1N@?]O:#9QW58RN-6+Q&=:
MG0792M*T%L003;5Z,C3:\LKE)BE$K[U\$&W3 DKY/+5]9.)R-^_7T8?GGHH^
M5-9*N1'>)"F<FX\VIHWVTMD7^J*,/CP78/64O^YO(9OA)IK?* [=3LJLW1'8
M16W<Q-&7&8ZT&<:#=0@#Z^[\S#C.M]8=#A>5TJ)@,BA-]$%Q8VXX2XF=U@VM
M?71,8[>?U=GZ^S*1CUH\?-W 3 6G/[/+U(!*%[(D5Q:,:FKTN]>COBM3&5Z'
MBJB:QNNTYE<%$>?QE!])#-E)ZXPG26-2L!>H/6ZO:O@BT6BA<9.AW^6D8;OZ
M@U1@3MK;WH-%(!E=H-@P[QS_++N<\QP"IPZ74+G8@78<4]'FMF5N!R2N('IV
MRP8$IFULZ50TMON?!.?V_<Y&FFTHV(;A.@;[&R-MR>J5*E6$8HNIU$RI&]V>
M%3GD'D#DCZ*GK6%W2/IU1/O@Q8TWN<.,>*2GSP+C. &]PBWJVF EI=$>6C!*
MXB:1[V.16P5Z 3TZ8?=7C@"+]XII(2FVI6&6Z**P3,ON2X-!BXE;"/Y:,8WR
MBFE QY_Y.;CC3I.YFUVPVM"2C&/--5IO"Z+*66NY9S*%V;#-MC?KR#E(C]K)
M/9YH6#4O3SG.XQ <8NE=EXF#ULS;IN2*GGG>@NG4GTC2-/=Q5XKV<WTC,M5A
MNE/8M&T4-_NTQ.<:FQ0566_C';(<N@Z=T^7K^BIJ_1Q<T 60%SQKL'U8M=QV
MV'[R$F:C2F?+E62KRJ4UR2F7F=5R$[OSJ'_V$N;U62'GBY@/S@HY'QI$E\WC
M.M/NK)"O+3K=SW47@>'2306C_9 0L#_N=$9],C,;R8MB'ZI%!G'?.W;8#WPA
MZ4&"^S9C?KC872T/W>\D=S$T<H<.!EI^19M#&VAVCZ)%?=J?0%YF.W&K/?@]
M)_E&Y_"TY!FD(U+.6I>TY4K"(*#4)=I>#<B<JO8CYY&_EFC>H#CI&\47M:_/
M4LP_+QM8IWN\ --9#H6;R5*5N$:1+4<R _+*!L8G&Q@=8W5Y1.)W-LW;_U*>
M%M>;LJIFJ=ZH S?&E &M7-P$[,G]\L(%Z ?..+P>&@! 3^W-7(!&K-?9>F/*
M25!:0,HNKBLMFRY;S7[<0H3?U.OL M97W<[NP?IJ: "P/G6,W'9V"KU]I/O/
MC3Z'KM&KU+$.,";0>@?C)BCAO4:.GG'I]#2O2DK3WL"XA0Y/:2WY69*'J,<O
M&D_>U^,70[^Z&)7@<=Q//K4K&4"P0,?KVCW?*A_S8_W+'GCSM<K0J>9JI$:Q
M/)JLM,;:(BG%36'?)=)/"80ORM>]7#\>5&5+CL?3?JIF&:#H(TD?>QJ#K0<&
MP6ZCONGGYMF^3,KHDC< B>*Q.\;^%FU^'O*\*MD<@D=\XT33C;U#Z>*RD>=C
MO6I@0ZXT6@$LGTJU5]6X*<MOVQMQFPT_4RB"W,3PO"9<&K(<*AU6<SBV-J(+
M?,T-<K)Q\VQ_:A.NZ 'N&8VT: WH-E7*K66DNTX:"YU98>FX.0OQW)[V\\7A
MO&UO^GC"[.G";S?0;ZLK3#18HH2O^"Z%:+-EMI/O5=!.)*4AW)Z>OZQB\?HX
MV_.:Q0?'V9X/#::_]2U!^79!D(R%,$B8Y:H,"CD@4*B(IMG("<(+KL^!Z\T6
M+O?V =B&X9%#G2NZ Z%)K07%%B5M<N\4\;33FB1:TW&.DWHCT"HB3LDT(EE?
M>'=GP">F'E*6*^BV*4%N ]'GF#BJU/H5%-@KQ*@+FUIQ%CE]$ZUM(-_ VM-F
M:U(!IDF/>\!S4UW?N"U-IE<UC[K&6KH@[X=43-.&8@$*VPEV5NY,G/V_4]>)
MO;)2!3BR*NY;&_9E]))7;$BOE#?E?GD@R%"LZ^#-@0J'.Y[MC]QNVGQC^*X'
MM"53+KKW.IS\VC[9T@GHM"4PQ^84R-4VD,!PS!Y&#IW'\IGW6'56._D)7GW=
M<KYE\B&L^BB7O_XN[\'C9,;]XR,DH0YK8_EO$FK&<%5P5U=<[UIQ:;Z_70,7
MQB,S-\O*;'Z\Z<X7UG0^C5Q>[B7/H<KS36B\1#FRHDRMYU"PH-B!QB$_U.4V
M*Z%6Z'(RH@R[7832)%N(7(CPDN-0Y?@M+EY"''DA+GC!$]3$,R=;$LS49MBJ
M#2D2*]7+I#)=I:+7B?4ES-\BS&_Q$76A/MNAGCQF<(]_?RT;:TF;#;'6UXKL
M9/N*B4Y+B84:6=&(7H+4V^;D,T%Z/C3 0V$._*UH@J["#E@3MC75#7<&NZ4O
M:V[P)'%:SP5KTH"B9)&N[G#&NK$"AG@!E,-VRSU"JEB*)S-HLX_2*AC 7C.?
MGM8BZPG=IL)?_WID^(<D EA2?8]^)Q!>$C#JVN5=0+V/E%T? .CMBE)H8SX%
MVF[@'C'C3C>5*CBI&K5PRIK!9BJU0?1.4??!T-VV^O?F&1/&\G@0=B*O#ZN8
M,!LG** -F'S#,:S^YF4G?':JP1 T@!+@1]M;CQRT7-/BO2FUL-T7]([+U37W
MTKS@\YD;N>=QME@FYO20[\KDO,JTL?Z0M)SH\OC>+$^<?C/-T+R!YVZ%O-U%
M[:N0&&75F9$E^FT*&?5DHJ=0N5[R!8DH=U [VZ65.O4$NJ,E]O'FEAY;.(A0
MX@GQL%A^;A<D40*&PP)OF?(T?E=R:#6 (<-M+ HT 7J#S&/8Y[W'_G[H*FLV
MNMWZ#,6=-8HF$N1J&;W&5F\@=4VEO_YUR?3/D4S!%'_<I.^A$M$G@4,#,^9M
MJT)33])O.(]MX8SNX7RX>@SGXPCWJ2[%& ..H>'Z<>=Z[F-Z\N8M2OAXXB0[
MO85<HIKI9%$LEPPN^JKR+:Z/0]ZG5P!H]Z>J/_3PKP(<]5"+^0+XU="  .Z5
M=F<#=NI\JN_.2N],==L$FDAY^48(M8/">;/U@)!P#>'ZN%Q#Y=F@;"JV14>V
M9"%PGR PA>Z?Y&$A'LMN.QX\U66]!+Q[]5BA;P&[TTX#4M>6T+"DD0)O:N4%
M.D\6V;; R^F.4)D;#IUI8]$'ZUNMO(6,OTF'"!>_[NP.60&[L\$W'?BJ4KW7
MM(!N$#=VT.]O4!GP%%;#D1(%R>%*JE-Y.ZU%KDSD28T)GJ>R[[9$N,?0T$3N
M&6T/KC5TYD)#9SZFH?N/-'3+)I-9L3K.4GBBH*R'"M@4HKL?P)^&?C3I,.'B
M5T-G@C?HZ"X)A>Z[$"?V5UX^H0XG0*&VT[C7BHNCD.ID0Y6A+%4&FW(WMU &
MZ<@E![S(_VI"'^ZE%4"P@OITW;9#@VO._^G@I TM(&E0I("A2=KDL-,TYQA]
MD,U,$!0H3;JAM"M98Q Y6_A!XW1[KC%9,OHL@PE1E/8MN( D5C02S"4+* <^
MK[K=CCI,9BDH#3MXC^D/EY7H)TCN\_GNE&/&[H\N%[PCSU2[U*G(:UU&%VU1
M!(6LJI69N//Y6^4YO.U40<ISP@*V/)^"FLQ*BL$WBQ#3Z,C9ZAC(<UCLQH*1
M9]:Q<BDVSXTXL&ZLF.ZP*@#E)<\?8# 6$0;?E^=->;"VS)I:0I'I(M\I3[6N
M8D8_$(N>/(?%;C]KMY>+7?FP%KNPL=-HMI5L 96*.5$RIWQ)CUYCS0\O=MVD
MUX]9['I.Q/"L]=@Z)L!,!MIMRJ$-K9\9#;-J(_KNR>]>CXT81!_E+@. *8OW
MJ0IN$4N9UE!YT<E*LT6LRP8^F_I\0=5/O/8L@Y]HIE'!%&137B2P"94"QK(?
MX7TB+X/_O)3"LPQ^+I>&PV31GLAJ6<EKR+@(F>[+X+\@&BV#/\@R8WDQAHY,
M3G+F6!*P-)J*,TQ_H<&/2H+V;64*R9JU6:%%H7)O5<L5>VV:3R/1M]-/+-A_
M3B+V67Y<G\LL>O(&%]%>=UE0<TH'S$'TDWPO/^[[4\G/\N,H=$)7N=I\3BW*
MJ5:VS:"VR,<_M_AK_+@H0/0;_+A&44IVNEF'DMG,L#B<K\VQF(@S3'^A'Q>5
MA;FW?MS 8@E'+,BB##:I4K_(CF@M>LWS(^K'!<S6I'?LTCE3VU!QYRLR7DUT
MQP":"01OC=',.^??7'"XHJI0E-SOBD"5E'U+.'K< !K851K3!F-(FB#-@4*O
M-/AF]Z7/W9J3*D<Q:E>&*$F079,D&<#"R$:7_@EY M$G*1F@^OKL5M"O@MH[
M.B$7&JC](LR2B6FMUAQFT45=:&3-?)'+Z7&T>S%DVM59YL?)L0+4@'NKL^)[
M;Y[;/I1EVQ 5Z$Z]H"L*,)*I*\U">/U.+H\S9Z QU@UUN\O8NP^G2<=S87IB
MT6"M"L92ZL@@6^Y]QGPB<@D&;^?*3>H<RO0?D>?KZN*"KH>CY]XG;,R6IKX
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M,^O9H%>,K(/XEA1[-1H$+4(#UU.W&V9Y/'G,%9TN0LN-T@WB1J)N?P.(HK2
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M-#;]R.53HX>W[S"S 2/K1@'@URQF*9GJ2OT>&,HE@+9R@PE>&S4CAYU(F["
M:SR3G^;P;6M$C(9K5 %E@K,AAU2FA;9AQ'*UY7GF(1&.>?##X4M-7UE.J\Z8
M36_0&CHE6R:[*A28R/FW$5&] 7/MJ'H_LO)]3_7VIK(.DOE:2:8SRZD^9,;+
M3CZ.S'R>ZL7#4;T?Y_!MU4M)FRFFH.B*LDFMR#;Y->#TE^K]&(=#4;U^.'RI
M>I7VVBA5)8>D:OF.KE1QI"1+<>3E=ZC>@+EV5+U^2@K]J%ZI1UA#(R$6*79>
M82M-@Q;4<>0B]$BK7BSPG4T?+R&\IWN')@GG5+>\H!:R;-3->B-K*/&WKM_K
M]CZ_2O2>%*<*):N;GY=R'-M)BR9)R^-,*G++"Y&6XBA4A]Z38F )QC)!D4F.
M[0T0"R&8[LJ)OZ+^7@\J*BR^+<6&KO2P9F::Y%0QI>E+OJV,E_%G\;>'04&6
M!.8^YVS=EN$B4B!+IL,OT9J-(RU<8A6:B+^:_DX9OMJX&)@_C08DP[,TDF%4
MLYU$)7'D"$,'%&;U. 9'SY-A-/#-VEZ'R^QI=^KI*AB>)PB*+BA, D%51Y0+
M);(W73CQ%^O0>7ZUOQ1S&7^<Z8/]I>=# VJ!^DF 7.9&EIU^SA@N@,+9,T!L
MB)7)FYDX0N%[=JP_E>D9'D\?>7ZZ"$8GX$B#JB3G+,G9)=@69B1/-7,O7^ZC
M\$ S")[V!X^+H<^$QU6VU&DWF*Q4IN1>HYH===*CY2J6BX[?I1&>R/(4CV6.
M+#]=!*,1!DJS4M#S1IV""#Z1%SSHP40<@?!DC9!"L(Q/>)P/?28\+C6"H\]P
M:9W#&C(I$26Y394MI/3R$2+)<IS'\2/+3Q?!: 1A:<CSW!*HE(IR;:.KYAM2
M],Y)B;Y&P!$<]PF/\Z'/A,>E1LB52IDVKJ_:%)T?F FM*@W3]3@ZB]^F$9['
M<C<XW+F"^#Y4/%P%HQ,8"A25B=!F4!8 AF87P[&^>>F$CP$$]V)%?T[DU=#G
M N12*TRD-:=3*RR!JK-5MR 6><D>QW'=]GNTPG.9?JQSWQZ*>;@(1B?4&J.D
MS+070$[7!&H^!LM!;1!'\_!,G9#T^M>=LLKWX'$U])GPN-0(I097[&@=AZ/2
MR4%5+337Y=DTCB'D]VB$Y[(<Y;'T14HYT/QBLTK,R)G,#[E:,;\9LDF:%GHO
M/^&CCJ274_:9;+H8^ER 7&J%H9/L)]DU(5)2%ZFIHW%O7B!??D(DF9XY3R%E
M LXPHJ.N5FS61B,48N5$D<?E.LR__(0/!Y<9_^FF3+#IID_#XZJI3W-<S)<3
M$DHAZ0P]+&UZI0X=1^/PC6L.SV)Y\ISER8 U@F!VK76SPV*HE*MQYCIOM-;J
M2R-\&!Y)__!(1@0>5ZN0S'0(RHRI<2K"C?)K8I5=QM(T?)M&>![+L7.68P%K
M!-H:R069)I<HK4L4U6_7UHE"'('P9(V ^8<'%A%X7&J$ALE5QLPF4Y$AW:]#
MOF44-"V.0/@VC?!4EM\[6^-K1<FY-+>H8)G"$$T+= TGF4J%6<8Q?/SFHN2W
M\'C6Z1A[>. 7\ AJWXEE*5.[5L_/.)9=Z_GRO$Y.H]?")^+PP/W# X\J/&[[
M$]!(]!*-!N&@>!5!R\-.!I2Q^&N/[UZO?"(\[IYD]C7=416SAF'7.CU*;157
M!9LS\Y",8Q[BF;KCJ:=Z?1(<EZZF"J=*N[II3CA2!LDFH\N=$HBCCO@-Q[B=
M-D3MS$6PVZ-(GC/KB4XI)_<F-1KRE5&REHB_-_&]YN)J@]0]@%P-#>Q$JU/P
M4=$$784=L"9L:ZH;TM6YEEL2$II8UP6@5&U#,D5I>X;C'A#(K+-V(;'*HVHB
MNS"'2DI@VI'5#;<G>X:&^[,-$A'?VIW@ 9,+[I>F)0G;\^:,_9&;/,4W5TQ.
MK4YDT$^K0W2$S3-<;%E[<XY19^B',PC>^;Z60^KJ7-?@X73DPZ@VM("D09$"
MAB9ID\-AQ]5>09GADT:1DF8XK&-K:#(Q:"%S:ZHG=M^>Z^_.'WP&'(;K!]:H
M5L7D )MO=42:FF+%%S@B'QZ^,06>2U^'$Z!0V]<^G7N5EW0+"E--5_2)TP6*
M#8NV:P&9/0"\[K[;8Y;-J30__:KO_D/JQES?87 _^&.0\P[*U;5S][)4T>L9
M;#APT!YE2FNAF93L5.1,CA=&7)'R< +P75J^"["'3_3:"E\PX7 BZRTN?/XQ
M'Q2C-_R+NCG="P6VK>H^MY^,H;MWL1Q&<6_L^G_>O.?>J^8=[T#<$^SK$)A0
M+ )!4B3+#1PZ*YU2H>$L)46!)%"DL>ZJ%+"'\[S #-J().JRH^;("9S(*<F.
MK/+T080][#Y$A?! @2$8&A@HWOA4G\;$'4"L"4*PA*G5Y$BN51FLU$G)R$>V
M /CS@'@"&EP3&Y['_2W@2#:<46M8:^@<;%NC!-94DN-A9+.M40?'Y]WS"R0%
MDY+#/?A@Z;V#?KCR7*M;1[SOD%.&0+&F)#!@6W?</QW&'>.Y *ZVK4NJ9$'Q
M\,F5]W7S#/?=3?>WJGC/=,-A0G"Y9DK>:QZ/<S_<;9E$,ETN#WMR*3ER_[=V
M>D0M<L;+\XQNT7"/O0\3\>O.TTWJ[U_'/_G#$@4L[3E3N!]1N!X:7J1Z7Q!H
M8P*T-R%&4=)<[M6E)11=<KJT]@ZO)4P36F;>:8"9;FR3OA<!AT=W5^T(E@V4
M@_[R+SMU27!Y#8^<VO^RT.;%9=Y)5V6VG5='K5J2Z\#(Q2P/Y.2"QE^7@0\P
MYQ1.O,^=<(7R-E]_5#;@8M/*K41BK"4PT2NW9QFGOY;3PUQKK#I*LEMY2>!+
M N_M('IRLO9'">"&QS1^P>D )7.+EMS!-D.9> G@2P CO%KRWE):P$(UP)7,
MH,.M=-1.9.E%EQF!<70/3ODNT,810.\NK@>,F'9; $4ZW4C(])0? BZYR"ZD
MR,7=,4#,MQX.$# (4(&IKZM)MH?6-,JPQ '2K<XCFPN,!P@"ZRWOQY=C74:(
MMN):W-T:6@-:4]VESA*:UFEE[?Q3""]]OC;<Z(IMP8HF[$&AK+">F6D2#(J/
M)QDQH6/,(GH=*'='H'Y^]H=4V?7T?Y0Q\9,1"P-"[9[B=,4U7N+(!,7,K08V
M'D1O@3UV$(I$A<?]$/(M%@YFJ &!:1M;O[^BS6WKN(#UW@!V"@S(&&[,L+]3
MJE)9P')/[J)L3K6*;;'+U9:15$QWXC__:/%M%]^C[,D(/B)M[/RAYX&PWJ\V
M,[WI+,=!H3VSAGF@H^7(^<TO$ ;OC]W4A&%8SU7:: &29Q:4DQLSG$K97)V-
MG%<>!^OY;;HH#!C,V358)SAS@SKM9+6$8'0AG7O!(,K:H"-9'A4JFB@M)=&-
M.$_\9:$FZ4;7U7:, <TMQ=UX%FB"MQ&$G$IPO+N4@$*/Q^ZPP[:X>K74[& Z
M.J989I FS;J09*)W&I@'@YNSW_/WL]./F38XI>N(%3#$-^X%I<X5W8%P6\U*
MS\]JFDN#IFT/]"[@:I5&,[6839P"&KF0Z6#++V9W,O'O3N^'L'$KR0PTQKJA
M>MC=SI/3I&,U$[.0$X6\CAARK3?O"$8MX_3[D1/6=[BX%=0[LXL)$]';3/3B
MWQ,3CQ\U@..-[>BT8.GN;+R+JZ#A@Q@H])I<(<>5AZ@S0!J\->G, 15M23[0
M9H\!'\3Y>L 0&?"AW[J'[J-V855!JKF55M1E.-&Z-,U,2TQTV[L_TRY$+MMZ
M*V%_QT,\$(G31&@0$UB4QL>%&KE"=FO=0ANC:G;>(#-H:3HN10X%CYS .S-\
M >$M$ X4H@UZ>0P'FFLX;'*(O:*  EDM+7?Q AHY#\,O$FY-\4=#X=8*S"=U
M C-/\$H*:0!9=<14-BL(*<:*+1*^4R=$L<_65W1"D6:=^L8HSS@ZN>EGD')?
MB.")\)'4"5& PBWST/;*Y[;L]ZX:8"VIMGJH@]292J:QZ'101ZU:?(62F=4F
MDNP^SN*O?[W+BVG\.C5_CZ78>+$>**U)BZ)GL^049K.M,1-)_^XI+(W!PO>S
M]]$UY5R.I1M5BTKW^Q.:1Z=$3XND-_#:1_?T_.:C!?1G@SG;2U=!HL>GN)XD
MY_.@G,#JT3NVZ 7F#X$Y^*6W7=/!4VZM $=6Q;VM85\B+Z_8D%XI7B,1:'A+
M3 QPO!%Y(,A0K.O@1(("5( #Q8(!5AUHJ-YWAQ)[F)O;Z_101M7>>)R2.F0S
MLXZ<UW7L0_:&%(?>,0'0(DQM=^I"&$V [-$P'B"C^0P7YYRC)=$B,V TS(Z<
MPQ8D&N+!^C=;4-']L6D)[+)!Z7M0:.I+5RE+9E.W#B5?A8+#YMN+%B&KI%/J
M@]9@!#J1JSM\R.NW,PO-7T?];WU$+Q=@0M@X$X#05S374 +ERB* 1'=1TC,H
MA8)T6F77J^0"P^*'BZ_2(3:^;PC6X#8P\,J\5%AT:IJL%N&0,:'$;?0?;1R^
M'1B!N@E;C8%E?32OWI=R><V<^X0F[OX:D+JVA*YJ'2GP9CMK?36:CL?%E(:F
M4V.ZJ_+RB.M&5E'<:6>]+^7ZV/3#@0&6#2<VQC*AP6"0UW,C$N<W5 \IDW:Q
MDI7G_1<,O@:#3*@%G>^G2+J2 00+=*;0 '-H6Y)@5C3A[P^G0QC;$*;@;;,#
M:YJ:U*?=J8'2A4I"Z0L3I)V(G UYD *Y2Z1O27>\0][8^"S^P,@ 11])^A@8
M*F#K@6$PL43J:'>UPBF[V1.["<0NPT+<TG"W:/."7F#0JP/16/M''&&:TD3;
M?J:)[H6MSB]2D.ZG#T#)-*IYLN)D*A0I%>79>*8";A,Y*_H E&=4"Q>+7Z;W
M#X-KS39T,R_IIB!!38 F,=E^PIEU17!IL;W8$\3KJ;W]/#!]JDUXMJ6B,H66
MU*E#JKDBR?7B!MW/4_"E=0.#L4M_8$IFY] %WO6_WVYV_3Q0AUE5Z/2;O19*
M\KA@%%NR1(EQ ^H]&KV@&!@4"4/7= ,$";^-H[?&:6).<8MQ8M,7G)YJ\W&#
MWS5=7I +#G)S"RYU_W![D\%\#WASU';4>3\IR5*GD^>24#!F5N36>!\![XPZ
MX8+.+UU_&OPF4+,#M;<=(#I$C2H3LMU-\#R<@WJ)C9W"NR3+2]\%![CQ6/(.
M_&E#$P)WPL0'JJY\ZSZKP)3(^;P*9+M3FJFN#EQ-8M=@_#U*O?1@4(7INSY[
MMFGI[I3-\Q3DMI3M>N\LJ;LQHF;M[MN63#GOY-VP<:H"X^HX6*! LPV7K@Z!
M36@]OLV;/92'EWHS=G^OZ7K2+G$D4^180 N=SHIBDZU(9C/?TOB8RSPG\M=!
M_8@[9T>6WF)/*"_P=O?H \:&5L42A8T$GQ!!/+HBV$_015'M#6@T72[RN>YL
M52!&D?1S'HD@_A+!EPB^*X)8=$50RSKHJI(HH?(BH;=SJ<$"=;1(AKB/1!![
MB>!+!(,704(0O/C"9;, I248*? S4FA 4;+>DT&IWJH;2K:\H19HA37'4RGE
MV+'T1)\@@^_QY[O$\!YG?[00WMK3^D (D]&U@]UB!AW,D4R.DYB<HDXF#1-;
M1C+=\4@&DR\[^!TB&(5. 9\0P0@G9!21[&_FQ1R0%V8_OP&%W'1MQS(:?"5D
M7B(8RX3,#.(2L:ZD;<ZIY-:]?C71;-;^?_:^O#EQ)(GW__<I*GIV9GLB#"-Q
MT][=" S8QA>8P]WN%R^(0BI 1DA8!YC^]*^R2A+B] %N"UR[,6X;I#JR,G^9
ME965N9>6J'#("!'<2X=,^?'<'K;+6EKZ?B7?Z,7+A[OSZEYJ0>&0.5@1Y ?6
M:>^*5#I@[IJ.C?FSZN;$;/9-U\:&"EF\"#'FDG_Z)Z/PHB< CZ-J\>DTU6N6
M,S_.[(DN]V_K-Y$3 '_5PS/VV/_54WZ?<V Y'9/2[UM^SKL*]AW#,;A3M>I:
MKQ^*-6@2XYY@R_O:KMBV2]1F7[-4EC7*6^]&*G;7'I"K<AEWNF8]?SK64O>1
M7>^U4_87_R5S?J>#__<J9O#B!8? !]-@7.X]4GZ"0 B;UW614_&LKWG+JCGI
M/,GUQW)B6.AIQNE9_4=I;U?]Y1/?LZ5/OGWI.>N7B,(FV)S0F4R]GWV++'K1
M=Y>*Q:F7S\](C?0&VE0O9&N:<EV_BMR)UMLYZT5TW=[FV8\<,=%B>;LP+_?5
M;EJ*2U*-6*RXU;NQ_$FU457NG');RMQ?3@;?;WZ,E-P!@>F+Z"I8/AHLGTK$
MT^_/\H-I]C%_,N@4I,8H9?_$I_5V^^2 4/Y%=!4L'PV63Z9_!\J/3[NV["1^
M68.&>E>?G/5SU<KDH%%^!5T%R[\_R[]LW]Z\/.^>ROG:S_)PF%$KFGO5E7#D
M3LSW8=_^X0O^5DOV[N;[\,<D-RVT'OO-JIM,- KCBX-&I-?8G9^ *5;9>H.K
M7^V'BGDWE#*&<WF6.>DVK[N1.T/\*,OL$S#%*FLH'7N<GI?S#;GUZ&IC<Y)H
MX)L?!VVNO\9V.3BF6.OVO4G?5\I%DBM+Q4SE>R]G=CKEF[TU&C[<[;OCI4]Z
M!WKY=UCYY_9##8W2Q33NL*Z3Z0DV_//PPGW9F=9.GJQR0\WEW<MJ89(>'Y"-
M\6J.V7ZCLX;4[W0,F8])R1WR:'HI/>M.=C-O94\[49]T3VXU/,"X,+H^-T;-
MWL7>*K;M=D'[QIFY=SH@E]OM^V:C$#MIUP:7IZ?YTF6^.WBZ>7<;^'6Z0WY_
MLP';?2CG3O\I@]F'=0*64C@:ZMHTR/0:6P/B0':PQ40&IUBS*#.XY&0:_'I.
MYPIW^:=79$STN=:"9RK&R'5L]L"B_@DU>4VP[5K,H7-JD4>7&,IT=7NA)^&B
MB6M9FM'S&NX1)2<YT]9P<'F?KQC?6[4+,QM=!;5V36:13*L797NQ?]EJSL:Q
M83EW.IAU?+!B)!L883],O/<6T]W(U&U3SM9,1=8'":NLI<_=F\>GZ&7\BIA,
M?7(VW@==85EJ.O^0Z+KE1KV>[\9N4S@6W<V,P.NH,_INN#+3F%Y>G)^=G+0:
M]S^'9_6JV2_>1=9C^]D9(?')[.O*I9S-=S%I2X_2SUY*:1=^GI<CRYT1L04$
M7G]TY.P[B>EN9*J;^G7BXHYYV[KL9$8_BMTS6[H6,B78> ,;[X.N2*4<M_TX
MO=&D,VW0<T^,5'(XB.SQDL#KJ#/Z;KCRRCY5VG?IATDKX5S78C^U7Z.K0F31
M]K,SPG/9=YMX0%1<ZT,!(845L<(0,SC"QM0KX[V <ANS\>HZ5</\KNABO.>5
M5NF2R^1EMT7<ZVZ[,[HK]>\C!V;/9.!]*;6V![#-&7G7TWG/MG_/L6>=_#)U
MUR&ORD=^I2F4G$LYH+/M)V4P=>^3Y;-\2J%]/7;NVI$[W'R& Y<(\KZLMIJ4
M!\9D?NUH+M>%LY=SV@_Z0THG%JE$S?O*E=S$5H\X:YC1K>!!Y\S,_FJ=_7J\
MO!CD3M5N8M_@<#7AWI<CWTSR V7:"GQO,%6 ]7G-=.6\0GFOX5/K_#1C-_7*
MI'4I-;,EW)CD^]$KZ_I"/GT)K02>;LV:%]BP;6*<:"94*WA=X=@U;"CI=\/!
MR8^)TOK^/?LT*$Y^=:\>]DUWKZ.+8+D7[&<CLHW!3J=0;%V<3 >/XT:]F6Q<
M_\IV]PT//^TVYOW<+;]O&^,Z5W*LU+^Z:IT]7IW^K.;O\7UAWSCPD+<Q'\5D
M'[&-:5:<AX?8\ <IX[/J0Z-8/FDVGB+G#!3;F,@S[3MO8Y[.)O?C?.ZDWWH\
MP^>_GISS2;&R;Z#Y2;<Q'\6:[["-Z73;U4D'_Q@/8DKSP>@[PTSK=-^\/I]@
M&[,SEGNNUH?/2@4Z+E6C%I$V)@TX<-(<C=CE)T5W5:*>6N80['/788U5NV5L
M&9K1L_T;F2?3U0W,G>YY]V \5GS(79^/.M:T-+BT,IK[=)6JF%>1T]P^9[PC
M?6;'?W,$VB5G1:[:Q4>R(;LN",W0-6;MA+*EEMIVK%U.R&X+:ZTJ78]?=\I]
MY-P\OY4I-Y!+L.@[L6C-(EUB641EQ/=X\VS\5&E<F^W6X"PMXU[^YMKHMB*G
MNW\K;ZZBTT$SY6)R]H]3W_CJRKGJ]MU3*7-?&E[>%>MU-;HQCP>DOJ-8(R J
MZCOUTY1:Y.?]SQ9I&=/FW4WL[ON/S\V4'Z&^/SN+KE3?N7$[^<,R[Y.MQT+Z
M]-Y\&M>TZ&V]#U=]1X$I5U7:7.__J5H];)C&UDZ?:KTQZ55/RV/)/?E53;MF
MO781O0MISSA]YHBQ[YZ>R-N5OX<QK<=!Z:Y<+(TD]ZST:'>KIIVJ[9M3_' 9
M,XJ(^5QBH5=DG:T85"5AO4FL(7SNAXGW:EUEH%O7$CGI==56IF5U3B('EL^F
M_MF6#@>-=JO4<%-S="IX%4/5QIKJ8CV4K(H8FFG=4>&C!HO-ENU4,["A$+A&
MU]=(E_])B5CM=NECEL=+%S_4=M[Z5<Q+Q9JD]1H73=M2(^=-!'Q;.7L_B]0;
MI_^I6"C87DRPI095ZGB1/&)U36L(!&-V;HO*FW\EM5E/&5<W-\7IX.SN!-_=
M#=0[DH@LVLQ-SJ].MWYVGY(!*H9B#BDI:"\PN2M3X>%EX?WA&3&(167,4 OJ
M4#,TFY6W&Y/R$^S2_1QZ#]_+%V?)Q_NN5!TT?OV\&3Y]_Z5&SCKR>6/#O&<;
MOA=-_*#99I6A_1ZJI^;D4W4L/31;U>M$.W/1TJJ7T0S2VRO5$P63>)UG:W?(
M<SOLUK631V(,M/P3/IL\:-_'F<C9+7N$/%%@FW4**R <)(-PIN#6,PVRF%*C
MH*J:%^^%-;5B%/%(<[#N,4POA[7A-2G5RXESQ7%N6@_E="=R:#-SB6^8\8QE
M-D[Y4RFI7;)*_REU>S6ZOKUN#;\K%Q?E9!??32-K\4::5:* *HNLTM5UQ;W*
MJK^DL\9]\5&9/LK]7^^.!/M%.4JJ$.UF?P4"9-O$*2B4XVPMT.#<\=JQR1A#
M^*VN$\6AQE+-,ND0G"E+/>WO*N7$?>>Q66KURIJ5?WJPK'L]Z496QE9-U_>M
MOFB^[RA@LAQ+O)1-PH_^#C:AIJ_FD"MJQ%#$<;#1TSHZ8<2T3Z:\FCSD)Y_#
MYE6D])BF;-AXV+]JE,KX^]6H&[O!W5(]LN>3KYC\#*;7S_Z@6&CIMFRC]D.S
M>Y>-\U:L<3K*ZV>GZ40U"J#\6RYNWF=JC>'CL)>6OC]6KE/.4\](ER*6/?X=
MXKVEU6:_VFE43^5*6RMK=U>M_G6A9]Q%(I?^@A4L2Q]M!3^[8?+*/S"WYWR(
M$NV3V(6582##"ZFG7=6-U*!8;]5KG?MQ;A+="..U<PT%&*V?[$%ODM[.'J&J
M-1Y3)#,_KY(_TXT[::JVNW?=IWL[EXVL[GT!4RQ-4;#"'"NH1*/[9-]9.]$5
MJW#1S-^V2"T7>S0'UX4?U]%WGRPO/YW6MV!:![7DW*K(M),27^*+Y+#N5'^,
M:BU<K%UFQN.*3-[?6GZM225E8DEI5R95LIV"N:?:@^1CM6E1([I5+9Q>]V,Q
M?62G(S;W%)3)DE*[-*A6RWHIUKB5S0<[UR*Q7O/7=[G>3[V_/H^JR+AT5\;(
M!L? @'^&BBVUC?U8D[8A-4L_FIF;T6!JGDTN^K5I[%=JQCM#GO>2[_Z#M_S.
M_&_]OZ&W9WH>6:;J*O2#F]ORV=GI]_2@<?GK\MX:/DPGM=O5_7KO;-%KN55O
M#W_=#A\O'G^6I._5@IGM6!?C].7R3#7;3"7D[#?ZRC;39*O2OAM:A<D)+M4'
MPUCVZC)]J\6^U]?-DKVR19^*:SOFD*JO'Q<EY;K?*IE2]=;X6?AUVY3NUZVI
M_](6_7:QHNF4[=LE63=M4HH1*=.]2B>N[G))<]V:^B]MT6^I?6-TZIANIT\'
MWP>5PE6]E9'[\F1UAZ4M>KIN#Z8]^<F,30J#Z5B_2O1)[T36UO1TO45/#!=U
MG8GFSYM)JE ZE;.M:>RJ?M:ME9LW]VN6,?3>%KW;$"INM[/ER?WUG:HD)&UZ
MDAW??G]XS%_UECOFT,7>V:+35J/4OG_(YXJM4W,ZN)RVI^7S!E%^R,N<X\LF
M?>7U'9;@.)NP[KQYGEQ<U"N7Z;0MX5_GR8M;=YBL5F<$9N??)-S8C4LE!3NF
M]<:!+;T/'Y:(80XU8U6S+Z7P7!/_S(_^%9A%FVUG;Z_'M:&6Z;5P.V]<-I*3
M:JFP@M&Y[J&_;L-NW.!L#]L7S43O9^N^/!VGIV?7/U+)9&8-;GCO;-'K?;N;
MO>]KB=[Y2?FRFRZ=MHP?EII;(UCW6_3$?.+M[.6]DT])5;J7G!+Y9R9[DGKL
MK.F-O;&-VN%!I>WKGY.F\G#[Z PR>B)KC;N)7+*^!JZ\=[8!+;K]:%=C=2=;
M>BBJ@T9M8)YFI^EF_V)-E_#"YO[^T9Z^4:8W74LA-O^S3[#*3"W*V?_[#_V!
M;&>J4XMMB)]B$TUU^M]D2?KS>(1553-Z,9UTG6^I>"H[^\@"\OJ?F?QT@W:C
ML\B#XR\+K5H]S8@YYNA;-IX8.<=4P&)]PEI(2'$Y33\*]4I?'OFO=JD-%NOB
MH:9/O_V[23=L-KHA$U2G4S?^?<0_H?_:5.%W_WW,GK:U7X0V!-VP?K_17Q'\
ME^'_0OL8]2W2_>^7/YK5(OW3'F%CKD?V^S<#@O]TWNJ$#]?[Z,O_FKBC$V1V
M41&L1,.AH *M4)IB^M]H!6T5G6#K6\=T^L>+9%ZB7XA Z7@VS0>]&Z+X"T@'
M0JV5;W+H(U@@^+MC6I0]@B?B0#S;U#45_2&Q__E/P O)%5_/"'^\0%U5LT<Z
MGE(EJVL&B75TNK\^!BL[IAFP!V#O>*3)\=<]NC[;RK-OA0A!GQEKMM9A=M.W
MOJ;2ONE;?_V12TC)XV I1[LB.ILAUK6>\4TA<-MB:<[K239K*A$\%ZQ-XN4S
MP0QNVHETGF!,2#N9S=%M;RZ?:G<4.=ONYA1%[N:R&:)DOG V_IBY=U:L%Q7=
M.3'LF+I*GVW=5)KE$FHT"\URXS__=#YRR5XQ[$:YV*I7FI5R Q5N2JC\HWA>
MN#DKHV+U^KK2:%2J-Y&:R_S@OV.[3\'",8TC5(H7XR@AI5/Y8, AP'OKD%-Q
M:8G1I7FM(<?E/!FN ,YY-1(:3 <K@YYENH8:4TS=M+[Y6.6W"#BXU!P G!3/
MT*YXPXETG+;,T8_J H,$A$/8=4P&/ SW^<_M5R^SX]4[K=:O__I#SDC';,6H
M+4!GP6QI34&>PZ,.FO&-OB%D8/#\@+.T9"KLY@X$U7]AV'.#+:N=RF0:60=/
M?TK#T[21=G[H=YW^Y)EARU+LDK/8W(@%R[T#RX6-!&;X)5+QM,^&'M/%O,_F
M&6^>F]C5">>_7S3ZFDT4NI2FWJ$;:]/IF$]?WHG9"H;A8KU.1J;EA)AN4HZ5
M'MQ8;EH>5HS4&2[T6^E?O56*UJ=8@_1,@EH5U)@.*1.&*91GL_WKCWPVE9EI
MV 7&7*W!_5=! %_RTV]]A7+)K]8MA9N;5N$*U<NU:KV):JUZHU6X::)F%5&M
MTZ2JA3<L)Y%I(3G]5?V;?U ]1<WS,@JIID M%8I-1+^6\\G4CO72V]CL/8RC
MZ.G94[H^3I^@KF8K6.>+-*4["$1H:RI: =\A@?NFPCD6;;2OXBF\18SWDK@:
M\[66N2L])'*-K'UY7SL;GTKNB3R>5GY]/T_V;S>AQ-R@=S_@HFM9[)(%T/.>
MTF1YS,[%Q?=F;!2[D,C=8/0K)1MF?]1[9J%*1.'GB7"PL$)%;7KW",'@UVJV
MP]E\;#V3W([%JUK_8!L[DE3>;^7?M+#!S:DE \ 9WE]F3VL_[@>9ICK$[MFP
M=\[.4[8T %+K#( 7:?=-#-JL%VX:%=#8+U'FU?I&9<X__@T:/<PG*]GDF<T)
M&W=HZK5RO5(MH=-Z]?KE5M-[_*1$_]VDBBY"[!*((9Q*LR$,!YUJ.D%4@*@R
M_?:;-JEE%F4 '?-^0Y!!+A(WDGZC]R6<--SAJ9*XKR5OGYF-),FQ9#XGK38%
MQ&XU$@Z2]V>H.NFQ:YB& QEU0DRE2KW!J)XV3LM3O?E4MDJIFG3R'%/]J%X7
M4+%:IUJ@T R\@^]A+^[:ROI:?L**P\@#9R4SLB!L(WM$%(CY49%F(,VQD=+'
M%NWO;^%,?#_/3A3,5.\D(MU5DZJ22K25CB2W4^ENKIW+=++M="J=2*4R<C*O
MI+R3"/Y&4VG+5NK[CZ+;J4C3GU*A6W,J,5PH4&&5%I_\<9VHIDRW][UU-KT;
MG-X;S=*U<@N"O?ADL]23GZ;7B<=R3,W*1M8B>?FVT$XNMRF?VTZ7-!Z5\C!U
MV3]3;U*U8G;23BT_F:\,:T\D<](M5Q6CGG@Z(3_4ZUOZI-^[P\X/?7[BQVD*
M%&T:V>2;_\LBT'GL!<>'"C]V]%>!V>J,:[P/^/DL^V3.G@\;^/R9T(F;Q^F.
M1?]3_<&-B<7*7WA<P]?;>R--7PCQB]>PSSOOQ;&OV7C8$-$[LLPQ8-#NG0H<
M[N&:OC7RJFVQ&&*65,V:%DW50W_*$V:F451=^<$8N)?G_<&T?UF^J1?:$N.>
MEWOX2A1/)ABB1=9H@7\<=7_7[SV6IXF?*EZ *<^?$+;UZ,(TG*ODXZ_42)'.
MBJ6Q?NEH5\IICRZ,_*J%22=B"3F=DC*9S4OS#Y.OJ,A8_@5+M%'%,WX';[+I
M](F%'EQ+LU5- 3H#'=#&MZE1H(6%A[4#60>U7^SOF2T0':[>FF*5>#W>B*/R
M<*2;4TJR>>9$-V9\8=K1XI@72?5ZN^&%1D)TUGN+^:9?.=\]7.CWA^^"JEK$
MMKU_KC2#R*$=56%0T',YMR"7W7I"25>?QK&3T?*.:A-P)Q*2A&KFA.@Z:C@6
M(<X+'/F;&CQ:=3SS>TB3")%&TAHI[6F0Z;0:_8O>]'%\TKVH+!]G;)I)P]4H
MN"=E:5N*L/<W'8HB7QA^&]6*]->JU30G1HAF%>5T6+_L31KELXNFT7V\&/YJ
MMEY'LS(=^72LZ?IJ$VU+-OH0 ]>C&%/U5:M&>Z-:.^S7(*7N(*8,Y)NRIJ6N
M2OW>9>LF_3JR%2G(T,D9&A:6[2O7I6;"E86?VFANOW'?NY2<S$7B=G!V6QZU
M)B>XW!I/Z+[V=69M/I6!BUJ?R*+UJ H>JY%%&5T;81V1)Z*PC/_T8TC'9Q^D
M:4IY" $3K3) _V$^B]T'9^_$7(S"P<8F*9JY/F'P<O;81@[1R:AO&@09;#]Z
M!%LAW06&0'1_CREBJ.0;^OKNM@0HP@+M<(8>#-,O;BOY[W+W853.]&]O8X_U
M1*<GO\ZR2F]M./S]FPZ"(+6B7H/56#H(ZB4>&P7IZ>=EZ_O@KI)Q=/?<=%YI
M84JI6)9:F>)4Z+=XNA=@\,&UZ?9ZNEF69X5<D,5DE5A$12/7LETXKW!,1)^
M:7IG[HFO'8\WJ9J 0*V"XGQ#8?^VDLWE,$ZDV_EN)M5.97&JG>N0;CN3P/EN
M0NHH4C>WZ#>^;F=OSDBOV6E]_]$M7#JCZNVOLY7^[<?AR?#,THJ.I)GG)\:H
MIG2G#CR96'PR<=FZ?QST1MW!Y:_>(-T;/K13!)[TO>O1]D7[ PMQW)>7JMM4
M+I[/K]>X_[RTG<0.VI#3$1E(<G,CKS3F/!(_?V<HPF8/R]/L"S/_EV"ESW]3
M(!7(6VR]Q":J@"E K1=K)C>1I$Q(^[YR]L#N^\T4%H;Q< KP(+"O;S/Z/S<C
M)#=.?P\8 4(XUH$#>5+Z4,W(^]XS#B9]S7]@9DN\UJ5/C:B7:;'HNS/>(7]8
MR'3W++>IG.@P( \<(#'SNGH62V1_EG'C7KV]S3>>\I>%=H(94YM\D7P4B WC
M"%'A1&.LNP3]2XI+4C:-UEWZ>%XR9HNZ00G_'I[W)?H58]YDPGQV+O34!5<4
M 0N.JY.KNVK2>AI4R:33[-:L2JQW2UDP\0P+0LS79V6S309J-*)* /;?XF__
M/4!8]I32+/:0<N*H?_K0*J:>$N5A[RQOMJ:CLTMU0CDQ]0PG-NG>]@;;*GY$
M9[K9P3JZQM8 SLB>X4ZAXG:50?4ERN[)/A_EQT^W%:G1J:BFUGV<%$YOO2BV
M3>N;BV<2Z3\1'Q8JH*([=+D?!]6(-2*041H%HUVM%-/1AZHM3O'SNXI:^'R:
M=#MF7ZU3B5P<MYJ]5J,\G%[\U(JC7C,U $Y_B4ZM"4Y]W5R%,MX59*]4R_I(
M4[Y?2R>3@79^8SXF3S)R78%#6J&6?P]2O2A=\4L4<+*JWYP_WCT-R]7Q:?NI
M%$N9SD/!"P[?M)(EPDY0L#5%K,"\C;Z"@P%99$3_@-! HX?D?V1)DIP^TH ^
MQ';@T@1&+*$='%3GXLGL3(N?O$V+_RW 4:CQ;81CM<)N6,-LP7VZ+I2+PZKQ
M,$D7[T@,KDV\1&%7!4\*A?W>8+Y2-3?,S)UKZE:QY5X]M"KNE=4C*@#Z^ZKF
MW8;9O/88/)JWCG_/@7YOU8'^QI,!TR#OET9BC]=KEU/A,@4U=!6X:-*9(J5/
ME &B[PZ0QI<J=+%4LZE9!*'<L8%A3FA[!-MTF53ZA>U"D!6VD4JZFL'OG=9=
M_^0W):61M_(AUJ%,$.??W_MI%-;FEGQKZH@7A46''P(4C6E/,;Z&W\[9/VVW
M*4TF,:MS,A@F2^V'%*[KE^/)2L*^403Y7]#.QMRH-S.=_?P$=TK33'39^%-+
MI&$Z%(0?70T@F")O%S(]6"Q)B[T!DA>3E,V ^4-E<GV7JP4S<7-;.<&GW4JK
M^*!9[J_R1:(P$H(9$6[^+((YZ1-V07->.K^AK[(G77VJ&4$P581U/9#.L-AV
MB/< ;?E%DAI2I+Z)#=(+>A:2#R&5?FOTV*,CBRB$Q3[+"=X&2P5GHZ^T9;J#
M0+:K])'=-R%%!.(5/NB+V%F$FPFVE[&&O>Q-Z6]J Q@J^IH(S;M#-R/TH<X#
MG16\Q)ZG;\)XO,9@PV&SD;#A8MM!>8FWH.*I'7\M*@SZUQ7U9W]Z*0W=9'U\
MES'/+.DC4.$><B=_-"P\W^5-]9V@/G)B_+D1"8$\4E$<:HY#)9A 45O+-,#7
MH4\1&1-KBJ#:K845YMXL80?SU%$+4#5K(VQA+!G\M&?F*?6QK!%KHJ_P:_8X
MD4S$@VV!QA+4C"!!S6_!+3[\ (F(_?>K(2:AG-Y=#GOM^T&C\C.;41-FXR+7
M$Q C(&8/_3FO Q'F!M#I^P1A1:$@8F%  A D\ $8*S^E^Q0CMO(+F_(Q_=4S
M(4#:%7-(Z3$] L.'-D?- QAK#_4L<^+T_:_CU 0B;&S,Y\#NR;"+A4#5A'2\
M;H3L:_G8?^S9!]:/SW\03![OX35C]9^<\XK(B4XLX?M%PC9<_-"8VKNU@SM$
M3:7E9#LEDP3](67:.:+@=K:;34OI3#JIY-7%&S:EOC,:)L]'U0$N:K&?1L>>
MW&7]S#[S=W$*Q?%3K)/]V4K4I(O[TLF/L_M<P4LU,_?D\-YJ6-7,N34@E]ED
MIM3,NPT'GDPN/FE6C&;"T,CM8-IZ/#$DK3V48[?TR:7L665\<_ECXI#D8/J]
MI]^>3WZJ2F9E3JS$T+VIG^HWW\N9PO?<CX?A35%7X,[04N]Z][[;,NXGE4'U
MH?5@34N/K5X3(AS])Z-]N^@%4>Q]S2$QRB<*Z+B)A8-#I41<>O_PRCG&OUH-
M%Z\(R5\[F7@Z^7OG\@KMNE*?OO0\+"W%9?G]C\0^Z+0O(<4SF=^[<(5W8+]4
M//.^1^D+%@<#A'?@QY=?GOLX5%G!KL^<U[)<$VRIP0#KF=8[I.>?9>*UBEXG
MP4ELNO.H_R3ELEU.-'^=#6[KRFDGY=^*W636WZRRY]X>4' (()H1(!H%$&VL
M,]CW 4P7C?95:/J!]0 XE# *G[BV9A#;#J!$Z]1^NM*%:4N-U&DWE[Y5\M7<
MQ+L,O[M#CNTSY41*/[RS)'XXKGXD^/PF:'VM\?,^*_Q1<%M>[?(08+LCL/7I
M>\;(6^34#4#W+FV>%/,7Z;KTO=Z<CF)UY?RFWEMW]VQ'%5@^5?:J-SE4NQL<
MEY",ZH7Q'7!>PTYIJ($-@1Z.B5R;.SUI][Q<F1.4YO&/0.!H!/K2I]#Y1*-=
MTVZ106=K@EE$*<<,=@,;BH9U<'I 3FUXV/:J9=L(\AYJZL:PON17/'\F/>?$
M1-ON^J+B 'V!T(AC13^\P;.Z$>5&<(MCQR&01A.XD_(/E**@<\$]=N0?I&O#
MMDT-2?C(=X>3;I>P,TC#RQ8(;[+[&09E6(!9R]21215*B(]G!K]+YVSYW(I2
M4NIKY^\@ A%;'4R;C56?=#)E,1-?Y31JQ1M0<C>;R$#ZJ;]AXO#T7'QK1Z<J
M("0M7<T:\@/'$>T;PT-4P%@TI,I&C%U5<[QQQ5\5D_B!:J>B=*T"#-RT"K/E
M.]5Q+Y2Y[=RUTP_I7Y-^.9&0.V=&97B;--^SZE?T).7PA+Z+[%E4$=Q^VAS=
MC5BF-C0+'5RKV<*X,9-7V[]L8/MMA$\96<)&'DG,7_,BAKHZ"R2B'RFF97DC
M,;G"M2R((3)!',>:Z=KZU)?&5;W&HR!M?H6]4\UH.$.G#%,H!A-;D+KI]9WQ
MH#0'5V4\Z=_>]*]:O8>6D+JH6X.;A0)L,\;_)C7M. O/.-N7PY"L,(43A+.
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ME='55?$HJ$@26U61A(G%@0#R3S(67NC]062V7"N,_%"=G4LR9/$ %*D-VLX
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M@!F=$(B,0C4Z?3,.AHW+NV"C8]J-:6<"-@.E%N4[ND*,[IP;PKBDNLP.\!;
M4_N:T2?,4O%,QXX&,MTW3%8E.X OSUYA,_68EJX?,7J4[JK_[H+8&-2^#F"!
M97"@V.3R%0=_'Z%&1&%H A]#N6T08J-G?X.FX-2&(D4',)V1A^?=9\2!(3!\
M< EC0Q\Y$=@*U/0E("+3.<L+'NM2\8(*WO0KI@&^VG\? RH!K6D_KN';219A
MY(%N!H2V0V7 G-+9'M.)^Y8FY02KHSF>K )=V Q4S1ZY#N&V^#PHL7XX @9+
MA;!* 8VN$J$KJ#"[WZ7=0,\K,"IDL3%F757^EC,6A3E*B0X!GO/6!*QL9BJ&
MU\\S+MG0+,(P@!T@.)@C6)>"E,V!@)L&<RO,<=UG54K"P-H\_L\_VO_0YFV/
M1WGO54^Y=5T=&(5M\F#P% ',=1/UN7&94L=(XR(9*N*^BJ"JR;KWD=MC3A.X
M?0221TTGKQFZCC%8QVF(]QFW^3/W6(<: RY$JH+N!FIS+F>6]_%,%,!&\D5,
MX[8-9Q^%>>5\9@$FI1\R&QO05@\TV8JY&*8!;Q-'XV87I4W'-@&\&9-[4QU
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M'-I7A]'/P)IB\YAZU2@7!(RFRMYJ:_YC$GUU?OC4ZM.^-;X&.PD_<S:+05O
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M*W>0V;IEZ40\C3J"@<5_-05H"Z8W>++ 2VBT8JP(7\+KE6X>]DJ"9XK="M+
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MAK95HB&6R-HP#@+F&K@T*/53'G"ML=F%NN7#Y;)8<(OF:CI=4=PC0O-Q5,
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M$N'XX]6Z#;B_A*OAQ!8K4=:P2)1P>0U_M:.D%7YPV=6\9_#)NC:Q8;,,^S&
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MW[K@6T4RY^O$V5'V+7+:IUQ)L6KZPT=T'+JU>N D?KZJ01::./@E?OBG/,O
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M2]$(^,.:RYQM[@JYI02E(@^%*_'5Z>SP.5I7A88([_(6_.+1\\-C^T6M?]K
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MK30@P2!X!9XG\!<_FG)WMC4/Q5()SC-+&YO(<\;\);ZJ$@7Q<5=5"HG0.TK
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MP&?*A2T-UP,-MK"U[$ AGDY^W=8O0P<LW,<(<_LCXS445:^WUU3 WC4A=]F
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M&$%XZ=87]%H/6@ 9K:HV^-4XO*%-Y<G?[Y[>MT'QHY2"#S!V'QIKQL*M''4
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M;?X>@2-BBF7WFB>'91<V.:I*9 8/\GH::1),"Q&69:YG1V_B18[6[?Y10PL
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MGDC0%XW0@]'[.(()29/QA019Q;XT_=9#<4H,/S=(@=D :(@8)8$&;8,9L(3
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M]X$!XG.C4ZLJ_&BS&WZ$N@]J?0@-[-='>SZ1<"XIUD3-D+WCY5?)_T(T3 1
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M<[ ?I-/XK?'1<HVG,BR;3$OOT1FR0,%341.8Z)#V(4J@J%9*\F"4]\EHR$V
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M9QND)1_'F=TCVSX6=[K3VYE.!A>3WL[DHN=-^A>NYT\O_.Z.WV^)?L<;%K7
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MT^QV^QW+N<G=0S7B%R9GT*O2K\O]A_#5?$&.TE:ST^\,K $(T)&RG.$ND$[
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MI*B$?,KT"G<\PC; 4NFQ#[_LU)/[5<Y=V<P8R_W8V:'KGWVQ./3&,:P<#MV
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M?5F=2!Y/C4@^J0Y+/"#.43ARR9 ,/^(_NNB9,_G?9>>*K(UYU>=\5?CL%L6
MU=\)IJE2"5!/B"]89"**O%=)_VZ)P;8M%U<053+WI2BQCN9L3D[TR23=OW*=
M@U.[DFL3:S*6M)@3;-F,,BV6,42&U0W(FYK)HJYBSH!Z9<E'+<N4Z%K1*-K!
MU-;Y 9KWI&D^%\L.K;MVDK.5CT'A(JVBHZH/*20E)"2[?8TPBZ'"STI<0NH#
MRX])B4DL2RVWJ .K+:'\#9@3%PG+ON@J.,?**/:PB9CQ4$&T+F1")HAXQD&B
M6!B#T^78R*; ,:12Q%B"'&ZV7N2F25R[TK.*45>4$G R>(3)X+T'Y((_8U4
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M'2#@RV4 "GS==R8WSJMVLZ4;--S6AD&#?,,8"Q?AX*^#;';7XQW'SP4BOL^
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M0<>$#B@(3(\@LAY^8S99=!QI.M(4JF)UD7. .<R8$BGEB(/KLS;V3.52;8Q
M.?JF:_%]=$5PF1*5)L $%\PH%"F:)D$Z4Z5/<ZPC@?_2SSY<#+Q$@=I@S]Y@
M&UE;):N]OHO'RYPU9O33 J.?OGG#T"J[G/&F3WKI\^E-"KH0E=S[ LMCBGEM
M",40<^$/EB4QV-L20Z)/4]&!Q0ID$4R@@$L12+1BF;+@#RL,0/ ;9-Q5B9M
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M\QZ]0QA$W9921*:PP;'KE_0C.J0L2.$HQU1 G!.>RMO0_4J7(O7H!/EN($$
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M"U5=G9\UC.M O/;=#^[ #[D!(U):TU'@X=FWXC*\,@48@S$_  -&!OASLN)
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M*V)_R*CN=.8)ITW^%LTQC(Q&"!/AB\'H*]8^2HMLOH9QK>3#FA6@J^B.T#_
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M=FIS!FP=9AD))&%#5!8O;'/>J-(T8* [-B].Y\@*SK)BUYKR8_.VJQ%,HM;
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M\99(&5(K[JPPT[]!_ 6&'X!D VD7,_1S0 !.&&A"?,I1SJ5?@2QEH$#'XM-
M[L= #8CZ<>8!NH,0?N4?H47MCEUX"][F80@?AGE=BN\VC'-0[ZD?[+,IO,1_
M\&$BM' P'H/F!ID*CCJ'W;E(&"#<9PRUD3M#D>U*N8Y:F/GW0@%WWT;@2JDI
MK]@ML%5D7,)L9F[E&%,#$R 12PGG&!([D%;!%9>&1,NR7[,WJ:*X0,GD@[/P
M%<#B)SCU2)"KW>]US%3/1+ 5# NX,FJ 2F&^!3Z=><$]YU'#N$RW@I[&%'SZ
M*?O.%Q87X8X%!,$<PL\]ZV>U%C<WY@)H7^<T(9O-/%#=^([G3H'VWC2,ZSG$
M<%* "SA!L( H@+=&+AA'',<QY6JF+ 83#'3@XK(X8DZ "Q6?B9@8LFB"Z(>/
M2E_"0O/1C0: S_@'\Q/4O.#AMLP\]F"FT<;I-HZI?#?8:EM"1BYL#MB,*(2C
M+8F1>0#\3^MG$CI>!'.B.&3(R4>8;8= <D#88X0'=RS7X<>NGP1)E-F9R#DL
M/SU2+PJCU!(1&D8&#Z3%L':<AE&@?%"<CWWBEEC_0<%U+NA4L,7I#5@XTA_&
M#9Y-F'^3">DP\(!90$@P'P!P"M"%+Z=2=)<GY];MUEVCBUQP]=TAVI5WW#=^
M2V[ "3'6;?UOQZY.FP%. K+QE9"Z<\$<QH@F\'L DEHL'42/$%?N%##F\K%Q
MGLG6+U*VFL8=R"-\1\2W4%[X2C[)$=+-RPD^A8T40J^1<97C)!@K@Y-R?=X8
MLR2,$N0 &/9NX@)7PD_NV*(P#_F0XX(8*AT?.1FCJ2! /66=_V0[;;S5JC@K
M!H#P.'LW\(%GYA*@+20 PB$WBI Z:%])H88+7UPQN)+!K3L"$(P#:=%+-P"&
M FPD0_F2BL^*^%%D(G#G?B1(IVD0@O#DH",]Y?6M"KLY_)10V@!K&!L4B(\K
MPEV#U(N9BD!N@?,-N%Y&66L590WC=Z'Z%(AR;^37OJR/'T=AN[LU"CM6AL+5
MP=9CLK45)AVU!O3.M\&>1JR^@)1F'BGN^&&:FL ^!QSD&G X^ :"B)"XD*02
M+PNHY D('C'#A[UM(J-9Z")L@XRV9;1:ZG+ 2L[X0"PJ>TY&9'!BL-8CH3N&
M'G.G@ N4"D'B*8M3+'<=>469BE%&'Z!XBN/DJ4UI4FD'@5\> &26%_HR*I\O
M0UF_4;H>- @5_%)PXRH&]P80.#)KD,1@(R41-R4&@""R5W(3(^G>! 'R/8L"
M85 C($><Q<*\ @N-29?^&<!F:0@[.C%>NV\,NV$9L:#G):GY%KZ&[]$N S-%
M6/NP_,2?,7>DF#;E,4D1:,V('^&OD!&/0A;#AR!,%X0S*.9?'""UIW)@PY%N
MW^#^(G<$G#1*40N?)IQY (HA!F# =1?#2./8=E2<_JV0-:]A!/YCR&?Q"H[6
M0C/[N3K_ _,V%?[2+(N$0P03X:BPDI]L(50*M=9>*BU^"^Z01(5P$-&I'"TN
M4"'N/D^%*W0W'((&-T9)F!YW@.WK!NCVP=0B+(8Q<06Q 1^C#$6P<WEH.H>F
MM'F9,91VHU1CPFY4 DAY  O\)V4"GL5PAG.NY48I!](CF57>E$3N[(3(%T?=
M+6&#E$H)&XF:#8? VJ&0Y^A7X.;1![6D]LP?7>,*C^0)-9<A:WGV94K[06PM
MB.*C/)F & F';I0A'(4)@&C! H*78FFBX"H[5HKKUV+K4O#.8Z@H;Q6N@Q#0
MB![TE/UPI\E4 .<-[LO=N+%,GL#CG$#)[Q.6B@H!L:^VF^YS?CP_C-&@R+VY
ML-(T!APE8*HN8$S*$L1Y+23$PW[0]006$1GODM"OA"/TQ3=.DQOXI=%%_6YW
M%X,*R][-6L/Z89='@,)4/@P:Y\B\P$SPDG>?#0@$=@I"PC-:PLQPQ R?@97%
MF;ZT/9R\[;%N4E,=>BU([6 \7\8:(P^LA_R&ERR-4<)3ZR#3>< !@!EQ%);3
M?D+8P'3XZ@-Z081Z1)!E* 3IW +)61_A>NLCVP:LTO.$4 ?9%WL OCB0LIKE
MI/B,R1UFWD%WK8.72O&'?BE%^!H9\E39C3.EHRNYN)WJR(L=*5>5*@ ]S3']
MB(\DY8X3 ,TPB.)<:$AB(E,,249$RY%///:8I8H$PW-13HOX&,=:-I#62S'\
M4>[U]5(-*4'D2S6,RYRS+RS1M<3-8&<*>#*2E-G0\+,Y<8A#-+E'3*5:,G(Q
MUNFY HZ9"@,PC5V4%R[SA(Z#L3$*+>*BL? 7C4H>=+7IH(L.NLH\Z%JCGA?.
MOD3$)9(G%<BVP3BOXX1RE.S^H&#(*081FN%X%*1B5;GCF=0%2-,K4$K-DA"V
M+P\&Q 1Y*S<G*5&.KWUIOHY(IZC/$ZRT!^/QFIIM<XQCD(IY4;!DJJ7>HE*"
MN*NY?E^RTA9\2&FGJ4B@U&1K@C:O07=Y+D^D6P($M)(6M(E:A<9>^A*-B'F(
M[2&+3!R0C0WA&:&-)4-#JP:6*PX-T<22GAH&,.;>=A:$PR'0_4'+-H/). C7
MP@\>JZ%L1][K6N^@SW_2,*[6VG<;HDNQR.!:,<.6=+WK#[UDQ)6]5T=7UM76
ME4WC<P^8RG:C_6/9Q!8(S+YX8JQC?P:NW7N">3OWY1\S;O' ?,Y=0E8I&L98
MNE)3 Q[#UB5;"7XZBMD/I:CDTTQ5FFO.QC)66;"$T?Q5H@ D8S)$[(/*0Q\#
MEH> 5/).)&G(J'XD,]5AO0RYF@.$@ZD[S+(UE#>TDFAAO)9B8,B\8>)EKB?:
M[+ 3'IEJTU+<W".XD+'4=W@>G^3V\48G73HW2+92*N8<JROOIZ8'L,$- #0$
M\-QG:24LDG(!(Z<A]^4=#X25$ACS4*4(1,OPI"(98\J!JT*8&^S#&_@G\Z2'
M(.RD?8>8E>22UR^NHF!,/$F P&^%J E3UA+3H9L-NE%%PZ6"B&';D4J757ZJ
MCTD+7FI3X;+E=*Z@2P4,?/>/)'2CD;N0:[O,JD%XPWSWOW/)H[8J,V0\4&QB
M!9C; NN163(C-TJ-V93X4'\G Y2.Z-UAQ,7+ L<LBG@<+2U 23D%5X2^8J#\
M@G#801(!VB+A4@Y2C9&!6.23A/)H<-,.<U+[-HAE#!IP#^OGDGG3'88BQ ';
M&\,?XF@N\$8BN4EDFL O/;Z $&&UI'=-A%F/(\Q?B*1PG6^2S5"^X('I_3Q+
M.IUE<?U*#XELK;'TIWF,"4) :".V!J4BZCR?"M0.'A ,0+1,T[.!3 JBD!D"
MHHS@#MC#3/EE!#;\$.-E(D$H_<L46FH.LJ5UAGP&,@V)%V81B(B!!--,'V'5
M!V 1I["?!7<"S^I'*Y98AC<\J3QZ$'EO<9T8DDZY<WYV(>,-TSR9XJ-W >AH
M<_EX59+2F-\)^8-6&A@+?X#A$,]SCP4L@E 2#+!@,AW(V)QZOG])FJ_ .!;_
M>;:CLM#=>Q_QY#3"@-$"7.W3E,=3DFOD"?F%C]:=>/;\K!H!G75FP;-29MJR
MK:?Y:+Z,M2Z<:JH\C9]L6PR3^1CBU](:6GB4QL13/P$84-F4*C]!XE[Z.P"2
MU!]:.N3&47).%.HHZ3&M9!PTTX/\E720M5#>37J/=N;-P]$5B8/])S7(>?7*
M:2@D.^%Y!\>4TU"0UJE\FH-DC *S', ]?Y#L%[_7DM1[E.50Z2R'2AZQ=>B(
MC8[8GG?$Q@QW],NK;Z?G%U]^_\BB^"O*"K#Z+X$*WB$1B&\ZK5=RRF(=',5$
MO2?=1GNOG,J%B\L%W]-8L\"7&@ JU2<),Z]XZ399&(!1/S6$3:G<#/2[XC@$
M>:B2?<35-LP*2&]@Y5QO\+: 5,0*4S/ %1Y<%$?9!;4-/Y4:1L7+\,5\Z*5A
MX*H7KI'#'U,WCCDWE8V P8*YY9*^[#(3;#OF)2"Q(S'NAKT'X&G?"]&?]PC=
M*!T=?)]P(:KS( PCO.F4QCB8CU$9& >GO^2@W_Z.\?<BG9\UU/(8'3R=PHU+
M :2J$/JI#,1OI@Q!T?EH08JP;,,AOW5A(X#4(48XY\ZL\%[G.7*K5"GOX0UY
M*/A%&K,8_LV"M_)#GAODDY2LY%]K^5/ET'$\UAB/,;Z"@0S!89_8O6%W5>4;
MXVK&A^X8BPY@D%"$>B5E*_-.NO 8DYX'N7,LR<0I(UKX:+J%P11,%!D4P=^
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MD88B"(31HT2+ F(#J.?4BCT3@5YA.5$R^$/]$CS1:>*C:S<+ X F?/#8'79
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MA7M!O>=#<3@K@W=-VTSKQA%GZ,493\OUD%A<_7>E4=#VS<\VFEP=69*ENCR
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M=NE9M)]W.F('W-*,)SVGB%JX"&Y::N@T$#C!!Q;*.T2QDA+0*PV47.KGL7^
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MB!UP2S.>])PB:N&*L&FIH=- X 0?6"CO$,5*2D"O-%!RJ9_'_@'*>9ZQ /V
M\[R;ZP#]@/.\GR5)G8*6A>C7G R]'O'7 [J+04C _S9!__V@%.2]V9^+$WT>
MUA<X*8YR0>D >[IK#FEJ#&ZRU'1 1"\Y)#*#6RP5Z(OH%LU:-530H6GA\%7=
MR8*C+!74B^@H(C..7'O&-&(7T35(Z"#-"95T@/P5<?$\ISB;/1>Z3LZ>4Z\
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MB@,DG=@FXP+KB&^R32#IP(A VPE-VZE VXD.QX2D[7*KHNTNG!&R_-$SB^J
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MM1B3M]'"T./]YM'1D=1R[NEZ4.1+M0%V1W>F11GL> \V'&D"(#4=)@.0*J:
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MHP*P8%R+ SA+;),!SA)30,!9*1 0<-9*6;"#VB&P8((#LA=8L /<-6T32#
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M UK\,5Q(O>\@UX"(P4'$@,R%92[SP@1D,( [>!2'PR@"J0ND+A!"Q!$'0H@
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MTNF)XX&'<^;A[Y]$Y-/#FZU&]?A;X^2@=M&LG5\>+=S#F[ZCW_1)QHU=CSJ
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M]"RDU)%-RC]*ENS[O)XZ&.S6\'^,B/<9>QLO79"V9L^TV,WWL!'6;K,[&&U
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M;XD"<226_/#_OA!?/DH-^BMY7G+0;YP 'J'/:QG>B29[!<Y1M>0JM]D?]!4
M30":<$03KEA.>V)-^<7E<D!K<JXU]!L$.+ Q^_6X/J ?U0<$^WK=ZO(3JT-2
MC/A2]H$(O)V%H)A/)@/H*?#OLL6<;TE#7]MH3JCYWTXFVE<M5LT?Y!^2"X H
MQU*4.7L),7=D @H%%.JW4F5WHE"Y"SQ^;67)YU:VH'NNG5:D)Y7<?B$R@D5!
M"?UXJ9KGWX)SF7]%>".7?W:'ZI^G,X^7\XTSFHO]O*U3MV*40T].YI$0Z;'7
M:^ ^[_PJ0T(/<9<^+6K0?+ ?(?T%/IG_P?TEJ0)68OTK/:K?*%:^TJ/N<5O%
M"A,"L[ZOQ?^O#N3MD6:-"*KI)"/U=3.$A[NBQM4A<I64]26]8 \D 1_IU  Z
M#73Z78=9GT^GT1<ZC4JZ92EABU+W<%68E-;*;HTL]G]R[=DI=+K::_@SG%M:
MW-K8DI7ZKC$<UI+R7_++W_@#\JI.WW8"X*5KXFF*.W?BOU!C,5 U+Q4&'W)U
MR'L<86O!PE5!6'/AL.;*&;2W4XEGS0?D)W]X?3R]C(_4<8-?0>H1^-SQ54N0
M(!01R<YXRM?,91OJS"7RX!(A,'T^EP@ " "0M_,? $ N[9#]'H!,66=LN&/2
MYV0_G.R%-0]/=58ZW'#T0%/4R?VOJ\C[XXV0AYN*'CTJD/$Y(>[= \@]>DD
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MW>>#.4-%'[3O;?'VH62W4;=1;L6RB\$:. /DPE^EXOMC?B[57],3-WB=A:C
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M$WF3SP[:I\PC_2/O@<_K3U,J#1U: 9HDK0QB,=C$<=G+[^6XN)Z!-0E5..+
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M#V G-4!.%<1-^!L]XB;YXEHL^-HK^B:2$>[?!.L:09-_RC<"[)QJHR'9Z$Y
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M7(4]R?*A,7$8P&=\D0EW<@=IXH8T?R(8E <A7]\$9MOKM@5UEZ8ORWPGH*.
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M<+@O@1^;A*$L1-JIF"0,0/<+I,E@1^.WL*15OU+*@J8!,\B13(1.H8^0WQE
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M!=:)VR@TQL)JHFN$41N+V86>T\EUKWA95B2= AH) >)C("BL4Y ?"+X;)TA
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MR8+1257HQY!B,=$-1[D)9"Z2$9G86'K!ZH\I*Y(WY\RW\Q,QD^,L@+IGIDY
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M[8-!4W" ^?_8>\_FU-%U3?C[_ IJG7?/=%<9CQ!Y]U17$43.( /^0@D0()1
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MA*&'\3O(,\4P/=;(#E)L<98IC^7%O"(.VL?IHZFI68#$/OGMV&?: B>F3NO
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ME&51B_<Y=A(WMA_.WW> QE1,O@!X'Q:.X-'W@;;, :91 ?LS.^)#P04TX'_
M6]\%VL#\9+X8%?1*C#$WR5W&6K_DJ&;FU[_TN<3%D77Q6HOG[^NO")"'C#D'
MGR/M%G55XB>FQ&FA'B^OH!H'QJ.L3)Z?X#Y/H$^FP#A#VP1-@6ZG94"4XWT^
MKX.*W@UY5U-1(=M^.RQA0[[S&K8GY#KX4HBPT@]_$13DKOJM%1>4C+TK75/A
M%!@LD.:"0-W@->P>KC$UW>04XMR<2*/BV?*)"J*J/;C6K>MMM*]Z0_],)3.M
M59><PKYRE,"]1//C69'.2]^O9'9"/;5OB3++RC1=H_.Y:"8_!8XV]7S</^<H
M&53P1=^/I6]"[H"XA1-R$SIN->'1EB$X\(%$23? #^R)SD)PES(Z+AP@PJ!<
MXQ>P  6\/$D%4:E=388.1HA'$:Z-VQN*XN87^CE$1FJ_MN[[(_EP)D1RK+Q.
MT%2QFBMTE[WNHNYO%CO@PQ.]8M=FQ/;+M%+/+^-[MEC,Q">JT-^).>!;-M1
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MP%#]H)$:7![WLMGW*AB0\(IJP&,?(P./_L[Y1F4FIFQB,^TT'L"?&B A4&-
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M7O&.5,S(;,_A7(][JG"Y!CI.04%; J9.)1X8)]->O,D9GH],0)",)ETX757
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MPF;,([.'FP[T0Y $Q'+PD@H_!U;(9E+ T+!^A3?'@8 (?A:B04/\!-.SWY6
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MR9IS<),MY$V<V)3Q\^ <H@\XAP><PU?!.=#O@G.(?@^<0R0TD01% &HQ9&A
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M M\)7_9F\Y@VSYMKRIQUME5Z':VWJ<RWS0.O\YT:5US)*Y&.S-0.5WY))9O
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M))UR1UST-6J%GG:&+_O-8LJ:D;4Z'J>'?%:<GU8K/GWB SJP9S@\K !YR:^
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MO6?MHGW\V#7+@<.W(;1:SKT'<EHKVR]+K7)CQ5JZ9 [&7%6AYV^-O,.(B.=
M<$U8[KY\LI^1;[MN>B7,4[5.HS*KB_U,*Y'+MH3710NZ<,&E&+]GXYG?@6_8
MP(V"GH4)$5S5#?V% ?(XXOC=;.#MZ^@>L*\.KZ6]&E\L)M9@:9:8(9/(@\<O
M3;1*?/S!9M4KM'JIS*;!\^O5F U;K4QT73)>#'-[WJY@7]+>6DF\R+?&(0/
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M,K'Y%$'&_S:]J_+NAQ#\;L&89P<B"(H0X,"6A-T(( +4 NCDJ9DW'81Q3-T
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MAZ,9AE-JWNZ^T^OVZU6M=PI!?EHMYWB0GC)DOM25]'2>$XSEY:J!??;G#D'
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M^ONGEV+W-^3;P*[!BNQ?A3<L\'/[PR%$T&E]<Q%93H)G<1T;J+AAGUBGYRZ
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MB020@^7[5TE:Z&.)]L)A2-SN<OFE*<:I&[=%@9Z4X'E262"8@+= U@$=?>]
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MVS;>.W""K_;="SGF>W+,^QL*XL_4E^(8%!ZZ42_*UZSAH!W]99(Y <<-R(:
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M97^OI1OO0-[__C2><"#L@^_#DR^;$(_C227=7)'"*$;B[6&K*T]9=KZ(HQ+
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M!ZS3M)AB6S%DO\)FM(JM22@A'[9Q-27+#JKID60U!8770I4 4(6U#6$J[8H
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M)\!6O&E['8MC-=X$Q >0EP"BR0923%;6X$DP(!FRUB[O1=^28CY",(?[*OG
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M A\\$A(J ,"((!>!TQ[Q.& CS23!#ESZ@^;^9Q2L)U4/_^BW)()-T7_$T.]
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M.IVTRR[/1%$?*0KR($=P*E9HI5N.FV:5>*L515.:P&=<+K]9J)TBDZ 'Z^:
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M/HCDCR62WY\Y>!?)=>$C9_F%8H/-;B4Q!B^W>5.8HN"N**TDS5C,82VSY-5
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MTQ05G!X\$T@MW;"?8Z@D,N8L#(_9/9$,O\VO>$5#$_HDN!6 XJ<84(W@D4!
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MZWIUB6'+G)1/-$JYL2@RD#U.F,-&_;\$^XVZ?)A/X77;LO;G@",05GZ_,QT
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MUV\ODU=D6Y+T0 @@+#7] \ O^LV*23TW*A 4TV7Y;4>H)EQ\8-ON1WNK[JP
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M// :]\+@7'__KU?:3CU*VQ^E[;]6VLX'\\J<7"%=>HEKK$JX? :K2N542YM
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M\06'[D/!-*QH4J ZE<%H65]/,$(8&/;$S5(I>8(F[44/AW__L&@XI9KW8BE
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MWHJ%X)$X'6#HGAAZ.YY#_] Z6;\A H]$B0 3?L!$P!(!(@)$!++)CY@(6")
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M-\;8AEG0BT^0]Y,1<U]&"M 2H.61T!*(,9\BAHC$ X:Y U[>MM/NBI? 4/N
MA LXR8^("21<@)< +^_ "S"A8P%B;H:8_>Z)@J'!E:@STP?M!#P2WZ7ZH+2:
MNPYS.\R#>@](X^>J*;^DJPIR&>\*P#N!*Z ^7U!?/""_CY,??6_@!>3W;2!X
M!8*,1>+D_< 9?S\TAP?OW ?>K[]I\/P%G"\\W(/33<R7QX&)5U$<0KTK#P%S
MJRNY0,8_%H5X):K>I;XQNAJ-O.XL!T1"WQ8^5R:2YSRQAR*0[Z>J'X=D-IV5
M0EZUUF>4,K!++G7I[C$@_LIP _ *H;2F"SGM=>C\:%W]PPBGQ5K7H9D?K;O?
M(IH]#_X[$,W6]+NBR DT^SN@=>"!?P."^JWH'D&AWH7_O*SW/Q/\ON=,LE-X
M7*7GN)=PY,<19?M'_9K)():)6B[8J%U "U D#TS(YSX'J!P%130V_=)JHS3,
M:3:CV%&/A'>V5FB4\%19'37C:JUA](?\H#::%.5/321Y:6B(7%+X--X=-]0P
MJ?=A&]&ID6-@&2SL^10YTZO@"D3F1^;Y^BE! 12^C\#Y7&.6\Z4I]Y(^.5X1
MF,5XT<PX&!FS5=Z2F$SC\;JM NF6'L7RE5PXUF!SK:G(5YK*<D3# FKRUU^"
MC#[%8C>2;W'_L?;%0Y(NO/KRU^FN9/O<Z63O$D6W,'TND45-R*](A,#?*HJN
M3)WI1F;<2U:-*PE[180K'3:G2>MB,1E+Y0;,E\]N>Z>D.IH5A?Z8!L"#T>W#
M"0_[/:7X;LX.LV0OEPGWC5Z]H/2GXU7CUU\<CY#$B1@+^X1,^*4/R(1-K,*D
M3(Y8K"3%F#6)22:1_J9DTN[%"^0@Y]34TISN+(KQV;*>=@&9T!$R]JVTW6M2
MTP>6K2_UY!W X.7%^HP^7M*J'ZDA?S3E^)[AB!]N)=J4@+"S $UL[M].>XHF
M<ZUXKCU*5#*\F6![A$,LQ!(#1T11B>-NHN'KHL?72LDGZ!&:$VW0,A<I-3R*
M%XG":JVD1PP<$!,[0<_5(ZM^=R7>G#CY5MVF_T(8]XZ9QC['34LWT:JT\&Q:
M=8AHOH+IB5Z>;MPD9FKT^LW88-7",,*EUL**GN)<#77D^_4W&OM@S-3W;/'U
M8UN_X9$_7>_M/[GAJ]#G)X5(@\O5F/1"F&24?IQ3*0<?:LD''#0%.U>VV?5Z
M+LZ<C#*WE^DJG1ST%C(04N2OOPG\B8@F;B.E[IVS<>4PYS<P1+XX#>*'!3 _
M*7'<2D.)U=/AF%KKS*)I(YQ:T_PWC4SUU-J$,RJ<JU+32::[;G?H4AHVQ<<B
M^.EH[.\5P/PDF0P6U9)ESZ<X5FNUE0G?7*V2\C<EDRZI,$E:Y8MJ*14?T\V"
M6]<G,(!)13#Z<976G:.5_@""OZSM-TOV@SCD+76<3P)=W41X/E3GK5XF1<T'
MW;D:BZH-%\8A$]&'B$/>2+?X!#WMV+@=3ZT=)D/1<949QNJ+Q%3^HCBDSVYO
MKAB:]/M]C+^CE>1G,SQ'S;S0H1Q,);A&6M7:78%+N#>)5JK.(CL;E3J$6E/I
MDN;4$]%, HY<P'_])3^:X?F(S'.G .:WAT*0X?G58<[/2I]ZUATWJF*+PU*+
MN3L6U5A8+[H/&>;,Y3/D=%@9I]F2-,>;\;7*]='H&?+77PI[P@CR=AZCSS@[
M2/"\,!CJ=TGDD\#757S'SXHJICTI)E)1F\TXR5BEIF9Z\4;O<]>ZO@U\I;5R
MN=09EL:9.=X6TU1?5,4^<$03Y^)>WRH\^EDJ*<A9LE_HIDDLA;?+>39A-*C,
M-PV/9J-=RG&97ENMT8Q&.=5ZMY:%X5$R$O]>RNXA(J8^4Y-!?N?CQ%5OI1M]
M$KB+<RR_)IPFI4[Y$DVXN#YC1U!017#B$>*JMU)*/D'/$F],.*,Y)##*'95D
M@FP,TMU&D-\9Y'?>)F+ZR5N*KI@U6W8!;V6F0S/5 ,\9<=';U,37.1PKF>L^
MG>&SU)(E%D*AT$'S@7_])8/\SILTD+Y'QQ$?&E/;6.F=@?)M Z>?%$)TKYK*
M)$;YEBI-4F*'ZE4=HO^8^:%X*K?.4HFBHT[G]>QZQ3M.,@5G89.__L:B3W3\
M@5-M_";F[GWF()'T 0*EGQ1-Y7*3S"6U43?#\_4598>5I3CYIH%2;-BA4SC=
MJ&&.0%J2EC?HW!QXEO$]S_*;!DH_226SGEHBQ+5855MF3:[B)CWJKKXIE62B
M<LUD<ZLL5EH6;2O*C$OS"NR7$(W0IV3R,(+^(:*BWTO#!WFDOE9Q/@FHT6&U
M7,E7)"6SZI;:RTG1+7?3#(QW$O1#Q#MOI%M\@IYDKY@C)L744@T[=J8KBU9F
MU;E"/?O#M_D[>$L*'&IH*N"I>4E;2/"@\ V\;H5/7_.><6X/FD+VG:#H>TJ\
M*Q0.8V[1V3(D&LY0D[YI)/+C:>)W!Y3?HY,?U)_M)JF7J]742LUUDGRGHXH=
MB7C0OIM9+*P4ISF))7J%,3-CU=4XUN#B,+A(DO$GZE9W*(^0J7)QGJ9O&XQ]
MHNG]5YD+]X=,T)(N@,O#P\67N5W7 PSR[O[/YH'U\O?$![RV5??!C5X=GA/'
MLI71ROM(T<&+[3]1ZM0 Q8D=@-MC*02-"%Y?A23P;6" @+?;8]X.*7;(530M
M9$J"(>O@?2';L'D-;!J8-^$AM"V \?1L?X2D)?Q9"AFC$#^;F<82/4U;A?YS
MH:4&0_7]22*>8K/&2BVMN%4FWY*$'MXXF[J"G;?+8/SXV2[;?53A5W!MVZ@)
MM@&L,OC+Y\(BZ6Z532?8_ !;]<,5SI;;,_XP-SD<>X=5EYG.-&,E;>,<YXV\
MJJ$O )XD+S9BM2%&]O^>,N"D![LO 4AMT"8^/\G[TK'1MS/SJ+V@BIP>A.4!
M%FNS"AN68V&16,=X^==?*G+:7B@$*%>#>%7T$"_+IB0#>,.# T*20G!J5$B&
MAB4@&+ "("($$![:X"$$$1%R+"!HT'*P4@0+M\3$V[:I#!U$-E/)'AMBR "R
M#BTUMZ&AD+49!3=#=BND0(D7QB$;O%482Y%0882^@$@W-(,ALM#8BY&% &S@
M@T.68>CHN8"/7WOXT_.37F."[>F!ZS&3 )@6Y][N,=@0G!((7TT"SH<D1D*M
MMYZ]_=:.,R^!B3+:@A<@ IP;,I2B.Y"KP9X,>%>V^PKXR'X6#$\AB%$$+0N"
MUAU+D(*VR'T1J@ #BK0 )_*5M(,TNP"B&6&(!X!$]+E%%XQ?AB0=4F!:$A"?
MAZ+X$R+2IY#+@Y/!Q9IFN-8?=*Z/AWO3X58#-R96G)7"<GO=Q9MC$N:<7.+L
M[<LEY-\BUJXYM@6%*> E9G/,-E2!;;"EI :PM/'CAERJ9"Z+0W.ZQ$I5LM#,
MR^T,2X)W2T 4S,#;@8,H72_^H>CAL3?#"6CW5U7G\S>QRX-G2,UOG[ )8@@P
M\CVSI#_;'_8W!:EDLZ$IOPPCI.D[>R>L22-[WP *F][>P2<;-P3#_@MW;IO;
MMVZ>AGLG>M//14^)41$"?^UR25069YX/67T$Z&\+DNWO86C>_1F:$J^&70"$
M?V<&D . 5OZ8DL9#"73TS-W?^:%E:(XM_0OG<\? T:#<M"!]_4$_@6]+O[&G
M,/C3/T<0N-NHOO?$5L&9=_]^,@Q!QP.$^0AA;[M_L5>O;V^,L$TD%;WX!'<_
M&2\X%:'NR4D!8@*&"? 2X.73%@$49/=$S(\U"3Z?OO&F^7W7,=1?%!U_W9Z]
M^Z72(4S0;S>=I/PFNR<BQ/-(=\AJ=RWAN2\X/^I#04UV5P@^-/GA]P/>E0=Y
M;Y._WSO!.Q#L@6"_D6#_,1#[C.SV*6/Y@XAN*WBN+($W93>!  X$\/<5)P\.
MI#=#I0&4 LWT[3032D0.P;R=0#D%RLD/['-;[^#*[%-U8.:*EX]NC Y9*)"Q
M@8Q%1 *+[$.HRCZ0L8&,O37[V,;LTKCZ/;IC79FWV$V:+LHNO%#^O@JA'RY\
MWZ0>_#M13WVKNU%NYWNE\[DD0Y\5!^_88\AK,(<UQ-NA(J\[O+D*;;)MKV*P
M0!GLLZ/?HP8J=I]2'W^!81-(\5G)TVE9,SPX3ERGC#1 O%_!<)7.?5[RT>-1
M],=TV#W1E?/JEZZFE.YYEBN.$_*53?I-P_%!)PQ?=L+(DF0TO>2(CAK.K[N5
M=%,>FR3#T5STQITP?A[/W?_,5Q.9;^8+^T]\W*:/ZLT$R)>T.;U.,U,@1;3D
M3$WU,YE$II6>MQRZWDVF-"A%J%]_\5B$?$V&?(M(0 ?% ;ZKLW]E4\MGI[N;
M]?5X'D^ ^&\(AFM;!8]'UH_GR&<-<R0IW\65OQLC_JC9/I=JI8>:[7-M%?6S
M4'[_,W]OE_1*FL9G!L.Y:\^3-D/?U1?RT<7/W1L=^TN8O>Q5W1U0]XZ#GTS)
M_&#<JCY7H^FD$3;54G?6%LP2O>KU?!GXWG48]')(S\2L!BI6,PKILH2U&LWQ
MN&$5U7#%1?T8OR#T'4@U/X+A)UUG?\DTWIO)F7?'QX=O2YGA"_'QG2SY2&A\
MC!5G1+G2**ESC4WI;8>=+\=(S%P:&P_Z_[ZK_R]L)VK"SI?7[M=[M[N@=_7?
M933-$& 'UO.Z->,U7SW;+%<J-U,VE<AGU>DJIA+EDENH=V0X@2C^<K-<8Q1Z
MLXLLZOH#_KAIR(I:E8J.N>V5^UJWTDB(0=U:S[0QA1I?0LU,;]29^0O$V .W
M5JX/)T17JQ(8FUN,E2S%\**K,,!TBN"OME9V]+V&O^\A'>.Y+>QA-V;P-VD#
M&NLIY"KV.,2'W(VL#O.>L 9/FO**#K^\>3]ZSW.KY4^TP+TRYU\XD.QFY.#=
M V<-L_D,J/U)9?51>UW+<?$B%LZ.!;?25W4V#0=71J+Q8RV%F-NZ9N_DDT3S
ME]7"?@OJ_4.'-E+P:SH?"V-)=#2I-KH(81OY#7ZJC8Y1 I%EG79!GO.#=M=6
MF'RF.XJ5$HV:8#(<<Z,NR.]3U  )X$!OL[EB/>MM("-R_Q\_G?W+;/\<"4$%
M[_6K1DK#ZY0\-ESKTF[^L#.VU^';\&0::MZ>:=7K\'U0"P',HT W$C?6=CXA
M4C[&3/(HP?L6?($IC<%S83]TS;"LT&_T$,.QP-^M?_[<S3 ZMN&\O^R"^8 U
MOKH;]68'J!DU[]C&]@.O&37ZY.*&U?$/]JO>^J+H(73TC0FP01/*>S4'C9(!
M7OR'%SQ"!DV.?8B7MZKY [P$<BS 2R#'_(X7(,>( "\WP\OE?3 N,X]_0M.+
MUP7X]VA2$'NI2<&;X(E&:.H[]2GHP_ASYB#^[*4E1?&G;7[2QSK+!!SU11P5
M?PL K^'?P_'IOR<-3]YN\/&F#8)%Z&_5X\-+];JH,4Q ).\@DF]&(\0U)*C/
MDD7:ET6>%5W0G*.X]M6XQ6<@N4,[%.34^3'G[[-Y1I>%?_QX\IMD.UX[2Z.@
M VZ56MM[GO+FT@W=W&[7Y"1=,GF-T45&G"JZ8MDF\B WUX>;:]Q)-U/,1>?]
M$5936^M!=;KLKD7WX)8_>KL$CN@NTZ@^H_+&"B]-,*D][E1(AN L6N:B,)\Q
M\80E3B<>!V(H$$/7B=[X\>2^$D/$@1@B;B"&&M-14TG.)5U5$DL^YTZ4[H*2
MOUX,)<(U2DDJX6I&<?&*$*V,._UL X@AZM??Z!.%G>:2?6F^X^?NTP]#<A^_
M70_.$IPE.$MPEN L_CD+U#=0A2NZPV_T$KI%V;LK$C2)-Z%)-#YZ3Q3NZQ:7
M12^&80AR:]$]-P4(1Q/'=T#_<W#5M;/28"J78?[9FF)[Y]I<L1'(*I.EL'>3
MQH_ J__PFLNOK&U0)A'9];K^L[/F("!".!:)QOX;VOL9 N0$FC!-; ]F!VE@
MFZ\=9H)M/WSC1F^#&CA8D, CB'C KYN#D7B$CMT(64>V-O7LD/"AL0G-PO]M
MUU)GR1?^#*P=8)QI!U<\FX]^_6VC?#QC%$IYB776CG3Y_8N_EXCU$-+G 'A$
M_=ODTDR32JP&K%UB2[E>.YN;QK*.SG!P:>P&@#O/W @ZB@WX0#B] (/E'^ M
M5BCIF+H5\DH#0UZ^<ZABB,I(\8SJ+Q=<KQ_MX:1N00\Q,U/18/T%@3)AJ\;"
MJ\J GZ"*C%T9#A)6*.II&R%-LL%O(5XVI4U6+<K2/\";/>;M$'!!T#T<?+CE
MS&8:6@X^&"O6P1]-":7HBIO,?[CJ^?&14-TQ+0?.WMF4G!QL-%3VML-LUS]M
M<X"E!7Q.Q8QL]N35#.S> DO>5P>GA&G%?.@ K3!E/ZPLPQX"_^31_[AZF94Q
MV8BR:IBC:V$>DU<=VCU+[9]*C'];D-BNI"VD'3FA_X6G8.5X6PPQE #.4:4$
M$ ,[R'EU-P#+X/BNX6AP'7 N 0!%U.> P/XU)5LQ$41#$J K!4@L]!?\7P2H
MF6,"R2.AE&J(3\GC5-[C5*"5P%L@< %NIF<7[1%0) 3SR@U8J'*X_F(BV2 7
MO=$"W_*2S"^K3A$,RT9'LM%7-NT0CO++T9:.P8?JE?9> =-6O"V,#1,2)?C.
M;_R?RZI1#F(+NU\LT^::L+01!1'@;Q5^J4R=Z290 #]I*S:L2"CH(JSS='CM
MN6*E)>F*87840:H#^"E0%F05'1:P,+J8&BO2R/M5X;7:"(A6R=P\5YV6C$1U
M:EAJJ6XV*;D2UAR<.5O. A-S+$G?QAS@>S?E+! S7K%#<T=,F0TM[96@:-U!
M3-:(W%CEJSEW4>DXLUS.W1)W")&S=5*+ FGB-_$/@O=S.9 !C MP(BT$T0@_
MV+#!;[AL0]E-"8AF@*[.9DD;D-R&M/^)A-*'M6S62\5L: .GHO(]]5" /+ZZ
MKO%6]%+LB5S"7*<26*J.*7*KV+9,4;Y'X6,B'9WTYG*QC1&4023L8BXE\BXL
M:")?+F6#N+PU*HZCAK="1=U.D$T>F[396H7@J"*KU$J,>P]4U)<3>KY:YA4L
MU>L7JA-G;,I4X]=?+$*]B(HG*.AGD@ M66WUM%\SN%/EJ!,/_>]&.F]TSD7%
MI;>N+;T53LO%7+6-&]@HTZKWJ915%L@Z\UKQ*1+. *]'POGVU:=0YKU6:9J=
M%:U,4YC'L"XQ+Q53$LFWUH F=..4) [T]UL5I2?4<:#!KUFT^-".PN'.7LOT
MV-)(""AO<"X(]J2A.X")MND?-P/G>_H8[-]6C<!_&.8?/^NXAA4X737!-LX[
M6?QL9@(+4D0?,AO+]QGV=0U P1TK C#MP3I%1"N!FR7QX",@^!0;^ET2,&@=
MTT1F^W,=M;2$>2M;NP9)FE!F*0D.%+.AC:QY>G8%MA8_9"S @Q)<Q8<$WAJ#
M7[<[&B)J4$;/#I4]!HB0Q[LM72AN/1N-ZTQ-QDWRZ:8Z#=/E4JRAA+O-\Q(7
MNU2+ICQ8;&G9RFP!@6"P \&AM.V/$OI<5@TZL^**>,>9AGO5LOQ:9Z07Q"VR
MA;VF1;619PE;*0#$'5810QTW&D%RD@NG%M2:G,:P6J\O281%R;4I,HK/"$H/
M@-8?Y&U #%_D<6#[=LEM(>I6"VUWU18D=4Y*!)=C<'?&RQ>[$Q[H:KIT"#C/
MET#28 ]RY;C<2PF*5&<==5!HB(L1T[(8 +DQ<!8]Y_B,,Z&#/9L6'/9USM';
M=Q\*L(@>>!C>IK:.PX$_\BW!WW:-2\"?M:UA4>ZLJBP?966>H)++1!(J>$5_
M"?H;'TV93B51 ?I<6^W7AP-X'H+\;+C@%:&Y"_S JG#%@G_S0E;P.X=KO;C!
M3B(+@NGLP@\[2\0K,+?L[6O/BD5@;.[</&"BAN ]/]2N80UL)02<0L4*C4QC
M>DIK6R&ZU12[[BF^46/''7HV</&9+_LA3EF4H_PLO>(':LJA1K%^;]4=DN]W
MGA#;''&+1PV,1U-G;6-6Z%(Y$<MK&&$FN-S0JC1D1G[=7_*CZ_HAR.>+T9FU
M2J7+V*K(#2<]V2WH+O-%D-?"&=IHKV(-MD3+[GKILL5J#T'^E?XW,&9XCO<!
M)RKZML\$D& ;.6!=I3F%^/[PU+Y#_9*7?&2+COGK$]61LWP;*J)6#3G:&(\2
MK-(=\HUL>)6SS/=W:4)4M"&8%XRU??)APE*ZE1(&@JHTY;Z97UH57FB\03X
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M&.^X8;,LK$O9R0>5_$8\'T8DM\)@)PO.RFNNWNL1N5S*85=T>]$:-YE:,L;
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MP! \8%C[P%"0F:Z87BVUA;)3H0JSE?!V2QN7\^N:N3+@[=N7MW;@R&P@D06
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MQG7!9Q<L"_ 1. B0XW4TR\X+3P"LH3^=GY_6DN1V2Y%38L:)6A.6K*0H66G
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M>H\4#>P$S0&'>TA+&N_"][0DP91LWEPA9$"JCO@&V/]/.8S:[/O(O_[N6B+
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M;YT'#5/RS@(/?NC&[99'0BV@EM'A@49Z\F(;1Q=;[U9S4/^CO4/_Q#9,0%E
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M/G1 SP!:D3M75GOX(&]4JG?6!I7RJD#N0>CKU:MX1$)XGZC5PQZ9$$Z.SBM
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M0B)"+ JUN^D0$[)=DH=$%7*<RKLL:XOF%-TC\P+#.NC:B@:6AQ1TGE? $$)
M:-DI>%:(=Y,MD)3P*?94 W]H.OQ[SN@F9,*0-0^96@C<SPC@ 0)C@BLF-Q.4
MF"LG>/*ZD$[^P[+\V"RJAJE;<"&V3VD#Y@"#Z3*RS#MI1I6\^PRB94_239&1
M&(:<5POJO".4KEV@#H0'O*L^:?.LI8NFR!L9. XN[>SGA/=EN09^'RF)M9:/
MEL,53&S'&29BQ!=]DCP%$Q5R20)IR*+\&^!YC95<M@%4]EB"#\UA @Y>]I_;
MY?._'+4_/>F/*)RJ\"2=::TY6M$9)I%*)9GXK'D*93(TYW67RJ^A#M #OII0
M&"<TYC<$YD* E$R(98RIS!M&:,P80", N=U7#) S@$+XWXZFWR%FUG+[D@!Z
M>N3L:(]&VZB<:&OK0=N@ZQU,2M"=7'S2('?(&39X]B=GZ;"EJ<&K/CWA8W]2
MVP5I@/EKW)9V 4+EF]-YTK*LJL3(@IQDE5Z-%FU@4[&0 Z9F[)O+T$37%*2L
M.4^OBGYS(*1Y 87@CV ^AJ4H:(V1X )7C $D8=B%);KM5)% !RR%2_H)(^JA
M)2-;O/_SQF:XA@1H=F@?;,8 3&[RNB*JX%O+ 'X#NCPM,ZP4;K/0,!BAJL;Q
M,F(1> ,/;!L8D_L4P%AOZ(F-38":8C!+)3-T3G.DLC-RJ )0?7V\^2U41#CV
M#AWAC[*FF6W>-&4>,EA1S0"AS ':=2'ILJ+!RIIAZ?Q&.<0#/%=,8]6,F=$2
ME,)V]4AAF2+6-E .V.LA5$\(>#0R^&-7,0!Y9[TF,("8HF<1CE8IA (<"3/K
MB/QCM[,,T#D\;QJOH<?RI73@ZD!0P9>WG"+ TH VX,&(H<%;P-^N;.J,#94J
MD'I78-V'@C 0/1A>'?R&P%Y#Q>,N&7H^?-M1KXX) 06D(>ER">-+Y^.Z:Q%/
M.E,W "CYJ(B2 \IT&NF53K6Y9,HJUTD[MKQV^N W?3:Y;XU7@LY%Z'!55])6
M.#R)C\E3H"</Y;-]39+?QW$C<F!L#E4S:#&^%BDM@F6(JG *2&W?<=O3!I_@
MOT5&'FF!__:(="X:@F[0I6J"<F*.66\7"[-YJ7EE)XX8E<-&I$.6) 5W^N-1
ML<$SU$,Y<7N,\65\N4=DJ;=5QV<[=%JK+.<SU#Q!UR=")ZG-<FPF;K_AT.UD
MP&3P9EY'65F83PV#.W>2NRCC]4=X@!<M"W#6=BKN7TYEU-)0!NNVC%S'HR[<
MSE4^+T"9\J5]8JD<T-*3"6!'M'3HX?XM+YZO!TS F\X>>.C< EXG ^S^":?/
M2VU>L@:/7!7FAG ^B3HVH+OC_3L%WON%"@"N,5AB^'BXL(S<8!QX11IH19Z#
M%-W$ MX3S195R -+(4BB(Y.)ALA66Y6=6 ^[LQN)S^Q8+QPO<71FJ4A,5V@7
MZ@:(_7#B5 W:Y1P1<#H#C.XI V/'$84"P\K TBP1W]D!OM^PZ%_BWQZ;?A>V
MO SBY/ILN<Q-#-PDUKK4YKHM.S]-UHNV_4AL6<^RXW59E<-27JI3IA1U)F;'
M/E,9^2&N[->KY%%V##'F\:CH/2^Z803UO9GO/I$6GZ(+<5NV<<J)5BVYF!55
M/$F>QLIZ!\=MHK)_@1+[ [38L9.^UV<DR4DL4FEI3&+M>=08,KG6:)1^*..:
M2/9P8B;,!3I>2><<8E&8%67RJ<7^".:[CQ:3);U$CT:409?'$]99D,4N#;=R
M3X%!?$R+P: ?:+(_0)4=.SUR?6Y*U]MUMFM2(RP^*-M2K]:?L\F'<L@D<V+Q
M@]9$P?(3;=*(B%DJEWLZ9'\&\]U'E4W"BU)LU"B.I7"G$,F-N_%LEVV>/J;X
M$57FYD</\RT79\KW\RQ^JMP;S049<\ Z'N=TM"^=[+!'%"?$^R9@H4)C/HZE
M%P+9OW9]Q("Q])698QI8;YQK<#+5&RP+Y(5INFW^W:O8VRL]O(AW;IBKWSF2
M ,8&^454+<9C<$Y<_OH?^,<?(BN#R< RVNF_NQ6+$9BZ](IH,>R_-RF%90'A
M>=U/G!)1OQ1XDSC-A>$^Y-P?-_KW_P2'OSU]%V8U6=-_^@6]@7E-><CM/PE4
MVROPX;'.,U*8F8!7_V1DFW$,;YZ)U&O$KQ7^N:D)CJ!D+O8:B?TW%/@;+LC!
M:BK,*AQ8,Z^4."SS$_.G=YO_'2H#WGRIN>3\J?,RH-22AT_?>2XBC:G-?Q+X
M*THV@X_>Q*+X:R)V(V+MY;3CVY0V$P** .B@_]NI9_9$QWT&_!M(!I!;V7VJ
M[0[7^^K'KPY2=H!_,U"E 1'=L"[S*T#T4\RZN]+'%I#Q*XV=Y*) <:-:%1-+
M';W;&J922[,)5>8/]VV;*[ML1J^/S01#YQ-#0DNO*I2BD"/B\,I%NS&F*\/Q
M4&):?3U9[].\;-K@RNC^E?6BAA=$>KG$PLNN@FOM=F?1A3UGL?TKYY.)SL<S
M6 5;U!5J-E['F_TJO#*R?Z4S,M5">#0=4)E4EN179(/IEFUPY<';69S/E&B!
M34OU=#HQ3<ZUQA(GP96Q_2L).I77E3P^E*Q(S4D1?:'/E)JCZ.$XLT6"R+)F
M7Z;"%3E7;97M1J4,.Z8<C--<5-M6:T$;6%LH:*/RNBR)J@VN/!BGYJRTP:B\
M:F%69]:=Z#5JU9O#MQ^,LZ,G<!&31UFZG"3QF$*/L/R ',4.QUFS(S'16O<'
M5+N7T:36LA:F<S8LYMJ_,CYD%G2W.9A22K>8L!3*$HDE?.;!.,W$NC*E%F05
M*X^R7:(D&(F> Y&:#\99IV1,#.OC*!7N*6M.B7;$" U!P0[&V:ZVZ"919BJT
M-5DSB_&BF.AE2'#E =>UHJ7>)#>.SJE\F*Q8_+QF1D<0J\\?YY[&=^\;CU0Y
MF:T,1E$9*PN=DEZ/#RD-C 5>&KN%9O_ )MG>)O/&O4(>^B56U?? /#6R=<3\
MPB836<I=_]^X<9W*,\MZ?:<^@_/I,%6LR1+?I9Q4'%O6,=H^E65]^7KD_;/3
M3R7,F*XG<K^$94J89DA9C,^G3J:?4 3UY2C\9T?E/:))YE)6IHNU[>)Z5(R,
M5X/JR:@\8 I V.?7$4TT2S>GH87%Z, :0"T.:?2^NJ.+S(I;BO2M<T2W:TB#
MHO*C(]S4(1TRS?'S14J.B$6;\00=KENM6%Q83)4&K(<#6B'R6YF<E^]-W-L!
M45^/N#VQM-2PV6)&Y^<];-7/I3J#&HF(2_P><9%Y^-;TO1UNW/7HNQREEF0&
M&"2L)ZMT*5Y,%?@TI"_^FCIVR/<C:=B7$*#&'!;++7G9V0CUF/%2KZ[1D&7-
MAB;!34; J&#)ZXS A\ L+66.<FH_4?;ADK3K\:QK-MQNXMK,2-)\6.BL>WAK
M&AT(^^9TLX:D8?" KBI7$1ET/%CDC2K/P,I,KJZVX%X+M'K@@IJFZO['-$P?
MP_O14#H\.U7%A<4;**O2 4--RX!K?O@!(,?AE%&:2!*]B$='*U6J5JD9X%(>
M4&L.1@6\#?YZ6:-M<@HPY]ECTML[L<M/2*-3WYL4H'NVGP6D9>8&_]/_(S@H
M&'EZ X*)(]9-..WFYP)G_[WDW&$&U-3]MWI/\[8C+T/*2N"O1/P<L$(@U15X
MO@:>.0%LZR^)_SD,<0Y^NME,F Q_,XOH97;1B_U+F;&AR9;)?T;V\#3$3N"^
MR[D@D!/^390(8&5B3[H\'EV ^8\\!>8!"?,4F,>D2^HU$7G2Y?'H0KSB9Q&5
MGG3Y+;J\$['T33_L;HN0?,<BW%2!WW4%@KO%8TWFWKLD( * 7_Z_'Y$?'UV>
M*-J6OR.0;_)<I<3Q!1WOO#.X?C]^02R*$(50!?RB'O<87@1_\<_CC:_#6.<U
MW546YL/+<&RJ3^7Q<,KC"C0^_/=*#.[%)-]'-;C=G:XD_'\P8[B^][?B"^)I
M%-YE%!ZL)X*[5Z%R(4?D9>YJ\OU@L[P>5JRGV;]V8Z/-X9>YI?.C1+.Z;"AB
M7*"944HMMR-V/4O:W^V(O/]$;]<$_E)4YY;9<>8\>NZI"Z@5W# "0_8DI<68
M_BA%UHBMA\WRD,K@^4HA(T_M&+:S_XU_ )"#!.] VV0!:-S]06UVT,+X!BO7
M7LB+ABU'RS2OKG):9SH6A1JLXB1^_+I)DY>'%/7_7L],/[J0'W1E^4WC^[B4
M_'KQEZ\U0DL-IMODZ_1-O']*YMJ6]+$DZFDVKV8V4>5)=\/\WN.J!#L9&ZE9
M4FJG)^ON?&%.Y],/5QM^S&(2&XO9;#0L-N\82THQ)T(-3U(:72='46@QDS=I
MFW!_ ;Z>?7PLT;VV,7P0&GV+(+,E&E)X A1+2(3Y!MXP0SKPHK^K"_J,-I]F
M\Z-F$XI*#CRKZ E*(-H4F$Y+9.;XG&)2Y35/X@1N#<F@[8Q^HNT4',YJ<IIL
M8+U:GEN5QO/F4&B.8M!V1EY3AP"0WU7:GP'G,^!\I( 3GFOY%I[JMPXU+S29
M@]$D,9B*A%!(4^5)+)NCU;[.)6]V=.#+V4N?[3N Z_V##?3:9LO9+BV%Y6&W
M&Z94T6*;'P4Y^I"=W#F4U$E6JE$!;V/M&,V/>(YH9\L06?W(*38/->0;"._G
M=T=]!J4/2M%'[\)W_-C0U^[-!X$2M@C;%YV2.@3O/X2K\J;Y-AS"!V'WO[()
M>QN#^[/A^>M)9C*J\$Z%6I3(1KG;+I1K"CP.^WJD<8L'SW]M@/T3&%.W/C@'
MZ2::D#K0<&?0NP5>947>V"[:X0FX<(+6HX5QMT\QN4S%F#74F:1YR0DP>)XC
MS3/7(:@4_$;GY0Z*4DX+/QYY#046 !UOW5F"*ZJI=PPK P_=C34=59]OVUD9
M+^!5#B/#(XUHJ%51Y@'3J7S(D[EKCO?WU:K?1V'*N-"1HNDU(U$8B0_--7AJ
M$.B+T,0R 8]!N?)F,_=F@R8)NWN!:W@>8<^;L.D;:I: %L%P^R8 -2N++*\B
M? )X$\<O>5F;HR9@<UT3=$8Q7C>K!%0PD%$HD094_O[RAL8\&";$1>#10\ P
M7% M57:V.'(,.Q7!T]&C S!R@3<R,CP]*U@R8VJZ@Q[%;K3C=IK@?<Y1&'YW
M*F#"KZ$TSS(6&*2(^GE8JO\V<>*V>9GRJC>-P&-MH* @RH(W4NXE9%CLU!--
MC[%?-D8/+IF+&7MS2_5V$_"+%+][DAJ\"([38N3Z&' I4H64W_)F(QD^R8^J
M_;"4[S9P0>&H>*SHY')RU8EF89?5U\-C\ANU_Q<ZVPQ7[=)DKJYQ%@N^J#6I
M?#[7BTGM\KH\T)698S=^?\GV&Y\A1$>P;L<0'=^Y:#Y";<.=P?'3Z+$AEQ>Q
M6F]!$1&^V8BJY3EA@44$SSD"/N(^"9TS9[W!A!1H_T*,O",;@''!"/X&R@.H
M0%4S 4,#7M>!A.K<]@@ZP[*N\$!ZG&U?T]EI[ )HA40;</T&WP0,CH=( $#8
MD5RAMEL37QF%M,V"!?1'4'MX8K=5(88GFL$[(>[*YA#]5N.YLWTYIF VG0(-
M:SP#$3SJ"A,R@%X&C@<+._VHB$SP6ETT)%=K;E0%U).OH1I\B>NL[ND*7D>G
M]7G#V#2* D0:H]5A$)[7IH^.UPHQ\GI;*[,;?YRK-=V8:A-:;4,$1'%QVC;E
MI_<PA?M1T]>.CQJ6#L%43=?X'AJK'0& ;8]$#6(IO(1(75.!"_,2*ENZ!C]/
M)B!B9Z<OH?K8H)8,8E-R;O++G0<?>@M  -T@RWURZ!357>GQ7NMY2L[61_*D
M"XTFU&80;M'>;_X0#WY&8T57N.,]-80;2\8'_2_4R <JS1L;>&)DZ":(,RVX
M(P?],J<&3$\@4G0)B- U-%D3@&8JJNQ>F GSF/4)"4,Z@=^--#V2-KSV0_MA
M90U+KV6GWHI*;:O#MA?E28W WMU]8F,G7?KND)>&:O_@]<?-8M76ECHW-5M2
M/C&I92*ENKEDA1^_$K&C\.RHS^LE7 XN8DQ@!X&Q,N"9!)<OM[W^#I,3!X[V
MQKWVLQ?>*UL-\H3*)SQ4[K?&!O'"8);7A5N!&)&!X8!//+!M<.R:CMQ.M__N
MBZLXP**"1QHPD [<M#'XX&L-#!;V2D,6]B]^-8=>\M\O(94W7T/9+9B9UTIQ
M#\SLY<V%NG!ZP(%Q%=-MQ"D^BF"N[W=7:=(XI\B4-4[!VE1O-!,K<7L8OILT
M,3U^5..'BS1MC:M630\7ZA/8M^4X@N$+9&,8\[Q<ZJ-_.*2Y*XV&287M]&N]
M)I89$:R>:THBQ9UI4O%6:/";1,+%03S;2>L++$/%^E.EL\AF&*#R5.V02KY[
M#K0%<%*-.[F:'S2H&Z5T*PU 7,1=%8;35WO,=(*,:6>S/^@E@X]>UMID+;:^
MS^7<2AHP*D'?J1RY00#;< W<&#S/T-DHUQ*'2;*+\86Z! ;-#)J-YL<3!!]@
MZ)VT,)\:F)%1-D\3BJW*3')(.Q'8BO'UB-[Q\P.^(0?4::VV21<3A:>GS+CQ
M&U;\5&8JD((*!'P(U,*U7XPN*AHK:XKF-@UF9$Y;:;HU%EE1_9^X>R8:_OU3
M-('\L*B0[1_QEP<!#0PR/_>[*FQGOEW;UU![)_^TOQ2!(1T?LW@WKX(\KI:0
M+P%H &,5E)>XLAYX*[7_I^F%2KTW8OEXDL;XM;!41+J::Q?(,WKAK*5S6:*X
M37P% !A/+,!1]3"N1,CJ8%)>TB!8+>:[+:S&KNWC]L[E0\AO)P5]T\9$!#P#
M!1U]_3@6L.BA/HJZ81YWK@_L(Q,4>MD#9'0N (G_O6;D;TJ(&\9?SL$'FYNG
M&-4P%^00BS5[$J^W)!OX?QF6?G=%S;4<LEHZ8LZ5V123>JUN+M&*35*LB)"A
MC\>@;EJ3;&="T1BV,61OY#Q"I\R ?U^C0>Z$9[!T)\3OH*?L*M;C3+-AJOE>
M1BKP'KC..L]XJ<S[^OXWX[$Y9CG*O!\5);'32=-1,.69>28RN['7WY>CB25#
M=%=TG1"D9LHV)D(1>/UK7C^B!U&CH!UE,6?$31[PVEIA8T?C 3MZ:8!],P)F
M534N]\1.A,Z,\\/%&K<*)>YC2L)[$[);>^3;DJVH+J'!4042PODB1-RCE,1:
MPKJ4;O$Q.BSI\V4X,4T8LG!&74#'<\_IA)3U_;G IJ>!$JH;E^YQC-K%>LG?
M>=V;R8Y#W273@W:U?JBA_+PRTE%GMUQV5##R/]T\!G/[W=DWI,&;0PO$*PS@
M:_(=#N#%DF%F&_G,?%YB)*N3GRE Q=D"?\[/NVW\5YH)9K7%5$PIWADIC9[:
M)XR5 />'S\1_6XOEI@NWD<;) ,@E>JM!PFT2DO3J4 "O>!T-P>4ZA./64"WM
MDQ/>R0D5315@U;-;E=P"LBTNH;#5-#5C@855S:/43TVZ%5&C*P95YMO9RJA+
M"(QDOT%]*-?F+N5=ZLI@$&&XTQS2O9VIO;H0?Y]9WXS/>+ML;%LU%BP5_7I]
M">//OH3/OH3'F/7MOH0G>K2=+3Q\#-\#II2WU@*&6UYJ[]P>]JG]:S>1#LW#
M^5UL-SEWI%ILHZ_\HK(0HT ; )X]=OS"G1>WO2Y*7Z *$5@FY_DNL%OJ@WAU
M)]-VZK8.YF:K#.AXN,AGRVR@C?<=/54[Y4&\:0S.ULJ\;B'9#FJ,W8:(H_$$
M9Y.I"3N*3]C8*,HSQ&@<2?(C;AQ/\HD)'L<FJ?T6BIBD4\,R:==IGE$I)YHC
ME_/:T6:@?'1HYF/*E,#X:=^:,[D\3TV/-@.M34M=+5X>A6DFW3&GB6R4E@C8
M#/2@*20P'+5D?31(TXO&(!S3\IF^T;:/-0/%Y8EJZX,D22N-:'(^&32FF;SM
M0C[MS0AK]]/6K&W3X4I.T6>C=:&O-H^U^-0CK?5DS,D,QK3#*QV+CF-3FSS6
MXE/J1^)JOC7KT417P6?Q>@HS4\*Q)IOSKE!(EQ9,D2::D<0L7\A5UYIW6'CW
MRJJ1*4;:G#6EVY6R8T>RJ>0"MP.M,V]?.:Y"T^YEB$5#.E<OK@S*HV95CW1H
M);KLXZN"TB(*]@-4@$=A!7A@(E [P,F\A-J\@!PR*)YY'M80SZ=@(8NJZW6"
M:^]5'7YDN ^C>N&QBQ?4EQV=?5@"[8AL"#RB#_@0Y07@CW!5@ZXNM"L3407:
M##K#XN:@B>$50&[VOV1G6PD92",!G<H&%P99 %;G.=%$99&H)L#F@:UC8(4U
M&!J'LHK@IP<R7,%=9FAI3+0YCA;,4_4&S+<&PH8QHTJP4-S_E47'?, B\2N6
M]ZJ#7$,.%Q5MH'EEY[EL,;-;%PNWLV"I+=P$TT5>A74N\'L@U(:[AX8*R6'1
M+70,'B>+L[-L&@B"-=W=4749P-9T<RH".XR80@0\Q8)W:& )T9D"K\+6# GN
MV2V/:V"P9O@[-JX_"U;7T@WD08QA,T3XQ+%EACB-=U<.!/<@J(<\JD/NUZ&Y
MEF%^"'P90EN=&XY_(*[+>9G^\QFP"[,._M*.^J4L6YW260VK-]4AN6YVL$&4
M?-]&9V#[<M?6I)TTX,\IF).T<^H9>6,M6$YM\35^_]#TD<<<G)O.>.,_N-9[
M5ED=X]VJ-(MA=6E8U5ECT!TFR(]6Y/LE]E5FIND-1C<!_QS/SA+9BH55<8Z@
M"187B.:(X9IA^\<O$Y[5.U)I[SUKIU3PVO SE^Q3HYGYBVIL4T'>9/&W270O
M2JM)![.+D3PF+2):*Q4;+#!'_7A+W_VW-( &AZ>%!!X_@(U!%!]23K,G-3,E
M*CPC'6),KZ(EU+HW>D#N_UXLGI])6^)Q:=N/U'.<TAO4L7@A-TIU9W:6''^\
MF>^[:5M;%;AFW1PUZ/K CF$M=MFI$<*/7Q'BD+9NU\W'(V_D<<D[70FM/)UI
MY.@V4V<['9MJ1YOO;LGZ<?(V%UB66[-"21)S,;64226)<@Z0ESA$>_HORD=H
M)G 0='=)@&MP@44F/L<B$SM\03PBL5>IBC.*JT,&XVM8>:B0Y5Q-$&YOD6NU
M:'71#.<)3.P*ML.OUZWQ"NAGV$S[,H/L ??<6+3W2?BUK3*U*!C*B!)C6*^"
MU^1,>=8MU#]1<X>+9;.9K(XYC,@D4J5(+5<HCP#5(X=G1C_!*G^ M@]LE6<\
M(9*K8MRBG6)JU>N#U:V5/U%M\\L&UC=[0HQFG"67%%M3/F\U 6V/J.V'I.T#
MFV29R_37\UR*D19&/[UFLJGIROI$N<T9 F:$V7B*;G-3378L@>6ZL&OV$;G]
M%(_K ^2-/BYYN[D$-IB'$RE:;*1D11"J!KXD/X^\J8)9:>4+=)46)_J:GCBX
M4=)@K?XQA_J(QW6/[,8M#3'I)>FVY0X?(3K*A)TBN5AI5G0Y65A3"ZS8-B93
M,>98S=O[7>EPA1356:I.,TG2J ^[_;0"Z]3J1Q$'W"=]VS3(0]#YMJ(M6_2Z
M/!]E!QA1=ZC\FM.&"16B,QTI2OROO[L+7L#QP7PK.M&QV3 ]==X,YL-UWMVO
MO?5IZ4&\T586B@ \V46Q&C57@AK+GCOM=$)\_)4]9 6@ZL]5.&7')='28_$.
M56_9X7F!&F32$+KCV &&#ZTG<<TM@L-S2 >;9J?1)/QLMYOVQI,H[^WO\-UF
M2^^Z $H;F!+./3HFFB%M#@L(W8V9"WG5<&<\4D:E#B$,Z0'E+&-.OMJ/1B+Q
M=QY".K5+_&[U[_.O;P'J:%ZB*GCT.6X%N'X54^P6GI$4T<: R,_%=MH^@3NS
MV:TQ_$U= ZV@BG9JX,DQPUM.6-L!#(4EFZC\CE$#Z(!C=#S<*^J%=<^3P$UP
MV@9<>HANI?MJR"/AP\@!=D0,SFQNW[J&H,U.><Z2^?K$<TYSNJ90*\#J*B-O
MK:5IZN+8@N"U6D[3P4155)ZJB[R1=K;#)W6>.2P]: TKY31=D0>TTYM8";D[
M':<(\D:E!^^&BO'F'6(V<_09;*+)LF9#UA*V! *<B#:W8640^,^]Q@C]A;8I
M-<L <F[\O448@L\!B[$I%4"??7BQG]\ (@>!I6X[LZ-VH6C+=6[P/_T_@H.%
M _%**F%U(>M6)?IEL:B&D[%,S?_"+>!$W^S4>0: 9;UKMI6T2;<VT]2/=*'_
M<3%0>N0UF7IVN3_"+('[+N>3@R[WOX$O'(D^Z?)X=,%?H\DG71Z/+JE7XBS:
M^),N3SWVI,M3CSTZ78 >.]M7X$F7WZ++>_L(O>4>WVT1DN]8A)LJ\+NNP$%*
MXIU+ D(W^.7_^Q'[\='EB;PFXOY!OTUH.5^%T.F9D'^$\(;KESQW#O+X@IX[
MP3. M4#43BV06S\2P5_\#E#CP"I^<8GZ'C*4?&O*YRCN4O7PWUTZ!Z6%^*BT
MX-AK O].T@*3D ?K]&22WV:2;\8CQ#5TYH-U9Z1?VZ]78_L'F]OGFP@W'GNP
M9?C/5=K $5^AE>H=H!7!0TT$1K+=6F)D5#"!-MAU![QM% F;YCJ9D,=TOBXS
M3J)$Q ;3W68FD7>417C[0-N]SLBF@; ]J2:DGEBUI%XZD9G'XEBO,X,GDB,_
M?D5>XK'D;3H(/Z7_FTO_??H*/Y3T'ZO!O$CZN^,&T\NE=1;+J*-J5M 8/9HG
M;R'],7O:2RZL.4GQ[?)D7.Y0_%(E@?3'?_R*OD03B3/2__5"0-(0F5"#86%O
MFZ_@NC^NRKJ?E_YY_:H]%^;.4WTHC?8^?P;^"D7.DSC_]!Q>:*SY3JY$E5,*
M3@SG'<?*W,2U*>NYSB#=R?:H7D&.4TTZ61R,A%$4NC;XR[$"SZ=2>"J%BSR;
MIU+XJ)MS7"DD$KU"TN*9&6:5)*R628D5>]2\A5*(EN3L:BH6"UB[EA530I;I
ML]$F4 IQJ!1BL7-*X5LD<#KP;,HSAKMY#+>K(R) 1W":!>L)'T$?WC3%<_>9
M/Y1Z?']E^[54'9$4.Y&6P)4DISE,=W"NUR-X".(6@<%=XIG:>:J%S\S]W'WF
M#Z46]KVFB2RS5B7!K;%\>Y!9L,X"GZYO$A9%!@*-X\5<0:H7!E8EU:ZKQ3Y4
M"\ #BK]@Q)LYGW]07?PA,O2G%/OOLO#U:OWO=%(A<!)KT_5VKL.#/QZ(-T1Z
M<UO-BT9HRLN<#QJWV8C[VF<L]IGHYH>"K+$!UA3,B4)ML0^/])0:3@?/Z?$"
MUAMGPU5APM1CO"?-(I ICC3/7.>!0-\?>S0&.Z/Y<PVYD_U$5, CIB8PNE-@
MWZ?.G/WXU38!C4(M?NYA^H<:.HPLE0>0X;H:*C&JQ>A.B$ G4Z-NIZ&T!@Q$
MB+',J::#IW-'6UR[':\,-#M].[NY.[L7'Z 4'L_T&OD%0$DWEUOSV_6,Q2&,
M,IC4%N]A5X0.#GSO_>Z%^&EM6,+9V21",>J@D:XZNME?"^]NNK"18[AB6W;P
MN('<+#:)8$GQHT>3&V*YJ388H4;GRTFGR"[;E2*.6E>=Z[[@HWLB#%2/8N84
M^#C"=$M_8#Y?0Z@-B-M8T2?C?A-R3C18G7<QY=7-^5N_6PQL,2RZ0+-N@P>7
M"XPIH\/^,(R#(+Z]J7-><S? U.AT'_C_B]>6VWV>.T139U3#G=,&>!38&7BD
M5)=X$]X"ABLN&9.7G9#*"YHINKUG C>^>..9RXR*EF(NB[ 7#6J'V+* ,X=C
MXU@8]RZ#[Z!67GLZ$B&\&P@T 2XF _Q"&1TRYMR9!?@? 9V/':]_HL(S[I@A
M.*S.H3/AZ(W,'+R?1:?T9,8V7,!9(.,JK[^$5'3B]P5.B@4K C%_68B _^(V
M7!<5N#J;KD*;-X.%F$!@VI<->'W@=#1C'A5B0P,C")#4Q1\^\DB.!RN.#D\R
MH26CB[S;L&X"EE?3C2#99%Y $"((Z%5Q88[13%RO '"(I@ #"3^X! Q]DVX=
MB6>WCF>WCF/,^N%N'6<=M1MZ#:?=GZU^?]GIV+-IZ@ T'1!\=XI 2T,, 6C+
M1:A+X(6N7O34AJOV LZ#[W*XJ[#!C];&8'@0:F#/BT#O@BTD4,,\&.Q;,J/[
MP-Y'S)[[0M>]@<;(L RHUEY"BL:!B;] Y>VJ3/]MI_P;J%#1**#Q@BI=LTRH
MYL #P(B!MO.[Y%9A,ZA0-.A>!<WIUA8R'O@2N.=2V ID54<)RAY4NQQ+8**3
M3BR;O=DB51%.!/&14=3UB4 (LOG[]_PC4UROR96VDB4GV9<-;)J/+)2SB!?G
M':2.CGH:.\A1:J,YDBZAN:.0%VI7G\\'@VR?<C(+:R[$3'RNPWYD\2,^D>>)
M''.)]OO3'9(>^ Z?&+E>.Q A@32*JNGW)*S;P(4J  >+1Y@)&03<0:UXUH):
M*52?3  7ZZ%[ARG[\P[$+(DC,8L[1R!.@>E!_X-?BIIE /^P" VYJ)R:[PND
M/ACW$H'W'(U[+%D.([$_\8A7\ XH?"KO2B]R^,RI:/BC@Q38U010,U;!C1XY
MD+.!NN-!)0=<+G 'M^FZ 7M&>)N42,%L[O.&&.*!<ZNY;=,8OX%<Z"_X/G@%
M@?U+*BYX+GQ:RWT:%Z*V=VW:SJ'K\7__?MD1#M>G1Q-2 25D!*P!6T!"HD (
M#N ,;OO-WJQ[*3Y*;%39YF^X2]L138B=4@2F:BER5F#_%E%L0S"/7GO(8!]3
M@H5%KSFDI!4KQ1EZ.":GV95>_%CWTBTA KW X3JWT0H?U8'E19\B.O-)C5Y4
M6L0,*VIT;&"#P# 1.]ZE%)(>4M#OJFT"@>--GZ!N:PU-M0S?F!Z0]89H<5^*
MK)> O)TB:P<MNDM<V"$F#5?< WZK3])@J?=(O@, U^HU2XU**Q^FF!3>X'%5
ME],E$MB]$_AOD-P!27W9-HQQ[=U>SUJ/%>:\CN8'0]= ZRZW61?4'< W,Z;;
M_BE(#[\&M1G4$[*AA7B@\D7H2(-[7<0T?M,_UG>Z(">->96? .O\&@KH^M0Q
M!PIU)N%W5">SX60;VH/;.E/X*!5@U=2U6)6$0S]@T,:6$*Y3=!4&[Y+JD*Q@
MHDJ56^MQU'!J\E)\M][:Y+;@P"#?<I!$O&J@=0KT/$T[VTN\7J=HMNZ,BH9A
M\5Q1!5,5M>/.7A9OXF0QA]M4>-165KT>JXH&A) _I>B"_.LF:R #&"Y<'$J4
MP#;0;M?F8^9^3RI O #+?V#FQW4:468C^)) "NR4>"#MZUI1.""?C0,VU@V6
MX(][0NJVWW&;I&[>HTU>CHZ=P' LU/CB7FLPG@3>EI\_0GX<I!S0'MDVW2V2
MC^:I%M5@=G5/=7FA*V2%;4Y,/)A3Z"_#FD 84%64(2O(HBI8R%P#16K^[290
M.XP\!U$U\X*Z9=[0W\(#VBZ";]7=Z:[(_M"NHJLNZ*0<X);ZQ.<5GU7VNRGG
M>^,8YA1Z>2P_XU5V@><IPWE_8O\Z+>>#:?YT:D:4LQ@WP^KULIU>1\RU,FG^
M^)4\D^5_]3D&8>#-Y[JV=/MK R60W#8W(Q&/6, +@%EI#@$ZH@ %\+3H(>+!
MIMRP= *I.86'W[O]Y8":6XK0_YORC&Q.6:2?>!/.R$!1#PG4H>PUQO))'P(V
M$,P:GL]W!P@T&2G#%J-P)(#]K3G@8J#UO%;/L*O[K:&(]WB8X\51!::M*=44
M3><D^[[1 1Q.J@%,C,*PO(4J3XS C:>@CDEY"^E(K;PL.OUJO&9Y^!*7J[+\
M!*(37D6,"%9)Y$;QGB2)^4%+:"O:E.N^NX$3XGJO2>P66G>+6EQ7:[R) -9/
MM'%B<BL-9U-5NMZJ:2TNU1NWIQ!X/G;$>_53C9H:;/('D78-!H'N_EDL<TON
M<'*.-1N:^13=LS2#&-4JJU+CW8CUO\L=16E=*RILODXO6G9^%:]6%VT*:,#$
M&]RQ80G?7\IJ6=>7NNU&\Z>QQ>\1=TS9U1F[S&A4G!.B&7;:[X^C]L<L'N6%
M<YL>SYX)# !MT\"I)K?^<WVR[0=]U.[)J:C*YN@BB2D+A[3*'2XL\+!; 1Y_
M/23\9G\;V*OM_H-G18S@9K;K-'L[IIN4V*Y#AD(!/RS]9&7RK7VHZZH+4N4"
M7Q]CJ!T]4I;369$=C]-8F.TN=*IIF''8%.$D2#X#N0 -1/1:PP>2'FC+SDU_
M>;Z,JVL Y8#;$^0FCY&,S_;&+]4_C\5$Q*)LE>Q$)8>U:RM:$C/]I*)_T!'W
MN CPR98WMBS5F8+W3T%D>53_\!$[PS2R?%KB.TFJT2]-A7'!AH@H9QUOU!P!
M[=+OJA2X4P!9P6U7#']Y9+WR4#[JM3DLNZ":X=Q*DJ1,>"QV3:L@]N1/]VI:
M%<WBN<9Z*M4SO=2 [<_'D4+S#9^7,0R-=0N:4*#F:9Z 'XR4D+NU_549["OQ
M$I>H9FI:*CW$^%1TO2+BIM9IOKMEU^6\A'*C7 _0/KC4QSEL/B[H9EJA:UBY
M$.'C4E?MC&!4=<9OAG;.;=!M^A5YP&D.;0O:4-$9JM. O==AB=>MO>@O[ \M
M4O7QHKE65*E=4&=K+$%W"ZL/FK+?\[#?8)N@W1,%<F8M:Y$4[2Q;3B6:U5)-
MN)/TMM\]UV ]%%1"AQYXB+-XEY_<=(]?E8BR\.A\ $HKC7G3YGGU8#_<)_,7
MSEW#=!O)LOS<1#L#P+TD=5'16%E3-#E4 [^V>,,:*Z)AH-8BCY6_#NR^X;B_
M_3;DEX"4C*H"GF+]KCM^:I%!<X5I1T!].#T],#TWW1>8/R3R?LU-A>%:JU"K
M0>YZ4@KLLL3<U)D.FC?\(CT$QJJO/DT)@3445+<6@ ,?+&6.MM:V%0*<9TP:
MGN+>UTQ2H=RG-!53,%ZVV_%BKF-4N'-]M3XKVTU4K&YG:D0Y++\>.=6LHO']
M,8S1SM6T'Z@;R$$N]XB[^RY^(=Y!5S.7Q6YDRW:A1M['1!E4"@ILLKFSO($.
M=>C6$Y>U>,$"8:JF.UM;\)E\QI9&D6),6'1I)3QJ<ZFJQ;;B'\PQG9@B8K2#
M]Q_G+B4QZY>GPWB$ZI552#5,6D[>SUUH5X5E=<O=5&$W X-_;D?F'1\ "LQX
M"9$DZ56]9AK@"__L KP!@FX@?\OO%&=,>=[\PJ:N+*JH9C;@+#V@/?O_[5U9
M<Z)*%/XKUGW*K=(,BKB\3)6*<0_N)KY8+$T@@"#@^NMOGVXV)V3B6-[)S:UY
M22(!;/A.GS[+=TX_(,FE"UHIC4^"?N#=1:)%0(1$.B'<(?<%*EO &0L?&_[_
M-*YE\OA>KG,/"0D>F<!! ;Q=QP[$@V3U,WO-QI9/SMY#909>(;'\Z#"J\]W1
MTDAW9Z,].$CVO201.AQ.6#HC4B:7CXA4VJJ*?R:)@ (<"4E^=(&F5\04ZM \
M^T!/\D!T041+!DR:>K<[[O0XSF/$4YOMCK86*PCO;05;6.5+T0(<?P#=.08E
M%?%G!M@#L;;6#PJM'FQDEY"^6*4%+^4F*S4[F-1:A?UJWLRM7W>5:7W18:9G
M<83B+ZZA4SL@-X?/, 1&"?8#B?T.K#!:$);*AEFMA+G47#M:L]4>V%6FS_;7
M+6RX%^Y9EGN[Q2\1O_\*D.+A,X'LZ0TWIQF";5CZ"[_C#?N1\?>?!N12GBW$
M7&&_;$ZTH]*7GT3IV"- <I5R-975E+&WO@?6"7CDE-F$IVNH 9+,]BP41V1V
MHKG]T-RY#GUJ\\1H_W8TR]UE:<J?QENFX#T)^JHZ.''-Z]!LD!=':@^&HBNX
MI"&4,H>7%V(9X(Q2D6SGJ[N#<F)GLTWO>)3MQ<OKXVG_UW?FGF&8?#J2%+T[
M),H:K!R!<@ZA)-\9,[&)O4'L:I*OH)3.B(:6.;L*SOB4^?[;)4!W-_(SZ[6[
MALA71;G)*$QI\B\J9F P?C"GO>W,\_WFT)PUYIW'B6T.2O76Z.?*&<C^"J7U
M ??V?50O2F?_P?8J;&L1 A\@S"NC)R[7[?F&[DX;''_B7FO\"\SU I?2C22;
MH=W\''/K71JI'X.1O2KWGOUJD1'FS/&(\LM2N5[<2%\?M@MW0B;()88;[H@<
M>X=$/9-7E;XKLC;>5RK&=-&?64,F+W.-UO.">V]79/PA1TK'L6U,"C\3SAY=
M1$E%[-MYF85B,3S+$#F=QLS)F0G"^Z4)&BJGJ\%R/Y5?1QO?*)F%LKM3"Q5V
M_%Z.YO]C1%\I&+$81"*")W 8-4^5C*9:%*L/UH/-M#9MZ:AW%CT)CR5=,K!_
M9-E8_\91;^(L10%O$M(&M._TOV^>BOL"1M9E=9Y4$;NVC)#B87!@CO7I[LN0
M[Q)<7O?"*NDA5-1.[>;!T:F0"RKQ6=.S7\.)P0[55J,_0\.5)DW7BTY1&?V$
M[0%T,2<8"< (0XE['I#<!7C:P=[069)I!2E0XA&^,=L2HX\\Z[/ @G2,U 8M
M& YBWRAZR# 00!XUR3I!!]$55;36)8@KX=MINJ3[^!;@NA.FDXO$J,+3P3<C
M<DE"%>86ZR09@DUN-F/A>ZXQ#HF:;-H(UM]:I)\#/OZ-T'/#5A:.N,Z-:P_Q
M=]+(UIW^1]1O(^HU()!<*.@G5#>-O&&5&'&"VJU&+E\Y:-CPJ*2E>2^7\\1H
MWHAL,O(4"@8MHA9553>!H !_XHM^39 S9U(&JR<IF(_*[&526BOZ<:B-YIMD
M$X\TV0>%WMLBP;G[N*=(LJ_"[7M-7-NB\<LU-ZG<LKE)<EOYH*_(V<;RY\>@
MEPC+I/9$V=FZDMX2)>IY\DVRE2/^I?F6^?T?4$L#!!0    ( .0]:%B=M(M&
M,P<  & I   9    >&]M82TR,#(S,3(S,7AE>#$P9#$P+FAT;>U::W/;MA+]
M*Z@[;9(9\R')C1U*]8PLJZT[<9QIY-[V(T@N130@P0*@9/77=Q>DK(?M-NZ5
MITDJ3R*+>"S.[IY=+&$,OO"\<9GS,H&4_3"Y?,U2E=0%E)8E&KC%UKFP.9NH
MJN(ENP2MA93L3(MT"HQU0O\;O]/M^J'GG0Y0UJB=I,J(]8*3H!MVCUC8B[I'
M4?<5&UZRY]>3T0LW^/QJ-/GU[;A9]>WUV>N+$3OP@N!_O5$0G$_.FXXC/^RP
MB>:E$5:HDLL@&+\Y8 >YM544!//YW)_W?*6GP>2G(+>%/ JD4@;\U*8'IP-J
MP4_@Z>F@ ,M9DG-MP'Y[<#WYSCO!$598":>#8/F[&1NK='$Z2,6,&;N0\.U!
MP?54E)Y55=0+*]O'F0%V;XVY\>8BM7G4"<.O^A5/4U%./0F9C3H=__CEJDV+
M:;YJ5(URD0;)K9@!25^3FTC@.HJ5S?O;2]PWLUK.RU1IO8P70BZB9T,MN'QV
M^.P'D#.P(N'XW:!9/0-:9,_Z;K 1?T#4Z:)^4I3@Y=# ]#NO^HT!HE9W&KVQ
M3#.3>F?"B%A(81=1+M(42AS_]9<GW;#7'P0T%BU7/81RQ*6(M?@PG!U<K4"G
M+&%V_%?88N'&>BAFBE:A]B5R<ANC_Z0?:_6([T4Q$048]@;F["=5\!(1N!9"
ML@9BWBP;*YFBJ/%-CFI;"HE.. CBO]+RB7WQ.#5VY+E'Z!0^I4X'IV_4#(H8
M-.L<,LP_7;93\'N'/-HADQQ[##NK=6EVZXPG!O[SQ9"-+X<7KP/<K*[?77S_
M9L^E?]DEY[@5LH90T=X9_\@9:QOD;[6Q(ELT3:)$(#;JO:SL#ATV-&RA:O:^
M5/-#]XUK8%!44BVP3HP7[)>KRR$;*5TIS:F68<]M#HRLT0W[(U5@W;EP3YW^
M"U;5VM0<T5C%:)@%71BF,H;%Z566B033_M@)=S7L<*H!W+?4E:7#>HH:LV/:
M&#KXB5F)8W?J*E8VK+"XO=TUUF'<RED"\=FOI$J9.A0M2J=:#AI0*TXSL-(C
MH&X)-W"%!YL+E:+M7;L&BXVD? PE9%A&)&AFCIYS\S1*<F"Q<F69TEB0QR#5
M?!,CK;*)\>GCXQXN[4/F_PV9:Y2J'2_@1N!JQ*(ESS=8=,A$R91VHQ52@@%"
M%+$$(LG]Q&IBL* HT% @PS9B<9W,)((S.R>3L>>=[@NO0#UR5B%,E6Y0[ZUK
MN@W23$DDIX.-8S*A#<7?@N##*C9;9=8BO'/<-ZQ$RXQR 1D;WT!2TTO-,K)]
M=K;8C'J;"\-NB7_H.ALPS.0<7U31)CQ)0()V\8]6,I9K2]&^72;NP^43#9<K
MRI#H>MP"5OEQF32WZ+*>@AN&M%& _[(:'W%V BZQ0Y9!8O>L^$19,=E(#>17
MY  1(,&$(S$M-DZ^261M*,?P6U[$@$D/RJ98V=KAW6&8!E,A-9H:!%<Q=?P;
M/1?<6LI2%PBZQC1I($64-$TYBMXN@634K-*J$ 8'%#P%DD7K4>50+E0)AVR>
M@YN%99&D\7,M4#Q2>AN#J9/\#H81AL,4A6_729L9$\7\7@NL6OA2?%.5H'/=
MIF'06<W.@,&EVOIJ,W'[;,O2!69Z3+LI[D4S#,*TM3/E<GR8"<XRGAB!CD0E
M,3,G5JM2)#@/BZ_GHD2'T!$9J]*,U";SK8TB1-S6NO7C@D8Z@Q"D:_^=SS*T
M.IEL[-[7AHG;:;IA&!ZRZU(0#]AX)<\=+?*$M#7-8+WT5E5)M /MII+/7ZPZ
M+$U!UQFR4(%.4HV.MSM.2EYVFTW.D5DQD2FMY<*-FF$$I/C] ?O0 XIPH];2
M$#'4;<BX M; E4+B[%/34Z:FW66BMQ*X <=<YU%Z%6GB$-.0):9A(Q9JM<9M
MJ'DS@+UO/\*SAW>8G#!BY>)P?_*PU^GST.F)0^9'4>  W(T_)=!7]+:,FWFV
M+'7.%-<I/9QCK918I7=\C/TY$NMSU.F)>>?.?8Q5;3TY3!*HL";<GW/_)W7Z
M ++5_TPA5_BED+0'[EZBI-+1EZ'[N=-+&**:J$G?[G0[!)%1^+Z"D (3L/4_
M]PV"^F.$N8*4"E-)OHA$Z6P=2Y6\[RM\,<NDFB\=?/>:Q4-G&:[)D]S8S?85
MDFV,[>F'8Q9HHH1L!<?*6E7TY[FPX)F*)Q"5^/;*9;^] >(?'3D>M.QC2Q:N
M4_U>_5I&T9IKETGH2DO+W_J4.<_]K:1F>J_G?]/>B6D$?.B\EP_.>AQ5UFU4
M:?#FFE<HF&W\/!)<9P<:?6S,?\!.=VY,-.:J=W93YVXNZYZLY3)W+>=D=2OG
M;XV]'3F-\8^[.T[US:.S7QMYKJ6]^-,V/72_85>1\/'/>FR=<\XMK&^5S46Z
MYC/72ZDQ3]Y/M4)B;_%_[3K<9D=+KNUB(&R9MG$1KVW:N(>W?<>OXE.T@0;^
MWN.9!1WQF:(@:LCVTC\Z_JH?NS^_M7?R0F>@YNZ@NXQX^B=02P,$%     @
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MIE@&.Z<'NT$(1!T0A;,/:,15S2-M9L-6^R2ZIPEA-0,,Z<T=-68*2['6C(^
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MZ[UD@*.;1^<1S!"1%;B/M-USQM^M3X.0>MO"[)73IJ@Z7$Y5K*8<[_7H&*-
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M2E\">1JL.61CM!2?JG0FYR M.L]R'>.LU$J20;<K>VBK$6!TT@JZP1KC["S
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MF9C  ?E3TVW,2YT<ZG$JC9,O_X5)+=X"679T\;DN/M?%Y[KX7!>?^RO'YQZ
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MN5=JH$R!:6MP*#<EW7$$,\=#,Q/HQ,D&<?)LR^(D^(=D*"R#\_ >.^RA:M*
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M0RQT?YB&2_B?:3&+?_G_4$L#!!0    ( .0]:%@;!C8=4S@! *VD"@ 9
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MA)B[6Q9BME\28F+?+F:1(.OM$6!FGLZHIPX[FRJ*C<-.;%3KX%[P= ?1[T7
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M%YK46*%L'HSN.AAU,%HG''88?.M%I1%1YV;I37CC+)[-%;_F 28T:M=5@72
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MZA^RHLH#DD2EEK)0U)M[EA;\;5%1B8);6!>2S5L"ZH>8DH8O<TXF&'E=.-F
M0KN:T]93%?I>RPI]YU%0D[<JFU59TT];5*V2>-H"M]8A1HS>Q<EE=T7'&;M>
MK4GK*;@0.6@-DB"#O"<%11T3N+0.]K9-FH(B?!^.0[-(HCXRQ,^B:\Y[00RF
M1FXZG^]C?;Z[SN?K?+[?G<^WJ0B8IK -)[/,I&:K]1:!QLJJU7-[BUKMS5:+
MZO^LJKMH8:*P4&6:R /C!56.:/+<#5?9W%,.MJA6.>QRMWAP1[-"DFHN&IW9
MQS7%#)3[2Z!L;V[F5[2G;"TYU,NP89=F$%47@P"[<HSC1 VOP9I=UEO@8$O3
M<#N&8\1&-@T&>.-M&DP/K;IA"^')NP>[^S(\^5ZE0\=@CX(PHO*Q<&+GV!#M
MM5%<?MK"K9-0L;(D:MNO9<*^=VP;8S+,6E=%KC%].3 ($M?JLHGL#'9JF<R9
MQ[9):YMEW=&!025;,3G>^I@ B"1"$=(U,E"4F5CUFM[:W&HK?L7";<5F?YU;
M6N[)/0_<WMS:@7E:-\QO%>VWC19K=EGS:2H,*\H]TV+9OJ5@S&IF_GDB(=I4
M/VWV@ PB!YG4=,I:CEO_]ZW_HCC=O>.+H5>]._264>R4CBWJSQLB)JV'9017
MR#=L[/92C?2]>C@M@MSBTK)]B#_+CB9;;SQNZI[:X>'D<Q@,4H&/^BM0RDZ)
M3Y9MN4AT5#ROZH%$M\?T/#K"71K![1MX2+-DH4E&# <-B0X^5+R[%@&!VAOA
MPK76UA.W1F+G@%6K2/JT-%&_:5.0?<<["_[?-P+C.[#*WI?9HQTP/PV8!\L!
M<Y=<E+"_9YI3D6*:,6V>^5P"LV*#K&QG\2AZ)=^ESKN3%R.1 AR/!J:2H6D<
M2_4A2N^JHM(N58&HJ_F 2T30S\6R 93#+-M!KIHVP2H/&..C7$8F91+TYC9
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M&1T2Y9FD0LVWSTS%(:ET>EH<!'F^,0]37^JDA",$QWV*F%!!NRJY3M6QD7V
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MJ'A/Y4">#3F Y3%1,PS/A_.>T /\S9C>=U0-*,RI>^87;].+9627&IQ2"8:
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M@/?EV_-X(5U9)4NZ4JM\"8HBQ:H?YO739(8@%UP'Z+D"H&+2<0I#&8H13'6
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M_X(_\R5$P\]\6U;WX:MCP(7PJ,_20>P415F2TLEK[=O,.%&7Y4',CB6RJO0
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M/P+]9NRDI(=8=66'LK0;K&W-DD:R3QMY*DO*,2MQ05NOO-.(^@Z@T%$'%.J
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MF?=<)=<@)@ZX/ \]?[Y3O"D_T#+>2*RY9!E;K?$ZLVG[WOQ&""2# /%CK[/
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MH\S!AS=V$O1OQ&T4BRVD7O;QXF]3<+Q'<^D)M$AL%]Y&60;]@7;OB?Z?Y&B
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MB+_%XREYS.R<>@T.^CPV7EHM;M0Z\NBVD5N%CJKG^?L4\(KB.93:+0I9 &H
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MQ<43Y%PO*E%#Y$RTQ0@8;2IL88+7I>2,C5Z4D0O)K[*N5IEBEICF"C,2-*N
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MZ]/!.@ENTW0 $<7L+K0DF7#VNAHSN(,%=((/E0QBE#N&;/X&BLL)@!T0YSL
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M16M,.3P5PB]]"'Y.!;&'8*E=8QLOWQ-J:@XQ#<,)=<08*3)+_'N"-(,$C^3
M-:YR-- =H[#?@:\H!=/0ZG5''607XY<' W?I[/2)0:D9"1-PF6HU.[37@];"
M?@"OA_[PF^W<77:+*7\[K[3:10D<*>+]")6>T<THTE!Z_<%*(B?=F"+=&#,4
M@1^&(U UZIB@L7YZ_":OK^C7)V]H8Q".2Q:'O]8.2G-!2SJMQL$4W%<,J2RL
MUE=MX5E7ULM3?X5VC]8A1<K/J+;52NW;3M?BJ<H7G,DG8$D*)R=1WH4K@-#
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MO%@N";M=, +F<JY&DB[O"/%N]+=QE-[?_/9[;::J?)>.O2,T%._@W&3K=8>
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M];S>Z?K>9:W3:]%/%XT._+6-/_8Z5]T>O,SWZA\OF^W/=7D*/;\+WRY\L7>
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MA],G;XX7Q$\<G'GFCEFYO-V;9#8>.@9OG[J,%B^5G7FS/4J;A4=G!;#K10F
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MZ7_UVEZS76MYM?>=>OUCO=5S]=L6U?!,O9.^-@P'"?K<29P[7/F_XD'Z=8:
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M3O37?C*<PW]NII/Q?_U_4$L#!!0    ( .0]:%C!Q4I(>&H   M: P 9
M>&]M82TR,#(S,3(S,7AE>#$P9#8T+FAT;>U]"U/BVK;N7\E=N\X]NHMV\1*U
M76?5142E&]$&[,<Z=>I4@(#IAH1. HB__HXQYC,OQ&X;:<VNVJM50C(SYYAC
MCL<WOO'7_WGSIN[<FD[?&A@7W<NF,7#[LXGE!$;?L\P _KJP@UNCZTZGIF-<
M6IYGC\?&B6</1I9A%/)[^WN%8G$O_^;-WW_!O6K\2Z[SUBC]>?AG,5\L&_G2
MVV+Y;?G0J%X:.S?=VBY=?'I5ZWZYKK.G7M^<-!LUXX\W?_[YJ53[\\_3[BG[
MH+R7+QA=SW1\.[!=QQS_^6>]]8?QQVT03-_^^>=BL=A;E/9<;_1GM_WG;3 9
ME_\<NZYO[0V"P1]__X5_@?]:YN#OOR968!K]6]/SK>"__KCIGKTYA"L".QA;
M?__UI_B77=MS!\N__QK8<\,/EF/KO_Z8F-[(=MX$[O1M*3\-CN&;?\+'D6ON
MWBSL07#[MI#/_\?QU!P,;&?T9FP-@[>%PMY!1?W-LT>WZH\N>[FWGC4V WMN
MX=U7/'L"O]Q:=(=2!7[7G@E?G(JO#5TG>#,T)_9X^?8_N_;$\HV6M3#:[L1T
M_C/'_@+_^I9G#__SF*[V[7L+1@7W#*R[X(TYMD<P*GS2,1O$6_[NO=!#%FPP
M/7<\@ _K=[=VSPY0."KEO_[LP4Q--S0LO%H\9V[[,(RQ'2S?WMJ#@>7 !?_W
M7X?%?.GXKS_QPE\TKJ\S/["'R_#(:O5VM]IH&8W3>JO;.&O43XU&Z^RJ?5GM
M-JY:QD6U8YS4ZRVC_KG6O#F%3W<:K=-&K=J%'T^^O#7^^]___O?_[!IG[:M+
MHWM1A^LN&B>-+GRI5KWIU WXL0&WN.I>P#=WC=95UX!;U]N-:M.HMO!V\%?\
M(FVYJ[/0T[L7U2Y]V*Z?-SK==K75-6HWG>[59;7=:'ZA&U1KW9MJ$W[IMNO5
M;L>  5^W&Q_A&<95VZA=M<[8JU6;>S2ML<W1'UNF!R(2W!Y']TF2^#_YLO1!
MIUD>^XOM@#@$M#1JE0S\?Z'(?L AF(9C3F $_WLQ_E;8+Y6.]@O% ]SWYFKY
M[U2;]1Q.2;?=.+FA&<89[-3;'QNU1NO<J)ZWZ_5+F*U?MSD>_;8#4MNF;[A#
MX]3J6Y.>Y1F%_9P!&KRT)6/L6<'"LIPM&<U*&?@,>P?.NLZNT6S6<)ES?_6\
MOV%Z.]9X;'DYPW0&6_(>'7=LC9?&T/6,Z<R#S6B1$/PU$R.C6PVLONN9N$W?
M]-VQZ[W]5Y[^=QS]=&P[UML9/-C#GV(?TSW?^N[8'@A]7#GN6'W\T  [ F1M
M]C?.SK,, *R-TDYO%\>PD<?OV#8]+&<\+$VUJ_;U59LTMBY0UZ8':YP#B\L(
M;BWXQS)NMT>XMF<DJR>XW30*T:UZ/?/ 6O1QMXK)A?]X;'KADA^Q-E8?BV3F
MP<^!.V&6WB^V[!)-E1]_+?;?6T]\N6?VOXT\%S9#9,]H+QW^@%NUL&K'N'N$
ME9M/FAO^)]VZYG\*&==1XWEJCJPW/7!3OKTQAR!";\WQPESZ?*H/*GOE@_\X
M[KD>;&!NI.1CYOAFS/S?:_%_:U-OE6[H5D^:9#*C10=&6^=7NS1/-.YK$'0Y
MU+B8\:U4B>PD;6>A(.*O[MSRAF-W(83@%RYB>&S179XPMM#F.RA.P[/W1OTE
MP! "V#B3M[/IU/+ZH->CXB[NQ9\.QHCV +:3^=]B$Q!=LGOZY>YMX5CIP+>+
M6SN(/?2GIHO]2A:% Z]FCH]U.>!_6O7ZIG'K6</_^N-?_]MU^^#C[!=AF^[_
M\7?5"VS8Q49CSSBMGS5:#;0Z.N3YB(W/_M%?1<[;X<%1Z:B\#P,<V/YT;"[?
M]L9N_YO0[@5KHJ;0[($M-(-YT;2$F+V\T,/\S@68_3MC +^ JR*.#*Z2RL=)
M0P*Q-0.^K4*B\EH64E^R[1]M(4'"$D^8U3JL5/F-E=A1/JK$CA*.YA>JJ])D
MHP)N*G?10 D4]M+$6N@;VR'SD:D=IEGV]XH'_T':XBA953SGRYU:0]NA=?(S
M);NM$OA\NG3%H#*5F:G,1-DX"*G,XLM2F?!RYY9C>>;8:*"O-_4L7"CCVK.=
MOCT=6YD:W5JIW#XU"H,J/8T:S;SGEZ9>'^W&'&K>,[C/F QD"53?MT<.(2NN
MSE@JMEUM=<[J[78=/NUTZMW,P?[]UOHW<K!AM.7,6LRLQ239.%+68O'%.=CX
M<B;H8\PJ:VK8'3)@V=#R/(L^L0)?I/IJ8UA79V2<FH&5J>5ME=GMLR6/,B6;
M*=EDV2CD0TKV9;GD^')MZ_O,1E5Z9CLF^.&@/CL!Z$_4MOZQ<6EZW_!OH'?;
M"(@9P-]:+IC*3#,W'#_P9FQZFA;H.B]SXK=6CK=.\>*@,L6;*=Y$V2B$%&_I
M92G>@HJ%7GLN8G9<QP<-.S(]7$ZR9J7Y*PQ>5,+X0=P SG3NMHKP]NE<&-1^
MIG,SG9LD&\60SBV_+)T++X=Y)R?(M.6V"M_V:<OBDVG++,WTTK3H8X/YA9*>
M9FKL&>WZ=;O>J;>Z5"#2H933IVH;:_D:]2RQ]/NM[N^36,+15C(S,#,#DV2C
MK,S TDM++.'+M:VI9_FP(E3>YY.3_<GT8/<$-BND9!6?F0;>5O'</D.QG.G3
M3)^FR,9^2)^^L!P2OMS,F]MS<\RR1*MT:Z91MU5 MT^C[C^91LU<[Y>F:1_M
M[E0TU_OCGE&[^EAO@9O=$;C.3KW9K+?) Y<4 L?BKW6XN(M7GM;/JC?-;J;%
M?KO%_XT\\TIF26:69(IL: 5"Y1?GF=/+H=]MU$!*'; 8,WMQ:\5P^^S%@TQO
M9GHS138.0WKSA7G@\'+29LU4Y_9+XO:I3AA4(9_ISDQW)@G'44AWOC @)KQ<
MS75\Z_O,<OIZ[L>HSWF]T:DU-&?C##6TM=*Y??KTZ.GT:1:[?&EZ]K$!H6)>
MQ2X_[BE*ZDPA_7;+^/M$(7&TA8RG*#,)$X5#J\W9?VEA2'RYZG3JVDX@*LXS
M--!VR^+6&8 XJ$Q[9MHS63B*(>WYLH*1^'(URPM,VQ&.=+6?<61NM3!NG_HL
M9NHS4Y]IPE$*J<^7%8_$EZNYD^G8QNY^K(T?EGPW7=,QJB//(EZ.3)5NJV!N
MGRJ%016*F2K-5&F2<)1#JO1EU7NSE_/F-J9UJ(D;_9RY\5LKBMNG/,N9\LR4
M9YIP[(>4Y_[+4I[[5"4Y-OMD<&;*<^M%<?N4)_8&RBC:LR3XT^0CM0*>CXT]
MHUMO7S9:Q)MQ;'1NVA\;'ZO-3#O]=FOZ&V7$*T^GSS)C\'?56VG"H17F5%Y<
M1AQ>KFMY$]NAFNY,RVZK!&Z?#7B0Z<Q,9Z8)QV%(9[ZP/#B\7'TXA->CEA69
M]MQ^6=P^[7F8:<],>Z8)QU%(>[ZP-/B1(A7*%.:VBM_V*<RC+.28A1R?*N!3
MTNMND*ZWT3JM7[8:9XT:Q1V-Z^J7RWHKZP#Y&Z[K[Q-VQ-$6LB8YF1&8*!Q:
M(<[!2PL[XLLU8 4FCCVT^YGSO-52N'6V( [JJ?1F9@N^-'WZZ%.X&+(%P1B\
M;'1J]6:SVJI?W72,Z_;5QT8'FSAD*NJW6]C?R!C$PIBL>U=F#"8*AU88<_CB
MC$'LG3.QG$%6_[+-\K=]9F ITYB9QDP3CG)(8[ZL##2^W#F*IX,-99OFXMCX
M9,)"41O9KF>;8Z.W--[-O.4Q_M?V!W8_\[&W652W3[F6'U2N,14+'I3IO86U
MOI5R$YB]L151;R729_ [%R?2O9KT_!&Z:>A.;_K6>'P,@@[NFCE^8X[MD?.6
MW39RAZ?1RR1-["E]D"C+XZ_RENG7'7LW-A_LO[>>W%12[-[TW;'KO15RK\U6
M^ ,^+>C*DTKBO^<3IU$[)@J%O8/*?X@_,8T>_AN>'B6F]D>@ZCS+_/;&',)K
MO37'"W/I\SD\J.R50?'QO<O^EH\LR\2\>Z/->&AO\H>&SQ;QQZ1#-'Y,RY'^
MXE7].O,#>[@,+VMH!V(#[YX]MH.EL .XPBH=K[0WM.6-SM5Z4Y!9*J_$4MD/
M62HO"^V!+]=R RS4S8R/;96^[3,^L+XL(_S/]&6B<%1"^O)E,1NPEP/Q-)G-
M@0[=M>>B$9+Q;&VQ0&Z?"L62MH-,A68J-$DX#D(J]&7Q&^#+57T?O+LLG[#-
M KA]*O,@4YF9RDP3CL.0RJR\+)4)+W<V\X);I'3U_9F'#(69M;FU@KA]JO,P
M4YV9ZDP3CJ.0ZCQX6:H37H[E7H^-VFPR8\MDM*V)-; M7T_,-B:3F0/+F6G6
M[973[=.L1YEFS31KBG"4\R'->OBB-"N^7 TF/;"\J>EE34^W5P2W3FGBH J'
MF=+,E&:2<!1"2O/H92E->+D36 )8N4Q?;JOT;9^^+&3Z,M.7:<)1U/5E(?^R
M]"6\W*7EC<!#-YV!T0!K<^1E]<A;+8S;ISZ+F?K,U&>:<(1*]PHOJW0/7^["
M,G'E,O]\:\5O^Q1F*5.8F<),$XY0Y5[A957NT<OU;ZW!;(RMJ\#DK-_=VCT[
M"V]NKS!NG_HL9^HS4Y]IPA$J)RJ\K'*B,I43.6^NK<#.G/1M%L'M4YK[F=+,
ME&::<(1JB@HOJZ8(7PX#F[ ( Z-[:WL#X]KT@J5Q8CG6T.[;II=ADK98,+=/
ME58>5*7;6ZC_#"-+5!K:'5!H8\+)J1B*\=MM8MVY5VI4PRM\!I\CE)&5=/.4
MB1]X,Z8ZFQ;L7L_/YOG1\WP2GN<3>SS&>>Z88^M!>HG7PK62D:W\YF0K[*A^
M=JJ57Z:9=-5""D6]JH'_+Q39#S (,,-\XZ]>:"1<-_3<\0"NZ%2;];_^[/V=
M6WU9[:K5;3=.;JAK0;5U:G3J[8^-6J-U;E3/V_4Z=C' VQ@[ 3X2I[.8/_YK
M)FY)8QY8?9=EO2/;)OHI;I&WL+LL#W^*?<ST'=A\-@ZM.O(LB]5@SF@=BX7C
MW9PQ,-'",WW4;Z=6WYKT+,\H[.>,8KY8RADP2-K]<$W/"A:6Y1B?KRZKQLY-
M9]=H-FLYPX2OC<V%Z5G&V)[8>+>Q+>KE^^YD:CI+8V>3;]H!38D-M/77Q+,1
M/K?&2V/H>L9TYH$P6O36&QD3;9S*L?!JP"8NX0!I7,\Q@#(,8*>WBV/8R./9
M>3&#_4/B4W-A_MF%>R$1ZJL/-BLTX(/%]@:,(;BUX!_+N(6%.J;5^MQN&H5M
M%?WKF=>_-?VH](L7H9)"?)6]7V,4<DLA:M2E*]YVO=;H5IN=M[_62'W$4?#I
MHMZN5SLY@VD1PUTXOH&G%ZH*G$3K^PR7UR:MZ >D0N2T'V_M>PPLWX;Q&H%K
M^/"7',BG$WAV;Q98(,A4H)\S&$$V1U_!!7-KB5^0KV>88 C;\,YD.\#U=C!F
M?H>8#O@AAU_!OY'0TIQU^7WQ&*GZO@5WL!W#NH.[.B.+-+('9X\]1P+-H>=.
MM$?B]\5OQK4'CLX63K(:KC;/4S%JG RS#W(#BL+DK@2M"N[0PL'Q4\PGW^)_
MF89C3F!6_O?H6[OTJ>L5*Y5RM?&A-B\M9\'[HP4'O-;&8(O!9)_"\1];BZFY
MQ,_@L5QX\,Y]T[\U0#>3:N9[(;PN_#W[UC3 K^-OGC4<XXD#O\)#4'*&MF,Z
M?>1$A2NQGL0'-=HWIW8 ?Y(RB<\@.1"[D#T/K6K\#"Z=F^.9)?Z>*E^6[R>/
M];>0(3'[K@'# +>%%'G/NC7'PY#6T;ZK)(I,;-?Q;^VIL;"#6P,/HV3Q>-<^
MVU\$L]MZ+7_O+.[NSX8?W[]_7SMI'52YM& X'>=6V)"&5@JTY()IF?W;E >\
M[T0>D');)NH#\)!M/\#W@O>-OQJ;@1P8IB"L?38>F Y_%GG^Y<7Y_I>/0?GP
ML%*[O+DX6,X77\_KQ<)T>5^X2'NQ'=OICV<#DG^4>G<\YB83RG/DD;B98;/@
MK[XQ 'D,*4LV+?%A-2X>/RS:# &((3X"_^4V;5R[3RT/6QRPY\(PYLCVMVHB
MF5FSS?M!>U$39P16Q@QH>>C ,FE]?-(>UF0Z)H]&*$MP8-0L^K>X8CW+&-B^
M9XU,#V/PJ/%N]CI[QM""KX!J 0EP<:+-.^DG_")[Z0>FIW7U*6=T<8[.KMKU
M'.HY>&_?QJ'KJGDR"V:D4><6*-R S8X)%N3  "/0PF,%IY69A"/7'="OJ%4Q
MVA2^9X[N2"<TC(.T_ #,(+-/A&B+6QLD#>89[]M;@E[_YKB+L34860/V3=02
MML4NP U.:P@NYQ VE[OPF?&G11">,!U7*$[C^;B'+=9UF_90>N*-/S7[&%A<
M>.;T6+6O:>RMG;.*QUIXZ(G6/!)UZ7F_XHY20ZG,0IYGCD_K9XU6H\N:[D3#
M/1M<K*3M0B'4=2+/&';5HLNQP'/22@ION<":?+#)DA/5MH8P486#<DE,5.(D
MBIS1)OR_4POL*S*1?/0 ]XS_^Z]")7]\XXS)$L+-OK#!!AK@=9HJX 88K,O
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M &V?3#JX=.R_=NG %3^SXG#S7$S#$HM2W\32+=-##(U'1$@)L'0*(;[V2>V
M?0\3-<BV6J:(XRQPF52@5# 4L 8">7WL/<4X>X_&T'.P08:><\LA+ZI!]'G@
MQJ/3=LTJ<,96B+7G+$)4'/%LUW2)722BDS4RQ)%V%VA?X7X^\MIL&;534A>
M!X2#Y&DMX5# 8U7=*EB1XE&$./<1CYH/>('8).%+C,J%*&%8X&0\HR2L;RS
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MW_TBCPNP\>M#U=]!?S-M]+(V1:M!"+7K2W\]ECPR.7G#3SZ=>U#,X]$>+_?
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MG^5D5#-QT&=8#^;%[V=8CPSK\1*Q'HI.+R6C^.@&=CG.3Q4_;?!DSQFSJ2O
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MX^>J:$C-XU+PMF>PU-N7E=F4_DLH).3IV6+IL%Q(3:T?'N17I-;W-\G11V+
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M8\?<Y10+&&30NIQ113S#+A#6L6\B1#[2?4)]05*\R(84B GAG"^B[RUCKJ'
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ML>9!(3XI7IT"VZI?ET??/-^>W<_O_OG:*/A>Z?!085@I&1<^6.3<#2Q^E,Q
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MOLJ\ZX^;,CH CFBAR@?&UH^016=N+1FRSU-_UKZM]V*(5\<;F.;IW[(-"H8
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M$&>@?W!O;D:#YK$K>30PUE1PNU:R,OI@0S;BF#"SQ$N>A34=3)4A;^LD\)P
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MD5.*_E-5FX-1\P)FZG<#9/V"DH'F+J+^>L.%J$02H/0-)0,8^HJ>'\C_X(;
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M$9(^P6I$_#2:J!+53&K84BPV/UX"*L60>'  1*:(V;Z.E@-E5!3/FK9S5X2
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M[M6A?+6=B2C4,,9)Z+O11$V %F'I2XB48BEV ^[@F!1L@DR0W6X#7 C)N52
M(*P#J3,A%ZTJ'=*:E6KN<,M!/HQD(\LY4["\\M)W9.>)V/H&TB43&4X2DB9
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MU=+C.8J8MN!0?CBS%AQUTWM90PW9@=YH)5H(WHC49H]3@(*Z[!F]5H<WHA-
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MC2.;+P]C8E%X713S<!0X<_AC$D^]G_X_4$L#!!0    ( .0]:%@U"A')V@,
M $ 6   8    >&]M82TR,#(S,3(S,7AE>#(Q9#$N:'1M[5AM;]LV$/XKG(HL
M+3"]VDELR1'0.!FZUFF*5,:VCY1(2T0I4:!H*^ZO[U$OB5^*-6B:8<4<(#9U
M1QZ/S]T]IF[RBVE>%1DN$DK0F^AZAHA(ECDM%$HDQ0JD-5,9BD19X@)=4RD9
MY^A",I)2A%S'.K%<S[,<TPPG8&O:+1*%CP;VR/8<;XB<@>\-_1,7O;Y&+^?1
M]%4S^?)F&OW]X:K=]</\8O;'%!FF;?\YF-KV9739*H:6XZ)(XJ)BBHD"<]N^
M>F\@(U.J]&V[KFNK'EA"IG9T:V<JYT.;"U%1BRABA!,M@4^*23C)J<(HR;"L
MJ#HWYM'OY@AF**8X#2=V_]W.C059AQ/"5JA2:T[/C1S+E!6F$J4_<$H5P$H;
MU#MS[LR:$97YKN,<!24FA!6IR>E"^:YKG9T^R"1+LP>A: _G2\JQ8BNJK?_#
MWCD\9+2Q,#B%YXT]86'9+UN(0ID+G#.^]H^GF+-8LN/?CM]0OJ**)1C&%>!J
M5E2RQ7'03*_89PIN@5'."MKOXEK>*%#T3IE@)04_M31HW?+!(Z3_1^VW=D&;
M^JH7$<MIA=[3&MV*'!?@02/1GNPYH6TUCW7K1"PX"5:L8C'C3*W]C!%""]CN
MUQ<CSQD$$UO/AK"4!PQ^$ ;.$S&(GP# YHF-\.HN@S,KY+F6.['C]H1[!9AP
MBB4L45FP6XO?*+%VI:[48,$%5NVP*SPPJ$3NNS3O)5WY6F/OJ*N^\=@:C8]Z
MJPT\YX8VHBD&QYSV.\5"$BK-1'".RXKZ_6 3=UW4'>3Z' EH@)%WZES)WF0?
MG19T17KYBDH=7]Y%"_BC,W$"%AZBUI-2$\$3:]C%L1GMP+2QDP#K %7=YV#_
M;-82EWX,OP.?S!K.^DWH[_4XK@1?*AIHHG/^'5YSQYM ?*ULVY6@?&39M4G9
M?2IRB,=_+1ZVDKIXGB$PS\*X>XC\*%)M>)S01$BLPZT924C_A=/\[6FU4_ZR
M .K2HSUUXY(/^<(T6W]<QA4C#$L&/HD%4AE%4Y'##7*-'MC[68KC$(,N!F^7
MDE6$)5JE8W C4URPS\W4G2#\[!7Q_5<M(_SKYOHUBFB2%0!]ND8S1:PM^OB)
ML_0IN%Q0F2\)WH/B?Y\K+^<?7Z'9;'I($B.\A!M$C24]9,ENELS?H1G+F:+D
MD"=&."\T$N@='(*(_) MF]ER.T/N@4\>PR=V\QZ]?:-_KD;/X_HZW_$*DMV_
MM<<X^91* ?>YG6O?1A=C6]$YZ.TX[/1=B<U&XW:C8DMVWT<L<4K-]LT0+Q25
M/EX)N#NVN75V:@W/CH*N7='*G*;MV?9&FV9K^ 502P,$%     @ Y#UH6*A:
M42WH P  '@T  !@   !X;VUA+3(P,C,Q,C,Q>&5X,C-D,2YH=&WM5VUOVS80
M_BLW!VU:('J7+45R#22VTP:-G<!6T.TC)=$649D4*":.]^MW>EL<-\':81DV
MH (LG8^\E^=(ZAX-?]&T*<\(3V@*GZ+9%:0BN=M0KB"1E"C4;IG*(!)%03C,
MJ)0LS^%<LG1- 2Q3[^N6;>NFIHV&Z&O<&@D>@&/XAFW:+IA.8+M!OP]G,WAW
M&XW?UY,GU^/HMYMI$_7F]OSJ<@P]S3"^.&/#F$239L#530LB27C)%!.<Y(8Q
MG?>@ERE5!(:QW6[UK:,+N3:BA9&I3>X:N1 EU5.5]D;#2H-W2M+1<$,5@20C
MLJ3J0^\VNM!\G*&8RNEH:'3/9FXLTMUHF+)[*-4NIQ]Z&R+7C&M*%(%C%BI$
M2P.'#^8\:%N6JBRP3/--6) T97RMY72E LO2O<&C3K)U]J@4#;A TIPH=D\K
M[WM^DYP2&<1"9>%AB.<LB\YN);C25F3#\EUP/"8YBR4[/CG^1/-[JEA"4"ZQ
ML%I))5L=A_7TDOU. Q\!YHQ3+:--GKIU&BKZH#1TLL9HE39L2A*TU8B?C1JQ
M#2UA3K>P$!O",6*MJ2+O!=TV86*1IV%,DJ]K*>YX&ARMZ@N]3Q\R%C,%MJ-;
M0R/&VA?_!$[+^@N@"1X$*@^05O8O@T6L-=2;I7:.>&;186&_0?PT =MOPVFX
MX$IL:IM[5B+^G*E=D+$TI1SS>'ODVZ83#HW*X<^*O%9%GCT+W[WU7\*^C[8W
M&E_/E]-Y!-<7<#F?3&^F>,._B^G'RV4T74PGW?OQ;#R^OIU'E_./<'&YF,&K
MGX6_M\[?+O'_;$5_!&AO](5"(GA9-4TE0&44&$^$+(0DU<L9XAU(NJ*28I?%
M(5C0-2M5.[A4V##KACL7I0Z.XVCVX-3MGY[4LM6W7&O0RI[EVIW><SW';&7?
M\MU.?^I[5BO;INL,O%;&+NWXG>P[7B<[MG/:R8.^[?I >-K\]6RS[V(KAPLA
M-[#4FJ$7LV^3[[NFY^Q9H;P"<2>Q!E@1!6E-$&9$)AE@X(HAG$#3O_BZ*V!5
M3Y&S9NZ*<20HC.2X)&VXLG+ZZ_7L#,:/A3X!4A38*BL_6&:5L1+..+]#PT43
MN\O*,K7/L!*RCK5#$Z \Q4@3FM!-3"4X5IV9H_\;K]>?A^P[#IE1&K@\N6!*
M47A+-D6(I/0NP?6[NKKYC^>^1.I\(:L]7";B!*I<</-Q1EX[[S_W0)4W5#^_
M>?XXAB<'=C_OA@8W]TQV#A]IG):(7,C@R*RO<(_,/AUHD[8/0)C=+MZGT:WJ
M"8L^9.@%65,MQN^1KQI9(6<)R+U@:=BP9V^@N]Z;,!8RI;)EU&9-ZAOF7W]*
MC/X 4$L#!!0    ( .0]:%@;E7-!5@@  .\H   8    >&]M82TR,#(S,3(S
M,7AE>#,Q9#$N:'1M[5IM;]LX$OXKO"QZ;0#+LN.D2>TT0)MD-\5MFD7/Q=Y]
MI"3:XD42M21EQ_?K[QE2MF7'W>;%Z37H%FAL4\/AO#Q\9BCI^&]!<%ZDO(A%
MPBZ&E[^R1,55+@K+8BVXQ>A4VI0-55GR@ET*K666L?=:)F/!6+?3/FAW]_;:
MG2 X.8:NTWJ2*OJL%QZ%>YV]?=;I]?<.^IU#]NZ2O?H\/-UUPF=7I\-__W;N
M5_WM\_M?/YRRG2 ,?^^=AN'9\,Q?V&]WNFRH>6&DE:K@61B>?]QA.ZFU93\,
MI]-I>]IK*ST.AY_"U.;9?I@I940[L<G.R3&-X*_@R<EQ+BQG<<JU$?;MSN?A
MS\$1)*RTF3@Y#N>?7C92R>SD.)$39NPL$V]W<J['L@BL*ON]3FD'F!GB\IK,
M33"5B4W[W4[GQ:#D22*+<9")D>UWN^W#U\LQ+<?I<E!YY_I:9-S*B2#M#;UQ
M)KCN1\JF@_4E-LTLY_-&JK#!B.<RF_5?GO),1EJ^;+V\$-E$6!ES?#<(;&"$
MEJ.7 R=NY'\%=,/#3!8B2(4WM+UW-+#BQ@;0,L9R-#KP,>E#F-'_(_]))D0;
M31C*7!CV44S9)Y7S LN[$3*C8<'4+QFI+(&J\YM41M*R7K?=/0XC1+W\)A[&
MV )"?Q,73X6V<@1K*9/?TL?_5 8+S_[$25+V,#]W3CZTV-54%.RB&J?"M%CL
MW)PQFW+;/PY)W1-ZVGVSNO_>0&*#ZVY(%@FRW0](IH[%ZSH6G>W$HMMF'UC*
M)X)I,9%B"H:TJ32,%T7%,PR62EN0)OM9Z1RL&OR#J1'[U]7E.W:J-"XZ; Q^
ML*CMM=G<X\>H><^-JT@LG['K0DTS@=K5\@FH(Y\H*"D4BAYT<UD@,3-6%597
M JNBHKF*B)1PEN.7EDC:B,<8TDSEH">KO-PM@4+$PABN9R22\VN!=1LZ#<82
M&(,E,\H!K4$"L=0HPQ!#83:P)!&:35,9I\Q4]&<Y?RJTJ)60 [DTJ!:405^X
MM3"EB)V!I+>$:2J!FQ-,2U@T:X;A1\-7K\V^B W!1K) ]"F1RVBW  R(X[)N
M7)?%"-O6;5%\C[,J@4YDM!':%M @=39C)1)"6"*,H9%:@*7.DUE;&GA,7(5O
MD42500 (44BC6\XX>V)N4C;*U-3,X:/%6!J+KLDR3H/>;EC9:J# S(VY9>V/
M!H3]-ANN1.WO/QWM=0\'IDYU7;IH4ZD1*K70/O ?&-?"I0ZID%$F*,1, "]1
M)DU*\B26@U&(5>AW(DV<*5-A'G&-5IE756J%%AS#AKU"RA(!#/B\G-^@9RW0
M;;_#-OY499#H]GC0/7@E=MW4[D'2^"6I;RD\=$@]HZW>0)3/,)ERYW5&N[N[
MSK-U:&&YJ7!U[5D5]&ZO??!XT/!==B8,UD;X'"E_/;4MJA<QK\S=IQ!Q1P)Y
MJE?RI4!5&@JPC2?2.'* E"B<'FJOEK32I"9_1D#BZUJPS&2KIBVZ*$$QL,6H
M3";N*&>JR,A$<BW) >DKEB/+@C15AJJ(VR?&E1Q')3B!P2"<J=RDD@-Q<95Q
M8D"XY8Q85B/,\+6M69+Q+1(D")+"?)$\*U+:#L2B=8C=>7/?0MK=:>'.@ -(
M)S(A''&#DSG1'S? (/4L!"ZNDWFB 3W)(YE).Z,2M6E9@KW#A$NW1^R*:*/G
M<2Q[4SM45FB0#4)))36.E4Z< :[[&8L"E3(#ZG!%E 1G$D%GYY$%V,L23-=^
M+M@ZVAJVXMVM--?G$YY5CB<H>6(T0A,C)PB[V=",+,KJ'7C/_]S<GS@X8B(X
MR_@N*%*5_;(%=V%FOI 6U.*-OMXNLVC>/+H=)GPDZ)Q&RI\<43C+/P91G:TC
M*@%;^4#?3AB=I^KVPEW9B(I[<!05.17'E::T-"K*!JVY,A;C=$,'NDP,17]4
M*$A">S4I-XMZ243A "02QZ#.@9K=9CBA78NL/LBMR;<>[=.S \T6^NZ#!_?=
M[EY*,D=;:[D5B1F:&5_N2MK3]ZB?MYJDA6T<C9)5M2DDXP:@,L^EM4+00ANF
M10H%D:XE$K8Y!:\ ,5",(0K#)[5J<R"+/RH)TQUHJR(F!W:?OLG^[C@%3?8[
M').I%W&W2*&)CBRQ%$A87246S>Y4\&NB?=\+..)W78R[2S,_,M\+!G5?ZD]Y
M&WB )YAHQ((&O@B9NO?!%.0>+4K+UQZ#PF.J'.%#0IPS-5]NO+GP["AB:UWP
M.Y2/D<8^:R$CPG$#<NKN=]7);WDRE\5$P6=B](*/Z]MVNJ83D9>9F@E<G:;*
M4PA?@1:@L)7ZM.UVLKLI24]!R6O H&;?([>?R@2IAG:*1J>W<ABC1U4.'&]W
M"#'T4,V=!FH3(N!=Z"!66<9+(_KS+\W5T-\.:N?H$1<%&*E;!2)9M/K\C$;\
MT[ W!R_(<ZOGB\XCY2-BD_GXA$H*>H :S5:5M8:#SHM&2.<+N? "Q6_J*/NO
M:\_G&FL1(NA.W#Q>\]_!5/.R'X%$KH,IXO'59WZ+ZSS"4;RR8D"/'I<.N\=_
MVWG8=QM=.*PT0K$)47[FW2'BGY76?VWR5T:^OXR$5M,&>I+4/-61^BLQN4>1
M.4,=Z;-+KE'NCUJ,WEM8B=8],%OS7:2L53E2<L/<S33V4\?]^RX"]V=/NA\;
MRM"$[.KW\X_LXO,O%^?_O!7&[QQH#]E\3UQ@'X ^XJ;G";WMO5C1>/U@\5K%
M7PA\<@0^!Y ]AM].4RE&[/Q&Q!6U">S*WYK8S'.A:X7GA?;_>Q9X0&>0+AKJ
MB,?78ZVJ(J%.7NG^G%,:;Z>M7J@-W%LS>,Y"*^_%U4,KK\6MOW)7XD 7^(:-
MCY#2/I\HF=3 .WS=WC]<L)\?Z[BW]/RK?.[=P)/_ 5!+ P04    " #D/6A8
M]!Y-OW0(  #B*0  &    'AO;6$M,C R,S$R,S%X97@S,60R+FAT;>U::V_;
M.!;]*YP,NFT R_(C;E([#9 F*5K,I"U:=W;W(R71$3>2J"$I.]Y?O^>2LJ,X
M[C0/)]N@4Z"Q39&7]W%X[KV2]G\)@I,BY44L$O9N?/H[2U1<Y:*P+-:"6XS.
MI$W96)4E+]BIT%IF&7NC97(F&.MVVH-VM]=K=X+@8!^RCNI%JABR?K@7]CJ]
M'=;I#WN#86>/'9ZR%U_'1]MN\O''H_&_/YWX73]]??/[^R.V%83A/_M'87@\
M/O87=MJ=+AMK7AAII2IX%H8G'[;85FIM.0S#V6S6GO7;2I^%X\]A:O-L)\R4
M,J*=V&3K8)]&\%?PY& _%Y:S..7:"/MZZ^OX;;"'&5;:3!SLAXM//S=2R?Q@
M/Y%39NP\$Z^W<J[/9!%850[[G=*.L#+$Y94Y%\%,)C8==CN=9Z.2)XDLSH),
M3.RPVVWOOKP<T_(LO1Q4WKBA%AFW<BI(>D-NG FNAY&RZ6AUBW4KR\6ZB2IL
M,.&YS.;#YT<\DY&6SUO/WXEL*JR,.;X;.#8P0LO)\Y&;;N1_!63#PDP6(DB%
M5[3=VQM9<6$#2#G#=C0Z\CX98C*C_WO^DU2(UJHPEKDP[(.8L<\JYP6V=R.D
M1D.#F=\R4ED"42<7J8RD97VHL!]&\'KY*!;&. )"/XJ)1T);.8&V%,G'M/$_
ME<'&\[\PDH3=S<ZM@_<M-DYQT; WE2Y,B\7.SCFS*;?#_9#D/:"IW5=7#^ K
MS%ACNQN218)P#P.:4SOC9>V,SF:<T6VS]RSE4\&TF$HQ T7:5!K&BZ+B&09+
MI2U8D[U5.@>M!K\Q-6'_^GAZR(Z4QD4'CM%/YK5>FRTLOH^8-]RXE,3R.3LO
MU"P32%XM'X#:\XF"D$(AZT$VEP4",V=5874EL"M2FDN)" EG.7YIB:!->(PA
MS50.?K+*S[LVH1"Q,(;K.4W)^;G O@V9!F,)E,&6&<6 ]J )L=3(PYB&S&R@
M22(TFZ4R3IFIZ,_E^IG0HA9"!N32(%U0!'WFUL*4(G8*DMP2JJD$9DZQ+&'1
MO.F&GPU?_3;[)C8$F\@"WJ= 7GJ[!6!@.B[KQG593'!LW1'%]SBK$LA$1!NN
M;0$-4F=S5B(@A"7"&"JI)5CJ.)F5K8''Q*7X%LVH,DP 0A3"Z+8S3I^8FY1-
M,C4S"_AH<2:-1=ED&:=!KS>T;#508!;*7-/V9P/"3ANYJNFU?_RZU^ONCDP=
MZCIUT:%2$Z1JH;WCWS.NA0L=0B&C3)"+F0!>HDR:E.;3M!R,0JQ"OQ-IXDR9
M"NN(:[3*O*A2*]3@&#;L!4*6"&# Q^7D D5K@7+[$,?X<Y5A1K?/@^[@A=AV
M2[N#I/%+4N%2>.B0>$9'O8$H'V%2Y<;[3+:WMYUEJ]#"=C/A\MJ32NC=?GMP
M?]#P;78L#/:&^QPI?S^T+<H7,:_,S9<0<4<"<:IW\JE 51H"<(RGTCARP"Q1
M.#E47EW22I.:?). P->YX#*2K9JVZ*($Q4 7HS*9N%[.5)&1B>1:D@'29RQ'
ME@5)J@QE$7=.C$LYCDK0@D$A-%5N4<F!N+C*.#$@S')*7&8CK/"YK9F2\2T2
M-!$DA?4B>5*DM!F(1:L0N_'AOH:TF]/"C0$'D$YE0CCB!JTYT1\WP"#5+ 0N
MKI-%H $]R2.923NG%+5N6X*]PX0+MT?LE:F-FL>Q[$5M4%FA0#9P):74.%8Z
M<0JXZN=,%,B4&5"'*Z(D.-,45'8>68"]+,%T[:>"K;V-82O>WDAQ?3+E6>5X
M@H(G)A,4,7(*MYLUQ<@RK=Z ]_S/]?6)@R,6@K.,KX(B5=EO:W 39N;+V8)*
MO,GWRV46+8I'=\*$]P3U:23\P1&%9OX^B.IL'%$)V,H[^GK J)^JRPMW92TJ
M;L%1E.14'%>:PM+(*&NDYLI8C-,='<@R,03]62$A">W%I-PL\R41A0.02!R#
M.@-J=INC0SL76=W(K<QOW=NF)P>:#=3=@SO7W>Y>2K) 6^OR*!(S-"-^>2KI
M3-\B?UXKDI:Z<11*5M6JT!PW )%Y+JT5@C9:LRQ22(AT+9'0S0EX 8B!8@Q1
M&#ZI5%L 6?Q92:CN0%L5,1FP_?!%]@_'*2BR#]$F4RWB[I%"$K4LL10(6)TE
MEL7N3/!SHGU?"SCB=U6,NTNS:)EO!8.Z+O5=WAH>X D6&K&D@6]"IJY]L 2Q
M1XG2\KG'(/&8*H?[$!!G3,V7:V\N/#F*V%@5?(CT,=$X9RU$1#AN0$S=_:XZ
M^"U/YK*8*MA,C%[PL_JVG:[I1.1EIN8"5V>I\A3"KT +4-A(?MIT.=E=%Z2'
MH.058%"Q[Y$[3&6"4$,Z>:/3O]*,T;,J!X[76X08>JKFNH%:A0AX%SJ(59;Q
MTHCAXDMS-]2WH]HX>L9%#D;H1OY9UZO!,S++ZH7$A1N\N399C$\I7R#!UU"U
MJJPE[/3:@^ZSALL6$'?N&[1W:B>Z;RN/WQJ;4;SI/MO"&XO?P4SS<AB!(LZ#
M&:S][B.]Y74>H=&NK!C1DT72J_%T;S//\JYC!ZU(PQ'K\.)7WAP _E%H_=<F
M-PK)8+>]L_=W2!XM)*'5=(0>YK@\5,O\':?<(HD<(T\,V2G72.=[+48O)EQQ
MU^U06U-:I*Q5.<)RP=S],O9KQ_W[ 3SW5\^R[^O+T(1L_.[CZ>$7]N;KYP]?
MKCGR1\?:70[@ ^?0NP&0*.HIHF]S;T\TWS%8OCSQ-P@?!80_/L[NPW)?1"'1
M.OPA8\$^:322U.JTV%M7[OMF[2B58E*/4 /PT=^D>/#J_T$MOP=TW)$+7?&_
MJ#W^O]W/'8JE=-EE1#P^/].J*A+J790>+OBU\4+>U0NU@KT5A1>,?.55P'KH
MRIN JV\9EFAA U_#\@EB/.13)9/Z$.Z^;._L+C.!'^NX%Q/]VXON=<B#_P%0
M2P,$%     @ Y#UH6*-]2%D2!P  U!\  !@   !X;VUA+3(P,C,Q,C,Q>&5X
M,S)D,2YH=&WM66MOVS84_2MW+KHF@"59MI.XDFL@=9TE6),4B;-N'RF)LKC2
MHD91<;Q?OTM*LF77?259T0(IT"3BX[YX[B%Y.?S%LB9I0M*01G Z/7\+D0B+
M.4T5A)(2A:T+IA*8BBPC*9Q3*1GG\%JR:$8!W(Y]8+O=KMVQK-$098VK22+U
MH.<,G&ZGVX=.S^L>>*X+Q^>P=S,=[YO!;R['T[_>34JM[VY>OST;0\MRG/>]
ML>.\F;XI._IVQX6I)&G.%!,IX8XSN6A!*U$J\QQGL5C8BYXMY,R97CF)FO.^
MPX7(J1VIJ#4:ZA;\24DT&LZI(A F1.94O6K=3$^L 8Y03'$Z&CKU[W)L(*+E
M:!BQ6\C5DM-7K3F1,Y9:2F1>KY,I'V<ZV+TUYLY:L$@EGMOI//<S$D4LG5F<
MQ@J]MX\.UVV2S9)UHRB=\R3E1+%;JJ4WY(:<$ND%0B7^MHI=,[-Z7BQ29<5D
MSOC2>S$FG 62O6B_.*7\EBH6$OP[Q\!:.94L?N&;X3G[EZ)L])"SE%H)+0VU
MNP-?T3MEH909JM.M?AD3#P>#_C\H?VL3@ITF3-F<YG!!%W EYB1%]:9%F]&P
M8%&J# 2/4-3D+F$!4]#KVN[0"3#JV7?Q,,04H/*[N#B>7$W/3L[&Q].SRXOO
MZ>/?1:Y8O/R,DUK8_?QLC=X5,B\(SE<"5$)!TG\*)JGA%LQ B(5$8F$I7!6<
M@MLCEMO?"_9!Q&;X-0T+B>!&-9,[S-H4^>8X5+K;?=GKMX'D0%!81*,V[.D9
MOSX;=+L=OSG:-+G^/I TTA)UKJ"J@XX6,TY(AFL,ASW]-=7Y#^Z@UG^3,DUD
MUPKY+(>QB"CL8>^-?6V/;=3E'A[Y6M)^&RX7-(738I;0O(U2&8W19#1?)R1<
MQC$+40N*_?/R_!@ER4Q(8BQIFCT6<V3896UQVY@\33"Z.;PN9(JBKVG*A(0_
M4!Z\DS1G$<:R#2<LU?QM)I3:RQ9&>%.[UE4I:0,E80()E318 O8C#'2@54)0
M7K5> <U-M!.6 VK%P? A%0M.D?F]H:/A4")5D0 C%P@94?FJU6FA0,XKHEM]
MYQD)Z^\*4.4,*Q2<DRRG7OV'?W_$N[L07U$W\J<2<XUROT'F^M,X8'&R%(7R
M8G9'HUU9TJ#=TG*O2A(E\7]4>U4-&U1[A(J:G??@BG4JW^IU"@FO[#(FH@O^
M(D&D6CK U,,%DB3S&T94"U$9Z]K;)FWV/R#CMZPM/[4@-$K."=^@OJJI-9JN
M4:FA[Q[Y.1RG:8'8O:*8* C!%$YP-)XUK-\U:1AP+G%'!)/\\(:&=!X@.GMN
M&_"\T3,(QJ @PI4&[[C$=UCF'#80I1#^.)5H;EGO+VV("\XQ(= >KO/!''VV
MN"O7.;&FDCVRK[-CU7"P%ZTHK,E$OD[/5=;H)7 T;AR#O:<<^IERJ/LCYA!+
M8_UI0!CB(((K&.G=M0EPB F3"/ ,-P\-Y;8>0/ \CQ/1 ,PY[,@0RMBC 1RO
M]A$4&9F3IMEE<%3!RTP0&2TWLWQKC[$_#?;=Q^I!\U3]TY]^SB[@_=GT8G)]
M#>]/)U>3RY,RI 5RELQ1/ZY.0O!\H(]"V,%PA\70YF931OXBJW@.ZD#FQ>ZH
M? .JCNR#'4F ^&^-5#)T4,/#O-;'HHX?D:4V_IS(,#&4W&\>%_3J&\6O6N8:
MT:K9[ZLHK5S;0_2B6E9](]* 1SS7G&0N7*10HLKA@[Y]Z#XO::;64H.BHI]5
M*F_%IB2\)F^MX=*D!3BP^Q6 S%];-[B&-H$:8BX67L(B/+^MOBU-.EZ ]^</
MU@)#\,5;88.+5T-)D M>*-HT^'%NA!_O"N[+9BQVI4LY4P..Y<A!G*EE[;6&
MRJ#;Z?E-9)2I7_U<L<;FUO#%]:G@4T7'S>X 0\(B>-8Q_[YA_?X7#L*H?>Z6
M^5#:<7('+M]/+N#TYK?3R?5&=!\84<W1/V,X'^^BWKCGK:[I]X[JCQ^XA^#P
M$[?@1\'C=XW<3M[[_R*W?5S]2N)\(LO[DN7T]/+\^!I>WUQ=/+'EH[)ELW;U
M1)>?1^+]*WN[,5O?M![M,O69HL#CWISN1X!/Y9.?IWS2^_'*)RROB^!5D9"$
MH:EBE$5QVBA KDJ+3(&YF.F:/\Y/A8*(TCE>ZV/&ZV?3K8<,G<>KHN!8S.<L
MS^N:2B4#Y0>ZFA-6SP0H*5BBIIA*JJF I;HXD"ZU%HS9SF<%4V/8UKU^.^EM
MOIV(CX9^Z;T%]A8)5?I!8$XB_5 0"TFU'!*K2G&$EM<%C%7P]C%2LJHPZ4,A
M]FM/9C2E$AEM[;1V@J,%!4$C-JI9>8&A+UU_6(&I^3-9504"$GZ828$!U)P@
MI%=OW(TGV,V.*LN[6UG?V:A%5.^\5=/&V^_VNW*&+EME%<!$TR.W@D55-AT=
MVOVCU1&C;.L8G\KW:O, /OH/4$L#!!0    ( .0]:%BH_^E.8BL  ,V2 0 7
M    >&]M82TR,#(S,3(S,7AE>#1D.2YH=&WM?6=SVU:Z\%_!Z\W>E68@BI0L
M%RGK&;<DOM>)/;9RL_OIG4/@4$0, @R*:.ZOOT\Y#85%$DG1,C+C2"*!4Y]>
M?_Q_1T=OD[%( AEZOUS^^MX+TZ"<R*3P@DR* CZ=1<78NTRG4Y%XO\HLB^+8
M>Y5%X97TO$&_=]8;G)ST^D='+WZ$L5ZKE]+DW#L]?G9\TC]Y[/5/ST\>GY\\
M]U[^ZAW\?OGZD!Y^\^'UY;\_ON59/_[^ZOV[U]ZCH^/C/TY?'Q^_N7S#7SSN
M]0?>92:2/"JB-!'Q\?';WQYYC\9%,3T_/I[-9KW9:2_-KHXO/QV/BTG\^#A.
MTUSVPB)\].)'_ 3^+T7XXL>)+(07C$66R^*?CWZ__.GH&3Q11$4L7_QXK'_R
ML\,TG+_X,8RNO;R8Q_*?CR8BNXJ2HR*=GI_VI\4%O'D,7]>>^7HTB\)B?#[H
M]_]^,15A&"571[$<%>>#0>_I$_M9%EV-[8<I;^X\D[$HHFN)HSOC!K$4V?DP
M+<87]2G:WISJ]T9I4AR-Q"2*Y^?_>)E%(OZ'_X]?9'PMBR@0\'L.QWJ4RRP:
M_>."'LZC_T@8&?8W@<V.I5[E<_BDD%^+(Q%'5S ;?G[!1T+'X>&_P0G_@FL8
MMJ[A,IK(W/M-SKQ/Z40DL +Z!%?B+&+&TP[3.(2AWGX=1\.H $!X_N/Q$$Y]
MNHL=!H !,M-;W.X.W[S]_/K3NX^7[S[\YGWXR7O]\N.[RY?OO<^7'U[_SPZW
M_&>9%]%HSA]%20@G<#YX-BV<0\!]XY"WV_JC%Y=CZ8W2.$YG@ ->E'O""V4>
M9-$4@=A+1UX!3[Q.)Q/XZW.1!E]\[X=^K]]_>N9-1>9=B[B4W@$^]%]_>W9R
MTK_X\1C7<)=5\1'AF^=1 2<1M%V1NZ2[3_GH!:U^<''H>Q\S.0*B"B33V>\]
M[[:VIDUNV!-)"'=.=$MD<R\'<@SOPLW_Z\.O+^'JLVF:"8*&@]UN>B8WL4]?
M;73'-U;FW_#BTS+;((AY:>;="X$ ^6B^253I>9<-8OBL]^3D[._>9W@6A@%\
M*2<E,W[OH\RFLBA%O)<DQ:QXB[3%)^*">VL2F/O;\BOOC5W-9UK-1@FJ%,'8
MR^04Q@6.C7Q5>(-CD [[(+9'*,7(O(!?X&,Z"X?+(L3B.(.G%SF UNE3"UJO
MOCG0>K5ET(*3P[VE20Q )8,R \&;.9=SFG 15U&.9QYZTS++2P%S%RF<:D \
M;7"B7_ALAWC[%922!-2IET&!7P^>GSZ&"4$Z CTLA)'NX5#=-6V4J.G!=BO3
M;DJ$C:-$FMEZ@^<7UU$.VDD<%?/S<12"S*SVVC^]N.^=;E%CJ8K#^Z2A-#:]
M93SY628R$W'/VP227#J$!)6CLABG&1Q-B"0DRG.@K^44?S]Y^M0_/3V%?R>.
M!.W>2L][&<=>6A9Y 4P1N4+[<T37@'1'83SG*4+?&Y4Q_#4544@<-4D3D><R
MS\4PEBR56"7.U=]@S4.1D_7'.X@.6]G,:YG!'0(<%,2)WB6!%?GOF^@M6]MF
MN<E!M.!X7LV/8C'+Z22 060 XG@QB2='(^ A]W$J:DF;E]3@$-0IO)$P T*B
M0J>*'OA>S.YCVV]^?OU^\^*\19R\G$Q0)%QA *D+&(!C?X$D!F *. )P$16Y
MAW)?)HNY-T0!!&0@F002Z02^.,U29%)I8F65)6!.%V. ,$BG2L:9C2,0,\<"
MI,&AE(DWBF*8'X!4LGDNU]/5 ?IEDJ#@^ EDX*Q PO!3FDV\0?_H?]088U@N
MFIBM]"ZF4[@3)#8MB\=KN2<A8A';T>QFEWSG370=P4)"[Q-^FF^._XQA?)G1
M<8->7@5%NGZ\!++_XHUG,I"H(81J.3G;=T $SJ)AB0 %4#0;2W@I X8RITL%
MJ U$/D9%/<4O9E$NB>!-!( P:F]!+%""'F7IQ"M@E01<^!, '%?U*A59B$M\
M W ?%"FL]P _WS%AQ%5LEBS2CF-Y)9 !BVL1Q71BHQ*.UM[Q]POV_YN2AKM)
MH'^+^C-#?2O0 \&]8JX$5X*4MHA9($L3D)S2 FEZQEJXT:^K!'R62 )6 -4T
M(^$(Q@)@+PI$M+P<3J*BX#$%CZC6D>/["B%[J"9*.&C $X,U,.1?982H H@!
M)-MWT;>RB -X;29A6OCI/(,<I:8V5_9(JR$'(*)]P".ZRSJ$;V%4>T+T1I%>
M,<JC/.?E<&4 Q(#4>5[?O3);\&PXASLXG2Q\&&7J6#+D#< 21.P#%0GBDB1;
M?$W&2L.&386:*( 0#/OCJ;QAEI9(M8821I7M<_'Q^WS \(A(%@_NUW?.E"L*
M^38$S/LG2._ E17GPJ%SI'S$!O$37IGOE4D,TK7S$0(=@A=02F:\L!#Y%<\J
MMRS1Y8C^2L;.3QC.3E2\C)&Y9VBT(%./8K,(%#F#@K8"."P9[JE$^=1^ B/2
MU;#Y0XW4>(7(/0*U-7PHZ"4W4#0BN:50-V!V#N?%E]7</Y]_>BTS%EL"P/PL
MC94%,*@<$I]KSV$8]/907:Z^LVE<PF6V7QI.T<"-= F$D,0'H(9$(4E!G#<&
MM6LF8\1&<\8OV-L4!7R%!JT#ZE-F\%0HU E#+WY+D8C)R90.%P[I<P3#BVRC
M?.*758)1@N)02*N +_AN481. $!S^Q&N;VI7JSZ$:Y^6&6!;3AL IH!:P9"9
M2Q5MN@M_\4G+GY^4_/D^ DH2,N%YXTJ?F[G[=PK+KY% *0"([90^2KQY&I>,
ML1E@--E<CLJIOU2@-C3((2LL1 #1!M))FC^I1'DN"R28$Q$E9.,'8N3(AS"G
M*W1[8E2PP#U1*T:>&T>"3)5(>K6NY>P"H5+ICF:U==G@("+V<%]FW!W!(&M"
M&EV9$2R[1KPPP-@_F7ZS(JMT&1$B]DN4YLF 0XS&MTH4#>B,;:UT;:(92"0%
MB'$T>"AS.!ID]3@=6P<5M(S*HLSD_9K:\7J\OOVW60-T_6#NP0A]WRX%CC[C
M_X\S/?=0!%^N0-)-PJ,@C=/L_&]]^N_"B2&K?J&F!L2I+*6O-G@$KQ3IA(/>
MU$=N0)OZJ!+/5H^5FXHK>33,I/AR1(3I7,0S,<\O.)#MZ9/>XZ=_OQB";B0S
M%=S6KT7 ?3>1=5L/PKJ15T/#6[2IN1Z] %2-[D:;?T](54<BO%3?L8:BI;Z4
M@0]8@/\<VMMP<P.)]=FZJMF\C^^RV8MH;ITB10GR<G9-T]MU*9\M!O0 CR4!
M,P VI-)?F+J33J:9]32=250\74:-WVE94S^G#,2!4 :X&,3APAD+(P*R*. /
M4)>0Z:BN4&N+7IL@B_8.K1GJKRLJC=^4A'EQL$-:3ZO0X:.EX N.@O8NU_:K
M-Y:4DR&;:=1=P:( 7XJRT,OF ^UY'\SE!R+APT_+PM7XC2G!&^(7AGW3,+30
MM>WE:+A)7.#0;U8,##R?TC0+#R@/*)48<J'$,_:^Z9TU-$W@[09ZS)41'-=!
MCR!-W0<NC]5%K6B@"!&D91PV9!.M\.)[!&IKR3XP@=+4:5!2A0(X,8$A)[")
MHT)\D:BD*Q<67,XK-L$H088W048'1I<V!+3(K&5F8_K"TP]3D#+L^><<O*X/
MP" 3N5T,VK5,],!MK/4(W"4^J#I05=U0=6JQ.-;)W[;'RM=&+4,E OLTC>#0
M4ORS0G$<XN1227C,H<\+SF3+_K&;.,2\E_3W&U"'B4*>#GSOI']RZGMGP-I.
M'=:F;NI?L!"DYT6$H^YQ6->_MAO6]?S9XQKO7Q2I2+<Q\)\H86$9Q%>B\>B5
MYOB-<#5@4F@L5%R Z+:-WMA7?=M1[H27B DLZO__$G]Y<G;Z>/#T]#$FR8BM
M0PK2M-L$QNZG>/N'9#)B]/NP!4C;;#- ;!;![MZRM?[FN-I"O"6!(1/)%_(Q
M&ZG=B+:." TJ ?*(]:Q[\/"Y>ZSMR6*XU=9DL3L=?D4U;VCF]J1I";>ZKI9;
M@6.8QF)^'B5D*!C&<+H7-[LJ7(92LG&1P#4+>91/12#/DW26B2D1Y^=/GC[?
M )MY] )H<(0NQ)0$;') LL?+\O56@5:]P((SRIE%)>97T6B07<I<^Z7BN8NQ
M &@(<0@E?Y9Z#<42*+6F'8*3>XL7)5GSV<9M6BYXXM+6M'%UZ'(?Z-+FCW1<
M"=58'U3A!;FYVUZK."50SV4_Q@W)+ ^-SR\2"MN6@AHE6\)UZ$$=[YN8O0J9
M:U/L&J,7X%4%>T^?W!5[.V3]%I#5\A5D52N8%$,K&;40/TD[IAAO5">5%B_0
M )3FLF4L!'_/,M-E8'\SZK$Y&N%CF+JTJKC\"L/F.CXC1,L!6\TN<.*.W788
M?.\8S/904%$!$:O83,P) 5A;,!4?P]T/@24E& AU8$UPE<\#Q[!#7HB&B)LV
ME,=#+?8BLE1&LP9D-WP T,R-*$16.S4C*OJA<P]S0+R8"!&- Y0I.:SN$-:C
M-HAQ+T"/1%:)<]DQCNY&:UW+M*'#O$WVQ>9<Z#WRF=\%?KT_)"O70-[=Z#8*
M[K9T7I'@10R#XL/9CP*09&*_W4AOWQ/LG,B4 5A9>Y0%](>3LUZ_O\"KY$T!
M=#FF!G^;2Y%Y!PBAUR*6G)SYPTEO< 8#F@<.,4Y0+U_[&W3T^E^ER "P.39'
MP#X$NN28'8DA.IEP38,SX(*AH#C"_Q8)O#/WO9?3+(I][[]+=+G ?C\$13J4
MV85BP^C+0"[,,3;63*&Y)S&Q* =&5WC"&Y9Y1!@*LU! 25+UVS$;G)%3Q@8,
M6PNUW@]=#\S:/IT*8Z%<,'61T60B 44+2?*##&2H<#@!O$'_2B#YH^H*.9/,
M4 7X( Q521\76%1. +HFU-F+0,&6;%R+_8J&AX4Z8(BQ]#RM(92^%090!<@B
M0&O!GC>L@*12=*(LM\?AZX,$X-2G0/<(5TPV]H&)T9JD)<LX/_1[3P?/GIXY
ML+?$L.S3V!C"->' 9(&YVIB#IV%-1;=>4UHQR5,P5!HNWJ': NYS5C$I@^P4
M+A??BC'%2?OD%45(<X:N[MN]C14XSK>%\;E14I*?Q[DYG1Z"$)12>!,!*> 5
M1KHY^2/J@<($U5):1%NZA"H!X8B=Y/8S8.8KMV5EW.HC-($3-8 1=HHV];HP
MG"X,9Q?<WXUJ_6@XVEZ* I<+8TFM+W45(43>QKR\Y_V.VE]%\ZL%(2PG-;68
M6IVFMCCBM4UMC;)UW(+3N$0!6)-_B;YN'1%BJ5Q(]+1,B(6$#A>KSLK1"3PI
MAR?A:_)K)3)'L2]%W1ZV;V<M//DP57+$)Q-UM)=(\D&)N12<;7SUFI\RRP46
MRWI@_?L39NUK0"3YD3$ 2TZ('8)PAQB33AF1*+4FC2G/(")[9D$"MG"#MF 9
M@;3 _,/)$Q2QC3SC:[ G&,^T>%&'[][R+9\LW_'I_>[XK.=*<)O9\>GR'3]>
M?\<F"FK3FS[;^#4_7K[ILSW8],G&;WH?=G4;C/WNF<EGM(_#&;8P%99*A/>:
M0U\IQY93#E,$@%B9L]YBFM!>,B!:/U6Q"KBX"(MGHKYX,NZ%<A1AYO)0QNGL
MT%?AFGX=.!EL5YAX6B$8A1_XXWD?#02YPJ.:^IKJ/%"2C.K+5-O DC4P,-J=
M%N$%:N6WPPB6PUKU85<:LS,^:!1Z].*/%O_.XHL7NZ[:THZ%&P@69&#+R5KI
M.\#:L"(MM_6@DFN*(ZT3=<C)PW$*% =M\#E7U_9^$WDH_E(/_2JR+_)>B@/Q
M,C8;DXF[P$?_G69?U 9-.;K[V.*_/[_=:,5&99W"<;V7$_@Z /7Q_?O7NZYX
MRPOX]>VGS5Y?:L$T\_XJ4P6P5,) W:+Z@I7P? X/3Y3IF^I%H DYSUE:9 #S
M[8E53@\6;VI)'2*'8G1IY'-D%%Y-"2J<-H":LPFA=HL=,J%'IK#,3 $DIEI>
M[8$3_86"0U,4VH'HH"6'P<GZHD.+S-8)#YWP4*W_5X>1^Q(?EA]+4<GA(6>)
MAF562#'BC7TM\,"-8Y0+4D'9#_#/1_U'7B#C6)GUS=\8%:'_UCX/]AP$L#(Q
MS>6Y_N7B3M"[*)9D2>@(KO\H%G,@S^>CZ*L,VR#>\3'PPK5-O\C@7Z@WY82#
MX $5H?OE;4#0[(QB- (1JW71$F%3;5$GSB+4/:C%FF"4ZKJJ#]T9:\R2'21*
MTFPBX@H2J8\>O2!G: !LEETWE.^( 2(RR]F:H:W9E/,W!_[)B5V9ARZSJ8=,
M@>WV6$!!TP!^76-324G IJSRZ4%X>'!ZV,[0X<.A3( ED5Z/Y;BR?!Q-?558
M)YXS:]%_^=H'BO6 5$T6WP,Y[8I]A>R?=C=88'L:$>B@-!MDJE_/]?OYR@%J
M52!,&3#ESS"A>GP<E$C\568!^O:M^_BL;X(C"A"SXD96)P89+9[$R3JUY:VP
M!JDJ2I17JQ(=2*Y,1NLB9JL6IRU;]D)5^$'S,LRB;-!A8[BQR*O5!^D(D1=K
M3RX]S5]';OU4=40<[T#5M2J?8$GO<I&$@R%)(#-21Z0TX9"%0PHB-(05L>\8
MZ<8QT9Y[CB>\>P#PIN().T[2<9([<1(KY5!>;YSF%&K$\5$NU34B$A9W8#P>
MEG$L@4ZF$:Q9#--KH!.)C(A.S%!)S)3TCC1$13#E978-HCO\081P[AT@M:#:
M"(C\B6(WY+4E6N.NH4I/&P6"5%@FY4!C4*:MH1"2 G+0HN@<ZI*+S9!L.@25
MH$1K!35K3.465;+#R)1KM"_A=HS%P6F20?[Q*2C$F[9 M%WX8OG[Y9M/&R@S
M?3M0,]:92O*NJA:@#_"P88!;:IC8L26DMZ<,Z>Q)[^1L7WA2%Z_5Q6O=-B^;
MN S'$QD+D65132\:(&C3[$0T>K=VC5RY-%/MTLP:<3)W.9F>5LK>C7SKYB^X
MKG_E0%[;&D)O4.5KV@HU46N>V^IWN7V$J97AFU!2$UY-I3?I=[3&*=.>T9^4
M7*$8>+."$8,T"B,K4J .3&2I,796#EVI*+JRY^+;X0>52\0)@%L=:XO&1E.N
MO5Z#5-5[&>J3V[S1L4&MMUA ;^]:\.Q1>QJ+--]V/ +5YF[0A ;"RVHM]^4H
M4NMF<,!5N&](P5I)?.VA6](E2I'29: 5TUGA+3G$YY2BX>7IA$NFHZ=J!<W0
M&5HD[^H#3+9W J0"B68]MS;E"946)V&'"Q*1N0ADHD2E'*5)#J?'%:$.U\N[
ML+%2%!8,=T]+.>\L&)T%8Z.V<%3P(J)B0ZR*Q\EMY")$K#H8J%B0<E)+:+-0
MO"BU#5V0U=2C>M3Y+9R26T!X35RW-GZD?<!"=]D@URKW=%A( !HI;X+*3CKD
M'X9";V7*6>;K#Q2*9A.#)'53WM25C5)EM5YQ:<:6SI?%E?2*,88BE)-#!*B#
M$]-1S-+.C^2_;HK*^VR_/GN\+[:"COIWU/].U'_0>_RD_W3@'40]V6/J2C4"
MO==B"EJ=$Z1D*J:&>"T4G73!&9O\#!$3$F\#<D<ZKQBO5.Z[I)P]I*K:!R!^
M$&5 83!>B0I?8L;2U54FKY!.!F*JQ3WV%ZXEF%'$ F((^<X<)5/5$G!J5>J,
M3&5H7BJ^+3%CKA.^L!=ZWEV-33>VI&Q<#ZF$0;%2XG1R<UH;KV7"T+:.A0]4
M\OO6-&U0S67M"]9:SXJ((@R/61;;9[V]U.99]08:I15[$!GHT=E"B?0%]BO-
MU%,.%E3S.J3)GR<SD@Q;@K\ ??-"BI"=-]I=M#T]S*8.#K,--DA1I80J=B>N
M0P"4I(P+[:%S(YY&&7O1A!N7X%(;@E93;<+:PY;""U6BB#"15)8F"[PQU>:.
MP;9H,RA%GL<V_^%ZYF+?.8ZE&KP.?&U6?[&.1I,<;YM(N1Y%0GY0.HKYGD4A
MWIF@[G_;[BWRDI]2(MC3--=@%.5M%;\74\U[CL*L4[%-1F5.I,#^ I5:)1Z)
MRM5>H]HGBR@VDC/='5 '(">5ZAVG9_6PY&I \DS6S7V*RZ]KXF\/O>ZP]L%L
M_1O$VH;989-HJIE6DS8H*>N<[&C12,L=5IU0<:2J!$2HA8_F2,-Y'0?;>L'F
M:8R%CSA=H&I[(VFC.G?%$.T.Q<H=VFSNNN85ZW5:F3I+]PZ^LK4(Y.A,7)F@
M<QUB17D/N6D^6+?'^[AJ;&FI'L\%M29 2A;E*MD&$RN6S#",5+!Z_D7/YAP6
MSV IJFJ&JL*WE K<'%S_69^D[;NVB0^-H@I"/5T)B$>DH1:9(!,@T?76"E@K
MDCS63$:A8K/J_+3D#ZM,@F@*\NKOO<^]:KE:'4:DAV\# :X-!AO *\%(LWGK
MW<?8CT9%*>'!+8,!!9!8DNH(?CD*$ >H)RDE(KJ; !#]</E:I2CFWL\4XOTN
M"7H4<*<:=:;9E4BB_P@54G&_=T"PUW:0JOI4HJ.Z:*%J4908ONA^N+#80R3(
M=1U&*[VK:$N5,C8K5#)\#?J; @!3:].HW2TZ=2= =3%R78S<=R2TKK"I=8IF
M6S!.%RWV;:#C6ACPOYP8IAJE;P+@O5_6,.3;M#(;BI6DU2:2/1AI)@$?21X#
M4 Y3P@JT_U:J"Y,UTZ;BKU-5@]SNT5=/8Y,MZFM=^1)KK.9.,">7"345BMG:
MKX63P_4\& =JB[F<BHR%%R=I@PW#IO-,95,VJ= ,R3E[Y'UC?(^C+[)ZB$[!
M7UBL>D\G"3M)<(>M=1/)_^$5L[1:K%<G_BGOCR)<U.X4)@--((II%XW $Z<_
M7DGM!ZB@KJVLRAY/5" HS1]OR50Y?)>81?C&]SF!(T2<Y"UQ/TN/96[3<:_2
MRW.)JR#!VQUBI8)0FH:A),>.1E$V84\E)46FE9;=II?GDR?>R?&IR;R\&4B:
M#JH$#AH\&"YX\P#EL @D]":N9.F.L'0S+M=?M_PF/-$$ =2\:=,HL*O )!BD
M/2)ISP3H>Z@>AGK>L][I4]N+[M5:O>B,F<*\U>@K^,VTJSNM=3Q<WJRNT0CQ
M81<TK32K:^R=HS;B^>J^JGO5UJX+E.H"I>X4*+6WC?H:&'JQIU&37=9_1PP>
M%C'X!ML0=L2A(PX=<=@J<:@A^K)6$*K+R^Y[@79"0T<7.KJP6[JP'^U0FPK]
M-]$.M2-/'7GJR-,VR5/7ZW7-7J_W2('VR(WP\/J^-CCC[?J^DF=E2BTQDTK"
MO-_O]Y=T@3UP<NKK1O54&]4/E[2(]?O/3WL+6GHVN;X9)T6G60_>5:\NG+MK
M/GN'YK.5H!H5/?H NM$NZJ]Z9[?1@^S$^ETRBH?=(K0)Z-PB5!/[]:CZ^MU$
MV]2W;783;6$<>]5-M L$[@*!MT6YOLFFK21$_=??!D_Z%^T]3"LMTA<U,&TA
M,UMIV:K)I)59#YQ&KHL)YNTZ8#;/YG3)V2QJ=;J8!&^\/Z;_]*QY/*;KZ_:/
MY_&2XUG4/G27QW/6 CVF/^SVC^=LR?$\V8/C.6F%GI-=0<^3)<?S= ^.IXWV
MK"&LW>1X4.FM9CYP0D6M7$NEBM%B<T1[\= V'4IGYZJZ+A/@IYXJ&J]J-F$M
MTU OK*7.OJ1M!&OH:SJ"P7ZA;"+36 25L$N5DVD+B#I=Q4CX;NMK1B+B*G61
M]'NMB'-)$5VW-5.G12M275_(:Y*(B<12,VBAP*=9IVLY"M74A3K!L$:9CCJ]
MKNM"?-<NQ"T8OB==B%M(8]W:N#E">>,.A+[U1%ILY6!C/F-!98*PG28!IBT5
MMX2,5)IJ.*Q)T] 'C?!+VQZV@.GWW3.YY4!TSV26?]:4; Z4Z7$Q5!ZN:*Z\
M3[U=;)=;/H2MM+IM-;=UK6ZWT^KV#D;\/6J*V_&RCI?M$R_;QQ:^+<="6-FU
M\.W"E?8T7(G2GKL6OFG7PK=KX7L/@:]="X2.DSP03M*U\-U""]\WGVIJR$/I
M4]L%G'0!)[<M0])U9]UP=];U6[&2ZW1?^K&VF(*WW8]U76N139.(5@3T=DU<
M][<L7]?$]7;NW#LU<=TT;GW[W5\;&SOD*E 9&68K-F_?1&#PN2)F#9Y>8 .C
ML8A'_GIM8^^2=K#;!K.[Z"^[<+-=7]E.K=[[OK*./ZQK,;NQ%K--"GG+%K-K
M#+2_+68QAB_:;P-K5UF@XP0/A!,,>B=GIX/3KL=LUV/V9HI;UV-VFR:;2G/:
M5J5L0=?:MB"::M?:YM3?5]?:O3,(W4^7'G?&,,JGP(//HX1&&\98=*XYCO)#
M*&Y6&1%;WSZ PWSTXI4,1(EENT1+9HLMMV&0' W^@V,03?K%V& [E=>PZ>BK
M@[G:F%F%D95Q$4VX;H5IZX>HU[I,:TLP^>>N36'E9&:&.M=</]&>M0)2*0<4
MY.GM18_G-GJ]9I?GCFQT9&,/6G<W4:UKW=TU ;Y;/S7'#K\8RE8V&.D:?6^Q
M_YJ3FFL=MTQAEO9DVYR"TE&&![/U!T\9NF;BMVHFSKF!.^DHWI6)^EZB]C9'
MM-JZT-N<WJX5O?P>6]$O!("N'WW7C_[&/+WK1[_'8FLGL:_?&WVQF-XFTM^[
MQ/X==5)_B)I\%^K]0#NP;P7^=MR^O3G_CMJWMV22=.W;]Z%]>_-B=MR^O<4+
M?+?V[<T=K6C?WA($LD[[=EVO)UW8PMU[F5-@#GIQ_55>]#:H,\YT2@+!R?=,
MCKVGMO#J%!M-0[^9ONX(/*=K]W5O[M-;=@K45"T_K]@5NU(W7?SL+EN/ XE>
MT!TT$%/$+<6R@TP20E1Z!^JVH*"#1,"XF6VU]A3_9MH&=V5(.BQ_(%B>FF:]
M+4WR.OSK\*_#O]WAWQ88;;JP&7>3V^YQ7EJ'\1W&/Q",=[K<;A[=6YMO[[5<
MO>DRO-54/9%SFI%M'<ZVK5OU#C<I6-?P=5( 6=7U-9T/JHWBODNCSGXWZ?VE
M8<YNVES(BMS2V;!BGV\8/YOC<';* =>,$_F130,;BCS*#YD*F*BS''O#C(!0
M4,THV^<S*$IA[<I)0T[?'<SM!X!]0\T]*\E!BK@OHC9^E=PL:L;9!#.NW [\
MX!R[07BWL-PT. L[C=L,-D["98L(B9T8VH3.:LU(E;?)[J"6!=YP<3<5<G&5
ML,R5G/B&RZB>^TJS=A<A^M C1._7@;[G_4/_L)U:TB$<&TFXMJ 7Y6CK(N-<
M3GTEO^UI]_TJWDZ3%KK]NLOI*3V]45$1_>E -P1Y^/*(!6_L[4T%P1(1IU=I
MF?,GMO+"WHJ"78T^M_?V0DC!.NM.ZJ%*[$TK46F:11?<H(]ZPF !YPB[_%',
ME,GTI=3%M=*40XD,I5&YBISVIFY(7A#&F+)LR[B>-Y0X@"-^SNM)RASM25&S
MJ$)1&"9[)J,$:"APP<;#V'/\<:]_RB)L[I94L:54N/QIM2*G]UNJ,YC1FX_]
MF#"W7-0RLI&S+MR1.DL =9R$(H57I%RK&6FQF-T^&D4QQJ7F3M5^5.AF"9Z5
M#8'#7CCR",,WG DH)9@BXF 2'-G7 7$HBZDC@]&&D@,_ .F>]YX__WMK%"V=
MNAM7<5#L/ SYE>U<\,%T+G@?32*N;;W!0,5#!BN;TK.P:<*2*[/]%PRJ8&F"
M  N0"=-IOM)$H[V#AHX>S<I8YO07X!<6 ].V N[5P -U 1M._"H7.'MI,/V(
M@?F-U5L3C:R?IS'<WUYR@'<4@X?!=T+)^2943O<S(2%A(KY@81[7E(1OJ:J:
MBRCYK*4I5 /;%Q5] 'K*:^&8O,D0P)PK^3@O5U\AJ8DT&8";UG00KGCGS:B0
M!$#VC&M12#<4KAK*4M&"_':^H=&1Z3XSF F6]IC:*JBX[R/Y585#-X; 5CJF
M.H4I'H)I>BGQ2B:OG"NSFH6Z1^1F( SEB F[K%RE;V[==WD7'R?O7V>]V,YI
M20K8N]GEL<B@JA)RA^+OGN3\!%*UP.L &+RT32DV$Q+,Z,_BCJUP/W*F=/I@
MZ$C[MOZ&A-5D4$;Y;U06929K\LPR":U:.KVM$K,U0_JV0$YKVBN^-%<B$ U2
M+7M3DY5\:WH$M49%T1K>;).D?$Y-=$IJH&CGUBUV9J1@V#8+JI+%%APPO(R<
M7E7BJM2YJ=*Q2DZ1X_%8,"Y+'"@I[%BJ6K">+:1]<$, .@/=VZ%KC]?Y-G?K
MVQ1.+SE,(DAC;:97L E8/$50);F(7&=D<W&;_7@J8U$973%M&2LFF^9R)KV)
M)2*A2NTYH>-Z$IL)VNA^M$\>T$J<PY/>R5D7ZM"1@P=!#EBPB*7N@$@%MX<H
M^"KKB.JE@%J&<LE'7$B@UG92.$X977#3;2S9H7.'SATZ;YV[HY<4>&LL"?^H
M4"Y@Y(CYO2UT09]04 QQ7,>+73=&,,]N;>Y:>92J!ZM.*66N)026!U0'U8GX
M8AK^J17D;ME=MR<A%Q&L%0MLZC<7\$='6#K"TA&6'1 68[;$CME*8ZB:S!CI
MD0"5<9Z:!BV&[@!M6%Q@Q]05P1)+*]J5KJ8,WH$N7X(9H9R>JX-$ %T.EY31
M?V@F/*R77R_NT&@0>P4'CXZT8)RBJ5>8).:EA]PLS286&7@6=1Y<$"LUU$LR
MIB^ULD95:,>^E:ON8+IN<F>9W4*)AJ4.>2S27R^GX'NZ17O%(2R_8@&'G.R#
MJFQQI (GD8P2E2&]Y%T2I-DT5=4 D<CDCM<'7=-1QOZ,6,R<V@UYZL6IRFO7
MF?*.^"+*8IQF<+/A.G&B9,2U+@&J]XV><3)?D..IQ;RG/ 3YPJ1^*N/ 9EPW
MKQ]&_C.E:+F6C/Y%2^P2D#NI8-=2P82<L"M0UO=>S>&69KFU$ (OQZHG7I@&
M)77S061EGJ,+:\1SOQK/Z13:(#?<2/<EL14@@-1HDD-<*KJ.8GFEBU9]&]D6
MK@[1]?KJ2,4#(15+(A@6\ESR/F!F52Y5K1[^O>J_OQ$?[S!]%:9W\>Z[CW?O
MJ&M'7>]8"2:F;N18\,CW0+.'>_Z/]+UI+,,K60V3 S#%4%ZTJ22!HJ(@P:DX
M>NZ+J$I^<84S4"UE@A'^5QGV54L*W_LSC;#?-/Q>9G9X3/$I='2H>1J%.E.)
M$M4H0<_-55J=MD'CE&%67A&EQY\!ZCM8RK*CV9UTUM&/'4AG',,ZB0AEE<!F
MG#AH9BGF%7,@A8CH@HALX]EG5V^'KQV^/BA\1>1DM#P:@EX4>F*&]5 9C:?
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M%*X*0ST>IN$<?HR+2?SB_P!02P,$%     @ Y#UH6&R%T#:J&@  9YL  !8
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M#H=U+K689'+3R)E&]*"$BTDT6<$-\!!\_#2=IC'2H$6G"EA?1W"E%$#7.-6
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M((VDV\C!&V)+2O><Y(N)D5;[$A]Y!N[5['L?Z?=:)9L%_]?!*>)E4+L%85'
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MA<+Z%/87&F4 "'\N#2[71)A.'JP6RCK#E#)PZ?'MU(_N(?G?*_45\7+TF>*
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MH?,.:%.!9VUW 8"BVTO/]__^P^C)\&0S&L859&YXD*++2-'D*E(4;%KXIRP
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M5+*"/_,RSU[^/U!+ 0(4 Q0    ( .0]:%B-CN+LR2H  +#S 0 1
M      "  0    !X;VUA+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( .0]:%@4
MH+,4?!4  #XH 0 5              "  ?@J  !X;VUA+3(P,C,Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " #D/6A8=J_IL$U^  #-!PH %0
M@ &G0   >&]M82TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ Y#UH6*7/
MLU_CX@  >OX- !4              ( !)[\  'AO;6$M,C R,S$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( .0]:%@O;^PL)*D  /#R#0 5              "
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M>#$P9#$V+FAT;5!+ 0(4 Q0    ( .0]:%@;!C8=4S@! *VD"@ 9
M      "  0SL!P!X;VUA+3(P,C,Q,C,Q>&5X,3!D-C,N:'1M4$L! A0#%
M  @ Y#UH6,'%2DAX:@  "UH# !D              ( !EB0) 'AO;6$M,C R
M,S$R,S%X97@Q,&0V-"YH=&U02P$"% ,4    " #D/6A8 O-'0X9   "4\P$
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M,S%D,BYH=&U02P$"% ,4    " #D/6A8HWU(61('  #4'P  &
M    @ %FZ0D >&]M82TR,#(S,3(S,7AE>#,R9#$N:'1M4$L! A0#%     @
MY#UH6*C_Z4YB*P  S9(! !<              ( !KO ) 'AO;6$M,C R,S$R
M,S%X97@T9#DN:'1M4$L! A0#%     @ Y#UH6&R%T#:J&@  9YL  !8
M         ( !11P* 'AO;6$M,C R,S$R,S%X97@Y-RYH=&U02P4&     !(
,$@#8!   (S<*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>xoma-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xoma="http://www.xoma.com/20231231"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xoma-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_VIuDTnkCcEaZC79EMJ-tOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_D67_o-ekW0mCOHoAiNEOOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_XnnLT8lCQE-Kb6QqSuciIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iss2YrFnEUiSmHE-waxCwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2015_To_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_QVblxPuRZEOw9F6rNagv6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_d7MCNo9BZ0e94zx26toTQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:U.s.DepartmentOfDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_DqEQ-FxkkkC-biVtuHiWlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yFyujZtG9UWuos2_NLxJPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AloraPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:U.s.DepartmentOfDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2cm7F_6WkkiGYRgSmohdVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AloraPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_2qKuJw7LF0SNxUkiCX8mrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_CcXbeenPEESy7c73GXsaSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QrBLuliLBkmZRyyHG3qE9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_gy86xQDN_kOxX3_roA0-UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_plbEBxZzaEaRWFV0Pyn4DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0EETUtBX8UGfAIbmhgJkXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:Tak079AndTak169Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-11-01</startDate>
            <endDate>2006-11-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_vL3apDyaZkCu6f5YXyWb4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_HJ3psyCDL0yJ_bjXgwInwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2027_To_7_1_2027_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_zKMEytddB06_SjlQuaXQbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsInterestAndAdministrativeFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-07-01</startDate>
            <endDate>2027-07-01</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_mDE0bA7PrUqp9g8geI29AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ac_n1xmN8US4lumZOLANeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NH5EPARofEyZbj-06mGtVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_0JMorE6cGUCpbiydWrq72g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_keBCQhbHw0y8_i0w3euIAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_riSbvYPSGkWe1QwZUDB4KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-TWqBbOPI0edg96_YaJDsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vfK6Z82DIk-illPE02g4gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_yk_WkugXu0KU1E5kCoC55w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_KY6LHuuUC0ara8OGoTqocg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_qvLnAbo6Nki2UZIKe_V1Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_-Bb_xc6BGUyWHxxOSoMlCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_HzgT7NkX4kK_7iaixTGPCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_wNITwyTcekq4e2_GA1wpag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_3t-rhj3dwU6-3CO8uFyHug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_d4I_Xv63ZU-hiLOrOkWuoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KiCr-hkOokmigDvDkoN0tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="Duration_12_15_2023_To_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wemVoEFoIkCvcBgBQtS_rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="Duration_1_11_2024_To_1_11_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_kHKXEon0m0elwS6IFTsLdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-11</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_GWb50yHWG0Gjencq1GEsyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Dnn6lWiT3UCbGZqz1uHJdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_pF2mvqFuzU-4j2j-TN-FwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tdEEOHOCzUWim85LeSnQxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CmMun3MJHE2TK0PBPfLoYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vN14m3xAIUKgXMq-xvIgWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-26</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Qs55blBy0EiU6L4gvsU5Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FmZheOiEbUS5CMSbMHjZ9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bTPXO4suRkSuGzADvtOkDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_RfM78mIKA0-JJnpILkNCiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_Yf9nqgko7Ey_J1Vum-XNLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Knb1VMkj50OkZMrcsYVZ7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_x9Ly_6nZa0eN0KZmAKFNgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pH08PwEje0KIRv6GUczeEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_dtGtLvan-0WILGKknRPEsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_jXEG7wv2O0iixCaiWgcKIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_n0AlLUReN0Kwv0E-hFvvxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uYT0rItyzEy3DCuVTQGaFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TYLM5-VARkS0pBu28e5EGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_10_30_2023_To_10_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5j_H144ha0GnzzpObzRcdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_LUAacl6AYUSQlLyvLbzF7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ws-dALFRwk6XAWf156awmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_2QhgXTVMF0OhuPGA7tPfmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_0uMMRf1S3kW4lhwL-tOXmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-10</startDate>
            <endDate>2021-03-10</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_dAlGQw-3xkK1mBDxc6h3UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_U6eB0xdgwk-Ra02haIYfXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:AldoxorubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_7RTgXi3MwkO02DSrEMpnRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:ArimoclomolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fbE-TTiMOE6nIPU6Gv7BJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XtN01G-WQUmOgtwp6LiEzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_8AcX-7SvuE20tV_Gwrd56A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_w_Edg6XtwkWHPpb5BqgAXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_IsgrsUJM7Ey5ytOSIHjpJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_4l7SozYSsUOT0k7UTF6fPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_kmKo9NmoskKPrR6gM-lu1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Mf0qw7fgPkO317ZtY5HXgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="Duration_1_7_2024_To_1_7_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqWQZEkxck6aUZbAhDxrIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-07</startDate>
            <endDate>2024-01-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_5P20gVnqp0OL89sgLmEIrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-21</instant>
        </period>
    </context>
    <context id="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_q9ObqQzmnkSHnjz07UVHxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TalpheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AcquisitionOfEconomicInterestAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bEwMjcvCoE6dg4CchXXb4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AloraPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:TalpheraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_IHaDD6BBE0CO38D7GY_WoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-06</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_6gbf0-HRZ0qDTY9O_kyUlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ZfHh5QPIlkK7My1pRgpLNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember__6fnOc6OPUS1I5ZlPUpdTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:Tak079AndTak169Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-11-01</instant>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_w1WsQS9rPkSjRRaxRFYrUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:OtherAntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-02-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m5q_NDHLs0qf2z319qyN2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ukWUu5ueDkGldRKA40hqKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_cJ_3I5gqVUm-_Sd9MucR6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_odyIaKodm0SEW_jiL6wZ-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_stqAZ05QWkerRkwBioCcUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_N0BzlyOR4kSuTcSqKfN20g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ZZqIGqDsP0OAXaFzszUtlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_hcyXjuHEYE6D8CUHcrJ5bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Tfg4rgDuq0ufRwK2q3MQ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-RitWGIJ-ESF55jlLrVWtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IUqLnYwi60W0DrGdz3BX1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_0LRcdmUtxkWsPDjZRSRzxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fTTbXC7jbkqFXemFP-meAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Linvwi1eaEmv0RwYC9mmXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-30</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-22</instant>
        </period>
    </context>
    <context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zkpfoJr1ZUGbwa1B55RwJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3MSAG2w_VE-njv8TBWI0TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xoma:KinnateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_6yQg3Qhf9UiWbaQF-yGsrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_op1dbIKXI0auw-rLczKFjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_gaTRiap1pEa9KzeA121uZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M2cfbs9j8kSBfzVpqthphw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VUzwcKDVUk-lZVV-EniucQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_ics5zZQKZEC1GLHClhw50g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_4_2024_To_3_4_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tizzAxoxlky8Xls0hG3qmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_J15_C70NX0OmaYeWNB6hKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_fTV55Dy5KEqyHnrS7IKYNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_2_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BoZJ1cjf3EanYPBMyrtXzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8FHApOZ_VkCpJPR1XZCtyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_0w8sMVVLj02yx0033CwvXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_G2fgy4TWqkGEN64FdHGrUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_nAi2n-UX2kK0kjYHslutOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_q0p4FSRc_k6TcIpryO7R1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_IY_E1K2-GEeCZwiLEBu6nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_QuC48dJf8E23DlxZlazDSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_UE-JgzEHekiIYzHV9qlY6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yrXa87g-0alNOMlRI8rYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wVVTmZ48EeiZT2WPXZvIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ERGTIkxok0qRddaD8mnHPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3taukphaKkSilr_NFe1nOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Syt95SBUbUaxMwPVZJcalg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHYxtsKmG0-hqBTHhnVlsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_1fyMNRl8D0iF9dish_Goew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_L1ce77euREyOrnX7bZ8mMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2XEI2tAvkOn0kqT8ijqUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3N60csckskq31gE5arvXmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y8PfkqfeykCg9sfic1605Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_XU7qWkz2d0WVvDm9lTapaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MFi4TV8yEkS7ZFZpxsfd3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YtSAydDkdkaz5GXFSbOn6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gJUEPmVke0CACVsCCPaSeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_WdFrStI1SEmbrCQr_uf_3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QfRHcV6u0k2_QDklTWc_9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_xw9SMS1FDku23HM0n9XH7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QK1CLkfR8kOQoYbaZOfjJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_9t7Xrh4erUm2DCAqplH8xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-03</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_7AXSy2l_dkerjh7MaB675Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_bkupJ_siykOMKkRtcBeUdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_9_2024_To_1_9_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VAnZAL0inEKRzb4syNlviQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-09</startDate>
            <endDate>2024-01-09</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_p17Cp-2md0-zORF_i9yfng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_CPv_k4GysE6N0cJwFt__ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_kZe5UeB58EqVvQzsj0tFKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_q-zvA0nnJ0u9IWbpCyBZaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_VgCo7QDMrEqWqhFOY8kLUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6NH2D73ShkWYzzOp3xcTJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4_9OfpHHLEma607A2lr0HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pPNS9kuKzkGEzka8BT7FTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z14Y_ls6nU-Legw_e3KnHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NYJResI69kesGeTfzxA53w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_Yo1Pn10MbE-IQC5dhETm3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeTerminatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_DppoP7EaukOr-8wuDeS7oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_MQ2JB34wHEqnnlhOE_S-2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_7XNCE9fHSkejCdV6XNu2Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_PFwhQNdS_0Cvqwhdk5-nJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Q_GOADvcjEiY8_k6u1blBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_GaicAvhvREu045tkaseAEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__tLB0mm090OfA60OC8q_xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Nbz01A2AFUSN9o9T7YGxsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9F82xQd9GUyY0FWq2yw9Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7KxJyjjuEU-w1MGzNb9A3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jr06nKWQnkWcc1gc9wl75w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_JTU393H8zkS60pP-6_KFDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_RX8jSTjVsUCam5xpFx-k_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LLR4GBlfWEaaPy6t-ixdjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ATjJ9C3tUEuB5MOkEX8QXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_wMQi5PD-5kOVp3Do-Cz7aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_hM9ty2-MVUGlezJJB5CGZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pXkK2dzdNkSrOgN1r7fWyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IgF4YIWD40C1TLHU9oQ6EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ZvNKstqm10OSTijaRyyBgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_U9y-4g4fU0Ke5Az40er2DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_0srFpIQZjEeXreNfgIZggA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember__0KUigoyNEiSFG6EHS-pKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_lpNhrc2ivk27vYMf2Vaqrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_srt_AsiaPacificMember_h1HPzeTFJEK9m12ZpTyuCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_3-ttz87lbUGOlay7J25Yhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_77WH8ueaj0uJk0NC9iLw_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_VbPaWFBrc0Cn_MDgoar4GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_b-w3yCVO1UaXJ0_RnOHO7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_qTQ_SCTqPUOorHOyhK5FRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_fi1CUmq620GKCFSjTShMsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_qCQ7jqMcRkubKcfhZC2tng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__ZprmCypEEWlgZ0NIIwirQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_ukrOvK0wPUCoC4cxRPdRLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7PuIiwOfIE6NRKYOTnb75w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_5vFgsQWMw0WyWVDC99pPgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_dLKjanUZa0iaV3DbfG2Dlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_OSC8ojzXEkSJ5RzL03Kwhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_W8GylEFUmkCZLuCLShF-2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lQhUbx-dW0yCv6mncYCFTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wFKkAjcle0uyGz1v162nrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HGWd0mh5bECM6w9TDjLMqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AvM2tRL06EKNen-3oQQBug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Kfw2xvvPLECdksugQSkyRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_MTSivgxXa0q5d0yr9jPQ4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_hxT-8FvU4kmmkr5WaUc5tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jkZrlo9E8kGwNk50O_JF4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uRoDrOQqBEOHxxDn5GD5-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_FPhDw6eFSkewkz9kjfMtWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lPc163Jack2g_3qJHGxkJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tb-jqf59g0qRtmd2zX4zHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsOperatingExpensesMember_bIl9zjrGREO247K9VPfUHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_pFJTova4jkOtP18qsB8a9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsInterestAndAdministrativeFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_r98Y34qxLkWbmrz_8S1ntw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">xoma:CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_t-cr-ApM602C1aypIMKmig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_oha9lcQVn0qkzi_7xjYWFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_cEbwO1-SA0ytFO3kPI9NlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_da-F0GyQwUWPIo1MwVDeDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_qkBguZsiw0WaOQD5kUxKeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_z_A_YFI4skKZFdejnGMUfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_B23R2xU4FUqRYRyOEOTGqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_quH6qxcvP0mDXAhJavVYWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_zym9UWjuxU-PBpIgDKhAWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_rdiiaR-KVUigBcn6d96uPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Nr-S-s7kcESAiUgmLUMTDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7QPtDO1XZ0iO8szQG-XtMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T1PJ_hKJ-UOq76YTlyMzXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_G45ViXWaZkGa0Q9Yg2KbNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AbZx0laHAUueU-IhDRrrDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_IvhJyfS6z0K0hCQsSwDDPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Whkoa4BKGkO7vhoZPfvTBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Eizh1l00wEuCnFSN_xaUow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lRxrGJiyCEKBTolJ2-Gkiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_iWAtZr3dFESpISINrOcmfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3AEODlP3-0mydkDGCWhqyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_vTX9rZqalUujaAzAws_s7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2-MEI4pSCUuGeRcjC_EN9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lyRMP8iHEkWMJ8bT6bvwDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_YlNIDoBrLEe-2gkq_aWe3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-17</startDate>
            <endDate>2023-05-17</endDate>
        </period>
    </context>
    <context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yoj2ix91MkCiAGkREHt-GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-17</startDate>
            <endDate>2023-05-17</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cvrkp9vamEm0URrVmBMi4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_9GG7R2owREOBYs3nJiZ6Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_PEaFlgcRP0SaaPOSqZfozQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gixUoEw130mjwVDdF_iufA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_KMb4kPRqak6KcEpfavYKYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_GMUFTnTyUE64YJmDNxHjhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_NJAjCjk_ZUKFBzZS4OOcWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-16</startDate>
            <endDate>2023-10-16</endDate>
        </period>
    </context>
    <context id="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_Zy4X4SxAdEiV-KmbfWpDCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-16</startDate>
            <endDate>2023-10-16</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_0bVnFNKbb0e1H3F_2kLeBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_BNfFBH3i0E-67OZGzWGTOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_csVtxNTS10i9KUsxBrQxmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lPhZaHPsnUm-UbBxAw8vBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_OtbkDkOCv0OoiEEXRKx3Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_MsUIfPz7IkeOXLe_QrDnng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_96UqI17DZ06cOK2CPIIPvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ttlhuKLBjUSSxoBHpLChMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_er3W3MMAy02J-0HZT7aH1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_-jTxUsLwB0m38qsZl5cPRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JWDlj2gMFEij2eL1xesPfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r_AdKEQIsUaSBQTdOEh1Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-10</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_xAActchtNUCUQIYwmgGrBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_4MybQZKMoUeRtb31Nl4fZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_DR_dvBy6JkSRBmbQK4UTeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_3WHRj7yXxk6Z9Qfmyl4VIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Y2l7YTUwo0u38OqVPbafow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_RRcaFO6M3kOh_ZaU4q8qig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_lw1Ws7NAP02fg7d3o1Pq3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_RWlyVdx2GUC3EPptM1fY5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5IIqeHWkV0S9mtFRdVUKvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_LXJN7Whj9UecRjtZBao0Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_w6rQaC_PqEy9fPUmEuULSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_pSxax3Usz0yR4JG-1OD69Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_LJGNT1o0fESPY6CsLc4PAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYNuuYoVaUKIMN5qjgyD0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2023_us-gaap_AwardDateAxis_xoma_AwardDateMay2023ToOctober2023Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DWNUD9UHZ0yY-M_tgTpaEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">xoma:AwardDateMay2023ToOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wI-J9wnFokegnVOOPhGPfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_kICVKVDR1EKuBrC70GhfGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_NxeZNU-uwEaleSn6kV2D0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Pp3_l5-Makmyd588cc5PtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_FOSyLzrHjUO4zX7-HXcfvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_zoPI7MqTT0ymJt_IEkPwzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1fqxYlQgQEOjj4he88QfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_Nk99SOMJtE6XXgO_0hAWnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_8W6Ja3W_5UWikBBaH31LWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_Ye9pux6Zk0mWff5iTCN7xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_DDySBRqQAkmCyGXaQYbaTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_owbhffF5n065fOVm_kbUVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_YBo9bC2_zEW-HCuFI8kpXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_th5gLhVhr0ODI3lXcg-R3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3v-L0Vww2EuNWdV3-uHeDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_PMJBCIy7IECiFkjfjmaUzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ng_SQm0kE0GmhyCm9FCUWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zyoQf6ApEUqf3zXcyWmu_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TadyAKEHAkuV3__epaLGSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hxgRGUCPFUSaOcTTwES4QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_X3OFdmWYO06HF_9VjwDAbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_n8y0wI3G0kq3oR95Yq0yng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_iLQLrl8HzEq0ISsfhi5yuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VF70Yp-79UiP9lmggMs1vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ldCXzpF9akqsXBzaD9hxuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_je2iAxI6uUyI9xWXJ3NNKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EqHsm_Ei50WL1NlCKjVHOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_qpOCxF4gTE6XGswl1hQRNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_S4-V_keLEEabfoR9Fvi4Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_Edowbx1RqE2mAginFGRXDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_N5YIECe8E0C6IWg8obbENA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gec80tyUmkKY9InWUPJo7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QT17Poc1lk2rEi5HuNqx_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IK179fae_0q0Zg4c_AZHEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f4zBuaboQUKb6pXCfGs0MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_j8MHpbryDkKr6iuxL4IoLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_D_s-_E21uUaiUOWarzVcYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_GvxISMo_UkG51ag9NMnfUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aLLtLfhuF06YDmKVCRRdMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_4Zo0UeZYZUeUnyTVN-VWXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_8v_3XroY3UqA5FYoxvPiFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ORSwgOFEv0uBzO5uoRPJVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rqkDVECDp0uGDqsfOos4Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_JXd_9rzC90CP0igSJTsrdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jWEJG3qYf0OkSzZNmxWzdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Pt94Ra0jTUOM2_6JUiOKAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QmfRiBqenki9xaGwjiWv6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2022_To_11_21_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_EnsamhLSDEaWLpf-NafDRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_J3mRtOXpPUaCPK6vvI1eRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2024_k3qOTrtuaUOAFMh--lps5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A">
        <measure>xoma:agreement</measure>
    </unit>
    <unit id="Unit_Standard_product_SNQEGGFW5kSKzKYrmjywPQ">
        <measure>xoma:product</measure>
    </unit>
    <unit id="Unit_Standard_EUR_mzQmqJqZD0WOAo7brJv5KA">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ">
        <measure>xoma:period</measure>
    </unit>
    <unit id="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A">
        <measure>xoma:customer</measure>
    </unit>
    <unit id="Unit_Standard_facility_D1loseD-e06fL52LV83oPQ">
        <measure>xoma:facility</measure>
    </unit>
    <unit id="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">
        <measure>xoma:D</measure>
    </unit>
    <unit id="Unit_Standard_M_kyg1xo-wAkyvlL2hegB1iw">
        <measure>xoma:M</measure>
    </unit>
    <unit id="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA">
        <measure>xoma:installment</measure>
    </unit>
    <unit id="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_segment_m_JT2gZUYEyv5yGMX4336Q">
        <measure>xoma:segment</measure>
    </unit>
    <unit id="Unit_Standard_Y_f7Yhi2gHBEKf5DFUnXrd8A">
        <measure>xoma:Y</measure>
    </unit>
    <unit id="Unit_Standard_Right_7KYt940OV0yye1Z67B4qbA">
        <measure>xoma:Right</measure>
    </unit>
    <unit id="Unit_Standard_payment_MZwTcjQqtk6l27rvf283Rw">
        <measure>xoma:payment</measure>
    </unit>
    <unit id="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">
        <measure>xoma:item</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_hWa8ca6Z-EqiYcS6XiIxUQ_2_1">0000791908</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_mkc00NdGP0GaF4btOFQnWg_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_hUl0MgJd7k-EJAHZv_0DlQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_Wl0pReUL3kCnhxPQjzwxQQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      id="Hidden_7iaka6Lt9kSEJjKqsMpKnQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      id="Hidden_eY9I4y5F7kurZvVqqkIZyQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Hidden_uT0ww-rbBkm3D_j4aRlKvw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Hidden_2NQIBaFfIUCjiruzEJ2Apw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Hidden_khMIdZhyK0mu3RvV6oGr0w">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Hidden_2cFVKmg_YkSIZ76d2oSJ8g">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"
      id="Hidden_Cv47HXb4lU6Gk7g1sUGDKg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"
      id="Hidden_tWLXBs-0PkugkSEbpf7Pgw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA"
      id="Hidden_OsMuzAskf0GM04gVLpsjFg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA"
      id="Hidden_MmJIXWQRREOzDoz4cg9BcA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA"
      id="Hidden_yKNGHsYxl0ua6mlZdK34eA">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Y2l7YTUwo0u38OqVPbafow"
      id="Hidden_W5XKDOrmOUCVyHTuQ-wVXw">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_UE-JgzEHekiIYzHV9qlY6Q"
      decimals="2"
      id="Hidden__s_2kpVZCEW7Qrum_VkryA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_10_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_3WHRj7yXxk6Z9Qfmyl4VIA"
      id="Hidden_UjdHxsUKK0CGYSg7vc8W1w">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <xoma:LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A"
      id="Hidden_oKAPgn6owUGhjjDbJEhNww">http://www.xoma.com/20231231#LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived</xoma:LongTermRightReceivableNonCurrentCreditLossExpenseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Hidden_3mFvOmJiKUCxDAEe7fSXPQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      id="Hidden_tzBx_nlwlk2NnJLZtAgZ4Q"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      id="Hidden_xQxEZRom10ipxNjFLhAhoQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      id="Hidden_mFboUZF-aEWaGrU2CAFHmQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__tLB0mm090OfA60OC8q_xw"
      decimals="3"
      id="Hidden_xpK_StUG00ybbYZa3HpmVA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9F82xQd9GUyY0FWq2yw9Bw"
      decimals="3"
      id="Hidden_-jeY11JkkU-_yKExwXSvYw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7KxJyjjuEU-w1MGzNb9A3Q"
      decimals="3"
      id="Hidden_XJQ4j8H56EGkjfAn5W1EYw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <xoma:EmploymentPeriodRetirementEligible
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Mf0qw7fgPkO317ZtY5HXgQ"
      id="Hidden_PLUg0go3Uk-_7O-a0gyV7w">P12M</xoma:EmploymentPeriodRetirementEligible>
    <xoma:DepositarySharesRatioToPreferredStock
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow"
      decimals="INF"
      id="Hidden_0WqPQZjVdk-rCh1KkH7IeA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0.001</xoma:DepositarySharesRatioToPreferredStock>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_OtbkDkOCv0OoiEEXRKx3Dg"
      decimals="5"
      id="Hidden_H7Lo4FtfLUG9U_8NFt12cA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_MsUIfPz7IkeOXLe_QrDnng"
      decimals="5"
      id="Hidden_btS0jg_C4kSqwPe0vi-i5w"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_csVtxNTS10i9KUsxBrQxmg"
      decimals="5"
      id="Hidden_dSMEchMnFkqWypW9UGk7Lw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lPhZaHPsnUm-UbBxAw8vBg"
      decimals="5"
      id="Hidden_3oD01eoLEkipHZzpjVu_VA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_0bVnFNKbb0e1H3F_2kLeBg"
      decimals="5"
      id="Hidden_OTKsEhaqhEaFde7pn0r-XA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_BNfFBH3i0E-67OZGzWGTOQ"
      decimals="5"
      id="Hidden_7zNSlE5m30-23n_Xhxv1Cw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_NJAjCjk_ZUKFBzZS4OOcWQ"
      decimals="5"
      id="Hidden_s0Q6hKWcX0SArB1No9n7mA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_10_16_2023_To_10_16_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_Zy4X4SxAdEiV-KmbfWpDCA"
      decimals="5"
      id="Hidden_ZPUZL4tmokqcSqnQL-SrmQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_KMb4kPRqak6KcEpfavYKYg"
      decimals="5"
      id="Hidden_YeDNFyDyWkiXwMYXPzULTA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_GMUFTnTyUE64YJmDNxHjhw"
      decimals="5"
      id="Hidden__Df-kChCN02M1zGD5YLDDA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_466S7tayZ0mF5n5tXlVbhw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_wE-Dju-8yEmIn4GaAhU5zg">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_S7sKYPGvF0uB1vyIzWH3hQ">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_tJJWT-p-J0eVkpz41nohpg">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_tmYK7FPXYk6TdmauGmgHPQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_eJ2N0lNlh0a3numFc2YP3Q">001-39801</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_d0gkpR5nFEylTxErD4P0BQ">XOMA CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_o6SCdu1jnkuKHhkyhKENRA_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_StL3qz4pc0GCDvlKtiLcFg_0_1">52-2154066</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_AkAl88uA1EuR2c5Oxv-BpQ">2200 Powell Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_0iS4ixk6bUShJgyqvBfJIg">Suite 310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_IcFmRKgwSEGJTnfqJmzTUg">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_eDfk-ck1NEii4LDhgKUN5g">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_YgK0t6J2QkGQEpUwBaEUvw_3_1">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_JQI9W1fjpE6hQQ-qR2bg1Q">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_g2qSA0xZKUWkVI6tluHotQ">204-7200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A"
      id="Tc_-oMOG-27ZEaSYdQQ9Sx9KA_2_0">Common Stock, par value $0.0075 </dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A"
      id="Tc_vOwLVO3rxkOewbTfPrI-gQ_2_2">XOMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_36ZL3Z5SV0yd_fVfxYs87A"
      id="Tc_phFjUC4x2EmgG9oUypGKdw_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg"
      id="Tc_xsHp9vxQI0SbIdoifqwAFQ_3_0">8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg"
      id="Tc_e1CvUTgUSEmyJZiCpgT4kQ_3_2">XOMAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg"
      id="Tc_lpicWM0BwkiHNoq3B61Rcw_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw"
      id="Tc_3OlNHqVxmEOvF_xD-4otjA_4_0">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw"
      id="Tc_Srm7AuxMAECmOnjw5CVe-w_4_2">XOMAO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_wlcrAJT9QUeP8-qokMAXMw"
      id="Tc_So6VuolrCUuLjUIuLrgedA_4_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_5bqlZeEEsE2TzGkQRcFb4A_1_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_ibPZu0Jos0S4Ff85Qc9O8w_1_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_V5oBC9J5R0WRTyp-RcHNRg_2_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_Hus5j5zwhE221bGnImQ3oQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_yMVnjcTkLEawhQNhLUgjUQ">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_UiJjieCTxEiQfr12_Yw5LA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_J3mRtOXpPUaCPK6vvI1eRA"
      decimals="0"
      id="Narr_AXJpupWrK0iSjmDURxb6XQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">123749750</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_4_2024_k3qOTrtuaUOAFMh--lps5A"
      decimals="INF"
      id="Narr_uoaRRvrAi0CH4ESA5k_uHw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11625826</dei:EntityCommonStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ"
      id="Narr_HxFDfUSCw0iX3AKlWFtcvw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ"
      id="Narr_P43-eYyK_keh2MYxlIPNIA">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ"
      id="Narr_xLT7NSq_4kGgn5IcOhJW0A">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_dbSOF1I_iEiVLUhMAgnVNQ"
      id="Narr_z5EOs4rM40GupkV3bNTKzQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_bteudAFYf0W3EXKlgqTVKg">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_RCdzKIcCMES5B39ElBs52Q">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_Eh8SAcU5oUOp3Lpc4w1wYg">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_hmsciegP9ECWRSRe22KL7Q_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">153290000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_ag0mnlekwEyonog_GPEhew_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_gn9p3xcN60SVp4bVIRk_-Q_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">160000</us-gaap:RestrictedCashCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_Tif3EANFG0uyD_l6Sci0WA_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">161000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_ro_ILmP6bU2Bg5vPOYuUWA_7_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">335000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_-h-AolC5DEG8tLzDSbJNfg_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1004000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_BIjr4b-m_06FdXD_C_L3xw_8_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_3m2nxPULGEGXGXY4tXwCjg_9_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14215000</xoma:RightsReceivableCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_0jLQPaPhNUaIF13Wrs0PoA_9_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2366000</xoma:RightsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_MeASCJoD7EeBEeZEYH145A_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">483000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_qNSXX7jQzE2Ykp4xJklTIg_10_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">725000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_K4_oD_8wrUGXepfEjAHrNQ_11_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">169313000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_1zBnWrpzFkO6aZfkrFkb-g_11_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">61253000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_GkX5HXUEr0KVJQzDt6EuFg_13_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_kmGLj6bSSEWd_Rgif9ArcA_14_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_7tAuHepEwUOA0bCOuB9O9Q_14_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_QDGjCW0PZUaHPdINRx-oTA_15_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">378000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_cByeAI2Wc0yKVbbV2Iwaww_15_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">29000</us-gaap:OperatingLeaseRightOfUseAsset>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_5WlqY1hAxUmbFSDx9GJSBw_16_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57952000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_LMNAf5OEn02qzgMp8D8x5w_16_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">63683000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_VvYlu3JlkEuV6-b3jQEFAA_17_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_ajhYe4QUa0KJIYCbyODUqg_18_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">533000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_KAc83PL750ORaDSoht4NkA_18_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">260000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_Mt9mRUzyC0aSmvyp79Xo-Q_19_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">234301000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_5kJeOLmeh0W-HaQowIRkWQ_19_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">140382000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_ywh9EXnBuE2WwqbYc5zSig_23_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">653000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_9EuZFWSA40S8KmI2pWMDkQ_23_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">524000</us-gaap:AccountsPayableCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_7l_3t-QMdU2M83d-mWMUzQ_24_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2768000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_0iWkVKOQx0WXOSbbvaRXuQ_24_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2918000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_1XbSkHtKzE6yH7X8-lwAWA_25_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7000000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_rWC0ygyMZkC2Td0GgWtXTg_25_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_RlwqS_dUVUWdaJg7QYTxFg_26_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">54000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_BUURm264ukO8HIJQyoXpSw_26_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">34000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_71wWXP5uCEe8p59SfJH6qA_27_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2113000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_rBISOREiUUSrRR3XTkZv7w_27_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1899000</us-gaap:DeferredIncomeCurrent>
    <xoma:AccruedPreferredStockDividendCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_ijYmrmfuNkSgOr4HPR13zg_28_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1368000</xoma:AccruedPreferredStockDividendCurrent>
    <xoma:AccruedPreferredStockDividendCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_RFBBPtYtqkaAabjxT8dSbQ_28_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1368000</xoma:AccruedPreferredStockDividendCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_DzhhI1mesEujT8a5xvjs-g_29_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5543000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_K1rlzKvTAEuSHJg2NhpncA_30_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">19499000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_P3n_in_RjkK7mNTFNbqnGQ_30_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6818000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_RU4FiQqX3k6jOcZ-iYMMKw_31_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7228000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_i2_5Ueyy70KTZb2uvlOESA_31_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9550000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_szVEDZZoqUeeQY5nPVPTAg_32_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">335000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_mlK8ZpxPzU-Rq9AvdDZv1A_33_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">118518000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_R1gBmAelTkyJD10Wqv5ByQ_34_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">145580000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_jNbqXedd2k2tyF8rZ7NW9Q_34_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">16368000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Narr_eD6nxub-0EaFKBmogdysPw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_BJrGjAbBhEKEEXM0Lq6Z1A"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Narr_8gJxpW913USZf_BcVXqFpA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_svnEO6XW0EuWE-eiEbweHQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_er3W3MMAy02J-0HZT7aH1A"
      decimals="INF"
      id="Narr_tPXGlI4WUU-pEWBMCxl0HQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg"
      decimals="INF"
      id="Narr_45uU6FXaGECAjKys6j18Uw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"
      decimals="INF"
      id="Narr_jqaMYRI-00ypxPOKtHvmrw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"
      decimals="INF"
      id="Narr_wD9gAsCG402gv2nVIhFt9w"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"
      decimals="INF"
      id="Narr_EDRSLescwk60j7PlAeouAQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"
      decimals="INF"
      id="Narr_LLiecn2qCk6wHkGUk6biUQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"
      decimals="-3"
      id="Tc_w8lsLyoUpEabiaen1jTMKw_40_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">49000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"
      decimals="-3"
      id="Tc_EfifcxGfTU2JX_aYSrnf5A_40_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">49000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ttlhuKLBjUSSxoBHpLChMg"
      decimals="INF"
      id="Narr_wvVjwo8PFkunkV0DvnJDOw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_96UqI17DZ06cOK2CPIIPvA"
      decimals="INF"
      id="Narr_h6KqniROXUSJutggaut8eA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"
      decimals="INF"
      id="Narr_i1Mmx4I9SUGwFBoT3rLb1A"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"
      decimals="INF"
      id="Narr_WxYsaDthd0-0XNSOfj09mw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"
      decimals="INF"
      id="Narr_Cq3vqaFVB0GUKp-nQmdXAA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"
      decimals="INF"
      id="Narr_WGoO-AMcVkaniJ3RRL5eNw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA"
      decimals="INF"
      id="Narr_sfHoXNsAhkaaZrwlM5J3lA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA"
      decimals="INF"
      id="Narr_Xnp0xq916UKPV0G6nFr5Lg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_sonaxLce20qXK3JbwXnwNA"
      decimals="INF"
      id="Narr_XuEXA8YX4UuVFDbnXMXKWg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_ePwAXQo2FEWSXViDUh4qJA"
      decimals="INF"
      id="Narr_U7xp5FCGdUy4i68SyIhAMw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Narr_BO3YvwrJyEq3zAVhEa9yHQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_erh5ptuFBE2Tq3zW3neeeg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Narr_Fri_DWP_Y0qStLhknF6uSA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_c3aDChbsh0SwzKl5Nn28Hw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_uiPjpsQZgkeoQ48N_AK-OA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11495492</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_odf2RGBCoU-TikEWHiFqeg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11495492</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Narr_7AoUGvyGHkK8gKefhqePzg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11454025</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Narr_Ifl4JYVJ3US9V5Q-Jz1nrQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11454025</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_I2riWmF2okmhDC8oulKevA_43_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">86000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc__UUq2ajzokKvLVW-Neyy7A_43_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">86000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_-NoaY2Nh6kaKlM0rK7sqLg_44_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1311809000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_z8GyWnxDykKI0tduaY9Chg_44_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1306271000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_S_q8SjlX7kC0Pcx6wdRMPw_45_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1223223000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_zKgnKlZN9Ey4UULO9nhxVg_45_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1182392000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_PQraEevPS0CAMnKJsfbiDw_46_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">88721000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_qtVo4ol-C02VOCjCHjW8dA_46_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">124014000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_9Xvv-U6Qnku_Y93u1EcXCQ_47_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">234301000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_5z3rIwxwO0eFlQWkv2J04A_47_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">140382000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_w-Hf69_Rfku0VyBeEI-6pQ_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_GQJsb4EjlEqix6FIyJVVHw_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_yOGlS_-21U6NXZOHkjM-Ng_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2108000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_ZAnXioX6sEasuYzSqO0ZfA_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1877000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_1wh2xR9fpUOSDHE__LCjOQ_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4758000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_5aDOZkTn3UiKxN2jXceUmw_7_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6027000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_e4TrPYxazE6BgVlQ2H9NNQ_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">143000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_9lgf9wzVHkCVUYsyv_bYiA_10_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">153000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_kpMznbThW0WyAhTI4ozgUQ_11_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">25606000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_GT5dPPnboUazw59I9jLeEQ_11_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">23191000</us-gaap:GeneralAndAdministrativeExpense>
    <xoma:LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_JSZukDTt-UGocCDAeQbVmw_12_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15828000</xoma:LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived>
    <us-gaap:LitigationSettlementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_jZXhYjcZk0iBZJxPMbJkNg_13_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4132000</us-gaap:LitigationSettlementExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_yZAWGPRKNEmlZjRYePNsUQ_14_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">897000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_yZZIj-s9hUy-xlwnqaDZZQ_14_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">97000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_F3vTI27ll0SY6R2aN4tuug_15_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">46606000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_KgA6gaXk0E6Naxm6sRqiMg_15_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">23441000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_3lmEYtZdBkOl8__4HgGM8g_17_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-41848000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_uyb3Mztax0ChJc1GYUIgzA_17_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17414000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_aGUargVRF0GTCy-8NEsrmw_20_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">569000</us-gaap:InterestExpenseDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_TXQ2mcQQ0UCOD3ucv7rueQ_21_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1586000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_Z3Thon9DvEqtOCOzgLelgQ_21_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">295000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_wEKbvXRVc0aa2F7o-T_C8w_22_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_xy7dtGMmAEu6LHHnEYTtPQ_22_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_WUDIsOItwUeoJHg0g2L7IQ_23_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_uNZV8hpI6EK99gU5UAcCoQ_24_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_uNZV8hpI6EK99gU5UAcCoQ_24_3_2"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_c_0s8mQWfUi1aZUV33eHmg_24_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_c_0s8mQWfUi1aZUV33eHmg_24_6_2"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17104000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_lkTOEPJVr0iREyPfVEn5BA_25_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-46303000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_lkTOEPJVr0iREyPfVEn5BA_25_3_2"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-46303000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_zFZcAj5SrU-9Fo516qV70Q_25_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_zFZcAj5SrU-9Fo516qV70Q_25_6_2"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_bVwXq6cd6kujN2ecMBGcmg_26_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-4.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_bVwXq6cd6kujN2ecMBGcmg_26_3_2"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-4.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Tc_MmFIdpmECkyiPd915RMETA_26_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Tc_MmFIdpmECkyiPd915RMETA_26_6_2"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="0"
      id="Tc_JJzqP1xmJ0OYPkpD3ygWXg_27_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11471</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="0"
      id="Tc_JJzqP1xmJ0OYPkpD3ygWXg_27_3_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11471</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="0"
      id="Tc_qx940NZw8USQFnWDsH2hkQ_27_6"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11413</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="0"
      id="Tc_qx940NZw8USQFnWDsH2hkQ_27_6_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11413</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ"
      decimals="-3"
      id="Tc_6T2eRzXt-Ea20j5T__ax5g_4_1"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ"
      decimals="-3"
      id="Tc_1tFjK5l0m0quCh0KjQ0Gng_4_4"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3N60csckskq31gE5arvXmg"
      decimals="-3"
      id="Tc_YIl-XCa0906_hR3S_EYCzw_4_6"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y8PfkqfeykCg9sfic1605Q"
      decimals="-3"
      id="Tc_K5cZkLZu9kSuc3c45lZGqw_4_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g"
      decimals="-3"
      id="Tc_EAKNQJ2IfkCBX3O5iMF81g_4_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11454000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g"
      decimals="-3"
      id="Tc_o2q9aHyzYEKEpB86M5pjbQ_4_19"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3taukphaKkSilr_NFe1nOQ"
      decimals="-3"
      id="Tc_yxoiD3fjZE6ZAvbxfkCflw_4_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1306271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ERGTIkxok0qRddaD8mnHPg"
      decimals="-3"
      id="Tc_bc9-UHZO10KJdvrxZbvGXw_4_25"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1182392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_XHzZzTbP7U-arJJTJWLNQA_4_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">124014000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8FHApOZ_VkCpJPR1XZCtyg"
      decimals="-3"
      id="Tc_QQL_S6iF_UiozYwOx9I7iw_5_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">28000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw"
      decimals="-3"
      id="Tc_GhMcxsjP90ytTmL2IRridA_5_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">235000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_9BWxFB86DkuNMVRUe-d7Iw_5_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">235000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw"
      decimals="-3"
      id="Tc_Pmb2EVCJYka8rokUuXhFFw_6_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_8rvr4OayHUC1uYbNQq3Xwg_6_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw"
      decimals="-3"
      id="Tc_T-Hhj5cjVUWh8Bk_IYd9jw_7_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_yp-fD7Zn70iuTmaulbEWXA_7_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8FHApOZ_VkCpJPR1XZCtyg"
      decimals="-3"
      id="Tc_bNJz7QWslUmD4oxllANXGQ_8_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">13000</xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw"
      decimals="-3"
      id="Tc_1P4Xv6WHEEqybtOF-kWifQ_8_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">206000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_GAHMPqFvpUCaLAtLgMitvQ_8_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">206000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_g8aimMeDRE2HcttNUjE5bw"
      decimals="-3"
      id="Tc_B4oPaB4MP0qNo0h4Zb-PTA_9_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5472000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_SAUJKSfkiEGRCs3awNOH-A_9_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5472000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JWDlj2gMFEij2eL1xesPfg"
      decimals="-3"
      id="Tc_vz8r6GW-R0KCyjgM42PooQ_10_25"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_r_E4DMeXUUaQG8D33cQCew_10_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_L1ce77euREyOrnX7bZ8mMQ"
      decimals="-3"
      id="Tc_yYxx986w10m2gEkgloTChg_11_1"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_L1ce77euREyOrnX7bZ8mMQ"
      decimals="-3"
      id="Tc_j9K8FszWSESbAGBWYAUV3A_11_4"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_1fyMNRl8D0iF9dish_Goew"
      decimals="-3"
      id="Tc_gRuMQqdxeEmlnqGKArdFuw_11_6"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2XEI2tAvkOn0kqT8ijqUg"
      decimals="-3"
      id="Tc_qRCZa9qOLUymiWqfMPkaqQ_11_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg"
      decimals="-3"
      id="Tc_M3NDjWrUrkS_uwrcvg_LBw_11_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11495000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg"
      decimals="-3"
      id="Tc_-eOVE32buUeoar4oNSo7KQ_11_19"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wVVTmZ48EeiZT2WPXZvIg"
      decimals="-3"
      id="Tc_cyp4_pgFakCS8mfUfHHckw_11_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1311809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9yrXa87g-0alNOMlRI8rYw"
      decimals="-3"
      id="Tc_dLnpUPG8M0uDsywpLC3ctw_11_25"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1223223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_dwSidYUBz0u5uLEDMM-q-Q_11_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">88721000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w"
      decimals="-3"
      id="Tc_yTO40TT2JUWD1XLB530RTA_4_1"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_E0gOJUKppEqH5Q8RP0ud_w"
      decimals="-3"
      id="Tc_gRiQcYTDDEidx0DF8eVxPA_4_4"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_XU7qWkz2d0WVvDm9lTapaA"
      decimals="-3"
      id="Tc_FZI7l1qsWEuo9DfGKjwEtg_4_6"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MFi4TV8yEkS7ZFZpxsfd3w"
      decimals="-3"
      id="Tc_5bXUCoOkmEKhT_0sQ69OkQ_4_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YtSAydDkdkaz5GXFSbOn6A"
      decimals="-3"
      id="Tc_G3GKx0yQHkiYVE63E1fmWA_4_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YtSAydDkdkaz5GXFSbOn6A"
      decimals="-3"
      id="Tc_tN8shUhFqk-VvXFXc0FYwg_4_19"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHYxtsKmG0-hqBTHhnVlsA"
      decimals="-3"
      id="Tc_liaqXwiW5EKuLqEFfof3tA_4_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1307030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Syt95SBUbUaxMwPVZJcalg"
      decimals="-3"
      id="Tc_9H5ASYbW8EKUwF3gJHbiXw_4_25"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1165288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ"
      decimals="-3"
      id="Tc_Q9fxGAjRSECu78jil6ZFvA_4_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">141876000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g"
      decimals="-3"
      id="Tc_6o-7SQj2sUuoxfdxDp26xw_5_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">129000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g"
      decimals="-3"
      id="Tc_HlT_E_Bf7Uq-kEbQqPte_A_5_19"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ"
      decimals="-3"
      id="Tc_7rodXzjGXUinQMs7Toe0Lg_5_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">929000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_XFpilFYdg02a5TG-kjfcfw_5_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">930000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ"
      decimals="-3"
      id="Tc_lNA8446J7UieZ67MGZjrwg_6_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_ByjpEl58Ak6ECjxM9WsMhQ_6_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b8mjr8AXRE-bWkAWlE9W4g"
      decimals="-3"
      id="Tc_Oo5ZCO2d1EK_ZXKvLzgGQA_7_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">10000</xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ"
      decimals="-3"
      id="Tc_sLq828DcQUWJNdz4nB9OJQ_7_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">176000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_pmhvQ-IWKUWb4UarWhDCDA_7_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">176000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hx4QLpMQMUmWcJJE3faVyQ"
      decimals="-3"
      id="Tc_KFQB0qsBSk-Q4or8NpUMqg_8_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5472000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_2etUdxxHH0e5SHtYArbKrQ_8_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5472000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r_AdKEQIsUaSBQTdOEh1Fg"
      decimals="-3"
      id="Tc_fqIlo4Gd6kyj65vDACoN3A_9_25"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_mOs-qxn98E-ujXqGtneWRA_9_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ"
      decimals="-3"
      id="Tc_KHJTUY2YikCJN1aRzxe6nQ_10_1"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_996eZ4FugkmHlBn-fFePVQ"
      decimals="-3"
      id="Tc_zZP14lN0106rvbucGWxGbw_10_4"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3N60csckskq31gE5arvXmg"
      decimals="-3"
      id="Tc_U0XELIrDEE2bdwAwZie4-w_10_6"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y8PfkqfeykCg9sfic1605Q"
      decimals="-3"
      id="Tc_gew35eLri0Wz8ggUaso9uw_10_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g"
      decimals="-3"
      id="Tc_MaR7_qvd3EewVtrOph-84A_10_16"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11454000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSsKjDQE0kWwK9FWRO_6-g"
      decimals="-3"
      id="Tc_i6ZhUgmuzESrKgrR6_m-3w_10_19"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3taukphaKkSilr_NFe1nOQ"
      decimals="-3"
      id="Tc_6f2AE90pw0mQFuDPFlPI2w_10_22"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1306271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ERGTIkxok0qRddaD8mnHPg"
      decimals="-3"
      id="Tc_mRX25Jq08kmEX_AtW8lF9g_10_25"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1182392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_aT3fyeD5SU2wwFUv6AkURw_10_28"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">124014000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_H26cW_vBQUWO5s4E9iVsXg_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_EQRzWmydaUSDWe1VnhtQ2Q_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17104000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_audLXrsm30iFciJDR_hyvg_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9099000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_9XcSStMOFEOIyLYx_2xCXQ_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3608000</us-gaap:ShareBasedCompensation>
    <xoma:LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_VG53TOVHL0-s2QRCM99_Bw_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15828000</xoma:LongTermRightsReceivableNonCurrentCreditLossExpenseAndImpairmentOfIntangibleAssetsFiniteLived>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_c9GN-WnKDUqFqDoo-pZLdg_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">75000</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_gOekGOKtq0ioMRUTc4JnDg_9_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">123000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_nTmZIfYgW0a9dcPY1jYJBA_9_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">85000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_XTlcDl8hS0K9042YQAwV_w_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">897000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_HsYKoqS1ok-juczKXSQ98w_10_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">97000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DepreciationNonproduction
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_CqHXWvWB9kiSrsIQ-Ygenw_11_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_MXXOVy3mg0mA_-J15af2tQ_11_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7000</us-gaap:DepreciationNonproduction>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_6z88Mz6OPkufVg0Gb_20bw_12_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">34000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc__seJdGWA_kaC_mdyh8Y3Ow_13_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-119000</xoma:OperatingLeasePaymentsNonCash>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_ZAJU2n4C4keOIZIqCByx1w_13_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-170000</xoma:OperatingLeasePaymentsNonCash>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_1QUq-NecA0S-_F0NzcF7ow_14_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-174000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_VBhbqKwZmEa0e5awyN0pTg_14_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-439000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_mj85wMNASk-Qd-9TSJw4Kg_16_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1003000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_UcNK7F4DOkiC_gfWj73v8Q_16_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-208000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc__qVCH8rasEis1AYEqNESSg_17_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-219000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_UgqDY6VCZUmoxvmwKaFhDw_17_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">71000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_4ndDMyOog0GfzVbdQvquow_18_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-523000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_dXMI62lB0UC8oVQNku-1JA_18_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1845000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_HxgT3x3nt06g3VFwk9WDtw_19_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-91000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_hpz3Y_I5mUWESu-luLwMlg_20_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-114000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_bZhSZYsJYkazKDBUk5YwoA_20_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-195000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_el1Q3tYpwEKOON7VMHR-dQ_21_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-2108000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_ChLRaOKToE-TqHLKuKAnbw_21_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-1877000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_6NMfehsLnE-AnSQwGYSIeQ_22_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-18158000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_o3Pqp1ZixUWmAjYPitPamQ_22_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-12879000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_aJTtwa-mPEComIZ-iLe-8Q_25_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14650000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_Be7PYKjeUUal94H-g6NXVA_25_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8000000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_jmXCzYuN7Eiijraj72aU6A_26_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">13956000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_-oqB5fsN-UyDl5kry7f_qw_26_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3026000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_PTVZjuifN0WXslOPUeShlQ_27_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15247000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_n-K8S51Qa0yJveQmpUtZJg_28_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">17000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_YlZ4vtYHjEaYGpj6ar-uXA_29_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-711000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_WkybNUGGgkqDV7W_tWhmRA_29_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-20221000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_vVg0Ub7bFUW6GxF7XwLYrQ_32_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">130000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_z33_-JKfakGmAywSRxqYjg_33_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4253000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfDividends
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_e-pCdYndzES6HcdwPy9QBw_34_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5472000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_874R5mxte0K6rL5QnHHgPA_34_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5472000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_phFYYgGICU-TWyL17z33bg_35_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">466000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_GoVQLuaHWEuQeSNFP-7pVw_35_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2419000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_q-IWTE6vOEapDfWlrwGT4Q_36_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">148000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_IJDSnGM2pEyIs8PjXjBj2A_36_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1398000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_H5EMpS3SG0OzzRvFen6ZKQ_37_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">120593000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_sXyEtGEnhk-flg--CqtJNg_37_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-4451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_8muhKvP4_kCDuf8iUYwynA_39_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">101724000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_Q9C9aQPjlEypGoDK9mGlmQ_39_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-37551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_He4EvKs3ck6FjAW8Nv_T7A_40_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ"
      decimals="-3"
      id="Tc_ZGg5drdrCU-E9hH0pWVIUg_40_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">95377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_hDi_dDshg0eSv9NmO6H3wg_41_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">159550000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_twAHjs1BzUOrXD5xic1FIg_41_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_uQz4JQLJlEmejI1UA4DJPQ_44_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">76000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_3jE6f4QX4U-X-1JlNDCvyw_45_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">468000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <xoma:IssuanceOfWarrantsDebtFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_T1VdZVBby0qzK6yf999OYw_47_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1470000</xoma:IssuanceOfWarrantsDebtFinancing>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_iKIIe2Xw-kebPZ7Ldllk5g_48_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">501000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_dUG2CmtF10qO1B356OHJZg_49_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1368000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_J2CbdDiuN0aNFPRPCcyqzQ_49_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1368000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <xoma:EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_PmizMcrk5UWKQwyR1yaTeQ_50_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000</xoma:EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition>
    <xoma:AccruedTransactionCostsRelatedToPurchaseAgreements
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_ZQ8Rv1qb0U6r9GZxvC2MWw_51_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">122000</xoma:AccruedTransactionCostsRelatedToPurchaseAgreements>
    <xoma:AccrualOfContingentConsiderationUnderPurchaseAgreements
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_FcEmebwwnkm1s55mW8jebA_52_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000</xoma:AccrualOfContingentConsiderationUnderPurchaseAgreements>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_PTM5IOZgqk6w1R7jACduxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Description of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;XOMA Corporation, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#x2019;s portfolio was built through the acquisition of rights to future milestone payments, royalties and commercial payments, since its royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. XOMA also acquires milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to the Company in a relatively short timeframe. &#160;The Company&#x2019;s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects most of its future revenue to be based on milestone payments the Company may receive for milestones and royalties associated with these programs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Liquidity and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December&#160;31, 2023, the Company had unrestricted and restricted cash and cash equivalents of $159.6 million primarily related to financing cash inflows received in December 2023 pursuant to the Blue Owl Loan Agreement (see Note 8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the Company had unrestricted cash and cash equivalents of $153.3 million and restricted cash of $6.3 million. As of December 31, 2023, $0.2 million of restricted cash was classified as current and $6.1 million was classified as non-current. The restricted cash balance may only be used to pay interest expense, administrative fees and other allowable expenses pursuant to the Blue Owl Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s current cash balance and its planned spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_6QDP4upInEajdL9U_xPBKQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_tDdRcfNJQE-HqC9xqNXDuw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">153300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_1QStCvqwQkqSKID1tdcc0w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6300000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_Eo9ho9y_eUCJKFqAs-AS4g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_rNYp1cMJ9ES87IZtzaPMFQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_gmpjYkx-IESa4BDk5dA4WQ">false</us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_symJqX6pvkenOiQMurz09w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of Presentation and Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Use of Estimates &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration, amortization of the Blue Owl Loan, valuation of warrants, accrued expenses and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, including estimates such as the Company&#x2019;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. In addition, the Company&#x2019;s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Unrestricted and Restricted Cash and Cash Equivalents &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrestricted cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total unrestricted and restricted cash and cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 159,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are generally in money market funds.&lt;span style="display:inline-block;width:2.25pt;"&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="font-style:italic;"&gt;Unrestricted Cash and Cash Equivalents &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the Company had an unrestricted cash balance of $124.9 million and an unrestricted cash equivalent balance of $28.4 million. As of December 31, 2022, the Company had an unrestricted cash balance of $27.5 million and an unrestricted cash equivalent balance of $30.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Cash &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL. As of December 31, 2023, the Company had a short-term restricted cash balance of $0.2 million and a long-term restricted cash balance of $6.1 million on its consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had no restricted cash or cash equivalent balances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;License of Intellectual Property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Milestone Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive loss in the period of sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Purchase of Rights to Future Milestones, Royalties and Commercial Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Allowance for Current Expected Credit Losses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#x2019;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Asset Acquisitions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (see Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#x2019;s consolidated statements of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset was amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represented the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset was carried at cost less accumulated amortization. Amortization was included in amortization of intangible assets in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheet and included a $14.2 million impairment charge in the &lt;span style="-sec-ix-hidden:Hidden_yKNGHsYxl0ua6mlZdK34eA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;consolidated statement of operations&lt;/span&gt;&lt;/span&gt; and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its headquarters in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Long-Term Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Long-term debt represents the Company&#x2019;s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the effective interest rate method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the effective interest rate method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Warrants &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company&#x2019;s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company&#x2019;s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The recognition, derecognition and measurement of a tax position is based on management&#x2019;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#x2019;s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#x2019;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#x2019;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#x2019;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Comprehensive (Loss) Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission&#x2019;s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt annual requirements under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_74FdCennt0uoMcA8Z-EUcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_RL8X3KX8TU-u7GrKzkJxpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Use of Estimates &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration, amortization of the Blue Owl Loan, valuation of warrants, accrued expenses and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, including estimates such as the Company&#x2019;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. In addition, the Company&#x2019;s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_8xHFRyBwh02obD6j_IgKnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Unrestricted and Restricted Cash and Cash Equivalents &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrestricted cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total unrestricted and restricted cash and cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 159,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are generally in money market funds.&lt;span style="display:inline-block;width:2.25pt;"&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="font-style:italic;"&gt;Unrestricted Cash and Cash Equivalents &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the Company had an unrestricted cash balance of $124.9 million and an unrestricted cash equivalent balance of $28.4 million. As of December 31, 2022, the Company had an unrestricted cash balance of $27.5 million and an unrestricted cash equivalent balance of $30.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Cash &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL. As of December 31, 2023, the Company had a short-term restricted cash balance of $0.2 million and a long-term restricted cash balance of $6.1 million on its consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had no restricted cash or cash equivalent balances. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_wE78pLUUrk-FpJEgdx97VQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of unrestricted and restricted cash and cash equivalents reported within the consolidated statements of cash flows (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrestricted cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total unrestricted and restricted cash and cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 159,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_eGE7c3vT_UGPOytjJmI5hw_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">153290000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_y5KvB8d2Gk2zxfOP3K9a8w_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_OCGCaJv3J0K2mQfVor-84g_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6260000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_7SuGn7WGU0Cm-8EEgy8_2Q_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">159550000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_QRKC7Xz9u0qNtJO0xub0VA_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_et3D9Xj9o0SKZgaoM6rOcQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">124900000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_vWuEQpqpnEuQ5ediMsRXFA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-5"
      id="Narr_vaGTnaYKK0eb3c1AnAeiiA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">27500000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-5"
      id="Narr_FPTLY0Bxf0i9E1H_Hz_7kQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember_r98Y34qxLkWbmrz_8S1ntw"
      decimals="-5"
      id="Narr__iafchRkT0OwUxg0iP98pQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6300000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_pFJTova4jkOtP18qsB8a9Q"
      decimals="-5"
      id="Narr_Yt5xL3HMAEy4so8rv6TDtQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5800000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_15_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsOperatingExpensesMember_bIl9zjrGREO247K9VPfUHA"
      decimals="-5"
      id="Narr_9qInSRuKeEqE3ZcljkUqoQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_70-9vwyMx0-c47QRjo_O1g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_NzMpsihC5ESXh9XP0ad6Rg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6100000</us-gaap:RestrictedCashNoncurrent>
    <xoma:RestrictedCashAdditionalToBeFunded
      contextRef="Duration_7_1_2027_To_7_1_2027_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_xoma_CashReserveAccountsInterestAndAdministrativeFeesMember_zKMEytddB06_SjlQuaXQbA"
      decimals="-5"
      id="Narr_IaziQVGyYE69-EH1BvjqmA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">800000</xoma:RestrictedCashAdditionalToBeFunded>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Narr_7S09LNSBFkuY7ekacPaAeQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_g7_QrrNkAUiKQElLos5oBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;License of Intellectual Property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Milestone Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_7Fn-XyvPck2gns0pZ_0e6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;</xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_v-Mm96XY306yZ1O1NBWxIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <xoma:EquitySecuritiesPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_s8qhw1lawU6XVftFAbkFAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive loss in the period of sale.&lt;/p&gt;</xoma:EquitySecuritiesPolicy>
    <xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_xR2STplUhkSg8ERIeiV_cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Purchase of Rights to Future Milestones, Royalties and Commercial Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;</xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock>
    <xoma:CreditLossContractWithCustomerAssetPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_KPuytmQa_UySYlzP5pNHhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Allowance for Current Expected Credit Losses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#x2019;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;&lt;/p&gt;</xoma:CreditLossContractWithCustomerAssetPolicyTextBlock>
    <xoma:AssetAcquisitionsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_UoBwHqhwMkuB2Mchopr34A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Asset Acquisitions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (see Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#x2019;s consolidated statements of cash flows. &lt;/p&gt;</xoma:AssetAcquisitionsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_d43RuZJcBE66Q78bHQym_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset was amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represented the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset was carried at cost less accumulated amortization. Amortization was included in amortization of intangible assets in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheet and included a $14.2 million impairment charge in the &lt;span style="-sec-ix-hidden:Hidden_yKNGHsYxl0ua6mlZdK34eA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;consolidated statement of operations&lt;/span&gt;&lt;/span&gt; and comprehensive loss.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_EnsamhLSDEaWLpf-NafDRA"
      id="Narr_dND_7SkoEkylHo7ind_Rnw">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA"
      decimals="-5"
      id="Narr_oz0fAYotp0mUGRBUZG1bFg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA"
      decimals="-5"
      id="Narr_wYwpTq2UP0y1LVrHSMW6OQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_dPIE5yS3VEeOEmSxIvyC9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its headquarters in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_NJt5NUAZskuHuGVPNrRJug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Long-Term Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Long-term debt represents the Company&#x2019;s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the effective interest rate method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized and recorded as interest expense throughout the expected life of the Blue Owl Loan using the effective interest rate method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <xoma:WarrantsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_8rlx0LIV_keM59-vdK0OhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Warrants &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company&#x2019;s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company&#x2019;s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.&lt;/p&gt;</xoma:WarrantsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_p79-MUn5REOQ8U080cv8Iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The recognition, derecognition and measurement of a tax position is based on management&#x2019;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_A46db6bVTUmn-VcclNOsXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#x2019;s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#x2019;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#x2019;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#x2019;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_zFrKFWlub0yF-8yZg5Mz6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Comprehensive (Loss) Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_VMwg4Y7cjU696DgM42UEPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission&#x2019;s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt annual requirements under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_CaU5uAPmyk2EIzjoYbjOfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Consolidated Financial Statement Details&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, equity securities consisted of an investment in Rezolute&#x2019;s common stock of $0.2 million and $0.3 million, respectively (see Note 4). For the years ended December 31, 2023 and 2022, the Company recognized a loss of $0.2 million and $0.4 million, respectively, due to the change in fair value of its investment in Rezolute&#x2019;s common stock in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Intangible Assets, Net &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, impairment charge and net carrying value of the Company&#x2019;s intangible assets as of December 31, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Charge &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,253&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,253&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $14.2 million impairment charge in the &lt;span style="-sec-ix-hidden:Hidden_W5XKDOrmOUCVyHTuQ-wVXw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;consolidated statements of operations&lt;/span&gt;&lt;/span&gt; and comprehensive loss.&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of intangible assets as of December 31, 2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Accrued and Other Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll, severance and retention costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,768&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Arbitration Proceeding &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In June 2021, the Company initiated a binding arbitration proceeding with one of its licensees (the &#x201c;Licensee&#x201d;) at the American Arbitration Association/International Centre for Dispute Resolution, and sought milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement had &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;expired. The panel ruled that the Company was responsible for the Licensee&#x2019;s costs as well as arbitrators&#x2019; fees and administrative fees previously incurred by the Licensee of $4.1 million, which the Company paid in April 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_w6rQaC_PqEy9fPUmEuULSQ"
      decimals="-5"
      id="Narr_0Ns4_1Ajwki6MeCuAaNyGQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_pSxax3Usz0yR4JG-1OD69Q"
      decimals="-5"
      id="Narr_vjp9EJAlbkS85m_2TV_UiA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_lw1Ws7NAP02fg7d3o1Pq3w"
      decimals="-5"
      id="Narr_SFsM8D3C5Uqf6mkPu45yVw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_RWlyVdx2GUC3EPptM1fY5A"
      decimals="-5"
      id="Narr_W69Pq2tpPESkEBY4HjOFIg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_du9X-q16hEa7Ojrk22zKGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, impairment charge and net carrying value of the Company&#x2019;s intangible assets as of December 31, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Charge &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,253&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,253&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $14.2 million impairment charge in the &lt;span style="-sec-ix-hidden:Hidden_W5XKDOrmOUCVyHTuQ-wVXw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;consolidated statements of operations&lt;/span&gt;&lt;/span&gt; and comprehensive loss.&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of intangible assets as of December 31, 2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_RRcaFO6M3kOh_ZaU4q8qig"
      decimals="-3"
      id="Tc_XNwmLc5AJkSKcpCx-TM-qg_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_RRcaFO6M3kOh_ZaU4q8qig"
      decimals="-3"
      id="Tc_7ZC0mhwJmU2V6Dgt9tQ0IQ_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">994000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Y2l7YTUwo0u38OqVPbafow"
      decimals="-3"
      id="Tc_wJRohUKtLkOsT_VmBdY5cQ_4_9"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14253000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_lxPfC00yxkerfpclASCwBQ_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_xquuyB8IVE6SHI2Q9vEH9w_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">994000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_fB5I6L2WgkaLNio-wG9uXA_5_9"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14253000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA"
      decimals="-5"
      id="Narr_uxTs1Y2sU0qP2YppBFt-lg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z_1n_qUoa0C9qQkT1zZkAA"
      decimals="-5"
      id="Narr_xc-mtl1h_02K0eu8gdujFw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ"
      decimals="-3"
      id="Tc_58KtJYOdX0Wgp_iBh5jS7Q_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ"
      decimals="-3"
      id="Tc_TJJ_EmuhHUSqXGRllAxU8Q_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_0cPLxJ4SW0KnErtdY-VJpQ"
      decimals="-3"
      id="Tc_KCE1wwuyw0CDTuJedoru9w_4_9"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_7Ro5wPzbC0qPSIIHMQKKQQ_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_8bLSK5qZTE-0Rzx_YyoGGg_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_UpnQeKCd1EyXjWQY664yyw_5_9"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_4y-NFZSTcky57yRHJBMiFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll, severance and retention costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,768&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_GXDTZ5Uq8E6seq3FVcVITA_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1203000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_Xhc3wlSi10eRzaOHwxTueA_3_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">562000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_Nena77wELU-6F7GGirN6sA_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">791000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_DGsz_uXx0E6B1iCgWt2nCA_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">867000</us-gaap:AccruedProfessionalFeesCurrent>
    <xoma:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_wXGRcb3AfkqMpTq5kbi-ng_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">149000</xoma:AccruedSalariesAndEmployeeBenefitsCurrent>
    <xoma:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_yqv-zPeN_0mgqalFClDpWg_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1449000</xoma:AccruedSalariesAndEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_oGe7zuzTt0WYYN-R3tPHAQ_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_IepiFQNAhkqA1l5EJpuLKA_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">40000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_C_rt1oisoU6Ux6BH6CE79A_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2768000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_OxRcDbKJREWZykmnPV5f3g_7_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2918000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:NumberOfArbitrationProceedingsInitiated
      contextRef="Duration_6_1_2021_To_6_30_2021_dtGtLvan-0WILGKknRPEsA"
      decimals="INF"
      id="Narr_l7v8-zp-x0aTPHOt2YBX2w"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">1</xoma:NumberOfArbitrationProceedingsInitiated>
    <us-gaap:LitigationSettlementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-5"
      id="Narr_jzALMjAAqEKjk_os3BGvMA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4100000</us-gaap:LitigationSettlementExpense>
    <xoma:LicensingAndOtherArrangementsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_E-n79cYtwUualAPFvn8bJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Licensing and Other Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Takeda&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Takeda Collaboration Agreement, the Company may receive an aggregate of up to $19.0 million relating to TAK-079 (mezagitamab) and low single-digit royalties on future sales of all products subject to this license. The Company&#x2019;s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#x2019;s right to receive royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#x2019;s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#x2019;s right to receive royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the first patient was dosed in Takeda&#x2019;s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $0.8 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022. &#160;No milestone revenue was recognized for the year ended December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized annual license fee revenue of $0.1 million from Takeda in the consolidated statement of operations and comprehensive loss for the each of the years ended December 31, 2023 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company has received $3.0 million of milestone payments since the inception of the agreement and is eligible to receive additional milestone payments of up to $16.0 million under the Takeda Collaboration Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Rezolute&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize RZ358 (previously known as &#x201c;X358&#x201d;) products for all indications. In addition, the Company entered into a common stock purchase agreement with &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock in connection with any future equity financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to an aggregate of $232.0 million based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#x2019;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute&#x2019;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the later of the date of expiration of the last valid patent claim covering the product in each country, or 12 years from the date of the first commercial sale of the product in each country. Rezolute&#x2019;s future royalty obligations in the U.S. will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid patent claim, until such a claim is confirmed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#x2019;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical study. Rezolute&#x2019;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of 12 years from the date of the first commercial sale of the product in each country or for so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licensee&#x2019;s obligation to make payments to Rezolute based on sales of such product in each country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#x2019; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute&#x2019;s equity financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute&#x2019;s common stock (as adjusted for the &lt;span style="-sec-ix-hidden:Hidden__s_2kpVZCEW7Qrum_VkryA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;:50 reverse stock split in October 2020). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No revenue was recognized for the year ended December 31, 2023. The Company recognized $2.0 million from contracts with customers in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Janssen&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMA&#x2019;s patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#x2019;s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#x2019;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#x2019;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized milestone payments of $1.5 million in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023. &#160;The Company did not recognize any revenue related to this arrangement in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;ObsEva &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#x2019;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#x2019;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA was eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. If ebopiprant was successfully commercialized, the Company would have been entitled to receive royalties on net sales that range from low to mid-teens from Organon and would have been required to make mid-single-digit royalty payments on net sales to Merck KGaA. The Company paid ObsEva a $15.0 million upfront payment at closing and would have paid potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company would have received pursuant to the Organon License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The transaction was treated as an acquisition of a finite-lived intangible asset (see Note 2). As such, the Company&#x2019;s cost to acquire said intangible asset was $15.2 million, which consisted of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, which was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the intangible asset at acquisition represented 17 years. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022. The Company recognized $0.9 million and $0.1 million of amortization expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA did not meet the definition of a derivative under ASC 815 and a liability would have been recognized at the time that the underlying revenue was recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 would require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expected the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would have been recorded.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 23, 2023, Organon notified the Company of its intent to terminate for convenience the Organon License Agreement, which &lt;span style="background:#ffffff;"&gt;XOMA assumed pursuant to the ObsEva IP Acquisition Agreement dated November 21, 2022.&lt;/span&gt; The termination was effective as of January 21, 2024. The Company will not be entitled to any milestone payments with respect to any milestone achieved by Organon following the notice of termination. No material early termination penalties will be payable by either party. The Company evaluated the related intangible asset balance for impairment in the fourth quarter of 2023 and recorded an impairment charge of $14.2 million, writing off the entire finite-lived intangible asset in the consolidated balance sheet and recognizing an intangible asset impairment in its &lt;span style="-sec-ix-hidden:Hidden_UjdHxsUKK0CGYSg7vc8W1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;consolidated statement of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;operations&lt;/span&gt;&lt;/span&gt; and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Novartis&#160;&#x2013; Anti-TGF&#x3b2; Antibody (NIS793)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#x3b2; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#x2019;s anti-transforming growth factor beta (&#x201c;TGF&#x3b2;&#x201d;) antibody program (now &#x201c;NIS793&#x201d;). Under the terms of the Anti-TGF&#x3b2; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#x3b2; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The Anti-TGF&#x3b2; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#x3b2; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon 180 days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that there were multiple promised goods and services under the Anti-TGF&#x3b2; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGF&#x3b2; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#x3b2; Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#x2019; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#x2019; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#x3b2; Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#x2019; first NIS793 Phase 3 clinical trial. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2023, Novartis communicated to the Company that it intends to discontinue development activities related to NIS793. Novartis will cease enrolling patients in the remaining active TGF&#xdf; clinical studies and will collect all data upon conclusion of these studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Novartis&#160;&#x2013; Anti-IL-1&#x3b2; Antibody (VPM087) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#x201c;VPM087&#x201d;), a novel anti-Interleukin-1 (&#x201c;IL-1&#x201d;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, pursuant to a separate agreement (the &#x201c;IL-1 Target License Agreement&#x201d;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#x201c;Exclusivity Option&#x201d;) to such intellectual property for the treatment and prevention of cardiovascular disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#x20ac;12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company&#x2019;s outstanding debt with Les Laboratories Servier (&#x201c;Servier&#x201d;) (the &#x201c;Servier Loan&#x201d;). In addition, Novartis extended the maturity date on the Company&#x2019;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#x2019;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;covered by the Company&#x2019;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#x2019; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;21, 2016, the Company entered into two royalty interest sale agreements (together, the &#x201c;Royalty Sale Agreements&#x201d;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#x2019;s limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Company&#x2019;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the period&#x2019;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $2.1 million and $1.9 million as revenue under the units-of-revenue method under these arrangements during the&#160;years ended December 31, 2023 and 2022, respectively. As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. As of December&#160;31, 2023, the Company classified $2.1 million and $7.2 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.&lt;/p&gt;</xoma:LicensingAndOtherArrangementsTextBlock>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember__6fnOc6OPUS1I5ZlPUpdTQ"
      decimals="-5"
      id="Narr_v0bGRKGv1UqmB6h1Y1lwZQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">19000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0EETUtBX8UGfAIbmhgJkXQ"
      id="Narr_9Gp_Lo4dc0Ws_PWNGF0Ftg">P13Y6M</xoma:RoyaltiesPeriodMinimum>
    <xoma:RoyaltiesPeriodMinimumScenarioOne
      contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_Tak079AndTak169Member_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0EETUtBX8UGfAIbmhgJkXQ"
      id="Narr_53as3vHUXkqTIpW9f9atgQ">P12Y</xoma:RoyaltiesPeriodMinimumScenarioOne>
    <xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate
      contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_w1WsQS9rPkSjRRaxRFYrUg"
      decimals="-5"
      id="Narr_F8hDVnsopkGP3U30Uth0Bw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3300000</xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_w1WsQS9rPkSjRRaxRFYrUg"
      id="Narr_1npef7JHtEmG0jWjoT_wpg">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_hxT-8FvU4kmmkr5WaUc5tw"
      decimals="-5"
      id="Narr_Dcgh_FsJ4Euv7xAyqVC0OA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_dLKjanUZa0iaV3DbfG2Dlw"
      decimals="-5"
      id="Narr_xiM8zPkmUUm22L2DC3ADdw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MilestoneMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_fi1CUmq620GKCFSjTShMsA"
      decimals="-5"
      id="Narr_QVdJMDj5zUGGA5coiWxkCg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_qCQ7jqMcRkubKcfhZC2tng"
      decimals="-5"
      id="Narr_d8cF6L8cO0CIe8St9tIUNw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_OSC8ojzXEkSJ5RzL03Kwhg"
      decimals="-5"
      id="Narr_l-T1o_JCTE2N8o1deUVh9g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA"
      decimals="-5"
      id="Narr_JvsNEEdL70uDZZzmcZHb2Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw"
      decimals="-5"
      id="Narr_bCG69XnSTE-4fRp9k9WfjQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA"
      decimals="-5"
      id="Narr_sxlOuSEjh02Ih5M4yuBVeg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw"
      decimals="-5"
      id="Narr_Quf8fTffhU6NMWC0qcY1oQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA"
      decimals="-5"
      id="Narr_H0r1yUlcQEWloymp8PEARA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_atbACUJBykqvSRT3SMz7fw"
      decimals="-5"
      id="Narr_vDFcfTH4eUmGdn7zNinqjA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_11_1_2020_To_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_MTSivgxXa0q5d0yr9jPQ4Q"
      decimals="-5"
      id="Narr_kLefBdEWEk2gcjmO3leSaw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_LiIfeK3KfUeuMf_bpVDhYA"
      decimals="-5"
      id="Narr_gcv21_e8WkqBKwiHoRoZTQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">16000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_IHaDD6BBE0CO38D7GY_WoQ"
      decimals="-5"
      id="Narr_PMYhdnDiIUm9UxQibeURMw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">232000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_gy86xQDN_kOxX3_roA0-UA"
      id="Narr_70h2ijo_5Uq0TbiIpcZt9g">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:PercentageOfDecreaseInFutureRoyaltyObligations
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A"
      decimals="2"
      id="Narr_6IabxAlOFkeHNg_RNvDhpw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.20</xoma:PercentageOfDecreaseInFutureRoyaltyObligations>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_plbEBxZzaEaRWFV0Pyn4DQ"
      id="Narr_4OBMjpErHEmRh5RQRFejZA">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A"
      id="Narr_Y9y7yjEiyUS67tOWI6nEpw">P90D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_khFxzHmm8EWbTezrhPaQ9A"
      decimals="-5"
      id="Narr_TaSwHhmuPESYua1pzzTYwg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities
      contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ"
      decimals="-5"
      id="Narr_0GtiJpbbuku8BGfaocpTRQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities>
    <xoma:LicenseAgreementInstallmentPaymentsReceived
      contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ"
      decimals="-5"
      id="Narr_HcCVxv3VbEC5LDy59d_L7w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8500000</xoma:LicenseAgreementInstallmentPaymentsReceived>
    <xoma:LicenseAgreementSharesReceived
      contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_xMbBKt2Tf0eWGPKvsviTLQ"
      decimals="INF"
      id="Narr_-ZbW--L3s0S-XikbCOEldw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">161861</xoma:LicenseAgreementSharesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AvM2tRL06EKNen-3oQQBug"
      decimals="-5"
      id="Narr_Zk7Zy2JsGUieYH0zD_FBuQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__ZprmCypEEWlgZ0NIIwirQ"
      decimals="-5"
      id="Narr_LjUERAr6O0uDzPtiqSgNhA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_W8GylEFUmkCZLuCLShF-2Q"
      decimals="-5"
      id="Narr_dEyBIwRNakyeJWZ6_xCrqg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw"
      decimals="-5"
      id="Narr_0-lQazqAikS4zIurC8X8Hg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g"
      decimals="-5"
      id="Narr_BIJ-0sD2zUqAwbGUot4c5g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g"
      decimals="-5"
      id="Narr_XbLq5o4aA0ep3wuf7VQNQw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw"
      decimals="-5"
      id="Narr_nkY4_KwZqUKQd5l2Sg572g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7_xckyuY3EG94cartqbV_g"
      decimals="-5"
      id="Narr_niDMWvk5fkS25v5KMGvZhA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_utL1-DhLLUGqLFZO9YaYAw"
      decimals="-5"
      id="Narr_hgVmpIGg10qJKyLfgsfrlA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw"
      decimals="-5"
      id="Narr_TfMI0yx-pkOYNgT8xeCDXQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw"
      decimals="-5"
      id="Narr_uawgqJCm5ky8B-M-iZhgfQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate>
    <xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_w3wGb4clnUmI4ZjnJHBwQw"
      decimals="4"
      id="Narr_Kd0BiWA05Ue4hmHulNzR7w"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0075</xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uRoDrOQqBEOHxxDn5GD5-A"
      decimals="-5"
      id="Narr_32LNZ4HFQ0WEfl2QnC87Vw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg"
      decimals="-6"
      id="Narr_M8C0LnA4WkSRl7loKPptFw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA"
      decimals="-6"
      id="Narr_wOLe3KY_HEyy7yVJToWEOg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg"
      decimals="-6"
      id="Narr_6cwetVbx2E-O6ZzwDK6FjA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA"
      decimals="-6"
      id="Narr_SQS7vGfLHE6kKOldYPN6aA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_bf_OwbaXvk-cTjnhtm6UFA"
      decimals="-5"
      id="Narr_xngm2k6nNU-S81Jt7IACig"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lVmkBXwcUWW7xkCwzfLjg"
      decimals="-5"
      id="Narr_-cPOECiP106PJVRCiyYV-Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_5vFgsQWMw0WyWVDC99pPgA"
      decimals="-5"
      id="Narr_bQaaJOAXeUeWzO6uuO5wzQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HGWd0mh5bECM6w9TDjLMqQ"
      decimals="-5"
      id="Narr_rvr4yQXwd06AetT98kcK8A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ"
      decimals="-5"
      id="Narr_pkZG2E_eREWXSRXOQwQ7GA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">475000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ"
      decimals="-5"
      id="Narr_gKQlPKeg1Uam2Si1rAIbpQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <xoma:MaximumEarnOutPayments
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ"
      decimals="-5"
      id="Narr_xhpe7Us4yUC3dC7PXqlSMw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">97500000</xoma:MaximumEarnOutPayments>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ"
      decimals="-5"
      id="Narr_TgYrsdF3hEGorMhOKOtRxA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ"
      decimals="-5"
      id="Narr_boRK_Rg15EG-vsq1yqxN8A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ"
      decimals="-5"
      id="Narr_UOqk4Ey7n065hIRVtbrn5g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_12YbqTDUgEir9xjrrYl3uQ"
      id="Narr_x36Nhb2MEEmzaRrN6adNZw">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_DR_dvBy6JkSRBmbQK4UTeA"
      decimals="-6"
      id="Narr_SuzgbTIkZ06i8Vw3RvlxWg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ORSwgOFEv0uBzO5uoRPJVQ"
      decimals="-5"
      id="Narr_T2Z8azg2SkO3Quaw3Uj8fQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rqkDVECDp0uGDqsfOos4Pw"
      decimals="-5"
      id="Narr__GhBPcczYUisuUqUZvuwdg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:AmortizationOfIntangibleAssets>
    <xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ"
      decimals="-5"
      id="Narr_qRyBN05oNU6eCgXaUjagTA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">46500000</xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments>
    <xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pWrCv6zh-U6SlOb014CjuQ"
      decimals="-5"
      id="Narr_dd3OXTSPWkOyTT-yM6xqqA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">51000000.0</xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_10_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_3WHRj7yXxk6Z9Qfmyl4VIA"
      decimals="-5"
      id="Narr_PswHrHUmDEuDBj9MTsXzXA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg"
      id="Narr_raZj1dx7GUG2f1B4rZEqhg">P180D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg"
      decimals="INF"
      id="Narr_3MQlNYOe4ke3SviFlop7uA"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">1</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tb-jqf59g0qRtmd2zX4zHA"
      decimals="-5"
      id="Narr_di0ppqls9E6gaknD9eWeww"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">37000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tb-jqf59g0qRtmd2zX4zHA"
      decimals="-5"
      id="Narr_DhuM34WPZEuUPpdr67uDYA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">37000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ZfHh5QPIlkK7My1pRgpLNQ"
      decimals="-5"
      id="Narr_EKx2UZDKnkKGS2eP7Ue0eg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">480000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lPc163Jack2g_3qJHGxkJA"
      decimals="-5"
      id="Narr_UB0TUUFxtUag9okm_4HxJg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xzsk4aGqeEuFxIQuOHtNXg"
      id="Narr_L9Ww6N0B8UmNRJCzwMQXNA">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jkZrlo9E8kGwNk50O_JF4g"
      decimals="-5"
      id="Narr_tNEvPhruBEqKfw8vY5--mg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jkZrlo9E8kGwNk50O_JF4g"
      decimals="-5"
      id="Narr_H2QaWYCCv0umDL9UIOVIew"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">17700000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_DDySBRqQAkmCyGXaQYbaTw"
      decimals="-5"
      id="Narr_IHC4OHbx80SL_u9td5B9mg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-7300000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Kfw2xvvPLECdksugQSkyRw"
      decimals="-5"
      id="Narr_K8vEkSRbK0yVugiIwyl6kA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">35000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw"
      decimals="-5"
      id="Narr_K15bbo7jWUuuDe1Qfxh1Wg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw"
      decimals="-5"
      id="Narr_zBhWjiLiBEerbKSfUAKsWw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw"
      decimals="-5"
      id="Narr_Hs1OzmsqGUe7kQbtNVV6Pw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw"
      decimals="-5"
      id="Narr_6i3q1vnZUEaovWIbGHXMsg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xGwYv98BhUqGaHzxtHwCIw"
      decimals="-5"
      id="Narr_AoMxnGNgK0O1P_8XiSntAA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_rHF6sTlIwUK0T7DaSw9hXw"
      decimals="-5"
      id="Narr_SK1Tul6-C0Cuv5CqLn28Hg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wFKkAjcle0uyGz1v162nrQ"
      decimals="-5"
      id="Narr_v_XnfSzX20iOVAY8VXRFXw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7PuIiwOfIE6NRKYOTnb75w"
      decimals="-5"
      id="Narr_E2KbdvRnkkm9Ji0qPR4JwQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      decimals="-5"
      id="Narr_Vamdixfgi0GzqzqjNEi5Kg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30000000.0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      decimals="-5"
      id="Narr_J8OI4i89L0WobQnzslqjdg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      decimals="-5"
      id="Narr_yqsVfzTm6k-eF6bSHTp9Og"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      decimals="-5"
      id="Narr_pCrcqI4v90W1cY6_lecX8Q"
      unitRef="Unit_Standard_EUR_mzQmqJqZD0WOAo7brJv5KA">12000000.0</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      decimals="-5"
      id="Narr_C2k0UM6Hg0WhjWjGPdmIHw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_IY_E1K2-GEeCZwiLEBu6nw"
      decimals="INF"
      id="Narr_o4GEr5Oo7kWiXB8JLX6L1g"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">539131</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_7AXSy2l_dkerjh7MaB675Q"
      decimals="4"
      id="Narr_AIpnSabH_E2ilt-9MiLrsg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">9.2742</us-gaap:SharesIssuedPricePerShare>
    <xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_IY_E1K2-GEeCZwiLEBu6nw"
      decimals="-5"
      id="Narr_7urI46B9mEmMN3VGmZG0EQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4800000</xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_7AXSy2l_dkerjh7MaB675Q"
      decimals="2"
      id="Narr_HJ4SONKx_Umm9upzazKPRg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">8.93</us-gaap:SharePrice>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      decimals="-5"
      id="Narr_Q7v30Kk1gkaVAoFo7oX6mw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</xoma:CommonStockPremium>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_6gbf0-HRZ0qDTY9O_kyUlg"
      decimals="-5"
      id="Narr_oasmn47QOky4F-z3XZsAzQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">438000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_yk_WkugXu0KU1E5kCoC55w"
      decimals="-5"
      id="Narr_PxxhLa7gwUqrMiCY63SaEw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:AgreementsNumber
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="INF"
      id="Narr_6EG_Qx_waEW55_IT_3yBWw"
      unitRef="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A">2</xoma:AgreementsNumber>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_e00Oc-1cLk2Fx2nCtT0T7w"
      id="Narr_EK9Ezbam2kyXpIm2Hhn9_g">P6M</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:ArrangementsNumber
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="INF"
      id="Narr_owRQsRpv0UmX7-excOC93g"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">1</xoma:ArrangementsNumber>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="INF"
      id="Narr_nJdgcAadr0mjpH-sGk1g-A"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:NumberOfPerformanceObligations>
    <xoma:LicenseAgreementTransactionPrice
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="-5"
      id="Narr_lO7YqFmEZEKp0s4fwHJ8mg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">40200000</xoma:LicenseAgreementTransactionPrice>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="-5"
      id="Narr_FllTTQOxd06hYSAPXidYKQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">25700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="-5"
      id="Narr_Xg5Do9skTkqmkyrQEJoo2Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="-5"
      id="Narr_Q5N3N725z0C9nIPtfZ3UkA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</xoma:CommonStockPremium>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="INF"
      id="Narr_E63PgAEpak-2cYZsaVbl_Q"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:NumberOfPerformanceObligations>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_saG2WM9OjU66hBmilNuzew"
      decimals="INF"
      id="Narr_WkU6y0pk0U-i3UTndc9ToA"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_FPhDw6eFSkewkz9kjfMtWw"
      decimals="-5"
      id="Narr_GfFJyuFJaE28FXooQd2IIQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A"
      decimals="-5"
      id="Narr_WSPihTb0M0i5VhIkGo3FgQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ"
      decimals="-5"
      id="Narr_l-AxThO_EkSrpyYHR71w1g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A"
      decimals="-6"
      id="Narr_8DOijJXBwE61zSrIYSz6Pw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ"
      decimals="-6"
      id="Narr_U6E7gxHVPk-nlUnIlAWy2A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_TItjj-mXeEaGOjSCEBTSxQ"
      decimals="-5"
      id="Narr_Et9s47fcy0WWOEEHzrXvYw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_uIakbGo7zUGzqKJk8Fdf2A"
      decimals="-5"
      id="Narr_fcI21WcpB0243fBj9x7FRg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lQhUbx-dW0yCv6mncYCFTQ"
      decimals="-5"
      id="Narr_lE_5ki5FkUGKFVuFOKXMYg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_ukrOvK0wPUCoC4cxRPdRLQ"
      decimals="-5"
      id="Narr_meiY8N20okmgfgBzimoBhQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:AgreementsNumber
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg"
      decimals="INF"
      id="Narr_Y41WDlwjeUWRwNdvz58wxA"
      unitRef="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A">2</xoma:AgreementsNumber>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_qvLnAbo6Nki2UZIKe_V1Tg"
      decimals="-5"
      id="Narr_bZhCP67WX0q0GAf8JlEeBg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_5P20gVnqp0OL89sgLmEIrw"
      decimals="-5"
      id="Narr_EV38E2cZUkecV1tR5KlHFw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4000000.0</xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones>
    <xoma:MilestonePeriodsNumber
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_5P20gVnqp0OL89sgLmEIrw"
      decimals="INF"
      id="Narr_h-kUuKve8UetLQ2DFay5fQ"
      unitRef="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ">3</xoma:MilestonePeriodsNumber>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_KY6LHuuUC0ara8OGoTqocg"
      decimals="-5"
      id="Narr_v_yXtr8DOUW2gr7UAjPOQQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">11500000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg"
      decimals="-5"
      id="Narr_Fqkct3ldjUeL7xeaJInR6A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">18000000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <xoma:AgreementsNumber
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_v4-7VUBeWkG4b4b4xyWAKg"
      decimals="INF"
      id="Narr_zfzfslL8D02nHtpSyxGojA"
      unitRef="Unit_Standard_agreement_n0TDXT6NpkyoGwJhPy-z4A">2</xoma:AgreementsNumber>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_b-w3yCVO1UaXJ0_RnOHO7Q"
      decimals="-5"
      id="Narr_qNqEaZox10G7Uu-Y3JD_2g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_qTQ_SCTqPUOorHOyhK5FRg"
      decimals="-5"
      id="Narr_tmze2wGByUyX7kqMVZ5tBA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1900000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_8W6Ja3W_5UWikBBaH31LWQ"
      decimals="-5"
      id="Narr_0RElS123PkqDfbLDTXO2qg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1900000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_8W6Ja3W_5UWikBBaH31LWQ"
      decimals="-5"
      id="Narr_PKGPKXjoskCbLQo10GygSw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9600000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_Nk99SOMJtE6XXgO_0hAWnQ"
      decimals="-5"
      id="Narr_644Ludc_KkqMTIpaUUdnYA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2100000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_Nk99SOMJtE6XXgO_0hAWnQ"
      decimals="-5"
      id="Narr_iYHH4v0dtk2rbVEiV3h4mA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7200000</us-gaap:DeferredIncomeNoncurrent>
    <xoma:RoyaltyPurchaseAgreementTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_HmwB08o3qEKDm6K1WF8jUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Royalty and Commercial Payment Purchase Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Short-term royalty and commercial payment receivables were $14.2 million and $2.4 million as of December 31, 2023 and 2022, respectively. Long-term royalty and commercial payment receivables were $58.0 million and $63.7 million as of December 31, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;LadRx Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The purchased rights related to arimoclomol include potential regulatory and commercial milestone payments of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The purchased payments related to aldoxorubicin include potential regulatory and commercial milestone payments of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages for sales of other licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and may pay up to an additional $6.0 million in regulatory and commercial sales milestone payments which included $5.0 million related to regulatory milestone payments and $1.0 million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin&lt;i style="font-style:italic;"&gt; &lt;/i&gt;payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.&lt;span style="display:inline-block;width:15.22pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, there was no change in the estimated fair value of the regulatory milestone payments from the initial value. &lt;span style="display:inline-block;width:0.86pt;"&gt;&lt;/span&gt;On January 11, 2024, the milestone was achieved and the Company made a $1.0 million milestone payment to LadRx (see Note 15).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023. &lt;span style="display:inline-block;width:1.41pt;"&gt;&lt;/span&gt; &lt;span style="display:inline-block;width:15.5pt;"&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:18pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Aptevo Commercial Payment Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables in its consolidated balance sheet which included a $9.6 million upfront payment and a $50,000 one-time payment, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet (the &#x201c;Aptevo Contingent Consideration&#x201d;) at inception. The Company paid the one-time payment of $50,000 in June 2023 when related receipts exceeded $0.5 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, the Company received total commercial payments pursuant to the Aptevo CPPA of $1.7 million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty receivable balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it has a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet date of December 31, 2023 and, as such, $2.0 million was recorded as short-term royalty and commercial payment receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Agenus Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (&#x201c;Incyte&#x201d;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#x2019;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone payment under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, no payments were probable to be received under the Agenus RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestone and royalty payments received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Bioasis Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that were being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the contingent future cash payments upon achievement of certain development milestones (the &#x201c;Bioasis Contingent Consideration&#x201d;) of $75,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon the closing of the Second Bioasis RPA for the purchased rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 20, 2023, Bioasis announced the suspension of all of its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, the Company recorded an impairment charge of $1.6 million in its &lt;span style="-sec-ix-hidden:Hidden_oKAPgn6owUGhjjDbJEhNww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;consolidated statement of operations&lt;/span&gt;&lt;/span&gt; and comprehensive loss and a reduction of $1.6 million under long-term royalty receivables related to the Bioasis RPA and Second Bioasis RPA. Due to the assessment that the credit loss will not potentially reverse in the future, the Company wrote off the royalty asset receivable and no allowance for credit losses was recorded as of December 31, 2023. The fair value of the Bioasis Contingent Consideration was reduced to zero with the change in the estimated fair value recognized in other income (expense), net in the consolidated statement of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Aronora&lt;span style="font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone and option payments (the &#x201c;Non-Royalties&#x201d;) related to five anti-thrombotic hematology product candidates. Three candidates were subject to Aronora&#x2019;s collaboration with Bayer (the &#x201c;Bayer Products&#x201d;), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the &#x201c;non-Bayer Products&#x201d;) for which the Company will receive a low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#x2019;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the &#x201c;Aronora Contingent Consideration&#x201d;). Pursuant to the Aronora RPA, if the Company receives at least $25.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#x201c;Royalty Milestones&#x201d;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, no payments were probable to be received under the Aronora RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Palobiofarma Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#x2019;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#x201c;Palo Licensed Products&#x201d;) that are being developed by Palo. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties&#x2019; entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Viracta Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestone payments and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 30, 2023, the Company earned a $5.0 million milestone payment pursuant to the Viracta RPA related to the FDA&#x2019;s acceptance of Day One Biopharmaceuticals&#x2019; NDA for tovorafenib. In accordance with the cost recovery method, the $5.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance. As of December 31, 2023, no further payments were probable to be received under the Viracta RPA in the near term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Kuros Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#x2019; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Affitech Commercial Payment Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#x2019;s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;upfront payment and $8.0 million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone payment tied to the U.S. marketing approvals and a $3.0 million milestone payment tied to the EC approvals. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Commercial payments are due from Roche within 60 days of December 31 and June 30 of each year. In accordance with the cost recovery method, commercial payments received are recorded as direct reductions of short-term and long-term receivable balances, as applicable. During the years ended December 31, 2022 and 2023, the Company received $0.5 million and $7.3 million from Roche, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it had a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet date of December 31, 2023 and, as such, $12.2 million was recorded as short-term royalty and commercial payment receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The achievement of the first and second sales-based milestone payment under the Affitech CPPA was considered probable as of December 31, 2023, and the Company recognized a $6.0 million contingent liability in the consolidated balance sheet. The Company may pay up to $6.0 million in additional sales-based milestone payments upon the achievement of certain incremental sales milestones in the future which are not assessed as probable and as a result not recorded as a contingent liability as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the royalty and commercial payment receivable activities during the years ended December 31, 2023 and 2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Kuros&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,366)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Acquisition of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;LadRx&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,284)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,673)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Viracta&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impairment of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bioasis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,575)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,109)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,024)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Recognition of contingent consideration:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,215&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:RoyaltyPurchaseAgreementTextBlock>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_y3UY36HyuUK0uh1i963zhA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</xoma:RightsReceivableCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-5"
      id="Narr_Y--cbn8DrU6v4d1hsuBDzQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2400000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_gfc2oJV9FkWwQvjSpuRmxw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">58000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-5"
      id="Narr_V46o1FbqfUGiaTLsbBYU4Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">63700000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_7RTgXi3MwkO02DSrEMpnRA"
      decimals="-5"
      id="Narr_ucApwLZ2okGZIR4tkWpTqw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">52500000</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet>
    <xoma:MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_7RTgXi3MwkO02DSrEMpnRA"
      decimals="-5"
      id="Narr_wo3vcGLycUS3wncqm4NILA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9500000</xoma:MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_U6eB0xdgwk-Ra02haIYfXQ"
      decimals="-5"
      id="Narr_6_KHDgL-oUOXtRn586beFg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">342700000</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw"
      decimals="-5"
      id="Narr_SnKoy3yDc0a6QnME2LVCDQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q"
      decimals="-5"
      id="Narr_yHXDPinoykSkKXs74Nt1dg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones>
    <xoma:ContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"
      decimals="-5"
      id="Narr_5mpBFStb7EOcza9KRMhk6A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:ContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q"
      decimals="-5"
      id="Narr_TDjFzNhcYUSzUko8E9rM0w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:ContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"
      decimals="-5"
      id="Narr_7qkHyRSbWU60xy_umoJ_7Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:ContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"
      decimals="-5"
      id="Narr_EdvP5zj2eEWGJwXFNC-zDA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_GqmSYeE3BkeikfFtsvO_5Q"
      decimals="-5"
      id="Narr_Cwb7AaYFFE2ceI_J1ek-1Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw"
      decimals="-5"
      id="Narr_kjAfs1w2DkSYpz0lcvU68Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_4zWVGKqXIUKp-GSILlHhyw"
      decimals="-5"
      id="Narr_oNkTajm2X0yQQkhUGB6xFw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"
      decimals="-5"
      id="Narr_PMMyEWCMLky6gr7i0d9CVw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA"
      decimals="-5"
      id="Narr_BUFjwIeF0ESO3uobBxBydw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_11_2024_To_1_11_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_kHKXEon0m0elwS6IFTsLdQ"
      decimals="-5"
      id="Narr_GNiRsshww06rdi4JatBihg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_PMJBCIy7IECiFkjfjmaUzw"
      decimals="-5"
      id="Narr_tepSHMW-zk-nAlJ9xwsueQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:MilestonesReceivableMaximum
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q"
      decimals="-5"
      id="Narr_oCcM7dGIDEq60M8TZfuw4A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5300000</xoma:MilestonesReceivableMaximum>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ"
      decimals="-5"
      id="Narr_t8rO8HH4A0GD7mpIYVRlwg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9700000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ"
      decimals="-5"
      id="Narr_LqmN-m0sn0mkHtAooC6XUw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9600000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q"
      decimals="-3"
      id="Narr_90WKhflQkEaW563tP1bxjQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000</xoma:MaximumPayableOnSalesMilestone>
    <xoma:CommercialPaymentThresholdOneTimePayment
      contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_MJO8HI4QJU6niyHHPwvzXQ"
      decimals="-5"
      id="Narr_EtU5_8tvmkq9Vdx9K3jSKw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">500000</xoma:CommercialPaymentThresholdOneTimePayment>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_0knG9b2NCE2Upbzsu0W68Q"
      decimals="-3"
      id="Narr_1DE8XS7A3E28kJKFWgPj8A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Dnn6lWiT3UCbGZqz1uHJdQ"
      decimals="-4"
      id="Narr_aIwe2oa_m0qx9w44w92aUA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_mDE0bA7PrUqp9g8geI29AQ"
      decimals="-5"
      id="Narr_BJv4lGP7fUOs82XLGD3UmA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">500000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ac_n1xmN8US4lumZOLANeA"
      decimals="-5"
      id="Narr_ev5JMpAfr0mRBLua04HitA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1700000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg"
      decimals="-5"
      id="Narr_TmxXgj1um0uhFTnvaQ9kcQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2000000.0</xoma:RightsReceivableCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg"
      decimals="-5"
      id="Narr_3O2RPxwH1U2X0AqDUrZLvg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pH08PwEje0KIRv6GUczeEA"
      decimals="2"
      id="Narr__0qtslkJNUGwGYp77XL46g"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.33</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pH08PwEje0KIRv6GUczeEA"
      decimals="INF"
      id="Narr_RK28KH7QWkuYgDYWaYI1Yw"
      unitRef="Unit_Standard_product_SNQEGGFW5kSKzKYrmjywPQ">6</xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-TWqBbOPI0edg96_YaJDsA"
      decimals="2"
      id="Narr_pBfQ4FnLiESxv8TXTpUC8A"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vfK6Z82DIk-illPE02g4gg"
      decimals="2"
      id="Narr_xBx6_Z2tSk-l7ZGbSHZBNg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.33</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_riSbvYPSGkWe1QwZUDB4KQ"
      decimals="2"
      id="Narr_9qLOdyrjjE-a61Jlcl9xfw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vfK6Z82DIk-illPE02g4gg"
      decimals="-5"
      id="Narr_xSMXyZwYvkOKRUMvCnXhZw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">59500000</xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bTPXO4suRkSuGzADvtOkDQ"
      decimals="-5"
      id="Narr_diPyGdSXhkaqRWCvqY97Cg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bTPXO4suRkSuGzADvtOkDQ"
      decimals="-5"
      id="Narr_EfL-LvbNdUmZHjRdk0UFOw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">15000000.0</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:MilestoneAchieved
      contextRef="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ws-dALFRwk6XAWf156awmQ"
      decimals="-5"
      id="Narr_dGayx2NsCEyhDRRL8lzlHA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10000000.0</xoma:MilestoneAchieved>
    <xoma:MilestoneAchieved
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_LUAacl6AYUSQlLyvLbzF7A"
      decimals="-5"
      id="Narr_uHl9ucPWVkCFKuhCd0PQkA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:MilestoneAchieved>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_LUAacl6AYUSQlLyvLbzF7A"
      decimals="-5"
      id="Narr_b6z_1pSxF0yQmpepqRC2Cg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TadyAKEHAkuV3__epaLGSw"
      decimals="-5"
      id="Narr_LiXfc6IEcU-LWQ2jk0nTPA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QrBLuliLBkmZRyyHG3qE9w"
      decimals="-5"
      id="Narr_J1JbITowtUiKyK_jERUxZw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">400000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Tfg4rgDuq0ufRwK2q3MQ0A"
      decimals="-3"
      id="Narr_qDRLaGpmpk21foRaIV87OA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ"
      decimals="-5"
      id="Narr_ytjN-icb1kyk1iKdCEuL3g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1200000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_z1qVfV90pkuTubkGCJqCUQ"
      decimals="-5"
      id="Narr_-6R4EGaT10KF6sCsbKzuJg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1200000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrentCreditLossExpense
      contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A"
      decimals="-5"
      id="Narr__-eBtOZi7kW3dB047VkGCQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1600000</xoma:LongTermRightsReceivableNonCurrentCreditLossExpense>
    <xoma:LongTermRightsReceivableNoncurrentDecreaseDueToImpairment
      contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BxuPuKsPH0qk74yE8rYU-A"
      decimals="-5"
      id="Narr_LlDVzB_zz0my7QPo4nEwow"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1600000</xoma:LongTermRightsReceivableNoncurrentDecreaseDueToImpairment>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw"
      decimals="-5"
      id="Narr_IujPki4ZcUC8FCVdHfP_rA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw"
      decimals="-5"
      id="Narr_08Y18578W0S0MV6Pef48ZQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w"
      decimals="INF"
      id="Narr_gZktRILmHU6FwmdNSW6U9w"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">5</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A"
      decimals="INF"
      id="Narr_68uwHQnUJU6MTlm6aAAR6Q"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A"
      decimals="INF"
      id="Narr_Xj7pBMTdlECWTz_1AtPwzQ"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">1</xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ukWUu5ueDkGldRKA40hqKw"
      decimals="INF"
      id="Narr_NRpRB719V0mXs2Z2EdyoEw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A"
      decimals="INF"
      id="Narr_M_ny79iq6ESRMa-kz0SpyQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zkpfoJr1ZUGbwa1B55RwJg"
      decimals="INF"
      id="Narr_pORA7IvOGEamy_rDIlp87w"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zkpfoJr1ZUGbwa1B55RwJg"
      decimals="INF"
      id="Narr_2dRYVzvhdUu1qobb9YeBkg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w"
      decimals="INF"
      id="Narr_QyRyLDXLLE6CV2wtO_O_3g"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w"
      decimals="INF"
      id="Narr_oJy8xQMzWUyamWzRrfjLyg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.05</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage>
    <xoma:AgreementPaymentPercentageFactor
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w"
      decimals="INF"
      id="Narr_2suQpCiAy0qIKiD8GgNzdQ"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:AgreementPaymentPercentageFactor>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw"
      decimals="-5"
      id="Narr_pVu5ZVgkVkiQJPA5DwdEmw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FmZheOiEbUS5CMSbMHjZ9g"
      decimals="-5"
      id="Narr_sfbNcOiGk0KBU4XFwSVSog"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentFutureCashPaymentsPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ukWUu5ueDkGldRKA40hqKw"
      decimals="-5"
      id="Narr_PBWIlPINpUysluXbaKn2gg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentFutureCashPaymentsPerProduct>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_OnaouEG9xk-Vx4rqoPw16A"
      decimals="INF"
      id="Narr_-e0LRNJfMkWAP6CBPiZhPQ"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_hcyXjuHEYE6D8CUHcrJ5bA"
      decimals="-5"
      id="Narr_oEvNeeqpbU-yPA3qHtVtuw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m5q_NDHLs0qf2z319qyN2A"
      decimals="-5"
      id="Narr_1t6XoJa32UCoLhol5Os0Yg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">25000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:MilestonesPaymentsToAggregateAmountOfPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw"
      decimals="-5"
      id="Narr_Ewxv2BKhG0W0wsgKj1nADw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">85000000.0</xoma:MilestonesPaymentsToAggregateAmountOfPerProduct>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw"
      decimals="-5"
      id="Narr_iKtY_SppBECw4s2NhpeBuA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw"
      decimals="-5"
      id="Narr_4zbWVAftykqvGYUy4RJoQg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YQ22BeyQV0eLwmnIt6Ffiw"
      decimals="-5"
      id="Narr_bGO-Xak-2EmMO-sikOKzag"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9000000.0</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_n-vZlTSnyUSKbOD_KdMe8w"
      decimals="-5"
      id="Narr_9AfKWsdTk0KEszpChqWAFw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Qs55blBy0EiU6L4gvsU5Ag"
      decimals="-5"
      id="Narr_slLcq5-6lUSYPOnDXSdqSQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zyoQf6ApEUqf3zXcyWmu_w"
      decimals="-5"
      id="Narr_L1wCiCbqt0Cbv12BVDjgRw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A"
      decimals="INF"
      id="Narr_KzUmwidLlk67q4eSwva64g"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">6</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vN14m3xAIUKgXMq-xvIgWQ"
      decimals="-5"
      id="Narr_pzsmpzvFNEiRrJyUKqOq6w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VMLzX9p8XkCk0v_raC02-A"
      decimals="-5"
      id="Narr_eEgNr2VcGE6v1KiF-_e3qg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3v-L0Vww2EuNWdV3-uHeDQ"
      decimals="-5"
      id="Narr_8RjTUEX7ak-QeNVYqrcf2g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig"
      decimals="INF"
      id="Narr_zN-nXUmOj0OroCeoqEclPQ"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CmMun3MJHE2TK0PBPfLoYA"
      decimals="-5"
      id="Narr_zC-m-uEC9UiLMwT2Em2MzA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">13500000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig"
      decimals="-5"
      id="Narr__8C_efc6wUaa79jWXly84Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">54000000.0</xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum>
    <xoma:MaximumConsiderationRetained
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig"
      decimals="-5"
      id="Narr_sZzCovRwkE-pvoMUKj5g7g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:MaximumConsiderationRetained>
    <xoma:RegulatoryAndCommercialMilestonesReceivableMaximum
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_KIZyJ9KCnES_04IQfnq4ig"
      decimals="-5"
      id="Narr_mQplSSi4xUmuig8r6ohrlA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57000000.0</xoma:RegulatoryAndCommercialMilestonesReceivableMaximum>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CmMun3MJHE2TK0PBPfLoYA"
      decimals="-5"
      id="Narr_sTFKBx-Lo0mew3ALBR3NhQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">13500000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:MilestoneAchieved
      contextRef="Duration_10_30_2023_To_10_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5j_H144ha0GnzzpObzRcdw"
      decimals="-5"
      id="Narr_ms0xVz0YtESFoIJD2_nIBA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:MilestoneAchieved>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_10_30_2023_To_10_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5j_H144ha0GnzzpObzRcdw"
      decimals="-5"
      id="Narr_pEcx6S3bW0uD9SUpOC6tcA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_th5gLhVhr0ODI3lXcg-R3A"
      decimals="-5"
      id="Narr_TX6Auoc7I0yIPtmmLV6aSg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:RightsReceivableCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_th5gLhVhr0ODI3lXcg-R3A"
      decimals="-5"
      id="Narr_tnVdS2er-UWJZFzlg6zaGQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w"
      decimals="INF"
      id="Narr_ovkZONCib0GzOQzUKZ-KCA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w"
      decimals="-5"
      id="Narr_KmL7WfbIIEinHvD2TnvItw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">25500000</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w"
      decimals="-5"
      id="Narr__jvgss21Hke-Uo-o9ALW3Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XtN01G-WQUmOgtwp6LiEzQ"
      decimals="-5"
      id="Narr_AIOpp6TynkKjTQz44Xtzgg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">142500000</xoma:MaximumPayableOnSalesMilestone>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_S4KINSuUMkKtpk0lZn229w"
      decimals="-5"
      id="Narr_H9Md8qI32kaK9qU4-jjpJw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7000000.0</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:MilestonePaymentReceivedCounterparty
      contextRef="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uYT0rItyzEy3DCuVTQGaFA"
      decimals="-5"
      id="Narr_A5kkfVUl_0qm2bpFPfDmVA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:MilestonePaymentReceivedCounterparty>
    <xoma:MilestonePaymentReceivablePercentage
      contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TYLM5-VARkS0pBu28e5EGA"
      decimals="INF"
      id="Narr_A-f27B7ZN0aMPUeVmgSMXA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.50</xoma:MilestonePaymentReceivablePercentage>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_TYLM5-VARkS0pBu28e5EGA"
      decimals="-5"
      id="Narr_W-lX9HwcSU2QWocnIqtTAA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ng_SQm0kE0GmhyCm9FCUWw"
      decimals="-5"
      id="Narr_b3QMUZZGiE-2s0qKIHyx8A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw"
      decimals="-5"
      id="Narr_MrYwcWrX1UmVoh_HXSeuQA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:CommercialSalesReceivablePercentageOnNetSales
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fTTbXC7jbkqFXemFP-meAQ"
      decimals="3"
      id="Narr_l_Q6PP8mw0OeFXIcnXaUSg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.005</xoma:CommercialSalesReceivablePercentageOnNetSales>
    <xoma:CommercialPaymentReceivableTerm
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fTTbXC7jbkqFXemFP-meAQ"
      id="Narr_lw747EVGP02oPDzLHRnzRQ">P10Y</xoma:CommercialPaymentReceivableTerm>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fbE-TTiMOE6nIPU6Gv7BJA"
      decimals="-5"
      id="Narr_aajDWhc27UaFkX4ghVC6ag"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">20000000.0</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw"
      decimals="-5"
      id="Narr_MkEKRIFTPEGQC-aezB-y5A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14000000.0</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_a1-3BLEwwkSDmRNuvkggkw"
      decimals="-5"
      id="Narr_lOcscJkzIkqeH3X1zHYz4g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ZZqIGqDsP0OAXaFzszUtlQ"
      decimals="-5"
      id="Narr_FsbU-S4qBEilbOSMZIjXQw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ZZqIGqDsP0OAXaFzszUtlQ"
      decimals="-5"
      id="Narr_XgmLK_4jFEGN7gKg0lZEsA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_fbE-TTiMOE6nIPU6Gv7BJA"
      decimals="-5"
      id="Narr_zW16U9j-cEq_hzuZSYKvXA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">12000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tdEEOHOCzUWim85LeSnQxw"
      decimals="-5"
      id="Narr_vUPQXYeW1E60OkCY0siaZA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_pF2mvqFuzU-4j2j-TN-FwA"
      decimals="-5"
      id="Narr_ux2536ldNUiKN65pRQLDNg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:CommercialPaymentPeriodDue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg"
      id="Narr_HDQT_nzK0EqoaTIYbOVrcA">P60D</xoma:CommercialPaymentPeriodDue>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NH5EPARofEyZbj-06mGtVQ"
      decimals="-5"
      id="Narr_ahMKFaeBhE2GJVioBG_cpw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">500000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sOsZuanuWEOdohXge_kSTg"
      decimals="-5"
      id="Narr_mNSw3aGLeUaqem6F_Oirug"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7300000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"
      decimals="-5"
      id="Narr_6bnWNH-CDUa8_5wnw5IDsg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">12200000</xoma:RightsReceivableCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"
      decimals="-5"
      id="Narr_7bihfa3Yn0ORwuW1-s87BA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:MaximumAdditionalPayableOnSalesMilestone
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"
      decimals="-5"
      id="Narr_ZDnp80qga06kSIeJTILoXg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:MaximumAdditionalPayableOnSalesMilestone>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"
      decimals="-5"
      id="Narr_QKO43phiuk6Dnt-d3dreMg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_h6VrB3WGW02XeHAqnj1HyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the royalty and commercial payment receivable activities during the years ended December 31, 2023 and 2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Kuros&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,366)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Acquisition of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;LadRx&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,284)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,673)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Viracta&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impairment of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bioasis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,575)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,109)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,024)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Recognition of contingent consideration:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,215&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ"
      decimals="-3"
      id="Tc_cBJLbeJi8U6qPSLZuPQfgw_2_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">69075000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_keBCQhbHw0y8_i0w3euIAA"
      decimals="-3"
      id="Tc_n_T3YgAE40Gb9g0s7c6i6w_4_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA"
      decimals="-3"
      id="Tc_DQ1bMNnhLk2ptmJBLUM0mA_5_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">526000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ShortTermRightsReceivableReclassification
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA"
      decimals="-3"
      id="Tc_qob-Z9eXhkW6TJcdgfg42w_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2366000</xoma:ShortTermRightsReceivableReclassification>
    <xoma:LongTermRightsReceivableReclassification
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember__5HgZssNBkitb5xIVP7reA"
      decimals="-3"
      id="Tc_OCH3tqs57Eq2xreZFdRF8A_7_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2366000</xoma:LongTermRightsReceivableReclassification>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_38ht9cjzn0eUJVIUqnc7Uw_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2366000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_WdVU8FSN4UGvJN4GPn7wmg_8_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">63683000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw"
      decimals="-3"
      id="Tc_NAhvgKKjyEyHMeafHs9IBA_10_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9650000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_CcXbeenPEESy7c73GXsaSA"
      decimals="-3"
      id="Tc_SnhnC9FK-ECX0-XD9EmVeg_11_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ"
      decimals="-3"
      id="Tc_mSHE2CjghkCvWoZNXWK-rw_13_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">7284000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw"
      decimals="-3"
      id="Tc_UhMVsv-tqU6CRPQMuAMcGw_14_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1673000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_0JMorE6cGUCpbiydWrq72g"
      decimals="-3"
      id="Tc_a0v6Wei740KRYiS3BaK6hA_15_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5000000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNoncurrentDecreaseDueToImpairment
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_8AcX-7SvuE20tV_Gwrd56A"
      decimals="-3"
      id="Tc_ly9o05FsjUegkoNzK0UtRQ_17_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1575000</xoma:LongTermRightsReceivableNoncurrentDecreaseDueToImpairment>
    <xoma:ShortTermRightsReceivableReclassification
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ"
      decimals="-3"
      id="Tc__Uo7q1URaEucL0CoccU88A_19_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">17109000</xoma:ShortTermRightsReceivableReclassification>
    <xoma:LongTermRightsReceivableReclassification
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ"
      decimals="-3"
      id="Tc_Mn8DiscaM0abiopwOptZpA_19_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">17109000</xoma:LongTermRightsReceivableReclassification>
    <xoma:ShortTermRightsReceivableReclassification
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw"
      decimals="-3"
      id="Tc_eJqCRNk7hUycSKRUGfdbMA_20_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2024000</xoma:ShortTermRightsReceivableReclassification>
    <xoma:LongTermRightsReceivableReclassification
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_QW9MiZ-YMEGYPQ4EcJeEAw"
      decimals="-3"
      id="Tc_tplBScxBAkeREWjQprsjrw_20_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2024000</xoma:LongTermRightsReceivableReclassification>
    <xoma:RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_you-dnbKHk-R5ZEb-hLQxQ"
      decimals="-3"
      id="Tc_sckhyR7RTkaOsXZyxff1SQ_22_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000</xoma:RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_vvri0dKOh06Cqe_E2NGuag_23_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14215000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_Ofqi3CWv90mNrtF3sraKHg_23_5"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57952000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_A_3WDr_T6UmsB_hYxlLMTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Fair Value Measurements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#160;&#x2013; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#160;&#x2013; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#160;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2023 Using: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,513&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The equity securities consisted of an investment in Rezolute&#x2019;s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2023 and 2022. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss. As of December 31, 2023 and 2022, the Company valued the equity securities using the closing price for Rezolute&#x2019;s common stock traded on the Nasdaq Stock Market of $0.99 and $2.07, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent Consideration &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the LadRx contingent consideration liability of $1.0 million at the inception of the LadRx Agreements represents the future consideration that is contingent upon the achievement of specified regulatory milestones for the product candidates related to arimoclomol and aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each product candidate. Such contingent consideration is remeasured at fair value at each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive loss until settlement. As of December 31, 2023, there were no changes in the estimated fair value from the initial value of $1.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The $0.1 million of contingent consideration as of December 31, 2022 recorded pursuant to the Bioasis RPA was written off during the second quarter of 2023 (see Note 5). &#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_at-uVa41MUK30gACYw2F7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2023 Using: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,513&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gec80tyUmkKY9InWUPJo7w"
      decimals="-3"
      id="Tc_y-CQUhbpg0i1tTPKn2sABw_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28352000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QT17Poc1lk2rEi5HuNqx_w"
      decimals="-3"
      id="Tc_LB9KTAleF02fZGcL3Vqveg_8_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28352000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw"
      decimals="-3"
      id="Tc_ZrS7UJW7E0-XY6R5OzZXMA_9_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28352000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ"
      decimals="-3"
      id="Tc_zauWPiAa2UeS7-S7tvqMPg_9_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28352000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw"
      decimals="-3"
      id="Tc_RayU2DdTRkyxVUb5-c35hg_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">161000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ"
      decimals="-3"
      id="Tc_Wh74J9eCeUuvrv6aYFllfw_10_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">161000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rrd59j2fuESRR9f-Q4a-vw"
      decimals="-3"
      id="Tc_hVNxRKAajESV5Kk2c3kpqQ_11_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28513000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ"
      decimals="-3"
      id="Tc_ngImWqMXkkKSmqx4ph_Yfw_11_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">28513000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-RitWGIJ-ESF55jlLrVWtA"
      decimals="-3"
      id="Tc_COUzYgHQ5USQAwkq8SG5nA_13_9"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6SyKJHGBBUSYZmGROohCVQ"
      decimals="-3"
      id="Tc_vaVDOVyf10qTLAItTZbvGA_13_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IK179fae_0q0Zg4c_AZHEQ"
      decimals="-3"
      id="Tc_weV4uOzkDEONR4TxOUHvOA_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f4zBuaboQUKb6pXCfGs0MQ"
      decimals="-3"
      id="Tc_r6UzCWs4jkGHibdhXAsf6Q_8_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA"
      decimals="-3"
      id="Tc_QQXU6ag8TEG_XPcTfzRiRg_9_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ"
      decimals="-3"
      id="Tc_iqbmg-lLWka1NrrQEdWZzw_9_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA"
      decimals="-3"
      id="Tc_9YRZCQfWBU-WZfZqPosQuA_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">335000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ"
      decimals="-3"
      id="Tc_1EMgfJHN90iFqeVvsfadKw_10_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">335000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_44tu_qyNi0GikguBn43mkA"
      decimals="-3"
      id="Tc_X0Bc83oBXkeU24WSJPOGpA_11_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30669000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ"
      decimals="-3"
      id="Tc_tdeGy9QAh0qrAH_H2b594w_11_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30669000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IUqLnYwi60W0DrGdz3BX1w"
      decimals="-3"
      id="Tc_uOKkcbbVT0e3Q4MarVc6qQ_13_9"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LsFc_V5jwU2tMP-ZizpLAQ"
      decimals="-3"
      id="Tc_OsZNNZYNG0mweDdbEsqs6g_13_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5IIqeHWkV0S9mtFRdVUKvw"
      decimals="2"
      id="Narr_UG7XqyJXrk-V6cPEpPcRsg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.99</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_LXJN7Whj9UecRjtZBao0Hg"
      decimals="2"
      id="Narr_wPaO_LBtwkqk1lX9ZD9Iow"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">2.07</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_cJ_3I5gqVUm-_Sd9MucR6w"
      decimals="-5"
      id="Narr_4HlCneWSDEqsYzoskYVxZg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA"
      decimals="-5"
      id="Narr_6wK7NYgyK0iUW2UMlpUeTw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"
      decimals="-5"
      id="Narr_2l2Upq16wkSDeajM3KIBlA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Linvwi1eaEmv0RwYC9mmXw"
      decimals="-5"
      id="Narr_n9fVOiTXSkqboSohcwOsNg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-100000</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_tR780hPYKUCUAXoKCBAw4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Lease Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company leases one facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term five months from its original expiration of February 28, 2023 to July 31, 2023 (the &#x201c;amended lease agreement&#x201d; or the &#x201c;amended lease&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company retained no option to further extend, renew or terminate the amended lease under the amended terms and all other material terms and conditions, including the monthly base rent, remained consistent with the original lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the&#160;right-of-use asset of $0.1 million to reflect the changes in the lease payments due to the extended lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;On June 27, 2023, the Company executed the second lease amendment for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing amended lease which expired in July 2023 (the &#x201c;new lease agreement&#x201d; or the &#x201c;new lease&#x201d;). The new lease agreement commenced November 10, 2023 and has a term of 65 months. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Under the new lease agreement, the Company retained access to its original premises under the amended lease which expired in July 2023, until the new premise became available on November 10, 2023. Payments made between when the lease expired in July 2023 and the commencement date of the new premises of November 10, 2023 were recorded as variable lease costs in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, the Company accounted for the new lease as a separate contract and the Company recognized an operating lease right-of-use assets of $0.4 million and operating lease liabilities of $0.4 million on November 10, 2023, the commencement date of the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table summarizes maturity of the new lease through the 65-month term of the Company&#x2019;s operating lease liabilities as of December 31, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rent&#160;Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (96)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total net lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, the total net lease liability was $0.4 million and $34,000, respectively. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 the Company&#x2019;s current and non-current operating lease liabilities were $0.1 million and $0.3 million, respectively. As of December 31, 2022 the Company&#x2019;s $34,000 lease liability was classified as a current liability. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating leases for the years ended December 31, 2023 and 2022, respectively (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Under the terms of the original, amended and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following information represents supplemental disclosure for the consolidated statements of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The present value assumptions used in calculating the present value of the lease payments for the Company&#x2019;s new and original operating lease as of December 31, 2023 and 2022, respectively, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.33 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023.&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;The new lease that commenced November 10, 2023 has a lease term of 65 months.&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:LeaseDisclosureTextBlock>
    <xoma:OperatingLeasesNumberOfLeasedFacilities
      contextRef="Duration_1_1_2023_To_1_31_2023_RfM78mIKA0-JJnpILkNCiQ"
      decimals="INF"
      id="Narr_jWaIAdu4cEiqZQZLK0InpQ"
      unitRef="Unit_Standard_facility_D1loseD-e06fL52LV83oPQ">1</xoma:OperatingLeasesNumberOfLeasedFacilities>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_xAActchtNUCUQIYwmgGrBw"
      id="Narr_wgGPjJLRXUitha87C3dafQ">P5M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_4MybQZKMoUeRtb31Nl4fZQ"
      id="Narr_kDe4H5Hu8kGUtaT_psgrCw">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <xoma:LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_4MybQZKMoUeRtb31Nl4fZQ"
      decimals="-5"
      id="Narr_z6T5HIo8lkmoWPdn6CwxOw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</xoma:LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug"
      id="Narr_evZqlIA5v0eAGr2vlq3w8A">P65M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug"
      decimals="-5"
      id="Narr_BouSCEsvRUejTxTpHdY_WA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug"
      decimals="-5"
      id="Narr__WXQdD4uckS0bll4EuHWpw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_ma-c_tUmm0GC8eiYU1oA2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table summarizes maturity of the new lease through the 65-month term of the Company&#x2019;s operating lease liabilities as of December 31, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rent&#160;Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (96)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total net lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug"
      id="Narr_1cCLMQKa-ESFgU2tdIY9fQ">P65M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_EpsC9DtxAkGOyouTpm1Rtg_2_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">83000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_UFHC7pYhz0u9QVWlcDEkRw_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">85000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_LcyMj2iB-EmqjxCGtXSj3w_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">88000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_7PzsC5bYHES9KL0iWKEYDA_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">91000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_hJSRlCFT4U-4r6j3fZ2ugg_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">102000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_4JGUIMJcKUyZWhdXitcujg_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">36000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_KR4sjUKeKEyZaBB9Kpc9Rw_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">485000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_1X1YGK2Q0UeKvCZdS1qO2g_9_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">96000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_R4DdA6jt8Uqz3ySGGw9d5w_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">389000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_ijXGdNunsECq8AW4BTsSrg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Narr_AGDzdazWxkyJBY3Pllyg4w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">34000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_vc9TvzpOq0CU5GKiLQHb8g"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_VC2ZYGK2D06POLd9gY_ITQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="0"
      id="Narr_7UPBC3YJbEymeRqQ6VokZg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">34000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_fOzp2KvEokWwRJCLE87Jaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating leases for the years ended December 31, 2023 and 2022, respectively (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Under the terms of the original, amended and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_4_pCeylGpkCnbsexOovcmg_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">131000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_DB69m1EHTE2WCYfH5HXyRg_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">177000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_lWnfUeUuoUuRljxQU51Gmg_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">44000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_jP1Ykys4TUG56lR-lc5LlQ_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">12000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_ODO0rhIZ0UWMcFmY0Z6Dtw_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">175000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_p28be9CxL0aMPLV2---XpA_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">189000</us-gaap:LeaseCost>
    <xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_DWlXEkHVlEOgfNyPubHK0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following information represents supplemental disclosure for the consolidated statements of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_74GmnRc1xkmtSF0gIsuKZA_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">126000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_i_gJFvd7S0Cs5l875_yXUg_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">202000</us-gaap:OperatingLeasePayments>
    <xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_VPNLIEwdeU-A55ova2J8Ug">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.33 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023.&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;The new lease that commenced November 10, 2023 has a lease term of 65 months.&lt;/div&gt;</xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      id="Narr_4zjaruO7LUWzF8JRe0_x5Q">P5Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      id="Narr_u4zsqsA7zEesWWEngqUzOw">P0Y2M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="4"
      id="Tc_fKS68VDFpkm3qsUvqNtbnQ_4_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0850</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="4"
      id="Tc_lBQx2cb420SZRVkhUUqv5g_4_5"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_11_10_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_pDPYR-idokym9Cgegk5iug"
      id="Narr_YCOadm6H402_EV1sti9bkw">P65M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_3v-QfUBLe0CJ6dK9ZlKbZg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Long-Term Debt &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 15, 2023, XOMA transferred to XRL, a newly formed wholly owned subsidiary, all its rights, title and interest in the commercial payments from Roche&#x2019;s VABYSMO under the Affitech CPPA and related assets (the &#x201c;Commercial Payments&#x201d;). The VABYSMO-related assets and rights transferred to XRL are referred to herein as the &#x201c;Transferred Assets.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Simultaneously, XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders, pursuant to which XRL was extended certain senior secured credit facilities in an aggregate principal amount of up to $140.0 million. The principal and interest of the loan are to be paid from the Commercial Payments. XRL is obligated to make semi-annual interest payments, starting in March 2024, at a fixed rate of 9.875% per annum until the commercial payment-backed loan is repaid, at which time the Commercial Payments will revert back to XOMA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any Commercial Payment in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The loan matures on December 15, 2038, provided that XRL may repay it in full at any time prior to December 15, 2038, subject to the terms of the Blue Owl Loan Agreement. The Blue Owl Loan includes (i) an initial term loan in an aggregate principal amount equal to $130.0 million and (ii) a delayed draw term loan in an aggregate principal amount of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;$10.0 million to be funded at the option of the XRL upon receipt by the lenders of payments of principal and interest from the proceeds of Commercial Payments in excess of an agreed upon amount on or prior to March 15, 2026. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The payment obligations under the Blue Owl Loan Agreement are limited to XRL, and Blue Owl has no recourse under the Blue Owl Loan Agreement against XOMA or any assets other than the Transferred Assets and XOMA&#x2019;s equity interest in XRL. In connection with the Blue Owl Loan Agreement, (i) XRL granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the Affitech CPPA and (b) all other assets of XRL and (ii) XOMA granted Blue Owl a first-priority perfected lien on, and security interest in 100% of the equity of XRL. The Blue Owl Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 15, 2023, the Company borrowed the initial term loan of $130.0 million and received $119.6 million, net of $4.1 million in fees and lender expenses and $6.3 million that was deposited into reserve accounts to pay interest, administrative fees and XRL&#x2019;s operating expenses (see Note 2). The Company also incurred $0.6 million of direct issuance costs related to the Blue Owl Loan Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Blue Owl Loan Agreement, XOMA issued to Blue Owl and certain funds affiliated with Blue Owl warrants to purchase: (i) up to 40,000 shares of XOMA&#x2019;s common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of XOMA&#x2019;s common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of XOMA&#x2019;s common stock at an exercise price of $50.00 per share (collectively, the &#x201c;Blue Owl Warrants&#x201d;) (see Note 12). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $1.5 million. As of December 31, 2023, all Blue Owl Warrants were outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The initial term loan of $130.0 million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the effective interest rate was determined to be 11.01%. The Company recorded a debt discount of $5.3 million, which included $3.8 million in allocated fees and lender expenses and $1.5 million for the fair value of the Blue Owl Warrants. The Company also recorded $0.6 million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $5.3 million and $0.6 million of direct debt issuance costs over the expected term of the initial term loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the closing date of December 15, 2023, the Company recorded the $0.3 million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of December 31, 2023, no amount had been drawn from the delayed draw term loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively as of December 31, 2023. The Company recorded $0.6 million in interest expense during the year ended December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the impact of the initial term loan on the Company&#x2019;s consolidated balance sheet as of December 31, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross principal &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unaccreted debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,939)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total carrying value net of unaccreted debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,061&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion of long-term debt &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,543)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Long-term debt on the Company&#x2019;s consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. There was no long-term debt on the Company&#x2019;s consolidated balance sheet as of December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Aggregate projected future principal payments of the initial term loan as of December 31, 2023, are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive loss for the&#160;year ended December&#160;31, 2023 relates to the initial term loan (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA"
      decimals="-5"
      id="Narr_RDsVKBBnCUG5h0prcpniHQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">140000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA"
      decimals="5"
      id="Narr_yzrGppba_UaGVT7RgY8sxA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.09875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_KoyQGmlq1ESuGVNCVUljSw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">130000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_Ye9pux6Zk0mWff5iTCN7xg"
      decimals="-5"
      id="Narr_ZuWK15uE7UujnLVqb6JGLw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <xoma:SecurityInterestInPercentageOfEquity
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_fY-bpj2dpUyn40FPYPn1uA"
      decimals="2"
      id="Narr_GwBe-CXX2k23gmfQwWufdw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:SecurityInterestInPercentageOfEquity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_wRH3kfSXnkSnBr367661pw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">130000000.0</us-gaap:DebtInstrumentFaceAmount>
    <xoma:ProceedsFromIssuanceOfLongTermDebtNet
      contextRef="Duration_12_15_2023_To_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wemVoEFoIkCvcBgBQtS_rg"
      decimals="-5"
      id="Narr_1-CMImu1OkSqwCVMPYlnOA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">119600000</xoma:ProceedsFromIssuanceOfLongTermDebtNet>
    <xoma:PaymentsOfFinancingCostsFeesAndLenderExpenses
      contextRef="Duration_12_15_2023_To_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_wemVoEFoIkCvcBgBQtS_rg"
      decimals="-5"
      id="Narr_XlpEd_jSdUW8uHS7mAd7Pw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4100000</xoma:PaymentsOfFinancingCostsFeesAndLenderExpenses>
    <xoma:AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_nCD7aZf5akCBjrSGX-1dig"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6300000</xoma:AmountDepositedIntoReserveAccountsToPayInterestAdministrativeFeesAndOperatingExpenses>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_zKpoy7bpOUWGDqA-E378Cg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww"
      decimals="0"
      id="Narr_8DQQ1TYCn0iiESWCmd2x2A"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww"
      decimals="2"
      id="Narr_RFqrZRNcyk-vPHKbdN8ohg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">35.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg"
      decimals="0"
      id="Narr_7F8OR8kQpkWhm6Hqn_VAVw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg"
      decimals="2"
      id="Narr_TKT3rcFvk06zq2NL3j2yxQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">42.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w"
      decimals="0"
      id="Narr_v5XgANaGzEaqYcv4HMlUJg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w"
      decimals="2"
      id="Narr_qDhiZzEgEEiylN9IFr8g1Q"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">50.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg"
      decimals="-5"
      id="Narr_w3TMrICDnUeuy954BcP70A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1500000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_-Vk72bi3M0i2gcEr8x19NA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">130000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="4"
      id="Narr_MDHWgGH7VkqwqYSIDSN6Ig"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.1101</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_mzoBaFsa5k2N9vGuaZcJ6A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <xoma:DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_f3tz_pyN0kyMUXLxu4Womw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3800000</xoma:DebtInstrumentUnamortizedDiscountAllocatedFeesAndLenderExpenses>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_hEbNChTsREONepAsq03GaA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1500000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_EHhf1Gt8q0-bDSpMIA5Srg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_gf0Aa5ylRkC3pm0v9Gkeaw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_2IpGDqTKnkmFeZPseiUzoA"
      decimals="-5"
      id="Narr_HQweZnHYGkGwPXczv5sruA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="As_Of_12_15_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_Ye9pux6Zk0mWff5iTCN7xg"
      decimals="-5"
      id="Narr_H6vZIUeii0WcEFAbEfYl9A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">300000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember_oha9lcQVn0qkzi_7xjYWFA"
      decimals="-3"
      id="Narr_86x8tlN-4UCvqB2qgIe3Ug"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-5"
      id="Narr_cQ4UkOKFyUmpgo6KCvYQbg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-5"
      id="Narr_LFevQeFvJ0OEBsS0zjdEqg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">118500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ"
      decimals="-5"
      id="Narr_BhNpDa5iN0CRqmeAErpHAg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">600000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_KBekyC4a2UmgbLvilKOwRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the impact of the initial term loan on the Company&#x2019;s consolidated balance sheet as of December 31, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross principal &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unaccreted debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,939)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total carrying value net of unaccreted debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,061&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion of long-term debt &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,543)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_ZRS9_y511ES5H4Vdt65KFA_2_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">130000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_WlJt6XlqakOSNgypjHpwwQ_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5939000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_8_0oy9VqnE-fz35xyBSCcw_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">124061000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_sYQzflBdakyx0KXJSYnTIA_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5543000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_VMU9gp4bG02qHc-gHNj00g_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">118518000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Narr_NLDemiluFEegbzId81L2gw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_3im1MW4NeUGaVXTaRhnysw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Aggregate projected future principal payments of the initial term loan as of December 31, 2023, are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_4xnx9U4vQUiJXsuC7_o48g_2_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6594000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_rj_JMZbxF0WP-vr7kbeh-g_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8767000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_S2GWjObZf0ely8B-mIcvgw_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">14200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_S3dx-q9Xo0qfc9Ru3zK3bQ_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">19155000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_ozOypNjtk0WnHZHAnZJnVQ_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">23872000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_dZsAGkaMkUWAxQ6ZtWUt2Q_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">57412000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_a3VqGo70E0a66mSxw4q11w"
      decimals="-3"
      id="Tc_Q2-eYBCb50aZv139_O-Q0A_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">130000000</us-gaap:DebtInstrumentCarryingAmount>
    <xoma:ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Group_ucarX5IKkki4503W4P5a2Q">Interest expense in the consolidated statements of operations and comprehensive loss for the&#160;year ended December&#160;31, 2023 relates to the initial term loan (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:ScheduleOfAccretionOfDebtDiscountsAndIssuanceCostsIncludedInInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ"
      decimals="-3"
      id="Tc_O_bY6iF3NEq9TnxhLGh3Nw_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">535000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ"
      decimals="-3"
      id="Tc_ja3GslGSs0GeK4NlOLHjrQ_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">34000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember_LgPfcklrM0eBgfdU6UrbBQ"
      decimals="-3"
      id="Tc_bHQzxJshEkCHiBJNiyMNFw_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">569000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_G3b0hLTolE-_U4_fggcftw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;9. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had pre-tax book loss of $40.8 million and $17.1 million for the years ended December 31, 2023 and 2022, respectively. The Company had no income tax provision for the year ended December 31, 2023 and a $15,000 income tax benefit for the&#160;year ended December&#160;31, 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#x2019;s actual effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock compensation and other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Nondeductible executive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_3mFvOmJiKUCxDAEe7fSXPQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tzBx_nlwlk2NnJLZtAgZ4Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Presentation for the fiscal year ended 2022 adjusted to conform with the fiscal year ended 2023 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The significant components of net deferred tax assets at December&#160;31, 2023 and 2022 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,974&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development and other tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalty Receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,329&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,326)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,329)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xQxEZRom10ipxNjFLhAhoQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_mFboUZF-aEWaGrU2CAFHmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The net increase in the valuation allowance was $8.0 million and $3.3 million, for the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company&#x2019;s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company&#160;has determined that total deferred tax assets should be fully offset by a valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February&#160;2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per&#160;year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2023 and 2022.&#160;To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had federal NOL carry-forwards of approximately $137.8 million and state NOL carry-forwards of approximately $22.1 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2017 Tax Cuts and Jobs Act, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;One of the provisions under the 2017 Tax Cuts and Jobs Act that became effective in tax years beginning after December 31, 2021 required the capitalization and amortization of research and experimental expenditures. The change in this U.S. tax law did not have an impact on the Company's consolidated financial statements. The Company will continue to evaluate the impact of this tax law change on future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#x201c;Inflation Act&#x201d;) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act did not have an impact on the Company&#x2019;s consolidated financial statements and related notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company&#x2019;s federal income tax returns for tax&#160;years 2020 and beyond remain subject to examination by the Internal Revenue Service. The Company&#x2019;s state income tax returns for tax&#160;years 2019 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future&#160;years are still subject to adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s activity related to its unrecognized tax benefits (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to current year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to prior year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2023, the Company has not accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-5"
      id="Narr_tuYEmP9SFUGPR4Fl44i1Rg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-5"
      id="Narr__fkX69lTmkGl0WjRDIVDCQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-4"
      id="Narr_ChiEzLk2XU6ABhxxIVLAIw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Narr_Di5XDSPsMU6HArLdaDXpTQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_G_PGWzGld0eP7rzO34J9cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_4jIYeTVX1UusxcEo8tBijA_3_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-15000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_AbPIHCBEA0iGp1XctbVloA_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_-ee3quFzH0uBw1jPfD2d_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock compensation and other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Nondeductible executive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_3mFvOmJiKUCxDAEe7fSXPQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tzBx_nlwlk2NnJLZtAgZ4Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Presentation for the fiscal year ended 2022 adjusted to conform with the fiscal year ended 2023 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="INF"
      id="Tc__GkFCfwBdkSCW5c-G8HB6w_3_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="INF"
      id="Tc_8-QJGimF20i1FFDHEVdB4A_3_4"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_WalWqfVCZ0afulQygLVQYA_4_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">-0.01</xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent>
    <xoma:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_IV3IrTUsh0GDeVClPN7fLw_5_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">-0.01</xoma:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent>
    <xoma:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Tc_xscOAO4woEyRrplxiOnEEw_5_4"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">-0.01</xoma:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_NzKqNVC6AEOx-GNA-a9QUQ_6_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">-0.19</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Tc_l0BuofMrVEGVQI9suzlIMQ_6_4"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_OUlPzXQ-wE-0G7DE2fBLRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The significant components of net deferred tax assets at December&#160;31, 2023 and 2022 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,974&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development and other tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalty Receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 858&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,329&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,326)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,329)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xQxEZRom10ipxNjFLhAhoQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_mFboUZF-aEWaGrU2CAFHmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_YktWUbzZ_EOHiYworwjdhA_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2336000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_IZwdtK6hWkO1PuKboeTcHA_3_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4732000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_CB2ps4_NUk2Bge--Us4Ysw_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30130000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_WX5EXEyd50Sm1TsMO7flRw_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">23974000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_ylYqYj7PrUa12yr0Ima7LQ_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">13176000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_9igEQlv5gEOpOdfS9oJeCQ_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">13176000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_xHQyQlDWwEWFZj9bRC-FcA_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5864000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_rIjqHVoKD0e8XAdKyKrhSw_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4715000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_7YzHumNG60y02riRD4QTWA_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1984000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_xQIKDJZeh0-vQRAmTjjlzg_7_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2408000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <xoma:DeferredTaxAssetsRoyaltyReceivable
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_RpKWdkYlSkCoMf_QkW2szA_8_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4080000</xoma:DeferredTaxAssetsRoyaltyReceivable>
    <xoma:DeferredTaxAssetsRoyaltyReceivable
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_Py9wKGEd60OvS7Z2v4NRLw_8_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">466000</xoma:DeferredTaxAssetsRoyaltyReceivable>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_H_cq3u8k2UK-V3PaUzW7BQ_9_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">756000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_1zVZewzRpUqAHmzJ2crZmA_9_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">858000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_FPWHHoep1k2h5zw4p1apBw_10_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">58326000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_U4_m13CPNUOSEfwIl5krlA_10_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50329000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_3Fmlo0Ny_UKcwk7lX4hC2A_11_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">58326000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_-jGHEavmy0aAyXnjqg_FAg_11_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50329000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-5"
      id="Narr_2SZ7EB9LR0qdTwWofZ651A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-5"
      id="Narr_LU8yAoYukUyJwaDxFR4tSw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA"
      decimals="-5"
      id="Narr_xk3sSFn4SUKTbVNRCHoWjQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">137800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_-jTxUsLwB0m38qsZl5cPRA"
      decimals="-5"
      id="Narr_6mDVFY_7I0aX8_19UstFJw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">22100000</us-gaap:OperatingLossCarryforwards>
    <xoma:OperatingLossCarryForwardSubjectToExpiration
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_E_NwP9mJgkaX6mZ0b1p7UA"
      decimals="-5"
      id="Narr_DcUXoPcrHUW37bhJ_odb9Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">13600000</xoma:OperatingLossCarryForwardSubjectToExpiration>
    <xoma:NetOperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_n0AlLUReN0Kwv0E-hFvvxQ"
      id="Narr_HPnPJugckE6vwOAOOukR_g">2036</xoma:NetOperatingLossCarryforwardsExpirationYear>
    <xoma:NetOperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_jXEG7wv2O0iixCaiWgcKIA"
      id="Narr_U6zZrTivTkaIS2Y2ZzTapw">2033</xoma:NetOperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_fTV55Dy5KEqyHnrS7IKYNQ"
      decimals="-5"
      id="Narr_7iaPHawnE0yohwff-UJo0Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <xoma:TaxCreditCarryForwardExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_VIuDTnkCcEaZC79EMJ-tOw"
      id="Narr_I241KtDPq0CaVmY4QtUtuw">2037</xoma:TaxCreditCarryForwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_J15_C70NX0OmaYeWNB6hKQ"
      decimals="-5"
      id="Narr_WR3Zxd6kLkuoB6YM66QXhA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">19800000</us-gaap:TaxCreditCarryforwardAmount>
    <xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Narr_E41WTAME4EykzUsvPCUxeA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.80</xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_oYdfOKns5E-dv1W91bC2xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s activity related to its unrecognized tax benefits (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to current year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to prior year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_AvxgokFwA0aFP_a8yw1Naw_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021__YTSA-B_PkKFF9DK9fkxNQ"
      decimals="-3"
      id="Tc__FqsSM15O0-6u9BJz4ClDA_3_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_szud6j0_jk2o6opA0UJA1A_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_F6LOTkufzkyV0XPmP-g3Yw_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <xoma:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_atVeWrGREEqP09tWRpAl_g_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <xoma:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_dfhaPmzlw0OXbhA2BQOdzQ_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_U8s8t52-b06dYCDTavKZFw_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_3l1CI6xJqUOGPpt7k9QG2A_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_P226hA0gDkKc7Uq71mdmLQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_GjY4rKPORkCIDqGPGAJkyw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_FpYzNnLq00qDeF4OIDbddA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_xRGo_nrtIEGduo_6oyUl7w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_ER69yZUtKUKGXTFGm5FunA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Stock Based Compensation and Other Benefit Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#x2019;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2015, the Company&#x2019;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#x201c;2015 ESPP&#x201d;), which replaced the Company&#x2019;s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July&#160;1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2015 ESPP initially provided for six-month offering periods ending on May&#160;31 and November&#160;30 of each&#160;year. At the end of each offering period, employees were able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2017, the Compensation Committee and the Board adopted, and in May&#160;2017, the Company&#x2019;s stockholders approved, an amendment to the Company&#x2019;s 2015 ESPP. The amendment (a)&#160;increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b)&#160;increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2023, the Company had 224,886 remaining authorized shares available for purchase under the ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Effective December 1, 2023, the 2015 ESPP consists of consecutive 24-month overlapping offering periods that begin on December 1 and June 1 and end 24 months later on November 30 and May 31, respectively. Each offering period &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;is comprised of four consecutive six-month purchase periods starting on December 1 and June 1 and ending on November 30 and May 31, respectively. Employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the purchase period. The plan includes a rollover mechanism for the purchase price if the fair market value of the Company&#x2019;s common stock on the purchase date is less than the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2023 and 2022, employees purchased 6,051 and 6,090 shares of common stock, respectively, under the 2015 ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Savings Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Section 401(k)&#160;of the Internal Revenue Code of 1986, the Board has adopted a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50% of their eligible compensation per payroll period, up to a maximum for 2023 and 2022 of $22,500 and $20,500, respectively (or $30,000 and $27,000, respectively, for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan&#160;year, in cash or in shares of the Company&#x2019;s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the&#160;years ended December 31, 2023 and 2022, and 100% was paid in common stock for each&#160;year. When available, the Company applies shares from plan forfeitures of terminated employees toward the Company&#x2019;s matching contribution. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Option Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2010 Plan Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2010, the Compensation Committee and Board adopted, and in July 2010 the Company&#x2019;s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three months from the date of termination of employment (longer in case of death, certain retirements or subject to certain terminations pursuant to the Retention Plan).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had 409,477 shares available for grant under the 2010 Plan. As of December&#160;31, 2023, options to purchase 2,730,068 shares of common stock were outstanding under the 2010 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Fair Value Assumptions of 2010 Plan Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the stock options granted under the 2010 Plan during the years ended December 31, 2023 and 2022, was estimated based on the following weighted average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.64 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The weighted-average grant-date fair value per share of the options granted under the 2010 Plan during the year ended December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$13.18&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$12.01&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock Option Inducement Awards &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Company&#x2019;s Chief Investment Officer, effective as of January&#160;1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the &#x201c;Stock Option Inducement Awards&#x201d;) when the Company&#x2019;s stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2023, the Company granted Mr. Hughes two separate non-qualified stock options to purchase: (i) 100,000 shares of the Company&#x2019;s common stock at a fair market value exercise price of $18.66 per share that vested in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 and (ii) 75,000 shares of the Company&#x2019;s common stock at an above fair market value exercise price of $30.00 per share that will vest in a series of 36 successive equal monthly installments from January 1, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2023, the Company granted Mr. Sitko two separate non-qualified stock options to purchase: (i) 300,000 shares of the Company&#x2019;s common stock at a fair market value exercise price of $18.66 per share and (ii) 250,000 shares of the Company&#x2019;s common stock at an above fair market value exercise price of $30.00 per share. 25% of the shares subject to Mr. Sitko&#x2019;s option grants vested and became exercisable on January 3, 2024, and the balance of the shares will vest and become exercisable in a series of 36 successive equal monthly installments thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value Assumptions of Stock Option Inducement Awards&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the year ended December 31, 2023, was estimated based on the following weighted average assumptions: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;No Stock Option Inducement Awards were granted during the year ended December 31, 2022.&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share in January 2023 was $11.91.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share in January 2023 was estimated based on the following weighted average assumptions: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.01 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Stock Option Inducement Awards were granted during the year ended December 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during January 2023 was $14.68.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The activity for all stock options for the year ended December 31, 2023, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,025,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,303)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,730,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,961,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $0.3 million and $2.8 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, $8.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.64 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Performance Stock Unit Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2023, the Company granted employees 430,400 PSUs under the 2010 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company&#x2019;s common stock as compared to four stock price hurdles over a three-year period from the May 2023 grant date (the &#x201c;performance period&#x201d;). A stock price hurdle is considered attained when, at any time during the performance period, the Company&#x2019;s volume-weighted average stock price equals or exceeds the hurdle stock price value for 30 consecutive calendar days. Upon attainment of a stock price hurdle, &lt;span style="-sec-ix-hidden:Hidden_xpK_StUG00ybbYZa3HpmVA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one third&lt;/span&gt;&lt;/span&gt; of the earned PSUs will vest immediately upon achievement, &lt;span style="-sec-ix-hidden:Hidden_-jeY11JkkU-_yKExwXSvYw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one third&lt;/span&gt;&lt;/span&gt; will vest upon the two-year anniversary of the grant date and &lt;span style="-sec-ix-hidden:Hidden_XJQ4j8H56EGkjfAn5W1EYw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one third&lt;/span&gt;&lt;/span&gt; will vest on the three-year anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the Company granted an additional 18,200 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value Assumptions of Performance Stock Unit Awards&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The range of grant date fair values of the PSUs granted during the year ended December 31, 2023 was estimated as follows: &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derived&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Hurdle Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Service Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11.42-17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.69-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10.16-16.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.93-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.07-14.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.12-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.12-13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.27-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates that it will recognize total stock-based compensation expense of approximately $6.9 million in aggregate for the PSUs granted in May and October 2023 using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The activity for all PSUs for the year ended December 31, 2023, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $2.8 million of stock-based compensation expense related to the PSUs during the year ended December 31, 2023. As of December 31, 2023, there was $4.1 million in unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of 1.38 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based Compensation Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All stock-based compensation expense is recorded in G&amp;amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense included in G&amp;amp;A &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Thomas Burns Equity Awards Modification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In April 2022 and November 2022, the Company entered into letter agreements with Thomas Burns that amended and supplemented his amended and restated employment agreement. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remained employed by the Company for a &lt;span style="-sec-ix-hidden:Hidden_PLUg0go3Uk-_7O-a0gyV7w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twelve&lt;/span&gt;&lt;/span&gt;-month period beginning on November 1, 2022, he would be deemed &#x201c;retirement eligible&#x201d; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. The unrecognized stock-based compensation cost for the unvested stock options as of November 1, 2022 was recognized over the shorter of (1) twelve months and (2) the remaining original vesting period (the &#x201c;Revised Vesting Term&#x201d;). During the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation expense of $1.4 million and $0.6 million, respectively, related to Mr. Burns&#x2019; option awards. As of December 31, 2023, there was no unrecognized compensation expense related to Mr. Burns&#x2019; stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Retention Bonus &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2022, the Company approved the Amended Retention Plan which provided that each of its then current employees, excluding the Chief Executive Officer, would be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#x201c;Initial Period&#x201d;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remained consistent with the Retention Plan. The Company accrued and recognized the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $0.6 million and $0.1 million for cash retention bonuses in operating expenses in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2022, the Company had $0.1 million of cash retention bonuses recorded in accrued and other liabilities in the consolidated balance sheet. All cash retention bonuses were paid in full on October 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;James R. Neal Departure and Continuity Incentive &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;James R. Neal retired as the Company&#x2019;s Chief Executive Officer effective as of December 31, 2022 (the &#x201c;Departure Date&#x201d;) and resigned as a member of the Board and Chairman of the Board, effective January 1, 2023. Pursuant to Mr. Neal&#x2019;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal was entitled to a cash payment of&#160;$1.2&#160;million (the &#x201c;Continuity Incentive&#x201d;) which was made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company recorded the full&#160;$1.2&#160;million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. The unpaid accrued Continuity Incentive&#160;recorded in accrued and other liabilities in the consolidated balance sheets as of December 31, 2022 was $1.2&#160;million. The Continuity Incentive was paid in full as of December 31, 2023.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw"
      decimals="2"
      id="Narr_3gBbru_zskC8Zpu8k8h16g"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_qpOCxF4gTE6XGswl1hQRNw"
      decimals="INF"
      id="Narr_h8jR6RcUHE6VNu18QJ8J4g"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">15000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw"
      decimals="2"
      id="Narr_dLAfqPSpUkWVNCbw0c9qyQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.10</xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_5_1_2015_To_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_QVblxPuRZEOw9F6rNagv6Q"
      id="Narr_kXTCT6psVkiaM9eq0ELRkg">P6M</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw"
      decimals="INF"
      id="Narr_1A3TBYHOV02Wyse1eMksoA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NYJResI69kesGeTfzxA53w"
      decimals="INF"
      id="Narr_Ap46r1E4GUqzSpVYr9qCoQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z14Y_ls6nU-Legw_e3KnHA"
      decimals="INF"
      id="Narr_1LgoeTBp70OXMc_4RAH7sQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pPNS9kuKzkGEzka8BT7FTA"
      decimals="INF"
      id="Narr_1NBs-wtjukSql7f--lFxSA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">265000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NYJResI69kesGeTfzxA53w"
      decimals="INF"
      id="Narr_4EoWv9YUZkqlKlCIkCXIZA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4_9OfpHHLEma607A2lr0HQ"
      decimals="INF"
      id="Narr_24fzjhLe7EW5u-JwGh3nIA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">224886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g"
      id="Narr_NKOrJGervEKZS-NLspnhGQ">P24M</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g"
      id="Narr_9B3cewzrZUuMhDBpQwIcEw">P24M</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4_9OfpHHLEma607A2lr0HQ"
      decimals="INF"
      id="Narr_9lcq-04wlUeUQpHlrkR5oA"
      unitRef="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ">4</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriods>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g"
      id="Narr_34-2rRokc0aCNbx0Fu2UwA">P6M</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriodWithinOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_zcq-D8PvhEK3dpQtYN2-5g"
      decimals="INF"
      id="Narr_gQ8K6Ejlb0KV-R_X3vWNLQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_3nDZG26ATEazScL4w1Wttw"
      decimals="INF"
      id="Narr_SfrwVbBdfkyaJTzAKmGpuA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_bkupJ_siykOMKkRtcBeUdQ"
      decimals="INF"
      id="Narr_D8YUGzgj40Sar9qbs08Wiw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Narr_BP91nIGUoUGhIn0UV3EXKA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.50</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Narr_Pv6kz6KYkEOagHh7c23-mw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.50</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_kICVKVDR1EKuBrC70GhfGA"
      decimals="0"
      id="Narr_G6BIEKKd4kCRg2c7E6GURg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">22500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Pp3_l5-Makmyd588cc5PtQ"
      decimals="0"
      id="Narr_dNb9VAHN_0yeOOBUm4C7ig"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">20500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_NxeZNU-uwEaleSn6kV2D0Q"
      decimals="0"
      id="Narr_uBbCLH4xI0Ck2aPWocT7DQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_FOSyLzrHjUO4zX7-HXcfvg"
      decimals="0"
      id="Narr_TaECcO7dYUuG3uP7B1MCow"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">27000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Narr_06QrcEzp5EmWszbZuo87QA">P50Y</xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum>
    <xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      id="Narr_jk7jynWtu0qZ35z59-D6FQ">P50Y</xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1fqxYlQgQEOjj4he88QfPA"
      decimals="2"
      id="Narr_ngUXajQ8jEmU4tfMPFSbHQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_zoPI7MqTT0ymJt_IEkPwzg"
      decimals="2"
      id="Narr_wllz4XcJ5kyBp8gDBerQmw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-5"
      id="Narr_32v21EukEEiOmgswnaDfgw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-5"
      id="Narr_FhP4NGtaw0mqHt8M8H5qoA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-5"
      id="Narr_OFRmhGomT0ue2SVdetgoBA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-5"
      id="Narr_PmMsKkgnl0itbv3F_KAfyA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="INF"
      id="Narr_e2nY6jE6LECqMMXSSYXHCA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage>
    <xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="INF"
      id="Narr_DLIiPx0elky2gp7XVWb2MQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      id="Narr_1xu20gXIgEOEZA3LZay7CA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_Yo1Pn10MbE-IQC5dhETm3Q"
      id="Narr_5cLJ5iCBj0qYM-3Nst7j6w">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6NH2D73ShkWYzzOp3xcTJA"
      decimals="INF"
      id="Narr_Mtawg4NBmkyeFG30uRiMPQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">409477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6NH2D73ShkWYzzOp3xcTJA"
      decimals="INF"
      id="Narr_ASHbws49FUaI7TtRUzStKA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2730068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_JTU393H8zkS60pP-6_KFDw"
      id="Narr_UsA6UcPdvUmk5HWePEhmRw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_RX8jSTjVsUCam5xpFx-k_w"
      id="Narr_FExOPQSSMEesQbAtLeCUPA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      id="Narr_GybP3d3iFECppDeWYUh5lg">P55Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      id="Narr_Ak2qKvXWAUWvtR-M-Vs-gA">P70Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_0srFpIQZjEeXreNfgIZggA"
      id="Tb_WJ712dUNikaLYRT3nmcVyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.64 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      decimals="2"
      id="Tc_oRy7usCRTE-S6RT74QqcbA_3_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ"
      decimals="2"
      id="Tc_jAhFmz1p0UKH0Ef86Q9YQg_3_4"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      decimals="2"
      id="Tc_gjsUL6Yiu0W-Rc3rmonWJg_4_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ"
      decimals="2"
      id="Tc_ed0MxqaVoUeaLRVBe1j4pQ_4_4"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      decimals="4"
      id="Tc_2sY6sNFdekic0E-WuUFTaQ_5_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ"
      decimals="4"
      id="Tc_vpfK6nOMNkaI1wF1Tn4Y9w_5_4"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      id="Narr_CBNMBKASb0WlmcuMzqzIxA">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ"
      id="Narr_OEts2d1bHEiWouHvma6DOg">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_3HmbMELkTE25JevOMAMgbg"
      decimals="2"
      id="Narr_4mEa5lRSzkuA4bbEpbxgVg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">13.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_WDkVmrRT6U2LzcDKH47KfQ"
      decimals="2"
      id="Narr_hehvjLHxjE6I52T9Q9GStA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">12.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_D67_o-ekW0mCOHoAiNEOOw"
      decimals="INF"
      id="Narr_1zEbazKOfUabc2sEIZ19sQ"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:SharePrice
      contextRef="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_9t7Xrh4erUm2DCAqplH8xw"
      decimals="2"
      id="Narr_UTU3SN7UbkyiUgFIBixoXw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">18.66</us-gaap:SharePrice>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_XnnLT8lCQE-Kb6QqSuciIw"
      decimals="INF"
      id="Narr_DdYal6lShk63NDoqtfbq9Q"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ"
      decimals="INF"
      id="Narr_6SKWZqNxg02cWotgwC68fg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ"
      decimals="2"
      id="Narr_-_Qfpx898EyFwhxw-OA8XA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_HSMle7AnGUWGg54Md-oysQ"
      decimals="INF"
      id="Narr_4MkcB7ZDykCqIwI8GKeZgg"
      unitRef="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA">4</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg"
      decimals="INF"
      id="Narr_Pr1Bc-D_zkqrj26vMLzvEg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg"
      decimals="2"
      id="Narr__ODw9rp3gU6uM6P344nf_Q"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HtN3OH0_CUWB9zxM_JSHHg"
      decimals="INF"
      id="Narr_5CCMweKrKkW4S6x6rAivzw"
      unitRef="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA">36</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_D67_o-ekW0mCOHoAiNEOOw"
      decimals="INF"
      id="Narr_s12t4udhlkWpnUpfMyCBQA"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_kZe5UeB58EqVvQzsj0tFKA"
      decimals="INF"
      id="Narr_gpLNoqT750ehzpkRmJ1G1w"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_kZe5UeB58EqVvQzsj0tFKA"
      decimals="2"
      id="Narr_9KdUrwkNGkmrHWoz57Oajw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_CPv_k4GysE6N0cJwFt__ZQ"
      decimals="INF"
      id="Narr_g2regQWlTUqF4PknP0JzsQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_CPv_k4GysE6N0cJwFt__ZQ"
      decimals="2"
      id="Narr_47j0G5TQo0-KGpj_7IlMTQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Nbz01A2AFUSN9o9T7YGxsQ"
      decimals="2"
      id="Narr_jZsfua1tlE6qR6PtvfRxDA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iss2YrFnEUiSmHE-waxCwQ"
      decimals="INF"
      id="Narr_dEy9vmr6Xke14NCCduLSyw"
      unitRef="Unit_Standard_installment_ZNw4ADF17Uy-LRGfPETNYA">36</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_lpNhrc2ivk27vYMf2Vaqrw"
      decimals="2"
      id="Narr_8VrXcGJMsEKuvqBxALzkVA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_lpNhrc2ivk27vYMf2Vaqrw"
      id="Tb_8XtHO3Amdkq7ANexAGVtQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;No Stock Option Inducement Awards were granted during the year ended December 31, 2022.&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw"
      decimals="2"
      id="Tc_4lDHhrrBxUi8V2aFgpG5dA_3_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw"
      decimals="2"
      id="Tc_ZY9PA7j7Uk67mVhiuUGW-g_4_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw"
      decimals="4"
      id="Tc_2OLUzKWhx0KgTYtEP7uxUQ_5_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_15029xz33kOOoFImgcJxDw"
      id="Narr_RlPUO0MkIkSRATBEQD76iQ">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_VgCo7QDMrEqWqhFOY8kLUQ"
      decimals="INF"
      id="Narr_31Mqyl7Wtki9GiDa1GjT1w"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_p17Cp-2md0-zORF_i9yfng"
      decimals="2"
      id="Narr_hVqiRGO3lE-mA4GujhpMpw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_p17Cp-2md0-zORF_i9yfng"
      decimals="2"
      id="Narr_TKp4JWLlg0e6pqLzGYjoGg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">11.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA"
      decimals="2"
      id="Narr_HHiYTOa0A0uZNNg2Ywhozg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember__0KUigoyNEiSFG6EHS-pKQ"
      id="Tb_GVzf40_Q7UaIFKt4i9UnlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.01 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Stock Option Inducement Awards were granted during the year ended December 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g"
      decimals="2"
      id="Tc_zZnGmE6WCEyybN2qt82TlQ_3_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g"
      decimals="2"
      id="Tc_1NKBdV49WkGjeKNKZ3ncRQ_4_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g"
      decimals="4"
      id="Tc_IvL2QuQUakus6iT6HR69gg_5_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_JxeNC5_Qpkao9BSx9I3X3g"
      id="Narr_qOfx-rG0XEy4V4htkbQOJw">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_q-zvA0nnJ0u9IWbpCyBZaQ"
      decimals="INF"
      id="Narr_kGNq3aqKdka7O59sFnbaow"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA"
      decimals="2"
      id="Narr_kGwFf_evEECFpuOCUz3gRw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_QjCQmqYAnE2BsXnG4CuyOA"
      decimals="2"
      id="Narr_Uzxbmv496UiiKH6tvrqFrA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">14.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_gPudZsvPvE6jncVmm2UMDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,025,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,303)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,730,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,961,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Tc_omW7BspUik6ngokuXuSDwQ_6_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2025542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="2"
      id="Tc_T-WCogPXg0KdkqGA2lmDsA_6_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">20.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      id="Tc_g6tcavpNd06mvqoCVNeqVQ_6_9">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-3"
      id="Tc_UnA-AduhDEygpSe1SgppvA_6_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="INF"
      id="Tc_9vBpViZAmkq3PQYXWNrMVQ_7_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">804302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_x_eJntkNJESG3wu382wunQ_7_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">23.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="INF"
      id="Tc_dzOg9gHjVkS8hcQY5x_OFQ_8_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">28473</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_cN6Wc_MBfUK7cnQtz_OiNQ_8_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">8.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="INF"
      id="Tc_M9EZPRLry0aU2KjglGfA9Q_9_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">71303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_o1JnKTFqnU6hA4nq1KztoQ_9_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">36.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Tc_wyjK3jZaOEiXxbduxzeySQ_10_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">2730068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="2"
      id="Tc_W6qUmY_ik0Olz0Wk_tB-Cg_10_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">20.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_gGRdrWU5_kGoKzd2Ug__sQ_10_9">P6Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_42qVV8Hzf0euM51rjSxprA_10_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10638000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Tc_Nrq3a9A7ikyuGC2M-1isAA_11_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1961143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="2"
      id="Tc_M_JBwyaDrEuk_ym2DBgEkw_11_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">19.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tc_8T48kL_XDkiKukEYrpkhig_11_9">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-3"
      id="Tc_RpExTHxmw0uF1NTWLCr95w_11_12"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">10606000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-5"
      id="Narr_vO3_dCcUZkihLv6dW_JLSg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-5"
      id="Narr_dg_3K92etk-Hy80FByHKFQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYNuuYoVaUKIMN5qjgyD0A"
      decimals="-6"
      id="Narr_Nr4QS5wJ1kqxX7uNOFz4wQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wI-J9wnFokegnVOOPhGPfA"
      id="Narr_jKoE2FWnMU-1XYqp4zGCAQ">P2Y7M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_MQ2JB34wHEqnnlhOE_S-2g"
      decimals="INF"
      id="Narr_tHC_UND0hEqEEvzffA0lpA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">430400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.
      contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg"
      decimals="INF"
      id="Narr_AvMFIp_NgkqLsj_oLKYZ9w"
      unitRef="Unit_Standard_item_O-Rt7DjCdkSPkoF7y5ThJw">4</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jr06nKWQnkWcc1gc9wl75w"
      id="Narr_G3igBWk-dEWljTGTrgIZgA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays
      contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_jiIiSCb7cUapc2JLeJNOMg"
      decimals="INF"
      id="Narr_F8e_7ggXC0-Z_eL2c8ZUpQ"
      unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">30</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9F82xQd9GUyY0FWq2yw9Bw"
      id="Narr_pz2oE6wcnkiQLXV508yKgQ">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7KxJyjjuEU-w1MGzNb9A3Q"
      id="Narr_gZ7k-NMV6kaFoem8dWa8iA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_DppoP7EaukOr-8wuDeS7oQ"
      decimals="-2"
      id="Narr_7JO_nzlo_EmfKBFRxH7YUg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">18200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_wyjoyeSEfUeyZH0bEyVJ9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derived&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Hurdle Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Service Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11.42-17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.69-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10.16-16.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.93-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.07-14.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.12-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.12-13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.27-2.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QK1CLkfR8kOQoYbaZOfjJg"
      decimals="2"
      id="Tc_gKiaD1WhQk-4nYstNomoGA_4_1"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">30.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_GaicAvhvREu045tkaseAEQ"
      decimals="INF"
      id="Tc_Df5HMG-5QUGSmdaMRixf7Q_4_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">243550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_hM9ty2-MVUGlezJJB5CGZA"
      decimals="2"
      id="Narr_aWGt-U4XGE-YoXPIiYmhyQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_U9y-4g4fU0Ke5Az40er2DA"
      decimals="2"
      id="Narr_TX8I4ZGuOkKq7VvJ8pxPDw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">17.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_hM9ty2-MVUGlezJJB5CGZA"
      id="Narr_BGS8GTf9MEar9UX2u2vdKA">P0Y8M8D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_U9y-4g4fU0Ke5Az40er2DA"
      id="Narr_cRjlZSrvCk-f8J2IyziDfA">P2Y7M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_xw9SMS1FDku23HM0n9XH7Q"
      decimals="2"
      id="Tc_oXYR5ZyS002w6zcy7m1_Ow_5_1"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">35.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Q_GOADvcjEiY8_k6u1blBg"
      decimals="INF"
      id="Tc_ITUzzqdpuEiqtxDN7BZXvg_5_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">91239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_wMQi5PD-5kOVp3Do-Cz7aA"
      decimals="2"
      id="Narr_XkOj_oM_wk6mjEWzTV7KDg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">10.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ZvNKstqm10OSTijaRyyBgA"
      decimals="2"
      id="Narr_W4iAB7kaJkKC8h7RIwPnjw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">16.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_wMQi5PD-5kOVp3Do-Cz7aA"
      id="Narr_W9-qbkqSXEC6qZWqk53kQw">P0Y11M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ZvNKstqm10OSTijaRyyBgA"
      id="Narr_T5hT8CzuAE678kAb5Pv9mg">P2Y7M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QfRHcV6u0k2_QDklTWc_9w"
      decimals="2"
      id="Tc_kuvFpfKV2kOk7KluP93E9Q_6_1"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">40.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_PFwhQNdS_0Cvqwhdk5-nJw"
      decimals="INF"
      id="Tc_GHE4mbMhDUKeq1R8zk_YTg_6_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">60024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ATjJ9C3tUEuB5MOkEX8QXQ"
      decimals="2"
      id="Narr_DlLLKVbKhEq1TdD6YdkdYw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IgF4YIWD40C1TLHU9oQ6EA"
      decimals="2"
      id="Narr_F3W6uwAXTkO7Al6uNPWOFw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">14.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_ATjJ9C3tUEuB5MOkEX8QXQ"
      id="Narr_8_Uaz2uR6kmaK72w1npUfw">P1Y1M13D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_IgF4YIWD40C1TLHU9oQ6EA"
      id="Narr_x1Qj_oRb206wfKg24QZDWQ">P2Y7M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_WdFrStI1SEmbrCQr_uf_3g"
      decimals="2"
      id="Tc_P_10KrzY7EaF6xU2vcIIVQ_7_1"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">45.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_7XNCE9fHSkejCdV6XNu2Yg"
      decimals="INF"
      id="Tc_1CGzF69JukmqPFzyauuBCw_7_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">53787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LLR4GBlfWEaaPy6t-ixdjQ"
      decimals="2"
      id="Narr_0bV7C17QO0uc4selHo7Gqw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">8.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pXkK2dzdNkSrOgN1r7fWyQ"
      decimals="2"
      id="Narr_E3gOrUGyF0KxJts3AhKqMQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">13.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_LLR4GBlfWEaaPy6t-ixdjQ"
      id="Narr_7-kLMHMeiEyWKTxjJwLWDA">P1Y3M7D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pXkK2dzdNkSrOgN1r7fWyQ"
      id="Narr_BXJG2jJCxk-utEWgdsEyVA">P2Y7M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"
      decimals="INF"
      id="Tc_DF0-iJmGeU2XIhApUkyh5Q_8_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">448600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_10_31_2023_us-gaap_AwardDateAxis_xoma_AwardDateMay2023ToOctober2023Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DWNUD9UHZ0yY-M_tgTpaEA"
      decimals="-5"
      id="Narr_gDZ-gZ05TUiU-g5-d2z5ag"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_CKrxJbrmx0KN4IRHgTEU4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 448,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"
      decimals="INF"
      id="Tc_F443Dx_2Vk-HzWMDRghr4A_7_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">448600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"
      decimals="2"
      id="Tc_lBpkCYEE9ESDqSu7PWBClA_7_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">15.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ"
      decimals="INF"
      id="Tc_Zk0OoIDLe0SQRhhQsJk-Mw_10_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">448600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ"
      decimals="2"
      id="Tc_h0Jp2LMQKkqlUCnTuUqxhw_10_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">15.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"
      decimals="-5"
      id="Narr_eLRCt69HFkmy5k2LKwIPVg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Pqk3DBo-rkKWpTcrK7yXXQ"
      decimals="-5"
      id="Narr_Pbj2WlN20UGvhiF6AadwiA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"
      id="Narr_PfTzOG_8J0-FhcwMYknUDQ">P1Y4M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_qaZTWtiAHEWf5K9QOcrA_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All stock-based compensation expense is recorded in G&amp;amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense included in G&amp;amp;A &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jWEJG3qYf0OkSzZNmxWzdw"
      decimals="-3"
      id="Tc_Pp6Hoy1Kj0eThVM4A2_s7g_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">9099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QmfRiBqenki9xaGwjiWv6g"
      decimals="-3"
      id="Tc_9-O6iBi-NEiw1Mc3MhVYFQ_3_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3608000</us-gaap:AllocatedShareBasedCompensationExpense>
    <xoma:EmploymentPeriodRetirementEligible
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_kmKo9NmoskKPrR6gM-lu1A"
      id="Narr_lWZ5gl2GhkaNGwvMVupGGw">P12M</xoma:EmploymentPeriodRetirementEligible>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_JXd_9rzC90CP0igSJTsrdg"
      decimals="-5"
      id="Narr_9D3jXqgJT026o29tJGCdaw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_Pt94Ra0jTUOM2_6JUiOKAw"
      decimals="-5"
      id="Narr_Pxj7qyxHi0CXYINjuhrg6Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_LJGNT1o0fESPY6CsLc4PAQ"
      decimals="-5"
      id="Narr_FpJsERcq50W2qKJCe4aSzQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <xoma:NumberOfPeriodsCashRetentionBonus
      contextRef="As_Of_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_Yf9nqgko7Ey_J1Vum-XNLg"
      decimals="INF"
      id="Narr__-Cv6z4m50OXYee2s6gOmw"
      unitRef="Unit_Standard_period_VmrAwBaDRkm-7LK5Qi-WRQ">2</xoma:NumberOfPeriodsCashRetentionBonus>
    <xoma:PeriodOneRetentionBonusEligibility
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_wNITwyTcekq4e2_GA1wpag"
      id="Narr_L8gXCciePUukZIQdvfASsA">P3M</xoma:PeriodOneRetentionBonusEligibility>
    <xoma:PeriodTwoRetentionBonusEligibility
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_wNITwyTcekq4e2_GA1wpag"
      id="Narr_FtsbJgVyNUa3Uga26Bx9BQ">P9M</xoma:PeriodTwoRetentionBonusEligibility>
    <xoma:RetentionBonusExpenseAccrued
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_vL3apDyaZkCu6f5YXyWb4w"
      decimals="-5"
      id="Narr_UcW6Gd0Hl02r9_GbsMQgAg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">600000</xoma:RetentionBonusExpenseAccrued>
    <xoma:RetentionBonusExpenseAccrued
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_HJ3psyCDL0yJ_bjXgwInwA"
      decimals="-5"
      id="Narr_l-E7oTy5QUK7gwzxwUJNXg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</xoma:RetentionBonusExpenseAccrued>
    <xoma:AccruedRetentionBonus
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_6yQg3Qhf9UiWbaQF-yGsrQ"
      decimals="-5"
      id="Narr_A-eDSCcZckiRgYrHxsMacQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</xoma:AccruedRetentionBonus>
    <xoma:AccruedCompensationContinuityIncentive
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_op1dbIKXI0auw-rLczKFjA"
      decimals="-5"
      id="Narr__PXX2GGCuUy7TvShRAOB5A"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1200000</xoma:AccruedCompensationContinuityIncentive>
    <xoma:CompensationExpenseEmploymentAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_0LRcdmUtxkWsPDjZRSRzxA"
      decimals="-5"
      id="Narr_djJf-qpSXkSHuwRZxdvmbg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1200000</xoma:CompensationExpenseEmploymentAgreement>
    <xoma:CompensationExpenseEmploymentAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_0LRcdmUtxkWsPDjZRSRzxA"
      decimals="-5"
      id="Narr_LC-fx8y6DkikzRt9B4V4lw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1200000</xoma:CompensationExpenseEmploymentAgreement>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_cJQXnHGT40a0vA6PuhcRtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Net Loss Per Share Attributable to Common Stockholders &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,813&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $18.50 per share as of December 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (40,831)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,104)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series A accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series B accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,350)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46,303)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,576)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.04)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.98)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_uvjtpF3W0ECbAEJFdJvBTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,813&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_GvxISMo_UkG51ag9NMnfUA"
      decimals="-3"
      id="Tc_Vsyl7Ua-fEuVbOKwOiNkNA_3_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_8v_3XroY3UqA5FYoxvPiFA"
      decimals="-3"
      id="Tc_bhCmlbv6cUOZeyw2UmRGnQ_3_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_D_s-_E21uUaiUOWarzVcYg"
      decimals="-3"
      id="Tc_UwCEz9rZJEyTX09aLK7nIw_4_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1793000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_4Zo0UeZYZUeUnyTVN-VWXQ"
      decimals="-3"
      id="Tc_I548DwdVIkGKtGVcr7YoMA_4_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">885000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_j8MHpbryDkKr6iuxL4IoLQ"
      decimals="-3"
      id="Tc_Nho7GEywQEuZ5WrTvHacXg_5_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">17000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aLLtLfhuF06YDmKVCRRdMQ"
      decimals="-3"
      id="Tc__yoatRzuw0OZgl9PQ00nxQ_5_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_4vL9y1vWZ0-fqDnWIcf2FA_6_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6813000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_C9pgZOdE0EqeWKPRaBwhiA_6_4"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5894000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_TR4nLNNCykGVBaVVkdVe2Q"
      decimals="INF"
      id="Narr_-VVRjH-Cbk-zZRw8jVkPLQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_A9wak7mh0EmoHMUrm_yhlg"
      decimals="2"
      id="Narr_SvedTawQYEmZEsOm4Bj_yA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">18.50</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_2AEt3n61DkyrAGOGYpLi-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (40,831)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,104)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series A accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series B accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,350)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46,303)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,576)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.04)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.98)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_RI_bSHeUk02U2x7JE8uEUg_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-40831000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_yLu_E5y3dUSDiAXU3bPTfQ_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mJ0giLRn4kCRURPbYv8wYg"
      decimals="-3"
      id="Tc_Q1vdEIZjO02abZK4AP4ddg_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2122000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_er3W3MMAy02J-0HZT7aH1A"
      decimals="-3"
      id="Tc_mbpCcEH9z0mkPUS52olpeg_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2122000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_96UqI17DZ06cOK2CPIIPvA"
      decimals="-3"
      id="Tc_Upt9BVSk1UyhAYb5MxBZBg_6_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3350000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ttlhuKLBjUSSxoBHpLChMg"
      decimals="-3"
      id="Tc_-hHwKgfCOkmqD_JibYfMFw_6_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3350000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_DdItBfQV9Ea4vAs3_dK98g_7_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-46303000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_DdItBfQV9Ea4vAs3_dK98g_7_3_2"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-46303000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_1uL5RVcai0eUMJ7WMCQl4w_7_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_1uL5RVcai0eUMJ7WMCQl4w_7_6_2"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="0"
      id="Tc_WnJS4jf7H0OnoryLs8cqbw_10_3"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11471</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="0"
      id="Tc_WnJS4jf7H0OnoryLs8cqbw_10_3_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11471</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="0"
      id="Tc_yFseof-iPUKQ8NGD_Y5sSA_10_6"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11413</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="0"
      id="Tc_yFseof-iPUKQ8NGD_Y5sSA_10_6_2"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11413</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_u2vqAJFSNkijTcmtuRunlw_11_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-4.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="2"
      id="Tc_u2vqAJFSNkijTcmtuRunlw_11_3_2"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-4.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Tc_mrOf8LIwSUKfEx_sZ1S2RA_11_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="2"
      id="Tc_mrOf8LIwSUKfEx_sZ1S2RA_11_6_2"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_nl8DLY_4l0KgTJrO6ZEoUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Capital Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Series X and Series Y Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sold directly to BVF 5,003 shares of Series X Convertible Preferred Stock in 2017 and 1,252.772 shares of Series Y Convertible Preferred Stock in 2018. There were no shares of Series Y Convertible Preferred Stock outstanding as of December 31, 2021, after BVF converted all Series Y Convertible Preferred Stock into common stock on April 15, 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were 5,003 shares authorized and issued of Series X Convertible Preferred Stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Series&#160;X and Series Y Convertible Preferred Stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&#x2014; &lt;/i&gt;Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Rights&#x2014; &lt;/i&gt;In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion&#x2014; &lt;/i&gt;Each share of Series&#160;X and Series Y Convertible Preferred Stock is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&#x2014; &lt;/i&gt;Series&#160;X and Series Y Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&#x2014; &lt;/i&gt;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the shares of Series&#160;X and Series Y Convertible Preferred Stock are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#x2019;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the Series&#160;X and Series Y Convertible Preferred Stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Series A Preferred Stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were 984,000 shares authorized and issued of Series A Preferred Stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&#x2014;&#160;&lt;/i&gt;Holders of &lt;span style="background:#ffffff;"&gt;the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board and declared by the Corporation, cumulative cash dividends at the rate of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;8.625%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per annum of the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.00&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the &lt;/span&gt;Series&lt;span style="background:#ffffff;"&gt; A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full dividend period shall be prorated and computed on the basis of a&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;360&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-day&#160;year consisting of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;twelve&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;30&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-day&#160;months.&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Rights&#x2014;&#160;&lt;/i&gt;In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of Series A Preferred Stock will &lt;span style="background:#ffffff;"&gt;rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or&#160;winding-up and on parity with respect to the &lt;/span&gt;distribution&lt;span style="background:#ffffff;"&gt; of assets with the Company&#x2019;s Series X Preferred Stock. &lt;/span&gt;The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Redemption and Special Optional Redemption&#x2014;&#160;&lt;/i&gt;The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, &lt;span style="background:#ffffff;"&gt;upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.00&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion&#x2014;&#160;&lt;/i&gt;The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (ii) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable, divided by (iii) &#160;the common stock price and (B) 1.46071 (the &#x201c;Share Cap&#x201d;). The common stock price to be &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company&#x2019;s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&#x2014;&#160;&lt;/i&gt;Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&#x2014;&lt;/i&gt;The Company evaluated the Series A Preferred Stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Depositary Shares Representing Interest in Series B Preferred Stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Each Series B Depositary Share represents &lt;span style="-sec-ix-hidden:Hidden_0WqPQZjVdk-rCh1KkH7IeA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/1000&lt;/span&gt;&lt;/span&gt; interest in a share of Series B Preferred Stock. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The spouse of James Neal, then Chief Executive Officer and Chairman of the Board, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&lt;/i&gt;&#x2014; Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals $2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Preference&lt;/i&gt; - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Redemption and Special Optional Redemption&lt;/i&gt; - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion &lt;/i&gt;- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the &#x201c;Conversion Rate&#x201d;); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the &#x201c;Share Cap&#x201d;), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&lt;/i&gt;&#x2014; Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&lt;/i&gt;&#x2014;The Company evaluated the Series B Preferred Stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Dividends&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, the Company&#x2019;s Board declared and paid cash dividends on the Company&#x2019;s Series A Preferred Stock and Series B Depositary shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A&#160;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&#160;Depositary Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Declaration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Payment Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 26, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_H7Lo4FtfLUG9U_8NFt12cA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_btS0jg_C4kSqwPe0vi-i5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;February 22, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_dSMEchMnFkqWypW9UGk7Lw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_3oD01eoLEkipHZzpjVu_VA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;April 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_OTKsEhaqhEaFde7pn0r-XA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7zNSlE5m30-23n_Xhxv1Cw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 26, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_s0Q6hKWcX0SArB1No9n7mA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ZPUZL4tmokqcSqnQL-SrmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 16, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 18, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YeDNFyDyWkiXwMYXPzULTA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__Df-kChCN02M1zGD5YLDDA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 15, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;BVF Ownership&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, BVF owned approximately 31.6% of the Company&#x2019;s total outstanding shares of common stock, and if all the shares of Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 52.3% of the Company&#x2019;s total outstanding shares of common stock. The Company&#x2019;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2023, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2018 Common Stock ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2021 Series B Preferred Stock ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31, 2023 and 2022, the following common stock warrants were outstanding:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2018, the Company issued SVB a warrant in connection with the legacy SVB Loan Agreement which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders&#x2019; equity on the consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2019, the legacy SVB Loan Agreement was amended to extend the draw period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;The warrant is classified in stockholders&#x2019; equity on the consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;In December 2023, in connection with the Blue Owl Loan, the Company issued the Blue Owl Warrants to certain funds affiliated with Blue Owl, which are exercisable in whole or in part to purchase up to an aggregate of &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;120,000&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of the Company&#x2019;s common stock, inclusive of warrants to purchase (i) up to &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;40,000&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of XOMA&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$35.00&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; per share; (ii) up to &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;40,000&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of XOMA&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$42.50&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; per share; and (iii) up to &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;40,000&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of XOMA&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$50.00&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; per share. The Blue Owl Warrants may be exercised on a cashless basis and are exercisable within &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;10 years&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; from the date of issuance or upon the consummation of certain acquisitions of the Company. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value per share of &lt;span style="letter-spacing:-0.1pt;"&gt;Blue Owl&lt;/span&gt; Warrants issued at the exercise prices of $35.00, $42.50 and $50.00 per share during the fourth quarter of 2023 was determined using the Black-Scholes Model &lt;span style="letter-spacing:-0.1pt;"&gt;to be &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$12.53&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;, &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$12.23&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$11.97&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; per share, respectively, &lt;/span&gt;based on the following weighted average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="letter-spacing:-0.1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate &lt;span style="letter-spacing:-0.1pt;"&gt;fair value of the Blue Owl Warrants &lt;/span&gt;of $1.5 million is classified in stockholders&#x2019; equity on the consolidated balance sheets.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_QuC48dJf8E23DlxZlazDSA"
      decimals="INF"
      id="Narr_SegTSigCdEu3sjU4MC6giQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_q0p4FSRc_k6TcIpryO7R1A"
      decimals="INF"
      id="Narr_c2eONn28Gkmm684QulhJtw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1252.772</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_cEbwO1-SA0ytFO3kPI9NlQ"
      decimals="INF"
      id="Narr_NWmnnW5wKUiMYj7bTc8BQw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_qkBguZsiw0WaOQD5kUxKeQ"
      decimals="INF"
      id="Narr_80N4WbpBIEqnO1BQgJOvUQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_da-F0GyQwUWPIo1MwVDeDw"
      decimals="INF"
      id="Narr_-GUWa7ORl0-Ozm02AU3HXg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_qkBguZsiw0WaOQD5kUxKeQ"
      decimals="2"
      id="Narr_O8qDj8pJakGjSNX7TxwKvg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_da-F0GyQwUWPIo1MwVDeDw"
      decimals="2"
      id="Narr_gdGIfpnSakiBKtcbCwpXkA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">5003</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_YBo9bC2_zEW-HCuFI8kpXw"
      decimals="INF"
      id="Narr_TiTDW4pfMUSfmKCuFHKIGQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_owbhffF5n065fOVm_kbUVw"
      decimals="INF"
      id="Narr_sd3HZsHXj02oUTJwZz--qw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <xoma:PreferredStockConversionPricePerShare
      contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_HzgT7NkX4kK_7iaixTGPCg"
      decimals="2"
      id="Narr_MYmznQSC-EiRQpUg4Vzq9g"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">4.03</xoma:PreferredStockConversionPricePerShare>
    <xoma:PreferredStockConversionPricePerShare
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_-Bb_xc6BGUyWHxxOSoMlCQ"
      decimals="2"
      id="Narr_kPSx6M-dlEWYG2REmBzVbw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">13.00</xoma:PreferredStockConversionPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_G2fgy4TWqkGEN64FdHGrUg"
      decimals="INF"
      id="Narr_O8e79_mnpEGEESlhlJeF3A"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="5"
      id="Narr_t_JFYlzupk-SbV1pM81V7Q"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"
      decimals="2"
      id="Narr_uIP82Xr_MkiEDC0OnzJYwQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="-5"
      id="Narr_i198d1H3E0iBx1RcQ_Rtkg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">24600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="-5"
      id="Narr_AwtFYGK_ck-HJBu7Fy4YSw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <xoma:ProceedsFromIssuanceOrSaleOfEquityNet
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="-5"
      id="Narr__VpZ_DO8HkqjpntShHYNdA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">22600000</xoma:ProceedsFromIssuanceOrSaleOfEquityNet>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"
      decimals="INF"
      id="Narr_K0_0KrxJPU6GuLsxsLLu2w"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"
      decimals="INF"
      id="Narr_octg4ErdbkyGmfkNqDE85A"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"
      decimals="INF"
      id="Narr_P6N_V9AwpEeVrlE4VkKp9g"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"
      decimals="INF"
      id="Narr_rkdYbcXmsUSVkpOCyKru6w"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">984000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="5"
      id="Narr_nLuuGZrTh0KgaMe8as63EA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"
      decimals="2"
      id="Narr_14Gx2K64S0qH93ZYpcicsg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockDividendPeriodYearProrated
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="INF"
      id="Narr_pTjkL2Cutk2qUAq5diqJ3Q"
      unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">360</xoma:PreferredStockDividendPeriodYearProrated>
    <xoma:PreferredStockDividendPeriodProratedMonthsInYear
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="INF"
      id="Narr_BOpPvTRNkEqzcCFbEhKVnQ"
      unitRef="Unit_Standard_M_kyg1xo-wAkyvlL2hegB1iw">12</xoma:PreferredStockDividendPeriodProratedMonthsInYear>
    <xoma:PreferredStockDividendPeriodMonth
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="INF"
      id="Narr_TeCEhxA_e0StgZQFe5FaUw"
      unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">30</xoma:PreferredStockDividendPeriodMonth>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rolW1N7h4Umd5nov_Rlfvg"
      decimals="INF"
      id="Narr_2ul7uaiY806jf0ZrOrSOrg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5DGtVBpG9UST6dsCOkf75Q"
      decimals="INF"
      id="Narr_FWpdnRNk40CamoRn4ciWaQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"
      decimals="2"
      id="Narr_Qy3Ox5BnVUem4ZWOqBkNIA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_iWAtZr3dFESpISINrOcmfg"
      decimals="2"
      id="Narr_SdpirEtK3ku7V6FmNxVtHg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">26.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Whkoa4BKGkO7vhoZPfvTBA"
      decimals="2"
      id="Narr_ohOyBqeYI0qF4Okt6WQqdQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.75</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_G45ViXWaZkGa0Q9Yg2KbNw"
      decimals="2"
      id="Narr_hfqZGC659UOq8prafOhSdA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.50</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Nr-S-s7kcESAiUgmLUMTDA"
      decimals="2"
      id="Narr_8hYg-s5ogU-D4Yf-YtrZDg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.25</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_quH6qxcvP0mDXAhJavVYWA"
      decimals="2"
      id="Narr_UKkXkPwJpEyT6cR08G_KhQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <xoma:PreferredStockRedemptionPricePerShareOptionalRedemption
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"
      decimals="2"
      id="Narr_D8E35zNBTkO2UDT5Erqcuw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</xoma:PreferredStockRedemptionPricePerShareOptionalRedemption>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"
      decimals="2"
      id="Narr_CrqppXkq_0WLPptQtUvfbA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockShareCap
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_j6-7PmsR40idbycZyaDjLw"
      decimals="5"
      id="Narr_wn3UskZo_ESVkuvIqaZjyw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1.46071</xoma:PreferredStockShareCap>
    <xoma:PreferredStockConvertibleThresholdConsecutiveTradingDays
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_C_UsL3TG9kWgKOe_Ib4K3g"
      decimals="INF"
      id="Narr_xzbwNYUEMUCX4enZv4fDZw"
      unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">10</xoma:PreferredStockConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA"
      decimals="INF"
      id="Narr_Hwledlm92kCLamGoMe4Hbg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow"
      decimals="2"
      id="Narr_Htr9ghtfT0ONud315VwhhQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA"
      decimals="-5"
      id="Narr_OYmfduWm0kKCyjepJMBwxA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">40000000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA"
      decimals="-5"
      id="Narr_Ga6vuzxfPEmyRk0exBiwig"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <xoma:ProceedsFromIssuanceOfPreferredStockNet
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mehlRJzNgUCka4NPokTGaA"
      decimals="-5"
      id="Narr_VkWuUFEpYUOi9_FnWD9ctg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">37100000</xoma:ProceedsFromIssuanceOfPreferredStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_t-cr-ApM602C1aypIMKmig"
      decimals="INF"
      id="Narr_nCFZNAeNX0-kaAuf7a6MDg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">8000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gJUEPmVke0CACVsCCPaSeQ"
      decimals="2"
      id="Narr_xgv82rJ_S0GywV6mSLhZPA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_t-cr-ApM602C1aypIMKmig"
      decimals="-5"
      id="Narr_ts5DpDqh7Ey0_xVhRPF2kQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">200000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"
      decimals="INF"
      id="Narr_JwPvkWuXV06NIlU-SSv9oQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">3600</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"
      decimals="INF"
      id="Narr_apQuUM0GwUCOMmMTidwW0w"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">3600</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"
      decimals="INF"
      id="Narr_6KSwIWoYc0m30sKHZ-jlrw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"
      decimals="INF"
      id="Narr_cn59iIWNUk-xz3rlnlZt4Q"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"
      decimals="5"
      id="Narr_XNTZ4K88pU-HPJ1sQri6JA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"
      decimals="5"
      id="Narr_y8naGbReD0qzykD9sCkrRw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ"
      decimals="2"
      id="Narr_nvXTtK38n0qgcP4FlaR2aw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25000.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockDividendAmountPerShare
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"
      decimals="2"
      id="Narr_DdAYprlTh0e0GympId_lfg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">2093.75</xoma:PreferredStockDividendAmountPerShare>
    <xoma:PreferredStockDividendPeriodYearProrated
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"
      decimals="0"
      id="Narr_pAzO0sujqUez3NGPYuZvRw"
      unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">360</xoma:PreferredStockDividendPeriodYearProrated>
    <xoma:PreferredStockDividendPeriodProratedMonthsInYear
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"
      decimals="INF"
      id="Narr_s5etKjH5R0GWJ2NRTBsBsw"
      unitRef="Unit_Standard_M_kyg1xo-wAkyvlL2hegB1iw">12</xoma:PreferredStockDividendPeriodProratedMonthsInYear>
    <xoma:PreferredStockDividendPeriodMonth
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Jd8rruKTWEmQFwDuUsBeCQ"
      decimals="0"
      id="Narr_rClM6DjYTUmt-i_BF5d8mw"
      unitRef="Unit_Standard_D_NnbRa3_SFkWkIALRU61h1w">30</xoma:PreferredStockDividendPeriodMonth>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_atcrv3EC4USWY-t-APVwyg"
      decimals="INF"
      id="Narr_BZdS2ic0VUuyVByW2pfJ9g"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZsCepEVHqEqkkrLsLM8rlA"
      decimals="INF"
      id="Narr_t5N-PQbchESsxD--12SaLA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ"
      decimals="2"
      id="Narr_yOqVx0B0A0SlouQ5Jd2Liw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25000.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Eizh1l00wEuCnFSN_xaUow"
      decimals="2"
      id="Narr_D84iyJRFEEubK5O7QyvIZw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">26000.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lRxrGJiyCEKBTolJ2-Gkiw"
      decimals="2"
      id="Narr_4-AwR4AzA0WiHQSo8CI7lw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">26.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AbZx0laHAUueU-IhDRrrDw"
      decimals="2"
      id="Narr_ARTYx049-EGfJj0DRVaXBA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25750.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_IvhJyfS6z0K0hCQsSwDDPA"
      decimals="2"
      id="Narr_RVO1M0Baj0KoTVucgqFvTg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.75</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7QPtDO1XZ0iO8szQG-XtMg"
      decimals="2"
      id="Narr__CwfSg6lgEehZGTbV63qIA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25500.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T1PJ_hKJ-UOq76YTlyMzXw"
      decimals="2"
      id="Narr_5h9oN2F_kkC0xQjcJiE4xg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.50</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_zym9UWjuxU-PBpIgDKhAWg"
      decimals="2"
      id="Narr_iovnRGm0xkuXIrhZqgTXtw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25250.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_rdiiaR-KVUigBcn6d96uPQ"
      decimals="2"
      id="Narr_LgvROXKTm0uvZ9erdl1zSg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.25</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_z_A_YFI4skKZFdejnGMUfQ"
      decimals="2"
      id="Narr_QDHZehbIiEu9kdyoJs17QQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25000.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_B23R2xU4FUqRYRyOEOTGqA"
      decimals="2"
      id="Narr_EGpEbV-3Qkimn_kpWfSGDA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <xoma:PreferredStockRedemptionPricePerShareOptionalRedemption
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ"
      decimals="2"
      id="Narr_w4Fg-qX5okeydzI5YJBDZg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25000.00</xoma:PreferredStockRedemptionPricePerShareOptionalRedemption>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ"
      decimals="2"
      id="Narr_aj2BeMo3Mk-pNPs80PKu5A"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">25000.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockShareCap
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F-DCGsy_v0Ku2-Q2iSlOAQ"
      decimals="2"
      id="Narr_4-KWyJQMFUCr0ofZDTFgKg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1253.13</xoma:PreferredStockShareCap>
    <xoma:PreferredStockShareCap
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_tkAhKKNZ80qLcM8sBFU9ow"
      decimals="5"
      id="Narr_7enMRM85PkSlnItVe_HNiQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">1.25313</xoma:PreferredStockShareCap>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_wkJlbVwldU6g7qDD72xMzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A&#160;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&#160;Depositary Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Declaration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Payment Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 26, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_H7Lo4FtfLUG9U_8NFt12cA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_btS0jg_C4kSqwPe0vi-i5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;February 22, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_dSMEchMnFkqWypW9UGk7Lw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_3oD01eoLEkipHZzpjVu_VA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;April 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_OTKsEhaqhEaFde7pn0r-XA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7zNSlE5m30-23n_Xhxv1Cw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 26, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_s0Q6hKWcX0SArB1No9n7mA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ZPUZL4tmokqcSqnQL-SrmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 16, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 18, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YeDNFyDyWkiXwMYXPzULTA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__Df-kChCN02M1zGD5YLDDA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 15, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_PEaFlgcRP0SaaPOSqZfozQ"
      decimals="5"
      id="Tc_w1dPVVI1kE6K7PqD41U9kg_4_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_gixUoEw130mjwVDdF_iufA"
      decimals="5"
      id="Tc_otEkfBWz1Um4DRzyyOUKVQ_4_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cvrkp9vamEm0URrVmBMi4Q"
      decimals="5"
      id="Tc_jBTImAm8ZEOHHvmujPgrZA_5_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_9GG7R2owREOBYs3nJiZ6Lg"
      decimals="5"
      id="Tc_-H-8sNvJ4EKIuJsHUbk2Ig_5_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_YlNIDoBrLEe-2gkq_aWe3w"
      decimals="5"
      id="Tc_dWlesQWMvUCgUfjiC-5Z9w_6_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yoj2ix91MkCiAGkREHt-GQ"
      decimals="5"
      id="Tc_Pu-HgcU2dUO2dZOVryjyPA_6_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2-MEI4pSCUuGeRcjC_EN9g"
      decimals="5"
      id="Tc_iWquTgIhnk2AJxd9p3rrvQ_7_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_7_26_2023_To_7_26_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_lyRMP8iHEkWMJ8bT6bvwDw"
      decimals="5"
      id="Tc_6zgDxZFGIUeeq0fGTwr5eQ_7_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_3AEODlP3-0mydkDGCWhqyQ"
      decimals="5"
      id="Tc_1Y8ESuc_4kq-r1SNID3qWg_8_3"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_18_2023_To_10_18_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_vTX9rZqalUujaAzAws_s7Q"
      decimals="5"
      id="Tc_0yHnbFjUgk-PtgqQkogPhA_8_6"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A"
      decimals="3"
      id="Narr_cAsWd6bK3kKil-NBlwcz5w"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.316</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIoL71ZYy0WEsixcN4iu5A"
      decimals="3"
      id="Narr_4BhqLYzz2k2_2uuBOxyTlA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.523</xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_dAlGQw-3xkK1mBDxc6h3UQ"
      decimals="-5"
      id="Narr_wh_5-_ZiI0ad7QzBKTVPyg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">30000000.0</xoma:MaximumValueOfStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares
      contextRef="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_d4I_Xv63ZU-hiLOrOkWuoA"
      decimals="2"
      id="Narr_jV6SyWYgyE2vG9q_oTyj4A"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_0uMMRf1S3kW4lhwL-tOXmQ"
      decimals="-5"
      id="Narr_osXiAV2DqkSp3av-2nhJyQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000000.0</xoma:MaximumValueOfStockToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2018_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_nAi2n-UX2kK0kjYHslutOA"
      decimals="INF"
      id="Narr_wyLnZHHzY0e2s8sv8ANttQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_2QhgXTVMF0OhuPGA7tPfmQ"
      decimals="-5"
      id="Narr_AfXMiliDb0yTJ-ZMlLPMHQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000000.0</xoma:MaximumValueOfStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares
      contextRef="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_3t-rhj3dwU6-3CO8uFyHug"
      decimals="2"
      id="Narr_gX9yWsxkMkm0iZHFPiV3og"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_5_2021_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_0w8sMVVLj02yx0033CwvXQ"
      decimals="INF"
      id="Narr_EugN6kNHSEGu0hqKl2MbMA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_3VUf5yPdlE-R3-AjvvSxYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA"
      decimals="2"
      id="Tc_93cl5tEq3024aEiiSbSlYQ_3_7"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TKHfF19PZEmm6dIiuLf0aA"
      decimals="INF"
      id="Tc_KphdVw2fLkqUMS8nCZq3GQ_3_9"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6332</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_S4-V_keLEEabfoR9Fvi4Yw"
      decimals="INF"
      id="Tc_G3aUKzkyyke0Uj_uGD9cbg_3_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6332</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_N5YIECe8E0C6IWg8obbENA"
      decimals="2"
      id="Tc_UPNqdqcchkmAhiDAHJi1GA_4_7"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_N5YIECe8E0C6IWg8obbENA"
      decimals="INF"
      id="Tc_9hlmn6Y8Xk22KEwPoYKupA_4_9"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">4845</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_Edowbx1RqE2mAginFGRXDw"
      decimals="INF"
      id="Tc_PuByR5dZ2UqJdkALW1hnxg_4_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">4845</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg"
      decimals="2"
      id="Tc_j_6m9VgCa06Wf11c_SxhHQ_5_7"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">35.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg"
      decimals="INF"
      id="Tc_90kmB78FbUW-jBEKB__14g_5_9"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ"
      decimals="2"
      id="Tc_7Xu5_UaJtES1XzYaHPTRyw_6_7"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">42.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ"
      decimals="INF"
      id="Tc_0XKgY-IhQEC9i_OggASb9g_6_9"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw"
      decimals="2"
      id="Tc_aizhdWp9NUKCNA3b4uPHSQ_7_7"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">50.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw"
      decimals="INF"
      id="Tc_8IE9AYMquUuyksPpmKz53Q_7_9"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Tc_bFOBNdDRpkWWVG1mzyWqQQ_8_9"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">131177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="INF"
      id="Tc_INoYwPHRfU6_Owr2PivVLg_8_11"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">11177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg"
      decimals="INF"
      id="Narr_m7zoG4K-L0iS6aa3s6qXAA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">6332</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg"
      decimals="2"
      id="Narr_9LeAUCRzdUmraa7998a6jQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_4l7SozYSsUOT0k7UTF6fPA"
      id="Narr_GQhp8uuuMkalgl8cmWNUiw">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_s2RwfBQiakaaApMHnpTgJg"
      decimals="-5"
      id="Narr_IB0MCtCo7EmcVr3Hv92zwQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw"
      decimals="INF"
      id="Narr_lXubxgrd3U-MrmBu--f6bA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">4845</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw"
      decimals="2"
      id="Narr_2Fr_AyENsUi6ziEo30C2Mg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_IsgrsUJM7Ey5ytOSIHjpJQ"
      id="Narr_2_K-s3TAJkm1yXb_IPeaEw">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AYEtyPBxrESd89uKOAw5vw"
      decimals="-5"
      id="Narr_oRKlGCEp7UOfgT8ojFcC6w"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg"
      decimals="0"
      id="Narr_1jw5W-6JdUCvmkaVgSHOsQ"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww"
      decimals="0"
      id="Narr_ODcbzKnl-kGkOEtk4yftTw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww"
      decimals="2"
      id="Narr_e9UH6wlw1Ey4MulIDin18A"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">35.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg"
      decimals="0"
      id="Narr_78W12jgpgU6LBFy2qHjIlA"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg"
      decimals="2"
      id="Narr_lkrJU__EsUKbfcyqAIVUAA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">42.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w"
      decimals="0"
      id="Narr_ktfueYRfm0GfofP3iDEFFw"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w"
      decimals="2"
      id="Narr_f-qJ5_PIbk-TH3FbV6DVcQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">50.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_w_Edg6XtwkWHPpb5BqgAXA"
      id="Narr_YaurxtFaP0WbFPdlEWYvHA">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_vFfs1t2zrkSdVRwGh8OIww"
      decimals="2"
      id="Narr_C1eB-EINlkeVEy960vO0Uw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">35.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_ky7q9BkbA0Sp4sZaFR__Bg"
      decimals="2"
      id="Narr_J0shzflXJ0CJ0oskD0eG9A"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">42.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_BOSOcVtE_06YKwkWNXpc8w"
      decimals="2"
      id="Narr_W2QAF9uCV0SwIz_I3bxYMQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">50.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf35.00PerShareMember_5-qyHE9S1Uquivow2SaNXg"
      decimals="2"
      id="Narr_mmF254Q67U-OuR56gqhmPw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">12.53</xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf42.50PerShareMember_kLz_jIoVm06ntKG6BfTMfQ"
      decimals="2"
      id="Narr_WiJvo0jqjUGpW0xXF9TYNA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">12.23</xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantsAtExercisePriceOf50.00PerShareMember_VNWmXw8yAUqhTOu32SAvJw"
      decimals="2"
      id="Narr_v_9vACr_B0WlnUJ6I9HeBA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">11.97</xoma:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_dd1EsJfkkUq64_xnkMMEjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_ics5zZQKZEC1GLHClhw50g"
      decimals="1"
      id="Tc_wqlqPwl4KUenxFoThbigNA_3_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M2cfbs9j8kSBfzVpqthphw"
      decimals="2"
      id="Tc_QPPucGysvEmtfgN18EoUOA_4_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.87</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_gaTRiap1pEa9KzeA121uZA"
      decimals="4"
      id="Tc_gyduQdols0WNGdxJbpQZgQ_5_2"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.0391</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VUzwcKDVUk-lZVV-EniucQ"
      decimals="0"
      id="Narr_mT8LM4g1S0S5Ue_ed2SDKg"
      unitRef="Unit_Standard_Y_f7Yhi2gHBEKf5DFUnXrd8A">10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember_us-gaap_DebtInstrumentAxis_xoma_BlueOwlCommercialPaymentBackedLoanAgreementMember_tREHGePegkiylA7PicMRLg"
      decimals="-5"
      id="Narr_O8af_LeyLEqJAPKVSHKNmw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1500000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_-7Ur4HbVXEaFCLsjPnjkow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Collaborative Agreements, Royalties and Milestone Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#x2019;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent Consideration &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Company&#x2019;s agreements with Bioasis, Aronora, Kuros, Affitech, ObsEva and Aptevo the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones and the Aptevo Contingent Consideration.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company included $75,000 for the Bioasis Contingent Consideration that represented the estimated fair value of the potential future payments of the Bioasis RPA as of December 31, 2022. The Bioasis Contingent Consideration was remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. During the second quarter of 2023, the estimated fair value of the Bioasis Contingent Consideration was reduced to $0 and, as such, no balance remains as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $1.0 million for the LadRx contingent consideration that represents the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin&lt;i style="font-style:italic;"&gt; &lt;/i&gt;at the inception of the LadRx Agreements. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of December 31, 2023, there has been no change in the estimated fair value from the initial value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the first quarter of 2023, the Company recorded a contingent liability of $50,000 under ASC 450 for the Aptevo Contingent Consideration at the inception of the Aptevo CPPA. During the year ended December 31, 2023, the contingent liability recorded pursuant to the Aptevo CPPA decreased to zero after the Company paid Aptevo $50,000 upon achievement of the related commercial sales milestone.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $6.0 million liability was recorded in contingent consideration under RPAs, AAAs and CPPAs and a corresponding $6.0 million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones and LadRx milestones will be recorded when the amounts, by product, are estimable and probable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, none of the Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones or LadRx milestones were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet&lt;b style="font-weight:bold;"&gt;.&lt;/b&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xoma:ContractualObligationEstimatedMilestonePayments
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="-5"
      id="Narr_-kGVP1gmdE65IyFFlMy4DA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6300000</xoma:ContractualObligationEstimatedMilestonePayments>
    <xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
      contextRef="As_Of_12_31_2023_SPXisgKSHU-SFp9lGF52Ow"
      decimals="INF"
      id="Narr_5ZdGi0NWqE23eQP4nKp2uA"
      unitRef="Unit_Standard_product_SNQEGGFW5kSKzKYrmjywPQ">1</xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_N0BzlyOR4kSuTcSqKfN20g"
      decimals="0"
      id="Narr_MwovrdhtRkG7fNC3JOtvcg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_odyIaKodm0SEW_jiL6wZ-g"
      decimals="0"
      id="Narr_aWe_NeZqBUubMuNr-HOflA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Z8mcTXNWQ0C_2crFQkiEdw"
      decimals="0"
      id="Narr_1iY6DTBrq0CE5XhmTqDCag"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_D4dRiZ8AV0eHOkByTaYQPQ"
      decimals="-5"
      id="Narr_Oe9Yt3_DGU2mwnla8ZUy3Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_LOW_ce68U0ezgvmiUMFSHA"
      decimals="-5"
      id="Narr_bL3AMYfKvUmitIGVR0Nczw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_stqAZ05QWkerRkwBioCcUQ"
      decimals="0"
      id="Narr_NB3tpmjh0kWRVF7R5f9ciQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p0uympX4ikiTTBU4ecrjtg"
      decimals="0"
      id="Narr_Xl47va2VxUO2gkQ9wsfgIg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Dnn6lWiT3UCbGZqz1uHJdQ"
      decimals="0"
      id="Narr_0RgzJBRe5U-krpv-7h7slg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"
      decimals="-5"
      id="Narr_JjgtMRaLtk6T_mPWnX2sxg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tDPGCppJakuTGjm4ikwgeA"
      decimals="-5"
      id="Narr_9fVLioULsEKeSDL_V2gakw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_mYK_QMr3TUm4vX1xHmR2Hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Concentration of Risk, Segment and Geographic Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents, restricted cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2023, three partners represented 44%, 32% and 21% of total revenues. For the year ended December 31, 2022, four partners represented&#160;33%, 31%, 13% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of December 31, 2023. There were no trade receivables, net balance as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Geographic Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Asia Pacific&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,758&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s property and equipment is held in the U.S.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Knb1VMkj50OkZMrcsYVZ7A"
      decimals="INF"
      id="Narr_2DLu0M1d2U2c1g2Q_adQ-w"
      unitRef="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A">3</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_n8y0wI3G0kq3oR95Yq0yng"
      decimals="2"
      id="Narr_ZEyQWkQCJE-jAy2bUx4J9A"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_X3OFdmWYO06HF_9VjwDAbw"
      decimals="2"
      id="Narr_NxHdQOt_PUOYw50RcvTN2g"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hxgRGUCPFUSaOcTTwES4QQ"
      decimals="2"
      id="Narr_Qq0DdzcgJkiF5nJC982KFg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.21</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_x9Ly_6nZa0eN0KZmAKFNgg"
      decimals="INF"
      id="Narr_NN4MqQ-G20iVgwyezzRbxA"
      unitRef="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A">4</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_EqHsm_Ei50WL1NlCKjVHOw"
      decimals="2"
      id="Narr_-IKtQ8Mbd02C79J3NFHK_A"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_je2iAxI6uUyI9xWXJ3NNKQ"
      decimals="2"
      id="Narr_evP0XtWg5Uayvd8iRheGuQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ldCXzpF9akqsXBzaD9hxuw"
      decimals="2"
      id="Narr_Fsg0s-c69USdholyugcdVA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VF70Yp-79UiP9lmggMs1vA"
      decimals="2"
      id="Narr_9HtLRGHUMUifrzUfy1sJoQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.12</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_iLQLrl8HzEq0ISsfhi5yuQ"
      decimals="INF"
      id="Narr_B-LAinj9OUa8AsOZVXBmlg"
      unitRef="Unit_Standard_customer_XJDcMhUDo0OQnZAzQT0Y4A">1</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_iLQLrl8HzEq0ISsfhi5yuQ"
      decimals="2"
      id="Narr_luUzKp_DY02OyEGzdoZ7nw"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_Y6PSmqmg50WqIM4txgn5DQ"
      decimals="-5"
      id="Narr_DbJiur56TEORw-pHEYCBuA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="INF"
      id="Narr_dXM0mwR1Ckmiw0thepiSBw"
      unitRef="Unit_Standard_segment_m_JT2gZUYEyv5yGMX4336Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_RZLKBULlYUyWfu7lVhb92A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Asia Pacific&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,758&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_3-ttz87lbUGOlay7J25Yhw"
      decimals="-3"
      id="Tc_wfM7kWiMukWB7Cp560WTjQ_3_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">3658000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_VbPaWFBrc0Cn_MDgoar4GA"
      decimals="-3"
      id="Tc_5whW8qupAEeSKfbKTEevnA_3_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4477000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_srt_AsiaPacificMember_h1HPzeTFJEK9m12ZpTyuCw"
      decimals="-3"
      id="Tc_KrFTYBTDWEWHl6EQU8IY_g_4_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_77WH8ueaj0uJk0NC9iLw_Q"
      decimals="-3"
      id="Tc_4JlDxhiIH0SNDi9gDaXc4Q_4_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1550000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      decimals="-3"
      id="Tc_28iT3RgdJkyQZBT1dWW2ew_5_3"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">4758000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_fllcuL7dz0GSYCqcyq1hzw"
      decimals="-3"
      id="Tc_3YgU11IFHkOHYuL9SOnIXw_5_6"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">6027000</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_D-SQ1ojs8Ue-gTzW1Rh4Yg"
      id="Tb_JPyT1Fr6H0WbD-MgfaO5eQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15. Subsequent Events &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January 2, 2024, the Board authorized the Company&#x2019;s first stock repurchase program, which permits the Company to purchase up to $50.0 million of its common stock through January 2027. Under the program, the Company has discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, as part of accelerated share repurchases or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at the Company&#x2019;s sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate the Company to acquire any particular amount of its common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. As of March 4, 2024, the Company has purchased a total of 660 shares of its common stock pursuant to the stock repurchase plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Appointment of Owen Hughes as Chief Executive Officer &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 7, 2024, the Board appointed Owen Hughes, previously Interim Chief Executive Officer, to serve as the Company&#x2019;s full-time Chief Executive Officer. In connection with this appointment, the Company and Mr. Hughes entered into an amendment and restatement of Mr. Hughes&#x2019; employment agreement (the &#x201c;Amended and Restated Employment Agreement&#x201d;), pursuant to which his annual base salary was increased to $575,000 and his initial target annual cash bonus amount was increased to 60% of his base salary, subject to the achievement of annual performance milestones to be established by the Board. Mr. Hughes is also eligible to receive certain termination benefits. On January 9, 2024, the Company granted Mr. Hughes a target award of 275,000 performance share units that will vest upon the Company&#x2019;s achievement of specified stock price performance conditions established by the Board and which are granted pursuant to, and are subject to the terms and conditions of, the Company&#x2019;s 2010 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquisition of Economic Interest in DSUVIA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2024, the Company acquired an economic interest in DSUVIA (sufentanil sublingual tablet) from Talphera, for $8.0 million. DSUVIA was approved in 2018 by the FDA for use in adults with indication in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales, a 75% royalty on net sales to the DoD, and up to $116.5 million in milestone payments. Under the terms of the agreement, the Company will receive 100% of all royalties and milestones related to DSUVIA sales until the Company receives $20.0 million. Thereafter, the Company fully retains the 15% royalty associated with DSUVIA commercial sales. The 75% royalties generated from DoD purchases and the remaining $116.5 million in potential milestone payments due from Alora will be shared equally between the Company and Talphera.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;FDA Acceptance of Arimoclomol NDA Resubmission&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx RPA, the Company made a $1.0 million milestone payment to LadRx in January 2024. As of December 31, 2023, the $1.0 million milestone payment was accrued in contingent consideration under RPAs, AAAs, and CPPAs in the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Kinnate Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 16, 2024, the Company entered into an Agreement and Plan of Merger with Kinnate and XRA 1 Corp., a Delaware corporation and a wholly-owned subsidiary of the Company, pursuant to which the Company expects to acquire Kinnate through a cash tender offer (the &#x201c;Offer&#x201d;) for a cash amount of between $2.3352 and $2.5879 per outstanding share of Kinnate common stock, par value $0.0001 per share (each, a &#x201c;Kinnate Share&#x201d;), consisting of a base price per Kinnate Share of $2.3352 and an additional price per Kinnate Share of up to $0.2527, &#160;plus one non-transferable contingent value right per Kinnate Share, representing the right to receive one or more potential cash payments equal to (i) 100% of net proceeds payable, if any, from any license, sale or disposition (each, a &#x201c;Disposition&#x201d;) entered into by Kinnate prior to the expiration of the Offer related to exarafenib, an inhibitor for the treatment of patients with lung cancer, melanoma and other solid tumors, and/or any other pan-RAF inhibitor, and (ii) 85% of net proceeds payable, if any, from any Disposition entered into by the Company or any of its affiliates after expiration of the Offer related to exarafenib or any other research program active at Kinnate at the closing of the related merger. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="As_Of_1_2_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BoZJ1cjf3EanYPBMyrtXzg"
      decimals="-5"
      id="Narr_PiKQnPagNUGK8yIcvSLI1Q"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">50000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_3_4_2024_To_3_4_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tizzAxoxlky8Xls0hG3qmg"
      decimals="INF"
      id="Narr_nVrppYYDXEyCqupg5t1prg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">660</us-gaap:TreasuryStockSharesAcquired>
    <xoma:EmploymentAgreementAnnualSalary
      contextRef="Duration_1_7_2024_To_1_7_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqWQZEkxck6aUZbAhDxrIQ"
      decimals="0"
      id="Narr_KqXE2TpfNUqLR2j0IoU5Yw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">575000</xoma:EmploymentAgreementAnnualSalary>
    <xoma:EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary
      contextRef="Duration_1_7_2024_To_1_7_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqWQZEkxck6aUZbAhDxrIQ"
      decimals="2"
      id="Narr_RWQJPLRG-Ea91Pe1nrlBJA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.60</xoma:EmploymentAgreementTargetAnnualCashBonusPercentOfBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_9_2024_To_1_9_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VAnZAL0inEKRzb4syNlviQ"
      decimals="0"
      id="Narr_D1Q1AIF1wE-_SmxWWcnisg"
      unitRef="Unit_Standard_shares_7EwYMVdc20iyB7vQWjq9Lg">275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_GWb50yHWG0Gjencq1GEsyg"
      decimals="-5"
      id="Narr_B9j2KD0dj0OOKwBz3tzmfQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">8000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2cm7F_6WkkiGYRgSmohdVg"
      decimals="2"
      id="Narr_ZaFxo1c9MUORNoRd9WbShA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.15</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yFyujZtG9UWuos2_NLxJPA"
      decimals="2"
      id="Narr_IkzNImcGOUqRwGx6MMqSEQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.75</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones
      contextRef="As_Of_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_srt_CounterpartyNameAxis_xoma_AloraPharmaceuticalsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_bEwMjcvCoE6dg4CchXXb4w"
      decimals="-5"
      id="Narr_l94ncFUIA0mqyAuKTd-geQ"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">116500000</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestones>
    <xoma:RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_GWb50yHWG0Gjencq1GEsyg"
      decimals="2"
      id="Narr_KlBDicbbB0-cVqrEQst6lg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:RoyaltyReceivablePercentageOnNetSalesAndPercentageOfMilestones>
    <xoma:RoyaltyAndMilestonesReceivableThreshold
      contextRef="Duration_1_1_2024_To_1_31_2024_dei_LegalEntityAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_2qKuJw7LF0SNxUkiCX8mrg"
      decimals="-5"
      id="Narr_e3wCaPDeBkeT8EPXJhgbHw"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">20000000.0</xoma:RoyaltyAndMilestonesReceivableThreshold>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_AllCustomersExcludingU.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_DqEQ-FxkkkC-biVtuHiWlA"
      decimals="2"
      id="Narr_RLouedPzhkOCW9YcXpb3HQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.15</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty
      contextRef="Duration_1_1_2024_To_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_srt_MajorCustomersAxis_xoma_U.s.DepartmentOfDefenseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_d7MCNo9BZ0e94zx26toTQw"
      decimals="2"
      id="Narr_pbHrtBmUN0KH3e6kVnT_hA"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.75</xoma:RoyaltyReceivablePercentageOnNetSalesSharedWithCounterparty>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty
      contextRef="As_Of_1_31_2024_srt_CounterpartyNameAxis_xoma_TalpheraMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AcquisitionOfEconomicInterestAgreementMember_q9ObqQzmnkSHnjz07UVHxg"
      decimals="-5"
      id="Narr_igAjuvN39UyvRyL4Do9QJA"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">116500000</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfMilestonesSharedWithCounterparty>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_11_2024_To_1_11_2024_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_kHKXEon0m0elwS6IFTsLdQ"
      decimals="-5"
      id="Narr_2LuVThs4d0Gz_yMDmoeXbg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_cJ_3I5gqVUm-_Sd9MucR6w"
      decimals="-5"
      id="Narr_m7jXKhZ63EWKny_yE0kvfg"
      unitRef="Unit_Standard_USD_Yj98CUFoykKy_yEHSecX1Q">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentToAcquireBusinessPricePerShareCashAmount
      contextRef="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3MSAG2w_VE-njv8TBWI0TA"
      decimals="4"
      id="Narr___OVbEnphEGHMo90L3LnGA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">2.3352</xoma:PaymentToAcquireBusinessPricePerShareCashAmount>
    <xoma:PaymentToAcquireBusinessPricePerShareCashAmount
      contextRef="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KiCr-hkOokmigDvDkoN0tw"
      decimals="4"
      id="Narr_ZcUWa-2wZEShydLcXabyKA"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">2.5879</xoma:PaymentToAcquireBusinessPricePerShareCashAmount>
    <xoma:CommonStockParOrStatedValuePerShareAcquiree
      contextRef="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew"
      decimals="4"
      id="Narr_H19vxdz3UUqKyycoWgjNzw"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.0001</xoma:CommonStockParOrStatedValuePerShareAcquiree>
    <xoma:PaymentToAcquireBusinessPricePerShareBaseCashAmount
      contextRef="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA"
      decimals="4"
      id="Narr_suUsttEPlUCVINSolM6BGQ"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">2.3352</xoma:PaymentToAcquireBusinessPricePerShareBaseCashAmount>
    <xoma:PaymentToAcquireBusinessPricePerShareAdditionalCashAmount
      contextRef="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA"
      decimals="4"
      id="Narr_DdQX5-JKtkirTC5Dz5jADg"
      unitRef="Unit_Divide_USD_shares_BJJRIK55s0azH3JQum3OOA">0.2527</xoma:PaymentToAcquireBusinessPricePerShareAdditionalCashAmount>
    <xoma:AcquisitionNumberOfContingentValueRights
      contextRef="Duration_2_16_2024_To_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_irqcY3sHJkaD9acE0d06SA"
      decimals="INF"
      id="Narr_hRw88kTWLUmP01c5CGYW5w"
      unitRef="Unit_Standard_Right_7KYt940OV0yye1Z67B4qbA">1</xoma:AcquisitionNumberOfContingentValueRights>
    <xoma:AcquisitionValueRightNumberOfCashPayments
      contextRef="Duration_2_16_2024_To_2_16_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3MSAG2w_VE-njv8TBWI0TA"
      decimals="INF"
      id="Narr_Ef4a9FmFo0GqHbyiIWKbTA"
      unitRef="Unit_Standard_payment_MZwTcjQqtk6l27rvf283Rw">1</xoma:AcquisitionValueRightNumberOfCashPayments>
    <xoma:ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer
      contextRef="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew"
      decimals="INF"
      id="Narr_PSk3PfGCLUeP_hbTnWI4dQ"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">1</xoma:ProceedsPayableLicenseSaleOrDispositionPriorToExpirationOfOffer>
    <xoma:ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer
      contextRef="As_Of_2_16_2024_us-gaap_BusinessAcquisitionAxis_xoma_KinnateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7JZ6TDzRu02sXOi_9Mz5Ew"
      decimals="INF"
      id="Narr_zeBlk1km60aSeHGC-18xhg"
      unitRef="Unit_Standard_pure_7QMvPmi6gUa_9nKS3wODAw">0.85</xoma:ProceedsPayableLicenseSaleOrDispositionAfterExpirationOfOffer>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
